<SEC-DOCUMENT>0000318154-22-000041.txt : 20220805
<SEC-HEADER>0000318154-22-000041.hdr.sgml : 20220805
<ACCEPTANCE-DATETIME>20220804195342
ACCESSION NUMBER:		0000318154-22-000041
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220805
DATE AS OF CHANGE:		20220804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMGEN INC
		CENTRAL INDEX KEY:			0000318154
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				953540776
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37702
		FILM NUMBER:		221138258

	BUSINESS ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320
		BUSINESS PHONE:		(805)447-1000

	MAIL ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMGEN
		DATE OF NAME CHANGE:	19870305
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>amgn-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:5d27ca97-9729-4191-8773-bd1da607be75,g:d96be9d2-9e3e-485f-8641-d09afcb6a74b,d:710475db76604b05901ef7473465ecf1--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:amgn="http://www.amgen.com/20220630" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>amgn-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80L2ZyYWc6ZDBlMWU1MDc4MDliNDljZGE5OGUyNDYzYjc4ODUxNTgvdGFibGU6ZjE0YjFjMmZjYmZkNGUwODg4YTcwMDQ4Mzc0ZGJkZGMvdGFibGVyYW5nZTpmMTRiMWMyZmNiZmQ0ZTA4ODhhNzAwNDgzNzRkYmRkY18yLTEtMS0xLTEyNzQ1Mg_84d8671e-5db0-4949-8d4e-c8b2d670fb66">0000318154</ix:nonNumeric><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80L2ZyYWc6ZDBlMWU1MDc4MDliNDljZGE5OGUyNDYzYjc4ODUxNTgvdGFibGU6ZjE0YjFjMmZjYmZkNGUwODg4YTcwMDQ4Mzc0ZGJkZGMvdGFibGVyYW5nZTpmMTRiMWMyZmNiZmQ0ZTA4ODhhNzAwNDgzNzRkYmRkY18zLTEtMS0xLTEyNzQ1Mg_7cb4d4a3-9e7e-484e-99c8-284d6fee324a">false</ix:nonNumeric><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80L2ZyYWc6ZDBlMWU1MDc4MDliNDljZGE5OGUyNDYzYjc4ODUxNTgvdGFibGU6ZjE0YjFjMmZjYmZkNGUwODg4YTcwMDQ4Mzc0ZGJkZGMvdGFibGVyYW5nZTpmMTRiMWMyZmNiZmQ0ZTA4ODhhNzAwNDgzNzRkYmRkY181LTEtMS0xLTEyNzQ1Mg_ded5b398-f0bb-4110-a4ae-22bc4ac6b89e">2022</ix:nonNumeric><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80L2ZyYWc6ZDBlMWU1MDc4MDliNDljZGE5OGUyNDYzYjc4ODUxNTgvdGFibGU6ZjE0YjFjMmZjYmZkNGUwODg4YTcwMDQ4Mzc0ZGJkZGMvdGFibGVyYW5nZTpmMTRiMWMyZmNiZmQ0ZTA4ODhhNzAwNDgzNzRkYmRkY182LTEtMS0xLTEyNzQ1Mg_6707c978-50dd-4bcd-aef4-08141bca261b">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80L2ZyYWc6ZDBlMWU1MDc4MDliNDljZGE5OGUyNDYzYjc4ODUxNTgvdGFibGU6ZjE0YjFjMmZjYmZkNGUwODg4YTcwMDQ4Mzc0ZGJkZGMvdGFibGVyYW5nZTpmMTRiMWMyZmNiZmQ0ZTA4ODhhNzAwNDgzNzRkYmRkY183LTEtMS0xLTEyNzQ1Mg_999bf045-e835-4c36-ae39-c8de69f8795b">12/31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="amgn-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i399851cc44354bd288c22867c4af295c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68c22f15a4f2449f827d166633453d03_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33b94f8a0ce843a681a635dc7e7fa22e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cccb85585694ce49af0de31a566d7f3_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia3c410d6b2f84e53be5c076dec22d865_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i78d9e005bccc4060bd5addba903c2c2c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38c160a3f1834d5e9d775a1dea85e514_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93db18973157470084da5a577ecb7c40_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71e71b4283ef4881a494fede3403b36c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i768868bd3bfe4a65a96efee550cef847_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43a801ced92f421e934618c8046f564b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bfeed5ecca54e718c3e7aefb7714ac5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i9027275ed49d4865b0705c7a15256e40_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ab9a3aeb1dc401e8f8036824d7fc7ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie57786644af74fb49b8f5e29302dab93_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id600cdce916f4b66a8dcd23e38e899e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4015add6967846b88c70abf91e4bfcd3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bdfa7c23e874b22a1a66bebad22d916_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6bebabfe867463fb2ce8c41e89ce28a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i727569817ab94b17a5a44e5e6554f39c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib84a6f83e673473a8ba69ec165a6aa32_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1743609e3cdb4aee821e866d6c0b7a5b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia449403700e84ad390099f266af55696_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib52f0a890ada46f0aaeaa5f7a392c87f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3453133454bb4b68987a91d14ea8ccda_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8de403afe8684433ba669a9d329718c4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c56073392354d1aa5fe73191ec6a1cd_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i950254b1c906440baad1c3cb0d696509_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib013f6621b494621aa9fdc2ca2c9a16a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i437ad630ad5c4d0db3b941130901471f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69e8f109a2db495c82bf5845b27d710b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa04a5eecd554471bd742d77f0241ab8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e8fdc8e1afb4a8b8179c89009d5c1aa_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedbaa8596a604e708e0f5d708642088d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87a50000054d41c4b6c8d975b42b1648_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e3e8fc000224eaa8d179f838cb7031a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37f513ac48e244eebc3ecfd6dbf5e0a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2639d3c097ee4df19d9460b38ce3c560_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e5bfcd24a084d2ba4ae4e9fd63a2a81_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaa3e87d3e094c2c82065bdcc86a2d5e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i230f8b81d2ba4f069528c27808330841_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f42e7ad02b549569ea5beaa0e813a56_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ff28f2746c54bdaaf782c67ac1f4302_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib96efcc5351148e2b1ec0411f0edc1ba_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac25314d738441bd880294e17a40ea59_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1a08827c17347a29bf672041a9ba9ab_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34f2d24ef5604859814eae53b155dccc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07da672f055a4104b16e0910367ec926_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a2ab422b4b24a8fba8a2d881b98b260_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i722f5ea9afa642bf9d0d9d90efe8e13a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fd41a82276046c7bcf592d2b6dc24da_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38c33764415f4b3db09298ed152df379_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa0252b377d44fb0a78ea5b3634c223a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7fd0dbb0ae849598e2ca788ff7aaa13_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86ca63c3b2e447a59ee34b73dfbdad9b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcb6da36e779490a98df897dc86555e5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33df105eb613462290a07079358e7409_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99dc635999d0465e8fcbdc0cee2c1601_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>amgn:segment</xbrli:measure></xbrli:unit><xbrli:context id="i46b0c7abfa194277afc81cba3b24f8a3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65b90579b9de4767a853da3e3573d8fa_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0f1d41da125426189de8e665937a530_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:RDTechnologyrightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf77564d8ed145dab51bea04209c327c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5b59ba800eb4416b405415f49916460_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amgn:MoleculeTypeAxis">amgn:AMG340Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8fc3ec2171642438fd51d30ae242218_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:RDTechnologyrightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7940c183b18d43b9ba4da67548953f71_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a5366d8b02a4ac58034f8465ae23d74_D20210416-20210416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:FivePrimeTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-16</xbrli:startDate><xbrli:endDate>2021-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51b02cfd80774125a1d4ff6c778112df_I20210416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:FivePrimeTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab9a0edff56e4078be3430ac408a5cf8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">amgn:GensentaIlacSanayiVsTicaretMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d17ec1f9653493f940934eadb627b3e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">amgn:GensentaIlacSanayiVsTicaretMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b8b7a38d735412895755cb950726b35_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">amgn:GensentaIlacSanayiVsTicaretMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icee014cde681480aad811d3d8701db0d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf9d9ddcf94242e3ad6ec1f3b60ca85f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6547eba45cd04dcbaeebbe712be8ec92_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e52109f70c0440aa0159863f2da64f0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a84ebe379724a65826c6f82bd6873e1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida701b321d2c4d2a891120940d3655c5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief82f7dcaf42426abffc36664a5809c7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fdc9fa81ab6432aaa23fe4128d28ae8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i053944749a2f483d9d310db2fc989a2c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eebec4167d24ee289c7c3c2cca1d35a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7337cf047dc447782a07d660fabea38_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c5378764431442fb224f6e38d910099_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4b87907d6674193b0d2c415cefc0caf_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i353f9f7d24934b85a5752777824c2c7f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib84507297bc345c8b3d5fff781c60e36_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fef643526f14918bd9831e91914bf50_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i402e9a1690cc42e797f5a6261ca0cbfb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3ea1a7432a342c2bed9d52592b75cf4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63940a8eea91432f83d73335dca6a9f4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05d9d5b7844d40b4a71f85abe0bce65a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cde61abea0348d2a159b88ebd8184b7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10be39accc2549a2bdd35da00b4aaa91_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b97f8b18b7146bf8f5d26e2d38206ab_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie08a8cd0c2ee4df4970b642309711818_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib449607d3a384e9b922bf56ee0f6ad54_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i844d0ba430b845fabf60df607d4a6b2b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d419bd679714fdcb7cab5ff036d1523_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78a1a713123344ccbeee9e7f0bd8b286_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3759a6d96c3d4557865f45756f379736_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13eca2061d94491bbf81135f296046bf_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6b5b0a2363145d7be3110c83773d028_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8d35c2137e343349add15c0fca41917_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ab66a4297fc4a5fa4fbdb2b993c893d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa47aecf963c462192f5f09066e709ae_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dab3465710546408078a65658bbbc86_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d1ec301cf824dcc9410f3838f666700_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d51cebbb7fc4745b1461e1227bf4a07_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic60e2a88b0ee40cdae005ed5c6d5e8fc_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i331261ad3dac42c582a5e9011635bd51_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide9a7be6cf844191ab232452edf77bd6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b9d8e979224414d8d3ad2e8695072bb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49646ee726c14e1e97ca5817d76e3e08_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab5d097d4d764906958b2308fa778f75_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bb35321c40c4726b08388b4209a9228_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2958c1dc2e954e58aa77a26a6d8e1d7a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70fcb018e33749d2af04537d60b71f20_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica9bbd963a304369b99b0572c2fff78c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81e998920660480b972899798b0bbb3c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if57c433f89bb427d95cc820d738a213b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49be0bf790014903a4b42b6e1b2727bd_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d6f96cf75ba4e419a31bf17c86c89c7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9166886eb5d468090bdacec2d9c6426_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedd4bef43f2e4c74bdbe761a290688d2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i866f0a6fa4484406b8ad21f3fb76f4a3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c0b9b0637ae4f75a113b9daf4ffbb97_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id00661e6164d4652a22a0e73d4ff73a6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c2f46c443024e00a31cb4dc9cd9e34b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c2e544419be4d83a0548a9dd2cb80a6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a69d719fa4e41389f7a488fa7f10932_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12b36c285b3e46d48bdcaa2313f4d40a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3c63f65b70944d59e9ddddf1020dbf9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27c7d03606704467ad677af2b7b1c3b1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60557b562a964b209eb858e7b3cb22e9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafda85002a2340d3b351231f4da2b4fb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i995fe6b5cc06494dac04f0ca72c967be_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i481df103ecf443b58ab69543c8ebfaa4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e20cfb3d44545709400adfd0900c274_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i198ddb00bf674c69a7441a2d3a026635_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ad4acdb144a4163bcbf1216e002c725_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac22074dabd64d2fbfdc167416335b44_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9ab9b8edfdb4a22b19ee432374d19ec_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2a35d4acbaa4f83be8e10b0e6e0300d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf38951506aa48f19b8b2388b7885ee1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d40692061a445c192ae0b68421a236a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f09cd5a2a344997a29f5dbf9e474e85_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f4bf88082934cdc8910614dccffc16b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43dfd6a72e0d4e86845ad7349de053e0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22a251c8f299431d94a6931aca67fc7f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8de2ea542474f83b6b3eca46a028b44_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i774b5e6996814c4abaaef4d66eabba88_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia32f2b66d9004689a58fa0ee82794077_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic110f3f8f6db447287b324ae25536ba2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2702f5653dc64085adaed969aa03d41a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i059b2fc16c164e18b5bc3641f7e47b0a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd43189867c0477aa56e3dd2bd1a3ca1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22ff43227695419d9aa80cbc49fe3fac_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf215bb9f1894adc8cb1984f634e46cb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i417472fa55034ae1828e69637b4f9dc6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if61ddc5649444d2890986cd3b336d8a6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9501d13f07544aa914a2f0472499317_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c91bcd0b0614b31b6ed09d75f6a89ee_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i447c6a3b3c654027a8f390447d27092a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i913293415a73440c8b746390caea2fe8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d14e200ac08498a8babed3b3c0ded3c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b05f801cd3a4927a0124fb231c84d76_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e7cc819d92f4e75acbc9963bc7090ef_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7ae2416c6aa4543a664b0bde8b33563_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9676f44123d40e2871ec3d2771a7a5f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecdf3a73b98a42dc9b239601a9ae31de_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45954dd51b7b41aa96b4593c6fb94f09_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6148be5d2f114eaba7d30900efe31d0c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib505cfceda644a379d36c8eb60ae289b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f37b029317a4d00a1a498b287de24f5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i280383856aef44de9c38a690e97f94a4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5d62159edfe46daa8cde42bb90fd594_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i599bea8fe9d342bf8a2319d0c99d8049_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if33d244e2dcc4deb97f437c4bf8015e5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4743b11647f495995b2a8eb1612ae62_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i019834958d7c4fdcb462b108564b7504_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3329340deea4c2893e19564ea8f5d50_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33575c61bd1a4b6483cadbb17231bd16_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76d8149329f846d4b8b397d30cbfffdb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i284e10e01d024a31b71cbe8084385e6a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18bb25efd7724f2ab8c17abd89376d32_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i799c05d5e6c148739756e62ed52efc0e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c26221f1ddc4730a672e6feda6527ac_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8df6d5b75ce4981805065f554e3fc61_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf0c82557a9f4c5a9dad46e4f1995240_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9080bae4bb24f77958c82064456abff_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90438b29fb8e47daa853e17a32039dbf_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69516fc5e36948efb30d55be4c11c00e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71f5357d2c814ae18ef9d15c743aa395_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceb2e90867824a3d91fa7756b41e93e0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f3ade07d4da4313b5b990be550c7fe7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d0a9ca182c34101bf19dd4a000ada97_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia06b5f63bc244d16b92988767f8bc100_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id43e33fcdb65467a8bb28d8ffb21869c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc7bc4cfc3564596be8443a8279385fb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i46acdac3da2c44dca21c41eba4598137_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82d3aa8175154da2ba3e9dab9d5064c0_I20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8082d2e09a5c4aa0a7f3731849ec0d16_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ea16251ca3344cd8e26c09cc1395a22_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbbc44571a8140188c44b0df13007242_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2f04eaab04b4d2c952875e4954ffda7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd41271077fb4ca086b8c963378ae207_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c7a0f871105442a9e599228c9451089_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02847d17ecc24c3f9024cc5f534c04a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea64a31893bd4a61a10bade5fb93931f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3ee9095509a4235b125b11b137e139e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:AvailableForSalesInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2192ca00bef0437697f96821d3d064c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:AvailableForSalesInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52bfb5d420974f909b489605f4ebb48e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81cbf2552fde457394dd38fa4c8d3a52_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i508f5bf239c54b9b938463f7ae92fea1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic408702ec02a49bf91a6056997008286_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i496aa2763a92482692aec0e597926c98_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a1cd1326d554d03be0c62860aaadc16_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic159ef06be114a82aece4d92d6710839_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i888296d1eab64b6b817ca5c5d9f69be8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cda008dddc94401b22d3259266fc7e7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdb22de342f041adb8e2b70cbc132e50_D20210930-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-30</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d79fa0d130e44d19361d654d95e141d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic76acadc687c4a66b5883e78b037a6ad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbd4bb3072a846dead8e321c6b0cf833_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f602482804d4aec8fdc3e408b13ed29_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa0314910b794236a904970854a1e630_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8b0ba79e4914ce8815964b9387a76dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fe68111c13942ef9c7a0d951601d88b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i401f6926d97c46c6a10162d5f3c2efde_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62aa67f340d349a684242e6f5ab5e761_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife312c8d8cce47d28d37a01320dd5c28_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d1c8a9209dc4f9fbe9812c8fcc8987d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia61f1d92e9464dd18e99ac1aa3b366de_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cce03dee4c34b2ea84da100e20fbd24_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i099607de031547a9bb9e43f15bb881fc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic07181533cda4f5e93039975aae670b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac2b57574dd942a2a453e505dabd533e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fb7461fd5694c57866568ce1e547030_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fb86733ee024515869430e8dbaa9324_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i571fbd60834f45a8a94ddbcd37f40d78_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e8e7fe1acc74cf88c35c02e48e41455_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic63e1fd5342a4cecb2063e44b0677f36_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0f38e5021744d62a72f6ec5c21139ea_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="chf"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit><xbrli:context id="i48b3751c36e94ecc8abd5b6bc07fb36c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cc181592b784672a897b345f8aafb1c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e0a5eb4088b4f5f9d9e54d6ac0cefa1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbf9488cc39340f688dc8239b97b3406_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d83b1f8089e4fe9b0149f04b0874977_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5811dbeccf214f488187b5c22f177a23_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9b1443716684a18a0944e9e9de23470_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d5c387b50044b74aa269b57c4e1b18e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7839d25e4a274cde83be70a336e9f23d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8771ce738edc4f2bbcd5cf45e51751ff_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i31014fe22b1e487c920ebfa34bb0d600_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i927ecd67dbbd46f6be54131a567097ee_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f9bc180a6994a85a80ac8530527b2f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5db64085db894eefb5186c861f5a0216_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="i56b164c7fe7e4938a4b2f2cb9f20f1e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i557c138915f74848aec303bcbcbdf1c5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id84e2ad3fd7d4d2ea16c4f1a15e443b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7ebb4dc9f2f4f4db89a7eba86ff7b3c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f508b06ff8341f99dde537d8acf7445_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07d1843d947d47519f7950d93a5562e9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointSixFivePercent2028NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e873215313140b1b47d44874f84d297_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointSixFivePercent2028NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a74363bd54f4d66ad0e46ef97698531_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A3002029NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5443e8b322b4d0faa4ade72d57d4e85_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A3002029NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28f107e649274e53ac4e7d54db6713eb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66c10d0d93a7485babc5ced3a0780a07_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f539453d5ef4ab6bfd15d005af9fe8d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d9dd73fd402413093a63fd14b1085e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34e92919299b42e89aac44fbf306409a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica06dde7221745f9b345032e886823b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic445c08da9214730a1fe68dffa9fde2f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointZeroPercent2032NotesMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0a1796124db4912a03941f9fc2bb729_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointZeroPercent2032NotesMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbe4cc4a9874400299d9ee262931fff2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A3352032NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ea8bdcd48224c638ca7517df56948a6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bc19466dfcd44729418b77c1b6cac7d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if160545557934f3ea7d7aa81db1e5fe6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied438a5ea64d4044aa5bbdbdd2f08fa8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ce84e57febe49528941c8a79c0b2aba_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if808837e20874be992a0d93186873f98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i044f15b088224513a42ca9d6a15c87ff_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id531ca5db21148f9bc34d2e8bb8f2623_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab08d658a45448438680f7c44651a436_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc8bbf8e715b4026a58db39d1e4ae27a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i867b4a6e48054979abbb390f7ca4bea4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointEightZeroPercent2041NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79f6ba2cbab24ee7a767a43344d52629_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointEightZeroPercent2041NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i869ffcf94f08470aa084a38887e74378_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8efceb2da34f4012a56d28bee80ece4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8f4719ca9b84ee8b1c7b311cb67831d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fe337886bb743ac9268549dea62a5c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3039eef43eab47d88f5e5bde9f8c3c1a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c41f818916d4143ab5f24b20c47b6b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8baade68d0aa42cd8eabab1268708b15_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i371510a8b04e43fc92b82fca221e37d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cf9e5efd50b441ba4249ec5547a64d8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb4f7f1f524943beb30880ef09f09b08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idebc81edd93d4d2f8a2a03384eb93dbe_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07b2f991bb9a47f29b3bcd5b53c1cdd5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08a78f74146a4495aeae7b6b14bd80a4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie836805159b74407a69e93d8523fe3ad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ed1c633fdd74b46948dd2c6f7afcf20_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc5590dec8034b22bdedd784acc302e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i735b048825ca4313aeb532048d7be90b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A300NotesDue20523002052NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad985efcbfe541aca64199c03a30ee03_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A300NotesDue20523002052NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d18f819d85a44c49e5108e4c3d42378_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4202052NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53e00d2be34d4b1ea7b97fd526f5d69b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4202052NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbd916f7493440e69704b449f2dd8102_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60c317ee474147a8b5d3b80406fb276d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17997eb7cd9343bd87243e19e6bb8d08_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4402062NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43ee6e408fa1493196ad37c5887d08e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4402062NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i951998b6f8314c8884444de5fada1e86_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OtherNotesDue2097Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a44e9649b29466fb790d1a57aca49b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OtherNotesDue2097Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia45a3444f1b94d7694e25c6b7581e9f6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31e27323c1154ea898dc24977e5b4dfa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A3002029NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cf0dda19fd445dca8eb54ae4d8870ae_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A3352032NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecb3cb0076694222ab5165cf391eb7d3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4202052NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7172737536943c5bd01dbe5c718b01f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4202052NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i531c563577e24bbe82274ae7b057ec74_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4402062NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f9a632bdc184d86b2d6cf5fa69e05d5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A3352032NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21ba53c9dd5540c5a2f72a1809b358f5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A3002029NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31a5a20370f74b839ba627dfd4b3d6d2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4402062NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2630ed6736474dd7ad352734abf1fa2f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4202052NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff44a3a4194340a88d27d0d51b2c7873_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:DebtSecuritiesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a36e5ea4cc14d90aa07055d396cca6d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:DebtSecuritiesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idff629d5adce4075abb77d3576767318_I20220224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amgn:AcceleratedStockRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="financial_institution"><xbrli:measure>amgn:financial_institution</xbrli:measure></xbrli:unit><xbrli:context id="i3919d433c5e54fd389f1bef01f418e40_D20220225-20220225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amgn:AcceleratedStockRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-25</xbrli:startDate><xbrli:endDate>2022-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i303708e74aba47d6a736f376e0cd1a13_D20220225-20220225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amgn:AcceleratedStockRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-25</xbrli:startDate><xbrli:endDate>2022-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10398ced71924f51bd433d3c641763e9_D20220225-20220225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amgn:AcceleratedStockRepurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-25</xbrli:startDate><xbrli:endDate>2022-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8752374757e479e9f64772ff1f4f9d4_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i264013b24e074db8b98a0699c239c4f9_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52e8d46fd29746e58d0e0bb604659f08_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i189dc1dfd5134a79a21430cb309a4d7a_D20220908-20220908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-08</xbrli:startDate><xbrli:endDate>2022-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d05e9eee4b64b31a25be9b446338707_D20220803-20220803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-03</xbrli:startDate><xbrli:endDate>2022-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9484214322149e8b56269486f6b1ee4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if90bc40ab2b74d9dbd7c8dc2378a4c5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i382be9663b374e42986e34c6b0cdaf0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7795fae62ffe42149d98ac8e3ee9adbc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibabad0c6499641edbeeabb37b49f2923_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5d912228ba649bfa2382a61c3174651_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08706db8953040b6812a751e8ae1b7e5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbe6768ff04b4640811983e177893ea9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd1b9d5af30a49189ced97fd5f9e0133_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd33995f144e48e6b6a85f69a49618b2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iececd00ead734bc7953b31ce1dccf7c9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90991e5bbd4f4703b8dab237d26ea063_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i933f3aa296ae418cb60f3b9a2da33c77_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b5fae63890c4e3292f6b182d8cf346f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b9fd427a0844181b055f4681aa465eb_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9548198fbd6c4177a20e2e6fba7e0baf_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f01a7222c3f477bb69c5b052545fbe3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd86ccb60742427aa61efd89dc5c4569_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecaa227f3a39471dbc0f18d223f8c464_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9808b39aaba54cfe9085c0980d313291_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff08a60f020c476cb26a704e747e026e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i156bec7df7e34d13b4f231715e12f0eb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id98e2a58d5f74741901a136b5593f566_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22e704ef21944a4b8eb938e4ffb99c17_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd26454e121845348d3b36a5d5d0b4be_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47f60abf400d4a86a9f3744f80bddf28_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7cce2fc95f840d0b58664ae7a9a19fa_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e40834754cb4ae7a332ab8f335a1c40_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03282f9364de4789b96025daf0d0ef74_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74c469c59c124e739fad89b0a0b0f7c7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae85a32427df4f04989f60eeef9b6bc4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00193fbac18e466684ae5e311d84cef6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d8850f784604d6b9bb2fd280095d18b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fd9a5ddb9454b129635afe3c05a87b2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee625aa2538245daa9d87d5a6f0f740d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57af36ff3831468c82ff7231dc809b4d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19fefe53694c4ef6b89048ac7afd4735_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i750f10007cf9428abc683565238431dc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15ca62a1ecc1459f914da217c657d346_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c3901a0af154ac48cb709ae944a36f3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57e8da8b9b31484fa254b68594a6327e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if220d1f3f0f04912b6ba27cf16233cd1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9fc102b18f140a29f8db148f3f14ac1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38493d297caf42bf8a474b00e8ce8499_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a9e16b4969645dc80f505eee050d8e6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81f067b439ab417c9ce2795ab841e2d7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46910804ec6546fe9f243b43a084cef9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54880ede06014f8ca9a628fc84c50f6b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91f42a5f589a46f1b73dde5f4b870252_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9182dc5218b74eb7a8e483c65d0897f3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i475adb709d5446f3a4125df7b276f9fc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f0e7a2ada564f7eb301bda6685da54c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if67bff899732472c854d894bb8a6b451_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia55251a67abe461c8b2a09b5a3574ab5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4724b1086cb34ab18e734978bd980565_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9146fbc7ea114428b4ba02cee98c579f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6874786949604cdb824d234c3030e75b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida17f2fa3cec491f86e599ca3185753d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c488f99cfba482dbefc73db9e50c640_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i685a8a148b704128a60fc78026d3c3e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic144f91dd75648e08f88041119a4fa00_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f08e0fe42834efe92d00613a0109c40_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8095682c0ef94a339c9e762b31198d03_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9021916491244d8fa2e070974be57f65_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9240e5bb1cb44e2e876685572c682103_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a563d28d08546408272809d7d6f60af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82eeb36d97d54dd1ab070623986e163d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedac67f993dd44d1a1c0c76f6096b1f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cb7f0273f314f8b830b51cffab82493_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if090df5bf17a41b3ac64e37545266583_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcec0bd4ab8240e38c59d5eba500ac8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95983e1a9dd248b6b5a91e82d2e18001_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i586c22e74161448191ba0b644c8f9eb0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bcba3fb9ae4401d8255f9419a4e9c3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36abb6d1f7574e63a06ec93cd761c060_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06ded0f429164b4ab474c99ae4db6e67_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14f51ae9652c4b4a9742afd91ac81e98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fe78984bfd5425d996816c13821a305_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib54f0b981864432aa40974753a26ac20_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6d1947469e94aadb86219cbb136c914_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i565eb34bf7064ea880a5c569316793d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc87b99380f9465fa749f246800d3c48_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3107f183897d4d47b3ae8ba81bc93c54_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i821465fc68c64ed594b4983fbb106d7b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib38d2c2296ce4775b07ee5a0181057d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2680f1cd22d24318b9fcb7fe45f7425b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefbf65ab82c24adaa0645594dc8fcaff_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8defa2bdb0084af3ae0cbfc5424bc98a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8362dfe3f447487fbcfb592560763e40_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i981e48d6e4474ce8b890550799a406fd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08fbdbb43e0a42089b7e2cf59e5ef985_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ae26a5ef2c2486bbe9a6346774e6921_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d3a7502c66a4094ac60caad8191426e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id566b59cbf154fdeb60a87ca0ef35553_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15d64ffdd06846b7844fc0773809a605_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic91a7bb478ff4fdcb59d644e21f41580_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i007735ddc25943c782bd306e4842d7e1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i218f08d9675e4f2a93d071febe505805_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i312524090a284ea3a18c66e1488acf48_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia79d481c2b0649f0ab76519c77d951cc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68137429bba74ac28b0ecf3eb2d7ec4c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d3fea5388d64fee80f159215bb2ffe9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78bda1111d894ca79b9e9971a476802a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i805f5c4cbf16443d9484e17037e0cf71_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8c48198203049e49f74000350f415ed_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id07132e210b94637823a00632d45e34d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85524ff13c9e4c88a235e0f4342b1c43_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcaf04737d1f428b931744a248c8be92_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ecd36ab401a4e70a51c743fc9ccdc8d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11dede7c485142b591bf4c1b589d93f5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8017a33df2447cf98803b972ba03d31_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0b85c703fd14ec3b991cc54cfc7ad38_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ed4d99ca27b46dfb95dbfc0558df5cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8076cfa2bcaa4ab494d93e38c4c28e31_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17d41c6ab5c14f9380e71043309fbdc8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">amgn:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd05bb4763c34ecb8925e75416037ff8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">amgn:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic74bae73be3b45d29ba2975a44af1c97_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ff1b52fa159466d99f80192dcb38c1b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04f12d226beb4801941ee9ae41184a68_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58b1f56bd6014a44b958229d8e11e34c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic08e134f84b54cd59491e20413185c0a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05e8cec02f334b38bc7a7a5dbf123867_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71fb031f34f648488a945f9c0e957284_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d46d6b8233243ecac66f70b9060cbd1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9a2634a12bd4b95b7c8f4f70a665670_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib097da5bd14d41edb20979d3673833c5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife1360142edd4db88451ac7ac6cbba55_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80f9a2035b3f4ef6803a4efbdaae94fe_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60819ab810454638b5cda1c40c6fcbe0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4620a07bcdfd4700a32de4f28a35ac57_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3f981e832314d97a18ace7194dec829_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i214b98a8995d4320b1feccd543454dfb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5f1f9fe211f40d8bb875fcebcc49a34_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibac2494da7b14b1cbcce6502366b8635_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbe23a3b8f0d470c8d4a49d6ccea2fa7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dd87d0fef6646d585035e3b89e9d2db_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i788c2b8522d14ae4b526f2caa3d298ba_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19dc6da2ca134f33b03794a8e15bdc9a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddf4e6ee507f42da9c63527f4cd46ce6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf3a9c3404d34ff4ac73b544cd1e2f86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c607fed913b4d45844cc65fc1906d04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e470b268fb34c43bee67b9119f09613_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bf6cd1b2403422ba77e0a6dc045346f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4eae23293d40463888c07bd1f600a1aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i565b2e8ffb1b400bb11bbac9aa7a32a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05b40e8931544e10b858fc7bf3becffb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3468cc5757b34eb384cc512b95a07626_D20220527-20220527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-27</xbrli:startDate><xbrli:endDate>2022-05-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="argument"><xbrli:measure>amgn:argument</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div id="i710475db76604b05901ef7473465ecf1_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM&#160;<ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGV4dHJlZ2lvbjpmM2U3MWZmY2YyMWQ0YjU5YjI2NzBkYWFhMTQ3OWI5Ml8xODc0_65264df9-5190-4684-a30c-20c86335701f">10-Q</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Mark One)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6MzdjNDFjMTQ0Njg1NDMwOWE3NTdmNWIxZjkyZWFlYmIvdGFibGVyYW5nZTozN2M0MWMxNDQ2ODU0MzA5YTc1N2Y1YjFmOTJlYWViYl8wLTAtMS0xLTEyNzQ1Mg_365ae59f-ae66-48f0-b190-fd721cc753ad">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 25.75pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGV4dHJlZ2lvbjpmM2U3MWZmY2YyMWQ0YjU5YjI2NzBkYWFhMTQ3OWI5Ml8xMzE_28fc9518-af29-4afc-8f90-9022ba1e2c14">June 30, 2022</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">or</span></div><div style="margin-bottom:1pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6ZWFkMTZmYzYzY2U1NDZiNjllNmQzYmUxMGY5OWIwM2UvdGFibGVyYW5nZTplYWQxNmZjNjNjZTU0NmI2OWU2ZDNiZTEwZjk5YjAzZV8wLTAtMS0xLTEyNzQ1Mg_bb617a9c-2bd7-4382-81c9-5d763641609f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 25.75pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commission File Number: <ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGV4dHJlZ2lvbjpmM2U3MWZmY2YyMWQ0YjU5YjI2NzBkYWFhMTQ3OWI5Ml8xODc1_548bb324-a7ac-42af-9a23-56c314f06f59">001-37702</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGV4dHJlZ2lvbjpmM2U3MWZmY2YyMWQ0YjU5YjI2NzBkYWFhMTQ3OWI5Ml8xODY5_e0b9b112-d8c0-45a3-b825-e0375e2a262d">Amgen Inc.</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:1pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6ZGMwNGU0N2M0NWQ3NGIwYThmNjUzODY3OTFjYTA5NGQvdGFibGVyYW5nZTpkYzA0ZTQ3YzQ1ZDc0YjBhOGY2NTM4Njc5MWNhMDk0ZF8wLTAtMS0xLTEyNzQ1Mg_71f27e58-bf67-438e-ab06-a12e0d5b73d7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6ZGMwNGU0N2M0NWQ3NGIwYThmNjUzODY3OTFjYTA5NGQvdGFibGVyYW5nZTpkYzA0ZTQ3YzQ1ZDc0YjBhOGY2NTM4Njc5MWNhMDk0ZF8wLTItMS0xLTEyNzQ1Mg_fba2a36a-031b-4d36-b29c-d9efde3c7460">95-3540776</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6ZGMwNGU0N2M0NWQ3NGIwYThmNjUzODY3OTFjYTA5NGQvdGFibGVyYW5nZTpkYzA0ZTQ3YzQ1ZDc0YjBhOGY2NTM4Njc5MWNhMDk0ZF8zLTAtMS0xLTEyNzQ1Mg_42cc8572-dbfb-4004-ad97-8c9cc53f186e">One Amgen Center Drive</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6ZGMwNGU0N2M0NWQ3NGIwYThmNjUzODY3OTFjYTA5NGQvdGFibGVyYW5nZTpkYzA0ZTQ3YzQ1ZDc0YjBhOGY2NTM4Njc5MWNhMDk0ZF8zLTItMS0xLTEyNzQ1Mg_8fe435e8-e388-4f6e-ad15-44369ab046ab">91320-1799</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6ZGMwNGU0N2M0NWQ3NGIwYThmNjUzODY3OTFjYTA5NGQvdGFibGVyYW5nZTpkYzA0ZTQ3YzQ1ZDc0YjBhOGY2NTM4Njc5MWNhMDk0ZF80LTAtMS0xLTEyNzQ1Mg_8ac92e90-7982-4668-87a4-b1481f226599">Thousand Oaks</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6ZGMwNGU0N2M0NWQ3NGIwYThmNjUzODY3OTFjYTA5NGQvdGFibGVyYW5nZTpkYzA0ZTQ3YzQ1ZDc0YjBhOGY2NTM4Njc5MWNhMDk0ZF81LTAtMS0xLTEyNzQ1Mg_71683f10-e34a-4b49-935d-633a5ee3556b">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:4pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGV4dHJlZ2lvbjpmM2U3MWZmY2YyMWQ0YjU5YjI2NzBkYWFhMTQ3OWI5Ml8xODcw_bac79787-0382-4a3d-a9d1-f6b42cf90a73">805</ix:nonNumeric>) <ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGV4dHJlZ2lvbjpmM2U3MWZmY2YyMWQ0YjU5YjI2NzBkYWFhMTQ3OWI5Ml8xODcx_dec5da73-0a69-42fa-bc85-f806762bdffe">447-1000</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-bottom:1pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"></td><td style="width:42.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i68c22f15a4f2449f827d166633453d03_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6YzcwYmUzODZmMTA0NDNjZThmNWJmODAwNDFjZTNlNTYvdGFibGVyYW5nZTpjNzBiZTM4NmYxMDQ0M2NlOGY1YmY4MDA0MWNlM2U1Nl8xLTAtMS0xLTEyNzQ1Mg_d070c686-85e9-4ace-86cf-dcad9aa1e9ea">Common stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i68c22f15a4f2449f827d166633453d03_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6YzcwYmUzODZmMTA0NDNjZThmNWJmODAwNDFjZTNlNTYvdGFibGVyYW5nZTpjNzBiZTM4NmYxMDQ0M2NlOGY1YmY4MDA0MWNlM2U1Nl8xLTEtMS0xLTEyNzQ1Mg_143005a8-c673-44f2-948e-0a3277eb6853">AMGN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i68c22f15a4f2449f827d166633453d03_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6YzcwYmUzODZmMTA0NDNjZThmNWJmODAwNDFjZTNlNTYvdGFibGVyYW5nZTpjNzBiZTM4NmYxMDQ0M2NlOGY1YmY4MDA0MWNlM2U1Nl8xLTItMS0xLTEyNzQ1Mg_1030c1ed-dba3-4226-9324-af224047cc13">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33b94f8a0ce843a681a635dc7e7fa22e_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6YzcwYmUzODZmMTA0NDNjZThmNWJmODAwNDFjZTNlNTYvdGFibGVyYW5nZTpjNzBiZTM4NmYxMDQ0M2NlOGY1YmY4MDA0MWNlM2U1Nl8yLTAtMS0xLTEyNzQ1Mg_a271f646-719b-4f81-8d9c-7c2c67d2c904">2.00% Senior Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33b94f8a0ce843a681a635dc7e7fa22e_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6YzcwYmUzODZmMTA0NDNjZThmNWJmODAwNDFjZTNlNTYvdGFibGVyYW5nZTpjNzBiZTM4NmYxMDQ0M2NlOGY1YmY4MDA0MWNlM2U1Nl8yLTEtMS0xLTEyNzQ1Mg_9e1b9b9b-6a32-4d8e-869c-66c00d17df63">AMGN26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33b94f8a0ce843a681a635dc7e7fa22e_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6YzcwYmUzODZmMTA0NDNjZThmNWJmODAwNDFjZTNlNTYvdGFibGVyYW5nZTpjNzBiZTM4NmYxMDQ0M2NlOGY1YmY4MDA0MWNlM2U1Nl8yLTItMS0xLTEyNzQ1Mg_5a6e4834-7584-41a1-86b0-70386f9ab0e4">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGV4dHJlZ2lvbjpmM2U3MWZmY2YyMWQ0YjU5YjI2NzBkYWFhMTQ3OWI5Ml8xODc2_34e99a4d-1d9c-48d8-80c9-72c493d349b8">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGV4dHJlZ2lvbjpmM2U3MWZmY2YyMWQ0YjU5YjI2NzBkYWFhMTQ3OWI5Ml8xODcy_1598bf14-1c05-4561-9d8d-af826d57ee60">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:1pt;margin-top:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:29.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.730%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6MGQ3ODU3ZGFjNGI3NDMxMmIwOWViYWQ3OTQyN2E1Y2QvdGFibGVyYW5nZTowZDc4NTdkYWM0Yjc0MzEyYjA5ZWJhZDc5NDI3YTVjZF8wLTAtMS0xLTEyNzQ1Mg_eaf5d86c-983a-442b-9a8d-ff197b9f8970">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6MGQ3ODU3ZGFjNGI3NDMxMmIwOWViYWQ3OTQyN2E1Y2QvdGFibGVyYW5nZTowZDc4NTdkYWM0Yjc0MzEyYjA5ZWJhZDc5NDI3YTVjZF8xLTEtMS0xLTEyNzQ1Mg_f1fe560b-444e-4895-a08a-7a3cb06cbd7e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6MGQ3ODU3ZGFjNGI3NDMxMmIwOWViYWQ3OTQyN2E1Y2QvdGFibGVyYW5nZTowZDc4NTdkYWM0Yjc0MzEyYjA5ZWJhZDc5NDI3YTVjZF8xLTMtMS0xLTEyNzQ1Mg_43a45c94-081b-403f-9a60-07c3f122e1d6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGV4dHJlZ2lvbjpmM2U3MWZmY2YyMWQ0YjU5YjI2NzBkYWFhMTQ3OWI5Ml8xODcz_16879ede-20d1-48b8-b760-a93d914bbced">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of August 1, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="i4cccb85585694ce49af0de31a566d7f3_I20220801" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGV4dHJlZ2lvbjpmM2U3MWZmY2YyMWQ0YjU5YjI2NzBkYWFhMTQ3OWI5Ml8xODEy_6aad1d35-688b-4c9d-b735-a60247adee2c">534,930,850</ix:nonFraction> shares of common stock, $0.0001 par value, outstanding.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-bottom:1pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:8.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page&#160;No.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_10">DEFINED TERMS AND PRODUCTS</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_10">ii</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_13">PART I - FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_16">FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_19">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_22">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_22">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_25">CONDENSED CONSOLIDATED BALANCE SHEETS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_25">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_28">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_28">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_31">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_31">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_34">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_34">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_76">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_76">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_106">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_106">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_109">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_109">42</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_112">PART II - OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_112">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_115">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_115">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_118">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_118">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_121">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_121">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_124">EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_124">50</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_127">INDEX TO EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_127">51</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_130">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i710475db76604b05901ef7473465ecf1_130">57</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined Terms and Products </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined terms</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use several terms in this Form 10-Q, including but not limited to those that are finance, regulation and disease-state related as well as names of other companies, which are given below.</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.661%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Tax Act</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Cuts and Jobs Act of 2017</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANDA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abbreviated New Drug Application</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">accumulated other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASR</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">accelerated share repurchase</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene, Ltd.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bergamo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratorio Quimico Farmaceutico Bergamo Ltda</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ChemoCentryx</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ChemoCentryx, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CMS</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centers for Medicare &amp; Medicaid Services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">coronavirus disease 2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eczac&#305;ba&#351;&#305;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EIS Eczac&#305;ba&#351;&#305; &#304;la&#231;, S&#305;nai ve Finansal Yat&#305;r&#305;mlar Sanayi ve Ticaret A.&#350;.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Medicines Agency</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">earnings per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FASB</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Accounting Standards Board</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Food and Drug Administration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fitch</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fitch Ratings, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Five Prime</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Five Prime Therapeutics, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FTC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal Trade Commission</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. generally accepted accounting principles</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gensenta</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gensenta &#304;la&#231; Sanayi ve Ticaret A.&#350;.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HHS</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Health &amp; Human Services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in-process research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRP</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">international reference pricing</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal Revenue Service</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIBOR</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">London Interbank Offered Rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lp(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lipoprotein(a)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MD&amp;A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">management&#8217;s discussion and analysis</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MFN</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">most-favored nation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moody&#8217;s</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moody&#8217;s Investors Service, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neumora</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neumora Therapeutics, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OECD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Organisation for Economic Co-operation and Development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PBM</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">pharmacy benefit manager</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PTAB</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent Trial and Appeal Board</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RAR</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Agent Report</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">rest of world</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard &amp; Poor&#8217;s Financial Services LLC</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SEC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Securities and Exchange Commission</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teneobio</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teneobio, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Treasury</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USPTO</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Patent and Trademark Office</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UTB</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">unrecognized tax benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The brand names of our products, our delivery devices and certain of our product candidates and their associated generic names are given below.</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:23.386%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aimovig</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aimovig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (erenumab-aooe)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMGEVITA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMGEVITA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (adalimumab)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (darbepoetin alfa)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AVSOLA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AVSOLA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (infliximab-axxq)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (blinatumomab)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corlanor</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corlanor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (ivabradine)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enbrel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (etanercept)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPOGEN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (epoetin alfa)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (romosozumab-aqqg)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMLYGIC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMLYGIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (talimogene laherparepvec)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANJINTI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANJINTI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (trastuzumab-anns)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (carfilzomib)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUMAKRAS/LUMYKRAS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUMAKRAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> / LUMYKRAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (sotorasib)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVASI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVASI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (bevacizumab-awwb)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (pegfilgrastim)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NEUPOGEN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NEUPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (filgrastim)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (romiplostim)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olpasiran</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olpasiran (formerly AMG 890)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Onpro</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Onpro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (apremilast)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parsabiv</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parsabiv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (etelcalcetide)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (denosumab)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (evolocumab)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RIABNI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RIABNI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (rituximab-arrx)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sensipar/Mimpara</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sensipar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/Mimpara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (cinacalcet)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEZSPIRE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEZSPIRE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (tezepelumab-ekko)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vectibix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vectibix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (panitumumab)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (denosumab)</span></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PART I &#8212; FINANCIAL INFORMATION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span><br/></span></div><div id="i710475db76604b05901ef7473465ecf1_16"></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FINANCIAL STATEMENTS</span></td></tr></table></div><div id="i710475db76604b05901ef7473465ecf1_19"></div><div style="margin-top:18pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per-share data)</span></div><div style="text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3c410d6b2f84e53be5c076dec22d865_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMy0xLTEtMS0xMjc0NTI_98efb387-04ef-4729-a1c3-07bc08108a38">6,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d9e005bccc4060bd5addba903c2c2c_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMy0zLTEtMS0xMjc0NTI_277a94a6-1fc3-4231-9c03-7ed1aae99801">6,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38c160a3f1834d5e9d775a1dea85e514_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMy01LTEtMS0xMjc0NTI_2b7895d9-3115-4e52-aca8-3bf5c06f6f46">12,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93db18973157470084da5a577ecb7c40_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMy03LTEtMS0xMjc0NTI_9d933c45-ae49-4f60-a9a8-fb0f2099e382">11,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e71b4283ef4881a494fede3403b36c_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfNC0xLTEtMS0xMjc0NTI_8ec274aa-f1e2-4633-b0cc-d1749f3f8ea1">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768868bd3bfe4a65a96efee550cef847_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfNC0zLTEtMS0xMjc0NTI_c9326106-8dd7-4110-9d63-2c0643f29be6">412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43a801ced92f421e934618c8046f564b_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfNC01LTEtMS0xMjc0NTI_c4607a90-be65-47b6-904c-7eca4af12cea">820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bfeed5ecca54e718c3e7aefb7714ac5_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfNC03LTEtMS0xMjc0NTI_2edfd645-a07a-436b-979d-6e2dfabf7c04">721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfNS0xLTEtMS0xMjc0NTI_b16b39aa-577f-4daa-abc6-d353b30eb2a4">6,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfNS0zLTEtMS0xMjc0NTI_48219afd-faec-4ae6-a460-0d6c74e36385">6,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfNS01LTEtMS0xMjc0NTI_42632cb5-f949-434c-a578-e623bd92ed3d">12,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfNS03LTEtMS0xMjc0NTI_2bb1f981-ed65-4325-88e9-507edc22801f">12,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfOC0xLTEtMS0xMjc0NTI_2ad45c8c-3a76-4907-a088-bcc6bfa54c39">1,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfOC0zLTEtMS0xMjc0NTI_effc166a-4125-4b32-8221-09718a859d6b">1,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfOC01LTEtMS0xMjc0NTI_dca94957-1cb3-4825-aea4-c262676081b4">3,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfOC03LTEtMS0xMjc0NTI_0fddad2a-a882-4bf8-8c3a-0d69faa666d9">3,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfOS0xLTEtMS0xMjc0NTI_16529007-cc7a-4188-87f6-629405df75b4">1,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfOS0zLTEtMS0xMjc0NTI_e06ff0ee-c1d5-4cf4-be33-f241357a7a5c">1,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfOS01LTEtMS0xMjc0NTI_c5e53584-be1c-4a60-82c7-7d31cc53f747">1,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfOS03LTEtMS0xMjc0NTI_ccd7e0cc-23e3-4cc1-9595-357d8d5231fb">2,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTAtMS0xLTEtMTI3NDUy_81df8c4b-da53-4bad-b868-be96ef4f775b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTAtMy0xLTEtMTI3NDUy_1a6c607d-6b9d-45b9-800e-da292ab0f540">1,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTAtNS0xLTEtMTI3NDUy_f70a66f8-ad5e-49d3-9c00-0b6686c899a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTAtNy0xLTEtMTI3NDUy_e0932dfe-6d2d-4056-a3d0-27f87d6b36bd">1,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTEtMS0xLTEtMTI3NDUy_351ebcfd-4a89-456e-928d-939b8f170a0e">1,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTEtMy0xLTEtMTI3NDUy_0cf80638-3085-4f87-bbb7-e021d8ddeade">1,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTEtNS0xLTEtMTI3NDUy_6cb112da-5a05-41ae-bade-76f79507f7da">2,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTEtNy0xLTEtMTI3NDUy_f36fe1b1-8af5-4d9a-ad9b-9c86ab2b08ef">2,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="amgn:OtherGeneralExpenseIncomeOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTItMS0xLTEtMTI3NDUy_f0f26eb3-5cfe-4c5a-8437-7a5f4e2df5f3">542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="amgn:OtherGeneralExpenseIncomeOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTItMy0xLTEtMTI3NDUy_97093fff-d110-4e78-9916-36446f2c9fa5">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="amgn:OtherGeneralExpenseIncomeOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTItNS0xLTEtMTI3NDUy_0a3bed7c-3b8b-494c-94bf-b444e83f2f8f">532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="amgn:OtherGeneralExpenseIncomeOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTItNy0xLTEtMTI3NDUy_27818426-5dda-45d8-aa5a-5cdd09a2792f">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTMtMS0xLTEtMTI3NDUy_3b798ac7-ed45-4a6f-9ae8-4969b7d2064f">4,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTMtMy0xLTEtMTI3NDUy_159b9a6a-3415-4e05-9159-3a949daa5142">5,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTMtNS0xLTEtMTI3NDUy_af97711b-6961-41a5-a648-dbb389a0cf89">8,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTMtNy0xLTEtMTI3NDUy_4ec231fc-e621-4907-89aa-02a861cba3df">9,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTUtMS0xLTEtMTI3NDUy_4c0958fd-0ff2-479f-af24-0d41efe211d5">2,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTUtMy0xLTEtMTI3NDUy_fa33458f-147d-4bb1-80dc-0451833b3459">828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTUtNS0xLTEtMTI3NDUy_8ab32a19-e833-42a6-8c97-4c914791781f">4,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTUtNy0xLTEtMTI3NDUy_6fbd5c48-36e7-4ca7-ae23-199a0b675754">2,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTgtMS0xLTEtMTI3NDUy_370ef145-871a-473f-bb68-c69c2b4bb002">328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTgtMy0xLTEtMTI3NDUy_59f9e2a1-9fbc-40ed-8bfc-c6371c615ce1">281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTgtNS0xLTEtMTI3NDUy_f4c9b540-2312-4165-a189-9ef5cb00535c">623</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTgtNy0xLTEtMTI3NDUy_f4767d5d-688a-4027-9850-b85d21d5edf3">566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTktMS0xLTEtMTI3NDUy_ae9c9671-aaba-4635-a022-28135a680f5e">317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTktMy0xLTEtMTI3NDUy_70bc1e7f-0cfe-4fe8-b3e3-5ff994aa7f48">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTktNS0xLTEtMTI3NDUy_bd5a938f-8f70-4c8b-a1f3-48d0b7f2506e">847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTktNy0xLTEtMTI3NDUy_0644a077-eff2-46eb-a967-4ebb22c32384">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjEtMS0xLTEtMTI3NDUy_8ab80e89-f22d-4a9a-9cdb-4b089c6cfbb8">1,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjEtMy0xLTEtMTI3NDUy_c27b88b0-81d3-4921-9b1a-d964d563d9c0">558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjEtNS0xLTEtMTI3NDUy_f3e15de9-8828-4e57-9a83-6d76cde58171">3,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjEtNy0xLTEtMTI3NDUy_089eb8f8-d4f1-41e9-8d23-b8f8dac0a1cb">2,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjMtMS0xLTEtMTI3NDUy_f7dab70f-cfa1-4bdb-b3e0-4188ad7be269">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjMtMy0xLTEtMTI3NDUy_58f52ee1-aeeb-411b-af5e-17ec8802bf6b">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjMtNS0xLTEtMTI3NDUy_d581e9bc-8f49-4c80-8973-b7dcca2d6b50">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjMtNy0xLTEtMTI3NDUy_ebf24536-5812-4cdb-adf4-338b6a452c18">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjUtMS0xLTEtMTI3NDUy_eed72fdd-fa49-4f6b-8634-c30f9b86eec5">1,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjUtMy0xLTEtMTI3NDUy_7705fe85-60a5-4897-9e40-138363e3aae4">464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjUtNS0xLTEtMTI3NDUy_e5e578c6-7f14-481f-8a08-fbaf41b57de6">2,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjUtNy0xLTEtMTI3NDUy_706a3cf2-5c97-4e9f-b4f2-011745b75d78">2,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjgtMS0xLTEtMTI3NDUy_19af39e8-f63b-4a54-ba22-57c5a086da9c">2.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjgtMy0xLTEtMTI3NDUy_f759bc9e-3472-442b-9bfe-daf8d0db779b">0.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjgtNS0xLTEtMTI3NDUy_05a7d363-c342-4348-b36a-974c86c89cdf">5.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjgtNy0xLTEtMTI3NDUy_9c24efa2-7409-4318-a2a2-e0c765df5cea">3.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjktMS0xLTEtMTI3NDUy_bf4dc8ea-3174-4e71-bfb3-4e2ee44793ad">2.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjktMy0xLTEtMTI3NDUy_b58d0705-53b8-49dd-a955-bca176b1f2cc">0.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjktNS0xLTEtMTI3NDUy_d3ac1ab1-fca7-48fd-bcc4-278dd55bdaee">5.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjktNy0xLTEtMTI3NDUy_4eb6c7b2-aaf6-4b81-8174-dbca2138e740">3.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in calculation of earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMzItMS0xLTEtMTI3NDUy_7dfd1b00-21da-4e05-957b-87663292194e">535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMzItMy0xLTEtMTI3NDUy_5af9f16d-c0a2-499f-be31-490f7ddc7046">573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMzItNS0xLTEtMTI3NDUy_faeaed5d-a971-4fd5-9be5-4081239cd867">541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMzItNy0xLTEtMTI3NDUy_c3f14bf2-3f68-486f-b1c9-cb53ab19c34e">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMzMtMS0xLTEtMTI3NDUy_af9e7b0d-a61c-4302-ba8d-ff111ce9e38a">537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMzMtMy0xLTEtMTI3NDUy_ec288214-d128-4333-bce6-5c6282bb3024">576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMzMtNS0xLTEtMTI3NDUy_3ac2b002-586f-4680-86a2-2d3273878f71">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMzMtNy0xLTEtMTI3NDUy_09aef0fe-052d-4565-ae09-297b91c266f3">578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfMi0xLTEtMS0xMjc0NTI_7cffa87f-2b82-45e6-bc2e-f70198802ac5">1,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfMi0zLTEtMS0xMjc0NTI_c0b1b612-8fae-4c72-af79-c267865b9de9">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfMi01LTEtMS0xMjc0NTI_629c2393-37bd-4591-b56d-f62fc5b4a218">2,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfMi03LTEtMS0xMjc0NTI_626ba5ea-6066-408a-8dfe-68063acf0ab1">2,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of reclassification adjustments and taxes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNC0xLTEtMS0xMjc0NTI_fc822e82-046a-4c98-a30b-32c75fae150d">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNC0zLTEtMS0xMjc0NTI_0665f817-3836-4cee-9f29-7b77e3ff76c2">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNC01LTEtMS0xMjc0NTI_811ff15b-a01b-42b6-99fd-e94b1ba1751a">116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNC03LTEtMS0xMjc0NTI_3050cc2e-ad90-45ad-8bcc-62f6f82ebb61">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNS0xLTEtMS0xMjc0NTI_8b162bfa-664b-49d2-80e0-400d9c24bdc4">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNS0zLTEtMS0xMjc0NTI_510d7ad5-e127-4b2b-9ec4-de6fc8664b6a">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNS01LTEtMS0xMjc0NTI_9e370018-d03d-4e93-a108-d2a1ff104796">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNS03LTEtMS0xMjc0NTI_ec26bd93-00f7-4e58-a1e3-87f5fc0ea247">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNy0xLTEtMS0xMjc0NTI_ab3b9428-c86e-4650-a915-5c5d60fd9e9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" sign="-" name="amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNy0zLTEtMS0xMjc0NTI_e54340a1-e2b6-4737-b8d1-83d0de129f00">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNy01LTEtMS0xMjc0NTI_63289549-fd48-45b4-9f0b-d28c3f2d6287">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNy03LTEtMS0xMjc0NTI_b6de968c-6f4b-4034-a192-d0a7f3931a40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of reclassification adjustments and taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfOC0xLTEtMS0xMjc0NTI_6ff93743-5ed6-4766-88d2-a5f0d7773959">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfOC0zLTEtMS0xMjc0NTI_22f48b1c-a4fc-4374-8c51-fd147d6a7e6d">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfOC01LTEtMS0xMjc0NTI_e32a9905-2ae2-4745-b983-9d0fca285f9d">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfOC03LTEtMS0xMjc0NTI_b9aa64d1-0284-4b11-b391-3b6f3962ae2c">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfOS0xLTEtMS0xMjc0NTI_4ad31b9b-4757-4a61-b2d2-046e2dedf8d6">1,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfOS0zLTEtMS0xMjc0NTI_e4b63295-9f1f-44fe-96a2-fab5893ee433">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfOS01LTEtMS0xMjc0NTI_3e55a7d2-705e-4293-8450-ea5fc77c009c">2,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfOS03LTEtMS0xMjc0NTI_57eea8ae-1b7f-499f-9c3d-51949cd12ce2">2,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per-share data)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfNC0xLTEtMS0xMjc0NTI_444fabd4-fc76-4f79-8c21-120d30b723a6">5,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfNC0zLTEtMS0xMjc0NTI_69f8301e-90be-495b-986d-9895bca18f1a">7,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfNS0xLTEtMS0xMjc0NTI_c0d4016e-5241-4a41-86af-3ef9600c8c9a">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfNS0zLTEtMS0xMjc0NTI_6c629c4c-5804-4d0f-8440-368e623d2446">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfNi0xLTEtMS0xMjc0NTI_71e9fee8-dac7-4515-b414-dd65314c6e2c">5,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfNi0zLTEtMS0xMjc0NTI_4315544c-92df-4999-8550-ed53e4fa8528">4,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfNy0xLTEtMS0xMjc0NTI_c907aaea-edda-4c8e-8b89-bc9ef519a2a9">4,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfNy0zLTEtMS0xMjc0NTI_4924663a-1677-4776-a630-c6e73756232f">4,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfOC0xLTEtMS0xMjc0NTI_4dda1006-4a2e-42c0-9454-a7c660e28095">2,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfOC0zLTEtMS0xMjc0NTI_57bf1d0f-b6d2-4240-b1df-c31d9e46fcb6">2,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfOS0xLTEtMS0xMjc0NTI_1a0d0dd4-6849-45f0-aac0-27dfe6317667">19,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfOS0zLTEtMS0xMjc0NTI_528c96c1-07a4-430e-8a52-05aec032451b">19,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTEtMS0xLTEtMTI3NDUy_5d2213b3-04d5-476c-b664-62a708eda5be">5,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTEtMy0xLTEtMTI3NDUy_2a11bbc2-2ac9-428c-9e02-0de5f489bb99">5,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTItMS0xLTEtMTI3NDUy_bbe8b7bd-6616-465b-a296-25d51540e9c1">13,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTItMy0xLTEtMTI3NDUy_686e098a-4093-4b72-90e4-35d1a23cbba7">15,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTMtMS0xLTEtMTI3NDUy_f7b1aa3d-2e1b-4184-a5c0-b9ecccc859f9">14,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTMtMy0xLTEtMTI3NDUy_6a0c1239-7b22-4881-b2d2-4e0f3a2ed210">14,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTQtMS0xLTEtMTI3NDUy_01c1887d-889a-49d0-8162-8e5ba0b8f08d">6,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTQtMy0xLTEtMTI3NDUy_01a5ca52-2446-4895-a701-d2b3ea37b8af">6,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTUtMS0xLTEtMTI3NDUy_7845efd1-b67b-4b44-9535-256738c1017e">59,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTUtMy0xLTEtMTI3NDUy_335f11a0-2ccd-4189-8066-930fba4cf8be">61,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTktMS0xLTEtMTI3NDUy_038e3e28-1e77-4abe-84c9-ea2e13c6779d">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTktMy0xLTEtMTI3NDUy_f3c9e786-24c8-4ca5-b1fe-822981902558">1,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjAtMS0xLTEtMTI3NDUy_60b1c2da-689f-440e-8eff-2cf865bf005e">10,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjAtMy0xLTEtMTI3NDUy_32bd112a-7472-4b8e-8d0d-fc02a0a76625">10,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjEtMS0xLTEtMTI3NDUy_58968aaa-11d4-4c60-ad41-75ec55d26fda">817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjEtMy0xLTEtMTI3NDUy_2d47bed5-ffdf-45ca-ad70-dae39060b283">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjItMS0xLTEtMTI3NDUy_b9d151ab-578f-41ca-8beb-5e0aee08371c">12,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjItMy0xLTEtMTI3NDUy_c529fa6f-f865-43c7-8e05-263f6ed4c4cd">12,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjQtMS0xLTEtMTI3NDUy_3d2cf386-8598-41fa-bf0d-8f946a3b07e5">35,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjQtMy0xLTEtMTI3NDUy_679d2ab2-5273-47bb-a461-1648aed10f76">33,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjUtMS0xLTEtMTI3NDUy_ea15d1ef-1823-43b4-8e83-66b46e3ccd5f">5,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjUtMy0xLTEtMTI3NDUy_5aa3ae72-4417-4416-88e5-487a552678dc">6,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjYtMS0xLTEtMTI3NDUy_0e2b092e-af48-4859-bc59-8b883459bc54">2,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjYtMy0xLTEtMTI3NDUy_b3cc6dc3-8287-412f-a090-b35ba74fb54f">2,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingencies and commitments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjgtMS0xLTEtMTI3NDUy_ef96204b-1f43-42f9-8436-0ba0a19a913a"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjgtMy0xLTEtMTI3NDUy_0936be25-2ca2-42ae-9cc1-d7c8238e1dc4"></ix:nonFraction></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock and additional paid-in capital; $<ix:nonFraction unitRef="usdPerShare" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzEtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZTgyZGZjMzRiZjdkNDIyZjliMzE0YTBiNTQ2ZTQ0MGFfNDk_1179f78a-e566-493e-bb13-16d0d2c83305"><ix:nonFraction unitRef="usdPerShare" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzEtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZTgyZGZjMzRiZjdkNDIyZjliMzE0YTBiNTQ2ZTQ0MGFfNDk_8c54805f-7110-4941-a70f-24508309fb03">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzEtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZTgyZGZjMzRiZjdkNDIyZjliMzE0YTBiNTQ2ZTQ0MGFfNjM_08dcdff6-1983-4b68-8057-3e36b148ed85"><ix:nonFraction unitRef="shares" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzEtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZTgyZGZjMzRiZjdkNDIyZjliMzE0YTBiNTQ2ZTQ0MGFfNjM_239e9515-bfb7-4afd-968a-d91717ca51bb">2,750.0</ix:nonFraction></ix:nonFraction> shares authorized; outstanding&#8212;<ix:nonFraction unitRef="shares" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzEtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZTgyZGZjMzRiZjdkNDIyZjliMzE0YTBiNTQ2ZTQ0MGFfOTc_937917b9-9e00-4b50-bd85-c97fe1bc0f8a">534.9</ix:nonFraction> shares in 2022 and <ix:nonFraction unitRef="shares" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzEtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZTgyZGZjMzRiZjdkNDIyZjliMzE0YTBiNTQ2ZTQ0MGFfMTE3_d54d4b36-2eba-4751-9779-0a99ded23e3b">558.3</ix:nonFraction> shares in 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:CommonStocksIncludingAdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzEtMS0xLTEtMTI3NDUy_addd95e6-bd1e-4854-811d-f173dfacbf5c">31,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:CommonStocksIncludingAdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzEtMy0xLTEtMTI3NDUy_e4a42bc9-8b7d-4ffb-90a4-78bf4aa18ac7">32,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzItMS0xLTEtMTI3NDUy_785ce116-a1c3-4bad-9517-b516c021a51e">28,252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzItMy0xLTEtMTI3NDUy_77445216-a6fa-4dd4-8f2f-cc11317c2efb">24,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzMtMS0xLTEtMTI3NDUy_5dcdaacb-d7bd-4f80-b4bb-00003075f2a0">672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzMtMy0xLTEtMTI3NDUy_0f5a33e2-3a46-4e8c-a256-c6c163de2e96">796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzQtMS0xLTEtMTI3NDUy_0396b42b-a866-4e66-9944-002eaf6bc75d">2,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzQtMy0xLTEtMTI3NDUy_6da657fc-9b2d-403e-83fa-40fe1ec3cd8f">6,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzUtMS0xLTEtMTI3NDUy_281aca3b-2e09-4910-a081-3e4cbfd099ef">59,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzUtMy0xLTEtMTI3NDUy_5f9a880b-b17d-46f1-844e-8a3ed78af465">61,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per-share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:40.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares<br/>of&#160;common<br/>stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>stock and<br/>additional<br/>paid-in&#160;capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ab9a3aeb1dc401e8f8036824d7fc7ec_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMS0xLTEtMS0xMjc0NTI_ca8d810f-c64f-4d0a-aac7-d0ed22f4c11f">558.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie57786644af74fb49b8f5e29302dab93_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMS0zLTEtMS0xMjc0NTI_cc141bb2-9992-4224-93b5-603b42dc569f">32,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id600cdce916f4b66a8dcd23e38e899e3_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMS01LTEtMS0xMjc0NTI_38b1d731-ca07-4c80-b9ac-79e02d769dff">24,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4015add6967846b88c70abf91e4bfcd3_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMS03LTEtMS0xMjc0NTI_dc29c20c-20e7-4079-8cca-5075767d4227">796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMS05LTEtMS0xMjc0NTI_f52649b1-56d3-4832-a710-3cf98eadb34e">6,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bdfa7c23e874b22a1a66bebad22d916_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMy01LTEtMS0xMjc0NTI_5e44f545-13bd-4c88-93cf-9d9a2c184984">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMy05LTEtMS0xMjc0NTI_7d1a5091-69d5-48f3-9c71-b16e120bc15f">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6bebabfe867463fb2ce8c41e89ce28a_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfNC03LTEtMS0xMjc0NTI_c0009812-7249-4cd1-a539-072705017800">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfNC05LTEtMS0xMjc0NTI_c69aae70-5c52-4e7f-b3e9-10540154984a">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfNS0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjplNWYyZDI5ZTYyZmI0NzM0OWVkNmY4YzRiYmY0NmMyMl80MA_2d0b1579-f392-4494-83b7-bfceada9bf00">1.94</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bdfa7c23e874b22a1a66bebad22d916_D20220101-20220331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfNS01LTEtMS0xMjc0NTI_167685bf-0a5a-473f-a775-ca9d902a89ef">1,034</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfNS05LTEtMS0xMjc0NTI_6e168e3f-d80a-43b3-8f16-72e3ce3e0557">1,034</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the Company&#8217;s equity award programs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i727569817ab94b17a5a44e5e6554f39c_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfNi0xLTEtMS0xMjc0NTI_eea95bb5-6156-47b6-9469-74e604971fe4">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib84a6f83e673473a8ba69ec165a6aa32_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfNi0zLTEtMS0xMjc0NTI_0072a3c3-864a-4563-920d-48690a4ba0cc">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfNi05LTEtMS0xMjc0NTI_51644693-5230-48d0-b696-b98284b96776">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib84a6f83e673473a8ba69ec165a6aa32_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfNy0zLTEtMS0xMjc0NTI_e82b324c-9eb7-43a9-b2e5-6b56e9a6314e">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfNy05LTEtMS0xMjc0NTI_e475f886-f435-423b-bfb1-b08deb3717cc">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax impact related to employee stock-based compensation expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib84a6f83e673473a8ba69ec165a6aa32_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfOC0zLTEtMS0xMjc0NTI_9b42f4c7-e534-4d7f-9e01-68f8708df597">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfOC05LTEtMS0xMjc0NTI_87509713-75f9-413b-b8b5-bf6b11272238">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock (Note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i727569817ab94b17a5a44e5e6554f39c_D20220101-20220331" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfOS0xLTEtMS0xMjc0NTI_4085422f-f112-4588-ae0d-65cc0846ac31">24.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib84a6f83e673473a8ba69ec165a6aa32_D20220101-20220331" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfOS0zLTEtMS0xMjc0NTI_50f69e5e-1fc9-44db-a6bf-470f2765cc8c">900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bdfa7c23e874b22a1a66bebad22d916_D20220101-20220331" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfOS01LTEtMS0xMjc0NTI_9b53439d-925b-41ff-a6fa-349846072f93">5,410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfOS05LTEtMS0xMjc0NTI_f9e8d8f9-b78f-4238-8444-d9f459c1a202">6,310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1743609e3cdb4aee821e866d6c0b7a5b_I20220331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTAtMS0xLTEtMTI3NDUy_e1458fa0-a70e-4dbb-82ec-d82edf049bbc">534.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia449403700e84ad390099f266af55696_I20220331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTAtMy0xLTEtMTI3NDUy_2dc91e6e-9b78-4c60-bb48-ba64e90e639c">31,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib52f0a890ada46f0aaeaa5f7a392c87f_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTAtNS0xLTEtMTI3NDUy_b7ff808f-f0c3-4ec6-b757-76607f6b2c92">29,568</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3453133454bb4b68987a91d14ea8ccda_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTAtNy0xLTEtMTI3NDUy_73555a5e-938c-4683-ba32-47fd272cc8ce">763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de403afe8684433ba669a9d329718c4_I20220331" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTAtOS0xLTEtMTI3NDUy_637c8cd1-6253-49ba-af90-d1802fbf0aad">916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c56073392354d1aa5fe73191ec6a1cd_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTItNS0xLTEtMTI3NDUy_15c7800c-1dde-4be6-aaca-b05208aa283b">1,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTItOS0xLTEtMTI3NDUy_02976f69-b76f-4ade-b85a-1c4db4101873">1,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950254b1c906440baad1c3cb0d696509_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTMtNy0xLTEtMTI3NDUy_56b134b9-758e-43d5-b8d8-7c3c41fe345f">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTMtOS0xLTEtMTI3NDUy_a77c9249-fcdb-4c22-8820-6cacbf6c8fec">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the Company&#8217;s equity award programs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib013f6621b494621aa9fdc2ca2c9a16a_D20220401-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTQtMS0xLTEtMTI3NDUy_7a926c65-74a5-400b-ae05-a7d12cab2306">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i437ad630ad5c4d0db3b941130901471f_D20220401-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTQtMy0xLTEtMTI3NDUy_0f92cb6b-16f5-4cba-884e-06e7d363cebc">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTQtOS0xLTEtMTI3NDUy_5b4dbf1b-6bdd-48a6-b231-5ca006a1f108">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i437ad630ad5c4d0db3b941130901471f_D20220401-20220630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTUtMy0xLTEtMTI3NDUy_f1062324-f191-47e0-84e2-d5df31339d0a">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTUtOS0xLTEtMTI3NDUy_8ac70314-e917-4054-a994-3bac7b005399">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax impact related to employee stock-based compensation expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i437ad630ad5c4d0db3b941130901471f_D20220401-20220630" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTYtMy0xLTEtMTI3NDUy_70413ada-d0b2-4197-8629-246a6a1bc4e9">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTYtOS0xLTEtMTI3NDUy_9fbc18f8-246a-4856-acee-a1ade38d8cab">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c56073392354d1aa5fe73191ec6a1cd_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTgtNS0xLTEtMTI3NDUy_c69f909b-7f26-44ad-86a1-f92e3e2344dd">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTgtOS0xLTEtMTI3NDUy_05a01d80-397e-490c-bafa-f0218e061c09">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69e8f109a2db495c82bf5845b27d710b_I20220630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTktMS0xLTEtMTI3NDUy_fa226af8-98b0-4f0b-93c7-34cd3a14f57e">534.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa04a5eecd554471bd742d77f0241ab8_I20220630" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTktMy0xLTEtMTI3NDUy_38cc8bf9-a855-4fc3-bcf2-b47a638daa85">31,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e8fdc8e1afb4a8b8179c89009d5c1aa_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTktNS0xLTEtMTI3NDUy_dfd63f28-2c9d-4cb7-9eb2-6f1131c8bab0">28,252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedbaa8596a604e708e0f5d708642088d_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTktNy0xLTEtMTI3NDUy_05430d6e-1034-4283-a5ec-8f87da7ddce4">672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTktOS0xLTEtMTI3NDUy_70e34e26-b3cf-4256-ae78-7b6868a3621c">2,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per-share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:40.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares<br/>of&#160;common<br/>stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>stock and<br/>additional<br/>paid-in&#160;capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87a50000054d41c4b6c8d975b42b1648_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMS0xLTEtMS0xMjc0NTI_19ff1352-2bd3-4f4e-a04f-635864e50bcc">578.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e3e8fc000224eaa8d179f838cb7031a_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMS0zLTEtMS0xMjc0NTI_0e6c8421-4f77-4e2d-b4f9-535b7da2427e">31,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37f513ac48e244eebc3ecfd6dbf5e0a0_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMS01LTEtMS0xMjc0NTI_783acee0-a9cb-4357-9aba-0c85154c2548">21,408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2639d3c097ee4df19d9460b38ce3c560_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMS03LTEtMS0xMjc0NTI_f60e0f71-a67c-421c-af03-35e4716af305">985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e5bfcd24a084d2ba4ae4e9fd63a2a81_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMS05LTEtMS0xMjc0NTI_658c3c97-c109-4fd3-b64b-f462cbf71f02">9,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaa3e87d3e094c2c82065bdcc86a2d5e_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMy01LTEtMS0xMjc0NTI_96015f44-e570-4b79-b9ce-2b40c2c56e61">1,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i230f8b81d2ba4f069528c27808330841_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMy05LTEtMS0xMjc0NTI_77ea3087-ba27-4546-97c9-da2f78dbad0c">1,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f42e7ad02b549569ea5beaa0e813a56_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfNC03LTEtMS0xMjc0NTI_2020888a-ff34-4ba3-a5c1-e7fe009e1de0">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i230f8b81d2ba4f069528c27808330841_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfNC05LTEtMS0xMjc0NTI_005ceab4-978c-4f33-acdf-245ac2f1f088">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i230f8b81d2ba4f069528c27808330841_D20210101-20210331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfNS0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjpjYzkxNjRkZGJmMDg0N2Q2ODMzOTg5NTdkODA5ODY0YV80MQ_1ab6070a-6e7b-493e-ad58-b54298d7e1f4">1.76</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifaa3e87d3e094c2c82065bdcc86a2d5e_D20210101-20210331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfNS01LTEtMS0xMjc0NTI_f37906e1-2611-48e3-bff3-f71093c62f1d">1,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i230f8b81d2ba4f069528c27808330841_D20210101-20210331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfNS05LTEtMS0xMjc0NTI_470eb2ef-3e9d-470a-93df-173be42b93e3">1,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the Company&#8217;s equity award programs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ff28f2746c54bdaaf782c67ac1f4302_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfNi0xLTEtMS0xMjc0NTI_b484d178-13b2-4f7b-93d3-a350f182e38e">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96efcc5351148e2b1ec0411f0edc1ba_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfNi0zLTEtMS0xMjc0NTI_542950ac-2fb8-49ba-83a9-55f4aaefe501">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i230f8b81d2ba4f069528c27808330841_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfNi05LTEtMS0xMjc0NTI_d534c392-2826-455b-b1e1-1782eeda8ed7">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96efcc5351148e2b1ec0411f0edc1ba_D20210101-20210331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfNy0zLTEtMS0xMjc0NTI_0ce1e85e-dc15-4499-a597-baa3ba110835">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i230f8b81d2ba4f069528c27808330841_D20210101-20210331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfNy05LTEtMS0xMjc0NTI_9bf4ec7c-f4b3-42d3-a625-4f6a8b9cf513">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax impact related to employee stock-based compensation expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib96efcc5351148e2b1ec0411f0edc1ba_D20210101-20210331" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfOC0zLTEtMS0xMjc0NTI_2f2bfbe1-57a2-42b4-91e3-f15dbc399726">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i230f8b81d2ba4f069528c27808330841_D20210101-20210331" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfOC05LTEtMS0xMjc0NTI_4d0deef2-28ac-40b6-9007-80222207ba9d">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2ff28f2746c54bdaaf782c67ac1f4302_D20210101-20210331" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfOS0xLTEtMS0xMjc0NTI_381b8623-acdc-48bf-8dbf-f905ab027ab5">3.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifaa3e87d3e094c2c82065bdcc86a2d5e_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfOS01LTEtMS0xMjc0NTI_19b36ef5-1332-4331-a9e2-9d5192eff93b">865</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i230f8b81d2ba4f069528c27808330841_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfOS05LTEtMS0xMjc0NTI_94634e65-9e39-49d8-b27e-e2e99fbba96c">865</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac25314d738441bd880294e17a40ea59_I20210331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTAtMS0xLTEtMTI3NDUy_ab23d296-91b6-4eef-9533-7111f963308f">575.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1a08827c17347a29bf672041a9ba9ab_I20210331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTAtMy0xLTEtMTI3NDUy_d78c3882-d197-4c04-86cd-a9ccd8ce613a">31,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34f2d24ef5604859814eae53b155dccc_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTAtNS0xLTEtMTI3NDUy_0a9128c1-aef3-4373-9b65-4c3ac5b23091">21,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07da672f055a4104b16e0910367ec926_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTAtNy0xLTEtMTI3NDUy_f1ebc290-3562-4639-a1ec-6a0f1e2dc5c5">833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a2ab422b4b24a8fba8a2d881b98b260_I20210331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTAtOS0xLTEtMTI3NDUy_33d77b6f-d25d-43fb-9ba1-58090b640507">9,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i722f5ea9afa642bf9d0d9d90efe8e13a_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTItNS0xLTEtMTI3NDUy_ec53b806-eb35-405e-9399-992456a1dc91">464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTItOS0xLTEtMTI3NDUy_263ed6ab-827e-482d-8cf1-f96187dc991a">464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fd41a82276046c7bcf592d2b6dc24da_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTMtNy0xLTEtMTI3NDUy_da041b43-e7e5-487e-849a-daf5caabfa44">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTMtOS0xLTEtMTI3NDUy_c6427ff3-ae4a-46c9-9cc2-36c478f34a77">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the Company&#8217;s equity award programs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38c33764415f4b3db09298ed152df379_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTUtMS0xLTEtMTI3NDUy_49a995ba-927a-4053-8010-59307d905eb1">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0252b377d44fb0a78ea5b3634c223a_D20210401-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTUtMy0xLTEtMTI3NDUy_a2a9b6cf-dc82-40af-942b-0f8a1b310acf">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTUtOS0xLTEtMTI3NDUy_b5160310-d87c-4eec-a320-428e47a0718a">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0252b377d44fb0a78ea5b3634c223a_D20210401-20210630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTYtMy0xLTEtMTI3NDUy_b3f5f8ce-1f02-4584-8712-85090009e2e6">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTYtOS0xLTEtMTI3NDUy_134d7096-278d-4866-9616-4a57c50dbca7">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax impact related to employee stock-based compensation expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa0252b377d44fb0a78ea5b3634c223a_D20210401-20210630" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTctMy0xLTEtMTI3NDUy_188b905e-8043-4562-ab1c-4c547cb25643">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTctOS0xLTEtMTI3NDUy_c19b74a1-be64-42d3-b0cb-ee69a7b02f2f">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i38c33764415f4b3db09298ed152df379_D20210401-20210630" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTgtMS0xLTEtMTI3NDUy_840a967f-0d39-4f5d-993a-79dff7946762">6.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i722f5ea9afa642bf9d0d9d90efe8e13a_D20210401-20210630" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTgtNS0xLTEtMTI3NDUy_79a3af68-867d-4f26-883c-4bca26b5db92">1,592</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTgtOS0xLTEtMTI3NDUy_72f2cc1f-324a-4539-8006-f4b81bfad01f">1,592</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i722f5ea9afa642bf9d0d9d90efe8e13a_D20210401-20210630" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTktNS0xLTEtMTI3NDUy_c67a7b15-3e04-4f26-882c-630ad6cff390">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTktOS0xLTEtMTI3NDUy_d667d0ca-523d-4873-b1c5-cc7e3b673c94">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7fd0dbb0ae849598e2ca788ff7aaa13_I20210630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMjAtMS0xLTEtMTI3NDUy_c92675cf-ed48-402c-86ea-ec28bc6c638f">569.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ca63c3b2e447a59ee34b73dfbdad9b_I20210630" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMjAtMy0xLTEtMTI3NDUy_295e8ce9-e0f9-49d2-a19d-aa3826da3d6f">31,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcb6da36e779490a98df897dc86555e5_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMjAtNS0xLTEtMTI3NDUy_112fcf27-0fce-4680-af08-bd6bc6b0960e">22,762</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33df105eb613462290a07079358e7409_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMjAtNy0xLTEtMTI3NDUy_192e90c5-e0ff-4066-a3da-513a2ad9ba29">868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99dc635999d0465e8fcbdc0cee2c1601_I20210630" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMjAtOS0xLTEtMTI3NDUy_cc62d23a-7f52-486d-8070-455c49992dbf">8,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMy0xLTEtMS0xMjc0NTI_1ac35239-b7b8-4135-9a5c-834539b40e32">2,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMy0zLTEtMS0xMjc0NTI_c74edabf-0d84-47ed-be92-c863f938f7aa">2,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation, amortization and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfNC0xLTEtMS0xMjc0NTI_2bc08a53-48bf-4d2e-9708-3ae4d743e255">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfNC0zLTEtMS0xMjc0NTI_56e2e5f3-30e9-421e-ba70-8e64ca572ab7">1,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfNS0xLTEtMS0xMjc0NTI_0cc8ef05-3333-48bf-9b8f-a8dab518f9e1">514</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfNS0zLTEtMS0xMjc0NTI_18a90090-8304-47a6-8e43-8b2ab7c3ffdf">137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfNi0xLTEtMS0xMjc0NTI_0759ae8e-efbf-4a28-aaf6-f19b6e0d3be8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfNi0zLTEtMS0xMjc0NTI_364f67b4-1cbd-480d-9a57-98961436c1ad">1,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments for equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfNy0xLTEtMS0xMjc0NTI_5c64bd97-7ad3-4ce9-976b-f11cde71502f">497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfNy0zLTEtMS0xMjc0NTI_cbdb4145-da93-43a8-a690-03a1f4aa26a6">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on divestiture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfOC0xLTEtMS0xNDYxOTM_474f9431-6400-4b69-a875-e47f59cfaa9b">560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfOC0zLTEtMS0xNDYyMDE_cb523b56-be03-4b9e-a961-e6f34fd20561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfOC0xLTEtMS0xMjc0NTI_4ddabf5e-7903-4163-a7e3-e3159fc5ef9f">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfOC0zLTEtMS0xMjc0NTI_8cf0a282-fd8e-4bdb-b371-cc5d5654568d">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of acquisitions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTAtMS0xLTEtMTI3NDUy_e650ef45-65ca-4661-8069-ba3aa87052c1">504</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTAtMy0xLTEtMTI3NDUy_7fbfc642-62b8-413c-8779-8c7a16f1c08f">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTEtMS0xLTEtMTI3NDUy_a61b16ce-65db-46b2-a927-23db687be872">410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTEtMy0xLTEtMTI3NDUy_3e9667f5-2784-4c4d-93b7-670e9477a1c5">167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTItMS0xLTEtMTI3NDUy_a36d63e3-745a-4b60-ae6e-71f4913d18a0">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTItMy0xLTEtMTI3NDUy_2d36d802-a5b4-4e24-8f31-c4428883f4c2">258</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTMtMS0xLTEtMTI3NDUy_bd04df50-d6c1-4e13-b171-aa95c2910e16">98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTMtMy0xLTEtMTI3NDUy_d7523962-88bd-4b21-bb84-27a6e3137070">156</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income taxes, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTQtMS0xLTEtMTI3NDUy_3efb31e9-55ea-4c4b-820c-397468eef18f">685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTQtMy0xLTEtMTI3NDUy_3de18174-0937-4d97-ba97-dd872ccd212f">930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="amgn:IncreaseDecreaseInNoncurrentTaxLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTUtMS0xLTEtMTI3NDUy_5b272193-20fd-4bdf-a9c1-491d0840c898">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="amgn:IncreaseDecreaseInNoncurrentTaxLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTUtMy0xLTEtMTI3NDUy_473b91d4-6c9f-474f-8ce4-a4370261bf4c">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTYtMS0xLTEtMTI3NDUy_ce0d6655-634d-46c4-9c73-181177f4f4ff">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTYtMy0xLTEtMTI3NDUy_fae77fd9-67a3-4770-b230-34713391f265">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTctMS0xLTEtMTI3NDUy_e4b41af5-8697-4fd3-be5d-66a4e956fad0">4,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTctMy0xLTEtMTI3NDUy_995a89ea-214f-42cb-bcba-b92af17fadb0">4,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjAtMS0xLTEtMTI3NDUy_239fbdc5-b95e-437b-8d6c-4708e4f5e4fc">1,976</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjAtMy0xLTEtMTI3NDUy_fc5e2762-9c12-4381-8bec-73959ad17fb4">8,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjEtMS0xLTEtMTI3NDUy_d277c8b0-79e8-48b5-953b-071f2d5c2010">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjEtMy0xLTEtMTI3NDUy_f2ccac1a-735f-4307-b090-3d4f2d1c8a0b">4,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjItMS0xLTEtMTI3NDUy_7df99710-4f65-4153-94fb-4100f62b283d">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjItMy0xLTEtMTI3NDUy_78d1334a-e9d9-4f17-af6e-c0925b6a6289">6,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjQtMS0xLTEtMTI3NDUy_57d6c55c-a887-49a2-9ce5-f2e790e61f7f">436</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjQtMy0xLTEtMTI3NDUy_8323cae6-5ab8-4f78-aef2-7d9a4952d4e8">351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjYtMS0xLTEtMTU1MDkx_c1adff2b-0ae1-49b6-98a8-24e25261eb8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjYtMy0xLTEtMTU1MDkx_bfbeacd3-63b7-4acf-bd69-cc9891ad15a6">1,626</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjYtMS0xLTEtMTI3NDUy_3e112aa7-8a9e-4d44-89af-398d07cb718b">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjYtMy0xLTEtMTI3NDUy_4842ac9e-8626-40de-8bef-f71b642a6b96">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjctMS0xLTEtMTI3NDUy_2533e523-dadd-4fc7-80cc-0050a9e0d647">2,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjctMy0xLTEtMTI3NDUy_acb6c31e-2f72-480e-bf85-dcd2b116ccdf">890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from issuance of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjktMS0xLTEtMTI3NDUy_9f0fd4e4-712a-415c-9ffd-992bbeaefb16">3,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjktMy0xLTEtMTI3NDUy_cee12795-6ef5-4451-bc52-d120a5400c72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock (Note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzItMS0xLTEtMTI3NDUy_68f9f6db-da77-4d36-bf86-b1ea77654598">6,360</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzItMy0xLTEtMTI3NDUy_ddab1d09-8613-4f81-ba67-8f4dc74a61ff">2,452</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzMtMS0xLTEtMTI3NDUy_cd3d82b8-7c9f-4e13-94e0-39b0c3da948d">2,118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzMtMy0xLTEtMTI3NDUy_513d2895-fe3a-4c87-b01a-194a61d30462">2,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzUtMS0xLTEtMTI3NDUy_79bb9c00-5aee-4d18-9b51-f6ddd9184949">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzUtMy0xLTEtMTI3NDUy_6e1f7139-5c25-45b6-9100-72f8c6058be4">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzYtMS0xLTEtMTI3NDUy_08af3742-8e36-4a4b-9060-068a399b3bd7">4,576</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzYtMy0xLTEtMTI3NDUy_66294074-31b7-465d-90e9-b984951e3bc1">4,561</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzctMS0xLTEtMTI3NDUy_612a09b3-00f1-474e-a200-4390e8605d3e">2,786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzctMy0xLTEtMTI3NDUy_4e986712-0484-4642-a3a8-c3971745c7e7">364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzgtMS0xLTEtMTI3NDUy_466dd9f4-5561-4663-ba0a-3a57470ef305">7,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e5bfcd24a084d2ba4ae4e9fd63a2a81_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzgtMy0xLTEtMTI3NDUy_70310dc0-2174-461b-84af-844311879e9a">6,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzktMS0xLTEtMTI3NDUy_b092823c-ba76-4557-bc9d-973a04eafed3">5,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99dc635999d0465e8fcbdc0cee2c1601_I20210630" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzktMy0xLTEtMTI3NDUy_708b1df7-ed87-4ec9-8fce-db78ba004326">6,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMGEN INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2022 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i710475db76604b05901ef7473465ecf1_37"></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zNy9mcmFnOjE3MDY3Y2UxNGZhNzRlNGViMzA3Yjc3OTgyZjJhNjhiL3RleHRyZWdpb246MTcwNjdjZTE0ZmE3NGU0ZWIzMDdiNzc5ODJmMmE2OGJfNDA3OQ_514992b3-9b94-4da7-aac3-c0ecdc9d3b1b" continuedAt="i38679a3dc41d453299bd437b7c085269" escape="true">Summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="i38679a3dc41d453299bd437b7c085269" continuedAt="iacbdcab040c04bfc99d0b1faa85bc288"><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="amgn:NatureOfOperationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zNy9mcmFnOjE3MDY3Y2UxNGZhNzRlNGViMzA3Yjc3OTgyZjJhNjhiL3RleHRyZWdpb246MTcwNjdjZTE0ZmE3NGU0ZWIzMDdiNzc5ODJmMmE2OGJfNDA0MQ_82fe463d-9e01-4711-b415-1bebc01801e0" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Inc. (including its subsidiaries, referred to as &#8220;Amgen,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics.&#160;We operate in <ix:nonFraction unitRef="segment" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zNy9mcmFnOjE3MDY3Y2UxNGZhNzRlNGViMzA3Yjc3OTgyZjJhNjhiL3RleHRyZWdpb246MTcwNjdjZTE0ZmE3NGU0ZWIzMDdiNzc5ODJmMmE2OGJfMjUz_46b37b32-417a-4dcb-9d30-e0d892c936d4">one</ix:nonFraction> business segment: human therapeutics.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="amgn:BasisOfPresentationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zNy9mcmFnOjE3MDY3Y2UxNGZhNzRlNGViMzA3Yjc3OTgyZjJhNjhiL3RleHRyZWdpb246MTcwNjdjZTE0ZmE3NGU0ZWIzMDdiNzc5ODJmMmE2OGJfNDA2NA_b36ee174-f128-4730-860b-b0ba488d50fa" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial information for the three and six months ended June 30, 2022 and 2021, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2021, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Report on Form 10-Q for the period ended March 31, 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zNy9mcmFnOjE3MDY3Y2UxNGZhNzRlNGViMzA3Yjc3OTgyZjJhNjhiL3RleHRyZWdpb246MTcwNjdjZTE0ZmE3NGU0ZWIzMDdiNzc5ODJmMmE2OGJfNDA5Nw_c7230432-2734-486e-b7ec-ad6122e6db8c" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity&#8217;s economic performance and the obligation to absorb losses of or the right to receive benefits from the entity that could potentially be significant to that entity. We do not have any significant interests in any</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zNy9mcmFnOjE3MDY3Y2UxNGZhNzRlNGViMzA3Yjc3OTgyZjJhNjhiL3RleHRyZWdpb246MTcwNjdjZTE0ZmE3NGU0ZWIzMDdiNzc5ODJmMmE2OGJfNDA0OQ_5cd1e1f7-f12e-4476-b5e4-a45cbab558ce" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zNy9mcmFnOjE3MDY3Y2UxNGZhNzRlNGViMzA3Yjc3OTgyZjJhNjhiL3RleHRyZWdpb246MTcwNjdjZTE0ZmE3NGU0ZWIzMDdiNzc5ODJmMmE2OGJfNDA2MA_c5d57700-fd0d-4148-ba8b-11b4559e51c6" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization, of $<ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-8" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zNy9mcmFnOjE3MDY3Y2UxNGZhNzRlNGViMzA3Yjc3OTgyZjJhNjhiL3RleHRyZWdpb246MTcwNjdjZTE0ZmE3NGU0ZWIzMDdiNzc5ODJmMmE2OGJfMjEwOQ_8f814c42-d4df-44a1-b62d-1f0dbb06f84b">9.0</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-8" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zNy9mcmFnOjE3MDY3Y2UxNGZhNzRlNGViMzA3Yjc3OTgyZjJhNjhiL3RleHRyZWdpb246MTcwNjdjZTE0ZmE3NGU0ZWIzMDdiNzc5ODJmMmE2OGJfMjExNg_42b6f5d9-b8f0-4ad4-b0e5-8faeb10b4608">8.8</ix:nonFraction> billion as of June 30, 2022 and December 31, 2021, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zNy9mcmFnOjE3MDY3Y2UxNGZhNzRlNGViMzA3Yjc3OTgyZjJhNjhiL3RleHRyZWdpb246MTcwNjdjZTE0ZmE3NGU0ZWIzMDdiNzc5ODJmMmE2OGJfNDA4Ng_6eae6213-8a83-480c-92d5-d77b0a2f3327" continuedAt="iaf14d9257204415bb884b0d3a03cc0bf" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard that expanded the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We do not expect the two standards to have a material impact on our condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iacbdcab040c04bfc99d0b1faa85bc288"><ix:continuation id="iaf14d9257204415bb884b0d3a03cc0bf">In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions.</ix:continuation></ix:continuation></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div id="i710475db76604b05901ef7473465ecf1_40"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfNDc5OQ_d04d13f4-a29a-4dff-be52-5a323961fc30" continuedAt="i0fb13a68018d42c385048f2e52b8ac94" escape="true">Acquisitions and divestitures</ix:nonNumeric></span></div><ix:continuation id="i0fb13a68018d42c385048f2e52b8ac94" continuedAt="i8890e781167541a28e4169c460711da1"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Teneobio, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 19, 2021, we acquired all of the outstanding stock of Teneobio, a privately held, clinical-stage biotechnology company developing a new class of biologics called human heavy-chain antibodies, which are single-chain antibodies composed of the human heavy-chain domain. The transaction, which was accounted for as a business combination, includes Teneobio&#8217;s proprietary bispecific and multispecific antibody technologies, which complement Amgen&#8217;s existing antibody capabilities and bispecific T-cell engager (BiTE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) platform and will enable significant acceleration and efficiency in the discovery and development of new molecules to treat diseases across Amgen&#8217;s core therapeutic areas. Upon its acquisition, Teneobio became a wholly owned subsidiary of Amgen, and its operations have been included in our condensed consolidated financial statements commencing on the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Measurement period adjustments for the six months ended June 30, 2022, included changes to the purchase price allocation and total consideration, resulting in a net increase of $<ix:nonFraction unitRef="usd" contextRef="i46b0c7abfa194277afc81cba3b24f8a3_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0MjQ0NA_9cbadb74-e00f-4d7f-9b94-0be51b569dcd">22</ix:nonFraction>&#160;million to goodwill. The measurement period adjustments resulted primarily from valuation inputs pertaining to certain acquired assets based on facts and circumstances that existed as of the acquisition date and did not result from events subsequent to the acquisition date. These adjustments did not have a significant impact on Amgen&#8217;s results of operations during the six months ended June 30, 2022, and would not have had a significant impact on prior-period results if these adjustments had been made as of the acquisition date. <ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMjc0ODc3OTA4NDY5Nw_bd314df0-4649-48ef-ad1c-a12e2d3351c4" continuedAt="i956d6deff4a149fcb11ee931f0bf538d" escape="true">The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify"><ix:continuation id="i956d6deff4a149fcb11ee931f0bf538d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.015%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46b0c7abfa194277afc81cba3b24f8a3_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfMS0yLTEtMS0xNDQ4MzA_44241372-d163-45df-8ef4-5b7db988a56d">993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46b0c7abfa194277afc81cba3b24f8a3_D20220101-20220630" decimals="-6" name="amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfMi0yLTEtMS0xNDQ4MzA_59d4e1b9-7a92-4c99-9e56-0e7ab0b66131">299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46b0c7abfa194277afc81cba3b24f8a3_D20220101-20220630" decimals="-6" name="amgn:Businessassetacquisitionconsiderationtransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfMy0yLTEtMS0xNDQ4MzA_c6f140b2-a842-415e-99b3-3de657dfdc87">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65b90579b9de4767a853da3e3573d8fa_I20220630" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfNS0yLTEtMS0xNDQ4MzI_ad889fa1-1c40-476f-83f3-c866975fc3ca">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65b90579b9de4767a853da3e3573d8fa_I20220630" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfNi0yLTEtMS0xNDQ4MzI_c7fae9b3-9fce-4832-b64c-e975ed8d3d2d">991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset &#8211; research and development technology rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0f1d41da125426189de8e665937a530_I20220630" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfNy0yLTEtMS0xNDQ4MzI_48120951-303c-4100-8e7b-4563ff67c53d">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets &#8211; licensing rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf77564d8ed145dab51bea04209c327c_I20220630" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfOC0yLTEtMS0xNDQ4MzI_88d7f31b-2a72-43ac-9418-fe0b8f528000">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65b90579b9de4767a853da3e3573d8fa_I20220630" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfOS0yLTEtMS0xNDQ4MzI_1ad18265-89f8-4433-8393-abd0794ea189">273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65b90579b9de4767a853da3e3573d8fa_I20220630" decimals="-6" name="amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfMTAtMi0xLTEtMTQ0ODMy_057c48e4-a75b-46c7-84b8-8162f5cc5ee1">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65b90579b9de4767a853da3e3573d8fa_I20220630" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfMTEtMi0xLTEtMTQ0ODMy_8e38ea83-06ae-4d89-b1ed-8e70ebc03bc2">244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65b90579b9de4767a853da3e3573d8fa_I20220630" decimals="-6" name="amgn:BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfMTItMi0xLTEtMTQ0ODMy_ebf360c9-2192-4564-b024-914d8bf716c4">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration for this transaction comprised (i) an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i46b0c7abfa194277afc81cba3b24f8a3_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0MjE5Mg_fbb47b7e-abe8-4d13-9de9-e4e9143098a8">993</ix:nonFraction>&#160;million, which included a working-capital adjustment, and (ii) future contingent milestone payments to Teneobio&#8217;s former equity holders of up to $<ix:nonFraction unitRef="usd" contextRef="i65b90579b9de4767a853da3e3573d8fa_I20220630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0MjIyMQ_65c405bb-688e-4e27-afe0-57f5bed86b72">1.6</ix:nonFraction>&#160;billion in cash, based on the achievement of various development and regulatory milestones with regard to the leading asset (AMG 340, formerly TNB-585) and to various development milestones for other drug candidates. The estimated fair values of the contingent consideration obligations aggregated $<ix:nonFraction unitRef="usd" contextRef="i46b0c7abfa194277afc81cba3b24f8a3_D20220101-20220630" decimals="-6" name="amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0MjI0OA_e801c0cf-36a9-49c7-b54d-072e5eaf9be7">299</ix:nonFraction>&#160;million as of the acquisition date and were determined using a probability-weighted expected return methodology. The assumptions in this method include the probability of achieving the milestones and the expected payment dates, with such amounts discounted to present value based on our pretax cost of debt. See Note 11, Fair value measurement, for information regarding the estimated fair value of these obligations as of June 30, 2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="i8890e781167541a28e4169c460711da1"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of acquired IPR&amp;D assets totaled $<ix:nonFraction unitRef="usd" contextRef="i65b90579b9de4767a853da3e3573d8fa_I20220630" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0MjI3NQ_ad312c9d-d6e1-4cd5-b872-a56ce3f97ae8">991</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="id5b59ba800eb4416b405415f49916460_I20220630" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0MjMwMg_18471c99-d1df-43c4-8387-aa992fcbf13c">784</ix:nonFraction>&#160;million relates to AMG 340, that is in a phase 1 clinical trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), and the balance relates to four separate preclinical oncology programs. The R&amp;D technology rights of $<ix:nonFraction unitRef="usd" contextRef="id8fc3ec2171642438fd51d30ae242218_D20220101-20220630" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0MjMyOQ_85e87a1d-c5b4-4759-b83f-7bda2570822a">115</ix:nonFraction>&#160;million relate to Teneobio&#8217;s proprietary bispecific and multispecific antibody technologies; the amount is being amortized over <ix:nonNumeric contextRef="id8fc3ec2171642438fd51d30ae242218_D20220101-20220630" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY2NTcwMg_aafa8313-e4ba-4c3d-b407-7e2132d31383">10</ix:nonNumeric> years by using the straight-line method. Teneobio has also licensed its technology and certain identified targets to various third parties, representing contractual agreements valued at $<ix:nonFraction unitRef="usd" contextRef="i7940c183b18d43b9ba4da67548953f71_D20220101-20220630" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0MjM1NQ_f97bffb4-8199-4805-b3a0-ad281ce6a49a">41</ix:nonFraction>&#160;million. The estimated fair values for these intangible assets were determined using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The projected cash flows were based on certain assumptions attributable to the respective intangible asset, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="i65b90579b9de4767a853da3e3573d8fa_I20220630" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0MjM5MQ_7f9a1d9f-efb5-4478-bb1b-c4addddc0b13">244</ix:nonFraction>&#160;million was recognized on temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="i65b90579b9de4767a853da3e3573d8fa_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0MjQxOA_9c9af170-8b71-4414-a321-4a6fed6d54f0">273</ix:nonFraction>&#160;million was recorded as goodwill, which is not deductible for tax purposes. The goodwill value represents expected synergies from both AMG 340 and the technologies acquired.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting for this acquisition is preliminary and will be finalized upon completion of our analysis of certain tax-related items as we obtain additional information during the measurement period of up to one year from the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Five Prime Therapeutics, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 16, 2021, Amgen completed its acquisition of Five Prime for a total cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i9a5366d8b02a4ac58034f8465ae23d74_D20210416-20210416" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfNjA0NzMxMzk4MTM4Mg_b9c00c51-5aa6-4213-8e06-8addad4bf422">1.6</ix:nonFraction>&#160;billion, net of cash acquired. The purchase price was funded with cash on hand. This transaction was accounted for as an asset acquisition because substantially all the value of the assets acquired was concentrated in the intellectual property rights of bemarituzumab, a phase 3 trial-ready, first-in-class program for gastric cancer. Five Prime&#8217;s operations have been included in our condensed consolidated financial statements commencing after the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the consideration to acquire Five Prime to: the bemarituzumab IPR&amp;D program of $<ix:nonFraction unitRef="usd" contextRef="i9a5366d8b02a4ac58034f8465ae23d74_D20210416-20210416" decimals="-8" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfNjA0NzMxMzk4MTk3Ng_da84faf7-b56c-455c-bd72-f3f001663024">1.5</ix:nonFraction>&#160;billion, which was expensed immediately in Acquired IPR&amp;D expense in the Condensed Consolidated Statements of Income; deferred tax assets of $<ix:nonFraction unitRef="usd" contextRef="i51b02cfd80774125a1d4ff6c778112df_I20210416" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfNjA0NzMxMzk4MjExMw_8c93f221-2192-4fab-aafa-b733bba0036b">177</ix:nonFraction>&#160;million; and other net liabilities of $<ix:nonFraction unitRef="usd" contextRef="i51b02cfd80774125a1d4ff6c778112df_I20210416" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfNjA0NzMxMzk4MjE0Nw_18bacb6f-718d-423f-9012-4f48286e6182">47</ix:nonFraction>&#160;million. The Acquired IPR&amp;D expense was not tax deductible.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Divestiture of Gensenta &#304;la&#231; Sanayi ve Ticaret A.&#350;.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 28, 2022, we entered into a share purchase agreement with Eczac&#305;ba&#351;&#305; under which Eczac&#305;ba&#351;&#305; will acquire all of our shares in Gensenta&#8212;a subsidiary in Turkey. Net assets related to Gensenta of $<ix:nonFraction unitRef="usd" contextRef="iab9a0edff56e4078be3430ac408a5cf8_I20220630" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfNjA0NzMxMzk3NTU5NA_448664c8-e3e4-4d97-9b64-a6681a31c9a7">80</ix:nonFraction>&#160;million met the criteria to be classified as held-for-sale and did not meet the criteria to be classified as discontinued operations. Upon closing of the transaction, we expect to receive $<ix:nonFraction unitRef="usd" contextRef="i7d17ec1f9653493f940934eadb627b3e_D20220701-20220930" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0Njg5OA_6689defe-c4e7-4847-a8a4-2f4dce2ae2ea">135</ix:nonFraction>&#160;million in cash. The transaction is expected to close in the third quarter of 2022 upon approval by the Turkish Competition Authority.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, held-for-sale assets and liabilities of $<ix:nonFraction unitRef="usd" contextRef="iab9a0edff56e4078be3430ac408a5cf8_I20220630" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfNjA0NzMxMzk4MjM4OQ_1d101574-0f6d-4778-a04f-260c6853bb59">100</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iab9a0edff56e4078be3430ac408a5cf8_I20220630" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfNjA0NzMxMzk4MjQzMA_46f3949e-becf-4ef1-b170-bea8c2a40067">20</ix:nonFraction>&#160;million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the three months ended June 30, 2022, we recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="i1b8b7a38d735412895755cb950726b35_D20220401-20220630" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY1NzQyNA_a1dc6833-0821-413f-bd4d-9d06af362274">560</ix:nonFraction>&#160;million recorded to Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign currency translation loss, with valuation allowances to Other current assets and Accrued liabilities in the Condensed Consolidated Balance Sheets.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RleHRyZWdpb246NGRmYmU0OGYxN2QyNDNhNjk3YmE0NDA5MWNhZTg2MzNfNTQ1_a6cb4f2c-d037-4d5f-8b35-4e546b2e5088" continuedAt="i584c6db80d144827a8bfa68d23fa28c0" escape="true">Revenues</ix:nonNumeric></span></div><ix:continuation id="i584c6db80d144827a8bfa68d23fa28c0" continuedAt="i79a98668002b4cbd8552f83edb12f1ab"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in <ix:nonFraction unitRef="segment" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RleHRyZWdpb246NGRmYmU0OGYxN2QyNDNhNjk3YmE0NDA5MWNhZTg2MzNfMjY_5dee4a5f-0d7a-4893-8131-cd45fb078287">one</ix:nonFraction> business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers&#8217; locations, are presented below. The majority of ROW revenues relates to products sold in Europe.</span></div><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RleHRyZWdpb246NGRmYmU0OGYxN2QyNDNhNjk3YmE0NDA5MWNhZTg2MzNfNTQ3_022f01eb-604d-4914-b813-7706f86ba946" continuedAt="i2fef51416bc645deb9a2b92ad2bcb044" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.144%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icee014cde681480aad811d3d8701db0d_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMy0yLTEtMS0xMjc0NTI_eca83299-162f-4aed-972c-32762c8c9c53">1,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf9d9ddcf94242e3ad6ec1f3b60ca85f_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMy00LTEtMS0xMjc0NTI_e66828f7-8292-4a18-a022-96b0f6fffc3c">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6547eba45cd04dcbaeebbe712be8ec92_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMy02LTEtMS0xMjc0NTI_efecf750-fba5-444d-86f9-3e8d4ea3f10e">1,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e52109f70c0440aa0159863f2da64f0_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMy04LTEtMS0xMjc0NTI_f23c07ec-b8ee-4856-86fe-3b90ae9da1b8">1,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a84ebe379724a65826c6f82bd6873e1_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMy0xMC0xLTEtMTI3NDUy_17f5a7a7-1fc0-4be9-ba26-d549fd6657f9">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida701b321d2c4d2a891120940d3655c5_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMy0xMi0xLTEtMTI3NDUy_098339b3-acd3-404a-9404-15caf5d02f80">1,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief82f7dcaf42426abffc36664a5809c7_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNC0yLTEtMS0xMjc0NTI_bd1e72e6-c484-4e8d-9184-6d2bec839bde">611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fdc9fa81ab6432aaa23fe4128d28ae8_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNC00LTEtMS0xMjc0NTI_1fce9fcb-e4a2-4221-b466-dc10750f9ed2">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i053944749a2f483d9d310db2fc989a2c_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNC02LTEtMS0xMjc0NTI_27a38e2d-fba8-4de9-a277-b1b0f603c44c">922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eebec4167d24ee289c7c3c2cca1d35a_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNC04LTEtMS0xMjc0NTI_6d3280dd-5ee7-4c5f-bf1d-ffda0ea6427a">538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7337cf047dc447782a07d660fabea38_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNC0xMC0xLTEtMTI3NDUy_38bc8cd1-c242-4bcc-94ba-49ba4c5c79e2">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c5378764431442fb224f6e38d910099_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNC0xMi0xLTEtMTI3NDUy_0cdf5029-2ef2-4d21-8d3c-95649b43e24e">814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4b87907d6674193b0d2c415cefc0caf_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNi0yLTEtMS0xMjc0NTI_a289ff91-2cb2-4f62-b410-ccd2f8138af0">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i353f9f7d24934b85a5752777824c2c7f_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNi00LTEtMS0xMjc0NTI_379281e9-2c7b-414c-8faa-900abe0b7e9c">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib84507297bc345c8b3d5fff781c60e36_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNi02LTEtMS0xMjc0NTI_b9e3f8a1-1d83-47a3-90c2-5b47e058d350">594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fef643526f14918bd9831e91914bf50_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNi04LTEtMS0xMjc0NTI_253b5a3a-35ab-42d9-8758-1eb04178e9e0">423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i402e9a1690cc42e797f5a6261ca0cbfb_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNi0xMC0xLTEtMTI3NDUy_cf5d37cc-fec6-4522-8cf0-f45510e45d08">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3ea1a7432a342c2bed9d52592b75cf4_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNi0xMi0xLTEtMTI3NDUy_986306e0-fac8-48c4-8151-04b7c2b0e8c6">534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63940a8eea91432f83d73335dca6a9f4_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNy0yLTEtMS0xMjc0NTI_75ea5198-d5bf-4f16-8b4b-29f157e4cac5">391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d9d5b7844d40b4a71f85abe0bce65a_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNy00LTEtMS0xMjc0NTI_32758696-346a-49cd-8fc8-ade8f67ac2ee">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cde61abea0348d2a159b88ebd8184b7_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNy02LTEtMS0xMjc0NTI_84f68c80-1122-4628-afcd-d1a2276adceb">533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10be39accc2549a2bdd35da00b4aaa91_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNy04LTEtMS0xMjc0NTI_d19dd0c8-c6db-4048-b0ed-aa53d0e19532">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b97f8b18b7146bf8f5d26e2d38206ab_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNy0xMC0xLTEtMTI3NDUy_a571ebe3-d52b-4b31-acdc-2581489795f4">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie08a8cd0c2ee4df4970b642309711818_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNy0xMi0xLTEtMTI3NDUy_e077a524-7103-4324-a293-ca8b7dd06918">488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib449607d3a384e9b922bf56ee0f6ad54_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOC0yLTEtMS0xMjc0NTI_26f7d316-8408-427e-a76c-b6c98e1797bc">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844d0ba430b845fabf60df607d4a6b2b_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOC00LTEtMS0xMjc0NTI_62818404-ed3b-4c77-b529-dc3ccd8d1e14">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d419bd679714fdcb7cab5ff036d1523_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOC02LTEtMS0xMjc0NTI_94dc851e-b871-4b2e-8a0a-8c8b57de3f0f">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a1a713123344ccbeee9e7f0bd8b286_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOC04LTEtMS0xMjc0NTI_91a52105-4414-4b27-ae84-cb1dbf72250e">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3759a6d96c3d4557865f45756f379736_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOC0xMC0xLTEtMTI3NDUy_1766f3c2-604a-42ab-86ed-336b7f99ce1b">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13eca2061d94491bbf81135f296046bf_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOC0xMi0xLTEtMTI3NDUy_3cb3e58d-ee57-4d02-b63b-79764298aa02">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6b5b0a2363145d7be3110c83773d028_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS0yLTEtMS0xNDczMDY_2ed269bf-219d-4da1-9b13-c223e98faea0">263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8d35c2137e343349add15c0fca41917_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS00LTEtMS0xNDczMDY_4225f32e-7484-4db8-9577-94f561de20c5">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ab66a4297fc4a5fa4fbdb2b993c893d_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS02LTEtMS0xNDczMDY_2665612a-b0a7-4044-86d3-0c38651ed5f5">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa47aecf963c462192f5f09066e709ae_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS04LTEtMS0xNDczMDY_ff51ae53-1578-4919-b398-98ff363cb312">434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dab3465710546408078a65658bbbc86_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS0xMC0xLTEtMTQ3MzA2_d78ab2c8-aecf-4c23-8fe4-2d56a2de1ed0">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d1ec301cf824dcc9410f3838f666700_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS0xMi0xLTEtMTQ3MzA2_f2919ca4-033d-480e-9729-3e533408d1bc">486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d51cebbb7fc4745b1461e1227bf4a07_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS0yLTEtMS0xNDA2MzU_b5504f28-bb39-4afb-b8e0-364332031b92">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic60e2a88b0ee40cdae005ed5c6d5e8fc_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS00LTEtMS0xNDA2MzU_8768f56e-7260-400e-bd17-719639f0d414">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i331261ad3dac42c582a5e9011635bd51_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS02LTEtMS0xNDA2MzU_81e54cc7-b2b6-4b47-af24-d03fa1272f96">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9a7be6cf844191ab232452edf77bd6_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS04LTEtMS0xNDA2MzU_d39c3417-a258-4324-b83c-1b465a051953">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b9d8e979224414d8d3ad2e8695072bb_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS0xMC0xLTEtMTQwNjM1_1a5073a2-14e9-4721-b30c-ecabcdc7d599">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49646ee726c14e1e97ca5817d76e3e08_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS0xMi0xLTEtMTQwNjM1_a171dad3-84d6-4630-8cfd-601b44f5a9f1">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab5d097d4d764906958b2308fa778f75_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS0yLTEtMS0xMjc0NTI_308d16cc-daad-45d3-9e96-9c2736d21a62">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bb35321c40c4726b08388b4209a9228_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS00LTEtMS0xMjc0NTI_a4a1d6f7-ec97-4885-b3f3-f8e723a9e520">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2958c1dc2e954e58aa77a26a6d8e1d7a_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS02LTEtMS0xMjc0NTI_843b5182-3333-4378-9b0b-c54420f033cf">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70fcb018e33749d2af04537d60b71f20_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS04LTEtMS0xMjc0NTI_aa7ddd72-63c2-423c-af5d-24c671bffd63">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica9bbd963a304369b99b0572c2fff78c_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS0xMC0xLTEtMTI3NDUy_152a5230-9ea6-44b3-9332-032ea24f8242">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81e998920660480b972899798b0bbb3c_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS0xMi0xLTEtMTI3NDUy_3743ae25-f13e-4bd2-9bb8-62837cefa1d8">280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57c433f89bb427d95cc820d738a213b_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTEtMi0xLTEtMTI3NDUy_53f88d98-4b0d-42b5-97ab-ff1f82c6e908">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49be0bf790014903a4b42b6e1b2727bd_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTEtNC0xLTEtMTI3NDUy_eed5b51a-e8ce-4a2f-a310-87e11eba5fe2">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6f96cf75ba4e419a31bf17c86c89c7_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTEtNi0xLTEtMTI3NDUy_d54d410c-2f6a-4f1f-92d5-cff3e06881c6">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9166886eb5d468090bdacec2d9c6426_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTEtOC0xLTEtMTI3NDUy_6b99791d-e0cb-40a0-b3ad-56864b2da0d4">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedd4bef43f2e4c74bdbe761a290688d2_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTEtMTAtMS0xLTEyNzQ1Mg_765b7de0-7687-4a41-8368-097749eeaf57">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866f0a6fa4484406b8ad21f3fb76f4a3_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTEtMTItMS0xLTEyNzQ1Mg_0a4e35b7-abb2-49b8-b916-2e0930575e21">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c0b9b0637ae4f75a113b9daf4ffbb97_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTItMi0xLTEtMTI3NDUy_8c5dbfa6-1346-4a0b-8006-5269984a5855">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id00661e6164d4652a22a0e73d4ff73a6_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTItNC0xLTEtMTI3NDUy_b2429096-a9e5-4557-afbb-baa99e257759">585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2f46c443024e00a31cb4dc9cd9e34b_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTItNi0xLTEtMTI3NDUy_0795b48c-6dae-409c-a247-dc5e1366b192">1,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2e544419be4d83a0548a9dd2cb80a6_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTItOC0xLTEtMTI3NDUy_613050b9-069d-4ffd-86d9-1670041a65cd">907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a69d719fa4e41389f7a488fa7f10932_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTItMTAtMS0xLTEyNzQ1Mg_26e41f4a-7f56-48d0-9d4e-260894cf09de">563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12b36c285b3e46d48bdcaa2313f4d40a_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTItMTItMS0xLTEyNzQ1Mg_c3bfdf23-fae3-45a7-9faf-d7a69d5f03d5">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c63f65b70944d59e9ddddf1020dbf9_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTMtMi0xLTEtMTI3NDUy_f5d44686-5cc6-442f-a16f-23e4b11b9aef">4,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27c7d03606704467ad677af2b7b1c3b1_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTMtNC0xLTEtMTI3NDUy_bd232228-02f4-448f-b30d-1a00def0e1c1">1,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3c410d6b2f84e53be5c076dec22d865_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTMtNi0xLTEtMTI3NDUy_8df0ba21-ce6c-4906-96ca-406870caaa6e">6,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60557b562a964b209eb858e7b3cb22e9_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTMtOC0xLTEtMTI3NDUy_2b819407-5df2-4be5-a06f-d971ea973bdf">4,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafda85002a2340d3b351231f4da2b4fb_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTMtMTAtMS0xLTEyNzQ1Mg_bca7bfcd-0bbc-41bb-bd0b-6b88a26a8c03">1,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d9e005bccc4060bd5addba903c2c2c_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTMtMTItMS0xLTEyNzQ1Mg_cf1d2583-bd1c-4735-a244-9fd89ef86220">6,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e71b4283ef4881a494fede3403b36c_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTQtNi0xLTEtMTI3NDUy_8ec274aa-f1e2-4633-b0cc-d1749f3f8ea1">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768868bd3bfe4a65a96efee550cef847_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTQtMTItMS0xLTEyNzQ1Mg_c9326106-8dd7-4110-9d63-2c0643f29be6">412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTUtNi0xLTEtMTI3NDUy_80eea368-b06a-47af-bef4-5ad36b8cd6b6">6,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTUtMTItMS0xLTEyNzQ1Mg_feb82c5a-d6f0-4573-8980-33debad8db59">6,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i995fe6b5cc06494dac04f0ca72c967be_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjAtMi0xLTEtMTI3NDUy_1db40b16-5036-4eb8-8d74-1ab403f6a5e9">1,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i481df103ecf443b58ab69543c8ebfaa4_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjAtNC0xLTEtMTI3NDUy_564c96e0-b017-43fd-86c8-ef00deca348e">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e20cfb3d44545709400adfd0900c274_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjAtNi0xLTEtMTI3NDUy_dcbea01c-85e0-46fb-b217-1d63aae15e05">1,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i198ddb00bf674c69a7441a2d3a026635_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjAtOC0xLTEtMTI3NDUy_47892b36-2cec-4d9d-a07b-9bbff45f65d6">2,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ad4acdb144a4163bcbf1216e002c725_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjAtMTAtMS0xLTEyNzQ1Mg_ae1ddbb2-fcee-417d-a8bd-178385d12ee2">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac22074dabd64d2fbfdc167416335b44_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjAtMTItMS0xLTEyNzQ1Mg_2f380621-cd00-4922-8629-e672986aa99f">2,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9ab9b8edfdb4a22b19ee432374d19ec_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjEtMi0xLTEtMTI3NDUy_6d82ff04-2e8a-4e63-ab91-9ecf27dc7ec9">1,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2a35d4acbaa4f83be8e10b0e6e0300d_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjEtNC0xLTEtMTI3NDUy_1611cc0a-f300-442c-a784-1bfa7aa0b595">581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf38951506aa48f19b8b2388b7885ee1_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjEtNi0xLTEtMTI3NDUy_92f327cf-bb38-44da-8bb2-17c9d93aca25">1,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d40692061a445c192ae0b68421a236a_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjEtOC0xLTEtMTI3NDUy_dce204f5-b478-454f-af07-94496a734863">1,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f09cd5a2a344997a29f5dbf9e474e85_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjEtMTAtMS0xLTEyNzQ1Mg_75a1cecf-de13-4e07-9dda-461cbefef20e">533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f4bf88082934cdc8910614dccffc16b_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjEtMTItMS0xLTEyNzQ1Mg_0620dbaa-b70e-4d2c-8f95-0d53a5acc651">1,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43dfd6a72e0d4e86845ad7349de053e0_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjItMi0xLTEtMTI3NDUy_370543ea-dd01-4f55-8e1a-904f1639a5c7">837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22a251c8f299431d94a6931aca67fc7f_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjItNC0xLTEtMTI3NDUy_d9cf91fa-697b-45d3-85b1-e5de77aa780b">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8de2ea542474f83b6b3eca46a028b44_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjItNi0xLTEtMTI3NDUy_e333f79d-11bd-44d3-b773-6e943766a1a1">1,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i774b5e6996814c4abaaef4d66eabba88_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjItOC0xLTEtMTI3NDUy_2ca42eda-786f-4fc2-b1ff-525ab2a98d86">789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia32f2b66d9004689a58fa0ee82794077_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjItMTAtMS0xLTEyNzQ1Mg_3655d92f-dace-4fa7-a7b8-361e45880974">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic110f3f8f6db447287b324ae25536ba2_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjItMTItMS0xLTEyNzQ1Mg_85eed944-c01f-44e4-a402-8f5303f09e32">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2702f5653dc64085adaed969aa03d41a_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtMi0xLTEtMTM2MjE3_a620bc98-80c5-49da-85ef-ee11df79a305">759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i059b2fc16c164e18b5bc3641f7e47b0a_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtNC0xLTEtMTM2MjUz_7f9db944-ccb8-403b-aa17-3de29d39a21d">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd43189867c0477aa56e3dd2bd1a3ca1_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtNi0xLTEtMTM2MTkz_b9277ba4-053c-4877-b596-a9f1eb9de11e">1,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ff43227695419d9aa80cbc49fe3fac_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtOC0xLTEtMTM2MjU1_1ab0faa2-8913-402b-9605-936f417631b8">689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf215bb9f1894adc8cb1984f634e46cb_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtMTAtMS0xLTEzNjI1Nw_a9c5507c-1d05-4a42-a74a-2f922b6c33e3">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i417472fa55034ae1828e69637b4f9dc6_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtMTItMS0xLTEzNjE5Mw_a850cd5e-c7a8-43ed-833c-351bd405b542">956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if61ddc5649444d2890986cd3b336d8a6_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtMi0xLTEtMTI3NDUy_e99fb249-55be-4e86-8698-5203621a4790">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9501d13f07544aa914a2f0472499317_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtNC0xLTEtMTI3NDUy_37c4f019-5624-4def-be70-22ea17c5803b">446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c91bcd0b0614b31b6ed09d75f6a89ee_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtNi0xLTEtMTI3NDUy_74c538c7-ad21-46c7-8231-474c45aed05a">715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i447c6a3b3c654027a8f390447d27092a_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtOC0xLTEtMTI3NDUy_80560c16-69de-43e3-b77e-eb9894c327e4">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i913293415a73440c8b746390caea2fe8_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtMTAtMS0xLTEyNzQ1Mg_c9068a83-969e-482a-861c-a98bd5df4ee3">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d14e200ac08498a8babed3b3c0ded3c_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtMTItMS0xLTEyNzQ1Mg_3153d81b-c7a0-4deb-8ee8-89203d03e816">722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b05f801cd3a4927a0124fb231c84d76_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtMi0xLTEtMTQ3Mjk3_cf423d01-c894-4bad-9a49-6238558f578a">567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e7cc819d92f4e75acbc9963bc7090ef_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtNC0xLTEtMTQ3Mjk3_e352ea14-b7e6-48fd-b738-96e7f0944b44">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ae2416c6aa4543a664b0bde8b33563_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtNi0xLTEtMTQ3Mjk3_d630bbd4-28e2-40c5-9f16-b810e2bd20c1">658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9676f44123d40e2871ec3d2771a7a5f_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtOC0xLTEtMTQ3Mjk3_026f3b36-52e8-4851-a2be-13025c75fc99">855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecdf3a73b98a42dc9b239601a9ae31de_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtMTAtMS0xLTE0NzI5Nw_98254cdb-ccc7-4173-a2c6-d580eea26ed3">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45954dd51b7b41aa96b4593c6fb94f09_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtMTItMS0xLTE0NzI5Nw_9af3c8aa-da84-43f1-b111-0a7b9546e5c3">968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6148be5d2f114eaba7d30900efe31d0c_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtMi0xLTEtMTI3NDUy_c6fb60d5-7a9e-44b6-b5a2-54b03f07a3ca">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib505cfceda644a379d36c8eb60ae289b_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtNC0xLTEtMTI3NDUy_99238ec0-332f-4ca1-b068-70ac5e5d99d1">335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f37b029317a4d00a1a498b287de24f5_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtNi0xLTEtMTI3NDUy_f63649a1-7577-4778-b8b5-0e0d6aca6a7f">654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i280383856aef44de9c38a690e97f94a4_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtOC0xLTEtMTI3NDUy_ddb1645e-a6d4-45c2-892f-6efb2bcb42fb">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5d62159edfe46daa8cde42bb90fd594_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtMTAtMS0xLTEyNzQ1Mg_f68eedab-3d7d-425f-9c10-59aabcc52fbd">290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i599bea8fe9d342bf8a2319d0c99d8049_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtMTItMS0xLTEyNzQ1Mg_b3697fbf-e4d5-427b-953c-a56fbfb3c64b">572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if33d244e2dcc4deb97f437c4bf8015e5_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjctMi0xLTEtMTI3NDUy_ef39e21c-24e0-4df5-8fd2-9c5eacb6d583">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4743b11647f495995b2a8eb1612ae62_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjctNC0xLTEtMTI3NDUy_21eec8dc-e620-4979-a41e-d0c93b8450d8">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i019834958d7c4fdcb462b108564b7504_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjctNi0xLTEtMTI3NDUy_0d1082af-f051-4df3-a1fe-04bcd1f4cb09">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3329340deea4c2893e19564ea8f5d50_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjctOC0xLTEtMTI3NDUy_9b3280e4-9521-4726-96c5-e9b1c34e602e">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33575c61bd1a4b6483cadbb17231bd16_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjctMTAtMS0xLTEyNzQ1Mg_dc813de9-e3a8-45b6-8d29-4cb971845ea7">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76d8149329f846d4b8b397d30cbfffdb_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjctMTItMS0xLTEyNzQ1Mg_15791ce5-d1ce-4886-9f68-df9dbba04f96">531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i284e10e01d024a31b71cbe8084385e6a_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjgtMi0xLTEtMTM2MzQ5_21c432cb-457c-425b-b81b-6376c17b18e5">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bb25efd7724f2ab8c17abd89376d32_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjgtNC0xLTEtMTM2MzUx_d086c6ab-bd90-4881-937a-615bf09f1210">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i799c05d5e6c148739756e62ed52efc0e_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjktNi0xLTEtMTQwNjc1_57460d25-98fc-495e-b353-74b706058fff">550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c26221f1ddc4730a672e6feda6527ac_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjgtOC0xLTEtMTM2MzUz_cd270592-cfa3-4371-9f68-e20a6fb4020e">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8df6d5b75ce4981805065f554e3fc61_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjgtMTAtMS0xLTEzNjM1Ng_e7f5acc0-a3d1-4b3f-b29f-3de651ee1d3b">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0c82557a9f4c5a9dad46e4f1995240_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjktMTItMS0xLTE0MDY3NQ_3f29be7b-5711-4b77-adc7-0c764eba533d">472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9080bae4bb24f77958c82064456abff_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjgtMi0xLTEtMTI3NDUy_d1c49172-efa7-4cbc-954f-9edf2108024c">1,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90438b29fb8e47daa853e17a32039dbf_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjgtNC0xLTEtMTI3NDUy_1a9ff8e6-b1a2-488b-9799-3435b69de097">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69516fc5e36948efb30d55be4c11c00e_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjgtNi0xLTEtMTI3NDUy_2db47c8d-d009-4c82-8f32-5fed4d490a8b">3,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f5357d2c814ae18ef9d15c743aa395_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjgtOC0xLTEtMTI3NDUy_d2195d72-ed8b-452e-bf10-5e95413c46c9">1,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb2e90867824a3d91fa7756b41e93e0_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjgtMTAtMS0xLTEyNzQ1Mg_91b3cf19-d384-45d9-91d8-7c5d009ed085">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f3ade07d4da4313b5b990be550c7fe7_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjgtMTItMS0xLTEyNzQ1Mg_be5a93a0-13e8-4bf5-a83d-606f9916ab0b">2,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d0a9ca182c34101bf19dd4a000ada97_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjktMi0xLTEtMTI3NDUy_fbcba5d6-4f44-4ccc-bf9b-1890c5cf3d41">8,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia06b5f63bc244d16b92988767f8bc100_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjktNC0xLTEtMTI3NDUy_25adf2e7-6c09-4e43-8382-b7552d76df7b">3,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38c160a3f1834d5e9d775a1dea85e514_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjktNi0xLTEtMTI3NDUy_25d9fa49-904b-403b-af61-39f998c803f2">12,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id43e33fcdb65467a8bb28d8ffb21869c_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjktOC0xLTEtMTI3NDUy_2ae15588-f335-40ab-b9ab-b0ea21c13bef">8,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bc4cfc3564596be8443a8279385fb_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjktMTAtMS0xLTEyNzQ1Mg_6b80561b-b8d1-4a0e-a679-acf929c6e088">3,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93db18973157470084da5a577ecb7c40_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjktMTItMS0xLTEyNzQ1Mg_d6ba994b-94dd-4df2-8a1b-fbd1ec50a758">11,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43a801ced92f421e934618c8046f564b_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMzAtNi0xLTEtMTI3NDUy_c4607a90-be65-47b6-904c-7eca4af12cea">820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bfeed5ecca54e718c3e7aefb7714ac5_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMzAtMTItMS0xLTEyNzQ1Mg_2edfd645-a07a-436b-979d-6e2dfabf7c04">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMzEtNi0xLTEtMTI3NDUy_27df0283-0834-4005-8bc7-dd9aad4c351e">12,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMzEtMTItMS0xLTEyNzQ1Mg_f6710791-d3a6-4e32-b4c3-f449ac0ac421">12,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"><ix:continuation id="i79a98668002b4cbd8552f83edb12f1ab" continuedAt="icbc33143c9b5444eb164cecddb30977b"><ix:continuation id="i2fef51416bc645deb9a2b92ad2bcb044" continuedAt="if0ba0729637e490a86f8f92a1f15a49b">(1)&#160;&#160;&#160;&#160;</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="icbc33143c9b5444eb164cecddb30977b"><ix:continuation id="if0ba0729637e490a86f8f92a1f15a49b">Hedging gains and losses, which are included in product sales, were not material for the three and six months ended June 30, 2022 and 2021.</ix:continuation></ix:continuation> </span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span><br/></span></div><div id="i710475db76604b05901ef7473465ecf1_46"></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfNTU2MA_8e747e9e-6c07-4197-9975-005d195a7329" continuedAt="i8a0577c6b3424ae0b19db4a19b696202" escape="true">Income taxes</ix:nonNumeric></span></div><ix:continuation id="i8a0577c6b3424ae0b19db4a19b696202" continuedAt="ic3248957814d40cda0d9ccc164194870"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the three and six months ended June 30, 2022, were <ix:nonFraction unitRef="number" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfMTA5OTUxMTYzMzYzOA_8ebd4f61-1f02-414a-a49b-3aa9f57934cf">14.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfMTA5OTUxMTYzMzY0Mw_82d66933-8502-498f-b9e8-4a42e7ddd71f">12.9</ix:nonFraction>%, respectively, compared with <ix:nonFraction unitRef="number" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfMTA5OTUxMTYzMzYyNA_a5436e9b-99a4-49a8-833f-f97803449c66">16.8</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfMTA5OTUxMTYzMzYzMw_78ca5838-51c3-4baf-a8f4-243e5c3c09af">12.6</ix:nonFraction>%, respectively, for the corresponding periods of the prior year. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our effective tax rate for the three months ended June 30, 2022, was primarily due to the prior year nondeductible IPR&amp;D expense arising from the acquisition of Five Prime, partially offset by current year unfavorable items including a loss on a nonstrategic divestiture. The increase in our effective tax rate for the six months ended June 30, 2022, was primarily due to current year unfavorable items compared to last year including a loss on a nonstrategic divestiture, partially offset by the prior year nondeductible IPR&amp;D expense arising from the acquisition of Five Prime and changes in earnings mix. The effective tax rates differ from the federal statutory rate primarily as a result of foreign earnings from the Company&#8217;s operations conducted in Puerto Rico, a territory of the United States treated as a foreign jurisdiction for U.S. tax purposes, that are currently subject to a tax incentive grant through 2035. In addition, the Company&#8217;s operations conducted in Singapore are subject to a tax incentive grant through 2034. These foreign earnings are also subject to U.S. tax at a reduced rate of 10.5%. See Note 2, Acquisitions and divestitures.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. territory of Puerto Rico imposes a 4% excise tax on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. We account for the excise tax as a manufacturing cost that is capitalized in Inventories and expensed in Cost of sales when the related products are sold. For U.S. income tax purposes, in 2022, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes can and have arisen with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. Tax authorities, including the IRS, are becoming more aggressive and are particularly focused on such matters.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received an RAR and a modified RAR from the IRS for the years 2010&#8211;2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for the years 2010&#8211;2012 that we received in May and July 2021, which seek to increase our U.S. taxable income for the years 2010&#8211;2012 by an amount that would result in additional federal tax of approximately $<ix:nonFraction unitRef="usd" contextRef="i46acdac3da2c44dca21c41eba4598137_I20210531" decimals="-8" name="amgn:ProposedAdditionalIncomeTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfMjcxNw_5b9dc86f-63b6-4310-84e2-9d122104f4b8">3.6</ix:nonFraction>&#160;billion plus interest. Any additional tax that could be imposed for the years 2010&#8211;2012 would be reduced by up to approximately $<ix:nonFraction unitRef="usd" contextRef="i46acdac3da2c44dca21c41eba4598137_I20210531" decimals="-6" name="amgn:RepatriationTaxOnProposedAdditionalTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfMjgzMA_4b891d7e-fed0-42ec-abb1-29cdf8bed72b">900</ix:nonFraction>&#160;million of repatriation tax previously accrued on our foreign earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2020, we received an RAR and a modified RAR from the IRS for the years 2013&#8211;2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010&#8211;2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013&#8211;2015 that we previously reported receiving in April 2022 that seeks to increase our U.S. taxable income for the years 2013&#8211;2015 by an amount that would result in additional federal tax of approximately $<ix:nonFraction unitRef="usd" contextRef="i82d3aa8175154da2ba3e9dab9d5064c0_I20220428" decimals="-8" name="amgn:ProposedAdditionalIncomeTax20132015" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfMzU1Mw_2c601a86-39b4-4e51-92fb-8a7777260dc0">5.1</ix:nonFraction>&#160;billion, plus interest. In addition, the Notice asserts penalties of approximately $<ix:nonFraction unitRef="usd" contextRef="i82d3aa8175154da2ba3e9dab9d5064c0_I20220428" decimals="-8" name="amgn:PenaltiesOnProposedAdditionalIncomeTax20132105" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfMzYzMQ_fe81ea6d-9f1f-4109-bfa1-29d73fb85058">2.0</ix:nonFraction>&#160;billion. Any additional tax that could be imposed for the years 2013&#8211;2015 would be reduced by up to approximately $<ix:nonFraction unitRef="usd" contextRef="i82d3aa8175154da2ba3e9dab9d5064c0_I20220428" decimals="-8" name="amgn:RepatriationTaxOnProposedAdditionalTax20132015" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfMzczMA_6404c708-27f7-4b3d-94b7-580b03a00139">2.2</ix:nonFraction>&#160;billion of repatriation tax previously accrued on our foreign earnings. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We firmly believe that the IRS positions set forth in the 2010&#8211;2012 and 2013&#8211;2015 Notices are without merit. We are contesting the 2010&#8211;2012 and 2013&#8211;2015 Notices through the judicial process, and we will seek consolidation of the two periods into one case in the U.S. Tax Court.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are currently under examination by the IRS for the years 2016&#8211;2018 with respect to issues similar to those for the 2010 through 2015 period. In addition, we have examinations by a number of state and foreign tax jurisdictions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final resolution of these complex matters is not likely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="ic3248957814d40cda0d9ccc164194870"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Results of Operations, Income Taxes, for further discussion and Part II, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 1A, Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Factors&#8212;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2022, the gross amounts of our UTBs increased by $<ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfNTM5OQ_db8a9aef-3b44-44b3-9ca0-9dbd22b0241a">50</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfMTY0OTI2NzQ0ODEyNg_91062859-0985-4e20-80a5-2dfe619cbb9b">95</ix:nonFraction> million, respectively, as a result of tax positions taken during the current year. Substantially all of the UTBs as of June 30, 2022, if recognized, would affect our effective tax rate.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i710475db76604b05901ef7473465ecf1_49"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RleHRyZWdpb246Mjg0OWE4MjFjZWU5NDY1OTg1NGY2NTkxOWI4MGNlNTNfNzEy_029583b7-8623-476d-ba32-284b75543b6b" continuedAt="i048203e1c3464f309a6637a6bb7efae3" escape="true">Earnings per share</ix:nonNumeric></span></div><ix:continuation id="i048203e1c3464f309a6637a6bb7efae3"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computation of basic EPS is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.</span></div><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RleHRyZWdpb246Mjg0OWE4MjFjZWU5NDY1OTg1NGY2NTkxOWI4MGNlNTNfNzI4_c2ba86f9-7699-4d7c-8fda-a185dbc5ef57" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computations for basic and diluted EPS were as follows (in millions, except per-share data):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (Numerator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income for basic and diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMy0xLTEtMS0xMjc0NTI_7cffa87f-2b82-45e6-bc2e-f70198802ac5">1,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMy0zLTEtMS0xMjc0NTI_c0b1b612-8fae-4c72-af79-c267865b9de9">464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMy01LTEtMS0xMjc0NTI_629c2393-37bd-4591-b56d-f62fc5b4a218">2,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMy03LTEtMS0xMjc0NTI_626ba5ea-6066-408a-8dfe-68063acf0ab1">2,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (Denominator):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for basic EPS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfNi0xLTEtMS0xMjc0NTI_7dfd1b00-21da-4e05-957b-87663292194e">535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfNi0zLTEtMS0xMjc0NTI_5af9f16d-c0a2-499f-be31-490f7ddc7046">573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfNi01LTEtMS0xMjc0NTI_faeaed5d-a971-4fd5-9be5-4081239cd867">541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfNi03LTEtMS0xMjc0NTI_c3f14bf2-3f68-486f-b1c9-cb53ab19c34e">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfNy0xLTEtMS0xMjc0NTI_0be22578-7143-442c-b218-953d694d5c6f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfNy0zLTEtMS0xMjc0NTI_7be79d5f-8a63-4f12-aa96-9835a906f852">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfNy01LTEtMS0xMjc0NTI_ff45db96-5992-4c1d-a1b8-f8ed314d2ae2">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfNy03LTEtMS0xMjc0NTI_fabdcb2a-0d4d-4cb9-be4f-f58fd9d84d0b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfOC0xLTEtMS0xMjc0NTI_8aac8d05-3678-4ed5-8329-4f8b064523d3">537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfOC0zLTEtMS0xMjc0NTI_c61f4ae7-e747-475f-a3da-8f285d4c2f7a">576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfOC01LTEtMS0xMjc0NTI_94e36912-cca4-4638-b9d5-8fb3927c9cb3">544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfOC03LTEtMS0xMjc0NTI_b86242b4-e84d-4c09-9357-793173c6feed">578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMTAtMS0xLTEtMTI3NDUy_dc749c09-7ff4-4453-9d29-813bfd6ff6fb">2.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMTAtMy0xLTEtMTI3NDUy_e63ab449-fe2f-4465-93ed-e66dd103fcc6">0.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMTAtNS0xLTEtMTI3NDUy_a2a88855-fb85-49bc-afab-2aa5ca906086">5.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMTAtNy0xLTEtMTI3NDUy_36db706c-25e8-4e34-8a8f-afd8dafa7cec">3.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMTEtMS0xLTEtMTI3NDUy_c01100d6-7c08-46c3-8ee4-688bb9bb914f">2.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMTEtMy0xLTEtMTI3NDUy_ea357730-cb59-478c-a8df-80cdaf2f0e68">0.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMTEtNS0xLTEtMTI3NDUy_907149cb-677e-4227-a72d-a5b74bfb4a01">5.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMTEtNy0xLTEtMTI3NDUy_bb79ab30-3b48-4d2a-bc17-a5bf43c46e29">3.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022 and 2021, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfNDk0NzgwMjMzODAzMw_05e15192-87fa-47cd-ac1d-e6a57ecacc5b" continuedAt="i1c7f8578c63047bdb99d7e641b801c3e" escape="true">Investments</ix:nonNumeric></span></div><ix:continuation id="i1c7f8578c63047bdb99d7e641b801c3e" continuedAt="i4580053264a4446289faa8c3847d8eb8"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-sale investments</span></div><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfNTY1OA_b3ddea09-5fac-484d-8c00-7a9e4cbb12a5" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8082d2e09a5c4aa0a7f3731849ec0d16_I20220630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMS0yLTEtMS0xMjc0NTI_48edb2a7-91c0-4d91-bdbe-99c190340cb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8082d2e09a5c4aa0a7f3731849ec0d16_I20220630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMS00LTEtMS0xMjc0NTI_e4dde22f-4594-4c51-8944-ad782e7f57a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8082d2e09a5c4aa0a7f3731849ec0d16_I20220630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMS02LTEtMS0xMjc0NTI_ba4dfb27-8f00-4259-9082-7d2d74af0195">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8082d2e09a5c4aa0a7f3731849ec0d16_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMS04LTEtMS0xMjc0NTI_4a7017b7-812f-4d6d-8236-77f21a21b0e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea16251ca3344cd8e26c09cc1395a22_I20220630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMi0yLTEtMS0xMjc0NTI_f9a1e9de-d1af-4a72-a2ed-41cdba808c11">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea16251ca3344cd8e26c09cc1395a22_I20220630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMi00LTEtMS0xMjc0NTI_b3b30cd0-32c0-41aa-9aa8-92910bc8f535">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea16251ca3344cd8e26c09cc1395a22_I20220630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMi02LTEtMS0xMjc0NTI_5cf75b8e-37d5-4386-84a2-a3c2e213565a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea16251ca3344cd8e26c09cc1395a22_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMi04LTEtMS0xMjc0NTI_92cb65e4-4e31-463b-b3c2-614582631e50">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbbc44571a8140188c44b0df13007242_I20220630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTItMi0xLTEtMTI3NDUy_c5230cb0-0a0c-4cbe-8a92-7f27aabca063">4,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbbc44571a8140188c44b0df13007242_I20220630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTItNC0xLTEtMTI3NDUy_39caeaa1-982f-4f04-be56-8d65338fcd7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbbc44571a8140188c44b0df13007242_I20220630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTItNi0xLTEtMTI3NDUy_0b99db1d-dc87-4e82-86a6-2b3bf4d11032">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbbc44571a8140188c44b0df13007242_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTItOC0xLTEtMTI3NDUy_97cdc12c-f56a-44d2-aa4d-e666879959c9">4,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f04eaab04b4d2c952875e4954ffda7_I20220630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTMtMi0xLTEtMTI3NDUy_e0551b31-4e7b-4ac1-99cd-a09c54420bf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f04eaab04b4d2c952875e4954ffda7_I20220630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTMtNC0xLTEtMTI3NDUy_8d055f53-b230-4cb7-8afa-44c158019974">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f04eaab04b4d2c952875e4954ffda7_I20220630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTMtNi0xLTEtMTI3NDUy_1a47ef7f-d4d1-4262-9797-2e9f4599b4fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f04eaab04b4d2c952875e4954ffda7_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTMtOC0xLTEtMTI3NDUy_f9f867b4-cd5d-4802-9c4e-ac311c0d40fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTYtMi0xLTEtMTI3NDUy_16a6a31f-a439-4f96-af96-1a7950c93004">6,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTYtNC0xLTEtMTI3NDUy_9d403729-dd0f-4f12-9e8c-d4b535b5b515">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTYtNi0xLTEtMTI3NDUy_5967036d-1df0-40ea-ae12-bd105e20a32b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTYtOC0xLTEtMTI3NDUy_4c2b1348-153b-464d-80f5-5919fd1d6684">6,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd41271077fb4ca086b8c963378ae207_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMS0yLTEtMS0xMjc0NTI_f1a0f231-c3c6-4656-ac13-1e11e911c7e2">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd41271077fb4ca086b8c963378ae207_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMS00LTEtMS0xMjc0NTI_34c3b0aa-8fa5-45fd-97e3-b53eb09dd566">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd41271077fb4ca086b8c963378ae207_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMS02LTEtMS0xMjc0NTI_280f1faa-6cf0-4daa-8cb1-b66660082320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd41271077fb4ca086b8c963378ae207_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMS04LTEtMS0xMjc0NTI_8819f199-4604-4fd0-b4c7-0fab49fc0bc9">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c7a0f871105442a9e599228c9451089_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMi0yLTEtMS0xMjc0NTI_22c37691-f54e-4ff6-8568-87ce33ae370a">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c7a0f871105442a9e599228c9451089_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMi00LTEtMS0xMjc0NTI_c5564d9c-984e-48f1-b7a0-66c32b45677a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c7a0f871105442a9e599228c9451089_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMi02LTEtMS0xMjc0NTI_bc843aff-c995-454c-89cf-fe06c6e4fcc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c7a0f871105442a9e599228c9451089_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMi04LTEtMS0xMjc0NTI_860273a6-d9e0-4f8b-a5d7-f3c678bbd8d2">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02847d17ecc24c3f9024cc5f534c04a2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTItMi0xLTEtMTI3NDUy_084d4764-14ff-40ae-9ed8-ca9a2c10fd36">5,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02847d17ecc24c3f9024cc5f534c04a2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTItNC0xLTEtMTI3NDUy_b7f89837-0d18-4a3a-9780-9be45ea7ed02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02847d17ecc24c3f9024cc5f534c04a2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTItNi0xLTEtMTI3NDUy_84aadb83-e67b-43a7-8cf8-a854cc6e33af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02847d17ecc24c3f9024cc5f534c04a2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTItOC0xLTEtMTI3NDUy_f963c757-e0de-4a1b-90fa-5949a6a33548">5,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea64a31893bd4a61a10bade5fb93931f_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTMtMi0xLTEtMTI3NDUy_2cecfa5b-bad5-497c-85be-bce5ac5e1ba3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea64a31893bd4a61a10bade5fb93931f_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTMtNC0xLTEtMTI3NDUy_e9ed3b6e-47e6-497f-a62d-d3ef09260ec0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea64a31893bd4a61a10bade5fb93931f_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTMtNi0xLTEtMTI3NDUy_5445ccee-f562-42a3-87e1-3838aec00944">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea64a31893bd4a61a10bade5fb93931f_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTMtOC0xLTEtMTI3NDUy_0b19ba06-8fe8-483e-bbfe-8abfa4bcc315">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTQtMi0xLTEtMTI3NDUy_f83f1f38-c9fd-4267-a1b3-e4a172c2118a">7,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTQtNC0xLTEtMTI3NDUy_e268cac4-9225-41b9-94f8-5cefb4163a86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTQtNi0xLTEtMTI3NDUy_ca7cae39-a9d0-43ee-a23c-adc23a0f1170">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTQtOC0xLTEtMTI3NDUy_21d100df-2cd2-4715-b926-977ca48835b0">7,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="amgn:FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfNTYzNg_80b52ac0-3a6d-4594-9968-4d8703e179b4" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3ee9095509a4235b125b11b137e139e_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOjdmNzg4MGJlMDE1NDQzZWRiMWZjNWMwYjRjY2RmYTNkL3RhYmxlcmFuZ2U6N2Y3ODgwYmUwMTU0NDNlZGIxZmM1YzBiNGNjZGZhM2RfMS0yLTEtMS0xMjc0NTI_2abcd866-c052-4c92-8738-31ed9529392e">4,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2192ca00bef0437697f96821d3d064c5_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOjdmNzg4MGJlMDE1NDQzZWRiMWZjNWMwYjRjY2RmYTNkL3RhYmxlcmFuZ2U6N2Y3ODgwYmUwMTU0NDNlZGIxZmM1YzBiNGNjZGZhM2RfMS00LTEtMS0xMjc0NTI_cb1e9cc2-9325-47ba-94fb-9e0b9fb35097">7,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3ee9095509a4235b125b11b137e139e_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOjdmNzg4MGJlMDE1NDQzZWRiMWZjNWMwYjRjY2RmYTNkL3RhYmxlcmFuZ2U6N2Y3ODgwYmUwMTU0NDNlZGIxZmM1YzBiNGNjZGZhM2RfMi0yLTEtMS0xMjc0NTI_9c1f799b-d9fc-4f72-bc12-8bef1fca20e9">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2192ca00bef0437697f96821d3d064c5_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOjdmNzg4MGJlMDE1NDQzZWRiMWZjNWMwYjRjY2RmYTNkL3RhYmxlcmFuZ2U6N2Y3ODgwYmUwMTU0NDNlZGIxZmM1YzBiNGNjZGZhM2RfMi00LTEtMS0xMjc0NTI_2ce5b7c0-ed9e-423a-96ee-ca1851225447">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3ee9095509a4235b125b11b137e139e_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOjdmNzg4MGJlMDE1NDQzZWRiMWZjNWMwYjRjY2RmYTNkL3RhYmxlcmFuZ2U6N2Y3ODgwYmUwMTU0NDNlZGIxZmM1YzBiNGNjZGZhM2RfMy0yLTEtMS0xMjc0NTI_b87bc774-6504-4969-85b7-53a7981214bd">6,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2192ca00bef0437697f96821d3d064c5_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOjdmNzg4MGJlMDE1NDQzZWRiMWZjNWMwYjRjY2RmYTNkL3RhYmxlcmFuZ2U6N2Y3ODgwYmUwMTU0NDNlZGIxZmM1YzBiNGNjZGZhM2RfMy00LTEtMS0xMjc0NTI_3c23921d-122a-4ef5-b9d2-5c4798a56435">7,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents in the above table excludes bank account cash of $<ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfNDY4_5034ef4b-9c8d-4280-ac4b-74bd4c82789a">770</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfNDc1_c8377ff0-1991-444b-86b2-86c4f2f33ae2">733</ix:nonFraction>&#160;million as of June 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest-bearing securities as of June 30, 2022 and December 31, 2021, mature in one year or less.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022 and 2021, realized gains and losses on interest-bearing securities were not material. Realized gains and losses on interest-bearing securities are recorded in Other (expense) income, net, in the Condensed Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held investments in equity securities with readily determinable fair values (publicly traded securities) of $<ix:nonFraction unitRef="usd" contextRef="i52bfb5d420974f909b489605f4ebb48e_I20220630" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTQ3NQ_33a1dfd7-f8b2-4b74-9911-9a309ebd440f">361</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i81cbf2552fde457394dd38fa4c8d3a52_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTQ4Mg_9e862bad-4fbd-437d-92eb-253e8eb9df33">611</ix:nonFraction> million as of June 30, 2022 and December 31, 2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. During the three months ended June 30, 2022 and 2021, net unrealized gains and losses on publicly traded securities were a $<ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTA5OTUxMTYzMzYwMw_aabc6f95-6e59-41fd-977a-da528a9f3e67">106</ix:nonFraction>&#160;million net loss and a $<ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTA5OTUxMTYzMzYxNw_3f97788b-b901-48b9-a91c-3abb8c998cca">25</ix:nonFraction>&#160;million net gain, respectively. During the six months ended June 30, 2022 and 2021, net unrealized losses on publicly traded securities were $<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTcwMA_ec2cff85-0d3c-4777-afe3-5f1ed0084f8f">276</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTcwNw_36e2445c-dc8d-4f51-a087-c456539b20d2">31</ix:nonFraction>&#160;million, respectively. Realized gains and losses on sales of publicly traded securities for the three and six months ended June 30, 2022 and 2021, were not material.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="i4580053264a4446289faa8c3847d8eb8"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held investments of $<ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTg2Nw_fac8c088-1c31-4478-9ada-ab97599952ef">280</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTg3NA_a18d05c0-a0d9-4016-ab6d-09ffa8db3d4b">262</ix:nonFraction> million in equity securities without readily determinable fair values as of June 30, 2022 and December 31, 2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. During the three and six months ended June 30, 2022 and 2021, upward adjustments and downward adjustments on these securities were not material. Adjustments were based on observable price transactions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method investments </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, we had an ownership interest in BeiGene of approximately <ix:nonFraction unitRef="number" contextRef="i508f5bf239c54b9b938463f7ae92fea1_I20220630" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMjM1Ng_4c2ca0d1-fb75-4bbc-87d4-2fb21eccabed">18.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ic408702ec02a49bf91a6056997008286_I20211231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMjc0ODc3OTA4Mjk5NA_8e6fba37-4eee-476b-8e2d-0e2fdd6c5263">18.4</ix:nonFraction>%, respectively, which is included in Other noncurrent assets in the Condensed Consolidated Balance Sheets and accounted for under the equity method of accounting. We amortize the difference between the fair value of equity securities acquired and our proportionate share of the carrying value of the underlying net assets of BeiGene over the useful lives of the assets that gave rise to this basis difference. This amortization and our share of the results of operations of BeiGene are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the Condensed Consolidated Statements of Income one quarter in arrears. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022 and 2021, the carrying value of our equity investment was adjusted by our share of BeiGene&#8217;s net loss of $<ix:nonFraction unitRef="usd" contextRef="i496aa2763a92482692aec0e597926c98_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzA3MA_4615e039-a47d-4235-aaa2-e773724244e0">80</ix:nonFraction>&#160;million and net income of $<ix:nonFraction unitRef="usd" contextRef="i0a1cd1326d554d03be0c62860aaadc16_D20210401-20210630" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzA3Nw_e840de2e-b7fd-481b-ab64-43a3167c478e">14</ix:nonFraction>&#160;million, respectively, and amortization of the basis difference of $<ix:nonFraction unitRef="usd" contextRef="i496aa2763a92482692aec0e597926c98_D20220401-20220630" decimals="-6" name="amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzEzOQ_c36c3aa1-5824-4a0a-8195-c829bba60ad9">48</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0a1cd1326d554d03be0c62860aaadc16_D20210401-20210630" decimals="-6" name="amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzE0Ng_a43cddb2-d59d-4a3d-85a2-8d51158a1456">42</ix:nonFraction>&#160;million, respectively. During the six months ended June 30, 2022 and 2021, the carrying value of our equity investment was adjusted by our share of BeiGene&#8217;s net losses of $<ix:nonFraction unitRef="usd" contextRef="ic159ef06be114a82aece4d92d6710839_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzI1Mw_c896b102-623f-4ab7-8bd3-616f8cabd30d">188</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i888296d1eab64b6b817ca5c5d9f69be8_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzI2MA_1e598e38-08de-494f-87d5-6e954c20eb79">83</ix:nonFraction>&#160;million, respectively, and amortization of the basis difference of $<ix:nonFraction unitRef="usd" contextRef="ic159ef06be114a82aece4d92d6710839_D20220101-20220630" decimals="-6" name="amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzMyNA_80234bb9-2de5-4a01-b931-4372b1741217">95</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i888296d1eab64b6b817ca5c5d9f69be8_D20210101-20210630" decimals="-6" name="amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzMzMQ_8366245e-ed78-4b8a-8869-3b6fb8a5b440">84</ix:nonFraction>&#160;million, respectively. As of June 30, 2022 and December 31, 2021, the carrying values of our investment in BeiGene totaled $<ix:nonFraction unitRef="usd" contextRef="i508f5bf239c54b9b938463f7ae92fea1_I20220630" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMjc0ODc3OTA4Mjg4Mg_b9c404ae-1591-4ece-83df-b6eae67f8196">2.5</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ic408702ec02a49bf91a6056997008286_I20211231" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMjc0ODc3OTA4Mjg5Ng_3ce4ea1f-c580-404f-bc8b-35e6596cd1ee">2.8</ix:nonFraction>&#160;billion, respectively, and the fair values of our investment totaled $<ix:nonFraction unitRef="usd" contextRef="i508f5bf239c54b9b938463f7ae92fea1_I20220630" decimals="-8" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMjc0ODc3OTA4Mjc4Mg_d8329e4e-f3fb-41b2-ad52-931a15d5dc47">3.1</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ic408702ec02a49bf91a6056997008286_I20211231" decimals="-8" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMjc0ODc3OTA4Mjc5Nw_6358c6e0-5358-4e6d-9f4c-3d2425ba23d2">5.1</ix:nonFraction>&#160;billion, respectively. As of June 30, 2022, we believe the carrying value of our equity investment in BeiGene is fully recoverable.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neumora Therapeutics, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2021, we acquired an approximately <ix:nonFraction unitRef="number" contextRef="i5cda008dddc94401b22d3259266fc7e7_I20210930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzUyNA_45fde6e4-762f-4fde-82bd-2b7e8780c67c">25.9</ix:nonFraction>% ownership interest in Neumora, a privately held company, for $<ix:nonFraction unitRef="usd" contextRef="i5cda008dddc94401b22d3259266fc7e7_I20210930" decimals="-6" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzU4OA_4fdd58c7-e121-4c7b-81d0-e9d9170a2ad2">257</ix:nonFraction>&#160;million, which is included in Other noncurrent assets in the Condensed Consolidated Balance Sheets, in exchange for a $<ix:nonFraction unitRef="usd" contextRef="icdb22de342f041adb8e2b70cbc132e50_D20210930-20210930" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzcwMQ_a381fd4c-7ea0-4f2b-a81d-f2fb33c682bc">100</ix:nonFraction>&#160;million cash payment and $<ix:nonFraction unitRef="usd" contextRef="icdb22de342f041adb8e2b70cbc132e50_D20210930-20210930" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzcyMQ_621e974f-bd37-4608-acc3-29e623129807">157</ix:nonFraction>&#160;million in noncash consideration primarily related to future services. Although our equity investment provides us with the ability to exercise significant influence over Neumora, we have elected the fair value option to account for our equity investment. Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period. We believe the fair value option best reflects the economics of the underlying transaction. As of June 30, 2022 and December 31, 2021, our ownership interest in Neumora was approximately <ix:nonFraction unitRef="number" contextRef="i1d79fa0d130e44d19361d654d95e141d_I20220630" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfNDI3Mw_34c1d622-f748-43d2-8b40-e8bd19cd857d">25.7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ic76acadc687c4a66b5883e78b037a6ad_I20211231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfNDI4MA_3be8de38-9d4c-4cc6-a89f-5d6d6d112046">25.9</ix:nonFraction>%, respectively, and the fair values of our investment were $<ix:nonFraction unitRef="usd" contextRef="i1d79fa0d130e44d19361d654d95e141d_I20220630" decimals="-6" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfOTg5NTYwNDY2MDI5NQ_5388bb8e-bf6f-4e03-bcf9-5a84e4d51086">131</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic76acadc687c4a66b5883e78b037a6ad_I20211231" decimals="-6" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfOTg5NTYwNDY2MDI4OA_731d3464-a3a5-4d43-bc53-b97b253a45c0">220</ix:nonFraction> million, respectively. Accordingly, for the reduction in fair value of our investment during the three and six months ended June 30, 2022, we recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="ifbd4bb3072a846dead8e321c6b0cf833_D20220401-20220630" decimals="-6" name="amgn:EquityMethodInvestmentChangeInCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMjc0ODc3OTA4MjgxMg_214e9501-576e-44c1-80ef-76bd7f7bd006">39</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0f602482804d4aec8fdc3e408b13ed29_D20220101-20220630" decimals="-6" name="amgn:EquityMethodInvestmentChangeInCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMjc0ODc3OTA4MjgzNw_2df54689-f84d-4b09-b972-2853e7af5bb8">89</ix:nonFraction>&#160;million, respectively, for the reduction in fair value of our investment in Other (expense) income, net, in the Condensed Consolidated Statements of Income. For information on determination of fair values, see Note 11, Fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limited partnerships</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held limited partnership investments of $<ix:nonFraction unitRef="usd" contextRef="iaa0314910b794236a904970854a1e630_I20220630" decimals="-6" name="us-gaap:AlternativeInvestment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfNDczNg_20503471-c3e9-4cab-96c1-1d17c1be478d">338</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib8b0ba79e4914ce8815964b9387a76dd_I20211231" decimals="-6" name="us-gaap:AlternativeInvestment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfNDc0Mw_03b79955-2125-42ce-a7bf-df2da1958161">573</ix:nonFraction> million as of June 30, 2022 and December 31, 2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. These investments, primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of June 30, 2022, unfunded additional commitments to be made for these investments during the next several years were $<ix:nonFraction unitRef="usd" contextRef="i1fe68111c13942ef9c7a0d951601d88b_I20220630" decimals="-6" name="us-gaap:InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfNTQwMA_2be2c92f-8a97-44bc-aa9e-1faf89aaf23c">209</ix:nonFraction>&#160;million. For the three months ended June 30, 2022 and 2021, net unrealized losses from our limited partnership investments were $<ix:nonFraction unitRef="usd" contextRef="i401f6926d97c46c6a10162d5f3c2efde_D20220401-20220630" decimals="-6" sign="-" name="amgn:AlternativeInvestmentNetGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTA5OTUxMTYzNDA0Ng_f5a02be9-ae83-4208-a2eb-a5a4ebb3eae2">60</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i62aa67f340d349a684242e6f5ab5e761_D20210401-20210630" decimals="-6" sign="-" name="amgn:AlternativeInvestmentNetGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTA5OTUxMTYzNDA2NA_f7f08a04-48a5-4a2d-9034-ae5e2b0d68db">43</ix:nonFraction>&#160;million, respectively. For the six months ended June 30, 2022 and 2021, net unrealized gains and losses from our limited partnership investments were a $<ix:nonFraction unitRef="usd" contextRef="ife312c8d8cce47d28d37a01320dd5c28_D20220101-20220630" decimals="-6" sign="-" name="amgn:AlternativeInvestmentNetGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTA5OTUxMTYzNDQyNg_92778825-3f71-4524-8816-c0ff3501ed71">220</ix:nonFraction>&#160;million net loss and a $<ix:nonFraction unitRef="usd" contextRef="i9d1c8a9209dc4f9fbe9812c8fcc8987d_D20210101-20210630" decimals="-6" name="amgn:AlternativeInvestmentNetGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTA5OTUxMTYzNDQ0Mg_603d4567-7ce2-4645-b0c9-a144137e21e0">165</ix:nonFraction>&#160;million net gain, respectively.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81NS9mcmFnOjlmMGUxZWIwMmY4ZDRkYTlhNmFlMjI0MDBiNzc4ZWM4L3RleHRyZWdpb246OWYwZTFlYjAyZjhkNGRhOWE2YWUyMjQwMGI3NzhlYzhfODQ_dd54cebb-fe7d-4c8b-8519-6370bc0a71de" continuedAt="i95a08f1c0d0243e8851046cf40a1ce3b" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="i95a08f1c0d0243e8851046cf40a1ce3b"><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81NS9mcmFnOjlmMGUxZWIwMmY4ZDRkYTlhNmFlMjI0MDBiNzc4ZWM4L3RleHRyZWdpb246OWYwZTFlYjAyZjhkNGRhOWE2YWUyMjQwMGI3NzhlYzhfODM_8d800b7d-b92d-46e3-a991-2c6fbe94fbae" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81NS9mcmFnOjlmMGUxZWIwMmY4ZDRkYTlhNmFlMjI0MDBiNzc4ZWM4L3RhYmxlOjJhN2YxZjI2YzZhMDRhZGFiZjI5ZWVlYzg5MGI1NTNlL3RhYmxlcmFuZ2U6MmE3ZjFmMjZjNmEwNGFkYWJmMjllZWVjODkwYjU1M2VfMS0xLTEtMS0xMjc0NTI_d1146598-6876-4736-82c5-776eaf06e95b">779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81NS9mcmFnOjlmMGUxZWIwMmY4ZDRkYTlhNmFlMjI0MDBiNzc4ZWM4L3RhYmxlOjJhN2YxZjI2YzZhMDRhZGFiZjI5ZWVlYzg5MGI1NTNlL3RhYmxlcmFuZ2U6MmE3ZjFmMjZjNmEwNGFkYWJmMjllZWVjODkwYjU1M2VfMS0zLTEtMS0xMjc0NTI_0510b7e7-b4eb-47d3-9b46-3090502a337d">647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81NS9mcmFnOjlmMGUxZWIwMmY4ZDRkYTlhNmFlMjI0MDBiNzc4ZWM4L3RhYmxlOjJhN2YxZjI2YzZhMDRhZGFiZjI5ZWVlYzg5MGI1NTNlL3RhYmxlcmFuZ2U6MmE3ZjFmMjZjNmEwNGFkYWJmMjllZWVjODkwYjU1M2VfMi0xLTEtMS0xMjc0NTI_c7b66cde-b9bb-495a-8b01-2d1ebb3a32dd">2,763</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81NS9mcmFnOjlmMGUxZWIwMmY4ZDRkYTlhNmFlMjI0MDBiNzc4ZWM4L3RhYmxlOjJhN2YxZjI2YzZhMDRhZGFiZjI5ZWVlYzg5MGI1NTNlL3RhYmxlcmFuZ2U6MmE3ZjFmMjZjNmEwNGFkYWJmMjllZWVjODkwYjU1M2VfMi0zLTEtMS0xMjc0NTI_8e7c2f52-b895-4b86-b309-1975662eacfe">2,367</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81NS9mcmFnOjlmMGUxZWIwMmY4ZDRkYTlhNmFlMjI0MDBiNzc4ZWM4L3RhYmxlOjJhN2YxZjI2YzZhMDRhZGFiZjI5ZWVlYzg5MGI1NTNlL3RhYmxlcmFuZ2U6MmE3ZjFmMjZjNmEwNGFkYWJmMjllZWVjODkwYjU1M2VfMy0xLTEtMS0xMjc0NTI_75e6d0b0-ff4b-4b03-bcc9-2dd7881858a6">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81NS9mcmFnOjlmMGUxZWIwMmY4ZDRkYTlhNmFlMjI0MDBiNzc4ZWM4L3RhYmxlOjJhN2YxZjI2YzZhMDRhZGFiZjI5ZWVlYzg5MGI1NTNlL3RhYmxlcmFuZ2U6MmE3ZjFmMjZjNmEwNGFkYWJmMjllZWVjODkwYjU1M2VfMy0zLTEtMS0xMjc0NTI_00572c50-57db-4d9b-9864-e224b4cece6f">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81NS9mcmFnOjlmMGUxZWIwMmY4ZDRkYTlhNmFlMjI0MDBiNzc4ZWM4L3RhYmxlOjJhN2YxZjI2YzZhMDRhZGFiZjI5ZWVlYzg5MGI1NTNlL3RhYmxlcmFuZ2U6MmE3ZjFmMjZjNmEwNGFkYWJmMjllZWVjODkwYjU1M2VfNC0xLTEtMS0xMjc0NTI_5dade705-a1a5-44e8-b62e-b7bb5e854692">4,554</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81NS9mcmFnOjlmMGUxZWIwMmY4ZDRkYTlhNmFlMjI0MDBiNzc4ZWM4L3RhYmxlOjJhN2YxZjI2YzZhMDRhZGFiZjI5ZWVlYzg5MGI1NTNlL3RhYmxlcmFuZ2U6MmE3ZjFmMjZjNmEwNGFkYWJmMjllZWVjODkwYjU1M2VfNC0zLTEtMS0xMjc0NTI_93c7face-366b-4912-a72b-a461e768140d">4,086</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt"><span><br/></span></div><div id="i710475db76604b05901ef7473465ecf1_58"></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTkyNg_77d1afc0-c7bb-4753-b754-2057086bf2c3" continuedAt="i99d37cd8a57f4927827a83fa55b7565e" escape="true">Goodwill and other intangible assets</ix:nonNumeric></span></div><ix:continuation id="i99d37cd8a57f4927827a83fa55b7565e" continuedAt="idf1343f4ebb444e8b30eda801ec3275f"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTkyNw_cb3978ff-725c-42d3-bcf3-82bab3917f7c" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amount of goodwill was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:82.331%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmE4NGUzZDBmMGIwOTQ1MWRhN2ZmNzA0NTAxMzRjYTI0L3RhYmxlcmFuZ2U6YTg0ZTNkMGYwYjA5NDUxZGE3ZmY3MDQ1MDEzNGNhMjRfMS0xLTEtMS0xMjc0NTI_bf668a03-0ce1-475f-a15e-3246fd55d4ce">14,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to goodwill resulting from acquisitions and divestitures, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmE4NGUzZDBmMGIwOTQ1MWRhN2ZmNzA0NTAxMzRjYTI0L3RhYmxlcmFuZ2U6YTg0ZTNkMGYwYjA5NDUxZGE3ZmY3MDQ1MDEzNGNhMjRfMi0xLTEtMS0xMjc0NTI_e2993e8f-f70c-4f53-8d37-ab5b23ad9538">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmE4NGUzZDBmMGIwOTQ1MWRhN2ZmNzA0NTAxMzRjYTI0L3RhYmxlcmFuZ2U6YTg0ZTNkMGYwYjA5NDUxZGE3ZmY3MDQ1MDEzNGNhMjRfMy0xLTEtMS0xMjc0NTI_587f5c90-bc13-416f-9d47-a899d3745fcc">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmE4NGUzZDBmMGIwOTQ1MWRhN2ZmNzA0NTAxMzRjYTI0L3RhYmxlcmFuZ2U6YTg0ZTNkMGYwYjA5NDUxZGE3ZmY3MDQ1MDEzNGNhMjRfNC0xLTEtMS0xMjc0NTI_0200459e-4fe6-4779-afa9-db19ace302c2">14,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Composed of adjustments to goodwill resulting from changes to the acquisition date fair values of net assets acquired in the acquisition of Teneobio and the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other intangible assets</span></div><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="amgn:ScheduleOfIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTk0MA_46512012-6d1f-416c-bcf1-da4b6607fc00" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed-product-technology rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia61f1d92e9464dd18e99ac1aa3b366de_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMy0xLTEtMS0xMjc0NTI_6315a2e4-ad23-4c81-8df2-568b5742ed65">25,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia61f1d92e9464dd18e99ac1aa3b366de_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMy0zLTEtMS0xMjc0NTI_0fe43f5d-4e03-4c97-a8f1-dcc12ac50b80">13,863</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia61f1d92e9464dd18e99ac1aa3b366de_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMy01LTEtMS0xMjc0NTI_c43d5fd2-61ba-4371-b02d-1b3d99f86dd7">11,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cce03dee4c34b2ea84da100e20fbd24_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMy03LTEtMS0xMjc0NTI_b7919ad8-4a67-4039-9bf1-7dada6c56ad7">25,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cce03dee4c34b2ea84da100e20fbd24_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMy05LTEtMS0xMjc0NTI_ccb6601b-6d96-496c-b00e-e07adf12a10b">12,769</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cce03dee4c34b2ea84da100e20fbd24_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMy0xMS0xLTEtMTI3NDUy_10d0a39b-53aa-4c33-853f-3fb0306b0087">12,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i099607de031547a9bb9e43f15bb881fc_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNC0xLTEtMS0xMjc0NTI_cf3233de-32c5-4688-965f-31847b357a2d">3,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i099607de031547a9bb9e43f15bb881fc_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNC0zLTEtMS0xMjc0NTI_ee3c75c0-7fd7-4688-b153-d73d72e60de6">3,050</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i099607de031547a9bb9e43f15bb881fc_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNC01LTEtMS0xMjc0NTI_d7e027d0-7009-4236-b5f4-0e09740237e2">814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic07181533cda4f5e93039975aae670b0_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNC03LTEtMS0xMjc0NTI_afe092f4-c4ae-4cf2-96a8-d1c9dd146e8f">3,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic07181533cda4f5e93039975aae670b0_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNC05LTEtMS0xMjc0NTI_cca39f04-83c6-44e4-b628-7854df9b4ea0">2,973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic07181533cda4f5e93039975aae670b0_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNC0xMS0xLTEtMTI3NDUy_97b1659d-c76f-4db5-bd75-ca1dca39bfaf">834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing-related rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac2b57574dd942a2a453e505dabd533e_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNS0xLTEtMS0xMjc0NTI_903ca88b-91d8-48b4-a0ea-f5f8cae08b71">1,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac2b57574dd942a2a453e505dabd533e_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNS0zLTEtMS0xMjc0NTI_85931f1a-3a77-46f2-b611-1ed0f6b2dba8">1,125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac2b57574dd942a2a453e505dabd533e_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNS01LTEtMS0xMjc0NTI_d99bbd97-0fd2-4d0a-af82-320f9428b29b">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fb7461fd5694c57866568ce1e547030_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNS03LTEtMS0xMjc0NTI_55819cd1-cb42-4f27-953b-acf6bea409cb">1,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fb7461fd5694c57866568ce1e547030_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNS05LTEtMS0xMjc0NTI_9f581cb8-19df-4604-a479-e61655e838f2">1,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fb7461fd5694c57866568ce1e547030_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNS0xMS0xLTEtMTI3NDUy_24eae4aa-eab8-48de-bdcf-9670844d1522">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development technology rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb86733ee024515869430e8dbaa9324_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNi0xLTEtMS0xMjc0NTI_ee77371f-cb6c-4dfd-bcdc-cec223d6a078">1,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb86733ee024515869430e8dbaa9324_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNi0zLTEtMS0xMjc0NTI_15852ef9-cb0b-44eb-b041-f98a9843b409">1,153</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb86733ee024515869430e8dbaa9324_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNi01LTEtMS0xMjc0NTI_236e04a8-247b-4c42-9bfc-b093503d96f9">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i571fbd60834f45a8a94ddbcd37f40d78_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNi03LTEtMS0xMjc0NTI_893d92d6-b95d-4148-ac03-c8446a5956af">1,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i571fbd60834f45a8a94ddbcd37f40d78_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNi05LTEtMS0xMjc0NTI_4c704a83-88b9-40f8-91cf-52737987c7a2">1,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i571fbd60834f45a8a94ddbcd37f40d78_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNi0xMS0xLTEtMTI3NDUy_ff203832-5bd4-4b17-811b-07129ab6bf63">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNy0xLTEtMS0xMjc0NTI_a4c417bc-8a9d-49b7-a3ae-e6eaa0f02529">32,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNy0zLTEtMS0xMjc0NTI_572f7596-d08f-4cef-b06e-4e1d955db7d7">19,191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNy01LTEtMS0xMjc0NTI_50944a35-5688-4295-9ed8-0359412ce3af">12,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNy03LTEtMS0xMjc0NTI_c13ad56a-0b4d-4b2f-b408-b2b3a477227b">32,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNy05LTEtMS0xMjc0NTI_452dc62a-6069-4630-90ba-f0229799b787">17,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNy0xMS0xLTEtMTI3NDUy_a6335c8e-02b1-4772-95ef-ec12eaae1f6d">14,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e8e7fe1acc74cf88c35c02e48e41455_I20220630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfOS0xLTEtMS0xMjc0NTI_15bf65db-fcf6-4ad5-8e57-3773dba9aa28">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e8e7fe1acc74cf88c35c02e48e41455_I20220630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfOS01LTEtMS0xMjc0NTI_dbc423c3-9528-47bb-902f-95bac9942915">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic63e1fd5342a4cecb2063e44b0677f36_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfOS03LTEtMS0xMjc0NTI_c875855a-8e41-47d4-93c3-b66aeb3274c1">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic63e1fd5342a4cecb2063e44b0677f36_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfOS0xMS0xLTEtMTI3NDUy_c6ecef41-d94c-4651-bff6-e5dd8c0fad0b">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="amgn:IdentifiableIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMTAtMS0xLTEtMTI3NDUy_0e6b678b-e805-4cbe-a800-714c5d989822">33,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="amgn:IdentifiableIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMTAtMy0xLTEtMTI3NDUy_0ddfe3a6-d001-45ae-9afe-2b53ccf016e2">19,191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMTAtNS0xLTEtMTI3NDUy_26d655dc-6223-4dee-aee7-fef0e0ebe7b9">13,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="amgn:IdentifiableIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMTAtNy0xLTEtMTI3NDUy_f5f19720-57e7-450d-b906-480e84abf7f6">33,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="amgn:IdentifiableIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMTAtOS0xLTEtMTI3NDUy_e6072625-d5d2-4d7d-b7d0-65750dba5c1b">17,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMTAtMTEtMS0xLTEyNzQ1Mg_9939d110-0b9a-4b3c-9503-71fbc21cd3b6">15,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed-product-technology rights consists of rights related to marketed products. Licensing rights primarily consists of contractual rights to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and upfront payments associated with royalty obligations for marketed products. Marketing-related rights primarily consists of rights related to the sale and distribution of marketed products. R&amp;D technology rights pertains to technologies used in R&amp;D that have alternative future uses.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="idf1343f4ebb444e8b30eda801ec3275f"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D consists of R&amp;D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. We review IPR&amp;D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022 and 2021, we recognized amortization associated with our finite-lived intangible assets of $<ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTU1OQ_6ae222b2-a62b-4c0b-b774-7428197850f1">629</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTU2Ng_cc0ec6f5-7360-472c-ae94-2dba65673278">652</ix:nonFraction> million, respectively. During the six months ended June 30, 2022 and 2021, we recognized amortization associated with our finite-lived intangible assets of $<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTA5OTUxMTYyOTk1Mw_39d8da03-cc89-46b4-822d-06075ad68684"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTA5OTUxMTYyOTk1Mw_50de9ab9-1f31-433a-a024-08a66ae8a414">1.3</ix:nonFraction></ix:nonFraction> billion in both periods. Amortization of intangible assets is primarily included in Cost of sales in the Condensed Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the remaining six months ending December 31, 2022, and the years ending December 31, 2023, 2024, 2025, 2026 and 2027, are $<ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTg4MQ_dcf362e3-45f3-449e-9776-4ee2b9888d19">1.3</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTg4NQ_4fe4eed4-685b-4dba-a3ec-658d05f51802">2.5</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTg4OQ_d55caac2-220e-48c1-9bb6-0d8c437f68f0">2.5</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTg5Mw_98beae63-d1cf-484a-99ad-e07a8b64fe6b">2.4</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTg5Nw_b88929b9-38e3-4e9d-b4b0-f7ee486ce3d8">1.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTkwNA_09c65854-47a7-4806-912c-0968171accdf">1.8</ix:nonFraction> billion, respectively.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTM1MQ_8be075ff-d843-4b41-918a-fff5dc67e881" continuedAt="i3037e32fdcc7487fbbee8f5bc72e57d6" escape="true">Financing arrangements</ix:nonNumeric></span></div><ix:continuation id="i3037e32fdcc7487fbbee8f5bc72e57d6" continuedAt="icd431a60966f46d9abb77deaca208dfb"><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTM0Nw_5089c5cc-a31b-43ec-9c7e-4227856bff3c" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our borrowings consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia0f38e5021744d62a72f6ec5c21139ea_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMS0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjpiZjUwZDk3Y2E0Nzk0NjRjODZhMDRiZWIyNTY0NDg4OV80_149571a9-b665-4ec1-b9d8-d4f53cfb8615">0.41</ix:nonFraction>% CHF<ix:nonFraction unitRef="chf" contextRef="ia0f38e5021744d62a72f6ec5c21139ea_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMS0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjpiZjUwZDk3Y2E0Nzk0NjRjODZhMDRiZWIyNTY0NDg4OV83_127ba532-d4f6-44ea-8eea-f3ae43b92622">700</ix:nonFraction> million bonds due 2023 (0.41% 2023 Swiss franc Bonds)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f38e5021744d62a72f6ec5c21139ea_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMS0xLTEtMS0xMjc0NTI_64ed0d58-f8ed-4e0b-bc2d-6878ed4d25b6">733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48b3751c36e94ecc8abd5b6bc07fb36c_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMS0zLTEtMS0xMjc0NTI_4861110c-0577-4610-a896-777200f5358c">767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8cc181592b784672a897b345f8aafb1c_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMi0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjpiN2QxNjUyMzMwYTg0OGEzOTNhYTc5MDM0NDdkNjJhZF80_d49f965a-3d05-4e66-a378-e5b3dc4cf62b">2.25</ix:nonFraction>% notes due 2023 (2.25% 2023 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cc181592b784672a897b345f8aafb1c_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMi0xLTEtMS0xMjc0NTI_99c1afef-7763-49ba-9638-9451cef09e5a">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0a5eb4088b4f5f9d9e54d6ac0cefa1_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMi0zLTEtMS0xMjc0NTI_6e0533cf-590e-4802-90b9-caf28dc02b31">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icbf9488cc39340f688dc8239b97b3406_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMy0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjpmNjE5ZWUwYjMxM2E0MDVhOTgyMzQ5N2E3NTVhZjJiMF80_0318647a-dc96-400b-bbe0-636216ddfb5a">3.625</ix:nonFraction>% notes due 2024 (3.625% 2024 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbf9488cc39340f688dc8239b97b3406_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMy0xLTEtMS0xMjc0NTI_cd432f64-97ff-43bb-9e08-6443efadb455">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d83b1f8089e4fe9b0149f04b0874977_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMy0zLTEtMS0xMjc0NTI_d3009640-d71a-49be-936d-bc07b3f7f384">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5811dbeccf214f488187b5c22f177a23_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNC0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjpmZTg0MmY4NDMyZDQ0MGI4YmMyYzg3YjVkZGExNTU1Zl80_c9da444c-8a52-4dbf-a53b-7180196d851f">1.90</ix:nonFraction>% notes due 2025 (1.90% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5811dbeccf214f488187b5c22f177a23_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNC0xLTEtMS0xMjc0NTI_0dc12b4b-a68e-4075-8ac7-094d7919197c">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9b1443716684a18a0944e9e9de23470_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNC0zLTEtMS0xMjc0NTI_df0850af-2c2d-47bb-b168-75686d1aa6f4">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d5c387b50044b74aa269b57c4e1b18e_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNS0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjpkMjc5NDRkMDFkNDg0Yjk0YjUxZmY1YjkxYjUwZmRhZV80_76af1dcb-29e5-4fa7-a087-1e9d2ec642bf">3.125</ix:nonFraction>% notes due 2025 (3.125% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d5c387b50044b74aa269b57c4e1b18e_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNS0xLTEtMS0xMjc0NTI_e4ef8b8e-e161-476a-adf2-061b2bde28d5">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7839d25e4a274cde83be70a336e9f23d_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNS0zLTEtMS0xMjc0NTI_b36b5b62-537d-4a08-9728-a01082ac4d76">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8771ce738edc4f2bbcd5cf45e51751ff_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNi0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjo5NWNmMTA1MGMxYTg0Yzg4YTcwMDkyMzBiNGRmZmU5NF80_88befa30-9175-40d8-9127-5655e893c023">2.00</ix:nonFraction>% &#8364;<ix:nonFraction unitRef="eur" contextRef="i8771ce738edc4f2bbcd5cf45e51751ff_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNi0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjo5NWNmMTA1MGMxYTg0Yzg4YTcwMDkyMzBiNGRmZmU5NF83_61dc3d43-8901-400b-b0db-a35f80687667">750</ix:nonFraction> million notes due 2026 (2.00% 2026 euro Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8771ce738edc4f2bbcd5cf45e51751ff_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNi0xLTEtMS0xMjc0NTI_fd546312-54f5-46bf-b501-56d03f97bd14">786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31014fe22b1e487c920ebfa34bb0d600_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNi0zLTEtMS0xMjc0NTI_f8c23094-d859-4f92-b42d-3548a45b5cab">853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i927ecd67dbbd46f6be54131a567097ee_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNy0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjo1YTFhM2FmYjQ3ODg0OTUzYWNhYWZmMDUxYTQzNTM0YV80_97c7282c-56fc-4ab2-849e-d09d0173e9b6">2.60</ix:nonFraction>% notes due 2026 (2.60% 2026 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927ecd67dbbd46f6be54131a567097ee_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNy0xLTEtMS0xMjc0NTI_7ac66002-2fbc-4858-b101-1deaecb85c0f">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f9bc180a6994a85a80ac8530527b2f2_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNy0zLTEtMS0xMjc0NTI_3c679c95-39e7-4e6b-84c9-24ac3ace6f89">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5db64085db894eefb5186c861f5a0216_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfOC0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjo1MGExNmE1ZmM5ODM0ZGUwYjkwZWQxOWM4NjUzOWU2MF80_2cc33f67-77a5-43ec-bff6-1980ecc07ee2">5.50</ix:nonFraction>% &#163;<ix:nonFraction unitRef="gbp" contextRef="i5db64085db894eefb5186c861f5a0216_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfOC0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjo1MGExNmE1ZmM5ODM0ZGUwYjkwZWQxOWM4NjUzOWU2MF83_34f21b03-dd9d-46b8-9e87-9ba5f730e4ac">475</ix:nonFraction> million notes due 2026 (5.50% 2026 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db64085db894eefb5186c861f5a0216_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfOC0xLTEtMS0xMjc0NTI_58f5762f-88bf-4292-9905-039398c0f729">579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b164c7fe7e4938a4b2f2cb9f20f1e0_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfOC0zLTEtMS0xMjc0NTI_8cc77857-2480-48c9-92ac-80eed887a95b">643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i557c138915f74848aec303bcbcbdf1c5_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfOS0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjpjMDZjMTdmMWRjZDA0ZWJhYjcwMWM3Y2VkY2IxOGEyN180_c77136c9-e08c-478d-a47c-b6a5937dea22">2.20</ix:nonFraction>% notes due 2027 (2.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557c138915f74848aec303bcbcbdf1c5_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfOS0xLTEtMS0xMjc0NTI_dbc40bcb-1505-4afa-88e8-3ef40bfaf2d9">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id84e2ad3fd7d4d2ea16c4f1a15e443b0_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfOS0zLTEtMS0xMjc0NTI_278386dc-338b-4919-ba75-00bb39a14b09">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7ebb4dc9f2f4f4db89a7eba86ff7b3c_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTAtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246MWFkMDU1ZTQxZWVmNDZhYmE4M2UzYmFhMTg3MTA0YjlfNA_976147e5-52e8-49da-9d05-313127251d67">3.20</ix:nonFraction>% notes due 2027 (3.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ebb4dc9f2f4f4db89a7eba86ff7b3c_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTAtMS0xLTEtMTI3NDUy_ce7d500e-9e62-427a-8dad-404340976fb6">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f508b06ff8341f99dde537d8acf7445_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTAtMy0xLTEtMTI3NDUy_134233d6-626e-44d8-84ca-5b09f6fb33f4">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07d1843d947d47519f7950d93a5562e9_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTEtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZmYwZjdkZDdiODhhNGE3YWE4ZDhjMjBiZTE5Y2I1ZGJfNA_c9f7477d-b798-4fe1-8324-06f04f29d33d">1.65</ix:nonFraction>% notes due 2028 (1.65% 2028 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d1843d947d47519f7950d93a5562e9_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTEtMS0xLTEtMTI3NDUy_916a2a88-6ada-4e8c-a168-5870efae2d27">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e873215313140b1b47d44874f84d297_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTEtMy0xLTEtMTI3NDUy_2ba268f2-48b9-4281-b3a0-dd5e9e321eeb">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a74363bd54f4d66ad0e46ef97698531_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTItMC0xLTEtMTI3NDUyL3RleHRyZWdpb246YjQxZjMyMDMxMWI3NDJhMDg2ZmE0N2FkNTA2Y2E1ZTBfNA_920bb73e-d4eb-4f9c-8e75-474f09390104">3.00</ix:nonFraction>% notes due 2029 (3.00% 2029 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a74363bd54f4d66ad0e46ef97698531_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTItMS0xLTEtMTI3NDUy_d416042d-cd63-413b-911b-8d6e0714cd7f">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5443e8b322b4d0faa4ade72d57d4e85_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTItMy0xLTEtMTI3NDUy_f68b446d-ffc3-4467-b1e5-29c9832eae11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i28f107e649274e53ac4e7d54db6713eb_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTMtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZTQzNzc1ZjA2MzBhNGM2OThjZDA0OTRhMmIxMDY4OTdfNA_0f58e1c6-88fe-4b16-86d8-6636a48d4b0e">4.00</ix:nonFraction>% &#163;<ix:nonFraction unitRef="gbp" contextRef="i28f107e649274e53ac4e7d54db6713eb_I20220630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTMtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZTQzNzc1ZjA2MzBhNGM2OThjZDA0OTRhMmIxMDY4OTdfNw_a16fdb4e-297c-40c3-9791-e579c0fdbc28">700</ix:nonFraction> million notes due 2029 (4.00% 2029 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28f107e649274e53ac4e7d54db6713eb_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTMtMS0xLTEtMTI3NDUy_8c25d3a4-7871-426c-8196-44cb11d804fd">853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66c10d0d93a7485babc5ced3a0780a07_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTMtMy0xLTEtMTI3NDUy_3a38f9f0-9429-438e-bdc6-4a3365c8b547">947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f539453d5ef4ab6bfd15d005af9fe8d_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTQtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246NGI5NTUyMTY5MzFiNGY3NTg4ZGQ1ZWU3YTUyNzViMjhfNA_ed86cae2-a002-4d7e-ab67-943fe8735c72">2.45</ix:nonFraction>% notes due 2030 (2.45% 2030 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f539453d5ef4ab6bfd15d005af9fe8d_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTQtMS0xLTEtMTI3NDUy_0b200458-b595-4489-9799-ff93f078e2ff">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d9dd73fd402413093a63fd14b1085e8_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTQtMy0xLTEtMTI3NDUy_362fc0e0-4e68-4b2c-bc03-a70e3ba63a64">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34e92919299b42e89aac44fbf306409a_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTUtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246M2M2MDE4YzRkYjNjNDlmYTk3YjA2NGRjZjJkNjA3MTBfNA_4bea8cf6-aa7e-4da6-affd-33ca6984a5d4">2.30</ix:nonFraction>% notes due 2031 (2.30% 2031 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34e92919299b42e89aac44fbf306409a_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTUtMS0xLTEtMTI3NDUy_ea3eb623-56df-435e-b38b-d955f6a767e8">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica06dde7221745f9b345032e886823b0_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTUtMy0xLTEtMTI3NDUy_8224b895-3619-427b-bafd-8549b083597d">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic445c08da9214730a1fe68dffa9fde2f_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTYtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246NzMyNTk2NDUzMDhkNGMxY2I5OWZkMWIwNmE5NTliYmJfNA_9f3ec101-2624-4126-9fc9-27e785feab5a">2.00</ix:nonFraction>% notes due 2032 (2.00% 2032 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic445c08da9214730a1fe68dffa9fde2f_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTYtMS0xLTEtMTI3NDUy_5fcf85e2-750c-4c25-9950-923cf6e98df3">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a1796124db4912a03941f9fc2bb729_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTYtMy0xLTEtMTI3NDUy_f2ebee32-c9e5-46f5-a3f1-fb72b95e3ba3">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idbe4cc4a9874400299d9ee262931fff2_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTctMC0xLTEtMTI3NDUyL3RleHRyZWdpb246NmQxMGFiNjM4M2Y4NDVmMGJmOThjMTdmMDk1YmFiOWNfNA_143226ea-b397-471c-bdc0-ad2255b744cd">3.35</ix:nonFraction>% notes due 2032 (3.35% 2032 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbe4cc4a9874400299d9ee262931fff2_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTctMS0xLTEtMTI3NDUy_4275d3e8-c3fd-4b59-a26d-183923e36464">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ea8bdcd48224c638ca7517df56948a6_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTgtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246NzE1MzhmOTg5MzMyNDNiY2E0YjEyNGFjMDU5OWM5YmNfNA_a61b61d9-5d7e-4bb4-aa87-ab8ccd2b543a">6.375</ix:nonFraction>% notes due 2037 (6.375% 2037 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ea8bdcd48224c638ca7517df56948a6_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTgtMS0xLTEtMTI3NDUy_3d283000-084c-4259-8c82-21f992a33ae4">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bc19466dfcd44729418b77c1b6cac7d_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTgtMy0xLTEtMTI3NDUy_d1419bfb-3779-4551-979f-d9c7345498be">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if160545557934f3ea7d7aa81db1e5fe6_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTktMC0xLTEtMTI3NDUyL3RleHRyZWdpb246NGNlNzUyMDk0Y2E5NGE5MWIwYzkzMDQyNDkxYmFlMDdfNA_f55c6787-46d6-4e34-9a24-28e00df287a1">6.90</ix:nonFraction>% notes due 2038 (6.90% 2038 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if160545557934f3ea7d7aa81db1e5fe6_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTktMS0xLTEtMTI3NDUy_9349432c-d475-4fdb-9093-ed25c4185152">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied438a5ea64d4044aa5bbdbdd2f08fa8_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTktMy0xLTEtMTI3NDUy_77a55edf-23e2-49da-941f-3f23b944ebe7">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ce84e57febe49528941c8a79c0b2aba_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjAtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246NjRlOGMwNzYzM2EzNDZlZDhkYzViYzc3OThiZGJkODZfNA_b0e31e76-6844-49a6-ba44-f7de2bcac0c2">6.40</ix:nonFraction>% notes due 2039 (6.40% 2039 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce84e57febe49528941c8a79c0b2aba_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjAtMS0xLTEtMTI3NDUy_57aa41d4-b66b-4686-bc92-c2f4793417d1">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if808837e20874be992a0d93186873f98_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjAtMy0xLTEtMTI3NDUy_258a227e-3aef-4fc5-944e-9898a0961ede">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i044f15b088224513a42ca9d6a15c87ff_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjEtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246NmVkYjZlMzYwYTExNDEwNTgwMjg2NGM1YTYyMTY0MWFfNA_f208b0c4-41c7-40d3-8433-0834c3183ba4">3.15</ix:nonFraction>% notes due 2040 (3.15% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i044f15b088224513a42ca9d6a15c87ff_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjEtMS0xLTEtMTI3NDUy_548f3b77-ee97-4631-a2b0-bf6da000403e">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id531ca5db21148f9bc34d2e8bb8f2623_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjEtMy0xLTEtMTI3NDUy_9f69207a-8c1d-4b0d-9e8b-2ad3a7d99169">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iab08d658a45448438680f7c44651a436_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjItMC0xLTEtMTI3NDUyL3RleHRyZWdpb246NjAzZmI3ZTI1ZTQzNGNjZTgzNzJmNDRlOTE1N2Q2NWRfNA_2928efc8-dcf8-4a74-8237-bb433fba0da5">5.75</ix:nonFraction>% notes due 2040 (5.75% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab08d658a45448438680f7c44651a436_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjItMS0xLTEtMTI3NDUy_32aa3ca5-ae8b-4260-b2e9-5cbeaf0402ab">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8bbf8e715b4026a58db39d1e4ae27a_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjItMy0xLTEtMTI3NDUy_a82cf8aa-72c1-4c02-bd25-74df6f24ddcb">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i867b4a6e48054979abbb390f7ca4bea4_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjMtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246NTFjNTI5MzJiOWEwNGQ3ZmJlODhkOTA1ZjYzZDFiYTJfNA_05c5b762-e7d2-4a93-9ff6-f5253adbe3b0">2.80</ix:nonFraction>% notes due 2041 (2.80% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867b4a6e48054979abbb390f7ca4bea4_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjMtMS0xLTEtMTI3NDUy_eeb30494-40d2-49cf-bded-4d3254b9830d">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f6ba2cbab24ee7a767a43344d52629_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjMtMy0xLTEtMTI3NDUy_ce41eb47-e13a-4a73-9597-55dcee863173">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i869ffcf94f08470aa084a38887e74378_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjQtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZjFjNzY4MGQ2NzMxNDc3NmIyMzQ3YTE1NjBmMzY3NDNfNA_3ffeb001-3101-4fae-a480-2994c9e7fbab">4.95</ix:nonFraction>% notes due 2041 (4.95% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i869ffcf94f08470aa084a38887e74378_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjQtMS0xLTEtMTI3NDUy_0055e714-7c55-4449-8ff8-e81417e714f5">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8efceb2da34f4012a56d28bee80ece4e_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjQtMy0xLTEtMTI3NDUy_7df0a2a9-3ef4-4252-a7a4-ab447bb55470">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8f4719ca9b84ee8b1c7b311cb67831d_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjUtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246YmI0Y2E5MTJkYTA2NDIzODlmNTY5NjM3OTVmNjE3MWZfNA_9bb1ea32-c8d9-4842-8a4f-44614e8b6c5f">5.15</ix:nonFraction>% notes due 2041 (5.15% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f4719ca9b84ee8b1c7b311cb67831d_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjUtMS0xLTEtMTI3NDUy_e39329f5-1b8b-4e2c-abc8-a0953152b4dd">729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fe337886bb743ac9268549dea62a5c1_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjUtMy0xLTEtMTI3NDUy_e1fd0b5d-7d0c-427d-9279-9fbca42b0e3d">729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3039eef43eab47d88f5e5bde9f8c3c1a_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjYtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246MGZkYWQxOWY4NjVjNDgzOGEzYjlmNmFjMTYwN2RmYTdfNA_8ee28276-4ae1-43b2-afb3-9cb7b248d7b1">5.65</ix:nonFraction>% notes due 2042 (5.65% 2042 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3039eef43eab47d88f5e5bde9f8c3c1a_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjYtMS0xLTEtMTI3NDUy_3cccef11-28ca-4e01-bd33-4e7ec33b5e0d">415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c41f818916d4143ab5f24b20c47b6b0_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjYtMy0xLTEtMTI3NDUy_4f3aaf0a-a3e8-4f7d-a6e3-ea0c9563b4f9">415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8baade68d0aa42cd8eabab1268708b15_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjctMC0xLTEtMTI3NDUyL3RleHRyZWdpb246OTAxMGY4ODRhYzg0NDZlOGJmZTM2NzdhZTcyYTY3MmNfNA_2c18403b-96d6-46c3-883a-211b68176487">5.375</ix:nonFraction>% notes due 2043 (5.375% 2043 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8baade68d0aa42cd8eabab1268708b15_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjctMS0xLTEtMTI3NDUy_63c8759d-b66f-4397-bcac-278f349a9fd5">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i371510a8b04e43fc92b82fca221e37d1_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjctMy0xLTEtMTI3NDUy_680edc23-45a4-4eec-a80f-9026a7e8eadf">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cf9e5efd50b441ba4249ec5547a64d8_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjgtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246MDQ2NDhmODBmMDg5NDE0ZGEwZDM0NDJkZGUzODdkMzNfNA_32ff5a07-ffc5-49ac-ab4f-d544d1c219ce">4.40</ix:nonFraction>% notes due 2045 (4.40% 2045 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf9e5efd50b441ba4249ec5547a64d8_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjgtMS0xLTEtMTI3NDUy_73b3f0a3-e8fd-4613-9e66-48dd676b0421">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb4f7f1f524943beb30880ef09f09b08_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjgtMy0xLTEtMTI3NDUy_9532b396-c5c1-4283-bad7-c09a02527fb2">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idebc81edd93d4d2f8a2a03384eb93dbe_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjktMC0xLTEtMTI3NDUyL3RleHRyZWdpb246MmIxYjVhNDg0NGNkNGJhZTg0YTc0NjEwYjVkYTc5NmZfNA_58522027-2494-44d5-b803-0c5417938962">4.563</ix:nonFraction>% notes due 2048 (4.563% 2048 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idebc81edd93d4d2f8a2a03384eb93dbe_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjktMS0xLTEtMTI3NDUy_889a3635-86f8-4040-ace9-b11ac914dde3">1,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b2f991bb9a47f29b3bcd5b53c1cdd5_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjktMy0xLTEtMTI3NDUy_85b5134c-eae7-46c0-a144-a6a3b32e6762">1,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i08a78f74146a4495aeae7b6b14bd80a4_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzAtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZTNlMTdlN2Y3YzE2NDYxY2IyN2U4MDQzZGFhOGRkMTZfNA_612af431-847b-4e4f-91d6-206ad9f473ae">3.375</ix:nonFraction>% notes due 2050 (3.375% 2050 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a78f74146a4495aeae7b6b14bd80a4_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzAtMS0xLTEtMTI3NDUy_69e247f5-9e84-4fe5-b4a6-ddaea002f46e">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie836805159b74407a69e93d8523fe3ad_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzAtMy0xLTEtMTI3NDUy_59d94c97-dd88-4ffd-b921-9eda139645ef">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ed1c633fdd74b46948dd2c6f7afcf20_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzEtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246NDA1ZTllOTBhNTU5NDM5NGIxM2I0M2EyYzJlOGZhYzJfNA_24e3d392-41cb-471d-9dce-87542f76bb1a">4.663</ix:nonFraction>% notes due 2051 (4.663% 2051 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed1c633fdd74b46948dd2c6f7afcf20_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzEtMS0xLTEtMTI3NDUy_2205429f-7159-4eb6-910b-3257ff5820f2">3,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc5590dec8034b22bdedd784acc302e8_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzEtMy0xLTEtMTI3NDUy_821e555b-1667-4ddb-897d-30d571706006">3,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i735b048825ca4313aeb532048d7be90b_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzItMC0xLTEtMTI3NDUyL3RleHRyZWdpb246MmZmZTExYjU5NzRhNDk1OTg4NTU2MjMzYjU4OGU0YTRfNA_c87ec9b5-5943-4dda-b36f-028197436f1d">3.00</ix:nonFraction>% notes due 2052 (3.00% 2052 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i735b048825ca4313aeb532048d7be90b_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzItMS0xLTEtMTI3NDUy_02ae38d3-9c76-4726-b3ea-c719cd038081">1,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad985efcbfe541aca64199c03a30ee03_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzItMy0xLTEtMTI3NDUy_7b07d682-3bee-4b60-affd-c1bb6fa0fc9a">1,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0d18f819d85a44c49e5108e4c3d42378_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzMtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZjJkM2E1YjM2NDk0NDJiZjgzNTY3YTBmYWQ2ODllOTlfNA_4ce7afbd-885b-48d1-b321-4bc048819ce8">4.20</ix:nonFraction>% notes due 2052 (4.20% 2052 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d18f819d85a44c49e5108e4c3d42378_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzMtMS0xLTEtMTI3NDUy_0a72b4cf-b74e-4f2a-86bf-cf026e643f7c">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53e00d2be34d4b1ea7b97fd526f5d69b_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzMtMy0xLTEtMTI3NDUy_a591982f-855e-4ba0-a951-dc74a3d6b12d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibbd916f7493440e69704b449f2dd8102_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzQtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZTU4NzU2MzI0ZGIyNDNlMWJmMWY5YzllZjQyZDRkMzdfNA_77310c1a-cfe7-4a22-a2f1-c8a8038d8387">2.77</ix:nonFraction>% notes due 2053 (2.77% 2053 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbd916f7493440e69704b449f2dd8102_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzQtMS0xLTEtMTI3NDUy_691f7ecc-3244-49de-8375-7eac3cb84fa7">940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c317ee474147a8b5d3b80406fb276d_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzQtMy0xLTEtMTI3NDUy_00f5bf2e-ac46-4eec-ac1e-e2c2cefe9fb7">940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i17997eb7cd9343bd87243e19e6bb8d08_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzUtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZjUzZWQwNDU1OTY0NDQ2MGJlNWJiMWFiZWRlNTU3NGJfNA_f3b4211e-1573-45ff-b1a6-02f0045dc200">4.40</ix:nonFraction>% notes due 2062 (4.40% 2062 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17997eb7cd9343bd87243e19e6bb8d08_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzUtMS0xLTEtMTI3NDUy_10e41c18-626e-40e6-99ee-1c7803cafebf">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43ee6e408fa1493196ad37c5887d08e3_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzUtMy0xLTEtMTI3NDUy_faac9574-ad06-4c4e-b618-cedf8c1d608b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes due 2097</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951998b6f8314c8884444de5fada1e86_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzYtMS0xLTEtMTI3NDUy_3399cde9-8b23-4cd2-ab6d-739918916922">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a44e9649b29466fb790d1a57aca49b3_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzYtMy0xLTEtMTI3NDUy_b1ade6a8-5423-4897-8376-49e3146e9100">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized bond discounts, premiums and issuance costs, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzctMS0xLTEtMTI3NDUy_839b02fc-9757-4ad3-b612-34047708a060">1,245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzctMy0xLTEtMTI3NDUy_2da8d1ef-4be6-48bb-80a8-cff5af8f4b42">1,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzgtMS0xLTEtMTI3NDUy_82a3ad1a-3e87-497f-92f9-686d484530eb">210</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzgtMy0xLTEtMTI3NDUy_442dde93-e017-4f5c-b190-c14b89988346">284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:OtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzktMS0xLTEtMTI3NDUy_5f520d71-1f70-4a20-852d-3fbe5b4e814a">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:OtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzktMy0xLTEtMTI3NDUy_98516f02-cbba-46de-86ef-49405d78b097">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNDAtMS0xLTEtMTI3NDUy_c516d5a6-5a6a-4c29-97f1-1db4c176fd6f">36,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNDAtMy0xLTEtMTI3NDUy_cbbfa84c-5e81-42e3-a8b8-4a14335b05af">33,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNDEtMS0xLTEtMTI3NDUy_e579a63b-377d-4e98-a04e-1335894c52a5">817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNDEtMy0xLTEtMTI3NDUy_3fd1dd78-030b-4dfb-b8d0-2aa82435eced">87</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNDItMS0xLTEtMTI3NDUy_683a30cc-f45d-4f2d-98cb-c2ee32a8e9f9">35,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNDItMy0xLTEtMTI3NDUy_12744e89-5a01-47ff-82e6-b7f8566fe9a4">33,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no material</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> differences between the effective interest rates and coupon rates of any of our borrowings, except for the <ix:nonFraction unitRef="number" contextRef="idebc81edd93d4d2f8a2a03384eb93dbe_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTk5_e448d4d6-2339-43ee-ae06-2761c3c3ad2e">4.563</ix:nonFraction>% 2048 Notes, the <ix:nonFraction unitRef="number" contextRef="i7ed1c633fdd74b46948dd2c6f7afcf20_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMjE4_114c089b-bbda-493e-b853-ad120cfc5f81">4.663</ix:nonFraction>% 2051 Notes and the <ix:nonFraction unitRef="number" contextRef="ibbd916f7493440e69704b449f2dd8102_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMjQw_2d621bd8-fbae-4547-888b-d6c5ea5b9708">2.77</ix:nonFraction>% 2053 Notes, which have effective interest rates of <ix:nonFraction unitRef="number" contextRef="idebc81edd93d4d2f8a2a03384eb93dbe_I20220630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMjk0_f3063281-937d-4f3c-9787-b5439b93a133">6.3</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i7ed1c633fdd74b46948dd2c6f7afcf20_I20220630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMjk4_a3679515-4e96-45d5-8fc5-499bf5dde497">5.6</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ibbd916f7493440e69704b449f2dd8102_I20220630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMzA1_919a5812-ae68-456a-ae08-0a189daf24ad">5.2</ix:nonFraction>%, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icd431a60966f46d9abb77deaca208dfb">During the three months ended March 31, 2022, we issued $<ix:nonFraction unitRef="usd" contextRef="ia45a3444f1b94d7694e25c6b7581e9f6_I20220331" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTM3OA_81e602cf-19cc-4e1d-8546-3b4e2b8680cf">4.0</ix:nonFraction>&#160;billion of debt consisting of $<ix:nonFraction unitRef="usd" contextRef="i31e27323c1154ea898dc24977e5b4dfa_I20220331" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTM4MA_300a4c16-9fe0-4d19-a87c-7f80280ff003">750</ix:nonFraction>&#160;million of the <ix:nonFraction unitRef="number" contextRef="i31e27323c1154ea898dc24977e5b4dfa_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTM5Mw_fbf4c9c1-10fd-4978-94d0-adb1c33db31f">3.00</ix:nonFraction>% 2029 Notes, $<ix:nonFraction unitRef="usd" contextRef="i7cf0dda19fd445dca8eb54ae4d8870ae_I20220331" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTM5NQ_86688254-f4f4-4728-8afd-ff932febc89c">1.0</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="i7cf0dda19fd445dca8eb54ae4d8870ae_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQwOQ_f3a052a3-a51c-47c0-a628-31ac993ddc04">3.35</ix:nonFraction>% 2032 Notes, $<ix:nonFraction unitRef="usd" contextRef="iecb3cb0076694222ab5165cf391eb7d3_I20220331" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQxNg_55fff7ea-0e12-4ab1-99fb-96d75fe1a310">1.0</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="if7172737536943c5bd01dbe5c718b01f_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQzMA_a1964a0c-163f-4724-aeb2-ddf7386829bf">4.20</ix:nonFraction>% 2052 Notes and $<ix:nonFraction unitRef="usd" contextRef="i531c563577e24bbe82274ae7b057ec74_I20220331" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQzNg_0c59b39f-4e4e-40cc-9024-43a7eea0820e">1.25</ix:nonFraction>&#160;billion of the <ix:nonFraction unitRef="number" contextRef="i531c563577e24bbe82274ae7b057ec74_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQzOA_4fd020a7-db7f-4452-a205-d300d0cad9f3">4.40</ix:nonFraction>% 2062 Notes. The <ix:nonFraction unitRef="number" contextRef="i31e27323c1154ea898dc24977e5b4dfa_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQ0NQ_3f107aec-7230-4f68-b5ef-962eb2872963">3.00</ix:nonFraction>% 2029 Notes were issued to finance eligible projects that meet specified criteria to benefit the environment. In the event of a change-in-control triggering event, as defined in the terms of the notes, we may be required to purchase all or a portion of these notes at a price equal to <ix:nonFraction unitRef="number" contextRef="i2f9a632bdc184d86b2d6cf5fa69e05d5_D20220101-20220331" decimals="INF" name="amgn:PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQ1Mg_732a0d9a-2774-451d-b591-9834906554c6"><ix:nonFraction unitRef="number" contextRef="i21ba53c9dd5540c5a2f72a1809b358f5_D20220101-20220331" decimals="INF" name="amgn:PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQ1Mg_dd90c2af-0d47-47fe-9480-d58c44d4afdd"><ix:nonFraction unitRef="number" contextRef="i31a5a20370f74b839ba627dfd4b3d6d2_D20220101-20220331" decimals="INF" name="amgn:PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQ1Mg_ee8018a0-1dfd-44f8-a4df-21eb17129d99"><ix:nonFraction unitRef="number" contextRef="i2630ed6736474dd7ad352734abf1fa2f_D20220101-20220331" decimals="INF" name="amgn:PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQ1Mg_eea10978-2cfa-4329-8479-4481f0e4372c">101</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the principal amount of the notes plus accrued and unpaid interest. In addition, these notes may be redeemed at any time at our option, in whole or in part, at the principal amount of the notes being redeemed plus accrued and unpaid interest and a make-whole amount, which are defined by the terms of the notes. The notes may be redeemed without payment of make-whole amounts if redemption occurs during a specified period of time immediately prior to the maturing of the notes. Such time periods range from <ix:nonNumeric contextRef="iff44a3a4194340a88d27d0d51b2c7873_D20220101-20220331" name="amgn:DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQ1Nw_67e07c42-48a0-4637-896f-9c7115562e5e">two months</ix:nonNumeric> to <ix:nonNumeric contextRef="i5a36e5ea4cc14d90aa07055d396cca6d_D20220101-20220331" name="amgn:DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQ1OA_cd68e0e7-9f7f-46d3-ae4d-d01494d0bfce">six months</ix:nonNumeric> prior to maturity.</ix:continuation></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i710475db76604b05901ef7473465ecf1_64"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMjMyMA_ff4bc03f-63b0-4dd8-91e1-7ae633bbe3be" continuedAt="i82753f454dd64aa5a882f0f9b631aedf" escape="true">Stockholders&#8217; equity</ix:nonNumeric></span></div><ix:continuation id="i82753f454dd64aa5a882f0f9b631aedf" continuedAt="id29ad6630b704232b85979901cd60cf0"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchase program</span></div><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="amgn:StockRepurchaseProgramTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMjMyMw_c296ffca-d266-4a1e-9239-fbcaef97a89d" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfMi0xLTEtMS0xMjc0NTI_e42f48d6-2f35-456e-a527-02da26b03e89">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfMi0zLTEtMS0xMjc0NTI_d647dc42-98b0-4529-a077-5fbec72feb6c">5,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i230f8b81d2ba4f069528c27808330841_D20210101-20210331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfMi01LTEtMS0xMjc0NTI_2a7de134-acee-483e-bc79-26e3eafbc1eb">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i230f8b81d2ba4f069528c27808330841_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfMi03LTEtMS0xMjc0NTI_24d3b8c1-8b6d-4de1-b3e0-b22fcde48ccb">865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfMy0xLTEtMS0xMjc0NTI_c700dc64-724d-49d3-9026-3eef24ebbaef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfMy0zLTEtMS0xMjc0NTI_c684e0e3-9a63-429d-ae8a-d22cfab964df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfMy01LTEtMS0xMjc0NTI_377838e8-d515-40e6-8ca4-57c47ae2a4d9">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfMy03LTEtMS0xMjc0NTI_7146ed82-7ae4-40ea-96ea-05a4a5cd6201">1,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock repurchases</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfNS0xLTEtMS0xMjc0NTI_3d3fa6f8-bb86-4232-a136-a24e4147d76b">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfNS0zLTEtMS0xMjc0NTI_f8b64df8-2bcd-4b90-b437-a95a9edf4e2b">5,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfNS01LTEtMS0xMjc0NTI_abbab923-0774-422f-889b-4ff79d0bff4f">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfNS03LTEtMS0xMjc0NTI_d349f4c2-e98b-40b1-80db-f106f67c0a98">2,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2022, the Company entered into ASR agreements with <ix:nonFraction unitRef="financial_institution" contextRef="idff629d5adce4075abb77d3576767318_I20220224" decimals="INF" name="amgn:NumberOfThirdPartyFinancialInstitutions" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMjI5OQ_4ed4c040-a0cd-41b3-a495-f3fb356392b2">three</ix:nonFraction> third-party financial institutions (Dealers). Under the ASR agreements, the Company made payments in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i3919d433c5e54fd389f1bef01f418e40_D20220225-20220225" decimals="-8" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMzM0_fbc23aa8-8c08-4486-b8a8-73d4c7e4226e">6.0</ix:nonFraction>&#160;billion on February 25, 2022, to the Dealers and received and retired an initial <ix:nonFraction unitRef="shares" contextRef="i3919d433c5e54fd389f1bef01f418e40_D20220225-20220225" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfNDEw_42d2a893-4f0f-4329-a9f2-a1c65196774a">23.3</ix:nonFraction>&#160;million shares of the Company&#8217;s common stock from the Dealers. The payments were recorded as reductions to shareholders&#8217; equity, consisting of a $<ix:nonFraction unitRef="usd" contextRef="i303708e74aba47d6a736f376e0cd1a13_D20220225-20220225" decimals="-8" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfNTUw_cf086b1b-f72b-448f-9695-71cc96000252">5.1</ix:nonFraction>&#160;billion increase to accumulated deficit, which reflects the value of the initial shares received, and a $<ix:nonFraction unitRef="usd" contextRef="i10398ced71924f51bd433d3c641763e9_D20220225-20220225" decimals="-8" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfNjQ5_1db0d22f-e3b5-459e-a87f-cbd1848ccad4">0.9</ix:nonFraction>&#160;billion decrease in additional paid-in capital, which reflects the value of the stock that remains to be delivered by the Dealers pending final settlement. The final number of shares to be repurchased by the Company will be based on the daily volume-weighted average stock price of the Company&#8217;s common stock during the terms of the ASR agreements, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreements. At settlement, under certain circumstances, one or more of the Dealers may be required to deliver additional shares of common stock to the Company, or under certain circumstances, the Company may be required to deliver shares of common stock or to make a cash payment, at its election, to a Dealer. The final settlement under the ASR agreements is scheduled to occur in the third quarter of 2022, subject to an earlier termination under certain limited circumstances, as set forth in the ASR agreements. In total, we repurchased <ix:nonFraction unitRef="shares" contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMTA5OTUxMTYzMDE0OQ_f8d532ce-735b-4784-8003-fbdce0483598">24.6</ix:nonFraction>&#160;million shares of common stock in the first quarter of 2022, including shares received under the ASR agreements. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, $<ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMTc0MQ_481cdd8b-62e5-415a-afcc-dc9d809b0c9b">4.6</ix:nonFraction> billion of authorization remained available under our stock repurchase program.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022 and December 2021, the Board of Directors declared a quarterly cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie8752374757e479e9f64772ff1f4f9d4_D20211201-20211231" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMTkwMw_0c7005f1-7f3b-44ee-a000-0fc2a23bbd08"><ix:nonFraction unitRef="usdPerShare" contextRef="i264013b24e074db8b98a0699c239c4f9_D20220301-20220331" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMTkwMw_a08b6268-ccf5-475e-a290-a963fefa0b25"><ix:nonFraction unitRef="usdPerShare" contextRef="i264013b24e074db8b98a0699c239c4f9_D20220301-20220331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMTkwMw_ac5f0147-d05a-4672-a5b4-a3518432707b"><ix:nonFraction unitRef="usdPerShare" contextRef="i52e8d46fd29746e58d0e0bb604659f08_D20220601-20220630" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMTkwMw_f7ac0f6f-730d-40bc-9cb3-830caa93f6bc">1.94</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> per share, which were paid in June 2022 and March 2022, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Board of Directors declared a quarterly cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="i189dc1dfd5134a79a21430cb309a4d7a_D20220908-20220908" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMjAyOQ_9a840eeb-7b63-4ccd-bdfd-ae7b562eaa3c"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d05e9eee4b64b31a25be9b446338707_D20220803-20220803" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMjAyOQ_d10b0cf9-fdb6-4705-9d1f-4cdf73900a14">1.94</ix:nonFraction></ix:nonFraction> per share, which will be paid on September 8, 2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="id29ad6630b704232b85979901cd60cf0"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span></div><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMjMyOA_a187d0f9-4d04-461f-83e6-db3ec7027a7e" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of AOCI were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>currency<br/>translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash&#160;flow<br/>hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Available-for-sale<br/>securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AOCI</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9484214322149e8b56269486f6b1ee4_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMS0xLTEtMS0xMjc0NTI_44a22a77-9035-484c-951b-ac356bb16bc2">844</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if90bc40ab2b74d9dbd7c8dc2378a4c5b_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMS0zLTEtMS0xMjc0NTI_fec9fedf-542d-4be9-80af-f6812a3e479a">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382be9663b374e42986e34c6b0cdaf0f_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMS01LTEtMS0xMjc0NTI_dba84f56-79c5-4bce-88dd-38d3bc73ffef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7795fae62ffe42149d98ac8e3ee9adbc_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMS03LTEtMS0xMjc0NTI_d1c80507-0ef7-4dc1-98b5-b403633bdeaf">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4015add6967846b88c70abf91e4bfcd3_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMS05LTEtMS0xMjc0NTI_e36f6ac1-1822-435f-b8fe-177cf8f7e4b6">796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibabad0c6499641edbeeabb37b49f2923_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMy0xLTEtMS0xMjc0NTI_9633c7c5-59bf-4dfd-abd1-a9aa420b51d2">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6bebabfe867463fb2ce8c41e89ce28a_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMy05LTEtMS0xMjc0NTI_17cc77e8-0d9e-43ae-a2ac-e4f4f4fccae6">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d912228ba649bfa2382a61c3174651_D20220101-20220331" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNC0zLTEtMS0xMjc0NTI_dd51e12b-eab5-4c4a-adf8-de69b8254ea3">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08706db8953040b6812a751e8ae1b7e5_D20220101-20220331" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNC01LTEtMS0xMjc0NTI_eadc6a76-aad0-4fed-939d-14fb04e208fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbe6768ff04b4640811983e177893ea9_D20220101-20220331" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNC03LTEtMS0xMjc0NTI_fd6e9e4c-f9da-43b2-843b-8015f729d1c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6bebabfe867463fb2ce8c41e89ce28a_D20220101-20220331" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNC05LTEtMS0xMjc0NTI_62752f4a-3929-49b8-9e12-804342eadaab">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d912228ba649bfa2382a61c3174651_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNS0zLTEtMS0xMjc0NTI_9e3b5946-3f23-4736-b3fa-cc3b310b8b0a">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08706db8953040b6812a751e8ae1b7e5_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNS01LTEtMS0xMjc0NTI_2255ab2e-dd8c-4120-9937-1ddae90e2150">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6bebabfe867463fb2ce8c41e89ce28a_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNS05LTEtMS0xMjc0NTI_58d6acec-705e-4462-8d74-764903fa96dc">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibabad0c6499641edbeeabb37b49f2923_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNy0xLTEtMS0xMjc0NTI_267813bf-9674-44e3-aff2-b595357837b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5d912228ba649bfa2382a61c3174651_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNy0zLTEtMS0xMjc0NTI_0be55b0d-0633-49e2-8f1d-9991206b2f66">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08706db8953040b6812a751e8ae1b7e5_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNy01LTEtMS0xMjc0NTI_51fa0814-ac8d-4030-a805-afdedbb5bda3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6bebabfe867463fb2ce8c41e89ce28a_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNy05LTEtMS0xMjc0NTI_8211a8db-71a2-4557-9085-3d4be02044e7">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd1b9d5af30a49189ced97fd5f9e0133_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfOC0xLTEtMS0xMjc0NTI_ad8466b2-f5b9-4a23-b6cf-086d802533a9">895</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd33995f144e48e6b6a85f69a49618b2_I20220331" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfOC0zLTEtMS0xMjc0NTI_fd04c936-09c1-4958-ac3f-a831dfb702ac">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iececd00ead734bc7953b31ce1dccf7c9_I20220331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfOC01LTEtMS0xMjc0NTI_a18348c8-b073-4aeb-878d-6961c40a73c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90991e5bbd4f4703b8dab237d26ea063_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfOC03LTEtMS0xMjc0NTI_a6858e71-af18-429c-b140-53ae2b05c813">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3453133454bb4b68987a91d14ea8ccda_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfOC05LTEtMS0xMjc0NTI_20fe6132-9511-47aa-865d-68c9b2ef6abb">763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i933f3aa296ae418cb60f3b9a2da33c77_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTAtMS0xLTEtMTI3NDUy_c264eaa9-cafb-4100-9f5c-353b84d15309">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i950254b1c906440baad1c3cb0d696509_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTAtOS0xLTEtMTI3NDUy_a4a8150b-1a1a-4391-a7a4-93cf36491d1b">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b5fae63890c4e3292f6b182d8cf346f_D20220401-20220630" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTEtMy0xLTEtMTI3NDUy_245a1bf2-970b-439d-9d0c-3a068c87086e">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b9fd427a0844181b055f4681aa465eb_D20220401-20220630" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTEtNS0xLTEtMTI3NDUy_d28a4369-38b1-4a77-8145-bc262bf3b71c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9548198fbd6c4177a20e2e6fba7e0baf_D20220401-20220630" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTEtNy0xLTEtMTI3NDUy_42bca2de-64da-4340-a77b-8fd79a5880ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950254b1c906440baad1c3cb0d696509_D20220401-20220630" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTEtOS0xLTEtMTI3NDUy_fffa543e-96c7-4141-8629-5ed3a9576212">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b5fae63890c4e3292f6b182d8cf346f_D20220401-20220630" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTItMy0xLTEtMTI3NDUy_3eb547fc-13ab-4013-958d-b5fd2b0fe4fb">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b9fd427a0844181b055f4681aa465eb_D20220401-20220630" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTItNS0xLTEtMTI3NDUy_ae0b3b10-87e4-424c-bed1-51b6b0b13126">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950254b1c906440baad1c3cb0d696509_D20220401-20220630" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTItOS0xLTEtMTI3NDUy_e35f4d9e-a7fb-45dd-a400-8268dfaf9c4a">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i933f3aa296ae418cb60f3b9a2da33c77_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTQtMS0xLTEtMTI3NDUy_d74929e5-d389-4b08-af2a-029b075d6fe6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b5fae63890c4e3292f6b182d8cf346f_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTQtMy0xLTEtMTI3NDUy_055dc456-27ac-4491-982b-90b2d2dc98ee">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b9fd427a0844181b055f4681aa465eb_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTQtNS0xLTEtMTI3NDUy_5fbfe265-6a17-40bb-9212-8a4929e87c58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i950254b1c906440baad1c3cb0d696509_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTQtOS0xLTEtMTI3NDUy_5b50572e-a5eb-4553-98a3-fc189ee5847b">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f01a7222c3f477bb69c5b052545fbe3_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTUtMS0xLTEtMTI3NDUy_7f115945-04c2-4b01-b697-6444ba55c14a">960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd86ccb60742427aa61efd89dc5c4569_I20220630" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTUtMy0xLTEtMTI3NDUy_53a1a423-a11f-4643-8f70-69a2dd46f96d">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecaa227f3a39471dbc0f18d223f8c464_I20220630" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTUtNS0xLTEtMTI3NDUy_f311ae3b-29af-417c-894c-f4697792a0d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9808b39aaba54cfe9085c0980d313291_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTUtNy0xLTEtMTI3NDUy_d18cce15-1417-4617-aa2f-856c12233122">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedbaa8596a604e708e0f5d708642088d_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTUtOS0xLTEtMTI3NDUy_1c57f0f4-eaca-4adb-a6d0-7bf104b81b97">672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMjMxOQ_5509cc41-c2b8-4927-adcf-9c4d8e259bd9" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of AOCI and into earnings, including related income tax expenses, were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Components of AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Statements of Income locations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contract gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff08a60f020c476cb26a704e747e026e_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMy0yLTEtMS0xMjc0NTI_ace1b77c-dba4-4ffd-9880-cb73d7e6ffdc">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i156bec7df7e34d13b4f231715e12f0eb_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMy00LTEtMS0xMjc0NTI_0f8f3146-6403-4b2b-8dd2-42146a8a2ab6">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contract (losses) gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id98e2a58d5f74741901a136b5593f566_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfNC0yLTEtMS0xMjc0NTI_e0c91ed7-dd9d-4143-b482-471e0090bdb0">185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e704ef21944a4b8eb938e4ffb99c17_D20210401-20210630" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfNC00LTEtMS0xMjc0NTI_aa042993-f19f-4626-ae9e-d2c3021248a4">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd26454e121845348d3b36a5d5d0b4be_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfNi0yLTEtMS0xMjc0NTI_2a0b6272-fe62-4c51-a18f-eb5464b64e14">132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47f60abf400d4a86a9f3744f80bddf28_D20210401-20210630" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfNi00LTEtMS0xMjc0NTI_5cb8b4c2-6fe7-4a32-967a-c80dbf0ee93a">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd26454e121845348d3b36a5d5d0b4be_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfNy0yLTEtMS0xMjc0NTI_1b9166fe-0572-44ba-b421-b09e9f8d0f51">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47f60abf400d4a86a9f3744f80bddf28_D20210401-20210630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfNy00LTEtMS0xMjc0NTI_334d1229-882b-432d-9124-a5cb11e7e88d">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd26454e121845348d3b36a5d5d0b4be_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfOC0yLTEtMS0xMjc0NTI_32e660e3-26ab-497c-9774-e45b8528aa1c">104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47f60abf400d4a86a9f3744f80bddf28_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfOC00LTEtMS0xMjc0NTI_0e416f98-8030-4af4-bec1-c575124e9b94">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Components of AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Statements of Income locations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contract gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cce2fc95f840d0b58664ae7a9a19fa_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMTctMi0xLTEtMTI3NDUy_33804f22-2fb1-438a-a9e9-7985c07eda78">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e40834754cb4ae7a332ab8f335a1c40_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMTctNC0xLTEtMTI3NDUy_10177215-512d-4ebb-9724-f7352f884442">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contract losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03282f9364de4789b96025daf0d0ef74_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMTgtMi0xLTEtMTI3NDUy_be875354-e111-40bb-bece-15e73b4d99b9">263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74c469c59c124e739fad89b0a0b0f7c7_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMTgtNC0xLTEtMTI3NDUy_bdd0d176-cefe-4670-9e70-c518eb13409d">86</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae85a32427df4f04989f60eeef9b6bc4_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMjAtMi0xLTEtMTI3NDUy_d2c3726b-9949-45d0-8aa9-6d4107fd6bc6">183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00193fbac18e466684ae5e311d84cef6_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMjAtNC0xLTEtMTI3NDUy_700f7658-e359-4d27-ac79-52758fca86d8">105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae85a32427df4f04989f60eeef9b6bc4_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMjEtMi0xLTEtMTI3NDUy_ea3e6cd1-4988-40f7-8ff0-6222546cc370">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00193fbac18e466684ae5e311d84cef6_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMjEtNC0xLTEtMTI3NDUy_82511089-3f21-401f-9197-ba69d6ca9673">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae85a32427df4f04989f60eeef9b6bc4_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMjItMi0xLTEtMTI3NDUy_9818e22c-c0d9-4e30-bb08-cad9dbef2d94">144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00193fbac18e466684ae5e311d84cef6_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMjItNC0xLTEtMTI3NDUy_3517bdad-c21b-4984-a490-2a3947f0f7a7">83</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i710475db76604b05901ef7473465ecf1_67"></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNjg5OA_0c100c10-d7c0-4775-8bdb-ae639bc115b0" continuedAt="i54db56c33c894316915ee36fc14003a3" escape="true">Fair value measurement</ix:nonNumeric></span></div><ix:continuation id="i54db56c33c894316915ee36fc14003a3" continuedAt="ib9b5a758e14b48cdb5ee134d619b98c8"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:</span></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:6.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations for which all significant inputs are observable either directly or indirectly&#8212;other than Level 1 inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs that are unobservable and significant to the overall fair value measurement</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of observable inputs can vary among different types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.</span></div><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNjkwMA_088a8379-e930-48b5-bb96-af2fd39777fe" continuedAt="icc7ff65435524aa0b57c054cb3543f22" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each major class of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>other&#160;observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurement as of June 30, 2022, using:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d8850f784604d6b9bb2fd280095d18b_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfNS0yLTEtMS0xMzc5Njg_347ba4e8-b28c-414c-bb6f-1f04d2c98365">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd9a5ddb9454b129635afe3c05a87b2_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfNS00LTEtMS0xMzc5Njg_3d5cfd0d-046b-451a-8dc7-987bc042bc25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee625aa2538245daa9d87d5a6f0f740d_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfNS02LTEtMS0xMzc5Njg_9c330a64-c1f5-4d38-9930-2ee33eef9a8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8082d2e09a5c4aa0a7f3731849ec0d16_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfNS04LTEtMS0xMzc5Njg_716feade-362d-4d5e-a9b4-258c37c5825b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57af36ff3831468c82ff7231dc809b4d_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfNi0yLTEtMS0xMjc0NTI_2447fe83-1ad7-4eac-8556-249efd127271">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fefe53694c4ef6b89048ac7afd4735_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfNi00LTEtMS0xMjc0NTI_518da254-005d-4183-9d0d-107efe9769d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i750f10007cf9428abc683565238431dc_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfNi02LTEtMS0xMjc0NTI_7f955f10-f807-4ead-9f55-99d1aabbc138">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea16251ca3344cd8e26c09cc1395a22_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfNi04LTEtMS0xMjc0NTI_90942ff4-ff40-4235-bbb3-9658b34d6bb7">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15ca62a1ecc1459f914da217c657d346_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTYtMi0xLTEtMTI3NDUy_f61b53fb-6dd8-476c-bce4-37a87948cb90">4,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c3901a0af154ac48cb709ae944a36f3_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTYtNC0xLTEtMTI3NDUy_88a7e6ca-4f67-4195-93b0-199ab1e91c7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57e8da8b9b31484fa254b68594a6327e_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTYtNi0xLTEtMTI3NDUy_2fdd8db4-5bf6-460b-a45a-39699dc432de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbbc44571a8140188c44b0df13007242_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTYtOC0xLTEtMTI3NDUy_f19901fd-37a0-4659-a6e7-81be9e14c9c9">4,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if220d1f3f0f04912b6ba27cf16233cd1_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTctMi0xLTEtMTI3NDUy_7021c511-d893-4abb-97b9-bff151944b7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9fc102b18f140a29f8db148f3f14ac1_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTctNC0xLTEtMTI3NDUy_9b755fce-2e3b-46c2-8c25-b6b6671127c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38493d297caf42bf8a474b00e8ce8499_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTctNi0xLTEtMTI3NDUy_f1585ff0-d32a-4769-8364-a81c2369424b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f04eaab04b4d2c952875e4954ffda7_I20220630" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTctOC0xLTEtMTI3NDUy_ccb4bfcd-bc4a-441e-b482-8ce600bca405">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52bfb5d420974f909b489605f4ebb48e_I20220630" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTgtMi0xLTEtMTI3NDUy_b8315025-65a9-4a64-a5a2-e358cbb378cb">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9e16b4969645dc80f505eee050d8e6_I20220630" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTgtNC0xLTEtMTI3NDUy_9b8f507c-2341-44e8-b922-d96e60962a4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81f067b439ab417c9ce2795ab841e2d7_I20220630" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTgtNi0xLTEtMTI3NDUy_a356a680-5103-42bd-999d-fdedc74cba60">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTgtOC0xLTEtMTI3NDUy_c9ca5b1d-7088-4741-957c-c91a936704ec">492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46910804ec6546fe9f243b43a084cef9_I20220630" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjAtMi0xLTEtMTI3NDUy_f08bb0eb-f3cd-4826-9a17-35bcf2631834">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54880ede06014f8ca9a628fc84c50f6b_I20220630" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjAtNC0xLTEtMTI3NDUy_78091614-a9c4-4a80-a076-f903d9e0bd57">413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91f42a5f589a46f1b73dde5f4b870252_I20220630" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjAtNi0xLTEtMTI3NDUy_0b990567-3bb3-404d-a146-32dfac2c0ad8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dc5218b74eb7a8e483c65d0897f3_I20220630" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjAtOC0xLTEtMTI3NDUy_382bcebe-a4b1-4c01-995e-3cfda7a70b89">413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475adb709d5446f3a4125df7b276f9fc_I20220630" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjEtMi0xLTEtMTI3NDUy_80d2b1b2-8ead-4326-aff2-7c2b61f5f950">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f0e7a2ada564f7eb301bda6685da54c_I20220630" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjEtNC0xLTEtMTI3NDUy_b885fc81-26b5-4bbd-8637-fcfda3b78840">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if67bff899732472c854d894bb8a6b451_I20220630" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjEtNi0xLTEtMTI3NDUy_067715b9-7b23-4cb7-bc3c-5f1abfe930d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia55251a67abe461c8b2a09b5a3574ab5_I20220630" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjEtOC0xLTEtMTI3NDUy_3297fd05-bcff-4938-a367-202b808a2962">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4724b1086cb34ab18e734978bd980565_I20220630" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjItMi0xLTEtMTI3NDUy_7fa9a2cb-d993-469b-87e3-0f5794923070">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9146fbc7ea114428b4ba02cee98c579f_I20220630" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjItNC0xLTEtMTI3NDUy_7af92ba6-44e2-4a77-be8a-d194a93426d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6874786949604cdb824d234c3030e75b_I20220630" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjItNi0xLTEtMTI3NDUy_a1b3455a-3661-4767-9c8d-7a1df4e8af80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida17f2fa3cec491f86e599ca3185753d_I20220630" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjItOC0xLTEtMTI3NDUy_6ce2b9f1-31a0-4331-a32c-81b50337c02e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52bfb5d420974f909b489605f4ebb48e_I20220630" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjQtMi0xLTEtMTI3NDUy_ab140bf4-4a75-4ee3-a582-bd5b18950a57">6,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9e16b4969645dc80f505eee050d8e6_I20220630" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjQtNC0xLTEtMTI3NDUy_2c0a470a-2b63-47e2-9406-59746df47247">442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81f067b439ab417c9ce2795ab841e2d7_I20220630" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjQtNi0xLTEtMTI3NDUy_c9ac9ccc-cb19-4380-bc31-91c04fdfe544">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjQtOC0xLTEtMTI3NDUy_576cf4b4-74b8-42c9-839b-3b59d462c3b9">7,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46910804ec6546fe9f243b43a084cef9_I20220630" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjgtMi0xLTEtMTI3NDUy_ce3e7a55-ca8a-4553-bcc2-85e502a34d23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54880ede06014f8ca9a628fc84c50f6b_I20220630" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjgtNC0xLTEtMTI3NDUy_7ef0438b-244a-4387-9659-db45e8765532">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91f42a5f589a46f1b73dde5f4b870252_I20220630" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjgtNi0xLTEtMTI3NDUy_df606bf5-7d1a-4db7-8d7b-edb61564aacf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dc5218b74eb7a8e483c65d0897f3_I20220630" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjgtOC0xLTEtMTI3NDUy_b49d4849-c557-4ad8-924e-94e3dbf36418">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475adb709d5446f3a4125df7b276f9fc_I20220630" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjktMi0xLTEtMTI3NDUy_ff3d5194-c56c-4c21-ac83-cad04f51dba9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f0e7a2ada564f7eb301bda6685da54c_I20220630" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjktNC0xLTEtMTI3NDUy_9c47e7a7-e303-40f3-8e12-6c8d01f0782f">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if67bff899732472c854d894bb8a6b451_I20220630" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjktNi0xLTEtMTI3NDUy_b5b8d9f9-01bb-42b3-9b1a-24db8aebea67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia55251a67abe461c8b2a09b5a3574ab5_I20220630" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjktOC0xLTEtMTI3NDUy_456f1b5e-3b21-49f0-9203-fcb110ed8d1c">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4724b1086cb34ab18e734978bd980565_I20220630" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzAtMi0xLTEtMTI3NDUy_1e99f60a-5c74-42c4-8bb5-31d6c9ed6cea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9146fbc7ea114428b4ba02cee98c579f_I20220630" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzAtNC0xLTEtMTI3NDUy_9c3cdbe8-bbf9-4f63-b0b5-9dfef5ef868c">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6874786949604cdb824d234c3030e75b_I20220630" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzAtNi0xLTEtMTI3NDUy_19725003-75e8-4e60-a9ca-f99ff820fb9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida17f2fa3cec491f86e599ca3185753d_I20220630" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzAtOC0xLTEtMTI3NDUy_b92e1fcd-64d3-4e21-8fb9-d9e5533da5c7">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52bfb5d420974f909b489605f4ebb48e_I20220630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzEtMi0xLTEtMTI3NDUy_901d70c8-7c3c-4178-90a4-8f2a8f4c6959">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9e16b4969645dc80f505eee050d8e6_I20220630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzEtNC0xLTEtMTI3NDUy_fc82a28c-cc50-4359-9928-5636c8c229f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81f067b439ab417c9ce2795ab841e2d7_I20220630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzEtNi0xLTEtMTI3NDUy_a5174806-4034-4297-9bb1-7161b86b733b">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzEtOC0xLTEtMTI3NDUy_9dc393c2-83d4-4f65-8dce-e0198fa5ee90">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52bfb5d420974f909b489605f4ebb48e_I20220630" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzItMi0xLTEtMTI3NDUy_3ad7e3ec-4159-4975-a391-e5bf5d35b425">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9e16b4969645dc80f505eee050d8e6_I20220630" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzItNC0xLTEtMTI3NDUy_e30be8fb-85ba-4051-9512-6c0e4846c9fa">1,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81f067b439ab417c9ce2795ab841e2d7_I20220630" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzItNi0xLTEtMTI3NDUy_635d6a4c-4bde-4f7d-8f45-e7ff2b8485d5">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzItOC0xLTEtMTI3NDUy_e3432aab-692e-4f3d-bdcc-04d9c3d86b02">1,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="ib9b5a758e14b48cdb5ee134d619b98c8" continuedAt="ie402ba2ac74e40dcb485d933134f8f07"><div style="margin-bottom:8pt"><ix:continuation id="icc7ff65435524aa0b57c054cb3543f22"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>other observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurement as of December 31, 2021, using:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c488f99cfba482dbefc73db9e50c640_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfNS0yLTEtMS0xMzc5Nzk_614f96bc-6357-4f09-8164-523391bfd1b4">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i685a8a148b704128a60fc78026d3c3e3_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfNS00LTEtMS0xMzc5Nzk_4bec2e53-3c03-438d-b647-d5a9748dff6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic144f91dd75648e08f88041119a4fa00_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfNS02LTEtMS0xMzc5Nzk_c2b3129f-c8b2-4c4c-9dad-1342f1a7109e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd41271077fb4ca086b8c963378ae207_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfNS04LTEtMS0xMzc5Nzk_a3979f02-20b5-4e86-b815-49589250d1b3">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f08e0fe42834efe92d00613a0109c40_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfNi0yLTEtMS0xMjc0NTI_1ae3149a-a5d2-4e12-b255-a26276e420d2">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8095682c0ef94a339c9e762b31198d03_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfNi00LTEtMS0xMjc0NTI_1a3393bd-2d89-46a8-9fb7-57b5c9ee317e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9021916491244d8fa2e070974be57f65_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfNi02LTEtMS0xMjc0NTI_41c5ee6c-7745-4224-882b-60862a7a128c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c7a0f871105442a9e599228c9451089_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfNi04LTEtMS0xMjc0NTI_f8a54c14-f134-4a61-92d6-7881cd9a691d">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9240e5bb1cb44e2e876685572c682103_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTYtMi0xLTEtMTI3NDUy_f5ab2e23-cc6b-41d4-880a-7304417d89fc">5,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a563d28d08546408272809d7d6f60af_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTYtNC0xLTEtMTI3NDUy_fca2e205-0dd1-4c66-a905-44244534f9a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82eeb36d97d54dd1ab070623986e163d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTYtNi0xLTEtMTI3NDUy_fd9648ad-275f-4afa-8b6d-ab9d7e7ae2fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02847d17ecc24c3f9024cc5f534c04a2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTYtOC0xLTEtMTI3NDUy_a5b6dab1-76e9-4afa-bb1b-71858f8f569f">5,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedac67f993dd44d1a1c0c76f6096b1f2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTctMi0xLTEtMTI3NDUy_a6459cfa-c57e-4d59-be47-44198bbd9221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cb7f0273f314f8b830b51cffab82493_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTctNC0xLTEtMTI3NDUy_bbd0cc25-80a2-42f7-a63f-d659824125be">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if090df5bf17a41b3ac64e37545266583_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTctNi0xLTEtMTI3NDUy_ad87dea4-e3a6-4849-ac00-1e8bfbe25aef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea64a31893bd4a61a10bade5fb93931f_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTctOC0xLTEtMTI3NDUy_f708972a-6331-4053-baae-66eecaffead1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81cbf2552fde457394dd38fa4c8d3a52_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTgtMi0xLTEtMTI3NDUy_4cc24dc2-07cd-4318-8f8b-36af67ca380e">611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcec0bd4ab8240e38c59d5eba500ac8f_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTgtNC0xLTEtMTI3NDUy_aceed23f-b54d-48c9-9dc2-e800fae589cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95983e1a9dd248b6b5a91e82d2e18001_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTgtNi0xLTEtMTI3NDUy_e0fbdbeb-1915-4e28-9d1b-6f832d854a94">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTgtOC0xLTEtMTI3NDUy_15bd09ef-2581-4568-8190-7ba39d210006">831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586c22e74161448191ba0b644c8f9eb0_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjAtMi0xLTEtMTI3NDUy_7fb6ca2a-8281-4e38-9754-b41d88d34f77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcba3fb9ae4401d8255f9419a4e9c3b_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjAtNC0xLTEtMTI3NDUy_bbec976d-c7d2-4ab2-8f80-c0d78da46dda">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36abb6d1f7574e63a06ec93cd761c060_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjAtNi0xLTEtMTI3NDUy_f4957ef7-dc64-425b-a81e-a4b7ff40b2d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ded0f429164b4ab474c99ae4db6e67_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjAtOC0xLTEtMTI3NDUy_709e4309-8fff-457d-bc25-e089f7d43a47">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14f51ae9652c4b4a9742afd91ac81e98_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjEtMi0xLTEtMTI3NDUy_0ebae141-10cf-44ff-a00f-7e06748c17d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fe78984bfd5425d996816c13821a305_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjEtNC0xLTEtMTI3NDUy_a62bbe3d-2f79-4111-9d4a-115a12893e87">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib54f0b981864432aa40974753a26ac20_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjEtNi0xLTEtMTI3NDUy_8964582d-e1d6-423f-b1b2-381b2dd632a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6d1947469e94aadb86219cbb136c914_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjEtOC0xLTEtMTI3NDUy_f53fccb9-dc1c-4d01-b629-c8f1aaae7909">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i565eb34bf7064ea880a5c569316793d2_I20211231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjItMi0xLTEtMTI3NDUy_a4325529-5504-4775-88fa-3a7559d1ab28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc87b99380f9465fa749f246800d3c48_I20211231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjItNC0xLTEtMTI3NDUy_dc876748-df18-4f11-9b02-68e5bd31c430">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f183897d4d47b3ae8ba81bc93c54_I20211231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjItNi0xLTEtMTI3NDUy_11df316d-ae54-44f2-aabd-016a33157e38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i821465fc68c64ed594b4983fbb106d7b_I20211231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjItOC0xLTEtMTI3NDUy_c9a8791e-a826-47eb-9b02-add7d2951bab">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81cbf2552fde457394dd38fa4c8d3a52_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjMtMi0xLTEtMTI3NDUy_d71c7317-7efa-4c71-8795-433f00a3abca">7,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcec0bd4ab8240e38c59d5eba500ac8f_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjMtNC0xLTEtMTI3NDUy_e57f2118-9290-40c2-b449-e399e63b7ba7">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95983e1a9dd248b6b5a91e82d2e18001_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjMtNi0xLTEtMTI3NDUy_799becef-fe11-45c2-b208-01b0c66720cc">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjMtOC0xLTEtMTI3NDUy_17a25259-5807-4051-b45a-019f0affad11">8,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586c22e74161448191ba0b644c8f9eb0_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjctMi0xLTEtMTI3NDUy_ca300d03-7fb8-4910-8fd7-49a65864888a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcba3fb9ae4401d8255f9419a4e9c3b_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjctNC0xLTEtMTI3NDUy_8cc7443a-9cdc-4102-891f-c3ada872d154">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36abb6d1f7574e63a06ec93cd761c060_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjctNi0xLTEtMTI3NDUy_eb801f9b-d54b-425d-9525-ee01bf3921d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ded0f429164b4ab474c99ae4db6e67_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjctOC0xLTEtMTI3NDUy_d91393e1-3a37-4639-9031-c116b9f87b41">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14f51ae9652c4b4a9742afd91ac81e98_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjgtMi0xLTEtMTI3NDUy_9dc6b21c-6af3-4eb3-8be3-a5dd1be3bebf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fe78984bfd5425d996816c13821a305_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjgtNC0xLTEtMTI3NDUy_ba5d7255-265c-4016-bc2f-035227292bd5">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib54f0b981864432aa40974753a26ac20_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjgtNi0xLTEtMTI3NDUy_e7577848-0940-4910-b1d8-9ae3697e8ee3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6d1947469e94aadb86219cbb136c914_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjgtOC0xLTEtMTI3NDUy_64882c04-c409-4f2f-a34b-4850257d878d">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i565eb34bf7064ea880a5c569316793d2_I20211231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjktMi0xLTEtMTI3NDUy_fbf865a7-9872-41c0-80d8-d713c537b2d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc87b99380f9465fa749f246800d3c48_I20211231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjktNC0xLTEtMTI3NDUy_04b9e6ba-72b8-4423-8820-aed482fc243a">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107f183897d4d47b3ae8ba81bc93c54_I20211231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjktNi0xLTEtMTI3NDUy_fd36f198-2d77-4f2f-af93-e50a93acb25b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i821465fc68c64ed594b4983fbb106d7b_I20211231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjktOC0xLTEtMTI3NDUy_b323b547-6c08-4b32-94be-dfefd25a3cee">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81cbf2552fde457394dd38fa4c8d3a52_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMzAtMi0xLTEtMTI3NDUy_640d8fb3-d10c-4003-a8e2-8299fef3e344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcec0bd4ab8240e38c59d5eba500ac8f_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMzAtNC0xLTEtMTI3NDUy_6047266e-8512-4749-a862-e7d1dff5ae8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95983e1a9dd248b6b5a91e82d2e18001_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMzAtNi0xLTEtMTI3NDUy_a4924502-3acb-4639-9048-bdc969661978">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMzAtOC0xLTEtMTI3NDUy_acc8fbfd-b499-4bf4-855f-652ddbc664df">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81cbf2552fde457394dd38fa4c8d3a52_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMzEtMi0xLTEtMTI3NDUy_c3398d83-296a-4ca8-8f0e-ae8ac2b3a69e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcec0bd4ab8240e38c59d5eba500ac8f_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMzEtNC0xLTEtMTI3NDUy_2926ffc6-809f-42ff-96d0-7d1b06759d3a">534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95983e1a9dd248b6b5a91e82d2e18001_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMzEtNi0xLTEtMTI3NDUy_054f2471-527f-44a1-afce-0a2755fc6597">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMzEtOC0xLTEtMTI3NDUy_57a55f35-2c80-4792-b3e2-e2801a42807c">876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-bearing and equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our U.S. Treasury securities, money market mutual funds and equity investments in publicly traded securities are based on quoted market prices in active markets, with no valuation adjustment. The fair value of equity securities without readily determinable fair values are initially valued at the transaction price and subsequently valued based on a combination of market performance and publicly available market information for similar companies that have actively traded equity securities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our foreign currency forward derivative contracts have maturities of <ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfMjIzOQ_4c20d42c-ff64-447d-aba5-92a07dcd450f">three years</ix:nonNumeric> or less, and all are with counterparties that have minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 12, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency-basis swap spreads. See Note 12, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest rate swap contracts are with counterparties that have minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 12, Derivative instruments.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="ie402ba2ac74e40dcb485d933134f8f07"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration obligations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our business acquisitions, we have incurred contingent consideration obligations as discussed below. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and they are reviewed quarterly by management in our R&amp;D and commercial sales organizations. The inputs include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes that increase or decrease the probabilities of achieving the related development, regulatory and commercial events or that shorten or lengthen the time required to achieve such events or that increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Condensed Consolidated Statements of Income.</span></div><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNjg5MQ_261f3bba-9ea6-4b55-80a3-56a645febd4d" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de403afe8684433ba669a9d329718c4_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfMi0yLTEtMS0xMjc0NTI_c332ac83-dfec-437c-9f9b-cdfc81285c57">330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a2ab422b4b24a8fba8a2d881b98b260_I20210331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfMi00LTEtMS0xMjc0NTI_80d9a7c2-5f5a-4441-be02-547cdc213593">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfMi02LTEtMS0xMzg5NTg_36805676-5dd6-47cd-a93d-fbb8b034365a">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e5bfcd24a084d2ba4ae4e9fd63a2a81_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfMi04LTEtMS0xMzg5NjU_ed3ad7ea-7aee-436a-b9d6-bdc004f16ab5">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="amgn:BusinessCombinationContingentConsiderationArrangementsPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNC0yLTEtMS0xMjc0NTI_59f3e1c9-54ed-44f3-b2d6-b2e75f55d809">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="amgn:BusinessCombinationContingentConsiderationArrangementsPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNC00LTEtMS0xMjc0NTI_aded6d36-ceb7-468c-9552-fcd650e88c15">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="amgn:BusinessCombinationContingentConsiderationArrangementsPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNC02LTEtMS0xNTE5NDM_7dde3a09-36e4-4324-98a6-712d8df430ef">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="amgn:BusinessCombinationContingentConsiderationArrangementsPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNC04LTEtMS0xMzg5NjU_07189bdc-7303-4178-a270-59cd63f9ca77">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in valuations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNS0yLTEtMS0xMjc0NTI_5a0543d0-0fb3-4297-87ca-81367fe57933">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNS00LTEtMS0xMjc0NTI_bbbf4dfa-6325-453a-b067-7b81a3f39091">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNS02LTEtMS0xNTE5NDM_5628f87b-2d1e-4318-bd7e-a580e873de73">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNS04LTEtMS0xMzg5NjU_38997cac-14fb-490f-8416-f25a30ba723d">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNi0yLTEtMS0xMjc0NTI_f3bc8952-4267-4180-874c-0e27f55893a2">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99dc635999d0465e8fcbdc0cee2c1601_I20210630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNi00LTEtMS0xMjc0NTI_97fb1b34-e3bd-452b-8ce5-5dc7626001dc">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNi02LTEtMS0xMzg5NTg_d155d5de-6a55-41e6-9d27-a99b70977154">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99dc635999d0465e8fcbdc0cee2c1601_I20210630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNi04LTEtMS0xMzg5NjU_9ccc496f-1fa7-4810-8fa5-5e0157319387">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, our contingent consideration obligations are primarily the result of our acquisition of Teneobio in October 2021, which obligates us to pay the former shareholders up to $<ix:nonFraction unitRef="usd" contextRef="ib38d2c2296ce4775b07ee5a0181057d4_I20211231" decimals="-8" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNTY2MQ_d4977e79-ec56-4079-ab39-f61690e050b7"><ix:nonFraction unitRef="usd" contextRef="i2680f1cd22d24318b9fcb7fe45f7425b_I20220630" decimals="-8" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNTY2MQ_d7351dee-676f-4853-b0c8-4ac119132407">1.6</ix:nonFraction></ix:nonFraction>&#160;billion upon achieving separate development and regulatory milestones with regard to various R&amp;D programs. See Note 2, Acquisitions and divestitures.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of the fair values of other financial instruments</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Borrowings</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair values of our borrowings by using Level 2 inputs. As of June 30, 2022 and December 31, 2021, the aggregate fair values of our borrowings were $<ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-8" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNjE0Mw_bf7fb218-b17b-43a7-a4c8-987be04e32ba">34.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-8" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNjE1MA_23dbb5b1-c26b-4723-adaa-b54dab3e3e62">37.9</ix:nonFraction> billion, respectively, and the carrying values were $<ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-8" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfMTA5OTUxMTYzNTQyOA_cc7def2d-5473-4794-8f49-037b1239d3d5">36.5</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231" decimals="-8" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNjIwNA_47b52320-527d-4c41-b696-5dec23f72410">33.3</ix:nonFraction> billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in BeiGene, Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of our investment in BeiGene by using Level 1 inputs. As of June 30, 2022 and December 31, 2021, the fair values were $<ix:nonFraction unitRef="usd" contextRef="i508f5bf239c54b9b938463f7ae92fea1_I20220630" decimals="-8" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNjU0Mw_66cd64e1-0112-4677-aa63-b33c356bdb27">3.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ic408702ec02a49bf91a6056997008286_I20211231" decimals="-8" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNjU1MA_146e7045-5358-45a7-a053-342dbcb5cb2e">5.1</ix:nonFraction>&#160;billion, and the carrying values were $<ix:nonFraction unitRef="usd" contextRef="i508f5bf239c54b9b938463f7ae92fea1_I20220630" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNjU4Mw_2ba70602-abd0-41d1-a198-b544d6f3b660">2.5</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ic408702ec02a49bf91a6056997008286_I20211231" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNjU5MA_79d5a076-d62b-47c4-9f8c-d707e1c11cb4">2.8</ix:nonFraction>&#160;billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2022 and 2021, there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis, except with respect to the impairment of net assets in connection with the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i710475db76604b05901ef7473465ecf1_70"></div><div style="margin-bottom:1pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfOTMzMQ_98ed5d33-e7c6-4b02-878f-c61600a04d60" continuedAt="i63ba18b8a27b4af99257d82551fd30ec" escape="true">Derivative instruments</ix:nonNumeric></span></div><ix:continuation id="i63ba18b8a27b4af99257d82551fd30ec" continuedAt="ifbacdd29ccea4be7b265e6dba952c21c"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative- trading purposes.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flow hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates primarily associated with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are partially offset by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales up to a maximum of three years into the future; and at any given point in time, a higher percentage of nearer-term projected product sales are being hedged than in successive periods.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, we had outstanding foreign currency forward contracts with aggregate notional amounts of $<ix:nonFraction unitRef="usd" contextRef="iefbf65ab82c24adaa0645594dc8fcaff_I20220630" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfMTUxMA_6947c790-069c-4e59-9cdf-cb224f8c9b0f">5.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i8defa2bdb0084af3ae0cbfc5424bc98a_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfMTUxNw_768761d3-c2c2-452a-b7a2-c0ce731f3395">5.7</ix:nonFraction> billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Condensed Consolidated Balance Sheets, and we reclassify them to Product sales in the Condensed Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to Other (expense) income, net, in the Condensed Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.</span></div><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfOTMyNg_ac7a3bb8-33f9-49f3-91e1-e5008642e494" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amounts and interest rates of our cross-currency swaps as of June 30, 2022, were as follows (notional amounts in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. dollars</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedged notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% 2023 Swiss franc Bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHF</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="chf" contextRef="i8362dfe3f447487fbcfb592560763e40_I20220630" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfMy0yLTEtMS0xMjc0NTI_94780afe-dd95-4d90-9496-3884e499650d">700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i981e48d6e4474ce8b890550799a406fd_I20220630" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfMy00LTEtMS0xMjc0NTI_258ce02a-374b-4f6e-ab67-a745d2ca314c">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8362dfe3f447487fbcfb592560763e40_I20220630" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfMy02LTEtMS0xMjc0NTI_53714d98-e1dd-40d4-ba97-93fcb0c26052">704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i08fbdbb43e0a42089b7e2cf59e5ef985_I20220630" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfMy04LTEtMS0xMjc0NTI_436cc0f6-badf-47c2-b5d5-8eac47c4e5a2">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% 2026 euro Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i8ae26a5ef2c2486bbe9a6346774e6921_I20220630" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNC0yLTEtMS0xMjc0NTI_747ac92a-c3dd-436d-9011-80ab8baa393c">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0d3a7502c66a4094ac60caad8191426e_I20220630" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNC00LTEtMS0xMjc0NTI_529baad9-5fde-4f67-a6b9-6cac90c6c6e7">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ae26a5ef2c2486bbe9a6346774e6921_I20220630" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNC02LTEtMS0xMjc0NTI_491f0b7f-26c7-4c4d-814d-f90f828c0377">833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id566b59cbf154fdeb60a87ca0ef35553_I20220630" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNC04LTEtMS0xMjc0NTI_f913827c-8861-46de-b138-ad4e73bd236b">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% 2026 pound sterling Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbp" contextRef="i15d64ffdd06846b7844fc0773809a605_I20220630" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNS0yLTEtMS0xMjc0NTI_3660ab2d-55ee-4609-ad27-c99953537887">475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic91a7bb478ff4fdcb59d644e21f41580_I20220630" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNS00LTEtMS0xMjc0NTI_b9ac7e71-3908-4115-826f-68958cb6f2bf">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d64ffdd06846b7844fc0773809a605_I20220630" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNS02LTEtMS0xMjc0NTI_d5e14611-d020-4be1-8143-a39cbf5e9a39">747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i007735ddc25943c782bd306e4842d7e1_I20220630" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNS04LTEtMS0xMjc0NTI_2a1e7528-928c-4d3e-a6ee-ad6f8ef6aafe">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% 2029 pound sterling Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbp" contextRef="i218f08d9675e4f2a93d071febe505805_I20220630" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNi0yLTEtMS0xMjc0NTI_2b046c03-b84c-4842-a5bd-039947063616">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i312524090a284ea3a18c66e1488acf48_I20220630" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNi00LTEtMS0xMjc0NTI_4a452cf5-0b69-4521-bc9a-68d9e125d81c">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i218f08d9675e4f2a93d071febe505805_I20220630" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNi02LTEtMS0xMjc0NTI_fbe807c9-4e95-4627-91f3-e1c312f0a9a3">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia79d481c2b0649f0ab76519c77d951cc_I20220630" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNi04LTEtMS0xMjc0NTI_3009e407-601d-46d7-807c-90aac4997281">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n the Condensed Consolidated Balance Sheets </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and are amortized into Interest expense, net, in the Condensed Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the six months ended June 30, 2022, and amounts expected to be recognized during the subsequent 12 months are not material.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="ifbacdd29ccea4be7b265e6dba952c21c" continuedAt="i01d48a8feb3f48bf939fbc4858949d93"><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfOTMxNw_90b95958-d7ca-46c2-8645-c706336c75cd" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68137429bba74ac28b0ecf3eb2d7ec4c_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfMi0yLTEtMS0xMjc0NTI_a355b5eb-c80d-47e0-914d-41fbd198b888">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d3fea5388d64fee80f159215bb2ffe9_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfMi00LTEtMS0xMjc0NTI_bab29d9d-bd1d-4af4-a68a-13a5e9491cc3">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78bda1111d894ca79b9e9971a476802a_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfMi02LTEtMS0xMjc0NTI_805b835e-6816-4c96-899d-b507a72c1736">330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i805f5c4cbf16443d9484e17037e0cf71_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfMi04LTEtMS0xMjc0NTI_c6cba145-bbf7-4d04-9f63-8badf1b03ac3">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8c48198203049e49f74000350f415ed_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfMy0yLTEtMS0xMjc0NTI_5146f83a-ebd2-47ab-bd56-5306580cd6c6">185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id07132e210b94637823a00632d45e34d_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfMy00LTEtMS0xMjc0NTI_85599bac-223b-44ef-92b9-555f00c85560">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85524ff13c9e4c88a235e0f4342b1c43_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfMy02LTEtMS0xMjc0NTI_7fbed6d8-af47-442b-b559-52b4c7a423d2">207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcaf04737d1f428b931744a248c8be92_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfMy04LTEtMS0xMjc0NTI_fa88d394-8d7c-4254-8014-45639576dd6a">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrealized gains (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ecd36ab401a4e70a51c743fc9ccdc8d_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfNS0yLTEtMS0xMjc0NTI_e4a55634-3d55-4a11-9020-958acf274552">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11dede7c485142b591bf4c1b589d93f5_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfNS00LTEtMS0xMjc0NTI_5c80f245-d616-4da8-a510-b597735fd77c">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8017a33df2447cf98803b972ba03d31_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfNS02LTEtMS0xMjc0NTI_2140871d-649a-42ac-8e8e-5a603ec6f99a">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0b85c703fd14ec3b991cc54cfc7ad38_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfNS04LTEtMS0xMjc0NTI_5eda7117-856c-4baa-8a68-57aa324c531b">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of both June 30, 2022 and December 31, 2021, we had interest rate swap contracts with aggregate notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i8ed4d99ca27b46dfb95dbfc0558df5cc_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNDc1Ng_1a2bccef-c603-4214-a25e-e3b9d6798c9b"><ix:nonFraction unitRef="usd" contextRef="i8076cfa2bcaa4ab494d93e38c4c28e31_I20220630" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNDc1Ng_81b9dd5f-849a-4abb-b81a-2f961923f7db">6.7</ix:nonFraction></ix:nonFraction>&#160;billion that hedge certain portions of our long-term debt issuances. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Condensed Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.</span></div><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfOTM1MQ_ae4173aa-1555-4426-9b6b-53fb98129a25" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying amounts of hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d41c6ab5c14f9380e71043309fbdc8_I20220630" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjAyMjhkMWQwZjMwZTQ2N2RiYjc3ZDhmYzZmZjk3NzIxL3RhYmxlcmFuZ2U6MDIyOGQxZDBmMzBlNDY3ZGJiNzdkOGZjNmZmOTc3MjFfMi0yLTEtMS0xMjc0NTI_a2b67a11-d266-4e84-8641-97168b04f84d">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd05bb4763c34ecb8925e75416037ff8_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjAyMjhkMWQwZjMwZTQ2N2RiYjc3ZDhmYzZmZjk3NzIxL3RhYmxlcmFuZ2U6MDIyOGQxZDBmMzBlNDY3ZGJiNzdkOGZjNmZmOTc3MjFfMi00LTEtMS0xMjc0NTI_7f01a0e2-5b3c-4852-80f5-fa95981f68bf">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d41c6ab5c14f9380e71043309fbdc8_I20220630" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjAyMjhkMWQwZjMwZTQ2N2RiYjc3ZDhmYzZmZjk3NzIxL3RhYmxlcmFuZ2U6MDIyOGQxZDBmMzBlNDY3ZGJiNzdkOGZjNmZmOTc3MjFfMi02LTEtMS0xMjc0NTI_2f58147c-57b5-405b-b747-5510fda0d22c">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd05bb4763c34ecb8925e75416037ff8_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjAyMjhkMWQwZjMwZTQ2N2RiYjc3ZDhmYzZmZjk3NzIxL3RhYmxlcmFuZ2U6MDIyOGQxZDBmMzBlNDY3ZGJiNzdkOGZjNmZmOTc3MjFfMi04LTEtMS0xMjc0NTI_7c267851-e90c-42c9-8222-e02e70b1ef06">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic74bae73be3b45d29ba2975a44af1c97_I20220630" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjAyMjhkMWQwZjMwZTQ2N2RiYjc3ZDhmYzZmZjk3NzIxL3RhYmxlcmFuZ2U6MDIyOGQxZDBmMzBlNDY3ZGJiNzdkOGZjNmZmOTc3MjFfMy0yLTEtMS0xMjc0NTI_0ec4fd75-bd3d-46b7-8589-b5a5243cea95">6,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ff1b52fa159466d99f80192dcb38c1b_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjAyMjhkMWQwZjMwZTQ2N2RiYjc3ZDhmYzZmZjk3NzIxL3RhYmxlcmFuZ2U6MDIyOGQxZDBmMzBlNDY3ZGJiNzdkOGZjNmZmOTc3MjFfMy00LTEtMS0xMjc0NTI_82e77bb7-7024-4e93-8b0c-38583a990339">6,729</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic74bae73be3b45d29ba2975a44af1c97_I20220630" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjAyMjhkMWQwZjMwZTQ2N2RiYjc3ZDhmYzZmZjk3NzIxL3RhYmxlcmFuZ2U6MDIyOGQxZDBmMzBlNDY3ZGJiNzdkOGZjNmZmOTc3MjFfMy02LTEtMS0xMjc0NTI_70eeba52-95f4-4964-943c-ebfadd537f2c">292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ff1b52fa159466d99f80192dcb38c1b_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjAyMjhkMWQwZjMwZTQ2N2RiYjc3ZDhmYzZmZjk3NzIxL3RhYmxlcmFuZ2U6MDIyOGQxZDBmMzBlNDY3ZGJiNzdkOGZjNmZmOTc3MjFfMy04LTEtMS0xMjc0NTI_77685a37-c3a7-4ab1-9026-6fff311c605d">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Current portion of long-term debt includes $<ix:nonFraction unitRef="usd" contextRef="i17d41c6ab5c14f9380e71043309fbdc8_I20220630" decimals="-6" name="amgn:HedgedLiabilityDiscontinuedFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNTgxNA_5d6ec789-0acc-460e-b94e-0498a85ad2ef">82</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idd05bb4763c34ecb8925e75416037ff8_I20211231" decimals="-6" name="amgn:HedgedLiabilityDiscontinuedFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNTgyMQ_e5cc1890-29a1-4c1a-8d46-803a4d2a5ee1">85</ix:nonFraction> million of carrying value with discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively. Long-term debt includes $<ix:nonFraction unitRef="usd" contextRef="ic74bae73be3b45d29ba2975a44af1c97_I20220630" decimals="-6" name="amgn:HedgedLiabilityDiscontinuedFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNTkzNw_44da8f2c-b827-4741-98bb-f01e5fa51fd5">399</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5ff1b52fa159466d99f80192dcb38c1b_I20211231" decimals="-6" name="amgn:HedgedLiabilityDiscontinuedFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNTk0NA_3d1fdf22-1754-4258-83c9-683597106005">440</ix:nonFraction> million of carrying value with discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Current portion of long-term debt includes $<ix:nonFraction unitRef="usd" contextRef="i17d41c6ab5c14f9380e71043309fbdc8_I20220630" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNjA4Mw_eec365ee-c1e3-4f5d-84b9-5e8db496e3ec">82</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idd05bb4763c34ecb8925e75416037ff8_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNjA5MA_0f8a3f3c-e43a-4bd2-b00f-ec7f920d7251">85</ix:nonFraction> million of hedging adjustments on discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively. Long-term debt includes $<ix:nonFraction unitRef="usd" contextRef="ic74bae73be3b45d29ba2975a44af1c97_I20220630" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNjIwOQ_5faac66a-4e62-411d-9a64-86538931afe3">299</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5ff1b52fa159466d99f80192dcb38c1b_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNjIxNg_2546d635-ba47-49b4-8186-55fe6f5caedb">340</ix:nonFraction> million of hedging adjustments on discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="i01d48a8feb3f48bf939fbc4858949d93" continuedAt="i61c53fac8bcb4f63bf442243bd4d322b"><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impact of hedging transactions</span></div><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfOTM2Mw_dead3966-7c6b-4995-80e0-c5f75bfb846f" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3c410d6b2f84e53be5c076dec22d865_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfMy0yLTEtMS0xMjc0NTI_98efb387-04ef-4729-a1c3-07bc08108a38">6,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfMy00LTEtMS0xMjc0NTI_ae9c9671-aaba-4635-a022-28135a680f5e">317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfMy02LTEtMS0xMjc0NTI_370ef145-871a-473f-bb68-c69c2b4bb002">328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38c160a3f1834d5e9d775a1dea85e514_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfMy04LTEtMS0xMjc0NTI_2b7895d9-3115-4e52-aca8-3bf5c06f6f46">12,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfMy0xMC0xLTEtMTI3NDUy_bd5a938f-8f70-4c8b-a1f3-48d0b7f2506e">847</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfMy0xMi0xLTEtMTI3NDUy_f4c9b540-2312-4165-a189-9ef5cb00535c">623</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04f12d226beb4801941ee9ae41184a68_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfNi0yLTEtMS0xMjc0NTI_545d91d4-95f8-4244-bfc0-6ef8ccef4b3b">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b1f56bd6014a44b958229d8e11e34c_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfNi04LTEtMS0xMjc0NTI_a83f96c2-c790-4bc9-a64a-d7c6e7bd8964">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic08e134f84b54cd59491e20413185c0a_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfNy00LTEtMS0xMjc0NTI_92f94ecf-20b2-44ef-874f-d720d55bac87">185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05e8cec02f334b38bc7a7a5dbf123867_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfNy0xMC0xLTEtMTI3NDUy_03f8d04d-0ac3-4b88-9284-5dc14e100ca5">263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71fb031f34f648488a945f9c0e957284_D20220401-20220630" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfMTAtNi0xLTEtMTI3NDUy_ebc59e09-1edf-4bfd-9c51-7c0f764448ec">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46d6b8233243ecac66f70b9060cbd1_D20220101-20220630" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfMTAtMTItMS0xLTEyNzQ1Mg_b60ba282-95e3-4c92-ae9d-73d0621db2d9">494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71fb031f34f648488a945f9c0e957284_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfMTEtNi0xLTEtMTI3NDUy_cd036763-39a9-4203-a817-82fcbd1f7df8">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46d6b8233243ecac66f70b9060cbd1_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfMTEtMTItMS0xLTEyNzQ1Mg_ee5653db-cf49-46a9-8185-2a575a9f00bc">450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d9e005bccc4060bd5addba903c2c2c_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfMy0yLTEtMS0xMjc0NTI_277a94a6-1fc3-4231-9c03-7ed1aae99801">6,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfMy00LTEtMS0xMjc0NTI_70bc1e7f-0cfe-4fe8-b3e3-5ff994aa7f48">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfMy02LTEtMS0xMjc0NTI_59f9e2a1-9fbc-40ed-8bfc-c6371c615ce1">281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93db18973157470084da5a577ecb7c40_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfMy04LTEtMS0xMjc0NTI_9d933c45-ae49-4f60-a9a8-fb0f2099e382">11,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfMy0xMC0xLTEtMTI3NDUy_0644a077-eff2-46eb-a967-4ebb22c32384">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfMy0xMi0xLTEtMTI3NDUy_f4767d5d-688a-4027-9850-b85d21d5edf3">566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9a2634a12bd4b95b7c8f4f70a665670_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfNi0yLTEtMS0xMjc0NTI_64f24ae0-3b98-4f31-86b9-5037378f802f">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib097da5bd14d41edb20979d3673833c5_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfNi04LTEtMS0xMjc0NTI_c410dfba-9a5f-4973-849b-7b421bf42f88">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife1360142edd4db88451ac7ac6cbba55_D20210401-20210630" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfNy00LTEtMS0xMjc0NTI_e342777d-96e4-4c27-9514-c0e36d179c7d">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80f9a2035b3f4ef6803a4efbdaae94fe_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfNy0xMC0xLTEtMTI3NDUy_b047ae22-8a62-4305-a513-b29a31d81e0f">86</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60819ab810454638b5cda1c40c6fcbe0_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfMTAtNi0xLTEtMTI3NDUy_75188da4-c9e9-4de4-9286-7a1a1b793b8b">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4620a07bcdfd4700a32de4f28a35ac57_D20210101-20210630" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfMTAtMTItMS0xLTEyNzQ1Mg_ffbee826-3c66-4702-9ed3-ac1254c68d30">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60819ab810454638b5cda1c40c6fcbe0_D20210401-20210630" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfMTEtNi0xLTEtMTI3NDUy_db135fba-ce7b-449d-90b7-3266d99203f0">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4620a07bcdfd4700a32de4f28a35ac57_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfMTEtMTItMS0xLTEyNzQ1Mg_684480b2-99d7-4ea7-8440-65332e860b50">97</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">__________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Gains on hedged items do not exactly offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of June 30, 2022, we expected to reclassify $<ix:nonFraction unitRef="usd" contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNzA5MQ_883b9c8e-5776-480b-8acf-7f97686baaec">179</ix:nonFraction> million of net gains on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="i61c53fac8bcb4f63bf442243bd4d322b"><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives not designated as hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of June 30, 2022 and December 31, 2021, the total notional amounts of these foreign currency forward contracts were $<ix:nonFraction unitRef="usd" contextRef="ie3f981e832314d97a18ace7194dec829_I20220630" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNzYzNw_00cd57f9-ed39-4b54-8ef2-f453b32add04">550</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i214b98a8995d4320b1feccd543454dfb_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNzY0NA_42e2135f-2162-4595-8d4f-b6462dca8ea4">680</ix:nonFraction> million, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the three and six months ended June 30, 2022 and 2021. </span></div><ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfOTMyMg_bda652cd-218a-42bc-8ed6-d034e98972f4" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Balance Sheets locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Balance Sheets locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging&#160;instruments:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f1f9fe211f40d8bb875fcebcc49a34_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjhjMWQzZTM2YmQzNTQzNzY4MmI4MzVhN2E4ZWU4ZjI1L3RhYmxlcmFuZ2U6OGMxZDNlMzZiZDM1NDM3NjgyYjgzNWE3YThlZThmMjVfMy00LTEtMS0xMjc0NTI_1d39180b-b1a6-4792-8bde-bae1dd5ab652">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac2494da7b14b1cbcce6502366b8635_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjhjMWQzZTM2YmQzNTQzNzY4MmI4MzVhN2E4ZWU4ZjI1L3RhYmxlcmFuZ2U6OGMxZDNlMzZiZDM1NDM3NjgyYjgzNWE3YThlZThmMjVfMy04LTEtMS0xMjc0NTI_babc9763-59c9-40ab-8cb3-c42c1fe19be3">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe23a3b8f0d470c8d4a49d6ccea2fa7_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjhjMWQzZTM2YmQzNTQzNzY4MmI4MzVhN2E4ZWU4ZjI1L3RhYmxlcmFuZ2U6OGMxZDNlMzZiZDM1NDM3NjgyYjgzNWE3YThlZThmMjVfNC00LTEtMS0xMjc0NTI_ffcbc2cd-78fc-4b44-87df-6c2675b057b9">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd87d0fef6646d585035e3b89e9d2db_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjhjMWQzZTM2YmQzNTQzNzY4MmI4MzVhN2E4ZWU4ZjI1L3RhYmxlcmFuZ2U6OGMxZDNlMzZiZDM1NDM3NjgyYjgzNWE3YThlZThmMjVfNC04LTEtMS0xMjc0NTI_c78e93e4-ab29-41de-be23-b9a0fd88d581">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i788c2b8522d14ae4b526f2caa3d298ba_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjhjMWQzZTM2YmQzNTQzNzY4MmI4MzVhN2E4ZWU4ZjI1L3RhYmxlcmFuZ2U6OGMxZDNlMzZiZDM1NDM3NjgyYjgzNWE3YThlZThmMjVfNS00LTEtMS0xMjc0NTI_586ba7f5-130d-427d-bbc6-48da5d17efea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19dc6da2ca134f33b03794a8e15bdc9a_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjhjMWQzZTM2YmQzNTQzNzY4MmI4MzVhN2E4ZWU4ZjI1L3RhYmxlcmFuZ2U6OGMxZDNlMzZiZDM1NDM3NjgyYjgzNWE3YThlZThmMjVfNS04LTEtMS0xMjc0NTI_6d8a88b4-bd06-4d4a-ba37-34ebf7c3df69">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf4e6ee507f42da9c63527f4cd46ce6_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjhjMWQzZTM2YmQzNTQzNzY4MmI4MzVhN2E4ZWU4ZjI1L3RhYmxlcmFuZ2U6OGMxZDNlMzZiZDM1NDM3NjgyYjgzNWE3YThlZThmMjVfNy00LTEtMS0xMjc0NTI_c0e735f2-2356-4921-ad8a-744db84c8ad2">442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf4e6ee507f42da9c63527f4cd46ce6_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjhjMWQzZTM2YmQzNTQzNzY4MmI4MzVhN2E4ZWU4ZjI1L3RhYmxlcmFuZ2U6OGMxZDNlMzZiZDM1NDM3NjgyYjgzNWE3YThlZThmMjVfNy04LTEtMS0xMjc0NTI_47b03901-c048-43d6-91e0-6ae55d5c196a">1,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Balance Sheets locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Balance Sheets locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf3a9c3404d34ff4ac73b544cd1e2f86_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmNjZTUzZmRiNzVkZDQwZjlhNjVmOGYwYWY3MzJhM2FmL3RhYmxlcmFuZ2U6Y2NlNTNmZGI3NWRkNDBmOWE2NWY4ZjBhZjczMmEzYWZfMy00LTEtMS0xMjc0NTI_7a4b1dad-43d5-4c36-b121-859056dbf480">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c607fed913b4d45844cc65fc1906d04_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmNjZTUzZmRiNzVkZDQwZjlhNjVmOGYwYWY3MzJhM2FmL3RhYmxlcmFuZ2U6Y2NlNTNmZGI3NWRkNDBmOWE2NWY4ZjBhZjczMmEzYWZfMy04LTEtMS0xMjc0NTI_0913470a-dac2-4389-85e5-572ad4b0d0eb">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e470b268fb34c43bee67b9119f09613_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmNjZTUzZmRiNzVkZDQwZjlhNjVmOGYwYWY3MzJhM2FmL3RhYmxlcmFuZ2U6Y2NlNTNmZGI3NWRkNDBmOWE2NWY4ZjBhZjczMmEzYWZfNC00LTEtMS0xMjc0NTI_e3012c0b-d751-4737-8dc5-a1dc827b63b4">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf6cd1b2403422ba77e0a6dc045346f_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmNjZTUzZmRiNzVkZDQwZjlhNjVmOGYwYWY3MzJhM2FmL3RhYmxlcmFuZ2U6Y2NlNTNmZGI3NWRkNDBmOWE2NWY4ZjBhZjczMmEzYWZfNC04LTEtMS0xMjc0NTI_cb753ccc-caec-4aea-b606-28a51bc5c569">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eae23293d40463888c07bd1f600a1aa_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmNjZTUzZmRiNzVkZDQwZjlhNjVmOGYwYWY3MzJhM2FmL3RhYmxlcmFuZ2U6Y2NlNTNmZGI3NWRkNDBmOWE2NWY4ZjBhZjczMmEzYWZfNi00LTEtMS0xMjc0NTI_b89727c0-a41c-4d0f-ab30-b8e34fa3e682">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i565b2e8ffb1b400bb11bbac9aa7a32a2_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmNjZTUzZmRiNzVkZDQwZjlhNjVmOGYwYWY3MzJhM2FmL3RhYmxlcmFuZ2U6Y2NlNTNmZGI3NWRkNDBmOWE2NWY4ZjBhZjczMmEzYWZfNi04LTEtMS0xMjc0NTI_b927e222-aeff-4237-8e20-2e83a03e3909">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05b40e8931544e10b858fc7bf3becffb_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmNjZTUzZmRiNzVkZDQwZjlhNjVmOGYwYWY3MzJhM2FmL3RhYmxlcmFuZ2U6Y2NlNTNmZGI3NWRkNDBmOWE2NWY4ZjBhZjczMmEzYWZfNy00LTEtMS0xMjc0NTI_2ec93e06-f4cf-4a1a-8e99-6f6cb08da40a">265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05b40e8931544e10b858fc7bf3becffb_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmNjZTUzZmRiNzVkZDQwZjlhNjVmOGYwYWY3MzJhM2FmL3RhYmxlcmFuZ2U6Y2NlNTNmZGI3NWRkNDBmOWE2NWY4ZjBhZjczMmEzYWZfNy04LTEtMS0xMjc0NTI_dd81d1a0-3dba-46ec-9ea8-1f879796eeac">534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative contracts that were in liability positions as of June 30, 2022, contain certain credit-risk-related contingent provisions that would be triggered if (i)&#160;we were to undergo a change in control and (ii)&#160;our or the surviving entity&#8217;s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts in the Condensed Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83My9mcmFnOjIzMDNmZDNhMDc5MDQ3ZTQ4Y2FjMDBlNmYxYzdhNjNhL3RleHRyZWdpb246MjMwM2ZkM2EwNzkwNDdlNDhjYWMwMGU2ZjFjN2E2M2FfNDk5Mw_d26650e4-c76b-4025-98b7-478715def3ee" continuedAt="i4430ea1d2e2e408fbbad564e92395079" escape="true">Contingencies and commitments</ix:nonNumeric></span></div><ix:continuation id="i4430ea1d2e2e408fbbad564e92395079" continuedAt="i48531133370e45bbb69726ec521f9892"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See our Annual Report on Form 10-K for the year ended December 31, 2021, Part I, Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business may be affected by litigation and government investigations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. Although it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain recent developments concerning our legal proceedings and other matters are discussed below:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ANDA Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla ANDA Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Apotex Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 14, 2022, Amgen filed a lawsuit in the U.S. District Court for the District of New Jersey (the New Jersey District Court) against Apotex Inc. (Apotex) for infringement of U.S. Patent Nos. 7,427,638, 9,872,854 and 10,092,541, which are listed in the Orange Book for Otezla. This lawsuit was based on Apotex&#8217;s submission of an ANDA seeking FDA approval to market a generic version of Otezla and seeks an order of the New Jersey District Court making any FDA approval of Apotex&#8217;s ANDA effective no earlier than the expiration of the applicable patents.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repatha Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Disputes in the International Region</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 21, 2022, Sanofi Biotechnology SAS filed an action against Amgen GmbH and Amgen (Europe) B.V. before the Regional Court of Dusseldorf alleging that the marketing and sale of Repatha infringes European Patent No. 2,756,004 (the EP&#8217;004 Patent), seeking infringement damages and injunctive relief. The EP&#8217;004 Patent is currently in opposition proceedings, initiated by Amgen and an anonymous third party, before the European Patent Office (EPO). A hearing before the Opposition Division of the EPO was held on June 8 and 9, 2022, and the Opposition Division upheld the validity of the claims at issue with narrowing amendments. The parties are awaiting the Opposition Division&#8217;s written opinion. Amgen filed a Notice of Appeal on July 6, 2022.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><ix:continuation id="i48531133370e45bbb69726ec521f9892"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Actions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sensipar Antitrust Class Actions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 11, 2022, the parties filed motions asking permission to seek interlocutory appeal of the U.S. District Court for the District of Delaware&#8217;s (the Delaware District Court&#8217;s) March 11, 2022 order denying Amgen&#8217;s Motion to Dismiss solely with respect to the reverse payment claim and the various state law claims. The plaintiffs did not oppose Amgen&#8217;s motion and instead argued all issues should be appealed at this time. Amgen filed its opposition to plaintiffs&#8217; motion on June 10, 2022, and reply briefs were filed on June 24, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HUMIRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Biosimilar Antitrust Actions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022, the U.S. Court of Appeals for the Seventh Circuit issued an opinion affirming the June 30, 2020 dismissal with prejudice by the U.S. District Court for the Northern District of Illinois of a consolidated complaint against Amgen along with AbbVie Inc., AbbVie Biotechnology Ltd., Samsung Bioepis Co. and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sandoz Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regeneron Pharmaceuticals, Inc. Antitrust Action</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2022, Regeneron Pharmaceuticals, Inc. (Regeneron) filed suit against Amgen in the Delaware District Court for federal and state antitrust and unfair competition violations and tortious interference with prospective business relations. Regeneron alleges that Amgen&#8217;s sales contracting practices for Repatha, ENBREL and Otezla with key insurers, third-party payors and PBMs have harmed the sales of its product PRALUENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and focuses on <ix:nonFraction unitRef="argument" contextRef="i3468cc5757b34eb384cc512b95a07626_D20220527-20220527" decimals="INF" name="amgn:LitigationSettlementNumberOfPrimaryArguments" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83My9mcmFnOjIzMDNmZDNhMDc5MDQ3ZTQ4Y2FjMDBlNmYxYzdhNjNhL3RleHRyZWdpb246MjMwM2ZkM2EwNzkwNDdlNDhjYWMwMGU2ZjFjN2E2M2FfMTA5OTUxMTY3NDAzNQ_dc7dd81e-eb31-49fb-8770-7ab14735fd7c">two</ix:nonFraction> primary arguments: that Amgen improperly bundled sales of Repatha with ENBREL, Otezla and potentially other products and sought exclusive or de facto exclusive formulary positioning for Repatha. Amgen&#8217;s initial responsive pleading was filed on August 1, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Tax Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. &amp; Subsidiaries v. Commissioner of Internal Revenue</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 4, Income taxes, for discussion of the IRS tax dispute and the Company&#8217;s petition in the U.S. Tax Court.</span></div></ix:continuation><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:8.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following MD&amp;A is intended to assist the reader in understanding Amgen&#8217;s business. MD&amp;A is provided as a supplement to and should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2021, and our Quarterly Report on Form 10-Q for the period ended March 31, 2022. Our results of operations discussed in MD&amp;A are presented in conformity with GAAP. Amgen operates in one business segment: human therapeutics. Therefore, our results of operations are discussed on a consolidated basis.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs and our management&#8217;s assumptions. In addition, we, or others on our behalf, may make forward-looking statements in press releases, written statements or our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls and conference calls. Such words as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;outlook,&#8221; &#8220;could,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;should,&#8221; &#8220;may,&#8221; &#8220;assume&#8221; and &#8220;continue&#8221; as well as variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and they involve certain risks, uncertainties and assumptions that are difficult to predict. We describe our respective risks, uncertainties and assumptions that could affect the outcome or results of operations in Item 1A. Risk Factors in Part II herein and in Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2021, and in Part II, Item 1A. Risk Factors of our Quarterly Report on Form 10-Q for the period ended March 31, 2022. We have based our forward-looking statements on our management&#8217;s beliefs and assumptions based on information available to our management at the time the statements are made. We caution you that actual outcomes and results may differ materially from what is expressed, implied or forecasted by our forward-looking statements. Reference is made in particular to forward-looking statements regarding product sales, regulatory activities, clinical trial results, reimbursement, expenses, EPS, liquidity and capital resources, trends, planned dividends, stock repurchases, collaborations and effects of pandemics. Except as required under the federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update publicly any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i710475db76604b05901ef7473465ecf1_79"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen is a biotechnology company committed to unlocking the potential of biology for patients suffering from serious illnesses. A biotechnology pioneer since 1980, Amgen has grown to be one of the world&#8217;s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal products are ENBREL, Prolia, Otezla, XGEVA, Aranesp, Neulasta, Repatha, KYPROLIS and Nplate. We also market a number of other products, including MVASI, Vectibix, EVENITY, BLINCYTO, EPOGEN, AMGEVITA, Aimovig, Parsabiv, KANJINTI, LUMAKRAS/LUMYKRAS, NEUPOGEN, Sensipar/Mimpara and TEZSPIRE.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 pandemic</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the onset of the pandemic in 2020, we have been closely monitoring the pandemic&#8217;s effects on our global operations. We continue to take appropriate steps to minimize risks to our employees, a significant number of whom have continued to work virtually. To date, our remote working arrangements have not significantly affected our ability to maintain critical business operations, and we have not experienced disruptions to or shortages of our supply of medicines. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the course of the pandemic we have experienced changes in demand for some of our products as fluctuations in the frequency of patient visits to doctors&#8217; offices have impacted the provision of treatments to existing patients and reduced diagnoses in new patients. During 2021, there was a gradual recovery in both patient visits and diagnosis rates that approached pre-pandemic levels. In 2022, the pandemic has continued to impact the healthcare sector, and our business, to varying degrees across our markets. To date in 2022, in most of our major markets, with the exception of the Asia Pacific region that has been affected by sustained lockdowns, we have seen greater stability in patient visits and demand patterns even in areas facing surges in the virus. Given the evolution of COVID-19 since its onset, including the proliferation of variants, we cannot predict the impact of future virus surges on our business and will continue to closely monitor the impact of COVID-19 on our business and on the healthcare sector more generally.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our drug development activities, we continue to work to mitigate COVID-19 effects on future study enrollment in our clinical trials around the world. We remain focused on effectively supporting the delivery of care and investigational drug supply to patients enrolled in our active clinical sites.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the ongoing pandemic and business impacts noted above, we believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital, capital expenditures and debt service requirements as well as to engage in capital-return and other business initiatives that we plan to pursue. For a discussion of risks the COVID-19 pandemic presents to our results, see Risk Factors in Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2021, and in Part II, Item 1A. Risk Factors of our Quarterly Report on Form 10-Q for the period ended March 31, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i710475db76604b05901ef7473465ecf1_82"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant developments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a summary of selected significant developments affecting our business that occurred since the filing of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022. For additional developments or for a more comprehensive discussion of certain developments discussed below, see our Annual Report on Form 10-K for the year ended December 31, 2021, and our Quarterly Report on Form 10-Q for the period ended March 31, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Products/Pipeline</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General Medicine</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Olpasiran</span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2022, we announced positive topline data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran (formerly AMG 890) in adult patients with lipoprotein(a), or Lp(a), levels over 150 nmol/L and evidence of atherosclerotic cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA (siRNA) designed to lower the body&#8217;s production of apolipoprotein(a), a key component of Lp(a) that has been associated with an increased risk of cardiovascular events. In the double-blind placebo-controlled treatment period, olpasiran was administered up to 225 mg subcutaneously every 12 weeks to patients with a median baseline Lp(a) of approximately 260 nmol/L. These data demonstrated a significant reduction from baseline in Lp(a) of up to or greater than 90 percent at week 36 (primary endpoint) and week 48 (end of treatment period) for the majority of doses. No new safety concerns were identified during this treatment period.</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Inflammation</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TEZSPIRE</span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In July 2022, our partner AstraZeneca plc announced that the Committee for Medicinal Products for Human Use of the EMA has recommended TEZSPIRE for marketing authorization in the European Union as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business development</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proposed acquisition of ChemoCentryx, Inc.</span></div><div style="margin-bottom:8pt;padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On August 4, 2022, Amgen announced its proposed acquisition of ChemoCentryx for $52.00</span><span style="color:#c00000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per share in cash, for a total transaction price of approximately $4.0&#160;billion. ChemoCentryx is a biopharmaceutical company focused on orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ChemoCentryx</span><span style="color:#c00000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">markets TAVNEOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the first approved orally administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA vasculitis)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction is expected to close in the fourth quarter of 2022.</span></div><div style="margin-bottom:8pt;padding-left:13.5pt"><span><br/></span></div><div id="i710475db76604b05901ef7473465ecf1_85"></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selected financial information</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is an overview of our results of operations (in millions, except percentages and per-share data):</span></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,114&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,012&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,594&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,526&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,832&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,427&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* Change in excess of 100%</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the following discussion of changes in product sales, any reference to unit demand growth or decline refers to changes in purchases of our products by healthcare providers (such as physicians or their clinics), dialysis centers, hospitals and pharmacies. In addition, any reference to increases or decreases in inventory refers to changes in inventory held by wholesaler customers and end users (such as pharmacies).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total product sales increased for the three months ended June 30, 2022, primarily driven by higher unit demand for certain brands including Repatha, Prolia, EVENITY, LUMAKRAS/LUMYKRAS and KYPROLIS, partially offset by declines in the net selling prices of certain products and unfavorable changes in foreign currency exchange rates. Total product sales increased for the six months ended June 30, 2022, primarily driven by higher unit demand for certain brands, including Repatha, Prolia, EVENITY, LUMAKRAS/LUMYKRAS and KYPROLIS, and by favorable changes to estimated sales deductions, partially offset by declines in the net selling prices of certain products and unfavorable changes in foreign currency exchange rates. For the remainder of 2022, we expect that net selling prices will continue to decline at a portfolio level, driven by increased competition.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the course of the COVID-19 pandemic we experienced changes in demand for some of our products as fluctuations in the frequency of patient visits to doctors&#8217; offices have impacted the provision of treatments to existing patients and reduced diagnoses in new patients. In general, declines in the sales of our products that were impacted by the dynamics of the pandemic were most significant in the early months of the pandemic, with product demand beginning to show some recovery in late 2020. During 2021, there was a gradual recovery in both patient visits and diagnosis rates that approached pre-pandemic levels; however, variants (including Omicron) began to impact the healthcare sector and our business in late 2021 and early 2022. This led to diminished capacity in the healthcare sector and reduced working days for our own sales force. For the second quarter 2022, we have seen the impact of these variants recede in most markets, with the exception of some markets in the Asia Pacific region, which has allowed us to engage in increased field-facing activities. Provider and patient activity has also increased, leading to improvements in demand for our products to pre-pandemic levels. However, the cumulative decrease in diagnoses over the course of the pandemic has suppressed the volume of new patients starting treatment, which continues to impact our business. Given the unpredictable nature of the pandemic, there could be intermittent disruptions in physician&#8211;patient interactions, and as a result, we may experience quarter-to-quarter variability. In addition, other changes in the healthcare ecosystem have the potential to introduce variability into product sales trends. For example, changes in U.S. employment have led to changes to the insured population. Growth in numbers of Medicaid enrollees and uninsured individuals may have a negative impact on product demand and sales. Overall, uncertainty remains around the timing and magnitude of our sales during the COVID-19 pandemic. See Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2021, and in Part II, Item 1A. Risk Factors of our Quarterly Report on Form 10-Q for the period ended March 31, 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues decreased for the three months ended June 30, 2022, driven by lower revenue from COVID-19 antibody material and increased for the six months ended June 30, 2022, primarily driven by higher revenue from COVID-19 antibody material. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses decreased for the three and six months ended June 30, 2022, primarily due to the Acquired IPR&amp;D expense related to the Five Prime acquisition in 2021, partially offset by a loss on a nonstrategic divestiture in 2022. See Note 2, Acquisitions and divestitures.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although changes in foreign currency exchange rates result in increases or decreases in our reported international product sales, the benefit or detriment that such movements have on our international product sales is partially offset by corresponding increases or decreases in our international operating expenses and our related foreign currency hedging activities. Further, while not designed to completely address foreign currency changes, our hedging activities seek to offset, in part, the effects of foreign currency exchange rate changes, both favorable and unfavorable, on our net income by hedging our net foreign currency exposure, primarily with respect to product sales denominated in euros. The net impact from changes in foreign currency exchange rates was not material for the three and six months ended June 30, 2022 and 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i710475db76604b05901ef7473465ecf1_88"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of operations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide product sales were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,281&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,114&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,012&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,706&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future sales of our products will depend in part on the factors discussed below and in the following sections of this report: (i) Part I, Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Overview, and Selected Financial Information; and (ii) Part II, Item 1A. Risk Factors, and in the following sections of our Annual Report on Form 10-K for the year ended December 31, 2021: (i) Part I, Item 1. Business&#8212;Marketing, Distribution and Selected Marketed Products; (ii) Part I, Item 1A. Risk Factors; and (iii) Part II, Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Overview, and Results of Operations&#8212;Product Sales, as well as in our Quarterly Report on Form 10-Q for the period ended March 31, 2022: (i) Part I, Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Results of Operations&#8212;Product Sales; and (ii) Part II, Item 1A. Risk Factors. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ENBREL</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total ENBREL sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL &#8212; U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL &#8212; Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ENBREL</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,068&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in ENBREL sales for the three and six months ended June 30, 2022, was primarily driven by lower net selling price and lower unit demand.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the remainder of 2022, we expect that net selling price will continue to decline driven by increased competition.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prolia</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Prolia sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia&#160;&#8212;&#160;U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia&#160;&#8212;&#160;ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Prolia</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global Prolia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales for the three and six months ended June 30, 2022, was primarily driven by higher unit demand.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Otezla sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.655%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla&#160;&#8212;&#160;U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla&#160;&#8212;&#160;ROW</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Otezla</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global Otezla sales for the three months ended June 30, 2022, was driven by higher unit demand and favorable changes to estimated sales deductions, partially offset by lower net selling price.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global Otezla sales for the six months ended June 30, 2022, was primarily driven by higher unit demand and favorable changes to estimated sales deductions, partially offset by lower net selling price and unfavorable changes to inventory.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of litigation related to Otezla, see Part IV&#8212;Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021, and Note 13, Contingencies and commitments, to the condensed consolidated financial statements in this Quarterly Report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total XGEVA sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA&#160;&#8212;&#160;U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA&#160;&#8212;&#160;ROW</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total XGEVA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales for the three and six months ended June 30, 2022, was primarily driven by higher net selling price and favorable changes to estimated sales deductions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aranesp</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Aranesp sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp &#8212; U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp &#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Aranesp</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in global Aranesp sales for the three months ended June 30, 2022, was primarily driven by lower net selling price.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in global Aranesp sales for the six months ended June 30, 2022, was driven by lower net selling price and unfavorable changes in foreign currency exchange rates, partially offset by favorable changes to estimated sales deductions and higher unit demand.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aranesp continues to face competition from a long-acting erythropoiesis-stimulating agent (ESA) and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also faces competition from biosimilar versions of EPOGEN, which will continue to impact sales in the future.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neulasta</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; U.S.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Neulasta</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in global Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales for the three and six months ended June 30, 2022, was primarily driven by lower net selling price and unit demand.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increased competition as a result of biosimilar versions of Neulasta has had and will continue to have a significant adverse impact on brand sales, including accelerating net price erosion and lower unit demand. We also expect other biosimilar versions, including biosimilars that will use an on-body injector that would compete with our Onpro injector, to be approved in the future. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of ongoing patent litigations related to these and other biosimilars, see Part IV&#8212;Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021, and Part I&#8212;Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repatha</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Repatha sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha &#8212; U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha &#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Repatha</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global Repatha sales for the three and six months ended June 30, 2022, was driven by higher unit demand, partially offset by lower net selling price. Contracting changes to support and expand Medicare Part D and commercial patient access and the inclusion of Repatha on China&#8217;s National Reimbursement Drug List as of January 1, 2022, resulted in the decrease to net selling price in 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of ongoing litigation related to Repatha, see Part IV&#8212;Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021; Part I&#8212;Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022; and Part I&#8212;Note 13, Contingencies and commitments, to the condensed consolidated financial statements in this Quarterly Report.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KYPROLIS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total KYPROLIS sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS &#8212; U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS &#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total KYPROLIS</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales for the three and six months ended June 30, 2022, was driven by higher unit demand, partially offset by lower net selling price.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has reported that it has granted tentative or final approval of ANDAs for generic carfilzomib products filed by a number of companies. The date of approval of those ANDAs for generic carfilzomib products is governed by the Hatch&#8211;Waxman Act and any applicable settlement agreements between us and certain companies that seek to develop generic carfilzomib products. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nplate</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Nplate sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate&#160;&#8212;&#160;U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate&#160;&#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Nplate</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in global Nplate sales for the three and six months ended June 30, 2022, was primarily driven by higher unit demand and net selling price.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other product sales by geographic region were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVASI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; U.S.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVASI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vectibix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; U.S.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vectibix&#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY&#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO &#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; U.S.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMGEVITA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aimovig &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aimovig &#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parsabiv &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parsabiv &#8212; ROW</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANJINTI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; U.S.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANJINTI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUMAKRAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; U.S.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUMYKRAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NEUPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; U.S.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NEUPOGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sensipar &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sensipar/Mimpara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212; ROW</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other &#8212; U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other &#8212; ROW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. &#8212; other products</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,939&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ROW &#8212; other products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other products</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,835&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM = not meaningful</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* Change in excess of 100%</span></div><div style="margin-top:7pt;padding-left:31.5pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other products include Corlanor, AVSOLA, TEZSPIRE, IMLYGIC and RIABNI as well as sales by Gensenta and Bergamo subsidiaries. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating expenses</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM = not meaningful</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* Change in excess of 100%</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales decreased to 22.9% and 23.9% of total revenues for the three and six months ended June 30, 2022, respectively, driven by lower COVID-19 antibody shipments, lower manufacturing costs and lower amortization expense from acquisition-related assets, partially offset by unfavorable product mix. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in R&amp;D expense for the three months ended June 30, 2022, was driven by lower marketed product support and lower expense resulting from acquisition-related activity, partially offset by higher spend in research and early pipeline.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in R&amp;D expense for the six months ended June 30, 2022, was driven by lower marketed product support and lower expense resulting from acquisition-related activity, partially offset by higher late-stage development program spend and research and early pipeline spend.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Acquired IPR&amp;D expense for the three and six months ended June 30, 2022, was due to the bemarituzumab program, which was acquired as part of the Five Prime acquisition in 2021. See Note 2, Acquisitions and divestitures.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in SG&amp;A expense for the three and six months ended June 30, 2022, was primarily driven by lower spend for marketed products and lower expense resulting from acquisition-related activity.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses for the three and six months ended June 30, 2022, consisted primarily of a loss on a nonstrategic divestiture. See Note 2, Acquisitions and divestitures. Other operating expenses for the three and six months ended June 30, 2021, consisted primarily of expenses related to cost saving initiatives.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nonoperating expense/income and income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonoperating expense/income and income taxes were as follows (dollar amounts in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(566)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in Interest expense, net, for the three and six months ended June 30, 2022, was primarily due to higher overall debt outstanding and higher LIBOR rates on debt for which we effectively pay a variable rate of interest through the use of interest rate swaps.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (expense) income, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in Other (expense) income, net, for the three and six months ended June 30, 2022, was primarily due to net losses recognized on our strategic equity investments in the current year compared with net gains recognized in the prior year and higher current year losses in connection with our BeiGene investment.</span></div><div id="i710475db76604b05901ef7473465ecf1_97"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our effective tax rate for the three months ended June 30, 2022, was primarily due to the prior year nondeductible IPR&amp;D expense arising from the acquisition of Five Prime, partially offset by current year unfavorable items, including a loss on a nonstrategic divestiture. The increase in our effective tax rate for the six months ended June 30, 2022, was primarily due to current year unfavorable items compared to last year including a loss on a nonstrategic divestiture, partially offset by the prior year nondeductible IPR&amp;D expense arising from the acquisition of Five Prime and changes in earnings mix. See Note 2, Acquisitions and divestitures.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Administration proposed and Congress is considering a variety of potentially significant changes to existing tax law. These changes, or others, could substantially increase taxes we pay to the U.S. government. Further, the OECD recently reached an agreement to align countries on a minimum corporate tax rate and an expansion of the taxing rights of market countries. If enacted, either by all OECD participants or unilaterally by individual countries, this agreement could result in tax increases in both the United States and foreign jurisdictions. The U.S. Treasury recently released final foreign tax credit regulations that eliminate U.S. creditability of the Puerto Rico Excise Tax beginning in 2023, which would increase our U.S. tax liability. However, the U.S. territory of Puerto Rico recently enacted Act 52-2022, which provides for an alternate fixed tax rate on industrial development income that is expected to be creditable under U.S. law. As part of this new law, eligible businesses would be subject to incremental income and withholding taxes in lieu of payment of the Puerto Rico Excise Tax. In order to qualify for the alternative fixed tax rate, we must amend our current tax grant with the Puerto Rico government by December 31, 2022. Once we qualify for this alternative fixed tax rate, which we expect to occur as of January 1, 2023, our tax expense will increase. While we expect these taxes to be partially offset by U.S. foreign tax credits, the U.S. Treasury has not yet issued guidance on whether the alternative fixed tax rate will be creditable under U.S. law.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received an RAR and a modified RAR from the IRS for the years 2010&#8211;2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for the years 2010&#8211;2012 that we received in May and July 2021, which seek to increase our U.S. taxable income for the years 2010&#8211;2012 by an amount that would result in additional federal tax of approximately $3.6&#160;billion plus interest. Any additional tax that could be imposed for the years 2010&#8211;2012 would be reduced by up to approximately $900&#160;million of repatriation tax previously accrued on our foreign earnings.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received an RAR and a modified RAR from the IRS for the years 2013&#8211;2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010&#8211;2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013&#8211;2015 that we previously reported receiving in April 2022 that seeks to increase our U.S. taxable income for the years 2013&#8211;2015 by an amount that would result in additional federal tax of approximately $5.1&#160;billion, plus interest. In addition, the Notice asserts penalties of approximately $2.0&#160;billion. Any additional tax that could be imposed for the years 2013&#8211;2015 would be reduced by up to approximately $2.2&#160;billion of repatriation tax previously accrued on our foreign earnings. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We firmly believe that the IRS positions set forth in the 2010&#8211;2012 and 2013&#8211;2015 Notices are without merit. We are contesting the 2010&#8211;2012 and 2013&#8211;2015 Notices through the judicial process, and we will seek consolidation of the two periods into one case in the U.S. Tax Court.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently under examination by the IRS for the years 2016&#8211;2018 with respect to issues similar to those for the 2010 through 2015 period. In addition, we have examinations by a number of state and foreign tax jurisdictions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final resolution of these complex matters is not likely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part II, Item 1A, Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Note 4, Income taxes, to the condensed consolidated financial statements for further discussion.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i710475db76604b05901ef7473465ecf1_100"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial condition, liquidity and capital resources</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected financial data were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,037&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,294&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,165&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,705&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,222&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our balance of cash, cash equivalents and marketable securities was $7.2 billion as of June 30, 2022. The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">class and issuer.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital allocation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with the objective to optimize our capital structure, we deploy our accumulated cash balances in a strategic manner and consider a number of alternatives, including investments in innovation, both internally and externally, strategic transactions (including those that expand our portfolio of products in areas of therapeutic interest), payment of dividends, stock repurchases and repayment of debt.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to invest in our business while returning capital to stockholders through the payment of cash dividends and stock repurchases, thereby reflecting our confidence in the future cash flows of our business and our desire to optimize our cost of capital. The timing and amount of future dividends and stock repurchases will vary based on a number of factors, including future capital requirements for strategic transactions, availability of financing on acceptable terms, debt service requirements, our credit rating, changes to applicable tax laws or corporate laws, changes to our business model and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periodic determination by our Board of Directors that cash dividends and/or stock repurchases are in the best interests of stockholders and are in compliance with applicable laws and the Company&#8217;s agreements. In addition, the timing and amount of stock repurchases may also be affected by our overall level of cash, stock price and blackout periods, during which we are restricted from repurchasing stock. The manner of stock repurchases may include block purchases, tender offers, ASRs and market transactions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022 and December 2021, the Board of Directors declared a quarterly cash dividend of $1.94 per share of common stock, which were paid on June 8, 2022 and March 8, 2022, respectively, an increase of 10% over quarterly cash dividend paid in each quarter in 2021. In August 2022, the Board of Directors declared a quarterly cash dividend of $1.94 per share of common stock, which will be paid on September 8, 2022 to all stockholders of record as of the close of business on August 18, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also returned capital to stockholders through our stock repurchase program. During the six months ended June 30, 2022, we executed trades to repurchase $5.4 billion of common stock, including $5.1 billion of an initial purchase under the ASR agreements described below. As of June 30, 2022, $4.6 billion of authorization remained available under our stock repurchase program.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we entered into ASR agreements under which we paid an aggregate amount of $6.0&#160;billion to the Dealers and retired an initial 23.3 million shares of common stock. Approximately $0.9&#160;billion of stock remains to be delivered by the Dealers pending final settlement, which will be based on the daily volume-weighted average stock price of our common stock during the terms of the ASR agreements, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreements. At settlement, which is scheduled to occur in the third quarter of 2022, the Dealers may be required to deliver additional shares of common stock to us, or under certain circumstances, we may be required to deliver shares of common stock or to make a cash payment, at our election, to the Dealers.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of stock repurchases and quarterly dividend payments, we have an accumulated deficit as of June 30, 2022 and December 31, 2021. Our accumulated deficit is not anticipated to affect our future ability to operate, repurchase stock, pay dividends or repay our debt given our continuing profitability and strong financial position.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital, capital expenditure and debt service requirements, our plans to pay dividends and repurchase stock and other business initiatives we plan to strategically pursue, including acquisitions and licensing activities. We anticipate that our liquidity needs can be met through a variety of sources, including cash provided by operating activities, sales of marketable securities, borrowings through commercial paper and/or syndicated credit facilities and access to other domestic and foreign debt markets and equity markets. See our Annual Report on Form&#160;10-K for the year ended December 31, 2021, Part I, Item&#160;1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global economic conditions may negatively affect us and may magnify certain risks that affect our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement includes a financial covenant that requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (consolidated earnings before interest, taxes, depreciation and amortization) to (ii) consolidated interest expense, each as defined and described in the credit agreement. We were in compliance with all applicable covenants under these arrangements as of June 30, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flows</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our summarized cash flow activity was as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,304)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,576)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,561)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities has been and is expected to continue to be our primary recurring source of funds. Cash provided by operating activities during the six months ended June 30, 2022, increased primarily due to higher net income, after adjustments for noncash items, partially offset by the impact of working capital items.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities during the six months ended June 30, 2022, was primarily due to net cash outflows related to marketable securities activity of $1.9 billion and capital expenditures of $436 million. Cash provided by investing activities during the six months ended June 30, 2021, was primarily due to net cash inflows related to marketable securities activity of $2.9 billion, partially offset by the acquisition of Five Prime for $1.6 billion and capital expenditures of $351 million. We currently estimate 2022 spending on capital projects to be approximately $950&#160;million. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities during the six months ended June 30, 2022, was primarily due to payments to repurchase our common stock of $6.4 billion, including amounts paid under the ASR agreements discussed above, and the payment of dividends of $2.1 billion, partially offset by proceeds from the issuance of debt of $4.0 billion. Cash used in financing activities during the six months ended June 30, 2021, was primarily due to payments to repurchase our common stock of $2.5 billion and the payment of dividends of $2.0 billion. See Note 9, Financing arrangements, and Note 10, Stockholders&#8217; equity, to the condensed consolidated financial statements for further discussion. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i710475db76604b05901ef7473465ecf1_103"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes to the financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. A summary of our critical accounting policies and estimates is presented in Part II, Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i710475db76604b05901ef7473465ecf1_106"></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about our market risk is disclosed in Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of our Annual Report on Form 10-K for the year ended December 31, 2021, and is incorporated herein by reference. There were no material changes during the six months ended June 30, 2022, to the information provided in Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONTROLS AND PROCEDURES</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain &#8220;disclosure controls and procedures,&#8221; as such term is defined under the Securities Exchange Act Rule 13a-15(e) that are designed to ensure that information required to be disclosed in Amgen&#8217;s Exchange Act reports gets recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information gets accumulated and communicated to Amgen&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to facilitate timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, Amgen&#8217;s management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, Amgen&#8217;s management necessarily was required to apply its judgment in evaluating the cost&#8211;benefit relationship of possible controls and procedures. We carried out an evaluation under the supervision and with the participation of our management, including Amgen&#8217;s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of Amgen&#8217;s disclosure controls and procedures. Based on their evaluation and subject to the foregoing, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management determined that as of June 30, 2022, no changes in our internal control over financial reporting had occurred during the fiscal quarter then ended that materially affected or are reasonably likely to materially affect our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8212; OTHER INFORMATION</span></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span><br/></span></div><div id="i710475db76604b05901ef7473465ecf1_115"></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LEGAL PROCEEDINGS</span></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">See Note 13, Contingencies and commitments, to the condensed consolidated financial statements included in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2022 and June 30, 2022, for discussions that are limited to certain recent developments concerning our legal proceedings. Those discussions should be read in conjunction with Part IV&#8212;Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i710475db76604b05901ef7473465ecf1_118"></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RISK FACTORS</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs and our management&#8217;s assumptions. These statements are not guarantees of future performance, and they involve certain risks, uncertainties and assumptions that are difficult to predict. You should carefully consider the risks and uncertainties our business faces. The risks described below are not the only ones we face. Our business is also subject to the risks that affect many other companies, such as employment relations, general economic conditions, geopolitical events and international operations. Further, additional risks not currently known to us or that we currently believe are immaterial may in the future materially and adversely affect our business, operations, liquidity and stock price. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below we provide in supplemental form the material changes to our risk factors that occurred during the past quarter. Our risk factors disclosed in Part I, Item 1A, of our Annual Report on Form 10-K for the year ended December 31, 2021, provide additional disclosure for these supplemental risks and are incorporated herein by reference.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected and are likely to continue to affect our profitability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend on the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans. Governments and private payers continue to pursue initiatives to manage drug utilization and contain costs. These payers are increasingly focused on costs, which have resulted, and are expected to continue to result, in lower reimbursement rates for our products or narrower populations for whom payers will reimburse. Continued intense public scrutiny of the price of drugs and other healthcare costs, together with payer dynamics, have limited, and are likely to continue to limit, our ability to set or adjust the price of our products based on their value, which can have a material adverse effect on our business. In the United States, particularly over the past few years, a number of legislative and regulatory proposals have been introduced to attempt to lower drug prices. These include proposals that would enable the U.S. government to negotiate drug prices directly, limit drug reimbursement in Medicare and/or the commercial market based on reference prices, impose penalties if drug prices are increased at a rate faster than inflation or permit importation of drugs from Canada. Additional proposals would require a rebate to the government for any price increase in excess of the Consumer Price Index for All Urban Consumers and/or to shift some of the costs of these Medicare Part D reforms to manufacturers to offset the costs. Certain proposals focused on drug pricing have been adopted, and additional proposals are likely to be adopted and implemented in some form. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Changing U.S. federal coverage and reimbursement policies and practices have affected and may continue to affect access to, pricing of and sales of our products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our U.S. business relies on reimbursement from federal government healthcare programs and commercial insurance plans regulated by federal and state governments. See Part I, Item 1. Business&#8212;Reimbursement of our Annual Report on Form 10-K for the year ended December 31, 2021. Our business has been and will continue to be affected by legislative actions changing U.S. federal reimbursement policy. Congress has focused on drug pricing reforms and oversight since 2018, and this activity is still ongoing and has intensified.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2019, a number of Congressional committees debated drug pricing reform proposals, and in 2020, Amgen participated in House Oversight and Reform Committee hearings on drug pricing practices. In 2019, the Senate Finance Committee advanced a bill that would, among other things, penalize pharmaceutical manufacturers for raising prices on drugs covered by Medicare Parts B and/or D faster than the rate of inflation, cap out-of-pocket expenses for Medicare Part D beneficiaries and require higher or additional manufacturer discounts in Medicare Part D. Additionally, in late 2019, a drug-pricing bill, H.R. 3, passed the House of Representatives and included provisions that, among other things, enabled direct price negotiations by the federal government on certain drugs, (with the maximum price paid by Medicare capped by prices derived from an international index), penalized failures to reach agreement with the government and required that manufacturers offer these negotiated prices to other payers. Provisions from H.R. 3 have </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">been incorporated and adapted into other proposed legislation, including the most recent reconciliation bill released by the Senate in July 2022, which included penalties if drug price benchmarks rise faster than inflation, Medicare price setting for certain drugs paid for under Parts B and D (whereby manufacturers must accept a price established by the government or face penalties on all U.S. sales), and Part D redesign including a cap on beneficiary spending and a new manufacturer discount program. This framework remains in discussion with policymakers in Congress and the Administration. There are other outstanding proposals that, if enacted and implemented, in whole or in part, could also affect access to and sales of our products, including, but not limited to, federal and various state proposals to allow importation of prescription medications from Canada or other countries. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Changing reimbursement and pricing actions in various states have negatively affected and may continue to negatively affect access to and have affected and may continue to affect sales of our products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In July 2021, the Administration issued an Executive Order designed to address anticompetitive behavior across multiple sectors, and for the healthcare sector, called for, among other things, the FDA to work with states and Indian tribes to develop prescription drug importation programs, more scrutiny of anticompetitive activity by the FTC, emphasized the need for actions to allow for greater competition from generics and biosimilars, and included a process and timeline for federal agencies to deliver to the Administration ideas that address drug pricing. Subsequently, in September 2021, HHS released a report that presented guiding principles for the Administration&#8217;s drug pricing proposals, including changes to promote competition throughout the prescription drug industry, highlighting potential legislative policies that Congress could pursue (including drug price negotiation in Medicare Parts B and D, making those negotiated prices available to commercial plans and legislation to speed the entry of biosimilar and generic drugs) and examples of potential administrative tools available to the HHS (including testing various models and enhanced focus of the FTC and the USPTO to address impediments to generic drug and biosimilar competition). Also, in response to the July 2021 Executive Order, the FDA sent a letter to the USPTO describing ways to strengthen coordination between the two agencies, offering training to help identify prior art and seeking USPTO&#8217;s views on practices that extend market exclusivities, whether pharmaceutical patent examiners need additional resources, and the effect of post-grant challenges at the PTAB on drug patents. In its reply to the FDA, on July 6, 2022, the USPTO affirmed its interest in coordinating with the FDA and outlined specific initiatives, including enhancing procedures for obtaining patents and easing the process for challenging issued patents before the PTAB.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislation enacted in 2021 also contained drug pricing reforms. For example, the Infrastructure Investment and Jobs Act includes a provision requiring manufacturers to provide refunds, beginning in 2023, to the government for discarded amounts of certain drugs (including certain Amgen products) from single use containers under Medicare Part B, and CMS recently released proposed regulations to implement this requirement. Also, the American Rescue Plan Act of 2021 includes a provision that increases the Medicaid rebate liability, beginning in 2024, by no </span><span style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">longer capping Medicaid rebates at 100% of the Average Manufacturer Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for certain medicines that raise prices in excess of inflation</span><span style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The implementation of a final rule issued by HHS that revises regulations under the federal antikickback statute to encourage PBMs to use rebates received from biopharmaceutical manufacturers to reduce patient cost-sharing at the point of sale under Medicare Part D has been delayed to January 1, 2027. However, the future of this rule remains uncertain because, among other issues, it is subject to litigation and because a permanent repeal is being considered in other legislation. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business has been, and is expected to continue to be, affected by changes in U.S. federal reimbursement policy resulting from federal regulations and federal demonstration projects. Over the past several years, federal agencies, including the CMS, announced a number of recommendations, policies, proposals and demonstration projects addressing drug pricing. The Administration has also developed and sought to advance a range of policy proposals that could affect U.S. federal reimbursement policy for drugs and biologics, including changes to Medicare Parts B and D. For example, in 2020, in response to an Executive Order, HHS released a rule to allow states to potentially enable the importation of certain drugs from Canada. This rule is in litigation, but should such litigation be unsuccessful, it could allow for the importation of Canadian versions of certain of Amgen&#8217;s products (including Otezla), that could have a material adverse effect on Amgen&#8217;s business. Also in response to an Executive Order, CMS released an interim final rule to implement the MFN pricing approach aimed at setting the reimbursement rate for 50 Medicare Part B drugs (including our products, such as Prolia, XGEVA, KYPROLIS, Neulasta, Nplate, EPOGEN and Aranesp) equal to the lowest adjusted price in 22 OECD nations for these drugs. In December 2021, subsequent to challenges, including procedural defects, CMS announced it was withdrawing the MFN rule. Notwithstanding the withdrawal of the rule, the MFN rule&#8217;s approach to drug pricing and other similar approaches remain of interest to policymakers. In connection with its withdrawal of the MFN rule, CMS noted that it will &#8220;&#8230; explore all options to incorporate value into payments for Medicare Part B drugs, improve beneficiaries&#8217; access to evidence-based care, and reduce drug spending for consumers and throughout the health care system.&#8221; Further, we expect continued significant focus on healthcare and similar drug pricing proposals for the foreseeable future, including proposals under which the government would set drug prices or limit drug reimbursement. In the second quarter of 2022, several Medicare Administrative Contractors issued notice, in contravention of TEZSPIRE&#8217;s FDA approved labeling, that TEZSPIRE would be added to their &#8220;self-administered drug&#8221; exclusion lists. While the effective date for adding TEZSPIRE to the exclusion list has been deferred until further notice, this exclusion, if implemented, would result in Medicare beneficiaries with severe asthma losing access to TEZSPIRE coverage under Medicare Part B and potentially also under Medicare Advantage.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS policy changes and demonstration projects to test new care, delivery and payment models can also significantly affect how drugs, including our products, are covered and reimbursed. For example, we believe that CMS&#8217;s Oncology Care Model demonstration (which has, beginning in 2016, provided participating physician practices with performance-based financial incentives that aim to manage or reduce Medicare costs without negatively affecting the efficacy of care) reduced utilization of certain of our oncology products by participating physician practices. While the Oncology Care Model demonstration ended on June 30, 2022, CMS announced a new oncology model (the Enhancing Oncology Model) that will run for five years (from July 2023 through June 2028) that builds on this prior demonstration program. Further, HHS&#8217;s September 2021 comprehensive plan to address drug pricing included potential future mandatory models that link payment for prescription drugs and biologics to factors such as: improved patient outcomes, reductions in health disparities, patient affordability and lower overall costs; bundled payment models; total cost of care models; models in which Medicare Part B savings from utilization of biosimilars, generics, or other high-value products are shared between prescribing providers and the government; additional Medicare Part D cost-sharing support for biosimilars and generics; and potential expansion of the Part D Senior Savings Model to additional classes of drugs. CMS also recently finalized a national Medicare coverage determination for certain Alzheimer&#8217;s disease medications that received accelerated FDA approvals that limits coverage to only patients in qualifying clinical trials, thereby suggesting that accelerated regulatory approval does not necessarily result in full Medicare coverage. In this dynamic environment, particularly in light of the pressures on healthcare budgets as a result of the pandemic, we are unable to predict which or how many federal policy, legislative, regulatory, executive or administrative changes may ultimately be, or effectively estimate the consequences to our business if, enacted and implemented. However, to the extent that these or other federal government initiatives further decrease or modify the coverage or reimbursement available for our products, require that we pay increased rebates or shift other costs to us, limit or affect our decisions regarding the pricing of or otherwise reduce the use of our U.S. products, or limit our ability to offer co-pay assistance to commercial patients, such actions could have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face risks related to the reporting of pricing data that affects reimbursement of and discounts provided for our products. U.S. government price reporting regulations are complex and may require biopharmaceutical manufacturers to update certain previously submitted data. If our submitted pricing data are incorrect, we may become subject to substantial fines and penalties or other government enforcement actions, which could have a material adverse effect on our business and results of operations. In addition, as a result of restating previously reported price data, we may be required to pay additional rebates and provide additional discounts. The prior Administration finalized a rule (the implementation of which has been delayed by the current Administration) mandating price and cost-sharing transparency for almost all health plans and insurers in the individual and group commercial markets. Further, the current Administration finalized transparency provisions required under the Consolidated Appropriations Act of 2021 for health plans and insurer reporting of certain drug pricing information by December 27, 2022, and each June thereafter, resulting in a biennial public report highlighting drug pricing trends and the impact of prescription drug costs on premiums and out-of-pocket costs. It is unclear how group health plans and health insurers may respond.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Changing reimbursement and pricing actions in various states have negatively affected and may continue to negatively affect access to and have affected and may continue to affect sales of our products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, government actions or ballot initiatives can also affect how our products are covered and reimbursed and/or create additional pressure on our pricing decisions. A number of states have adopted, and many other states are considering, drug importation programs or other new pricing actions, including proposals designed to require biopharmaceutical manufacturers to publicly report proprietary pricing information, limit price increases or place a maximum price ceiling or cap on biopharmaceutical products. Existing and proposed state pricing laws have added complexity to the pricing of drugs and may already be affecting industry pricing decisions. For example, a California law, the constitutionality of which is currently being challenged, purports to require biopharmaceutical manufacturers to notify health insurers and government health plans at least 60 days before scheduled prescription drug price increases that exceed certain thresholds. Similar laws exist in Oregon and Washington. States are also seeking to change the way they pay for drugs for patients covered by state programs. California adopted a 2020&#8211;21 budget that incorporates international pricing into Medicaid supplemental rebate negotiations and allows its Medicaid program to seek federal approval to extend supplemental rebates to non-Medicaid populations. New York has established a Medicaid drug spending cap, and Massachusetts implemented a new review and supplemental rebate negotiation process. Other states may consider implementing similar policies and procedures as they face budget deficits from the effects of the COVID-19 pandemic. Additionally, Colorado, Florida, Maine, New Hampshire, New Mexico and Vermont have enacted laws, and several other states have proposed bills, to implement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">importation of drugs from Canada. The FDA recently met with representatives from Colorado, Florida, Maine and New Mexico to discuss those states&#8217; proposed importation programs, and the FDA may be working towards approving such plans. Other states could adopt similar approaches or could pursue different policy changes in a continuing effort to reduce their costs. Ultimately, as with U.S. federal government actions, existing or future state government actions or ballot initiatives may also have a material adverse effect on our product sales, business and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;U.S. commercial payer actions have affected and may continue to affect access to and sales of our products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payers, including healthcare insurers, PBMs, integrated healthcare delivery systems (vertically-integrated organizations built from consolidations of healthcare insurers and PBMs) and group purchasing organizations, increasingly seek ways to reduce their costs. With increasing frequency, payers are adopting benefit plan changes that shift a greater proportion of drug costs to patients. Such measures include more limited benefit plan designs, high deductible plans, higher patient copay or coinsurance obligations and more significant limitations on patients&#8217; use of manufacturer commercial copay assistance programs. Further, government regulation of payers may affect these trends. For example, CMS finalized a policy in May 2020 (for plan years starting on or after January 1, 2021, which remains standing policy for 2022) that has caused commercial payers to more widely adopt copay accumulator adjustment programs. Payers have sought, and continue to seek, price discounts or rebates in connection with the placement of our products on their formularies or those they manage, particularly in treatment areas in which the payer has taken the position that multiple branded products are therapeutically comparable. Payers also control costs by imposing restrictions on access to or usage of our products, such as Step Therapy, or requiring that patients receive the payer&#8217;s prior authorization before covering the product or that patients use a mail-order pharmacy or a limited network of payer fully-owned mail-order or specialty pharmacies. Payers have also chosen to exclude certain indications for which our products are approved or chosen to exclude coverage entirely. For example, some payers require physicians to demonstrate or document that the patients for whom Repatha has been prescribed meet payer utilization management criteria, and these requirements have served to limit and may continue to limit patient access to Repatha treatment. In an effort to reduce barriers to access, we reduced the net price of Repatha by providing greater discounts and rebates to payers, including PBMs that administer Medicare Part D prescription drug plans. However, affordability of patient out-of-pocket co-pay cost has limited and may continue to limit patient use. For example, in late 2018 and early 2019, in response to a very high percentage of Medicare patients abandoning their Repatha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prescriptions rather than paying their co-pay, we introduced a set of new National Drug Codes to make Repatha available at a lower list price in an attempt to address affordability for patients, particularly those on Medicare, and on December 31, 2019, we discontinued the higher list price option for Repatha. Despite these net and list price reductions, some payers have restricted and may continue to restrict patient access, and have changed and may continue to change formulary coverage for Repatha, and they may seek further discounts or rebates or take other actions that could reduce our sales of Repatha. These factors have served to limit and may continue to limit patient affordability and use, and negatively affect Repatha sales.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, significant consolidation in the health insurance industry has resulted in a few large insurers and PBMs, which places greater pressure on pricing and usage negotiations with biopharmaceutical manufacturers, significantly increasing discount and rebate requirements and limiting patient access and usage. For example, in the United States, as of the beginning of 2021, the top five integrated health plans and PBMs controlled about 85% of all pharmacy prescriptions. The consolidation among insurers, PBMs and other payers, including through integrated healthcare delivery systems and/or with specialty or mail-order pharmacies and pharmacy retailers, has increased the negotiating leverage such entities have over us and other biopharmaceutical manufacturers, and has resulted in greater price discounts, rebates and service fees realized by those payers. In 2019, 2020 and 2021, CVS, Express Scripts and United Health Group, respectively, each created Rebate Management Organizations that further increase their respective leverage to negotiate deeper discounts. Ultimately, additional discounts, rebates, fees, coverage changes, plan changes, restrictions or exclusions imposed by these commercial payers could have a material adverse effect on our product sales, business and results of operations. Policy reforms advanced by Congress or the Administration that refine the role of PBMs in the U.S. marketplace could have downstream implications or consequences for our business and how we interact with these entities. For example, on June 7, 2022, the FTC launched an inquiry into the business practices of PBMs, and the results of such inquiry could have an effect on manufacturer interactions with PBMs, resulting in changes to access to certain medicines. See our Annual Report on Form 10-K for the year ended December 31, 2021, Part I, Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of sales at certain of our wholesaler distributors and at one free-standing dialysis clinic business and consolidation of private payers may negatively affect our business.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Government and commercial payer actions outside the United States have affected and will continue to affect access to and sales of our products</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, we expect countries will also continue to take actions to reduce their drug expenditures. See Part I, Item 1. Business&#8212;Reimbursement of our Annual Report on Form 10-K for the year ended December 31, 2021. IRP has been widely used by many countries outside the United States to control costs based on an external benchmark of a product&#8217;s price in other countries. IRP policies can change quickly and frequently and may not reflect differences in the burden of disease, indications, market structures, or affordability differences across countries or regions. Other expenditure control practices, including but not limited to the use of revenue clawbacks, rebates and percentage caps on price increases, are used in various foreign jurisdictions as well. In addition, countries may refuse to reimburse or may restrict the reimbursed population for a product when their national health technology assessments do not consider a medicine to demonstrate sufficient clinical benefit beyond existing therapies or to meet certain cost effectiveness thresholds. For example, despite the EMA&#8217;s approval of Repatha for the treatment of patients with established atherosclerotic disease, the reimbursement for Repatha in France prior to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020 was limited to a narrower patient population (such as those with homozygous familial hypercholesterolemia (HoFH)) following a national health technology assessment, which had limited our efforts in France to expand Repatha access to the broader patient population covered by the approved label. Some countries decide on reimbursement between potentially competing products through national or regional tenders that often result in one product receiving most or all of the sales in that country or region. Failure to obtain coverage and reimbursement for our products, a deterioration in their existing coverage and reimbursement, or a decline in the timeliness or certainty of payment by payers to physicians and other providers has negatively affected, and may further negatively affect, the ability or willingness of healthcare providers to prescribe our products for their patients and otherwise negatively affect the use of our products or the prices we realize for them. Such changes have had, and could in the future have, a material adverse effect on our product sales, business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income and other taxes in the United States and other jurisdictions in which we do business. As a result, our provision for income taxes is derived from a combination of applicable tax rates in the various places we operate. Significant judgment is required for determining our provision for income tax.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes can and have arisen with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts, and such tax authorities (including the IRS) are becoming more aggressive in their audits and are particularly focused on such matters. In 2017, we received an RAR and a modified RAR from the IRS for the years 2010&#8211;2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS administrative appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Notices for the years 2010&#8211;2012 that we received in May and July 2021 which seek to increase our U.S. taxable income for the years 2010&#8211;2012. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010&#8211;2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013&#8211;2015 that we previously reported receiving in April 2022 that seeks to increase our U.S. taxable income for the years 2013&#8211;2015 and asserts penalties. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We firmly believe that the IRS positions set forth in the 2010&#8211;2012 and 2013&#8211;2015 Notices are without merit. We are contesting the 2010&#8211;2012 and 2013&#8211;2015 Notices through the judicial process, and we will seek consolidation of the two periods into one case in the U.S. Tax Court. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently also under examination by the IRS for the years 2016, 2017 and 2018 with respect to issues similar to those for the 2010 through 2015 period. In addition, we are under examination by a number of state and foreign tax jurisdictions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final resolution of these complex matters is not likely within the next 12 months. We continue to believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse effect on the results of our operations. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part I, Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Results of Operations, Income Taxes, and Part I&#8212;Note 4, Income taxes, to the condensed consolidated financial statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes and results of operations in the future could be adversely affected by changes to our operating structure, changes in the mix of income and expenses in countries with differing tax rates, changes in the valuation of deferred tax assets and liabilities and changes in applicable tax laws, regulations or administrative interpretations thereof. The 2017 Tax Act is complex and a large volume of regulations and guidance has been issued and could be subject to different interpretations. We could face audit challenges to our application of the 2017 Tax Act. The Administration proposed and Congress is considering a variety of potentially significant changes to existing tax law. These changes, or others, could substantially increase taxes we pay to the U.S. government. Further, the OECD recently reached an agreement to align countries on a minimum corporate tax rate and an expansion of the taxing rights of market countries. If enacted, either by all OECD participants or unilaterally by individual countries, this agreement could result in tax increases in both the United States and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">foreign jurisdictions. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Treasury recently released final foreign tax credit regulations that eliminate U.S. creditability of the Puerto Rico Excise Tax beginning 2023, which would increase our U.S. tax liability. However, the U.S. territory of Puerto Rico recently enacted Act 52-2022, which provides for an alternate fixed tax rate on industrial development income that is expected to be creditable under U.S. law. As part of this new law, eligible businesses would be subject to incremental income and withholding taxes in lieu of payment of the Puerto Rico Excise Tax. In order to qualify for the alternative fixed tax rate, we must amend our current tax grant with the Puerto Rico government by December 31, 2022. Once we qualify for this alternative fixed tax rate, which we expect to occur as of January 1, 2023, our tax expense will increase. While we expect these taxes to be partially offset by U.S. foreign tax credits, the U.S. Treasury has not yet issued guidance on whether the alternative fixed tax rate will be creditable under U.S. law.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to existing tax law in the United States, the U.S. territory of Puerto Rico, or other jurisdictions, including the changes and potential changes discussed above, could result in tax increases where we do business and could have a material adverse effect on the results of our operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our efforts to collaborate with or acquire other companies, products, or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful, and may result in unanticipated costs, delays or failures to realize the benefits of the transactions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek innovation through significant investment in both internal R&amp;D and external transactions, including collaborations, partnerships, alliances, licenses, joint ventures, mergers and acquisitions (collectively, acquisition activity). Acquisition activities may be subject to regulatory approvals or other requirements that are not within our control. There can be no assurance that such regulatory or other approvals will be obtained or that all closing conditions required in connection with our acquisition activities will be satisfied or waived, which could result in us being unable to complete the planned acquisition activities. In addition, antitrust scrutiny by regulatory agencies and changes to regulatory approval process in the U.S. and foreign jurisdictions may cause approvals to take longer than anticipated to obtain, not be obtained at all, or contain burdensome conditions, which may jeopardize, delay or reduce the anticipated benefits of acquisitions to us and could impede the execution of our business strategy.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition activities are complex, time consuming and expensive and may result in unanticipated costs, delays or other operational or financial problems related to integrating the acquired company and business with our company, which may divert our management&#8217;s attention from other business issues and opportunities and restrict the full realization of the anticipated benefits of such transactions within the expected timeframe or at all. We may pay substantial amounts of cash, incur debt or issue equity securities to pay for acquisition activities, which could adversely affect our liquidity or result in dilution to our stockholders, respectively. Further, failures or difficulties in integrating or retaining new personnel or in integrating the operations of the businesses, products or assets we acquire (including related technology, commercial operations, compliance programs, manufacturing, distribution and general business operations and procedures) may affect our ability to realize the benefits of the transaction and grow our business and may result in us incurring asset impairment or restructuring charges. These and other challenges may arise in connection with our proposed acquisition of ChemoCentryx, in addition to our acquisitions of Otezla, Five Prime, Teneobio and/or our collaborations with BeiGene and Kyowa Kirin Co., Ltd., or with other acquisition activities, which could have a material adverse effect on our business, results of operations and stock price.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, we had one outstanding stock repurchase program, under which the repurchase activity was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">purchased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average<br/>price paid<br/>per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total number<br/>of shares purchased<br/>as part of publicly announced program</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum dollar<br/>value that may<br/>yet be purchased<br/>under the program</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 1 - 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,579,263,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 1 - 31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,579,263,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1 - 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,579,263,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">___________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As part of the stock repurchase program, the Company entered into ASR agreements with three third-party financial institutions (Dealers) in February 2022. Under the ASR agreements, the Company made payments in an aggregate amount of $6.0 billion to the Dealers and received and retired an initial 23,258,997 shares of common stock. Approximately $0.9 billion of stock was held back by the Dealers pending final settlement of the ASR agreement, which will be based on the volume-weighted average stock price of the Company&#8217;s common stock during the term of the ASR agreements, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreements. At settlement, which is scheduled to occur in the third quarter of 2022, the Dealers may be required to deliver additional shares of common stock to the Company, or under certain circumstances, the Company may be required to deliver shares of common stock or to make a cash payment, at its election, to the Dealers.</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span><br/></span></div><div id="i710475db76604b05901ef7473465ecf1_124"></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:30.409%"><tr><td style="width:1.0%"></td><td style="width:34.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:62.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;6.&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBITS</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference is made to the Index to Exhibits included herein.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_127"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO EXHIBITS</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312519228830/d787825dex21.htm">Asset Purchase Agreement, dated August 25, 2019, by and between Amgen Inc. and Celgene Corporation.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on August 26, 2019 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312519270139/d655928dex101.htm">Amendment No. 1 to the Asset Purchase Agreement, dated October 17, 2019, by and between Amgen Inc. and Celgene Corporation.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on October 17, 2019 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a23amendmentno2toapa.htm">Amendment No. 2 to the Asset Purchase Agreement, dated October 17, 2019, by and between Amgen Inc. and Celgene Corporation.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a24letteragreementv3.htm">Letter Agreement, dated November 21, 2019, by and between Amgen Inc. and the parties named therein re: Treatment of Certain Product Inventory in connection with Amgen&#8217;s acquisition of Otezla.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312519228830/d787825dex22.htm">Irrevocable Guarantee, dated August 25, 2019, by and between Amgen Inc. and Bristol-Myers Squibb Company.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on August 26, 2019 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815421000045/amgn-ex27_202193021xq3.htm">Agreement and Plan of Merger, dated July 27, 2021, by and among Amgen Inc., Teneobio, Inc., Tuxedo Merger Sub, Inc., and Fortis Advisors LLC.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential)(Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2021 on November 3, 2021 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000144530513001107/amgn-exh31_2013331xq1.htm">Restated Certificate of Incorporation of Amgen Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (As Restated March 6, 2013.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2013 on May 3, 2013 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516466178/d46204dex31.htm">Amended and Restated Bylaws of Amgen Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (As Amended and Restated February 15, 2016.) (Filed as an exhibit to Form 8-K on February 17, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/0000318154-97-000008.txt">Form of stock certificate for the common stock, par value $.0001 of the Company.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 1997 on May 14, 1997 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Indenture, dated January 1, 1992. (Filed as an exhibit to Form S-3 Registration Statement filed on December 19, 1991 and incorporated herein by reference.)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312508040431/dex43.htm">Agreement of Resignation, Appointment and Acceptance dated February 15, 2008.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2007 on February 28, 2008 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/0000898430-97-001006.txt">First Supplemental Indenture, dated February 26, 1997.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on March 14, 1997 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/0000898430-97-001433.txt">8-1/8% Debentures due April 1, 2097.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on April 8, 1997 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/0000898430-97-001433.txt">Officer&#8217;s Certificate of Amgen Inc., dated April 8, 1997, establishing a series of securities entitled &#8220;8 1/8% Debentures due April 1, 2097.&#8221;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on April 8, 1997 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000104746903026118/a2115639zex-4_1.htm">Indenture, dated August 4, 2003.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form S-3 Registration Statement on August 4, 2003 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/0000318154-98-000005.txt">Corporate Commercial Paper - Master Note between and among Amgen Inc., as Issuer, Cede &amp; Co., as Nominee of The Depository Trust Company, and Citibank, N.A., as Paying Agent.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March&#160;31, 1998 on May&#160;13, 1998 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312507126045/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated May 30, 2007, including form of the Company&#8217;s 6.375% Senior Notes due 2037.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 30, 2007 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312508121768/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated May 23, 2008, including form of the Company&#8217;s 6.90% Senior Notes due 2038</a>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as exhibit to Form 8-K on May 23, 2008 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312509007552/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated January 16, 2009, including form of the Company&#8217;s 6.40% Senior Notes due 2039.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as exhibit to Form 8-K on January 16, 2009 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312510055545/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated March 12, 2010, including form of the Company&#8217;s 5.75% Senior Notes due 2040.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as exhibit to Form 8-K on March 12, 2010 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312510211595/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated September 16, 2010, including form of the Company&#8217;s 4.95% Senior Notes due 2041.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on September 17, 2010 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312511178620/dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated June 30, 2011, including form of the Company&#8217;s 5.65% Senior Notes due 2042.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on June 30, 2011 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312511306300/d254287dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated November 10, 2011, including form of the Company&#8217;s 5.15% Senior Notes due 2041.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on November 10, 2011 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312511329468/d265264dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated December 5, 2011, including form of the Company&#8217;s 5.50% Senior Notes due 2026.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on December 5, 2011 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312512234621/d352967dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated May 15, 2012, including form of the Company&#8217;s 5.375% Senior Notes due 2043.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 15, 2012 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312512390074/d410209dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated September 13, 2012, including form of the Company&#8217;s 4.000% Senior Notes due 2029.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on September 13, 2012 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312514209848/d732359dex41.htm">Indenture, dated May 22, 2014, between Amgen Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 22, 2014 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312514209848/d732359dex42.htm">Officers&#8217; Certificate of Amgen Inc., dated May 22, 2014, including form of the Company&#8217;s 3.625% Senior Notes due 2024.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 22, 2014 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312515165541/d919213dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated May 1, 2015, including forms of the Company&#8217;s 3.125% Senior Notes due 2025 and 4.400% Senior Notes due 2045.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit on Form 8-K on May 1, 2015 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516476783/d129782dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of February 25, 2016, including form of the Company&#8217;s 2.000% Senior Notes due 2026.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit on Form 8-K on February 26, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516495970/d156859dex41.htm">Form of Permanent Global Certificate for the Company&#8217;s 0.410% bonds due 2023.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit on Form 8-K on March 8, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516495970/d156859dex42.htm">Terms of the Bonds for the Company&#8217;s 0.410% bonds due 2023.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit on Form 8-K on March 8, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516621372/d203675dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of June 14, 2016, including forms of the Company&#8217;s 4.563% Senior Notes due 2048 and 4.663% Senior Notes due 2051.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on June 14, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312516686451/d187158dex43.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of August 19, 2016, including forms of the Company&#8217;s 2.250% Senior Notes due 2023 and 2.600% Senior Notes due 2026.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on August 19, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312517331065/d472956dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of November 2, 2017, including in the form of the Company&#8217;s 3.200% Senior Notes due 2027.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on November 2, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312520044757/d894000dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of February 21, 2020, including forms of the Company&#8217;s 1.900% Senior Notes due 2025, 2.200% Senior Notes due 2027, 2.450% Senior Notes due 2030, 3.150% Senior Notes due 2040 and 3.375% Senior Notes due 2050.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on February 21, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312520134934/d925911dex43.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of May 6, 2020, including form of the Company&#8217;s 2.300% Senior Notes due 2031.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 6, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312520222579/d60848dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of August 17, 2020, including forms of the Company&#8217;s 2.770% Senior Notes due 2053.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on August 18, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312520222579/d60848dex43.htm">Registration Rights Agreement, dated as of August 17, 2020, by and among Amgen Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, as lead dealer managers, and BNP Paribas Securities Corp., Deutsche Bank Securities Inc., RBC Capital Markets, LLC, Blaylock Van, LLC and Siebert Williams Shank &amp; Co., LLC, as co-dealer managers.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on August 18, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312521240434/d213858dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of August 9, 2021, including forms of the Company&#8217;s 1.650% Senior Notes due 2028, 2.000% Senior Notes due 2032, 2.800% Senior Notes due 2041 and 3.000% Senior Notes due 2052</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. (Filed as an exhibit to Form 8-K on August 9, 2021 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312522048514/d302710dex42.htm">Officer&#8217;s Certificate of Amgen Inc., dated as of February 22, 2022, including forms of the Company&#8217;s 3.000% Senior Notes due 2029, 3.350% Senior Notes due 2032, 4.200% Senior Notes due 2052 and 4.400% Senior Notes due 2062</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. (Filed as an exhibit to Form 8-K on February 22, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312513145924/d475543ddef14a.htm#toc475543_21">Amgen Inc. Amended and Restated 2009 Equity Incentive Plan.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as Appendix C to the Definitive Proxy Statement on Schedule 14A on April 8, 2013 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815415000010/amgn-ex102_2015331xq1.htm">First Amendment to Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, effective March 4, 2015.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2015 on April 27, 2015 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815416000035/amgn-ex103_2016331xq1.htm">Second Amendment to Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, effective March 2, 2016.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2016 on May 2, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815422000010/amgn-ex104_20211231xq4.htm">Form of Grant of Stock Option Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended and Restated on December 2, 2021.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815422000010/amgn-ex105_20211231xq4.htm">Form of Restricted Stock Unit Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended and Restated on December 2, 2021.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815418000004/exhibit106performanceaward.htm">Amgen Inc. 2009 Performance Award Program. (As Amended on December 12, 2017.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2017 on February 13, 2018 and incorporated herein by reference.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815422000010/amgn-ex107_20211231xq4.htm">Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended and Restated on December 2, 2021.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815421000010/amgn-ex108_20201231xq4.htm">Amgen Inc. 2009 Director Equity Incentive Program. (As Amended and Restated on October 21, 2020.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2020 on February 9, 2021 and incorporated herein by reference.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312509105621/dex107.htm">Form of Grant of Non-Qualified Stock Option Agreement for the Amgen Inc. 2009 Director Equity Incentive Program.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on May 8, 2009 and incorporated herein by reference.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1010-amgenxdirectorrs.htm">Form of Restricted Stock Unit Agreement for the Amgen Inc. 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1011-amgenxdirectorca.htm">Form of Cash-Settled Restricted Stock Unit Agreement for the Amgen 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815414000004/amgn-ex109_20131231x10k.htm">Amgen Inc. Supplemental Retirement Plan. (As Amended and Restated effective October 16, 2013.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2013 on February 24, 2014 and incorporated herein by reference.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815416000053/amgn-ex1012_2016930xq3.htm">First Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 14, 2016.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2016 on October 28, 2016 and incorporated herein by reference.)</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1014-secondamendmento.htm">Second Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 23, 2019).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815422000010/amgn-ex1015_20211231xq4.htm">Third Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 20, 2021.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000095012311048073/v58996exv10w9.htm">Amended and Restated Amgen Change of Control Severance Plan. (As Amended and Restated effective December 9, 2010 and subsequently amended effective March 2, 2011.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2011 on May 10, 2011 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815422000021/amgn-ex1017_2022331xq1.htm">Amgen Inc. Executive Incentive Plan.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (As Amended and Restated effective January&#160;1, 2022.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2022 on April 28, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815414000004/amgn-ex1015_20131231x10k.htm">Amgen Nonqualified Deferred Compensation Plan. (As Amended and Restated effective October 16, 2013.)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2013 on February 24, 2014 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815416000053/amgn-ex1017_2016930xq3.htm">First Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective October 14, 2016.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2016 on October 28, 2016 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1021-secondamendmentt.htm">Second Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective January 1, 2020.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815422000010/amgn-ex1023_20211231xq4.htm">Third Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective January 1, 2022. </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815420000031/petergriffith-signedof.htm">Agreement between Amgen Inc. and Peter Griffith, dated October 18, 2019.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2020 on May 1, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815422000010/amgn-ex1025_20211231xq4.htm">Aircraft Time Sharing Agreement, dated December 3, 2021, by and between Amgen Inc. and Robert A. Bradway.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312519312129/d834361dex101.htm">Second Amended and Restated Credit Agreement, dated December 12, 2019, among Amgen Inc., the Banks therein named, Citibank, N.A., as administrative agent, and JPMorgan Chase Bank, N.A., as syndication agent</a>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on December 12, 2019 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312513312834/d573775dex1054.htm">Collaboration and License Agreement between Amgen Inc. and Celltech R&amp;D Limited dated May 10, 2002 (portions of the exhibit have been omitted pursuant to a request for confidential treatment) and Amendment No. 1, effective June 9, 2003, to Collaboration and License Agreement between Amgen Inc. and Celltech R&amp;D Limited (portions of the exhibit have been omitted pursuant to a request for confidential treatment).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K/A for the year ended December 31, 2012 on July 31, 2013 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815417000004/amgn-ex1032_20161231x10k.htm">Amendment No. 2 to Collaboration and License Agreement, effective November 14, 2016, between Amgen Inc. and Celltech R&amp;D Limited (portions of the exhibit have been omitted pursuant to a request for confidential treatment).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2016 on February 14, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815419000037/amgn-ex282019630xq2.htm">Letter Agreement, dated June 25, 2019, by and between Amgen Inc. and UCB Celltech (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2019 on July 31, 2019 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1012140/000095012311047784/f58570exv10w1wi.htm">Collaboration Agreement, dated April 22, 1994, by and between Bayer Corporation (formerly Miles, Inc.) and Onyx Pharmaceuticals, Inc.</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2011 by Onyx Pharmaceuticals, Inc. on May 10, 2011 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1012140/000095014906000261/f20295exv10w1xiy.htm">Amendment to Collaboration Agreement, dated April 24, 1996, by and between Bayer Corporation and Onyx Pharmaceuticals, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2006 by Onyx Pharmaceuticals, Inc. on May 10, 2006 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1012140/000095014906000261/f20295exv10w12.htm">Amendment to Collaboration Agreement, dated February 1, 1999, by and between Bayer Corporation and Onyx Pharmaceuticals, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2006 by Onyx Pharmaceuticals, Inc. on May 10, 2006 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1012140/000119312512081975/d265452dex101v.htm">Settlement Agreement and Release, dated October 11, 2011, by and between Bayer Corporation, Bayer AG, Bayer HealthCare LLC and Bayer Pharma AG and Onyx Pharmaceuticals, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2011 by Onyx Pharmaceuticals, Inc. on February 27, 2012 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1012140/000119312512081975/d265452dex101iv.htm">Fourth Amendment to Collaboration Agreement, dated October 11, 2011, by and between Bayer Corporation and Onyx Pharmaceuticals, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2011 by Onyx Pharmaceuticals, Inc. on February 27, 2012 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815415000022/amgn-ex1043_2015630xq2.htm">Side Letter Regarding Collaboration Agreement, dated May 29, 2015, by and between Bayer HealthCare LLC and Onyx Pharmaceuticals, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2015 on August 5, 2015 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815420000031/sideletterregardingcol.htm">Side Letter Regarding Collaboration Agreement and Stivarga Agreement, dated February 13, 2020, by and between Onyx Pharmaceuticals, Inc. and Bayer HealthCare LLC.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2020 on May 1, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815417000009/amgn-exhibit1040_2017033110q.htm">Sourcing and Supply Agreement, dated January 6, 2017, by and between Amgen USA Inc., a wholly owned subsidiary of Amgen Inc., and DaVita Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2017 on April 27, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815417000021/amgn-ex1041amgenxnovartism.htm">Exclusive License and Collaboration Agreement, dated August 28, 2015, by and between Amgen Inc. and Novartis Pharma AG</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2017 on July 26, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815417000021/amgn-ex1042amend1tolicense.htm">Amendment No. 1 to the Exclusive License and Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2017 on July 26, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815417000021/amgn-ex1043amend2tonovarti.htm">Amendment No. 2 to the Exclusive License and Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2017 on July 26, 2017 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312522023401/d275986dex101.htm">Amendment No. 3 to the Exclusive License and Collaboration Agreement, dated January 31, 2022, by and between Amgen Inc. and Novartis Pharma AG</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential). (Filed as an exhibit to the Company&#8217;s Current Report on Form 8-K on January 31, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1041bridgecollaborati.htm">Collaboration Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene Switzerland GmbH, a wholly-owned subsidiary of BeiGene, Ltd.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1041-firstamendment.htm">First Amendment to Collaboration Agreement, dated April 20, 2022, by and between Amgen Inc. and BeiGene Switzerland GmbH, and BeiGene, Ltd.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815420000017/a1042guaranteeagreement.htm">Guarantee, dated as of October 31, 2019, made by and among BeiGene, Ltd. and Amgen Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312520003926/d848812dex991.htm">Share Purchase Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene, Ltd.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Schedule 13D on January 8, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000119312520003926/d848812dex992.htm">Amendment No. 1 to Share Purchase Agreement, dated December 6, 2019, by and among BeiGene, Ltd. and Amgen Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Schedule 13D on January 8, 2020 and incorporated herein by reference.)</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815420000060/a1046restatedamendment.htm">Restated Amendment No. 2 to Share Purchase Agreement, dated September 24, 2020, by and among BeiGene, Ltd. and Amgen Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2020 on October 29, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1046-collaborationa.htm">Collaboration Agreement dated March 30, 2012 by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, a wholly owned subsidiary of AstraZeneca Pharmaceuticals LP</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1047-amendmentno1to.htm">Amendment No. 1 to the Collaboration Agreement, dated October 1, 2014, by and among Amgen Inc., AstraZeneca Collaboration Ventures, LLC and AstraZeneca Pharmaceuticals LP</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) </span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815420000048/amgn-ex10492020630xq2.htm">Amendment Nos. 2 through 6 to the March 30, 2012 Collaboration Agreement between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, dated May 2 and 27 and October 2, 2016, January 31, 2018, and May 15, 2020, respectively</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2020 on July 29, 2020 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/318154/000031815421000010/amgn-ex1050_20201231xq4.htm">Amendment No. 7 to the Collaboration Agreement, dated December 17, 2020, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2020 on February 9, 2021 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815422000010/amgn-1051_20211231xq4.htm">Amendment No. 8 to the Collaboration Agreement, dated November 19, 2021, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.)(Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.51</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000031815421000034/amgn-ex1049_2021630xq2.htm">License and Collaboration Agreement, dated June 1, 2021, by and between Amgen Inc. and Kyowa Kirin Co., Ltd.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2021 on August 4, 2021 and incorporated herein by reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.52</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/318154/000119312522052558/d290205dex101.htm">Form of ASR Agreement.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Filed as an exhibit to Form 8-K on February 24, 2022 and incorporated herein by</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">reference.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex31_2022630xq2.htm">Rule 13a-14(a) Certifications.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-ex32_2022630xq2.htm">Section 1350 Certifications.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(* = filed herewith)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(** = furnished herewith and not &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(+ = management contract or compensatory plan or arrangement)</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i710475db76604b05901ef7473465ecf1_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:1pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.330%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">August 4, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;PETER H. GRIFFITH</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peter H. Griffith</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.41
<SEQUENCE>2
<FILENAME>exhibit1041-firstamendment.htm
<DESCRIPTION>FIRST AMENDMENT TO COLLABORATION AGREEMENT BETWEEN AMGEN AND BEIGENE
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i59aff73472854956ab674886049ced77_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBIT 10.41</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;*&#93;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div><div style="text-indent:459pt"><font><br></font></div><div style="text-indent:459pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FIRST AMENDMENT TO COLLABORATION AGREEMENT</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">This Amendment to the Collaboration Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">&#8221;) is entered into as of April 20, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;text-decoration:underline">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">&#8221;) by and among Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;text-decoration:underline">Amgen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">&#8221;), BeiGene Switzerland GmbH, a Swiss corporation with a principal place of business at Aeschengraben 27, 4051 Basel, Switzerland (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;text-decoration:underline">BeiGene</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">&#8221;), and BeiGene, Ltd., a Cayman Islands exempted company incorporated with limited liability with its registered offices c&#47;o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, P.O. Box 1348, Grand Cayman KY1-1108, Cayman Islands (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;text-decoration:underline">BeiGene Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">&#8221;).  BeiGene and Amgen are sometimes referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">.&#8221;  This Amendment amends that certain Collaboration Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">&#8221;), entered into as of October 31, 2019, by and between Amgen and BeiGene and, solely with respect to Section&#160;13.6 thereof, BeiGene Parent.  Capitalized terms used but not defined herein have the meanings given to them in the Agreement. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Agreement contains certain terms and conditions relating to the financial responsibilities of the Parties in connection with the development and commercialization of certain Amgen proprietary Products for the treatment of oncology-related diseases and conditions&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Parties desire to amend the Agreement upon the terms and conditions set forth herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements contained herein, the Parties, intending to be legally bound hereby, do agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AGREEMENT</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:27.75pt;text-decoration:underline">Amendment to Section 1.48 of the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">.  Section&#160;1.48 of the Agreement is hereby amended and replaced in its entirety as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Section 1.48&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means both internal and external costs and expenses (including the cost of allocated FTEs at the FTE Rate and Sales Force FTEs at the Sales Force FTE Rate).  &#91;*&#93;&#8221;</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:27.75pt;text-decoration:underline">New Section 1.170</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">.  The following is hereby inserted as a new Section&#160;1.170 of the Agreement&#58;  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Section&#160;1.170&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Hainan Bo Ao</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean Pilot Zone in the Hainan province where Bo Ao Product may be stored and then imported into the Collaboration Territory with a patient application prior to Regulatory Approval for the Bo Ao Product in the Collaboration Territory.&#8221;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:27.75pt;text-decoration:underline">New Section 1.171</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">.  The following is hereby inserted as a new Section&#160;1.171 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Section&#160;1.171&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bo Ao Support Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all actual and, if reasonably practicable, documented costs incurred by Amgen and&#47;or its Affiliates and pre-approved pursuant to the Supply Agreement, if applicable, &#91;*&#93;&#8221;  </font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:27.75pt">New Section 1.172.  The following is hereby inserted as a new Section&#160;1.172 of the Agreement&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">&#8220;Section 1.172&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;text-decoration:underline">Product Team</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">&#8221; means, for any Product &#91;*&#93;.&#8221;  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:27.75pt">New Section 1.173.  The following is hereby inserted as a new Section&#160;1.173 of the Agreement&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">&#8220;Section 1.173&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;text-decoration:underline">Work Package Team</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">&#8221; means, for any Product &#91;*&#93;.&#8221;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:27.75pt;text-decoration:underline">Amendment to Section 7.1.2 of the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">.  The following text is hereby inserted as a new Section&#160;7.1.2(d), Section 7.1.2(e), Section 7.1.2(f), and Section&#160;7.1.2(g), respectively, of the Agreement&#58; &#91;*&#93;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:27.75pt;text-decoration:underline">Amendments to Section 7.2 of the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">.  </font></div><div style="margin-bottom:10pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:10.37pt">The first paragraph of Section&#160;7.2 (Profit Sharing) of the Agreement is hereby amended and replaced in its entirety as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Section 7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Profit Sharing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Prior to the Transition Date designated by the Joint Steering Committee (generally the second Launch Readiness Review for a Product) for an In-Line Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Transition Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) pursuant to Section 3.1.1 (Transition and Development of Products) and Section&#160;5.1.2(b) (Initial In-Line Product Transition), &#91;*&#93; set forth in the definition of &#8220;Commercialization and Related Costs.&#8221;  The Joint Steering Committee has designated the Transition Date for each In-Line Product as follows&#58;  XGEVA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, &#91;*&#93;&#59; BLINCYTO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, &#91;*&#93;&#59; and Kyprolis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, &#91;*&#93;. </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For the avoidance of doubt, &#91;*&#93; from Amgen to BeiGene pursuant to Section 3.1.1 (Transition and Development of Products) and Section 5.1.2(b) (Initial In-Line Product Transition).</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;&#91;*&#93; set forth in the definition of &#8220;Commercialization and Related Costs&#8221; for each Pipeline Product until &#91;*&#93; prior to the anticipated launch date for such Pipeline Product (such date to be designated for each Pipeline Product by the Joint Alliance Committee and subject to adjustment by the Joint Alliance Committee in the event the anticipated launch date changes) (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Initiation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;The Parties will share in Profits generated by Products in the Collaboration Scope&#58;  (i)&#160;with respect to In-Line Products, beginning on &#91;*&#93; and ending upon &#91;*&#93; for such In-Line Product&#59; (ii) with respect to Pipeline Products, beginning on &#91;*&#93; and ending upon &#91;*&#93; for such Pipeline Product&#59; and (iii) for such longer period as set forth in Section 5.1 for each Retained In-Line Product and each Retained Pipeline Product (i.e., for so long as such Retained In-Line Product or Retained Pipeline Product, as applicable, is sold in the Collaboration Territory)&#59; in each case as follows&#58;&#8221;</font></div><div style="margin-bottom:10pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:9.75pt">Section 7.2.3 (FTE Rate) of the Agreement is hereby amended and restated in its entirety as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Section&#160;7.2.3.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">FTE Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The FTE Rate used for calculation of Costs pursuant to this Article VII (Financial Consideration) with respect to any activity will be the relevant FTE Rate for &#91;*&#93; in which such activity was undertaken.  </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Effective as of &#91;*&#93;, the Parties agree that the Costs (calculated using the development FTE Rate (as defined in Section 1.72(i)) or commercial FTE Rate (as defined in Section 1.72(ii)), as applicable) of FTEs performing Product Team&#47;Work Package Team strategy activities (i.e.  Support to advise </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">on the China specific aspects of the Global Development Plan) for Pipeline Products incurred by the Parties or their respective Affiliates&#58; (i)&#160;prior to Regulatory Approval, in accordance with the Development Plan and Development Budget will be deemed Amgen Pipeline Product Global Development Costs and subject to Global Development Cost-Share Payments in accordance with Section 7.1.2 (Global Development Cost Share) and (ii)&#160;after Regulatory Approval (including strategy activities for new indications or label expansion after Regulatory Approval), in accordance with the Commercialization Plan and Commercialization Budget, will be deemed to be Commercialization and Related Costs and included in the collaboration profit sharing pursuant to Section&#160;7.2 (Profit Sharing).  The Product Team and Work Package Team FTEs will be initially set, and shall in no event exceed, &#91;*&#93; to support the Pipeline Products.  The table below sets out the 2021 baseline budget for Product Team&#47;Work Package Team strategy FTEs based on the Pipeline Product portfolio as of the Amendment Effective Date. &#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;The Product Team and Work Package Team FTE allocation for Pipeline Products will be adjusted by Amgen &#91;*&#93; based on relevant factors, &#91;*&#93;.&#8221;</font></div><div style="margin-bottom:10pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:10.37pt">The following is hereby inserted as a new Section&#160;7.2.8 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Section 7.2.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Hainan Bo Ao Cost-Share Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in this Agreement, with respect to the AMG 510 (also known as sotorasib or LUMAKRAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bo Ao Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the Parties desire to initiate the Profit-sharing arrangement set forth in Section&#160;7.2 prior to applicable Initiation Date, subject to the following terms and conditions&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Commercialization and Related Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Prior to the applicable Initiation Date, costs (including Costs for outside services and expenses (e.g., consultants, agency fees, etc.)) for the following activities shall be considered &#8220;Commercialization and Related Costs&#8221; for purposes of determining &#8220;Amgen Costs&#8221; or &#8220;BeiGene Costs,&#8221; as applicable&#58; </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;&#91;*&#93;&#59;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Medical Affairs Activities Costs incurred in connection with Hainan Bo Ao in or for the Collaboration Territory prior to commercialization and during commercialization&#59;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;all Costs incurred by the Parties or their respective Affiliates associated with any recalls of the Bo Ao Product in the Collaboration Scope and in or for the Collaboration Territory&#59;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;all Costs incurred by the Parties or their respective Affiliates with respect to product liability claims for the Bo Ao Product in the Collaboration Scope in the Collaboration Territory&#59;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;all Costs incurred by the Parties or their respective Affiliates associated with any returns and withdrawals of the Bo Ao Product in the Collaboration Scope in the Collaboration Territory&#59;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;any Third Party IP Payments to the extent not already included in Manufacturing Actual Costs&#59; and</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(viii)&#160;&#160;&#160;&#160;all unrecovered Indirect taxes, including, for the avoidance of doubt, unrecovered VAT surcharge, incurred by either Party arising with respect to payments to be made under Section 7.2.7 (Calculation of Collaboration Profits). &#91;*&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercialization and Related Costs for purposes of this Section 7.2.8 shall not include &#91;*&#93; or any Cost subject to an indemnification obligation under Article XIII.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Manufacturing Actual Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Manufacturing Actual Costs incurred with respect to the Bo Ao Product in connection with Hainan Bo Ao shall be deemed &#8220;Amgen Costs&#8221; for purposes of the calculations set forth under Section&#160;7.2 (Profit Sharing).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Net Revenues.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net Revenues from the sale or transfer for value of the Bo Ao Product in Hainan Bo Ao shall be considered &#8220;Net Revenues&#8221; for purpose of Section&#160;7.2 (Profit Sharing).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Support Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Bo Ao Support Costs incurred with respect to Bo Ao Product in connection with Hainan Bo Ao shall be deemed &#8220;Amgen Costs&#8221; for purposes of the calculations set forth under Section&#160;7.2 (Profit Sharing).&#8221;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:27.75pt;text-decoration:underline">Amendment to Section&#160;7.9 of the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">.  Section 7.9 (Overruns) of the Agreement is hereby supplemented and amended by adding the following at the end of the existing Section&#160;7.9&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Without limiting the foregoing, the Parties further agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;While the final overrun calculation is based on annual amounts, the Parties agree to perform quarterly assessments of cost variances for the Overrun Categories shown below, recognizing that both Parties have quarterly reporting requirements.</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;In any given calendar quarter, the quarterly profit share and development cost share calculations will reflect up to a maximum of &#91;*&#93;&#160;of the planned amounts of the &#8220;Overrun Categories&#8221; (with an exception for materiality described in Section&#160;7.9(e) below).</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;To the extent costs exceed &#91;*&#93; of the budgeted amount in a given calendar quarter, the following shall apply&#58;  The Parties agree that they will track variances above &#91;*&#93; of the planned amount into subsequent calendar quarters, to comply with the annual nature of the cost overage calculation in this Section&#160;7.9.  &#91;*&#93;  If, at a later time, joint approval is obtained from each Party&#8217;s finance representative to the JAC for additional activities and related spending beyond the &#91;*&#93; cap, an adjustment will be made in the subsequent period.</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;To the extent costs are below budget in a given calendar quarter, actual variances resulting in underspend will be reimbursable in a subsequent period to the extent costs are for a pre-agreed upon activity that had a timing difference and the rationale for the variance is communicated, along with the rationale for why the activity&#47;spend will be performed in a subsequent period.  The Parties may agree to a new activity to take the place of the activity that did not occur and the costs of such activity will be reimbursed if under the &#91;*&#93; expense cap, unless otherwise agreed.  Agreement will be obtained by each Party&#8217;s finance representatives to the JAC.</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;The Parties have agreed to a US$&#91;*&#93; dollar threshold for calendar quarter reconciliation of cost overruns, to eliminate the inefficient analysis of greater than &#91;*&#93; variance for smaller dollar amount categories.  &#91;*&#93;</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;Costs will be evaluated for overrun in the following manner&#58; &#91;*&#93;</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;The baseline for the overrun calculation pursuant to this Section&#160;7.9 will be the most recently approved Global Development Budget or Commercialization Budget, as applicable.&#8221;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:27.75pt;text-decoration:underline">New Section&#160;7.12 of the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">.  The following is hereby inserted as a new Section&#160;7.12 of the Agreement&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Section 7.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Cost-Share Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Parties expect that from time-to-time one Party may perform activities that are the responsibility of the other Party or a Party may request that the other Party provide services or conduct activities that are not contemplated by the Agreement.  In these instances, if the JAC approves such activities and the budget for such activities, the Party performing the activity for the benefit of the other Party shall be reimbursed for the reasonable costs of providing such services or conducting such activities.  Such costs shall be documented in writing and the Party providing such service shall be reimbursed quarterly to the Party performing such service concurrently with the Compensating Payment made pursuant to Section 7.2.7 (Calculation of Collaboration Profits).  As of the Effective Date, the Parties have agreed that Amgen shall be reimbursed for the following activities as set forth below&#58; &#91;*&#93;&#8221;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:22.25pt;text-decoration:underline">Supply Price Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">.  The Supply Price Schedule is hereby amended to include the following as a new row&#58;</font></div><div style="padding-left:112.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.083%"><tr><td style="width:1.0%"></td><td style="width:51.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:4.25pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">.  </font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:27.75pt">Except as specifically amended above, the Agreement shall continue to be in full force and effect.</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:28.37pt">This Amendment and its effect are subject to and shall be construed and enforced in accordance with the laws of the State of New York, U.S.A.</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:29.59pt">This Amendment may be executed in counterparts with the same effect as if both Parties had signed the same document.  All such counterparts will be deemed an original, will be construed together and will constitute one and the same instrument.  Signature pages of this Amendment may be exchanged by facsimile or other electronic means without affecting the validity thereof.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Parties have executed this Amendment as of the Amendment Effective Date.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%">AMGEN INC.</font></div><div style="margin-bottom:10pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.998%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Rachna Khosla</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Rachna Khosla</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; SVP Business Development</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%">BEIGENE SWITZERLAND GMBH</font></div><div style="margin-bottom:10pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.998%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Beatriz Martinez-Lahuerta</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Beatriz Martinez-Lahuerta</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Assistant General Counsel, Head of Legal, Europe &#38; New Markets</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%">BEIGENE, LTD.</font></div><div style="margin-bottom:10pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.998%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Angus Grant</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Angus Grant</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Senior Vice President, Chief Business Executive</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.46
<SEQUENCE>3
<FILENAME>exhibit1046-collaborationa.htm
<DESCRIPTION>COLLABORATION AGREEMENT BETWEEN AMGEN AND ASTRAZENECA
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i841f4189a89841e58389acdfd7f2e502_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 10.46</font></div><div style="margin-bottom:6pt;text-align:right"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;*&#93;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Collaboration Agreement</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by and between</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Amgen Inc.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AstraZeneca Collaboration Ventures, LLC</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i841f4189a89841e58389acdfd7f2e502_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Table of Contents </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">DEFINITIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SCOPE AND GOVERNANCE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1  Purpose of the Collaboration</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.2  Ex-Territory Activities</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.3  Committees and Teams</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.4  Joint Product Teams.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">19</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.5  Joint Steering Committee.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">20</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.6  Collaboration Review Committee</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.7  Reporting</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.8  No Authority to Amend or Modify</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">22</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.9  Alliance Managers</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">22</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.10  Patent Coordinators</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">22</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">DEVELOPMENT AND REGULATORY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">22</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.1  Development Matters</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">22</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.2  Regulatory Matters</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">24</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.3  Brand Security and Anti-Counterfeiting</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">25</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.4  Product Complaints, Recalls and Returns</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.5  Clinical Trial Register</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.6  Sharing of Data and Know-How</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">MANUFACTURING</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.1  Allocation of Manufacturing Responsibility</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.2  Manufacturing Lead</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">27</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.3  &#91;*&#93; Updates</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">27</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.4  Distribution</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">27</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.5  Quality and Safety Agreements</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.6  Shortage&#59; Allocation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">COMMERCIALIZATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.1  Allocation of Commercial Responsibility</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.2  Commercial Lead</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.3  Initial Plans&#59; &#91;*&#93; Updates</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.4  All Sales by Distribution Party</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">29</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.5  Training</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">29</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.6  Information Concerning Products</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">29</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.7  Promotional Materials</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">29</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.8  Detailing Reports and Audit Rights</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">30</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.9  Competing Products</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">30</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.10  Sales Force &#91;*&#93;</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">31</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">PERFORMANCE STANDARDS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">32</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;i</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.1  Collaborative Activities</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">32</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.2  Diligence and Performance Standards</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">32</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.3  Violation of Laws</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">32</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.4  Use of Affiliates and Third Party Contractors</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">32</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.5  Management of Personnel</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">33</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">UP-FRONT PAYMENT AND</a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </a></font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">PROFIT&#47;EXPENSE SHARING</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">33</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.1  Up-front Payment</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">33</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.2  Profit&#47;Expense Sharing</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">33</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.3  Example</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">37</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.4  Calculation of Net Revenues</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">37</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.5  Excluded Losses</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">38</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.6  Manufacturing Costs Calculation and True-Up</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">39</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.7  Budget Deadlocks</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">39</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.8  Program Recommitment</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">39</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">PAYMENTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">42</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.1  Appropriate Measure of Value</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">42</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.2  No Other Compensation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">42</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.3  Currency</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">42</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.4  Audits</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">43</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.5  Blocked Currency</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">43</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.6  Taxes</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">43</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.7  Late Payment</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">45</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.8  Change in Accounting Periods</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">45</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">DISTRACTING PRODUCTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">45</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9.1  Distracting Program</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">45</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9.2  Post-Effective Date Affiliates</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">46</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9.3  Termination, Divestiture or Inclusion</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">46</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9.4  Pre-Clinical Research and Development Programs</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">48</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9.5  Reasonable Restrictions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">48</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">INTELLECTUAL PROPERTY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">49</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.1  Invention Ownership</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">49</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.2  Copyright Ownership&#59; Certain Confidential Information</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">49</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.3  Joint Ownership</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">49</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.4  License Grant by Amgen</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">50</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.5  License Grant by Partner</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">50</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.6  Prosecution and Maintenance</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">50</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.7  Defense and Settlement of Third Party Claims of Infringement</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">52</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.8  Enforcement</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">52</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.9  Patent Term Extensions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">53</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.10  Trademarks.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">53</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CONFIDENTIALITY, PUBLICATIONS AND PRESS RELEASES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">54</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ii</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.1  Confidentiality&#59; Exceptions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">54</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.2  Authorized Disclosure</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">55</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.3  Confidential Treatment of Terms and Conditions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">56</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.4  Press Releases</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">56</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.5  Prior Agreement</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">56</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.6  Publications and Program Information</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">56</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">REPRESENTATIONS AND WARRANTIES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">57</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.1  Mutual Representations and Warranties</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">57</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.2  Amgen Representations and Warranties</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">58</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.3  Mutual Covenants</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">59</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.4  Amgen Covenant</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">60</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.5  AstraZeneca Covenant</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">60</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.6  Disclaimer of Warranties</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">60</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.7  Limitation of Liability</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">INDEMNIFICATION AND INSURANCE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.1  Indemnity by Partner</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.2  Indemnity by Amgen</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.3  Claim for Indemnification</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.4  Defense of Third Party Claims</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">62</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.5  Insurance</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">62</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">TERM AND TERMINATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">62</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.1  Term</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">63</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2  Termination for Convenience</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">63</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.3  Termination for Breach</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">63</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.4  Termination for Insolvency</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">63</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.5  Termination for Challenge</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">63</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.6  Effects of Termination</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">64</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">MISCELLANEOUS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">71</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.1  Affiliates</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">71</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.2  Assignment</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">71</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.3  Choice of Law&#59; Jurisdiction</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">71</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.4  Construction</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">71</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.5  Counterparts</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">72</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.6  Entire Agreement</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">72</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.7  Force Majeure</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">72</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.8  Further Assurances</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">72</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.9  Headings</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">72</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.10  No Set-Off</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">72</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.11  Notices</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">73</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.12  Relationship of the Parties</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">73</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.13  Severability</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">73</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iii</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.14  Third Party Beneficiaries</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">74</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.15  Waivers and Modifications</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">74</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.16  &#91;*&#93;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i841f4189a89841e58389acdfd7f2e502_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">74</a></font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iv</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Schedules</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG827 Territory</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Amgen Distribution Countries</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Commercial Allocation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Completed Clinical Trials</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93; Designated Endpoints &#91;*&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Development&#47;Commercial Lead</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Distracting Product</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Invoice</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Press Release</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Products</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Profit (Loss) Example</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Quality Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stage 1 Clinical Trial</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">v</font></div><div><font><br></font></div></div></div><div id="i841f4189a89841e58389acdfd7f2e502_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaboration Agreement</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This Collaboration Agreement (this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) is entered into as of the 30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of March, 2012 (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Effective Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) by and between Amgen Inc., a Delaware corporation with a place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Amgen&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), and AstraZeneca Collaboration Ventures, LLC, a Delaware limited liability company with a place of business at 1800 Concord Pike, Wilmington, Delaware 19850 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Partner&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  Amgen and Partner are sometimes referred to herein individually as a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Party&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and collectively as the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Parties&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. AstraZeneca Pharmaceuticals LP, the parent corporation of Partner (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;AstraZeneca&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), &#91;*&#93; is a party to this Agreement &#91;*&#93;.</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Recitals</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, Amgen is a global biopharmaceutical company that researches, develops, manufactures and commercializes novel therapeutics to treat grievous illness&#59;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, Amgen has developed certain proprietary Products (as defined below) for the treatment of certain diseases and conditions&#59; and</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, Amgen and Partner desire to collaborate, and share certain expenses and revenues, with respect to the development, manufacture and commercialization of the Products as set forth in more detail herein.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;NOW, THEREFORE, in consideration of the premises and the mutual promises set forth herein, and intending to be legally bound, the Parties agree as follows&#58;</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">DEFINITIONS</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:18pt">&#8220;Access and Pricing Plan&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the country specific plan for a Product approved by the JSC that sets forth the proposed price, target population and reimbursement target.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:18pt">&#8220;Affiliate&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means, with respect to a Party, any Person which controls, is controlled by or is under common control with such Party.  For purposes of this definition only, &#8220;control&#8221; means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such Person, whether by the ownership of more than fifty percent (50%) of the securities entitled to be voted generally or in the election of directors of such Person, or by contract or otherwise.  For clarity, Kirin-Amgen, Inc. shall not be considered an Affiliate of Amgen.  Notwithstanding the foregoing, for the purposes of Article 9 (Distracting Products) and Section 1.51 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Distracting Transaction&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) only, &#91;*&#93;.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:18pt">&#8220;Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:18pt">&#8220;Alliance Manager&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 2.9 (Alliance Managers).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:18pt">&#8220;AMG157 Data Package&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 14.2 (Termination for Convenience).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:18pt">&#8220;AMG157 Termination Event&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 14.2 (Termination for Convenience).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:18pt">&#8220;AMG827 Territory&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means Australia, Canada, Mexico, New Zealand, the United States (its territories and possessions), all European countries, including those listed in Column 1 of the AMG827 Territory Schedule attached hereto, all Central and South American countries, including those listed in Column 2 of AMG827 Territory Schedule attached hereto, and those certain African and Middle East countries listed in Column 3 of AMG827 Territory Schedule attached hereto. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:18pt">&#8220;Amgen&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:18pt">&#8220;Amgen Costs&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 7.2.2 (Amgen Costs).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Amgen Distribution Countries&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means those countries listed on the Amgen Distribution Countries Schedule.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Amgen Housemarks&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (i) the corporate logo of Amgen, (ii) the trademark &#8220;Amgen&#8221;, (iii) any other trademark, trade name or service mark (whether registered or unregistered) containing the word &#8220;Amgen&#8221;, and (iv) any other trademark or service mark associated with goods or services of Amgen or its Affiliates, but excluding the Product Trademarks and trademarks, trade names or service marks associated with goods or services outside the scope of this Agreement&#59; and all intellectual property rights residing in any of the foregoing.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Amgen Indemnitees&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the meaning set forth in Section 13.1 (Indemnity by Partner).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Amgen Intellectual Property&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means any Know-How, Patent, electronic media registrations (including domain names, usernames, websites, blogs and the like), or Copyright controlled by Amgen or its Affiliates that (i) as of the Effective Date is being used in connection with the research and development of any of the Products, or (ii) is used (but is not generated or conceived) during the Term by either Party or its Affiliates in the performance of this Agreement.  Amgen Intellectual Property specifically excludes Program Intellectual Property.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Amgen Sales Force Costs&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the allocable share of Amgen&#8217;s or its Affiliates&#8217; sales force costs for sales representatives that Detail Products in the Collaboration Scope in accordance with this Agreement, calculated in accordance with Section 7.2.11 (Calculation of Sales Force Costs). </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Anti-Corruption Laws&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the US Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money laundering or terrorism.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Applicable Laws&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means, individually and collectively, any federal, state, local, national and supra-national laws, treaties, statutes, ordinances, rules and regulations, including any rules, regulations, guidance, guidelines or requirements having the binding effect of law of national securities exchanges, automated quotation systems or securities listing organizations, Governmental Authorities, courts, tribunals, agencies other than Governmental Authorities, legislative bodies and commissions that are in effect from time to time during the Term and applicable to a particular activity hereunder. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Assisting Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 13.4 (Defense of Third Party Claims).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;AstraZeneca&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Audited Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 8.4 (Audits).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Auditing Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 8.4 (Audits).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Brand Plan&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the global, cross-functional commercialization plan for a Product approved by the JSC, including any applicable Global Payer Plan and country specific Access and Pricing Plan.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Bundle&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means any Product sold together with another pharmaceutical compound for a single price, including combination products or more than one product sold together.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;cGMP&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in the applicable Quality Agreement.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Collaboration Review Committee&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;CRC&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the review committee established pursuant to Article 2 (Scope and Governance).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Collaboration Profit (Loss)&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 7.2.8 (Calculation of Profit (or Loss)).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Collaboration Scope&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means, with respect to a particular Product, any and all uses of such Product in the applicable Collaboration Territory.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Collaboration Territory&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the world, except for the Excluded Territory for AMG557 and AMG827. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Commercialization Budget&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 2.4.1.3.  An initial Commercialization Budget for each Product will be approved by the JSC not later than three (3) months after initiation of the first Phase 3 Trial for such Product.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Commercial Lead&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 5.2 (Commercial Lead).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Commercially Reasonable Efforts&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means, with respect to activities of a Party related to a Product under this Agreement, the efforts and resources typically used by that Party in the conduct of such activities with respect to products of comparable market potential, taking into account all relevant factors including, as applicable, stage of development, efficacy and safety relative to competitive products in the marketplace, actual or anticipated Governmental Authority approved labeling, the nature and extent of market exclusivity (including patent coverage and regulatory exclusivity), and cost and likelihood of obtaining Regulatory Approval.  For purposes of clarity, Commercially Reasonable Efforts will be determined on a country-by-country basis within the Collaboration Territory, and it is anticipated that the level of effort may be different for different countries and may change over time, reflecting changes in the status of a Product and the country(ies) involved.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.31.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Competing Product&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 5.9 (Competing Products).</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.32.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Confidential Information&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 11.1 (Confidentiality&#59; Exceptions).</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.33.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Continued Development Meeting&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means on a Product-by-Product basis, a meeting of the JSC to be held promptly following the completion of the Stage 1 Clinical Trial(s) for such Product, in which the JSC will discuss plans for the next phase of development of each such Product.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.34.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Contract Interest Rate&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means &#91;*&#93;, plus the thirty (30) day U.S. Dollar LIBOR rate effective for the date that payment was due, as published by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">The Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Eastern U.S. Edition, on the date such payment was due (or, if unavailable on such date, the first date thereafter on which such rate is available), or, if lower, the maximum rate permitted by Applicable Law.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.35.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Copyright&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means all right, title, and interest in and to all copyrightable works and any copyright registration or corresponding legal right.  </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.36.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Costs&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means both internal and external costs and expenses (including the cost of allocated FTEs at the FTE Rate).</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.37.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Country Plans&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 5.1 (Allocation of Commercial Responsibility).</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.38.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Critical Matters&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means (A)&#160;all decisions made by the CRC, JSC and JPTs that, in the reasonable opinion of either Party, are likely to have any of the following impacts&#58;  (i) &#91;*&#93; under a Development Plan or Brand Plan&#59; (ii)&#160;a change to a Development Plan or Brand Plan that results in the lesser of (a)&#160;an increase of &#91;*&#93; or more (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that such amount is at least &#91;*&#93;) and (b)&#160;&#91;*&#93; or more, in each case, to the then-current budgeted amount of Development Costs and&#47;or General Costs for any specific calendar year under the applicable Development Budget, Operations Budget or Commercialization Budget or the amounts estimated under Sections 7.2.1 (Partner Costs) and 7.2.2 (Amgen Costs)&#59; (iii)&#160;a change to a Development Plan or Brand Plan </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that results in a decrease of &#91;*&#93; (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that such amount is at least &#91;*&#93;) or more to the then-current budgeted amount of Development Costs and&#47;or  General Costs for any specific calendar year under the applicable Development Budget, Operations Budget or Commercialization Budget or the amounts estimated under Sections 7.2.1 (Partner Costs) and 7.2.2 (Amgen Costs)&#59; or (iv)&#160;a change to a Development Plan (including any plans with respect to a contemplated Regulatory Approval set forth therein) or Brand Plan that would, based upon &#91;*&#93;, result in &#91;*&#93; of a Product for any specific calendar year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under the applicable Development Plan or Brand Plan&#59; (B)&#160;agreement of the initial Commercialization Budget for each Product&#59; (C)&#160;agreement of the initial Brand Plan (or material updates thereto reflecting the launch of a new indication), Global Payer Plan and any Access and Pricing Plan for each Product&#59; and (D)&#160;deadlocks with respect to the approval of an annual Development Budget, Operations Budget or Commercialization Budget as provided for under Section 7.7 (Budget Deadlocks).    </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.39.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Defending Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 13.4 (Defense of Third Party Claims).</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.40.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Designated Amgen Activities&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means those development, regulatory, manufacturing, access and commercial activities for which Amgen is responsible pursuant to this Agreement, including such activities allocated to it by any of the committees and teams established under this Agreement.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.41.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Designated Partner Activities&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means those development, regulatory, manufacturing, access and commercial activities for which Partner is responsible pursuant to this Agreement, including such activities allocated to it by any of the committees and teams established under this Agreement.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.42.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Designated Regulatory Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 3.2.1 (Designated Regulatory Party).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.43.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Detail&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means an interactive face-to-face visit by a sales representative with a medical professional having prescribing authority or who is able to influence prescribing decisions, within the target audience during which approved uses, safety, effectiveness, contraindications, side effects, warnings or other relevant characteristics of a pharmaceutical product are discussed in an effort to increase prescribing preferences of a pharmaceutical product for its approved uses.  Detail includes First Position Details, Second Position Details and Other Details.  Details will not include (i)&#160;activities conducted by medical support staff (such as medical science liaisons) or (ii)&#160;E-details, activities conducted at conventions or similar gatherings and activities performed by market development specialists, managed care account directors and other personnel not performing face-to-face sales calls or not specifically trained with respect to a pharmaceutical product.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Detailing&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the act of performing Details and to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> &#8220;Detail&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means to perform Details.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.44.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Development Budget&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 2.4.1.1.  The initial Development Budgets will be agreed in writing by the Parties as soon as reasonably practicable on or after the Effective Date. </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.45.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Development Costs&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means with respect to all Products&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.45.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">all Costs associated with obtaining, maintaining and renewing Regulatory Filings and Regulatory Approvals pertaining to a Product in accordance with the applicable Development Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.45.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">all Costs incurred by the Parties or their respective Affiliates in performing activities designated to the Parties under the applicable Development Plan, as applicable (including the Costs of clinical trials and related support to obtain marketing approval for a Product and other lifecycle management activities as well as Phase 4 Trials, development of related devices, observational research </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and any economic value evidence generation in support of reimbursement activities such as health technology assessment submissions)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.45.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">all manufacturing Costs not otherwise included in Manufacturing Standard Cost or Manufacturing Actual Costs, including stability testing and other CMC support costs for such Products, Costs relating to the development of manufacturing processes, scale-ups, validations and technology transfers for Products&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.45.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">for any clinical supply of Products, (i) the Manufacturing Standard Cost, if it is manufactured in the Manufacturing Lead&#8217;s (or its designee&#8217;s) clinical manufacturing facility, or (ii)&#160;all Manufacturing Actual Costs, if it is manufactured in the Manufacturing Lead&#8217;s (or its designee&#8217;s) non-clinical (i.e., commercial) manufacturing facility&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.45.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">all Costs for other materials (such as non-Party comparator drugs and placebo) obtained for use in clinical trials of or related to a Product&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.45.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">all Costs associated with engineering, conformance, or other manufacturing activities required to achieve commercial scale production of a Product, CMC filing requirements, and the like not otherwise included in Manufacturing Actual Costs for such Product.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All to the extent incurred after the Effective Date.  For clarity, Development Costs are exclusive of and do not include General Costs.  Except to the extent already included in overhead, Development Costs shall not include either Party&#8217;s Costs to the extent they solely relate to legal, accounting, finance or alliance management activities associated with overseeing execution of and compliance with this Agreement.  </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.46.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Development Lead&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 3.1.2 (Development Lead).</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.47.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Development Plan&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the plan approved by the JSC for each Product (which plan will be updated annually and will cover a period of at least &#91;*&#93; years) covering&#58; (i)&#160;the research and development (including Phase 4 Trials) of the Products in the Collaboration Scope, including observational research and payer evidence generation including economic value&#59; (ii)&#160;the preparation and submission of Regulatory Filings&#59; and (iii) the obtaining, maintenance or expansion of Regulatory Approvals of the Products in the Collaboration Scope.  The initial Development Plans covering calendar years &#91;*&#93; will be agreed in writing by the Parties as soon as reasonably practicable on or after the Effective Date.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.48.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Distracting Product&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means, with respect to a given Product, any product, &#91;*&#93;, directed at &#91;*&#93; the Product Target or any Distracting Target &#91;*&#93;.  For clarity, a &#91;*&#93; antibody that binds to &#91;*&#93; shall be a Distracting Product unless the Parties agree otherwise.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.49.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Distracting Program&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the clinical development, manufacture or commercialization (including Detailing, selling, promoting or distributing) of any Distracting Product.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.50.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Distracting Target&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth on the Distracting Product Schedule.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.51.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Distracting Transaction&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means any transaction entered into by a Party or its Affiliates on or after the Effective Date whereby a Third Party that is engaged in a Distracting Program becomes an Affiliate of a Party or any of its Affiliates.  </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.52.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Distracting Transaction Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 9.3.3 (Inclusion).</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.53.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Distribution Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 4.4 (All Sales by Distribution Party).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.54.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Divest&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means, with respect to any Distracting Program, the sale, exclusive license or other transfer of all right, title and interest in and to such Distracting Program, including technology, intellectual property and other assets materially relating thereto, to a Third Party, without the retention or reservation of any rights or interest (other than an economic interest, reversion rights or other similar rights typical of a licensor in an exclusive license agreement) in such Distracting Program by such Party or its Affiliates.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.55.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Early Stage Programs&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 4.1 (Allocation of Manufacturing Responsibility).</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.56.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Effective Date&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.57.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Europe&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means those countries, nations, states or other territories under the jurisdiction of the European Medicines Agency (or any successor agency thereto), as such jurisdiction may change from time to time, and Iceland, Liechtenstein, Norway and Switzerland.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.58.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Excluded Territory&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (i) with respect to AMG557, Japan, and (ii) with respect to AMG827, all countries not included within the AMG827 Territory. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.59.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Excluded Territory Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means (i)&#160;in relation to AMG827, the AMG827 Technology Transfer Agreement by and among Kyowa Hakko Kirin Co., Ltd., Amgen and Kirin-Amgen, Inc., the Research, Development and Technology Disclosure Agreement&#58; AMG827 by and among Kyowa Hakko Kirin Co., Ltd., Amgen and Kirin-Amgen, Inc., and the AMG827 License Agreement between Kirin-Amgen, Inc., all dated October 29, 2010 and (ii) in relation to AMG557, means the License Agreement by and between Amgen and Takeda Pharmaceutical Company Limited dated February 1, 2008, in each case as the same have been amended and may be amended from time to time hereafter in accordance with terms of this Agreement.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.60.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;First Position Detail&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a Detail in which the applicable pharmaceutical product is Detailed before any other product and&#47;or the predominant portion of time is devoted to the Detailing of such pharmaceutical product.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.61.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Force Majeure&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 15.7 (Force Majeure).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.62.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;FTE&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;means, with respect to a person (other than an employee that Details a Product), the equivalent of the work of one (1) employee full time for one (1) year (consisting of at least a total of &#91;*&#93; weeks or &#91;*&#93; hours per year (excluding vacations and holidays)).&#160; Overtime, and work on weekends, holidays and the like &#91;*&#93; be counted &#91;*&#93; toward the number of hours that are used to calculate the FTE contribution.  For an employee that Details a Product, FTEs will be calculated as set forth in Section 7.2.11 (Calculation of Sales Force Costs).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.63.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;FTE Rate&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;means, for the period commencing on the Effective Date until such time as the Parties agree otherwise, (i)&#160;&#91;*&#93; for activities conducted in the U.S., and (ii)&#160;for all other geographic locations &#91;*&#93; multiplied by a cost of living adjustment between the U.S. and such other geographic location as set forth in the then most current edition of &#91;*&#93; (or in the event such geographic location is not listed, the nearest listed geographic location that is most comparable to such non-listed geographic location).  The FTE Rate will be increased by &#91;*&#93;.  The FTE Rate shall include costs of salaries, benefits, supplies, other employee costs, facility costs, depreciation and supporting general and administration allocations.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.64.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;GAAP&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the then-current generally accepted accounting principles in the United States as established by the Financial Accounting Standards Board or any successor entity or other entity generally recognized as having the right to establish such principles in the United States, in each case consistently applied.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.65.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;General Costs&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means with respect to all Products&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.65.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">all Costs, other than Amgen Sales Force Costs and Partner Sales Force Costs, associated with activities related to the commercialization of Products, including&#58; sales, pricing, access, coverage (including risk sharing arrangements), reimbursement, presentation, purchase of ancillary items or devices, contracting, launch timing, distribution, marketing messaging, product positioning, development of training materials, sales tracking and auditing, market research and product usage surveys, provision of medical affairs support staff, and scientific and medical advisory boards (including any global medical conferences)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.65.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">all Amgen Sales Force Costs and Partner Sales Force Costs incurred in accordance with the Brand Plan and calculated in accordance with Section 7.2.11 (Calculation of Sales Force Costs)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.65.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">all training Costs incurred in accordance with Section 5.5 (Training)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.65.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">all defense, enforcement and cooperation Costs incurred within or materially related to the Collaboration Scope in accordance with Section 10.7 (Defense and Settlement of Third Party Claims), Section 13.4 (Defense of Third Party Claims) and Section 10.8 (Enforcement) (&#91;*&#93;)&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.65.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">all Costs with respect to product liability claims for Products in the Collaboration Scope &#91;*&#93;&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.65.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">all Costs associated with any recalls, returns and withdrawals of a Product in the Collaboration Scope (&#91;*&#93;)&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.65.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">all Costs incurred in connection with Prosecution and Maintenance of Amgen Intellectual Property and Program Intellectual Property in accordance with Section 10.6 (Prosecution and Maintenance) within or materially related to the Collaboration Scope&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.65.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">all Manufacturing Actual Costs for any samples of Products provided in the Collaboration Scope&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.65.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">for any commercial supply of Products, all Manufacturing Actual Costs for Products sold&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.65.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33pt">all manufacturing Costs not otherwise included in Manufacturing Actual Costs, including stability testing and other CMC support costs for such Products, but only to the extent such costs are not included in Development Costs under Section 1.45.3&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.65.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33pt">any amounts paid by either Party to Third Parties for rights to manufacture, use or sell a Product in or for the Collaboration Scope to the extent not already included in Manufacturing Actual Costs&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that &#91;*&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All to the extent incurred after the Effective Date.  For clarity, General Costs are exclusive of and do not include Development Costs.  Except to the extent already included in overhead, General Costs shall not include either Party&#8217;s Costs to the extent they solely relate to legal, accounting, finance or alliance management activities associated with overseeing execution of and compliance with this Agreement.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.66.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Global Payer Plan&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the global plan for a Product approved by the JSC that sets forth the strategic direction, positioning, value proposition and reimbursement for such Product.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.67.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Governmental Authority&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means any government or supranational administrative agency, commission or other governmental or supranational authority, body or instrumentality, or any federal, state, local, domestic or foreign governmental or supranational regulatory body.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.68.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Government Official&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means (i)&#160;any Person employed by or acting on behalf of a Governmental Authority&#59; (ii)&#160;any political party, party official or candidate&#59; (iii)&#160;any Person who holds or performs the duties of an appointment, office or position created by custom or convention&#59; and (iv)&#160;any Person who holds himself out to be the authorized intermediary of any of the foregoing.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.69.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Housemarks&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the Amgen Housemarks or the Partner Housemarks, as the case may be.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.70.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;IFRS&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the then-current International Financial Reporting Standards, consistently applied.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.71.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Indemnified Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 13.3 (Claim for Indemnification).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.72.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Indemnifying Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 13.3 (Claim for Indemnification).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.73.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Indirect Taxes&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means VAT, sales taxes, consumption taxes and other similar taxes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.74.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Infringement Claim&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 10.7 (Defense and Settlement of Third Party Claims of Infringement).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.75.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Invention&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means any idea, concept, discovery, invention, improvement or trade secret.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.76.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Inventorship Margin&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 7.2.8.2 (Profit).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.77.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Joint Claim&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 13.4 (Defense of Third Party Claims).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.78.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Joint Product Team&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;JPT&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the individual Product teams established pursuant to Article 2 (Scope and Governance).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.79.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Joint Steering Committee&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;JSC&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the steering committee established pursuant to Article 2 (Scope and Governance).</font></div><div><font><br></font></div><div style="margin-bottom:0.06pt;margin-top:0.06pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.80.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Key Regulatory Filings&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means any (i)&#160;Investigational New Drug Application (or similar filing outside the United States)&#59; (ii)&#160;Biologic Licensing Application (or similar filing outside the United States)&#59; (iii)&#160;briefing books&#59; and (iv)&#160;any other Regulatory Filing designated a Key Regulatory Filing by written agreement of the Parties.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.81.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Know-How&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means all tangible and intangible techniques, information, technology, practices, trade secrets, Inventions (whether patentable or not), methods, processes, knowledge, know-how, conclusions, skill, experience, test data and results (including pharmacological, toxicological, manufacturing, and clinical test data and results), regulatory documentation, analytical and quality control data, results or descriptions, software and algorithms, including works of authorship and Copyrights, and materials, including biological materials, compositions and the like.  Know-How does not include Patents, Product Trademarks, Amgen Housemarks, Partner Housemarks, or Program Patents and Trademarks.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.82.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Losses&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 13.1 (Indemnity by Partner).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.83.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Manufacturing Actual Costs&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means (i)&#160;&#91;*&#93;.  Manufacturing Actual Costs will be calculated consistently with other products manufactured by the Manufacturing Lead </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and in accordance with GAAP or IFRS, as applicable.  For clarity, in the event that the Manufacturing Lead uses a contract manufacturer to perform any manufacturing activities under this Agreement, Manufacturing Actual Costs for such activities will be the price the Manufacturing Lead pays such contract manufacturer for such activities, plus the Costs to manage and to process materials obtained from such contract manufacturer. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.84.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Manufacturing Lead&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 4.2 (Manufacturing Lead).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.85.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Manufacturing Standard Costs&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means, with respect to a Product, &#91;*&#93;.  For clarity, (i)&#160;where Amgen is the Manufacturing Lead, Amgen&#8217;s internal clinical standard cost methodology for clinical product &#91;*&#93;, and (ii) in the event that the Manufacturing Lead uses a contract manufacturer to perform any manufacturing activities under this Agreement, Manufacturing Standard Cost for such activities will be the price the Manufacturing Lead pays such contract manufacturer for such activities, plus the Costs to manage and to process materials obtained from such contract manufacturer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.86.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Material Anti-Corruption Law Violation&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means a violation of an Anti-Corruption Law relating to the subject matter of this Agreement which would if it were publicly known, in the reasonable view of a Party, have a material adverse effect on it or on its reputation because of its relationship with the other Party.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.87.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Medarex Agreement&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means that certain Research and Commercialization Agreement by and among Medarex, Inc., GenPharm International, Inc. and Amgen dated as of December 23, 2002. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.88.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;&#91;*&#93;&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means Partner&#8217;s proprietary antibody &#91;*&#93; that is currently in clinical development.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.89.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Net Revenues&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means&#58;  (i) the aggregate of the gross invoiced sales prices for Products that are sold or transferred for value by either Party or their respective Affiliates to Third Parties in the Collaboration Territory, minus the following amounts incurred or paid (each as recognized by GAAP or IFRS, as applicable, and each to the extent not already deducted when calculating Manufacturing Actual Costs) by such selling Party or its Affiliates with respect to such sales or transfers for value (regardless of the period in which such amounts are incurred or paid)&#58; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.89.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">trade, cash, prompt payment or quantity discounts&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.89.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">payments to Governmental Authorities, returns, refunds, allowances, rebates and chargebacks&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.89.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">retroactive price reductions applicable to sales of such Product&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.89.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">fees paid to distributors, wholesalers, selling agents (excluding any sales representatives of a Party or any of its Affiliates), group purchasing organizations and managed care entities&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.89.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">the standard inventory cost (actual acquisition or manufacture cost) of devices used for dispensing or administering such Product that are shipped with such Product and included in the gross invoiced sales prices&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.89.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">credits or allowances for product replacement, whether cash or trade&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.89.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">any tax, tariff, duty or governmental charge levied on the sales, transfer, transportation or delivery of such Product (including any tax such as a value added or similar tax or government charge), other than franchise or income tax of any kind whatsoever&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.89.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">&#91;*&#93;&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.89.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">&#91;*&#93;&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.89.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33pt">any import or export duties or their equivalent borne by the relevant seller&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">plus (ii) any Recoveries made pursuant to Section 10.8 (Enforcement).</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.90.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Non-Suspending Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 7.8 (Program Recommitment).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.91.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;North America&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the United States and Canada.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.92.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;&#91;*&#93;&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 7.2.8.1.2 (Quarterly Cap).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.93.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Operations Budget&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 2.4.1.2. The initial Operations Budgets will be agreed in writing by the Parties as soon as reasonably practicable on or after the Effective Date.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.94.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Other Detail&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means any Detail other than a First Position Detail or a Second Position Detail.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.95.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Out-License Election&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 7.8.2.4 (Out-License).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.96.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Partner&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.97.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Partner Costs&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 7.2.1 (Partner Costs).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.98.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Partner Housemarks&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (i) the corporate logo of Partner, (ii) the trademark &#8220;AstraZeneca&#8221; and &#8220;MedImmune&#8221;, (iii) any other trademark, trade name or service mark (whether registered or unregistered) containing the word &#8220;AstraZeneca&#8221; or &#8220;MedImmune&#8221;, and (iv) any other trademark or service mark associated with goods or services of Partner or its Affiliates, but excluding the Product Trademarks and trademarks, trade names or service marks associated with goods or services outside the scope of this Agreement&#59; and all intellectual property rights residing in any of the foregoing.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.99.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:12pt">&#8220;Partner Indemnitees&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 13.2 (Indemnity by Amgen).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.100.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Partner Intellectual Property&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means any Know-How, Patents, electronic media registrations (including domain names, usernames, websites, blogs and the like), or Copyright controlled by Partner or its Affiliates that is used (but is not generated or conceived) during the Term by either Party or its Affiliates in the performance of this Agreement.  Partner Intellectual Property specifically excludes Program Intellectual Property.  </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.101.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Partner Sales Force Costs&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the allocable share of Partner&#8217;s (or its Affiliates&#8217;) costs for sales representatives that Detail Products in the Collaboration Scope in accordance with this Agreement, calculated in accordance with Section 7.2.11 (Calculation of Sales Force Costs).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.102.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Party&#8221; or &#8220;Parties&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.103.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Party Representatives&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 12.3.3.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.104.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Patent Coordinator&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means those employees of each of the Parties appointed pursuant to Section 2.10 (Patent Coordinators) to serve as each such Party&#8217;s primary liaison with the other Party on matters relating to intellectual property as described in this Agreement.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.105.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Patent Extensions&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 10.9 (Patent Term Extensions). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.106.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Patents&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the issued patents and pending patent applications (including certificates of invention, applications for certificates of invention and priority rights) in any country or region, including all provisional applications, refilings, substitutions, continuations, continuations-in-part, divisions, renewals, all letters patent granted thereon, and all reissues, re-examinations and patent term extensions thereof, and all international or foreign counterparts of any of the foregoing (including supplemental protection certificates, patents of addition and the like).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.107.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Person&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means an individual, corporation, partnership, limited liability company, limited partnership, trust, business trust, association, joint stock company, joint venture, pool, syndicate, &#8220;group&#8221; as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, sole proprietorship, unincorporated organization, Governmental Authority or any other form of entity not specifically listed herein.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.108.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Phase 1 Trial&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a clinical trial of a pharmaceutical product that meets the definition of a Phase 1 study for the United States as described in 21 C.F.R. &#167;312.21(a), or its successor regulation, or the equivalent regulation in any other country, including the Phase 1 part of any clinical trial that is a combination Phase 1 Trial and Phase 2 Trial.  A </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Phase 1(b) Trial&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means a Phase 1 Trial that is designed to demonstrate evidence of clinical impact.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.109.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Phase 2 Trial&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a clinical trial of a pharmaceutical product that meets the definition of a Phase 2 study for the United States as described in 21 C.F.R. &#167;312.21(b), or its successor regulation, or the equivalent regulation in any other country.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.110.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Phase 3 Trial&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a clinical trial of a pharmaceutical product that meets the definition of a Phase 3 study for the United States as described in 21 C.F.R. &#167;312.21(c), or its successor regulation, or the equivalent regulation in any other country.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.111.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Phase 4 Trial&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means any clinical study initiated in the Collaboration Territory for a Product following the first Regulatory Approval for the sale of such Product in the Collaboration Scope for the indication being studied.  Phase 4 Trials may include epidemiological studies, modeling and pharmacoeconomic studies, and post-marketing surveillance studies, as well as any clinical study or research study sponsored and conducted by an individual not employed by or on behalf of either Party.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.112.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Product&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means any pharmaceutical product containing one of the pharmaceutical compounds listed on the Products Schedule &#91;*&#93;.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.113.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Product Intellectual Property&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means Amgen Intellectual Property, Partner Intellectual Property, and Program Intellectual Property.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.114.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Product Target&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;has the meaning set forth on the Distracting Product Schedule.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.115.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Product Trademarks&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means any trademark, trade name or service mark (whether registered or unregistered) selected by the JPT for use on, with, or to refer to a Product (other than Amgen Housemarks and Partner Housemarks, as applicable) or used with patient support or other information or services or Promotional Materials associated with a Product in the Collaboration Territory during the Term, and all intellectual property rights residing in the foregoing.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.116.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Program Intellectual Property&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means any Know-How, Patents, Product Trademark, trademark application, electronic media registrations (including domain names, usernames, websites, blogs and the like), or Copyright generated or conceived by Amgen, Partner or their respective Affiliates, whether solely or jointly (or together with a Third Party), during the Term as a result of carrying out the Designated Amgen Activities or the Designated Partner Activities, as applicable.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.117.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Program Notice&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 9.4 (Pre-Clinical Research and Development Programs).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.118.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Program Patents and Trademarks&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 10.6.3 (Program Intellectual Property).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.119.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Promotional Materials&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 5.7 (Promotional Materials).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.120.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Prosecution and Maintenance&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the preparation, filing, and prosecution of patent applications and maintenance of patents, as well as re-examinations and reissues with respect to such patents, together with the conduct of interferences, post&#8211;grant proceedings (including without limitation post-grant review, inter-partes review, and derivation proceedings in the U.S.) and the defense of oppositions with respect to such patent application or patent&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Prosecute and Maintain&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the correlative meaning.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.121.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Quarterly Cap&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 7.2.8.1.2 (Quarterly Cap).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.122.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Quality Agreement&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means that certain Quality Agreement dated as of the date hereof between the Parties (and substantially in the form attached hereto as the Quality Agreement Schedule) regarding the clinical use of Products manufactured by Amgen, and any subsequent quality agreements between the Parties related to Products supplied pursuant to this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.123.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Recoveries&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means all monies received by either Party from a Third Party in connection with the final, non-appealable judgment (or judgment with respect to which the time period for appeal has expired), award or settlement of any enforcement with respect to any Product Intellectual Property, to the extent such judgment, award or settlement pertains to activities within the Collaboration Scope. </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.124.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Re-Entry Notice&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 7.8.2.1 (Re-Entry Period).</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.125.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Re-Entry Period&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 7.8.2.1 (Re-Entry Period).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.126.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Regulatory Approval&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means an approval for a Product from a Governmental Authority necessary for the research, development, manufacture, distribution, pricing, reimbursement, marketing or sale of such Product.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.127.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Regulatory Filing&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means any filing with any Governmental Authority with respect to the research, development, manufacture, distribution, pricing, reimbursement, marketing or sale of a Product.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.128.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Reimbursed Development Costs&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means any Development Costs incurred by either Party for which Amgen is entitled to reimbursement from a Third Party pursuant to the Excluded Territory Agreements&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that &#91;*&#93; shall not be a Reimbursed Development Cost. </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.129.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Researching Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 9.4 (Pre-Clinical Research and Development Programs).</font></div><div><font><br></font></div><div style="margin-bottom:0.06pt;margin-top:0.06pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.130.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Safety Agreement&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means that certain Safety Agreement to be entered into between the Parties within ninety (90) days of the Effective Date regarding adverse event reporting with respect to Products manufactured by Amgen, and any subsequent safety agreements between the Parties related to Products supplied pursuant to this Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.131.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Second Position Detail&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a Detail in which the applicable pharmaceutical product is Detailed in the second position (i.e., no more than one (1) other product is presented to or discussed with the healthcare professional before such Product) and&#47;or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the second most predominant portion of time is devoted to the Detailing of such pharmaceutical product.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.132.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Segregate&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means, with respect to two (2) programs&#58; (i) to restrict and prevent all program-related contacts and communications between personnel (whether employees, consultants, Third Party contractors or otherwise and whether or not located within the Collaboration Territory (for the purposes of this definition, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Personnel&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">)) working on or involved with the development or commercialization of the first program and Personnel working on or involved with the development or commercialization of the second program&#59; (ii) to ensure that Personnel that are working on the first program will not simultaneously work on the second program and vice versa&#59; (iii) to ensure that confidential information relating to the first program is not shared with or accessed by Personnel that are working on the second program and vice versa&#59; and (iv)&#160;from time-to-time, upon the reasonable request of the other Party, to provide information requested relating to the foregoing items (i) through (iii), and to reasonably cooperate to enable the other Party to verify that such restrictions are in place and sufficient to achieve the foregoing.  For clarity, &#91;*&#93; as set forth herein.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.133.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Specifications&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in the applicable Quality Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.134.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Stage 1 Clinical Trial&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means, with respect to each Product, the trial or trials set forth in the Stage 1 Clinical Trial Schedule.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.135.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Stage 2 Clinical Trial&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means, with respect to each Product, the trial or trials mutually agreed upon by the Parties at such time either Party provides a Suspension Election with respect to such Product under Section 7.8.1.1 (Suspension Election) (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that if the Parties are unable to agree upon such trial or trials, then Stage 2 Clinical Trial shall be deemed to be first study in the next phase of development (i.e., the first Phase 3 Trial if the Stage 1 Clinical Trial was a Phase 2b Trial, the first Phase 2b Trial if it were a Phase 2a Trial, the first Phase 2a Trial if it were a Phase 1b Trial, etc.).</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.136.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Sublicensing Revenue&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means with respect to any Terminated Products, all cash payments (and the fair market value of all non-cash consideration) received by the Continuing Party and&#47;or any of its Affiliates from any Third Party in consideration for a transaction, series of transactions or other arrangement in which such Third Party obtains a license (or sublicense) of the Product Intellectual Property (or any option or other right to obtain a license of the Product Intellectual Property), including, without limitation, up-front payments, milestones, royalties, and research funding (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that with respect to research funding payments, only the amounts in excess of the Continuing Party&#8217;s external costs and internal costs directly related to such research activities will be included). </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.137.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Suspending Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 7.8 (Program Recommitment).</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.138.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Suspension Election&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 7.8.1.1 (Suspension Election).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.139.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Taxes&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means any tax, excise or duty, other than taxes and withholdings upon income. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.140.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Technical Feasibility&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means, with respect to any Product manufactured, the first date on which, in the good-faith determination of the Manufacturing Lead, there is a high probability that (i)&#160;such related Product candidates will obtain Regulatory Approval for the sale of such Product candidate and (ii)&#160;the related costs will be recoverable through the commercialization of such manufactured Product.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.141.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Term&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the period commencing on the Effective Date and continuing in perpetuity, unless and until</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">earlier terminated pursuant to any provision of this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.142.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Termination Election&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 7.8.1.4 (Subsequent Termination).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.143.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Third Party&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means any Person that is not a Party, or an Affiliate of a Party.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.144.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Third Party Claim&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means any claim, action, lawsuit, or other proceeding brought by any Third Party.  Third Party Claim includes any Infringement Claim.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.145.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Total Costs&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means all General Costs, Unreimbursed Development Costs and Reimbursed Development Costs. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.146.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;United States&#8221; or &#8220;U.S.&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the United States of America and its territories and possessions.  </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.147.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Unreimbursed Development Costs&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means any Development Costs incurred by either Party for which Amgen is not entitled to reimbursement from a Third Party pursuant to the Excluded Territory Agreements&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that &#91;*&#93; shall be an Unreimbursed Development Cost.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.148.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;VAT&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the tax imposed by Council Directive 2006&#47;112&#47;EC of the European Community and any national legislation implementing that directive together with legislation supplemental thereto and in particular, in relation to the United Kingdom, the tax imposed by the Value Added Tax Act of 1994 or other tax of a similar nature imposed in other countries in the Collaboration Territory.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.149.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6pt">&#8220;Withholding Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> has the meaning set forth in Section 8.6.1 (Withholding).</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">SCOPE AND GOVERNANCE</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Purpose of the Collaboration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The purpose of the collaboration is for the Parties to collaborate in the development, manufacture and commercialization of the Products and for the Parties to share in certain costs and revenues related to the Products, all as described in more detail herein.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Ex-Territory Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">No Rights in Excluded Territory.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties acknowledge that no rights are granted hereunder to Partner with respect to the applicable Product in any country in the Excluded Territory, and that Partner will have no authority with respect to the research, development, manufacture or commercialization of such applicable Products in the Excluded Territory.  As between the Parties, Amgen or its licensees will have the sole right to research, develop, manufacture and commercialize such Products in the Excluded Territory.  Partner hereby acknowledges that (i)&#160;Amgen has previously licensed rights for AMG557 in Japan to Takeda Pharmaceutical Company Limited, and (ii)&#160;Amgen obtained its rights for AMG827 under license from Kirin-Amgen, Inc. and its right to develop, manufacture and commercialize AMG827 is subject to certain agreements between Amgen and Kirin-Amgen, Inc.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">License Grant by Partner.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent Amgen is required under any Excluded Territory Agreement to grant rights to a Third Party under any intellectual property rights, Know-How, Regulatory Filings or Regulatory Approvals with respect to a Product in the Excluded Territory, Partner hereby grants Amgen a license (with the right to sublicense) in and to any Partner Intellectual Property, Program Intellectual Property, Know-How, Regulatory Filings or Regulatory Approvals as necessary for Amgen to comply with its obligations under any such Excluded Territory Agreement. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Kirin-Amgen Royalty Payments.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Additionally, any royalties payable to Kirin-Amgen, Inc. with respect to AMG827 under an Excluded Territory Agreement shall be paid directly by Amgen and shared by the Parties in a manner consistent with Section 7.2.8.2 (Profit).  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Subsequent Rights in Excluded Territory.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Amgen obtains the right to develop and commercialize Products in all or part of the Excluded Territory, then, upon the request of Partner (made no later than sixty (60) days following receipt of written notice from Amgen regarding such Excluded Territory rights), Amgen and Partner will enter into good faith discussions for the inclusion of such rights under this Agreement on terms to be agreed by Parties (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that if the Parties are unable to agree upon such terms within &#91;*&#93; of the initiation of such discussions, Amgen shall be free to develop and commercialize Products in such Excluded Territory itself or with a Third Party).  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Prior Consultation.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Amgen will consult with Partner in advance with respect to&#58; (i)&#160;&#91;*&#93;&#59; (ii)&#160; &#91;*&#93;&#59; and (iii)&#160;&#91;*&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Committees and Teams</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Formation.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Promptly but not later than sixty (60) days following the Effective Date, the Parties will establish (i)&#160;a single, cross-functional Collaboration Review Committee&#59; (ii)&#160;a single, cross-functional Joint Steering Committee&#59; and (iii)&#160;a cross-functional Joint Product Team for each Product.  The JSC and each JPT will each have the right to establish subcommittees or working teams with respect to issues within its area of responsibility as it sees fit (e.g., development, regulatory, pricing, access, manufacturing, commercial or operations), including </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">local or regional commercialization&#47;operations teams to facilitate the performance of its responsibilities or a finance team to facilitate the implementation of the cost allocations provided in this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Membership.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The CRC will be comprised of three (3) members appointed by each of the Parties or such other number of members as agreed by the Parties (with representatives from each Party for each of development, manufacturing and commercialization).  The JSC will be comprised of five (5) members appointed by each of the Parties or such other number of members as agreed by the Parties.  The CRC and JSC will each be led by two (2) co-chairs, one (1) appointed by each of the Parties.  Each Party will designate such number of members to each JPT as it deems appropriate in order to accomplish the activities for which it is responsible.  Each Party will ensure that the CRC, JSC and JPT members appointed by it have (i)&#160;the appropriate level of seniority and decision-making authority commensurate with the responsibilities of the committee or team to which they are appointed, and (ii)&#160;a range of expertise in the development, manufacture and commercialization of therapeutic products to enable an efficient cross-functional committee or team structure.  Each Party will have the right to replace its committee or team members by written notice to the other Party.  In the event any committee or team member becomes unwilling or unable to fulfill his or her duties hereunder, the Party that appointed such member will promptly appoint a replacement by written notice to the other Party.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Meetings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The CRC will meet semi-annually, via teleconference or videoconference or otherwise (with at least one (1) meeting per calendar year being in person), or as otherwise agreed by the Parties.  Additionally, either Party may request a meeting of the CRC to resolve any Critical Matters requiring resolution.  The JSC will meet quarterly, via teleconference or videoconference or otherwise (with at least one (1) meeting per calendar year being in person and with at least one (1) meeting per calendar year being scheduled as appropriate to approve &#91;*&#93;), or as otherwise agreed by the Parties.  Each JPT and each subcommittee and working team established hereunder will establish a meeting frequency and meeting protocol necessary to coordinate and conduct the activities for which it is responsible, as agreed by the Parties.  Any in-person meetings of the CRC or JSC will be held on an alternating basis between Partner&#8217;s and Amgen&#8217;s headquarters, unless otherwise agreed by the Parties.  Each Party will be responsible for its own expenses relating to such meetings.  As appropriate, other employee representatives of the Parties may attend such meetings as non-voting participants, but no Third Party personnel may attend unless otherwise agreed by the Parties.  Either Party may also call for special meetings of the CRC and JSC as reasonably required to resolve a Critical Matter escalated to the CRC or JSC pursuant to Section 2.4.2 (JPT Deadlocks) or 2.5.2 (JSC Deadlocks) below&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the requesting Party provides at least ten (10) business days&#8217; prior written notice to the co-chair of such committee appointed by the other Party and such notice includes a proposed agenda for such meeting.  All committee and team meetings must have at least two (2) members appointed by each Party in attendance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All committee and team meetings will be conducted in English, and all documents (including Development Plans, Development Budgets, clinical trial protocols for the Products, Operations Budgets, Brand Plans and Commercialization Budgets) will be in English.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Decision-Making.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the terms of this Agreement (including Sections 2.4.2 (JPT Deadlocks) and 2.5.2 (JSC Deadlocks) below), the decisions of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CRC, JSC, JPTs and any subcommittees and working teams established hereunder will be made by consensus of the members thereof, with each Party having one (1) vote.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Joint Product Teams</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Responsibilities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Except for decisions expressly reserved to the JSC or CRC pursuant to Section 2.5 (Joint Steering Committee) or 2.6 (Collaboration Review Committee), respectively, each JPT will (i)&#160;establish subcommittees and working teams as necessary to coordinate and conduct its activities hereunder&#59; (ii)&#160;coordinate with and oversee the activities of any such subcommittees and working teams&#59; and (iii)&#160;be responsible for all operational matters regarding the development, manufacture and commercialization of the Products, including&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4.1.1.the following development matters&#58; (i) developing the Development Plan for the applicable Product in the Collaboration Territory and annual updates (or any other updates) thereto&#59; (ii)&#160;developing the &#91;*&#93; expense budget for development activities to be undertaken pursuant to the collaboration (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Development Budget&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) for such Product in the Collaboration Territory and annual updates (or any other updates) thereto&#59; (iii)&#160;preparing all clinical trial protocols for such Product&#59; (iv)&#160;providing for communication and discussion between the Parties to optimize the efficacy and safety of the development of such Product in the Collaboration Territory&#59; (v)&#160;reviewing and monitoring the activities and progress against the Development Plan, including regulatory matters, site enrollment, patient enrollment, progress of trials, data received and data analysis&#59; (vi)&#160;developing observational research and any payer and economic value evidence generation plans for inclusion in the Development Plan&#59; (vii)&#160;communicating with the Parties regarding all of the foregoing&#59; and (viii)&#160;making such decisions as are specified in Article 3 (Development and Regulatory) to be made by the JPT&#59;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4.1.2.the following operations matters&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;overseeing supply of the applicable Product (in accordance with the applicable Quality Agreement)&#59; (ii)&#160;reviewing cost of goods of such Product, including yields, success rates and other relevant production statistics&#59; (iii)&#160;preparing a draft supply forecast for such Product&#59; (iv)&#160;developing the &#91;*&#93; expense budget for manufacturing activities to be undertaken pursuant to the collaboration, including CMC, process development and device-related activities (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Operations Budget&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) for such Product in the Collaboration Territory and annual updates (or any other updates)  thereto&#59; (v)&#160;reviewing other operational issues relating to the manufacture or supply of such Product and any related devices&#59; and (vi)&#160;making such decisions as are specified in Article 4 (Manufacturing) to be made by the JPT&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4.1.3.the following commercialization matters&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;preparing the Brand Plan for the applicable Product and annual updates (or any other updates) thereto&#59; (ii)&#160;developing the &#91;*&#93; expense budget for commercialization activities to be undertaken pursuant to the Brand Plans and Country Plans (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Commercialization Budget&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) for such Product in the Collaboration Territory and annual updates (or any other updates) thereto&#59; (iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">preparing on an annual basis a three year sales forecast for such Product&#59; (iv)&#160;conducting consolidation of expense and sales forecasts from the country or regional level for such Product&#59; (v)&#160;reviewing the tactical alignment of commercialization activities with expense budget allocations&#59; (vi)&#160;monitoring and reporting on the competitive landscape </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for such Product in the Collaboration Territory&#59; (vii)&#160;establishing a process for reviewing and approving Promotional Materials and training materials and programs for such Product&#59; (viii)&#160;developing a global pricing policy for the applicable Product&#59; and (ix)&#160;making such decisions as are specified in Article 5 (Commercialization) to be made by the JPT.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">JPT Deadlocks.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If a JPT is unable to reach consensus on a non-Critical Matter, the decision will be made by the members of such JPT appointed by&#58; (i)&#160;the applicable Development Lead, in the case of matters under Section 2.4.1.1&#59; (ii)&#160;the applicable Manufacturing Lead, in the case of matters under Section 2.4.1.2&#59; and (iii)&#160;the applicable Commercialization Lead, in the case of matters under Section 2.4.1.3.  If a JPT is unable to reach consensus on a Critical Matter, the members of such JPT appointed by either Party will have the right to require that such issue be escalated to the JSC for determination&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that if, in the good faith determination of the Development Lead, the Manufacturing Lead or the Commercialization Lead, as applicable, resolution of such Critical Matter requires exigent action pursuant to Applicable Law or to prevent a material adverse effect on a Product or a Party, the members of such JPT appointed by the Development Lead, the Manufacturing Lead or the Commercialization Lead, as applicable, will have the right to make an interim decision pending JSC determination.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Responsibilities.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The JSC will (i)&#160;oversee the activities of the Parties hereunder generally, each Joint Product Team and any subcommittees or working teams established hereunder, (ii)&#160;establish subcommittees and working teams as necessary to coordinate and conduct its activities hereunder, and (iii)&#160;be responsible for&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5.1.1.the following development matters&#58; (i)&#160;approving the Development Plan for each Product in the Collaboration Territory and annual updates thereto&#59; (ii)&#160;approving the Development Budget for each Product in the Collaboration Territory and &#91;*&#93; updates thereto&#59; (iii)&#160;reviewing and approving all clinical trial protocols for the Products&#59; and (iv)&#160;making such decisions as are specified in Article 3 (Development and Regulatory) to be made by the JSC&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5.1.2.the following operations matters&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;approving the Operations Budget for each Product in the Collaboration Territory&#59; (ii)&#160;approving the draft supply forecast for each Product&#59; and (iii)&#160;making such decisions as are specified in Article 4 (Manufacturing) to be made by the JSC&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5.1.3.the following commercialization matters&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;approving the Brand Plans and integrating such plans with the Development Plans&#59; (ii)&#160;approving a global pricing policy for the applicable Product&#59; (iii)&#160;reviewing sales forecasts for each Product&#59; (iv) approving the Commercialization Budget for each Product in the Collaboration Territory&#59; and (v)&#160;making such decisions as are specified in Article 5 (Commercialization) to be made by the JSC. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">JSC Deadlocks.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If the JSC is unable to reach consensus on a non-Critical Matter, the decision will be made by the members of the JSC appointed by (i)&#160;the applicable Development Lead, in the case of matters under Section 2.5.1.1&#59; (ii)&#160;the applicable Manufacturing Lead, in the case of matters under Section 2.5.1.2&#59; and (iii)&#160;the applicable Commercialization Lead, in the case of matters under Section 2.5.1.3.  If the JSC is unable to reach consensus on a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Critical Matter, the members of the JSC appointed by either Party will have the right to require that such issue be escalated to the CRC for determination&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that if, in the good faith determination of the Development Lead, the Manufacturing Lead or the Commercialization Lead, as applicable, resolution of such Critical Matter requires exigent action pursuant to Applicable Law or to prevent a material adverse effect on a Product or a Party, the members of the JSC appointed by the Development Lead, the Manufacturing Lead or the Commercialization Lead, as applicable, will have the right to make an interim decision pending CRC determination.  </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Collaboration Review Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The CRC will be responsible for (i)&#160;providing general oversight of the collaboration&#59; (ii)&#160;resolving any matters specifically designated to it under this Agreement&#59; and (iii)&#160;resolving any Critical Matters escalated to it from the JSC.  For clarity, all decisions of the CRC will be made by consensus of the members of the CRC, with each Party having one (1) vote, unless expressly set forth in this Agreement to the contrary.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party will keep the applicable committee or team fully and promptly informed of progress and results of activities for which it is responsible or that it is permitted to conduct hereunder through its members on such committee or team and as otherwise provided herein.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">No Authority to Amend or Modify</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything herein to the contrary, no committee or team will have any authority to amend, modify or waive compliance with this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Promptly after the Effective Date, each Party will appoint a person who will oversee interactions between the Parties between meetings of the committees and teams established hereunder (each, an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Alliance Manager&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  The Alliance Mangers will have the right to attend all meetings of the CRC, the JSC, the JPTs and any subcommittees and working teams established hereunder, as non-voting participants at such meetings.  Each Party may in its sole discretion replace its Alliance Manager at any time by notice in writing to the other Party.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Patent Coordinators</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties will each appoint a Patent Coordinator for each Product promptly after the Effective Date.  The Patent Coordinators will serve as the primary contacts and forum for discussion between the Parties with respect to intellectual property matters involving each Product worldwide, and will cooperate with respect to the activities set forth in Article 10 (Intellectual Property).  For each Product, the associated Patent Coordinators will discuss a strategy with regard to Prosecution and Maintenance, defense and enforcement of Product Intellectual Property, and defense against allegations that the activities hereunder infringe, or obtaining or amending licenses to, Third Party Patents or Know-How.  The Patent Coordinators will meet as often as agreed by them (and at least semi-annually if requested), via teleconference or videoconference or as otherwise agreed, to discuss matters arising out of the activities set forth in Article 10 (Intellectual Property).  Each Party may in its sole discretion replace any of its Patent Coordinators at any time by notice in writing to the other Party.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">DEVELOPMENT AND REGULATORY</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Development Matters.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Allocation of Development and Regulatory Responsibility.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The JSC will (i)&#160;allocate development and regulatory activities to Amgen or Partner on a country-specific or activity-specific basis, taking into consideration all relevant factors (including the strategic objectives and capabilities of each Party) and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;determine whether operational responsibility for any such activity should be transferred from Partner to Amgen or vice versa.  Unless and until determined otherwise by the JSC in accordance with the foregoing, the initial allocation of operational responsibility for development and regulatory activities for each Product will be as set forth in the applicable Development Plan.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Development Lead.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  On a Product-by-Product basis, one Party will oversee development and regulatory activities for such Product in the Collaboration Scope (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Development Lead&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  The Development Lead for each Product is set forth in the Development&#47;Commercial Lead Schedule.  Absent agreement by the JSC to the contrary (as indicated in the applicable Development Plan), it is the expectation of the Parties that the Development Lead will have primary responsibility for day-to-day development activities relating to the relevant Product, including generating protocols, conducting clinical trials, and data collection, verification and analysis.  Following the Effective Date, the Parties will promptly meet to coordinate the transition of development and regulatory activities from Amgen to Partner with respect to Products for which Partner is the designated Development Lead in a manner so as to not unduly delay or hamper the development of the relevant Products.  The Parties will amend the applicable Development Budgets and Operations Budgets to reflect the reasonable costs to be incurred by each Party in connection with such transfer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">&#91;*&#93; Updates.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The JSC will review and approve updates to the Development Plans and Development Budgets prior to &#91;*&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Conduct of Development.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Parties will cooperate in the conduct of the activities set forth in the applicable Development Plan, including the preparation of protocols and the development of documents therefor.  Both Parties will collaborate to achieve globally aligned regulatory documents and interactions for each Product.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Sharing of Materials.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that it becomes necessary for one Party to provide the other Party with tangible research or biological materials (other than a Product for clinical or commercial use), the Parties will enter into an appropriate material transfer agreement related thereto, which agreement will be subject to this Agreement and will be interpreted consistent with the terms hereof.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Ownership of Development and Safety Data.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Party will solely own all data generated by it or its designee in its development activities conducted hereunder, and such data will be subject to the license from Partner to Amgen under Section 10.5 (License Grant by Partner) or from Amgen to Partner under Section 10.4 (License Grant by Amgen), as applicable.  Notwithstanding the foregoing, the Development Lead will own the global safety database, the developmental core safety information (DCSI), and core data sheet for each Product.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Regulatory Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Designated Regulatory Party.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except as set forth in Section 3.2.4 (Manufacturing Matters), the JSC will allocate, on a Product-by-Product and country-specific basis, operational responsibility for regulatory activities to a Party (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Designated Regulatory Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) although there will be a presumption that the Development Lead will also be the Designated Regulatory Party.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Regulatory Communications and Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Designated Regulatory Party will prepare, submit and maintain all Regulatory Filings and obtain all Regulatory </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Approvals for which it is responsible in accordance with the applicable Development Plan.  The other Party will cooperate with the Designated Regulatory Party, at its reasonable request, with respect to any regulatory matters for which the Designated Regulatory Party is responsible.  Unless exigent action is required with respect to such Regulatory Filing or material communication, the Designated Regulatory Party will provide the other Party with copies of Key Regulatory Filings prior to submission within a reasonable amount of time (but not less than five (5) business days) to allow such Party to review and comment on such Key Regulatory Filings, and the Designated Regulatory Party will consider all comments and proposed revisions from the other Party in good faith prior to submission (but in the event of a disagreement between the Parties with respect to such comments and proposed revisions, (i)&#160;if the Development Lead&#8217;s determination is consistent with the then-current Development Plan, then the Development Lead&#8217;s determination shall prevail, and (ii)&#160;if the Development Lead&#8217;s determination is not consistent with the then-current Development Plan, then such matter shall be escalated to the JSC for review (and if a Critical Matter, further escalated to the CRC)).  The Designated Regulatory Party will consult with the other Party regarding, and keep the other Party informed of, the status of the preparation of all Regulatory Filings it submits, Governmental Authority review of any such Regulatory Filings, and all Regulatory Approvals that it obtains with respect to a Product.  Upon request of the other Party, the Designated Regulatory Party will provide to the other Party copies of all final Regulatory Filings it submits.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Regulatory Meetings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Designated Regulatory Party will consult with the other Party reasonably in advance of the date of any anticipated meeting with a Governmental Authority and will consider any timely recommendations made by the other Party in preparation for such meeting.  Upon the request of the other Party, the Designated Regulatory Party will permit the other Party to attend particular meetings between the Designated Regulatory Party and the applicable Governmental Authority.  The Designated Regulatory Party will request that the applicable Governmental Authority allow at least one (1) representative of the other Party to attend, solely as an observer, such meetings&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the foregoing will not apply to informal meetings or unscheduled teleconferences or meetings or teleconferences otherwise intended by the Governmental Authority to be between it and the Designated Regulatory Party&#8217;s representatives only.  The other Party will strictly follow the Designated Regulatory Party&#8217;s instructions with respect to any meeting which it attends, and will not discuss the contents of any such meeting with any Governmental Authority except as required by Applicable Law or authorized by the Designated Regulatory Party in writing.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Manufacturing Matters.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In order to assist the Designated Regulatory Party, the Manufacturing Lead will prepare &#91;*&#93; in English for the relevant Product, and the Designated Regulatory Party will modify as appropriate such module for use in Regulatory Filings in the Collaboration Territory.  The Manufacturing Lead will have the option, in order to protect proprietary manufacturing information, to take over operational responsibility from the Designated Regulatory Party for some or all correspondence and for specified official communications, including the preparation and submission of all Regulatory Filings required to be filed with any Governmental Authority in the Collaboration Territory with respect to the manufacture of a Product (except to the extent such transfer of operational responsibility is prohibited by Applicable Law or a Governmental Authority).  With respect to any such correspondence and communication, each Party will </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">promptly provide the other with copies of material written correspondence as reasonably necessary to permit each Party to comply with its relevant regulatory obligations or as otherwise reasonably requested&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the Manufacturing Lead will not be required to disclose proprietary or competitively sensitive information unless such disclosure is required by Applicable Law.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Ownership of Regulatory Filings and Regulatory Approvals.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Development Lead for a Product will own all right, title and interest in and to any and all Regulatory Filings and Regulatory Approvals directed to such Product and all such Regulatory Filings and Regulatory Approvals will be held in the name of the Development Lead, and the other Party will execute all documents and take all actions as are reasonably requested by the Development Lead to vest such title in the Development Lead, subject to Section 3.1.6 (Ownership of Development and Safety Data) and Section 3.2.4 (Manufacturing Matters).  The Development Lead hereby grants to the other Party a non-exclusive, non-transferable (except in connection with a permitted assignment, sublicense or subcontract) &#8220;right of reference&#8221; (as defined in 21 C.F.R. &#167;314.3(b)) with respect to such Regulatory Filings and Regulatory Approvals solely as necessary for the other Party, if such other Party is the Designated Regulatory Party, to prepare, submit and maintain Regulatory Filings for which it is responsible or as otherwise necessary to perform its obligations hereunder or to comply with Applicable Law.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Brand Security and Anti-Counterfeiting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties will establish contacts for communication regarding brand security issues and will each reasonably cooperate with the other with respect thereto.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Product Complaints, Recalls and Returns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties&#8217; rights and obligations with respect to nonconformance, recalls and returns of Products will be governed by the applicable Quality Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Clinical Trial Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Development Lead will, in accordance with Applicable Law and its internal policies, publish the results or summaries of clinical trials relating to a Product on a clinical trial register maintained by it and the protocols of clinical trials relating to such Product on www.ClinicalTrials.gov (or an equivalent register, or as otherwise required by Applicable Law or such Party&#8217;s policies).  The other Party will have the right to publish results or summaries (in the identical form as published by the Development Lead) if the Development Lead has already published in accordance with the foregoing sentence, or the applicable JPT approves such publication.  The Parties will cooperate to establish timelines and procedures for JPT review of publications and presentations. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Sharing of Data and Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.6.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Generally.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Each Party shall (and shall cause its Affiliates to) reasonably cooperate with the other Party to promptly share and provide access to (i)&#160;all clinical trial data and results within the Program Intellectual Property, and (ii)&#160;such other Know-How within the Product Intellectual Property as is reasonably necessary for the other Party to exercise its rights or fulfill its obligations under this Agreement.  The JSC may establish reasonable policies to effectuate such exchange of data and Know-How between the Parties. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.6.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Manufacturing Know-How.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">   For clarity, except as provided in Section 3.2.4 (Manufacturing Matters) above, the Manufacturing Lead shall not be obligated </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to share with the other Party or provide the other Party access to Know-How related to the manufacture of a Product unless and until such Party becomes the Manufacturing Lead with respect to such aspect of manufacturing of such Product, in which case the Manufacturing Lead shall promptly provide the other Party with access to such manufacturing Know-How within the Product Intellectual Property as is reasonably necessary for such Party to fulfill its obligations as Manufacturing Lead with respect to such Product.  All such transfer of manufacturing Know-How shall be overseen and facilitated by the JPT for the applicable Product.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">MANUFACTURING</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Allocation of Manufacturing Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Amgen will be responsible for the supply of clinical and commercial product for AMG827.  Amgen will be responsible for the initial supply of clinical product for all other Products (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Early Stage Programs&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  Amgen will elect at least &#91;*&#93; days prior to the initiation of the first &#91;*&#93; for each Early Stage Program whether or not to continue supplying later stage clinical material and commercial material for such Early Stage Program itself or through a contract manufacturing organization.  If Amgen elects not to do so, then Partner will have &#91;*&#93; days to elect to manufacture such later stage clinical material and commercial material for such Early Stage Program (including conducting any process development work related thereto).  If neither Party elects to manufacture later stage clinical material and commercial material for such Early Stage Program, then the Parties will mutually agree upon a Third Party manufacturer to conduct process development and clinical and commercial manufacturing.  In any event, Amgen will continue to supply clinical material (in the form that exists prior to such election) until such time as Partner or such Third Party manufacturer completes commercial process development and begins to supply such later stage clinical material&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that, if Partner elects to manufacture later stage clinical material and commercial material, then Partner will promptly and diligently undertake such efforts as are necessary to assume responsibility for such activities.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Manufacturing Lead</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Party that actually manufactures (itself or through a designee) a specific Product will be the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Manufacturing Lead&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for such manufactured Product.  For clarity, one Party may be the Manufacturing Lead for drug substance and the other Party may be the Manufacturing Lead for drug product.  Subject to Section 4.6 (Shortage&#59; Allocation), the Manufacturing Lead will use Commercially Reasonable Efforts to supply Product in a manner sufficient to fulfill demand for the Product in the Collaboration Territory.  Additionally, if Partner elects to become the Manufacturing Lead for a Product in accordance with Section 4.1 (Allocation of Manufacturing Responsibility) or is otherwise appointed the Manufacturing Lead by the CRC, the Parties will, with respect to Products manufactured by Partner, negotiate in good faith supplements to the definitions of Manufacturing Standard Costs and Manufacturing Actual Costs in order to make such definitions consistent, on a GAAP or IFRS basis (as applicable), with the manner in which Partner accounts for its other products.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">&#91;*&#93; Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The JSC will review and approve updates to the Operations Budgets prior to &#91;*&#93;.  Additionally, after Technical Feasibility has been achieved with respect to a Product, on a quarterly basis the Manufacturing Lead will inform the JSC of any expected decrease in &#91;*&#93; that is expected to result in &#91;*&#93;.  At the request of the other Party, the Manufacturing Lead will inform the other Party of &#91;*&#93; and will discuss with the other Party &#91;*&#93; with respect thereto. The Manufacturing Lead will have the sole right to determine which of its manufacturing sites will be used to manufacture a Product and may transfer the manufacturing of such Product from one site to another, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so long as such transfer would not reasonably be likely to have a material adverse effect on the continued supply of such Product.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Amgen will be solely responsible for the distribution of Products in the Amgen Distribution Countries.  Partner will be solely responsible for the distribution of Products in all other countries in the Collaboration Territory.  The Party that actually distributes Products in a particular country will be deemed the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Distribution Party&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for such country.  The Manufacturing Lead of drug product will supply Products for commercial use in labeled, finished form (unless otherwise agreed to by the JSC) to the other Party for distribution in the countries for which the non-Manufacturing Lead for drug product has been allocated distribution responsibility.  The non-Manufacturing Lead will reimburse the Manufacturing Lead for such Product at the Manufacturing Lead&#8217;s Manufacturing Actual Cost upon delivery of such Product to the non-Manufacturing Lead.  Such reimbursement will not be included in the calculation of Collaboration Profit (Loss) under Section 7.2 (Profit&#47;Expense Sharing), but rather the non-Manufacturing Lead will be entitled to include such payment as part of Amgen Costs or Partner Costs, as applicable, upon sale of such Product to a Third Party.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Quality and Safety Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Concurrently with the execution of this Agreement, the Parties have entered into the Quality Agreement with respect to the supply of Products by Amgen to Partner for clinical use.  Within ninety (90) days of the Effective Date, the Parties will enter into the Safety Agreement with respect to the supply of Products by Amgen to Partner for clinical use.  One year prior to the anticipated first commercial launch of a Product, the Parties will enter into a Quality Agreement with respect to the supply of Products by Amgen to Partner for commercial use and will work in good faith to revise the existing Safety Agreement as necessary.  In the event that Partner becomes a Manufacturing Lead for a Product, the Parties will enter into a Quality Agreement with respect thereto and will work in good faith to revise the existing Safety Agreement as necessary.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Shortage&#59; Allocation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that the Manufacturing Lead reasonably believes that it will not be able to supply requirements for a Product in accordance with a mutually agreed upon supply forecast, the Manufacturing Lead shall provide prompt written notice to the other Party thereof.  If the Manufacturing Lead actually cannot supply a Product in accordance with such mutually agreed upon supply requirements, then the Manufacturing Lead will undertake to allocate the manufacturing of Products with its other products so as to not &#91;*&#93;.  For clarity, if the Manufacturing Lead cannot actually supply requirements for a Product in accordance with a mutually agreed upon supply forecast, the Manufacturing Lead will reasonably allocate its manufacturing capacity over all its products in the following order of prioritization&#58; (a) to &#91;*&#93;&#59;  (b)&#160;to &#91;*&#93;&#59;  (c) to &#91;*&#93;&#59; and (d) to &#91;*&#93;.  </font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">COMMERCIALIZATION</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Allocation of Commercial Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The JSC will (i)&#160;allocate commercial activities to Amgen or Partner on a Product-by-Product basis and country-specific or activity-specific basis, and (ii)&#160;determine whether operational responsibility for any such activity should be transferred from Partner to Amgen or vice versa.  Allocations of commercial operational responsibility for countries and regions may be set forth in country plans developed by the applicable JPT that are consistent with the allocation of responsibility established by the JSC and the Brand Plan, taking into account the planned launch timing for the relevant country (as such plans may be updated or modified from time-to-time by the applicable JPT, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Country Plans&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  The initial allocation of commercial activities, as well as the guidelines for allocating commercial activities in the future, is as set forth in the Commercial Allocation Schedule.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Commercial Lead</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For each Product, one Party will oversee commercialization activities with respect to all indications for such Product in the Collaboration Scope (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Commercial Lead&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  The Commercial Lead for each Product will be as set forth on the Development&#47;Commercial Lead Schedule.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Initial Plans&#59; &#91;*&#93; Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  An initial Brand Plan for each Product will be approved by the JSC not later than three (3) months after initiation of the first Phase 3 Trial for such Product&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the initial Global Payer Plan and each initial Access and Pricing Plan will be approved by the JSC at such times as the JSC so determines.  The JSC will review and approve updates to the Brand Plans and Commercialization Budgets prior to &#91;*&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">All Sales by Distribution Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Only the Distribution Party with respect to a particular Product in a particular country is authorized to sell such Product in such country.  The Distribution Party will have the sole right, in such Party&#8217;s discretion, to take orders for and returns of, issue credits for, sell, and book sales for, such Product.  The non-Distribution Party will promptly forward to the Distribution Party all orders for, and requests to order, such Product.  The Distribution Party will have the right to refuse or cancel any order for such Product without liability to the other Party.  The non-Distribution Party will not interfere with any agreement of the Distribution Party or any of its Affiliates related to such Product, including contracting for the sale of such Product.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Training</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The JPT will establish a process by which the Parties will review, comment on and approve training materials and programs, and training of the Parties&#8217; sales forces for commercialization of the Products will be conducted using only training materials and programs approved in accordance with such process.  Each Party will train its respective sales representatives with respect to the promotion of a Product (and update such training from time to time as appropriate) which training will include compliance training as appropriate, all in accordance with the applicable Brand Plan.  The Commercial Lead for a Product will own all right, title and interest in the training materials developed hereunder for such Product (except with respect to any Housemarks of the other Party contained therein), and the non-Commercial Lead will execute all documents and take all actions as are reasonably requested by the Commercial Lead to vest title to such training materials in the Commercial Lead.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Information Concerning Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party will ensure that no claims or representations in respect of a Product or the characteristics thereof are made by or on behalf of it or its Affiliates (by sales force members or otherwise) that have not been approved by the JPT and neither Party will make any claim or representation that does not represent an accurate summary or explanation of the labeling of such Product. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Promotional Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The JPT will establish a process by which the Parties will review, comment on and approve all written sales, promotion and advertising materials relating to a Product, and other media and materials used to promote the Products or educate the public regarding an indication treated with a Product (collectively and including translations, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Promotional Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  All Promotional Materials will be produced by the applicable Commercial Lead in accordance with the Brand Plan and such process and any use thereof by the non-Commercial Lead will be subject to prior approval of the Commercial Lead.  All Promotional Materials will include, to the extent permitted by Applicable Law, the Amgen Housemarks and the Partner Housemarks.  Unless otherwise determined by the applicable JPT, the Commercial Lead will be responsible for the printing and delivery to the other Party of Promotional Materials for use in such other Party&#8217;s Detailing obligations hereunder.  Other than a Party&#8217;s use and distribution of Promotional Materials that are approved in accordance with the foregoing process and used and distributed in connection with a Party&#8217;s Detailing of a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Product, neither Party will produce or modify (other than as concepts for consideration by the other Party), or distribute or otherwise use any Promotional Material relating to a Product.  If so instructed by the applicable JPT, a Party will immediately cease to use any Promotional Materials and will collect and destroy any such materials from its sales representatives (and record and document such collection and destruction (and provide a copy of such documentation to the other Party upon request)).  The Commercial Lead for a Product will own all right, title and interest in and to any and all Promotional Materials for such Product (except with respect to any Housemarks of the other Party included in any Promotional Materials), and the non-Commercial Lead will execute all documents and take all actions as are reasonably requested by the Commercial Lead to vest title to such Promotional Materials in the Commercial Lead.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Detailing Reports and Audit Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.8.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party will provide the other Party with a report, in such form and manner as determined by the JSC, within forty-five (45) calendar days after the end of each calendar month, setting forth the following information regarding the efforts of the reporting Party&#8217;s sales force in Detailing each Product during the preceding month&#58; (i)&#160;the total number of Details made by such sales force, including a breakdown of First Position Details, Second Position Details and Other Details by target and frequency of Detail by customer priority&#59; and (ii)&#160;such other information as may be specified by the JSC.  In any country in the Collaboration Territory where the Parties are co-Detailing a Product, each Party will provide the foregoing information with respect to such Product &#91;*&#93;.  In any country in the Collaboration Territory where the Parties are not co-Detailing a Product, each Party will provide the foregoing information with respect to such Product &#91;*&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.8.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party will keep complete and accurate records of its Detailing of Products in sufficient detail to permit the other Party to audit its performance of Details hereunder.  During regular business hours, with not less than ten (10) business days&#8217; advance written notice and under reasonable obligations of confidentiality, a Party will permit the other Party or its authorized representatives to&#58; (i) have access to the records of Detailing activities maintained by such Party for purposes of verifying the accuracy of reports described in Section 5.8.1 (Reporting)&#59; and (ii) audit such records&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that such audits may not be performed by a Party more than once per calendar year, such records will be open (in such form as may be available or reasonably requested) to inspection for at least three (3) years following the end of the period to which they pertain, and such records for any particular calendar year will only be subject to one (1) audit.  Any and all audits undertaken pursuant to this Section 5.8.2 (Audits) will be performed at the sole and exclusive expense of the auditing Party and will not be included in Amgen Costs or Partner Costs, as the case may be, for purposes of calculating Collaboration Profit (Loss).  If an audit reveals an overstatement of Details of greater than &#91;*&#93; of the correct amount for the audited period, then the audited Party will pay the reasonable out-of-pocket cost of such inspection.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Competing Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If either Party or its Affiliates has sales representatives Detailing both a Product and a non-Product that is approved by a Governmental Authority for use in the same indication as such Product (a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Competing Product&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), then, in addition to the reporting obligations contained in Section 5.8.1 (Reporting), such Party will provide to specified employees of the other Party (as specified by such Party&#8217;s JSC members) with a report within thirty (30) calendar days after the end of each calendar month, setting forth &#91;*&#93;.  The purpose of such report shall be solely to substantiate the calculation of Sales Force Costs.  It shall only be used by the specified employees and it </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall not be used by either Party in violation of any Applicable Law.  If the JSC or CRC authorizes a sales representative to Detail a Product in the First Position Detail, then &#91;*&#93;.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Sales Force &#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On a country-by-country and Product-by-Product basis, during the period of time beginning &#91;*&#93; of such Product in such country, if either Party intends to &#91;*&#93; in such country that are expected to &#91;*&#93; such Product, then such Party shall provide the other Party with at least sixty (60) days&#8217; prior written notice.  In such event, at the request of either Party, the JSC shall meet to &#91;*&#93; in such country (with escalation to the CRC if the JSC is unable to agree on such &#91;*&#93;).  The Party that has &#91;*&#93; during the applicable period (but not to exceed &#91;*&#93; that are in excess of its &#91;*&#93;.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">PERFORMANCE STANDARDS</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Collaborative Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Activities to be undertaken by the Parties hereunder will be conducted in a collaborative manner as determined by the committee or team overseeing such activities, and in accordance with the terms and conditions of this Agreement, as applicable.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Diligence and Performance Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.    Subject to the decisions made by and oversight of the committees and teams established hereunder, each Party will use, and will assure that each of its Affiliates uses, Commercially Reasonable Efforts in the performance of its and their activities hereunder.  Each Party will conduct, and ensure that each of its Affiliates conducts, all of its and their activities with respect to the development, registration, manufacture, distribution, promotion and commercialization of a Product in accordance with this Agreement, the applicable Development Plan, the applicable Brand Plan, applicable Global Payer Plan, applicable Access and Pricing Plan, applicable Country Plans, accepted national and international pharmaceutical industry codes of practices in and for the Collaboration Territory (including the Pharmaceutical Research and Manufacturers of America (PhRMA) Code of Pharmaceutical Marketing Practices and the American Medical Association (AMA) Guidelines on Gifts to Physicians from Industry, as the same may be amended from time to time), and all Applicable Law.  The Parties will provide each other with all reasonably requested cooperation to enable each of them to comply with Applicable Law and accepted national and international pharmaceutical industry standards, including permitting each Party to verify the other Party&#8217;s compliance therewith.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Violation of Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Each Party will promptly notify the other Party of any violation of Applicable Law by its personnel with respect to the conduct of activities under this Agreement.  In the event of any such violation, the Parties will promptly confer regarding any such violation and will promptly take remedial or preventative action as may be reasonably required by the applicable JPT with respect thereto.  The Parties will have the right to require that any personnel that materially violates Applicable Law or applicable national or international pharmaceutical industry codes of practices cease to perform activities under this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Use of Affiliates and Third Party Contractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party will perform the activities designated to it itself or through any of its Affiliates, and any proposed use of a Third Party to conduct such activities will be subject to the other Party&#8217;s prior written consent, such consent not to be unreasonably withheld&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that (i)&#160;Partner&#8217;s consent will not be required for activities Amgen has, prior to the Effective Date, arranged to have performed by Third Parties and which have been disclosed to Partner prior to the Effective Date, and (ii)&#160;either Party will be permitted to, upon thirty (30) days&#8217; prior written notice to the other Party, engage a Third Party contract manufacturer, contract research organization, contract sales organization, distributor or wholesaler without the other Party&#8217;s consent.  Cost overruns resulting from either </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Party&#8217;s use of a Third Party to conduct any such activities will be subject to Section 7.2.6 (Overruns). Each Party will be responsible for compliance by its respective Affiliates and Third Party contractors with this Agreement and will be responsible for all acts and omissions of such Affiliates and Third Party contractors as if committed or omitted by the applicable Party.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Management of Personnel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party will have sole authority and responsibility for recruiting, hiring, managing, compensating (including paying for all benefits, wages, special incentives, workers&#8217; compensation and employment taxes), disciplining, firing and otherwise controlling the personnel provided by such Party for performance of its obligations hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that each Party will require its personnel to be subject to a confidentiality agreement and Invention assignment commitment prior to, and as a condition of, such personnel performing any such activities hereunder.  Each Party will provide the day-to-day management of its sales representatives and other personnel, including furnishing administrative support, financial resources, equipment and supplies.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">UP-FRONT PAYMENT AND PROFIT&#47;EXPENSE SHARING</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Up-front Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As partial consideration for the rights granted to Partner by Amgen pursuant to the terms of this Agreement, Partner will pay to Amgen a non-refundable, non-creditable payment equal to Fifty Million Dollars ($50,000,000.00) within fifteen (15) days after the Effective Date, payable by wire transfer of immediately available funds in accordance with wire transfer instructions of Amgen that will be provided in writing to Partner prior to the Effective Date.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Profit&#47;Expense Sharing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties will share in profits and losses generated by Products in the Collaboration Scope as follows&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Partner Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Within forty-five (45) days after the end of each calendar quarter Partner will provide to Amgen a detailed, itemized report of its Development Costs and General Costs, on a Product-by-Product basis, incurred by Partner or its Affiliates in accordance with this Agreement (collectively, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Partner Costs&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) in such quarter in the format set forth in the Invoice Schedule attached hereto.  In addition to the annual JSC approval of the relevant budgets for each Product, prior to the end of each calendar year, Partner will provide Amgen with a non-binding estimate of its Development Costs and General Costs for each Product for the &#91;*&#93; period (detailed on a calendar year basis) following the &#91;*&#93; covered by such approved budget&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the Parties will review and discuss such estimated costs at the JSC.    </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Amgen Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Within forty-five (45) days after the end of each calendar quarter Amgen will provide to Partner a detailed, itemized report of its Development Costs and General Costs, on a Product-by-Product basis, incurred by Amgen or its Affiliates in accordance with this Agreement (collectively, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Amgen Costs&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) in such quarter in the format set forth in the Invoice Schedule attached hereto. In addition to the annual JSC approval of the relevant budgets for each Product, prior to the end of each calendar year, Amgen will provide Partner with a non-binding estimate of its Development Costs and General Costs for each Product for the &#91;*&#93; period (detailed on a calendar year basis) following the &#91;*&#93; covered by such approved budget&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the Parties will review and discuss such estimated costs at the JSC.  For clarity, any costs incurred by or on behalf of Amgen in connection with the research and development of AMG557 for the sole benefit of Japan or the research and development of AMG827 for the sole benefit of the applicable Excluded Territory will not be included in Amgen Costs.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">FTE Rate.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The FTE Rate used for calculation of Costs pursuant to this Article 7 (Profit&#47;Expense Sharing) with respect to any activity will be the relevant FTE Rate for the calendar year in which such activity was undertaken.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Income Taxes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  For the avoidance of doubt, income and withholding taxes imposed on either of the Parties hereunder will not be included in cost sharing hereunder.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Exchange Rate.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  For purposes of calculating quarterly balancing payments as set forth in Section 7.2.9 (True-Up), Net Revenues, Amgen Costs and Partner Costs will be converted from local currency (if different from U.S. Dollars) to U.S. Dollars in accordance with Section 8.3.2 (Conversions).  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Overruns.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Party will promptly notify the other Party upon becoming aware that the anticipated Costs to be incurred by such Party for a given calendar year will be in excess of the applicable Development Budget, Operations Budget or Commercialization Budget.  Unless otherwise agreed by the Parties in advance, in writing, Costs reported by a Party pursuant to Section 7.2.1 (Partner Costs) or 7.2.2 (Amgen Costs) incurred with respect to a Product in excess of &#91;*&#93; percent (&#91;*&#93;%) of the aggregate amounts budgeted to be incurred by or on behalf of such Party for its activities for such Product in such calendar year in the then-current applicable Development Budget, Operations Budget or Commercialization Budget, respectively, will not be included in the calculation of profit (or loss) pursuant to Section 7.2.8 (Calculation of Profit (or Loss))&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that such Partner Costs and Amgen Costs in excess of such amount will be included in the calculation of profit (or loss) pursuant to Section 7.2.8 (Calculation of Profit (or Loss)) (A)&#160;to the extent such Costs were attributable to&#58; (i)&#160;a change in Applicable Law&#59; (ii)&#160;a Force Majeure event&#59; &#91;*&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Net Revenues</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Within five (5) business days prior to the end of each calendar quarter, each Party will provide the other Party with a reasonably detailed estimate of Net Revenues for such calendar quarter in the countries for which it is the Distribution Party.  Within thirty (30) days after the end of each calendar quarter, each Party will provide the other Party with a report of Net Revenues for such calendar quarter in the countries for which it is the Distribution Party, which report will contain a detailed and itemized calculation of Net Revenues for each Product in such countries during such calendar quarter. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:103.5pt;text-align:justify;text-indent:-67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:40.5pt">Calculation of Profit (or Loss)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.8.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Costs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:111.6pt;text-align:justify;text-indent:-39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.8.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Allocation.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">On a calendar quarter-by-calendar quarter basis, Partner will be responsible for one hundred percent (100%) of the following cost items, in the order set forth below, up to the Quarterly Cap for such calendar quarter.  Thereafter, Amgen shall be responsible for one hundred percent (100%) of such costs for such calendar quarter.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:136.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.8.1.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Unreimbursed Development Costs and General Costs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  First, Partner will be responsible for one hundred percent (100%) of Unreimbursed Development Costs and General Costs up to the Quarterly Cap.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:136.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.8.1.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reimbursed Development Costs.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If, following reimbursement for Unreimbursed Development Costs and General Costs, the Quarterly Cap has not yet been met, then Partner will be responsible for one hundred percent (100%) of Reimbursed Development Costs up to the Quarterly Cap. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:111.6pt;text-align:justify;text-indent:-39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.8.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Quarterly Cap.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Quarterly Cap&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for a given calendar quarter shall, during the applicable calendar year set forth below, be as follows&#58;</font></div><div style="padding-left:111.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.165%"><tr><td style="width:1.0%"></td><td style="width:33.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Calendar Year</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Quarterly Cap</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2012</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">65% of Total Costs for the applicable calendar quarter - &#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2013</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">65% of Total Costs for the applicable calendar quarter + &#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2014</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">65% of Total Costs for the applicable calendar quarter</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2015 and each year thereafter</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50% of Total Costs for the applicable calendar quarter</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:112.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Development Costs and General Costs for any calendar quarter will only include &#91;*&#93; of Development Costs and General Costs incurred in the conduct of the &#91;*&#93; set forth in the Development Plan for &#91;*&#93;.  In the event either (i)&#160;the designated endpoints set forth on the &#91;*&#93; Designated Endpoints &#91;*&#93; Schedule for the &#91;*&#93; are met, or (ii)&#160;the Parties agree to initiate a &#91;*&#93;, then Amgen shall have the right to allocate an amount equal to &#91;*&#93; of the Development Costs and General Costs incurred after the Effective Date in the conduct of the &#91;*&#93; between&#58; (a)&#160;a one-time success milestone payment from Partner to Amgen (payable within forty-five (45) days of notice from Amgen of the allocation between (a) and (b) provided below) and (b)&#160;an immediate increase (applied evenly) to the Quarterly Cap for the subsequent four (4) calendar quarters.  Amgen shall notify Partner in writing as to the allocation, which must total one hundred percent (100%) between (a) and (b).  Additionally as of the Effective Date, the Parties agree that the &#91;*&#93; set forth in the Development Plan for &#91;*&#93; is optional for the &#91;*&#93;. The Parties will evaluate whether or not it is beneficial to conduct the &#91;*&#93; as part of such trial. If the Parties disagree, then Amgen shall have the right, &#91;*&#93;, to conduct the &#91;*&#93;.) If the &#91;*&#93; meets the designated endpoints set forth on the &#91;*&#93;, then Partner will reimburse Amgen &#91;*&#93; of the Costs associated with the &#91;*&#93; (to be allocated between a milestone or increase to the Quarterly Cap as set forth in the forgoing sentence at Amgen&#8217;s option) and any Costs associated with the &#91;*&#93; incurred after such endpoints have been met will be included in Amgen Costs and shared in accordance with Section 7.2.8.1 (Costs).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Profit.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The total profit for a calendar quarter will be calculated by Amgen by first deducting from aggregate Net Revenues for each Product for such quarter a percentage of such Net Revenues equal to the applicable &#8220;Inventorship Margin&#8221; set forth below, which will be paid to Amgen to reflect Amgen&#8217;s inventorship of the Products&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:191.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.284%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Inventorship Margin</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG827</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Other Products</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:103.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Additionally, &#91;*&#93;.  After deduction of the Inventorship Margin &#91;*&#93;, the remaining Net Revenues will be shared by the Parties equally.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">True-up.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Within sixty (60) days after the end of each calendar quarter, Amgen will calculate and provide to Partner a report of the amount each Party is responsible for under Section 7.2.8.1 (Costs) for such quarter, and a report of the amount each Party is entitled to under Section 7.2.8.2 (Profit).  The resulting amounts under Sections 7.2.8.1 (Costs) and 7.2.8.2 (Profit) will be the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Collaboration Profit (Loss)&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for such calendar quarter.   A balancing payment will be made between the Parties in order to effect the profit and loss sharing allocation set forth in Section 7.2.8 (Calculation of Profit (or Loss)).  The net paying Party will make a payment pursuant to this Section 7.2.9 (True-up) within thirty (30) days after delivery of such report of Collaboration Profit (Loss).  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:3pt">Payments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Payments pursuant to this Article 7 (Profit&#47;Expense Sharing) will be made in accordance with the provisions of Article 8 (Payments). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:3pt">Calculation of Sales Force Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Sales force FTE costs for each of the Parties will be determined by including in Partner Costs or Amgen Costs, as the case may be, a pro rata portion of each Party&#8217;s sales representative&#8217;s FTE Rate as follows&#58; (i) &#91;*&#93; if such sales representative Details only a single Product (and no other products) with the approval of the CRC&#59; (ii)&#160;&#91;*&#93; if such sales representative Details two (2) products with a Product as the First Position Detail or Details only a Product without the approval of the CRC&#59; (iii) &#91;*&#93; if such sales representative Details three (3) or more products with a Product as the First Position Detail&#59; (iv)&#160;&#91;*&#93; if such sales representative Details two (2) products with a Product as the Second Position Detail&#59; (v) &#91;*&#93; if such sales representative Details three (3) or more products with a Product as the Second Position Detail&#59; and (vi) &#91;*&#93; if such sales representative Details three (3) or more products with a Product as the Other Detail.  If a sales representative Details more than one (1) Product, then the foregoing percentages will be aggregated for each such Product.  For the avoidance of doubt, if a sales representative Details a Product in more than one (1) position, then a pro rata share of the foregoing percentages, to be calculated based on the time spent by such sales representative on Detailing such Product in each such position, will be included in Partner Costs or Amgen Costs, as the case may be.  For periods in which sales representatives are performing activities in support of the collaboration but are not Detailing Products (e.g., during launch preparation or training), FTE costs will be calculated based upon percent of effort, resource utilization or other reasonable measure, in each case calculated and allocated in accordance with the applicable Party&#8217;s accounting procedures, consistently applied.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:3pt">Kirin-Amgen and Takeda Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For clarity, the Parties agree and acknowledge that any payments received by Amgen from (i) in the case of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG827, Kirin-Amgen, Inc. or Kyowa Hakko Kirin Co., Ltd and (ii) in the case of AMG557, Takeda Pharmaceutical Company Limited, in each case pursuant to the related Excluded Territory Agreement with such Third Party, shall be excluded from the calculation of Collaboration Profit (Loss).  Any such payments shall not, in any way (in part or in full), reduce Amgen Costs hereunder, and Amgen shall be entitled to retain any such payments in full without compensation to, or any separate accounting or audit right undertaken by, Partner. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Example</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Profit (Loss) Example Schedule sets forth an example of calculation and true-up of the Collaboration Profit (Loss).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Calculation of Net Revenues</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In calculating Net Revenues for the purposes of this Article 7 (Profit&#47;Expense Sharing)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.4.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Free Products.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any disposal of a Product at no charge for, or use of a Product without charge in, clinical or pre-clinical trials, given as free samples, or distributed at no charge to patients unable to purchase the same will not be included in Net Revenues.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.4.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Bundled Products.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Where a Product is sold in a Bundle, then for the purposes of calculating Net Revenues under this Agreement, such Product will be deemed to be sold for an amount equal to &#91;X &#247; (X + Y)&#93; &#215; Z, where&#58; X is the average sales price during the applicable reporting period generally achieved for such dosage form of such Product in the Collaboration Scope&#59; Y is the sum of the average sales price during the applicable reporting period generally achieved in the Collaboration Territory, when sold alone, by each pharmaceutical product in the relevant dosage form included in the Bundle (excluding such Product)&#59; and Z equals the price at which the Bundle was actually sold.  In the event that such Product or one or more of the other pharmaceutical products in the Bundle are not sold separately in the relevant dosage form, Net Revenues from the sale of such Bundle will be reasonably allocated between such Product and the other product(s) in such Bundle based upon their relative values and the Parties will determine the equitable fair market prices to apply to such Bundle&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that in the event of a disagreement with respect to such relative values, the Parties will engage a mutually agreed upon independent expert to make the final determination with respect thereto.  Notwithstanding the foregoing, no Product will be sold in a Bundle if such sale would violate Applicable Law.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Excluded Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following losses will not be charged to the Collaboration Profit (Loss)&#58;  (i)&#160;losses of a Party to the extent attributable to a breach of this Agreement by such Party, or (ii)&#160;losses subject to indemnification pursuant to Section 13.1 (Indemnity by Partner) or Section 13.2 (Indemnity by Amgen).  </font></div><div><font><br></font></div><div style="margin-bottom:0.06pt;margin-top:0.06pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Manufacturing Costs Calculation and True-Up</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Manufacturing Standard Costs for a Product, calculated as part of Development Costs, will be included in Amgen Costs and Partner Costs, as applicable, at the time of manufacture of such Product.  Prior to Technical Feasibility, Manufacturing Actual Costs for a Product intended for use in a clinical trial, calculated as part of Development Costs, will be included in Amgen Costs and Partner Costs, as applicable, at the time of manufacture of such Product.  After Technical Feasibility, Manufacturing Actual Costs for a Product intended for use in a clinical trial, calculated as part of Development Costs, will be included in Amgen Costs and Partner Costs, as applicable, at the time such Product is shipped to a site for use of such Product in a clinical trial.  Subject to Section 4.4 (Distribution), Manufacturing Actual Costs for a Product for commercial use, calculated as part of General Costs, will be included in Amgen Costs and Partner Costs, as applicable, at the time of sale of such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.06pt;margin-top:0.06pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Product.  In addition, due to the fact that Manufacturing Actual Costs may not be known at the time such costs are to be included within the Collaboration Profit (Loss), for the purposes of determining Development Costs or General Costs for a particular calendar quarter, the Manufacturing Lead will, to the extent any manufacturing costs are to be calculated using Manufacturing Actual Costs, use the then-current estimated Manufacturing Actual Costs for such calendar quarter.  By March 31 of each calendar year, the Manufacturing Lead will reconcile the estimated Manufacturing Actual Costs included in Development Costs and General Costs in the prior calendar year with the final Manufacturing Actual Costs for such Product and provide such reconciliation to the other Party.  If such reconciliation leads to an over or under payment by either Party, a balancing payment will be made between the Parties in order to maintain the intended profit and loss sharing allocation set forth in this Agreement within thirty (30) days after delivery of such reconciliation report by the Manufacturing Lead and agreement thereon by the Parties.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Budget Deadlocks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that the JSC is unable to approve &#91;*&#93; Development Budget, Operations Budget or Commercialization Budget prior to the expiration of any such budget, then, until approval of such budget by the CRC, each Party will be entitled to continue the Designated Amgen Activities and Designated Partner Activities, as applicable, and include its Development Costs and General Costs, as applicable, in the calculation of Collaboration Profit (Loss) for any calendar quarter not covered by an approved budget, until such time as the aggregate Development Costs and General Costs of such Party included in the calculation of Collaboration Profit (Loss) for &#91;*&#93; equal the amount of such Party&#8217;s Development Costs and General Costs included in the then most recent estimate provided under Sections 7.2.1 (Partner Costs) and 7.2.2 (Amgen Costs), as applicable, plus &#91;*&#93; of such estimate. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Program Recommitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#91;*&#93;, after the applicable Continued Development Meeting for a Product has been held and upon consultation at the CRC, in the event either (or both) Party(ies) do not wish to continue to participate in the continued development and commercialization of such Product, each Party will have the right to suspend its participation by providing the other Party with a written notice thereof on or prior to &#91;*&#93; days following the applicable Continued Development Meeting.  A Party so suspending its commitment will be referred to as a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Suspending Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and a Party not doing so a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Non-Suspending Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.8.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Suspension.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.8.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Suspension Election.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If only one Party delivers a notice of suspension with respect to a Product (a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Suspension Election&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), then the remaining provisions of this Section 7.8 (Program Recommitment) shall apply.  If both Parties deliver a notice of suspension with respect to a Product, then the Agreement shall be deemed to be terminated with respect to such Product in accordance with Section 14.2 (Termination for Convenience) and Section 14.6.1 (Product by Product Termination) and Amgen shall be the Continuing Party with respect to such Product.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.8.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Transition.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Upon making a Suspension Election, the Suspending Party will, at the Non-Suspending Party&#8217;s cost, undertake all reasonable efforts to effect a smooth and orderly transition of its development, regulatory and commercial activities and responsibilities under this Agreement with respect to such Product to the Non-Suspending Party.  If the Suspending Party is the Manufacturing Lead for such Product, then, at the Non-Suspending Party&#8217;s cost, the Suspending Party will use all reasonable efforts to continue to supply Product for clinical use and complete any commercial process development activities initiated prior to the effective </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date of such Suspension Election&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that, the Manufacturing Lead will have the right to transition such manufacturing to a contract manufacturer or, if agreed to by the Non-Suspending Party, to the Non-Suspending Party.  For clarity, from and after the effective date of any Suspension Notice, the Suspending Party shall not be liable for any Development Costs or General Costs for such Product committed before the effective date of the Suspension Notice but not yet incurred at that date or otherwise incurred after such date.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.8.1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Committee Participation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Upon making a Suspension Election and until such time as the Suspending Party elects to resume funding its share of Development Costs and General Costs with respect to such Product pursuant to Section 7.8.2 (Re-Entry Right) below, the Suspending Party&#8217;s right to participate on the CRC, the JSC, any JPT and any subcommittee or subteam thereunder will be limited to a right to participate in any meetings brought before such committee or team without any right to vote on any matter that specifically relates to such Product (for clarity the Suspending Party will retain the right to vote on any matter that relates to any other Product).  Additionally, if the Suspending Party was the Development Lead and Commercial Lead for such Product, then the Non-Suspending Party shall be the Development Lead and Commercial Lead going forth, and the Suspending Party shall not be entitled to resume such role even if such Party elects to resume funding its share of Development Costs and General Costs with respect to such Product pursuant to Section 7.8.2 (Re-Entry Right) below.  Additionally, the Non-Suspending Party shall promptly share with, and provide access to, the Suspending Party (i)&#160;all clinical trial data and results within the Program Intellectual Property, (ii)&#160;such other Know-How within the Product Intellectual Property generated before the date of the Suspension Election&#59; and (iii)&#160;any other information reasonably requested by the Suspending Party related to such Product. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.8.1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Subsequent Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Non-Suspending Party subsequently decides that it is no longer willing to continue further development and commercialization of the Product, then the Non-Suspending Party may elect to terminate further development and commercialization by providing the Suspending Party with &#91;*&#93; prior written notice (a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Termination Election&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  If the Suspending Party is Partner and Amgen delivers a Termination Election during the Re-Entry Period, then upon receipt of such Termination Election from Amgen, Partner shall have the right upon prior written notice, delivered by no later than &#91;*&#93; following receipt of Amgen&#8217;s Termination Election, to elect to continue with the further development and commercialization of the Product, in which case, Partner shall thereafter be deemed to be the Non-Suspending Party and Amgen shall be deemed to be the Suspending Party.  If Partner does not elect within such &#91;*&#93; period to continue with such development or commercialization or if Partner is the Non-Suspending Party, then upon the effective date of a Termination Election, the Agreement shall be deemed to be terminated with respect to such Product in accordance with Section 14.2 (Termination for Convenience) and Section 14.6.1 (Product by Product Termination) and Amgen shall be the Continuing Party with respect to such Product. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.8.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Re-Entry Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.8.2.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Re-Entry Period.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  With respect to any non-terminated Product subject to a Suspension Election, at any time beginning upon receipt of the Suspension Election until &#91;*&#93; following the receipt of the flash memo for the applicable Stage 2 Clinical Trial for such Product and receipt of any information requested by the Suspending Party that is reasonably necessary to determine whether to re-enter the program (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Re-Entry Period&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), the Suspending Party will have the right to re-enter the program by written notice (a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Re-Entry Notice&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) to the Non-Suspending Party, effective as of the date of receipt of such notice by the Non-Suspending Party.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.8.2.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Re-Entry Payment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event of such re-entry, the Suspending Party will pay the Non-Suspending Party an amount equal to &#91;*&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.8.2.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Lapse.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If the Suspending Party fails to provide the Re-Entry Notice with respect to a Product during the applicable Re-Entry Period, then the Suspending Party shall be deemed to have terminated the Agreement with respect to such Product in accordance with Section 14.2 (Termination for Convenience) and Section 14.6.1 (Product by Product Termination). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">7.8.2.4.Out-license.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If, during the Re-Entry Period for a Product, the Non-Suspending Party elects to grant to a bona fide Third Party the exclusive right to develop or commercialize such Product in any country within the Collaboration Territory, then the Non-Suspending Party will provide the Suspending Party with &#91;*&#93; prior written notice (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Out-License Election&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  If the Suspending Party fails to provide a Re-Entry Notice within &#91;*&#93; of receipt of the Out-License Election and the Out-License Election relates to only certain countries within the Collaboration Territory, then the Suspending Party&#8217;s  right to re-enter the program shall exclude such countries.   If the Suspending Party fails to provide a Re-Entry Notice within &#91;*&#93; of receipt of the Out-License Election and the Out-License Election relates to all countries within the Collaboration Territory, then, then the Suspending Party&#8217;s right to provide a Re-Entry Notice with respect to such Product shall terminate. </font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">PAYMENTS</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Appropriate Measure of Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each of the Parties acknowledges that the value provided by the other hereunder is comprised of many related items, including performance of various services, access to development, regulatory, manufacturing and commercial expertise, clinical data and other financial and non-financial consideration and that the amount of the Inventorship Margin, and the ratio of profit and expense sharing set forth herein are intended to capture such value as an aggregate.  Therefore, the increase, decrease or lapse of any particular items or rights (including Patents), including allocation of operational responsibilities between the Parties, will not affect the amount of such payment, or the ratio of profit and expense sharing and the Parties agree that both the amount and duration of such payment and the ratio of profit and expense sharing are reasonable.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">No Other Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Other than as explicitly set forth in this Agreement, neither Party will be obligated to pay any additional fees, milestone payments, royalties or other payments of any kind to the other hereunder.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Payments.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All payments made hereunder between the Parties will be made in U.S. Dollars except as set forth in Section 8.5 (Blocked Currency) or as otherwise agreed by the Parties.  Each Party will pay all sums due hereunder by wire transfer, or electronic funds transfer (EFT) in immediately available funds.  If the EFT option is chosen by Amgen or Partner, a completed electronic funds transfer form will be provided in a timeframe that facilitates timely payment.  Each Party will promptly notify the other Party of the appropriate account information to facilitate any such payments.  All amounts set forth in any budget established under this Agreement will be expressed in U.S. Dollars except as otherwise agreed by the Parties.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Conversions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  With respect to amounts required to be converted into another currency for calculation or payment, hereunder, such amounts will be converted using a rate of exchange which corresponds to the rate used for conversion between the relative currencies by whichever Party recorded the relevant receipt or expenditure, for the respective reporting period in its books and records that are maintained in accordance with GAAP or IFRS, as the case may be.  If a Party is not required to perform such a currency conversion for its GAAP or IFRS reporting with respect to the applicable period, then for such period such Party will make such conversion using the rate of exchange which corresponds to the noon buying rate as published in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Wall Street Journal, Eastern U.S. Edition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> on the second to last business day of the calendar quarter (or such other publication as agreed-upon by the Parties) in which such receipt or expenditure was incurred.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party will keep complete and accurate records pertaining to the activities to be conducted hereunder in sufficient detail to permit the other Party (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Auditing Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) to confirm the accuracy of all payments due hereunder, and such records will be open (in such form as may be available or reasonably requested) to inspection for &#91;*&#93; following the end of the period to which they pertain.  The Auditing Party will have the right, at its own expense to have an independent, certified public accountant, selected by it, perform a review of the records of the other Party (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Audited Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) applicable to amounts payable hereunder (including any records kept in the ordinary course of the Audited Party&#8217;s business) during regular business hours, with not less than ten (10) business days&#8217; advance written notice and under reasonable obligations of confidentiality.  The report of such accountant will be made available to both Parties simultaneously, promptly upon its completion.  The Auditing Party&#8217;s right to perform an audit pertaining to any calendar year will expire &#91;*&#93; after the end of such year and the books and records for any particular calendar year will only be subject to one (1) audit.  Should an inspection pursuant to this Section 8.4 (Audits) lead to the discovery of a payment discrepancy, then the appropriate Party will pay to the other the amount of the discrepancy (plus, if the error was in favor of the Auditing Party, interest accrued at the Contract Interest Rate, compounded annually from the day the relevant payment(s) were due).  If a payment discrepancy was greater than &#91;*&#93; of the correct amount for the audited period and the discrepancy was in favor of the Audited Party, then the Audited Party will pay the reasonable out-of-pocket cost of such inspection, but in no case will the costs of an audit pursuant to this Section 8.4 (Audits) be included in Partner Costs or Amgen Costs or otherwise included in the calculation of Collaboration Profit (Loss).  This Section 8.4 (Audits) does not apply to or include manufacturing audits or regulatory inspections. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Blocked Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Applicable Law in the Collaboration Territory prevents the prompt remittance of any payments with respect to sales therein, the paying Party will have the right and option to make such payments by depositing the amount thereof in local currency to the other Party&#8217;s account in a bank or depository in such country.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.6.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Withholding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If Applicable Law requires a Party to pay or withhold Taxes with respect to any payment to be made pursuant to this Agreement, the paying Party will notify the other in writing of such payment or withholding requirements prior to making the payment and provide such assistance to the receiving Party, including the provision of such documentation as may be required by a tax authority, as may be reasonably necessary in such Party&#8217;s efforts to claim an exemption from or reduction of such Taxes.  Each Party will withhold any Taxes required by law to be withheld from the amount due, remit such Taxes to the appropriate tax authority, and furnish the other Party with proof of payment of such Taxes promptly following payment thereof.  If Taxes are paid to a tax authority, each Party will provide the other such assistance as is reasonably required to obtain a refund of Taxes withheld, or obtain a credit with respect to Taxes paid.  In the event that the governing tax authority retroactively determines that a payment made by a Party to the other pursuant to this Agreement should have been subject to withholding (or to additional withholding) for Taxes, and such Party (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Withholding Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) remits such withholding Taxes to the tax authority, the Withholding Party will have the right to offset such amount, including any interest and penalties that may be imposed thereon (except to the extent any such interest or penalties result from the negligence of the Withholding Party), against future payment obligations of the Withholding Party under this Agreement (or, at the option of the Withholding Party, the Withholding Party will have the right to invoice the other Party for such amount, and the other Party will pay such amount within sixty (60) days of the receipt of such invoice)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the Withholding Party may also pursue reimbursement by any other available remedy.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.6.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Indirect Taxes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  All payments are exclusive of Indirect Taxes.  If any Indirect Taxes are chargeable in respect of any payments, the paying Party shall pay such Indirect Taxes at the applicable rate in respect of such payments following receipt, where applicable, of an Indirect Taxes invoice in the appropriate form issued by the receiving Party in respect of those payments.  The Parties shall issue invoices for all amounts payable under this Agreement consistent with Indirect Tax requirements and irrespective of whether the sums may be netted for settlement purposes.  If such amounts of Indirect Taxes are refunded by the applicable Governmental Authority or other fiscal authority subsequent to payment, the Party receiving such refund will transfer such amount to the paying Party within forty-five (45) days of receipt. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.6.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Employee Taxes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Each Party shall be responsible for taxes based on, imposed on or calculated by reference to any employees employed by that Party.</font><font style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.6.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Imports.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;For the avoidance of doubt, the Parties acknowledge and agree that none of the upfront payment or royalties payable under this Agreement are related to the license (or right) to import or any import of Products.&#160; The Parties shall cooperate in accordance with Applicable Laws to ensure where permissible no import duties are paid on imported Product.&#160; The Parties shall cooperate to ensure that the Party responsible for shipping values clinical Product in accordance with Applicable Laws and minimises where permissible any such duties and any related import taxes that are not reclaimable from the relevant authorities.&#160; The receiving Party shall be responsible for any import clearance, including payment of any import duties and similar charges, in connection with any Products transferred to such Party under this Agreement. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.6.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Payment Flows.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Parties recognize that this Agreement is global in nature and does not set out in detail how the financial flows will be implemented at a legal entity level in order to achieve the economic sharing of profits and losses generated by the Products as set forth in this Agreement.  At least eighteen (18) months prior to first commercial launch of a Product, the Parties will discuss and agree upon the principles for such profit and loss sharing at a legal entity level.  The Parties will use reasonable efforts to minimize the impact on both Parties of irrecoverable and&#47;or non-creditable Indirect Taxes, including, where appropriate, causing their local Affiliates to enter into a &#8220;Marketing Services Agreement&#8221; with one another or otherwise discussing how to address the issue.  For clarity, the provisions of this Section 8.6.5 (Payment Flows) will in no way change the allocation between the Parties of Development Costs and General Costs set forth in Section 7.2.8.1 (Costs) or of Net Revenues set forth in Section 7.2.8.2 (Profits).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Late Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any payments or portions thereof due hereunder which are not paid when due will bear interest at the Contract Interest Rate, compounded annually, calculated on the number of days such payment is delinquent.  This Section 8.7 (Late Payment) will in no way limit any other remedies available to either Party.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Change in Accounting Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  From time to time, either of the Parties may change its accounting and financial reporting practices from calendar quarters and calendar years to fiscal quarters and fiscal years or vice versa.  If a Party notifies the other in writing of a change in its accounting and financial reporting practices from calendar quarters and calendar years to fiscal quarters and fiscal years or vice versa, then thereafter, beginning with the period specified in the notice, the Parties will cooperate to determine a way to report and reconcile each Party&#8217;s accounting periods so as to facilitate payments to be made hereunder. </font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">DISTRACTING PRODUCTS</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Distracting Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as set forth in Sections 9.2 (Post-Effective Date Affiliates), 9.3 (Termination, Divestiture or Inclusion) and 9.4 (Pre-Clinical Research and Development Programs)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Partner will not, during the Term and, other than in the event of termination by Partner pursuant to Section 14.3 (Termination for Breach), for &#91;*&#93; thereafter, itself or through its Affiliates, conduct or participate in, or advise, assist or intentionally enable any Third Party to conduct or participate in, any Distracting Program anywhere in the world&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that &#91;*&#93;&#59;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Amgen will not, during the Term, itself or through its Affiliates, conduct or participate in, or advise, assist or intentionally enable any Third Party to conduct or participate in, any Distracting Program in the Collaboration Territory&#59; and  </font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#91;*&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Post-Effective Date Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If a Party enters into a Distracting Transaction then it will provide notice to the other Party, within &#91;*&#93; business days after the closing of the Distracting Transaction, describing in reasonable detail, to the extent permitted by Applicable Law and without disclosing any proprietary information, the Distracting Program.  During the pendency of any potential Distracting Transaction, and until the provisions of Section 9.3 (Termination, Divestiture or Inclusion) are fully implemented, the Party entering into the Distracting Transaction will Segregate the Distracting Program from programs for the Products.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Termination, Divestiture or Inclusion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The notice provided pursuant to Section 9.2 (Post-Effective Date Affiliates) will include a notification as to whether the Party entering into the Distracting Transaction intends to Divest, terminate or include in the collaboration the Distracting Program in accordance with this Section 9.3 (Termination, Divestiture or Inclusion)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.3.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Divestiture.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If a Party elects to Divest the Distracting Program, then it will Segregate such Distracting Program from the programs for the Products and Divest such Distracting Program within &#91;*&#93; months of the closing of the Distracting Transaction.  The divesting Party and its Affiliates (including the Affiliate with the Distracting Program) will not directly or indirectly assert any intellectual property or proprietary right embodied in the Distracting Program and under the control of the divesting Party or its Affiliates as a result of the Distracting Transaction, against or with respect to Products or otherwise obstruct the Parties&#8217; (or their Affiliates, sublicensees&#8217;, contractors&#8217; or agents&#8217;) efforts under this Agreement or, if Partner is the divesting Party, Amgen&#8217;s (or its Affiliates, sublicensees&#8217;, contractors&#8217; or agents&#8217;) efforts with respect to Products in the Excluded Territory.  If the divesting Party fails to complete a divestiture of the Distracting Program within &#91;*&#93; months of the closing of the Distracting Transaction, then such Party will be deemed to have chosen to terminate the Distracting Program, effective as of such &#91;*&#93; month anniversary, and will promptly comply with the requirements of Section 9.3.2 (Termination)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that if at the expiration of such &#91;*&#93; month period, the divesting Party has agreed terms with a Third Party to Divest the Distracting Program then such &#91;*&#93; month period will be extended as required for the divesting Party and such Third Party to consummate the transaction, but in no event will such extension exceed an additional &#91;*&#93; days.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.3.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Termination.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If a Party elects to terminate such Distracting Program, it will terminate all activities of such Distracting Program within &#91;*&#93; days after the closing of the Distracting Transaction, during which period it will Segregate such Distracting Program from the programs for the Products.  The terminating Party and its Affiliates will not directly or indirectly assert any intellectual property or proprietary right of the Distracting Program against or with respect to Products or otherwise to obstruct the Parties&#8217; (or their Affiliates, sublicensees&#8217;, contractors&#8217; or agents&#8217;) efforts under this Agreement or if Partner is the terminating Party, Amgen&#8217;s (or its Affiliates, sublicensees&#8217;, contractors&#8217; or agents&#8217;) efforts with respect to Products in the Excluded Territory during such termination period or thereafter.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.3.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:9pt">Inclusion.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If a Party elects to include the Distracting Program in the collaboration, then such Party (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Distracting Transaction Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) will provide written notice within &#91;*&#93; days after the closing of the Distracting Transaction of such election to the other Party, together with a non-confidential summary of the related Distracting Program.  If the non-Distracting Transaction Party desires to evaluate such Distracting Program, then the non-Distracting Transaction Party will notify the Distracting Transaction Party within &#91;*&#93; days of its receipt of such notice.  Promptly after the Distracting Transaction Party&#8217;s receipt of such evaluation notice, the Distracting Transaction Party will provide the non-Distracting Transaction Party with a confidential summary of the Distracting Program, including material pre-clinical and clinical data and proposed development plan and budget (as well as such other information that the non-Distracting Transaction may reasonably request), which summary will be deemed to be Confidential Information of the Distracting Transaction Party under this Agreement (and the non-Distracting Transaction Party shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">entitled to use such information solely for the purpose of evaluating whether to include such Distracting Program in the collaboration).  Within &#91;*&#93; days of its receipt of such summary, the non-Distracting Transaction Party will notify the Distracting Transaction Party of its election to either (i)&#160;include the Distracting Program in the collaboration or (ii)&#160;decline to include such Distracting Program in the collaboration.  If the non-Distracting Transaction Party agrees in writing to include such Distracting Program in the collaboration, then (a)&#160;the Distracting Program will be included under the terms of this Agreement and all the technology, intellectual property and tangible materials (including biological compounds, chemical compounds, intermediates, assays, screens, animal models and reagents) of such Distracting Program will be considered within the Product Intellectual Property&#59; (b)&#160;the Distracting Products included in the Distracting Program will be deemed Products hereunder&#59; (c)&#160;a JPT will be formed for each such Distracting Product and each such JPT will develop a Development Plan and Development Budget for each Distracting Product, for review and approval by the JSC&#59; (d)&#160;all Development Costs, General Costs and profits with respect to each such Distracting Product &#91;*&#93;&#59; and (e)&#160;the Parties will enter into an amendment or supplement to this Agreement to the extent necessary to specify which Party will be the Development Lead, Manufacturing Lead, and Commercial Lead, plus such other changes, modifications and assignments as are reasonably necessary to effectuate the addition of such Distracting Product.  If the non-Distracting Transaction Party does not agree to include such Distracting Program in the collaboration, then (i)&#160;from and after the date of such election, the obligations of the Distracting Transaction Party set forth in Section 9.1 (Distracting Program) will no longer apply with respect to such Distracting Program, and (ii)&#160;the non-Distracting Party shall destroy the confidential summary of the Distracting Program provided to it by the Distracting Transaction Party (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the non-Distracting Party shall be entitled to retain one (1) copy of such information for its record-keeping purposes).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Pre-Clinical Research and Development Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything in this Article 9 (Distracting Products), either Party will have the right, either itself or through its Affiliates, to conduct non-clinical research and non-clinical development on any Distracting Product, subject to this Section 9.4 (Pre-Clinical Research and Development).  At least &#91;*&#93; days prior to the anticipated initiation of the first &#91;*&#93; for such Distracting Product, the Party conducting such activities (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Researching Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) will notify the non-Researching Party and provide a non-confidential summary of the related Distracting Program to the non-Researching Party (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Program Notice&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  If the non-Researching Party desires to evaluate such Distracting Program, then the non-Researching Party will notify the Researching Party within thirty (30) days of its receipt of the Program Notice.  Promptly after the Researching Party&#8217;s receipt of such evaluation notice, the Researching Party will provide the non-Researching Party with a confidential summary of the Distracting Program, including material pre-clinical data and proposed development plan and budget (as well as such other information that the non-Researching Party may reasonably request), which summary will be deemed to be Confidential Information of the Researching Party under this Agreement (and the non-Researching Party shall be entitled to use such information solely for the purpose of evaluating whether to include such Distracting Program in the collaboration).  Within &#91;*&#93; days of its receipt of such summary, the non-Researching Party will notify the Researching Party of its election to either (i)&#160;include the Distracting Program in the collaboration, in which case the terms of Section 9.3.3 (Inclusion) will apply with respect to such Distracting Program (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the Researching Party will be entitled to receive a &#91;*&#93;) or (ii)&#160;decline to include such Distracting Program in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">collaboration.  If the non-Researching Party declines to include such Distracting Program in the collaboration, then (i)&#160;from and after the date of such election, the obligations of the Researching Party set forth in Section 9.1 (Distracting Program) will no longer apply with respect to such Distracting Program, and (ii)&#160;the non-Researching Party shall destroy the confidential summary of the Distracting Program provided to it by the Researching Party (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the non-Research Party shall be entitled to retain one (1) copy of such information for its record-keeping purposes).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Reasonable Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each of the Parties acknowledges the provisions of this Article 9 (Distracting Products) are reasonable and necessary to protect the legitimate interests of the other Party and to encourage the free sharing of information between the Parties with respect to Products, and each of the Parties agrees not to contest such limitations in any proceeding.  Each Party acknowledges that the other Party would not have entered into this Agreement absent the restrictions set forth in this Article 9 (Distracting Products) and that a breach or threatened breach of this Article 9 (Distracting Products) would be likely to result in irreparable harm to such Party for which there is no adequate remedy at law.  Therefore, the Parties will be entitled to obtain from any court of competent jurisdiction injunctive relief, specific performance, and an equitable accounting of any earnings, profits or benefits arising out of any such breach without the requirement to post a bond or to demonstrate irreparable harm, balancing of harms, consideration of the public interest or inadequacy of monetary damages as a remedy.  Nothing in this Section 9.5 (Reasonable Restrictions) is intended or will be construed to limit in any way either Party&#8217;s right to equitable relief or any other remedy for breach of this or any other provision of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:3pt">INTELLECTUAL PROPERTY</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Invention Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party will own all right, title, and interest in and to all Inventions that are made by or on behalf of such Party, solely or independent of the other Party, and all intellectual property rights related thereto, and any Invention that is jointly made will be owned jointly by the Parties.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Inventorship will be determined according to United States Patent Law (without reference to any conflict of law principles).  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Copyright Ownership&#59; Certain Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party will own all right, title, and interest in and to all Copyrights created pursuant to this Agreement that are authored by or on behalf of such Party, solely or independent of the other Party, and all intellectual property rights related thereto.  The Parties will jointly own all right, title, and interest in and to all Copyrights created pursuant to this Agreement that are authored by or on the behalf of the Parties jointly, and all intellectual property rights related thereto.  Notwithstanding the foregoing, any Copyrights pertaining to Promotional Materials or training materials for a Product will be owned solely by the Commercial Lead for such Product.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Joint Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as expressly provided in this Agreement, it is understood that neither Party will have any obligation to obtain any approval or consent of, nor pay a share of the proceeds to or account to, the other Party to practice, enforce, license, assign or otherwise exploit Inventions or intellectual property (including Copyrights and Product Trademarks) owned jointly by the Parties hereunder, and each Party hereby waives any right it may have under the laws of any jurisdiction to require such approval, consent or accounting.  Each Party agrees to cooperate with the other Party, as reasonably requested, and to take such actions as may be required to give effect to this Section&#160;10.3 (Joint Ownership) in a particular country within the Collaboration Territory.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.06pt;margin-top:0.06pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">License Grant by Amgen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Amgen hereby grants and causes its Affiliates to grant to Partner during the Term a &#91;*&#93;, fully-paid, royalty-free license to Amgen Intellectual Property and Program Intellectual Property solely (i)&#160;to the extent necessary to conduct the Designated Partner Activities and (ii)&#160;to exercise and perform Partner&#8217;s other rights and obligations under the terms of this Agreement.  Such license is sublicensable by Partner or its Affiliates solely in accordance with Section 6.4 (Use of Affiliates and Third Party Contractors).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">License Grant by Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Partner hereby grants and causes its Affiliates to grant to Amgen and its Affiliates a &#91;*&#93;, fully-paid, royalty-free license to Partner Intellectual Property and Program Intellectual Property solely (i)&#160;to the extent necessary to conduct the Designated Amgen Activities and (ii)&#160;to exercise and perform Amgen&#8217;s other rights and obligations under the terms of this Agreement.  The foregoing license is sublicensable by Amgen or its Affiliates in accordance with Section 6.4 (Use of Affiliates and Third Party Contractors).  Additionally, Partner hereby grants and causes its Affiliates to grant to Amgen and its Affiliates a &#91;*&#93;, irrevocable, fully-paid, royalty-free, world-wide license to Partner Intellectual Property and Program Intellectual Property solely to use, make, have made, sell, offer for sale and import Products for all uses in the Excluded Territory (which license is sublicensable by Amgen or its Affiliates to Third Parties to whom Amgen or its Affiliates also grant a license in the Excluded Territory to Know-How or Patents owned or controlled by Amgen with respect to Product(s) , or the manufacture, formulation or use thereof&#59; &#91;*&#93;).    </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Prosecution and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.6.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:3pt">Amgen Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the provisions of Section 2.10 (Patent Coordinators), Amgen will control, itself or through outside counsel, and have final decision making authority (after consultation with Partner in accordance with the terms and conditions of this Agreement) with respect to the Prosecution and Maintenance of the Patents within the Amgen Intellectual Property in the Collaboration Territory that claim a Product, and with respect to preparation and filing for any Patent Extensions.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.6.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:3pt">Partner Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the provisions of Section 2.10 (Patent Coordinators), Partner will control, itself or through outside counsel, and have final decision making authority (after consultation with Amgen in accordance with the terms and conditions of this Agreement) with respect to the Prosecution and Maintenance of the Patents within the Partner Intellectual Property in the Collaboration Territory that claim a Product, and with respect to preparation and filing for any Patent Extensions.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.6.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:3pt">Program Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the provisions of Section 2.10 (Patent Coordinators), Amgen will have the first right (but not the obligation) to control, through outside counsel, and have final decision making authority (after consultation with Partner in accordance with the terms and conditions of this Agreement) with respect to the Prosecution and Maintenance of the Patents and Product Trademarks within the Program Intellectual Property (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Program Patents and Trademarks&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), and with respect to preparation and filing for any Patent Extensions.  If Amgen desires to abandon the prosecution of a Program Patent or Trademark, then it will inform Partner thereof in writing with sufficient advance notice to reasonably enable Partner to assume the filing or prosecution of such Program Patent or Trademark (but in no event later than &#91;*&#93; days prior to the next deadline for any action that may be taken with respect such Program Patent or Trademark with the U.S. Patent and Trademark Office or any non-U.S. patent office) at Partner&#8217;s non-reimbursable cost.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.6.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:3pt">Review and Comment Rights - Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Through the Patent Coordinators&#58; (i) the filing Party will provide the non-filing Party with copies of and an opportunity to review and comment upon the text of the applications relating to the applicable Patents at least &#91;*&#93; days before filing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that if it is not reasonably practicable to provide such application in such &#91;*&#93; day period, then the filing Party will provide either a draft copy of such application or a statement of intent to file such application in such &#91;*&#93; day period&#59; (ii) the filing Party will provide the non-filing Party with a copy of each submission made to and document received from a patent authority, court or other tribunal regarding any Patent reasonably promptly after making such filing or receiving such document, including a copy of each application for each Patent as filed together with notice of its filing date and application number&#59; (iii) the filing Party will keep the non-filing Party advised of the status of all material communications, and actual and prospective filings or submissions regarding the Patents, and will give the non-filing Party copies of and an opportunity to review and comment on any such material communications, filings and submissions proposed to be sent to any patent authority or judicial body&#59; and (iv) the filing Party will consider in good faith the non-filing Party&#8217;s comments on such communications, filings and submissions for the Patents.  With respect to any filings or other materials provided to the non-filing Party under this Section 10.6 (Prosecution and Maintenance), the filing Party will have the right to redact any manufacturing information and any information relating to any product other than Products from any such filings and materials.  Either Patent Coordinator may escalate to the JSC whether to obtain any license to Third Party Patents or Know-How&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that in the event of a disagreement at the JSC with respect to such decision, Amgen will make the final decision with respect thereto. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.6.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:3pt">Review and Comment Rights - Product Trademarks.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Through the Patent Coordinators&#58; (i) the filing Party will provide the non-filing Party with copies of and an opportunity to review and comment upon the text of each application relating to registration of a Product Trademark at least &#91;*&#93; business days before filing&#59; (ii) the filing Party will provide the non-filing Party with a copy of each submission made to and document received from a trademark registration authority, court or other tribunal regarding any Product Trademark reasonably promptly after making such filing or receiving such document, including a copy of each application for registration of each Product Trademark as filed together with notice of its filing date and application number&#59; (iii) the filing Party will keep the non-filing Party advised of the status of all material communications, and actual and prospective filings or submissions regarding the application for registration of Product Trademarks, and will give the non-filing Party copies of and an opportunity to review and comment on any such material communications, filings and submissions proposed to be sent to any trademark registration authority or judicial body&#59; and (iv) the filing Party will consider in good faith the non-filing Party&#8217;s comments on such communications, filings and submissions for the Product Trademarks. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Defense and Settlement of Third Party Claims of Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If a Third Party asserts that Patents, Know-How or other rights owned or controlled by it are infringed by the activities hereunder of either of the Parties, then defense of such claim (an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Infringement Claim&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) will be managed in accordance with the provisions of Section 13.4 (Defense of Third Party Claims), with coordination and cooperation between the Defending Party and Assisting Party occurring via the Patent Coordinators.  If either Party seeks to initiate a nullification, declaratory judgment, revocation, or opposition proceeding against any such Patents, Know-How or other rights in response to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prospective or actual Third Party Claims of Infringement, the Parties will coordinate and cooperate in regard to such proceedings in accordance with the procedures set forth in Section 13.4 (Defense of Third Party Claims), with coordination and cooperation between the Defending Party and Assisting Party occurring via the Patent Coordinators.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as expressly set forth in this Section 10.8 (Enforcement), each Party will retain all its rights to control the enforcement of its own intellectual property.  Amgen will have the first right (but not the obligation) to enforce the Program Intellectual Property against any Third Party that is developing, manufacturing, selling, or importing a product or service that competes with a Product&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that Partner will have the right to approve in writing any settlement of any claim, suit or action involving its intellectual property that admits the invalidity or unenforceability of its intellectual property or imposes on Partner restrictions or obligations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Amgen fails to bring any such action or proceeding within forty-five (45) days (or twenty-five (25) days in the case of an action brought under the Biologics Price Competition and Innovation Act of 2009 (or any amendment or successor statute thereto) or within the time frame of any other relevant regulatory or statutory framework that may govern) of a request by Partner to do so (or, if sooner, five (5) days before the time limit, if any, set forth in the relevant laws and regulations for the filing of such actions), or earlier notifies Partner in writing of its intent not to bring such action or proceeding, then Partner will have the right (but not the obligation) to bring any such action or proceeding by counsel of its own choice&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that Amgen will have the right to approve in writing any settlement of any claim, suit or action involving its intellectual property that admits the invalidity or unenforceability of its intellectual property or imposes on Amgen restrictions or obligations.  The non-enforcing Party will reasonably assist the enforcing Party with respect to any such enforcement in the Collaboration Territory, including, in the event that it is determined that the non-enforcing Party is an indispensable Party to such action, by being named as a Party in such action, and cooperate in any such action at the enforcing Party&#8217;s request.   Without limiting the foregoing, the enforcing Party will keep the non-enforcing Party advised of all material communications, actual and prospective filings or submissions regarding such action, and will provide the non-enforcing Party copies of and an opportunity to review and comment on any such material communications, filings and submissions (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the enforcing Party will have the right to redact any manufacturing information and any information relating to any product other than Products from any such materials).  All Recoveries will be retained by or paid to Amgen (whether Amgen is the enforcing Party or not), but to the extent such Recoveries were obtained with respect to a Product or a product that competes directly with a Product, the same shall be included in Net Revenues for the period in which such Recovery is made. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Patent Term Extensions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each non-filing Party will provide reasonable assistance to the filing Party in connection with obtaining supplementary protection certificates, patent term extensions or similar protection for Patents (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Patent Extensions&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) within the Product Intellectual Property or otherwise licensed or assigned hereunder as determined by the Patent Coordinators.  To the extent reasonably and legally required to obtain any such Patent Extensions in a particular country, the non-filing Party will make available to the filing Party copies of all necessary documentation to enable the filing Party to use the same for the purpose of obtaining Patent Extensions in such country.  Notwithstanding Section 10.6 (Prosecution and Maintenance) above, the Patent Coordinator for the Commercial Lead will have the right to make the final decision as to which Patents within the Amgen Intellectual Property, Partner Intellectual Property or Program Intellectual Property will be extended with respect to the Product(s) for which such Party is the Commercial Lead.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt;text-decoration:underline">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.10.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:33pt">Title</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties will jointly own all right, title and interest in and to the Product Trademarks unless the local laws of any country prohibit joint ownership in which case Amgen shall own the Product Trademarks in those countries. Neither Party will, and will ensure that its Affiliates do not&#58; (i)&#160;challenge any Product Trademark or the registration thereof in any country&#59; (ii)&#160;file, register or maintain any registrations for any trademarks or trade names that are confusingly similar to any Product Trademark (other than for a Product), in any country without the express prior written consent of the other Party&#59; or (iii)&#160;authorize or assist any Third Party to do the foregoing.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.10.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:33pt">Required Use and Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.10.2.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24pt">Promotional Materials and all packaging and package inserts for Products in the Collaboration Scope will display the Amgen Housemarks and the Partner Housemarks to the extent allowed by Applicable Law and in accordance with the Brand Plan.  Except for the use of the Amgen Housemarks and the Partner Housemarks as may be expressly set forth in the Brand Plan, each Party will promote Products in the Collaboration Scope only under the Product Trademarks.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.10.2.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24pt">Each Party agrees that it and its Affiliates will&#58; (i)&#160;ensure that each use of the Product Trademarks and the other Party&#8217;s Housemarks by such Party is accompanied by an acknowledgement that such Product Trademarks are jointly owned and such Housemarks are owned by the other Party&#59; (ii)&#160;not use such Product Trademarks or the other Party&#8217;s Housemarks in a way that might materially prejudice their distinctiveness or validity or the goodwill of the other Party therein&#59; and (iii)&#160;not use any trademarks or trade names so resembling any of such Product Trademarks or the other Party&#8217;s Housemarks as to be likely to cause confusion or deception.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.10.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:33pt">Housemark Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.10.3.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24pt">To Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Amgen hereby grants to Partner a &#91;*&#93;, royalty-free license to use the Amgen Housemarks solely as set forth in the Promotional Materials and other materials provided to it by Amgen, and solely to develop, manufacture and commercialize Products in the Collaboration Scope in accordance with the Brand Plan, Country Plans and this Agreement.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.10.3.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24pt">To Amgen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Partner hereby grants to Amgen a &#91;*&#93;, royalty-free license to use the Partner Housemarks solely as set forth in the Promotional Materials and other materials provided to it by Partner, and solely to develop, manufacture and commercialize Products in the Collaboration Scope in accordance with the Brand Plan, Country Plans and this Agreement. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.10.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:33pt">Respect of Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Partner will not have, assert or acquire any right, title or interest in or to any Amgen Housemarks or the goodwill pertaining thereto, and Amgen will not have, assert or acquire any right, title or interest in or to any Partner Housemarks or the goodwill pertaining thereto, in each case by means of entering into or performing under this Agreement, except in each case for the limited licenses explicitly provided in this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.10.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:33pt">Infringement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Each Party will monitor the Product Trademarks against infringing uses within the Collaboration Scope and will promptly notify the other Party of any infringement or threatened infringement of any of the Product Trademarks of which it becomes aware.  The Patent Coordinators will </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determine what action, if any, to take in response to any such infringement or threatened infringement of any Product Trademark.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:3pt">CONFIDENTIALITY, PUBLICATIONS AND PRESS RELEASES</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Confidentiality&#59; Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that, during the Term and for &#91;*&#93; years thereafter, the receiving Party will keep confidential and will not publish or otherwise disclose or use for any purpose any and all information or materials related to the activities contemplated hereunder that is furnished to it by the other Party pursuant to this Agreement and is identified by the disclosing Party as confidential, proprietary or the like or that the receiving Party has reason to believe is confidential based upon its own similar information (collectively, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Confidential Information&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  For clarity, except for rights expressly granted herein, both Parties will have no right to and will not utilize any Confidential Information of the other Party for activities outside the Collaboration Scope or for activities related to products other than the Products.  Notwithstanding the foregoing, Confidential Information will not include any information to the extent that it can be established by written documentation by the receiving Party that such information&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">was obtained or was already known by the receiving Party or its Affiliates without obligation of confidentiality as a result of disclosure from a Third Party that the receiving Party did not know was under an obligation of confidentiality to the disclosing Party with respect to such information&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party through no act or omission of the receiving Party or its Affiliates in breach of this Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party or its Affiliates in breach of this Agreement&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">was independently discovered or developed by the receiving Party or its Affiliates (without reference to or use of Confidential Information of the disclosing Party).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Authorized Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as expressly provided otherwise in this Agreement, each Party may use and disclose Confidential Information of the other Party solely as follows&#58; (i) as reasonably necessary in conducting the activities contemplated under this Agreement&#59; (ii) with respect to Confidential Information generated in the course of the activities conducted hereunder, to the extent pertaining specifically to a Product, for use by Amgen in connection with a Product in the Excluded Territory or disclosure by Amgen to a partner or licensee for use with respect to a Product in the Excluded Territory&#59; (iii) to the extent such disclosure is to a Governmental Authority, as reasonably necessary in filing or prosecuting patent, copyright and trademark applications in accordance with this Agreement, prosecuting or defending litigation in accordance with this Agreement, complying with applicable governmental regulations with respect to performance under this Agreement, filing Regulatory Filings, obtaining Regulatory Approval or fulfilling post-approval regulatory obligations for a Product, or otherwise required by Applicable Law, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that if a Party is required by Applicable Law to make any such disclosure of the other Party&#8217;s Confidential Information it will, except where impracticable for necessary disclosures (for example, in the event of medical emergency), give reasonable advance notice to the other Party of such disclosure requirement and, in the case of each of the foregoing exceptions pursuant to this subsection (iii), will use its reasonable efforts to secure confidential treatment of such Confidential Information required to be disclosed&#59; (iv) to advisors </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(including lawyers and accountants) on a need to know basis in support of the purposes of this Agreement, in each case under appropriate confidentiality provisions or professional standards of confidentiality substantially equivalent to those of this Agreement&#59; and (v) to the extent mutually agreed to by the Parties.  Neither Party will disclose Confidential Information of the other Party to its personnel or to an Affiliate except to the extent such personnel or Affiliate needs to know such information for the performance of such Party&#8217;s activities hereunder.  </font></div><div><font><br></font></div><div style="margin-bottom:0.06pt;margin-top:0.06pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Confidential Treatment of Terms and Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties agree that the terms and conditions of this Agreement will be Confidential Information of each Party, and such material terms and conditions will not be disclosed, except (i) as otherwise permitted under Section 11.2 (Authorized Disclosure) and (ii) if required by Applicable Law (including disclosure of a redacted version of this Agreement in a relevant SEC filing).  Notwithstanding the foregoing, with respect to complying with the disclosure requirements of any Governmental Authority in connection with any required filing of this Agreement, the Parties will consult with one another concerning which terms of this Agreement will be requested to be redacted in any public disclosure of this Agreement, and in any event each Party will seek reasonable confidential treatment for any public disclosure by any such Governmental Authority.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Press Releases</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding Section 11.3 (Confidential Treatment of Terms and Conditions), the Parties will issue a joint press release to announce the execution of this Agreement, which is attached hereto as the Press Release Schedule (or such other joint press release as may be mutually agreed upon in writing by the Parties) and is for use in responding to inquiries about this Agreement.  Thereafter, Partner and Amgen may each disclose to Third Parties (including media interviews and disclosures to financial analysts) the information contained in such press release (but only such information) without the need for further approval by the other&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that such information is still accurate.  Each Party will have the right to issue additional press releases and disclosures in regards to the terms of this Agreement only with the prior written consent of the other Party, such consent not to be unreasonably withheld (or as required to comply with Applicable Law).   For any such proposed press release or disclosure, the disclosing Party will provide &#91;*&#93; business days&#8217; notice to the other Party and will reasonably consider the other Party&#8217;s comments that are provided within &#91;*&#93; business days after such notice, or such shorter notice and comment periods as are reasonably required under the circumstances but not less than &#91;*&#93; business days.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Prior Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement supersedes the Confidential Disclosure Agreement between Amgen and MedImmune, LLC (an Affiliate of AstraZeneca) dated September 14, 2011, as amended and supplemented, including any written requests thereunder with respect to information disclosed thereunder relating to the Products and activities related thereto.  All confidential information exchanged between the Parties and their respective Affiliates under such agreement will be deemed Confidential Information of the disclosing Party disclosed hereunder and will be subject to the terms of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Publications and Program Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as permitted pursuant to Section 3.5 (Clinical Trial Register), the Development Lead for a Product will have the sole right to publish and make scientific presentations with respect to such Product, and to issue press releases (except with respect to the terms of this Agreement, which is governed by Section 11.4 (Press Releases)) or make other public disclosures regarding any such Product (including with respect to its development, commercialization and regulatory matters), and the other Party will not do so without the Development Lead&#8217;s prior written consent, except as required by Applicable Law&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that any publication or presentation to be made by the Development Lead that names the other Party will </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">require the prior consent of the other Party.  The Development Lead will keep the relevant committee or team informed of its general publication strategy and presentation calendar.  The Development Lead will consider any reasonable comments regarding such strategy from the other Party.  In addition, the Development Lead will deliver to the other Party a copy of any proposed written publication or outline of presentation to be made by the Development Lead with respect to any scientific data pertaining to a Product in the Collaboration Scope in advance of submission for publication or presentation at least &#91;*&#93; days in advance of submission (or, where a copy of such publication or presentation is not available at such time, a draft or outline of such publication or a description of such presentation), and the other Party will have the right to&#58; (i) require a delay in submission of not more than &#91;*&#93; days to enable patent applications protecting the other Party&#8217;s rights in Inventions owned by such Party&#59; and (ii)&#160;prohibit disclosure of any of its Confidential Information in any such proposed publication or presentation.  Publications and presentations will be subject to policies mutually agreed by the Patent Coordinators to ensure appropriate protection of intellectual property rights.  If there is any dispute between the Parties with regard to a proposed publication, presentation or other communication regarding this Agreement, such dispute shall be referred to the JSC for resolution (with the Development Lead for the Product having the final decision).</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:3pt">REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Mutual Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each of the Parties hereby represents and warrants, as of the Effective Date to the other Party as follows&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">It is duly organized and validly existing under the Applicable Law of its jurisdiction of incorporation and it has full corporate power and authority and has taken all corporate action necessary to enter into and perform this Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">This Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance with its terms.  The execution, delivery and performance of this Agreement, and compliance with its terms and provisions, and the consummation of the transaction contemplated hereby, by such Party will not materially conflict, interfere or be inconsistent with, result in any material breach of or constitute a material default under, any agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound, nor to its knowledge violate any Applicable Law.  The person or persons executing this Agreement on such Party&#8217;s behalf have been duly authorized to do so by all requisite corporate action&#59;  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">It has not been debarred or the subject of debarment proceedings by any Governmental Authority&#59;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">To its knowledge, it and its Affiliates have not violated any Anti-Corruption Law&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">It has not granted any right to any Third Party relating to any intellectual property or proprietary right licensed, granted or assigned by it to the other Party hereunder that conflicts with the rights licensed, granted or assigned to the other Party hereunder.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Amgen Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition to the representations and warranties set forth in Section 12.1 (Mutual Representations and Warranties), Amgen hereby represents and warrants to Partner that, as of the Effective Date&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Amgen has not received written notice from any Third Party that any issued and enforceable Patent of such Third Party would be infringed by the importation, manufacture, distribution, marketing or sale of a Product (except, in each case, where Amgen may have since such time obtained a license to the relevant Patent)&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Amgen is the sole owner of all right, title and interest in the Patents included within Amgen Intellectual Property or otherwise has the right to grant to Partner the rights to such Patents, and the Amgen Intellectual Property is not subject to any lien or other encumbrance in favor of any Third Party that conflicts with the rights or licenses of Partner hereunder&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">No patent application or registration within the Amgen Intellectual Property is the subject of any pending interference, opposition, cancellation, or patent protest pursuant to 37 C.F.R. &#167;1.291&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">To Amgen&#8217;s knowledge, no Third Party is &#91;*&#93; in the Collaboration Scope&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">To Amgen&#8217;s knowledge, the development of the Products in the Collaboration Scope by or on behalf of Amgen &#91;*&#93;&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">To Amgen&#8217;s knowledge, there is no &#91;*&#93;.  For the purposes of this Section 12.2.6, &#8220;&#91;*&#93;&#8221; does not include claims for &#91;*&#93; for the &#91;*&#93; related to &#91;*&#93;&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Amgen has made available to Partner true and correct copies of the following&#58;  (i) all material Regulatory Filings for the Collaboration Territory&#59; (ii) all material correspondence with Governmental Authorities with respect to such Regulatory Filings&#59; (iii) all minutes of any material meetings, telephone conferences or discussions with Governmental Authorities with respect to such Regulatory Filings&#59; and (iv) all final clinical trial reports, in each case with respect to the Products and to the extent in existence as of the Effective Date&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Amgen is the owner of &#91;*&#93; Regulatory Filings for the Products in the Collaboration Scope&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Except as would not be reasonably expected to have a material adverse effect on the development, manufacture or commercialization of Products, Amgen has filed with the relevant Governmental Authorities all required notices, amendments and annual reports, as well as adverse event reports, with respect to the Regulatory Filings for the Products in the Collaboration Scope in existence as of the Effective Date&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33pt">To Amgen&#8217;s knowledge, there is no pending action or action threatened in writing by relevant Governmental Authorities to place a clinical hold order on, or otherwise terminate or suspend, any of the Regulatory Filings for a Product in existence as of the Effective Date&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33pt">The Completed Clinical Trials Schedule contains a complete list of all clinical trials carried out by or on behalf of Amgen or its Affiliates in relation to the Products for which dosing of patients was completed before the Effective Date&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2.12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33pt">Amgen has provided Partner with true and correct copies of &#91;*&#93;&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2.13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33pt">No written notice has been given or received by Amgen that &#91;*&#93; prior to the Effective Date&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2.14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33pt">Amgen has &#91;*&#93;. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Mutual Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party hereby covenants to the other Party that, during the Term&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.3.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">it will not grant any right to any Third Party relating to any intellectual property or proprietary right licensed or assigned by it to the other Party hereunder that conflicts with the rights granted to the other Party hereunder&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.3.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">it will not knowingly use in connection with the research, development, manufacture or commercialization to take place pursuant to this Agreement any employee, consultant or investigator that has been debarred or the subject of debarment proceedings by any regulatory agency&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.3.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Each Party agrees, on behalf of itself, its officers, directors and employees and on behalf of its Affiliates, agents, representatives, consultants and subcontractors hired in connection with the subject matter of his Agreement (together with the Party, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Party Representatives&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) that in connection with any Designated Partner Activities or Designated Amgen Activities, as applicable&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.3.3.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30pt">Each Party&#8217;s respective Party Representatives shall not directly or indirectly pay, offer or promise to pay, or authorize the payment of any money, or give, offer or promise to give, or authorize the giving of anything else of value, to&#58;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:140.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;any Government Official in order to influence official action&#59;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:140.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;any Person (whether or not a Government Official) (a) to influence such Person to act in breach of a duty of good faith, impartiality or trust (&#8220;acting improperly&#8221;), (b) to reward such Person for acting improperly, or (c) where such Person would be acting improperly by receiving the money or other thing of value&#59;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;any other Person while knowing or having reason to know that all or any portion of the money or other thing of value will be paid, offered, promised or given to, or will otherwise benefit, a Government Official in order to influence official action for or against either Party in connection with the matters that are the subject of this Agreement&#59; or</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:140.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;any Person to reward that Person for acting improperly or to induce that Person to act improperly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.3.3.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30pt">Each Party&#8217;s Party Representatives shall not, directly or indirectly, solicit, receive or agree to accept any payment of money or anything else of value in violation of the Anti-Corruption Laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.3.3.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30pt">Each Party, on behalf of itself and its other Party Representatives, represents and warrants to the other Party that for the term of this Agreement and &#91;*&#93; thereafter each Party shall maintain accurate books and reasonably detailed records in connection with the performance of its obligation under this Agreement including all records required to establish compliance with Sections 12.3.3.1 and 12.3.3.2 above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.3.3.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30pt">Each Party shall promptly provide the other Party with written notice of the following events&#58;</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:140.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Upon becoming aware of any breach or violation by a Party or its Party Representative of any representation, warranty or undertaking set forth in Sections 12.3.3.1 and 12.3.3.2.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:140.4pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Upon receiving a formal notification that it is the target of a formal investigation by a Governmental Authority for a Material Anti-Corruption Law Violation or upon receipt of information from any of its Party Representatives connected with this Agreement that any of them is the target of a formal investigation by a Governmental Authority for a Material Anti-Corruption Law Violation.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Amgen Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as would not be reasonably expected to have a material adverse effect on the development, manufacture or commercialization of Products, Amgen and its Affiliates will &#91;*&#93;.  Amgen will notify Partner in writing of any &#91;*&#93;.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">AstraZeneca Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#91;*&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Disclaimer of Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  EXCEPT AS SET FORTH IN THIS ARTICLE 12 (REPRESENTATIONS AND WARRANTIES), PARTNER AND AMGEN EXPRESSLY DISCLAIM ANY AND ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE COLLABORATION, PRODUCT INTELLECTUAL PROPERTY, AMGEN HOUSEMARKS, PARTNER HOUSEMARKS, PRODUCT TRADEMARKS, THIS AGREEMENT, OR ANY OTHER SUBJECT MATTER RELATING TO THIS AGREEMENT, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OR NONINFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  NOTWITHSTANDING ANY OTHER PROVISION CONTAINED HEREIN, OTHER THAN TO THE EXTENT RESULTING FROM A PARTY&#8217;S BREACH OF ARTICLE 9 (DISTRACTING PRODUCTS) OR SECTION 11.1 (CONFIDENTIALITY&#59; EXCEPTIONS), IN NO EVENT WILL PARTNER OR AMGEN BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING LOST PROFITS, BUSINESS OR GOODWILL) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES IN CONNECTION WITH A BREACH OR ALLEGED BREACH OF THIS AGREEMENT.  THE FOREGOING SENTENCE WILL NOT LIMIT THE OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE OTHER PARTY FROM AND AGAINST SUCH DAMAGES AS ARE AWARDED TO A THIRD PARTY WITH RESPECT TO THIRD PARTY CLAIMS UNDER SECTION 13.1 (INDEMNITY BY PARTNER) OR SECTION 13.2 (INDEMNITY BY AMGEN). </font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:3pt">INDEMNIFICATION AND INSURANCE</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Indemnity by Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Partner will defend, indemnify, and hold harmless Amgen, its Affiliates, and their respective directors, officers, employees, agents and representatives (collectively, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Amgen Indemnitees&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), at Partner&#8217;s cost and expense, from and against any and all liabilities, losses, costs, damages, fees or expenses (including reasonable legal expenses and attorneys&#8217; fees) (collectively, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Losses&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) arising out of any Third Party Claims brought against any Amgen Indemnitee to the extent such Losses result from&#58; &#91;*&#93;.  The indemnification obligations under this Section 13.1 (Indemnity by Partner) exclude Losses to the extent they arise from &#91;*&#93; below in Section 13.2 (Indemnity by Amgen). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Indemnity by Amgen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Amgen will defend, indemnify, and hold harmless Partner, its Affiliates, and their respective directors, officers, employees, agents and representatives (collectively, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Partner Indemnitees&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), at Amgen&#8217;s cost and expense, from and against any and all Losses arising out of any Third Party Claims brought against any Partner </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Indemnitee to the extent such Losses result from&#58; &#91;*&#93;.  The indemnification obligations under this Section 13.2 (Indemnity by Amgen) exclude Losses to the extent they arise from &#91;*&#93; above in Section 13.1 (Indemnity by Partner). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Claim for Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Whenever any Third Party Claim or Loss arises for which a Partner Indemnitee or an Amgen Indemnitee (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Indemnified Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) may seek indemnification under this Article 13 (Indemnification and Insurance), the Indemnified Party will promptly notify the other Party (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Indemnifying Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) of the Third Party Claim or Loss&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the failure by an Indemnified Party to give such notice will not relieve the Indemnifying Party of its indemnification obligation under this Agreement except and only to the extent that the Indemnifying Party is actually prejudiced as a result of such failure.  The Indemnifying Party will have exclusive control of the defense and settlement of all Third Party Claims for which it is responsible for indemnification and will assume defense thereof at its own expense promptly upon notice of such Third Party Claim.  In no event will the Indemnifying Party settle any Third Party Claim without the prior written consent of the Indemnified Party if such settlement (x)&#160;does not include a complete release from liability on such Third Party Claim, or (y) includes any admission of wrongdoing by the Indemnified Party or that any intellectual property or proprietary right of the Indemnified Party is invalid or unenforceable.  The Indemnified Party will have the right to employ separate counsel at the Indemnifying Party&#8217;s expense and to control its own defense of the applicable Third Party Claim if&#58; (i) there are or may be legal defenses available to the Indemnified Party that are different from or additional to those available to the Indemnifying Party&#59; or (ii) in the reasonable opinion of counsel to the Indemnified Party, a conflict or potential conflict exists between the Indemnified Party and Indemnifying Party that would make such separate representation advisable.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Defense of Third Party Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided in Section 13.3 (Claim for Indemnification), each Party (such Party referred to as the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Defending Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) will have the sole right, but not the obligation, to defend against any Third Party Claims made against it with respect to its activities hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that any Third Party Claims relating to a nullification, declaratory judgment, opposition or revocation proceeding against any Product Intellectual Property will be governed by the provisions of Section 10.8 (Enforcement).  Each Party will notify the other Party (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Assisting Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) as promptly as practicable if any such Third Party Claim is commenced or threatened against it, including any Infringement Claim.  The Assisting Party will reasonably assist the Defending Party and cooperate in any such litigation at Defending Party&#8217;s reasonable request.  Without limiting the foregoing, the Defending Party will keep the Assisting Party advised of all material communications, actual and prospective filings or submissions regarding such action, and will provide the Assisting Party copies of and an opportunity to review and comment on any such communications, filings and submissions&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that each Party will have the right to redact from any information disclosed to the other hereunder any information relating to a product other than a Product or relating to the manufacture of a Product.  The Defending Party will control the defense and settlement of Third Party Claims, with the costs thereof being included in General Costs, to the extent provided in Section 1.65.4.  The Defending Party will not settle such Third Party Claim without the prior written consent of the other Party (such consent not to be unreasonably withheld), unless such settlement&#58; &#91;*&#93;.  In the event that a Third Party Claim is brought against both of the Parties (a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Joint Claim&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), then the Parties will determine whether to defend against such Joint Claim, which of the Parties should be the Defending Party or whether the Parties should jointly control such defense and the strategy for such defense.  In the case of an Infringement Claim, the coordination and cooperation set forth in this Section 13.4 (Defense of Third Party Claims) will be accomplished via the Patent Coordinators.  This Section 13.4 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Defense of Third Party Claims) will not apply to employment or similar personnel-related claims. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each of the Parties will, at their own respective expense (and not subject to cost sharing hereunder) procure and maintain during the Term, insurance policies adequate to cover their obligations hereunder and consistent with the normal business practices of prudent pharmaceutical companies of similar size and scope (or reasonable self-insurance sufficient to provide materially the same level and type of protection).  Such insurance will not create a limit to either Party&#8217;s liability hereunder.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:3pt">TERM AND TERMINATION</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement will become effective on the Effective Date and will continue during the Term.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Termination for Convenience</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.2.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Either Party will have the right to terminate this Agreement, either in whole or on a Product-by-Product basis, by providing the other Party with &#91;*&#93; prior written notice (or, after First Commercial Sale of a Product, &#91;*&#93; prior written notice with respect to such Product)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that a notice of termination with respect to a particular Product may only be provided after the Continued Development Meeting for such Product has occurred and a notice of termination with respect to the Agreement in whole may only be provided after the Continued Development Meetings for all Products have occurred.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.2.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">&#91;*&#93;. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Termination for Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event of a material breach of this Agreement, the non-breaching Party will have the right to terminate this Agreement, either in whole or (if such breach solely applies to a specific Product(s)) with respect to the applicable Product(s).  The non-breaching Party may terminate this Agreement, whether in its entirety or on a Product-by-Product basis (as applicable), by written notice to the breaching Party, which notice will specify the nature of such breach in reasonable detail.  Such termination will become effective on the date that is &#91;*&#93; days after the delivery thereof to the breaching Party (or, in the case of a failure to pay amounts due hereunder, &#91;*&#93; days) unless, during the &#91;*&#93; day (or &#91;*&#93; day) period after delivery of such notice to the breaching Party, the breaching Party has cured such breach to the reasonable satisfaction of the non-breaching Party.   Notwithstanding the foregoing, in the event of a good faith dispute as to whether performance has been made by either Party pursuant to this Agreement, including any good faith dispute as to payments due under this Agreement, the relevant cure period with respect thereto will be tolled pending resolution of such dispute in accordance with the applicable provisions of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that if such dispute relates to payment, the cure period will only apply with respect to payment of disputed amounts, and not with respect to undisputed amounts.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Termination for Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Either Party will have the right to terminate this Agreement immediately upon written notice, if&#58; (i)&#160;the other Party becomes insolvent&#59; (ii) the other Party files a petition in bankruptcy, or if an involuntary petition in bankruptcy is filed against the other Party and such involuntary petition is not dismissed within seventy-five (75) days and the other Party (a) fails to assume this Agreement in any such bankruptcy proceeding within thirty (30) days after filing or (b)&#160;assumes and assigns this Agreement to a Third Party&#59; or (iii)&#160;a receiver or guardian has been appointed for the other Party who is not discharged within seventy-five (75) days after appointment.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Termination for Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Either Party will have the right to terminate this Agreement on a Product-by-Product basis by written notice to the other Party, if such other Party, its Affiliates or licensees bring or join any challenge to the validity or enforceability of (i) if Amgen is the challenging Party, any Partner Intellectual Property or any Program Intellectual Property, in each case as and to the extent such Partner Intellectual Property or Program Intellectual Property applies to the Product in the Collaboration Scope that is the subject of the termination notice&#59; and (ii)&#160;if Partner is the challenging Party, any Amgen Intellectual Property (or any intellectual property corresponding to any such Amgen Intellectual Property in the Excluded Territory) or any Program Intellectual Property, in each case as and to the extent such Amgen Intellectual Property or Program Intellectual Property applies to a Product in the Collaboration Scope that is the subject of the termination notice.  Notwithstanding the foregoing, nothing in this Section 14.5 (Termination for Challenge) will either&#58; (a)&#160;prevent either Party from asserting any defense or counterclaim in an action for infringement of intellectual property, brought against such Party or its Affiliates, or any Third Party that such Party or any of its Affiliates is obligated to indemnify, or responding in any other manner to such an action for infringement&#59; or (b) allow a Party to terminate this Agreement in the event the other Party asserts any such defense or counterclaim or otherwise responds in any such action for infringement.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Effects of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.6.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:3pt">Product by Product Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   Upon the termination of this Agreement by a Party with respect to one or more Products (each, a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Terminated Product&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), the following will apply&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.6.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30pt">Termination of Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Terminated Product will thereafter cease to be a Product for all purposes of this Agreement&#59; and accordingly, for purposes of this Section 14.6 (Effects of Termination)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Continuing Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the Party that is not the Terminating Party&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Continuing Scope&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means with respect to a particular Terminated Product, the uses, countries and territories within the Collaboration Scope for such Terminated Product immediately prior to the Termination Effective Date&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Termination Effective Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means, with respect to a particular Terminated Product, the effective date of such termination with respect to such Terminated Product&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Terminated Product Intellectual Property Rights&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means (a)&#160;the Terminating Party&#8217;s rights in and to the Program Intellectual Property and (b) (1) to the extent the Terminating Party is Amgen, the Amgen Terminated Product IP or (2) to the extent the Terminating Party is Partner, the Partner Terminated Product IP.  For such purposes, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Amgen Terminated Product IP&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Partner Terminated Product IP&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> mean, respectively, Amgen Intellectual Property and Partner Intellectual Property, but substituting for each reference to &#8220;Product&#8221; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Product Trademark&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> therein, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Terminated Product&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Terminated Product Trademark,&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> respectively&#59; and  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Terminated Product Promotional Materials&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Terminated Product Trademarks&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> mean, respectively, Promotional Materials and Product Trademarks with respect to the Terminated Product (i.e., for such purposes, substituting in the definition of Promotional Materials and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Product Trademark a reference to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Terminated Product&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for each reference to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Product&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Terminating Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means (a)&#160;the Party terminating the Agreement in the case of termination pursuant to Section 14.2 (Termination for Convenience)&#59; (b)&#160;the non-breaching Party in the case of termination pursuant to Section 14.3 (Termination for Breach)&#59; (c)&#160;the non-insolvent Party in the case of termination pursuant to Section 14.4 (Termination for Insolvency)&#59; and (d)&#160;the non-challenging Party in the case of termination pursuant to Section 14.5 (Termination for Challenge).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.6.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30pt">Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Termination of this Agreement with respect to a Terminated Product will not release either Party from any liability (including any payment obligations) with respect to such Terminated Product that, at the time of such termination, has already accrued to the other Party or which is attributable to activities prior to such termination.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.6.1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30pt">Continuing Party&#8217;s Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Continuing Party will have the sole right, as between the Parties, to develop, manufacture and commercialize the Terminated Product within the Continuing Scope.   Accordingly, upon the Termination Effective Date for such Terminated Product, or such earlier time as specified below, and in each case subject to Section 14.6.1.5 (Amgen&#8217;s Rights Outside Continuing Scope) below&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Terminated Product Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Terminating Party will grant, and hereby grants, to the Continuing Party an exclusive, royalty-free license, including the right to grant and authorized sublicenses, under the Terminated Product Intellectual Property Rights to make, have made, use, sell, offer for sale and import the Terminated Product within the Continuing Scope.   The Terminating Party will, subject to clause (vii) of this Section 14.6.1.3, immediately cease all of its development, manufacturing and commercialization activities for the Terminated Product.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment of Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Terminating Party will assign, and hereby assigns, to the Continuing Party all of the Terminating Party&#8217;s rights, title and interest in and to the Terminated Product Trademarks for such Terminated Product (including any goodwill associated therewith), including all registrations therefore.  Accordingly, the Terminating Party will cease all use of such Terminated Product Trademark.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Terminated Product Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Terminating Party will promptly transfer to the Continuing Party, at no cost, copies of all data, reports, records, materials and other Know-How in its possession or control that relate to the Terminated Product (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Terminated Product Data&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), with such data to the extent they relate specifically to the Terminated Product becoming the Continuing Party&#8217;s Confidential Information and shall cease to be the Terminating Party&#8217;s Confidential Information.  The Terminated Product Data will be provided in electronic form reasonably usable by the Continuing Party and, if reasonably necessary or useful in connection with the Continuing Party&#8217;s (or its designee&#8217;s) further commercialization, development or exploitation of the Terminated Product within the Continuing Scope, will include original hardcopies or duplicate copies thereof, as required.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Terminating Party will promptly return to the Continuing Party, or destroy at the Continuing Party&#8217;s request (and certify such destruction to the Continuing Party), all relevant records and materials in the Terminating Party&#8217;s possession or control containing Confidential Information of the Continuing Party that is&#58; (a) related to the Terminated Product within the Continuing Scope and (b) not reasonably necessary for the Terminating Party to exercise any remaining rights or fulfill any remaining obligations it has under this Agreement after such termination&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the Terminating Party (1)&#160;may keep one copy of such Confidential Information of the Terminating Party for archival purposes or as otherwise required under Applicable Law&#59; and (2) ensures such copies are Segregated from any Distracting Program).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Samples and Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Terminating Party will promptly transfer to the Continuing Party, or destroy at the Continuing Party&#8217;s request (and certify such destruction to the Continuing Party), all samples, Terminated Product Promotional Materials, sales training materials and any other documents, or materials primarily intended for use in commercialization of the Terminated Product within the Continuing Scope.   </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment of Regulatory Filings and Approvals&#59; Copyrights&#59; Domain Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Terminating Party will, at its own expense (other than with respect to any fee payable to the relevant Governmental Authority in connection with the relevant assignment, which will be borne by the Continuing Party), assign, and hereby assigns, to the Continuing Party all Regulatory Filings and Regulatory Approvals related to the Terminated Product within the Continuing Scope, and all copyrights, copyright registrations, domain names and domain name registrations related to the Terminated Product (or to the Terminated Product Promotional Materials) within the Continuing Scope.  The Terminating Party will promptly submit any necessary notices to Governmental Authorities to effect such assignments.  If Applicable Laws prevent or delay the transfer of ownership of any such Regulatory Filing or Regulatory Approval to the Continuing Party, the Terminating Party will grant, and does hereby grant, to the Continuing Party an exclusive and irrevocable right of access and reference to such Regulatory Filing and Regulatory Approvals for purposes of developing and commercializing the Terminated Product within the Continuing Scope, and will cooperate fully to make the benefits of such Regulatory Filings and Regulatory Approvals available to the Continuing Party or its designee(s) for purposes within the Continuing Scope for such Terminated Product.  Promptly upon request following the notice of termination, the Terminating Party will provide to the Continuing Party copies of all such Regulatory Filings and Regulatory Approvals.  For purposes of this Section 14.6.1 (Product by Product Termination), references to Product in the defined terms Regulatory Filings and Regulatory Approvals shall be replaced with references to Terminated Product.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the applicable notice period prior to the Termination Effective Date, the Terminating Party will continue to meet its obligations to develop, manufacture, and commercialize Products within the Collaboration Scope, in accordance with the applicable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Development Plan, Brand Plan and Country Plan and this Agreement and bear its proportionate share of expenses with respect thereto, unless otherwise agreed by the Parties or specified in this Section 14.6 (Effects of Termination).  Upon request by the Continuing Party, the Terminating Party will undertake reasonable efforts to effect a smooth and orderly transition of all development, manufacturing and commercial activities and responsibilities under this Agreement with respect to the Terminated Product to the Continuing Party (or, in the case of manufacturing activities, to a mutually agreed upon Third Party contract manufacturer), as soon as reasonably possible, to enable the Continuing Party to continue the development, manufacturing  and commercialization of the Terminated Product in the Continuing Scope.  Without limiting the foregoing&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:112.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Continued Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Terminating Party will transfer to the Continuing Party all quantities of the Terminated Product in its possession for which the manufacturing costs were shared by the Parties under Article 7 (Profit&#47;Expense Sharing).  In addition, the Terminating Party will, at the Continuing Party&#8217;s cost and expense, reasonably cooperate, as requested by the Continuing Party, to ensure uninterrupted supply of the Terminated Product.  To the extent the Terminating Party was responsible for manufacturing the Terminated Product as of the Termination Effective Date, then the Terminating Party will continue to provide for manufacturing of such Terminated Product for the Continuing Party, at the fully-burdened manufacturing cost therefore, from the date of notice of such termination with respect to such Terminated Product, until the sooner to occur of such time as the Continuing Party is able, using Commercially Reasonable Efforts to do so, to secure an acceptable alternative manufacturing source from which sufficient quantities of Terminated Product may be procured or &#91;*&#93; months from the Termination Effective Date.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:112.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Terminating Party is, as of the Termination Effective Date, party to any Third Party contracts that pertain solely to the Continuing Scope with respect to a Terminated Product, then it will provide the Continuing Party notice and (to the extent permitted to do so) copies thereof&#59; and the Terminating Party will assign to the Continuing Party any such contracts requested by the Continuing Party, to the extent it has the right under such contract(s) to do so (and will use Commercially Reasonable Efforts to obtain any required consents).  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.6.1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30pt">Distracting Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything herein to the contrary, if Amgen is terminating this Agreement pursuant to Section 14.2 (Termination for Convenience), Article 9 (Distracting Products) will continue to apply with respect to the Terminated Product for &#91;*&#93; thereafter.  In addition, for any termination hereunder, with respect to Article 9 (Distracting Product), each reference to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Product&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Product Target&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in the definitions of Distracting Product and Distracting Target will be deemed to a reference to include the Terminated Product and the Product Target corresponding to such Terminated Product. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.6.1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30pt">Amgen&#8217;s Rights outside Continuing Scope</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the foregoing provisions of this Section 14.6.1 (Product by Product Termination)&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Terminated Product Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Partner will grant, and hereby grants (effective upon the Termination Effective Date), to Amgen an &#91;*&#93;, royalty-free, &#91;*&#93; license, including the right to grant and authorize sublicenses, under the Partner Terminated Product IP and Partner&#8217;s rights in and to the Program Intellectual Property to use, sell, offer for sale and import Terminated Products in the Excluded Territory, and to make and have made the Terminated Product for use and sale in the Excluded Territory, and the last sentence of Section 2.2 (Ex-Territory Activities) shall continue to apply with respect to the Terminated Product.  In addition, Amgen will retain, and not assign to Partner, Amgen&#8217;s right, title or interest in the Terminated Product Trademarks in the Excluded Territory.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Terminated Product Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Amgen is the Terminating Party with respect to a Terminated Product, upon request by Amgen from time to time, Partner will promptly provide to Amgen at no cost, copies of Terminated Product Data then in Partner&#8217;s possession or control that relate to such Terminated Product, for use in the Excluded Territory in relation to the Terminated Product.  Such Terminated Product Data will be provided in electronic form reasonably usable by Amgen and, if reasonably necessary or useful in connection with Amgen&#8217;s (or its designee&#8217;s) further commercialization, development or exploitation of Terminated Products in the Excluded Territory, will include original hardcopies or duplicate copies thereof, as required.    </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Filings&#59; Regulatory Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Partner will grant, and does hereby grant (effective upon the Termination Effective Date), to Amgen an exclusive and irrevocable right of access and reference to any and all Regulatory Filings and Regulatory Approvals for the Terminated Product for purposes in the Excluded Territory, and will cooperate fully to make the benefits of such Regulatory Filings and Regulatory Approvals available to Amgen or its designee(s) for purposes in the Excluded Territory.  Promptly upon request by Amgen from time to time, Partner will provide to Amgen copies of all Regulatory Filings and Regulatory Approvals (and all underlying data) with respect to such Terminated Product held by or on behalf of Partner.    </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Excluded Territory Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that Amgen is the Terminating Party for either AMG827 or AMG557, Partner, at the request of Amgen, will enter into good faith negotiations for the purpose of establishing direct communications and engagement between Partner and (i) Kirin-Amgen, Inc., in the case of AMG827, and (ii) Takeda Pharmaceutical Company Limited, in the case of AMG557, as necessary to fulfill Amgen&#8217;s obligations under the applicable Excluded Territory Agreement. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.6.1.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30pt">Royalty Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On a Terminated Product-by-Terminated Product basis, other than with respect to the AMG157 Termination Event, the Continuing Party will pay to the Terminating Party a tiered royalty on aggregate Terminated Product Net Revenues for such Terminated Product by the Continuing Party and its Affiliates (but not by its licensees or sublicensees) as follows&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:104.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.637%"><tr><td style="width:1.0%"></td><td style="width:50.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Calendar Year Net Revenues for Terminated Product</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Royalty Rate</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Less than or equal to &#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Greater than &#91;*&#93; and less than or equal to &#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Greater than &#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Additionally, &#91;*&#93;, the Continuing Party will pay to the Terminating Party &#91;*&#93; of any and all Sublicensing Revenues received by the Continuing Party and&#47;or its Affiliates.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Additionally, if Partner is the Continuing Party, Partner will pay to Amgen an additional royalty equal to the applicable Terminated Product Inventorship Margin on Terminated Product Net Revenues by Partner, its Affiliates and sublicensees.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:104.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Such royalty will be payable quarterly within thirty (30) days of the end of the calendar quarter for which such royalties are owed.   Each royalty payment will be accompanied by a report setting forth Partner&#8217;s calculation of Net Revenues and royalties owed for the applicable quarter.  For such purposes, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Terminated Product Net Revenues&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Net Revenues,&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Terminated Product Inventorship Margin&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> will mean the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Inventorship Margin,&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> but for such purposes substituting in such definitions (including in each definition referenced in such definitions) a reference to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Terminated Product&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for each reference to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Product&#59;&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and Sections 7.4 (Calculation of Net Revenues) and 8.3 (Currency) through 8.7 (Late Payment) (inclusive) will apply with respect to such royalty payments, mutatis mutandis.    </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.6.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:3pt">Termination of Agreement in Entirety.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event (i) this Agreement is terminated by Partner in its entirety under Section 14.2 (Termination for Convenience) or is terminated in its entirety under Sections 14.3 (Termination for Breach) through 14.5 (Termination for Challenge) (inclusive), or (ii) if as of the Termination Effective Date with respect to a Terminated Product, there are no other Products then being developed or commercialized under this Agreement, and Partner is not then developing or commercializing a Terminated Product as the Continuing Party under Section 14.6.1 (Product by Product Termination) above&#59; then in either such case, the Agreement will terminate in whole, and all provisions of this Agreement will terminate as of the effective date of such termination, except as expressly set forth in Sections 14.6.1 (Product by Product Termination) and 14.6.3 (Survival) below. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.6.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:3pt">Survival.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Articles 1 (Definitions), 7 (Profit&#47;Expense Sharing) (with respect to periods prior to termination), 8 (Payments) (with respect to periods prior to termination), 9 (Distracting Products) (only with respect to such continuing periods as expressly referenced in such Article), 13 (Indemnification and Insurance) (with respect to periods prior to termination), and 15 (Miscellaneous) and Sections 2.2 (Ex-Territory Activities), 3.4 (Product Complaints, Recalls and Returns), 5.8 (Detailing Reports and Audit Rights) (with respect to periods prior </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to termination), 5.9 (Competing Products) (with respect to periods prior to termination), 10.1 (Invention Ownership), 10.3 (Joint Ownership), 10.4 (License Grant by Amgen) (only with respect to the transition period referenced in clause (vii) of Section 14.6.1.3 (Transition)), 10.5 (License Grant by Partner), 10.8 (Enforcement) (with respect to enforcement against activities that took place prior to or termination), 10.9 (Patent Term Extensions) (with respect to periods prior to termination), 10.10.3 (Housemark Licenses) (with respect to the transition period referenced in clause (vii) of Section 14.6.1.3 (Transition) and the sell-off period referenced therein), 11.1 (Confidentiality&#59; Exceptions), 11.2 (Authorized Disclosure), 11.3 (Confidential Treatment of Terms and Conditions), 11.5 (Prior Agreement), and this 14.6 (Effects of Termination) (with all Products deemed Terminated Products and Amgen being the Continuing Party for all Terminated Products) will survive termination of this Agreement for any reason.  Except as otherwise provided in this Section 14.6 (Effects of Termination), all rights and obligations of the Parties under this Agreement will terminate upon termination of this Agreement for any reason.    </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.6.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:3pt">No Limitation of Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The rights provided in this Article 14 (Term and Termination) will be in addition and without prejudice to any other rights which the Parties may have with respect to any default or breach of the provisions of this Agreement.  Termination is not the sole remedy under this Agreement and, whether or not termination is effected, all other remedies at equity or law will remain available to the Parties except as expressly agreed otherwise herein.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:3pt">MISCELLANEOUS</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party will have the right to exercise its rights and perform its obligations hereunder through its Affiliates (including by licensing rights hereunder where such rights are held in the name of any such Affiliate)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that such Party will be responsible for its Affiliates&#8217; performance hereunder.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred (whether by operation of Applicable Law, general succession or otherwise) by either Party without the prior written consent of the other Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that either Party may assign this Agreement, or rights and obligations hereunder, without prior written consent to any Affiliate (as long as such entity remains an Affiliate of the relevant Party), or in connection with the transfer or sale of all or substantially all of the business to which this Agreement relates.  Any assignment not in accordance with this Agreement will be void ab initio.  Subject to the foregoing, the rights and obligations of the Parties under this Agreement will be binding upon and inure to the benefit of the successors and permitted assigns of the Parties.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Choice of Law&#59; Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement will be governed by, and enforced and construed in accordance with, the laws of the State of New York without regard to its conflicts of law provisions, except as to any issue which depends upon the validity, scope or enforceability of any Patent, which issue will be determined in accordance with the laws of the country in which such patent was issued.  Each of the Parties hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the state and federal courts of the State of New York for any matter arising out of or relating to this Agreement and the transactions contemplated hereby, and agrees not to commence any litigation relating thereto except in such courts.  Each of the Parties hereby irrevocably and unconditionally waives any objection to the laying of venue of any matter arising out of this Agreement or the transactions contemplated hereby in the state and federal courts of the State of New York and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such matter brought in any such court has been brought in an inconvenient forum.  The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Parties agree that a final judgment in any such matter will be conclusive and may be enforced in other jurisdictions by suits on the judgment or in any other manner provided by law.  Any proceeding brought by either Party under this Agreement will be exclusively conducted in the English language.  The United Nations Convention for the International Sale of Goods will not apply to the transactions contemplated herein.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The definitions of the terms herein will apply equally to the singular and plural forms of the terms defined.  Whenever the context may require, any pronoun will include the corresponding masculine, feminine and neuter forms.  The words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; will be deemed to be followed by the phrase &#8220;without limitation&#8221;.  The word &#8220;or&#8221; is used in the inclusive sense (and&#47;or).  The Parties each acknowledge that they have had the advice of counsel with respect to this Agreement, that this Agreement has been jointly drafted, and that no rule of strict construction will be applied in the interpretation hereof.  Unless the context requires otherwise&#58; (i) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein)&#59; (ii) any reference to any Applicable Law herein will be construed as referring to such Applicable Law as from time to time enacted, repealed or amended&#59; (iii) any reference herein to any person will be construed to include the person&#8217;s permitted successors and assigns&#59; (iv) the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof&#59; and (v) all references herein to Articles, Sections, or Schedules, unless otherwise specifically provided, will be construed to refer to Articles, Sections or Schedules of this Agreement.  This Agreement has been executed in English, and the English version of this Agreement will control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in counterparts with the same effect as if both Parties had signed the same document.  All such counterparts will be deemed an original, will be construed together and will constitute one and the same instrument.  Signature pages of this Agreement may be exchanged by facsimile or other electronic means without affecting the validity thereof.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement, including the attached Schedules, constitutes the entire agreement between the Parties as to the subject matter of this Agreement, and supersedes and merges all prior or contemporaneous negotiations, representations, agreements and understandings regarding the same.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither Party will be liable for delay or failure in the performance of any of its obligations hereunder (other than the payment of money) to the extent such delay or failure is due to causes beyond its reasonable control, including acts of God, fires, floods, pandemics, earthquakes, labor strikes, acts of war, terrorism or civil unrest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Force Majeure&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the affected Party promptly notifies the other Party in writing (and continues to provide monthly status updates to the other Party for the duration of the effect)&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> further that the affected Party uses its Commercially Reasonable Efforts to avoid or remove such causes of non-performance and to mitigate the effect of such occurrence, and will continue performance with reasonable dispatch whenever such causes are removed.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party agrees to do and perform all such further acts and things and will execute and deliver such other agreements, certificates, instruments and documents necessary or that the other Party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and to evidence, perfect or otherwise confirm its rights hereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Headings and captions are for convenience only and are not to be used in the interpretation of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt;text-decoration:underline">No Set-Off</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as expressly set forth in Section 7.2.9 (True-Up), Section 8.6.1 (Withholding) or Section 8.6.2 (Indirect Taxes), no Party will have the right to deduct from amounts otherwise payable hereunder any amounts payable to such Party (or its Affiliates) from the other Party (or its Affiliates), whether pursuant to this Agreement or otherwise.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given by this Agreement will be in writing, in English, and will be delivered by hand or overnight courier with tracking capabilities or mailed postage prepaid by registered or certified mail addressed as set forth below unless changed by notice so given&#58;</font></div><div style="padding-left:117.35pt;text-indent:-81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to Amgen&#58;&#160;&#160;&#160;&#160;Amgen Inc.<br>One Amgen Center Drive</font></div><div style="padding-left:117.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Thousand Oaks, California 91320-1799</font></div><div style="padding-left:117.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58;  Corporate Secretary  <br>Telephone&#58;  805-447-1000<br>Facsimile&#58;  &#91;*&#93;</font></div><div style="padding-left:117.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to Partner&#58;&#160;&#160;&#160;&#160;   AstraZeneca Collaboration Ventures, LLC</font></div><div style="padding-left:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">One MedImmune Way</font></div><div style="padding-left:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Gaithersburg, Maryland 20878</font></div><div style="padding-left:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58;  President</font></div><div style="padding-left:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Telephone&#58;  &#91;*&#93;</font></div><div style="padding-left:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Facsimile&#58;  &#91;*&#93;</font></div><div style="padding-left:117pt"><font><br></font></div><div style="padding-left:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">With a copy to the Secretary of AstraZeneca Collaboration Ventures, LLC at the above address.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any such notice will be deemed given on the date delivered.  A Party may add, delete (so long as at least one person is remaining), or change the person or address to which notices should be sent at any time upon written notice delivered to the other Party in accordance with this Section 15.11 (Notices).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt;text-decoration:underline">Relationship of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160; Each Party is an independent contractor under this Agreement.&#160; Nothing contained herein will be deemed to create an employment, agency, joint venture or partnership relationship between the Parties or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other Party.&#160; The Parties will operate their own businesses separately and independently and they will hold themselves out as, act as, and constitute independent contractors in all respects and not as principal and agent, partners or joint venturers.  Neither party will have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever.&#160; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the fullest extent permitted by Applicable Law, the Parties waive any provision of Applicable Law that would render any provision in this Agreement invalid, illegal or unenforceable in any respect.  If any provision of this Agreement is held to be invalid, illegal or unenforceable, in any respect or to any extent, then in such respect and to such extent such provision will be given no effect by the Parties and will not form part of this Agreement.  To the fullest extent permitted by Applicable Law, all other provisions of this Agreement will remain in full force and effect and the Parties will use their commercially reasonable efforts to negotiate a provision in replacement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the provision held invalid, illegal or unenforceable that is consistent with Applicable Law and achieves, as nearly as possible, the original intention of the Parties. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt;text-decoration:underline">Third Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as expressly provided with respect to Amgen Indemnitees or Partner Indemnities in Article 13 (Indemnification and Insurance), there are no Third Party beneficiaries intended hereunder and no Third Party will have any right or obligation hereunder.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt;text-decoration:underline">Waivers and Modifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The failure of any Party to insist on the performance of any obligation hereunder will not be deemed to be a waiver of such obligation.  Waiver of any breach of any provision hereof will not be deemed to be a waiver of any other breach of such provision or any other provision on such occasion or any other occasion.  No waiver, modification, release or amendment of any right or obligation under or provision of this Agreement will be valid or effective unless in writing and signed by all Parties hereto. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#91;*&#93;.</font></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">*********</font></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Signature page follows)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</font></div><div><font><br></font></div></div></div><div id="i841f4189a89841e58389acdfd7f2e502_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ASTRAZENECA COLLABORATION&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;AMGEN INC.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VENTURES, LLC</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Peter Greenleaf&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;By&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; David J. Scott&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Peter Greenleaf&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58;   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">David J. Scott&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">President&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Title&#58;   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SVP, General Counsel &#38; Secretary&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ASTRAZENECA PHARMACEUTICALS LP&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Ann Booth Barbarin&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Ann Booth Barbarin&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assistant Secretary&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;S-1</font></div></div></div><div id="i841f4189a89841e58389acdfd7f2e502_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMG827 Territory</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.489%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Column 1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Column 2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Column 3</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">European Countries</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Central and South American Countries</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">African and Middle East Countries</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Albania</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antigua and Barbuda</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Algeria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andorra</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angola</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Armenia</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bahamas</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bahrain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barbados</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angola</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Azerbaijan</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belize</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benin</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belarus</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bolivia</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Botswana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Burkina Faso</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bosnia-Herzg.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chile</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cameroon</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bulgaria</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central African Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Croatia</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Congo (Democratic Republic of)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cuba</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Congo (Republic of the)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dominica</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cote D&#8217;Ivoire&#47;Ivory Coast</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estonia</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dominican Republic</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cyprus</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finland</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ecuador</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Djibouti</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">El Salvador</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Georgia</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">French Guiana</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eritrea</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grenada</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ethiopia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greece</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Guatemala</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gabon</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hungary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Guyana</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gambia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iceland</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Honduras</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ghana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jamaica</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gibraltar</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nicaragua</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greenland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latvia</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panama</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iran</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lithuania</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paraguay</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iraq</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liechtenstein</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peru</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saint Kitts and Nevis</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jordan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Macedonia</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saint Lucia</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kazakhstan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malta</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saint Vincent and the Grenadines</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenya</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moldova</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Suriname</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kuwait</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monaco</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trinidad and Tobago</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kyrgyzstan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uruguay</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesotho</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norway</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Venezuela</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lebanon</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liberia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libya</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Romania</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Madagascar</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malawi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Marino</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mauritania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serbia and Montenegro</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mauritius</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.489%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Column 1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Column 2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Column 3</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovakia</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Morocco</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovenia</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mozambique</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Namibia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Niger</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nigeria</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oman</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Qatar</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rwanda</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saudi Arabia</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senegal</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seychelles</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sierra Leone</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Somalia</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sudan</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swaziland</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Syria</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tajikistan</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tanzania</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tunisia</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkmenistan</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uganda</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uzbekistan</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yemen</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zambia</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zimbabwe</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i841f4189a89841e58389acdfd7f2e502_16"></div><hr style="page-break-after:always"><div style="min-height:58.32pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amgen Distribution Countries</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.946%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td><td colspan="3" style="background-color:#ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td><td colspan="3" style="background-color:#ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td><td colspan="3" style="background-color:#ffffff;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="6" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i841f4189a89841e58389acdfd7f2e502_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercial Allocation</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMG827-</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Respiratory- </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Partner will have the sole right to Detail Products in the Respiratory market in the Collaboration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Territory.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Rheumatology- </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Amgen will have the sole right to Detail Products in the Rheumatology market in North America, Europe, Australia and New Zealand.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the Rheumatology market in all other countries in the Collaboration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Territory, the Parties shall enter into discussions regarding the allocation of Details beginning &#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior to the anticipated first commercial launch of AMG827 for a Rheumatology indication.  The JSC shall agree upon the allocation of Details between the Parties taking into account all relevant factors &#91;*&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that if the JSC is unable to agree upon the allocation of Details in any country, then such matter shall be escalated to the CRC&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, further, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that if the CRC is unable to agree upon the allocation of Details in any country, &#91;*&#93;.  To the extent less than one hundred percent (100%) of the Details in any such country have been allocated to the Parties, the Parties shall &#91;*&#93;.  If the Parties in the aggregate elect to Detail in excess of one hundred percent (100%) of the Details in any such country, then each Party will be entitled to only &#91;*&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Dermatology- </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Amgen will have the sole right to Detail Products in the Dermatology market in North America.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the Dermatology market in all other countries in the Collaboration Territory, Partner will have the sole right to Detail Products, provided, that, to the extent Amgen has or develops a commercial capability to Detail Products consistent with the Brand Plan in the Dermatology market in any such country, so that in such country Amgen would have the capability to provide &#91;*&#93; percent (&#91;*&#93;%) of the Details in that country, Amgen will have the right to provide &#91;*&#93; percent (&#91;*&#93;%) of such Details in such country, provided that Amgen shall not have the right to provide Details in countries which collectively represent in excess of &#91;*&#93; percent (&#91;*&#93;%) of &#91;*&#93; of all countries in the Collaboration Territory &#91;*&#93;.  If Amgen determines that it wishes to build a commercial capability in a country (without necessarily having sufficient capability to provide &#91;*&#93; percent (&#91;*&#93;%) of the Details in that country) the Parties will discuss in good faith allocation of Details in such country to determine what is in the best interests of the Product in that country according to the then current Brand Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Additional Indications-</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For all market segments other than Respiratory, Rheumatology and Dermatology, the Parties shall enter into discussions regarding the allocation of Details beginning &#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior to the anticipated first commercial launch of AMG827 for such market segment.  The JSC shall agree upon the allocation of Details between the Parties taking into account all relevant factors &#91;*&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that if the JSC is unable to agree upon the allocation of Details in any country, then such matter shall be escalated to the CRC&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, further, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that if the CRC is unable to agree upon the allocation of Details in any country, &#91;*&#93;.  To the extent less than one hundred percent (100%) of the Details in any such country have been allocated to the Parties, the Parties shall &#91;*&#93;.  If the Parties in the aggregate elect to Detail in excess of one hundred percent (100%) of the Details in any such country, then each Party will be entitled to only &#91;*&#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Definitions-</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Dermatology&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the branch of medicine dealing with the skin and its diseases or disorders, including psoriasis and atopic dermatitis.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Respiratory&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the branch of medicine dealing with inflammatory respiratory diseases or disorders and obstructive respiratory diseases or disorders, including asthma and chronic obstructive pulmonary disease (COPD).</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Rheumatology&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the branch of medicine dealing with rheumatic diseases or disorders, including rheumatoid arthritis, systemic lupus erythematosus (SCE), psoriatic arthritis, and ankylosing spondylitis.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">All Other Products-</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For all other Products, the Parties shall, on a market segment basis, enter into discussions regarding the allocation of Details for a Product beginning &#91;*&#93; prior to the anticipated first commercial launch of such Product for such market segment.  The JSC shall agree upon the allocation of Details between for such Product in such market segment the Parties taking into account all relevant factors (&#91;*&#93;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that if the JSC is unable to agree upon the allocation of Details in any country, then such matter shall be escalated to the CRC&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, further, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that if the CRC is unable to agree upon the allocation of Details in any country, &#91;*&#93;.  To the extent less than one hundred percent (100%) of the Details in any such country have been allocated to the Parties, the Parties shall &#91;*&#93;.  If the Parties in the aggregate elect to Detail in excess of one hundred percent (100%) of the Details in any such country, then each Party will be entitled to only &#91;*&#93;.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i841f4189a89841e58389acdfd7f2e502_22"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Completed Clinical Trials</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMG 139</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">Ph 1a FIH single ascending dose study (20080767)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMG 157</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">Ph 1a FIH single ascending dose study (20070620)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">Ph 1b multiple ascending dose study (20080390)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMG 557</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">Ph 1a FIH single ascending dose study in SLE subjects (2006132)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">Ph 1b MAD in SLE subjects (2007169) </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMG 827 </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">Ph1 device preference study in HV (20110106)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">Ph 1a FIH single ascending dose study (20060279)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">Ph 1b multiple ascending dose study in RA (20070264)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">Ph 2 multiple dose, dose ranging study in RA (20090061)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">Ph 2 open label extension study in RA (20090402)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">Ph 2 multiple dose, dose ranging study in psoriasis (20090062)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">Ph 2 multiple dose, dose ranging study in CD (20090072)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">Ph 2 open label extension study in CD (201000008)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">Ph 2 multiple dose, dose ranging study in asthma (20090203)</font></div><div style="padding-left:36pt"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;*&#93; Designated Endpoints &#91;*&#93;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All of the following criteria must be met for a go decision to commence a &#91;*&#93; Trial.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#183;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.45pt">&#91;*&#93;&#58; A statistically significant &#91;*&#93; and clinically significant (&#91;*&#93;) change in &#91;*&#93; from &#91;*&#93; at &#91;*&#93; for &#91;*&#93; and the &#91;*&#93; performs similarly to or better than the &#91;*&#93;.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#183;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.45pt">&#91;*&#93;&#58; A trend in &#91;*&#93; of &#91;*&#93; from &#91;*&#93; for &#91;*&#93; and the &#91;*&#93;. &#91;*&#93; are defined as &#91;*&#93; leading to &#91;*&#93; for &#91;*&#93;. The &#91;*&#93; in &#91;*&#93; will be &#91;*&#93; with the &#91;*&#93;. If the &#91;*&#93;, then &#91;*&#93; and the &#91;*&#93;.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#183;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.45pt">&#91;*&#93;&#58; There are no &#91;*&#93; that &#91;*&#93;.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development&#47;Commercial Lead</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:117.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.253%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amgen</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Partner</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG827</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG139</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG557</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG157</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG181</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">-</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.45pt">Specifically with regard to AMG827 at the global level, the Parties will work closely through the JPT on the commercial strategy for the Respiratory market for AMG827 with Amgen taking the primary responsibility for &#91;*&#93;.    </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.45pt">&#91;*&#93;. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.45pt">The Parties will cooperate to ensure that &#91;*&#93; is made available to the JPT at both the global and regional level.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.45pt">This arrangement will be noted in the press release and other approved communications as &#8220;&#91;*&#93;&#8221; or with words of similar import.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i841f4189a89841e58389acdfd7f2e502_25"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Distracting Product</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.807%"><tr><td style="width:1.0%"></td><td style="width:18.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Product</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Product Target</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Distracting Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">*</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG 139</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG 157</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG 181</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG 557</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG 827</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Distracting Target includes (i) any &#91;*&#93;&#59; (ii) any &#91;*&#93;&#59; (iii)&#160;any &#91;*&#93;&#59; (iv) any &#91;*&#93;&#59; and (v) any &#91;*&#93;. For avoidance of doubt, the Distracting Product Schedule lists &#91;*&#93;.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i841f4189a89841e58389acdfd7f2e502_28"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Invoice</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amgen Inc. </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Invoice Template </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2nd Quarter 2012 - Example Period </font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:0.24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:11.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.991%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.013%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">A</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">B</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">C&#160;&#61;&#160;A&#160;+&#160;B</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">D</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">E</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">F&#160;&#61;&#160;D&#160;+&#160;E</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">G&#160;&#61;&#160;A&#160;-&#160;F</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" rowspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-style:italic;font-weight:700;line-height:100%">&#60;&#60;&#60;&#160;Amount&#160;Billed&#160;or&#160;Reimbursed&#160;to&#160;Partner</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="30" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total&#160;Quarterly&#160;Spend*</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="30" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amgen&#8217;s Share of...**</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount&#160;due</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">Product</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amgen</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Partner</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amgen&#8217;s&#160;Spend</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Partner&#8217;s&#160;Spend</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total&#160;Spend</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(From)&#47;To&#160;Amgen</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:15.35pt;text-indent:-12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;139&#160;&#160;</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:17pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:15.35pt;text-indent:-12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;157&#160;&#160;</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:17pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:15.35pt;text-indent:-12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;181&#160;&#160;</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:17pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:15.35pt;text-indent:-12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;557&#160;&#160;</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:17pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:15.35pt;text-indent:-12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;827&#160;&#160;</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:15.35pt;text-indent:-12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">Notes </font></div><div style="margin-top:1.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">* Total spend derived from Column K on Page 2 and Column C on Page 3 </font></div><div style="margin-top:1.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">** Amgen&#8217;s Share of Total Spend derived from Column L on Page 2 and Column D on Page 3 </font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amgen Inc. </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Invoice Template </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2nd Quarter 2012 - Example Period </font></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Step 1&#58; Calculation of Total </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">AMGEN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> Cost less Amount Reimbursed by 3rd Party </font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.873%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.947%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.873%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.947%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.120%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.947%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.640%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.120%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.827%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">A</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">B</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">C&#160;&#61;&#160;A&#160;+&#160;B</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">D&#160;&#61;&#160;C&#160;x&#160;35%</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">E&#160;&#61;&#160;C&#160;-&#160;D</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">F</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">G</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">H&#160;&#61;&#160;F&#160;+&#160;G</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">I&#160;&#61;&#160;H&#160;x&#160;70%</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">J&#160;&#61;&#160;H&#160;-&#160;I</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">K&#160;&#61;&#160;C&#160;+&#160;H</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">L&#160;&#61;&#160;D&#160;+&#160;I</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">M&#160;&#61;&#160;E&#160;+&#160;J</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="54" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Costs Excluding AMG827 Ph2b<br>Asthma Study</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="54" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Costs for AMG827 Ph2b Asthma<br>Study</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="30" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Amgen Costs</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="30" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:100%">Gross Spend</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:100%">Amgen</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:100%">Share</font></div></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:100%">Partner</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:100%">Share</font></div></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="30" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:100%">Gross Spend</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:100%">Amgen</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:100%">Share</font></div></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.5pt;font-weight:700;line-height:100%">Partner</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.5pt;font-weight:700;line-height:100%">Share</font></div></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">Function</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">Product</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:700;line-height:100%;text-decoration:underline">OSE</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:700;line-height:100%;text-decoration:underline">FTE</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:700;line-height:100%;text-decoration:underline">Total</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:700;line-height:100%;text-decoration:underline">35%</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:700;line-height:100%;text-decoration:underline">65%</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:700;line-height:100%;text-decoration:underline">OSE</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:700;line-height:100%;text-decoration:underline">FTE</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:700;line-height:100%;text-decoration:underline">Total</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:700;line-height:100%;text-decoration:underline">70%</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:700;line-height:100%;text-decoration:underline">30%</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:700;line-height:100%;text-decoration:underline">Total</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:700;line-height:100%">Amgen</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:700;line-height:100%">Share</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:700;line-height:100%">Partner</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:700;line-height:100%">Share</font></div></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" rowspan="6" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:7.67pt;padding-right:7.67pt;text-align:center;text-indent:-12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:700;line-height:100%">R&#38;D</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;139</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;157</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;181</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;557</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;827</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Sub-Total&#160;R&#38;D</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" rowspan="6" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:7.67pt;padding-right:7.67pt;text-align:center;text-indent:-12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:700;line-height:100%">Operations</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG 139</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;157</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;181</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;557</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;827</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Sub-Total&#160;Ops</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" rowspan="6" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:7.67pt;padding-right:7.67pt;text-align:center;text-indent:-12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:700;line-height:100%">Commercial</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG 139</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;157</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;181</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;557</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;827</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:26pt"><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Sub-Total&#160;Comm&#8217;l&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" rowspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.75pt;margin-top:0.05pt;padding-left:7.67pt;padding-right:7.67pt;text-align:center;text-indent:-12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG 139</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;157</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;181</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;557</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:0 1pt"></td><td colspan="3" style="background-color:#d8d8d8;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">AMG&#160;827</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Grand&#160;Total</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="background-color:#ffff00;border-bottom:1.5pt solid #000000;border-left:0.75pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffff00;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="background-color:#ffff00;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="background-color:#ffff00;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="background-color:#ffff00;border-bottom:1.5pt solid #000000;border-left:0.75pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffff00;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="background-color:#ffff00;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="background-color:#ffff00;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="background-color:#ffff00;border-bottom:1.5pt solid #000000;border-left:0.75pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffff00;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="background-color:#ffff00;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">-&#160;&#160;</font></td><td colspan="3" style="background-color:#ffff00;border-bottom:1.5pt solid #000000;border-right:0.75pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;&#160;</font></td></tr></table><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%;text-decoration:underline">Notes </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1. Page reflects Total Costs Incurred by&#47;Reimbursed to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">AMGEN only</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2. The values in the &#8220;Total&#8221; Row will be used for the following purposes on Page 1 </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">- Determine the combined (Amgen + Partner) Total Cost of all programs in a quarter </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">- Deduct the actual expenses incurred&#47;paid by Amgen from Amgen&#8217;s share of quarterly expenses </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amgen Inc. </font></div><div style="margin-top:1.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Invoice Template</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:1.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2nd Quarter 2012 - Example Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><font><br></font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Costs Incurred by Partner</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:0.19pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:15.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.433%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">A</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">B</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">C&#160;&#61;&#160;B+A</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">D&#160;&#61;&#160;35%&#160;x&#160;C</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">E &#61; C-D</font></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amgen <br>Share</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Partner&#160;Share</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Function</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;FTE&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;OSE&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Total&#160;<br>Costs&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">65%</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">R&#38;D</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMG 139</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMG 157</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMG 181</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMG 557</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMG 827</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160; &#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operations</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMG 139</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMG 157</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMG 181</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMG 557</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMG 827</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160; &#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMG 139</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMG 157</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMG 181</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMG 557</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMG 827</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160; &#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMG 139</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMG 157</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMG 181</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMG 557</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMG 827</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160; &#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="background-color:#ffff00;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td><td colspan="3" style="background-color:#ffff00;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td><td colspan="3" style="background-color:#ffff00;border-bottom:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;</font></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:1.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1. On this tab, Amgen will capture the quarterly spend incurred by partner for aggregation purposes </font></div><div style="margin-top:1.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2. Table above is a placeholder&#47;stand-in which will be replaced by the quarterly actual cost summary provided by partner </font></div><div style="margin-top:1.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3. The values in the &#8220;Total&#8221; Row will be used for the following purposes on Page 1 </font></div><div style="margin-top:1.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">- Determine the combined (Amgen + Partner) Total Cost of all programs in a quarter </font></div><div style="margin-top:1.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">- Deduct the actual expenses incurred&#47;paid by partner from the partner&#8217;s share of quarterly expenses </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Press Release</font></div><div><font><br></font></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></div><div><font><br></font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">News Release </font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:18pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AMGEN AND ASTRAZENECA ANNOUNCE COLLABORATION </font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">TO JOINTLY DEVELOP AND COMMERCIALIZE CLINICAL- </font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">STAGE INFLAMMATION PORTFOLIO </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Collaboration Comprises Five Monoclonal Antibodies </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Brodalumab (AMG 827) Phase 3 Trial Planned in 2012 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">THOUSAND OAKS, Calif. and LONDON (April 2, 2012)&#8212;Amgen (NASDAQ&#58;AMGN) and AstraZeneca Plc, today announced an agreement to jointly develop and commercialize five monoclonal antibodies from Amgen&#8217;s clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827)). </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The companies believe all the molecules have novel profiles and offer the potential to deliver important treatments across multiple indications in inflammatory diseases. The collaboration will provide Amgen with additional resources to optimally progress its portfolio, and Amgen will benefit from the strong respiratory, inflammation and asthma development expertise of MedImmune, AstraZeneca&#8217;s biologics arm. The collaboration will also capitalize on AstraZeneca&#8217;s global commercial reach in respiratory and gastrointestinal diseases. The agreement does not include certain territories previously partnered by Amgen for brodalumab with Kyowa Hakko Kirin and AMG 557 with Takeda. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the terms of the agreement, AstraZeneca will make a one-time $50 million upfront payment and the companies will share both costs and profits. Based on current plans, approximately 65 percent of costs for the 2012-2014 period will be funded by AstraZeneca. Thereafter, the companies will split costs equally. Amgen will book sales globally and will retain a low single-digit royalty for brodalumab and a mid single-digit royalty for the rest of the portfolio, after which the companies will share profits equally. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca will lead the development and commercialization strategy of AMG 139, AMG 157 and AMG 181, while Amgen will lead the development and commercialization strategy of brodalumab and AMG 557. Each development and commercialization lead will be under the oversight of joint governing bodies. For brodalumab, commercial promotion will be split. Amgen will promote in dermatology indications in the United States (U.S.) and Canada, and in rheumatology indications in U.S., Canada and Europe. AstraZeneca will promote in respiratory and, initially, in dermatology indications of brodalumab across all territories outside the U.S., Canada and those markets where Amgen has existing partnerships. Allocation of promotional rights for other territories, indications and molecules will be agreed later between the companies. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;We are delighted to join forces with Amgen in developing and commercializing these novel clinical-stage assets that add value to our pipeline and build on our expertise in biologics. This creative collaboration will make the most of both companies&#8217; respective capabilities, including AstraZeneca&#8217;s extensive global reach, to help bring these potentially innovative treatment options for a variety of respiratory and inflammatory diseases to patients around the world,&#8221; said David Brennan, Chief Executive Officer, AstraZeneca. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;We are very excited at the prospect of collaborating with a well-respected organization like AstraZeneca to advance our inflammation pipeline,&#8221; said Kevin Sharer, Chairman and CEO at Amgen. &#8220;We believe this collaboration has the potential to bring more therapies to patients sooner, across more geographic areas. We are impressed with AstraZeneca&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">extensive experience in developing and launching products in the respiratory and gastroenterology areas, and believe this collaboration is an opportunity to work with a partner that has leading regulatory and commercial expertise in inflammation indications.&#8221; </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-ENDS- </font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO EDITORS </font></div><div style="margin-top:4.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">About the inflammation portfolio included in the agreement </font></div><div style="margin-top:4.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the agreement, the companies will jointly develop and commercialize the following five assets from Amgen&#8217;s clinical-stage portfolio&#58; </font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Brodalumab (AMG 827)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> is a human monoclonal antibody that binds to and blocks signaling via the IL-17 receptor. Brodalumab is being investigated for psoriasis (completed Phase 2 and planned Phase 3), psoriatic arthritis (Phase 2) and asthma (Phase 2). </font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMG 139 </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">is a human monoclonal antibody. AMG 139 is being investigated in Phase 1b for Crohn&#8217;s disease. </font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMG 181 </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">is a human monoclonal antibody. AMG 181 is being investigated in Phase 1a and Phase 1b for ulcerative colitis and Crohn&#8217;s disease. </font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMG 557</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> is a human monoclonal antibody that binds to B7-related protein 1 (B7RP-1). AMG 557 is being investigated in Phase 1b for autoimmune diseases such as systemic lupus erythematosus. </font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMG 157</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> is a human monoclonal antibody that blocks interaction of thymic stromal lymphopoietin (TSLP) with the TSLP receptor. AMG 157 is being investigated in Phase 1b for asthma. </font></div></td></tr></table></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">About Amgen </font></div><div style="margin-top:4.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science&#8217;s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people&#8217;s lives. To learn more about our pioneering science and our vital medicines, visit </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">www.amgen.com</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Follow us on </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">www.twitter.com&#47;amgen</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">About AstraZeneca </font></div><div style="margin-top:4.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit&#58; </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">www.astrazeneca.com</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amgen Forward Looking Statements </font></div><div style="margin-top:4.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This news release contains forward-looking statements that are based on Amgen&#8217;s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described.&#160;All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results.&#160;Forward-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen&#8217;s most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K.&#160;Please refer to Amgen&#8217;s most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to Amgen&#8217;s business.&#160;Unless otherwise noted, Amgen is providing this information as of April&#160;2, 2012 and expressly disclaims any duty to update information contained in this news release. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects.&#160;Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain&#59; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product.&#160;Further, preclinical results do not guarantee safe and effective performance of product candidates in humans.&#160;The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models.&#160;The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures.&#160;Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with Amgen&#8217;s products after they are on the market.&#160;Amgen&#8217;s business may be impacted by government investigations, litigation and products liability claims.&#160;Amgen depends on third parties for a significant portion of its manufacturing capacity for the supply of certain of its current and future products and limits on supply may constrain sales of certain of its current products and product candidate development. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, sales of Amgen&#8217;s products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement.&#160;Government and others&#8217; regulations and reimbursement policies may affect the development, usage and pricing of Amgen&#8217;s products.&#160;In addition, Amgen competes with other companies with respect to some of its marketed products as well as for the discovery and development of new products.&#160;Amgen believes that some of its newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Amgen&#8217;s products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with its products.&#160;In addition, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors and there can be no guarantee of Amgen&#8217;s ability to obtain or maintain patent protection for its products or product candidates.&#160;Amgen cannot guarantee that it will be able to produce commercially successful products or maintain the commercial success of its existing products.&#160;Amgen&#8217;s stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of its products or product candidates.&#160;Further, the discovery of significant problems with a product similar to one of Amgen&#8217;s products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on Amgen&#8217;s business and results of operations. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The scientific information discussed in this news release related to Amgen&#8217;s product candidates is preliminary and investigative.&#160;Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.&#160;Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated.&#160;Only the FDA can determine whether the products are safe and effective for these uses. Healthcare&#160;professionals should&#160;refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CONTACT&#58; Amgen, Thousand Oaks </font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christine Regan, 805-447-5476 (media) </font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arvind Sood, 805-447-1060 (investors) </font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:18pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASTRA ZENECA CONTACTS </font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:27pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:0.07pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.606%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.896%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.918%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Media&#160;Enquiries</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Esra Erkal-Paler</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+44 20 7604 8030</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sarah Lindgreen</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+44 20 7604 8033</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investor&#160;Enquiries&#160;UK</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="padding-left:0.02pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.792%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Ward-Lilley</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+44 20 7604 8122 mob&#58; +44 7785 432613</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karl H&#229;rd</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+44 20 7604 8123 mob&#58; +44 7789 654364</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nicklas Westerholm</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+44 20 7604 8124 mob&#58; +44 7585 404950</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investor Enquiries&#160;US</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ed Seage</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+1 302 886 4065 mob&#58; +1 302 373 1361</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jorgen Winroth</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+1 212 579 0506 mob&#58; +1 917 612 4043</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i841f4189a89841e58389acdfd7f2e502_31"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Products</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.793%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Product</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG 139</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG 157</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG 181</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG 557</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG 827</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i841f4189a89841e58389acdfd7f2e502_34"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Profit (Loss) Example</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This schedule provides examples of the calculation of the Inventorship Margin and the calculation of the Profit (Loss) True-Up pursuant to Section 7.2.8 (Calculation of Profit (or Loss)).</font></div><div style="margin-bottom:12pt;margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">I.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Inventorship Margin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Assume for purposes of this example that Net Revenues are as follows&#58;  </font></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.306%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Q1 2017</font></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Q2 2017</font></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Q3 2017</font></td><td colspan="3" style="border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Q4 2017</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Net Revenues (excluding AMG827)&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-right:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Net Revenues (AMG827 only)&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-right:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-left:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-right:1.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Taking the third quarter as a representative example, the Inventorship Margin would be calculated as follows&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In Q3 2017, quarterly Net Revenues (excluding AMG827) are &#91;*&#93; and quarterly Net Revenues (AMG827 only) are &#91;*&#93;.  The &#91;*&#93;% rate is applied to the &#91;*&#93; in Q3 2017 Net Revenues (excluding AMG827) and the &#91;*&#93;% rate is applied to the &#91;*&#93; in Q3 2017 Net Revenues (AMG827 only).  The Inventorship Margin for the quarter is therefore &#91;*&#93; (&#91;*&#93; x &#91;*&#93; + &#91;*&#93; x &#91;*&#93; &#61; &#91;*&#93;).</font></div><div style="margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">II.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Collaboration Profit (Loss)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To determine the Collaboration Profit (Loss) in accordance with Section 7.2.8 (Calculation of Profit (or Loss)), each Party&#8217;s share of Net Revenues must be determined pursuant to Section 7.2.8.2 (Profits) and Total Costs pursuant to Section 7.2.8.1 (Costs) for the quarter.  </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Assume for purposes of this example that Net Revenues for Q3 2017 are &#91;*&#93; and the Inventorship Margin is &#91;*&#93; (consistent with the example above).  Further assume the following for Q3 2017&#58;  </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:3.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amgen</font></td><td colspan="3" style="border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Partner</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Net Revenues</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-right:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Inventorship Margin</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-right:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Share of Net Revenues</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-right:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaboration Costs</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-right:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">True-Up Payment</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-right:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-right:1.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In such a case, each Party&#8217;s share of Net Revenues for Q3 2017 would be &#91;*&#93; (&#91;*&#93;-&#91;*&#93; &#61; &#91;*&#93; &#47; &#91;*&#93; &#61; &#91;*&#93;). </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Party&#8217;s share of the Total Costs for Q3 2017 would be &#91;*&#93;, representing Total Costs of &#91;*&#93; multiplied by the Quarterly Cap of 50% for Q3 2017.  In this example, each Party incurred &#91;*&#93; of costs in such quarter, thus no netting would be required.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In this example, Partner would be entitled to a true-up payment from Amgen of &#91;*&#93;, representing Partner&#8217;s share of the Net Revenues less the amount of Net Revenues collected by Partner in Q3 2017 (&#91;*&#93;-&#91;*&#93; &#61; &#91;*&#93;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If, however, the Total Costs that had been incurred by each Party in the quarter differed, then each Party&#8217;s share of the Collaboration Profit (Loss) for Q3 2017 for the quarter would need to be adjusted.  For this example, assume the following&#58;</font></div><div style="padding-left:3.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amgen</font></td><td colspan="3" style="border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Partner</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Net Revenues</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-right:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Inventorship Margin</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-right:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Share of Net Revenues</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-right:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaboration Costs</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-right:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">True-Up Payment</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-right:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-right:1.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In such a case, each Party&#8217;s share of Net Revenues for Q3 2017 would still be &#91;*&#93;, (&#91;*&#93;-&#91;*&#93; &#61; &#91;*&#93; &#47; &#91;*&#93; &#61; &#91;*&#93;). </font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Additionally, each Party&#8217;s share of the Total Costs for Q3 2017 would still be &#91;*&#93;, representing Total Costs of &#91;*&#93; multiplied by the Quarterly Cap of 50% for Q3 2017.  However, Partner would owe &#91;*&#93; to Amgen as reimbursement for its share of Total Costs ((&#91;*&#93; x &#91;*&#93;) - &#91;*&#93; &#61; &#91;*&#93;).</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In this example, Partner would be entitled to a true-up payment of &#91;*&#93;, representing Partner&#8217;s share of the Net Revenues, less (i)&#160;the amount of Net Revenues collected by Partner in Q3 2017 and (ii) the amount owed to Amgen to cover Partner&#8217;s share of Total Costs (&#91;*&#93;-&#91;*&#93; - &#91;*&#93; &#61; &#91;*&#93;).</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Quality Agreement</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:13.5pt;font-weight:700;line-height:100%">Finished Drug Product and Placebo </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:13.5pt;font-weight:700;line-height:100%">QUALITY AGREEMENT </font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:13.5pt;font-weight:400;line-height:100%">Between </font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:13.5pt;font-weight:700;line-height:100%">AstraZeneca Collaboration Ventures, LLC </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:13.5pt;font-weight:400;line-height:100%">Hereafter referred to as &#8220;PARTNER&#8221; </font></div><div style="margin-top:13.5pt;text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:13.5pt;font-weight:400;line-height:100%">and </font></div><div style="margin-top:13.5pt;text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:13.5pt;font-weight:700;line-height:100%">Amgen Inc. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:13.5pt;font-weight:400;line-height:100%">Hereafter referred to as &#8220;AMGEN&#8221; </font></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">This Quality Agreement is intended by the Parties to set forth a plan for the quality assurance groups of AMGEN and PARTNER to work in relation to the manufacture, labeling, packaging, testing, release, shipment and storage of the clinical drug product supply of AMG 139, AMG 157, AMG 181, AMG 557, AMG 827, and the placebo form of the clinical drug products for PARTNER&#8217;s use in the Collaboration Territory. The specific details for each molecule will be outlined in addendums to the Quality Agreement. By signing below, the respective quality assurance representatives acknowledge and agree to the provisions of this Quality Agreement. </font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:0.04pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.619%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreed and accepted for&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreed and accepted for&#58;</font></td></tr><tr style="height:12pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Partner</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amgen Inc.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Printed</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Printed</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Michael Kinley</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Astrid McLean</font></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Sr. Director, Quality Assurance</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Director, Quality Assurance</font></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="margin-top:13.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effective Date&#58;&#160;&#160;&#160;&#160; March&#160;30, 2012 </font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:13.5pt;font-weight:700;line-height:100%">Table of contents </font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.914%"><tr><td style="width:1.0%"></td><td style="width:5.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.284%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BACKGROUND INFORMATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</font></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SCOPE</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</font></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEFINITIONS</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</font></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESPONSIBILITIES</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</font></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COMMUNICATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</font></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BATCH DISPOSITION (PRODUCT RELEASE)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</font></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LABEL APPROVAL</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</font></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUALITY CONTROL</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</font></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REFERENCE SAMPLES</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</font></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RETENTION SAMPLES</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</font></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RECEIVING, SHIPPING, STORAGE AND DESTRUCTION</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</font></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CHANGE CONTROL</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</font></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INVESTIGATIONS OF NONCONFORMANCES, DISCREPANCIES (POST&#160;DISTRIBUTION NC&#8217;S)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</font></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AUDITS AND INSPECTIONS</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</font></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DISPUTE RESOLUTION</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</font></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CUSTOMER COMPLAINTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</font></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">STOCK RECOVERY</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</font></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESPONSIBLE PERSONS&#58; CONTACT INFORMATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14</font></td></tr><tr style="height:7pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:12pt;text-indent:-12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT A</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.801%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BACKGROUND INFORMATION</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Amgen Inc. (hereinafter referred to as &#8220;AMGEN&#8221;) and Partner (hereinafter referred to as &#8220;PARTNER&#8221;) (hereinafter referred to individually as &#8220;Party&#8221; or collectively as &#8220;Parties&#8221;) have entered into that certain Collaboration Agreement dated as of March&#160;30, 2012 (the &#8220;Collaboration Agreement&#8221;), pursuant to which AMGEN supplies PARTNER with Drug Product and Placebo.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:18pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.801%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SCOPE</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Quality Agreement defines the quality obligations of the Parties and their respective affiliates or approved contractors, with respect to the manufacture, labeling, packaging, testing, release, shipment and storage of Product in accordance with the Collaboration Agreement.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The provisions of this Quality Agreement supplement the provisions of the Collaboration Agreement. The terms of the Collaboration Agreement shall remain in full force and effect. In the event of any conflict between the Collaboration Agreement and this Quality Agreement, the Collaboration Agreement shall govern over the conflict.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Quality Agreement may be amended only by mutual written agreement of the Parties.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibits to this Quality Agreement are intended to provide additional definition to the applicable topic and, as such, should be updated to reflect the current information and business process, as applicable. Amendment of the Exhibits does not require re-approval of the Quality Agreement unless the Quality Agreement itself is affected. Exhibits and all amendments of Exhibits shall be approved by mutually written agreement by the Parties.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All activities under this Quality Agreement shall be performed in compliance with standard industry practices, regulatory agency guidelines, AMGEN specifications, and all applicable federal, state, and local laws and regulations, including, without limitations, cGMPs.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Quality Agreement shall expire at the termination, cancellation, or expiration, as the case may be, of AMGEN&#8217;s obligation to supply Drug Product and Placebo for PARTNER&#8217;s clinical use.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER&#8217;s use of Product shall be limited to use in clinical trials approved by the Joint Steering Committee (JSC) as defined in the Collaboration Agreement and where PARTNER has been allocated responsibility to conduct such clinical trials.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.801%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DEFINITIONS</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All capitalized terms not otherwise defined in this Quality Agreement shall have the definition set forth in the Collaboration Agreement.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As used in this Quality Agreement, the following terms shall have the following meanings&#58;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:15pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:18.39pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.229%"><tr><td style="width:1.0%"></td><td style="width:24.609%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.041%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.950%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CoA</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certificate of Analysis prepared by AMGEN for the Product representing the analytical results of the Product.</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CoC</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certificate of Compliance or Quality Assurance Disposition (QAD), prepared by AMGEN for the Product representing that the Product was manufactured according to cGMP requirements.</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposition</font></div><div style="margin-bottom:0.75pt;padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Manager</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN Quality Assurance staff member qualified to perform the comprehensive quality assessment and make the disposition decision.</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposition</font></div><div style="margin-bottom:0.75pt;padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Package</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Documentation set provided to PARTNER representing AMGEN batch disposition of the Product.</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Drug&#160;Product</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG 139, AMG 157, AMG 181, AMG 557, AMG 827 Drug Product in finished form as manufactured by AMGEN under the terms of the Collaboration Agreement.</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Final&#160;Release</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Release of Product by AMGEN or PARTNER in accordance with standard operating procedures (&#8220;SOPs&#8221;).</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cGMP</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All applicable laws and regulations relating to current Good Manufacturing Practices, as promulgated by the United States Food and Drug Administration (FDA) and &#8216;Good Manufacturing Practices as defined in EC Volume IV of The Rules Governing Medical Products in the European Community&#8217;.</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Manufacturer&#8217;s</font></div><div style="margin-bottom:0.75pt;padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Release</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Release of Product by AMGEN, according to its SOPs. Manufacturer&#8217;s Release signifies that Product has been produced using approved processes, in compliance with applicable cGMP regulations, and meets the specifications established for the Product, as determined by review of all appropriate documentation.</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Material&#160;Change</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A change which materially modifies the regulatory filing for the Product or is determined by AMGEN to have significant potential to materially affect the Safety, Quality, Identity, Potency, or Purity of the Product.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18.37pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.229%"><tr><td style="width:1.0%"></td><td style="width:29.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.041%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.163%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nonconformance</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deviations incurred during the manufacture, labeling, packaging, testing, storage or shipment of the Product, which AMGEN determined to have the potential to impact the Safety, Quality, Identity, Potency, or Purity of the Product, upon preliminary evaluation and required performing an investigation according to AMGEN SOPs.</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OOS Result</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">An examination, measurement or test result that does not conform with pre-established specification requirements established by the relevant Party.</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Placebo</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A mock treatment or drug that has no effect on the illness, given in a clinical trial to the control group to help differentiate the specific versus non-specific effects of an experimental treatment.</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Product</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Drug Product and finished Placebo as manufactured by AMGEN for PARTNER under the terms of the Collaboration Agreement.</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Regulatory Agency</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A public authority or government agency responsible for protecting and promoting public health through regulation or rulemaking (codifying and enforcing rules and regulations and imposing supervision or oversight for the benefit of the public at large).</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Reference&#160;Sample&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sample collected from the manufacture of Product for the purpose of being analyzed, should the need arise, to support significant investigations.</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Retention&#160;Samples&#160;&#160;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A fully packaged unit from a batch of finished Product stored for identification purposes.</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN Quality Specifications</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN approved set of analytical methods, requirements, and limits as used to judge the identity, purity and potency of all source materials, raw materials, and finished filled, labeled and packaged Product which comprises the Product.</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stock Recovery</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The removal or correction of a non-marketed product used in a clinical trial for reasons related to product Safety, Quality, Identity, Potency, or Purity, that has not been marketed or that has not left the direct control of PARTNER.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.801%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RESPONSIBILITIES</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:27pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting any other provision of this Quality Agreement, the Parties agree that this Quality Agreement is intended to carry out the following guiding principles&#58;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.1.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties&#8217; quality obligations with respect to the manufacture, labeling, packaging, testing, release, shipment and storage of Product are as set forth in this Quality Agreement and the Collaboration Agreement.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.1.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties shall comply with all Applicable Laws in the conduct of activities under this Quality Agreement.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.1.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties acknowledge that AMGEN and PARTNER shall each have the right to perform responsibilities hereunder through their Affiliates and contractors.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.1.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties shall collaborate to address any disagreements.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:22.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.801%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">COMMUNICATION</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:22.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN and PARTNER agree to provide verbal communication to one another, in a timely manner, as necessary or appropriate for a given issue. Both Parties also agree to follow-up and clarify promptly in writing those important verbal communications to ensure clarity of issues. All official communications and documentation between AMGEN and PARTNER will be conducted in English.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.1.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The forwarding by PARTNER of any written communication from any global Regulatory Agency concerning the Product outlined in this document shall be done within 3 business days in the original language in which it was received by PARTNER with supplementary comments in English. An English translated version will also be forwarded.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.1.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The forwarding of any oral communication from any global Regulatory Agency concerning the Product outlined in this document shall be done within 3 business days in the original language in which the notes concerning the correspondence were taken by PARTNER with supplementary comments in English. An English translated version will also be forwarded.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Routine verbal and written communications required herein shall be delivered to the individuals indicated in EXHIBIT A or their delegates.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.801%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BATCH DISPOSITION (PRODUCT RELEASE)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN Quality Responsibility</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN shall be responsible for the Manufacturer&#8217;s Release of the Product to PARTNER.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN shall provide to PARTNER the Disposition Package for each batch of Product supplied to PARTNER, upon shipment. The documents to be included in the Disposition Package will be outlined in amendments which are specific to the Product.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Disposition Package for the batch will include a list of Nonconformance(s) incurred during the manufacture, labeling, packaging, testing, or storage of the Product. The list of Nonconformance(s) will include a summary of only lot-specific Nonconformances determined by AMGEN to have significant potential to adversely impact the Safety, Quality, Identity, Potency, or Purity of the Product, according to AMGEN procedures or regulatory filing. Such list will be sent to PARTNER upon shipment of the Product by AMGEN to PARTNER.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN shall use commercially reasonable efforts to mitigate the risk of Transmissible Spongiform Encephalopathy (TSE) for raw materials and components used during perform of Services per current requirements of Regulatory Agencies and current compendial requirements.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER Quality Responsibility</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER shall be responsible for the Final Release of the Product for clinical distribution after reviewing the Disposition Package provided by AMGEN and any shipping records and, if applicable, results of acceptance testing as conducted by a PARTNER qualified laboratory.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event PARTNER provides AMGEN with notice of Nonconformance of the Product within 60 days from the date of delivery of Product, AMGEN and PARTNER agree to collaborate to investigate the Nonconformance prior to the disposition of the lot by PARTNER according to each Party&#8217;s respective failure investigation policies and procedures in accordance with the Quality Agreement.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event PARTNER is responsible for a specific European clinical trial, a PARTNER QP or one authorized by PARTNER, will be responsible for certification of Product according to the requirements set out in the European cGMPs.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:13.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.801%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LABEL APPROVAL</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Physical Label Creation and Approval</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Physical labels for Product will be generated and approved according to established procedures of AMGEN, for any such activities performed by such Party.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Label Application</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1.2.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN is responsible for labeling and bulk packaging of the clinical supplies.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1.2.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN shall apply physical labels to Product prior to supply to PARTNER.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:13.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.801%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">QUALITY CONTROL</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN Quality Control Laboratory Testing Responsibility</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN will conduct testing of Product according to AMGEN Quality Specifications and its methods, policies and procedures.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER Importation and Testing Responsibility</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER shall be responsible for preparing all documents required for import clearance and entry of shipment with reasonable cooperation from AMGEN. Product batches will be evaluated by PARTNER upon receipt for conformance to applicable import and transport requirements, such as temperature monitoring, damage and documentation requirements.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER is responsible for sampling upon receipt and conducting testing, as required. Such testing will be conducted by PARTNER (or if AMGEN expressly consent in writing, by appropriately qualified laboratories) by appropriately qualified personnel according to testing procedures mutually agreed by the Parties.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If AMGEN expressly consents to PARTNER using a contract laboratory for import testing, then PARTNER is responsible for shipping Product to its contract laboratory to perform import testing, if necessary.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the case of OOS, an investigation will be performed per Section&#160;13 (INVESTIGATION OF NONCONFORMANCES, DISCREPANCIES) of this Quality Agreement and PARTNER should notify and obtain consent from AMGEN prior to conducting testing using any other analytical method during the investigation.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stability Tesing</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN will conduct routine stability testing of the Product according to AMGEN&#8217;s clinical stability program requirements.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN will communicate the expiration of each lot in the Disposition Package.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN shall notify PARTNER within two (2)&#160;business days of any confirmed stability failure of the Product and provide periodic updates on the OOS investigation.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER will not conduct any stability testing on the Product unless authorized to do so by AMGEN.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN will provide PARTNER the current Stability Summary Report, including trending, upon request.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:18pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.801%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">REFERENCE SAMPLES</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN shall retain Reference Samples for each manufactured lot of Product released to PARTNER for a minimum of five (5)&#160;years after the expiration period. This period may be shortened if the period of stability of the material, as indicated in its specification, is shorter.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:18pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RETENTION SAMPLES</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER shall retain Retention Samples for each packaged lot of Product released for clinical distribution per established PARTNER procedure.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:18pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RECEIVING, SHIPPING, STORAGE and DESTRUCTION</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless otherwise agreed by the Parties, AMGEN shall ship Product EXW (Incoterms 2010) AMGEN&#8217;s facility.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER is responsible for reviewing temperature recording data upon receipt of Product shipment.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER is responsible for adequate storage of the Product upon receipt according to the storage requirements specified in the product specification.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Shipping excursions will be investigated per Section&#160;13 (INVESTIGATIONS OF NONCONFORMANCES, DISCREPANCIES) of this Quality Agreement.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER is responsible for reviewing temperature recording data of the Product according to the storage requirements if a temperature excursion is identified at a clinical investigation site.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.5.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER notifies AMGEN of any shipping Nonconformances, such as temperature excursions, upon receiving shipping records.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.5.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN shall provide PARTNER adequate training and relevant stability data to support temperature excursions obtained at clinical investigation sites, provided that, AMGEN shall not have any obligation to conduct new tests to support assessment of temperature excursions. If a temperature excursion exceeds any of the limits supported by the stability data, AMGEN shall provide reasonable support to properly assess the product impact, if requested by PARTNER.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER shall be responsible for the destruction of any unused and partially used Product in accordance with Applicable Laws and regulations.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:13.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.835%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CHANGE CONTROL</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN shall notify PARTNER of AMGEN&#8217;s intention to implement such Material Change and the details of such Material Change for the material changes of manufacturing of the Product, specifically impacting the following documents, if applicable&#58; (1)&#160;Analytical Methods, (2)&#160;Master Batch&#47;Labeling&#47;Packaging Records, (3)&#160;Primary Packaging Components Specifications, (4)&#160;Product Specifications, and (5)&#160;Raw Material&#47;Component Specifications.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within fourteen (14)&#160;calendar days after the receipt of such notification, to the extent such Material Change impacts a Regulatory Filing for which PARTNER is the Designated Regulatory Party, PARTNER shall provide to AMGEN a writtenassessment of whether the Material Change constitutes a change which is reportable to Governmental Authorities.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If a Material Change requires the approval of a Governmental Authority in the Collaboration Territory, then, where PARTNER is the Designated Regulatory Party, PARTNER shall use reasonable efforts to file for such approval within sixty (60)&#160;days of receipt of the necessary documentation from AMGEN and obtain necessary regulatory approvals.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER shall provide updates to AMGEN of any regulatory submissions relating to said changes.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER shall inform AMGEN of any required regulatory change and reporting category in writing within two (2)&#160;business days after PARTNER first becomes aware of such information. PARTNER must inform AMGEN of the request in writing, at a minimum the request should describe the proposed change and rationale.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:18pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">INVESTIGATIONS OF NONCONFORMANCES, DISCREPANCIES (POST&#160;DISTRIBUTION NC&#8217;S)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If a Nonconformance is identified after a Product batch has been shipped to PARTNER, AMGEN shall inform PARTNER within two (2)&#160;business days of such Nonconformance.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN will provide support, as necessary and reasonable, to enable PARTNER to comply with applicable regulatory reporting requirements that may result from the occurrence of a post-distribution Nonconformance.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Party shall inform the other Party as soon as reasonably possible of issues which may adversely impact Product quality, safety, efficacy or adverse events relating to the batch of Product received by PARTNER.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:18pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AUDITS AND INSPECTIONS</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER Audits</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.1.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All audits of AMGEN are limited to the facilities where the Products are manufactured, Quality Systems and documentation directly related to the Products, and Batch Records related to lots provided to PARTNER, The scope, agenda, and timeline must be approved by AMGEN prior to each audit.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.1.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All audits of AMGEN facilities will be conducted during regular business hours in the presence of AMGEN representatives. Audits shall be conducted by not more than two (2)&#160;PARTNER representatives at each AMGEN facility, and, unless otherwise agreed upon by AMGEN, for not more than two (2)&#160;business days at each site. PARTNER shall provide AMGEN written notification of such audit no less than one hundred twenty days (120)&#160;days in advance. The written notification must clearly state the scope of the audit and regulatory standards to be used to conduct the audit. PARTNER may conduct an audit once in a twelve (12)&#160;month period, upon AMGEN&#8217;s approval of the audit request.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.1.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition to the annual audit described in Section&#160;14.1.2 above, PARTNER is permitted to request an unplanned &#8220;For Cause&#8221; audit during the case of a quality or regulatory event. AMGEN will consider any such request in good faith, but will have sole discretion whether or not to grant such request.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.311%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.1.3.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Such &#8220;For Cause&#8221; audits require prior written notice by PARTNER to AMGEN and shall be conducted during AMGEN&#8217;s normal business hours. Each party must approve the audit scope, agenda and timeline prior to conducting the audit. For Cause audits shall be conducted by not more than two (2)&#160;PARTNER representatives at each AMGEN facility, and, unless otherwise agreed upon by AMGEN, for not more than two (2)&#160;business days.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Audit Findings</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.2.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER shall provide AMGEN a copy of the audit report within thirty (30)&#160;calendar days of completion of an audit. After delivery of the audit report, AMGEN shall provide PARTNER with a written response to such report within thirty (30)&#160;calendar days from AMGEN&#8217;s receipt of the report from PARTNER. All information contained in the audit report shall be deemed the confidential information of AMGEN under the Collaboration Agreement.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Regulatory Agency Inspections</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.3.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER shall notify AMGEN immediately upon notification by any Regulatory Agency or other Government Authority of any intended inspection of AMGEN&#8217;s facilities or records relating to the manufacturing, testing, packaging, labeling, and storage of the Product.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.3.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER shall have the right to have a maximum of one (1)&#160;representative present during a regulatory inspection of AMGEN&#8217;s facilities that perform manufacturing or testing of Product. Presence of PARTNER during an inspection at an AMGEN facility will be according to the direction of AMGEN. PARTNER representative shall not have direct participation during inspection discussions with Regulatory Agency inspector(s).</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.3.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN shall provide PARTNER with a copy of the final response immediately after submission to the Regulatory Agency.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.3.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER is responsible for the arrangement of interpreters and translation of documents which may be required by the Regulatory Agency during inspection of AMGEN facilities. AMGEN shall have the right to arrange interpreter and document translation services upon agreement with PARTNER or if PARTNER fails to do so.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:18pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DISPUTE RESOLUTION</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Disputes relating to non-compliance or nonconformance of Product with the product specifications shall be governed by the terms set forth in the Collaboration Agreement. The provisions of Section&#160;15.3 (choice of law&#59; jurisdiction) of the Collaboration Agreement are deemed incorporated into this Quality Agreement.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:18pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CUSTOMER COMPLAINTS</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any information related to customer complaints (i.e., communication that alleges deficiencies relating to the identity, quality, durability, reliability, safety, effectiveness, or performance of a drug, condition of labeling, or packaging, after it is released by PARTNER for clinical studies) shall be forwarded to AMGEN within one (1)&#160;business day after PARTNER first becomes aware of such information.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN shall investigate according to AMGEN&#8217;s applicable policy and procedures customer complaints submitted by PARTNER. Complaints which require an AMGEN investigation will be sent to this e-mail address&#58; XXXXXXXXX&#64;amgen.com</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMGEN shall provide PARTNER with an Interim Report within 30 days and an investigation closure Final Report within forty-five (45)&#160;days of receipt of the customer complaint.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:18pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.855%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">STOCK RECOVERY</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any problems are discovered and identified as recall&#47;stock recovery issues related to the Product, the discovering Party shall notify the other immediately.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTNER and AMGEN shall each notify the other Party within three (3)&#160;business days if it becomes aware that any Product is alleged or proven to be the subject of a recall or stock recovery in the Collaboration Territory.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties shall meet to discuss the circumstances that merit the Product recall or stock recovery and to determine the appropriate course of action. Such course of action shall be consistent with the internal SOP of the Party having the right to control such recall pursuant to this section.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If either Party proposes to initiate a Stock Recovery or other corrective action with respect to the Product in the Collaboration Territory, the Parties will promptly discuss such proposed action. Any decisions by the Parties shall be governed by the terms of the Collaboration Agreement. The Parties shall cooperate, as reasonably necessary, in the implementation of such actions.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties shall cooperate and promptly perform investigations into the root causes leading up to the Product Stock Recovery, when appropriate. Investigation reports regarding the defect or cause for such regulatory reporting shall be provided to the corresponding Party within an appropriate timeframe dependent on regulatory reporting requirements.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties shall each maintain complete and accurate records of any Stock Recovery it has the right to control pursuant to this section of the Quality Agreement for such periods as may be required by legal requirements, but in any event for no less than three (3)&#160;years from the date of Stock Recovery.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Party maintains the responsibility for Product distributed within the Collaboration Territory for its own clinical studies.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:18pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RESPONSIBLE PERSONS&#58; CONTACT INFORMATION</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The individuals listed in EXHIBIT A shall be the key points of contact between AMGEN and PARTNER relating to the rights and obligations of the Parties in this Quality Agreement. The responsible individuals, or their respective delegates, must be notified in official communications as required by this Quality Agreement.</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">EXHIBIT A </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Responsible Persons and Contact Information </font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:18pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:13.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:27.59pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.795%"><tr><td style="width:1.0%"></td><td style="width:22.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.845%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="21" style="background-color:#bfbfbf;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt;padding-right:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:3.35pt;padding-right:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMGEN</font></div><div style="margin-bottom:0.75pt;padding-left:3.35pt;padding-right:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:1.67pt;padding-right:1.67pt;text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font></div><div style="margin-bottom:0.75pt;padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#bfbfbf;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Email Address</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#bfbfbf;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contact Number</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#bfbfbf;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Responsibility</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">XXXXXXXXX</font></div><div style="margin-bottom:0.75pt;padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">XXXXXXXXX</font></div><div style="margin-bottom:0.75pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">XXXXXXXXX</font></div><div style="margin-bottom:0.75pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Manager,</font></div><div style="margin-bottom:0.75pt;padding-right:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International Quality</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">XXXXXXXXX</font></div><div style="margin-bottom:0.75pt;padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">XXXXXXXXX</font></div><div style="margin-bottom:0.75pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">XXXXXXXXX</font></div><div style="margin-bottom:0.75pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Director,</font></div><div style="margin-bottom:0.75pt;padding-right:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International Quality</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:18pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:13.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:27.59pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.795%"><tr><td style="width:1.0%"></td><td style="width:22.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.845%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="21" style="background-color:#bfbfbf;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt;padding-right:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:3.35pt;padding-right:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PARTNER</font></div><div style="margin-bottom:0.75pt;padding-left:3.35pt;padding-right:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:1.67pt;padding-right:1.67pt;text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font></div><div style="margin-bottom:0.75pt;padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#bfbfbf;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Email Address</font></div><div style="margin-bottom:0.75pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#bfbfbf;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contact Number</font></div><div style="margin-bottom:0.75pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#bfbfbf;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.67pt;padding-right:1.67pt;text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Responsibility</font></div><div style="margin-bottom:0.75pt;padding-right:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">XXXXXXXXX</font></div><div style="margin-bottom:0.75pt;padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">XXXXXXXXX</font></div><div style="margin-bottom:0.75pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">XXXXXXXXX</font></div><div style="margin-bottom:0.75pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director of QA and EU&#160;QP</font></div><div style="margin-bottom:0.75pt;padding-right:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">XXXXXXXXX</font></div><div style="margin-bottom:0.75pt;padding-left:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">XXXXXXXXX</font></div><div style="margin-bottom:0.75pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">XXXXXXXXX</font></div><div style="margin-bottom:0.75pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Director,</font></div><div style="padding-right:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:0.75pt;padding-right:3.35pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality Assurance</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:18pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-top:13.5pt;text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit A Version Date&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March&#160;30, 2012</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.031%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.448%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.448%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.031%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.448%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.448%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.431%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Agreed and accepted for&#58;</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:0.75pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Partner</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Agreed and accepted for&#58;</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:0.75pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amgen Inc.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Printed</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:0.75pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Name&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Michael Kinley</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Printed</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:0.75pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Name&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Astrid McLean</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Sr.&#160;Director,&#160;Quality&#160;Assurance</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;Director, Quality Assurance</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:0.18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stage 1 Clinical Trial</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:111.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.234%"><tr><td style="width:1.0%"></td><td style="width:33.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Product</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stage 1 Clinical Trial</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG139</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG157</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG181</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG557</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG827</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.47
<SEQUENCE>4
<FILENAME>exhibit1047-amendmentno1to.htm
<DESCRIPTION>FIRST AMENDMENT TO COLLABORATION AGREEMENT BETWEEN AMGEN AND ASTRAZENECA
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8f5e6f39c3fd4a11a1fa4b27fd39cd66_1"></div><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">EXHIBIT 10.47</font></div><div style="margin-top:22.9pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;*&#93;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">AMENDMENT NO. 1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">TO THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COLLABORATION AGREEMENT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">This Amendment No. 1 to the Collaboration Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) is entered into as of the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> day of October, 2014 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Amgen Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, a Delaware corporation with a place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Amgen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">AstraZeneca Collaboration Ventures, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, a Delaware limited liability company with a place of business at 1800 Concord Pike, Wilmington, Delaware 19850 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  Amgen and Partner are sometimes referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;.  AstraZeneca Pharmaceuticals LP, the parent corporation of Partner (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">AstraZeneca</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), &#91;*&#93; of the Agreement (as defined below) is a party to this Amendment &#91;*&#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, Amgen and Partner entered into that certain Collaboration Agreement, dated as of March 30, 2012 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;)&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, Amgen and Partner wish to update certain portions of the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, in consideration of the mutual promises and covenants hereinafter set forth, the Parties hereto agree to amend the Agreement as follows&#58;</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 1 - AMENDMENT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Amendment to Certain Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  The Parties hereby agree that the following defintions in the Agreement are hereby deleted in their entirety and replaced with the following&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8220;Excluded Territory&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (i) with respect to AMG557 and AMG570, Japan, and (ii) with respect to AMG827, all countries not included within the AMG827 Territory. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#8220;Excluded Territory Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means (i)&#160;in relation to AMG827, the AMG827 Technology Transfer Agreement by and among Kyowa Hakko Kirin Co., Ltd., Amgen and Kirin-Amgen, Inc., the Research, Development and Technology Disclosure Agreement&#58; AMG827 by and among Kyowa Hakko Kirin Co., Ltd., Amgen and Kirin-Amgen, Inc., and the AMG827 License Agreement between Kirin-Amgen, Inc., all dated October 29, 2010 and (ii) in relation to AMG557 and AMG570, means the License Agreement by and between Amgen and Takeda Pharmaceutical Company Limited dated February 1, 2008, in each case as the same have been amended and may be amended from time to time hereafter in accordance with terms of this Agreement.</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Amendment to Certain Schedules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Parties hereby agree that the following schedules to the Agreement are hereby deleted in their entirety and replaced with the schedules set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:6pt">Development&#47;Commercial Lead Schedule&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:6pt">Distracting Product Schedule&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:6pt">Products Schedule&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:6pt">Stage 1 Clinical Trial Schedule.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Parties hereby acknowledge that (a)&#160;in accordance with Section 9.4 (Pre-Clinical Research and Development Programs) of the Agreement, the Inventorship Margin for AMG570 shall be </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;*&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">percent (</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">%), and (b)&#160;in accordance with Section 9.3.3 (Inclusion) of the Agreement, (i)&#160;all Development Costs and General Costs for AMG570 shall be shared on a </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;*&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">basis, and (ii)&#160;all Net Revenues for AMG570 shall, after the deduction of the Inventorship Margin for AMG570, be shared on a </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;*&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">basis.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt;text-decoration:underline">Manufacturing Lead</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Parties hereby agree that, notwithstanding the provisions of Section 4.1 (Allocation of Manufacturing Responsibility) of the Agreement to the contrary, Amgen shall not be required to elect whether or not to continue as the Manufacturing Lead for AMG570 and AMG557 until </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 2 &#8211; REFERENCE TO AND EFFECT ON THE AGREEMENT</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Reference to Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Upon and after the effectiveness of this Amendment, each reference in the Agreement to &#8220;this Agreement&#8221;, &#8220;hereunder&#8221;, &#8220;hereof&#8221; or words of like import referring to the Agreement shall mean and be a reference to the Agreement as modified and amended hereby.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Effectiveness of Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Upon execution and delivery of this Amendment by both Parties, the amendments set forth above shall be effective as of the Amendment Effective Date.  Except as specifically amended above, the Agreement is and shall continue to be in full force and effect and is hereby in all respects ratified and confirmed and shall constitute the legal, valid, binding and enforceable obligations of the Parties.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">No Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of either Party under the Agreement, nor constitute a waiver of any provision of the Agreement.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 3 &#8211; MISCELLANEOUS</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This Amendment will be governed by, and enforced and construed in accordance with, the laws of the State of New York without regard to its conflicts of law provisions.  Each of the Parties hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the state and federal courts of the State of New York for any matter arising out of or relating to this Amendment and the transactions contemplated hereby, and agrees not to commence any litigation relating thereto except in such courts.  Each of the Parties hereby irrevocably and unconditionally waives any objection to the laying of venue of any matter arising out of this Amendment or the transactions contemplated hereby in the state and federal courts of the State of New York and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such matter brought in any such court has been brought in an inconvenient forum.  The Parties agree that a final judgment in any such matter will be conclusive and may be enforced in other jurisdictions by suits on the judgment or in </font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any other manner provided by law.  Any proceeding brought by either Party under this Amendment will be exclusively conducted in the English language.  The United Nations Convention for the International Sale of Goods will not apply to the transactions contemplated herein.  </font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The heading for each article and section in this Amendment has been inserted for convenience of reference only and is not intended to limit or expand on the meaning of the language contained in the particular article or section.</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></div><div style="margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Signature page follows&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3</font></div></div></div><div id="i8f5e6f39c3fd4a11a1fa4b27fd39cd66_4"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS THEREOF, duly authorized representatives of the Parties hereto have executed this Amendment as of the date first set forth above.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ASTRAZENECA COLLABORATION VENTURES, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMGEN INC.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Pascal Soriot</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Robert A. Bradway</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pascal Soriot</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Robert A. Bradway</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CEO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chairman and Chief Executive Officer</font></td></tr><tr style="height:27pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ASTRAZENECA PHARMACEUTICALS LP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" rowspan="4" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Pascal Soriot</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pascal Soriot</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CEO</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Appendix I</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedules</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development&#47;Commercial Lead</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:117.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.128%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amgen</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Partner</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG827</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG139</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG557</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG157</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG570</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMG181</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMG827 Respiratory-</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:30.45pt">Specifically with regard to AMG827 at the global level, the Parties will work closely through the JPT on the commercial strategy for the Respiratory market for AMG827 with Amgen taking the primary responsibility for &#91;*&#93;.    </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:30.45pt">The Parties will &#91;*&#93;. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:30.45pt">The Parties will cooperate to ensure that &#91;*&#93; is made available to the JPT at both the global and regional level.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:30.45pt">This arrangement will be noted in the press release and other approved communications as &#8220;&#91;*&#93;,&#8221; or with words of similar import.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMG570-</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Parties hereby agree that Amgen shall be the initial Development Lead and Commercial Lead for AMG570.  The Parties shall &#91;*&#93;, provided that, in the event that the Parties are unable to &#91;*&#93; if it elects to do so.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Distracting Product</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.871%"><tr><td style="width:1.0%"></td><td style="width:18.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product Target</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distracting Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 139</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 157</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 181</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 557</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 570</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 827</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distracting Target includes (i) any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; (ii) any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; (iii)&#160;any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; (iv) any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; and (v) any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;*&#93;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> For avoidance of doubt, the Distracting Product Schedule lists without limitation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding anything contained in the Agreement to the contrary, Amgen&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;*&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">program referred to internally at Amgen as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;*&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">shall not be a Distracting Product so long as such molecule is the subject of that certain License Agreement dated as of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;*&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by and between Amgen and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, as amended.  </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><br></font></div><div><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Products</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.057%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 139</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 157</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 181</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 557</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 827</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG 570</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stage 1 Clinical Trial</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:111.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.089%"><tr><td style="width:1.0%"></td><td style="width:33.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stage 1 Clinical Trial</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG139</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG157</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG181</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG557</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG827</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG570</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>5
<FILENAME>amgn-ex31_2022630xq2.htm
<DESCRIPTION>RULE 13A-14(A) CERTIFICATIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icf1a64b5190848399ea73b76cef955b4_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31</font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert A. Bradway, Chairman of the Board, Chief Executive Officer and President of Amgen Inc., certify that&#58;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Amgen Inc.&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this quarterly report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">August 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ROBERT A. BRADWAY</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert A. Bradway</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="icf1a64b5190848399ea73b76cef955b4_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Peter H. Griffith, Executive Vice President and Chief Financial Officer of Amgen Inc., certify that&#58;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Amgen Inc.&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report&#59;</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this quarterly report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">August 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PETER H. GRIFFITH</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter H. Griffith</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>amgn-ex32_2022630xq2.htm
<DESCRIPTION>SECTION 1350 CERTIFICATIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic62f571548a140a4973e4492560e7d3e_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. &#167; 1350, as created by Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the &#8220;Company&#8221;) hereby certifies that&#58;</font></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the accompanying Quarterly Report on Form 10-Q of the Company for the period ended June 30, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">August 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ROBERT A. BRADWAY</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert A. Bradway</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 of the Sarbanes-Oxley Act of 2002 (&#8220;Section 906&#8221;), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section&#160;906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="ic62f571548a140a4973e4492560e7d3e_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Financial Officer</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. &#167; 1350, as created by Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the &#8220;Company&#8221;) hereby certifies that&#58;</font></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the accompanying Quarterly Report on Form 10-Q of the Company for the period ended June 30, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">August 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PETER H. GRIFFITH</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter H. Griffith</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 of the Sarbanes-Oxley Act of 2002 (&#8220;Section 906&#8221;), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section&#160;906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>amgn-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5d27ca97-9729-4191-8773-bd1da607be75,g:d96be9d2-9e3e-485f-8641-d09afcb6a74b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amgn="http://www.amgen.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amgen.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.amgen.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1001002 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncome" roleURI="http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.amgen.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1003004 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.amgen.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1007008 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Summaryofsignificantaccountingpolicies" roleURI="http://www.amgen.com/role/Summaryofsignificantaccountingpolicies">
        <link:definition>2101101 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesPolicies" roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesDetails" roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesDetails">
        <link:definition>2403401 - Disclosure - Summary of significant accounting policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.amgen.com/role/Acquisitions">
        <link:definition>2104102 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.amgen.com/role/AcquisitionsTables">
        <link:definition>2305301 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAggregateConsiderationPaidDetails" roleURI="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails">
        <link:definition>2406402 - Disclosure - Acquisitions - Aggregate Consideration Paid (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.amgen.com/role/AcquisitionsNarrativeDetails">
        <link:definition>2407403 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.amgen.com/role/Revenues">
        <link:definition>2108103 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.amgen.com/role/RevenuesTables">
        <link:definition>2309302 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetails" roleURI="http://www.amgen.com/role/RevenuesDetails">
        <link:definition>2410404 - Disclosure - Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incometaxes" roleURI="http://www.amgen.com/role/Incometaxes">
        <link:definition>2111104 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesDetails" roleURI="http://www.amgen.com/role/IncometaxesDetails">
        <link:definition>2412405 - Disclosure - Income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Earningspershare" roleURI="http://www.amgen.com/role/Earningspershare">
        <link:definition>2113105 - Disclosure - Earnings per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareTables" roleURI="http://www.amgen.com/role/EarningspershareTables">
        <link:definition>2314303 - Disclosure - Earnings per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareDetails" roleURI="http://www.amgen.com/role/EarningspershareDetails">
        <link:definition>2415406 - Disclosure - Earnings per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.amgen.com/role/Investments">
        <link:definition>2116106 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.amgen.com/role/InvestmentsTables">
        <link:definition>2317304 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsDetails" roleURI="http://www.amgen.com/role/InvestmentsDetails">
        <link:definition>2418407 - Disclosure - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsFairValuesbyClassificationDetails" roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails">
        <link:definition>2419408 - Disclosure - Investments (Fair Values by Classification) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAvailableforsaleInvestmentsDetailsTextual" roleURI="http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual">
        <link:definition>2420409 - Disclosure - Investments (Available-for-sale Investments) (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsFairValuesbyContractualMaturityDetails" roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails">
        <link:definition>2421410 - Disclosure - Investments (Fair Values by Contractual Maturity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsEquitySecuritiesDetailsTextual" roleURI="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual">
        <link:definition>2422411 - Disclosure - Investments (Equity Securities) (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsBeiGeneDetails" roleURI="http://www.amgen.com/role/InvestmentsBeiGeneDetails">
        <link:definition>2423412 - Disclosure - Investments (BeiGene) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNeumoraTherapeuticsIncDetails" roleURI="http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails">
        <link:definition>2424413 - Disclosure - Investments (Neumora Therapeutics, Inc.) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" roleURI="http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails">
        <link:definition>2425414 - Disclosure - Investments Investments (Limited Partnership Investments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.amgen.com/role/Inventories">
        <link:definition>2126107 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.amgen.com/role/InventoriesTables">
        <link:definition>2327305 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.amgen.com/role/InventoriesDetails">
        <link:definition>2428415 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwillandotherintangibleassets" roleURI="http://www.amgen.com/role/Goodwillandotherintangibleassets">
        <link:definition>2129108 - Disclosure - Goodwill and other intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsTables" roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsTables">
        <link:definition>2330306 - Disclosure - Goodwill and other intangible assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsGoodwillRollForwardDetails" roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails">
        <link:definition>2431416 - Disclosure - Goodwill and other intangible assets (Goodwill Roll Forward) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails">
        <link:definition>2432417 - Disclosure - Goodwill and other intangible assets (Identifiable Intangible Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsDetailsTextual" roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual">
        <link:definition>2433418 - Disclosure - Goodwill and other intangible assets (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financingarrangements" roleURI="http://www.amgen.com/role/Financingarrangements">
        <link:definition>2134109 - Disclosure - Financing arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsTables" roleURI="http://www.amgen.com/role/FinancingarrangementsTables">
        <link:definition>2335307 - Disclosure - Financing arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" roleURI="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails">
        <link:definition>2436419 - Disclosure - Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingarrangementsDetailsTextual" roleURI="http://www.amgen.com/role/FinancingarrangementsDetailsTextual">
        <link:definition>2437420 - Disclosure - Financing arrangements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Stockholdersequity" roleURI="http://www.amgen.com/role/Stockholdersequity">
        <link:definition>2138110 - Disclosure - Stockholders' equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityTables" roleURI="http://www.amgen.com/role/StockholdersequityTables">
        <link:definition>2339308 - Disclosure - Stockholders' equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityShareRepurchaseProgramDetails" roleURI="http://www.amgen.com/role/StockholdersequityShareRepurchaseProgramDetails">
        <link:definition>2440421 - Disclosure - Stockholders' equity (Share Repurchase Program) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityDetailsTextualDetails" roleURI="http://www.amgen.com/role/StockholdersequityDetailsTextualDetails">
        <link:definition>2441422 - Disclosure - Stockholders' equity (Details Textual) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityComponentsofAOCIDetails" roleURI="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails">
        <link:definition>2442423 - Disclosure - Stockholders' equity (Components of AOCI) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityReclassificationsoutofAOCIDetails" roleURI="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails">
        <link:definition>2443424 - Disclosure - Stockholders' equity (Reclassifications out of AOCI) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Fairvaluemeasurement" roleURI="http://www.amgen.com/role/Fairvaluemeasurement">
        <link:definition>2144111 - Disclosure - Fair value measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementTables" roleURI="http://www.amgen.com/role/FairvaluemeasurementTables">
        <link:definition>2345309 - Disclosure - Fair value measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementDetails" roleURI="http://www.amgen.com/role/FairvaluemeasurementDetails">
        <link:definition>2446425 - Disclosure - Fair value measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementDetailsTextual" roleURI="http://www.amgen.com/role/FairvaluemeasurementDetailsTextual">
        <link:definition>2447426 - Disclosure - Fair value measurement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementContingentConsiderationObligationsDetails" roleURI="http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails">
        <link:definition>2448427 - Disclosure - Fair value measurement (Contingent Consideration Obligations) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Derivativeinstruments" roleURI="http://www.amgen.com/role/Derivativeinstruments">
        <link:definition>2149112 - Disclosure - Derivative instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsTables" roleURI="http://www.amgen.com/role/DerivativeinstrumentsTables">
        <link:definition>2350310 - Disclosure - Derivative instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsDetailsTextual" roleURI="http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual">
        <link:definition>2451428 - Disclosure - Derivative instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsCrosscurrencySwapsDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails">
        <link:definition>2452429 - Disclosure - Derivative instruments (Cross-currency Swaps) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails">
        <link:definition>2453430 - Disclosure - Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails">
        <link:definition>2454431 - Disclosure - Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails">
        <link:definition>2455432 - Disclosure - Derivative instruments (Summary of Income and Expense Line Items) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsFairValueofDerivativesDetails" roleURI="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails">
        <link:definition>2456433 - Disclosure - Derivative instruments (Fair Value of Derivatives) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingenciesandcommitments" roleURI="http://www.amgen.com/role/Contingenciesandcommitments">
        <link:definition>2157113 - Disclosure - Contingencies and commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsDetails" roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsDetails">
        <link:definition>2458434 - Disclosure - Contingencies and commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="amgn_LossContingencyPatentsExpiredNumber" abstract="false" name="LossContingencyPatentsExpiredNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_FourPercentPoundSterlingNotesDue2029Member" abstract="true" name="FourPercentPoundSterlingNotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AranespMember" abstract="false" name="AranespMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_RepatriationTaxOnProposedAdditionalTax20132015" abstract="false" name="RepatriationTaxOnProposedAdditionalTax20132015" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_RepathaevolocumabMember" abstract="true" name="RepathaevolocumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_A3352032NotesMember" abstract="true" name="A3352032NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_SixPointThreeSevenFivePercentNotesDue2037Member" abstract="true" name="SixPointThreeSevenFivePercentNotesDue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_NovartisPharmaAGMember" abstract="true" name="NovartisPharmaAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OnePointSixFivePercent2028NotesMember" abstract="true" name="OnePointSixFivePercent2028NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" abstract="true" name="FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AlternativeInvestmentNetGainLoss" abstract="false" name="AlternativeInvestmentNetGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_ForeignAndOtherGovernmentRelatedDebtSecuritiesMember" abstract="true" name="ForeignAndOtherGovernmentRelatedDebtSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OtezlaANDAPatentLitigationMember" abstract="true" name="OtezlaANDAPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_LitigationSettlementDamagesSoughtValue" abstract="false" name="LitigationSettlementDamagesSoughtValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_ThreePointFourFivePercentNotesDue2020Member" abstract="true" name="ThreePointFourFivePercentNotesDue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" abstract="true" name="OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_CorporateDebtSecuritiesIndustrialMember" abstract="true" name="CorporateDebtSecuritiesIndustrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_A300NotesDue20523002052NotesMember" abstract="true" name="A300NotesDue20523002052NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_NumberOfAssertedPatents" abstract="false" name="NumberOfAssertedPatents" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount" abstract="false" name="DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_AvailableForSalesInvestmentsMember" abstract="true" name="AvailableForSalesInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_HedgedLiabilityDiscontinuedFairValueHedge" abstract="false" name="HedgedLiabilityDiscontinuedFairValueHedge" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_MortgageAndAssetBackMember" abstract="true" name="MortgageAndAssetBackMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" abstract="true" name="TwoPercentEuroNotesDueTwoThousandTwentySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointFourFivePercentNotesDue2030Member" abstract="true" name="TwoPointFourFivePercentNotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_LitigationSettlementNumberOfPrimaryArguments" abstract="false" name="LitigationSettlementNumberOfPrimaryArguments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_BasicAndDilutedEarningPerShareAbstract" abstract="true" name="BasicAndDilutedEarningPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" abstract="false" name="ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_PenaltiesOnProposedAdditionalIncomeTax20132105" abstract="false" name="PenaltiesOnProposedAdditionalIncomeTax20132105" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_StockRepurchaseProgramTableTextBlock" abstract="false" name="StockRepurchaseProgramTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_FourPointOneZeroPercentNotesDue2021Member" abstract="true" name="FourPointOneZeroPercentNotesDue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_BusinessCombinationContingentConsiderationRollForward" abstract="true" name="BusinessCombinationContingentConsiderationRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_ProposedAdditionalIncomeTax" abstract="false" name="ProposedAdditionalIncomeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_OtherShortTermInterestBearingSecuritiesMember" abstract="true" name="OtherShortTermInterestBearingSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointThreeZeroPercentNotesDue2031Member" abstract="true" name="TwoPointThreeZeroPercentNotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_Businessassetacquisitionconsiderationtransferred" abstract="false" name="Businessassetacquisitionconsiderationtransferred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_OtherGeneralExpenseIncomeOtherAdjustments" abstract="false" name="OtherGeneralExpenseIncomeOtherAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_EnbrelMember" abstract="false" name="EnbrelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" abstract="false" name="OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_SixPointNineZeroPercentNotesDue2038Member" abstract="true" name="SixPointNineZeroPercentNotesDue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" abstract="true" name="OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent" abstract="false" name="PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amgn_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" abstract="true" name="AccumulatedOtherAdjustmentAttributabletoParentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OtherNotesDue2097Member" abstract="true" name="OtherNotesDue2097Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_BeiGeneMember" abstract="true" name="BeiGeneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_A3002029NotesMember" abstract="true" name="A3002029NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" abstract="true" name="DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" abstract="true" name="ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_HumiraBiosimilarAntitrustClassActionsMember" abstract="true" name="HumiraBiosimilarAntitrustClassActionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" abstract="false" name="OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_EquityMethodInvestmentChangeInCarryingValue" abstract="false" name="EquityMethodInvestmentChangeInCarryingValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_LongTermDebtCurrentMaturitiesMember" abstract="true" name="LongTermDebtCurrentMaturitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_KyprolisANDAPatentLitigationMember" abstract="true" name="KyprolisANDAPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" abstract="false" name="BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_MoleculeTypeDomain" abstract="true" name="MoleculeTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ProposedAdditionalIncomeTax20132015" abstract="false" name="ProposedAdditionalIncomeTax20132015" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_NumberOfThirdPartyFinancialInstitutions" abstract="false" name="NumberOfThirdPartyFinancialInstitutions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_LossContingencyNumberOfLawsuits" abstract="false" name="LossContingencyNumberOfLawsuits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" abstract="true" name="ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" abstract="false" name="IdentifiableIntangibleAssetsAccumulatedAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_GensentaIlacSanayiVsTicaretMember" abstract="true" name="GensentaIlacSanayiVsTicaretMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_RepatriationTaxOnProposedAdditionalTax" abstract="false" name="RepatriationTaxOnProposedAdditionalTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_IncreaseDecreaseInNoncurrentTaxLiability" abstract="false" name="IncreaseDecreaseInNoncurrentTaxLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_MoleculeTypeAxis" abstract="true" name="MoleculeTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" abstract="true" name="TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" abstract="true" name="TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" abstract="true" name="FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_BasisOfPresentationPolicyTextBlock" abstract="false" name="BasisOfPresentationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_TeneobioIncMember" abstract="true" name="TeneobioIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" abstract="true" name="ThreePointThreeSevenFivePercentNotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FivePointThreeSevenFivePercentNotesDue2043Member" abstract="true" name="FivePointThreeSevenFivePercentNotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" abstract="true" name="AcquiredResearchAndDevelopmentTechnologyRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ThreePointOneFivePercentNotesDue2040Member" abstract="true" name="ThreePointOneFivePercentNotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointEightZeroPercent2041NotesMember" abstract="true" name="TwoPointEightZeroPercent2041NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_SixPointFourZeroPercentNotesDue2039Member" abstract="true" name="SixPointFourZeroPercentNotesDue2039Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointZeroPercent2032NotesMemberMember" abstract="true" name="TwoPointZeroPercent2032NotesMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_BusinessCombinationContingentConsiderationArrangementsPayments" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_KyprolisMember" abstract="true" name="KyprolisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" abstract="true" name="TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_XgevaMember" abstract="false" name="XgevaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" abstract="true" name="AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_IdentifiableIntangibleAssetsGross" abstract="false" name="IdentifiableIntangibleAssetsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_FivePointOneFivePercentNotesDue2041Member" abstract="true" name="FivePointOneFivePercentNotesDue2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" abstract="true" name="FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_NatureOfOperationsPolicyTextBlock" abstract="false" name="NatureOfOperationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_AMG340Member" abstract="true" name="AMG340Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ThreePointSixTwoFivePercentNotesDue2024Member" abstract="true" name="ThreePointSixTwoFivePercentNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" abstract="true" name="TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" abstract="false" name="EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_NeumoraTherapeuticsIncMember" abstract="true" name="NeumoraTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_HospiraMember" abstract="true" name="HospiraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_CrossCurrencySwapContractsMember" abstract="true" name="CrossCurrencySwapContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" abstract="false" name="BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_CorporateDebtSecuritiesOtherMember" abstract="true" name="CorporateDebtSecuritiesOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" abstract="true" name="TwoPointSixZeroNotesDueTwoZeroTwoSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_RDTechnologyrightsMember" abstract="true" name="RDTechnologyrightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" abstract="true" name="FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" abstract="true" name="FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_A4402062NotesMember" abstract="true" name="A4402062NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OtherCurrentNoncurrentAssetsMember" abstract="true" name="OtherCurrentNoncurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" abstract="false" name="PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amgn_FivePrimeTherapeuticsIncMember" abstract="true" name="FivePrimeTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" abstract="true" name="FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ThreePointTwoZeroNotesDue2027Member" abstract="true" name="ThreePointTwoZeroNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ThreePointSixTwoFivePercentNotesDue2022Member" abstract="true" name="ThreePointSixTwoFivePercentNotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember" abstract="true" name="OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OtezlaMember" abstract="true" name="OtezlaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_LossContingencyAppealPeriod" abstract="false" name="LossContingencyAppealPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amgn_FourPointNineFivePercentNotesDue2041Member" abstract="true" name="FourPointNineFivePercentNotesDue2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_KANJINTIPatentLitigationMember" abstract="true" name="KANJINTIPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TeneobioMember" abstract="true" name="TeneobioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_DebtExchangeAdditionalCashConsideration" abstract="false" name="DebtExchangeAdditionalCashConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amgn_TwoPointSixFiveNotesDue2022Member" abstract="true" name="TwoPointSixFiveNotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_CorporateDebtSecuritiesFinancialMember" abstract="true" name="CorporateDebtSecuritiesFinancialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_FivePointSevenFivePercentNotesDue2040Member" abstract="true" name="FivePointSevenFivePercentNotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" abstract="false" name="ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_OtherMortgageAndAssetBackedMember" abstract="true" name="OtherMortgageAndAssetBackedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember" abstract="true" name="OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_NeulastaMember" abstract="false" name="NeulastaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_DerivativeAssetsFairValueDisclosureAbstract" abstract="true" name="DerivativeAssetsFairValueDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" abstract="false" name="FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_FivePointSixFivePercentNotesDue2042Member" abstract="true" name="FivePointSixFivePercentNotesDue2042Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_PatentTrialAndAppealBoardPatentChallengesMember" abstract="true" name="PatentTrialAndAppealBoardPatentChallengesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ProliaMember" abstract="false" name="ProliaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_SensiparAntitrustClassActionsMember" abstract="true" name="SensiparAntitrustClassActionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_AcceleratedStockRepurchaseAgreementMember" abstract="true" name="AcceleratedStockRepurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_TwoPointTwoZeroNotesDue2020Member" abstract="true" name="TwoPointTwoZeroNotesDue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ThreePointEightSevenFivePercentNotesDue2021Member" abstract="true" name="ThreePointEightSevenFivePercentNotesDue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_A4202052NotesMember" abstract="true" name="A4202052NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_A2.00SeniorNotesDue2026Member" abstract="true" name="A2.00SeniorNotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amgn_ScheduleOfIntangibleAssetsTableTextBlock" abstract="false" name="ScheduleOfIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amgn_NplateMember" abstract="true" name="NplateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>amgn-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5d27ca97-9729-4191-8773-bd1da607be75,g:d96be9d2-9e3e-485f-8641-d09afcb6a74b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="amgn-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_86d85a0d-7eb4-40b3-a291-5a0fa5db3860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_488697e9-3bd1-4e21-acff-243ae6a54034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_86d85a0d-7eb4-40b3-a291-5a0fa5db3860" xlink:to="loc_us-gaap_NetIncomeLoss_488697e9-3bd1-4e21-acff-243ae6a54034" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_212d646f-caa8-4dae-8dc0-9fc40e30ef96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_86d85a0d-7eb4-40b3-a291-5a0fa5db3860" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_212d646f-caa8-4dae-8dc0-9fc40e30ef96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6f2a1943-b55a-44f4-b3d6-648951f4213a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4efbcc1d-57d7-4346-8877-a8f8c7eb340c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6f2a1943-b55a-44f4-b3d6-648951f4213a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4efbcc1d-57d7-4346-8877-a8f8c7eb340c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_6e726404-180f-41f6-a98a-8bc46abfe4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6f2a1943-b55a-44f4-b3d6-648951f4213a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_6e726404-180f-41f6-a98a-8bc46abfe4f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_052f211a-c9de-473c-9430-f17d24885774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6f2a1943-b55a-44f4-b3d6-648951f4213a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_052f211a-c9de-473c-9430-f17d24885774" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_2308d9a1-9c7a-4a7d-a579-7b2d9a4a86f9" xlink:href="amgn-20220630.xsd#amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6f2a1943-b55a-44f4-b3d6-648951f4213a" xlink:to="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_2308d9a1-9c7a-4a7d-a579-7b2d9a4a86f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="amgn-20220630.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3279bff9-e0bc-43e5-9f5d-4647789f0497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_63975030-1231-4e55-a20d-0528f856dd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3279bff9-e0bc-43e5-9f5d-4647789f0497" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_63975030-1231-4e55-a20d-0528f856dd6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d1cfda57-457c-4f61-8da0-e2baf3e9821e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3279bff9-e0bc-43e5-9f5d-4647789f0497" xlink:to="loc_us-gaap_CostsAndExpenses_d1cfda57-457c-4f61-8da0-e2baf3e9821e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8f26980c-28cb-449b-8242-37ca4cd0d04f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_034f2d29-5350-4b2b-892c-2641df0bf238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8f26980c-28cb-449b-8242-37ca4cd0d04f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_034f2d29-5350-4b2b-892c-2641df0bf238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1b2d8576-a9e4-47c2-a088-35a215908894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8f26980c-28cb-449b-8242-37ca4cd0d04f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1b2d8576-a9e4-47c2-a088-35a215908894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1b7564a5-7eb1-42c5-ba36-42865fe9dfea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8f26980c-28cb-449b-8242-37ca4cd0d04f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1b7564a5-7eb1-42c5-ba36-42865fe9dfea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherGeneralExpenseIncomeOtherAdjustments_460acc39-63e8-4090-8a07-9c77f4961268" xlink:href="amgn-20220630.xsd#amgn_OtherGeneralExpenseIncomeOtherAdjustments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8f26980c-28cb-449b-8242-37ca4cd0d04f" xlink:to="loc_amgn_OtherGeneralExpenseIncomeOtherAdjustments_460acc39-63e8-4090-8a07-9c77f4961268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_8846e9b7-52a6-4dad-b468-640c6e839499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8f26980c-28cb-449b-8242-37ca4cd0d04f" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_8846e9b7-52a6-4dad-b468-640c6e839499" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8b227c72-fa0e-409b-a410-e784573b2a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4e4b3a77-4eec-40ff-ae93-0e678e57eca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8b227c72-fa0e-409b-a410-e784573b2a53" xlink:to="loc_us-gaap_OperatingIncomeLoss_4e4b3a77-4eec-40ff-ae93-0e678e57eca2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_0b8b6abc-f89b-4415-be68-ffa3a68ba089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8b227c72-fa0e-409b-a410-e784573b2a53" xlink:to="loc_us-gaap_InterestExpenseDebt_0b8b6abc-f89b-4415-be68-ffa3a68ba089" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1048fddd-1e48-4283-b73a-322100dabb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8b227c72-fa0e-409b-a410-e784573b2a53" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1048fddd-1e48-4283-b73a-322100dabb4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_688fe39e-f295-4a8d-8a72-c931924f2ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6857b2f0-ea23-4319-ac3e-e7cd84c5f397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_688fe39e-f295-4a8d-8a72-c931924f2ef9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6857b2f0-ea23-4319-ac3e-e7cd84c5f397" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_61869ac6-822a-4e97-abdc-e659731d00ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_688fe39e-f295-4a8d-8a72-c931924f2ef9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_61869ac6-822a-4e97-abdc-e659731d00ce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="amgn-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f57159b5-8520-42c2-8fb9-84b17b5c43a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ac886016-ecdd-4820-a0c0-52b06d881830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f57159b5-8520-42c2-8fb9-84b17b5c43a0" xlink:to="loc_us-gaap_AccountsPayableCurrent_ac886016-ecdd-4820-a0c0-52b06d881830" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_fedc16d0-e9da-4386-bd77-83351a0f98d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f57159b5-8520-42c2-8fb9-84b17b5c43a0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_fedc16d0-e9da-4386-bd77-83351a0f98d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ce306aa3-6229-4881-802b-4483384c7fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f57159b5-8520-42c2-8fb9-84b17b5c43a0" xlink:to="loc_us-gaap_LongTermDebtCurrent_ce306aa3-6229-4881-802b-4483384c7fb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f0071a6f-6933-4ce7-8574-07902897e4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_57454cd6-8ee8-4bb7-8365-f9df5018906a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f0071a6f-6933-4ce7-8574-07902897e4ad" xlink:to="loc_us-gaap_LiabilitiesCurrent_57454cd6-8ee8-4bb7-8365-f9df5018906a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_df45be89-204c-4d98-b219-3c7e2c45a70e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f0071a6f-6933-4ce7-8574-07902897e4ad" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_df45be89-204c-4d98-b219-3c7e2c45a70e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_e6f33e38-0349-4dc7-bc9a-04b38ef34039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f0071a6f-6933-4ce7-8574-07902897e4ad" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_e6f33e38-0349-4dc7-bc9a-04b38ef34039" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a976884f-0fcc-45da-87e6-ec653e326b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f0071a6f-6933-4ce7-8574-07902897e4ad" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a976884f-0fcc-45da-87e6-ec653e326b7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_68298a99-bd4b-43cc-85a2-bd764c850786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f0071a6f-6933-4ce7-8574-07902897e4ad" xlink:to="loc_us-gaap_StockholdersEquity_68298a99-bd4b-43cc-85a2-bd764c850786" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9288f6f9-48d7-4380-9825-e5786eb43541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f0071a6f-6933-4ce7-8574-07902897e4ad" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9288f6f9-48d7-4380-9825-e5786eb43541" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e68e4232-1e43-4efd-8c16-0cd64e533402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_54a9a0b3-7c03-4d42-b655-cc9d0935641e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e68e4232-1e43-4efd-8c16-0cd64e533402" xlink:to="loc_us-gaap_AssetsCurrent_54a9a0b3-7c03-4d42-b655-cc9d0935641e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9da9ff07-99fc-4745-b6d8-d1ad947edae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e68e4232-1e43-4efd-8c16-0cd64e533402" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9da9ff07-99fc-4745-b6d8-d1ad947edae6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7c563372-eee0-4b8e-bbae-fab6f9348912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e68e4232-1e43-4efd-8c16-0cd64e533402" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7c563372-eee0-4b8e-bbae-fab6f9348912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_86a07747-8c70-4a40-a0b5-414e30fa1def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e68e4232-1e43-4efd-8c16-0cd64e533402" xlink:to="loc_us-gaap_Goodwill_86a07747-8c70-4a40-a0b5-414e30fa1def" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8f5175c5-3395-468b-a43f-92e63b5d2e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e68e4232-1e43-4efd-8c16-0cd64e533402" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8f5175c5-3395-468b-a43f-92e63b5d2e4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f8301c12-bf3e-4be4-822c-6e02e5788277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_15be0d3b-56f1-4e7d-9483-866e67dad7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f8301c12-bf3e-4be4-822c-6e02e5788277" xlink:to="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_15be0d3b-56f1-4e7d-9483-866e67dad7a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f586f99f-d45a-461b-8844-974163d0c866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f8301c12-bf3e-4be4-822c-6e02e5788277" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f586f99f-d45a-461b-8844-974163d0c866" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_51c2bd1c-b726-47eb-8769-748f53e3bc83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f8301c12-bf3e-4be4-822c-6e02e5788277" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_51c2bd1c-b726-47eb-8769-748f53e3bc83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_049fb5ef-683a-4e77-ac33-96a5f38f1547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2e29d2fe-3965-4863-8b0e-b16be4f2139a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_049fb5ef-683a-4e77-ac33-96a5f38f1547" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2e29d2fe-3965-4863-8b0e-b16be4f2139a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_cb5531a0-c642-443a-9dc5-113b80f77675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_049fb5ef-683a-4e77-ac33-96a5f38f1547" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_cb5531a0-c642-443a-9dc5-113b80f77675" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f41a3993-0366-4e0c-90a0-ed595aa7ec30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_049fb5ef-683a-4e77-ac33-96a5f38f1547" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f41a3993-0366-4e0c-90a0-ed595aa7ec30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2b24bcd7-be5a-4481-b387-c8ff29f6698b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_049fb5ef-683a-4e77-ac33-96a5f38f1547" xlink:to="loc_us-gaap_InventoryNet_2b24bcd7-be5a-4481-b387-c8ff29f6698b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_259d0aa7-f72b-43b1-98eb-ccfc2a61cd12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_049fb5ef-683a-4e77-ac33-96a5f38f1547" xlink:to="loc_us-gaap_OtherAssetsCurrent_259d0aa7-f72b-43b1-98eb-ccfc2a61cd12" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="amgn-20220630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5eb303c1-96b4-463d-855a-bafedc126928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_89b99fb6-a089-47ec-a5aa-1cbdccf69f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5eb303c1-96b4-463d-855a-bafedc126928" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_89b99fb6-a089-47ec-a5aa-1cbdccf69f5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability_f3790291-e1cb-4034-ac38-be095d8d438f" xlink:href="amgn-20220630.xsd#amgn_IncreaseDecreaseInNoncurrentTaxLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5eb303c1-96b4-463d-855a-bafedc126928" xlink:to="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability_f3790291-e1cb-4034-ac38-be095d8d438f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_af45f985-7e0c-478c-8128-4490c9e63e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5eb303c1-96b4-463d-855a-bafedc126928" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_af45f985-7e0c-478c-8128-4490c9e63e36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3b8d9457-be74-42cd-8950-e7616adf98a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5eb303c1-96b4-463d-855a-bafedc126928" xlink:to="loc_us-gaap_NetIncomeLoss_3b8d9457-be74-42cd-8950-e7616adf98a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_fb1b7e81-c608-43d4-a0fd-e1c7bda85e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5eb303c1-96b4-463d-855a-bafedc126928" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_fb1b7e81-c608-43d4-a0fd-e1c7bda85e1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fd046232-5f6b-41d6-9ece-f73a772d58b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5eb303c1-96b4-463d-855a-bafedc126928" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fd046232-5f6b-41d6-9ece-f73a772d58b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1b4b30d8-1bca-45f5-a145-6a9d75ed7502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5eb303c1-96b4-463d-855a-bafedc126928" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1b4b30d8-1bca-45f5-a145-6a9d75ed7502" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_1da2dadd-8428-4269-87df-477de0c27ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5eb303c1-96b4-463d-855a-bafedc126928" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_1da2dadd-8428-4269-87df-477de0c27ec7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ffabcb32-224b-4d6c-aa20-12af28d70dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5eb303c1-96b4-463d-855a-bafedc126928" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ffabcb32-224b-4d6c-aa20-12af28d70dcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_36b2d610-2644-468b-b26b-dc4c2b3bdcd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5eb303c1-96b4-463d-855a-bafedc126928" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_36b2d610-2644-468b-b26b-dc4c2b3bdcd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_4057b362-0ff3-4311-87b2-ad6dbe3ab5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5eb303c1-96b4-463d-855a-bafedc126928" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_4057b362-0ff3-4311-87b2-ad6dbe3ab5ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_96d37db8-2e11-46e5-9ca2-b71d5054219e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5eb303c1-96b4-463d-855a-bafedc126928" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_96d37db8-2e11-46e5-9ca2-b71d5054219e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_73e49299-952f-43f3-aa44-8c3e3a7a922b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5eb303c1-96b4-463d-855a-bafedc126928" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_73e49299-952f-43f3-aa44-8c3e3a7a922b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_b0bceb94-c85c-41c6-93d0-2068af686257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5eb303c1-96b4-463d-855a-bafedc126928" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_b0bceb94-c85c-41c6-93d0-2068af686257" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_13f8526e-a57f-4505-b5ed-88e6e3308cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ec08de79-0a5e-4242-9517-d85ae53833bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_13f8526e-a57f-4505-b5ed-88e6e3308cef" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ec08de79-0a5e-4242-9517-d85ae53833bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_03ecc4e8-7cff-4973-98de-98434bb35545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_13f8526e-a57f-4505-b5ed-88e6e3308cef" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_03ecc4e8-7cff-4973-98de-98434bb35545" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_088f1b99-14ae-454c-8970-8011439a790d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_13f8526e-a57f-4505-b5ed-88e6e3308cef" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_088f1b99-14ae-454c-8970-8011439a790d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c27f5e0e-fa8f-451b-9ae1-1ab15c91626b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_13f8526e-a57f-4505-b5ed-88e6e3308cef" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c27f5e0e-fa8f-451b-9ae1-1ab15c91626b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_33df009f-f2d6-4955-ba8e-252afd7aca7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_13f8526e-a57f-4505-b5ed-88e6e3308cef" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_33df009f-f2d6-4955-ba8e-252afd7aca7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_371a8ecf-c8bc-414c-bdfe-f1af82b76df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b31010b7-7c14-47fd-989c-d4db5d47f267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_371a8ecf-c8bc-414c-bdfe-f1af82b76df5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b31010b7-7c14-47fd-989c-d4db5d47f267" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_fdd55cbb-bb61-4e5e-b59e-1ed721085597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_371a8ecf-c8bc-414c-bdfe-f1af82b76df5" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_fdd55cbb-bb61-4e5e-b59e-1ed721085597" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5eae3f39-23aa-4dba-9279-dbaab5491fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_371a8ecf-c8bc-414c-bdfe-f1af82b76df5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5eae3f39-23aa-4dba-9279-dbaab5491fe3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_55d7ec10-e4e9-4d85-b5f0-afb1bcc99421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_371a8ecf-c8bc-414c-bdfe-f1af82b76df5" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_55d7ec10-e4e9-4d85-b5f0-afb1bcc99421" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_a7e43253-b5d1-4ad5-afbd-c4da0a7fd942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_371a8ecf-c8bc-414c-bdfe-f1af82b76df5" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_a7e43253-b5d1-4ad5-afbd-c4da0a7fd942" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_36caa49f-47bb-41ea-9ab3-caf65b49c2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_371a8ecf-c8bc-414c-bdfe-f1af82b76df5" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_36caa49f-47bb-41ea-9ab3-caf65b49c2e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8f91f820-167d-4c6f-bf06-df6ffba277c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_371a8ecf-c8bc-414c-bdfe-f1af82b76df5" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8f91f820-167d-4c6f-bf06-df6ffba277c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6b2d07f1-9ca4-465b-af3c-9225d3c4c0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_17aeee07-3f3f-4bd0-8252-81c2a72a21c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6b2d07f1-9ca4-465b-af3c-9225d3c4c0cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_17aeee07-3f3f-4bd0-8252-81c2a72a21c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f932b6d7-3752-48d6-b551-ac6d0e16aa28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6b2d07f1-9ca4-465b-af3c-9225d3c4c0cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f932b6d7-3752-48d6-b551-ac6d0e16aa28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51caa077-0a97-4bc9-be59-0172fbed99e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6b2d07f1-9ca4-465b-af3c-9225d3c4c0cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51caa077-0a97-4bc9-be59-0172fbed99e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#AcquisitionsAggregateConsiderationPaidDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_41089f39-4959-4b39-854d-94b6f6349ede" xlink:href="amgn-20220630.xsd#amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_2b545d70-5420-4291-82f2-bbad8ce2670c" xlink:href="amgn-20220630.xsd#amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_41089f39-4959-4b39-854d-94b6f6349ede" xlink:to="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_2b545d70-5420-4291-82f2-bbad8ce2670c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_14f4941c-8188-4d95-a670-d6439a66fda3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_41089f39-4959-4b39-854d-94b6f6349ede" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_14f4941c-8188-4d95-a670-d6439a66fda3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_85652d6b-94d3-41a9-aa7e-51263df13560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_41089f39-4959-4b39-854d-94b6f6349ede" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_85652d6b-94d3-41a9-aa7e-51263df13560" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9426a17e-8d84-4331-a11b-58e9cbfeec44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_41089f39-4959-4b39-854d-94b6f6349ede" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_9426a17e-8d84-4331-a11b-58e9cbfeec44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c0e1089c-98b6-4f21-95c7-759677d3438e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_41089f39-4959-4b39-854d-94b6f6349ede" xlink:to="loc_us-gaap_Goodwill_c0e1089c-98b6-4f21-95c7-759677d3438e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b4a80255-ece0-4b15-b79e-6cc90ff4d45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_41089f39-4959-4b39-854d-94b6f6349ede" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b4a80255-ece0-4b15-b79e-6cc90ff4d45b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Businessassetacquisitionconsiderationtransferred_fd745b8f-78f1-40cf-8d89-b5c2c21e0029" xlink:href="amgn-20220630.xsd#amgn_Businessassetacquisitionconsiderationtransferred"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_df20abf6-91eb-4be8-b999-5405b3d3eb40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_Businessassetacquisitionconsiderationtransferred_fd745b8f-78f1-40cf-8d89-b5c2c21e0029" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_df20abf6-91eb-4be8-b999-5405b3d3eb40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_1343b7a8-9a9e-4095-9ecd-49e0fde76831" xlink:href="amgn-20220630.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amgn_Businessassetacquisitionconsiderationtransferred_fd745b8f-78f1-40cf-8d89-b5c2c21e0029" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_1343b7a8-9a9e-4095-9ecd-49e0fde76831" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/EarningspershareDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#EarningspershareDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/EarningspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a12ac7b4-f872-4fbe-971d-e0348882c4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_32f48d15-3ab5-41a0-b2da-eedf24059142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a12ac7b4-f872-4fbe-971d-e0348882c4ce" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_32f48d15-3ab5-41a0-b2da-eedf24059142" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d2e9d2d5-d9ee-449d-b14b-b46c52b56483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a12ac7b4-f872-4fbe-971d-e0348882c4ce" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d2e9d2d5-d9ee-449d-b14b-b46c52b56483" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#InvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ae8ccb31-0b93-4ef9-a5a5-8f796d6f154b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1d869240-836a-4020-b2c3-fd2941c8df90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ae8ccb31-0b93-4ef9-a5a5-8f796d6f154b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1d869240-836a-4020-b2c3-fd2941c8df90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_76b6803b-4124-4ab7-ba14-5a2f159df3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ae8ccb31-0b93-4ef9-a5a5-8f796d6f154b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_76b6803b-4124-4ab7-ba14-5a2f159df3d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d22faf23-41c2-4f07-83a2-7bac3d99d941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ae8ccb31-0b93-4ef9-a5a5-8f796d6f154b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d22faf23-41c2-4f07-83a2-7bac3d99d941" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#InvestmentsFairValuesbyClassificationDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_854ec68d-b207-47b1-860c-563e437ab493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_bbe2c5ca-fa0a-4bd8-a7d4-fcdcc8beea7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_854ec68d-b207-47b1-860c-563e437ab493" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_bbe2c5ca-fa0a-4bd8-a7d4-fcdcc8beea7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_826ae285-21fa-4ed0-9dfa-eb7c21119344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_854ec68d-b207-47b1-860c-563e437ab493" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_826ae285-21fa-4ed0-9dfa-eb7c21119344" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#InvestmentsFairValuesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7e24d8c1-37d2-40c1-a6ee-d2a5defef2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_3587f03b-2ce0-450a-b802-ace1bace3fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7e24d8c1-37d2-40c1-a6ee-d2a5defef2f3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_3587f03b-2ce0-450a-b802-ace1bace3fbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_5dc8ad04-3856-486b-acb5-5b2b04935f7e" xlink:href="amgn-20220630.xsd#amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7e24d8c1-37d2-40c1-a6ee-d2a5defef2f3" xlink:to="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_5dc8ad04-3856-486b-acb5-5b2b04935f7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue_b06f1c2f-97b2-4d2c-9b41-a603e40e6759" xlink:href="amgn-20220630.xsd#amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7e24d8c1-37d2-40c1-a6ee-d2a5defef2f3" xlink:to="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue_b06f1c2f-97b2-4d2c-9b41-a603e40e6759" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_5ef0be03-d0be-4aa7-a47c-0d857edb0e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7e24d8c1-37d2-40c1-a6ee-d2a5defef2f3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_5ef0be03-d0be-4aa7-a47c-0d857edb0e60" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InventoriesDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_28114d31-0620-4e7b-97e6-a3c0a4b421f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_800f7901-fbf9-4005-adcf-a13988efa898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_28114d31-0620-4e7b-97e6-a3c0a4b421f8" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_800f7901-fbf9-4005-adcf-a13988efa898" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_34977af4-d410-4978-b7d3-e8b3ff9179a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_28114d31-0620-4e7b-97e6-a3c0a4b421f8" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_34977af4-d410-4978-b7d3-e8b3ff9179a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_6790fa61-2390-4eee-afc3-f8564d1a326a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_28114d31-0620-4e7b-97e6-a3c0a4b421f8" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_6790fa61-2390-4eee-afc3-f8564d1a326a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_41eb728e-7920-4c81-89ea-8c1908c577e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsGross_79a03c05-5077-46b1-9b75-0b4bbd46b62e" xlink:href="amgn-20220630.xsd#amgn_IdentifiableIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_41eb728e-7920-4c81-89ea-8c1908c577e1" xlink:to="loc_amgn_IdentifiableIntangibleAssetsGross_79a03c05-5077-46b1-9b75-0b4bbd46b62e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_90b63d07-d723-4530-90d5-2027893a768d" xlink:href="amgn-20220630.xsd#amgn_IdentifiableIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_41eb728e-7920-4c81-89ea-8c1908c577e1" xlink:to="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_90b63d07-d723-4530-90d5-2027893a768d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e5fe6c62-41e5-4ed3-94fb-3499303f8483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1f76e9f9-8782-4ccd-957b-e1eec5469fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e5fe6c62-41e5-4ed3-94fb-3499303f8483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1f76e9f9-8782-4ccd-957b-e1eec5469fba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_61b1ee5e-dd9f-4774-a9f0-a935b022d2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e5fe6c62-41e5-4ed3-94fb-3499303f8483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_61b1ee5e-dd9f-4774-a9f0-a935b022d2f3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6474ea01-9339-41e1-8f97-9ba389db3edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_5278f0ca-99ae-45c7-bf1f-b05e29c20621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_6474ea01-9339-41e1-8f97-9ba389db3edc" xlink:to="loc_us-gaap_LongTermDebtCurrent_5278f0ca-99ae-45c7-bf1f-b05e29c20621" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4ea2760a-3c85-45fc-be6f-868301f0d44a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_6474ea01-9339-41e1-8f97-9ba389db3edc" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4ea2760a-3c85-45fc-be6f-868301f0d44a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#FairvaluemeasurementDetails"/>
  <link:calculationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f5ddd141-75b9-458e-ae33-11589f77f384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b8875416-e248-4be3-b43b-3c550ca671b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f5ddd141-75b9-458e-ae33-11589f77f384" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b8875416-e248-4be3-b43b-3c550ca671b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c9866b6f-fa2b-42bd-8ce0-69c7f0966153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f5ddd141-75b9-458e-ae33-11589f77f384" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c9866b6f-fa2b-42bd-8ce0-69c7f0966153" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_7d623a89-d92c-49d1-80ac-481a1d92ae13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f5ddd141-75b9-458e-ae33-11589f77f384" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_7d623a89-d92c-49d1-80ac-481a1d92ae13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_541f1dd1-bae6-4496-8ec1-294058699725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateFairValueHedgeAssetAtFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f5ddd141-75b9-458e-ae33-11589f77f384" xlink:to="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_541f1dd1-bae6-4496-8ec1-294058699725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_e4713325-5ab8-477e-891e-89182b4297f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1f61d445-baa6-4e8d-accf-f4538fc17579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_e4713325-5ab8-477e-891e-89182b4297f5" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1f61d445-baa6-4e8d-accf-f4538fc17579" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_8c62b39f-1e8d-43e8-86f3-e99116bd46fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_e4713325-5ab8-477e-891e-89182b4297f5" xlink:to="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_8c62b39f-1e8d-43e8-86f3-e99116bd46fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3f544868-3f9c-41b8-9133-d4c0b7659800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_e4713325-5ab8-477e-891e-89182b4297f5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3f544868-3f9c-41b8-9133-d4c0b7659800" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>amgn-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5d27ca97-9729-4191-8773-bd1da607be75,g:d96be9d2-9e3e-485f-8641-d09afcb6a74b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.amgen.com/role/CoverPage" xlink:type="simple" xlink:href="amgn-20220630.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/CoverPage" xlink:type="extended" id="ic386999ac9794563878bdab8008d5996_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_817b68d7-37eb-410a-8dec-22115b82c9b8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_DocumentType_817b68d7-37eb-410a-8dec-22115b82c9b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_3479088c-5867-4e01-8fca-17fe348e39f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_DocumentQuarterlyReport_3479088c-5867-4e01-8fca-17fe348e39f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3ea5fa7a-0724-4ffd-9c3f-1a5e69441a46" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_DocumentPeriodEndDate_3ea5fa7a-0724-4ffd-9c3f-1a5e69441a46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_07087878-f8ce-4a3f-a738-8d1ae4bd64eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_DocumentTransitionReport_07087878-f8ce-4a3f-a738-8d1ae4bd64eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_92f68771-a6b8-44fa-909a-660cdcdddf26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityFileNumber_92f68771-a6b8-44fa-909a-660cdcdddf26" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_27acf58e-1309-404b-adf4-06805094d9d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityRegistrantName_27acf58e-1309-404b-adf4-06805094d9d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_04fb52c3-102d-4d14-8fc7-9c1abac096d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityCentralIndexKey_04fb52c3-102d-4d14-8fc7-9c1abac096d9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_57afc141-26f8-49b0-92dc-92060f8c2d2b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_AmendmentFlag_57afc141-26f8-49b0-92dc-92060f8c2d2b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c32914f2-7de4-4160-be55-8d20287a3067" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_DocumentFiscalYearFocus_c32914f2-7de4-4160-be55-8d20287a3067" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b7e54049-62f9-41bb-a15e-3818a79982cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b7e54049-62f9-41bb-a15e-3818a79982cd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9985b5b6-d280-4a15-9372-7f0b293463e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_CurrentFiscalYearEndDate_9985b5b6-d280-4a15-9372-7f0b293463e3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e344211d-ccf2-404b-83c1-e8451818886d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e344211d-ccf2-404b-83c1-e8451818886d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a360e1e7-cfcd-470a-9c81-edd14c087264" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityTaxIdentificationNumber_a360e1e7-cfcd-470a-9c81-edd14c087264" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_809b9fd9-c687-4dd2-9aae-e2f66ad96caa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityAddressAddressLine1_809b9fd9-c687-4dd2-9aae-e2f66ad96caa" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ae5612f2-b9a8-48d3-8311-6058ba291469" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityAddressCityOrTown_ae5612f2-b9a8-48d3-8311-6058ba291469" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a5a3f12d-7247-4018-bf8f-fe1e9b4b7b22" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityAddressStateOrProvince_a5a3f12d-7247-4018-bf8f-fe1e9b4b7b22" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_db791ccf-d7a6-462f-a41e-52320ad74a5f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityAddressPostalZipCode_db791ccf-d7a6-462f-a41e-52320ad74a5f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c5633b75-e21e-4431-ace5-f18b1be66cbe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_CityAreaCode_c5633b75-e21e-4431-ace5-f18b1be66cbe" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_676f2bec-f97c-4673-bd5a-f06451db75f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_LocalPhoneNumber_676f2bec-f97c-4673-bd5a-f06451db75f7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_364a547a-3c10-45ff-a831-bb432e9023d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_Security12bTitle_364a547a-3c10-45ff-a831-bb432e9023d3" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b3bcf46f-6a15-4b9c-b0d0-6183a8b9db9d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_TradingSymbol_b3bcf46f-6a15-4b9c-b0d0-6183a8b9db9d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a0dd435a-5580-4293-84aa-d81ac3502dd3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_SecurityExchangeName_a0dd435a-5580-4293-84aa-d81ac3502dd3" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c5d4a74a-e991-47f1-8ff6-1a52a57dd1a0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityCurrentReportingStatus_c5d4a74a-e991-47f1-8ff6-1a52a57dd1a0" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_44f38142-9af6-400f-802a-ca2135b3e6b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityInteractiveDataCurrent_44f38142-9af6-400f-802a-ca2135b3e6b5" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b9408885-007e-4549-aca1-30b2c49ce5dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityFilerCategory_b9408885-007e-4549-aca1-30b2c49ce5dc" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_315760b6-6772-47fc-bd07-9df5c9bbf50f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntitySmallBusiness_315760b6-6772-47fc-bd07-9df5c9bbf50f" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_cf1efbc8-e059-4b7e-9ab4-d8c0e70eb340" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityEmergingGrowthCompany_cf1efbc8-e059-4b7e-9ab4-d8c0e70eb340" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3c9c8248-7529-43ab-8802-9c49aa4d68b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityShellCompany_3c9c8248-7529-43ab-8802-9c49aa4d68b2" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1c14ed18-2873-4827-b48f-4d32b46dbd26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1c14ed18-2873-4827-b48f-4d32b46dbd26" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_f2cae794-ae3b-4878-9af7-2874e4960f85" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntitiesTable_f2cae794-ae3b-4878-9af7-2874e4960f85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_ec80ccae-3461-4ca0-a6d8-94a94e4db73c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_f2cae794-ae3b-4878-9af7-2874e4960f85" xlink:to="loc_dei_EntityListingsExchangeAxis_ec80ccae-3461-4ca0-a6d8-94a94e4db73c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_ec80ccae-3461-4ca0-a6d8-94a94e4db73c_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_ec80ccae-3461-4ca0-a6d8-94a94e4db73c" xlink:to="loc_dei_ExchangeDomain_ec80ccae-3461-4ca0-a6d8-94a94e4db73c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_f8b316db-c53a-4cb1-abfe-c77335beee72" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_ec80ccae-3461-4ca0-a6d8-94a94e4db73c" xlink:to="loc_dei_ExchangeDomain_f8b316db-c53a-4cb1-abfe-c77335beee72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS_57141774-6290-400e-8d86-056ee99a17f3" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNGS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_f8b316db-c53a-4cb1-abfe-c77335beee72" xlink:to="loc_exch_XNGS_57141774-6290-400e-8d86-056ee99a17f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fa5e95a9-b370-4ac8-9239-82ad1734e409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_f2cae794-ae3b-4878-9af7-2874e4960f85" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fa5e95a9-b370-4ac8-9239-82ad1734e409" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fa5e95a9-b370-4ac8-9239-82ad1734e409_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fa5e95a9-b370-4ac8-9239-82ad1734e409" xlink:to="loc_us-gaap_ClassOfStockDomain_fa5e95a9-b370-4ac8-9239-82ad1734e409_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dc25efc7-af24-41e7-a178-6d64fc37567b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fa5e95a9-b370-4ac8-9239-82ad1734e409" xlink:to="loc_us-gaap_ClassOfStockDomain_dc25efc7-af24-41e7-a178-6d64fc37567b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a0257759-39f9-4d67-867b-07a8315eab4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_dc25efc7-af24-41e7-a178-6d64fc37567b" xlink:to="loc_us-gaap_CommonStockMember_a0257759-39f9-4d67-867b-07a8315eab4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member_8f25796c-c4cb-4148-add5-83c13ef2093c" xlink:href="amgn-20220630.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_dc25efc7-af24-41e7-a178-6d64fc37567b" xlink:to="loc_amgn_A2.00SeniorNotesDue2026Member_8f25796c-c4cb-4148-add5-83c13ef2093c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="amgn-20220630.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended" id="i027c00c3beff4afdb87c7aa88013f5de_CondensedConsolidatedStatementsofIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_26f18056-6a4e-4578-b0bd-1dafe33319ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_RevenuesAbstract_26f18056-6a4e-4578-b0bd-1dafe33319ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_00dfed52-2234-4e33-8a43-71131f7a40d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_26f18056-6a4e-4578-b0bd-1dafe33319ec" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_00dfed52-2234-4e33-8a43-71131f7a40d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_4bf2b166-03a7-4322-be78-6bc98ca2554c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_4bf2b166-03a7-4322-be78-6bc98ca2554c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_cb0395df-a7e2-40c1-8176-52301eda28e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4bf2b166-03a7-4322-be78-6bc98ca2554c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_cb0395df-a7e2-40c1-8176-52301eda28e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_fa18504b-4960-4f18-b53f-42c05053fb68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4bf2b166-03a7-4322-be78-6bc98ca2554c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_fa18504b-4960-4f18-b53f-42c05053fb68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_3da3d7e0-1d9d-408a-9d53-8faa8df8acc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4bf2b166-03a7-4322-be78-6bc98ca2554c" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_3da3d7e0-1d9d-408a-9d53-8faa8df8acc1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b5d179ff-6347-4ff6-b05a-eb78b89d052e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4bf2b166-03a7-4322-be78-6bc98ca2554c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b5d179ff-6347-4ff6-b05a-eb78b89d052e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherGeneralExpenseIncomeOtherAdjustments_b1ae751b-db01-434c-9355-55d86ea05384" xlink:href="amgn-20220630.xsd#amgn_OtherGeneralExpenseIncomeOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4bf2b166-03a7-4322-be78-6bc98ca2554c" xlink:to="loc_amgn_OtherGeneralExpenseIncomeOtherAdjustments_b1ae751b-db01-434c-9355-55d86ea05384" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2136f545-9242-4922-a190-8cbe16662c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4bf2b166-03a7-4322-be78-6bc98ca2554c" xlink:to="loc_us-gaap_CostsAndExpenses_2136f545-9242-4922-a190-8cbe16662c63" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a2bece7e-6cdf-4411-80fb-73ac4a0b1940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_OperatingIncomeLoss_a2bece7e-6cdf-4411-80fb-73ac4a0b1940" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a697f7fb-e376-49ce-8b95-0b22a83cf5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_InterestExpenseDebt_a697f7fb-e376-49ce-8b95-0b22a83cf5f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_eed1b428-42c1-4952-a70d-21a474d7c4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_eed1b428-42c1-4952-a70d-21a474d7c4ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6235f2d4-04ce-4b83-baa2-f00367fe1bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6235f2d4-04ce-4b83-baa2-f00367fe1bcc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d8daf013-19ff-4d0e-b118-be74f4a52615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d8daf013-19ff-4d0e-b118-be74f4a52615" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ab02e69b-3a20-4762-a31e-7910d271cb34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_NetIncomeLoss_ab02e69b-3a20-4762-a31e-7910d271cb34" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cbdde887-9dd9-4345-a66e-ff60024c5f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_EarningsPerShareAbstract_cbdde887-9dd9-4345-a66e-ff60024c5f80" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a2a99f62-4a01-4ea4-be8a-8c69bd178213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cbdde887-9dd9-4345-a66e-ff60024c5f80" xlink:to="loc_us-gaap_EarningsPerShareBasic_a2a99f62-4a01-4ea4-be8a-8c69bd178213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_28e101db-97de-498e-ac80-159521759c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cbdde887-9dd9-4345-a66e-ff60024c5f80" xlink:to="loc_us-gaap_EarningsPerShareDiluted_28e101db-97de-498e-ac80-159521759c29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_72c8056e-fc59-4ea8-a637-93f6ae39f1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_72c8056e-fc59-4ea8-a637-93f6ae39f1ca" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_76300186-29ed-4798-a60f-af07b01b7ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_72c8056e-fc59-4ea8-a637-93f6ae39f1ca" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_76300186-29ed-4798-a60f-af07b01b7ddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d8a9f45b-a4a5-4e6e-afb6-1b3b23212df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_72c8056e-fc59-4ea8-a637-93f6ae39f1ca" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d8a9f45b-a4a5-4e6e-afb6-1b3b23212df0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_50bfbd27-8504-4478-8b00-6fa38ea11536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_StatementTable_50bfbd27-8504-4478-8b00-6fa38ea11536" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_814a4db2-9f0b-4957-b54f-9f2a91abd615" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_50bfbd27-8504-4478-8b00-6fa38ea11536" xlink:to="loc_srt_ProductOrServiceAxis_814a4db2-9f0b-4957-b54f-9f2a91abd615" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_814a4db2-9f0b-4957-b54f-9f2a91abd615_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_814a4db2-9f0b-4957-b54f-9f2a91abd615" xlink:to="loc_srt_ProductsAndServicesDomain_814a4db2-9f0b-4957-b54f-9f2a91abd615_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_10007571-c9eb-45e2-8318-dec4287ab559" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_814a4db2-9f0b-4957-b54f-9f2a91abd615" xlink:to="loc_srt_ProductsAndServicesDomain_10007571-c9eb-45e2-8318-dec4287ab559" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_21f87582-402c-47a0-bd7d-8f222eac8b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_10007571-c9eb-45e2-8318-dec4287ab559" xlink:to="loc_us-gaap_ProductMember_21f87582-402c-47a0-bd7d-8f222eac8b7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_9c5d35ac-92fc-4318-b64a-06b6aa8146db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_10007571-c9eb-45e2-8318-dec4287ab559" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_9c5d35ac-92fc-4318-b64a-06b6aa8146db" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="amgn-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="ieb49e273d5b74a8d846fa61ecf51ee89_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5da11441-bc36-44d7-aec5-369d87003c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5da11441-bc36-44d7-aec5-369d87003c01" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_490246b1-3496-442d-a562-c451bcbbc613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_490246b1-3496-442d-a562-c451bcbbc613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b441e6e8-f290-4393-84c5-4a2f9d5dc74b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_StockholdersEquity_b441e6e8-f290-4393-84c5-4a2f9d5dc74b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_87cd1921-c225-449c-9da1-2ac68ade8082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_NetIncomeLoss_87cd1921-c225-449c-9da1-2ac68ade8082" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_11b7acba-fe10-4169-8e33-9168f809220f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_11b7acba-fe10-4169-8e33-9168f809220f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_680e6781-75c2-4756-bd6d-890fee175436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_DividendsCommonStockCash_680e6781-75c2-4756-bd6d-890fee175436" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_20a409e6-4fea-49e3-ba88-b592401b2c94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_20a409e6-4fea-49e3-ba88-b592401b2c94" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_fd206a6a-8417-4576-a35a-4541479257b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_fd206a6a-8417-4576-a35a-4541479257b5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5cde7b53-c3a7-4d83-82b3-216c91d0351f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5cde7b53-c3a7-4d83-82b3-216c91d0351f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b5e7300a-44ce-49b0-b961-3b4a7a95497d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b5e7300a-44ce-49b0-b961-3b4a7a95497d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_21f08daa-1679-4db0-8855-466567ac876f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_21f08daa-1679-4db0-8855-466567ac876f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_39b30298-631b-420d-af81-7be6fe2b51ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_39b30298-631b-420d-af81-7be6fe2b51ab" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_dd738cf5-8767-4248-9b39-a35dbede7af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_StockholdersEquityOther_dd738cf5-8767-4248-9b39-a35dbede7af2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4b820afb-6512-4a88-97d2-7cc44ee6a698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9c689784-009d-4a36-897a-4dde746d3e57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9f4eeccc-aad7-44fc-94c0-a0856c74271e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5da11441-bc36-44d7-aec5-369d87003c01" xlink:to="loc_us-gaap_StatementTable_9f4eeccc-aad7-44fc-94c0-a0856c74271e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_72808c0a-34a8-431b-99ab-119706070fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9f4eeccc-aad7-44fc-94c0-a0856c74271e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_72808c0a-34a8-431b-99ab-119706070fc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_72808c0a-34a8-431b-99ab-119706070fc0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_72808c0a-34a8-431b-99ab-119706070fc0" xlink:to="loc_us-gaap_EquityComponentDomain_72808c0a-34a8-431b-99ab-119706070fc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_86ea4486-d26a-4fc4-9c69-bba6daeb04bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_72808c0a-34a8-431b-99ab-119706070fc0" xlink:to="loc_us-gaap_EquityComponentDomain_86ea4486-d26a-4fc4-9c69-bba6daeb04bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_fc90b545-db32-4021-9aaf-4da00e50ed36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_86ea4486-d26a-4fc4-9c69-bba6daeb04bd" xlink:to="loc_us-gaap_CommonStockMember_fc90b545-db32-4021-9aaf-4da00e50ed36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_98e087f3-1910-47cb-b3fb-13cac309631f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_86ea4486-d26a-4fc4-9c69-bba6daeb04bd" xlink:to="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_98e087f3-1910-47cb-b3fb-13cac309631f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_be5d90c0-8df2-4475-b852-b42d9c7691d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_86ea4486-d26a-4fc4-9c69-bba6daeb04bd" xlink:to="loc_us-gaap_RetainedEarningsMember_be5d90c0-8df2-4475-b852-b42d9c7691d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5f3f6f05-5ea9-4213-84a7-6fc0cce51e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_86ea4486-d26a-4fc4-9c69-bba6daeb04bd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5f3f6f05-5ea9-4213-84a7-6fc0cce51e0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_edae7446-4878-4d53-adc3-62e872b3f69a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9f4eeccc-aad7-44fc-94c0-a0856c74271e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_edae7446-4878-4d53-adc3-62e872b3f69a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_edae7446-4878-4d53-adc3-62e872b3f69a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_edae7446-4878-4d53-adc3-62e872b3f69a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_edae7446-4878-4d53-adc3-62e872b3f69a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_24e025ac-c735-4e36-9329-2b2947812e1a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_edae7446-4878-4d53-adc3-62e872b3f69a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_24e025ac-c735-4e36-9329-2b2947812e1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5ad795b4-cb13-4ecf-a1b6-3c8734f48f3d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_24e025ac-c735-4e36-9329-2b2947812e1a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5ad795b4-cb13-4ecf-a1b6-3c8734f48f3d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#AcquisitionsAggregateConsiderationPaidDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" xlink:type="extended" id="i4010c78d14684300810c8db510de5e48_AcquisitionsAggregateConsiderationPaidDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_4a82159f-46dc-41f7-9c60-64728766088c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_4a82159f-46dc-41f7-9c60-64728766088c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_494f37b6-b26b-4d1e-ba29-3fe522f761bd" xlink:href="amgn-20220630.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_494f37b6-b26b-4d1e-ba29-3fe522f761bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Businessassetacquisitionconsiderationtransferred_80839fbc-734d-43e1-9181-6bb729cc489a" xlink:href="amgn-20220630.xsd#amgn_Businessassetacquisitionconsiderationtransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_amgn_Businessassetacquisitionconsiderationtransferred_80839fbc-734d-43e1-9181-6bb729cc489a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d44be0fa-f3e5-4a2a-a08d-47814d248918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d44be0fa-f3e5-4a2a-a08d-47814d248918" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5a312423-36e5-48cd-9fb8-8ddb58a805de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5a312423-36e5-48cd-9fb8-8ddb58a805de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_322a766a-5908-4dcb-81b9-660c97da524f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_322a766a-5908-4dcb-81b9-660c97da524f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0f865059-1b07-43e1-a770-7cf8d22c6a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_us-gaap_Goodwill_0f865059-1b07-43e1-a770-7cf8d22c6a5d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_920d322d-5e35-4582-9f95-dc082fc3cef4" xlink:href="amgn-20220630.xsd#amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_920d322d-5e35-4582-9f95-dc082fc3cef4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7b671eb2-f09b-40b4-871f-1691413cba93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7b671eb2-f09b-40b4-871f-1691413cba93" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_3299aafc-613c-41ce-8b5f-82add278968d" xlink:href="amgn-20220630.xsd#amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_3299aafc-613c-41ce-8b5f-82add278968d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c1fb4e22-1cc6-4982-9f10-605a64ff2041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c1fb4e22-1cc6-4982-9f10-605a64ff2041" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bb74f0af-56c4-4005-bd65-55b655d8316c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c1fb4e22-1cc6-4982-9f10-605a64ff2041" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bb74f0af-56c4-4005-bd65-55b655d8316c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bb74f0af-56c4-4005-bd65-55b655d8316c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bb74f0af-56c4-4005-bd65-55b655d8316c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bb74f0af-56c4-4005-bd65-55b655d8316c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3d63635-2a62-4a40-a2a8-aac858b100cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bb74f0af-56c4-4005-bd65-55b655d8316c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3d63635-2a62-4a40-a2a8-aac858b100cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioMember_7076fa39-9279-4bb3-9c68-0aa42fcaec77" xlink:href="amgn-20220630.xsd#amgn_TeneobioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3d63635-2a62-4a40-a2a8-aac858b100cd" xlink:to="loc_amgn_TeneobioMember_7076fa39-9279-4bb3-9c68-0aa42fcaec77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_cb448094-ca37-4cd8-973a-cb8d233a88a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c1fb4e22-1cc6-4982-9f10-605a64ff2041" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_cb448094-ca37-4cd8-973a-cb8d233a88a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cb448094-ca37-4cd8-973a-cb8d233a88a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_cb448094-ca37-4cd8-973a-cb8d233a88a7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cb448094-ca37-4cd8-973a-cb8d233a88a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_76501f1d-17ed-4e9d-871a-5e7d5560bbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_cb448094-ca37-4cd8-973a-cb8d233a88a7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_76501f1d-17ed-4e9d-871a-5e7d5560bbf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a2452c56-efae-4cf9-a48b-15143693b789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_76501f1d-17ed-4e9d-871a-5e7d5560bbf4" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a2452c56-efae-4cf9-a48b-15143693b789" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70b01f5c-27fe-4172-a3fe-2a472328fffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c1fb4e22-1cc6-4982-9f10-605a64ff2041" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70b01f5c-27fe-4172-a3fe-2a472328fffc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_70b01f5c-27fe-4172-a3fe-2a472328fffc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70b01f5c-27fe-4172-a3fe-2a472328fffc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_70b01f5c-27fe-4172-a3fe-2a472328fffc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4073f5b-ba7b-4e5a-b1e6-94a1ef4fb165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70b01f5c-27fe-4172-a3fe-2a472328fffc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4073f5b-ba7b-4e5a-b1e6-94a1ef4fb165" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RDTechnologyrightsMember_ab46ca5f-1597-4103-9667-de367b1cfd1f" xlink:href="amgn-20220630.xsd#amgn_RDTechnologyrightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4073f5b-ba7b-4e5a-b1e6-94a1ef4fb165" xlink:to="loc_amgn_RDTechnologyrightsMember_ab46ca5f-1597-4103-9667-de367b1cfd1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_37e2b069-f4a8-4975-a3de-eb80bc9f7e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4073f5b-ba7b-4e5a-b1e6-94a1ef4fb165" xlink:to="loc_us-gaap_LicensingAgreementsMember_37e2b069-f4a8-4975-a3de-eb80bc9f7e26" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/AcquisitionsNarrativeDetails" xlink:type="extended" id="icbb329bd00e64d91bd76db7d2f26256d_AcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_1e273ee6-db4d-4718-ad79-be5ad2b55c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_1e273ee6-db4d-4718-ad79-be5ad2b55c60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_cd7676e6-cf01-413f-b192-fb0de20bca9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_cd7676e6-cf01-413f-b192-fb0de20bca9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_1fb48d56-944e-45e2-a43b-c84d50425598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_1fb48d56-944e-45e2-a43b-c84d50425598" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_086d49f4-d519-441b-af99-040df32fd773" xlink:href="amgn-20220630.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_086d49f4-d519-441b-af99-040df32fd773" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_85417f28-3833-4b25-957d-6fe8e898b470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_85417f28-3833-4b25-957d-6fe8e898b470" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_b5a8e88e-89db-42f6-aede-ecb0ed9b1f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_b5a8e88e-89db-42f6-aede-ecb0ed9b1f16" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ea0da135-f344-49e4-aa92-637481e0bc12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ea0da135-f344-49e4-aa92-637481e0bc12" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_fbd29332-d686-4b2e-9c05-5c0d950ad7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_fbd29332-d686-4b2e-9c05-5c0d950ad7f2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8db1fb76-5096-4a57-8489-001840f428ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_Goodwill_8db1fb76-5096-4a57-8489-001840f428ea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates_5eaaad67-b82c-49d6-8cae-6e674ebec98c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates_5eaaad67-b82c-49d6-8cae-6e674ebec98c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_1439f518-0801-43c5-a826-ee7092d50b67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_1439f518-0801-43c5-a826-ee7092d50b67" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_447659b4-6192-44a2-bc53-5d017a6f69f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_447659b4-6192-44a2-bc53-5d017a6f69f2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_a014dd92-e892-4957-95eb-de1365ba4f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_a014dd92-e892-4957-95eb-de1365ba4f1c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_662832ae-bdaf-4c7b-a0b1-9560d1b1cd95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_662832ae-bdaf-4c7b-a0b1-9560d1b1cd95" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_c01968ce-047b-44ef-a48b-75c33ac8a2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_c01968ce-047b-44ef-a48b-75c33ac8a2cb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_e6598d74-26fd-4787-9c81-d1aef73c72bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_e6598d74-26fd-4787-9c81-d1aef73c72bb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_7dc2ec4f-2b78-4548-8769-9fe3b55bc2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_7dc2ec4f-2b78-4548-8769-9fe3b55bc2e5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_f95f6464-a634-4a81-addd-93a8da735f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_f95f6464-a634-4a81-addd-93a8da735f62" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_13c05f0d-1d4d-46cd-b053-76ca3c6fc45f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_13c05f0d-1d4d-46cd-b053-76ca3c6fc45f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_838c496b-7d23-4b6f-9f9c-b9e960cb7ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_838c496b-7d23-4b6f-9f9c-b9e960cb7ea5" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_fd4354bd-fc5c-4dff-920e-00021e64c283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_fd4354bd-fc5c-4dff-920e-00021e64c283" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_e9ee37c4-492e-4a94-a8ff-49a3078be6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_e9ee37c4-492e-4a94-a8ff-49a3078be6e3" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_c49d4b1c-f67e-420a-a516-f479039f9775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_c49d4b1c-f67e-420a-a516-f479039f9775" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_80f35d72-8460-4f29-a328-efde3d210aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_80f35d72-8460-4f29-a328-efde3d210aed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_80f35d72-8460-4f29-a328-efde3d210aed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_80f35d72-8460-4f29-a328-efde3d210aed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_80f35d72-8460-4f29-a328-efde3d210aed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac08d3f4-8e4e-4339-ac24-3909522f7613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_80f35d72-8460-4f29-a328-efde3d210aed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac08d3f4-8e4e-4339-ac24-3909522f7613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioMember_ae3f4b9c-fa16-452c-8af7-51a5cb0e9bb7" xlink:href="amgn-20220630.xsd#amgn_TeneobioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac08d3f4-8e4e-4339-ac24-3909522f7613" xlink:to="loc_amgn_TeneobioMember_ae3f4b9c-fa16-452c-8af7-51a5cb0e9bb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePrimeTherapeuticsIncMember_41ff0b9b-abd6-463f-b9b5-7642d9c64412" xlink:href="amgn-20220630.xsd#amgn_FivePrimeTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac08d3f4-8e4e-4339-ac24-3909522f7613" xlink:to="loc_amgn_FivePrimeTherapeuticsIncMember_41ff0b9b-abd6-463f-b9b5-7642d9c64412" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d55bd640-4d2f-414a-be29-69436ce1ab68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d55bd640-4d2f-414a-be29-69436ce1ab68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d55bd640-4d2f-414a-be29-69436ce1ab68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d55bd640-4d2f-414a-be29-69436ce1ab68" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d55bd640-4d2f-414a-be29-69436ce1ab68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5bc65de2-bdd2-4e8c-a6e7-6984091a4ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d55bd640-4d2f-414a-be29-69436ce1ab68" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5bc65de2-bdd2-4e8c-a6e7-6984091a4ae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_ae347ec5-9569-48fb-bf5c-060f8193260b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5bc65de2-bdd2-4e8c-a6e7-6984091a4ae7" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_ae347ec5-9569-48fb-bf5c-060f8193260b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeAxis_e074efdb-00c1-48ae-af3a-e956390ebe49" xlink:href="amgn-20220630.xsd#amgn_MoleculeTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:to="loc_amgn_MoleculeTypeAxis_e074efdb-00c1-48ae-af3a-e956390ebe49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeDomain_e074efdb-00c1-48ae-af3a-e956390ebe49_default" xlink:href="amgn-20220630.xsd#amgn_MoleculeTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amgn_MoleculeTypeAxis_e074efdb-00c1-48ae-af3a-e956390ebe49" xlink:to="loc_amgn_MoleculeTypeDomain_e074efdb-00c1-48ae-af3a-e956390ebe49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeDomain_29a75eba-33f7-4eeb-865c-b1e647801960" xlink:href="amgn-20220630.xsd#amgn_MoleculeTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amgn_MoleculeTypeAxis_e074efdb-00c1-48ae-af3a-e956390ebe49" xlink:to="loc_amgn_MoleculeTypeDomain_29a75eba-33f7-4eeb-865c-b1e647801960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AMG340Member_878d6c9b-1c03-4957-9674-17adf3609a55" xlink:href="amgn-20220630.xsd#amgn_AMG340Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_MoleculeTypeDomain_29a75eba-33f7-4eeb-865c-b1e647801960" xlink:to="loc_amgn_AMG340Member_878d6c9b-1c03-4957-9674-17adf3609a55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54c7ddd6-1fcc-4249-961a-2cd0c8e641a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54c7ddd6-1fcc-4249-961a-2cd0c8e641a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54c7ddd6-1fcc-4249-961a-2cd0c8e641a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54c7ddd6-1fcc-4249-961a-2cd0c8e641a0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54c7ddd6-1fcc-4249-961a-2cd0c8e641a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a785ab77-4fce-4e6d-b157-4d6e6ab48995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54c7ddd6-1fcc-4249-961a-2cd0c8e641a0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a785ab77-4fce-4e6d-b157-4d6e6ab48995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RDTechnologyrightsMember_20e5b0e9-5f0a-404e-ba24-d6794b794b24" xlink:href="amgn-20220630.xsd#amgn_RDTechnologyrightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a785ab77-4fce-4e6d-b157-4d6e6ab48995" xlink:to="loc_amgn_RDTechnologyrightsMember_20e5b0e9-5f0a-404e-ba24-d6794b794b24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_2d736b0d-81ee-4496-a6d4-7333e8266740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a785ab77-4fce-4e6d-b157-4d6e6ab48995" xlink:to="loc_us-gaap_LicensingAgreementsMember_2d736b0d-81ee-4496-a6d4-7333e8266740" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e8ce04dc-2b5e-4b02-92fc-73b690992fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e8ce04dc-2b5e-4b02-92fc-73b690992fae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e8ce04dc-2b5e-4b02-92fc-73b690992fae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e8ce04dc-2b5e-4b02-92fc-73b690992fae" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e8ce04dc-2b5e-4b02-92fc-73b690992fae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6091088f-f1e5-41ec-9220-4a5b0a76f21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e8ce04dc-2b5e-4b02-92fc-73b690992fae" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6091088f-f1e5-41ec-9220-4a5b0a76f21c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GensentaIlacSanayiVsTicaretMember_820f48dc-0085-45ed-8d13-0bfd8293bb5a" xlink:href="amgn-20220630.xsd#amgn_GensentaIlacSanayiVsTicaretMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_6091088f-f1e5-41ec-9220-4a5b0a76f21c" xlink:to="loc_amgn_GensentaIlacSanayiVsTicaretMember_820f48dc-0085-45ed-8d13-0bfd8293bb5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_88917a87-33dc-4bd3-a276-eb436d31cb18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_88917a87-33dc-4bd3-a276-eb436d31cb18" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_88917a87-33dc-4bd3-a276-eb436d31cb18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_88917a87-33dc-4bd3-a276-eb436d31cb18" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_88917a87-33dc-4bd3-a276-eb436d31cb18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e8dd0c80-d374-4b53-9cbf-0de376099d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_88917a87-33dc-4bd3-a276-eb436d31cb18" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e8dd0c80-d374-4b53-9cbf-0de376099d5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GensentaIlacSanayiVsTicaretMember_afda5e83-1fd8-4f2d-b401-835e563a0afe" xlink:href="amgn-20220630.xsd#amgn_GensentaIlacSanayiVsTicaretMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e8dd0c80-d374-4b53-9cbf-0de376099d5c" xlink:to="loc_amgn_GensentaIlacSanayiVsTicaretMember_afda5e83-1fd8-4f2d-b401-835e563a0afe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_b5415159-c546-40b6-94ae-949a96ccdf38" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:to="loc_srt_StatementScenarioAxis_b5415159-c546-40b6-94ae-949a96ccdf38" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b5415159-c546-40b6-94ae-949a96ccdf38_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_b5415159-c546-40b6-94ae-949a96ccdf38" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b5415159-c546-40b6-94ae-949a96ccdf38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_bec63f7a-6699-4c0d-bb91-c8ce7d15c132" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_b5415159-c546-40b6-94ae-949a96ccdf38" xlink:to="loc_srt_ScenarioUnspecifiedDomain_bec63f7a-6699-4c0d-bb91-c8ce7d15c132" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_77a50374-8afc-4671-85f9-8153d028e911" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_bec63f7a-6699-4c0d-bb91-c8ce7d15c132" xlink:to="loc_srt_ScenarioForecastMember_77a50374-8afc-4671-85f9-8153d028e911" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis_5a17668b-e784-4933-9132-f1e1bd07267c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:to="loc_us-gaap_NatureOfExpenseAxis_5a17668b-e784-4933-9132-f1e1bd07267c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_5a17668b-e784-4933-9132-f1e1bd07267c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NatureOfExpenseAxis_5a17668b-e784-4933-9132-f1e1bd07267c" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_5a17668b-e784-4933-9132-f1e1bd07267c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_e8790b11-cbf3-455e-8dc5-0ab21ff013c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NatureOfExpenseAxis_5a17668b-e784-4933-9132-f1e1bd07267c" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_e8790b11-cbf3-455e-8dc5-0ab21ff013c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_73ca49a5-7abc-45e6-87a0-0d44cfa967bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_73ca49a5-7abc-45e6-87a0-0d44cfa967bd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_73ca49a5-7abc-45e6-87a0-0d44cfa967bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_73ca49a5-7abc-45e6-87a0-0d44cfa967bd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_73ca49a5-7abc-45e6-87a0-0d44cfa967bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b50ce536-753a-4428-8d03-d1489a9e8d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_73ca49a5-7abc-45e6-87a0-0d44cfa967bd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b50ce536-753a-4428-8d03-d1489a9e8d7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_f76e61a1-bfc9-485a-ad1a-48a1539eaf27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b50ce536-753a-4428-8d03-d1489a9e8d7f" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_f76e61a1-bfc9-485a-ad1a-48a1539eaf27" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#RevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/RevenuesDetails" xlink:type="extended" id="i8cbfb701a9884a32ab3938b6e3f26bb7_RevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_834490bb-7031-4e15-b94b-cb11f812bfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fec06913-def5-4cef-8572-a9eabecf7eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_834490bb-7031-4e15-b94b-cb11f812bfbc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fec06913-def5-4cef-8572-a9eabecf7eb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_396cb35a-8df2-4c45-a529-e18dbe91b860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_834490bb-7031-4e15-b94b-cb11f812bfbc" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_396cb35a-8df2-4c45-a529-e18dbe91b860" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a7cb9fe2-d4f3-46aa-90e4-5b9bc19cab6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_396cb35a-8df2-4c45-a529-e18dbe91b860" xlink:to="loc_srt_ProductOrServiceAxis_a7cb9fe2-d4f3-46aa-90e4-5b9bc19cab6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a7cb9fe2-d4f3-46aa-90e4-5b9bc19cab6d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a7cb9fe2-d4f3-46aa-90e4-5b9bc19cab6d" xlink:to="loc_srt_ProductsAndServicesDomain_a7cb9fe2-d4f3-46aa-90e4-5b9bc19cab6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dfedd504-d53e-4694-8d38-916d21e8ca73" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a7cb9fe2-d4f3-46aa-90e4-5b9bc19cab6d" xlink:to="loc_srt_ProductsAndServicesDomain_dfedd504-d53e-4694-8d38-916d21e8ca73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dfedd504-d53e-4694-8d38-916d21e8ca73" xlink:to="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EnbrelMember_adfaf5b9-60c5-4700-8f8f-397ee5f5402a" xlink:href="amgn-20220630.xsd#amgn_EnbrelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:to="loc_amgn_EnbrelMember_adfaf5b9-60c5-4700-8f8f-397ee5f5402a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProliaMember_3d5985c7-39eb-4b53-a6e7-e3a2c6842ea2" xlink:href="amgn-20220630.xsd#amgn_ProliaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:to="loc_amgn_ProliaMember_3d5985c7-39eb-4b53-a6e7-e3a2c6842ea2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaMember_2c5a4ef8-b14d-4257-8d7b-4895439fcc80" xlink:href="amgn-20220630.xsd#amgn_OtezlaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:to="loc_amgn_OtezlaMember_2c5a4ef8-b14d-4257-8d7b-4895439fcc80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_XgevaMember_27443303-30db-44ec-bc85-37a7976fd889" xlink:href="amgn-20220630.xsd#amgn_XgevaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:to="loc_amgn_XgevaMember_27443303-30db-44ec-bc85-37a7976fd889" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AranespMember_81bbb991-df1f-4987-9d5e-eb867a242951" xlink:href="amgn-20220630.xsd#amgn_AranespMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:to="loc_amgn_AranespMember_81bbb991-df1f-4987-9d5e-eb867a242951" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeulastaMember_25817fad-2538-480c-af53-e504013fa643" xlink:href="amgn-20220630.xsd#amgn_NeulastaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:to="loc_amgn_NeulastaMember_25817fad-2538-480c-af53-e504013fa643" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepathaevolocumabMember_3f74a93c-6a78-4418-9ecf-c845bafb7c91" xlink:href="amgn-20220630.xsd#amgn_RepathaevolocumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:to="loc_amgn_RepathaevolocumabMember_3f74a93c-6a78-4418-9ecf-c845bafb7c91" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyprolisMember_6c770d47-3736-4479-98ce-78198c714ab2" xlink:href="amgn-20220630.xsd#amgn_KyprolisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:to="loc_amgn_KyprolisMember_6c770d47-3736-4479-98ce-78198c714ab2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NplateMember_a6a447a1-75f1-4cf6-91fd-05331844a774" xlink:href="amgn-20220630.xsd#amgn_NplateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:to="loc_amgn_NplateMember_a6a447a1-75f1-4cf6-91fd-05331844a774" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherProductsMember_42f0c56d-fc4a-4424-8cf9-43f272197666" xlink:href="amgn-20220630.xsd#amgn_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:to="loc_amgn_OtherProductsMember_42f0c56d-fc4a-4424-8cf9-43f272197666" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_e6103127-4f82-40f9-b6c1-6fe6cc832c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dfedd504-d53e-4694-8d38-916d21e8ca73" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_e6103127-4f82-40f9-b6c1-6fe6cc832c8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7134476a-7eb8-4338-a07c-bb82e20270e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_396cb35a-8df2-4c45-a529-e18dbe91b860" xlink:to="loc_srt_StatementGeographicalAxis_7134476a-7eb8-4338-a07c-bb82e20270e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7134476a-7eb8-4338-a07c-bb82e20270e1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_7134476a-7eb8-4338-a07c-bb82e20270e1" xlink:to="loc_srt_SegmentGeographicalDomain_7134476a-7eb8-4338-a07c-bb82e20270e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b39e0e13-191f-40f9-9669-a0c0b1f2bcdf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_7134476a-7eb8-4338-a07c-bb82e20270e1" xlink:to="loc_srt_SegmentGeographicalDomain_b39e0e13-191f-40f9-9669-a0c0b1f2bcdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c26da6a7-7f29-4b4f-ac39-a75301655945" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b39e0e13-191f-40f9-9669-a0c0b1f2bcdf" xlink:to="loc_country_US_c26da6a7-7f29-4b4f-ac39-a75301655945" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_5a0ab316-a3da-41af-baca-efbb3ba9eb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b39e0e13-191f-40f9-9669-a0c0b1f2bcdf" xlink:to="loc_us-gaap_NonUsMember_5a0ab316-a3da-41af-baca-efbb3ba9eb8a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#IncometaxesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/IncometaxesDetails" xlink:type="extended" id="i7627de8128924d958fbaa4a0d427bcc6_IncometaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_d19f6fd1-e869-49ef-aea1-ad229e29b1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_25ecfce1-e9cc-441c-b63f-e2e814f8c889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_d19f6fd1-e869-49ef-aea1-ad229e29b1d2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_25ecfce1-e9cc-441c-b63f-e2e814f8c889" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProposedAdditionalIncomeTax_35d62b1c-a710-46cb-893d-2e448aa9f739" xlink:href="amgn-20220630.xsd#amgn_ProposedAdditionalIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_d19f6fd1-e869-49ef-aea1-ad229e29b1d2" xlink:to="loc_amgn_ProposedAdditionalIncomeTax_35d62b1c-a710-46cb-893d-2e448aa9f739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepatriationTaxOnProposedAdditionalTax_a4f665c4-0ff8-468a-90e4-24ae9489f541" xlink:href="amgn-20220630.xsd#amgn_RepatriationTaxOnProposedAdditionalTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_d19f6fd1-e869-49ef-aea1-ad229e29b1d2" xlink:to="loc_amgn_RepatriationTaxOnProposedAdditionalTax_a4f665c4-0ff8-468a-90e4-24ae9489f541" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProposedAdditionalIncomeTax20132015_06002d8f-41ab-4514-8c3b-346ae045a02c" xlink:href="amgn-20220630.xsd#amgn_ProposedAdditionalIncomeTax20132015"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_d19f6fd1-e869-49ef-aea1-ad229e29b1d2" xlink:to="loc_amgn_ProposedAdditionalIncomeTax20132015_06002d8f-41ab-4514-8c3b-346ae045a02c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105_e4f2bf5b-20ee-4fa7-8ab1-260d66a0697a" xlink:href="amgn-20220630.xsd#amgn_PenaltiesOnProposedAdditionalIncomeTax20132105"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_d19f6fd1-e869-49ef-aea1-ad229e29b1d2" xlink:to="loc_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105_e4f2bf5b-20ee-4fa7-8ab1-260d66a0697a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepatriationTaxOnProposedAdditionalTax20132015_ab6daa3b-ba3a-4dd6-85ca-8fc1e40c08d7" xlink:href="amgn-20220630.xsd#amgn_RepatriationTaxOnProposedAdditionalTax20132015"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_d19f6fd1-e869-49ef-aea1-ad229e29b1d2" xlink:to="loc_amgn_RepatriationTaxOnProposedAdditionalTax20132015_ab6daa3b-ba3a-4dd6-85ca-8fc1e40c08d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7f8f09ba-810d-4c0a-a591-fc48b0eaa4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_d19f6fd1-e869-49ef-aea1-ad229e29b1d2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7f8f09ba-810d-4c0a-a591-fc48b0eaa4c7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_ebcb6d31-e9ff-4862-8c02-b14ac668df42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_d19f6fd1-e869-49ef-aea1-ad229e29b1d2" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_ebcb6d31-e9ff-4862-8c02-b14ac668df42" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_083b067c-719b-4ea3-aad0-2bbc641f6664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_ebcb6d31-e9ff-4862-8c02-b14ac668df42" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_083b067c-719b-4ea3-aad0-2bbc641f6664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_083b067c-719b-4ea3-aad0-2bbc641f6664_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_083b067c-719b-4ea3-aad0-2bbc641f6664" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_083b067c-719b-4ea3-aad0-2bbc641f6664_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_bdcc4c95-e3d4-4567-8afd-e8a070a4b970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_083b067c-719b-4ea3-aad0-2bbc641f6664" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_bdcc4c95-e3d4-4567-8afd-e8a070a4b970" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_3d753eaa-4177-45b8-86ca-f16db02ce1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_bdcc4c95-e3d4-4567-8afd-e8a070a4b970" xlink:to="loc_us-gaap_DomesticCountryMember_3d753eaa-4177-45b8-86ca-f16db02ce1ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_522f57c0-214a-4f7f-b8db-c4d44dfeb6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_ebcb6d31-e9ff-4862-8c02-b14ac668df42" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_522f57c0-214a-4f7f-b8db-c4d44dfeb6f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_522f57c0-214a-4f7f-b8db-c4d44dfeb6f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_522f57c0-214a-4f7f-b8db-c4d44dfeb6f1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_522f57c0-214a-4f7f-b8db-c4d44dfeb6f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0c0f5cdc-2da5-430b-a0ec-a8723b8f8ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_522f57c0-214a-4f7f-b8db-c4d44dfeb6f1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0c0f5cdc-2da5-430b-a0ec-a8723b8f8ba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c23478c4-622d-4ac9-9122-84a4c144815e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0c0f5cdc-2da5-430b-a0ec-a8723b8f8ba2" xlink:to="loc_us-gaap_SubsequentEventMember_c23478c4-622d-4ac9-9122-84a4c144815e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#InvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsDetails" xlink:type="extended" id="i25772708734d49b5b2661e532979be80_InvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3dd7268a-b846-403b-a33d-74613a20305c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_671d86d0-7bba-476c-b4ea-64e2a22c5c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3dd7268a-b846-403b-a33d-74613a20305c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_671d86d0-7bba-476c-b4ea-64e2a22c5c24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_98bc35f5-44a7-4e5b-bf4d-4b28ee322f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3dd7268a-b846-403b-a33d-74613a20305c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_98bc35f5-44a7-4e5b-bf4d-4b28ee322f28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cabd7f46-84a5-46ff-b627-8945b660ca00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3dd7268a-b846-403b-a33d-74613a20305c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cabd7f46-84a5-46ff-b627-8945b660ca00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_95149c99-3dbb-4952-965f-2738d5b9c942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3dd7268a-b846-403b-a33d-74613a20305c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_95149c99-3dbb-4952-965f-2738d5b9c942" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2380574a-2637-48e6-84a8-985f99039782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3dd7268a-b846-403b-a33d-74613a20305c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2380574a-2637-48e6-84a8-985f99039782" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1e67d5dc-ba35-429e-82df-4fce0748c1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2380574a-2637-48e6-84a8-985f99039782" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1e67d5dc-ba35-429e-82df-4fce0748c1bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1e67d5dc-ba35-429e-82df-4fce0748c1bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1e67d5dc-ba35-429e-82df-4fce0748c1bd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1e67d5dc-ba35-429e-82df-4fce0748c1bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1e67d5dc-ba35-429e-82df-4fce0748c1bd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_3d5c65ce-804e-4554-b8cf-34f6acbba15c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_3d5c65ce-804e-4554-b8cf-34f6acbba15c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_926d8605-17f7-43ca-bcc1-2dc62c5190a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_926d8605-17f7-43ca-bcc1-2dc62c5190a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_73c2e13f-e6b9-476f-a78d-a163af5c9fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_73c2e13f-e6b9-476f-a78d-a163af5c9fbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_528f38bf-32f0-413a-b26c-76433ef36938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_528f38bf-32f0-413a-b26c-76433ef36938" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesFinancialMember_186a4a9f-eef1-4c0e-99ca-c8e3883abf12" xlink:href="amgn-20220630.xsd#amgn_CorporateDebtSecuritiesFinancialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_amgn_CorporateDebtSecuritiesFinancialMember_186a4a9f-eef1-4c0e-99ca-c8e3883abf12" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesIndustrialMember_84125201-60c3-4736-9698-8cb92525ed21" xlink:href="amgn-20220630.xsd#amgn_CorporateDebtSecuritiesIndustrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_amgn_CorporateDebtSecuritiesIndustrialMember_84125201-60c3-4736-9698-8cb92525ed21" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesOtherMember_3374ea53-93dc-40fe-89e3-97290e98e2dd" xlink:href="amgn-20220630.xsd#amgn_CorporateDebtSecuritiesOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_amgn_CorporateDebtSecuritiesOtherMember_3374ea53-93dc-40fe-89e3-97290e98e2dd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_92210404-8874-4f9c-8ab1-6db94f46a14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_92210404-8874-4f9c-8ab1-6db94f46a14e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_516e7a5b-92ad-4171-a742-4e7318c52d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_516e7a5b-92ad-4171-a742-4e7318c52d8a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c3c13956-2a31-4776-a072-e82f79dae1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c3c13956-2a31-4776-a072-e82f79dae1ab" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_5f02120a-3305-4bb5-b6a5-609495728dbc" xlink:href="amgn-20220630.xsd#amgn_OtherShortTermInterestBearingSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_5f02120a-3305-4bb5-b6a5-609495728dbc" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#InvestmentsFairValuesbyClassificationDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="extended" id="ia9451a07c3cd45038163959c81bcb543_InvestmentsFairValuesbyClassificationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_15324f7e-532f-49a7-98af-d6b745a924be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_0867e42a-7fd2-4837-ac07-4033cf8325cc" xlink:href="amgn-20220630.xsd#amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_15324f7e-532f-49a7-98af-d6b745a924be" xlink:to="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_0867e42a-7fd2-4837-ac07-4033cf8325cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ec55046b-718d-4087-8aa9-ff175db0e98e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_0867e42a-7fd2-4837-ac07-4033cf8325cc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ec55046b-718d-4087-8aa9-ff175db0e98e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c17f752d-a2bb-4870-9497-6773d0e57773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_0867e42a-7fd2-4837-ac07-4033cf8325cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c17f752d-a2bb-4870-9497-6773d0e57773" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fee175bd-b9eb-4bea-9e0d-195271f11ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_0867e42a-7fd2-4837-ac07-4033cf8325cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fee175bd-b9eb-4bea-9e0d-195271f11ba2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a5ab8f30-20af-4303-b18f-2ba3d05188da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_15324f7e-532f-49a7-98af-d6b745a924be" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a5ab8f30-20af-4303-b18f-2ba3d05188da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7296c942-1026-416a-9096-551ee269000f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a5ab8f30-20af-4303-b18f-2ba3d05188da" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7296c942-1026-416a-9096-551ee269000f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7296c942-1026-416a-9096-551ee269000f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7296c942-1026-416a-9096-551ee269000f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7296c942-1026-416a-9096-551ee269000f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_124477b0-67b2-406e-bf1c-ed5d0e61c034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7296c942-1026-416a-9096-551ee269000f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_124477b0-67b2-406e-bf1c-ed5d0e61c034" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSalesInvestmentsMember_458742c1-6b82-4860-aa57-3972f7ac8f06" xlink:href="amgn-20220630.xsd#amgn_AvailableForSalesInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_124477b0-67b2-406e-bf1c-ed5d0e61c034" xlink:to="loc_amgn_AvailableForSalesInvestmentsMember_458742c1-6b82-4860-aa57-3972f7ac8f06" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual" xlink:type="simple" xlink:href="amgn-20220630.xsd#InvestmentsAvailableforsaleInvestmentsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual" xlink:type="extended" id="i8b442b41bd3249299baa9964b5b61464_InvestmentsAvailableforsaleInvestmentsDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f674a955-d866-49aa-b2d0-c53deeeea441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90b22114-bad2-484e-b500-3494b625425f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f674a955-d866-49aa-b2d0-c53deeeea441" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90b22114-bad2-484e-b500-3494b625425f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c21034d3-4775-44bb-b3ce-aaaf9b29c73c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f674a955-d866-49aa-b2d0-c53deeeea441" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c21034d3-4775-44bb-b3ce-aaaf9b29c73c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual" xlink:type="simple" xlink:href="amgn-20220630.xsd#InvestmentsEquitySecuritiesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual" xlink:type="extended" id="i7e63df9832124a75bc49cada9e0d39b9_InvestmentsEquitySecuritiesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2831c25-96b6-4fd9-b49d-c1b81acbbc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_5724bdd4-85b7-4210-aad3-862aa62dadaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2831c25-96b6-4fd9-b49d-c1b81acbbc1f" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_5724bdd4-85b7-4210-aad3-862aa62dadaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_bf9d73b3-d50f-4db2-8f4d-a61a3d757035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2831c25-96b6-4fd9-b49d-c1b81acbbc1f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_bf9d73b3-d50f-4db2-8f4d-a61a3d757035" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5f409783-3976-4e0a-891b-8a5f8438f289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2831c25-96b6-4fd9-b49d-c1b81acbbc1f" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5f409783-3976-4e0a-891b-8a5f8438f289" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_c672b31c-c578-4ab8-b476-0b7799fd3b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2831c25-96b6-4fd9-b49d-c1b81acbbc1f" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_c672b31c-c578-4ab8-b476-0b7799fd3b5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7a8aae55-838b-4307-9169-9f1a6470ba34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2831c25-96b6-4fd9-b49d-c1b81acbbc1f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7a8aae55-838b-4307-9169-9f1a6470ba34" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a51996f8-9dff-4852-ab66-09c40e4361c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7a8aae55-838b-4307-9169-9f1a6470ba34" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a51996f8-9dff-4852-ab66-09c40e4361c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a51996f8-9dff-4852-ab66-09c40e4361c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a51996f8-9dff-4852-ab66-09c40e4361c1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a51996f8-9dff-4852-ab66-09c40e4361c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ff3cab7-4cad-4aa2-a307-a64dade9d382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a51996f8-9dff-4852-ab66-09c40e4361c1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ff3cab7-4cad-4aa2-a307-a64dade9d382" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a5f6d991-e43b-41cd-a019-bf15bf09f976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ff3cab7-4cad-4aa2-a307-a64dade9d382" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a5f6d991-e43b-41cd-a019-bf15bf09f976" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsBeiGeneDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#InvestmentsBeiGeneDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsBeiGeneDetails" xlink:type="extended" id="i8834333201e245e4aec71d70a62e7702_InvestmentsBeiGeneDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_2e585bae-54de-4b5e-9945-0b173d29d73b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_348c3054-488c-42c1-8ca3-0a945200a0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_2e585bae-54de-4b5e-9945-0b173d29d73b" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_348c3054-488c-42c1-8ca3-0a945200a0fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_243dcc4d-fa52-42fe-b7d4-173ae3745cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_2e585bae-54de-4b5e-9945-0b173d29d73b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_243dcc4d-fa52-42fe-b7d4-173ae3745cc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_064eae16-6b4c-4ae2-b75d-871a71d07371" xlink:href="amgn-20220630.xsd#amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_2e585bae-54de-4b5e-9945-0b173d29d73b" xlink:to="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_064eae16-6b4c-4ae2-b75d-871a71d07371" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_5da966c3-5fc1-45bd-b58b-b7cae8f69c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_2e585bae-54de-4b5e-9945-0b173d29d73b" xlink:to="loc_us-gaap_EquityMethodInvestments_5da966c3-5fc1-45bd-b58b-b7cae8f69c89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_72bad605-2734-4498-b063-51dc82d5e26d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_2e585bae-54de-4b5e-9945-0b173d29d73b" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_72bad605-2734-4498-b063-51dc82d5e26d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_4abc1be1-f54b-489f-afd7-39742b00e32c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_2e585bae-54de-4b5e-9945-0b173d29d73b" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_4abc1be1-f54b-489f-afd7-39742b00e32c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_41be6c84-533b-4a26-8d1d-9911f3ef78f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_4abc1be1-f54b-489f-afd7-39742b00e32c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_41be6c84-533b-4a26-8d1d-9911f3ef78f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41be6c84-533b-4a26-8d1d-9911f3ef78f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_41be6c84-533b-4a26-8d1d-9911f3ef78f4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41be6c84-533b-4a26-8d1d-9911f3ef78f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5e2669f-772e-4905-b317-5dbae0c4aa17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_41be6c84-533b-4a26-8d1d-9911f3ef78f4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5e2669f-772e-4905-b317-5dbae0c4aa17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_aaceffd0-5e89-4183-8fce-d5a0e83e263f" xlink:href="amgn-20220630.xsd#amgn_BeiGeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5e2669f-772e-4905-b317-5dbae0c4aa17" xlink:to="loc_amgn_BeiGeneMember_aaceffd0-5e89-4183-8fce-d5a0e83e263f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#InvestmentsNeumoraTherapeuticsIncDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" xlink:type="extended" id="i145a1e53a39643a9a8cfcd8503a27731_InvestmentsNeumoraTherapeuticsIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_1eaa1b2a-2a2e-419a-a22f-ffe53e1bd765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a819819d-ca41-4e51-839f-0c68b6c08904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_1eaa1b2a-2a2e-419a-a22f-ffe53e1bd765" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a819819d-ca41-4e51-839f-0c68b6c08904" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_c0320482-af0d-4f7b-9085-31897c8657e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_1eaa1b2a-2a2e-419a-a22f-ffe53e1bd765" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_c0320482-af0d-4f7b-9085-31897c8657e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_a75f3a94-822c-44a3-bfba-5a91769f90c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_1eaa1b2a-2a2e-419a-a22f-ffe53e1bd765" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_a75f3a94-822c-44a3-bfba-5a91769f90c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_73c90dea-260b-4d1c-9401-3c847b16c882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_1eaa1b2a-2a2e-419a-a22f-ffe53e1bd765" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_73c90dea-260b-4d1c-9401-3c847b16c882" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_c81fdd75-dd8d-40aa-a0f5-d9d544d7f759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_1eaa1b2a-2a2e-419a-a22f-ffe53e1bd765" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_c81fdd75-dd8d-40aa-a0f5-d9d544d7f759" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValue_9d095938-19aa-40c5-86b7-923370fcb1dd" xlink:href="amgn-20220630.xsd#amgn_EquityMethodInvestmentChangeInCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_1eaa1b2a-2a2e-419a-a22f-ffe53e1bd765" xlink:to="loc_amgn_EquityMethodInvestmentChangeInCarryingValue_9d095938-19aa-40c5-86b7-923370fcb1dd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_31bd5e03-5414-4f8c-aa14-3f7548e5b09e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_1eaa1b2a-2a2e-419a-a22f-ffe53e1bd765" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_31bd5e03-5414-4f8c-aa14-3f7548e5b09e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_082e4e1d-258a-465d-801d-a11f0158d6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_31bd5e03-5414-4f8c-aa14-3f7548e5b09e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_082e4e1d-258a-465d-801d-a11f0158d6dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_082e4e1d-258a-465d-801d-a11f0158d6dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_082e4e1d-258a-465d-801d-a11f0158d6dc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_082e4e1d-258a-465d-801d-a11f0158d6dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_43584d0f-6c27-4232-b641-8322deed1cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_082e4e1d-258a-465d-801d-a11f0158d6dc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_43584d0f-6c27-4232-b641-8322deed1cf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeumoraTherapeuticsIncMember_b206fdbf-56de-4557-a58d-290ab0843414" xlink:href="amgn-20220630.xsd#amgn_NeumoraTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_43584d0f-6c27-4232-b641-8322deed1cf7" xlink:to="loc_amgn_NeumoraTherapeuticsIncMember_b206fdbf-56de-4557-a58d-290ab0843414" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" xlink:type="extended" id="i2c20edcc1bd049949afc8a1e0eda0d0f_InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_8d9b39b3-881c-4a6a-bdbd-6027fc98b156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestment_3b4496bb-c0aa-4e7f-8f7d-ada65830495d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AlternativeInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_8d9b39b3-881c-4a6a-bdbd-6027fc98b156" xlink:to="loc_us-gaap_AlternativeInvestment_3b4496bb-c0aa-4e7f-8f7d-ada65830495d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount_4c625877-413b-4513-9696-897cdcdd89e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_8d9b39b3-881c-4a6a-bdbd-6027fc98b156" xlink:to="loc_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount_4c625877-413b-4513-9696-897cdcdd89e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AlternativeInvestmentNetGainLoss_94b19c93-93c0-4ad3-acbd-20df3ac14504" xlink:href="amgn-20220630.xsd#amgn_AlternativeInvestmentNetGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_8d9b39b3-881c-4a6a-bdbd-6027fc98b156" xlink:to="loc_amgn_AlternativeInvestmentNetGainLoss_94b19c93-93c0-4ad3-acbd-20df3ac14504" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_dc8e3311-ab49-4215-991a-ddf3832bf74b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_8d9b39b3-881c-4a6a-bdbd-6027fc98b156" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_dc8e3311-ab49-4215-991a-ddf3832bf74b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_00a1c34f-d24c-4d76-9a9f-4eec5284b868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_dc8e3311-ab49-4215-991a-ddf3832bf74b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_00a1c34f-d24c-4d76-9a9f-4eec5284b868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_00a1c34f-d24c-4d76-9a9f-4eec5284b868_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_00a1c34f-d24c-4d76-9a9f-4eec5284b868" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_00a1c34f-d24c-4d76-9a9f-4eec5284b868_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_baba750a-e846-41da-80d3-92dd091a401f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_00a1c34f-d24c-4d76-9a9f-4eec5284b868" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_baba750a-e846-41da-80d3-92dd091a401f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_be4546db-6335-4475-a0b5-10757905f5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_baba750a-e846-41da-80d3-92dd091a401f" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_be4546db-6335-4475-a0b5-10757905f5d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_a27f68bb-c28f-421f-a73d-ea00c25f976a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_dc8e3311-ab49-4215-991a-ddf3832bf74b" xlink:to="loc_us-gaap_InvestmentTypeAxis_a27f68bb-c28f-421f-a73d-ea00c25f976a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a27f68bb-c28f-421f-a73d-ea00c25f976a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_a27f68bb-c28f-421f-a73d-ea00c25f976a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a27f68bb-c28f-421f-a73d-ea00c25f976a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_ffeff988-67c0-441c-a3fd-cca87a1c4630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_a27f68bb-c28f-421f-a73d-ea00c25f976a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_ffeff988-67c0-441c-a3fd-cca87a1c4630" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_7526bd97-119e-49f4-9ceb-6fa84c3377c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_PartnershipInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_ffeff988-67c0-441c-a3fd-cca87a1c4630" xlink:to="loc_srt_PartnershipInterestMember_7526bd97-119e-49f4-9ceb-6fa84c3377c7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="extended" id="i88b3834ce4994c1db6d6973073fa6998_GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_c612c819-bbb3-4a21-9e15-4c795989dfea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_89b1e1a3-528d-4707-9db9-2eefb30030f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_c612c819-bbb3-4a21-9e15-4c795989dfea" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_89b1e1a3-528d-4707-9db9-2eefb30030f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d99e517f-fb3a-402b-82a1-377906eaedee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_c612c819-bbb3-4a21-9e15-4c795989dfea" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d99e517f-fb3a-402b-82a1-377906eaedee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4ccba3f0-8de6-442b-b66e-20b079240162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d99e517f-fb3a-402b-82a1-377906eaedee" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4ccba3f0-8de6-442b-b66e-20b079240162" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4ccba3f0-8de6-442b-b66e-20b079240162_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4ccba3f0-8de6-442b-b66e-20b079240162" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4ccba3f0-8de6-442b-b66e-20b079240162_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ba889e01-07dd-4a0b-b68d-423ed988692a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4ccba3f0-8de6-442b-b66e-20b079240162" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ba889e01-07dd-4a0b-b68d-423ed988692a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_d217c418-d2c1-434e-8505-7e59d48630f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ba889e01-07dd-4a0b-b68d-423ed988692a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_d217c418-d2c1-434e-8505-7e59d48630f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_23fedd77-6250-46bc-b898-d54b1c340ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_13453d14-8ee8-4f2d-8d53-c03ee29af3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_23fedd77-6250-46bc-b898-d54b1c340ab9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_13453d14-8ee8-4f2d-8d53-c03ee29af3b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c77655c4-c8ef-4e28-bf03-45bb48861a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_23fedd77-6250-46bc-b898-d54b1c340ab9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c77655c4-c8ef-4e28-bf03-45bb48861a3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0a02588d-9c50-46fa-b94c-1b7a5c418a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_23fedd77-6250-46bc-b898-d54b1c340ab9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0a02588d-9c50-46fa-b94c-1b7a5c418a0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e303980c-fb5e-48ee-be4d-1d5021ba430d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_23fedd77-6250-46bc-b898-d54b1c340ab9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e303980c-fb5e-48ee-be4d-1d5021ba430d" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69b79c4b-fb36-45bd-a192-50355380395a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e303980c-fb5e-48ee-be4d-1d5021ba430d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69b79c4b-fb36-45bd-a192-50355380395a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69b79c4b-fb36-45bd-a192-50355380395a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69b79c4b-fb36-45bd-a192-50355380395a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69b79c4b-fb36-45bd-a192-50355380395a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac1ac54-e1dc-4f82-a3ab-bd0b4c228aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69b79c4b-fb36-45bd-a192-50355380395a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac1ac54-e1dc-4f82-a3ab-bd0b4c228aea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_8ebfb35a-234e-4933-b719-6a0625bfa586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac1ac54-e1dc-4f82-a3ab-bd0b4c228aea" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_8ebfb35a-234e-4933-b719-6a0625bfa586" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_f7a99bc7-e06c-48c1-8146-4bcf4054f678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac1ac54-e1dc-4f82-a3ab-bd0b4c228aea" xlink:to="loc_us-gaap_LicensingAgreementsMember_f7a99bc7-e06c-48c1-8146-4bcf4054f678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_7de3b343-2309-4a15-a791-8752a1bd2514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac1ac54-e1dc-4f82-a3ab-bd0b4c228aea" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_7de3b343-2309-4a15-a791-8752a1bd2514" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_399f6beb-d78f-4940-8c0b-8ad29ca70579" xlink:href="amgn-20220630.xsd#amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac1ac54-e1dc-4f82-a3ab-bd0b4c228aea" xlink:to="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_399f6beb-d78f-4940-8c0b-8ad29ca70579" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="extended" id="if096917fdd2b4ae2979eb5e3e572f5a0_FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d65ac211-0724-48a2-b731-58f027c59dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d65ac211-0724-48a2-b731-58f027c59dd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c25f4d0f-044b-464c-9c5f-2bf439f5802e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c25f4d0f-044b-464c-9c5f-2bf439f5802e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_40975540-80d4-457d-a374-d9fff1b2f61e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_40975540-80d4-457d-a374-d9fff1b2f61e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_5fe99972-332a-404b-835e-37eaed4ba0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_5fe99972-332a-404b-835e-37eaed4ba0ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_65ebeff0-8740-44a5-9971-23b4f708209c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_us-gaap_OtherLongTermDebt_65ebeff0-8740-44a5-9971-23b4f708209c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8a317784-f986-44c5-9a85-3f13839538f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_us-gaap_LongTermDebt_8a317784-f986-44c5-9a85-3f13839538f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ebc7c21a-e092-48a2-b30d-c38ed2c43bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_us-gaap_LongTermDebtCurrent_ebc7c21a-e092-48a2-b30d-c38ed2c43bf7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a7735907-8cec-40a5-80b2-5da8a05034a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a7735907-8cec-40a5-80b2-5da8a05034a6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8c2d901b-e341-4bab-a246-138a988b2c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8c2d901b-e341-4bab-a246-138a988b2c1e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_10a8258e-931f-4639-b672-d68a58a3b1ce" xlink:href="amgn-20220630.xsd#amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_10a8258e-931f-4639-b672-d68a58a3b1ce" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_35a4dd07-67c0-49f2-b64f-5fd7c036fc26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_us-gaap_DebtInstrumentTable_35a4dd07-67c0-49f2-b64f-5fd7c036fc26" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_01053194-9740-4bf1-ba79-04b8fbee9a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_35a4dd07-67c0-49f2-b64f-5fd7c036fc26" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_01053194-9740-4bf1-ba79-04b8fbee9a26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_01053194-9740-4bf1-ba79-04b8fbee9a26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_01053194-9740-4bf1-ba79-04b8fbee9a26" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_01053194-9740-4bf1-ba79-04b8fbee9a26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_58623c7b-9c31-443b-8420-7a06fbb14054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_01053194-9740-4bf1-ba79-04b8fbee9a26" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_58623c7b-9c31-443b-8420-7a06fbb14054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_cb2666a7-e05d-47d3-b4c3-42b9d9789a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_58623c7b-9c31-443b-8420-7a06fbb14054" xlink:to="loc_us-gaap_NotesPayableToBanksMember_cb2666a7-e05d-47d3-b4c3-42b9d9789a7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f1dc5490-327f-41dd-b13c-d8cce5afe1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_35a4dd07-67c0-49f2-b64f-5fd7c036fc26" xlink:to="loc_us-gaap_DebtInstrumentAxis_f1dc5490-327f-41dd-b13c-d8cce5afe1d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f1dc5490-327f-41dd-b13c-d8cce5afe1d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f1dc5490-327f-41dd-b13c-d8cce5afe1d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f1dc5490-327f-41dd-b13c-d8cce5afe1d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f1dc5490-327f-41dd-b13c-d8cce5afe1d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroNotesDue2020Member_64e9bffe-fef5-4c75-96da-692eae5aff7b" xlink:href="amgn-20220630.xsd#amgn_TwoPointTwoZeroNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointTwoZeroNotesDue2020Member_64e9bffe-fef5-4c75-96da-692eae5aff7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_4d42c7b6-1060-4e5d-b9fb-a86cf11357dc" xlink:href="amgn-20220630.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_4d42c7b6-1060-4e5d-b9fb-a86cf11357dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_50959a09-ffcb-4b9a-bc6c-d5e7ac2f4d9a" xlink:href="amgn-20220630.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_50959a09-ffcb-4b9a-bc6c-d5e7ac2f4d9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_5bb615a9-064a-48df-90b6-8d992251d479" xlink:href="amgn-20220630.xsd#amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_5bb615a9-064a-48df-90b6-8d992251d479" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_15aafd97-6f9f-4aa7-896e-3ae59312e42f" xlink:href="amgn-20220630.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_15aafd97-6f9f-4aa7-896e-3ae59312e42f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember_131e0fe4-79fb-4817-a026-58e324bed162" xlink:href="amgn-20220630.xsd#amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember_131e0fe4-79fb-4817-a026-58e324bed162" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_5fa59de1-3a1c-42a7-967f-95a9bfa36fb4" xlink:href="amgn-20220630.xsd#amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_5fa59de1-3a1c-42a7-967f-95a9bfa36fb4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixFiveNotesDue2022Member_20040640-d9fa-41c2-93a9-1823cbc25bb0" xlink:href="amgn-20220630.xsd#amgn_TwoPointSixFiveNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointSixFiveNotesDue2022Member_20040640-d9fa-41c2-93a9-1823cbc25bb0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_bc81e714-6dfe-4695-98c5-b6657b7ae484" xlink:href="amgn-20220630.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_bc81e714-6dfe-4695-98c5-b6657b7ae484" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_d5bac637-720f-4e2e-b2bc-db49de89777a" xlink:href="amgn-20220630.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_d5bac637-720f-4e2e-b2bc-db49de89777a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_8a15197b-cf11-445b-9b21-6f16405fe481" xlink:href="amgn-20220630.xsd#amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_8a15197b-cf11-445b-9b21-6f16405fe481" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_ee2a5855-b52f-42f9-95aa-5e346361be6c" xlink:href="amgn-20220630.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_ee2a5855-b52f-42f9-95aa-5e346361be6c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember_71fba5c0-ba40-425a-a546-b3d00ca4f498" xlink:href="amgn-20220630.xsd#amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember_71fba5c0-ba40-425a-a546-b3d00ca4f498" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_a177afc1-ef73-47eb-995c-697af1548128" xlink:href="amgn-20220630.xsd#amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_a177afc1-ef73-47eb-995c-697af1548128" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_caa1edf8-8dde-4473-ab7c-ba3c7a5ce293" xlink:href="amgn-20220630.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_caa1edf8-8dde-4473-ab7c-ba3c7a5ce293" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_4470f5a9-56e7-4c0f-9f8f-50c7481231bd" xlink:href="amgn-20220630.xsd#amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_4470f5a9-56e7-4c0f-9f8f-50c7481231bd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_d7033f93-50de-4796-acc8-b5231f6a2757" xlink:href="amgn-20220630.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_d7033f93-50de-4796-acc8-b5231f6a2757" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_b865aa20-a6b6-4d5e-91c7-3cfbf529621b" xlink:href="amgn-20220630.xsd#amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_b865aa20-a6b6-4d5e-91c7-3cfbf529621b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointTwoZeroNotesDue2027Member_c0cbf71e-b89e-40d0-962f-64723d6511e4" xlink:href="amgn-20220630.xsd#amgn_ThreePointTwoZeroNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_ThreePointTwoZeroNotesDue2027Member_c0cbf71e-b89e-40d0-962f-64723d6511e4" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointSixFivePercent2028NotesMember_549267d6-c906-4c8a-9547-fe9ff96cc8e1" xlink:href="amgn-20220630.xsd#amgn_OnePointSixFivePercent2028NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_OnePointSixFivePercent2028NotesMember_549267d6-c906-4c8a-9547-fe9ff96cc8e1" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A3002029NotesMember_7a561308-c780-4259-a767-2f7d535aea15" xlink:href="amgn-20220630.xsd#amgn_A3002029NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_A3002029NotesMember_7a561308-c780-4259-a767-2f7d535aea15" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_4564cb91-70ef-49ec-b0d5-c0088da5154a" xlink:href="amgn-20220630.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_4564cb91-70ef-49ec-b0d5-c0088da5154a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_f46966dd-8321-4ea8-b5fa-13502028bc6c" xlink:href="amgn-20220630.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_f46966dd-8321-4ea8-b5fa-13502028bc6c" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_a83ca970-8704-4550-a35e-8628d08ad37f" xlink:href="amgn-20220630.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_a83ca970-8704-4550-a35e-8628d08ad37f" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointZeroPercent2032NotesMemberMember_f8c88bef-d443-44ec-ae12-5fb04ce067d7" xlink:href="amgn-20220630.xsd#amgn_TwoPointZeroPercent2032NotesMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointZeroPercent2032NotesMemberMember_f8c88bef-d443-44ec-ae12-5fb04ce067d7" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A3352032NotesMember_93a0dba1-014e-4989-8e7d-63e2afb32c22" xlink:href="amgn-20220630.xsd#amgn_A3352032NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_A3352032NotesMember_93a0dba1-014e-4989-8e7d-63e2afb32c22" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_1db97e92-8172-45de-b501-e7ee67d6c4d0" xlink:href="amgn-20220630.xsd#amgn_SixPointThreeSevenFivePercentNotesDue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_1db97e92-8172-45de-b501-e7ee67d6c4d0" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_887a548b-6524-4524-b388-61ac988913d1" xlink:href="amgn-20220630.xsd#amgn_SixPointNineZeroPercentNotesDue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_887a548b-6524-4524-b388-61ac988913d1" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_69c0bb2c-64d1-426a-b881-e916dfedb827" xlink:href="amgn-20220630.xsd#amgn_SixPointFourZeroPercentNotesDue2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_69c0bb2c-64d1-426a-b881-e916dfedb827" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_771216c4-c9ae-435d-b7d7-db7e6b380d00" xlink:href="amgn-20220630.xsd#amgn_ThreePointOneFivePercentNotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_771216c4-c9ae-435d-b7d7-db7e6b380d00" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_89bdfdd8-7c05-45cb-b4d5-9e86d3135202" xlink:href="amgn-20220630.xsd#amgn_FivePointSevenFivePercentNotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_89bdfdd8-7c05-45cb-b4d5-9e86d3135202" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointEightZeroPercent2041NotesMember_b53a604d-7641-4926-913b-545b51db698e" xlink:href="amgn-20220630.xsd#amgn_TwoPointEightZeroPercent2041NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointEightZeroPercent2041NotesMember_b53a604d-7641-4926-913b-545b51db698e" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointNineFivePercentNotesDue2041Member_f383fd37-af58-4af3-94fd-64b57a72748a" xlink:href="amgn-20220630.xsd#amgn_FourPointNineFivePercentNotesDue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FourPointNineFivePercentNotesDue2041Member_f383fd37-af58-4af3-94fd-64b57a72748a" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointOneFivePercentNotesDue2041Member_abb177e7-260f-43e7-a5ce-aa6623b6fbb1" xlink:href="amgn-20220630.xsd#amgn_FivePointOneFivePercentNotesDue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FivePointOneFivePercentNotesDue2041Member_abb177e7-260f-43e7-a5ce-aa6623b6fbb1" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSixFivePercentNotesDue2042Member_8fb753ff-87d0-4bd2-96ba-fa9254718b1f" xlink:href="amgn-20220630.xsd#amgn_FivePointSixFivePercentNotesDue2042Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FivePointSixFivePercentNotesDue2042Member_8fb753ff-87d0-4bd2-96ba-fa9254718b1f" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_142af042-19d5-4a8e-91d6-c95ff5e1f1e6" xlink:href="amgn-20220630.xsd#amgn_FivePointThreeSevenFivePercentNotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_142af042-19d5-4a8e-91d6-c95ff5e1f1e6" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_5ab88819-82f3-4176-83aa-76c21b1c1ea5" xlink:href="amgn-20220630.xsd#amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_5ab88819-82f3-4176-83aa-76c21b1c1ea5" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_2a78eeff-dd42-44c3-a706-3ee64ef6fdb9" xlink:href="amgn-20220630.xsd#amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_2a78eeff-dd42-44c3-a706-3ee64ef6fdb9" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_1e9b0e0f-07a7-4c8a-9308-0ba51d66293f" xlink:href="amgn-20220630.xsd#amgn_ThreePointThreeSevenFivePercentNotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_1e9b0e0f-07a7-4c8a-9308-0ba51d66293f" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_36123af8-5c61-45e7-ab6c-a20f0fbe1612" xlink:href="amgn-20220630.xsd#amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_36123af8-5c61-45e7-ab6c-a20f0fbe1612" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A300NotesDue20523002052NotesMember_f1b6e144-de24-4dff-ad87-a3bdfafae20a" xlink:href="amgn-20220630.xsd#amgn_A300NotesDue20523002052NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_A300NotesDue20523002052NotesMember_f1b6e144-de24-4dff-ad87-a3bdfafae20a" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A4202052NotesMember_e8d88f66-fbb3-407e-851e-0cadbd825894" xlink:href="amgn-20220630.xsd#amgn_A4202052NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_A4202052NotesMember_e8d88f66-fbb3-407e-851e-0cadbd825894" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_93ef57a0-158f-42f0-9a2a-d2882bef5f6a" xlink:href="amgn-20220630.xsd#amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_93ef57a0-158f-42f0-9a2a-d2882bef5f6a" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A4402062NotesMember_3eb55fde-edd3-43c0-910b-ab190b4326e9" xlink:href="amgn-20220630.xsd#amgn_A4402062NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_A4402062NotesMember_3eb55fde-edd3-43c0-910b-ab190b4326e9" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherNotesDue2097Member_db4c06ad-2f82-4734-80ea-c8b3f3e47417" xlink:href="amgn-20220630.xsd#amgn_OtherNotesDue2097Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_OtherNotesDue2097Member_db4c06ad-2f82-4734-80ea-c8b3f3e47417" xlink:type="arc" order="44"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsDetailsTextual" xlink:type="simple" xlink:href="amgn-20220630.xsd#FinancingarrangementsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FinancingarrangementsDetailsTextual" xlink:type="extended" id="icbf49c1b613a421fa5b2f9d08f8b968a_FinancingarrangementsDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_40a3b23b-8ca9-4148-b685-7c824167f5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ce2fabe1-b9aa-4001-8b19-97ddc5f5611c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40a3b23b-8ca9-4148-b685-7c824167f5b7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ce2fabe1-b9aa-4001-8b19-97ddc5f5611c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_24d044d7-bdfa-4d4a-be74-9c1a622b0215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40a3b23b-8ca9-4148-b685-7c824167f5b7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_24d044d7-bdfa-4d4a-be74-9c1a622b0215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e122bd8b-8b92-476a-88fb-9759351e736b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40a3b23b-8ca9-4148-b685-7c824167f5b7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e122bd8b-8b92-476a-88fb-9759351e736b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_b4b4231e-48e4-40ba-9874-ec80cd8ba91c" xlink:href="amgn-20220630.xsd#amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40a3b23b-8ca9-4148-b685-7c824167f5b7" xlink:to="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_b4b4231e-48e4-40ba-9874-ec80cd8ba91c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount_51fb8383-7a94-43bd-bf6d-398115ae12b0" xlink:href="amgn-20220630.xsd#amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40a3b23b-8ca9-4148-b685-7c824167f5b7" xlink:to="loc_amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount_51fb8383-7a94-43bd-bf6d-398115ae12b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent_36fda5e3-ebba-46e2-b222-d073e60f2572" xlink:href="amgn-20220630.xsd#amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40a3b23b-8ca9-4148-b685-7c824167f5b7" xlink:to="loc_amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent_36fda5e3-ebba-46e2-b222-d073e60f2572" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7a6e566a-18a2-46c7-887a-f24e62554f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40a3b23b-8ca9-4148-b685-7c824167f5b7" xlink:to="loc_us-gaap_DebtInstrumentTable_7a6e566a-18a2-46c7-887a-f24e62554f02" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_34269ec1-009d-444a-8232-032e4acd25f1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7a6e566a-18a2-46c7-887a-f24e62554f02" xlink:to="loc_srt_RangeAxis_34269ec1-009d-444a-8232-032e4acd25f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_34269ec1-009d-444a-8232-032e4acd25f1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_34269ec1-009d-444a-8232-032e4acd25f1" xlink:to="loc_srt_RangeMember_34269ec1-009d-444a-8232-032e4acd25f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4abe0bae-919d-418a-9d98-14fd09d2e6e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_34269ec1-009d-444a-8232-032e4acd25f1" xlink:to="loc_srt_RangeMember_4abe0bae-919d-418a-9d98-14fd09d2e6e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d628ab8c-bbdc-4c32-8efa-a27937606acd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4abe0bae-919d-418a-9d98-14fd09d2e6e5" xlink:to="loc_srt_MinimumMember_d628ab8c-bbdc-4c32-8efa-a27937606acd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_de29bfcf-ba25-4630-a082-9194aaeb9be6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4abe0bae-919d-418a-9d98-14fd09d2e6e5" xlink:to="loc_srt_MaximumMember_de29bfcf-ba25-4630-a082-9194aaeb9be6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_25adf769-fa03-477a-ba78-6802b16b7332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7a6e566a-18a2-46c7-887a-f24e62554f02" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_25adf769-fa03-477a-ba78-6802b16b7332" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_25adf769-fa03-477a-ba78-6802b16b7332_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_25adf769-fa03-477a-ba78-6802b16b7332" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_25adf769-fa03-477a-ba78-6802b16b7332_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f754588a-98af-45cc-a0b7-86a4f7fb7c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_25adf769-fa03-477a-ba78-6802b16b7332" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f754588a-98af-45cc-a0b7-86a4f7fb7c0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_1f2072eb-6932-4ee7-ad2f-7398ec8f8220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f754588a-98af-45cc-a0b7-86a4f7fb7c0e" xlink:to="loc_us-gaap_NotesPayableToBanksMember_1f2072eb-6932-4ee7-ad2f-7398ec8f8220" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesPayableMember_85bd19b6-c8f5-4729-8340-b8c0d069e3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f754588a-98af-45cc-a0b7-86a4f7fb7c0e" xlink:to="loc_us-gaap_DebtSecuritiesPayableMember_85bd19b6-c8f5-4729-8340-b8c0d069e3dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9daa3293-1901-4328-a9a0-58b67c82d99a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7a6e566a-18a2-46c7-887a-f24e62554f02" xlink:to="loc_us-gaap_DebtInstrumentAxis_9daa3293-1901-4328-a9a0-58b67c82d99a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9daa3293-1901-4328-a9a0-58b67c82d99a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9daa3293-1901-4328-a9a0-58b67c82d99a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9daa3293-1901-4328-a9a0-58b67c82d99a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_974eddb4-d7ff-4f60-869a-266428d56906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9daa3293-1901-4328-a9a0-58b67c82d99a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_974eddb4-d7ff-4f60-869a-266428d56906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_ef98526d-18eb-49a7-afdf-0fa7bdb8f6ac" xlink:href="amgn-20220630.xsd#amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_974eddb4-d7ff-4f60-869a-266428d56906" xlink:to="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_ef98526d-18eb-49a7-afdf-0fa7bdb8f6ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_7349bb05-a33c-4de1-82b1-0c7819b8e8c7" xlink:href="amgn-20220630.xsd#amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_974eddb4-d7ff-4f60-869a-266428d56906" xlink:to="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_7349bb05-a33c-4de1-82b1-0c7819b8e8c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_1c326eb0-5c15-45b9-9dde-e87dc7bee272" xlink:href="amgn-20220630.xsd#amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_974eddb4-d7ff-4f60-869a-266428d56906" xlink:to="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_1c326eb0-5c15-45b9-9dde-e87dc7bee272" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A3002029NotesMember_ad527881-ac93-49ea-b23f-dd3223fa3fc0" xlink:href="amgn-20220630.xsd#amgn_A3002029NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_974eddb4-d7ff-4f60-869a-266428d56906" xlink:to="loc_amgn_A3002029NotesMember_ad527881-ac93-49ea-b23f-dd3223fa3fc0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A3352032NotesMember_b9441996-efff-464f-b249-189ee398d098" xlink:href="amgn-20220630.xsd#amgn_A3352032NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_974eddb4-d7ff-4f60-869a-266428d56906" xlink:to="loc_amgn_A3352032NotesMember_b9441996-efff-464f-b249-189ee398d098" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A4202052NotesMember_2ab42e15-be8a-4f50-8d79-c7bd3b7a522b" xlink:href="amgn-20220630.xsd#amgn_A4202052NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_974eddb4-d7ff-4f60-869a-266428d56906" xlink:to="loc_amgn_A4202052NotesMember_2ab42e15-be8a-4f50-8d79-c7bd3b7a522b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A4402062NotesMember_6a9db71e-abbe-47cb-9b49-eb5b3ff9471a" xlink:href="amgn-20220630.xsd#amgn_A4402062NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_974eddb4-d7ff-4f60-869a-266428d56906" xlink:to="loc_amgn_A4402062NotesMember_6a9db71e-abbe-47cb-9b49-eb5b3ff9471a" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#StockholdersequityDetailsTextualDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" xlink:type="extended" id="icb6e6aa04aa1488e9556a1914c972b38_StockholdersequityDetailsTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7de02199-eeca-485f-838e-c78edc752d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_67075e92-541b-4358-a954-7807560b4234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7de02199-eeca-485f-838e-c78edc752d55" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_67075e92-541b-4358-a954-7807560b4234" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f5f94341-7800-42bc-984c-da7badd2d722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7de02199-eeca-485f-838e-c78edc752d55" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f5f94341-7800-42bc-984c-da7badd2d722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_68fa0edd-dc09-47a4-a401-6525e0d686ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7de02199-eeca-485f-838e-c78edc752d55" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_68fa0edd-dc09-47a4-a401-6525e0d686ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a05e3b0c-bd7f-4810-8576-3a77da91df28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7de02199-eeca-485f-838e-c78edc752d55" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a05e3b0c-bd7f-4810-8576-3a77da91df28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_e246bb8f-1d15-4625-bd2f-306651d08d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7de02199-eeca-485f-838e-c78edc752d55" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_e246bb8f-1d15-4625-bd2f-306651d08d20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_4d319dce-50c1-4da5-a0d1-90eb4a5696a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7de02199-eeca-485f-838e-c78edc752d55" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_4d319dce-50c1-4da5-a0d1-90eb4a5696a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_ee1f3aea-c6fb-4d8c-8680-500f86b32fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7de02199-eeca-485f-838e-c78edc752d55" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_ee1f3aea-c6fb-4d8c-8680-500f86b32fd5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfThirdPartyFinancialInstitutions_19cb5a86-9dd3-4952-9c89-c0b3ade8fae2" xlink:href="amgn-20220630.xsd#amgn_NumberOfThirdPartyFinancialInstitutions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7de02199-eeca-485f-838e-c78edc752d55" xlink:to="loc_amgn_NumberOfThirdPartyFinancialInstitutions_19cb5a86-9dd3-4952-9c89-c0b3ade8fae2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_948df946-8f0b-4f83-8b61-921053f0ea64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_7de02199-eeca-485f-838e-c78edc752d55" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_948df946-8f0b-4f83-8b61-921053f0ea64" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_f8b0892a-2e45-48f9-bbdf-ca01984b8529" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_948df946-8f0b-4f83-8b61-921053f0ea64" xlink:to="loc_srt_StatementScenarioAxis_f8b0892a-2e45-48f9-bbdf-ca01984b8529" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f8b0892a-2e45-48f9-bbdf-ca01984b8529_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_f8b0892a-2e45-48f9-bbdf-ca01984b8529" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f8b0892a-2e45-48f9-bbdf-ca01984b8529_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6ad9f025-ccbd-4592-b9cb-34513fc88bb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_f8b0892a-2e45-48f9-bbdf-ca01984b8529" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6ad9f025-ccbd-4592-b9cb-34513fc88bb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4e7919e1-43fe-4800-8034-a53acb9a1a2c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_6ad9f025-ccbd-4592-b9cb-34513fc88bb0" xlink:to="loc_srt_ScenarioForecastMember_4e7919e1-43fe-4800-8034-a53acb9a1a2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_ca1f24bf-87ae-4af4-a215-a398f81aa662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_948df946-8f0b-4f83-8b61-921053f0ea64" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_ca1f24bf-87ae-4af4-a215-a398f81aa662" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_ca1f24bf-87ae-4af4-a215-a398f81aa662_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_ca1f24bf-87ae-4af4-a215-a398f81aa662" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_ca1f24bf-87ae-4af4-a215-a398f81aa662_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_d3c0f530-e648-4673-afa4-890ae3e1a59a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_ca1f24bf-87ae-4af4-a215-a398f81aa662" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_d3c0f530-e648-4673-afa4-890ae3e1a59a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcceleratedStockRepurchaseAgreementMember_b87bfe02-f326-4208-b8b3-8f3a05e835bf" xlink:href="amgn-20220630.xsd#amgn_AcceleratedStockRepurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_d3c0f530-e648-4673-afa4-890ae3e1a59a" xlink:to="loc_amgn_AcceleratedStockRepurchaseAgreementMember_b87bfe02-f326-4208-b8b3-8f3a05e835bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f92a5217-5a99-4e72-913c-20330982c976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_948df946-8f0b-4f83-8b61-921053f0ea64" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f92a5217-5a99-4e72-913c-20330982c976" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f92a5217-5a99-4e72-913c-20330982c976_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f92a5217-5a99-4e72-913c-20330982c976" xlink:to="loc_us-gaap_EquityComponentDomain_f92a5217-5a99-4e72-913c-20330982c976_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a3d13935-3330-4832-b0df-f8141a037fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f92a5217-5a99-4e72-913c-20330982c976" xlink:to="loc_us-gaap_EquityComponentDomain_a3d13935-3330-4832-b0df-f8141a037fc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_05ce252a-9788-4c97-8d13-16c447ea06e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a3d13935-3330-4832-b0df-f8141a037fc2" xlink:to="loc_us-gaap_RetainedEarningsMember_05ce252a-9788-4c97-8d13-16c447ea06e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_5e013921-861e-481a-ae43-342e978244cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a3d13935-3330-4832-b0df-f8141a037fc2" xlink:to="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_5e013921-861e-481a-ae43-342e978244cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c0b8b47b-967a-405f-bb26-881a64ce44f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_948df946-8f0b-4f83-8b61-921053f0ea64" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c0b8b47b-967a-405f-bb26-881a64ce44f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c0b8b47b-967a-405f-bb26-881a64ce44f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c0b8b47b-967a-405f-bb26-881a64ce44f0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c0b8b47b-967a-405f-bb26-881a64ce44f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_777ab480-7658-4740-9e60-a5ed7653e2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c0b8b47b-967a-405f-bb26-881a64ce44f0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_777ab480-7658-4740-9e60-a5ed7653e2d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_057fcfad-3e39-474d-82c0-4dffe5696aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_777ab480-7658-4740-9e60-a5ed7653e2d3" xlink:to="loc_us-gaap_SubsequentEventMember_057fcfad-3e39-474d-82c0-4dffe5696aac" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#StockholdersequityComponentsofAOCIDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" xlink:type="extended" id="i65328e8318434bb1845ca3742f51f735_StockholdersequityComponentsofAOCIDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_22d6a30b-f2e0-4f87-93a8-136cf7cc4667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_decd9ee2-3296-444f-b130-525e0900b2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_22d6a30b-f2e0-4f87-93a8-136cf7cc4667" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_decd9ee2-3296-444f-b130-525e0900b2c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6dea1384-1123-4c49-b067-2140725ca6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_decd9ee2-3296-444f-b130-525e0900b2c8" xlink:to="loc_us-gaap_StockholdersEquity_6dea1384-1123-4c49-b067-2140725ca6d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_7415ab14-2094-4fea-82f0-2b76a9fa8ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_decd9ee2-3296-444f-b130-525e0900b2c8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_7415ab14-2094-4fea-82f0-2b76a9fa8ca2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_f24bfc9f-8c75-446c-995b-ad9711fc6e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_decd9ee2-3296-444f-b130-525e0900b2c8" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_f24bfc9f-8c75-446c-995b-ad9711fc6e4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_05350239-b09b-4b4d-8567-474c0f66bb96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_decd9ee2-3296-444f-b130-525e0900b2c8" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_05350239-b09b-4b4d-8567-474c0f66bb96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_421632d6-413e-4d50-8f23-9139fa4ffd20" xlink:href="amgn-20220630.xsd#amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_decd9ee2-3296-444f-b130-525e0900b2c8" xlink:to="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_421632d6-413e-4d50-8f23-9139fa4ffd20" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_6d03400a-de32-4c32-a8ae-de651d1b7f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_decd9ee2-3296-444f-b130-525e0900b2c8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_6d03400a-de32-4c32-a8ae-de651d1b7f4c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d762a156-7e44-4c01-bc6c-b5a8dcb8a484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e213948c-f486-4e7b-aeda-fa410e4c1bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_22d6a30b-f2e0-4f87-93a8-136cf7cc4667" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e213948c-f486-4e7b-aeda-fa410e4c1bc3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_61964f77-9954-4a7b-aa2a-433d66fb8222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e213948c-f486-4e7b-aeda-fa410e4c1bc3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_61964f77-9954-4a7b-aa2a-433d66fb8222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_61964f77-9954-4a7b-aa2a-433d66fb8222_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61964f77-9954-4a7b-aa2a-433d66fb8222" xlink:to="loc_us-gaap_EquityComponentDomain_61964f77-9954-4a7b-aa2a-433d66fb8222_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f1502450-b944-496e-a322-1fb7a62139ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61964f77-9954-4a7b-aa2a-433d66fb8222" xlink:to="loc_us-gaap_EquityComponentDomain_f1502450-b944-496e-a322-1fb7a62139ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_d4467b9d-6090-4975-becb-e5f25932959c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f1502450-b944-496e-a322-1fb7a62139ae" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_d4467b9d-6090-4975-becb-e5f25932959c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_16388185-d144-4c52-ba11-b8766666765a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f1502450-b944-496e-a322-1fb7a62139ae" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_16388185-d144-4c52-ba11-b8766666765a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_b9b0ef71-0e07-4ee4-88ec-d5b1cbe413d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f1502450-b944-496e-a322-1fb7a62139ae" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_b9b0ef71-0e07-4ee4-88ec-d5b1cbe413d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_9bdf6ff2-9f83-4bae-bab6-233908b716b1" xlink:href="amgn-20220630.xsd#amgn_AccumulatedOtherAdjustmentAttributabletoParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f1502450-b944-496e-a322-1fb7a62139ae" xlink:to="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_9bdf6ff2-9f83-4bae-bab6-233908b716b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7fbab0b3-fd9b-4dca-a6bd-362e288b6997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f1502450-b944-496e-a322-1fb7a62139ae" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7fbab0b3-fd9b-4dca-a6bd-362e288b6997" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#StockholdersequityReclassificationsoutofAOCIDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" xlink:type="extended" id="ie395dbd8e4764c018e2a89a98abef962_StockholdersequityReclassificationsoutofAOCIDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_d1b243ae-64ff-4e57-b97d-7e0b3b7dd7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_02a1a7cc-04b7-472b-86df-60e4b80e113c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_d1b243ae-64ff-4e57-b97d-7e0b3b7dd7e3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_02a1a7cc-04b7-472b-86df-60e4b80e113c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_84bd8a06-0401-4c37-854b-1a79be06a3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_d1b243ae-64ff-4e57-b97d-7e0b3b7dd7e3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_84bd8a06-0401-4c37-854b-1a79be06a3ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_577609c9-1b80-4f56-9544-ed10e720542f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_d1b243ae-64ff-4e57-b97d-7e0b3b7dd7e3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_577609c9-1b80-4f56-9544-ed10e720542f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f1b3af87-dce6-466b-bc6c-3632189a8722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_d1b243ae-64ff-4e57-b97d-7e0b3b7dd7e3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f1b3af87-dce6-466b-bc6c-3632189a8722" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5defcb7b-62f0-4dbf-92ae-cd9f78c16958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_d1b243ae-64ff-4e57-b97d-7e0b3b7dd7e3" xlink:to="loc_us-gaap_NetIncomeLoss_5defcb7b-62f0-4dbf-92ae-cd9f78c16958" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2aea6a0c-534c-4ac4-8bde-fa5e836b5093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_d1b243ae-64ff-4e57-b97d-7e0b3b7dd7e3" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2aea6a0c-534c-4ac4-8bde-fa5e836b5093" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d3078a5d-18e0-46ad-ac2c-393334da27a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2aea6a0c-534c-4ac4-8bde-fa5e836b5093" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d3078a5d-18e0-46ad-ac2c-393334da27a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d3078a5d-18e0-46ad-ac2c-393334da27a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d3078a5d-18e0-46ad-ac2c-393334da27a2" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_d3078a5d-18e0-46ad-ac2c-393334da27a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_f108981d-f235-4cb6-9d1f-14c36c422902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d3078a5d-18e0-46ad-ac2c-393334da27a2" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_f108981d-f235-4cb6-9d1f-14c36c422902" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_19412492-9cc1-42b4-afb4-4a200396952e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_f108981d-f235-4cb6-9d1f-14c36c422902" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_19412492-9cc1-42b4-afb4-4a200396952e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_038ee94e-3642-4375-a67e-8be2182ea0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2aea6a0c-534c-4ac4-8bde-fa5e836b5093" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_038ee94e-3642-4375-a67e-8be2182ea0f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_038ee94e-3642-4375-a67e-8be2182ea0f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_038ee94e-3642-4375-a67e-8be2182ea0f2" xlink:to="loc_us-gaap_HedgingRelationshipDomain_038ee94e-3642-4375-a67e-8be2182ea0f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e4ec5b61-9989-4599-9003-57b91bd3e2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_038ee94e-3642-4375-a67e-8be2182ea0f2" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e4ec5b61-9989-4599-9003-57b91bd3e2d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_d75c2379-d700-47dd-a921-039bd7a8396e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e4ec5b61-9989-4599-9003-57b91bd3e2d5" xlink:to="loc_us-gaap_CashFlowHedgingMember_d75c2379-d700-47dd-a921-039bd7a8396e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3252773b-8151-496e-ae8a-cef855bfd0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2aea6a0c-534c-4ac4-8bde-fa5e836b5093" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3252773b-8151-496e-ae8a-cef855bfd0bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3252773b-8151-496e-ae8a-cef855bfd0bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3252773b-8151-496e-ae8a-cef855bfd0bc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3252773b-8151-496e-ae8a-cef855bfd0bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a242c73b-d4cd-4f4a-b0a1-e9eed1e7cefe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3252773b-8151-496e-ae8a-cef855bfd0bc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a242c73b-d4cd-4f4a-b0a1-e9eed1e7cefe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_756145f8-c5fd-49c4-b410-d2d2dd99fd62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a242c73b-d4cd-4f4a-b0a1-e9eed1e7cefe" xlink:to="loc_us-gaap_ForeignExchangeContractMember_756145f8-c5fd-49c4-b410-d2d2dd99fd62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_02a5d238-948a-4eab-9385-00b980656a48" xlink:href="amgn-20220630.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a242c73b-d4cd-4f4a-b0a1-e9eed1e7cefe" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_02a5d238-948a-4eab-9385-00b980656a48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_87800476-4c8a-4032-85c4-f2954b1a0523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2aea6a0c-534c-4ac4-8bde-fa5e836b5093" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_87800476-4c8a-4032-85c4-f2954b1a0523" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_87800476-4c8a-4032-85c4-f2954b1a0523_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_87800476-4c8a-4032-85c4-f2954b1a0523" xlink:to="loc_us-gaap_EquityComponentDomain_87800476-4c8a-4032-85c4-f2954b1a0523_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7db0497a-24a2-47aa-8a75-69b2ea688071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_87800476-4c8a-4032-85c4-f2954b1a0523" xlink:to="loc_us-gaap_EquityComponentDomain_7db0497a-24a2-47aa-8a75-69b2ea688071" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_d4d16282-40e9-40e1-bff4-34ec2ee21e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7db0497a-24a2-47aa-8a75-69b2ea688071" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_d4d16282-40e9-40e1-bff4-34ec2ee21e97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_66f7e305-66ae-4661-b83f-4fd7c25a80a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7db0497a-24a2-47aa-8a75-69b2ea688071" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_66f7e305-66ae-4661-b83f-4fd7c25a80a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1a4c8471-d19e-4435-bbbb-74d09afe971f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2aea6a0c-534c-4ac4-8bde-fa5e836b5093" xlink:to="loc_srt_ProductOrServiceAxis_1a4c8471-d19e-4435-bbbb-74d09afe971f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1a4c8471-d19e-4435-bbbb-74d09afe971f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1a4c8471-d19e-4435-bbbb-74d09afe971f" xlink:to="loc_srt_ProductsAndServicesDomain_1a4c8471-d19e-4435-bbbb-74d09afe971f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6d2f35c6-0283-4386-9e3f-27642032f5ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1a4c8471-d19e-4435-bbbb-74d09afe971f" xlink:to="loc_srt_ProductsAndServicesDomain_6d2f35c6-0283-4386-9e3f-27642032f5ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e0014359-e95b-43e5-9acc-dd14f08491e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6d2f35c6-0283-4386-9e3f-27642032f5ea" xlink:to="loc_us-gaap_ProductMember_e0014359-e95b-43e5-9acc-dd14f08491e4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#FairvaluemeasurementDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementDetails" xlink:type="extended" id="i5311ad1131ba4c4c84238f7178073f82_FairvaluemeasurementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6060760e-c786-4f49-97c9-8245c98a84c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_ce4358e7-ef94-43a9-8a71-b17c00fbba14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6060760e-c786-4f49-97c9-8245c98a84c0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_ce4358e7-ef94-43a9-8a71-b17c00fbba14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_14ec2f07-0758-4b54-a156-7b168e545092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ce4358e7-ef94-43a9-8a71-b17c00fbba14" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_14ec2f07-0758-4b54-a156-7b168e545092" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_62659406-e386-4734-8435-70fa8919650b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ce4358e7-ef94-43a9-8a71-b17c00fbba14" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_62659406-e386-4734-8435-70fa8919650b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_eb46490a-61f8-47f8-acc6-059f892cc8c6" xlink:href="amgn-20220630.xsd#amgn_DerivativeAssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ce4358e7-ef94-43a9-8a71-b17c00fbba14" xlink:to="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_eb46490a-61f8-47f8-acc6-059f892cc8c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2a5d3f6b-8af2-44ca-9b84-6199dc0aab4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_eb46490a-61f8-47f8-acc6-059f892cc8c6" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2a5d3f6b-8af2-44ca-9b84-6199dc0aab4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_29d8abb1-6fb1-4046-bf31-29ab12a14d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateFairValueHedgeAssetAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_eb46490a-61f8-47f8-acc6-059f892cc8c6" xlink:to="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_29d8abb1-6fb1-4046-bf31-29ab12a14d99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_091c9f13-1341-4214-ba96-7415a1096d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ce4358e7-ef94-43a9-8a71-b17c00fbba14" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_091c9f13-1341-4214-ba96-7415a1096d45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_64524e4f-658b-4e73-aa52-09b976b246a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6060760e-c786-4f49-97c9-8245c98a84c0" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_64524e4f-658b-4e73-aa52-09b976b246a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_05c25ad6-91d6-42ba-abf6-c02ddfca768f" xlink:href="amgn-20220630.xsd#amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_64524e4f-658b-4e73-aa52-09b976b246a6" xlink:to="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_05c25ad6-91d6-42ba-abf6-c02ddfca768f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_52321a1c-f8e1-4804-9dcd-41353ef87f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_05c25ad6-91d6-42ba-abf6-c02ddfca768f" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_52321a1c-f8e1-4804-9dcd-41353ef87f9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_7c00bf3b-f58d-4f23-aea8-23c0399a8e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_05c25ad6-91d6-42ba-abf6-c02ddfca768f" xlink:to="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_7c00bf3b-f58d-4f23-aea8-23c0399a8e31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c5dbfdd8-cb2b-499b-a05b-6a4c5a72624b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_05c25ad6-91d6-42ba-abf6-c02ddfca768f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c5dbfdd8-cb2b-499b-a05b-6a4c5a72624b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_f4d5dd5e-db27-4266-811c-d195d3ac89a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_64524e4f-658b-4e73-aa52-09b976b246a6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_f4d5dd5e-db27-4266-811c-d195d3ac89a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b5643bf9-76ae-4283-b349-78aec50dc7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6060760e-c786-4f49-97c9-8245c98a84c0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b5643bf9-76ae-4283-b349-78aec50dc7e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_56dc72f5-f2d1-4262-b3ee-1e4d6ab3159a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b5643bf9-76ae-4283-b349-78aec50dc7e0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_56dc72f5-f2d1-4262-b3ee-1e4d6ab3159a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_56dc72f5-f2d1-4262-b3ee-1e4d6ab3159a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_56dc72f5-f2d1-4262-b3ee-1e4d6ab3159a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_56dc72f5-f2d1-4262-b3ee-1e4d6ab3159a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_56dc72f5-f2d1-4262-b3ee-1e4d6ab3159a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_c7c54ec0-87ad-4c57-af16-0fbfeaf6bff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_c7c54ec0-87ad-4c57-af16-0fbfeaf6bff2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_d3e826bc-d8b0-440f-8675-0adbe6a2649c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_d3e826bc-d8b0-440f-8675-0adbe6a2649c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4d0ec3a6-1315-4c83-ac67-d5bbfe4c76db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4d0ec3a6-1315-4c83-ac67-d5bbfe4c76db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_5ee70c1f-c427-47d8-8086-740718eeeb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_5ee70c1f-c427-47d8-8086-740718eeeb7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesFinancialMember_90f5580b-41f2-4d87-9363-c74094acd791" xlink:href="amgn-20220630.xsd#amgn_CorporateDebtSecuritiesFinancialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_amgn_CorporateDebtSecuritiesFinancialMember_90f5580b-41f2-4d87-9363-c74094acd791" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesIndustrialMember_e0dcb38f-aebb-4986-845b-6d0e05f777ec" xlink:href="amgn-20220630.xsd#amgn_CorporateDebtSecuritiesIndustrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_amgn_CorporateDebtSecuritiesIndustrialMember_e0dcb38f-aebb-4986-845b-6d0e05f777ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesOtherMember_740dad23-ff73-4239-857b-cdde01c5018a" xlink:href="amgn-20220630.xsd#amgn_CorporateDebtSecuritiesOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_amgn_CorporateDebtSecuritiesOtherMember_740dad23-ff73-4239-857b-cdde01c5018a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_fb31fffe-ba72-44c5-bb49-a661e9f0f900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_fb31fffe-ba72-44c5-bb49-a661e9f0f900" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_122a888e-a7c5-4c5e-be90-f506ac61e7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_122a888e-a7c5-4c5e-be90-f506ac61e7bc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3acfb5b9-56eb-4e67-ab7e-614a3ef54992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3acfb5b9-56eb-4e67-ab7e-614a3ef54992" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_57556721-10d4-4122-ba61-1f94a368c188" xlink:href="amgn-20220630.xsd#amgn_OtherShortTermInterestBearingSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_57556721-10d4-4122-ba61-1f94a368c188" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_0695e764-4892-46f4-897a-72acf0c66a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_0695e764-4892-46f4-897a-72acf0c66a8b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForeignAndOtherGovernmentRelatedDebtSecuritiesMember_32e836da-d57b-4e84-979a-bf970d150d2d" xlink:href="amgn-20220630.xsd#amgn_ForeignAndOtherGovernmentRelatedDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_amgn_ForeignAndOtherGovernmentRelatedDebtSecuritiesMember_32e836da-d57b-4e84-979a-bf970d150d2d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MortgageAndAssetBackMember_c12213ca-7b9e-47de-b19c-62b94774319a" xlink:href="amgn-20220630.xsd#amgn_MortgageAndAssetBackMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_amgn_MortgageAndAssetBackMember_c12213ca-7b9e-47de-b19c-62b94774319a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherMortgageAndAssetBackedMember_8d2d4cab-aef5-46fd-ac98-03f8acac0a08" xlink:href="amgn-20220630.xsd#amgn_OtherMortgageAndAssetBackedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_amgn_OtherMortgageAndAssetBackedMember_8d2d4cab-aef5-46fd-ac98-03f8acac0a08" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e301dd9-efff-4f30-b9d1-f266e4ae43d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b5643bf9-76ae-4283-b349-78aec50dc7e0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e301dd9-efff-4f30-b9d1-f266e4ae43d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e301dd9-efff-4f30-b9d1-f266e4ae43d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e301dd9-efff-4f30-b9d1-f266e4ae43d0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e301dd9-efff-4f30-b9d1-f266e4ae43d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1cc00f4-e9cd-41a0-97c8-1e4f977cacbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e301dd9-efff-4f30-b9d1-f266e4ae43d0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1cc00f4-e9cd-41a0-97c8-1e4f977cacbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_80dec30f-071a-4351-b613-d2f81e189d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1cc00f4-e9cd-41a0-97c8-1e4f977cacbe" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_80dec30f-071a-4351-b613-d2f81e189d82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_68c1776c-bed5-4c60-b927-cc2ba9d860b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1cc00f4-e9cd-41a0-97c8-1e4f977cacbe" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_68c1776c-bed5-4c60-b927-cc2ba9d860b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0160fe84-765e-4d67-ad22-4a5a0dbd49f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1cc00f4-e9cd-41a0-97c8-1e4f977cacbe" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0160fe84-765e-4d67-ad22-4a5a0dbd49f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_51cdb08d-f14c-41fa-b495-5e6852b769a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b5643bf9-76ae-4283-b349-78aec50dc7e0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_51cdb08d-f14c-41fa-b495-5e6852b769a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_51cdb08d-f14c-41fa-b495-5e6852b769a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_51cdb08d-f14c-41fa-b495-5e6852b769a1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_51cdb08d-f14c-41fa-b495-5e6852b769a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_69176758-2211-4460-ae04-a07cf3c3bafc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_51cdb08d-f14c-41fa-b495-5e6852b769a1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_69176758-2211-4460-ae04-a07cf3c3bafc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_8d73bfad-b8c5-4404-8024-3a39fef56b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_69176758-2211-4460-ae04-a07cf3c3bafc" xlink:to="loc_us-gaap_ForeignExchangeContractMember_8d73bfad-b8c5-4404-8024-3a39fef56b74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_02b02cdb-7d1d-4034-a9e4-04df9ff921eb" xlink:href="amgn-20220630.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_69176758-2211-4460-ae04-a07cf3c3bafc" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_02b02cdb-7d1d-4034-a9e4-04df9ff921eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_82f8bbd1-d8c6-42db-bd95-81bbffeb2b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_69176758-2211-4460-ae04-a07cf3c3bafc" xlink:to="loc_us-gaap_InterestRateSwapMember_82f8bbd1-d8c6-42db-bd95-81bbffeb2b2f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementDetailsTextual" xlink:type="simple" xlink:href="amgn-20220630.xsd#FairvaluemeasurementDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementDetailsTextual" xlink:type="extended" id="i33ab9c5e9607458c9ef2458ca63907a7_FairvaluemeasurementDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fce48c17-2885-4b70-afd2-8f61253247ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_6af8f51b-c052-4a69-ac45-fa6c9feec88d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fce48c17-2885-4b70-afd2-8f61253247ac" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_6af8f51b-c052-4a69-ac45-fa6c9feec88d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_d264295b-62d4-4a97-9019-d22f0cddfdc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fce48c17-2885-4b70-afd2-8f61253247ac" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_d264295b-62d4-4a97-9019-d22f0cddfdc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_8c6123be-00e4-453b-929d-487f010f2621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fce48c17-2885-4b70-afd2-8f61253247ac" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_8c6123be-00e4-453b-929d-487f010f2621" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_19ecda19-60ea-4d7d-a297-b349d4c58159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fce48c17-2885-4b70-afd2-8f61253247ac" xlink:to="loc_us-gaap_LongTermDebt_19ecda19-60ea-4d7d-a297-b349d4c58159" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_c36c32d2-1186-41fc-b29f-591d91d848e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fce48c17-2885-4b70-afd2-8f61253247ac" xlink:to="loc_us-gaap_EquityMethodInvestments_c36c32d2-1186-41fc-b29f-591d91d848e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_05760dbc-70fb-4ddf-a020-e154e25a5a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fce48c17-2885-4b70-afd2-8f61253247ac" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_05760dbc-70fb-4ddf-a020-e154e25a5a3e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7172e928-52a5-4c8b-bff1-894a457bb242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fce48c17-2885-4b70-afd2-8f61253247ac" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7172e928-52a5-4c8b-bff1-894a457bb242" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e3907d3d-daf2-4afd-8e09-0f1a71cfeeed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7172e928-52a5-4c8b-bff1-894a457bb242" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e3907d3d-daf2-4afd-8e09-0f1a71cfeeed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e3907d3d-daf2-4afd-8e09-0f1a71cfeeed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e3907d3d-daf2-4afd-8e09-0f1a71cfeeed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e3907d3d-daf2-4afd-8e09-0f1a71cfeeed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a04a6cea-c1e4-41dd-b8f0-0a6c1f78667d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e3907d3d-daf2-4afd-8e09-0f1a71cfeeed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a04a6cea-c1e4-41dd-b8f0-0a6c1f78667d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_0a4a7d05-e883-400d-bef8-174866855736" xlink:href="amgn-20220630.xsd#amgn_BeiGeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a04a6cea-c1e4-41dd-b8f0-0a6c1f78667d" xlink:to="loc_amgn_BeiGeneMember_0a4a7d05-e883-400d-bef8-174866855736" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioIncMember_d02eaf8e-334b-44ce-bfb1-52d953012c2e" xlink:href="amgn-20220630.xsd#amgn_TeneobioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a04a6cea-c1e4-41dd-b8f0-0a6c1f78667d" xlink:to="loc_amgn_TeneobioIncMember_d02eaf8e-334b-44ce-bfb1-52d953012c2e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual" xlink:type="simple" xlink:href="amgn-20220630.xsd#DerivativeinstrumentsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual" xlink:type="extended" id="i62ec6c0398bf48eabf03436da3a00eb5_DerivativeinstrumentsDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dbb9b5d7-20b5-4ad3-82b7-e52b2fd38a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_31ac7d09-6c51-4c0d-94ec-61bceeb2661d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dbb9b5d7-20b5-4ad3-82b7-e52b2fd38a54" xlink:to="loc_us-gaap_DerivativeNotionalAmount_31ac7d09-6c51-4c0d-94ec-61bceeb2661d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_11b74505-2ad2-41b7-b050-a0b8f089f5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dbb9b5d7-20b5-4ad3-82b7-e52b2fd38a54" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_11b74505-2ad2-41b7-b050-a0b8f089f5d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_870846cd-8883-4e66-8af0-2e5ef8da47d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dbb9b5d7-20b5-4ad3-82b7-e52b2fd38a54" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_870846cd-8883-4e66-8af0-2e5ef8da47d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fd3783fe-248d-47f5-9324-89507916da29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_870846cd-8883-4e66-8af0-2e5ef8da47d5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fd3783fe-248d-47f5-9324-89507916da29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fd3783fe-248d-47f5-9324-89507916da29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fd3783fe-248d-47f5-9324-89507916da29" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fd3783fe-248d-47f5-9324-89507916da29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_94f70141-b79d-411e-a3c0-b18e9f815858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fd3783fe-248d-47f5-9324-89507916da29" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_94f70141-b79d-411e-a3c0-b18e9f815858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_3c371a97-1881-4eca-885b-7e23e9f02c90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_94f70141-b79d-411e-a3c0-b18e9f815858" xlink:to="loc_us-gaap_ForwardContractsMember_3c371a97-1881-4eca-885b-7e23e9f02c90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b935fb36-fc31-4c4e-be30-a6a6e19acb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_94f70141-b79d-411e-a3c0-b18e9f815858" xlink:to="loc_us-gaap_InterestRateSwapMember_b935fb36-fc31-4c4e-be30-a6a6e19acb2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_90394468-f7df-48f8-832b-fb17849109f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_870846cd-8883-4e66-8af0-2e5ef8da47d5" xlink:to="loc_us-gaap_HedgingDesignationAxis_90394468-f7df-48f8-832b-fb17849109f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_90394468-f7df-48f8-832b-fb17849109f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_90394468-f7df-48f8-832b-fb17849109f4" xlink:to="loc_us-gaap_HedgingDesignationDomain_90394468-f7df-48f8-832b-fb17849109f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_1ee5891d-4ee3-4f40-a22a-9ada11dd8b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_90394468-f7df-48f8-832b-fb17849109f4" xlink:to="loc_us-gaap_HedgingDesignationDomain_1ee5891d-4ee3-4f40-a22a-9ada11dd8b5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_cc4400ec-2305-4808-b5be-98dd2e9c7b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_1ee5891d-4ee3-4f40-a22a-9ada11dd8b5e" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_cc4400ec-2305-4808-b5be-98dd2e9c7b48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_a07046df-d030-40df-9f42-6cb3541e9429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_1ee5891d-4ee3-4f40-a22a-9ada11dd8b5e" xlink:to="loc_us-gaap_NondesignatedMember_a07046df-d030-40df-9f42-6cb3541e9429" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#DerivativeinstrumentsCrosscurrencySwapsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" xlink:type="extended" id="ide1d7928b12a439cbe333e0a2652c269_DerivativeinstrumentsCrosscurrencySwapsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_d566f568-f7a1-431a-9c97-e6d614097df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_f5c4810d-3496-481a-9862-4f4a81914c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_d566f568-f7a1-431a-9c97-e6d614097df3" xlink:to="loc_us-gaap_DerivativeNotionalAmount_f5c4810d-3496-481a-9862-4f4a81914c38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_bec2b27d-5d21-4029-81ad-8a47130dd45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_d566f568-f7a1-431a-9c97-e6d614097df3" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_bec2b27d-5d21-4029-81ad-8a47130dd45b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_7e504cff-c5c6-4cf4-8a65-104e84cd8c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_d566f568-f7a1-431a-9c97-e6d614097df3" xlink:to="loc_us-gaap_DerivativeTable_7e504cff-c5c6-4cf4-8a65-104e84cd8c2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a915f73e-7e2d-4b18-b560-cf99380ae8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_7e504cff-c5c6-4cf4-8a65-104e84cd8c2c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a915f73e-7e2d-4b18-b560-cf99380ae8ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_a915f73e-7e2d-4b18-b560-cf99380ae8ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a915f73e-7e2d-4b18-b560-cf99380ae8ac" xlink:to="loc_us-gaap_HedgingRelationshipDomain_a915f73e-7e2d-4b18-b560-cf99380ae8ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0eedae6a-316f-46be-9dbf-e9515ff80a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a915f73e-7e2d-4b18-b560-cf99380ae8ac" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0eedae6a-316f-46be-9dbf-e9515ff80a2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_ca4bb348-bbd5-4d13-bbd9-d92b99c2953f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0eedae6a-316f-46be-9dbf-e9515ff80a2c" xlink:to="loc_us-gaap_CashFlowHedgingMember_ca4bb348-bbd5-4d13-bbd9-d92b99c2953f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6582f1ec-2c3f-4e00-bf3c-08a1da208548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_7e504cff-c5c6-4cf4-8a65-104e84cd8c2c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6582f1ec-2c3f-4e00-bf3c-08a1da208548" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6582f1ec-2c3f-4e00-bf3c-08a1da208548_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6582f1ec-2c3f-4e00-bf3c-08a1da208548" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6582f1ec-2c3f-4e00-bf3c-08a1da208548_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4bd00d3b-9eed-4b44-a38a-e4f88b036af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6582f1ec-2c3f-4e00-bf3c-08a1da208548" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4bd00d3b-9eed-4b44-a38a-e4f88b036af9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_5d445010-4472-445e-a0eb-5ff7013ab029" xlink:href="amgn-20220630.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4bd00d3b-9eed-4b44-a38a-e4f88b036af9" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_5d445010-4472-445e-a0eb-5ff7013ab029" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_e40abf47-fbaa-4c2d-ad56-172608a806cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_7e504cff-c5c6-4cf4-8a65-104e84cd8c2c" xlink:to="loc_srt_CurrencyAxis_e40abf47-fbaa-4c2d-ad56-172608a806cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_e40abf47-fbaa-4c2d-ad56-172608a806cf_default" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_e40abf47-fbaa-4c2d-ad56-172608a806cf" xlink:to="loc_currency_AllCurrenciesDomain_e40abf47-fbaa-4c2d-ad56-172608a806cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_9eda031e-5f44-4fc0-809d-15ea63018aeb" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_e40abf47-fbaa-4c2d-ad56-172608a806cf" xlink:to="loc_currency_AllCurrenciesDomain_9eda031e-5f44-4fc0-809d-15ea63018aeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_c4345486-f9c0-4998-93d3-d253c0ae4ce7" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_9eda031e-5f44-4fc0-809d-15ea63018aeb" xlink:to="loc_currency_EUR_c4345486-f9c0-4998-93d3-d253c0ae4ce7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_3a245045-832c-4eb9-bb32-3927e020349a" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_9eda031e-5f44-4fc0-809d-15ea63018aeb" xlink:to="loc_currency_CHF_3a245045-832c-4eb9-bb32-3927e020349a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_e63afad0-3e14-47c4-9458-b96d097f3b59" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_9eda031e-5f44-4fc0-809d-15ea63018aeb" xlink:to="loc_currency_GBP_e63afad0-3e14-47c4-9458-b96d097f3b59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_20ede496-2964-4845-adb5-1c246ab1853d" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_9eda031e-5f44-4fc0-809d-15ea63018aeb" xlink:to="loc_currency_USD_20ede496-2964-4845-adb5-1c246ab1853d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ed2b7c82-0052-4680-be75-443cc2e7b0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_7e504cff-c5c6-4cf4-8a65-104e84cd8c2c" xlink:to="loc_us-gaap_DebtInstrumentAxis_ed2b7c82-0052-4680-be75-443cc2e7b0a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ed2b7c82-0052-4680-be75-443cc2e7b0a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ed2b7c82-0052-4680-be75-443cc2e7b0a5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ed2b7c82-0052-4680-be75-443cc2e7b0a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_da71eaee-8a61-4931-815b-b3798b2f83b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ed2b7c82-0052-4680-be75-443cc2e7b0a5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_da71eaee-8a61-4931-815b-b3798b2f83b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_8a7ba0c4-4f6e-4589-b069-9e4044e4eca5" xlink:href="amgn-20220630.xsd#amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da71eaee-8a61-4931-815b-b3798b2f83b2" xlink:to="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_8a7ba0c4-4f6e-4589-b069-9e4044e4eca5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_acdafab8-7739-426f-86b3-0c89ef777807" xlink:href="amgn-20220630.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da71eaee-8a61-4931-815b-b3798b2f83b2" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_acdafab8-7739-426f-86b3-0c89ef777807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_53c38287-e3a5-4213-9da2-d9fd49ccf22f" xlink:href="amgn-20220630.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da71eaee-8a61-4931-815b-b3798b2f83b2" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_53c38287-e3a5-4213-9da2-d9fd49ccf22f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_95aa1194-6478-4d77-941b-f5acb631777c" xlink:href="amgn-20220630.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da71eaee-8a61-4931-815b-b3798b2f83b2" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_95aa1194-6478-4d77-941b-f5acb631777c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_288bf33f-b661-4259-85b0-fd21462dbb6e" xlink:href="amgn-20220630.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da71eaee-8a61-4931-815b-b3798b2f83b2" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_288bf33f-b661-4259-85b0-fd21462dbb6e" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" xlink:type="extended" id="i978cca7c56b845119aa85cff11b4b83c_DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2e0a626c-b890-44cd-9919-a10f744cf474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_bf71e397-ace6-4bc3-a085-42332da6c752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2e0a626c-b890-44cd-9919-a10f744cf474" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_bf71e397-ace6-4bc3-a085-42332da6c752" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bfb6f518-8f54-43b6-9055-fe34f8551119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2e0a626c-b890-44cd-9919-a10f744cf474" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bfb6f518-8f54-43b6-9055-fe34f8551119" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c66a95da-c5c4-4cfb-a9c8-a77a12ba6eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bfb6f518-8f54-43b6-9055-fe34f8551119" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c66a95da-c5c4-4cfb-a9c8-a77a12ba6eb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_c66a95da-c5c4-4cfb-a9c8-a77a12ba6eb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c66a95da-c5c4-4cfb-a9c8-a77a12ba6eb4" xlink:to="loc_us-gaap_HedgingRelationshipDomain_c66a95da-c5c4-4cfb-a9c8-a77a12ba6eb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7156c488-1a2f-4db9-93cf-d1759d005c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c66a95da-c5c4-4cfb-a9c8-a77a12ba6eb4" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7156c488-1a2f-4db9-93cf-d1759d005c32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_aadfdfcc-583a-4763-8e3e-6ff1cde93e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7156c488-1a2f-4db9-93cf-d1759d005c32" xlink:to="loc_us-gaap_CashFlowHedgingMember_aadfdfcc-583a-4763-8e3e-6ff1cde93e53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_63d58bef-6a18-4e1e-8f87-102c9a8c9dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bfb6f518-8f54-43b6-9055-fe34f8551119" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_63d58bef-6a18-4e1e-8f87-102c9a8c9dc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_63d58bef-6a18-4e1e-8f87-102c9a8c9dc0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_63d58bef-6a18-4e1e-8f87-102c9a8c9dc0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_63d58bef-6a18-4e1e-8f87-102c9a8c9dc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6b413450-768f-4ab5-9513-8fa6b4e6a3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_63d58bef-6a18-4e1e-8f87-102c9a8c9dc0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6b413450-768f-4ab5-9513-8fa6b4e6a3c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_db98588a-fc78-4631-94b1-689be366f2df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b413450-768f-4ab5-9513-8fa6b4e6a3c4" xlink:to="loc_us-gaap_ForeignExchangeContractMember_db98588a-fc78-4631-94b1-689be366f2df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_fcf52eca-6f4d-4507-879d-ab8a918e0dac" xlink:href="amgn-20220630.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b413450-768f-4ab5-9513-8fa6b4e6a3c4" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_fcf52eca-6f4d-4507-879d-ab8a918e0dac" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails" xlink:type="extended" id="i7a7728c65bd44413a6f0456c40265d84_DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a7db6e13-e109-45ab-9406-df68a8ccbc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_e4b917a5-49a1-4c3f-be41-14370b87c844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a7db6e13-e109-45ab-9406-df68a8ccbc0f" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_e4b917a5-49a1-4c3f-be41-14370b87c844" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_8160726b-f48e-4cf3-bb11-709cf4ae8767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a7db6e13-e109-45ab-9406-df68a8ccbc0f" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_8160726b-f48e-4cf3-bb11-709cf4ae8767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge_63d5d569-2f69-4de3-b8c8-43cc23498ccc" xlink:href="amgn-20220630.xsd#amgn_HedgedLiabilityDiscontinuedFairValueHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a7db6e13-e109-45ab-9406-df68a8ccbc0f" xlink:to="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge_63d5d569-2f69-4de3-b8c8-43cc23498ccc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_ea324e4b-137b-4ec0-bf28-10905d4a5d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a7db6e13-e109-45ab-9406-df68a8ccbc0f" xlink:to="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_ea324e4b-137b-4ec0-bf28-10905d4a5d43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_cd0889bc-f994-41b8-82a9-be77e03f7198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_a7db6e13-e109-45ab-9406-df68a8ccbc0f" xlink:to="loc_us-gaap_DerivativeTable_cd0889bc-f994-41b8-82a9-be77e03f7198" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_b1c286d1-a647-463f-b1ff-18446157ff5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_cd0889bc-f994-41b8-82a9-be77e03f7198" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_b1c286d1-a647-463f-b1ff-18446157ff5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b1c286d1-a647-463f-b1ff-18446157ff5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_b1c286d1-a647-463f-b1ff-18446157ff5e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b1c286d1-a647-463f-b1ff-18446157ff5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e6131278-f310-47d7-8143-29ab9e52a7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_b1c286d1-a647-463f-b1ff-18446157ff5e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e6131278-f310-47d7-8143-29ab9e52a7be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtCurrentMaturitiesMember_852bd4c3-c37e-4124-9770-cc37bbff7f4f" xlink:href="amgn-20220630.xsd#amgn_LongTermDebtCurrentMaturitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e6131278-f310-47d7-8143-29ab9e52a7be" xlink:to="loc_amgn_LongTermDebtCurrentMaturitiesMember_852bd4c3-c37e-4124-9770-cc37bbff7f4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_e3b661fd-ade1-419f-b5b6-d8ba9d20b477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e6131278-f310-47d7-8143-29ab9e52a7be" xlink:to="loc_us-gaap_LongTermDebtMember_e3b661fd-ade1-419f-b5b6-d8ba9d20b477" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" xlink:type="extended" id="id49be51479384740b1d2f0ed5021dd0e_DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_db042a08-d44c-4a3f-9278-0bd496bfe2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f070afeb-4142-46e2-8482-8e4b64821d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_db042a08-d44c-4a3f-9278-0bd496bfe2e0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f070afeb-4142-46e2-8482-8e4b64821d77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d5928782-c5ac-468f-9455-7e50e366611f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_db042a08-d44c-4a3f-9278-0bd496bfe2e0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d5928782-c5ac-468f-9455-7e50e366611f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_45dab039-9495-44e7-965e-1427f77692db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_db042a08-d44c-4a3f-9278-0bd496bfe2e0" xlink:to="loc_us-gaap_InterestExpenseDebt_45dab039-9495-44e7-965e-1427f77692db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_ef5571ac-5f78-443a-99a8-71944c7649c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_db042a08-d44c-4a3f-9278-0bd496bfe2e0" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_ef5571ac-5f78-443a-99a8-71944c7649c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_70ba1d03-cf2b-4188-a76d-aaae15921db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_db042a08-d44c-4a3f-9278-0bd496bfe2e0" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_70ba1d03-cf2b-4188-a76d-aaae15921db4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_c2d6c57f-b5eb-4ea0-89d0-97df5a3afa70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_db042a08-d44c-4a3f-9278-0bd496bfe2e0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_c2d6c57f-b5eb-4ea0-89d0-97df5a3afa70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_eb7a1d73-29a1-4c53-9e17-2b1f9612e5c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_c2d6c57f-b5eb-4ea0-89d0-97df5a3afa70" xlink:to="loc_srt_ProductOrServiceAxis_eb7a1d73-29a1-4c53-9e17-2b1f9612e5c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eb7a1d73-29a1-4c53-9e17-2b1f9612e5c1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_eb7a1d73-29a1-4c53-9e17-2b1f9612e5c1" xlink:to="loc_srt_ProductsAndServicesDomain_eb7a1d73-29a1-4c53-9e17-2b1f9612e5c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aecf25a2-2c38-44d5-ac88-d50706884a80" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_eb7a1d73-29a1-4c53-9e17-2b1f9612e5c1" xlink:to="loc_srt_ProductsAndServicesDomain_aecf25a2-2c38-44d5-ac88-d50706884a80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_bf48c2bc-9a81-428a-bea7-83cb7f03a150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aecf25a2-2c38-44d5-ac88-d50706884a80" xlink:to="loc_us-gaap_ProductMember_bf48c2bc-9a81-428a-bea7-83cb7f03a150" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_adace4c7-2276-495c-9f1b-0c50635f373d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_c2d6c57f-b5eb-4ea0-89d0-97df5a3afa70" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_adace4c7-2276-495c-9f1b-0c50635f373d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_adace4c7-2276-495c-9f1b-0c50635f373d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_adace4c7-2276-495c-9f1b-0c50635f373d" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_adace4c7-2276-495c-9f1b-0c50635f373d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_862e9475-af23-4df3-aa1c-2e2c39062810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_adace4c7-2276-495c-9f1b-0c50635f373d" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_862e9475-af23-4df3-aa1c-2e2c39062810" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_187439b4-c723-4783-9fbc-1c5d4d174749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_862e9475-af23-4df3-aa1c-2e2c39062810" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_187439b4-c723-4783-9fbc-1c5d4d174749" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_005899d4-3742-4e17-9183-44ca5a60a6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_c2d6c57f-b5eb-4ea0-89d0-97df5a3afa70" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_005899d4-3742-4e17-9183-44ca5a60a6a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_005899d4-3742-4e17-9183-44ca5a60a6a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_005899d4-3742-4e17-9183-44ca5a60a6a0" xlink:to="loc_us-gaap_EquityComponentDomain_005899d4-3742-4e17-9183-44ca5a60a6a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_531b11a3-9ac4-4d07-914a-4984ab29adf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_005899d4-3742-4e17-9183-44ca5a60a6a0" xlink:to="loc_us-gaap_EquityComponentDomain_531b11a3-9ac4-4d07-914a-4984ab29adf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e263f708-74aa-4b94-b268-b570fb1b8629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_531b11a3-9ac4-4d07-914a-4984ab29adf2" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e263f708-74aa-4b94-b268-b570fb1b8629" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ec8bb8c8-708b-4a57-afeb-d7c1467716c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_c2d6c57f-b5eb-4ea0-89d0-97df5a3afa70" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ec8bb8c8-708b-4a57-afeb-d7c1467716c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ec8bb8c8-708b-4a57-afeb-d7c1467716c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ec8bb8c8-708b-4a57-afeb-d7c1467716c2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ec8bb8c8-708b-4a57-afeb-d7c1467716c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b45bf0b7-3cd9-461d-b8cb-2a359a1348bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ec8bb8c8-708b-4a57-afeb-d7c1467716c2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b45bf0b7-3cd9-461d-b8cb-2a359a1348bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_2ceadb51-b89d-4a0c-8573-26465ff861f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b45bf0b7-3cd9-461d-b8cb-2a359a1348bf" xlink:to="loc_us-gaap_ForeignExchangeContractMember_2ceadb51-b89d-4a0c-8573-26465ff861f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_a28e873f-92be-4c32-b44e-08fe231ba5fa" xlink:href="amgn-20220630.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b45bf0b7-3cd9-461d-b8cb-2a359a1348bf" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_a28e873f-92be-4c32-b44e-08fe231ba5fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_e93ffe7a-dbe6-4ea5-b7ee-7b3cd805f5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b45bf0b7-3cd9-461d-b8cb-2a359a1348bf" xlink:to="loc_us-gaap_InterestRateSwapMember_e93ffe7a-dbe6-4ea5-b7ee-7b3cd805f5a4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#DerivativeinstrumentsFairValueofDerivativesDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" xlink:type="extended" id="ia9737951943e41119de64c376736627c_DerivativeinstrumentsFairValueofDerivativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_d1900779-c598-4317-8841-7a0a83bc9888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_e29b7998-3b83-4e4d-a76a-f583f74ac6fd" xlink:href="amgn-20220630.xsd#amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_d1900779-c598-4317-8841-7a0a83bc9888" xlink:to="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_e29b7998-3b83-4e4d-a76a-f583f74ac6fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_0a092bd3-bd75-4e5a-a373-7d00ac360d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_e29b7998-3b83-4e4d-a76a-f583f74ac6fd" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_0a092bd3-bd75-4e5a-a373-7d00ac360d78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_4676abe7-a6a3-48d4-a269-c122f8051c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_0a092bd3-bd75-4e5a-a373-7d00ac360d78" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_4676abe7-a6a3-48d4-a269-c122f8051c7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_2339bf74-2a20-4f1d-9335-fcf5051025f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_e29b7998-3b83-4e4d-a76a-f583f74ac6fd" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_2339bf74-2a20-4f1d-9335-fcf5051025f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0c35c71d-2000-4365-9f17-f22d12b7bae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_2339bf74-2a20-4f1d-9335-fcf5051025f4" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0c35c71d-2000-4365-9f17-f22d12b7bae9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b1f43085-a090-40fa-9870-fdc889d9e59c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_d1900779-c598-4317-8841-7a0a83bc9888" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b1f43085-a090-40fa-9870-fdc889d9e59c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_0b692753-1af9-4d19-8ba8-a23f07e48adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b1f43085-a090-40fa-9870-fdc889d9e59c" xlink:to="loc_us-gaap_HedgingDesignationAxis_0b692753-1af9-4d19-8ba8-a23f07e48adf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_0b692753-1af9-4d19-8ba8-a23f07e48adf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_0b692753-1af9-4d19-8ba8-a23f07e48adf" xlink:to="loc_us-gaap_HedgingDesignationDomain_0b692753-1af9-4d19-8ba8-a23f07e48adf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c9c3d021-e6f0-4f7d-81f8-3a36b7891bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_0b692753-1af9-4d19-8ba8-a23f07e48adf" xlink:to="loc_us-gaap_HedgingDesignationDomain_c9c3d021-e6f0-4f7d-81f8-3a36b7891bc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e71912cf-c868-4137-886a-a8c436d46a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_c9c3d021-e6f0-4f7d-81f8-3a36b7891bc7" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e71912cf-c868-4137-886a-a8c436d46a04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_87a09659-5059-44d8-8d82-28d63cbf31f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_c9c3d021-e6f0-4f7d-81f8-3a36b7891bc7" xlink:to="loc_us-gaap_NondesignatedMember_87a09659-5059-44d8-8d82-28d63cbf31f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_942c4d6a-4e6a-419e-9b1e-bdaf3bcf0ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b1f43085-a090-40fa-9870-fdc889d9e59c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_942c4d6a-4e6a-419e-9b1e-bdaf3bcf0ba7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_942c4d6a-4e6a-419e-9b1e-bdaf3bcf0ba7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_942c4d6a-4e6a-419e-9b1e-bdaf3bcf0ba7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_942c4d6a-4e6a-419e-9b1e-bdaf3bcf0ba7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0c3d836b-2e64-425c-816b-2d614bdfd036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_942c4d6a-4e6a-419e-9b1e-bdaf3bcf0ba7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0c3d836b-2e64-425c-816b-2d614bdfd036" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_042df90e-dfe8-41d9-9187-e13bea365916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0c3d836b-2e64-425c-816b-2d614bdfd036" xlink:to="loc_us-gaap_ForeignExchangeContractMember_042df90e-dfe8-41d9-9187-e13bea365916" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_8a085fbb-32f9-4591-938d-7875d44a6987" xlink:href="amgn-20220630.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0c3d836b-2e64-425c-816b-2d614bdfd036" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_8a085fbb-32f9-4591-938d-7875d44a6987" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_c912bc07-d2ad-4ea3-b5b7-8317dfd803ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0c3d836b-2e64-425c-816b-2d614bdfd036" xlink:to="loc_us-gaap_InterestRateSwapMember_c912bc07-d2ad-4ea3-b5b7-8317dfd803ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3f795c40-586e-43bf-a09f-38960cc6f88e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b1f43085-a090-40fa-9870-fdc889d9e59c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3f795c40-586e-43bf-a09f-38960cc6f88e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3f795c40-586e-43bf-a09f-38960cc6f88e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3f795c40-586e-43bf-a09f-38960cc6f88e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3f795c40-586e-43bf-a09f-38960cc6f88e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cba1f8cc-3c98-405f-b9fa-04f1662c6f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3f795c40-586e-43bf-a09f-38960cc6f88e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cba1f8cc-3c98-405f-b9fa-04f1662c6f60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherCurrentNoncurrentAssetsMember_00b74e5a-15a7-49ca-afc0-d5684d7f22ae" xlink:href="amgn-20220630.xsd#amgn_OtherCurrentNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cba1f8cc-3c98-405f-b9fa-04f1662c6f60" xlink:to="loc_amgn_OtherCurrentNoncurrentAssetsMember_00b74e5a-15a7-49ca-afc0-d5684d7f22ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_860fb23f-09cd-46c6-9836-2b8f2d12ccfb" xlink:href="amgn-20220630.xsd#amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cba1f8cc-3c98-405f-b9fa-04f1662c6f60" xlink:to="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_860fb23f-09cd-46c6-9836-2b8f2d12ccfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_5ec60b6e-d23d-4ec8-82a2-7b5fa50a86f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cba1f8cc-3c98-405f-b9fa-04f1662c6f60" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_5ec60b6e-d23d-4ec8-82a2-7b5fa50a86f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_4ae7b4fd-4400-4b88-bdc5-6c00ae272f71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cba1f8cc-3c98-405f-b9fa-04f1662c6f60" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_4ae7b4fd-4400-4b88-bdc5-6c00ae272f71" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#ContingenciesandcommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsDetails" xlink:type="extended" id="if6dfd5b25503406bba1c8f242aa6b2d4_ContingenciesandcommitmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LitigationSettlementDamagesSoughtValue_1422e469-2105-4b96-aa66-4cba2330b093" xlink:href="amgn-20220630.xsd#amgn_LitigationSettlementDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_amgn_LitigationSettlementDamagesSoughtValue_1422e469-2105-4b96-aa66-4cba2330b093" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_dd14df6c-7cd7-4736-a310-7c7ab323e29d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_dd14df6c-7cd7-4736-a310-7c7ab323e29d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_bc728abd-3f6e-4a2c-a8f9-3e7fdf479385" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_bc728abd-3f6e-4a2c-a8f9-3e7fdf479385" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfLawsuits_5a0831bf-e1b5-4a87-9a24-fb1c617ac61a" xlink:href="amgn-20220630.xsd#amgn_LossContingencyNumberOfLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_amgn_LossContingencyNumberOfLawsuits_5a0831bf-e1b5-4a87-9a24-fb1c617ac61a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_e6bde7a8-52c1-4fc2-99a4-23b03c3d42bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_e6bde7a8-52c1-4fc2-99a4-23b03c3d42bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyPatentsExpiredNumber_b39ea44c-2e21-4ea5-9b3a-8deb4e218cce" xlink:href="amgn-20220630.xsd#amgn_LossContingencyPatentsExpiredNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_amgn_LossContingencyPatentsExpiredNumber_b39ea44c-2e21-4ea5-9b3a-8deb4e218cce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyAppealPeriod_841eef43-699c-4bb4-b49f-6af1637e24d6" xlink:href="amgn-20220630.xsd#amgn_LossContingencyAppealPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_amgn_LossContingencyAppealPeriod_841eef43-699c-4bb4-b49f-6af1637e24d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfAssertedPatents_0d21bce5-3f9c-4f23-8afa-311a450c15c2" xlink:href="amgn-20220630.xsd#amgn_NumberOfAssertedPatents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_amgn_NumberOfAssertedPatents_0d21bce5-3f9c-4f23-8afa-311a450c15c2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_dc629fec-aba9-4a69-a915-cce2078f5c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_us-gaap_LitigationSettlementExpense_dc629fec-aba9-4a69-a915-cce2078f5c35" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_5fdf3a40-1ac2-4b8a-819a-94bbd2604627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_5fdf3a40-1ac2-4b8a-819a-94bbd2604627" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_d755984b-7969-418e-b4ed-1dc5d8b723ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsFoundInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_d755984b-7969-418e-b4ed-1dc5d8b723ef" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_a175a192-3138-4a52-bbd5-4df3f53519aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_a175a192-3138-4a52-bbd5-4df3f53519aa" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_b6229af3-e16f-436d-9dc3-9583ca845ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_b6229af3-e16f-436d-9dc3-9583ca845ff4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LitigationSettlementNumberOfPrimaryArguments_045a57aa-a1dc-4fc1-afbd-d848b78c6aa2" xlink:href="amgn-20220630.xsd#amgn_LitigationSettlementNumberOfPrimaryArguments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_amgn_LitigationSettlementNumberOfPrimaryArguments_045a57aa-a1dc-4fc1-afbd-d848b78c6aa2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_538a4d86-b2a3-4d94-b209-7326442e13d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_us-gaap_LossContingenciesTable_538a4d86-b2a3-4d94-b209-7326442e13d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5c8439d5-4601-4133-9472-528b83952dad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_538a4d86-b2a3-4d94-b209-7326442e13d4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5c8439d5-4601-4133-9472-528b83952dad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5c8439d5-4601-4133-9472-528b83952dad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5c8439d5-4601-4133-9472-528b83952dad" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5c8439d5-4601-4133-9472-528b83952dad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_729fdbf1-2de7-4d5f-911c-1dbb85d94933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5c8439d5-4601-4133-9472-528b83952dad" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_729fdbf1-2de7-4d5f-911c-1dbb85d94933" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b56aa714-9bc1-42f3-921b-74b7cdbb953a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_729fdbf1-2de7-4d5f-911c-1dbb85d94933" xlink:to="loc_us-gaap_SubsequentEventMember_b56aa714-9bc1-42f3-921b-74b7cdbb953a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d063f347-3271-48d0-bbf4-913819ce85ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_538a4d86-b2a3-4d94-b209-7326442e13d4" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d063f347-3271-48d0-bbf4-913819ce85ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_d063f347-3271-48d0-bbf4-913819ce85ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d063f347-3271-48d0-bbf4-913819ce85ba" xlink:to="loc_us-gaap_LossContingencyNatureDomain_d063f347-3271-48d0-bbf4-913819ce85ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_76b085c6-732b-47d4-9b06-1ff670da6b07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d063f347-3271-48d0-bbf4-913819ce85ba" xlink:to="loc_us-gaap_LossContingencyNatureDomain_76b085c6-732b-47d4-9b06-1ff670da6b07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PatentTrialAndAppealBoardPatentChallengesMember_a2d1ecb2-53b6-4a94-b224-c58bdc9ff6c6" xlink:href="amgn-20220630.xsd#amgn_PatentTrialAndAppealBoardPatentChallengesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_76b085c6-732b-47d4-9b06-1ff670da6b07" xlink:to="loc_amgn_PatentTrialAndAppealBoardPatentChallengesMember_a2d1ecb2-53b6-4a94-b224-c58bdc9ff6c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f6e9a78b-59b7-44ed-a481-1049e96a34be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_538a4d86-b2a3-4d94-b209-7326442e13d4" xlink:to="loc_srt_LitigationCaseAxis_f6e9a78b-59b7-44ed-a481-1049e96a34be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f6e9a78b-59b7-44ed-a481-1049e96a34be_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_f6e9a78b-59b7-44ed-a481-1049e96a34be" xlink:to="loc_srt_LitigationCaseTypeDomain_f6e9a78b-59b7-44ed-a481-1049e96a34be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4e2dc737-9193-4aa2-a1dc-ff51a710690d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_f6e9a78b-59b7-44ed-a481-1049e96a34be" xlink:to="loc_srt_LitigationCaseTypeDomain_4e2dc737-9193-4aa2-a1dc-ff51a710690d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HospiraMember_c3091b89-1263-498d-8b99-bc93177c1a10" xlink:href="amgn-20220630.xsd#amgn_HospiraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4e2dc737-9193-4aa2-a1dc-ff51a710690d" xlink:to="loc_amgn_HospiraMember_c3091b89-1263-498d-8b99-bc93177c1a10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KANJINTIPatentLitigationMember_ac108c63-812d-448d-9266-8751f0004307" xlink:href="amgn-20220630.xsd#amgn_KANJINTIPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4e2dc737-9193-4aa2-a1dc-ff51a710690d" xlink:to="loc_amgn_KANJINTIPatentLitigationMember_ac108c63-812d-448d-9266-8751f0004307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HumiraBiosimilarAntitrustClassActionsMember_1f50aee9-904b-4c69-8992-4a3daf82f5f0" xlink:href="amgn-20220630.xsd#amgn_HumiraBiosimilarAntitrustClassActionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4e2dc737-9193-4aa2-a1dc-ff51a710690d" xlink:to="loc_amgn_HumiraBiosimilarAntitrustClassActionsMember_1f50aee9-904b-4c69-8992-4a3daf82f5f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SensiparAntitrustClassActionsMember_31212459-dffa-4895-a417-4b6660114e18" xlink:href="amgn-20220630.xsd#amgn_SensiparAntitrustClassActionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4e2dc737-9193-4aa2-a1dc-ff51a710690d" xlink:to="loc_amgn_SensiparAntitrustClassActionsMember_31212459-dffa-4895-a417-4b6660114e18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyprolisMember_6c3ec859-b04f-4a50-bf1d-3027ca8c17f6" xlink:href="amgn-20220630.xsd#amgn_KyprolisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4e2dc737-9193-4aa2-a1dc-ff51a710690d" xlink:to="loc_amgn_KyprolisMember_6c3ec859-b04f-4a50-bf1d-3027ca8c17f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyprolisANDAPatentLitigationMember_af0a8590-9140-41dc-9400-9742ab46a543" xlink:href="amgn-20220630.xsd#amgn_KyprolisANDAPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4e2dc737-9193-4aa2-a1dc-ff51a710690d" xlink:to="loc_amgn_KyprolisANDAPatentLitigationMember_af0a8590-9140-41dc-9400-9742ab46a543" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NovartisPharmaAGMember_0bd22261-6fd4-4eb1-babb-4ee327112b7a" xlink:href="amgn-20220630.xsd#amgn_NovartisPharmaAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4e2dc737-9193-4aa2-a1dc-ff51a710690d" xlink:to="loc_amgn_NovartisPharmaAGMember_0bd22261-6fd4-4eb1-babb-4ee327112b7a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaANDAPatentLitigationMember_fdbd24dc-99b9-472a-a8e4-8040983d0a99" xlink:href="amgn-20220630.xsd#amgn_OtezlaANDAPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4e2dc737-9193-4aa2-a1dc-ff51a710690d" xlink:to="loc_amgn_OtezlaANDAPatentLitigationMember_fdbd24dc-99b9-472a-a8e4-8040983d0a99" xlink:type="arc" order="7"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>amgn-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5d27ca97-9729-4191-8773-bd1da607be75,g:d96be9d2-9e3e-485f-8641-d09afcb6a74b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_62c79f65-e4f2-45f7-a0e8-855238bf24a6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_829d4de9-99fc-4fff-bfc5-3bdeb2cbd4e9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09b2c750-673c-4067-a101-17c68fd1448c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f73c8a21-2e4d-4423-9953-831ac37d13bf_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in AOCI [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_6b91311f-e4a5-4fe4-9ce4-6f62c485b98f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_55e42c4e-96e9-427c-bf3b-b6ae26d6b298_terseLabel_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_label_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Other Adjustment, before Tax</link:label>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_documentation_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Other Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:href="amgn-20220630.xsd#amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:to="lab_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_GBP_fd925650-dfad-42c6-9d7b-6889f8cd7108_terseLabel_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:label id="lab_currency_GBP_label_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_GBP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP" xlink:to="lab_currency_GBP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_c5a4e886-84a2-4465-af21-180d01446e9e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c7637f49-700f-462d-8682-891295575d20_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_c0f62470-cd27-4353-aa51-0a98c2b63a0e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets, Current</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_d7c892e9-56ea-40b6-9ca2-7b976a92954f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LongTermDebtCurrentMaturitiesMember_5812cc5f-4242-4d33-8107-a0194dc0d825_terseLabel_en-US" xlink:label="lab_amgn_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt [Member]</link:label>
    <link:label id="lab_amgn_LongTermDebtCurrentMaturitiesMember_label_en-US" xlink:label="lab_amgn_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities [Member]</link:label>
    <link:label id="lab_amgn_LongTermDebtCurrentMaturitiesMember_documentation_en-US" xlink:label="lab_amgn_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtCurrentMaturitiesMember" xlink:href="amgn-20220630.xsd#amgn_LongTermDebtCurrentMaturitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LongTermDebtCurrentMaturitiesMember" xlink:to="lab_amgn_LongTermDebtCurrentMaturitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_9eca959a-8ecd-44c4-9750-df851baa1398_terseLabel_en-US" xlink:label="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% notes due 2050 (3.375% 2050 Notes) [Member]</link:label>
    <link:label id="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_label_en-US" xlink:label="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Seven Five Percent Notes Due 2050 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_documentation_en-US" xlink:label="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Three Seven Five Percent Notes Due 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:href="amgn-20220630.xsd#amgn_ThreePointThreeSevenFivePercentNotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:to="lab_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_fba9672c-d946-4c1d-a1e4-adae43ac56ed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_ab35e514-0f74-498a-89bc-01542d696c3e_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_9d12b229-fe34-4892-aa48-ba0cc3be2dc7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_8175a3cf-d799-439a-878d-242262a36679_terseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligation for acquisition</link:label>
    <link:label id="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_label_en-US" xlink:label="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions</link:label>
    <link:label id="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_documentation_en-US" xlink:label="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:href="amgn-20220630.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:to="lab_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_53b094c2-e06b-437a-a6ab-b15e0f4a5047_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_08c99d2a-ea4d-450c-85cb-6a90cdb3efd7_verboseLabel_en-US" xlink:label="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of both derivatives designated as hedging instruments and not designated as hedging instruments included in Condensed Consolidated Balance Sheets</link:label>
    <link:label id="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_label_en-US" xlink:label="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_documentation_en-US" xlink:label="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:href="amgn-20220630.xsd#amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:to="lab_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_623cea4f-2574-4601-ac29-63199abec66b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency contract [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_27f25fed-dbcc-4e06-943f-b627ebd7458f_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency contracts [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XNGS_308227ed-370a-4db9-8481-896d31edb1a5_terseLabel_en-US" xlink:label="lab_exch_XNGS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The NASDAQ Global Select Market [Member]</link:label>
    <link:label id="lab_exch_XNGS_label_en-US" xlink:label="lab_exch_XNGS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNGS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNGS" xlink:to="lab_exch_XNGS" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherGeneralExpenseIncomeOtherAdjustments_5878cef9-1f0a-40dc-95e2-019fdcafcd5e_terseLabel_en-US" xlink:label="lab_amgn_OtherGeneralExpenseIncomeOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_amgn_OtherGeneralExpenseIncomeOtherAdjustments_label_en-US" xlink:label="lab_amgn_OtherGeneralExpenseIncomeOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other General Expense (Income), Other Adjustments</link:label>
    <link:label id="lab_amgn_OtherGeneralExpenseIncomeOtherAdjustments_documentation_en-US" xlink:label="lab_amgn_OtherGeneralExpenseIncomeOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other General Expense (Income), Other Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherGeneralExpenseIncomeOtherAdjustments" xlink:href="amgn-20220630.xsd#amgn_OtherGeneralExpenseIncomeOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherGeneralExpenseIncomeOtherAdjustments" xlink:to="lab_amgn_OtherGeneralExpenseIncomeOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LitigationSettlementDamagesSoughtValue_e3f4d59d-fed6-45f4-b679-9fb85b4d4c47_terseLabel_en-US" xlink:label="lab_amgn_LitigationSettlementDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount awarded from settlement</link:label>
    <link:label id="lab_amgn_LitigationSettlementDamagesSoughtValue_label_en-US" xlink:label="lab_amgn_LitigationSettlementDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Damages Sought, Value</link:label>
    <link:label id="lab_amgn_LitigationSettlementDamagesSoughtValue_documentation_en-US" xlink:label="lab_amgn_LitigationSettlementDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LitigationSettlementDamagesSoughtValue" xlink:href="amgn-20220630.xsd#amgn_LitigationSettlementDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LitigationSettlementDamagesSoughtValue" xlink:to="lab_amgn_LitigationSettlementDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge_06a4ef5c-c0dc-4929-a40f-451efc3ff745_terseLabel_en-US" xlink:label="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value with discontinued hedging relationships</link:label>
    <link:label id="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge_label_en-US" xlink:label="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Discontinued Fair Value Hedge</link:label>
    <link:label id="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge_documentation_en-US" xlink:label="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Discontinued Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:href="amgn-20220630.xsd#amgn_HedgedLiabilityDiscontinuedFairValueHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:to="lab_amgn_HedgedLiabilityDiscontinuedFairValueHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b349a34-6682-4dc5-913e-3d6ae49e5ee4_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LitigationSettlementNumberOfPrimaryArguments_6576d2ee-a2fb-40e7-b566-7206ed2273e2_terseLabel_en-US" xlink:label="lab_amgn_LitigationSettlementNumberOfPrimaryArguments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Number Of Primary Arguments</link:label>
    <link:label id="lab_amgn_LitigationSettlementNumberOfPrimaryArguments_label_en-US" xlink:label="lab_amgn_LitigationSettlementNumberOfPrimaryArguments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Number Of Primary Arguments</link:label>
    <link:label id="lab_amgn_LitigationSettlementNumberOfPrimaryArguments_documentation_en-US" xlink:label="lab_amgn_LitigationSettlementNumberOfPrimaryArguments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Number Of Primary Arguments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LitigationSettlementNumberOfPrimaryArguments" xlink:href="amgn-20220630.xsd#amgn_LitigationSettlementNumberOfPrimaryArguments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LitigationSettlementNumberOfPrimaryArguments" xlink:to="lab_amgn_LitigationSettlementNumberOfPrimaryArguments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_96e41a10-f1ae-4ea0-8949-1e1a538238b3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ef4034b8-96d5-4a59-8892-5fcbd92de040_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_7d090c56-7505-49c2-aaa6-097a7cfaf33d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_26faccc7-957b-4214-b0ff-d6c6a01ba7a2_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9b2203b2-b250-435c-9c1c-d31bef551024_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3dd0ec27-4123-4d1d-b563-f1d4770b4b74_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_06c39861-e436-472c-9f51-cdb20f6799cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_78fadca2-99c7-4c67-9c01-bdec932ba654_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets [Member]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsGross_3baa2be5-f656-4f82-b587-26bb9e1f6e5b_terseLabel_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying amount</link:label>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsGross_label_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable Intangible Assets Gross</link:label>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsGross_documentation_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsGross" xlink:href="amgn-20220630.xsd#amgn_IdentifiableIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_IdentifiableIntangibleAssetsGross" xlink:to="lab_amgn_IdentifiableIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_df02c48c-6cc6-4f9f-9485-0305824feb5b_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_01177fb1-1943-4f28-b5e5-4974317c7f02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_5edd2aa3-fa4c-4eee-b96d-1324c5c441a7_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointSixFivePercentNotesDue2042Member_a9ff8859-8d79-4f7c-8e3b-19af82976b22_terseLabel_en-US" xlink:label="lab_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.65% notes due 2042 (5.65% 2042 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FivePointSixFivePercentNotesDue2042Member_label_en-US" xlink:label="lab_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Six Five Percent Notes Due 2042 [Member]</link:label>
    <link:label id="lab_amgn_FivePointSixFivePercentNotesDue2042Member_documentation_en-US" xlink:label="lab_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Six Five Percent Notes Due 2042 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:href="amgn-20220630.xsd#amgn_FivePointSixFivePercentNotesDue2042Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:to="lab_amgn_FivePointSixFivePercentNotesDue2042Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_e9cfbb94-a3b7-412b-afd3-629ac57cc426_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_994e60ad-774e-4b83-8150-09a007ae38af_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency and cross-currency swap contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointNineFivePercentNotesDue2041Member_404f256c-0a1f-4bbd-96d3-1a09c58cbf19_terseLabel_en-US" xlink:label="lab_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% notes due 2041 (4.95% 2041 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FourPointNineFivePercentNotesDue2041Member_label_en-US" xlink:label="lab_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Nine Five Percent Notes Due 2041 [Member]</link:label>
    <link:label id="lab_amgn_FourPointNineFivePercentNotesDue2041Member_documentation_en-US" xlink:label="lab_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Nine Five Percent Notes Due 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:href="amgn-20220630.xsd#amgn_FourPointNineFivePercentNotesDue2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:to="lab_amgn_FourPointNineFivePercentNotesDue2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_2ac52dab-bb8f-4567-9598-57e91c59a624_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_93e73511-f31c-4911-be4e-7c6dfe559bb4_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2f455a86-f2e1-4ab4-ba91-643bd3eeba2c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income for basic and diluted EPS</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4544c29b-c61b-4c46-9f90-df424beae339_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointFourFivePercentNotesDue2020Member_15cc0b81-f05c-4c14-8778-1d132dffae83_terseLabel_en-US" xlink:label="lab_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.45% notes due 2020 (3.45% 2020 Notes) [Member]</link:label>
    <link:label id="lab_amgn_ThreePointFourFivePercentNotesDue2020Member_label_en-US" xlink:label="lab_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Four Five Percent Notes Due 2020 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointFourFivePercentNotesDue2020Member_documentation_en-US" xlink:label="lab_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Four Five Percent Notes Due 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:href="amgn-20220630.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:to="lab_amgn_ThreePointFourFivePercentNotesDue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_a4dac2eb-ced8-45c8-81b2-e65e207e8767_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_5f5c53d5-6955-49f5-8223-eb90fdd5850f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_20eac149-d78d-47fd-a44b-7927e742b30c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e5e22ea5-eeb3-402e-8654-b76ac9ee49c9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_848b636b-12c4-4f19-ba3b-e72b88eb3ef1_terseLabel_en-US" xlink:label="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% &#163;475 million notes due 2026 (5.50% 2026 pound sterling Notes) [Member]</link:label>
    <link:label id="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_9269eaca-086c-48ed-8eed-f251fccebc02_verboseLabel_en-US" xlink:label="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% 2026 pound sterling Notes [Member]</link:label>
    <link:label id="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_label_en-US" xlink:label="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]</link:label>
    <link:label id="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_documentation_en-US" xlink:label="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:href="amgn-20220630.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:to="lab_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SixPointNineZeroPercentNotesDue2038Member_2426e282-28d3-4c05-b096-ae5373d3b2df_terseLabel_en-US" xlink:label="lab_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.90% notes due 2038 (6.90% 2038 Notes) [Member]</link:label>
    <link:label id="lab_amgn_SixPointNineZeroPercentNotesDue2038Member_label_en-US" xlink:label="lab_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Nine Zero Percent Notes Due 2038 [Member]</link:label>
    <link:label id="lab_amgn_SixPointNineZeroPercentNotesDue2038Member_documentation_en-US" xlink:label="lab_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Nine Zero Percent Notes Due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:href="amgn-20220630.xsd#amgn_SixPointNineZeroPercentNotesDue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:to="lab_amgn_SixPointNineZeroPercentNotesDue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_401ac485-28af-4aea-bf65-1e4f86e70519_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_71277ac4-e371-44bb-9f66-c648792de16c_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_0e126c51-80a2-4b2a-845f-9a9c422c22ec_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_0a8682cf-6a68-4cc0-ab7b-f315d2b6b365_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b8081f7b-c622-4b60-ae63-d07ef094595f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in unrecognized tax benefits resulting from tax positions taken during the current period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_XgevaMember_8b63a38e-7d7b-4a09-aa6a-278992ab54df_terseLabel_en-US" xlink:label="lab_amgn_XgevaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XGEVA&#174; (denosumab) [Member]</link:label>
    <link:label id="lab_amgn_XgevaMember_label_en-US" xlink:label="lab_amgn_XgevaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XGEVA [Member]</link:label>
    <link:label id="lab_amgn_XgevaMember_documentation_en-US" xlink:label="lab_amgn_XgevaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XGEVA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_XgevaMember" xlink:href="amgn-20220630.xsd#amgn_XgevaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_XgevaMember" xlink:to="lab_amgn_XgevaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ee3013ce-2098-4e94-a531-fc19ab9beb12_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d570e981-48b8-4876-9143-dcd1c331e5b7_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest-bearing securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a83b339c-6424-4cf8-bf2c-266815b81d4d_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-bearing securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_dd1f62f2-b0c0-4e2d-8ecf-eef66694ecb4_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_9f59512c-dce7-4716-a992-6bf1748d97a1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_GensentaIlacSanayiVsTicaretMember_7624042f-9ae1-4c70-a461-f17de070b17c_terseLabel_en-US" xlink:label="lab_amgn_GensentaIlacSanayiVsTicaretMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gensenta Ilac Sanayi vs Ticaret</link:label>
    <link:label id="lab_amgn_GensentaIlacSanayiVsTicaretMember_label_en-US" xlink:label="lab_amgn_GensentaIlacSanayiVsTicaretMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gensenta Ilac Sanayi vs Ticaret [Member]</link:label>
    <link:label id="lab_amgn_GensentaIlacSanayiVsTicaretMember_documentation_en-US" xlink:label="lab_amgn_GensentaIlacSanayiVsTicaretMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gensenta Ilac Sanayi vs Ticaret</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GensentaIlacSanayiVsTicaretMember" xlink:href="amgn-20220630.xsd#amgn_GensentaIlacSanayiVsTicaretMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_GensentaIlacSanayiVsTicaretMember" xlink:to="lab_amgn_GensentaIlacSanayiVsTicaretMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_42d63e18-0b85-4853-85ba-72966fa184a4_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_79c999fb-0d9c-41c7-bc07-41ab70f16f22_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_73b62e18-3ef6-4ca3-869b-3275faf8e811_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_216a2da7-cb2a-4a6f-97ac-5b36b951a56d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0276dd72-4c0b-4bf6-bba2-e957bda65dfd_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted prices in active markets for identical assets (Level 1) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_4cd58695-c742-4125-9872-28c8a8d0789f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Fair Value Hedge Liability at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue" xlink:to="lab_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock_e980799b-ae17-43bb-a58c-ccf9943c0bc3_terseLabel_en-US" xlink:label="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of long-term instruments exchanged</link:label>
    <link:label id="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock_label_en-US" xlink:label="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments Exchanged [Table Text Block]</link:label>
    <link:label id="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock_documentation_en-US" xlink:label="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments Exchanged [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:href="amgn-20220630.xsd#amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:to="lab_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RepatriationTaxOnProposedAdditionalTax20132015_411d0be1-5cee-4656-8ac8-2448fa781d20_terseLabel_en-US" xlink:label="lab_amgn_RepatriationTaxOnProposedAdditionalTax20132015" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation tax on proposed additional tax 2013-2015</link:label>
    <link:label id="lab_amgn_RepatriationTaxOnProposedAdditionalTax20132015_label_en-US" xlink:label="lab_amgn_RepatriationTaxOnProposedAdditionalTax20132015" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation tax on proposed additional tax 2013-2015</link:label>
    <link:label id="lab_amgn_RepatriationTaxOnProposedAdditionalTax20132015_documentation_en-US" xlink:label="lab_amgn_RepatriationTaxOnProposedAdditionalTax20132015" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation tax on proposed additional tax 2013-2015</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepatriationTaxOnProposedAdditionalTax20132015" xlink:href="amgn-20220630.xsd#amgn_RepatriationTaxOnProposedAdditionalTax20132015"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RepatriationTaxOnProposedAdditionalTax20132015" xlink:to="lab_amgn_RepatriationTaxOnProposedAdditionalTax20132015" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_35b824ab-3421-4c10-88e9-fe519aa1ebc8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding&#8212;534.9 shares in 2022 and 558.3 shares in 2021</link:label>
    <link:label id="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stocks, Including Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:to="lab_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_26a7bc0b-9f40-4a95-9f0b-97c7ba1365f1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_be5bf699-969b-4b3a-a51f-a64fb9f8f65f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_09b0daa7-679a-4154-8e41-0a441661deec_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_945cda51-78b6-4230-9cb2-9d4b9a223157_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CrossCurrencySwapContractsMember_cc5f3218-1bfe-402d-ad43-8dd364204a92_netLabel_en-US" xlink:label="lab_amgn_CrossCurrencySwapContractsMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swap contract [Member]</link:label>
    <link:label id="lab_amgn_CrossCurrencySwapContractsMember_eaaa1d46-c5a0-4d0b-8616-a352c6c35a95_terseLabel_en-US" xlink:label="lab_amgn_CrossCurrencySwapContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swap contracts [Member]</link:label>
    <link:label id="lab_amgn_CrossCurrencySwapContractsMember_27204c25-90b5-4099-8045-aafb2e6018e8_verboseLabel_en-US" xlink:label="lab_amgn_CrossCurrencySwapContractsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swap contracts [Member]</link:label>
    <link:label id="lab_amgn_CrossCurrencySwapContractsMember_label_en-US" xlink:label="lab_amgn_CrossCurrencySwapContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Swap Contracts [Member]</link:label>
    <link:label id="lab_amgn_CrossCurrencySwapContractsMember_documentation_en-US" xlink:label="lab_amgn_CrossCurrencySwapContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross currency swap contracts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember" xlink:href="amgn-20220630.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CrossCurrencySwapContractsMember" xlink:to="lab_amgn_CrossCurrencySwapContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_11f72c65-ec00-4bf9-bcc7-0f07b9082f19_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_b8d1bcf9-8c00-464b-b473-cd62ac549c52_terseLabel_en-US" xlink:label="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.70% notes due 2022 (2.70% 2022 Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_label_en-US" xlink:label="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Seven Zero Percent Notes Due Two Zero Two Two [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_documentation_en-US" xlink:label="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Seven Zero Percent Notes Due Two Zero Two Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" xlink:href="amgn-20220630.xsd#amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" xlink:to="lab_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_0468196c-159c-486f-bbf5-0455c319b52d_terseLabel_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_label_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_documentation_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member" xlink:href="amgn-20220630.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A2.00SeniorNotesDue2026Member" xlink:to="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_d8c15581-adbb-484b-a890-65e630e6948e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsExchangeAxis_dd61d986-acca-4802-bbfb-971a75044406_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_dc674d56-45ff-4e99-b41a-de4930caedad_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_7ff9a350-ccc6-4f5a-8862-b69fde54953f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_8479c21e-de2d-4da6-9b88-85d1c7cfc2c6_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_0f8a50a8-5d80-4faa-8a32-6b5ab52ff47a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_35f51e0e-3dc8-46a2-ae62-323d4aec08c0_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_cf1cc2a6-31fe-4454-b1cd-4c891c5aaf1c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired, cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_0a3c490f-aaa8-4d15-a2eb-777edd9e1223_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications out of accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A4202052NotesMember_00d6e8b7-bad7-4aa7-809b-3863754c248d_terseLabel_en-US" xlink:label="lab_amgn_A4202052NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.20% 2052 Notes [Member]</link:label>
    <link:label id="lab_amgn_A4202052NotesMember_label_en-US" xlink:label="lab_amgn_A4202052NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.20% 2052 Notes [Member]</link:label>
    <link:label id="lab_amgn_A4202052NotesMember_documentation_en-US" xlink:label="lab_amgn_A4202052NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.20% 2052 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A4202052NotesMember" xlink:href="amgn-20220630.xsd#amgn_A4202052NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A4202052NotesMember" xlink:to="lab_amgn_A4202052NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_71ccd0a1-bf68-4077-a34f-2fe1bbed9904_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66496c5e-08d4-40a1-a975-e9aa9a814693_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointZeroPercent2032NotesMemberMember_aa2e0f1e-3bc0-4280-a9c6-78f9d6561e73_terseLabel_en-US" xlink:label="lab_amgn_TwoPointZeroPercent2032NotesMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% notes due 2032 (2.00% 2032 Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointZeroPercent2032NotesMemberMember_label_en-US" xlink:label="lab_amgn_TwoPointZeroPercent2032NotesMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two point zero percent 2032 Notes Member [Member]</link:label>
    <link:label id="lab_amgn_TwoPointZeroPercent2032NotesMemberMember_documentation_en-US" xlink:label="lab_amgn_TwoPointZeroPercent2032NotesMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two point zero percent 2032 Notes Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointZeroPercent2032NotesMemberMember" xlink:href="amgn-20220630.xsd#amgn_TwoPointZeroPercent2032NotesMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointZeroPercent2032NotesMemberMember" xlink:to="lab_amgn_TwoPointZeroPercent2032NotesMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RepathaevolocumabMember_30201305-9049-4f79-8410-4f799251a8b9_terseLabel_en-US" xlink:label="lab_amgn_RepathaevolocumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatha (evolocumab) [Member]</link:label>
    <link:label id="lab_amgn_RepathaevolocumabMember_label_en-US" xlink:label="lab_amgn_RepathaevolocumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatha (evolocumab) [Member]</link:label>
    <link:label id="lab_amgn_RepathaevolocumabMember_documentation_en-US" xlink:label="lab_amgn_RepathaevolocumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatha (evolocumab) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepathaevolocumabMember" xlink:href="amgn-20220630.xsd#amgn_RepathaevolocumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RepathaevolocumabMember" xlink:to="lab_amgn_RepathaevolocumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2caeacae-99e4-42a5-9ae2-114fcc691494_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_2cd7225c-1a42-4ea8-a57a-e5e497dde0e3_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c2ae8a4c-964d-48c8-9075-689707e466fd_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock_06aee823-d407-4724-a91a-4e1fd20297e8_terseLabel_en-US" xlink:label="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of notional amounts and interest rates for cross-currency swaps</link:label>
    <link:label id="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock_label_en-US" xlink:label="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps [Table Text Block]</link:label>
    <link:label id="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock_documentation_en-US" xlink:label="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:href="amgn-20220630.xsd#amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:to="lab_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member_824ed087-a689-4f58-89d3-874d63d26932_terseLabel_en-US" xlink:label="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.30% notes due 2031 (2.30% 2031 Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member_label_en-US" xlink:label="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Three Zero Percent Notes Due 2031 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member_documentation_en-US" xlink:label="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Three Zero Percent Notes Due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:href="amgn-20220630.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:to="lab_amgn_TwoPointThreeZeroPercentNotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_5fe791a9-d9b6-4f78-8136-90f23e1cf5ae_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_26be2e93-bb38-48c9-8be8-548c6b0b8d53_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f20f75b2-ccd5-4052-b862-7799c145721d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_d619686e-243f-42d3-9cb1-8fdfe9d80c07_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing arrangements</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_48152277-1123-4ee2-9518-244b0fb9a72f_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_2e85f974-eede-4d1f-ab9d-b43c64cb0619_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LossContingencyPatentsExpiredNumber_de51655c-34e5-40b7-aa76-9bf85b1c5d34_terseLabel_en-US" xlink:label="lab_amgn_LossContingencyPatentsExpiredNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of asserted patents expired</link:label>
    <link:label id="lab_amgn_LossContingencyPatentsExpiredNumber_label_en-US" xlink:label="lab_amgn_LossContingencyPatentsExpiredNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Expired, Number</link:label>
    <link:label id="lab_amgn_LossContingencyPatentsExpiredNumber_documentation_en-US" xlink:label="lab_amgn_LossContingencyPatentsExpiredNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Expired, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyPatentsExpiredNumber" xlink:href="amgn-20220630.xsd#amgn_LossContingencyPatentsExpiredNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LossContingencyPatentsExpiredNumber" xlink:to="lab_amgn_LossContingencyPatentsExpiredNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketingRelatedIntangibleAssetsMember_110bcaa9-13b3-4928-8929-95fbe82f9456_terseLabel_en-US" xlink:label="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing-Related Rights [Member]</link:label>
    <link:label id="lab_us-gaap_MarketingRelatedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing-Related Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:to="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_20f9b8e5-31db-4710-ba80-8d45ba78f0f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue_349b532f-e64f-4ee1-8482-092d135d40ee_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments,Quoted Market Price</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Quoted Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:to="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_a318f19c-ca56-4714-ab9d-92f36a378a48_verboseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed-Product-Technology Rights [Member]</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_e1c16f8f-a3a3-49b3-a691-643f7c6c42f2_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_StockRepurchaseProgramTableTextBlock_3cd6ca30-6b8f-4468-97c5-df1aae7151dc_terseLabel_en-US" xlink:label="lab_amgn_StockRepurchaseProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of activity under our stock repurchase program</link:label>
    <link:label id="lab_amgn_StockRepurchaseProgramTableTextBlock_label_en-US" xlink:label="lab_amgn_StockRepurchaseProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program [Table Text Block]</link:label>
    <link:label id="lab_amgn_StockRepurchaseProgramTableTextBlock_documentation_en-US" xlink:label="lab_amgn_StockRepurchaseProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_StockRepurchaseProgramTableTextBlock" xlink:href="amgn-20220630.xsd#amgn_StockRepurchaseProgramTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_StockRepurchaseProgramTableTextBlock" xlink:to="lab_amgn_StockRepurchaseProgramTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_a0655fed-f707-47b4-a74e-c0db2eff8343_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CorporateDebtSecuritiesIndustrialMember_3da6b38d-ba66-4211-a42e-009bbca62bd1_terseLabel_en-US" xlink:label="lab_amgn_CorporateDebtSecuritiesIndustrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities - Industrial [Member]</link:label>
    <link:label id="lab_amgn_CorporateDebtSecuritiesIndustrialMember_label_en-US" xlink:label="lab_amgn_CorporateDebtSecuritiesIndustrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Industrial [Member]</link:label>
    <link:label id="lab_amgn_CorporateDebtSecuritiesIndustrialMember_documentation_en-US" xlink:label="lab_amgn_CorporateDebtSecuritiesIndustrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities industrial Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesIndustrialMember" xlink:href="amgn-20220630.xsd#amgn_CorporateDebtSecuritiesIndustrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CorporateDebtSecuritiesIndustrialMember" xlink:to="lab_amgn_CorporateDebtSecuritiesIndustrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_aeba05ba-36b3-4956-ab6f-03ffc94b6cc5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_f510ba56-36d7-44c4-89a7-2692b50b3207_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AcceleratedStockRepurchaseAgreementMember_09175407-c693-4cd4-9d9a-49fed88f39ed_terseLabel_en-US" xlink:label="lab_amgn_AcceleratedStockRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated stock repurchase agreement</link:label>
    <link:label id="lab_amgn_AcceleratedStockRepurchaseAgreementMember_label_en-US" xlink:label="lab_amgn_AcceleratedStockRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated stock repurchase agreement [Member]</link:label>
    <link:label id="lab_amgn_AcceleratedStockRepurchaseAgreementMember_documentation_en-US" xlink:label="lab_amgn_AcceleratedStockRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated stock repurchase agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcceleratedStockRepurchaseAgreementMember" xlink:href="amgn-20220630.xsd#amgn_AcceleratedStockRepurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AcceleratedStockRepurchaseAgreementMember" xlink:to="lab_amgn_AcceleratedStockRepurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_2d41b654-0bb9-4d07-85c9-3c1f8c208fb4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AvailableForSalesInvestmentsMember_335f861b-4a8b-4fe6-9641-629cb3844aa4_verboseLabel_en-US" xlink:label="lab_amgn_AvailableForSalesInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale investments [Member]</link:label>
    <link:label id="lab_amgn_AvailableForSalesInvestmentsMember_label_en-US" xlink:label="lab_amgn_AvailableForSalesInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sales Investments [Member]</link:label>
    <link:label id="lab_amgn_AvailableForSalesInvestmentsMember_documentation_en-US" xlink:label="lab_amgn_AvailableForSalesInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sales investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSalesInvestmentsMember" xlink:href="amgn-20220630.xsd#amgn_AvailableForSalesInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AvailableForSalesInvestmentsMember" xlink:to="lab_amgn_AvailableForSalesInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability_62717284-9657-4fff-92ef-b3899b4e418f_terseLabel_en-US" xlink:label="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term tax liabilities</link:label>
    <link:label id="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability_label_en-US" xlink:label="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Noncurrent Tax Liability</link:label>
    <link:label id="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability_documentation_en-US" xlink:label="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Noncurrent Tax Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:href="amgn-20220630.xsd#amgn_IncreaseDecreaseInNoncurrentTaxLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:to="lab_amgn_IncreaseDecreaseInNoncurrentTaxLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_5d89f001-813c-439e-a605-8b2952eaedde_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2f2c4033-3ffc-4278-a36e-3343bda13223_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_9dbb4a3f-21d2-4fe4-af92-4b32f01f61bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ae69cad5-e40f-4b29-b84c-692b9e4b13cb_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_adc23cab-e229-4ad2-971b-5e22a8912ecc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_4f6b87f3-3b30-4e29-b54d-dbe06dffdb73_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_e697042c-b075-45ba-92f1-ecc75ebdebc2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_7c7a9e45-cf5e-4871-8c9d-d5e6e214ab54_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount received from settlement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_43036080-45d4-4918-802c-6b8366486102_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NatureOfOperationsPolicyTextBlock_0d464062-0c85-4a38-8c3d-08cbe0739ae9_verboseLabel_en-US" xlink:label="lab_amgn_NatureOfOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business</link:label>
    <link:label id="lab_amgn_NatureOfOperationsPolicyTextBlock_label_en-US" xlink:label="lab_amgn_NatureOfOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature Of Operations [Policy Text Block]</link:label>
    <link:label id="lab_amgn_NatureOfOperationsPolicyTextBlock_documentation_en-US" xlink:label="lab_amgn_NatureOfOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Describes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as "predominately", "about equally", or "major and other". This element is also referred to as "Business Description".</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NatureOfOperationsPolicyTextBlock" xlink:href="amgn-20220630.xsd#amgn_NatureOfOperationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NatureOfOperationsPolicyTextBlock" xlink:to="lab_amgn_NatureOfOperationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DebtExchangeAdditionalCashConsideration_5619a632-7fc0-4569-b812-08d19898a822_terseLabel_en-US" xlink:label="lab_amgn_DebtExchangeAdditionalCashConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">debt exchange additional cash consideration</link:label>
    <link:label id="lab_amgn_DebtExchangeAdditionalCashConsideration_label_en-US" xlink:label="lab_amgn_DebtExchangeAdditionalCashConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt exchange additional cash consideration</link:label>
    <link:label id="lab_amgn_DebtExchangeAdditionalCashConsideration_documentation_en-US" xlink:label="lab_amgn_DebtExchangeAdditionalCashConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt exchange additional cash consideration paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtExchangeAdditionalCashConsideration" xlink:href="amgn-20220630.xsd#amgn_DebtExchangeAdditionalCashConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DebtExchangeAdditionalCashConsideration" xlink:to="lab_amgn_DebtExchangeAdditionalCashConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_25dc6306-b4c6-4149-a766-e92f1626d867_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_fb7f459c-48cc-421d-a864-0e14a0752857_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts [Member]</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_20f86d03-3d24-49f8-aae2-2b1be9ca34d5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_86bda653-fab0-4e60-811e-fb0170d22169_netLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap agreements [Member]</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ed223b87-942a-4bdc-bfc8-a642f7b6a873_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_7b2ed9ee-1151-49ad-81e9-3177e24652eb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_d5969d9d-9f00-413e-8494-fd15e654949c_terseLabel_en-US" xlink:label="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% notes due 2021 (3.875% 2021 Notes) [Member]</link:label>
    <link:label id="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_label_en-US" xlink:label="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Eight Seven Five Percent Notes Due 2021 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_documentation_en-US" xlink:label="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Eight Seven Five Percent Notes Due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:href="amgn-20220630.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:to="lab_amgn_ThreePointEightSevenFivePercentNotesDue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_5d674a0c-46eb-43a8-957d-67a32f82a15d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_ae193864-ee39-412d-a65a-09be6071a7ef_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_b6f32e46-06a6-44d4-bed8-70848e473459_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2586be8b-aedc-407b-b3ad-fd896df67a62_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_f3cc7f9e-de0c-4b45-9ede-1f18fd87b9a2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d61ff5e9-7996-4e16-83c4-418c888ec7c6_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, additional authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_14825fe2-85e9-4dc4-b921-3fcbbd0605b3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_42af5a90-38eb-4fcd-a9af-99a20e776b58_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other mortgage- and asset-backed securities [Member]</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_89e0d403-34bf-4484-8097-362363210e69_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_4d4f66df-9931-4f43-a6aa-454604ffc675_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives in fair value hedging relationships</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_3026ba8a-7a69-467a-a1d8-e19ed3a64eee_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_d77f0935-199d-42d5-a947-e30b2c28d2fd_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_f455e5b9-8b5c-4e14-9b5c-9ebb3b60016b_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForwardContractsMember_4af59d8a-b42d-41ed-b6b2-498e047962a2_terseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts [Member]</link:label>
    <link:label id="lab_us-gaap_ForwardContractsMember_label_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractsMember" xlink:to="lab_us-gaap_ForwardContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CorporateDebtSecuritiesOtherMember_67b8826e-2253-482d-9a88-3bf1dd610f6b_terseLabel_en-US" xlink:label="lab_amgn_CorporateDebtSecuritiesOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities - Other [Member]</link:label>
    <link:label id="lab_amgn_CorporateDebtSecuritiesOtherMember_label_en-US" xlink:label="lab_amgn_CorporateDebtSecuritiesOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Other [Member]</link:label>
    <link:label id="lab_amgn_CorporateDebtSecuritiesOtherMember_documentation_en-US" xlink:label="lab_amgn_CorporateDebtSecuritiesOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesOtherMember" xlink:href="amgn-20220630.xsd#amgn_CorporateDebtSecuritiesOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CorporateDebtSecuritiesOtherMember" xlink:to="lab_amgn_CorporateDebtSecuritiesOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_7eb63ae9-e428-4e6a-beba-0385ad4fb37b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:to="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember_4ddf1535-bede-4d4a-8833-f78ed8515100_terseLabel_en-US" xlink:label="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humira Biosimilar Antitrust Class Actions [Member]</link:label>
    <link:label id="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember_label_en-US" xlink:label="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humira Biosimilar Antitrust Class Actions [Member]</link:label>
    <link:label id="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember_documentation_en-US" xlink:label="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humira Biosimilar Antitrust Class Actions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HumiraBiosimilarAntitrustClassActionsMember" xlink:href="amgn-20220630.xsd#amgn_HumiraBiosimilarAntitrustClassActionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_HumiraBiosimilarAntitrustClassActionsMember" xlink:to="lab_amgn_HumiraBiosimilarAntitrustClassActionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_fcd17606-bc5f-4be6-92e8-d167985532f8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of derivatives included in the Condensed Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember_9cf6d5ed-5c15-4367-aec0-974e5e475247_terseLabel_en-US" xlink:label="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential mortgage-backed securities [Member]</link:label>
    <link:label id="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential Mortgage-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_1022d374-e1cf-4e8f-a7f3-e2247834a69d_terseLabel_en-US" xlink:label="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.40% notes due 2045 (4.40% 2045 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_label_en-US" xlink:label="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]</link:label>
    <link:label id="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_documentation_en-US" xlink:label="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:href="amgn-20220630.xsd#amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:to="lab_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_81a4848b-b6f2-4c25-8de2-391c6de6dbb8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of amounts of income and expense line items</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_f9616aa6-5f1d-487b-8376-39caaf353ea6_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_b430c7f7-e5e8-4231-9713-c432965c82b2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TeneobioMember_44645a69-d409-4e9c-80d6-2a1093cda43d_terseLabel_en-US" xlink:label="lab_amgn_TeneobioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teneobio</link:label>
    <link:label id="lab_amgn_TeneobioMember_label_en-US" xlink:label="lab_amgn_TeneobioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teneobio [Member]</link:label>
    <link:label id="lab_amgn_TeneobioMember_documentation_en-US" xlink:label="lab_amgn_TeneobioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teneobio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioMember" xlink:href="amgn-20220630.xsd#amgn_TeneobioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TeneobioMember" xlink:to="lab_amgn_TeneobioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8d1e0dcf-2ebd-415c-96da-561921fb1161_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount_9c4c02f1-d5bf-4823-8b3e-24d83a51d335_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Company, Financial Support to Investee Contractually Required, Amount</link:label>
    <link:label id="lab_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount_label_en-US" xlink:label="lab_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Company, Financial Support to Investee Contractually Required, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount" xlink:to="lab_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_19be618e-c68f-4cdc-8d19-654ee52b2660_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_ed315622-13dd-4e34-b231-abb1850f87a9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember_010c4d2c-a847-44a7-b4bd-56dbd907b93f_terseLabel_en-US" xlink:label="lab_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.90% notes due 2025 (1.90% 2025 Notes) [Member]</link:label>
    <link:label id="lab_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember_label_en-US" xlink:label="lab_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Nine Zero Percent Notes Due Two Zero Two Five [Member]</link:label>
    <link:label id="lab_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember_documentation_en-US" xlink:label="lab_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Nine Zero Percent Notes Due Two Zero Two Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember" xlink:href="amgn-20220630.xsd#amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember" xlink:to="lab_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8093856b-7dbf-4a30-93f5-0a44741f36c3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_c4ee0c8c-6c92-44d3-9c4e-b67c5562164e_totalLabel_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired, net</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_label_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Assets acquired and Liabilities assumed, net</link:label>
    <link:label id="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_documentation_en-US" xlink:label="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquired asset acquisition, Assets acquired and Liabilities assumed, net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:href="amgn-20220630.xsd#amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:to="lab_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_8daedc69-01c4-4bdd-b83c-5346640979c2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash&#160;flow hedges [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount_768d5f59-bd78-4110-85da-63fa98b3ac4a_terseLabel_en-US" xlink:label="lab_amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Period without Payment of Make Whole Amount</link:label>
    <link:label id="lab_amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount_label_en-US" xlink:label="lab_amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Period without Payment of Make Whole Amount</link:label>
    <link:label id="lab_amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount_documentation_en-US" xlink:label="lab_amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Period without Payment of Make Whole Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount" xlink:href="amgn-20220630.xsd#amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount" xlink:to="lab_amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_7cc5ad29-dbab-4ee3-a912-dc55a4a504c5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_f78a1c84-5bb3-4dc1-b84a-3c3d343e0251_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_7f0472f2-5514-4cb2-aa54-e1c2fa7ae02c_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_360c903f-e576-44d1-9855-4bd05e4637f3_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValue_c35c24dc-2437-4a4c-9735-24520b737805_terseLabel_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, change in carrying value</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValue_label_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, change in carrying value</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentChangeInCarryingValue_documentation_en-US" xlink:label="lab_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, change in carrying value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:href="amgn-20220630.xsd#amgn_EquityMethodInvestmentChangeInCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:to="lab_amgn_EquityMethodInvestmentChangeInCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointOneZeroPercentNotesDue2021Member_25d39625-5dae-4659-a4ef-292c3257ed15_terseLabel_en-US" xlink:label="lab_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.10% notes due 2021 (4.10% 2021 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FourPointOneZeroPercentNotesDue2021Member_label_en-US" xlink:label="lab_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point One Zero Percent Notes Due 2021 [Member]</link:label>
    <link:label id="lab_amgn_FourPointOneZeroPercentNotesDue2021Member_documentation_en-US" xlink:label="lab_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point One Zero Percent Notes Due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:href="amgn-20220630.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:to="lab_amgn_FourPointOneZeroPercentNotesDue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_3f3e178c-468f-47d5-b000-f7765839fa6b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0e85fd7f-0c41-44d6-94c9-25a280700a86_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2ed2ac36-6f9d-477e-a3ae-fe6543ea7fd8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in capital, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_6a5b3fc7-95eb-48b2-892f-65911556766b_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A3352032NotesMember_c10e4bb4-ca7d-46cf-86c0-6e0417668881_terseLabel_en-US" xlink:label="lab_amgn_A3352032NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.35% 2032 Notes [Member]</link:label>
    <link:label id="lab_amgn_A3352032NotesMember_label_en-US" xlink:label="lab_amgn_A3352032NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.35% 2032 Notes [Member]</link:label>
    <link:label id="lab_amgn_A3352032NotesMember_documentation_en-US" xlink:label="lab_amgn_A3352032NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.35% 2032 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A3352032NotesMember" xlink:href="amgn-20220630.xsd#amgn_A3352032NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A3352032NotesMember" xlink:to="lab_amgn_A3352032NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_678bc280-d1aa-49f7-aca7-3d10233e7e94_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_f41251de-6565-45cf-88a7-909ac8e6032e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_ba00fdd0-3b4c-430a-8fc7-6fe757bb7573_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_7a83d1b5-b6dd-4864-ad50-b621239f8b58_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Investments Acquired</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Investments Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b4d19936-c7d2-4356-b285-a38f24f97fdd_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_303509e1-c97d-4cd0-91ab-a35544b0872b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SixPointFourZeroPercentNotesDue2039Member_97301bc1-64c7-42e1-adb8-cfea5bc57278_terseLabel_en-US" xlink:label="lab_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.40% notes due 2039 (6.40% 2039 Notes) [Member]</link:label>
    <link:label id="lab_amgn_SixPointFourZeroPercentNotesDue2039Member_label_en-US" xlink:label="lab_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Four Zero Percent Notes Due 2039 [Member]</link:label>
    <link:label id="lab_amgn_SixPointFourZeroPercentNotesDue2039Member_documentation_en-US" xlink:label="lab_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Four Zero Percent Notes Due 2039 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:href="amgn-20220630.xsd#amgn_SixPointFourZeroPercentNotesDue2039Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:to="lab_amgn_SixPointFourZeroPercentNotesDue2039Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_19467c7e-288d-4cc6-80d3-2b6dd5e7f101_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c571f982-71f5-44d0-9228-79e794f90005_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_32297f07-4af2-47fe-95c4-d94b64217f07_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract" xlink:to="lab_us-gaap_DerivativeAssetFairValueNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_729eb5a5-d605-4826-8897-38f50649b7db_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:to="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f7a43ee9-1a7b-4cd3-a960-9e3f394bf516_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_425ac401-ef7f-44ec-b890-aa8b0c1b92f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_41820de7-4e65-422d-a5b8-4e95c8c00080_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_c474fa2c-63d2-429b-9118-157ca94e377f_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ccb36a48-f3a0-498a-96d2-411c1f0e0155_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_6a4b176a-773b-49ff-9504-48fd773e7755_terseLabel_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label id="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_documentation_en-US" xlink:label="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:href="amgn-20220630.xsd#amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:to="lab_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_306098ad-689f-4b5e-ab9a-2ec22155b3fa_terseLabel_en-US" xlink:label="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Seven Seven Percent Notes Due Two Zero Five Three</link:label>
    <link:label id="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_label_en-US" xlink:label="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Seven Seven Percent Notes Due Two Zero Five Three [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_documentation_en-US" xlink:label="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Seven Seven Percent Notes Due Two Zero Five Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:href="amgn-20220630.xsd#amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:to="lab_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_KANJINTIPatentLitigationMember_940d8303-ecd4-43a1-bc19-94d8b367047a_terseLabel_en-US" xlink:label="lab_amgn_KANJINTIPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KANJINTI Patent Litigation [Member]</link:label>
    <link:label id="lab_amgn_KANJINTIPatentLitigationMember_label_en-US" xlink:label="lab_amgn_KANJINTIPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KANJINTI Patent Litigation [Member]</link:label>
    <link:label id="lab_amgn_KANJINTIPatentLitigationMember_documentation_en-US" xlink:label="lab_amgn_KANJINTIPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KANJINTI Patent Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KANJINTIPatentLitigationMember" xlink:href="amgn-20220630.xsd#amgn_KANJINTIPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_KANJINTIPatentLitigationMember" xlink:to="lab_amgn_KANJINTIPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_MoleculeTypeAxis_f094327d-bcbb-43aa-af8e-bd378dbcc77c_terseLabel_en-US" xlink:label="lab_amgn_MoleculeTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecule, Type [Axis]</link:label>
    <link:label id="lab_amgn_MoleculeTypeAxis_label_en-US" xlink:label="lab_amgn_MoleculeTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecule, Type [Axis]</link:label>
    <link:label id="lab_amgn_MoleculeTypeAxis_documentation_en-US" xlink:label="lab_amgn_MoleculeTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecule, Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeAxis" xlink:href="amgn-20220630.xsd#amgn_MoleculeTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_MoleculeTypeAxis" xlink:to="lab_amgn_MoleculeTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_fd5eb8a2-4fdc-485d-b835-314ffd5d1d58_verboseLabel_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets</link:label>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_label_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Of Available For Sale Investments By Classification In Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_documentation_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:href="amgn-20220630.xsd#amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:to="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_f7c12613-5a54-47c3-be3c-32d6569daa0f_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e1f8823e-3a6a-4d46-9574-61fc1e27591e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_397f2d5e-fec4-4f47-be24-288e2ab4effb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8f479e09-56db-4fcc-8c8f-8438aedc8c81_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of reclassification adjustments and taxes:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_46b5eccd-7ee0-4a17-b4fa-9196388022f9_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_41199e7f-f82f-4d6e-828d-41cb3d6b53ab_verboseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_04e6bfd1-059b-4e84-838a-096262d6dd69_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_974b3568-fe86-4660-b9c7-a52e48d54097_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_144d5e9c-f0bb-4d5c-a3a0-ecc34c976a29_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherMortgageAndAssetBackedMember_1c1ffe04-100f-459f-b1ea-08bb2872dbf8_terseLabel_en-US" xlink:label="lab_amgn_OtherMortgageAndAssetBackedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Mortgage and asset backed</link:label>
    <link:label id="lab_amgn_OtherMortgageAndAssetBackedMember_label_en-US" xlink:label="lab_amgn_OtherMortgageAndAssetBackedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Mortgage and asset backed [Member]</link:label>
    <link:label id="lab_amgn_OtherMortgageAndAssetBackedMember_documentation_en-US" xlink:label="lab_amgn_OtherMortgageAndAssetBackedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Mortgage and asset backed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherMortgageAndAssetBackedMember" xlink:href="amgn-20220630.xsd#amgn_OtherMortgageAndAssetBackedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherMortgageAndAssetBackedMember" xlink:to="lab_amgn_OtherMortgageAndAssetBackedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_f2535531-4b09-4992-9d20-4c8b1e242c37_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_0cd51b18-afe2-4607-97fe-c1ef1d8b64a7_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization charges associated with finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_1ac50347-5046-4a58-8f88-5fb1ab8a5b56_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ab5ee880-a6f4-4659-aa5a-a2bc48f87638_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_d2b3c38f-ae25-4147-a2fc-7ecb4869cc69_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic EPS (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfAssertedPatents_1ec646cc-e181-4f0a-8cb0-95d5555ad56d_terseLabel_en-US" xlink:label="lab_amgn_NumberOfAssertedPatents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Asserted Patents</link:label>
    <link:label id="lab_amgn_NumberOfAssertedPatents_label_en-US" xlink:label="lab_amgn_NumberOfAssertedPatents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Asserted Patents</link:label>
    <link:label id="lab_amgn_NumberOfAssertedPatents_documentation_en-US" xlink:label="lab_amgn_NumberOfAssertedPatents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Asserted Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfAssertedPatents" xlink:href="amgn-20220630.xsd#amgn_NumberOfAssertedPatents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfAssertedPatents" xlink:to="lab_amgn_NumberOfAssertedPatents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_2feb57a0-f270-4ce0-93dc-ac3aba76c81b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrealized gains (losses)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePrimeTherapeuticsIncMember_15b6bdab-5699-4926-afc7-1ebac803fa85_terseLabel_en-US" xlink:label="lab_amgn_FivePrimeTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Prime Therapeutics, Inc.</link:label>
    <link:label id="lab_amgn_FivePrimeTherapeuticsIncMember_label_en-US" xlink:label="lab_amgn_FivePrimeTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Prime Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_amgn_FivePrimeTherapeuticsIncMember_documentation_en-US" xlink:label="lab_amgn_FivePrimeTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Prime Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePrimeTherapeuticsIncMember" xlink:href="amgn-20220630.xsd#amgn_FivePrimeTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePrimeTherapeuticsIncMember" xlink:to="lab_amgn_FivePrimeTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e7971f5b-52a8-41c2-a5d8-1c48c769b362_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_db0af526-a69d-4c7e-a3a9-9181f1b6e352_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f2ad6368-ccfa-46ec-880d-cca6e893ccec_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_edcbfdab-9419-4ba5-bcd7-7318e7bd03da_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_24219b61-00cc-4a2f-aff9-7cc1a1dbf6f6_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_819b9db2-a8b0-4410-908c-5317278fa4af_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ba1a45ee-8b02-46fb-8ed0-b1f7464efc1b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1b59881e-bd04-47f3-a52e-1e38fbc4f323_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_867bf271-11d9-4d2b-b9ac-86e8f4c3f0e8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5df74572-9a5d-4341-a68e-eceaef600e36_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_9703c547-ca74-461c-8a94-b914a5e47505_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Numerator):</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_d1750108-560f-48d9-9ede-99c359057438_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Length of time hedged in foreign currency contracts (or less)</link:label>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_label_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Length of Time, Foreign Currency Cash Flow Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:to="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_e47706ae-551d-4992-b01b-ece57197a2fc_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market mutual funds [Member]</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_68ac9805-b6ab-4b61-80bf-f726bb1a4522_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_059a4049-6a25-4813-b0e0-94cdf9b5fbef_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit [Member]</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_f5c428bf-0082-4d5d-ad88-563c1db6f935_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared on common stock</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EnbrelMember_f64314fb-9e29-443f-b6ed-801c74409310_terseLabel_en-US" xlink:label="lab_amgn_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enbrel&#174; (etanercept) [Member]</link:label>
    <link:label id="lab_amgn_EnbrelMember_label_en-US" xlink:label="lab_amgn_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ENBREL [Member]</link:label>
    <link:label id="lab_amgn_EnbrelMember_documentation_en-US" xlink:label="lab_amgn_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ENBREL.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EnbrelMember" xlink:href="amgn-20220630.xsd#amgn_EnbrelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EnbrelMember" xlink:to="lab_amgn_EnbrelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_5b338646-face-4d9e-8aa2-b404990a1fa8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_c96642c5-bf43-4873-ab55-7b909862b7f5_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of common stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_PartnershipInterestMember_2e6f3a3e-3a65-4bf0-a89c-11bc5ddac029_terseLabel_en-US" xlink:label="lab_srt_PartnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Partnership [Member]</link:label>
    <link:label id="lab_srt_PartnershipInterestMember_label_en-US" xlink:label="lab_srt_PartnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partnership Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_PartnershipInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_PartnershipInterestMember" xlink:to="lab_srt_PartnershipInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_cbe45b0a-0a21-4ad2-b4a9-5e20873ce1fc_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of reclassification adjustments and taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_057b99ac-455e-4d66-a1ef-44d8f43adee3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with the Company&#8217;s equity award programs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointOneFivePercentNotesDue2041Member_94df609b-759b-4881-8012-dab060cf7d37_terseLabel_en-US" xlink:label="lab_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.15% notes due 2041 (5.15% 2041 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FivePointOneFivePercentNotesDue2041Member_label_en-US" xlink:label="lab_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point One Five Percent Notes Due 2041 [Member]</link:label>
    <link:label id="lab_amgn_FivePointOneFivePercentNotesDue2041Member_documentation_en-US" xlink:label="lab_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point One Five Percent Notes Due 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:href="amgn-20220630.xsd#amgn_FivePointOneFivePercentNotesDue2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:to="lab_amgn_FivePointOneFivePercentNotesDue2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_6e4e2018-f1e8-4777-be85-b575bde09802_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock (Note 10)</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7a665142-e732-48bd-b579-8b571de362a1_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_ff1cf4a2-6081-48d0-a745-c1c60c62c4b3_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_ef98a6fd-2a13-40a6-8e95-c6bdb1712d4e_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_2d1bee4e-46b3-426f-8553-d40ca7e93863_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ae007910-0d30-4d71-b7de-cdb3a2529f8c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_deb6114e-9131-471f-8fec-a19d1d710bb0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_dd518837-3647-4ae7-a588-9d37d9d1f25c_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_ddeb570f-1bde-4033-9e0a-9d65ace338dc_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_867102ed-69c5-47ab-9fd0-9c8f9febb92e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_990043e1-9f9c-46b6-8a5e-05176ed065c0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_f1fa9d9b-a204-4d18-9826-ae0d6be2905a_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7c405a06-d820-4ce7-8a34-e8be0f3c28f8_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_eb2a9f3a-86b3-40e6-9602-00ff90cbda38_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ad3ad83b-f120-42f2-8a8d-dccbccee21e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_0663e466-2054-46e5-9015-8a7679fe6f8c_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e0c37c42-ba7f-49e4-ba89-92a53e700f34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_9a26f74b-4276-47c8-943c-694431d13e1e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_cd75a67e-af88-4bdb-a754-a413a176204f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_4c7b015d-4507-4897-8965-0344f7976dc4_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_a008d0b3-1abc-4604-aa83-0b86d7eeef5c_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_4240e552-9dfe-44eb-b900-cf6040f6f5f8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueNetAbstract_0cef7611-6e3d-4347-aa8e-8ac6a7dfdf48_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueNetAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset of Collateral [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4853e692-2d98-4704-b446-30e47d116ca7_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_e8fb16de-56e1-4d37-b7fd-815c84910a38_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointTwoZeroNotesDue2027Member_bc976128-ebf7-4f90-a32f-b56c686183a8_terseLabel_en-US" xlink:label="lab_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.20% notes due 2027 (3.20% 2027 Notes) [Member]</link:label>
    <link:label id="lab_amgn_ThreePointTwoZeroNotesDue2027Member_label_en-US" xlink:label="lab_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Two Zero Notes Due 2027 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointTwoZeroNotesDue2027Member_documentation_en-US" xlink:label="lab_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Two Zero Notes Due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:href="amgn-20220630.xsd#amgn_ThreePointTwoZeroNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:to="lab_amgn_ThreePointTwoZeroNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_52884d25-ac5b-4473-b719-46ffac56a3a4_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BeiGeneMember_25652b6f-bff2-43de-8820-0287c260a9b5_terseLabel_en-US" xlink:label="lab_amgn_BeiGeneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement with BeiGene, Ltd. [Member]</link:label>
    <link:label id="lab_amgn_BeiGeneMember_label_en-US" xlink:label="lab_amgn_BeiGeneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BeiGene [Member]</link:label>
    <link:label id="lab_amgn_BeiGeneMember_documentation_en-US" xlink:label="lab_amgn_BeiGeneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BeiGene [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember" xlink:href="amgn-20220630.xsd#amgn_BeiGeneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BeiGeneMember" xlink:to="lab_amgn_BeiGeneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_83091413-4e01-40ae-9a7f-086e79d31df4_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_85f93509-5d28-4276-aa30-77b0a3728f53_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying amounts</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_dad37694-7c56-4813-8e72-bba597d5efbe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_143d0a4c-7b87-4cce-b7c2-e4cb5a7846b9_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RepatriationTaxOnProposedAdditionalTax_6ef329fd-6cc2-4f2d-a00e-571598289687_terseLabel_en-US" xlink:label="lab_amgn_RepatriationTaxOnProposedAdditionalTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation tax on proposed additional tax</link:label>
    <link:label id="lab_amgn_RepatriationTaxOnProposedAdditionalTax_label_en-US" xlink:label="lab_amgn_RepatriationTaxOnProposedAdditionalTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation tax on proposed additional tax</link:label>
    <link:label id="lab_amgn_RepatriationTaxOnProposedAdditionalTax_documentation_en-US" xlink:label="lab_amgn_RepatriationTaxOnProposedAdditionalTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation tax on proposed additional tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepatriationTaxOnProposedAdditionalTax" xlink:href="amgn-20220630.xsd#amgn_RepatriationTaxOnProposedAdditionalTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RepatriationTaxOnProposedAdditionalTax" xlink:to="lab_amgn_RepatriationTaxOnProposedAdditionalTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NovartisPharmaAGMember_6f53b21a-fafe-490e-89c5-84368e652132_terseLabel_en-US" xlink:label="lab_amgn_NovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Pharma AG</link:label>
    <link:label id="lab_amgn_NovartisPharmaAGMember_label_en-US" xlink:label="lab_amgn_NovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Pharma AG [Member]</link:label>
    <link:label id="lab_amgn_NovartisPharmaAGMember_documentation_en-US" xlink:label="lab_amgn_NovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Pharma AG</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NovartisPharmaAGMember" xlink:href="amgn-20220630.xsd#amgn_NovartisPharmaAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NovartisPharmaAGMember" xlink:to="lab_amgn_NovartisPharmaAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_7c3029bf-68d5-483c-8197-4859f4d28889_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9fc2e501-eccc-4857-a341-fd358d9a1abd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in valuations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d1128ef5-ae38-4d4f-9209-3774b2020848_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_9d816439-f0c5-4c4a-981e-99df565d59a9_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales [Member]</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_0ada51d6-3229-4e01-ae65-c09ed397ae8e_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_d87ed977-8232-4ad0-81ac-0c9a3e3ef5a9_terseLabel_en-US" xlink:label="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.20% notes due 2027 (2.20% 2027 Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_label_en-US" xlink:label="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_documentation_en-US" xlink:label="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:href="amgn-20220630.xsd#amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:to="lab_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_df7c5efc-02af-45ae-9a0f-4b0db31e1b06_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury bills [Member]</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6225e239-7916-4382-b690-dcb0472d30b1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0d36c624-01a4-4547-8e96-3881b63cd612_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_44c6b3e5-2a87-4c4d-ba2e-9eb7080baca5_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments to income</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_9bc6a3df-25e6-4fb2-8c6f-661aec3f6a19_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_676c0bb3-410b-49be-ba7c-a7f7c2c4b765_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointEightZeroPercent2041NotesMember_a05f3aee-8d40-4ccd-bcfd-8dd2f42d7c6b_terseLabel_en-US" xlink:label="lab_amgn_TwoPointEightZeroPercent2041NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% notes due 2041 (2.80% 2041 Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointEightZeroPercent2041NotesMember_label_en-US" xlink:label="lab_amgn_TwoPointEightZeroPercent2041NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two point eight zero percent 2041 Notes [Member]</link:label>
    <link:label id="lab_amgn_TwoPointEightZeroPercent2041NotesMember_documentation_en-US" xlink:label="lab_amgn_TwoPointEightZeroPercent2041NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two point eight zero percent 2041 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointEightZeroPercent2041NotesMember" xlink:href="amgn-20220630.xsd#amgn_TwoPointEightZeroPercent2041NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointEightZeroPercent2041NotesMember" xlink:to="lab_amgn_TwoPointEightZeroPercent2041NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_d85fdc2d-0e87-44f7-8c78-93153fdb5271_negatedLabel_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable Intangible Assets Accumulated Amortization</link:label>
    <link:label id="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_documentation_en-US" xlink:label="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets accumulated amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:href="amgn-20220630.xsd#amgn_IdentifiableIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:to="lab_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_246b6449-f4ed-4f8d-9579-c88f48e6b4c1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_e7bef8d0-14ed-4d8b-b761-c11f72296186_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0138a519-79ea-4266-955d-f8d5e91b344d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other recent accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_8ab6a54b-433f-4422-a7be-43e9bc92deb1_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities without readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_2f638118-94dc-42de-a495-e0bc0fa5f3e5_terseLabel_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_label_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_cbc4f051-a0e4-4ed5-bb99-518cc9c68865_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in capital, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_dff4c11a-7beb-44a3-a679-872981fc6cd2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a0a93092-77e9-4abb-b8f7-3d6a5ac23bc6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_c6d906aa-afe8-4c10-b2c3-3cf0dfafce23_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_ac9add00-fb00-4c9f-b69e-13f3a579dbd3_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_9f61cb40-1877-49b0-b8c2-4ea2e02a1674_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NeulastaMember_19478168-3f42-4782-8c35-502cb67f89be_terseLabel_en-US" xlink:label="lab_amgn_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta&#174; (pegfilgrastim) [Member]</link:label>
    <link:label id="lab_amgn_NeulastaMember_label_en-US" xlink:label="lab_amgn_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta [Member]</link:label>
    <link:label id="lab_amgn_NeulastaMember_documentation_en-US" xlink:label="lab_amgn_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeulastaMember" xlink:href="amgn-20220630.xsd#amgn_NeulastaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NeulastaMember" xlink:to="lab_amgn_NeulastaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_1050c371-0b7d-48a6-b796-4b859353a8a1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_5bdc9453-ced3-4992-9018-58056d41bf58_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased, Shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_b731bef1-8f2b-41d3-b458-4121f994c5ba_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging adjustments on discontinued hedging relationships</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AranespMember_702b8b1d-4dfa-49a4-a770-19b9b730d09e_terseLabel_en-US" xlink:label="lab_amgn_AranespMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aranesp&#174; (darbepoetin alfa) [Member]</link:label>
    <link:label id="lab_amgn_AranespMember_label_en-US" xlink:label="lab_amgn_AranespMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aranesp [Member]</link:label>
    <link:label id="lab_amgn_AranespMember_documentation_en-US" xlink:label="lab_amgn_AranespMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aranesp.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AranespMember" xlink:href="amgn-20220630.xsd#amgn_AranespMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AranespMember" xlink:to="lab_amgn_AranespMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1c7fd177-ae22-47b1-a262-49bbf637addd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangible assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0b2ce6ed-de29-4b84-955b-0179da3bb6fa_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a703b73f-ca98-482f-82db-28501447b2a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_e942a1e2-9b10-4216-88e0-939fe3973ad1_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_315f46c6-e22e-4cfc-8009-5c00b4e1f59c_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherNotesDue2097Member_8b303b38-9dc6-4476-878f-0603852a5fe0_terseLabel_en-US" xlink:label="lab_amgn_OtherNotesDue2097Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other notes due 2097 [Member]</link:label>
    <link:label id="lab_amgn_OtherNotesDue2097Member_label_en-US" xlink:label="lab_amgn_OtherNotesDue2097Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Notes Due 2097 [Member]</link:label>
    <link:label id="lab_amgn_OtherNotesDue2097Member_documentation_en-US" xlink:label="lab_amgn_OtherNotesDue2097Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Notes Due 2097 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherNotesDue2097Member" xlink:href="amgn-20220630.xsd#amgn_OtherNotesDue2097Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherNotesDue2097Member" xlink:to="lab_amgn_OtherNotesDue2097Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_402309f3-e5bc-44a8-9333-368b677d258e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_feb8b0a1-ea9f-41ac-8680-0e50bd9deb62_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock_50b2b3d8-b12f-4ce1-af57-154965c84044_terseLabel_en-US" xlink:label="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of identifiable intangible assets</link:label>
    <link:label id="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Intangible Assets [Table Text Block]</link:label>
    <link:label id="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of finite-lived and indefinite-lived identifiable intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:href="amgn-20220630.xsd#amgn_ScheduleOfIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:to="lab_amgn_ScheduleOfIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_d1972d08-bd5a-40de-985a-b06c95298bd7_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_e02f9c9c-2fea-4476-971d-b70f9a38697d_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing rights</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3df517b6-1d33-4b5b-a9ad-1d2d17c83953_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_d92db5ad-1ce0-4744-8047-555e02aebd9b_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_6efef6fb-d6b3-43db-a9e9-5277b3d2f6c5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ddcc9582-7e9e-4901-b6a1-8610484c64bf_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_042a33dd-06b0-4223-9020-1a75500e1ef4_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares for diluted EPS (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7872c467-aa45-4204-8b9c-1137f6674646_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization on property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_519e03af-138b-4ce5-8903-ef67055977db_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d7c2a1af-8e80-45da-9d03-99ed78787e22_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_a58365c6-2409-4792-b87b-72aaeb5536dc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total derivative liabilities, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A4402062NotesMember_53ce4ea9-9481-44bf-9244-24a5105fb95a_terseLabel_en-US" xlink:label="lab_amgn_A4402062NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.40% 2062 Notes [Member]</link:label>
    <link:label id="lab_amgn_A4402062NotesMember_label_en-US" xlink:label="lab_amgn_A4402062NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.40% 2062 Notes [Member]</link:label>
    <link:label id="lab_amgn_A4402062NotesMember_documentation_en-US" xlink:label="lab_amgn_A4402062NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.40% 2062 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A4402062NotesMember" xlink:href="amgn-20220630.xsd#amgn_A4402062NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A4402062NotesMember" xlink:to="lab_amgn_A4402062NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_337b0ce1-566b-4615-b768-89d2eb8fecb2_terseLabel_en-US" xlink:label="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.375% notes due 2037 (6.375% 2037 Notes) [Member]</link:label>
    <link:label id="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_label_en-US" xlink:label="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Three Seven Five Percent Notes Due 2037 [Member]</link:label>
    <link:label id="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_documentation_en-US" xlink:label="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Three Seven Five Percent Notes Due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:href="amgn-20220630.xsd#amgn_SixPointThreeSevenFivePercentNotesDue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:to="lab_amgn_SixPointThreeSevenFivePercentNotesDue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_516a0eda-e99b-4a19-9998-36fe2c9cabd1_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_674aaf95-d22c-4de8-91a9-b447b41d07db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_d9e7e00c-8527-43cb-9481-3cb771107c22_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CorporateDebtSecuritiesFinancialMember_d8cd8158-0f08-47c8-90a0-7b53f317499d_terseLabel_en-US" xlink:label="lab_amgn_CorporateDebtSecuritiesFinancialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities - Financial [Member]</link:label>
    <link:label id="lab_amgn_CorporateDebtSecuritiesFinancialMember_label_en-US" xlink:label="lab_amgn_CorporateDebtSecuritiesFinancialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Financial [Member]</link:label>
    <link:label id="lab_amgn_CorporateDebtSecuritiesFinancialMember_documentation_en-US" xlink:label="lab_amgn_CorporateDebtSecuritiesFinancialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities financial Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesFinancialMember" xlink:href="amgn-20220630.xsd#amgn_CorporateDebtSecuritiesFinancialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CorporateDebtSecuritiesFinancialMember" xlink:to="lab_amgn_CorporateDebtSecuritiesFinancialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_3a41c8a3-a82c-4a84-89b0-28d6d753636a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_81217b2a-2c63-4d38-b03e-fc737c60715d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_7371407f-2a2f-4ef7-9aca-83f2ce2b21b2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents allegedly infringed upon</link:label>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:to="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BasisOfPresentationPolicyTextBlock_129a0447-9850-4fce-aa26-e334843a6d9c_verboseLabel_en-US" xlink:label="lab_amgn_BasisOfPresentationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_amgn_BasisOfPresentationPolicyTextBlock_label_en-US" xlink:label="lab_amgn_BasisOfPresentationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis Of Presentation [Policy Text Block]</link:label>
    <link:label id="lab_amgn_BasisOfPresentationPolicyTextBlock_documentation_en-US" xlink:label="lab_amgn_BasisOfPresentationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shows the basis of presentation of financial information for interim periods.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BasisOfPresentationPolicyTextBlock" xlink:href="amgn-20220630.xsd#amgn_BasisOfPresentationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BasisOfPresentationPolicyTextBlock" xlink:to="lab_amgn_BasisOfPresentationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b2047f29-e228-41d8-b465-c160f9a2ef50_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5580bc4b-c6ca-4ebf-9256-31ba11946c4a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_cb797d3d-c74c-47a0-91fd-22104175da24_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term tax liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_0a728bc7-411d-4c8d-9b0e-4cfffe348fa6_terseLabel_en-US" xlink:label="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.663% notes due 2051 (4.663% 2051 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_label_en-US" xlink:label="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]</link:label>
    <link:label id="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_documentation_en-US" xlink:label="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:href="amgn-20220630.xsd#amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:to="lab_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_c33db25a-0532-427c-ab41-9ae974ffbe8b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherProductsMember_ba2403dd-2344-4675-b477-cd9854d0ddd8_terseLabel_en-US" xlink:label="lab_amgn_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other products [Member]</link:label>
    <link:label id="lab_amgn_OtherProductsMember_label_en-US" xlink:label="lab_amgn_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_amgn_OtherProductsMember_documentation_en-US" xlink:label="lab_amgn_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherProductsMember" xlink:href="amgn-20220630.xsd#amgn_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherProductsMember" xlink:to="lab_amgn_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_5fe3e09b-1b6c-4694-bfea-353a773183e0_verboseLabel_en-US" xlink:label="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% 2022 euro Notes [Member]</link:label>
    <link:label id="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_label_en-US" xlink:label="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member]</link:label>
    <link:label id="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_documentation_en-US" xlink:label="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:href="amgn-20220630.xsd#amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:to="lab_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent_68524921-f74f-4749-ab0e-c21ce061d338_terseLabel_en-US" xlink:label="lab_amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event</link:label>
    <link:label id="lab_amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent_label_en-US" xlink:label="lab_amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event</link:label>
    <link:label id="lab_amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent_documentation_en-US" xlink:label="lab_amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent" xlink:href="amgn-20220630.xsd#amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent" xlink:to="lab_amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4891b3eb-5f68-486f-8269-dc6fb293dd4e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_60143ecd-1c6b-485a-ba6a-7e53b5df4620_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ff3b31c4-c5b7-4754-873d-e07bc0ee9677_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ProliaMember_3d98ce7e-54c0-49ec-895a-1fdc2df4f489_terseLabel_en-US" xlink:label="lab_amgn_ProliaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prolia&#174; (denosumab) [Member]</link:label>
    <link:label id="lab_amgn_ProliaMember_label_en-US" xlink:label="lab_amgn_ProliaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prolia [Member]</link:label>
    <link:label id="lab_amgn_ProliaMember_documentation_en-US" xlink:label="lab_amgn_ProliaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prolia.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProliaMember" xlink:href="amgn-20220630.xsd#amgn_ProliaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ProliaMember" xlink:to="lab_amgn_ProliaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_Businessassetacquisitionconsiderationtransferred_051a99a1-e8f2-4ecd-b8c9-ffa83a3e997c_totalLabel_en-US" xlink:label="lab_amgn_Businessassetacquisitionconsiderationtransferred" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business asset acquisition, consideration transferred</link:label>
    <link:label id="lab_amgn_Businessassetacquisitionconsiderationtransferred_label_en-US" xlink:label="lab_amgn_Businessassetacquisitionconsiderationtransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business asset acquisition, consideration transferred</link:label>
    <link:label id="lab_amgn_Businessassetacquisitionconsiderationtransferred_documentation_en-US" xlink:label="lab_amgn_Businessassetacquisitionconsiderationtransferred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business asset acquisition, consideration transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Businessassetacquisitionconsiderationtransferred" xlink:href="amgn-20220630.xsd#amgn_Businessassetacquisitionconsiderationtransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_Businessassetacquisitionconsiderationtransferred" xlink:to="lab_amgn_Businessassetacquisitionconsiderationtransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0752600a-97f9-4c37-b5a7-38d100cf3dc8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_f9034c01-da4e-4620-9980-73780eb926b1_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9d8138ad-92f8-41f6-a9ca-04546ecb3ec7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_58cba07f-78b6-4105-92b6-c21dce149d67_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_4d356c04-4976-456f-b2a9-8710f6279322_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in capital [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Including Additional Paid in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates_19e65043-8db1-4f5b-ab0a-c60035d8498f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses and Interests in Affiliates</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses and Interests in Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_22eec398-fd48-45f9-9202-a3a609c3dade_terseLabel_en-US" xlink:label="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.375% notes due 2043 (5.375% 2043 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_label_en-US" xlink:label="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Three Seven Five Percent Notes Due 2043 [Member]</link:label>
    <link:label id="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_documentation_en-US" xlink:label="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Three Seven Five Percent Notes Due 2043 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:href="amgn-20220630.xsd#amgn_FivePointThreeSevenFivePercentNotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:to="lab_amgn_FivePointThreeSevenFivePercentNotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_f295c18b-e83d-42a9-9154-52bc3f672636_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_95f81cf3-14c8-41b4-8526-e00511b6c84d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_9b7be1b8-6ddf-43a2-8d5b-776de71efdbe_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_93897b74-7663-4be7-8654-bd43922f1a79_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedge [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e4a95bfb-9d7b-425b-88f7-525733058d0b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPercentPoundSterlingNotesDue2029Member_194a6d77-5aa3-48bf-a3f9-ffe70f4bc3a3_terseLabel_en-US" xlink:label="lab_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% &#163;700 million notes due 2029 (4.00% 2029 pound sterling Notes) [Member]</link:label>
    <link:label id="lab_amgn_FourPercentPoundSterlingNotesDue2029Member_a69148c5-791b-46f4-91dd-88955f0bc036_verboseLabel_en-US" xlink:label="lab_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% 2029 pound sterling Notes [Member]</link:label>
    <link:label id="lab_amgn_FourPercentPoundSterlingNotesDue2029Member_label_en-US" xlink:label="lab_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Percent Pound Sterling Notes Due 2029 [Member]</link:label>
    <link:label id="lab_amgn_FourPercentPoundSterlingNotesDue2029Member_documentation_en-US" xlink:label="lab_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Percent Pound Sterling Notes Due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:href="amgn-20220630.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:to="lab_amgn_FourPercentPoundSterlingNotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_03f38530-c595-44fb-8819-e6fe36af029f_terseLabel_en-US" xlink:label="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.125% notes due 2025 (3.125% 2025 Notes) [Member]</link:label>
    <link:label id="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_label_en-US" xlink:label="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point One Two Five Percent Notes Due Two Zero Two Five [Member]</link:label>
    <link:label id="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_documentation_en-US" xlink:label="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point One Two Five Percent Notes Due Two Zero Two Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:href="amgn-20220630.xsd#amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:to="lab_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_fdf767a9-3e04-4d0e-9f3b-36c8d826ad43_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_de8231f3-7965-4e7b-97e0-348c1b892b3e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_093141b6-edee-4665-8044-32a808f5ec4d_verboseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets, net</link:label>
    <link:label id="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_label_en-US" xlink:label="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)</link:label>
    <link:label id="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_documentation_en-US" xlink:label="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:href="amgn-20220630.xsd#amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:to="lab_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_8ee58a4b-0051-4616-ae93-99aa05dec5f9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_963a56da-42cc-4db2-ae6a-b23a1aec486f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_0330d38c-2165-4b3c-aff6-268897c01c82_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_d3ad4e6e-4b67-49ce-80be-a6fbbe595748_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d8f0d4a7-334f-448d-8bfc-ee4195cf67e0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_4e8da36d-2228-48c6-bc23-35e404026b13_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_0cddf449-c4ba-45af-8677-90b8c85eb790_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_58d1892c-f858-40a5-9f6c-d823fce2148e_terseLabel_en-US" xlink:label="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) [Member]</link:label>
    <link:label id="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_cc9861b8-6321-4398-a409-9fb00f24139b_verboseLabel_en-US" xlink:label="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.41% 2023 Swiss franc Bonds [Member]</link:label>
    <link:label id="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_label_en-US" xlink:label="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member]</link:label>
    <link:label id="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_documentation_en-US" xlink:label="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:href="amgn-20220630.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:to="lab_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_35bbc3ad-4abb-4465-a533-751b1a27bac5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_807c97d2-2ee9-42f7-b17d-6f59434ed8cf_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on divestiture</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_64d38803-5d6b-4f9e-a67a-3e0505b3810a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50ac8ab9-a14f-40d8-bd97-e518d026946f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_df3aab70-ff38-4174-98f8-dd3914ded9b6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_32863379-7aea-4bb6-a647-1151195c2dba_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_15408f12-52dc-476a-8072-913ab0f093f8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_39c8ec73-1bab-4115-99c8-95f0dbe0c22a_terseLabel_en-US" xlink:label="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_label_en-US" xlink:label="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:label id="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_documentation_en-US" xlink:label="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:href="amgn-20220630.xsd#amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:to="lab_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock_f2e83595-7145-4a8b-b0fd-7d8af7929286_verboseLabel_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets</link:label>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock_label_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values of Available for Sale Investments By Classification In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock_documentation_en-US" xlink:label="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of fair values of available-for-sale investments by classification in the consolidated balance sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:href="amgn-20220630.xsd#amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:to="lab_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointTwoZeroNotesDue2020Member_0d77d19a-e680-496e-8938-34fddfd347ef_terseLabel_en-US" xlink:label="lab_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.20% notes due 2020 (2.20% 2020 Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoZeroNotesDue2020Member_label_en-US" xlink:label="lab_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Notes Due 2020 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoZeroNotesDue2020Member_documentation_en-US" xlink:label="lab_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Zero Notes Due 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:href="amgn-20220630.xsd#amgn_TwoPointTwoZeroNotesDue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:to="lab_amgn_TwoPointTwoZeroNotesDue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesPayableMember_3a567edc-4ceb-4e1c-90ce-497915164009_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Payable [Member]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesPayableMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesPayableMember" xlink:to="lab_us-gaap_DebtSecuritiesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_00f28af1-88d1-42e1-8bcf-14b6bed2e1d3_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, amortization and other</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A300NotesDue20523002052NotesMember_9b2e8631-72d1-4a73-8ddb-021b6f637dda_terseLabel_en-US" xlink:label="lab_amgn_A300NotesDue20523002052NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.00% notes due 2052 (3.00% 2052 Notes)</link:label>
    <link:label id="lab_amgn_A300NotesDue20523002052NotesMember_label_en-US" xlink:label="lab_amgn_A300NotesDue20523002052NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.00% notes due 2052 (3.00% 2052 Notes) [Member]</link:label>
    <link:label id="lab_amgn_A300NotesDue20523002052NotesMember_documentation_en-US" xlink:label="lab_amgn_A300NotesDue20523002052NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.00% notes due 2052 (3.00% 2052 Notes)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A300NotesDue20523002052NotesMember" xlink:href="amgn-20220630.xsd#amgn_A300NotesDue20523002052NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A300NotesDue20523002052NotesMember" xlink:to="lab_amgn_A300NotesDue20523002052NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_63545818-41b2-478e-91a2-1fe6ff912e7c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a18213fc-bb14-4354-b1da-f75fcf2dc3e7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_550a2248-c405-40de-b7aa-b05cd3e25f22_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized bond discounts, premiums and issuance costs, net</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherCurrentNoncurrentAssetsMember_981a886c-d568-477f-b3c4-6f58842e5327_verboseLabel_en-US" xlink:label="lab_amgn_OtherCurrentNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets/Other assets [Member]</link:label>
    <link:label id="lab_amgn_OtherCurrentNoncurrentAssetsMember_label_en-US" xlink:label="lab_amgn_OtherCurrentNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Noncurrent Assets [Member]</link:label>
    <link:label id="lab_amgn_OtherCurrentNoncurrentAssetsMember_documentation_en-US" xlink:label="lab_amgn_OtherCurrentNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets/other non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherCurrentNoncurrentAssetsMember" xlink:href="amgn-20220630.xsd#amgn_OtherCurrentNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherCurrentNoncurrentAssetsMember" xlink:to="lab_amgn_OtherCurrentNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f8434591-ea0c-47e5-a338-5fcb88ae254d_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_099da7df-0126-449d-b30b-37eb82574941_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_7395b20c-b66f-455a-8121-04eab4996263_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired, licensing rights</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_68bd41d8-0d05-4c87-9f00-4fb5cfbdacb0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_f6b8f4e4-1c68-427f-946a-b486ad7af181_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_9c6d77cd-8df1-486f-be69-0c2fc74de2c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of interest rate swaps</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Rate Derivatives [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_166eebd8-e842-4e75-84e3-9e77e7737dcd_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2890fa1c-1b73-4fef-b818-d77bc1735c97_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_cff4d404-8f0c-4de4-86fa-a8547a65bc29_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_02affdc1-cfb6-486c-ad0f-48f82b6aca83_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_e23efdeb-5800-4b3e-a6f8-5c1a100135cf_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_KyprolisANDAPatentLitigationMember_c8d37463-81a8-46c0-a961-cff6a9911725_terseLabel_en-US" xlink:label="lab_amgn_KyprolisANDAPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyprolis ANDA Patent Litigation</link:label>
    <link:label id="lab_amgn_KyprolisANDAPatentLitigationMember_label_en-US" xlink:label="lab_amgn_KyprolisANDAPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyprolis ANDA Patent Litigation [Member]</link:label>
    <link:label id="lab_amgn_KyprolisANDAPatentLitigationMember_documentation_en-US" xlink:label="lab_amgn_KyprolisANDAPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyprolis ANDA Patent Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyprolisANDAPatentLitigationMember" xlink:href="amgn-20220630.xsd#amgn_KyprolisANDAPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_KyprolisANDAPatentLitigationMember" xlink:to="lab_amgn_KyprolisANDAPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PatentTrialAndAppealBoardPatentChallengesMember_27f5be7e-c817-4402-b40f-e7d93f9cbd2b_terseLabel_en-US" xlink:label="lab_amgn_PatentTrialAndAppealBoardPatentChallengesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Trial and Appeal Board Patent Challenges [Member]</link:label>
    <link:label id="lab_amgn_PatentTrialAndAppealBoardPatentChallengesMember_label_en-US" xlink:label="lab_amgn_PatentTrialAndAppealBoardPatentChallengesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Trial And Appeal Board Patent Challenges [Member]</link:label>
    <link:label id="lab_amgn_PatentTrialAndAppealBoardPatentChallengesMember_documentation_en-US" xlink:label="lab_amgn_PatentTrialAndAppealBoardPatentChallengesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Trial And Appeal Board Patent Challenges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PatentTrialAndAppealBoardPatentChallengesMember" xlink:href="amgn-20220630.xsd#amgn_PatentTrialAndAppealBoardPatentChallengesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PatentTrialAndAppealBoardPatentChallengesMember" xlink:to="lab_amgn_PatentTrialAndAppealBoardPatentChallengesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMember_6cdc0390-118d-45a3-833b-65c83daca1fb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt [Member]</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember" xlink:to="lab_us-gaap_LongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_e4f6a901-fb1d-4767-a4fe-d5cc5b001bda_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum additional consideration due contingent on certain milestones</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_135e4084-d1ac-4315-bdeb-fd6381f35f95_terseLabel_en-US" xlink:label="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% notes due 2023 (2.25% 2023 Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_label_en-US" xlink:label="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Five Percent Notes Due Two Zero Two Three [Member]</link:label>
    <link:label id="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_documentation_en-US" xlink:label="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Five Percent Notes Due Two Zero Two Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:href="amgn-20220630.xsd#amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:to="lab_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_b580b46f-2da7-4948-987c-8b6689206894_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total carrying value of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_cacafa18-cf7e-4f19-9ff6-ebd250637f37_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_a5124d4a-6271-49d7-b4f6-b55189a8c435_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_SensiparAntitrustClassActionsMember_25e9e3cc-ab4c-4787-b483-fc3a37cd597c_terseLabel_en-US" xlink:label="lab_amgn_SensiparAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensipar Antitrust Class Actions [Member]</link:label>
    <link:label id="lab_amgn_SensiparAntitrustClassActionsMember_label_en-US" xlink:label="lab_amgn_SensiparAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensipar Antitrust Class Actions [Member]</link:label>
    <link:label id="lab_amgn_SensiparAntitrustClassActionsMember_documentation_en-US" xlink:label="lab_amgn_SensiparAntitrustClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensipar Antitrust Class Actions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SensiparAntitrustClassActionsMember" xlink:href="amgn-20220630.xsd#amgn_SensiparAntitrustClassActionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_SensiparAntitrustClassActionsMember" xlink:to="lab_amgn_SensiparAntitrustClassActionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_f29e52a2-3934-4086-867b-7bf762946935_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in capital, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CHF_de69d293-e109-4111-b442-5b051e3d8ac4_terseLabel_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:label id="lab_currency_CHF_label_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF" xlink:to="lab_currency_CHF" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointSixFiveNotesDue2022Member_f8fdddcb-e0aa-44b7-a3d6-b5d5d9f61996_terseLabel_en-US" xlink:label="lab_amgn_TwoPointSixFiveNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.65% notes due 2022 (2.65% 2022 Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSixFiveNotesDue2022Member_label_en-US" xlink:label="lab_amgn_TwoPointSixFiveNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Six Five Notes Due 2022 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSixFiveNotesDue2022Member_documentation_en-US" xlink:label="lab_amgn_TwoPointSixFiveNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Six Five Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixFiveNotesDue2022Member" xlink:href="amgn-20220630.xsd#amgn_TwoPointSixFiveNotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointSixFiveNotesDue2022Member" xlink:to="lab_amgn_TwoPointSixFiveNotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_492aa2c4-0727-471d-91de-37b75a4be7cb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a0bb8e15-7ba2-47d3-b4b5-63cb997e5231_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ecbef602-c3c8-470d-b2ff-6994875133b1_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AlternativeInvestmentNetGainLoss_bae7d0bc-02a7-46b1-8fb4-9513771bdfe5_terseLabel_en-US" xlink:label="lab_amgn_AlternativeInvestmentNetGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) from limited partnership investments</link:label>
    <link:label id="lab_amgn_AlternativeInvestmentNetGainLoss_label_en-US" xlink:label="lab_amgn_AlternativeInvestmentNetGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Net Gain (Loss)</link:label>
    <link:label id="lab_amgn_AlternativeInvestmentNetGainLoss_documentation_en-US" xlink:label="lab_amgn_AlternativeInvestmentNetGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Net Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AlternativeInvestmentNetGainLoss" xlink:href="amgn-20220630.xsd#amgn_AlternativeInvestmentNetGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AlternativeInvestmentNetGainLoss" xlink:to="lab_amgn_AlternativeInvestmentNetGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7ac08e91-358b-4688-ba0f-b7690902cf91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_df40a8b8-4400-49e9-84df-ef6e4ae7d8ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_0f30a2cd-2121-41bb-bcbf-9921246ac22f_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c7c57865-9323-4563-ac31-53783ab6b1c1_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_7b26fa54-1b36-40a2-bb61-4c88b3999b1a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_afb761b1-f02b-4632-b135-b46abdfc2e52_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_1b14a501-7741-4078-9dc9-22863fc33282_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instrument [Member]</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_2b8ea50e-1c94-44a0-bd45-e80a7925889c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7a6e9730-0651-4492-982f-f5ba11700c2e_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_fa85eaa0-61be-44a7-bb3c-4863f0d9e41b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessCombinationContingentConsiderationRollForward_95dea9d7-018a-4132-88ee-7111ecb9cf6f_terseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationContingentConsiderationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration [Roll Forward]</link:label>
    <link:label id="lab_amgn_BusinessCombinationContingentConsiderationRollForward_label_en-US" xlink:label="lab_amgn_BusinessCombinationContingentConsiderationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration [Roll Forward]</link:label>
    <link:label id="lab_amgn_BusinessCombinationContingentConsiderationRollForward_documentation_en-US" xlink:label="lab_amgn_BusinessCombinationContingentConsiderationRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationContingentConsiderationRollForward" xlink:href="amgn-20220630.xsd#amgn_BusinessCombinationContingentConsiderationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessCombinationContingentConsiderationRollForward" xlink:to="lab_amgn_BusinessCombinationContingentConsiderationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_843a265c-1f3b-42cd-b5f7-64d8bc05d8f0_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_cdcf08a6-93fc-4afb-a2e8-b4478ff74d74_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, dividends declared per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_a22997b1-3f7c-4bbe-8a9a-a1533896348e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_15b0cfc2-dc08-4a81-88b5-f62a6870131e_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7d32c019-bb94-40be-a8d9-dd9bc1245199_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LossContingencyNumberOfLawsuits_50cf18f8-8131-4f2d-bd39-2b47af054700_terseLabel_en-US" xlink:label="lab_amgn_LossContingencyNumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits</link:label>
    <link:label id="lab_amgn_LossContingencyNumberOfLawsuits_label_en-US" xlink:label="lab_amgn_LossContingencyNumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Lawsuits</link:label>
    <link:label id="lab_amgn_LossContingencyNumberOfLawsuits_documentation_en-US" xlink:label="lab_amgn_LossContingencyNumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfLawsuits" xlink:href="amgn-20220630.xsd#amgn_LossContingencyNumberOfLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LossContingencyNumberOfLawsuits" xlink:to="lab_amgn_LossContingencyNumberOfLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_8cbfc94f-1b65-47fe-88e8-3c83082d2825_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_c5bd2d3a-a8f5-42a1-ad93-b8ce7cbb27f8_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_8051f7e4-cdfb-4c5e-972c-ae34c36c0708_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1bc3a92b-d64a-425b-ae8a-b2c47c366a2d_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_a157c589-8081-48d0-8377-b53930b74674_terseLabel_en-US" xlink:label="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event</link:label>
    <link:label id="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_label_en-US" xlink:label="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event</link:label>
    <link:label id="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_documentation_en-US" xlink:label="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:href="amgn-20220630.xsd#amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:to="lab_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_d47af6de-fd5f-4470-9b4f-f8c30805bf3b_terseLabel_en-US" xlink:label="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.563% notes due 2048 (4.563% 2048 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_ca576bda-2f31-47e1-bb0e-195aa21b08f2_verboseLabel_en-US" xlink:label="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.563% notes due 2048 (4.563% 2048 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_label_en-US" xlink:label="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]</link:label>
    <link:label id="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_documentation_en-US" xlink:label="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:href="amgn-20220630.xsd#amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:to="lab_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermDebt_6329be5f-c3b4-45fc-855c-b934e4e2ee96_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebt" xlink:to="lab_us-gaap_OtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_17a7efab-c599-4e70-a8c4-7e015d88f070_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock, Shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_87700d8d-1178-46d3-858b-0f9da9e97231_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_40cf88eb-e1c3-4611-8c9d-0ea0b4790522_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_0aec574a-22b1-446e-b173-c395c4fdc4ae_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtezlaANDAPatentLitigationMember_1be8199a-af63-4b83-a587-9ede12f8019a_terseLabel_en-US" xlink:label="lab_amgn_OtezlaANDAPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otezla ANDA Patent Litigation [Member]</link:label>
    <link:label id="lab_amgn_OtezlaANDAPatentLitigationMember_label_en-US" xlink:label="lab_amgn_OtezlaANDAPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otezla ANDA Patent Litigation [Member]</link:label>
    <link:label id="lab_amgn_OtezlaANDAPatentLitigationMember_documentation_en-US" xlink:label="lab_amgn_OtezlaANDAPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otezla ANDA Patent Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaANDAPatentLitigationMember" xlink:href="amgn-20220630.xsd#amgn_OtezlaANDAPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtezlaANDAPatentLitigationMember" xlink:to="lab_amgn_OtezlaANDAPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_68a1e3d9-62cd-4b08-a9e5-be2bdb68d14c_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_e92798e7-2e0f-48c6-9b78-15fc94b61626_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Member]</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointFourFivePercentNotesDue2030Member_0333f6bf-308d-44fa-ac7c-b9566567a596_terseLabel_en-US" xlink:label="lab_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% notes due 2030 (2.45% 2030 Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointFourFivePercentNotesDue2030Member_label_en-US" xlink:label="lab_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Four Five Percent Notes Due 2030 [Member]</link:label>
    <link:label id="lab_amgn_TwoPointFourFivePercentNotesDue2030Member_documentation_en-US" xlink:label="lab_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Four Five Percent Notes Due 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:href="amgn-20220630.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:to="lab_amgn_TwoPointFourFivePercentNotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_f62705d2-22b3-4d36-8e2a-013c4dc01de3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_79979c26-b648-4c8f-97d5-ea2c9d55db84_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ac4eef86-ce77-4f83-97fa-c770f757c3d8_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with the Company&#8217;s equity award programs, Shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_LossContingencyAppealPeriod_067c4ab6-6be5-4cbb-89d2-a28f4103c662_terseLabel_en-US" xlink:label="lab_amgn_LossContingencyAppealPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, appeal period</link:label>
    <link:label id="lab_amgn_LossContingencyAppealPeriod_label_en-US" xlink:label="lab_amgn_LossContingencyAppealPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, appeal period</link:label>
    <link:label id="lab_amgn_LossContingencyAppealPeriod_documentation_en-US" xlink:label="lab_amgn_LossContingencyAppealPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, appeal period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyAppealPeriod" xlink:href="amgn-20220630.xsd#amgn_LossContingencyAppealPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_LossContingencyAppealPeriod" xlink:to="lab_amgn_LossContingencyAppealPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0c2317cd-6c76-4708-bc0f-98e9296cd22a_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other government-related debt securities - U.S. [Member]</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_FivePointSevenFivePercentNotesDue2040Member_6f92d028-6a22-4f1a-86f6-e770bcc1d99e_terseLabel_en-US" xlink:label="lab_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% notes due 2040 (5.75% 2040 Notes) [Member]</link:label>
    <link:label id="lab_amgn_FivePointSevenFivePercentNotesDue2040Member_label_en-US" xlink:label="lab_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Seven Five Percent Notes Due 2040 [Member]</link:label>
    <link:label id="lab_amgn_FivePointSevenFivePercentNotesDue2040Member_documentation_en-US" xlink:label="lab_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Seven Five Percent Notes Due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:href="amgn-20220630.xsd#amgn_FivePointSevenFivePercentNotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:to="lab_amgn_FivePointSevenFivePercentNotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9844fa88-717b-448a-bc3c-66f7802d7465_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_KyprolisMember_8570f284-b10d-4f99-9a41-d72d65d7d68c_terseLabel_en-US" xlink:label="lab_amgn_KyprolisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KYPROLIS&#174; (carfilzomib) [Member]</link:label>
    <link:label id="lab_amgn_KyprolisMember_label_en-US" xlink:label="lab_amgn_KyprolisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyprolis [Member]</link:label>
    <link:label id="lab_amgn_KyprolisMember_documentation_en-US" xlink:label="lab_amgn_KyprolisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyprolis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyprolisMember" xlink:href="amgn-20220630.xsd#amgn_KyprolisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_KyprolisMember" xlink:to="lab_amgn_KyprolisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_78fa3e23-e7d0-4454-98de-9a69a70957b3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6f4fa473-da8f-46ee-a61c-67543cd01ed1_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_95275b6a-b18f-45cc-b155-f80fa9bfd980_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_7555193f-24ea-45af-8b7f-dce7d6ecbde2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_2b6fef0d-a518-4ee9-ae33-fa9db8507fec_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury notes [Member]</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105_e3f6fb2d-ce21-483e-8203-513d11266052_terseLabel_en-US" xlink:label="lab_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Penalties on proposed additional income tax 2013-2015</link:label>
    <link:label id="lab_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105_label_en-US" xlink:label="lab_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Penalties on proposed additional income tax 2013-2105</link:label>
    <link:label id="lab_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105_documentation_en-US" xlink:label="lab_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Penalties on proposed additional income tax 2013-2015</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105" xlink:href="amgn-20220630.xsd#amgn_PenaltiesOnProposedAdditionalIncomeTax20132105"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105" xlink:to="lab_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d130e8ce-f2ee-40e6-80ef-be6971671b95_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2974cae8-bfbe-4803-b838-800124b9ed13_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_MoleculeTypeDomain_ba4aef23-575a-4a32-bc14-b9552ade9773_terseLabel_en-US" xlink:label="lab_amgn_MoleculeTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecule, Type [Domain]</link:label>
    <link:label id="lab_amgn_MoleculeTypeDomain_label_en-US" xlink:label="lab_amgn_MoleculeTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecule, Type [Domain]</link:label>
    <link:label id="lab_amgn_MoleculeTypeDomain_documentation_en-US" xlink:label="lab_amgn_MoleculeTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecule, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeDomain" xlink:href="amgn-20220630.xsd#amgn_MoleculeTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_MoleculeTypeDomain" xlink:to="lab_amgn_MoleculeTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_8c8e9f41-c1c4-40df-9c82-9de84794aae1_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_24da4144-84a7-4bda-bd5c-a96e3a53ffed_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in calculation of earnings per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_156175d9-a47f-4d98-b59c-9f73e08ed058_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares (Denominator):</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_d059641a-025f-4501-9778-18c1e46484c1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_5efde3e2-701b-4a30-bdac-aa847c5120aa_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_2d9c13b3-5815-41a7-94e8-74d50d001801_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_89dc5807-af63-42af-a433-a6e5fb290f44_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_5ca6c09f-0f91-4204-832e-8bebe7322cd0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_15a2eb4c-edf6-475b-9d5c-51cbcf9286d3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A3002029NotesMember_70f38ee1-2e14-485e-b67b-e9d60c9f3212_terseLabel_en-US" xlink:label="lab_amgn_A3002029NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.00% 2029 Notes [Member]</link:label>
    <link:label id="lab_amgn_A3002029NotesMember_label_en-US" xlink:label="lab_amgn_A3002029NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.00% 2029 Notes [Member]</link:label>
    <link:label id="lab_amgn_A3002029NotesMember_documentation_en-US" xlink:label="lab_amgn_A3002029NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.00% 2029 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A3002029NotesMember" xlink:href="amgn-20220630.xsd#amgn_A3002029NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A3002029NotesMember" xlink:to="lab_amgn_A3002029NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_1f64139e-dd19-447f-bdd9-414c53b83e59_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_5d3aea24-5a15-4921-95bb-d9cad36abb50_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of available-for-sale interest-bearing security investments by contractual maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_232fe64f-33e9-4acf-bf8f-4bb835d661a3_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_RDTechnologyrightsMember_e72bada8-7034-4734-b8da-bda810072c20_terseLabel_en-US" xlink:label="lab_amgn_RDTechnologyrightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R &amp; D Technology rights</link:label>
    <link:label id="lab_amgn_RDTechnologyrightsMember_label_en-US" xlink:label="lab_amgn_RDTechnologyrightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R &amp; D Technology rights [Member]</link:label>
    <link:label id="lab_amgn_RDTechnologyrightsMember_documentation_en-US" xlink:label="lab_amgn_RDTechnologyrightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R &amp; D Technology rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RDTechnologyrightsMember" xlink:href="amgn-20220630.xsd#amgn_RDTechnologyrightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_RDTechnologyrightsMember" xlink:to="lab_amgn_RDTechnologyrightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember_e444fef0-0eac-4362-89a9-399ba2ac5ed2_terseLabel_en-US" xlink:label="lab_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% &#8364;1,250 million notes due 2022 (1.25% 2022 euro Notes) [Member]</link:label>
    <link:label id="lab_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember_label_en-US" xlink:label="lab_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Five Percent Euro Notes due Two Zero Two Two [Member]</link:label>
    <link:label id="lab_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember_documentation_en-US" xlink:label="lab_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Five Percent Euro Notes due Two Zero Two Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember" xlink:href="amgn-20220630.xsd#amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember" xlink:to="lab_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c6a3356a-74bd-41ae-93cd-79c6a2367bb1_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_473227d2-a551-4781-a668-adf99bd26311_terseLabel_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% notes due 2024 (3.625% 2024 Notes) [Member]</link:label>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_label_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Two Five Percent Notes Due 2024 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_documentation_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Two Five Percent Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:href="amgn-20220630.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:to="lab_amgn_ThreePointSixTwoFivePercentNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19457c5c-659e-463b-89d1-4be62eab4721_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b8be87c9-a0f3-4dbf-87cf-26afb62e1262_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares for basic EPS (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_b1e8307c-2e81-4434-9951-89ed447b4d70_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US [Member]</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_a6e8d71f-80c8-42b3-bbdf-2c54cd0cc14f_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AlternativeInvestment_b72752f7-7cc6-46e8-8c3b-fdb493804ee1_terseLabel_en-US" xlink:label="lab_us-gaap_AlternativeInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative investments</link:label>
    <link:label id="lab_us-gaap_AlternativeInvestment_label_en-US" xlink:label="lab_us-gaap_AlternativeInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AlternativeInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestment" xlink:to="lab_us-gaap_AlternativeInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_11cc838c-7241-4010-b879-abc8ad547876_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_4631aaf2-29a6-4f74-98e5-26a470a2c93e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_faad4578-9617-4099-ad71-389f80b0285d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_b24089c5-e968-4abc-9937-3d75fc7d406c_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period of amortization</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_2234a979-997f-469e-b1eb-e56db6954ec0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amounts</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2c009a44-adbc-45cf-8794-a77975d5d7a4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2e522cc2-3459-488c-b3bd-ac25a6c55501_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_be767a19-4118-484f-a068-909d284765d1_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued income taxes, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OnePointSixFivePercent2028NotesMember_f2736441-a438-40b9-aa4f-689375ff0580_terseLabel_en-US" xlink:label="lab_amgn_OnePointSixFivePercent2028NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% notes due 2028 (1.65% 2028 Notes) [Member}</link:label>
    <link:label id="lab_amgn_OnePointSixFivePercent2028NotesMember_label_en-US" xlink:label="lab_amgn_OnePointSixFivePercent2028NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One point six five percent 2028 Notes [Member]</link:label>
    <link:label id="lab_amgn_OnePointSixFivePercent2028NotesMember_documentation_en-US" xlink:label="lab_amgn_OnePointSixFivePercent2028NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One point six five percent 2028 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointSixFivePercent2028NotesMember" xlink:href="amgn-20220630.xsd#amgn_OnePointSixFivePercent2028NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OnePointSixFivePercent2028NotesMember" xlink:to="lab_amgn_OnePointSixFivePercent2028NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_cf1f6145-3b76-4afd-a600-765cb7a082f3_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_ce96330f-9ba9-460d-afb8-7c872a7bcedb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_70354cea-0453-45ab-9892-b38bc9e74785_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs (Level 3) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2f124bc2-ab84-493a-9a04-323462335fe6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_7e8e5051-4250-489f-99eb-c946224b78e0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ProposedAdditionalIncomeTax_7b5223c6-616f-4537-84be-54a3d1395339_terseLabel_en-US" xlink:label="lab_amgn_ProposedAdditionalIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposed additional income tax</link:label>
    <link:label id="lab_amgn_ProposedAdditionalIncomeTax_label_en-US" xlink:label="lab_amgn_ProposedAdditionalIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposed additional income tax</link:label>
    <link:label id="lab_amgn_ProposedAdditionalIncomeTax_documentation_en-US" xlink:label="lab_amgn_ProposedAdditionalIncomeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposed additional income tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProposedAdditionalIncomeTax" xlink:href="amgn-20220630.xsd#amgn_ProposedAdditionalIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ProposedAdditionalIncomeTax" xlink:to="lab_amgn_ProposedAdditionalIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_979cda03-2409-456f-af90-bac0b23b1d69_terseLabel_en-US" xlink:label="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% notes due 2026 (2.60% 2026 notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_label_en-US" xlink:label="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Six Zero Notes Due Two Zero Two Six [Member]</link:label>
    <link:label id="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_documentation_en-US" xlink:label="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Six Zero Notes Due Two Zero Two Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:href="amgn-20220630.xsd#amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:to="lab_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_2f7af993-4b76-4e15-b204-a4691f8d3068_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsFoundInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Found Infringed upon, Number</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsFoundInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Found Infringed upon, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsFoundInfringedUponNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber" xlink:to="lab_us-gaap_GainContingencyPatentsFoundInfringedUponNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_73e1e0e7-f483-40d5-befb-0d70bb06fef7_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_8649dfad-ea3f-49b6-9a17-7787374ca10d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract_6771f59e-ea41-4234-ac7b-56e580be63f3_verboseLabel_en-US" xlink:label="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives:</link:label>
    <link:label id="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets Fair Value Disclosure [Abstract]</link:label>
    <link:label id="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract_documentation_en-US" xlink:label="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:href="amgn-20220630.xsd#amgn_DerivativeAssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:to="lab_amgn_DerivativeAssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NumberOfThirdPartyFinancialInstitutions_ec1c8bad-75aa-4935-9186-552f0f81fad9_terseLabel_en-US" xlink:label="lab_amgn_NumberOfThirdPartyFinancialInstitutions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Third-Party Financial Institutions</link:label>
    <link:label id="lab_amgn_NumberOfThirdPartyFinancialInstitutions_label_en-US" xlink:label="lab_amgn_NumberOfThirdPartyFinancialInstitutions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Third-Party Financial Institutions</link:label>
    <link:label id="lab_amgn_NumberOfThirdPartyFinancialInstitutions_documentation_en-US" xlink:label="lab_amgn_NumberOfThirdPartyFinancialInstitutions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Third-Party Financial Institutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfThirdPartyFinancialInstitutions" xlink:href="amgn-20220630.xsd#amgn_NumberOfThirdPartyFinancialInstitutions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NumberOfThirdPartyFinancialInstitutions" xlink:to="lab_amgn_NumberOfThirdPartyFinancialInstitutions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_76d7a6a5-aeb1-4859-ab83-967bd1615124_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_06070a66-04a1-4836-a6d7-bbebdaa5ab12_terseLabel_en-US" xlink:label="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_label_en-US" xlink:label="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Adjustment Attributable to Parent [Member]</link:label>
    <link:label id="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_documentation_en-US" xlink:label="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:href="amgn-20220630.xsd#amgn_AccumulatedOtherAdjustmentAttributabletoParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:to="lab_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4e297de4-a9a9-419c-b588-493bb3b8b1fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_6a39c835-2ae4-4b28-b848-8dcfdc46014c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_34580c53-137f-4d73-8ec4-ddb1978aa06c_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtezlaMember_6af4c746-d171-462f-9e53-f6a793aca619_terseLabel_en-US" xlink:label="lab_amgn_OtezlaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otezla (apremilast) [Member]</link:label>
    <link:label id="lab_amgn_OtezlaMember_label_en-US" xlink:label="lab_amgn_OtezlaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otezla [Member]</link:label>
    <link:label id="lab_amgn_OtezlaMember_documentation_en-US" xlink:label="lab_amgn_OtezlaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otezla [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaMember" xlink:href="amgn-20220630.xsd#amgn_OtezlaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtezlaMember" xlink:to="lab_amgn_OtezlaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ee45c268-d250-4dd2-818d-a005fefce424_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_d39a45a1-497a-4f38-99ea-b330fbefad83_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_69f2287a-709b-4a12-9bd4-c6f21aa16245_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on fair value hedging relationships, Hedged items</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_164c97eb-fa7c-4f5b-a485-154bca9a65c5_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_b6f0f000-bb0d-48d1-9225-29f12e10036e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_022f9209-03df-4f26-9bd9-cfe3d470485e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_16237eeb-3711-4fc3-bd0b-89f960d1a7fd_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount available for stock repurchases under a board approved stock repurchase plan</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_ad00b433-f204-468b-b195-4fd531698869_verboseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_e1dda1a6-d52a-4b05-b3a3-4ebfdc46b261_verboseLabel_en-US" xlink:label="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives:</link:label>
    <link:label id="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments Liabilities Fair Value Disclosure [Abstract]</link:label>
    <link:label id="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_documentation_en-US" xlink:label="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments liabilities fair value disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:href="amgn-20220630.xsd#amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:to="lab_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_e5c6d364-ca5b-4195-8b1d-6d14e16df260_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROW [Member]</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_ed96994c-340e-4ec4-a912-6cbecf28fb13_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instrument [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_15d422bb-03ca-4c82-a3b9-28232ffc25d9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a039f52a-d1e9-4571-95ee-38688689e282_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_b1f796fa-f676-4789-a381-9e2c5c456469_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_202075b9-3aa3-4860-82d3-a102d3305106_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant other observable inputs (Level 2) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_b002a60e-7502-4c2f-8f20-9acab086c5c3_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_6fdd4c8c-609c-4ade-adb2-0883e490f083_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_7f500ba8-1702-4838-934c-30449b27899f_terseLabel_en-US" xlink:label="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes) [Member]</link:label>
    <link:label id="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_af6364ff-b2f0-4ae8-ba7c-9e199e5c8c13_verboseLabel_en-US" xlink:label="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.00% 2026 euro Notes [Member]</link:label>
    <link:label id="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_label_en-US" xlink:label="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Percent Euro Notes Due Two Thousand Twenty Six [Member]</link:label>
    <link:label id="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_documentation_en-US" xlink:label="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Percent Euro Notes Due Two Thousand Twenty Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:href="amgn-20220630.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:to="lab_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_e5e8ae21-b0f6-4b89-b2b1-9953e3cc532c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_6e643f90-62a6-48d3-b1a2-b505bcb2548f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1ee0aad4-9c37-437a-8f0c-e4bc6f67b892_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_25bb3bb7-3fd9-401b-aecc-f84093656d60_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6723811a-4e53-4536-bec0-0341ad6cfb63_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7562bdcc-1f5b-462e-ae35-246d07e36281_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted EPS (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_44bf9a5e-f0e0-4015-b508-223b57997475_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_3a7c9ac8-c1bc-4dcb-b1b8-fb994153ac32_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_10c35fb2-2e5f-4d6a-8057-bb4ceb531bcd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_0aeb823c-09b7-470c-94c2-176199fec932_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_043e8f30-695e-42c5-beec-b963ab86c725_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_a42d0e18-c263-4cba-954f-cb3c9f0e78bb_terseLabel_en-US" xlink:label="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Technology Rights [Member]</link:label>
    <link:label id="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_label_en-US" xlink:label="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Research And Development Technology Rights [Member]</link:label>
    <link:label id="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_documentation_en-US" xlink:label="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired research and development technology rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:href="amgn-20220630.xsd#amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:to="lab_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_5c31d9af-e22e-4d5d-975d-7c62598d2c95_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0532c61a-d1a7-4fbf-b051-1c13b33cda44_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives Balance Sheet Location By Derivative Contract Type By Hedging Designation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a42aec6f-09a9-498a-874e-7969ad80e38e_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect of changes in accounting principles, net of tax</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1cd0f412-2b9f-4f1d-9bc1-490f3af6f034_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AMG340Member_56628764-138d-4737-906d-38a904eaeffa_terseLabel_en-US" xlink:label="lab_amgn_AMG340Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG 340</link:label>
    <link:label id="lab_amgn_AMG340Member_label_en-US" xlink:label="lab_amgn_AMG340Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG 340 [Member]</link:label>
    <link:label id="lab_amgn_AMG340Member_documentation_en-US" xlink:label="lab_amgn_AMG340Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG 340</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AMG340Member" xlink:href="amgn-20220630.xsd#amgn_AMG340Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AMG340Member" xlink:to="lab_amgn_AMG340Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_21d02205-f567-4bfa-9488-211d1427042e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total derivative assets, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_ba2d90bc-3624-4646-aa79-38dbed0f4f42_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other government-related debt securities - Foreign and other [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_e3edbc2d-b1fb-48c9-8445-b91febb25af6_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_803cd2f8-ce36-4f3a-a158-844f0d7b8da9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_5efdf99f-c77f-47b3-a163-f43cb0be097c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f1dd5842-ec88-4f34-952c-916f2c3259d7_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_9e27578c-57f6-42af-b29f-1eed6fa387f3_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_09ddea31-5359-4897-a299-a382a59ccb27_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NeumoraTherapeuticsIncMember_9fa42a21-1956-4738-9486-e291d97e3a7f_terseLabel_en-US" xlink:label="lab_amgn_NeumoraTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neumora Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_amgn_NeumoraTherapeuticsIncMember_label_en-US" xlink:label="lab_amgn_NeumoraTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neumora Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_amgn_NeumoraTherapeuticsIncMember_documentation_en-US" xlink:label="lab_amgn_NeumoraTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neumora Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeumoraTherapeuticsIncMember" xlink:href="amgn-20220630.xsd#amgn_NeumoraTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NeumoraTherapeuticsIncMember" xlink:to="lab_amgn_NeumoraTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_0cfbf1d9-9089-4fed-9ee0-70e406a2a7a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_dcbf915e-dc19-4ffb-9d0a-96bd9d36216f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_a2e220ee-89f0-4655-9474-b726451eb0b3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Fair Value Hedge Asset at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateFairValueHedgeAssetAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:to="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ExchangeDomain_84188691-2b77-4811-9443-2596ce6b67f0_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="lab_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ForeignAndOtherGovernmentRelatedDebtSecuritiesMember_c9e3ad1d-2b46-4a82-af39-7b224c03cc39_terseLabel_en-US" xlink:label="lab_amgn_ForeignAndOtherGovernmentRelatedDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">foreign and other government-related debt securities</link:label>
    <link:label id="lab_amgn_ForeignAndOtherGovernmentRelatedDebtSecuritiesMember_label_en-US" xlink:label="lab_amgn_ForeignAndOtherGovernmentRelatedDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">foreign and other government-related debt securities [Member]</link:label>
    <link:label id="lab_amgn_ForeignAndOtherGovernmentRelatedDebtSecuritiesMember_documentation_en-US" xlink:label="lab_amgn_ForeignAndOtherGovernmentRelatedDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">foreign and other government-related debt securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForeignAndOtherGovernmentRelatedDebtSecuritiesMember" xlink:href="amgn-20220630.xsd#amgn_ForeignAndOtherGovernmentRelatedDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ForeignAndOtherGovernmentRelatedDebtSecuritiesMember" xlink:to="lab_amgn_ForeignAndOtherGovernmentRelatedDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_TeneobioIncMember_6f98a602-9494-4a30-a1b1-c458c88ad287_terseLabel_en-US" xlink:label="lab_amgn_TeneobioIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teneobio Inc.</link:label>
    <link:label id="lab_amgn_TeneobioIncMember_label_en-US" xlink:label="lab_amgn_TeneobioIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teneobio Inc. [Member]</link:label>
    <link:label id="lab_amgn_TeneobioIncMember_documentation_en-US" xlink:label="lab_amgn_TeneobioIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teneobio Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioIncMember" xlink:href="amgn-20220630.xsd#amgn_TeneobioIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_TeneobioIncMember" xlink:to="lab_amgn_TeneobioIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_13db8800-16f1-4a12-954c-a72316b26355_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_aebc7af1-d038-4896-9684-f9961cbc5c64_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_52fa2b13-61bc-4c02-9e6e-19848b43cd7e_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_80975b0b-e0ca-4c46-953b-832af27ac916_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_226052c3-e5e1-4477-8286-28e081b59975_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue_60b3943b-df09-449d-a13b-b02971c64a99_terseLabel_en-US" xlink:label="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value</link:label>
    <link:label id="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue_label_en-US" xlink:label="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value</link:label>
    <link:label id="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue_documentation_en-US" xlink:label="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue" xlink:href="amgn-20220630.xsd#amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue" xlink:to="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_96e33812-dd84-401e-bac6-c8e0393975b3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2c66fc72-f5b0-4bb1-9dab-0f449c1bfec4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_dda465c5-05e0-4a84-a08b-855229cc61ca_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_b51f47af-57e9-4442-910d-08186f3129d4_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency and cross-currency swap contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFixedInterestRate_79991644-f96e-4c35-b923-a61bae99a704_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rates</link:label>
    <link:label id="lab_us-gaap_DerivativeFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Fixed Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFixedInterestRate" xlink:to="lab_us-gaap_DerivativeFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_2fb214df-7093-48ae-93cc-7f3a53411b26_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_b8629c79-e250-4e9c-b979-4472f7599373_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of revenue by product and by geographic area</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OtherShortTermInterestBearingSecuritiesMember_cdfefa84-8b3e-4502-9c31-92411c9037d5_verboseLabel_en-US" xlink:label="lab_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term interest-bearing securities [Member]</link:label>
    <link:label id="lab_amgn_OtherShortTermInterestBearingSecuritiesMember_label_en-US" xlink:label="lab_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short Term Interest Bearing Securities [Member]</link:label>
    <link:label id="lab_amgn_OtherShortTermInterestBearingSecuritiesMember_documentation_en-US" xlink:label="lab_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term interest bearing securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:href="amgn-20220630.xsd#amgn_OtherShortTermInterestBearingSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:to="lab_amgn_OtherShortTermInterestBearingSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_6f4b3d35-70a4-4ba9-9eb4-99607300dd48_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6d4bac07-911e-4de1-ab89-91daa904dc92_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for the six months ending December 31, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_HospiraMember_9e8c8a53-0670-42ce-8cb5-ad80fbb1da05_terseLabel_en-US" xlink:label="lab_amgn_HospiraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospira, Inc. [Member]</link:label>
    <link:label id="lab_amgn_HospiraMember_label_en-US" xlink:label="lab_amgn_HospiraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospira [Member]</link:label>
    <link:label id="lab_amgn_HospiraMember_documentation_en-US" xlink:label="lab_amgn_HospiraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospira [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HospiraMember" xlink:href="amgn-20220630.xsd#amgn_HospiraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_HospiraMember" xlink:to="lab_amgn_HospiraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointOneFivePercentNotesDue2040Member_c3ec77c8-b63e-4f97-8f8d-d4e4c75300b5_terseLabel_en-US" xlink:label="lab_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% notes due 2040 (3.15% 2040 Notes) [Member]</link:label>
    <link:label id="lab_amgn_ThreePointOneFivePercentNotesDue2040Member_label_en-US" xlink:label="lab_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point One Five Percent Notes Due 2040 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointOneFivePercentNotesDue2040Member_documentation_en-US" xlink:label="lab_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point One Five Percent Notes Due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:href="amgn-20220630.xsd#amgn_ThreePointOneFivePercentNotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:to="lab_amgn_ThreePointOneFivePercentNotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_b1704996-092c-4970-9450-d5bb96b8d265_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_9cf4df94-00c1-40d0-b36a-e3715fe3bd28_terseLabel_en-US" xlink:label="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.85% notes due 2021 (1.85% 2021 Notes) [Member]</link:label>
    <link:label id="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_label_en-US" xlink:label="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Eight Five Percent Notes Due Two Zero Two One [Member]</link:label>
    <link:label id="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_documentation_en-US" xlink:label="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Eight Five Percent Notes Due Two Zero Two One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:href="amgn-20220630.xsd#amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:to="lab_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_e972fce6-008e-488c-b898-b4d6c2ddf3c7_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_NplateMember_5258a043-c4fd-4e8c-b444-2c8165b3f70e_verboseLabel_en-US" xlink:label="lab_amgn_NplateMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nplate [Member]</link:label>
    <link:label id="lab_amgn_NplateMember_label_en-US" xlink:label="lab_amgn_NplateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nplate [Member]</link:label>
    <link:label id="lab_amgn_NplateMember_documentation_en-US" xlink:label="lab_amgn_NplateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nplate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NplateMember" xlink:href="amgn-20220630.xsd#amgn_NplateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_NplateMember" xlink:to="lab_amgn_NplateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfExpenseAxis_914ded12-91dc-4e45-9320-81fe3bac6e03_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfExpenseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:label id="lab_us-gaap_NatureOfExpenseAxis_label_en-US" xlink:label="lab_us-gaap_NatureOfExpenseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfExpenseAxis" xlink:to="lab_us-gaap_NatureOfExpenseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_70659f63-a082-4b23-a0e7-fd4478016ece_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_4d8e6abb-7a23-4d38-891d-541adbd0dda6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments_e00a924a-b442-4037-bbc5-c5adfbe82c8a_negatedTerseLabel_en-US" xlink:label="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments_label_en-US" xlink:label="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Payments</link:label>
    <link:label id="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments_documentation_en-US" xlink:label="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationContingentConsiderationArrangementsPayments" xlink:href="amgn-20220630.xsd#amgn_BusinessCombinationContingentConsiderationArrangementsPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BusinessCombinationContingentConsiderationArrangementsPayments" xlink:to="lab_amgn_BusinessCombinationContingentConsiderationArrangementsPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ProposedAdditionalIncomeTax20132015_5eaf870a-c1aa-46f8-9d97-c5e2007c5395_terseLabel_en-US" xlink:label="lab_amgn_ProposedAdditionalIncomeTax20132015" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposed additional income tax 2013-2015</link:label>
    <link:label id="lab_amgn_ProposedAdditionalIncomeTax20132015_label_en-US" xlink:label="lab_amgn_ProposedAdditionalIncomeTax20132015" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposed additional income tax 2013-2015</link:label>
    <link:label id="lab_amgn_ProposedAdditionalIncomeTax20132015_documentation_en-US" xlink:label="lab_amgn_ProposedAdditionalIncomeTax20132015" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposed additional income tax 2013-2015</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProposedAdditionalIncomeTax20132015" xlink:href="amgn-20220630.xsd#amgn_ProposedAdditionalIncomeTax20132015"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ProposedAdditionalIncomeTax20132015" xlink:to="lab_amgn_ProposedAdditionalIncomeTax20132015" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2bf77041-8d7d-446a-975e-e1710334493f_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_37fed45b-ba34-4d41-84c0-6d9e02c4167e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for 2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_880d7310-3a0a-4cf1-a33d-79b64d58d010_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bad76b83-d307-4757-b576-8b721aa19f60_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_ba51e38f-8665-4ae2-b6c9-12af55479584_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax impact related to employee stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_46a34100-0574-4903-8e0e-f63618723a54_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_6ec729a0-dea7-42c4-925f-8c0df7a8f731_verboseLabel_en-US" xlink:label="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities/Other noncurrent liabilities [Member]</link:label>
    <link:label id="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_label_en-US" xlink:label="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities Other Non Current Liabilities [Member]</link:label>
    <link:label id="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities/other non-current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:href="amgn-20220630.xsd#amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:to="lab_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_143ac93a-a0ff-4a51-8f9a-9c1270d11d90_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_9fd30285-ddcf-49e7-aca0-bc96b8a70dba_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_e442e8b4-ceac-41af-8134-e68c6bb0bc85_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_c8b47823-03d1-4ad0-8336-4ba010f6422d_terseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_77e8765b-b392-4368-a075-ce8d2d40c1a2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_0b0121a6-c99e-4ea2-9ebd-1adff682a274_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes [Member]</link:label>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable to Banks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableToBanksMember" xlink:to="lab_us-gaap_NotesPayableToBanksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_69354657-7132-402b-923f-6f7100ee1334_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_6b3b5dc5-2fdc-4eed-a220-5f876de6be67_terseLabel_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% notes due 2022 (3.625% 2022 Notes) [Member]</link:label>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_label_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Two Five Percent Notes Due 2022 [Member]</link:label>
    <link:label id="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_documentation_en-US" xlink:label="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Two Five Percent Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:href="amgn-20220630.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:to="lab_amgn_ThreePointSixTwoFivePercentNotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad7ff6d0-bdc0-47c8-baa8-42b4cf35d587_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_c8a7e513-fca9-4dca-8f6a-56af1ba76a41_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity method investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_04b4863b-f5af-4976-8ec1-cbc7d977b554_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_BasicAndDilutedEarningPerShareAbstract_23054bcb-02c3-4136-8f6c-90afbeb964c3_verboseLabel_en-US" xlink:label="lab_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of basic and diluted earnings per share</link:label>
    <link:label id="lab_amgn_BasicAndDilutedEarningPerShareAbstract_label_en-US" xlink:label="lab_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic And Diluted Earning Per Share [Abstract]</link:label>
    <link:label id="lab_amgn_BasicAndDilutedEarningPerShareAbstract_documentation_en-US" xlink:label="lab_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earning per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:href="amgn-20220630.xsd#amgn_BasicAndDilutedEarningPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:to="lab_amgn_BasicAndDilutedEarningPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8eb93f64-7e53-447f-9d59-4503fdcc7191_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_0318fbce-e429-4dfa-90c9-23db84e313fe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_f7c27278-4dca-4de0-86c4-96444e6ebce8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_83f334a9-1b35-4158-97c0-69e0bbf15b70_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_57fad849-b362-4cbb-8104-42bca30b079e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_96620758-7c22-48f2-abff-692eb42d6cb7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_74aea831-567b-488a-9c9d-5ec654aeebfe_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated amortization of finite-lived intangible assets for 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_27d49bd1-bbe7-429c-82c6-e202268c105c_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation for basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_8aeea43e-1778-4922-83cc-c64da539e07a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_3f535e42-823f-484c-a2e5-6a6168c88be5_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_MortgageAndAssetBackMember_8b245a7b-1d41-43b0-84cb-081dc8ed6865_terseLabel_en-US" xlink:label="lab_amgn_MortgageAndAssetBackMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and asset back</link:label>
    <link:label id="lab_amgn_MortgageAndAssetBackMember_label_en-US" xlink:label="lab_amgn_MortgageAndAssetBackMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and asset back [Member]</link:label>
    <link:label id="lab_amgn_MortgageAndAssetBackMember_documentation_en-US" xlink:label="lab_amgn_MortgageAndAssetBackMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and asset back</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MortgageAndAssetBackMember" xlink:href="amgn-20220630.xsd#amgn_MortgageAndAssetBackMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_MortgageAndAssetBackMember" xlink:to="lab_amgn_MortgageAndAssetBackMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_c6ecdf3b-fcae-42bc-acca-03ec823a9b53_terseLabel_en-US" xlink:label="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value</link:label>
    <link:label id="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_label_en-US" xlink:label="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value</link:label>
    <link:label id="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_documentation_en-US" xlink:label="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:href="amgn-20220630.xsd#amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:to="lab_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>amgn-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5d27ca97-9729-4191-8773-bd1da607be75,g:d96be9d2-9e3e-485f-8641-d09afcb6a74b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amgen.com/role/CoverPage" xlink:type="simple" xlink:href="amgn-20220630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2837e711-1d5c-4942-ac6c-6e5c4b624cb5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_f2cae794-ae3b-4878-9af7-2874e4960f85" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2837e711-1d5c-4942-ac6c-6e5c4b624cb5" xlink:to="loc_dei_EntitiesTable_f2cae794-ae3b-4878-9af7-2874e4960f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_ec80ccae-3461-4ca0-a6d8-94a94e4db73c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_f2cae794-ae3b-4878-9af7-2874e4960f85" xlink:to="loc_dei_EntityListingsExchangeAxis_ec80ccae-3461-4ca0-a6d8-94a94e4db73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_f8b316db-c53a-4cb1-abfe-c77335beee72" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_ec80ccae-3461-4ca0-a6d8-94a94e4db73c" xlink:to="loc_dei_ExchangeDomain_f8b316db-c53a-4cb1-abfe-c77335beee72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS_57141774-6290-400e-8d86-056ee99a17f3" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNGS"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_f8b316db-c53a-4cb1-abfe-c77335beee72" xlink:to="loc_exch_XNGS_57141774-6290-400e-8d86-056ee99a17f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fa5e95a9-b370-4ac8-9239-82ad1734e409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_f2cae794-ae3b-4878-9af7-2874e4960f85" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fa5e95a9-b370-4ac8-9239-82ad1734e409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dc25efc7-af24-41e7-a178-6d64fc37567b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fa5e95a9-b370-4ac8-9239-82ad1734e409" xlink:to="loc_us-gaap_ClassOfStockDomain_dc25efc7-af24-41e7-a178-6d64fc37567b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a0257759-39f9-4d67-867b-07a8315eab4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_dc25efc7-af24-41e7-a178-6d64fc37567b" xlink:to="loc_us-gaap_CommonStockMember_a0257759-39f9-4d67-867b-07a8315eab4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member_8f25796c-c4cb-4148-add5-83c13ef2093c" xlink:href="amgn-20220630.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_dc25efc7-af24-41e7-a178-6d64fc37567b" xlink:to="loc_amgn_A2.00SeniorNotesDue2026Member_8f25796c-c4cb-4148-add5-83c13ef2093c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_f2cae794-ae3b-4878-9af7-2874e4960f85" xlink:to="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_817b68d7-37eb-410a-8dec-22115b82c9b8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_DocumentType_817b68d7-37eb-410a-8dec-22115b82c9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_3479088c-5867-4e01-8fca-17fe348e39f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_DocumentQuarterlyReport_3479088c-5867-4e01-8fca-17fe348e39f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3ea5fa7a-0724-4ffd-9c3f-1a5e69441a46" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_DocumentPeriodEndDate_3ea5fa7a-0724-4ffd-9c3f-1a5e69441a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_07087878-f8ce-4a3f-a738-8d1ae4bd64eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_DocumentTransitionReport_07087878-f8ce-4a3f-a738-8d1ae4bd64eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_92f68771-a6b8-44fa-909a-660cdcdddf26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityFileNumber_92f68771-a6b8-44fa-909a-660cdcdddf26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_27acf58e-1309-404b-adf4-06805094d9d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityRegistrantName_27acf58e-1309-404b-adf4-06805094d9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_04fb52c3-102d-4d14-8fc7-9c1abac096d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityCentralIndexKey_04fb52c3-102d-4d14-8fc7-9c1abac096d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_57afc141-26f8-49b0-92dc-92060f8c2d2b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_AmendmentFlag_57afc141-26f8-49b0-92dc-92060f8c2d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c32914f2-7de4-4160-be55-8d20287a3067" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_DocumentFiscalYearFocus_c32914f2-7de4-4160-be55-8d20287a3067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b7e54049-62f9-41bb-a15e-3818a79982cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b7e54049-62f9-41bb-a15e-3818a79982cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9985b5b6-d280-4a15-9372-7f0b293463e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_CurrentFiscalYearEndDate_9985b5b6-d280-4a15-9372-7f0b293463e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e344211d-ccf2-404b-83c1-e8451818886d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e344211d-ccf2-404b-83c1-e8451818886d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a360e1e7-cfcd-470a-9c81-edd14c087264" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityTaxIdentificationNumber_a360e1e7-cfcd-470a-9c81-edd14c087264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_809b9fd9-c687-4dd2-9aae-e2f66ad96caa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityAddressAddressLine1_809b9fd9-c687-4dd2-9aae-e2f66ad96caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ae5612f2-b9a8-48d3-8311-6058ba291469" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityAddressCityOrTown_ae5612f2-b9a8-48d3-8311-6058ba291469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a5a3f12d-7247-4018-bf8f-fe1e9b4b7b22" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityAddressStateOrProvince_a5a3f12d-7247-4018-bf8f-fe1e9b4b7b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_db791ccf-d7a6-462f-a41e-52320ad74a5f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityAddressPostalZipCode_db791ccf-d7a6-462f-a41e-52320ad74a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c5633b75-e21e-4431-ace5-f18b1be66cbe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_CityAreaCode_c5633b75-e21e-4431-ace5-f18b1be66cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_676f2bec-f97c-4673-bd5a-f06451db75f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_LocalPhoneNumber_676f2bec-f97c-4673-bd5a-f06451db75f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_364a547a-3c10-45ff-a831-bb432e9023d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_Security12bTitle_364a547a-3c10-45ff-a831-bb432e9023d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b3bcf46f-6a15-4b9c-b0d0-6183a8b9db9d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_TradingSymbol_b3bcf46f-6a15-4b9c-b0d0-6183a8b9db9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a0dd435a-5580-4293-84aa-d81ac3502dd3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_SecurityExchangeName_a0dd435a-5580-4293-84aa-d81ac3502dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c5d4a74a-e991-47f1-8ff6-1a52a57dd1a0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityCurrentReportingStatus_c5d4a74a-e991-47f1-8ff6-1a52a57dd1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_44f38142-9af6-400f-802a-ca2135b3e6b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityInteractiveDataCurrent_44f38142-9af6-400f-802a-ca2135b3e6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b9408885-007e-4549-aca1-30b2c49ce5dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityFilerCategory_b9408885-007e-4549-aca1-30b2c49ce5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_315760b6-6772-47fc-bd07-9df5c9bbf50f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntitySmallBusiness_315760b6-6772-47fc-bd07-9df5c9bbf50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_cf1efbc8-e059-4b7e-9ab4-d8c0e70eb340" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityEmergingGrowthCompany_cf1efbc8-e059-4b7e-9ab4-d8c0e70eb340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3c9c8248-7529-43ab-8802-9c49aa4d68b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityShellCompany_3c9c8248-7529-43ab-8802-9c49aa4d68b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1c14ed18-2873-4827-b48f-4d32b46dbd26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_96676ee9-5399-4c50-8346-d757bc8250c1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1c14ed18-2873-4827-b48f-4d32b46dbd26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="amgn-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6c40c972-c1d0-4570-8fd0-0e717d3d3d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5008de81-190e-4d69-bccf-419f4d766345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6c40c972-c1d0-4570-8fd0-0e717d3d3d05" xlink:to="loc_us-gaap_NetIncomeLoss_5008de81-190e-4d69-bccf-419f4d766345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_422e59b2-bd8d-4710-b15c-74fe965b119b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6c40c972-c1d0-4570-8fd0-0e717d3d3d05" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_422e59b2-bd8d-4710-b15c-74fe965b119b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4fe9fceb-7ecf-492e-899f-7e6dd087ecd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_422e59b2-bd8d-4710-b15c-74fe965b119b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4fe9fceb-7ecf-492e-899f-7e6dd087ecd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_aac4176b-fb88-414d-9a8c-487ba6744dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_422e59b2-bd8d-4710-b15c-74fe965b119b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_aac4176b-fb88-414d-9a8c-487ba6744dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b6ea2f12-59b9-440a-ac6d-e3ba6b3741fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_422e59b2-bd8d-4710-b15c-74fe965b119b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b6ea2f12-59b9-440a-ac6d-e3ba6b3741fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_3ad5d5ba-caf5-4d84-a805-14fce7673e2a" xlink:href="amgn-20220630.xsd#amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_422e59b2-bd8d-4710-b15c-74fe965b119b" xlink:to="loc_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent_3ad5d5ba-caf5-4d84-a805-14fce7673e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7bc37b88-6575-4dc2-8e9a-57effdb75325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_422e59b2-bd8d-4710-b15c-74fe965b119b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7bc37b88-6575-4dc2-8e9a-57effdb75325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_41be772b-9830-4c20-a4a0-d7969ae31d91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6c40c972-c1d0-4570-8fd0-0e717d3d3d05" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_41be772b-9830-4c20-a4a0-d7969ae31d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="amgn-20220630.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_00ba09b4-8658-4ca8-b318-a12b5d1cb3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_50bfbd27-8504-4478-8b00-6fa38ea11536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_00ba09b4-8658-4ca8-b318-a12b5d1cb3a4" xlink:to="loc_us-gaap_StatementTable_50bfbd27-8504-4478-8b00-6fa38ea11536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_814a4db2-9f0b-4957-b54f-9f2a91abd615" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_50bfbd27-8504-4478-8b00-6fa38ea11536" xlink:to="loc_srt_ProductOrServiceAxis_814a4db2-9f0b-4957-b54f-9f2a91abd615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_10007571-c9eb-45e2-8318-dec4287ab559" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_814a4db2-9f0b-4957-b54f-9f2a91abd615" xlink:to="loc_srt_ProductsAndServicesDomain_10007571-c9eb-45e2-8318-dec4287ab559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_21f87582-402c-47a0-bd7d-8f222eac8b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_10007571-c9eb-45e2-8318-dec4287ab559" xlink:to="loc_us-gaap_ProductMember_21f87582-402c-47a0-bd7d-8f222eac8b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_9c5d35ac-92fc-4318-b64a-06b6aa8146db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_10007571-c9eb-45e2-8318-dec4287ab559" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_9c5d35ac-92fc-4318-b64a-06b6aa8146db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_50bfbd27-8504-4478-8b00-6fa38ea11536" xlink:to="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_26f18056-6a4e-4578-b0bd-1dafe33319ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_RevenuesAbstract_26f18056-6a4e-4578-b0bd-1dafe33319ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_00dfed52-2234-4e33-8a43-71131f7a40d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_26f18056-6a4e-4578-b0bd-1dafe33319ec" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_00dfed52-2234-4e33-8a43-71131f7a40d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_4bf2b166-03a7-4322-be78-6bc98ca2554c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_4bf2b166-03a7-4322-be78-6bc98ca2554c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_cb0395df-a7e2-40c1-8176-52301eda28e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4bf2b166-03a7-4322-be78-6bc98ca2554c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_cb0395df-a7e2-40c1-8176-52301eda28e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_fa18504b-4960-4f18-b53f-42c05053fb68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4bf2b166-03a7-4322-be78-6bc98ca2554c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_fa18504b-4960-4f18-b53f-42c05053fb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_3da3d7e0-1d9d-408a-9d53-8faa8df8acc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4bf2b166-03a7-4322-be78-6bc98ca2554c" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_3da3d7e0-1d9d-408a-9d53-8faa8df8acc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b5d179ff-6347-4ff6-b05a-eb78b89d052e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4bf2b166-03a7-4322-be78-6bc98ca2554c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b5d179ff-6347-4ff6-b05a-eb78b89d052e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherGeneralExpenseIncomeOtherAdjustments_b1ae751b-db01-434c-9355-55d86ea05384" xlink:href="amgn-20220630.xsd#amgn_OtherGeneralExpenseIncomeOtherAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4bf2b166-03a7-4322-be78-6bc98ca2554c" xlink:to="loc_amgn_OtherGeneralExpenseIncomeOtherAdjustments_b1ae751b-db01-434c-9355-55d86ea05384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2136f545-9242-4922-a190-8cbe16662c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4bf2b166-03a7-4322-be78-6bc98ca2554c" xlink:to="loc_us-gaap_CostsAndExpenses_2136f545-9242-4922-a190-8cbe16662c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a2bece7e-6cdf-4411-80fb-73ac4a0b1940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_OperatingIncomeLoss_a2bece7e-6cdf-4411-80fb-73ac4a0b1940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a697f7fb-e376-49ce-8b95-0b22a83cf5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_InterestExpenseDebt_a697f7fb-e376-49ce-8b95-0b22a83cf5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_eed1b428-42c1-4952-a70d-21a474d7c4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_eed1b428-42c1-4952-a70d-21a474d7c4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6235f2d4-04ce-4b83-baa2-f00367fe1bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6235f2d4-04ce-4b83-baa2-f00367fe1bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d8daf013-19ff-4d0e-b118-be74f4a52615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d8daf013-19ff-4d0e-b118-be74f4a52615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ab02e69b-3a20-4762-a31e-7910d271cb34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_NetIncomeLoss_ab02e69b-3a20-4762-a31e-7910d271cb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cbdde887-9dd9-4345-a66e-ff60024c5f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_EarningsPerShareAbstract_cbdde887-9dd9-4345-a66e-ff60024c5f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a2a99f62-4a01-4ea4-be8a-8c69bd178213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cbdde887-9dd9-4345-a66e-ff60024c5f80" xlink:to="loc_us-gaap_EarningsPerShareBasic_a2a99f62-4a01-4ea4-be8a-8c69bd178213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_28e101db-97de-498e-ac80-159521759c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cbdde887-9dd9-4345-a66e-ff60024c5f80" xlink:to="loc_us-gaap_EarningsPerShareDiluted_28e101db-97de-498e-ac80-159521759c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_72c8056e-fc59-4ea8-a637-93f6ae39f1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72c6a184-d843-4679-9666-4f64e1c01ff4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_72c8056e-fc59-4ea8-a637-93f6ae39f1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_76300186-29ed-4798-a60f-af07b01b7ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_72c8056e-fc59-4ea8-a637-93f6ae39f1ca" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_76300186-29ed-4798-a60f-af07b01b7ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d8a9f45b-a4a5-4e6e-afb6-1b3b23212df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_72c8056e-fc59-4ea8-a637-93f6ae39f1ca" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d8a9f45b-a4a5-4e6e-afb6-1b3b23212df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="amgn-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_82845098-16b2-4740-a28a-159dfbbc4e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b9fcbc9f-eb14-4959-bfae-7a1b1a40cdd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_82845098-16b2-4740-a28a-159dfbbc4e8d" xlink:to="loc_us-gaap_AssetsAbstract_b9fcbc9f-eb14-4959-bfae-7a1b1a40cdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e6d87613-1ab9-44da-becc-7335f2587a90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b9fcbc9f-eb14-4959-bfae-7a1b1a40cdd1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e6d87613-1ab9-44da-becc-7335f2587a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_334dfe88-4be8-4e4f-af66-955b5e45c640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e6d87613-1ab9-44da-becc-7335f2587a90" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_334dfe88-4be8-4e4f-af66-955b5e45c640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_dfaca24d-1898-4176-b69e-be965b3a18ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e6d87613-1ab9-44da-becc-7335f2587a90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_dfaca24d-1898-4176-b69e-be965b3a18ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_787dfac3-34a0-4d31-8759-c5b1da336868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e6d87613-1ab9-44da-becc-7335f2587a90" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_787dfac3-34a0-4d31-8759-c5b1da336868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ac4090e1-a31f-48b0-aba7-f88472e874bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e6d87613-1ab9-44da-becc-7335f2587a90" xlink:to="loc_us-gaap_InventoryNet_ac4090e1-a31f-48b0-aba7-f88472e874bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_b4256de1-08ce-4c88-b0bd-099ac64d6bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e6d87613-1ab9-44da-becc-7335f2587a90" xlink:to="loc_us-gaap_OtherAssetsCurrent_b4256de1-08ce-4c88-b0bd-099ac64d6bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_19beb0ee-7f47-41cb-9446-4f7fe49baca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e6d87613-1ab9-44da-becc-7335f2587a90" xlink:to="loc_us-gaap_AssetsCurrent_19beb0ee-7f47-41cb-9446-4f7fe49baca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_69ff397d-ae1c-4959-87b0-d0db6b7f4267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b9fcbc9f-eb14-4959-bfae-7a1b1a40cdd1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_69ff397d-ae1c-4959-87b0-d0db6b7f4267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6cd2f1da-5df7-45af-a13c-9fbe4a4bb269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b9fcbc9f-eb14-4959-bfae-7a1b1a40cdd1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6cd2f1da-5df7-45af-a13c-9fbe4a4bb269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2b915c8a-7d4d-4dba-bdae-c4fa71a9a518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b9fcbc9f-eb14-4959-bfae-7a1b1a40cdd1" xlink:to="loc_us-gaap_Goodwill_2b915c8a-7d4d-4dba-bdae-c4fa71a9a518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_75eaa782-4e95-43bf-ac0f-0d24562e6e83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b9fcbc9f-eb14-4959-bfae-7a1b1a40cdd1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_75eaa782-4e95-43bf-ac0f-0d24562e6e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_efad0a33-bf08-4803-9e4d-f7e6bcc12c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b9fcbc9f-eb14-4959-bfae-7a1b1a40cdd1" xlink:to="loc_us-gaap_Assets_efad0a33-bf08-4803-9e4d-f7e6bcc12c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d51cceed-bee0-4b3f-836e-dde02825bb05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_82845098-16b2-4740-a28a-159dfbbc4e8d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d51cceed-bee0-4b3f-836e-dde02825bb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2c98fd1c-2412-42ea-9f25-919930431568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d51cceed-bee0-4b3f-836e-dde02825bb05" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2c98fd1c-2412-42ea-9f25-919930431568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7fb5077b-384a-47a2-8c4d-f555fd30a464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2c98fd1c-2412-42ea-9f25-919930431568" xlink:to="loc_us-gaap_AccountsPayableCurrent_7fb5077b-384a-47a2-8c4d-f555fd30a464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_14ce2736-a1a9-4413-978d-18ef74c25586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2c98fd1c-2412-42ea-9f25-919930431568" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_14ce2736-a1a9-4413-978d-18ef74c25586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_a07a7a83-d265-4d59-9f83-0354977e3f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2c98fd1c-2412-42ea-9f25-919930431568" xlink:to="loc_us-gaap_LongTermDebtCurrent_a07a7a83-d265-4d59-9f83-0354977e3f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_19848800-8fe1-46dd-a1d0-c410a1309be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2c98fd1c-2412-42ea-9f25-919930431568" xlink:to="loc_us-gaap_LiabilitiesCurrent_19848800-8fe1-46dd-a1d0-c410a1309be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e7c90b10-e75e-4967-b4f6-4cc59b248adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d51cceed-bee0-4b3f-836e-dde02825bb05" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e7c90b10-e75e-4967-b4f6-4cc59b248adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_e31fd272-240c-40e4-812e-609b185f4a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d51cceed-bee0-4b3f-836e-dde02825bb05" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_e31fd272-240c-40e4-812e-609b185f4a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a525e085-5dca-4778-acda-c11c389626d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d51cceed-bee0-4b3f-836e-dde02825bb05" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a525e085-5dca-4778-acda-c11c389626d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_517a10ed-7280-46af-8681-d8aa4e607da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d51cceed-bee0-4b3f-836e-dde02825bb05" xlink:to="loc_us-gaap_CommitmentsAndContingencies_517a10ed-7280-46af-8681-d8aa4e607da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e7f1b8a0-3ab7-4d51-bfd3-cd311b06675c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d51cceed-bee0-4b3f-836e-dde02825bb05" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e7f1b8a0-3ab7-4d51-bfd3-cd311b06675c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_b9f30fb0-f5b3-480f-93d3-d571395587e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e7f1b8a0-3ab7-4d51-bfd3-cd311b06675c" xlink:to="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_b9f30fb0-f5b3-480f-93d3-d571395587e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18dd8ab8-bf50-4a7d-badf-3fd0ee13d615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e7f1b8a0-3ab7-4d51-bfd3-cd311b06675c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18dd8ab8-bf50-4a7d-badf-3fd0ee13d615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_56849520-be8b-4f3c-8090-1964c31da614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e7f1b8a0-3ab7-4d51-bfd3-cd311b06675c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_56849520-be8b-4f3c-8090-1964c31da614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4daf28f6-3689-436d-84d9-2a30596cfea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e7f1b8a0-3ab7-4d51-bfd3-cd311b06675c" xlink:to="loc_us-gaap_StockholdersEquity_4daf28f6-3689-436d-84d9-2a30596cfea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9f214863-86b3-4404-9d21-5a66793f14c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d51cceed-bee0-4b3f-836e-dde02825bb05" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9f214863-86b3-4404-9d21-5a66793f14c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="amgn-20220630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_48eeff53-988a-4ce6-9aca-74e15e5ce48a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a1ab90ab-dc14-410d-a284-9a91d3378e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_48eeff53-988a-4ce6-9aca-74e15e5ce48a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a1ab90ab-dc14-410d-a284-9a91d3378e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4097d9b2-3c6e-4ad7-91eb-262fbc286ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_48eeff53-988a-4ce6-9aca-74e15e5ce48a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4097d9b2-3c6e-4ad7-91eb-262fbc286ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_55b75314-a389-4939-a48b-fbef00ffcc1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_48eeff53-988a-4ce6-9aca-74e15e5ce48a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_55b75314-a389-4939-a48b-fbef00ffcc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="amgn-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ad745bc1-9692-4b60-8ec9-22b6f09a4f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9f4eeccc-aad7-44fc-94c0-a0856c74271e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ad745bc1-9692-4b60-8ec9-22b6f09a4f7f" xlink:to="loc_us-gaap_StatementTable_9f4eeccc-aad7-44fc-94c0-a0856c74271e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_72808c0a-34a8-431b-99ab-119706070fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9f4eeccc-aad7-44fc-94c0-a0856c74271e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_72808c0a-34a8-431b-99ab-119706070fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_86ea4486-d26a-4fc4-9c69-bba6daeb04bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_72808c0a-34a8-431b-99ab-119706070fc0" xlink:to="loc_us-gaap_EquityComponentDomain_86ea4486-d26a-4fc4-9c69-bba6daeb04bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_fc90b545-db32-4021-9aaf-4da00e50ed36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_86ea4486-d26a-4fc4-9c69-bba6daeb04bd" xlink:to="loc_us-gaap_CommonStockMember_fc90b545-db32-4021-9aaf-4da00e50ed36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_98e087f3-1910-47cb-b3fb-13cac309631f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_86ea4486-d26a-4fc4-9c69-bba6daeb04bd" xlink:to="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_98e087f3-1910-47cb-b3fb-13cac309631f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_be5d90c0-8df2-4475-b852-b42d9c7691d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_86ea4486-d26a-4fc4-9c69-bba6daeb04bd" xlink:to="loc_us-gaap_RetainedEarningsMember_be5d90c0-8df2-4475-b852-b42d9c7691d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5f3f6f05-5ea9-4213-84a7-6fc0cce51e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_86ea4486-d26a-4fc4-9c69-bba6daeb04bd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5f3f6f05-5ea9-4213-84a7-6fc0cce51e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_edae7446-4878-4d53-adc3-62e872b3f69a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9f4eeccc-aad7-44fc-94c0-a0856c74271e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_edae7446-4878-4d53-adc3-62e872b3f69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_24e025ac-c735-4e36-9329-2b2947812e1a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_edae7446-4878-4d53-adc3-62e872b3f69a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_24e025ac-c735-4e36-9329-2b2947812e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5ad795b4-cb13-4ecf-a1b6-3c8734f48f3d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_24e025ac-c735-4e36-9329-2b2947812e1a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5ad795b4-cb13-4ecf-a1b6-3c8734f48f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5da11441-bc36-44d7-aec5-369d87003c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9f4eeccc-aad7-44fc-94c0-a0856c74271e" xlink:to="loc_us-gaap_StatementLineItems_5da11441-bc36-44d7-aec5-369d87003c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5da11441-bc36-44d7-aec5-369d87003c01" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_490246b1-3496-442d-a562-c451bcbbc613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_490246b1-3496-442d-a562-c451bcbbc613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b441e6e8-f290-4393-84c5-4a2f9d5dc74b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_StockholdersEquity_b441e6e8-f290-4393-84c5-4a2f9d5dc74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_87cd1921-c225-449c-9da1-2ac68ade8082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_NetIncomeLoss_87cd1921-c225-449c-9da1-2ac68ade8082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_11b7acba-fe10-4169-8e33-9168f809220f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_11b7acba-fe10-4169-8e33-9168f809220f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_680e6781-75c2-4756-bd6d-890fee175436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_DividendsCommonStockCash_680e6781-75c2-4756-bd6d-890fee175436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_20a409e6-4fea-49e3-ba88-b592401b2c94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_20a409e6-4fea-49e3-ba88-b592401b2c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_fd206a6a-8417-4576-a35a-4541479257b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_fd206a6a-8417-4576-a35a-4541479257b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5cde7b53-c3a7-4d83-82b3-216c91d0351f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5cde7b53-c3a7-4d83-82b3-216c91d0351f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b5e7300a-44ce-49b0-b961-3b4a7a95497d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b5e7300a-44ce-49b0-b961-3b4a7a95497d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_21f08daa-1679-4db0-8855-466567ac876f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_21f08daa-1679-4db0-8855-466567ac876f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_39b30298-631b-420d-af81-7be6fe2b51ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_39b30298-631b-420d-af81-7be6fe2b51ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_dd738cf5-8767-4248-9b39-a35dbede7af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_StockholdersEquityOther_dd738cf5-8767-4248-9b39-a35dbede7af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4b820afb-6512-4a88-97d2-7cc44ee6a698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4b820afb-6512-4a88-97d2-7cc44ee6a698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9c689784-009d-4a36-897a-4dde746d3e57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2f6840a1-1c0f-4d0d-ab74-9f0724596665" xlink:to="loc_us-gaap_StockholdersEquity_9c689784-009d-4a36-897a-4dde746d3e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="amgn-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5522eba0-cbe4-4b3e-8def-2b34b2a50c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_debb220e-4d73-43ad-b3e2-50cd05525a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5522eba0-cbe4-4b3e-8def-2b34b2a50c1e" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_debb220e-4d73-43ad-b3e2-50cd05525a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="amgn-20220630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_eaa2b0d7-31f3-4586-a531-4e14297ae028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4df13169-aab1-4a50-acea-0b7a42f1f147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eaa2b0d7-31f3-4586-a531-4e14297ae028" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4df13169-aab1-4a50-acea-0b7a42f1f147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c445fc76-7662-4043-87a7-44d95f8d5427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4df13169-aab1-4a50-acea-0b7a42f1f147" xlink:to="loc_us-gaap_NetIncomeLoss_c445fc76-7662-4043-87a7-44d95f8d5427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_598d4503-5c87-40fb-91d0-c16150614976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4df13169-aab1-4a50-acea-0b7a42f1f147" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_598d4503-5c87-40fb-91d0-c16150614976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_83db7255-5f97-46fc-9312-a5acd2aaf6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4df13169-aab1-4a50-acea-0b7a42f1f147" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_83db7255-5f97-46fc-9312-a5acd2aaf6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_1c16bf4f-bf2f-4410-b395-d81d107916e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4df13169-aab1-4a50-acea-0b7a42f1f147" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_1c16bf4f-bf2f-4410-b395-d81d107916e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d84769ca-c3ea-4317-95fd-a7b061311dee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4df13169-aab1-4a50-acea-0b7a42f1f147" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d84769ca-c3ea-4317-95fd-a7b061311dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_3cde24aa-0a86-46d4-9d07-01426ca2607d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4df13169-aab1-4a50-acea-0b7a42f1f147" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_3cde24aa-0a86-46d4-9d07-01426ca2607d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_0cf1987c-b385-426d-bcdc-d32d8dc51367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4df13169-aab1-4a50-acea-0b7a42f1f147" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_0cf1987c-b385-426d-bcdc-d32d8dc51367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d3761cb2-4cf8-4a68-9c49-668cdfa342aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4df13169-aab1-4a50-acea-0b7a42f1f147" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d3761cb2-4cf8-4a68-9c49-668cdfa342aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6c49d79d-fd11-4c82-af97-c9a2fb669bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d3761cb2-4cf8-4a68-9c49-668cdfa342aa" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6c49d79d-fd11-4c82-af97-c9a2fb669bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_fe76d0ed-bcc2-4f51-927e-63cc40bc0bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d3761cb2-4cf8-4a68-9c49-668cdfa342aa" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_fe76d0ed-bcc2-4f51-927e-63cc40bc0bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d3038249-87ab-4f9c-a834-f0750a6e9728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d3761cb2-4cf8-4a68-9c49-668cdfa342aa" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d3038249-87ab-4f9c-a834-f0750a6e9728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_719fd09b-e9f0-4374-898f-2dd2955b4e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d3761cb2-4cf8-4a68-9c49-668cdfa342aa" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_719fd09b-e9f0-4374-898f-2dd2955b4e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_46b44f69-19cc-400a-9d7c-e466f4744a96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d3761cb2-4cf8-4a68-9c49-668cdfa342aa" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_46b44f69-19cc-400a-9d7c-e466f4744a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability_1dd30870-20fc-4111-911d-a05f2022a269" xlink:href="amgn-20220630.xsd#amgn_IncreaseDecreaseInNoncurrentTaxLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d3761cb2-4cf8-4a68-9c49-668cdfa342aa" xlink:to="loc_amgn_IncreaseDecreaseInNoncurrentTaxLiability_1dd30870-20fc-4111-911d-a05f2022a269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_fe987c8a-9dfc-4b12-a0b5-983d35f81ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d3761cb2-4cf8-4a68-9c49-668cdfa342aa" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_fe987c8a-9dfc-4b12-a0b5-983d35f81ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_98df75ce-7160-4a79-9dc2-0c9de06e7e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4df13169-aab1-4a50-acea-0b7a42f1f147" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_98df75ce-7160-4a79-9dc2-0c9de06e7e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4c78f586-68a7-4893-93d6-1b646644ebaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eaa2b0d7-31f3-4586-a531-4e14297ae028" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4c78f586-68a7-4893-93d6-1b646644ebaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c727e6fa-18c7-4476-8eaf-8f1e18c34207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4c78f586-68a7-4893-93d6-1b646644ebaf" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c727e6fa-18c7-4476-8eaf-8f1e18c34207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_bb79262b-a017-4cd5-9e49-69cea59c4e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4c78f586-68a7-4893-93d6-1b646644ebaf" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_bb79262b-a017-4cd5-9e49-69cea59c4e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_49c132e5-2802-4cc9-874b-54d0e482de25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4c78f586-68a7-4893-93d6-1b646644ebaf" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_49c132e5-2802-4cc9-874b-54d0e482de25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a177e19a-3ec1-4c74-9fcc-db6a80d27c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4c78f586-68a7-4893-93d6-1b646644ebaf" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a177e19a-3ec1-4c74-9fcc-db6a80d27c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_b90b00f8-cc6a-4181-b1e0-899c1e5aff44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4c78f586-68a7-4893-93d6-1b646644ebaf" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_b90b00f8-cc6a-4181-b1e0-899c1e5aff44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ba74781a-e513-498e-ade7-a44c0fc5eba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4c78f586-68a7-4893-93d6-1b646644ebaf" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ba74781a-e513-498e-ade7-a44c0fc5eba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6f381cae-d946-408b-bb6a-e8b8ecf074d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4c78f586-68a7-4893-93d6-1b646644ebaf" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6f381cae-d946-408b-bb6a-e8b8ecf074d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_78a5eeae-3a5b-4986-a0df-e4716c770535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4c78f586-68a7-4893-93d6-1b646644ebaf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_78a5eeae-3a5b-4986-a0df-e4716c770535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1666fd7d-a449-49d8-a259-233b4cb7bd86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eaa2b0d7-31f3-4586-a531-4e14297ae028" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1666fd7d-a449-49d8-a259-233b4cb7bd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5ed00948-6741-46e5-9978-8cae10f0eb08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1666fd7d-a449-49d8-a259-233b4cb7bd86" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5ed00948-6741-46e5-9978-8cae10f0eb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_0aae25e3-a9e9-4b81-ae4e-fbd25b14ce6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1666fd7d-a449-49d8-a259-233b4cb7bd86" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_0aae25e3-a9e9-4b81-ae4e-fbd25b14ce6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_25ddb99f-1468-40ab-b307-69162a665887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1666fd7d-a449-49d8-a259-233b4cb7bd86" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_25ddb99f-1468-40ab-b307-69162a665887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_c4e30b3b-946b-4b5b-9fd8-1357894c471d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1666fd7d-a449-49d8-a259-233b4cb7bd86" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_c4e30b3b-946b-4b5b-9fd8-1357894c471d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_dd32cd0d-b0a3-48a1-b991-6337dcb5850e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1666fd7d-a449-49d8-a259-233b4cb7bd86" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_dd32cd0d-b0a3-48a1-b991-6337dcb5850e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f22eb74e-498b-4bcb-8663-de6a666d3675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1666fd7d-a449-49d8-a259-233b4cb7bd86" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f22eb74e-498b-4bcb-8663-de6a666d3675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ea478049-c8fd-4008-98ca-25b8f7dcc127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eaa2b0d7-31f3-4586-a531-4e14297ae028" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ea478049-c8fd-4008-98ca-25b8f7dcc127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6e9147a8-a592-40a7-9ae6-ebb49bd96e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eaa2b0d7-31f3-4586-a531-4e14297ae028" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6e9147a8-a592-40a7-9ae6-ebb49bd96e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_440d54ae-72df-455b-9c8f-ce95de16f086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eaa2b0d7-31f3-4586-a531-4e14297ae028" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_440d54ae-72df-455b-9c8f-ce95de16f086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Summaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="amgn-20220630.xsd#Summaryofsignificantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Summaryofsignificantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ae51616d-fbf7-4833-a768-9913a3a70d24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_f3f3b122-5383-4c79-9a80-bfc7a685b412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae51616d-fbf7-4833-a768-9913a3a70d24" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_f3f3b122-5383-4c79-9a80-bfc7a685b412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="amgn-20220630.xsd#SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fc75f7cc-1c60-4808-bfb8-9c83be146532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NatureOfOperationsPolicyTextBlock_e351428d-74f3-40c2-ab68-8df8639c9a20" xlink:href="amgn-20220630.xsd#amgn_NatureOfOperationsPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc75f7cc-1c60-4808-bfb8-9c83be146532" xlink:to="loc_amgn_NatureOfOperationsPolicyTextBlock_e351428d-74f3-40c2-ab68-8df8639c9a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BasisOfPresentationPolicyTextBlock_0797eedb-0854-4f6a-825e-0ba34d5c0de2" xlink:href="amgn-20220630.xsd#amgn_BasisOfPresentationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc75f7cc-1c60-4808-bfb8-9c83be146532" xlink:to="loc_amgn_BasisOfPresentationPolicyTextBlock_0797eedb-0854-4f6a-825e-0ba34d5c0de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_95fabe0a-265a-440b-bc43-3330a6b75341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc75f7cc-1c60-4808-bfb8-9c83be146532" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_95fabe0a-265a-440b-bc43-3330a6b75341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_0f2e15b7-53c7-4698-b5aa-9074568c422d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc75f7cc-1c60-4808-bfb8-9c83be146532" xlink:to="loc_us-gaap_UseOfEstimates_0f2e15b7-53c7-4698-b5aa-9074568c422d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_634cca52-bfa9-450a-b377-f428c007af52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc75f7cc-1c60-4808-bfb8-9c83be146532" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_634cca52-bfa9-450a-b377-f428c007af52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_18862507-2564-4bdf-908d-09033b3f3b64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc75f7cc-1c60-4808-bfb8-9c83be146532" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_18862507-2564-4bdf-908d-09033b3f3b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#SummaryofsignificantaccountingpoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e4ead244-89cf-46d2-bbe3-1999565746bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6dd194e7-a1d7-4f1f-8b24-654412cf4415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4ead244-89cf-46d2-bbe3-1999565746bd" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6dd194e7-a1d7-4f1f-8b24-654412cf4415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_75bd7e53-a9c4-4942-9dc0-1f446455363d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4ead244-89cf-46d2-bbe3-1999565746bd" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_75bd7e53-a9c4-4942-9dc0-1f446455363d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Acquisitions" xlink:type="simple" xlink:href="amgn-20220630.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_83c7180b-eb77-4a31-a126-4f09dfc40f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_3aa03188-abda-4764-9dbb-614c2bdd6014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_83c7180b-eb77-4a31-a126-4f09dfc40f05" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_3aa03188-abda-4764-9dbb-614c2bdd6014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="amgn-20220630.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_123b035d-5105-43be-9622-d84f274f9a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_bd9ebbd4-d6b2-49d8-9f5f-f6c3d46de72c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_123b035d-5105-43be-9622-d84f274f9a4a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_bd9ebbd4-d6b2-49d8-9f5f-f6c3d46de72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#AcquisitionsAggregateConsiderationPaidDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0133614b-a0c4-4deb-9985-3faa450367af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c1fb4e22-1cc6-4982-9f10-605a64ff2041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0133614b-a0c4-4deb-9985-3faa450367af" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c1fb4e22-1cc6-4982-9f10-605a64ff2041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bb74f0af-56c4-4005-bd65-55b655d8316c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c1fb4e22-1cc6-4982-9f10-605a64ff2041" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bb74f0af-56c4-4005-bd65-55b655d8316c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3d63635-2a62-4a40-a2a8-aac858b100cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bb74f0af-56c4-4005-bd65-55b655d8316c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3d63635-2a62-4a40-a2a8-aac858b100cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioMember_7076fa39-9279-4bb3-9c68-0aa42fcaec77" xlink:href="amgn-20220630.xsd#amgn_TeneobioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3d63635-2a62-4a40-a2a8-aac858b100cd" xlink:to="loc_amgn_TeneobioMember_7076fa39-9279-4bb3-9c68-0aa42fcaec77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_cb448094-ca37-4cd8-973a-cb8d233a88a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c1fb4e22-1cc6-4982-9f10-605a64ff2041" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_cb448094-ca37-4cd8-973a-cb8d233a88a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_76501f1d-17ed-4e9d-871a-5e7d5560bbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_cb448094-ca37-4cd8-973a-cb8d233a88a7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_76501f1d-17ed-4e9d-871a-5e7d5560bbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a2452c56-efae-4cf9-a48b-15143693b789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_76501f1d-17ed-4e9d-871a-5e7d5560bbf4" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a2452c56-efae-4cf9-a48b-15143693b789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70b01f5c-27fe-4172-a3fe-2a472328fffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c1fb4e22-1cc6-4982-9f10-605a64ff2041" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70b01f5c-27fe-4172-a3fe-2a472328fffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4073f5b-ba7b-4e5a-b1e6-94a1ef4fb165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70b01f5c-27fe-4172-a3fe-2a472328fffc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4073f5b-ba7b-4e5a-b1e6-94a1ef4fb165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RDTechnologyrightsMember_ab46ca5f-1597-4103-9667-de367b1cfd1f" xlink:href="amgn-20220630.xsd#amgn_RDTechnologyrightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4073f5b-ba7b-4e5a-b1e6-94a1ef4fb165" xlink:to="loc_amgn_RDTechnologyrightsMember_ab46ca5f-1597-4103-9667-de367b1cfd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_37e2b069-f4a8-4975-a3de-eb80bc9f7e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4073f5b-ba7b-4e5a-b1e6-94a1ef4fb165" xlink:to="loc_us-gaap_LicensingAgreementsMember_37e2b069-f4a8-4975-a3de-eb80bc9f7e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c1fb4e22-1cc6-4982-9f10-605a64ff2041" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_4a82159f-46dc-41f7-9c60-64728766088c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_4a82159f-46dc-41f7-9c60-64728766088c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_494f37b6-b26b-4d1e-ba29-3fe522f761bd" xlink:href="amgn-20220630.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_494f37b6-b26b-4d1e-ba29-3fe522f761bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_Businessassetacquisitionconsiderationtransferred_80839fbc-734d-43e1-9181-6bb729cc489a" xlink:href="amgn-20220630.xsd#amgn_Businessassetacquisitionconsiderationtransferred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_amgn_Businessassetacquisitionconsiderationtransferred_80839fbc-734d-43e1-9181-6bb729cc489a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d44be0fa-f3e5-4a2a-a08d-47814d248918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d44be0fa-f3e5-4a2a-a08d-47814d248918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5a312423-36e5-48cd-9fb8-8ddb58a805de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5a312423-36e5-48cd-9fb8-8ddb58a805de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_322a766a-5908-4dcb-81b9-660c97da524f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_322a766a-5908-4dcb-81b9-660c97da524f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0f865059-1b07-43e1-a770-7cf8d22c6a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_us-gaap_Goodwill_0f865059-1b07-43e1-a770-7cf8d22c6a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_920d322d-5e35-4582-9f95-dc082fc3cef4" xlink:href="amgn-20220630.xsd#amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities_920d322d-5e35-4582-9f95-dc082fc3cef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7b671eb2-f09b-40b4-871f-1691413cba93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7b671eb2-f09b-40b4-871f-1691413cba93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_3299aafc-613c-41ce-8b5f-82add278968d" xlink:href="amgn-20220630.xsd#amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_045c820c-67b5-482d-8b5e-1556dc15d453" xlink:to="loc_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet_3299aafc-613c-41ce-8b5f-82add278968d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_66949586-91b2-44ce-8f84-0b097f76c53b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_66949586-91b2-44ce-8f84-0b097f76c53b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_80f35d72-8460-4f29-a328-efde3d210aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_80f35d72-8460-4f29-a328-efde3d210aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac08d3f4-8e4e-4339-ac24-3909522f7613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_80f35d72-8460-4f29-a328-efde3d210aed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac08d3f4-8e4e-4339-ac24-3909522f7613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioMember_ae3f4b9c-fa16-452c-8af7-51a5cb0e9bb7" xlink:href="amgn-20220630.xsd#amgn_TeneobioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac08d3f4-8e4e-4339-ac24-3909522f7613" xlink:to="loc_amgn_TeneobioMember_ae3f4b9c-fa16-452c-8af7-51a5cb0e9bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePrimeTherapeuticsIncMember_41ff0b9b-abd6-463f-b9b5-7642d9c64412" xlink:href="amgn-20220630.xsd#amgn_FivePrimeTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac08d3f4-8e4e-4339-ac24-3909522f7613" xlink:to="loc_amgn_FivePrimeTherapeuticsIncMember_41ff0b9b-abd6-463f-b9b5-7642d9c64412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d55bd640-4d2f-414a-be29-69436ce1ab68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d55bd640-4d2f-414a-be29-69436ce1ab68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5bc65de2-bdd2-4e8c-a6e7-6984091a4ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d55bd640-4d2f-414a-be29-69436ce1ab68" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5bc65de2-bdd2-4e8c-a6e7-6984091a4ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_ae347ec5-9569-48fb-bf5c-060f8193260b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5bc65de2-bdd2-4e8c-a6e7-6984091a4ae7" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_ae347ec5-9569-48fb-bf5c-060f8193260b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeAxis_e074efdb-00c1-48ae-af3a-e956390ebe49" xlink:href="amgn-20220630.xsd#amgn_MoleculeTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:to="loc_amgn_MoleculeTypeAxis_e074efdb-00c1-48ae-af3a-e956390ebe49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MoleculeTypeDomain_29a75eba-33f7-4eeb-865c-b1e647801960" xlink:href="amgn-20220630.xsd#amgn_MoleculeTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_MoleculeTypeAxis_e074efdb-00c1-48ae-af3a-e956390ebe49" xlink:to="loc_amgn_MoleculeTypeDomain_29a75eba-33f7-4eeb-865c-b1e647801960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AMG340Member_878d6c9b-1c03-4957-9674-17adf3609a55" xlink:href="amgn-20220630.xsd#amgn_AMG340Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_MoleculeTypeDomain_29a75eba-33f7-4eeb-865c-b1e647801960" xlink:to="loc_amgn_AMG340Member_878d6c9b-1c03-4957-9674-17adf3609a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54c7ddd6-1fcc-4249-961a-2cd0c8e641a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54c7ddd6-1fcc-4249-961a-2cd0c8e641a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a785ab77-4fce-4e6d-b157-4d6e6ab48995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54c7ddd6-1fcc-4249-961a-2cd0c8e641a0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a785ab77-4fce-4e6d-b157-4d6e6ab48995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RDTechnologyrightsMember_20e5b0e9-5f0a-404e-ba24-d6794b794b24" xlink:href="amgn-20220630.xsd#amgn_RDTechnologyrightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a785ab77-4fce-4e6d-b157-4d6e6ab48995" xlink:to="loc_amgn_RDTechnologyrightsMember_20e5b0e9-5f0a-404e-ba24-d6794b794b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_2d736b0d-81ee-4496-a6d4-7333e8266740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a785ab77-4fce-4e6d-b157-4d6e6ab48995" xlink:to="loc_us-gaap_LicensingAgreementsMember_2d736b0d-81ee-4496-a6d4-7333e8266740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e8ce04dc-2b5e-4b02-92fc-73b690992fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e8ce04dc-2b5e-4b02-92fc-73b690992fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6091088f-f1e5-41ec-9220-4a5b0a76f21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e8ce04dc-2b5e-4b02-92fc-73b690992fae" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6091088f-f1e5-41ec-9220-4a5b0a76f21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GensentaIlacSanayiVsTicaretMember_820f48dc-0085-45ed-8d13-0bfd8293bb5a" xlink:href="amgn-20220630.xsd#amgn_GensentaIlacSanayiVsTicaretMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_6091088f-f1e5-41ec-9220-4a5b0a76f21c" xlink:to="loc_amgn_GensentaIlacSanayiVsTicaretMember_820f48dc-0085-45ed-8d13-0bfd8293bb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_88917a87-33dc-4bd3-a276-eb436d31cb18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_88917a87-33dc-4bd3-a276-eb436d31cb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e8dd0c80-d374-4b53-9cbf-0de376099d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_88917a87-33dc-4bd3-a276-eb436d31cb18" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e8dd0c80-d374-4b53-9cbf-0de376099d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_GensentaIlacSanayiVsTicaretMember_afda5e83-1fd8-4f2d-b401-835e563a0afe" xlink:href="amgn-20220630.xsd#amgn_GensentaIlacSanayiVsTicaretMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e8dd0c80-d374-4b53-9cbf-0de376099d5c" xlink:to="loc_amgn_GensentaIlacSanayiVsTicaretMember_afda5e83-1fd8-4f2d-b401-835e563a0afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_b5415159-c546-40b6-94ae-949a96ccdf38" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:to="loc_srt_StatementScenarioAxis_b5415159-c546-40b6-94ae-949a96ccdf38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_bec63f7a-6699-4c0d-bb91-c8ce7d15c132" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_b5415159-c546-40b6-94ae-949a96ccdf38" xlink:to="loc_srt_ScenarioUnspecifiedDomain_bec63f7a-6699-4c0d-bb91-c8ce7d15c132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_77a50374-8afc-4671-85f9-8153d028e911" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_bec63f7a-6699-4c0d-bb91-c8ce7d15c132" xlink:to="loc_srt_ScenarioForecastMember_77a50374-8afc-4671-85f9-8153d028e911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis_5a17668b-e784-4933-9132-f1e1bd07267c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:to="loc_us-gaap_NatureOfExpenseAxis_5a17668b-e784-4933-9132-f1e1bd07267c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_e8790b11-cbf3-455e-8dc5-0ab21ff013c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NatureOfExpenseAxis_5a17668b-e784-4933-9132-f1e1bd07267c" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_e8790b11-cbf3-455e-8dc5-0ab21ff013c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_73ca49a5-7abc-45e6-87a0-0d44cfa967bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_73ca49a5-7abc-45e6-87a0-0d44cfa967bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b50ce536-753a-4428-8d03-d1489a9e8d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_73ca49a5-7abc-45e6-87a0-0d44cfa967bd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b50ce536-753a-4428-8d03-d1489a9e8d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_f76e61a1-bfc9-485a-ad1a-48a1539eaf27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b50ce536-753a-4428-8d03-d1489a9e8d7f" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_f76e61a1-bfc9-485a-ad1a-48a1539eaf27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bf7ecc9c-00eb-4b5a-b35e-b429fd892b2c" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_1e273ee6-db4d-4718-ad79-be5ad2b55c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_1e273ee6-db4d-4718-ad79-be5ad2b55c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_cd7676e6-cf01-413f-b192-fb0de20bca9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_cd7676e6-cf01-413f-b192-fb0de20bca9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_1fb48d56-944e-45e2-a43b-c84d50425598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_1fb48d56-944e-45e2-a43b-c84d50425598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_086d49f4-d519-441b-af99-040df32fd773" xlink:href="amgn-20220630.xsd#amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions_086d49f4-d519-441b-af99-040df32fd773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_85417f28-3833-4b25-957d-6fe8e898b470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_85417f28-3833-4b25-957d-6fe8e898b470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_b5a8e88e-89db-42f6-aede-ecb0ed9b1f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_b5a8e88e-89db-42f6-aede-ecb0ed9b1f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ea0da135-f344-49e4-aa92-637481e0bc12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ea0da135-f344-49e4-aa92-637481e0bc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_fbd29332-d686-4b2e-9c05-5c0d950ad7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_fbd29332-d686-4b2e-9c05-5c0d950ad7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8db1fb76-5096-4a57-8489-001840f428ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_Goodwill_8db1fb76-5096-4a57-8489-001840f428ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates_5eaaad67-b82c-49d6-8cae-6e674ebec98c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates_5eaaad67-b82c-49d6-8cae-6e674ebec98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_1439f518-0801-43c5-a826-ee7092d50b67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_1439f518-0801-43c5-a826-ee7092d50b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_447659b4-6192-44a2-bc53-5d017a6f69f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_447659b4-6192-44a2-bc53-5d017a6f69f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_a014dd92-e892-4957-95eb-de1365ba4f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_a014dd92-e892-4957-95eb-de1365ba4f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_662832ae-bdaf-4c7b-a0b1-9560d1b1cd95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_662832ae-bdaf-4c7b-a0b1-9560d1b1cd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_c01968ce-047b-44ef-a48b-75c33ac8a2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_c01968ce-047b-44ef-a48b-75c33ac8a2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_e6598d74-26fd-4787-9c81-d1aef73c72bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_e6598d74-26fd-4787-9c81-d1aef73c72bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_7dc2ec4f-2b78-4548-8769-9fe3b55bc2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_7dc2ec4f-2b78-4548-8769-9fe3b55bc2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_f95f6464-a634-4a81-addd-93a8da735f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_f95f6464-a634-4a81-addd-93a8da735f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_13c05f0d-1d4d-46cd-b053-76ca3c6fc45f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_13c05f0d-1d4d-46cd-b053-76ca3c6fc45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_838c496b-7d23-4b6f-9f9c-b9e960cb7ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_838c496b-7d23-4b6f-9f9c-b9e960cb7ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_fd4354bd-fc5c-4dff-920e-00021e64c283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_fd4354bd-fc5c-4dff-920e-00021e64c283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_e9ee37c4-492e-4a94-a8ff-49a3078be6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_e9ee37c4-492e-4a94-a8ff-49a3078be6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_c49d4b1c-f67e-420a-a516-f479039f9775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8b695525-fa98-49df-a82c-7ed5270a9fab" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_c49d4b1c-f67e-420a-a516-f479039f9775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Revenues" xlink:type="simple" xlink:href="amgn-20220630.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_091d677b-1578-4e5e-afcf-0e1fbfbc43e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7d9b512b-8703-4acb-bc6e-161a88869468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_091d677b-1578-4e5e-afcf-0e1fbfbc43e1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7d9b512b-8703-4acb-bc6e-161a88869468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesTables" xlink:type="simple" xlink:href="amgn-20220630.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_275481b4-a32a-42e3-9f57-09d6343c6f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_a0631206-cb66-4fec-9d91-a0c5306525b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_275481b4-a32a-42e3-9f57-09d6343c6f3f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_a0631206-cb66-4fec-9d91-a0c5306525b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/RevenuesDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#RevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/RevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_824a0dff-3755-4c2f-a274-db14c769d739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_91b3b08f-a368-437b-9468-ad50aa73dbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_824a0dff-3755-4c2f-a274-db14c769d739" xlink:to="loc_us-gaap_NumberOfOperatingSegments_91b3b08f-a368-437b-9468-ad50aa73dbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_396cb35a-8df2-4c45-a529-e18dbe91b860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_824a0dff-3755-4c2f-a274-db14c769d739" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_396cb35a-8df2-4c45-a529-e18dbe91b860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a7cb9fe2-d4f3-46aa-90e4-5b9bc19cab6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_396cb35a-8df2-4c45-a529-e18dbe91b860" xlink:to="loc_srt_ProductOrServiceAxis_a7cb9fe2-d4f3-46aa-90e4-5b9bc19cab6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dfedd504-d53e-4694-8d38-916d21e8ca73" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a7cb9fe2-d4f3-46aa-90e4-5b9bc19cab6d" xlink:to="loc_srt_ProductsAndServicesDomain_dfedd504-d53e-4694-8d38-916d21e8ca73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dfedd504-d53e-4694-8d38-916d21e8ca73" xlink:to="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EnbrelMember_adfaf5b9-60c5-4700-8f8f-397ee5f5402a" xlink:href="amgn-20220630.xsd#amgn_EnbrelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:to="loc_amgn_EnbrelMember_adfaf5b9-60c5-4700-8f8f-397ee5f5402a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProliaMember_3d5985c7-39eb-4b53-a6e7-e3a2c6842ea2" xlink:href="amgn-20220630.xsd#amgn_ProliaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:to="loc_amgn_ProliaMember_3d5985c7-39eb-4b53-a6e7-e3a2c6842ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaMember_2c5a4ef8-b14d-4257-8d7b-4895439fcc80" xlink:href="amgn-20220630.xsd#amgn_OtezlaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:to="loc_amgn_OtezlaMember_2c5a4ef8-b14d-4257-8d7b-4895439fcc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_XgevaMember_27443303-30db-44ec-bc85-37a7976fd889" xlink:href="amgn-20220630.xsd#amgn_XgevaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:to="loc_amgn_XgevaMember_27443303-30db-44ec-bc85-37a7976fd889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AranespMember_81bbb991-df1f-4987-9d5e-eb867a242951" xlink:href="amgn-20220630.xsd#amgn_AranespMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:to="loc_amgn_AranespMember_81bbb991-df1f-4987-9d5e-eb867a242951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeulastaMember_25817fad-2538-480c-af53-e504013fa643" xlink:href="amgn-20220630.xsd#amgn_NeulastaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:to="loc_amgn_NeulastaMember_25817fad-2538-480c-af53-e504013fa643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepathaevolocumabMember_3f74a93c-6a78-4418-9ecf-c845bafb7c91" xlink:href="amgn-20220630.xsd#amgn_RepathaevolocumabMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:to="loc_amgn_RepathaevolocumabMember_3f74a93c-6a78-4418-9ecf-c845bafb7c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyprolisMember_6c770d47-3736-4479-98ce-78198c714ab2" xlink:href="amgn-20220630.xsd#amgn_KyprolisMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:to="loc_amgn_KyprolisMember_6c770d47-3736-4479-98ce-78198c714ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NplateMember_a6a447a1-75f1-4cf6-91fd-05331844a774" xlink:href="amgn-20220630.xsd#amgn_NplateMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:to="loc_amgn_NplateMember_a6a447a1-75f1-4cf6-91fd-05331844a774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherProductsMember_42f0c56d-fc4a-4424-8cf9-43f272197666" xlink:href="amgn-20220630.xsd#amgn_OtherProductsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_20751c3c-66c7-43b7-80b7-0305f6a6b1d2" xlink:to="loc_amgn_OtherProductsMember_42f0c56d-fc4a-4424-8cf9-43f272197666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_e6103127-4f82-40f9-b6c1-6fe6cc832c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dfedd504-d53e-4694-8d38-916d21e8ca73" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_e6103127-4f82-40f9-b6c1-6fe6cc832c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7134476a-7eb8-4338-a07c-bb82e20270e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_396cb35a-8df2-4c45-a529-e18dbe91b860" xlink:to="loc_srt_StatementGeographicalAxis_7134476a-7eb8-4338-a07c-bb82e20270e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b39e0e13-191f-40f9-9669-a0c0b1f2bcdf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_7134476a-7eb8-4338-a07c-bb82e20270e1" xlink:to="loc_srt_SegmentGeographicalDomain_b39e0e13-191f-40f9-9669-a0c0b1f2bcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c26da6a7-7f29-4b4f-ac39-a75301655945" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b39e0e13-191f-40f9-9669-a0c0b1f2bcdf" xlink:to="loc_country_US_c26da6a7-7f29-4b4f-ac39-a75301655945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_5a0ab316-a3da-41af-baca-efbb3ba9eb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b39e0e13-191f-40f9-9669-a0c0b1f2bcdf" xlink:to="loc_us-gaap_NonUsMember_5a0ab316-a3da-41af-baca-efbb3ba9eb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_834490bb-7031-4e15-b94b-cb11f812bfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_396cb35a-8df2-4c45-a529-e18dbe91b860" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_834490bb-7031-4e15-b94b-cb11f812bfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fec06913-def5-4cef-8572-a9eabecf7eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_834490bb-7031-4e15-b94b-cb11f812bfbc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fec06913-def5-4cef-8572-a9eabecf7eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Incometaxes" xlink:type="simple" xlink:href="amgn-20220630.xsd#Incometaxes"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Incometaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c6972762-81fd-4a66-8eb2-3ffbd3da1cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_ab0c9d3a-0807-4f22-ac3e-665e9ae1659c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c6972762-81fd-4a66-8eb2-3ffbd3da1cb6" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_ab0c9d3a-0807-4f22-ac3e-665e9ae1659c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/IncometaxesDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#IncometaxesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/IncometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_48b8988b-2a85-4434-b912-37cd65e2f83c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_ebcb6d31-e9ff-4862-8c02-b14ac668df42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_48b8988b-2a85-4434-b912-37cd65e2f83c" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_ebcb6d31-e9ff-4862-8c02-b14ac668df42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_083b067c-719b-4ea3-aad0-2bbc641f6664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_ebcb6d31-e9ff-4862-8c02-b14ac668df42" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_083b067c-719b-4ea3-aad0-2bbc641f6664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_bdcc4c95-e3d4-4567-8afd-e8a070a4b970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_083b067c-719b-4ea3-aad0-2bbc641f6664" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_bdcc4c95-e3d4-4567-8afd-e8a070a4b970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_3d753eaa-4177-45b8-86ca-f16db02ce1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_bdcc4c95-e3d4-4567-8afd-e8a070a4b970" xlink:to="loc_us-gaap_DomesticCountryMember_3d753eaa-4177-45b8-86ca-f16db02ce1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_522f57c0-214a-4f7f-b8db-c4d44dfeb6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_ebcb6d31-e9ff-4862-8c02-b14ac668df42" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_522f57c0-214a-4f7f-b8db-c4d44dfeb6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0c0f5cdc-2da5-430b-a0ec-a8723b8f8ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_522f57c0-214a-4f7f-b8db-c4d44dfeb6f1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0c0f5cdc-2da5-430b-a0ec-a8723b8f8ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c23478c4-622d-4ac9-9122-84a4c144815e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0c0f5cdc-2da5-430b-a0ec-a8723b8f8ba2" xlink:to="loc_us-gaap_SubsequentEventMember_c23478c4-622d-4ac9-9122-84a4c144815e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_d19f6fd1-e869-49ef-aea1-ad229e29b1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_ebcb6d31-e9ff-4862-8c02-b14ac668df42" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_d19f6fd1-e869-49ef-aea1-ad229e29b1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_25ecfce1-e9cc-441c-b63f-e2e814f8c889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_d19f6fd1-e869-49ef-aea1-ad229e29b1d2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_25ecfce1-e9cc-441c-b63f-e2e814f8c889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProposedAdditionalIncomeTax_35d62b1c-a710-46cb-893d-2e448aa9f739" xlink:href="amgn-20220630.xsd#amgn_ProposedAdditionalIncomeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_d19f6fd1-e869-49ef-aea1-ad229e29b1d2" xlink:to="loc_amgn_ProposedAdditionalIncomeTax_35d62b1c-a710-46cb-893d-2e448aa9f739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepatriationTaxOnProposedAdditionalTax_a4f665c4-0ff8-468a-90e4-24ae9489f541" xlink:href="amgn-20220630.xsd#amgn_RepatriationTaxOnProposedAdditionalTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_d19f6fd1-e869-49ef-aea1-ad229e29b1d2" xlink:to="loc_amgn_RepatriationTaxOnProposedAdditionalTax_a4f665c4-0ff8-468a-90e4-24ae9489f541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ProposedAdditionalIncomeTax20132015_06002d8f-41ab-4514-8c3b-346ae045a02c" xlink:href="amgn-20220630.xsd#amgn_ProposedAdditionalIncomeTax20132015"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_d19f6fd1-e869-49ef-aea1-ad229e29b1d2" xlink:to="loc_amgn_ProposedAdditionalIncomeTax20132015_06002d8f-41ab-4514-8c3b-346ae045a02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105_e4f2bf5b-20ee-4fa7-8ab1-260d66a0697a" xlink:href="amgn-20220630.xsd#amgn_PenaltiesOnProposedAdditionalIncomeTax20132105"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_d19f6fd1-e869-49ef-aea1-ad229e29b1d2" xlink:to="loc_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105_e4f2bf5b-20ee-4fa7-8ab1-260d66a0697a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_RepatriationTaxOnProposedAdditionalTax20132015_ab6daa3b-ba3a-4dd6-85ca-8fc1e40c08d7" xlink:href="amgn-20220630.xsd#amgn_RepatriationTaxOnProposedAdditionalTax20132015"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_d19f6fd1-e869-49ef-aea1-ad229e29b1d2" xlink:to="loc_amgn_RepatriationTaxOnProposedAdditionalTax20132015_ab6daa3b-ba3a-4dd6-85ca-8fc1e40c08d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7f8f09ba-810d-4c0a-a591-fc48b0eaa4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_d19f6fd1-e869-49ef-aea1-ad229e29b1d2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7f8f09ba-810d-4c0a-a591-fc48b0eaa4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Earningspershare" xlink:type="simple" xlink:href="amgn-20220630.xsd#Earningspershare"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Earningspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_01e2bea0-b982-489f-a7f6-034d54bf1fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_80a9344c-8842-4bbc-8fe7-d9f415bcee6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_01e2bea0-b982-489f-a7f6-034d54bf1fa1" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_80a9344c-8842-4bbc-8fe7-d9f415bcee6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/EarningspershareTables" xlink:type="simple" xlink:href="amgn-20220630.xsd#EarningspershareTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/EarningspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_df851646-5dc4-4938-8920-b1e6e09aabf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_19946afe-d140-403c-a0e5-bec41755b012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_df851646-5dc4-4938-8920-b1e6e09aabf7" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_19946afe-d140-403c-a0e5-bec41755b012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/EarningspershareDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#EarningspershareDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/EarningspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_db6a1499-ab76-4e1f-9e75-05183e6156f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BasicAndDilutedEarningPerShareAbstract_eac3e9d3-e089-4a3e-a13a-2de92c93c57d" xlink:href="amgn-20220630.xsd#amgn_BasicAndDilutedEarningPerShareAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_db6a1499-ab76-4e1f-9e75-05183e6156f4" xlink:to="loc_amgn_BasicAndDilutedEarningPerShareAbstract_eac3e9d3-e089-4a3e-a13a-2de92c93c57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_3ae7a7d2-8afc-4192-be9f-b12647b81672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BasicAndDilutedEarningPerShareAbstract_eac3e9d3-e089-4a3e-a13a-2de92c93c57d" xlink:to="loc_us-gaap_NetIncomeLossAbstract_3ae7a7d2-8afc-4192-be9f-b12647b81672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4efed502-3b87-4523-b31d-6f059aa5ab2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_3ae7a7d2-8afc-4192-be9f-b12647b81672" xlink:to="loc_us-gaap_NetIncomeLoss_4efed502-3b87-4523-b31d-6f059aa5ab2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_855a72c8-bf67-437d-94ae-f8f004fadd97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BasicAndDilutedEarningPerShareAbstract_eac3e9d3-e089-4a3e-a13a-2de92c93c57d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_855a72c8-bf67-437d-94ae-f8f004fadd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19a98296-6736-4059-8091-2dc39d9f3eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_855a72c8-bf67-437d-94ae-f8f004fadd97" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19a98296-6736-4059-8091-2dc39d9f3eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_77ac6620-17cf-4820-9b67-f81026eb0659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_855a72c8-bf67-437d-94ae-f8f004fadd97" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_77ac6620-17cf-4820-9b67-f81026eb0659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_64f8030b-bcc3-4c82-943b-af52c592ee93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_855a72c8-bf67-437d-94ae-f8f004fadd97" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_64f8030b-bcc3-4c82-943b-af52c592ee93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d3c46e98-388d-4aff-8e09-879cbca3ccd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BasicAndDilutedEarningPerShareAbstract_eac3e9d3-e089-4a3e-a13a-2de92c93c57d" xlink:to="loc_us-gaap_EarningsPerShareBasic_d3c46e98-388d-4aff-8e09-879cbca3ccd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ed07c568-7660-4f10-a35a-63c1970b2645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BasicAndDilutedEarningPerShareAbstract_eac3e9d3-e089-4a3e-a13a-2de92c93c57d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ed07c568-7660-4f10-a35a-63c1970b2645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Investments" xlink:type="simple" xlink:href="amgn-20220630.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_28893e81-ceb3-4104-80a9-194034c76a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_43cb5f97-e958-4873-a621-47de78ecdb1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_28893e81-ceb3-4104-80a9-194034c76a9e" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_43cb5f97-e958-4873-a621-47de78ecdb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsTables" xlink:type="simple" xlink:href="amgn-20220630.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5ee03ec0-8882-4ad2-bc67-31813063f7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_62c3a15b-5fef-4d03-bfaf-e19aa19a0d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5ee03ec0-8882-4ad2-bc67-31813063f7c5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_62c3a15b-5fef-4d03-bfaf-e19aa19a0d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock_3092c09b-7aba-465b-a26b-b32049b6230c" xlink:href="amgn-20220630.xsd#amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5ee03ec0-8882-4ad2-bc67-31813063f7c5" xlink:to="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock_3092c09b-7aba-465b-a26b-b32049b6230c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_f2f5de8d-cedf-409e-8e5c-e045cff3fcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5ee03ec0-8882-4ad2-bc67-31813063f7c5" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_f2f5de8d-cedf-409e-8e5c-e045cff3fcc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#InvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_24fb6902-84c5-4c56-9567-578483c3d6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2380574a-2637-48e6-84a8-985f99039782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_24fb6902-84c5-4c56-9567-578483c3d6c6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2380574a-2637-48e6-84a8-985f99039782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1e67d5dc-ba35-429e-82df-4fce0748c1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2380574a-2637-48e6-84a8-985f99039782" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1e67d5dc-ba35-429e-82df-4fce0748c1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1e67d5dc-ba35-429e-82df-4fce0748c1bd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_3d5c65ce-804e-4554-b8cf-34f6acbba15c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_3d5c65ce-804e-4554-b8cf-34f6acbba15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_926d8605-17f7-43ca-bcc1-2dc62c5190a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_926d8605-17f7-43ca-bcc1-2dc62c5190a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_73c2e13f-e6b9-476f-a78d-a163af5c9fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_73c2e13f-e6b9-476f-a78d-a163af5c9fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_528f38bf-32f0-413a-b26c-76433ef36938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_528f38bf-32f0-413a-b26c-76433ef36938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesFinancialMember_186a4a9f-eef1-4c0e-99ca-c8e3883abf12" xlink:href="amgn-20220630.xsd#amgn_CorporateDebtSecuritiesFinancialMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_amgn_CorporateDebtSecuritiesFinancialMember_186a4a9f-eef1-4c0e-99ca-c8e3883abf12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesIndustrialMember_84125201-60c3-4736-9698-8cb92525ed21" xlink:href="amgn-20220630.xsd#amgn_CorporateDebtSecuritiesIndustrialMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_amgn_CorporateDebtSecuritiesIndustrialMember_84125201-60c3-4736-9698-8cb92525ed21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesOtherMember_3374ea53-93dc-40fe-89e3-97290e98e2dd" xlink:href="amgn-20220630.xsd#amgn_CorporateDebtSecuritiesOtherMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_amgn_CorporateDebtSecuritiesOtherMember_3374ea53-93dc-40fe-89e3-97290e98e2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_92210404-8874-4f9c-8ab1-6db94f46a14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_92210404-8874-4f9c-8ab1-6db94f46a14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_516e7a5b-92ad-4171-a742-4e7318c52d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_516e7a5b-92ad-4171-a742-4e7318c52d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c3c13956-2a31-4776-a072-e82f79dae1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c3c13956-2a31-4776-a072-e82f79dae1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_5f02120a-3305-4bb5-b6a5-609495728dbc" xlink:href="amgn-20220630.xsd#amgn_OtherShortTermInterestBearingSecuritiesMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c4ed247-3844-4064-abbb-a84a02a0f9f9" xlink:to="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_5f02120a-3305-4bb5-b6a5-609495728dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3dd7268a-b846-403b-a33d-74613a20305c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2380574a-2637-48e6-84a8-985f99039782" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3dd7268a-b846-403b-a33d-74613a20305c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_671d86d0-7bba-476c-b4ea-64e2a22c5c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3dd7268a-b846-403b-a33d-74613a20305c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_671d86d0-7bba-476c-b4ea-64e2a22c5c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_98bc35f5-44a7-4e5b-bf4d-4b28ee322f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3dd7268a-b846-403b-a33d-74613a20305c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_98bc35f5-44a7-4e5b-bf4d-4b28ee322f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cabd7f46-84a5-46ff-b627-8945b660ca00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3dd7268a-b846-403b-a33d-74613a20305c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cabd7f46-84a5-46ff-b627-8945b660ca00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_95149c99-3dbb-4952-965f-2738d5b9c942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3dd7268a-b846-403b-a33d-74613a20305c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_95149c99-3dbb-4952-965f-2738d5b9c942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#InvestmentsFairValuesbyClassificationDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_abd4c703-1b44-460c-9e4f-17b37295327a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a5ab8f30-20af-4303-b18f-2ba3d05188da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_abd4c703-1b44-460c-9e4f-17b37295327a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a5ab8f30-20af-4303-b18f-2ba3d05188da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7296c942-1026-416a-9096-551ee269000f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a5ab8f30-20af-4303-b18f-2ba3d05188da" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7296c942-1026-416a-9096-551ee269000f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_124477b0-67b2-406e-bf1c-ed5d0e61c034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7296c942-1026-416a-9096-551ee269000f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_124477b0-67b2-406e-bf1c-ed5d0e61c034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSalesInvestmentsMember_458742c1-6b82-4860-aa57-3972f7ac8f06" xlink:href="amgn-20220630.xsd#amgn_AvailableForSalesInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_124477b0-67b2-406e-bf1c-ed5d0e61c034" xlink:to="loc_amgn_AvailableForSalesInvestmentsMember_458742c1-6b82-4860-aa57-3972f7ac8f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_15324f7e-532f-49a7-98af-d6b745a924be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a5ab8f30-20af-4303-b18f-2ba3d05188da" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_15324f7e-532f-49a7-98af-d6b745a924be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_0867e42a-7fd2-4837-ac07-4033cf8325cc" xlink:href="amgn-20220630.xsd#amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_15324f7e-532f-49a7-98af-d6b745a924be" xlink:to="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_0867e42a-7fd2-4837-ac07-4033cf8325cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ec55046b-718d-4087-8aa9-ff175db0e98e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_0867e42a-7fd2-4837-ac07-4033cf8325cc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ec55046b-718d-4087-8aa9-ff175db0e98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c17f752d-a2bb-4870-9497-6773d0e57773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_0867e42a-7fd2-4837-ac07-4033cf8325cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c17f752d-a2bb-4870-9497-6773d0e57773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fee175bd-b9eb-4bea-9e0d-195271f11ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract_0867e42a-7fd2-4837-ac07-4033cf8325cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fee175bd-b9eb-4bea-9e0d-195271f11ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual" xlink:type="simple" xlink:href="amgn-20220630.xsd#InvestmentsAvailableforsaleInvestmentsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d26bf0b4-6b92-4086-9cef-f54adb9da395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_d11d2d4c-779a-4c72-b56e-ffec454116f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d26bf0b4-6b92-4086-9cef-f54adb9da395" xlink:to="loc_us-gaap_Cash_d11d2d4c-779a-4c72-b56e-ffec454116f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_ec7ae5cd-ffc9-4098-b766-b7411f1c3a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d26bf0b4-6b92-4086-9cef-f54adb9da395" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_ec7ae5cd-ffc9-4098-b766-b7411f1c3a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_ef16c23c-b123-4660-9e90-5bf95611b196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d26bf0b4-6b92-4086-9cef-f54adb9da395" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_ef16c23c-b123-4660-9e90-5bf95611b196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c21034d3-4775-44bb-b3ce-aaaf9b29c73c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d26bf0b4-6b92-4086-9cef-f54adb9da395" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c21034d3-4775-44bb-b3ce-aaaf9b29c73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f674a955-d866-49aa-b2d0-c53deeeea441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c21034d3-4775-44bb-b3ce-aaaf9b29c73c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f674a955-d866-49aa-b2d0-c53deeeea441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90b22114-bad2-484e-b500-3494b625425f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f674a955-d866-49aa-b2d0-c53deeeea441" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90b22114-bad2-484e-b500-3494b625425f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#InvestmentsFairValuesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75d7f84c-b752-4770-afa8-da6ad41b6c49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_fbcd38a4-4de1-478f-8271-4e0fbafce877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75d7f84c-b752-4770-afa8-da6ad41b6c49" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_fbcd38a4-4de1-478f-8271-4e0fbafce877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_a934d7a7-fb9e-4e83-9a5d-6f5aef87d545" xlink:href="amgn-20220630.xsd#amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75d7f84c-b752-4770-afa8-da6ad41b6c49" xlink:to="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_a934d7a7-fb9e-4e83-9a5d-6f5aef87d545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue_a41cc1c4-f9d9-4b0b-8b6b-b039d215ff0a" xlink:href="amgn-20220630.xsd#amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75d7f84c-b752-4770-afa8-da6ad41b6c49" xlink:to="loc_amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue_a41cc1c4-f9d9-4b0b-8b6b-b039d215ff0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_1faa6734-6844-4313-8526-b6f95a281d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75d7f84c-b752-4770-afa8-da6ad41b6c49" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_1faa6734-6844-4313-8526-b6f95a281d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a5afcfff-baa8-49ce-9cef-56d9f077b428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75d7f84c-b752-4770-afa8-da6ad41b6c49" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a5afcfff-baa8-49ce-9cef-56d9f077b428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual" xlink:type="simple" xlink:href="amgn-20220630.xsd#InvestmentsEquitySecuritiesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9c002c84-43f4-4564-a28a-7e6c3114cc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7a8aae55-838b-4307-9169-9f1a6470ba34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9c002c84-43f4-4564-a28a-7e6c3114cc3f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7a8aae55-838b-4307-9169-9f1a6470ba34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a51996f8-9dff-4852-ab66-09c40e4361c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7a8aae55-838b-4307-9169-9f1a6470ba34" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a51996f8-9dff-4852-ab66-09c40e4361c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ff3cab7-4cad-4aa2-a307-a64dade9d382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a51996f8-9dff-4852-ab66-09c40e4361c1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ff3cab7-4cad-4aa2-a307-a64dade9d382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a5f6d991-e43b-41cd-a019-bf15bf09f976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ff3cab7-4cad-4aa2-a307-a64dade9d382" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a5f6d991-e43b-41cd-a019-bf15bf09f976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2831c25-96b6-4fd9-b49d-c1b81acbbc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7a8aae55-838b-4307-9169-9f1a6470ba34" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2831c25-96b6-4fd9-b49d-c1b81acbbc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_5724bdd4-85b7-4210-aad3-862aa62dadaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2831c25-96b6-4fd9-b49d-c1b81acbbc1f" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_5724bdd4-85b7-4210-aad3-862aa62dadaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_bf9d73b3-d50f-4db2-8f4d-a61a3d757035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2831c25-96b6-4fd9-b49d-c1b81acbbc1f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_bf9d73b3-d50f-4db2-8f4d-a61a3d757035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5f409783-3976-4e0a-891b-8a5f8438f289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2831c25-96b6-4fd9-b49d-c1b81acbbc1f" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5f409783-3976-4e0a-891b-8a5f8438f289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_c672b31c-c578-4ab8-b476-0b7799fd3b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2831c25-96b6-4fd9-b49d-c1b81acbbc1f" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_c672b31c-c578-4ab8-b476-0b7799fd3b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsBeiGeneDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#InvestmentsBeiGeneDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsBeiGeneDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_82d2082b-6a7b-4166-a451-4a7ff10d5a96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_4abc1be1-f54b-489f-afd7-39742b00e32c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_82d2082b-6a7b-4166-a451-4a7ff10d5a96" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_4abc1be1-f54b-489f-afd7-39742b00e32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_41be6c84-533b-4a26-8d1d-9911f3ef78f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_4abc1be1-f54b-489f-afd7-39742b00e32c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_41be6c84-533b-4a26-8d1d-9911f3ef78f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5e2669f-772e-4905-b317-5dbae0c4aa17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_41be6c84-533b-4a26-8d1d-9911f3ef78f4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5e2669f-772e-4905-b317-5dbae0c4aa17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_aaceffd0-5e89-4183-8fce-d5a0e83e263f" xlink:href="amgn-20220630.xsd#amgn_BeiGeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5e2669f-772e-4905-b317-5dbae0c4aa17" xlink:to="loc_amgn_BeiGeneMember_aaceffd0-5e89-4183-8fce-d5a0e83e263f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_2e585bae-54de-4b5e-9945-0b173d29d73b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_4abc1be1-f54b-489f-afd7-39742b00e32c" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_2e585bae-54de-4b5e-9945-0b173d29d73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_348c3054-488c-42c1-8ca3-0a945200a0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_2e585bae-54de-4b5e-9945-0b173d29d73b" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_348c3054-488c-42c1-8ca3-0a945200a0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_243dcc4d-fa52-42fe-b7d4-173ae3745cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_2e585bae-54de-4b5e-9945-0b173d29d73b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_243dcc4d-fa52-42fe-b7d4-173ae3745cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_064eae16-6b4c-4ae2-b75d-871a71d07371" xlink:href="amgn-20220630.xsd#amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_2e585bae-54de-4b5e-9945-0b173d29d73b" xlink:to="loc_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity_064eae16-6b4c-4ae2-b75d-871a71d07371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_5da966c3-5fc1-45bd-b58b-b7cae8f69c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_2e585bae-54de-4b5e-9945-0b173d29d73b" xlink:to="loc_us-gaap_EquityMethodInvestments_5da966c3-5fc1-45bd-b58b-b7cae8f69c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_72bad605-2734-4498-b063-51dc82d5e26d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_2e585bae-54de-4b5e-9945-0b173d29d73b" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_72bad605-2734-4498-b063-51dc82d5e26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#InvestmentsNeumoraTherapeuticsIncDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_deb9f07d-b242-4531-b7ac-f8b41fbd5713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_31bd5e03-5414-4f8c-aa14-3f7548e5b09e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_deb9f07d-b242-4531-b7ac-f8b41fbd5713" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_31bd5e03-5414-4f8c-aa14-3f7548e5b09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_082e4e1d-258a-465d-801d-a11f0158d6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_31bd5e03-5414-4f8c-aa14-3f7548e5b09e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_082e4e1d-258a-465d-801d-a11f0158d6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_43584d0f-6c27-4232-b641-8322deed1cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_082e4e1d-258a-465d-801d-a11f0158d6dc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_43584d0f-6c27-4232-b641-8322deed1cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NeumoraTherapeuticsIncMember_b206fdbf-56de-4557-a58d-290ab0843414" xlink:href="amgn-20220630.xsd#amgn_NeumoraTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_43584d0f-6c27-4232-b641-8322deed1cf7" xlink:to="loc_amgn_NeumoraTherapeuticsIncMember_b206fdbf-56de-4557-a58d-290ab0843414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_1eaa1b2a-2a2e-419a-a22f-ffe53e1bd765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_31bd5e03-5414-4f8c-aa14-3f7548e5b09e" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_1eaa1b2a-2a2e-419a-a22f-ffe53e1bd765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a819819d-ca41-4e51-839f-0c68b6c08904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_1eaa1b2a-2a2e-419a-a22f-ffe53e1bd765" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a819819d-ca41-4e51-839f-0c68b6c08904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_c0320482-af0d-4f7b-9085-31897c8657e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_1eaa1b2a-2a2e-419a-a22f-ffe53e1bd765" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_c0320482-af0d-4f7b-9085-31897c8657e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_a75f3a94-822c-44a3-bfba-5a91769f90c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_1eaa1b2a-2a2e-419a-a22f-ffe53e1bd765" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_a75f3a94-822c-44a3-bfba-5a91769f90c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_73c90dea-260b-4d1c-9401-3c847b16c882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_1eaa1b2a-2a2e-419a-a22f-ffe53e1bd765" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_73c90dea-260b-4d1c-9401-3c847b16c882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_c81fdd75-dd8d-40aa-a0f5-d9d544d7f759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_1eaa1b2a-2a2e-419a-a22f-ffe53e1bd765" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_c81fdd75-dd8d-40aa-a0f5-d9d544d7f759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_EquityMethodInvestmentChangeInCarryingValue_9d095938-19aa-40c5-86b7-923370fcb1dd" xlink:href="amgn-20220630.xsd#amgn_EquityMethodInvestmentChangeInCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_1eaa1b2a-2a2e-419a-a22f-ffe53e1bd765" xlink:to="loc_amgn_EquityMethodInvestmentChangeInCarryingValue_9d095938-19aa-40c5-86b7-923370fcb1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4b52cb02-730f-4d99-952a-9a2b44dcc70c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_dc8e3311-ab49-4215-991a-ddf3832bf74b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4b52cb02-730f-4d99-952a-9a2b44dcc70c" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_dc8e3311-ab49-4215-991a-ddf3832bf74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_00a1c34f-d24c-4d76-9a9f-4eec5284b868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_dc8e3311-ab49-4215-991a-ddf3832bf74b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_00a1c34f-d24c-4d76-9a9f-4eec5284b868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_baba750a-e846-41da-80d3-92dd091a401f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_00a1c34f-d24c-4d76-9a9f-4eec5284b868" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_baba750a-e846-41da-80d3-92dd091a401f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_be4546db-6335-4475-a0b5-10757905f5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_baba750a-e846-41da-80d3-92dd091a401f" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_be4546db-6335-4475-a0b5-10757905f5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_a27f68bb-c28f-421f-a73d-ea00c25f976a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_dc8e3311-ab49-4215-991a-ddf3832bf74b" xlink:to="loc_us-gaap_InvestmentTypeAxis_a27f68bb-c28f-421f-a73d-ea00c25f976a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_ffeff988-67c0-441c-a3fd-cca87a1c4630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_a27f68bb-c28f-421f-a73d-ea00c25f976a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_ffeff988-67c0-441c-a3fd-cca87a1c4630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_7526bd97-119e-49f4-9ceb-6fa84c3377c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_PartnershipInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_ffeff988-67c0-441c-a3fd-cca87a1c4630" xlink:to="loc_srt_PartnershipInterestMember_7526bd97-119e-49f4-9ceb-6fa84c3377c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_8d9b39b3-881c-4a6a-bdbd-6027fc98b156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_dc8e3311-ab49-4215-991a-ddf3832bf74b" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_8d9b39b3-881c-4a6a-bdbd-6027fc98b156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestment_3b4496bb-c0aa-4e7f-8f7d-ada65830495d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AlternativeInvestment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_8d9b39b3-881c-4a6a-bdbd-6027fc98b156" xlink:to="loc_us-gaap_AlternativeInvestment_3b4496bb-c0aa-4e7f-8f7d-ada65830495d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount_4c625877-413b-4513-9696-897cdcdd89e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_8d9b39b3-881c-4a6a-bdbd-6027fc98b156" xlink:to="loc_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount_4c625877-413b-4513-9696-897cdcdd89e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AlternativeInvestmentNetGainLoss_94b19c93-93c0-4ad3-acbd-20df3ac14504" xlink:href="amgn-20220630.xsd#amgn_AlternativeInvestmentNetGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_8d9b39b3-881c-4a6a-bdbd-6027fc98b156" xlink:to="loc_amgn_AlternativeInvestmentNetGainLoss_94b19c93-93c0-4ad3-acbd-20df3ac14504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Inventories" xlink:type="simple" xlink:href="amgn-20220630.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3682a660-ab96-48ec-870d-e261b1f72d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_175515be-dc0f-42fc-b870-5db71b8c5f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3682a660-ab96-48ec-870d-e261b1f72d4a" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_175515be-dc0f-42fc-b870-5db71b8c5f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InventoriesTables" xlink:type="simple" xlink:href="amgn-20220630.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f660d97c-e7bc-4173-8cec-50b6e449bc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a5f24b8c-d0c2-4b95-96d6-9add359d1e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f660d97c-e7bc-4173-8cec-50b6e449bc0a" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a5f24b8c-d0c2-4b95-96d6-9add359d1e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/InventoriesDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e3870e5c-ab30-4c4b-a304-698eabe77eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_ad08c883-5dcb-41c8-be4a-090501e4d493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e3870e5c-ab30-4c4b-a304-698eabe77eb8" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_ad08c883-5dcb-41c8-be4a-090501e4d493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3e50483d-fa3d-4edb-b0a1-6ee931d15f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e3870e5c-ab30-4c4b-a304-698eabe77eb8" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3e50483d-fa3d-4edb-b0a1-6ee931d15f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_78a30a45-2724-4331-bb09-b252343395e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e3870e5c-ab30-4c4b-a304-698eabe77eb8" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_78a30a45-2724-4331-bb09-b252343395e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f4dc8025-334a-417a-948c-5bb775a6d07e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e3870e5c-ab30-4c4b-a304-698eabe77eb8" xlink:to="loc_us-gaap_InventoryNet_f4dc8025-334a-417a-948c-5bb775a6d07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Goodwillandotherintangibleassets" xlink:type="simple" xlink:href="amgn-20220630.xsd#Goodwillandotherintangibleassets"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Goodwillandotherintangibleassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a93846ca-4e6d-4bdb-900c-7156c981c44b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_7af3d7f2-e164-4e08-b6f8-17d41bf09c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a93846ca-4e6d-4bdb-900c-7156c981c44b" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_7af3d7f2-e164-4e08-b6f8-17d41bf09c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsTables" xlink:type="simple" xlink:href="amgn-20220630.xsd#GoodwillandotherintangibleassetsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4f6c7af4-14fd-4f9d-9512-50430572a4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_4da6745a-a4d7-4b73-9a39-1cfdec8af49f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4f6c7af4-14fd-4f9d-9512-50430572a4d1" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_4da6745a-a4d7-4b73-9a39-1cfdec8af49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfIntangibleAssetsTableTextBlock_8beaeec0-8b0f-4825-bc91-1df81b01e936" xlink:href="amgn-20220630.xsd#amgn_ScheduleOfIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4f6c7af4-14fd-4f9d-9512-50430572a4d1" xlink:to="loc_amgn_ScheduleOfIntangibleAssetsTableTextBlock_8beaeec0-8b0f-4825-bc91-1df81b01e936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#GoodwillandotherintangibleassetsGoodwillRollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2dadc9c3-1ce6-4ce5-8bb7-56e20010828c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_e381a5f1-47c2-4eff-8c67-2680ab03ae21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2dadc9c3-1ce6-4ce5-8bb7-56e20010828c" xlink:to="loc_us-gaap_GoodwillRollForward_e381a5f1-47c2-4eff-8c67-2680ab03ae21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_36c7b48f-75dd-4657-bb37-f4b1d3876179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e381a5f1-47c2-4eff-8c67-2680ab03ae21" xlink:to="loc_us-gaap_Goodwill_36c7b48f-75dd-4657-bb37-f4b1d3876179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_bfce4b57-6a5f-4c71-9f65-aa6b3ac0c247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e381a5f1-47c2-4eff-8c67-2680ab03ae21" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_bfce4b57-6a5f-4c71-9f65-aa6b3ac0c247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_5abfd070-31be-4f33-ace7-05eda5bdc141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e381a5f1-47c2-4eff-8c67-2680ab03ae21" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_5abfd070-31be-4f33-ace7-05eda5bdc141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_921e7c2a-317c-437f-a6bd-5ff26d46d7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e381a5f1-47c2-4eff-8c67-2680ab03ae21" xlink:to="loc_us-gaap_Goodwill_921e7c2a-317c-437f-a6bd-5ff26d46d7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bac114fc-1bc3-4170-b9e8-9ea7143fa79d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d99e517f-fb3a-402b-82a1-377906eaedee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bac114fc-1bc3-4170-b9e8-9ea7143fa79d" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d99e517f-fb3a-402b-82a1-377906eaedee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4ccba3f0-8de6-442b-b66e-20b079240162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d99e517f-fb3a-402b-82a1-377906eaedee" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4ccba3f0-8de6-442b-b66e-20b079240162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ba889e01-07dd-4a0b-b68d-423ed988692a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4ccba3f0-8de6-442b-b66e-20b079240162" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ba889e01-07dd-4a0b-b68d-423ed988692a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_d217c418-d2c1-434e-8505-7e59d48630f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ba889e01-07dd-4a0b-b68d-423ed988692a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_d217c418-d2c1-434e-8505-7e59d48630f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_c612c819-bbb3-4a21-9e15-4c795989dfea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d99e517f-fb3a-402b-82a1-377906eaedee" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_c612c819-bbb3-4a21-9e15-4c795989dfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_89b1e1a3-528d-4707-9db9-2eefb30030f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_c612c819-bbb3-4a21-9e15-4c795989dfea" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_89b1e1a3-528d-4707-9db9-2eefb30030f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e303980c-fb5e-48ee-be4d-1d5021ba430d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bac114fc-1bc3-4170-b9e8-9ea7143fa79d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e303980c-fb5e-48ee-be4d-1d5021ba430d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69b79c4b-fb36-45bd-a192-50355380395a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e303980c-fb5e-48ee-be4d-1d5021ba430d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69b79c4b-fb36-45bd-a192-50355380395a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac1ac54-e1dc-4f82-a3ab-bd0b4c228aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_69b79c4b-fb36-45bd-a192-50355380395a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac1ac54-e1dc-4f82-a3ab-bd0b4c228aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_8ebfb35a-234e-4933-b719-6a0625bfa586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac1ac54-e1dc-4f82-a3ab-bd0b4c228aea" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_8ebfb35a-234e-4933-b719-6a0625bfa586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_f7a99bc7-e06c-48c1-8146-4bcf4054f678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac1ac54-e1dc-4f82-a3ab-bd0b4c228aea" xlink:to="loc_us-gaap_LicensingAgreementsMember_f7a99bc7-e06c-48c1-8146-4bcf4054f678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_7de3b343-2309-4a15-a791-8752a1bd2514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac1ac54-e1dc-4f82-a3ab-bd0b4c228aea" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_7de3b343-2309-4a15-a791-8752a1bd2514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_399f6beb-d78f-4940-8c0b-8ad29ca70579" xlink:href="amgn-20220630.xsd#amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac1ac54-e1dc-4f82-a3ab-bd0b4c228aea" xlink:to="loc_amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember_399f6beb-d78f-4940-8c0b-8ad29ca70579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_23fedd77-6250-46bc-b898-d54b1c340ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e303980c-fb5e-48ee-be4d-1d5021ba430d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_23fedd77-6250-46bc-b898-d54b1c340ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_13453d14-8ee8-4f2d-8d53-c03ee29af3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_23fedd77-6250-46bc-b898-d54b1c340ab9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_13453d14-8ee8-4f2d-8d53-c03ee29af3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c77655c4-c8ef-4e28-bf03-45bb48861a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_23fedd77-6250-46bc-b898-d54b1c340ab9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c77655c4-c8ef-4e28-bf03-45bb48861a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0a02588d-9c50-46fa-b94c-1b7a5c418a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_23fedd77-6250-46bc-b898-d54b1c340ab9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0a02588d-9c50-46fa-b94c-1b7a5c418a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsGross_cac094b7-954e-488e-aec6-9dd65dd90586" xlink:href="amgn-20220630.xsd#amgn_IdentifiableIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bac114fc-1bc3-4170-b9e8-9ea7143fa79d" xlink:to="loc_amgn_IdentifiableIntangibleAssetsGross_cac094b7-954e-488e-aec6-9dd65dd90586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_4f73a49c-3e47-4a2e-8138-95f333196eec" xlink:href="amgn-20220630.xsd#amgn_IdentifiableIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bac114fc-1bc3-4170-b9e8-9ea7143fa79d" xlink:to="loc_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization_4f73a49c-3e47-4a2e-8138-95f333196eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ff7b2194-753a-4899-9a40-50fb348f2e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bac114fc-1bc3-4170-b9e8-9ea7143fa79d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ff7b2194-753a-4899-9a40-50fb348f2e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual" xlink:type="simple" xlink:href="amgn-20220630.xsd#GoodwillandotherintangibleassetsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_db0c8939-d17c-438d-869a-f701d7c4083c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5ce9fc13-b1a6-4ee0-8091-4fcb292b4d40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_db0c8939-d17c-438d-869a-f701d7c4083c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5ce9fc13-b1a6-4ee0-8091-4fcb292b4d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6b864e18-3e65-444f-bfcc-a90d056bfb31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_db0c8939-d17c-438d-869a-f701d7c4083c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6b864e18-3e65-444f-bfcc-a90d056bfb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e57396ef-41eb-4001-ac0d-c1378f8b0022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_db0c8939-d17c-438d-869a-f701d7c4083c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e57396ef-41eb-4001-ac0d-c1378f8b0022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_027bac70-bb03-49f9-b12c-f5269438bdb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_db0c8939-d17c-438d-869a-f701d7c4083c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_027bac70-bb03-49f9-b12c-f5269438bdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2c6268f2-3325-470d-962b-d1ab4664a3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_db0c8939-d17c-438d-869a-f701d7c4083c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2c6268f2-3325-470d-962b-d1ab4664a3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2bf9381c-434b-41cd-b459-2a75595e9da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_db0c8939-d17c-438d-869a-f701d7c4083c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2bf9381c-434b-41cd-b459-2a75595e9da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3c647265-cd4d-474e-905e-169fcb3eb97b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_db0c8939-d17c-438d-869a-f701d7c4083c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3c647265-cd4d-474e-905e-169fcb3eb97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Financingarrangements" xlink:type="simple" xlink:href="amgn-20220630.xsd#Financingarrangements"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Financingarrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3bf45840-6ec4-475c-9a87-94a5f98cc534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_3b3c7186-544e-4bc3-957d-6020394673f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3bf45840-6ec4-475c-9a87-94a5f98cc534" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_3b3c7186-544e-4bc3-957d-6020394673f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsTables" xlink:type="simple" xlink:href="amgn-20220630.xsd#FinancingarrangementsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d1abe55a-da73-4a5f-80ce-ed79e2cd1866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_435f953c-7767-473c-8946-5bd62ffa9136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d1abe55a-da73-4a5f-80ce-ed79e2cd1866" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_435f953c-7767-473c-8946-5bd62ffa9136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_9b05e516-b959-420e-924e-79daac39f271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d1abe55a-da73-4a5f-80ce-ed79e2cd1866" xlink:to="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_9b05e516-b959-420e-924e-79daac39f271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock_bc8b1f84-9370-44b5-aa50-1baf72db7327" xlink:href="amgn-20220630.xsd#amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d1abe55a-da73-4a5f-80ce-ed79e2cd1866" xlink:to="loc_amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock_bc8b1f84-9370-44b5-aa50-1baf72db7327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_84a5dbf4-923f-46a8-8e1a-01290a3c3faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_35a4dd07-67c0-49f2-b64f-5fd7c036fc26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_84a5dbf4-923f-46a8-8e1a-01290a3c3faa" xlink:to="loc_us-gaap_DebtInstrumentTable_35a4dd07-67c0-49f2-b64f-5fd7c036fc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_01053194-9740-4bf1-ba79-04b8fbee9a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_35a4dd07-67c0-49f2-b64f-5fd7c036fc26" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_01053194-9740-4bf1-ba79-04b8fbee9a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_58623c7b-9c31-443b-8420-7a06fbb14054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_01053194-9740-4bf1-ba79-04b8fbee9a26" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_58623c7b-9c31-443b-8420-7a06fbb14054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_cb2666a7-e05d-47d3-b4c3-42b9d9789a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_58623c7b-9c31-443b-8420-7a06fbb14054" xlink:to="loc_us-gaap_NotesPayableToBanksMember_cb2666a7-e05d-47d3-b4c3-42b9d9789a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f1dc5490-327f-41dd-b13c-d8cce5afe1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_35a4dd07-67c0-49f2-b64f-5fd7c036fc26" xlink:to="loc_us-gaap_DebtInstrumentAxis_f1dc5490-327f-41dd-b13c-d8cce5afe1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f1dc5490-327f-41dd-b13c-d8cce5afe1d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroNotesDue2020Member_64e9bffe-fef5-4c75-96da-692eae5aff7b" xlink:href="amgn-20220630.xsd#amgn_TwoPointTwoZeroNotesDue2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointTwoZeroNotesDue2020Member_64e9bffe-fef5-4c75-96da-692eae5aff7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_4d42c7b6-1060-4e5d-b9fb-a86cf11357dc" xlink:href="amgn-20220630.xsd#amgn_ThreePointFourFivePercentNotesDue2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_ThreePointFourFivePercentNotesDue2020Member_4d42c7b6-1060-4e5d-b9fb-a86cf11357dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_50959a09-ffcb-4b9a-bc6c-d5e7ac2f4d9a" xlink:href="amgn-20220630.xsd#amgn_FourPointOneZeroPercentNotesDue2021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FourPointOneZeroPercentNotesDue2021Member_50959a09-ffcb-4b9a-bc6c-d5e7ac2f4d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_5bb615a9-064a-48df-90b6-8d992251d479" xlink:href="amgn-20220630.xsd#amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember_5bb615a9-064a-48df-90b6-8d992251d479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_15aafd97-6f9f-4aa7-896e-3ae59312e42f" xlink:href="amgn-20220630.xsd#amgn_ThreePointEightSevenFivePercentNotesDue2021Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_ThreePointEightSevenFivePercentNotesDue2021Member_15aafd97-6f9f-4aa7-896e-3ae59312e42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember_131e0fe4-79fb-4817-a026-58e324bed162" xlink:href="amgn-20220630.xsd#amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember_131e0fe4-79fb-4817-a026-58e324bed162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_5fa59de1-3a1c-42a7-967f-95a9bfa36fb4" xlink:href="amgn-20220630.xsd#amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember_5fa59de1-3a1c-42a7-967f-95a9bfa36fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixFiveNotesDue2022Member_20040640-d9fa-41c2-93a9-1823cbc25bb0" xlink:href="amgn-20220630.xsd#amgn_TwoPointSixFiveNotesDue2022Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointSixFiveNotesDue2022Member_20040640-d9fa-41c2-93a9-1823cbc25bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_bc81e714-6dfe-4695-98c5-b6657b7ae484" xlink:href="amgn-20220630.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2022Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2022Member_bc81e714-6dfe-4695-98c5-b6657b7ae484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_d5bac637-720f-4e2e-b2bc-db49de89777a" xlink:href="amgn-20220630.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_d5bac637-720f-4e2e-b2bc-db49de89777a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_8a15197b-cf11-445b-9b21-6f16405fe481" xlink:href="amgn-20220630.xsd#amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember_8a15197b-cf11-445b-9b21-6f16405fe481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_ee2a5855-b52f-42f9-95aa-5e346361be6c" xlink:href="amgn-20220630.xsd#amgn_ThreePointSixTwoFivePercentNotesDue2024Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_ThreePointSixTwoFivePercentNotesDue2024Member_ee2a5855-b52f-42f9-95aa-5e346361be6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember_71fba5c0-ba40-425a-a546-b3d00ca4f498" xlink:href="amgn-20220630.xsd#amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember_71fba5c0-ba40-425a-a546-b3d00ca4f498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_a177afc1-ef73-47eb-995c-697af1548128" xlink:href="amgn-20220630.xsd#amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember_a177afc1-ef73-47eb-995c-697af1548128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_caa1edf8-8dde-4473-ab7c-ba3c7a5ce293" xlink:href="amgn-20220630.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_caa1edf8-8dde-4473-ab7c-ba3c7a5ce293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_4470f5a9-56e7-4c0f-9f8f-50c7481231bd" xlink:href="amgn-20220630.xsd#amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember_4470f5a9-56e7-4c0f-9f8f-50c7481231bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_d7033f93-50de-4796-acc8-b5231f6a2757" xlink:href="amgn-20220630.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_d7033f93-50de-4796-acc8-b5231f6a2757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_b865aa20-a6b6-4d5e-91c7-3cfbf529621b" xlink:href="amgn-20220630.xsd#amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember_b865aa20-a6b6-4d5e-91c7-3cfbf529621b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointTwoZeroNotesDue2027Member_c0cbf71e-b89e-40d0-962f-64723d6511e4" xlink:href="amgn-20220630.xsd#amgn_ThreePointTwoZeroNotesDue2027Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_ThreePointTwoZeroNotesDue2027Member_c0cbf71e-b89e-40d0-962f-64723d6511e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointSixFivePercent2028NotesMember_549267d6-c906-4c8a-9547-fe9ff96cc8e1" xlink:href="amgn-20220630.xsd#amgn_OnePointSixFivePercent2028NotesMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_OnePointSixFivePercent2028NotesMember_549267d6-c906-4c8a-9547-fe9ff96cc8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A3002029NotesMember_7a561308-c780-4259-a767-2f7d535aea15" xlink:href="amgn-20220630.xsd#amgn_A3002029NotesMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_A3002029NotesMember_7a561308-c780-4259-a767-2f7d535aea15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_4564cb91-70ef-49ec-b0d5-c0088da5154a" xlink:href="amgn-20220630.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_4564cb91-70ef-49ec-b0d5-c0088da5154a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_f46966dd-8321-4ea8-b5fa-13502028bc6c" xlink:href="amgn-20220630.xsd#amgn_TwoPointFourFivePercentNotesDue2030Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointFourFivePercentNotesDue2030Member_f46966dd-8321-4ea8-b5fa-13502028bc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_a83ca970-8704-4550-a35e-8628d08ad37f" xlink:href="amgn-20220630.xsd#amgn_TwoPointThreeZeroPercentNotesDue2031Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointThreeZeroPercentNotesDue2031Member_a83ca970-8704-4550-a35e-8628d08ad37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointZeroPercent2032NotesMemberMember_f8c88bef-d443-44ec-ae12-5fb04ce067d7" xlink:href="amgn-20220630.xsd#amgn_TwoPointZeroPercent2032NotesMemberMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointZeroPercent2032NotesMemberMember_f8c88bef-d443-44ec-ae12-5fb04ce067d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A3352032NotesMember_93a0dba1-014e-4989-8e7d-63e2afb32c22" xlink:href="amgn-20220630.xsd#amgn_A3352032NotesMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_A3352032NotesMember_93a0dba1-014e-4989-8e7d-63e2afb32c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_1db97e92-8172-45de-b501-e7ee67d6c4d0" xlink:href="amgn-20220630.xsd#amgn_SixPointThreeSevenFivePercentNotesDue2037Member"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_SixPointThreeSevenFivePercentNotesDue2037Member_1db97e92-8172-45de-b501-e7ee67d6c4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_887a548b-6524-4524-b388-61ac988913d1" xlink:href="amgn-20220630.xsd#amgn_SixPointNineZeroPercentNotesDue2038Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_SixPointNineZeroPercentNotesDue2038Member_887a548b-6524-4524-b388-61ac988913d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_69c0bb2c-64d1-426a-b881-e916dfedb827" xlink:href="amgn-20220630.xsd#amgn_SixPointFourZeroPercentNotesDue2039Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_SixPointFourZeroPercentNotesDue2039Member_69c0bb2c-64d1-426a-b881-e916dfedb827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_771216c4-c9ae-435d-b7d7-db7e6b380d00" xlink:href="amgn-20220630.xsd#amgn_ThreePointOneFivePercentNotesDue2040Member"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_ThreePointOneFivePercentNotesDue2040Member_771216c4-c9ae-435d-b7d7-db7e6b380d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_89bdfdd8-7c05-45cb-b4d5-9e86d3135202" xlink:href="amgn-20220630.xsd#amgn_FivePointSevenFivePercentNotesDue2040Member"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FivePointSevenFivePercentNotesDue2040Member_89bdfdd8-7c05-45cb-b4d5-9e86d3135202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointEightZeroPercent2041NotesMember_b53a604d-7641-4926-913b-545b51db698e" xlink:href="amgn-20220630.xsd#amgn_TwoPointEightZeroPercent2041NotesMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointEightZeroPercent2041NotesMember_b53a604d-7641-4926-913b-545b51db698e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointNineFivePercentNotesDue2041Member_f383fd37-af58-4af3-94fd-64b57a72748a" xlink:href="amgn-20220630.xsd#amgn_FourPointNineFivePercentNotesDue2041Member"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FourPointNineFivePercentNotesDue2041Member_f383fd37-af58-4af3-94fd-64b57a72748a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointOneFivePercentNotesDue2041Member_abb177e7-260f-43e7-a5ce-aa6623b6fbb1" xlink:href="amgn-20220630.xsd#amgn_FivePointOneFivePercentNotesDue2041Member"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FivePointOneFivePercentNotesDue2041Member_abb177e7-260f-43e7-a5ce-aa6623b6fbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointSixFivePercentNotesDue2042Member_8fb753ff-87d0-4bd2-96ba-fa9254718b1f" xlink:href="amgn-20220630.xsd#amgn_FivePointSixFivePercentNotesDue2042Member"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FivePointSixFivePercentNotesDue2042Member_8fb753ff-87d0-4bd2-96ba-fa9254718b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_142af042-19d5-4a8e-91d6-c95ff5e1f1e6" xlink:href="amgn-20220630.xsd#amgn_FivePointThreeSevenFivePercentNotesDue2043Member"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FivePointThreeSevenFivePercentNotesDue2043Member_142af042-19d5-4a8e-91d6-c95ff5e1f1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_5ab88819-82f3-4176-83aa-76c21b1c1ea5" xlink:href="amgn-20220630.xsd#amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember_5ab88819-82f3-4176-83aa-76c21b1c1ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_2a78eeff-dd42-44c3-a706-3ee64ef6fdb9" xlink:href="amgn-20220630.xsd#amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_2a78eeff-dd42-44c3-a706-3ee64ef6fdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_1e9b0e0f-07a7-4c8a-9308-0ba51d66293f" xlink:href="amgn-20220630.xsd#amgn_ThreePointThreeSevenFivePercentNotesDue2050Member"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_ThreePointThreeSevenFivePercentNotesDue2050Member_1e9b0e0f-07a7-4c8a-9308-0ba51d66293f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_36123af8-5c61-45e7-ab6c-a20f0fbe1612" xlink:href="amgn-20220630.xsd#amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_36123af8-5c61-45e7-ab6c-a20f0fbe1612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A300NotesDue20523002052NotesMember_f1b6e144-de24-4dff-ad87-a3bdfafae20a" xlink:href="amgn-20220630.xsd#amgn_A300NotesDue20523002052NotesMember"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_A300NotesDue20523002052NotesMember_f1b6e144-de24-4dff-ad87-a3bdfafae20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A4202052NotesMember_e8d88f66-fbb3-407e-851e-0cadbd825894" xlink:href="amgn-20220630.xsd#amgn_A4202052NotesMember"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_A4202052NotesMember_e8d88f66-fbb3-407e-851e-0cadbd825894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_93ef57a0-158f-42f0-9a2a-d2882bef5f6a" xlink:href="amgn-20220630.xsd#amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_93ef57a0-158f-42f0-9a2a-d2882bef5f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A4402062NotesMember_3eb55fde-edd3-43c0-910b-ab190b4326e9" xlink:href="amgn-20220630.xsd#amgn_A4402062NotesMember"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_A4402062NotesMember_3eb55fde-edd3-43c0-910b-ab190b4326e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherNotesDue2097Member_db4c06ad-2f82-4734-80ea-c8b3f3e47417" xlink:href="amgn-20220630.xsd#amgn_OtherNotesDue2097Member"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_06c63251-4b4d-476f-ab97-83ef0cc18f37" xlink:to="loc_amgn_OtherNotesDue2097Member_db4c06ad-2f82-4734-80ea-c8b3f3e47417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_35a4dd07-67c0-49f2-b64f-5fd7c036fc26" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d65ac211-0724-48a2-b731-58f027c59dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d65ac211-0724-48a2-b731-58f027c59dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c25f4d0f-044b-464c-9c5f-2bf439f5802e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c25f4d0f-044b-464c-9c5f-2bf439f5802e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_40975540-80d4-457d-a374-d9fff1b2f61e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_40975540-80d4-457d-a374-d9fff1b2f61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_5fe99972-332a-404b-835e-37eaed4ba0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_5fe99972-332a-404b-835e-37eaed4ba0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_65ebeff0-8740-44a5-9971-23b4f708209c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_us-gaap_OtherLongTermDebt_65ebeff0-8740-44a5-9971-23b4f708209c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8a317784-f986-44c5-9a85-3f13839538f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_us-gaap_LongTermDebt_8a317784-f986-44c5-9a85-3f13839538f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ebc7c21a-e092-48a2-b30d-c38ed2c43bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_us-gaap_LongTermDebtCurrent_ebc7c21a-e092-48a2-b30d-c38ed2c43bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a7735907-8cec-40a5-80b2-5da8a05034a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a7735907-8cec-40a5-80b2-5da8a05034a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8c2d901b-e341-4bab-a246-138a988b2c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8c2d901b-e341-4bab-a246-138a988b2c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_10a8258e-931f-4639-b672-d68a58a3b1ce" xlink:href="amgn-20220630.xsd#amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c63fa6b3-c9e3-4343-a872-de2729f674ff" xlink:to="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_10a8258e-931f-4639-b672-d68a58a3b1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtExchangeAdditionalCashConsideration_2178586e-0659-48b2-aaf1-177e7dc8a6f1" xlink:href="amgn-20220630.xsd#amgn_DebtExchangeAdditionalCashConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_84a5dbf4-923f-46a8-8e1a-01290a3c3faa" xlink:to="loc_amgn_DebtExchangeAdditionalCashConsideration_2178586e-0659-48b2-aaf1-177e7dc8a6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FinancingarrangementsDetailsTextual" xlink:type="simple" xlink:href="amgn-20220630.xsd#FinancingarrangementsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FinancingarrangementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7d860432-7b1c-41aa-a014-fcd19c21fe6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7a6e566a-18a2-46c7-887a-f24e62554f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7d860432-7b1c-41aa-a014-fcd19c21fe6b" xlink:to="loc_us-gaap_DebtInstrumentTable_7a6e566a-18a2-46c7-887a-f24e62554f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_34269ec1-009d-444a-8232-032e4acd25f1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7a6e566a-18a2-46c7-887a-f24e62554f02" xlink:to="loc_srt_RangeAxis_34269ec1-009d-444a-8232-032e4acd25f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4abe0bae-919d-418a-9d98-14fd09d2e6e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_34269ec1-009d-444a-8232-032e4acd25f1" xlink:to="loc_srt_RangeMember_4abe0bae-919d-418a-9d98-14fd09d2e6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d628ab8c-bbdc-4c32-8efa-a27937606acd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4abe0bae-919d-418a-9d98-14fd09d2e6e5" xlink:to="loc_srt_MinimumMember_d628ab8c-bbdc-4c32-8efa-a27937606acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_de29bfcf-ba25-4630-a082-9194aaeb9be6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4abe0bae-919d-418a-9d98-14fd09d2e6e5" xlink:to="loc_srt_MaximumMember_de29bfcf-ba25-4630-a082-9194aaeb9be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_25adf769-fa03-477a-ba78-6802b16b7332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7a6e566a-18a2-46c7-887a-f24e62554f02" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_25adf769-fa03-477a-ba78-6802b16b7332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f754588a-98af-45cc-a0b7-86a4f7fb7c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_25adf769-fa03-477a-ba78-6802b16b7332" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f754588a-98af-45cc-a0b7-86a4f7fb7c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_1f2072eb-6932-4ee7-ad2f-7398ec8f8220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f754588a-98af-45cc-a0b7-86a4f7fb7c0e" xlink:to="loc_us-gaap_NotesPayableToBanksMember_1f2072eb-6932-4ee7-ad2f-7398ec8f8220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesPayableMember_85bd19b6-c8f5-4729-8340-b8c0d069e3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f754588a-98af-45cc-a0b7-86a4f7fb7c0e" xlink:to="loc_us-gaap_DebtSecuritiesPayableMember_85bd19b6-c8f5-4729-8340-b8c0d069e3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9daa3293-1901-4328-a9a0-58b67c82d99a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7a6e566a-18a2-46c7-887a-f24e62554f02" xlink:to="loc_us-gaap_DebtInstrumentAxis_9daa3293-1901-4328-a9a0-58b67c82d99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_974eddb4-d7ff-4f60-869a-266428d56906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9daa3293-1901-4328-a9a0-58b67c82d99a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_974eddb4-d7ff-4f60-869a-266428d56906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_ef98526d-18eb-49a7-afdf-0fa7bdb8f6ac" xlink:href="amgn-20220630.xsd#amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_974eddb4-d7ff-4f60-869a-266428d56906" xlink:to="loc_amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember_ef98526d-18eb-49a7-afdf-0fa7bdb8f6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_7349bb05-a33c-4de1-82b1-0c7819b8e8c7" xlink:href="amgn-20220630.xsd#amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_974eddb4-d7ff-4f60-869a-266428d56906" xlink:to="loc_amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember_7349bb05-a33c-4de1-82b1-0c7819b8e8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_1c326eb0-5c15-45b9-9dde-e87dc7bee272" xlink:href="amgn-20220630.xsd#amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_974eddb4-d7ff-4f60-869a-266428d56906" xlink:to="loc_amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember_1c326eb0-5c15-45b9-9dde-e87dc7bee272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A3002029NotesMember_ad527881-ac93-49ea-b23f-dd3223fa3fc0" xlink:href="amgn-20220630.xsd#amgn_A3002029NotesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_974eddb4-d7ff-4f60-869a-266428d56906" xlink:to="loc_amgn_A3002029NotesMember_ad527881-ac93-49ea-b23f-dd3223fa3fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A3352032NotesMember_b9441996-efff-464f-b249-189ee398d098" xlink:href="amgn-20220630.xsd#amgn_A3352032NotesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_974eddb4-d7ff-4f60-869a-266428d56906" xlink:to="loc_amgn_A3352032NotesMember_b9441996-efff-464f-b249-189ee398d098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A4202052NotesMember_2ab42e15-be8a-4f50-8d79-c7bd3b7a522b" xlink:href="amgn-20220630.xsd#amgn_A4202052NotesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_974eddb4-d7ff-4f60-869a-266428d56906" xlink:to="loc_amgn_A4202052NotesMember_2ab42e15-be8a-4f50-8d79-c7bd3b7a522b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A4402062NotesMember_6a9db71e-abbe-47cb-9b49-eb5b3ff9471a" xlink:href="amgn-20220630.xsd#amgn_A4402062NotesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_974eddb4-d7ff-4f60-869a-266428d56906" xlink:to="loc_amgn_A4402062NotesMember_6a9db71e-abbe-47cb-9b49-eb5b3ff9471a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_40a3b23b-8ca9-4148-b685-7c824167f5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7a6e566a-18a2-46c7-887a-f24e62554f02" xlink:to="loc_us-gaap_DebtInstrumentLineItems_40a3b23b-8ca9-4148-b685-7c824167f5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ce2fabe1-b9aa-4001-8b19-97ddc5f5611c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40a3b23b-8ca9-4148-b685-7c824167f5b7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ce2fabe1-b9aa-4001-8b19-97ddc5f5611c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_24d044d7-bdfa-4d4a-be74-9c1a622b0215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40a3b23b-8ca9-4148-b685-7c824167f5b7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_24d044d7-bdfa-4d4a-be74-9c1a622b0215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e122bd8b-8b92-476a-88fb-9759351e736b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40a3b23b-8ca9-4148-b685-7c824167f5b7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e122bd8b-8b92-476a-88fb-9759351e736b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_b4b4231e-48e4-40ba-9874-ec80cd8ba91c" xlink:href="amgn-20220630.xsd#amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40a3b23b-8ca9-4148-b685-7c824167f5b7" xlink:to="loc_amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent_b4b4231e-48e4-40ba-9874-ec80cd8ba91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount_51fb8383-7a94-43bd-bf6d-398115ae12b0" xlink:href="amgn-20220630.xsd#amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40a3b23b-8ca9-4148-b685-7c824167f5b7" xlink:to="loc_amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount_51fb8383-7a94-43bd-bf6d-398115ae12b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent_36fda5e3-ebba-46e2-b222-d073e60f2572" xlink:href="amgn-20220630.xsd#amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40a3b23b-8ca9-4148-b685-7c824167f5b7" xlink:to="loc_amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent_36fda5e3-ebba-46e2-b222-d073e60f2572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Stockholdersequity" xlink:type="simple" xlink:href="amgn-20220630.xsd#Stockholdersequity"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Stockholdersequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8c41b8b8-53e0-441c-a327-1e6c6f4122f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6c6e24b7-28a2-4838-8785-be3f90d16f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8c41b8b8-53e0-441c-a327-1e6c6f4122f9" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6c6e24b7-28a2-4838-8785-be3f90d16f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityTables" xlink:type="simple" xlink:href="amgn-20220630.xsd#StockholdersequityTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3e3d475d-fd3c-4d5a-99a8-baf6a30ddc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_StockRepurchaseProgramTableTextBlock_ebb58940-ad1d-4bb3-884d-1bb8e0a2921e" xlink:href="amgn-20220630.xsd#amgn_StockRepurchaseProgramTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3e3d475d-fd3c-4d5a-99a8-baf6a30ddc6a" xlink:to="loc_amgn_StockRepurchaseProgramTableTextBlock_ebb58940-ad1d-4bb3-884d-1bb8e0a2921e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5ba962cb-8642-4b63-be58-ae758aedbdab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3e3d475d-fd3c-4d5a-99a8-baf6a30ddc6a" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5ba962cb-8642-4b63-be58-ae758aedbdab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_3cbdb4f6-b1df-4927-8038-a6d331277417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3e3d475d-fd3c-4d5a-99a8-baf6a30ddc6a" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_3cbdb4f6-b1df-4927-8038-a6d331277417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityShareRepurchaseProgramDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#StockholdersequityShareRepurchaseProgramDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityShareRepurchaseProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4c60d222-41b9-4a04-80b0-5c117cc52b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_937a26d9-cc44-49a0-a3b3-944c888c6075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4c60d222-41b9-4a04-80b0-5c117cc52b4f" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_937a26d9-cc44-49a0-a3b3-944c888c6075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f6530408-6168-4df6-94c3-3ca2adb2888a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4c60d222-41b9-4a04-80b0-5c117cc52b4f" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f6530408-6168-4df6-94c3-3ca2adb2888a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#StockholdersequityDetailsTextualDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_be5130ee-8e2c-42f4-b5a2-d8aebb3f6430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_948df946-8f0b-4f83-8b61-921053f0ea64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_be5130ee-8e2c-42f4-b5a2-d8aebb3f6430" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_948df946-8f0b-4f83-8b61-921053f0ea64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_f8b0892a-2e45-48f9-bbdf-ca01984b8529" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_948df946-8f0b-4f83-8b61-921053f0ea64" xlink:to="loc_srt_StatementScenarioAxis_f8b0892a-2e45-48f9-bbdf-ca01984b8529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6ad9f025-ccbd-4592-b9cb-34513fc88bb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_f8b0892a-2e45-48f9-bbdf-ca01984b8529" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6ad9f025-ccbd-4592-b9cb-34513fc88bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4e7919e1-43fe-4800-8034-a53acb9a1a2c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_6ad9f025-ccbd-4592-b9cb-34513fc88bb0" xlink:to="loc_srt_ScenarioForecastMember_4e7919e1-43fe-4800-8034-a53acb9a1a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_ca1f24bf-87ae-4af4-a215-a398f81aa662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_948df946-8f0b-4f83-8b61-921053f0ea64" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_ca1f24bf-87ae-4af4-a215-a398f81aa662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_d3c0f530-e648-4673-afa4-890ae3e1a59a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_ca1f24bf-87ae-4af4-a215-a398f81aa662" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_d3c0f530-e648-4673-afa4-890ae3e1a59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AcceleratedStockRepurchaseAgreementMember_b87bfe02-f326-4208-b8b3-8f3a05e835bf" xlink:href="amgn-20220630.xsd#amgn_AcceleratedStockRepurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_d3c0f530-e648-4673-afa4-890ae3e1a59a" xlink:to="loc_amgn_AcceleratedStockRepurchaseAgreementMember_b87bfe02-f326-4208-b8b3-8f3a05e835bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f92a5217-5a99-4e72-913c-20330982c976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_948df946-8f0b-4f83-8b61-921053f0ea64" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f92a5217-5a99-4e72-913c-20330982c976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a3d13935-3330-4832-b0df-f8141a037fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f92a5217-5a99-4e72-913c-20330982c976" xlink:to="loc_us-gaap_EquityComponentDomain_a3d13935-3330-4832-b0df-f8141a037fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_05ce252a-9788-4c97-8d13-16c447ea06e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a3d13935-3330-4832-b0df-f8141a037fc2" xlink:to="loc_us-gaap_RetainedEarningsMember_05ce252a-9788-4c97-8d13-16c447ea06e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_5e013921-861e-481a-ae43-342e978244cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a3d13935-3330-4832-b0df-f8141a037fc2" xlink:to="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_5e013921-861e-481a-ae43-342e978244cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c0b8b47b-967a-405f-bb26-881a64ce44f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_948df946-8f0b-4f83-8b61-921053f0ea64" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c0b8b47b-967a-405f-bb26-881a64ce44f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_777ab480-7658-4740-9e60-a5ed7653e2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c0b8b47b-967a-405f-bb26-881a64ce44f0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_777ab480-7658-4740-9e60-a5ed7653e2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_057fcfad-3e39-474d-82c0-4dffe5696aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_777ab480-7658-4740-9e60-a5ed7653e2d3" xlink:to="loc_us-gaap_SubsequentEventMember_057fcfad-3e39-474d-82c0-4dffe5696aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7de02199-eeca-485f-838e-c78edc752d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_948df946-8f0b-4f83-8b61-921053f0ea64" xlink:to="loc_us-gaap_ClassOfStockLineItems_7de02199-eeca-485f-838e-c78edc752d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_67075e92-541b-4358-a954-7807560b4234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7de02199-eeca-485f-838e-c78edc752d55" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_67075e92-541b-4358-a954-7807560b4234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f5f94341-7800-42bc-984c-da7badd2d722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7de02199-eeca-485f-838e-c78edc752d55" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f5f94341-7800-42bc-984c-da7badd2d722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_68fa0edd-dc09-47a4-a401-6525e0d686ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7de02199-eeca-485f-838e-c78edc752d55" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_68fa0edd-dc09-47a4-a401-6525e0d686ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a05e3b0c-bd7f-4810-8576-3a77da91df28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7de02199-eeca-485f-838e-c78edc752d55" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a05e3b0c-bd7f-4810-8576-3a77da91df28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_e246bb8f-1d15-4625-bd2f-306651d08d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7de02199-eeca-485f-838e-c78edc752d55" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_e246bb8f-1d15-4625-bd2f-306651d08d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_4d319dce-50c1-4da5-a0d1-90eb4a5696a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7de02199-eeca-485f-838e-c78edc752d55" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_4d319dce-50c1-4da5-a0d1-90eb4a5696a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_ee1f3aea-c6fb-4d8c-8680-500f86b32fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7de02199-eeca-485f-838e-c78edc752d55" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_ee1f3aea-c6fb-4d8c-8680-500f86b32fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfThirdPartyFinancialInstitutions_19cb5a86-9dd3-4952-9c89-c0b3ade8fae2" xlink:href="amgn-20220630.xsd#amgn_NumberOfThirdPartyFinancialInstitutions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7de02199-eeca-485f-838e-c78edc752d55" xlink:to="loc_amgn_NumberOfThirdPartyFinancialInstitutions_19cb5a86-9dd3-4952-9c89-c0b3ade8fae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#StockholdersequityComponentsofAOCIDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c2559b0f-46d9-4f33-b8db-2469abc6c727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e213948c-f486-4e7b-aeda-fa410e4c1bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c2559b0f-46d9-4f33-b8db-2469abc6c727" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e213948c-f486-4e7b-aeda-fa410e4c1bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_61964f77-9954-4a7b-aa2a-433d66fb8222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e213948c-f486-4e7b-aeda-fa410e4c1bc3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_61964f77-9954-4a7b-aa2a-433d66fb8222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f1502450-b944-496e-a322-1fb7a62139ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61964f77-9954-4a7b-aa2a-433d66fb8222" xlink:to="loc_us-gaap_EquityComponentDomain_f1502450-b944-496e-a322-1fb7a62139ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_d4467b9d-6090-4975-becb-e5f25932959c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f1502450-b944-496e-a322-1fb7a62139ae" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_d4467b9d-6090-4975-becb-e5f25932959c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_16388185-d144-4c52-ba11-b8766666765a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f1502450-b944-496e-a322-1fb7a62139ae" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_16388185-d144-4c52-ba11-b8766666765a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_b9b0ef71-0e07-4ee4-88ec-d5b1cbe413d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f1502450-b944-496e-a322-1fb7a62139ae" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_b9b0ef71-0e07-4ee4-88ec-d5b1cbe413d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_9bdf6ff2-9f83-4bae-bab6-233908b716b1" xlink:href="amgn-20220630.xsd#amgn_AccumulatedOtherAdjustmentAttributabletoParentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f1502450-b944-496e-a322-1fb7a62139ae" xlink:to="loc_amgn_AccumulatedOtherAdjustmentAttributabletoParentMember_9bdf6ff2-9f83-4bae-bab6-233908b716b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7fbab0b3-fd9b-4dca-a6bd-362e288b6997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f1502450-b944-496e-a322-1fb7a62139ae" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7fbab0b3-fd9b-4dca-a6bd-362e288b6997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_22d6a30b-f2e0-4f87-93a8-136cf7cc4667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e213948c-f486-4e7b-aeda-fa410e4c1bc3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_22d6a30b-f2e0-4f87-93a8-136cf7cc4667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_decd9ee2-3296-444f-b130-525e0900b2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_22d6a30b-f2e0-4f87-93a8-136cf7cc4667" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_decd9ee2-3296-444f-b130-525e0900b2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6dea1384-1123-4c49-b067-2140725ca6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_decd9ee2-3296-444f-b130-525e0900b2c8" xlink:to="loc_us-gaap_StockholdersEquity_6dea1384-1123-4c49-b067-2140725ca6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_7415ab14-2094-4fea-82f0-2b76a9fa8ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_decd9ee2-3296-444f-b130-525e0900b2c8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_7415ab14-2094-4fea-82f0-2b76a9fa8ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_f24bfc9f-8c75-446c-995b-ad9711fc6e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_decd9ee2-3296-444f-b130-525e0900b2c8" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_f24bfc9f-8c75-446c-995b-ad9711fc6e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_05350239-b09b-4b4d-8567-474c0f66bb96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_decd9ee2-3296-444f-b130-525e0900b2c8" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_05350239-b09b-4b4d-8567-474c0f66bb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_421632d6-413e-4d50-8f23-9139fa4ffd20" xlink:href="amgn-20220630.xsd#amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_decd9ee2-3296-444f-b130-525e0900b2c8" xlink:to="loc_amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax_421632d6-413e-4d50-8f23-9139fa4ffd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_6d03400a-de32-4c32-a8ae-de651d1b7f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_decd9ee2-3296-444f-b130-525e0900b2c8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_6d03400a-de32-4c32-a8ae-de651d1b7f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d762a156-7e44-4c01-bc6c-b5a8dcb8a484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_decd9ee2-3296-444f-b130-525e0900b2c8" xlink:to="loc_us-gaap_StockholdersEquity_d762a156-7e44-4c01-bc6c-b5a8dcb8a484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#StockholdersequityReclassificationsoutofAOCIDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c20c9f7c-acd0-4ed9-b5d4-7dc28eea143b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2aea6a0c-534c-4ac4-8bde-fa5e836b5093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c20c9f7c-acd0-4ed9-b5d4-7dc28eea143b" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2aea6a0c-534c-4ac4-8bde-fa5e836b5093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d3078a5d-18e0-46ad-ac2c-393334da27a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2aea6a0c-534c-4ac4-8bde-fa5e836b5093" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d3078a5d-18e0-46ad-ac2c-393334da27a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_f108981d-f235-4cb6-9d1f-14c36c422902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_d3078a5d-18e0-46ad-ac2c-393334da27a2" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_f108981d-f235-4cb6-9d1f-14c36c422902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_19412492-9cc1-42b4-afb4-4a200396952e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_f108981d-f235-4cb6-9d1f-14c36c422902" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_19412492-9cc1-42b4-afb4-4a200396952e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_038ee94e-3642-4375-a67e-8be2182ea0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2aea6a0c-534c-4ac4-8bde-fa5e836b5093" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_038ee94e-3642-4375-a67e-8be2182ea0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e4ec5b61-9989-4599-9003-57b91bd3e2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_038ee94e-3642-4375-a67e-8be2182ea0f2" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e4ec5b61-9989-4599-9003-57b91bd3e2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_d75c2379-d700-47dd-a921-039bd7a8396e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e4ec5b61-9989-4599-9003-57b91bd3e2d5" xlink:to="loc_us-gaap_CashFlowHedgingMember_d75c2379-d700-47dd-a921-039bd7a8396e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3252773b-8151-496e-ae8a-cef855bfd0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2aea6a0c-534c-4ac4-8bde-fa5e836b5093" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3252773b-8151-496e-ae8a-cef855bfd0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a242c73b-d4cd-4f4a-b0a1-e9eed1e7cefe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3252773b-8151-496e-ae8a-cef855bfd0bc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a242c73b-d4cd-4f4a-b0a1-e9eed1e7cefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_756145f8-c5fd-49c4-b410-d2d2dd99fd62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a242c73b-d4cd-4f4a-b0a1-e9eed1e7cefe" xlink:to="loc_us-gaap_ForeignExchangeContractMember_756145f8-c5fd-49c4-b410-d2d2dd99fd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_02a5d238-948a-4eab-9385-00b980656a48" xlink:href="amgn-20220630.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a242c73b-d4cd-4f4a-b0a1-e9eed1e7cefe" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_02a5d238-948a-4eab-9385-00b980656a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_87800476-4c8a-4032-85c4-f2954b1a0523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2aea6a0c-534c-4ac4-8bde-fa5e836b5093" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_87800476-4c8a-4032-85c4-f2954b1a0523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7db0497a-24a2-47aa-8a75-69b2ea688071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_87800476-4c8a-4032-85c4-f2954b1a0523" xlink:to="loc_us-gaap_EquityComponentDomain_7db0497a-24a2-47aa-8a75-69b2ea688071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_d4d16282-40e9-40e1-bff4-34ec2ee21e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7db0497a-24a2-47aa-8a75-69b2ea688071" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_d4d16282-40e9-40e1-bff4-34ec2ee21e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_66f7e305-66ae-4661-b83f-4fd7c25a80a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7db0497a-24a2-47aa-8a75-69b2ea688071" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_66f7e305-66ae-4661-b83f-4fd7c25a80a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1a4c8471-d19e-4435-bbbb-74d09afe971f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2aea6a0c-534c-4ac4-8bde-fa5e836b5093" xlink:to="loc_srt_ProductOrServiceAxis_1a4c8471-d19e-4435-bbbb-74d09afe971f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6d2f35c6-0283-4386-9e3f-27642032f5ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1a4c8471-d19e-4435-bbbb-74d09afe971f" xlink:to="loc_srt_ProductsAndServicesDomain_6d2f35c6-0283-4386-9e3f-27642032f5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e0014359-e95b-43e5-9acc-dd14f08491e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6d2f35c6-0283-4386-9e3f-27642032f5ea" xlink:to="loc_us-gaap_ProductMember_e0014359-e95b-43e5-9acc-dd14f08491e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_d1b243ae-64ff-4e57-b97d-7e0b3b7dd7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2aea6a0c-534c-4ac4-8bde-fa5e836b5093" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_d1b243ae-64ff-4e57-b97d-7e0b3b7dd7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_02a1a7cc-04b7-472b-86df-60e4b80e113c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_d1b243ae-64ff-4e57-b97d-7e0b3b7dd7e3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_02a1a7cc-04b7-472b-86df-60e4b80e113c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_84bd8a06-0401-4c37-854b-1a79be06a3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_d1b243ae-64ff-4e57-b97d-7e0b3b7dd7e3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_84bd8a06-0401-4c37-854b-1a79be06a3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_577609c9-1b80-4f56-9544-ed10e720542f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_d1b243ae-64ff-4e57-b97d-7e0b3b7dd7e3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_577609c9-1b80-4f56-9544-ed10e720542f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f1b3af87-dce6-466b-bc6c-3632189a8722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_d1b243ae-64ff-4e57-b97d-7e0b3b7dd7e3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f1b3af87-dce6-466b-bc6c-3632189a8722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5defcb7b-62f0-4dbf-92ae-cd9f78c16958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_d1b243ae-64ff-4e57-b97d-7e0b3b7dd7e3" xlink:to="loc_us-gaap_NetIncomeLoss_5defcb7b-62f0-4dbf-92ae-cd9f78c16958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Fairvaluemeasurement" xlink:type="simple" xlink:href="amgn-20220630.xsd#Fairvaluemeasurement"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Fairvaluemeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c2a1c39d-196e-477b-a138-1bcc0f74b566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_5cc76c7c-f8e5-4d90-bbcd-0660f9a6c2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c2a1c39d-196e-477b-a138-1bcc0f74b566" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_5cc76c7c-f8e5-4d90-bbcd-0660f9a6c2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementTables" xlink:type="simple" xlink:href="amgn-20220630.xsd#FairvaluemeasurementTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_46762446-e534-4e78-83ad-e686ede31be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_59fc0d4e-d703-45e0-98c7-9ebfa2736e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_46762446-e534-4e78-83ad-e686ede31be0" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_59fc0d4e-d703-45e0-98c7-9ebfa2736e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_985834e3-621c-4173-8786-ae32af3eecea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_46762446-e534-4e78-83ad-e686ede31be0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_985834e3-621c-4173-8786-ae32af3eecea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#FairvaluemeasurementDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_290fc641-f11b-42ca-9cca-4bd2591458bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b5643bf9-76ae-4283-b349-78aec50dc7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_290fc641-f11b-42ca-9cca-4bd2591458bc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b5643bf9-76ae-4283-b349-78aec50dc7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_56dc72f5-f2d1-4262-b3ee-1e4d6ab3159a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b5643bf9-76ae-4283-b349-78aec50dc7e0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_56dc72f5-f2d1-4262-b3ee-1e4d6ab3159a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_56dc72f5-f2d1-4262-b3ee-1e4d6ab3159a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_c7c54ec0-87ad-4c57-af16-0fbfeaf6bff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_c7c54ec0-87ad-4c57-af16-0fbfeaf6bff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_d3e826bc-d8b0-440f-8675-0adbe6a2649c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_d3e826bc-d8b0-440f-8675-0adbe6a2649c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4d0ec3a6-1315-4c83-ac67-d5bbfe4c76db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4d0ec3a6-1315-4c83-ac67-d5bbfe4c76db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_5ee70c1f-c427-47d8-8086-740718eeeb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_5ee70c1f-c427-47d8-8086-740718eeeb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesFinancialMember_90f5580b-41f2-4d87-9363-c74094acd791" xlink:href="amgn-20220630.xsd#amgn_CorporateDebtSecuritiesFinancialMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_amgn_CorporateDebtSecuritiesFinancialMember_90f5580b-41f2-4d87-9363-c74094acd791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesIndustrialMember_e0dcb38f-aebb-4986-845b-6d0e05f777ec" xlink:href="amgn-20220630.xsd#amgn_CorporateDebtSecuritiesIndustrialMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_amgn_CorporateDebtSecuritiesIndustrialMember_e0dcb38f-aebb-4986-845b-6d0e05f777ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CorporateDebtSecuritiesOtherMember_740dad23-ff73-4239-857b-cdde01c5018a" xlink:href="amgn-20220630.xsd#amgn_CorporateDebtSecuritiesOtherMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_amgn_CorporateDebtSecuritiesOtherMember_740dad23-ff73-4239-857b-cdde01c5018a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_fb31fffe-ba72-44c5-bb49-a661e9f0f900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_fb31fffe-ba72-44c5-bb49-a661e9f0f900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_122a888e-a7c5-4c5e-be90-f506ac61e7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_122a888e-a7c5-4c5e-be90-f506ac61e7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3acfb5b9-56eb-4e67-ab7e-614a3ef54992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3acfb5b9-56eb-4e67-ab7e-614a3ef54992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_57556721-10d4-4122-ba61-1f94a368c188" xlink:href="amgn-20220630.xsd#amgn_OtherShortTermInterestBearingSecuritiesMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_amgn_OtherShortTermInterestBearingSecuritiesMember_57556721-10d4-4122-ba61-1f94a368c188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_0695e764-4892-46f4-897a-72acf0c66a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_0695e764-4892-46f4-897a-72acf0c66a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ForeignAndOtherGovernmentRelatedDebtSecuritiesMember_32e836da-d57b-4e84-979a-bf970d150d2d" xlink:href="amgn-20220630.xsd#amgn_ForeignAndOtherGovernmentRelatedDebtSecuritiesMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_amgn_ForeignAndOtherGovernmentRelatedDebtSecuritiesMember_32e836da-d57b-4e84-979a-bf970d150d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_MortgageAndAssetBackMember_c12213ca-7b9e-47de-b19c-62b94774319a" xlink:href="amgn-20220630.xsd#amgn_MortgageAndAssetBackMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_amgn_MortgageAndAssetBackMember_c12213ca-7b9e-47de-b19c-62b94774319a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherMortgageAndAssetBackedMember_8d2d4cab-aef5-46fd-ac98-03f8acac0a08" xlink:href="amgn-20220630.xsd#amgn_OtherMortgageAndAssetBackedMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d9d6cf1-998a-43c0-9ab9-e1a350584b22" xlink:to="loc_amgn_OtherMortgageAndAssetBackedMember_8d2d4cab-aef5-46fd-ac98-03f8acac0a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e301dd9-efff-4f30-b9d1-f266e4ae43d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b5643bf9-76ae-4283-b349-78aec50dc7e0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e301dd9-efff-4f30-b9d1-f266e4ae43d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1cc00f4-e9cd-41a0-97c8-1e4f977cacbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e301dd9-efff-4f30-b9d1-f266e4ae43d0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1cc00f4-e9cd-41a0-97c8-1e4f977cacbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_80dec30f-071a-4351-b613-d2f81e189d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1cc00f4-e9cd-41a0-97c8-1e4f977cacbe" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_80dec30f-071a-4351-b613-d2f81e189d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_68c1776c-bed5-4c60-b927-cc2ba9d860b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1cc00f4-e9cd-41a0-97c8-1e4f977cacbe" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_68c1776c-bed5-4c60-b927-cc2ba9d860b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0160fe84-765e-4d67-ad22-4a5a0dbd49f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1cc00f4-e9cd-41a0-97c8-1e4f977cacbe" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0160fe84-765e-4d67-ad22-4a5a0dbd49f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_51cdb08d-f14c-41fa-b495-5e6852b769a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b5643bf9-76ae-4283-b349-78aec50dc7e0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_51cdb08d-f14c-41fa-b495-5e6852b769a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_69176758-2211-4460-ae04-a07cf3c3bafc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_51cdb08d-f14c-41fa-b495-5e6852b769a1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_69176758-2211-4460-ae04-a07cf3c3bafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_8d73bfad-b8c5-4404-8024-3a39fef56b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_69176758-2211-4460-ae04-a07cf3c3bafc" xlink:to="loc_us-gaap_ForeignExchangeContractMember_8d73bfad-b8c5-4404-8024-3a39fef56b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_02b02cdb-7d1d-4034-a9e4-04df9ff921eb" xlink:href="amgn-20220630.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_69176758-2211-4460-ae04-a07cf3c3bafc" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_02b02cdb-7d1d-4034-a9e4-04df9ff921eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_82f8bbd1-d8c6-42db-bd95-81bbffeb2b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_69176758-2211-4460-ae04-a07cf3c3bafc" xlink:to="loc_us-gaap_InterestRateSwapMember_82f8bbd1-d8c6-42db-bd95-81bbffeb2b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6060760e-c786-4f49-97c9-8245c98a84c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b5643bf9-76ae-4283-b349-78aec50dc7e0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6060760e-c786-4f49-97c9-8245c98a84c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_ce4358e7-ef94-43a9-8a71-b17c00fbba14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6060760e-c786-4f49-97c9-8245c98a84c0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_ce4358e7-ef94-43a9-8a71-b17c00fbba14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_14ec2f07-0758-4b54-a156-7b168e545092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ce4358e7-ef94-43a9-8a71-b17c00fbba14" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_14ec2f07-0758-4b54-a156-7b168e545092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_62659406-e386-4734-8435-70fa8919650b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ce4358e7-ef94-43a9-8a71-b17c00fbba14" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_62659406-e386-4734-8435-70fa8919650b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_eb46490a-61f8-47f8-acc6-059f892cc8c6" xlink:href="amgn-20220630.xsd#amgn_DerivativeAssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ce4358e7-ef94-43a9-8a71-b17c00fbba14" xlink:to="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_eb46490a-61f8-47f8-acc6-059f892cc8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2a5d3f6b-8af2-44ca-9b84-6199dc0aab4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_eb46490a-61f8-47f8-acc6-059f892cc8c6" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_2a5d3f6b-8af2-44ca-9b84-6199dc0aab4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_29d8abb1-6fb1-4046-bf31-29ab12a14d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateFairValueHedgeAssetAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_DerivativeAssetsFairValueDisclosureAbstract_eb46490a-61f8-47f8-acc6-059f892cc8c6" xlink:to="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_29d8abb1-6fb1-4046-bf31-29ab12a14d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_091c9f13-1341-4214-ba96-7415a1096d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ce4358e7-ef94-43a9-8a71-b17c00fbba14" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_091c9f13-1341-4214-ba96-7415a1096d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_64524e4f-658b-4e73-aa52-09b976b246a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6060760e-c786-4f49-97c9-8245c98a84c0" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_64524e4f-658b-4e73-aa52-09b976b246a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_05c25ad6-91d6-42ba-abf6-c02ddfca768f" xlink:href="amgn-20220630.xsd#amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_64524e4f-658b-4e73-aa52-09b976b246a6" xlink:to="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_05c25ad6-91d6-42ba-abf6-c02ddfca768f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_52321a1c-f8e1-4804-9dcd-41353ef87f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_05c25ad6-91d6-42ba-abf6-c02ddfca768f" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_52321a1c-f8e1-4804-9dcd-41353ef87f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_7c00bf3b-f58d-4f23-aea8-23c0399a8e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_05c25ad6-91d6-42ba-abf6-c02ddfca768f" xlink:to="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_7c00bf3b-f58d-4f23-aea8-23c0399a8e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c5dbfdd8-cb2b-499b-a05b-6a4c5a72624b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract_05c25ad6-91d6-42ba-abf6-c02ddfca768f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c5dbfdd8-cb2b-499b-a05b-6a4c5a72624b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_f4d5dd5e-db27-4266-811c-d195d3ac89a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_64524e4f-658b-4e73-aa52-09b976b246a6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_f4d5dd5e-db27-4266-811c-d195d3ac89a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementDetailsTextual" xlink:type="simple" xlink:href="amgn-20220630.xsd#FairvaluemeasurementDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8fa7b166-cb4d-4579-a0e0-017e1cb27c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7172e928-52a5-4c8b-bff1-894a457bb242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8fa7b166-cb4d-4579-a0e0-017e1cb27c16" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7172e928-52a5-4c8b-bff1-894a457bb242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e3907d3d-daf2-4afd-8e09-0f1a71cfeeed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7172e928-52a5-4c8b-bff1-894a457bb242" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e3907d3d-daf2-4afd-8e09-0f1a71cfeeed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a04a6cea-c1e4-41dd-b8f0-0a6c1f78667d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e3907d3d-daf2-4afd-8e09-0f1a71cfeeed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a04a6cea-c1e4-41dd-b8f0-0a6c1f78667d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BeiGeneMember_0a4a7d05-e883-400d-bef8-174866855736" xlink:href="amgn-20220630.xsd#amgn_BeiGeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a04a6cea-c1e4-41dd-b8f0-0a6c1f78667d" xlink:to="loc_amgn_BeiGeneMember_0a4a7d05-e883-400d-bef8-174866855736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TeneobioIncMember_d02eaf8e-334b-44ce-bfb1-52d953012c2e" xlink:href="amgn-20220630.xsd#amgn_TeneobioIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a04a6cea-c1e4-41dd-b8f0-0a6c1f78667d" xlink:to="loc_amgn_TeneobioIncMember_d02eaf8e-334b-44ce-bfb1-52d953012c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fce48c17-2885-4b70-afd2-8f61253247ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7172e928-52a5-4c8b-bff1-894a457bb242" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fce48c17-2885-4b70-afd2-8f61253247ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_6af8f51b-c052-4a69-ac45-fa6c9feec88d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fce48c17-2885-4b70-afd2-8f61253247ac" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_6af8f51b-c052-4a69-ac45-fa6c9feec88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_d264295b-62d4-4a97-9019-d22f0cddfdc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fce48c17-2885-4b70-afd2-8f61253247ac" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_d264295b-62d4-4a97-9019-d22f0cddfdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_8c6123be-00e4-453b-929d-487f010f2621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fce48c17-2885-4b70-afd2-8f61253247ac" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_8c6123be-00e4-453b-929d-487f010f2621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_19ecda19-60ea-4d7d-a297-b349d4c58159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fce48c17-2885-4b70-afd2-8f61253247ac" xlink:to="loc_us-gaap_LongTermDebt_19ecda19-60ea-4d7d-a297-b349d4c58159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_c36c32d2-1186-41fc-b29f-591d91d848e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fce48c17-2885-4b70-afd2-8f61253247ac" xlink:to="loc_us-gaap_EquityMethodInvestments_c36c32d2-1186-41fc-b29f-591d91d848e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_05760dbc-70fb-4ddf-a020-e154e25a5a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fce48c17-2885-4b70-afd2-8f61253247ac" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_05760dbc-70fb-4ddf-a020-e154e25a5a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#FairvaluemeasurementContingentConsiderationObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c4ab0669-4ff7-4bad-8e8c-a9e3fbd3ad64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationContingentConsiderationRollForward_3237b84f-0eb0-433c-8922-cf427363ab5e" xlink:href="amgn-20220630.xsd#amgn_BusinessCombinationContingentConsiderationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c4ab0669-4ff7-4bad-8e8c-a9e3fbd3ad64" xlink:to="loc_amgn_BusinessCombinationContingentConsiderationRollForward_3237b84f-0eb0-433c-8922-cf427363ab5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c7866f19-b167-4b43-8264-373ddbed3d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BusinessCombinationContingentConsiderationRollForward_3237b84f-0eb0-433c-8922-cf427363ab5e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c7866f19-b167-4b43-8264-373ddbed3d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_BusinessCombinationContingentConsiderationArrangementsPayments_dc1cd84b-6781-4d85-8c02-fdc005419946" xlink:href="amgn-20220630.xsd#amgn_BusinessCombinationContingentConsiderationArrangementsPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BusinessCombinationContingentConsiderationRollForward_3237b84f-0eb0-433c-8922-cf427363ab5e" xlink:to="loc_amgn_BusinessCombinationContingentConsiderationArrangementsPayments_dc1cd84b-6781-4d85-8c02-fdc005419946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ca0d8b83-64a2-4741-a509-0e4d60efaf39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BusinessCombinationContingentConsiderationRollForward_3237b84f-0eb0-433c-8922-cf427363ab5e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ca0d8b83-64a2-4741-a509-0e4d60efaf39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b62b27c4-9d46-4dc8-bcd5-222febcf9e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_BusinessCombinationContingentConsiderationRollForward_3237b84f-0eb0-433c-8922-cf427363ab5e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b62b27c4-9d46-4dc8-bcd5-222febcf9e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Derivativeinstruments" xlink:type="simple" xlink:href="amgn-20220630.xsd#Derivativeinstruments"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Derivativeinstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5e539b09-69ce-432f-b96a-3256da745ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_a5cfe63e-3f9c-49ed-af16-8f08ba798662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5e539b09-69ce-432f-b96a-3256da745ff2" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_a5cfe63e-3f9c-49ed-af16-8f08ba798662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsTables" xlink:type="simple" xlink:href="amgn-20220630.xsd#DerivativeinstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6476217b-1b29-4d7f-b35c-8fc412f2b789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock_0ea58fee-a385-46b7-a6b1-3626d2ab9271" xlink:href="amgn-20220630.xsd#amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6476217b-1b29-4d7f-b35c-8fc412f2b789" xlink:to="loc_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock_0ea58fee-a385-46b7-a6b1-3626d2ab9271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_c8c7337f-3e49-4539-a5bc-3e2945bd0350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6476217b-1b29-4d7f-b35c-8fc412f2b789" xlink:to="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_c8c7337f-3e49-4539-a5bc-3e2945bd0350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_a6e19eae-6d3d-40d8-98a8-424f6437c39a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6476217b-1b29-4d7f-b35c-8fc412f2b789" xlink:to="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_a6e19eae-6d3d-40d8-98a8-424f6437c39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_682e5bf3-6c7f-46d8-81ea-0a1928f5896d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6476217b-1b29-4d7f-b35c-8fc412f2b789" xlink:to="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_682e5bf3-6c7f-46d8-81ea-0a1928f5896d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_06eabce6-4b57-48c6-867a-c3967f8e49cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6476217b-1b29-4d7f-b35c-8fc412f2b789" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_06eabce6-4b57-48c6-867a-c3967f8e49cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual" xlink:type="simple" xlink:href="amgn-20220630.xsd#DerivativeinstrumentsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7943f901-a4b5-4a94-bf38-80e9625f3bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_870846cd-8883-4e66-8af0-2e5ef8da47d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7943f901-a4b5-4a94-bf38-80e9625f3bdf" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_870846cd-8883-4e66-8af0-2e5ef8da47d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fd3783fe-248d-47f5-9324-89507916da29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_870846cd-8883-4e66-8af0-2e5ef8da47d5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fd3783fe-248d-47f5-9324-89507916da29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_94f70141-b79d-411e-a3c0-b18e9f815858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fd3783fe-248d-47f5-9324-89507916da29" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_94f70141-b79d-411e-a3c0-b18e9f815858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_3c371a97-1881-4eca-885b-7e23e9f02c90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_94f70141-b79d-411e-a3c0-b18e9f815858" xlink:to="loc_us-gaap_ForwardContractsMember_3c371a97-1881-4eca-885b-7e23e9f02c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b935fb36-fc31-4c4e-be30-a6a6e19acb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_94f70141-b79d-411e-a3c0-b18e9f815858" xlink:to="loc_us-gaap_InterestRateSwapMember_b935fb36-fc31-4c4e-be30-a6a6e19acb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_90394468-f7df-48f8-832b-fb17849109f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_870846cd-8883-4e66-8af0-2e5ef8da47d5" xlink:to="loc_us-gaap_HedgingDesignationAxis_90394468-f7df-48f8-832b-fb17849109f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_1ee5891d-4ee3-4f40-a22a-9ada11dd8b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_90394468-f7df-48f8-832b-fb17849109f4" xlink:to="loc_us-gaap_HedgingDesignationDomain_1ee5891d-4ee3-4f40-a22a-9ada11dd8b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_cc4400ec-2305-4808-b5be-98dd2e9c7b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_1ee5891d-4ee3-4f40-a22a-9ada11dd8b5e" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_cc4400ec-2305-4808-b5be-98dd2e9c7b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_a07046df-d030-40df-9f42-6cb3541e9429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_1ee5891d-4ee3-4f40-a22a-9ada11dd8b5e" xlink:to="loc_us-gaap_NondesignatedMember_a07046df-d030-40df-9f42-6cb3541e9429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dbb9b5d7-20b5-4ad3-82b7-e52b2fd38a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_870846cd-8883-4e66-8af0-2e5ef8da47d5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dbb9b5d7-20b5-4ad3-82b7-e52b2fd38a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_31ac7d09-6c51-4c0d-94ec-61bceeb2661d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dbb9b5d7-20b5-4ad3-82b7-e52b2fd38a54" xlink:to="loc_us-gaap_DerivativeNotionalAmount_31ac7d09-6c51-4c0d-94ec-61bceeb2661d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_11b74505-2ad2-41b7-b050-a0b8f089f5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dbb9b5d7-20b5-4ad3-82b7-e52b2fd38a54" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_11b74505-2ad2-41b7-b050-a0b8f089f5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#DerivativeinstrumentsCrosscurrencySwapsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_358ba914-afd8-4e13-9740-8e613f680790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_7e504cff-c5c6-4cf4-8a65-104e84cd8c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_358ba914-afd8-4e13-9740-8e613f680790" xlink:to="loc_us-gaap_DerivativeTable_7e504cff-c5c6-4cf4-8a65-104e84cd8c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a915f73e-7e2d-4b18-b560-cf99380ae8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_7e504cff-c5c6-4cf4-8a65-104e84cd8c2c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a915f73e-7e2d-4b18-b560-cf99380ae8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0eedae6a-316f-46be-9dbf-e9515ff80a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a915f73e-7e2d-4b18-b560-cf99380ae8ac" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0eedae6a-316f-46be-9dbf-e9515ff80a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_ca4bb348-bbd5-4d13-bbd9-d92b99c2953f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0eedae6a-316f-46be-9dbf-e9515ff80a2c" xlink:to="loc_us-gaap_CashFlowHedgingMember_ca4bb348-bbd5-4d13-bbd9-d92b99c2953f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6582f1ec-2c3f-4e00-bf3c-08a1da208548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_7e504cff-c5c6-4cf4-8a65-104e84cd8c2c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6582f1ec-2c3f-4e00-bf3c-08a1da208548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4bd00d3b-9eed-4b44-a38a-e4f88b036af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6582f1ec-2c3f-4e00-bf3c-08a1da208548" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4bd00d3b-9eed-4b44-a38a-e4f88b036af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_5d445010-4472-445e-a0eb-5ff7013ab029" xlink:href="amgn-20220630.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4bd00d3b-9eed-4b44-a38a-e4f88b036af9" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_5d445010-4472-445e-a0eb-5ff7013ab029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_e40abf47-fbaa-4c2d-ad56-172608a806cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_7e504cff-c5c6-4cf4-8a65-104e84cd8c2c" xlink:to="loc_srt_CurrencyAxis_e40abf47-fbaa-4c2d-ad56-172608a806cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_9eda031e-5f44-4fc0-809d-15ea63018aeb" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_e40abf47-fbaa-4c2d-ad56-172608a806cf" xlink:to="loc_currency_AllCurrenciesDomain_9eda031e-5f44-4fc0-809d-15ea63018aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_c4345486-f9c0-4998-93d3-d253c0ae4ce7" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_9eda031e-5f44-4fc0-809d-15ea63018aeb" xlink:to="loc_currency_EUR_c4345486-f9c0-4998-93d3-d253c0ae4ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_3a245045-832c-4eb9-bb32-3927e020349a" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_9eda031e-5f44-4fc0-809d-15ea63018aeb" xlink:to="loc_currency_CHF_3a245045-832c-4eb9-bb32-3927e020349a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_e63afad0-3e14-47c4-9458-b96d097f3b59" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_GBP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_9eda031e-5f44-4fc0-809d-15ea63018aeb" xlink:to="loc_currency_GBP_e63afad0-3e14-47c4-9458-b96d097f3b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_20ede496-2964-4845-adb5-1c246ab1853d" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_9eda031e-5f44-4fc0-809d-15ea63018aeb" xlink:to="loc_currency_USD_20ede496-2964-4845-adb5-1c246ab1853d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ed2b7c82-0052-4680-be75-443cc2e7b0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_7e504cff-c5c6-4cf4-8a65-104e84cd8c2c" xlink:to="loc_us-gaap_DebtInstrumentAxis_ed2b7c82-0052-4680-be75-443cc2e7b0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_da71eaee-8a61-4931-815b-b3798b2f83b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ed2b7c82-0052-4680-be75-443cc2e7b0a5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_da71eaee-8a61-4931-815b-b3798b2f83b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_8a7ba0c4-4f6e-4589-b069-9e4044e4eca5" xlink:href="amgn-20220630.xsd#amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da71eaee-8a61-4931-815b-b3798b2f83b2" xlink:to="loc_amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember_8a7ba0c4-4f6e-4589-b069-9e4044e4eca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_acdafab8-7739-426f-86b3-0c89ef777807" xlink:href="amgn-20220630.xsd#amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da71eaee-8a61-4931-815b-b3798b2f83b2" xlink:to="loc_amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember_acdafab8-7739-426f-86b3-0c89ef777807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_53c38287-e3a5-4213-9da2-d9fd49ccf22f" xlink:href="amgn-20220630.xsd#amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da71eaee-8a61-4931-815b-b3798b2f83b2" xlink:to="loc_amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember_53c38287-e3a5-4213-9da2-d9fd49ccf22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_95aa1194-6478-4d77-941b-f5acb631777c" xlink:href="amgn-20220630.xsd#amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da71eaee-8a61-4931-815b-b3798b2f83b2" xlink:to="loc_amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member_95aa1194-6478-4d77-941b-f5acb631777c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_288bf33f-b661-4259-85b0-fd21462dbb6e" xlink:href="amgn-20220630.xsd#amgn_FourPercentPoundSterlingNotesDue2029Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da71eaee-8a61-4931-815b-b3798b2f83b2" xlink:to="loc_amgn_FourPercentPoundSterlingNotesDue2029Member_288bf33f-b661-4259-85b0-fd21462dbb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_d566f568-f7a1-431a-9c97-e6d614097df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_7e504cff-c5c6-4cf4-8a65-104e84cd8c2c" xlink:to="loc_us-gaap_DerivativeLineItems_d566f568-f7a1-431a-9c97-e6d614097df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_f5c4810d-3496-481a-9862-4f4a81914c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_d566f568-f7a1-431a-9c97-e6d614097df3" xlink:to="loc_us-gaap_DerivativeNotionalAmount_f5c4810d-3496-481a-9862-4f4a81914c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_bec2b27d-5d21-4029-81ad-8a47130dd45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_d566f568-f7a1-431a-9c97-e6d614097df3" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_bec2b27d-5d21-4029-81ad-8a47130dd45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8b230358-556a-45ba-ba71-802b2f4aba98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bfb6f518-8f54-43b6-9055-fe34f8551119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8b230358-556a-45ba-ba71-802b2f4aba98" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bfb6f518-8f54-43b6-9055-fe34f8551119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c66a95da-c5c4-4cfb-a9c8-a77a12ba6eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bfb6f518-8f54-43b6-9055-fe34f8551119" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c66a95da-c5c4-4cfb-a9c8-a77a12ba6eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7156c488-1a2f-4db9-93cf-d1759d005c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c66a95da-c5c4-4cfb-a9c8-a77a12ba6eb4" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7156c488-1a2f-4db9-93cf-d1759d005c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_aadfdfcc-583a-4763-8e3e-6ff1cde93e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7156c488-1a2f-4db9-93cf-d1759d005c32" xlink:to="loc_us-gaap_CashFlowHedgingMember_aadfdfcc-583a-4763-8e3e-6ff1cde93e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_63d58bef-6a18-4e1e-8f87-102c9a8c9dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bfb6f518-8f54-43b6-9055-fe34f8551119" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_63d58bef-6a18-4e1e-8f87-102c9a8c9dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6b413450-768f-4ab5-9513-8fa6b4e6a3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_63d58bef-6a18-4e1e-8f87-102c9a8c9dc0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6b413450-768f-4ab5-9513-8fa6b4e6a3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_db98588a-fc78-4631-94b1-689be366f2df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b413450-768f-4ab5-9513-8fa6b4e6a3c4" xlink:to="loc_us-gaap_ForeignExchangeContractMember_db98588a-fc78-4631-94b1-689be366f2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_fcf52eca-6f4d-4507-879d-ab8a918e0dac" xlink:href="amgn-20220630.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6b413450-768f-4ab5-9513-8fa6b4e6a3c4" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_fcf52eca-6f4d-4507-879d-ab8a918e0dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2e0a626c-b890-44cd-9919-a10f744cf474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_bfb6f518-8f54-43b6-9055-fe34f8551119" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2e0a626c-b890-44cd-9919-a10f744cf474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_bf71e397-ace6-4bc3-a085-42332da6c752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2e0a626c-b890-44cd-9919-a10f744cf474" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_bf71e397-ace6-4bc3-a085-42332da6c752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_65f8d38b-4d7a-4e73-baa0-e6a1f3ad6c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_cd0889bc-f994-41b8-82a9-be77e03f7198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_65f8d38b-4d7a-4e73-baa0-e6a1f3ad6c23" xlink:to="loc_us-gaap_DerivativeTable_cd0889bc-f994-41b8-82a9-be77e03f7198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_b1c286d1-a647-463f-b1ff-18446157ff5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_cd0889bc-f994-41b8-82a9-be77e03f7198" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_b1c286d1-a647-463f-b1ff-18446157ff5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e6131278-f310-47d7-8143-29ab9e52a7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_b1c286d1-a647-463f-b1ff-18446157ff5e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e6131278-f310-47d7-8143-29ab9e52a7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LongTermDebtCurrentMaturitiesMember_852bd4c3-c37e-4124-9770-cc37bbff7f4f" xlink:href="amgn-20220630.xsd#amgn_LongTermDebtCurrentMaturitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e6131278-f310-47d7-8143-29ab9e52a7be" xlink:to="loc_amgn_LongTermDebtCurrentMaturitiesMember_852bd4c3-c37e-4124-9770-cc37bbff7f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_e3b661fd-ade1-419f-b5b6-d8ba9d20b477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e6131278-f310-47d7-8143-29ab9e52a7be" xlink:to="loc_us-gaap_LongTermDebtMember_e3b661fd-ade1-419f-b5b6-d8ba9d20b477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a7db6e13-e109-45ab-9406-df68a8ccbc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_cd0889bc-f994-41b8-82a9-be77e03f7198" xlink:to="loc_us-gaap_DerivativeLineItems_a7db6e13-e109-45ab-9406-df68a8ccbc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_e4b917a5-49a1-4c3f-be41-14370b87c844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a7db6e13-e109-45ab-9406-df68a8ccbc0f" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_e4b917a5-49a1-4c3f-be41-14370b87c844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_8160726b-f48e-4cf3-bb11-709cf4ae8767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a7db6e13-e109-45ab-9406-df68a8ccbc0f" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_8160726b-f48e-4cf3-bb11-709cf4ae8767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge_63d5d569-2f69-4de3-b8c8-43cc23498ccc" xlink:href="amgn-20220630.xsd#amgn_HedgedLiabilityDiscontinuedFairValueHedge"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a7db6e13-e109-45ab-9406-df68a8ccbc0f" xlink:to="loc_amgn_HedgedLiabilityDiscontinuedFairValueHedge_63d5d569-2f69-4de3-b8c8-43cc23498ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_ea324e4b-137b-4ec0-bf28-10905d4a5d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a7db6e13-e109-45ab-9406-df68a8ccbc0f" xlink:to="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_ea324e4b-137b-4ec0-bf28-10905d4a5d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e1f59a2c-e037-4b92-b697-525c5513b5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_c2d6c57f-b5eb-4ea0-89d0-97df5a3afa70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e1f59a2c-e037-4b92-b697-525c5513b5f3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_c2d6c57f-b5eb-4ea0-89d0-97df5a3afa70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_eb7a1d73-29a1-4c53-9e17-2b1f9612e5c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_c2d6c57f-b5eb-4ea0-89d0-97df5a3afa70" xlink:to="loc_srt_ProductOrServiceAxis_eb7a1d73-29a1-4c53-9e17-2b1f9612e5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aecf25a2-2c38-44d5-ac88-d50706884a80" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_eb7a1d73-29a1-4c53-9e17-2b1f9612e5c1" xlink:to="loc_srt_ProductsAndServicesDomain_aecf25a2-2c38-44d5-ac88-d50706884a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_bf48c2bc-9a81-428a-bea7-83cb7f03a150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aecf25a2-2c38-44d5-ac88-d50706884a80" xlink:to="loc_us-gaap_ProductMember_bf48c2bc-9a81-428a-bea7-83cb7f03a150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_adace4c7-2276-495c-9f1b-0c50635f373d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_c2d6c57f-b5eb-4ea0-89d0-97df5a3afa70" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_adace4c7-2276-495c-9f1b-0c50635f373d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_862e9475-af23-4df3-aa1c-2e2c39062810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_adace4c7-2276-495c-9f1b-0c50635f373d" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_862e9475-af23-4df3-aa1c-2e2c39062810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_187439b4-c723-4783-9fbc-1c5d4d174749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_862e9475-af23-4df3-aa1c-2e2c39062810" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_187439b4-c723-4783-9fbc-1c5d4d174749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_005899d4-3742-4e17-9183-44ca5a60a6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_c2d6c57f-b5eb-4ea0-89d0-97df5a3afa70" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_005899d4-3742-4e17-9183-44ca5a60a6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_531b11a3-9ac4-4d07-914a-4984ab29adf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_005899d4-3742-4e17-9183-44ca5a60a6a0" xlink:to="loc_us-gaap_EquityComponentDomain_531b11a3-9ac4-4d07-914a-4984ab29adf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e263f708-74aa-4b94-b268-b570fb1b8629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_531b11a3-9ac4-4d07-914a-4984ab29adf2" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e263f708-74aa-4b94-b268-b570fb1b8629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ec8bb8c8-708b-4a57-afeb-d7c1467716c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_c2d6c57f-b5eb-4ea0-89d0-97df5a3afa70" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ec8bb8c8-708b-4a57-afeb-d7c1467716c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b45bf0b7-3cd9-461d-b8cb-2a359a1348bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ec8bb8c8-708b-4a57-afeb-d7c1467716c2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b45bf0b7-3cd9-461d-b8cb-2a359a1348bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_2ceadb51-b89d-4a0c-8573-26465ff861f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b45bf0b7-3cd9-461d-b8cb-2a359a1348bf" xlink:to="loc_us-gaap_ForeignExchangeContractMember_2ceadb51-b89d-4a0c-8573-26465ff861f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_a28e873f-92be-4c32-b44e-08fe231ba5fa" xlink:href="amgn-20220630.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b45bf0b7-3cd9-461d-b8cb-2a359a1348bf" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_a28e873f-92be-4c32-b44e-08fe231ba5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_e93ffe7a-dbe6-4ea5-b7ee-7b3cd805f5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b45bf0b7-3cd9-461d-b8cb-2a359a1348bf" xlink:to="loc_us-gaap_InterestRateSwapMember_e93ffe7a-dbe6-4ea5-b7ee-7b3cd805f5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_db042a08-d44c-4a3f-9278-0bd496bfe2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_c2d6c57f-b5eb-4ea0-89d0-97df5a3afa70" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_db042a08-d44c-4a3f-9278-0bd496bfe2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f070afeb-4142-46e2-8482-8e4b64821d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_db042a08-d44c-4a3f-9278-0bd496bfe2e0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f070afeb-4142-46e2-8482-8e4b64821d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d5928782-c5ac-468f-9455-7e50e366611f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_db042a08-d44c-4a3f-9278-0bd496bfe2e0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d5928782-c5ac-468f-9455-7e50e366611f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_45dab039-9495-44e7-965e-1427f77692db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_db042a08-d44c-4a3f-9278-0bd496bfe2e0" xlink:to="loc_us-gaap_InterestExpenseDebt_45dab039-9495-44e7-965e-1427f77692db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_ef5571ac-5f78-443a-99a8-71944c7649c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_db042a08-d44c-4a3f-9278-0bd496bfe2e0" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_ef5571ac-5f78-443a-99a8-71944c7649c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_70ba1d03-cf2b-4188-a76d-aaae15921db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_db042a08-d44c-4a3f-9278-0bd496bfe2e0" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_70ba1d03-cf2b-4188-a76d-aaae15921db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#DerivativeinstrumentsFairValueofDerivativesDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9baa3535-304f-4696-a01e-4099027cdb55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b1f43085-a090-40fa-9870-fdc889d9e59c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9baa3535-304f-4696-a01e-4099027cdb55" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b1f43085-a090-40fa-9870-fdc889d9e59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_0b692753-1af9-4d19-8ba8-a23f07e48adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b1f43085-a090-40fa-9870-fdc889d9e59c" xlink:to="loc_us-gaap_HedgingDesignationAxis_0b692753-1af9-4d19-8ba8-a23f07e48adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c9c3d021-e6f0-4f7d-81f8-3a36b7891bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_0b692753-1af9-4d19-8ba8-a23f07e48adf" xlink:to="loc_us-gaap_HedgingDesignationDomain_c9c3d021-e6f0-4f7d-81f8-3a36b7891bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e71912cf-c868-4137-886a-a8c436d46a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_c9c3d021-e6f0-4f7d-81f8-3a36b7891bc7" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e71912cf-c868-4137-886a-a8c436d46a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_87a09659-5059-44d8-8d82-28d63cbf31f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_c9c3d021-e6f0-4f7d-81f8-3a36b7891bc7" xlink:to="loc_us-gaap_NondesignatedMember_87a09659-5059-44d8-8d82-28d63cbf31f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_942c4d6a-4e6a-419e-9b1e-bdaf3bcf0ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b1f43085-a090-40fa-9870-fdc889d9e59c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_942c4d6a-4e6a-419e-9b1e-bdaf3bcf0ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0c3d836b-2e64-425c-816b-2d614bdfd036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_942c4d6a-4e6a-419e-9b1e-bdaf3bcf0ba7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0c3d836b-2e64-425c-816b-2d614bdfd036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_042df90e-dfe8-41d9-9187-e13bea365916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0c3d836b-2e64-425c-816b-2d614bdfd036" xlink:to="loc_us-gaap_ForeignExchangeContractMember_042df90e-dfe8-41d9-9187-e13bea365916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CrossCurrencySwapContractsMember_8a085fbb-32f9-4591-938d-7875d44a6987" xlink:href="amgn-20220630.xsd#amgn_CrossCurrencySwapContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0c3d836b-2e64-425c-816b-2d614bdfd036" xlink:to="loc_amgn_CrossCurrencySwapContractsMember_8a085fbb-32f9-4591-938d-7875d44a6987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_c912bc07-d2ad-4ea3-b5b7-8317dfd803ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0c3d836b-2e64-425c-816b-2d614bdfd036" xlink:to="loc_us-gaap_InterestRateSwapMember_c912bc07-d2ad-4ea3-b5b7-8317dfd803ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3f795c40-586e-43bf-a09f-38960cc6f88e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b1f43085-a090-40fa-9870-fdc889d9e59c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3f795c40-586e-43bf-a09f-38960cc6f88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cba1f8cc-3c98-405f-b9fa-04f1662c6f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3f795c40-586e-43bf-a09f-38960cc6f88e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cba1f8cc-3c98-405f-b9fa-04f1662c6f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtherCurrentNoncurrentAssetsMember_00b74e5a-15a7-49ca-afc0-d5684d7f22ae" xlink:href="amgn-20220630.xsd#amgn_OtherCurrentNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cba1f8cc-3c98-405f-b9fa-04f1662c6f60" xlink:to="loc_amgn_OtherCurrentNoncurrentAssetsMember_00b74e5a-15a7-49ca-afc0-d5684d7f22ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_860fb23f-09cd-46c6-9836-2b8f2d12ccfb" xlink:href="amgn-20220630.xsd#amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cba1f8cc-3c98-405f-b9fa-04f1662c6f60" xlink:to="loc_amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember_860fb23f-09cd-46c6-9836-2b8f2d12ccfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_5ec60b6e-d23d-4ec8-82a2-7b5fa50a86f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cba1f8cc-3c98-405f-b9fa-04f1662c6f60" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_5ec60b6e-d23d-4ec8-82a2-7b5fa50a86f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_4ae7b4fd-4400-4b88-bdc5-6c00ae272f71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cba1f8cc-3c98-405f-b9fa-04f1662c6f60" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_4ae7b4fd-4400-4b88-bdc5-6c00ae272f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_d1900779-c598-4317-8841-7a0a83bc9888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b1f43085-a090-40fa-9870-fdc889d9e59c" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_d1900779-c598-4317-8841-7a0a83bc9888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_e29b7998-3b83-4e4d-a76a-f583f74ac6fd" xlink:href="amgn-20220630.xsd#amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_d1900779-c598-4317-8841-7a0a83bc9888" xlink:to="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_e29b7998-3b83-4e4d-a76a-f583f74ac6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_0a092bd3-bd75-4e5a-a373-7d00ac360d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_e29b7998-3b83-4e4d-a76a-f583f74ac6fd" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_0a092bd3-bd75-4e5a-a373-7d00ac360d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_4676abe7-a6a3-48d4-a269-c122f8051c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_0a092bd3-bd75-4e5a-a373-7d00ac360d78" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_4676abe7-a6a3-48d4-a269-c122f8051c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_2339bf74-2a20-4f1d-9335-fcf5051025f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract_e29b7998-3b83-4e4d-a76a-f583f74ac6fd" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_2339bf74-2a20-4f1d-9335-fcf5051025f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0c35c71d-2000-4365-9f17-f22d12b7bae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueNetAbstract_2339bf74-2a20-4f1d-9335-fcf5051025f4" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0c35c71d-2000-4365-9f17-f22d12b7bae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/Contingenciesandcommitments" xlink:type="simple" xlink:href="amgn-20220630.xsd#Contingenciesandcommitments"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/Contingenciesandcommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6582dbac-b810-4a7d-b0ca-777e15c82032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2fb72ae7-d51d-4498-97dc-c0e767ade67d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6582dbac-b810-4a7d-b0ca-777e15c82032" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2fb72ae7-d51d-4498-97dc-c0e767ade67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amgen.com/role/ContingenciesandcommitmentsDetails" xlink:type="simple" xlink:href="amgn-20220630.xsd#ContingenciesandcommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/ContingenciesandcommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a70d4afd-34db-460d-85ea-74f9617a9f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_538a4d86-b2a3-4d94-b209-7326442e13d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a70d4afd-34db-460d-85ea-74f9617a9f12" xlink:to="loc_us-gaap_LossContingenciesTable_538a4d86-b2a3-4d94-b209-7326442e13d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5c8439d5-4601-4133-9472-528b83952dad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_538a4d86-b2a3-4d94-b209-7326442e13d4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5c8439d5-4601-4133-9472-528b83952dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_729fdbf1-2de7-4d5f-911c-1dbb85d94933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5c8439d5-4601-4133-9472-528b83952dad" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_729fdbf1-2de7-4d5f-911c-1dbb85d94933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b56aa714-9bc1-42f3-921b-74b7cdbb953a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_729fdbf1-2de7-4d5f-911c-1dbb85d94933" xlink:to="loc_us-gaap_SubsequentEventMember_b56aa714-9bc1-42f3-921b-74b7cdbb953a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d063f347-3271-48d0-bbf4-913819ce85ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_538a4d86-b2a3-4d94-b209-7326442e13d4" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d063f347-3271-48d0-bbf4-913819ce85ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_76b085c6-732b-47d4-9b06-1ff670da6b07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d063f347-3271-48d0-bbf4-913819ce85ba" xlink:to="loc_us-gaap_LossContingencyNatureDomain_76b085c6-732b-47d4-9b06-1ff670da6b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_PatentTrialAndAppealBoardPatentChallengesMember_a2d1ecb2-53b6-4a94-b224-c58bdc9ff6c6" xlink:href="amgn-20220630.xsd#amgn_PatentTrialAndAppealBoardPatentChallengesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_76b085c6-732b-47d4-9b06-1ff670da6b07" xlink:to="loc_amgn_PatentTrialAndAppealBoardPatentChallengesMember_a2d1ecb2-53b6-4a94-b224-c58bdc9ff6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f6e9a78b-59b7-44ed-a481-1049e96a34be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_538a4d86-b2a3-4d94-b209-7326442e13d4" xlink:to="loc_srt_LitigationCaseAxis_f6e9a78b-59b7-44ed-a481-1049e96a34be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4e2dc737-9193-4aa2-a1dc-ff51a710690d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_f6e9a78b-59b7-44ed-a481-1049e96a34be" xlink:to="loc_srt_LitigationCaseTypeDomain_4e2dc737-9193-4aa2-a1dc-ff51a710690d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HospiraMember_c3091b89-1263-498d-8b99-bc93177c1a10" xlink:href="amgn-20220630.xsd#amgn_HospiraMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4e2dc737-9193-4aa2-a1dc-ff51a710690d" xlink:to="loc_amgn_HospiraMember_c3091b89-1263-498d-8b99-bc93177c1a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KANJINTIPatentLitigationMember_ac108c63-812d-448d-9266-8751f0004307" xlink:href="amgn-20220630.xsd#amgn_KANJINTIPatentLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4e2dc737-9193-4aa2-a1dc-ff51a710690d" xlink:to="loc_amgn_KANJINTIPatentLitigationMember_ac108c63-812d-448d-9266-8751f0004307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_HumiraBiosimilarAntitrustClassActionsMember_1f50aee9-904b-4c69-8992-4a3daf82f5f0" xlink:href="amgn-20220630.xsd#amgn_HumiraBiosimilarAntitrustClassActionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4e2dc737-9193-4aa2-a1dc-ff51a710690d" xlink:to="loc_amgn_HumiraBiosimilarAntitrustClassActionsMember_1f50aee9-904b-4c69-8992-4a3daf82f5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_SensiparAntitrustClassActionsMember_31212459-dffa-4895-a417-4b6660114e18" xlink:href="amgn-20220630.xsd#amgn_SensiparAntitrustClassActionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4e2dc737-9193-4aa2-a1dc-ff51a710690d" xlink:to="loc_amgn_SensiparAntitrustClassActionsMember_31212459-dffa-4895-a417-4b6660114e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyprolisMember_6c3ec859-b04f-4a50-bf1d-3027ca8c17f6" xlink:href="amgn-20220630.xsd#amgn_KyprolisMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4e2dc737-9193-4aa2-a1dc-ff51a710690d" xlink:to="loc_amgn_KyprolisMember_6c3ec859-b04f-4a50-bf1d-3027ca8c17f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_KyprolisANDAPatentLitigationMember_af0a8590-9140-41dc-9400-9742ab46a543" xlink:href="amgn-20220630.xsd#amgn_KyprolisANDAPatentLitigationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4e2dc737-9193-4aa2-a1dc-ff51a710690d" xlink:to="loc_amgn_KyprolisANDAPatentLitigationMember_af0a8590-9140-41dc-9400-9742ab46a543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NovartisPharmaAGMember_0bd22261-6fd4-4eb1-babb-4ee327112b7a" xlink:href="amgn-20220630.xsd#amgn_NovartisPharmaAGMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4e2dc737-9193-4aa2-a1dc-ff51a710690d" xlink:to="loc_amgn_NovartisPharmaAGMember_0bd22261-6fd4-4eb1-babb-4ee327112b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_OtezlaANDAPatentLitigationMember_fdbd24dc-99b9-472a-a8e4-8040983d0a99" xlink:href="amgn-20220630.xsd#amgn_OtezlaANDAPatentLitigationMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4e2dc737-9193-4aa2-a1dc-ff51a710690d" xlink:to="loc_amgn_OtezlaANDAPatentLitigationMember_fdbd24dc-99b9-472a-a8e4-8040983d0a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_538a4d86-b2a3-4d94-b209-7326442e13d4" xlink:to="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LitigationSettlementDamagesSoughtValue_1422e469-2105-4b96-aa66-4cba2330b093" xlink:href="amgn-20220630.xsd#amgn_LitigationSettlementDamagesSoughtValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_amgn_LitigationSettlementDamagesSoughtValue_1422e469-2105-4b96-aa66-4cba2330b093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_dd14df6c-7cd7-4736-a310-7c7ab323e29d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_dd14df6c-7cd7-4736-a310-7c7ab323e29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_bc728abd-3f6e-4a2c-a8f9-3e7fdf479385" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_bc728abd-3f6e-4a2c-a8f9-3e7fdf479385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyNumberOfLawsuits_5a0831bf-e1b5-4a87-9a24-fb1c617ac61a" xlink:href="amgn-20220630.xsd#amgn_LossContingencyNumberOfLawsuits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_amgn_LossContingencyNumberOfLawsuits_5a0831bf-e1b5-4a87-9a24-fb1c617ac61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_e6bde7a8-52c1-4fc2-99a4-23b03c3d42bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_e6bde7a8-52c1-4fc2-99a4-23b03c3d42bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyPatentsExpiredNumber_b39ea44c-2e21-4ea5-9b3a-8deb4e218cce" xlink:href="amgn-20220630.xsd#amgn_LossContingencyPatentsExpiredNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_amgn_LossContingencyPatentsExpiredNumber_b39ea44c-2e21-4ea5-9b3a-8deb4e218cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LossContingencyAppealPeriod_841eef43-699c-4bb4-b49f-6af1637e24d6" xlink:href="amgn-20220630.xsd#amgn_LossContingencyAppealPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_amgn_LossContingencyAppealPeriod_841eef43-699c-4bb4-b49f-6af1637e24d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_NumberOfAssertedPatents_0d21bce5-3f9c-4f23-8afa-311a450c15c2" xlink:href="amgn-20220630.xsd#amgn_NumberOfAssertedPatents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_amgn_NumberOfAssertedPatents_0d21bce5-3f9c-4f23-8afa-311a450c15c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_dc629fec-aba9-4a69-a915-cce2078f5c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_us-gaap_LitigationSettlementExpense_dc629fec-aba9-4a69-a915-cce2078f5c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_5fdf3a40-1ac2-4b8a-819a-94bbd2604627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_5fdf3a40-1ac2-4b8a-819a-94bbd2604627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_d755984b-7969-418e-b4ed-1dc5d8b723ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsFoundInfringedUponNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_d755984b-7969-418e-b4ed-1dc5d8b723ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_a175a192-3138-4a52-bbd5-4df3f53519aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_a175a192-3138-4a52-bbd5-4df3f53519aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_b6229af3-e16f-436d-9dc3-9583ca845ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_b6229af3-e16f-436d-9dc3-9583ca845ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_LitigationSettlementNumberOfPrimaryArguments_045a57aa-a1dc-4fc1-afbd-d848b78c6aa2" xlink:href="amgn-20220630.xsd#amgn_LitigationSettlementNumberOfPrimaryArguments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9b5705c0-1937-4d8d-8c71-5a37b3004afa" xlink:to="loc_amgn_LitigationSettlementNumberOfPrimaryArguments_045a57aa-a1dc-4fc1-afbd-d848b78c6aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515704321232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Amgen Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3540776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Amgen Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Thousand Oaks<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91320-1799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">447-1000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534,930,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNGS', window );">The NASDAQ Global Select Market [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNGS', window );">The NASDAQ Global Select Market [Member] | 2.00% Senior Notes Due 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.00% Senior Notes due 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNGS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNGS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515796604416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,317<span></span>
</td>
<td class="nump">$ 464<span></span>
</td>
<td class="nump">$ 2,793<span></span>
</td>
<td class="nump">$ 2,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss), net of reclassification adjustments and taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation</a></td>
<td class="num">(65)<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent', window );">Cash flow hedges</a></td>
<td class="nump">156<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of reclassification adjustments and taxes</a></td>
<td class="nump">91<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 1,408<span></span>
</td>
<td class="nump">$ 429<span></span>
</td>
<td class="nump">$ 2,917<span></span>
</td>
<td class="nump">$ 2,227<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515703219040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 6,594<span></span>
</td>
<td class="nump">$ 6,526<span></span>
</td>
<td class="nump">$ 12,832<span></span>
</td>
<td class="nump">$ 12,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">1,510<span></span>
</td>
<td class="nump">1,637<span></span>
</td>
<td class="nump">3,071<span></span>
</td>
<td class="nump">3,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">1,039<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
<td class="nump">1,998<span></span>
</td>
<td class="nump">2,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">1,327<span></span>
</td>
<td class="nump">1,384<span></span>
</td>
<td class="nump">2,555<span></span>
</td>
<td class="nump">2,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_OtherGeneralExpenseIncomeOtherAdjustments', window );">Other</a></td>
<td class="nump">542<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,418<span></span>
</td>
<td class="nump">5,698<span></span>
</td>
<td class="nump">8,156<span></span>
</td>
<td class="nump">9,470<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">2,176<span></span>
</td>
<td class="nump">828<span></span>
</td>
<td class="nump">4,676<span></span>
</td>
<td class="nump">2,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, net</a></td>
<td class="num">(328)<span></span>
</td>
<td class="num">(281)<span></span>
</td>
<td class="num">(623)<span></span>
</td>
<td class="num">(566)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(317)<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="num">(847)<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">1,531<span></span>
</td>
<td class="nump">558<span></span>
</td>
<td class="nump">3,206<span></span>
</td>
<td class="nump">2,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,317<span></span>
</td>
<td class="nump">$ 464<span></span>
</td>
<td class="nump">$ 2,793<span></span>
</td>
<td class="nump">$ 2,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in usd per share)</a></td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="nump">$ 5.16<span></span>
</td>
<td class="nump">$ 3.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in usd per share)</a></td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="nump">$ 5.13<span></span>
</td>
<td class="nump">$ 3.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in calculation of earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">573<span></span>
</td>
<td class="nump">541<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">537<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="nump">578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 6,281<span></span>
</td>
<td class="nump">$ 6,114<span></span>
</td>
<td class="nump">$ 12,012<span></span>
</td>
<td class="nump">$ 11,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">$ 412<span></span>
</td>
<td class="nump">$ 820<span></span>
</td>
<td class="nump">$ 721<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_OtherGeneralExpenseIncomeOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other General Expense (Income), Other Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_OtherGeneralExpenseIncomeOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515703263440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,203<span></span>
</td>
<td class="nump">$ 7,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,980<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">5,327<span></span>
</td>
<td class="nump">4,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">4,554<span></span>
</td>
<td class="nump">4,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,258<span></span>
</td>
<td class="nump">2,367<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">19,322<span></span>
</td>
<td class="nump">19,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">5,158<span></span>
</td>
<td class="nump">5,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">13,927<span></span>
</td>
<td class="nump">15,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">14,865<span></span>
</td>
<td class="nump">14,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">6,022<span></span>
</td>
<td class="nump">6,524<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">59,294<span></span>
</td>
<td class="nump">61,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,256<span></span>
</td>
<td class="nump">1,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">10,545<span></span>
</td>
<td class="nump">10,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">817<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,618<span></span>
</td>
<td class="nump">12,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">35,705<span></span>
</td>
<td class="nump">33,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent', window );">Long-term tax liabilities</a></td>
<td class="nump">5,603<span></span>
</td>
<td class="nump">6,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">2,949<span></span>
</td>
<td class="nump">2,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Contingencies and commitments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital', window );">Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding&#8212;534.9 shares in 2022 and 558.3 shares in 2021</a></td>
<td class="nump">31,343<span></span>
</td>
<td class="nump">32,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(28,252)<span></span>
</td>
<td class="num">(24,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(672)<span></span>
</td>
<td class="num">(796)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">2,419<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 59,294<span></span>
</td>
<td class="nump">$ 61,165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of par value plus amounts in excess of par value or issuance value for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStocksIncludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515703316704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock and additional paid-in capital, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock and additional paid-in capital, shares authorized</a></td>
<td class="nump">2,750.0<span></span>
</td>
<td class="nump">2,750.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock and additional paid-in capital, shares outstanding</a></td>
<td class="nump">534.9<span></span>
</td>
<td class="nump">558.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515699278112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Number of shares of common stock [Member]</div></th>
<th class="th"><div>Common stock and additional paid-in capital [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Accumulated other comprehensive loss [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">578.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of beginning of period at Dec. 31, 2020</a></td>
<td class="nump">$ 9,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,802<span></span>
</td>
<td class="num">$ (21,408)<span></span>
</td>
<td class="num">$ (985)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income for basic and diluted EPS</a></td>
<td class="nump">1,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared on common stock</a></td>
<td class="num">(1,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax impact related to employee stock-based compensation expense</a></td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchases of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of end of period at Mar. 31, 2021</a></td>
<td class="nump">9,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,806<span></span>
</td>
<td class="num">(21,639)<span></span>
</td>
<td class="num">(833)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">578.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of beginning of period at Dec. 31, 2020</a></td>
<td class="nump">9,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,802<span></span>
</td>
<td class="num">(21,408)<span></span>
</td>
<td class="num">(985)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income for basic and diluted EPS</a></td>
<td class="nump">2,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">569.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of end of period at Jun. 30, 2021</a></td>
<td class="nump">8,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,877<span></span>
</td>
<td class="num">(22,762)<span></span>
</td>
<td class="num">(868)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, Shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of beginning of period at Mar. 31, 2021</a></td>
<td class="nump">9,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,806<span></span>
</td>
<td class="num">(21,639)<span></span>
</td>
<td class="num">(833)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income for basic and diluted EPS</a></td>
<td class="nump">464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax impact related to employee stock-based compensation expense</a></td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchases of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(1,592)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,592)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">569.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of end of period at Jun. 30, 2021</a></td>
<td class="nump">$ 8,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,877<span></span>
</td>
<td class="num">(22,762)<span></span>
</td>
<td class="num">(868)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2021</a></td>
<td class="nump">558.3<span></span>
</td>
<td class="nump">558.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of beginning of period at Dec. 31, 2021</a></td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,096<span></span>
</td>
<td class="num">(24,600)<span></span>
</td>
<td class="num">(796)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income for basic and diluted EPS</a></td>
<td class="nump">1,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared on common stock</a></td>
<td class="num">(1,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax impact related to employee stock-based compensation expense</a></td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchases of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(6,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(900)<span></span>
</td>
<td class="num">(5,410)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of end of period at Mar. 31, 2022</a></td>
<td class="nump">$ 916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,247<span></span>
</td>
<td class="num">(29,568)<span></span>
</td>
<td class="num">(763)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2021</a></td>
<td class="nump">558.3<span></span>
</td>
<td class="nump">558.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of beginning of period at Dec. 31, 2021</a></td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,096<span></span>
</td>
<td class="num">(24,600)<span></span>
</td>
<td class="num">(796)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income for basic and diluted EPS</a></td>
<td class="nump">$ 2,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at Jun. 30, 2022</a></td>
<td class="nump">534.9<span></span>
</td>
<td class="nump">534.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of end of period at Jun. 30, 2022</a></td>
<td class="nump">$ 2,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,343<span></span>
</td>
<td class="num">(28,252)<span></span>
</td>
<td class="num">(672)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, Shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of beginning of period at Mar. 31, 2022</a></td>
<td class="nump">916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,247<span></span>
</td>
<td class="num">(29,568)<span></span>
</td>
<td class="num">(763)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income for basic and diluted EPS</a></td>
<td class="nump">1,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in connection with the Company&#8217;s equity award programs</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax impact related to employee stock-based compensation expense</a></td>
<td class="num">(69)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at Jun. 30, 2022</a></td>
<td class="nump">534.9<span></span>
</td>
<td class="nump">534.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of end of period at Jun. 30, 2022</a></td>
<td class="nump">$ 2,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,343<span></span>
</td>
<td class="num">$ (28,252)<span></span>
</td>
<td class="num">$ (672)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515705491872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared per share (in usd per share)</a></td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515705131488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 2,793<span></span>
</td>
<td class="nump">$ 2,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and other</a></td>
<td class="nump">1,669<span></span>
</td>
<td class="nump">1,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(514)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Adjustments for equity method investments</a></td>
<td class="nump">497<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Loss on divestiture</a></td>
<td class="nump">560<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other items, net</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables, net</a></td>
<td class="num">(504)<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(410)<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">198<span></span>
</td>
<td class="num">(258)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(98)<span></span>
</td>
<td class="num">(156)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Accrued income taxes, net</a></td>
<td class="num">(685)<span></span>
</td>
<td class="num">(930)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_IncreaseDecreaseInNoncurrentTaxLiability', window );">Long-term tax liabilities</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">4,094<span></span>
</td>
<td class="nump">4,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(1,976)<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">6,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(436)<span></span>
</td>
<td class="num">(351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisitions, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,626)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">61<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(2,304)<span></span>
</td>
<td class="nump">890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Net proceeds from issuance of debt</a></td>
<td class="nump">3,954<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock (Note 10)</a></td>
<td class="num">(6,360)<span></span>
</td>
<td class="num">(2,452)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid</a></td>
<td class="num">(2,118)<span></span>
</td>
<td class="num">(2,024)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(4,576)<span></span>
</td>
<td class="num">(4,561)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">(Decrease) increase in cash and cash equivalents</a></td>
<td class="num">(2,786)<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">7,989<span></span>
</td>
<td class="nump">6,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 5,203<span></span>
</td>
<td class="nump">$ 6,630<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_IncreaseDecreaseInNoncurrentTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Noncurrent Tax Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_IncreaseDecreaseInNoncurrentTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515812630464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text">Summary of significant accounting policies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Inc. (including its subsidiaries, referred to as &#8220;Amgen,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics.&#160;We operate in one business segment: human therapeutics.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial information for the three and six months ended June 30, 2022 and 2021, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2021, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Report on Form 10-Q for the period ended March 31, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity&#8217;s economic performance and the obligation to absorb losses of or the right to receive benefits from the entity that could potentially be significant to that entity. We do not have any significant interests in any</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization, of $9.0&#160;billion and $8.8 billion as of June 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard that expanded the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We do not expect the two standards to have a material impact on our condensed consolidated financial statements.</span></div>In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515812630464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions and divestitures<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Teneobio, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 19, 2021, we acquired all of the outstanding stock of Teneobio, a privately held, clinical-stage biotechnology company developing a new class of biologics called human heavy-chain antibodies, which are single-chain antibodies composed of the human heavy-chain domain. The transaction, which was accounted for as a business combination, includes Teneobio&#8217;s proprietary bispecific and multispecific antibody technologies, which complement Amgen&#8217;s existing antibody capabilities and bispecific T-cell engager (BiTE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) platform and will enable significant acceleration and efficiency in the discovery and development of new molecules to treat diseases across Amgen&#8217;s core therapeutic areas. Upon its acquisition, Teneobio became a wholly owned subsidiary of Amgen, and its operations have been included in our condensed consolidated financial statements commencing on the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Measurement period adjustments for the six months ended June 30, 2022, included changes to the purchase price allocation and total consideration, resulting in a net increase of $22&#160;million to goodwill. The measurement period adjustments resulted primarily from valuation inputs pertaining to certain acquired assets based on facts and circumstances that existed as of the acquisition date and did not result from events subsequent to the acquisition date. These adjustments did not have a significant impact on Amgen&#8217;s results of operations during the six months ended June 30, 2022, and would not have had a significant impact on prior-period results if these adjustments had been made as of the acquisition date. The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset &#8211; research and development technology rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets &#8211; licensing rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration for this transaction comprised (i) an upfront cash payment of $993&#160;million, which included a working-capital adjustment, and (ii) future contingent milestone payments to Teneobio&#8217;s former equity holders of up to $1.6&#160;billion in cash, based on the achievement of various development and regulatory milestones with regard to the leading asset (AMG 340, formerly TNB-585) and to various development milestones for other drug candidates. The estimated fair values of the contingent consideration obligations aggregated $299&#160;million as of the acquisition date and were determined using a probability-weighted expected return methodology. The assumptions in this method include the probability of achieving the milestones and the expected payment dates, with such amounts discounted to present value based on our pretax cost of debt. See Note 11, Fair value measurement, for information regarding the estimated fair value of these obligations as of June 30, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of acquired IPR&amp;D assets totaled $991&#160;million, of which $784&#160;million relates to AMG 340, that is in a phase 1 clinical trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), and the balance relates to four separate preclinical oncology programs. The R&amp;D technology rights of $115&#160;million relate to Teneobio&#8217;s proprietary bispecific and multispecific antibody technologies; the amount is being amortized over 10 years by using the straight-line method. Teneobio has also licensed its technology and certain identified targets to various third parties, representing contractual agreements valued at $41&#160;million. The estimated fair values for these intangible assets were determined using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The projected cash flows were based on certain assumptions attributable to the respective intangible asset, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A deferred tax liability of $244&#160;million was recognized on temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $273&#160;million was recorded as goodwill, which is not deductible for tax purposes. The goodwill value represents expected synergies from both AMG 340 and the technologies acquired.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting for this acquisition is preliminary and will be finalized upon completion of our analysis of certain tax-related items as we obtain additional information during the measurement period of up to one year from the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Five Prime Therapeutics, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 16, 2021, Amgen completed its acquisition of Five Prime for a total cash consideration of $1.6&#160;billion, net of cash acquired. The purchase price was funded with cash on hand. This transaction was accounted for as an asset acquisition because substantially all the value of the assets acquired was concentrated in the intellectual property rights of bemarituzumab, a phase 3 trial-ready, first-in-class program for gastric cancer. Five Prime&#8217;s operations have been included in our condensed consolidated financial statements commencing after the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the consideration to acquire Five Prime to: the bemarituzumab IPR&amp;D program of $1.5&#160;billion, which was expensed immediately in Acquired IPR&amp;D expense in the Condensed Consolidated Statements of Income; deferred tax assets of $177&#160;million; and other net liabilities of $47&#160;million. The Acquired IPR&amp;D expense was not tax deductible.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Divestiture of Gensenta &#304;la&#231; Sanayi ve Ticaret A.&#350;.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 28, 2022, we entered into a share purchase agreement with Eczac&#305;ba&#351;&#305; under which Eczac&#305;ba&#351;&#305; will acquire all of our shares in Gensenta&#8212;a subsidiary in Turkey. Net assets related to Gensenta of $80&#160;million met the criteria to be classified as held-for-sale and did not meet the criteria to be classified as discontinued operations. Upon closing of the transaction, we expect to receive $135&#160;million in cash. The transaction is expected to close in the third quarter of 2022 upon approval by the Turkish Competition Authority.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, held-for-sale assets and liabilities of $100&#160;million and $20&#160;million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the three months ended June 30, 2022, we recognized a loss of $560&#160;million recorded to Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign currency translation loss, with valuation allowances to Other current assets and Accrued liabilities in the Condensed Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515790393632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text">Revenues<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers&#8217; locations, are presented below. The majority of ROW revenues relates to products sold in Europe.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.144%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,526&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:4pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div>(1)&#160;&#160;&#160;&#160;Hedging gains and losses, which are included in product sales, were not material for the three and six months ended June 30, 2022 and 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515708970560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text">Income taxes<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the three and six months ended June 30, 2022, were 14.0% and 12.9%, respectively, compared with 16.8% and 12.6%, respectively, for the corresponding periods of the prior year. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our effective tax rate for the three months ended June 30, 2022, was primarily due to the prior year nondeductible IPR&amp;D expense arising from the acquisition of Five Prime, partially offset by current year unfavorable items including a loss on a nonstrategic divestiture. The increase in our effective tax rate for the six months ended June 30, 2022, was primarily due to current year unfavorable items compared to last year including a loss on a nonstrategic divestiture, partially offset by the prior year nondeductible IPR&amp;D expense arising from the acquisition of Five Prime and changes in earnings mix. The effective tax rates differ from the federal statutory rate primarily as a result of foreign earnings from the Company&#8217;s operations conducted in Puerto Rico, a territory of the United States treated as a foreign jurisdiction for U.S. tax purposes, that are currently subject to a tax incentive grant through 2035. In addition, the Company&#8217;s operations conducted in Singapore are subject to a tax incentive grant through 2034. These foreign earnings are also subject to U.S. tax at a reduced rate of 10.5%. See Note 2, Acquisitions and divestitures.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. territory of Puerto Rico imposes a 4% excise tax on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. We account for the excise tax as a manufacturing cost that is capitalized in Inventories and expensed in Cost of sales when the related products are sold. For U.S. income tax purposes, in 2022, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes can and have arisen with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. Tax authorities, including the IRS, are becoming more aggressive and are particularly focused on such matters.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received an RAR and a modified RAR from the IRS for the years 2010&#8211;2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for the years 2010&#8211;2012 that we received in May and July 2021, which seek to increase our U.S. taxable income for the years 2010&#8211;2012 by an amount that would result in additional federal tax of approximately $3.6&#160;billion plus interest. Any additional tax that could be imposed for the years 2010&#8211;2012 would be reduced by up to approximately $900&#160;million of repatriation tax previously accrued on our foreign earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2020, we received an RAR and a modified RAR from the IRS for the years 2013&#8211;2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010&#8211;2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013&#8211;2015 that we previously reported receiving in April 2022 that seeks to increase our U.S. taxable income for the years 2013&#8211;2015 by an amount that would result in additional federal tax of approximately $5.1&#160;billion, plus interest. In addition, the Notice asserts penalties of approximately $2.0&#160;billion. Any additional tax that could be imposed for the years 2013&#8211;2015 would be reduced by up to approximately $2.2&#160;billion of repatriation tax previously accrued on our foreign earnings. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We firmly believe that the IRS positions set forth in the 2010&#8211;2012 and 2013&#8211;2015 Notices are without merit. We are contesting the 2010&#8211;2012 and 2013&#8211;2015 Notices through the judicial process, and we will seek consolidation of the two periods into one case in the U.S. Tax Court.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are currently under examination by the IRS for the years 2016&#8211;2018 with respect to issues similar to those for the 2010 through 2015 period. In addition, we have examinations by a number of state and foreign tax jurisdictions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final resolution of these complex matters is not likely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Results of Operations, Income Taxes, for further discussion and Part II, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 1A, Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Factors&#8212;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2022, the gross amounts of our UTBs increased by $50 million and $95 million, respectively, as a result of tax positions taken during the current year. Substantially all of the UTBs as of June 30, 2022, if recognized, would affect our effective tax rate.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515708905376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per share</a></td>
<td class="text">Earnings per share<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computation of basic EPS is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computations for basic and diluted EPS were as follows (in millions, except per-share data):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (Numerator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income for basic and diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (Denominator):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for basic EPS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022 and 2021, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515708964960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-sale investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,413&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,413&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.423%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,413&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents in the above table excludes bank account cash of $770 million and $733&#160;million as of June 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest-bearing securities as of June 30, 2022 and December 31, 2021, mature in one year or less.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022 and 2021, realized gains and losses on interest-bearing securities were not material. Realized gains and losses on interest-bearing securities are recorded in Other (expense) income, net, in the Condensed Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held investments in equity securities with readily determinable fair values (publicly traded securities) of $361 million and $611 million as of June 30, 2022 and December 31, 2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. During the three months ended June 30, 2022 and 2021, net unrealized gains and losses on publicly traded securities were a $106&#160;million net loss and a $25&#160;million net gain, respectively. During the six months ended June 30, 2022 and 2021, net unrealized losses on publicly traded securities were $276&#160;million and $31&#160;million, respectively. Realized gains and losses on sales of publicly traded securities for the three and six months ended June 30, 2022 and 2021, were not material.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held investments of $280 million and $262 million in equity securities without readily determinable fair values as of June 30, 2022 and December 31, 2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. During the three and six months ended June 30, 2022 and 2021, upward adjustments and downward adjustments on these securities were not material. Adjustments were based on observable price transactions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method investments </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, we had an ownership interest in BeiGene of approximately 18.2% and 18.4%, respectively, which is included in Other noncurrent assets in the Condensed Consolidated Balance Sheets and accounted for under the equity method of accounting. We amortize the difference between the fair value of equity securities acquired and our proportionate share of the carrying value of the underlying net assets of BeiGene over the useful lives of the assets that gave rise to this basis difference. This amortization and our share of the results of operations of BeiGene are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the Condensed Consolidated Statements of Income one quarter in arrears. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022 and 2021, the carrying value of our equity investment was adjusted by our share of BeiGene&#8217;s net loss of $80&#160;million and net income of $14&#160;million, respectively, and amortization of the basis difference of $48&#160;million and $42&#160;million, respectively. During the six months ended June 30, 2022 and 2021, the carrying value of our equity investment was adjusted by our share of BeiGene&#8217;s net losses of $188&#160;million and $83&#160;million, respectively, and amortization of the basis difference of $95 million and $84&#160;million, respectively. As of June 30, 2022 and December 31, 2021, the carrying values of our investment in BeiGene totaled $2.5&#160;billion and $2.8&#160;billion, respectively, and the fair values of our investment totaled $3.1&#160;billion and $5.1&#160;billion, respectively. As of June 30, 2022, we believe the carrying value of our equity investment in BeiGene is fully recoverable.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neumora Therapeutics, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2021, we acquired an approximately 25.9% ownership interest in Neumora, a privately held company, for $257&#160;million, which is included in Other noncurrent assets in the Condensed Consolidated Balance Sheets, in exchange for a $100&#160;million cash payment and $157&#160;million in noncash consideration primarily related to future services. Although our equity investment provides us with the ability to exercise significant influence over Neumora, we have elected the fair value option to account for our equity investment. Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period. We believe the fair value option best reflects the economics of the underlying transaction. As of June 30, 2022 and December 31, 2021, our ownership interest in Neumora was approximately 25.7% and 25.9%, respectively, and the fair values of our investment were $131 million and $220 million, respectively. Accordingly, for the reduction in fair value of our investment during the three and six months ended June 30, 2022, we recognized a loss of $39&#160;million and $89&#160;million, respectively, for the reduction in fair value of our investment in Other (expense) income, net, in the Condensed Consolidated Statements of Income. For information on determination of fair values, see Note 11, Fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limited partnerships</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held limited partnership investments of $338 million and $573 million as of June 30, 2022 and December 31, 2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. These investments, primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of June 30, 2022, unfunded additional commitments to be made for these investments during the next several years were $209&#160;million. For the three months ended June 30, 2022 and 2021, net unrealized losses from our limited partnership investments were $60&#160;million and $43&#160;million, respectively. For the six months ended June 30, 2022 and 2021, net unrealized gains and losses from our limited partnership investments were a $220&#160;million net loss and a $165&#160;million net gain, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515698452752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,763&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,554&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515705369056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and other intangible assets</a></td>
<td class="text">Goodwill and other intangible assets<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amount of goodwill was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:82.331%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to goodwill resulting from acquisitions and divestitures, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,865&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Composed of adjustments to goodwill resulting from changes to the acquisition date fair values of net assets acquired in the acquisition of Teneobio and the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other intangible assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.433%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed-product-technology rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,863)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,769)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,050)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing-related rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development technology rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,153)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,098&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,191)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,907&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,099&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,987)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,112&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,118&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,191)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,927&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,987)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,182&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed-product-technology rights consists of rights related to marketed products. Licensing rights primarily consists of contractual rights to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and upfront payments associated with royalty obligations for marketed products. Marketing-related rights primarily consists of rights related to the sale and distribution of marketed products. R&amp;D technology rights pertains to technologies used in R&amp;D that have alternative future uses.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D consists of R&amp;D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. We review IPR&amp;D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022 and 2021, we recognized amortization associated with our finite-lived intangible assets of $629 million and $652 million, respectively. During the six months ended June 30, 2022 and 2021, we recognized amortization associated with our finite-lived intangible assets of $1.3 billion in both periods. Amortization of intangible assets is primarily included in Cost of sales in the Condensed Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the remaining six months ending December 31, 2022, and the years ending December 31, 2023, 2024, 2025, 2026 and 2027, are $1.3 billion, $2.5 billion, $2.5 billion, $2.4 billion, $1.7 billion and $1.8 billion, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515708889408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Financing arrangements</a></td>
<td class="text">Financing arrangements<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our borrowings consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% notes due 2023 (2.25% 2023 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% notes due 2024 (3.625% 2024 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90% notes due 2025 (1.90% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125% notes due 2025 (3.125% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60% notes due 2026 (2.60% 2026 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% &#163;475 million notes due 2026 (5.50% 2026 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20% notes due 2027 (2.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20% notes due 2027 (3.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65% notes due 2028 (1.65% 2028 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00% notes due 2029 (3.00% 2029 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% &#163;700 million notes due 2029 (4.00% 2029 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% notes due 2030 (2.45% 2030 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.30% notes due 2031 (2.30% 2031 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% notes due 2032 (2.00% 2032 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.35% notes due 2032 (3.35% 2032 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.375% notes due 2037 (6.375% 2037 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.90% notes due 2038 (6.90% 2038 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% notes due 2039 (6.40% 2039 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15% notes due 2040 (3.15% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% notes due 2040 (5.75% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80% notes due 2041 (2.80% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% notes due 2041 (4.95% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15% notes due 2041 (5.15% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65% notes due 2042 (5.65% 2042 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.375% notes due 2043 (5.375% 2043 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40% notes due 2045 (4.40% 2045 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.563% notes due 2048 (4.563% 2048 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% notes due 2050 (3.375% 2050 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.663% notes due 2051 (4.663% 2051 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00% notes due 2052 (3.00% 2052 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20% notes due 2052 (4.20% 2052 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.77% notes due 2053 (2.77% 2053 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40% notes due 2062 (4.40% 2062 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes due 2097</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized bond discounts, premiums and issuance costs, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,522&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,309&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,705&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no material</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> differences between the effective interest rates and coupon rates of any of our borrowings, except for the 4.563% 2048 Notes, the 4.663% 2051 Notes and the 2.77% 2053 Notes, which have effective interest rates of 6.3%, 5.6% and 5.2%, respectively.</span></div>During the three months ended March 31, 2022, we issued $4.0&#160;billion of debt consisting of $750&#160;million of the 3.00% 2029 Notes, $1.0&#160;billion of the 3.35% 2032 Notes, $1.0&#160;billion of the 4.20% 2052 Notes and $1.25&#160;billion of the 4.40% 2062 Notes. The 3.00% 2029 Notes were issued to finance eligible projects that meet specified criteria to benefit the environment. In the event of a change-in-control triggering event, as defined in the terms of the notes, we may be required to purchase all or a portion of these notes at a price equal to 101% of the principal amount of the notes plus accrued and unpaid interest. In addition, these notes may be redeemed at any time at our option, in whole or in part, at the principal amount of the notes being redeemed plus accrued and unpaid interest and a make-whole amount, which are defined by the terms of the notes. The notes may be redeemed without payment of make-whole amounts if redemption occurs during a specified period of time immediately prior to the maturing of the notes. Such time periods range from two months to six months prior to maturity.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515705805776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' equity</a></td>
<td class="text">Stockholders&#8217; equity<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchase program</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock repurchases</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,410&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2022, the Company entered into ASR agreements with three third-party financial institutions (Dealers). Under the ASR agreements, the Company made payments in an aggregate amount of $6.0&#160;billion on February 25, 2022, to the Dealers and received and retired an initial 23.3&#160;million shares of the Company&#8217;s common stock from the Dealers. The payments were recorded as reductions to shareholders&#8217; equity, consisting of a $5.1&#160;billion increase to accumulated deficit, which reflects the value of the initial shares received, and a $0.9&#160;billion decrease in additional paid-in capital, which reflects the value of the stock that remains to be delivered by the Dealers pending final settlement. The final number of shares to be repurchased by the Company will be based on the daily volume-weighted average stock price of the Company&#8217;s common stock during the terms of the ASR agreements, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreements. At settlement, under certain circumstances, one or more of the Dealers may be required to deliver additional shares of common stock to the Company, or under certain circumstances, the Company may be required to deliver shares of common stock or to make a cash payment, at its election, to a Dealer. The final settlement under the ASR agreements is scheduled to occur in the third quarter of 2022, subject to an earlier termination under certain limited circumstances, as set forth in the ASR agreements. In total, we repurchased 24.6&#160;million shares of common stock in the first quarter of 2022, including shares received under the ASR agreements. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, $4.6 billion of authorization remained available under our stock repurchase program.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022 and December 2021, the Board of Directors declared a quarterly cash dividend of $1.94 per share, which were paid in June 2022 and March 2022, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Board of Directors declared a quarterly cash dividend of $1.94 per share, which will be paid on September 8, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of AOCI were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>currency<br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash&#160;flow<br/>hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Available-for-sale<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AOCI</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(844)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(796)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(895)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(763)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(960)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of AOCI and into earnings, including related income tax expenses, were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.220%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Components of AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Statements of Income locations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contract gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contract (losses) gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Components of AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Statements of Income locations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contract gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contract losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515708923264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurement</a></td>
<td class="text">Fair value measurement<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:</span></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:6.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.243%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations for which all significant inputs are observable either directly or indirectly&#8212;other than Level 1 inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs that are unobservable and significant to the overall fair value measurement</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of observable inputs can vary among different types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each major class of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>other&#160;observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurement as of June 30, 2022, using:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,774&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,347&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>other observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurement as of December 31, 2021, using:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,914&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-bearing and equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our U.S. Treasury securities, money market mutual funds and equity investments in publicly traded securities are based on quoted market prices in active markets, with no valuation adjustment. The fair value of equity securities without readily determinable fair values are initially valued at the transaction price and subsequently valued based on a combination of market performance and publicly available market information for similar companies that have actively traded equity securities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our foreign currency forward derivative contracts have maturities of three years or less, and all are with counterparties that have minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 12, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency-basis swap spreads. See Note 12, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest rate swap contracts are with counterparties that have minimum credit ratings of A&#8211; or equivalent by S&amp;P, Moody&#8217;s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 12, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration obligations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our business acquisitions, we have incurred contingent consideration obligations as discussed below. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and they are reviewed quarterly by management in our R&amp;D and commercial sales organizations. The inputs include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes that increase or decrease the probabilities of achieving the related development, regulatory and commercial events or that shorten or lengthen the time required to achieve such events or that increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Condensed Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in valuations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, our contingent consideration obligations are primarily the result of our acquisition of Teneobio in October 2021, which obligates us to pay the former shareholders up to $1.6&#160;billion upon achieving separate development and regulatory milestones with regard to various R&amp;D programs. See Note 2, Acquisitions and divestitures.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of the fair values of other financial instruments</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Borrowings</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair values of our borrowings by using Level 2 inputs. As of June 30, 2022 and December 31, 2021, the aggregate fair values of our borrowings were $34.4 billion and $37.9 billion, respectively, and the carrying values were $36.5 billion and $33.3 billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in BeiGene, Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of our investment in BeiGene by using Level 1 inputs. As of June 30, 2022 and December 31, 2021, the fair values were $3.1 billion and $5.1&#160;billion, and the carrying values were $2.5 billion and $2.8&#160;billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2022 and 2021, there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis, except with respect to the impairment of net assets in connection with the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515708810256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative instruments</a></td>
<td class="text">Derivative instruments<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative- trading purposes.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flow hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates primarily associated with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are partially offset by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales up to a maximum of three years into the future; and at any given point in time, a higher percentage of nearer-term projected product sales are being hedged than in successive periods.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, we had outstanding foreign currency forward contracts with aggregate notional amounts of $5.6 billion and $5.7 billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Condensed Consolidated Balance Sheets, and we reclassify them to Product sales in the Condensed Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to Other (expense) income, net, in the Condensed Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amounts and interest rates of our cross-currency swaps as of June 30, 2022, were as follows (notional amounts in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. dollars</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedged notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% 2023 Swiss franc Bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHF</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% 2026 euro Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% 2026 pound sterling Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% 2029 pound sterling Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n the Condensed Consolidated Balance Sheets </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and are amortized into Interest expense, net, in the Condensed Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the six months ended June 30, 2022, and amounts expected to be recognized during the subsequent 12 months are not material.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrealized gains (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of both June 30, 2022 and December 31, 2021, we had interest rate swap contracts with aggregate notional amounts of $6.7&#160;billion that hedge certain portions of our long-term debt issuances. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Condensed Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying amounts of hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Current portion of long-term debt includes $82 million and $85 million of carrying value with discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively. Long-term debt includes $399 million and $440 million of carrying value with discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Current portion of long-term debt includes $82 million and $85 million of hedging adjustments on discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively. Long-term debt includes $299 million and $340 million of hedging adjustments on discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impact of hedging transactions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.121%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.121%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(566)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">__________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Gains on hedged items do not exactly offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of June 30, 2022, we expected to reclassify $179 million of net gains on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months.</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives not designated as hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of June 30, 2022 and December 31, 2021, the total notional amounts of these foreign currency forward contracts were $550 million and $680 million, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the three and six months ended June 30, 2022 and 2021. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Balance Sheets locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Balance Sheets locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging&#160;instruments:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Balance Sheets locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Balance Sheets locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative contracts that were in liability positions as of June 30, 2022, contain certain credit-risk-related contingent provisions that would be triggered if (i)&#160;we were to undergo a change in control and (ii)&#160;our or the surviving entity&#8217;s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts in the Condensed Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515708909856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies and commitments</a></td>
<td class="text">Contingencies and commitments<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See our Annual Report on Form 10-K for the year ended December 31, 2021, Part I, Item 1A. Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business may be affected by litigation and government investigations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. Although it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain recent developments concerning our legal proceedings and other matters are discussed below:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ANDA Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla ANDA Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Apotex Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 14, 2022, Amgen filed a lawsuit in the U.S. District Court for the District of New Jersey (the New Jersey District Court) against Apotex Inc. (Apotex) for infringement of U.S. Patent Nos. 7,427,638, 9,872,854 and 10,092,541, which are listed in the Orange Book for Otezla. This lawsuit was based on Apotex&#8217;s submission of an ANDA seeking FDA approval to market a generic version of Otezla and seeks an order of the New Jersey District Court making any FDA approval of Apotex&#8217;s ANDA effective no earlier than the expiration of the applicable patents.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repatha Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Disputes in the International Region</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 21, 2022, Sanofi Biotechnology SAS filed an action against Amgen GmbH and Amgen (Europe) B.V. before the Regional Court of Dusseldorf alleging that the marketing and sale of Repatha infringes European Patent No. 2,756,004 (the EP&#8217;004 Patent), seeking infringement damages and injunctive relief. The EP&#8217;004 Patent is currently in opposition proceedings, initiated by Amgen and an anonymous third party, before the European Patent Office (EPO). A hearing before the Opposition Division of the EPO was held on June 8 and 9, 2022, and the Opposition Division upheld the validity of the claims at issue with narrowing amendments. The parties are awaiting the Opposition Division&#8217;s written opinion. Amgen filed a Notice of Appeal on July 6, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Actions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sensipar Antitrust Class Actions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 11, 2022, the parties filed motions asking permission to seek interlocutory appeal of the U.S. District Court for the District of Delaware&#8217;s (the Delaware District Court&#8217;s) March 11, 2022 order denying Amgen&#8217;s Motion to Dismiss solely with respect to the reverse payment claim and the various state law claims. The plaintiffs did not oppose Amgen&#8217;s motion and instead argued all issues should be appealed at this time. Amgen filed its opposition to plaintiffs&#8217; motion on June 10, 2022, and reply briefs were filed on June 24, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HUMIRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Biosimilar Antitrust Actions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022, the U.S. Court of Appeals for the Seventh Circuit issued an opinion affirming the June 30, 2020 dismissal with prejudice by the U.S. District Court for the Northern District of Illinois of a consolidated complaint against Amgen along with AbbVie Inc., AbbVie Biotechnology Ltd., Samsung Bioepis Co. and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sandoz Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regeneron Pharmaceuticals, Inc. Antitrust Action</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2022, Regeneron Pharmaceuticals, Inc. (Regeneron) filed suit against Amgen in the Delaware District Court for federal and state antitrust and unfair competition violations and tortious interference with prospective business relations. Regeneron alleges that Amgen&#8217;s sales contracting practices for Repatha, ENBREL and Otezla with key insurers, third-party payors and PBMs have harmed the sales of its product PRALUENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and focuses on two primary arguments: that Amgen improperly bundled sales of Repatha with ENBREL, Otezla and potentially other products and sought exclusive or de facto exclusive formulary positioning for Repatha. Amgen&#8217;s initial responsive pleading was filed on August 1, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Tax Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. &amp; Subsidiaries v. Commissioner of Internal Revenue</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 4, Income taxes, for discussion of the IRS tax dispute and the Company&#8217;s petition in the U.S. Tax Court.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515704216624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NatureOfOperationsPolicyTextBlock', window );">Business</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Inc. (including its subsidiaries, referred to as &#8220;Amgen,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics.&#160;We operate in one business segment: human therapeutics.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BasisOfPresentationPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial information for the three and six months ended June 30, 2022 and 2021, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2021, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Report on Form 10-Q for the period ended March 31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity&#8217;s economic performance and the obligation to absorb losses of or the right to receive benefits from the entity that could potentially be significant to that entity. We do not have any significant interests in any</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and equipment, net</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization, of $9.0&#160;billion and $8.8 billion as of June 30, 2022 and December 31, 2021, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Other recent accounting pronouncements</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard that expanded the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We do not expect the two standards to have a material impact on our condensed consolidated financial statements.</span></div>In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BasisOfPresentationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shows the basis of presentation of financial information for interim periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BasisOfPresentationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as "predominately", "about equally", or "major and other". This element is also referred to as "Business Description".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515698452752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text">The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset &#8211; research and development technology rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets &#8211; licensing rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515708850400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of revenue by product and by geographic area</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.144%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,526&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:4pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div>(1)&#160;&#160;&#160;&#160;Hedging gains and losses, which are included in product sales, were not material for the three and six months ended June 30, 2022 and 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515708886976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation for basic and diluted earnings per share</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computations for basic and diluted EPS were as follows (in millions, except per-share data):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (Numerator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income for basic and diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (Denominator):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for basic EPS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515708842272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,413&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,413&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock', window );">Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.423%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,413&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair values of available-for-sale investments by classification in the consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515705397984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,763&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,554&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515703480464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of goodwill</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amount of goodwill was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:82.331%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to goodwill resulting from acquisitions and divestitures, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,865&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Composed of adjustments to goodwill resulting from changes to the acquisition date fair values of net assets acquired in the acquisition of Teneobio and the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_ScheduleOfIntangibleAssetsTableTextBlock', window );">Schedule of identifiable intangible assets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.433%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed-product-technology rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,863)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,769)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,050)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing-related rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development technology rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,153)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,098&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,191)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,907&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,099&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,987)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,112&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,118&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,191)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,927&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,987)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,182&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ScheduleOfIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived and indefinite-lived identifiable intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ScheduleOfIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515708782976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of borrowings</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our borrowings consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% notes due 2023 (2.25% 2023 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% notes due 2024 (3.625% 2024 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90% notes due 2025 (1.90% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125% notes due 2025 (3.125% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60% notes due 2026 (2.60% 2026 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% &#163;475 million notes due 2026 (5.50% 2026 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20% notes due 2027 (2.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20% notes due 2027 (3.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65% notes due 2028 (1.65% 2028 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00% notes due 2029 (3.00% 2029 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% &#163;700 million notes due 2029 (4.00% 2029 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% notes due 2030 (2.45% 2030 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.30% notes due 2031 (2.30% 2031 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% notes due 2032 (2.00% 2032 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.35% notes due 2032 (3.35% 2032 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.375% notes due 2037 (6.375% 2037 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.90% notes due 2038 (6.90% 2038 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% notes due 2039 (6.40% 2039 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15% notes due 2040 (3.15% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% notes due 2040 (5.75% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80% notes due 2041 (2.80% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% notes due 2041 (4.95% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15% notes due 2041 (5.15% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65% notes due 2042 (5.65% 2042 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.375% notes due 2043 (5.375% 2043 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40% notes due 2045 (4.40% 2045 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.563% notes due 2048 (4.563% 2048 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% notes due 2050 (3.375% 2050 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.663% notes due 2051 (4.663% 2051 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00% notes due 2052 (3.00% 2052 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20% notes due 2052 (4.20% 2052 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.77% notes due 2053 (2.77% 2053 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40% notes due 2062 (4.40% 2062 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes due 2097</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized bond discounts, premiums and issuance costs, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,522&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,309&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,705&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515709001184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_StockRepurchaseProgramTableTextBlock', window );">Summary of activity under our stock repurchase program</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock repurchases</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,410&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Components of accumulated other comprehensive income</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of AOCI were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>currency<br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash&#160;flow<br/>hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Available-for-sale<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AOCI</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(844)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(796)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(895)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(763)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(960)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassifications out of accumulated other comprehensive income</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of AOCI and into earnings, including related income tax expenses, were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.220%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Components of AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Statements of Income locations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contract gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contract (losses) gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Components of AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Statements of Income locations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contract gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contract losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_StockRepurchaseProgramTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchase Program [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_StockRepurchaseProgramTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515703008368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each major class of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>other&#160;observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurement as of June 30, 2022, using:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,774&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,347&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;prices in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>other observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurement as of December 31, 2021, using:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,914&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in valuations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515705934560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock', window );">Schedule of notional amounts and interest rates for cross-currency swaps</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amounts and interest rates of our cross-currency swaps as of June 30, 2022, were as follows (notional amounts in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. dollars</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedged notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% 2023 Swiss franc Bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHF</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% 2026 euro Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% 2026 pound sterling Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% 2029 pound sterling Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrealized gains (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Derivatives in fair value hedging relationships</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying amounts of hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Current portion of long-term debt includes $82 million and $85 million of carrying value with discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively. Long-term debt includes $399 million and $440 million of carrying value with discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Current portion of long-term debt includes $82 million and $85 million of hedging adjustments on discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively. Long-term debt includes $299 million and $340 million of hedging adjustments on discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Summary of amounts of income and expense line items</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.121%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.121%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(566)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on fair value hedging relationships&#8212;interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">__________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Gains on hedged items do not exactly offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Fair values of derivatives included in the Condensed Consolidated Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Balance Sheets locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Balance Sheets locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging&#160;instruments:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other&#160;noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Balance Sheets locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Balance Sheets locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515796606304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Details)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization on property, plant and equipment | $</a></td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515704957232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Aggregate Consideration Paid (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 14,865<span></span>
</td>
<td class="nump">$ 14,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid</a></td>
<td class="nump">993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions', window );">Contingent consideration obligation for acquisition</a></td>
<td class="nump">299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_Businessassetacquisitionconsiderationtransferred', window );">Business asset acquisition, consideration transferred</a></td>
<td class="nump">1,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Fair value of assets acquired, cash</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">IPR&amp;D</a></td>
<td class="nump">991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities', window );">Other assets, net</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</a></td>
<td class="num">(244)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet', window );">Total assets acquired, net</a></td>
<td class="nump">1,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio | R &amp; D Technology rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Fair value of assets acquired, licensing rights</a></td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio | Licensing rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Fair value of assets acquired, licensing rights</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquired asset acquisition, Assets acquired and Liabilities assumed, net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_Businessassetacquisitionconsiderationtransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business asset acquisition, consideration transferred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_Businessassetacquisitionconsiderationtransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_RDTechnologyrightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_RDTechnologyrightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515698998592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 16, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Net increase in goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Loss on divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments to Acquire Businesses, Net of Cash Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,505<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=amgn_GensentaIlacSanayiVsTicaretMember', window );">Gensenta Ilac Sanayi vs Ticaret</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Disposal Group, Including Discontinued Operation, Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities', window );">Disposal Group, Including Discontinued Operation, Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Disposal Group, Including Discontinued Operation, Assets, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=amgn_GensentaIlacSanayiVsTicaretMember', window );">Gensenta Ilac Sanayi vs Ticaret | Other Operating Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Loss on divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=amgn_GensentaIlacSanayiVsTicaretMember', window );">Gensenta Ilac Sanayi vs Ticaret | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates', window );">Proceeds from Divestiture of Businesses and Interests in Affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Net increase in goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum additional consideration due contingent on certain milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions', window );">Contingent consideration obligation for acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio | R &amp; D Technology rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Value of intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average period of amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio | Licensing rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Value of intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember', window );">Teneobio | In-process Research and Development | AMG 340</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_FivePrimeTherapeuticsIncMember', window );">Five Prime Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments to Acquire Businesses, Net of Cash Acquired</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets', window );">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</a></td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Other liabilities</a></td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=amgn_GensentaIlacSanayiVsTicaretMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=amgn_GensentaIlacSanayiVsTicaretMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_TeneobioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_RDTechnologyrightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_RDTechnologyrightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_MoleculeTypeAxis=amgn_AMG340Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_MoleculeTypeAxis=amgn_AMG340Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_FivePrimeTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_FivePrimeTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515697967456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 6,594<span></span>
</td>
<td class="nump">$ 6,526<span></span>
</td>
<td class="nump">$ 12,832<span></span>
</td>
<td class="nump">$ 12,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6,281<span></span>
</td>
<td class="nump">6,114<span></span>
</td>
<td class="nump">12,012<span></span>
</td>
<td class="nump">11,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4,446<span></span>
</td>
<td class="nump">4,374<span></span>
</td>
<td class="nump">8,483<span></span>
</td>
<td class="nump">8,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,835<span></span>
</td>
<td class="nump">1,740<span></span>
</td>
<td class="nump">3,529<span></span>
</td>
<td class="nump">3,429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_EnbrelMember', window );">Enbrel&#174; (etanercept) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,051<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
<td class="nump">1,913<span></span>
</td>
<td class="nump">2,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_EnbrelMember', window );">Enbrel&#174; (etanercept) [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
<td class="nump">1,879<span></span>
</td>
<td class="nump">2,007<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_EnbrelMember', window );">Enbrel&#174; (etanercept) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_ProliaMember', window );">Prolia&#174; (denosumab) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">922<span></span>
</td>
<td class="nump">814<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
<td class="nump">1,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_ProliaMember', window );">Prolia&#174; (denosumab) [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">611<span></span>
</td>
<td class="nump">538<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
<td class="nump">1,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_ProliaMember', window );">Prolia&#174; (denosumab) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="nump">581<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtezlaMember', window );">Otezla (apremilast) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">594<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="nump">1,045<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtezlaMember', window );">Otezla (apremilast) [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">487<span></span>
</td>
<td class="nump">423<span></span>
</td>
<td class="nump">837<span></span>
</td>
<td class="nump">789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtezlaMember', window );">Otezla (apremilast) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_XgevaMember', window );">XGEVA&#174; (denosumab) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">488<span></span>
</td>
<td class="nump">1,035<span></span>
</td>
<td class="nump">956<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_XgevaMember', window );">XGEVA&#174; (denosumab) [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="nump">759<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_XgevaMember', window );">XGEVA&#174; (denosumab) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_AranespMember', window );">Aranesp&#174; (darbepoetin alfa) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">367<span></span>
</td>
<td class="nump">715<span></span>
</td>
<td class="nump">722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_AranespMember', window );">Aranesp&#174; (darbepoetin alfa) [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_AranespMember', window );">Aranesp&#174; (darbepoetin alfa) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">446<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NeulastaMember', window );">Neulasta&#174; (pegfilgrastim) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">310<span></span>
</td>
<td class="nump">486<span></span>
</td>
<td class="nump">658<span></span>
</td>
<td class="nump">968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NeulastaMember', window );">Neulasta&#174; (pegfilgrastim) [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">434<span></span>
</td>
<td class="nump">567<span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NeulastaMember', window );">Neulasta&#174; (pegfilgrastim) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember', window );">Repatha (evolocumab) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="nump">654<span></span>
</td>
<td class="nump">572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember', window );">Repatha (evolocumab) [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">319<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember', window );">Repatha (evolocumab) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">335<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_KyprolisMember', window );">KYPROLIS&#174; (carfilzomib) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="nump">604<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_KyprolisMember', window );">KYPROLIS&#174; (carfilzomib) [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">190<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_KyprolisMember', window );">KYPROLIS&#174; (carfilzomib) [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NplateMember', window );">Nplate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="nump">550<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NplateMember', window );">Nplate [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_NplateMember', window );">Nplate [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtherProductsMember', window );">Other products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,588<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">3,064<span></span>
</td>
<td class="nump">2,835<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtherProductsMember', window );">Other products [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">907<span></span>
</td>
<td class="nump">1,939<span></span>
</td>
<td class="nump">1,759<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=amgn_OtherProductsMember', window );">Other products [Member] | ROW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">585<span></span>
</td>
<td class="nump">563<span></span>
</td>
<td class="nump">1,125<span></span>
</td>
<td class="nump">1,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">$ 412<span></span>
</td>
<td class="nump">$ 820<span></span>
</td>
<td class="nump">$ 721<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_EnbrelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_EnbrelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_ProliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_ProliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_OtezlaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_OtezlaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_XgevaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_XgevaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_AranespMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_AranespMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_NeulastaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_NeulastaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_KyprolisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_KyprolisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_NplateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_NplateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amgn_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amgn_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515702476912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Apr. 28, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">16.80%<span></span>
</td>
<td class="nump">12.90%<span></span>
</td>
<td class="nump">12.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase in unrecognized tax benefits resulting from tax positions taken during the current period</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_ProposedAdditionalIncomeTax', window );">Proposed additional income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_RepatriationTaxOnProposedAdditionalTax', window );">Repatriation tax on proposed additional tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_ProposedAdditionalIncomeTax20132015', window );">Proposed additional income tax 2013-2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105', window );">Penalties on proposed additional income tax 2013-2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_RepatriationTaxOnProposedAdditionalTax20132015', window );">Repatriation tax on proposed additional tax 2013-2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_PenaltiesOnProposedAdditionalIncomeTax20132105">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Penalties on proposed additional income tax 2013-2015</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_PenaltiesOnProposedAdditionalIncomeTax20132105</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ProposedAdditionalIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proposed additional income tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ProposedAdditionalIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_ProposedAdditionalIncomeTax20132015">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proposed additional income tax 2013-2015</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_ProposedAdditionalIncomeTax20132015</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_RepatriationTaxOnProposedAdditionalTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repatriation tax on proposed additional tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_RepatriationTaxOnProposedAdditionalTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_RepatriationTaxOnProposedAdditionalTax20132015">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repatriation tax on proposed additional tax 2013-2015</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_RepatriationTaxOnProposedAdditionalTax20132015</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515699238832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Income (Numerator):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income for basic and diluted EPS</a></td>
<td class="nump">$ 1,317<span></span>
</td>
<td class="nump">$ 1,476<span></span>
</td>
<td class="nump">$ 464<span></span>
</td>
<td class="nump">$ 1,646<span></span>
</td>
<td class="nump">$ 2,793<span></span>
</td>
<td class="nump">$ 2,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares (Denominator):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares for basic EPS (in shares)</a></td>
<td class="nump">535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">541<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares for diluted EPS (in shares)</a></td>
<td class="nump">537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="nump">578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic EPS (in usd per share)</a></td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.16<span></span>
</td>
<td class="nump">$ 3.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted EPS (in usd per share)</a></td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.13<span></span>
</td>
<td class="nump">$ 3.65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515703604752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 6,413<span></span>
</td>
<td class="nump">$ 7,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">6,413<span></span>
</td>
<td class="nump">7,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. Treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">1,980<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">1,980<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">4,433<span></span>
</td>
<td class="nump">5,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">4,433<span></span>
</td>
<td class="nump">5,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember', window );">Other short-term interest-bearing securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515703571712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments (Fair Values by Classification) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract', window );"><strong>Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">$ 1,980<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total interest-bearing securities</a></td>
<td class="nump">6,413<span></span>
</td>
<td class="nump">7,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_AvailableForSalesInvestmentsMember', window );">Available-for-sale investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract', window );"><strong>Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">4,433<span></span>
</td>
<td class="nump">7,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,980<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total interest-bearing securities</a></td>
<td class="nump">$ 6,413<span></span>
</td>
<td class="nump">$ 7,304<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=amgn_AvailableForSalesInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=amgn_AvailableForSalesInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515705496672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments (Available-for-sale Investments) (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 770<span></span>
</td>
<td class="nump">$ 733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</a></td>
<td class="nump">$ 5,203<span></span>
</td>
<td class="nump">$ 7,989<span></span>
</td>
<td class="nump">$ 6,630<span></span>
</td>
<td class="nump">$ 6,266<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515705729104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments (Fair Values by Contractual Maturity) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total interest-bearing securities</a></td>
<td class="nump">$ 6,413<span></span>
</td>
<td class="nump">$ 7,304<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515704935344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Equity Securities) (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">$ 492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Equity Securities, FV-NI, Unrealized Gain (Loss)</a></td>
<td class="num">(106)<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="num">(276)<span></span>
</td>
<td class="num">$ (31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities without readily determinable fair value</a></td>
<td class="nump">280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">$ 361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 611<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515697805808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (BeiGene) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (Loss) from Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (497)<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember', window );">Collaborative arrangement with BeiGene, Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">18.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (Loss) from Equity Method Investments</a></td>
<td class="num">$ (80)<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="num">$ (188)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Carrying value of equity method investment</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Equity Method Investments,Quoted Market Price</a></td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentQuotedMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentQuotedMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515698433008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Neumora Therapeutics, Inc.) (Details) - Neumora Therapeutics, Inc. [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">25.90%<span></span>
</td>
<td class="nump">25.70%<span></span>
</td>
<td class="nump">25.70%<span></span>
</td>
<td class="nump">25.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment, Aggregate Cost</a></td>
<td class="nump">$ 257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1', window );">Noncash or Part Noncash Acquisition, Investments Acquired</a></td>
<td class="nump">$ 157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Equity Method Investments, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_EquityMethodInvestmentChangeInCarryingValue', window );">Equity method investment, change in carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_EquityMethodInvestmentChangeInCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment, change in carrying value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_EquityMethodInvestmentChangeInCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126960272&amp;loc=d3e32014-111567<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investments that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_NeumoraTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_NeumoraTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515697810944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments Investments (Limited Partnership Investments) (Details) - Fair Value Measured at Net Asset Value Per Share [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount', window );">Investment Company, Financial Support to Investee Contractually Required, Amount</a></td>
<td class="nump">$ 209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember', window );">Limited Partnership [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestment', window );">Alternative investments</a></td>
<td class="nump">338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_AlternativeInvestmentNetGainLoss', window );">Net gains (losses) from limited partnership investments</a></td>
<td class="num">$ (60)<span></span>
</td>
<td class="num">$ (43)<span></span>
</td>
<td class="num">$ (220)<span></span>
</td>
<td class="nump">$ 165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_AlternativeInvestmentNetGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Alternative Investment, Net Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_AlternativeInvestmentNetGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL6742756-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 35<br> -Paragraph 54B<br> -URI https://asc.fasb.org/extlink&amp;oid=126972413&amp;loc=SL7495116-110257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of financial support committed by investment company to investee that is contractually required.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 20<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=66023616&amp;loc=SL35737432-115832<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=srt_PartnershipInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=srt_PartnershipInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515706021472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 779<span></span>
</td>
<td class="nump">$ 647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">2,763<span></span>
</td>
<td class="nump">2,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,012<span></span>
</td>
<td class="nump">1,072<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 4,554<span></span>
</td>
<td class="nump">$ 4,086<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515705220496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets (Goodwill Roll Forward) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 14,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Net increase in goodwill</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Currency translation adjustment</a></td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 14,865<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515705017888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and other intangible assets (Identifiable Intangible Assets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amounts</a></td>
<td class="nump">$ 32,098<span></span>
</td>
<td class="nump">$ 32,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(19,191)<span></span>
</td>
<td class="num">(17,987)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">12,907<span></span>
</td>
<td class="nump">14,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_IdentifiableIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">33,118<span></span>
</td>
<td class="nump">33,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(19,191)<span></span>
</td>
<td class="num">(17,987)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">13,927<span></span>
</td>
<td class="nump">15,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="nump">1,020<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed-Product-Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amounts</a></td>
<td class="nump">25,537<span></span>
</td>
<td class="nump">25,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(13,863)<span></span>
</td>
<td class="num">(12,769)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">11,674<span></span>
</td>
<td class="nump">12,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amounts</a></td>
<td class="nump">3,864<span></span>
</td>
<td class="nump">3,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(3,050)<span></span>
</td>
<td class="num">(2,973)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">814<span></span>
</td>
<td class="nump">834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember', window );">Marketing-Related Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amounts</a></td>
<td class="nump">1,326<span></span>
</td>
<td class="nump">1,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,125)<span></span>
</td>
<td class="num">(1,112)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember', window );">Research and Development Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amounts</a></td>
<td class="nump">1,371<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,153)<span></span>
</td>
<td class="num">(1,133)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">$ 218<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_IdentifiableIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identifiable intangible assets accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_IdentifiableIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_IdentifiableIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identifiable intangible assets gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_IdentifiableIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515699170160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization charges associated with finite-lived intangible assets</a></td>
<td class="nump">$ 629<span></span>
</td>
<td class="nump">$ 652<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Total estimated amortization of finite-lived intangible assets for the six months ending December 31, 2022</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Total estimated amortization of finite-lived intangible assets for 2023</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Total estimated amortization of finite-lived intangible assets for 2024</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Total estimated amortization of finite-lived intangible assets for 2025</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Total estimated amortization of finite-lived intangible assets for 2026</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Total estimated amortization of finite-lived intangible assets for 2027</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515694826464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized bond discounts, premiums and issuance costs, net</a></td>
<td class="num">$ (1,245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,213)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Fair value adjustments</a></td>
<td class="num">(210)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Other</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total carrying value of debt</a></td>
<td class="nump">36,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current portion</a></td>
<td class="num">(817)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">$ 35,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_A4202052NotesMember', window );">4.20% 2052 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.25% notes due 2023 (2.25% 2023 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 1.90% notes due 2025 (1.90% 2025 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.00% &#8364;750 million notes due 2026 (2.00% 2026 euro Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.60% notes due 2026 (2.60% 2026 notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.50% &#163;475 million notes due 2026 (5.50% 2026 pound sterling Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 475,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.20% notes due 2027 (2.20% 2027 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.20% notes due 2027 (3.20% 2027 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 1.65% notes due 2028 (1.65% 2028 Notes) [Member}</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.00% 2029 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.00% &#163;700 million notes due 2029 (4.00% 2029 pound sterling Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.45% notes due 2030 (2.45% 2030 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.30% notes due 2031 (2.30% 2031 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.00% notes due 2032 (2.00% 2032 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.35% 2032 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.35%<span></span>
</td>
<td class="nump">3.35%<span></span>
</td>
<td class="nump">3.35%<span></span>
</td>
<td class="nump">3.35%<span></span>
</td>
<td class="nump">3.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 6.375% notes due 2037 (6.375% 2037 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.375%<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="nump">6.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 6.90% notes due 2038 (6.90% 2038 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 6.40% notes due 2039 (6.40% 2039 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.15% notes due 2040 (3.15% 2040 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.75% notes due 2040 (5.75% 2040 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 2.80% notes due 2041 (2.80% 2041 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.95% notes due 2041 (4.95% 2041 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.15% notes due 2041 (5.15% 2041 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="nump">5.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.65% notes due 2042 (5.65% 2042 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.65%<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="nump">5.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 5.375% notes due 2043 (5.375% 2043 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.40% notes due 2045 (4.40% 2045 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.563% notes due 2048 (4.563% 2048 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.563%<span></span>
</td>
<td class="nump">4.563%<span></span>
</td>
<td class="nump">4.563%<span></span>
</td>
<td class="nump">4.563%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.375% notes due 2050 (3.375% 2050 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 3,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,541<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.00% notes due 2052 (3.00% 2052 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.20% 2052 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | Two Point Seven Seven Percent Notes Due Two Zero Five Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.40% 2062 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | Other notes due 2097 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A4202052NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A4202052NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointSixTwoFivePercentNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointTwoZeroNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointTwoZeroNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OnePointSixFivePercent2028NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OnePointSixFivePercent2028NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A3002029NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A3002029NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointZeroPercent2032NotesMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointZeroPercent2032NotesMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A3352032NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A3352032NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointThreeSevenFivePercentNotesDue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointThreeSevenFivePercentNotesDue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointNineZeroPercentNotesDue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointNineZeroPercentNotesDue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_SixPointFourZeroPercentNotesDue2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_SixPointFourZeroPercentNotesDue2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointOneFivePercentNotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointOneFivePercentNotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointSevenFivePercentNotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointSevenFivePercentNotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointEightZeroPercent2041NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointEightZeroPercent2041NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointNineFivePercentNotesDue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointNineFivePercentNotesDue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointOneFivePercentNotesDue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointOneFivePercentNotesDue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointSixFivePercentNotesDue2042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointSixFivePercentNotesDue2042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointThreeSevenFivePercentNotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointThreeSevenFivePercentNotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ThreePointThreeSevenFivePercentNotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ThreePointThreeSevenFivePercentNotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A300NotesDue20523002052NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A300NotesDue20523002052NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A4402062NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A4402062NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_OtherNotesDue2097Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_OtherNotesDue2097Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515694809344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing arrangements (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amgn_A4202052NotesMember', window );">4.20% 2052 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.563% notes due 2048 (4.563% 2048 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.563%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.663%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | Two Point Seven Seven Percent Notes Due Two Zero Five Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.00% 2029 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent', window );">Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 3.35% 2032 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.35%<span></span>
</td>
<td class="nump">3.35%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent', window );">Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.20% 2052 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent', window );">Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes [Member] | 4.40% 2062 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent', window );">Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Debt Securities Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount', window );">Debt Instrument, Redemption Period without Payment of Make Whole Amount</a></td>
<td class="text">2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Debt Securities Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount', window );">Debt Instrument, Redemption Period without Payment of Make Whole Amount</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Period without Payment of Make Whole Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A4202052NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A4202052NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A3002029NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A3002029NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A3352032NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A3352032NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_A4402062NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_A4402062NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_DebtSecuritiesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_DebtSecuritiesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515703491728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Share Repurchase Program) (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased, Shares</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,410<span></span>
</td>
<td class="nump">$ 1,592<span></span>
</td>
<td class="nump">$ 865<span></span>
</td>
<td class="nump">$ 5,410<span></span>
</td>
<td class="nump">$ 2,457<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515703794208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Details Textual) (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 08, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 03, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 25, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 24, 2022 </div>
<div>financial_institution</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased, Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,410<span></span>
</td>
<td class="nump">$ 1,592<span></span>
</td>
<td class="nump">$ 865<span></span>
</td>
<td class="nump">$ 5,410<span></span>
</td>
<td class="nump">$ 2,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,310<span></span>
</td>
<td class="nump">1,592<span></span>
</td>
<td class="nump">$ 865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount available for stock repurchases under a board approved stock repurchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Dividends paid per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated deficit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,410<span></span>
</td>
<td class="nump">$ 1,592<span></span>
</td>
<td class="nump">$ 865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember', window );">Common stock and additional paid-in capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amgn_AcceleratedStockRepurchaseAgreementMember', window );">Accelerated stock repurchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased, Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_NumberOfThirdPartyFinancialInstitutions', window );">Number of Third-Party Financial Institutions | financial_institution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amgn_AcceleratedStockRepurchaseAgreementMember', window );">Accelerated stock repurchase agreement | Accumulated deficit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amgn_AcceleratedStockRepurchaseAgreementMember', window );">Accelerated stock repurchase agreement | Common stock and additional paid-in capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Dividends paid per share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_NumberOfThirdPartyFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Third-Party Financial Institutions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_NumberOfThirdPartyFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=amgn_AcceleratedStockRepurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=amgn_AcceleratedStockRepurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515703127568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Components of AOCI) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in AOCI [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 916<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="nump">$ 9,334<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="nump">$ 9,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of end of period</a></td>
<td class="nump">2,419<span></span>
</td>
<td class="nump">916<span></span>
</td>
<td class="nump">8,247<span></span>
</td>
<td class="nump">2,419<span></span>
</td>
<td class="nump">8,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign currency translation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in AOCI [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of beginning of period</a></td>
<td class="num">(895)<span></span>
</td>
<td class="num">(844)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(844)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of end of period</a></td>
<td class="num">(960)<span></span>
</td>
<td class="num">(895)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(960)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Cash&#160;flow hedges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in AOCI [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of beginning of period</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gains</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments to income</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Income taxes</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of end of period</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Available-for-sale securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in AOCI [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments to income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=amgn_AccumulatedOtherAdjustmentAttributabletoParentMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in AOCI [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of beginning of period</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of end of period</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in AOCI [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of beginning of period</a></td>
<td class="num">(763)<span></span>
</td>
<td class="num">(796)<span></span>
</td>
<td class="num">(833)<span></span>
</td>
<td class="num">(796)<span></span>
</td>
<td class="num">(985)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gains</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments to income</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Income taxes</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of end of period</a></td>
<td class="num">$ (672)<span></span>
</td>
<td class="num">$ (763)<span></span>
</td>
<td class="num">$ (868)<span></span>
</td>
<td class="num">$ (672)<span></span>
</td>
<td class="num">$ (868)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=amgn_AccumulatedOtherAdjustmentAttributabletoParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=amgn_AccumulatedOtherAdjustmentAttributabletoParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515704066064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Reclassifications out of AOCI) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 6,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,832<span></span>
</td>
<td class="nump">$ 12,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(847)<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">1,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,206<span></span>
</td>
<td class="nump">2,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(413)<span></span>
</td>
<td class="num">(305)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">1,317<span></span>
</td>
<td class="nump">$ 1,476<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="nump">$ 1,646<span></span>
</td>
<td class="nump">2,793<span></span>
</td>
<td class="nump">2,110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,012<span></span>
</td>
<td class="nump">11,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash&#160;flow hedges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="num">(132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(183)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">(104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income [Member] | Foreign currency contract [Member] | Cash&#160;flow hedges [Member] | Product sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income [Member] | Cross-currency swap contract [Member] | Cash&#160;flow hedges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(263)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Foreign currency contract [Member] | Cash&#160;flow hedges [Member] | Product sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Cross-currency swap contract [Member] | Cash&#160;flow hedges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">$ (185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (263)<span></span>
</td>
<td class="num">$ (86)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515696707968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurement (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">$ 6,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">7,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">310<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
<td class="nump">342<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember', window );">Cross-currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeAssetAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">6,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | Foreign currency contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | Cross-currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets (Level 1) [Member] | Interest rate swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeAssetAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | Foreign currency contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | Cross-currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs (Level 2) [Member] | Interest rate swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeAssetAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | Foreign currency contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | Cross-currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency and cross-currency swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (Level 3) [Member] | Interest rate swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeAssetsFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeAssetAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract', window );"><strong>Derivatives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue', window );">Interest rate swap contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury notes [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury notes [Member] | Significant other observable inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury notes [Member] | Significant unobservable inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. Treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">1,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. Treasury bills [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">1,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. Treasury bills [Member] | Significant other observable inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. Treasury bills [Member] | Significant unobservable inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">4,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market mutual funds [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">4,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market mutual funds [Member] | Significant other observable inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market mutual funds [Member] | Significant unobservable inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember', window );">Other short-term interest-bearing securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember', window );">Other short-term interest-bearing securities [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember', window );">Other short-term interest-bearing securities [Member] | Significant other observable inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember', window );">Other short-term interest-bearing securities [Member] | Significant unobservable inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Interest-bearing securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DerivativeAssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DerivativeAssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative financial instruments liabilities fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateFairValueHedgeAssetAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all derivative assets designated as interest rate fair value hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateFairValueHedgeAssetAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all derivative liabilities designated as interest rate fair value hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515709696432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge', window );">Length of time hedged in foreign currency contracts (or less)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Long-term debt, fair value</a></td>
<td class="nump">$ 34,400<span></span>
</td>
<td class="nump">$ 37,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value of debt</a></td>
<td class="nump">36,522<span></span>
</td>
<td class="nump">33,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember', window );">Collaborative arrangement with BeiGene, Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Equity Method Investments,Quoted Market Price</a></td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Carrying value of equity method investment</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioIncMember', window );">Teneobio Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum additional consideration due contingent on certain milestones</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentQuotedMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentQuotedMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amgn_TeneobioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amgn_TeneobioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515703330656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement (Contingent Consideration Obligations) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationContingentConsiderationRollForward', window );"><strong>Business Combination, Contingent Consideration [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 330<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 342<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_BusinessCombinationContingentConsiderationArrangementsPayments', window );">Payments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Net changes in valuations</a></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 310<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 310<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationContingentConsiderationArrangementsPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationContingentConsiderationArrangementsPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_BusinessCombinationContingentConsiderationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_BusinessCombinationContingentConsiderationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515709791328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months', window );">Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps</a></td>
<td class="nump">$ 179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember', window );">Forward Contracts [Member] | Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amounts</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember', window );">Forward Contracts [Member] | Derivatives not designated as hedging instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amounts</a></td>
<td class="nump">550<span></span>
</td>
<td class="nump">680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap [Member] | Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amounts</a></td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515705063088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments (Cross-currency Swaps) (Details) - Cash flow hedge [Member] - Cross-currency swap contracts [Member]<br> &#8364; in Millions, &#163; in Millions, SFr in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">0.41% 2023 Swiss franc Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amounts</a></td>
<td class="nump">$ 704<span></span>
</td>
<td class="nump">SFr 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">2.00% 2026 euro Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amounts</a></td>
<td class="nump">833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">5.50% 2026 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amounts</a></td>
<td class="nump">747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">4.00% 2029 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amounts</a></td>
<td class="nump">$ 1,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Euro Member Countries, Euro | 2.00% 2026 euro Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Switzerland, Francs | 0.41% 2023 Swiss franc Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">United Kingdom, Pounds | 5.50% 2026 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">United Kingdom, Pounds | 4.00% 2029 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">United States of America, Dollars | 0.41% 2023 Swiss franc Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">United States of America, Dollars | 2.00% 2026 euro Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">United States of America, Dollars | 5.50% 2026 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">United States of America, Dollars | 4.00% 2029 pound sterling Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rates</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515709689232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details) - Cash flow hedge [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax', window );">Total unrealized gains (losses)</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="num">$ (31)<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Foreign currency contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax', window );">Total unrealized gains (losses)</a></td>
<td class="nump">252<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cross-currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax', window );">Total unrealized gains (losses)</a></td>
<td class="num">$ (185)<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="num">$ (207)<span></span>
</td>
<td class="num">$ (60)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515703687984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</a></td>
<td class="num">$ (210)<span></span>
</td>
<td class="nump">$ 284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=amgn_LongTermDebtCurrentMaturitiesMember', window );">Current portion of long-term debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Hedged Liability, Fair Value Hedge</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_HedgedLiabilityDiscontinuedFairValueHedge', window );">Carrying value with discontinued hedging relationships</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease', window );">Hedging adjustments on discontinued hedging relationships</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember', window );">Long-term debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Hedged Liability, Fair Value Hedge</a></td>
<td class="nump">6,241<span></span>
</td>
<td class="nump">6,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</a></td>
<td class="num">(292)<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_HedgedLiabilityDiscontinuedFairValueHedge', window );">Carrying value with discontinued hedging relationships</a></td>
<td class="nump">399<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease', window );">Hedging adjustments on discontinued hedging relationships</a></td>
<td class="nump">$ 299<span></span>
</td>
<td class="nump">$ 340<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_HedgedLiabilityDiscontinuedFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Hedged Liability, Discontinued Fair Value Hedge</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_HedgedLiabilityDiscontinuedFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability hedged in fair value hedging relationship.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=amgn_LongTermDebtCurrentMaturitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=amgn_LongTermDebtCurrentMaturitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515709753920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments (Summary of Income and Expense Line Items) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 6,594<span></span>
</td>
<td class="nump">$ 6,526<span></span>
</td>
<td class="nump">$ 12,832<span></span>
</td>
<td class="nump">$ 12,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(317)<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="num">(847)<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, net</a></td>
<td class="num">(328)<span></span>
</td>
<td class="num">(281)<span></span>
</td>
<td class="num">(623)<span></span>
</td>
<td class="num">(566)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Gains (losses) on fair value hedging relationships, Hedged items</a></td>
<td class="nump">157<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="nump">494<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments</a></td>
<td class="num">(135)<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="num">(450)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash&#160;flow hedges [Member] | Cross-currency swap contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(185)<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="num">(263)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6,281<span></span>
</td>
<td class="nump">6,114<span></span>
</td>
<td class="nump">12,012<span></span>
</td>
<td class="nump">11,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash&#160;flow hedges [Member] | Foreign currency contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="num">$ (18)<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515699197040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments (Fair Value of Derivatives) (Details) - Derivatives designated as hedging instrument [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">$ 442<span></span>
</td>
<td class="nump">$ 265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">1,124<span></span>
</td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Foreign currency contracts [Member] | Other current assets/Other assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Foreign currency contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Cross-currency swap contracts [Member] | Other current assets/Other assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Cross-currency swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Interest rate swap contracts [Member] | Other current assets/Other assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total derivative assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Interest rate swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueNetAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total derivative liabilities, fair value</a></td>
<td class="nump">$ 591<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=amgn_OtherCurrentNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=amgn_OtherCurrentNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140515709009472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies and commitments (Details)<br></strong></div></th>
<th class="th">
<div>May 27, 2022 </div>
<div>argument</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_LitigationSettlementNumberOfPrimaryArguments', window );">Litigation Settlement, Number Of Primary Arguments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_LitigationSettlementNumberOfPrimaryArguments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Number Of Primary Arguments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_LitigationSettlementNumberOfPrimaryArguments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>amgn-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amgn="http://www.amgen.com/20220630"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:currency="http://xbrl.sec.gov/currency/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:exch="http://xbrl.sec.gov/exch/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="amgn-20220630.xsd" xlink:type="simple"/>
    <context id="i399851cc44354bd288c22867c4af295c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i68c22f15a4f2449f827d166633453d03_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i33b94f8a0ce843a681a635dc7e7fa22e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4cccb85585694ce49af0de31a566d7f3_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="ia3c410d6b2f84e53be5c076dec22d865_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i78d9e005bccc4060bd5addba903c2c2c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i38c160a3f1834d5e9d775a1dea85e514_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i93db18973157470084da5a577ecb7c40_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i71e71b4283ef4881a494fede3403b36c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i768868bd3bfe4a65a96efee550cef847_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i43a801ced92f421e934618c8046f564b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6bfeed5ecca54e718c3e7aefb7714ac5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9027275ed49d4865b0705c7a15256e40_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ab9a3aeb1dc401e8f8036824d7fc7ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie57786644af74fb49b8f5e29302dab93_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id600cdce916f4b66a8dcd23e38e899e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4015add6967846b88c70abf91e4bfcd3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4bdfa7c23e874b22a1a66bebad22d916_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if6bebabfe867463fb2ce8c41e89ce28a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i727569817ab94b17a5a44e5e6554f39c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib84a6f83e673473a8ba69ec165a6aa32_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1743609e3cdb4aee821e866d6c0b7a5b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia449403700e84ad390099f266af55696_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib52f0a890ada46f0aaeaa5f7a392c87f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3453133454bb4b68987a91d14ea8ccda_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8de403afe8684433ba669a9d329718c4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9c56073392354d1aa5fe73191ec6a1cd_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i950254b1c906440baad1c3cb0d696509_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib013f6621b494621aa9fdc2ca2c9a16a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i437ad630ad5c4d0db3b941130901471f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i69e8f109a2db495c82bf5845b27d710b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iaa04a5eecd554471bd742d77f0241ab8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3e8fdc8e1afb4a8b8179c89009d5c1aa_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iedbaa8596a604e708e0f5d708642088d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i87a50000054d41c4b6c8d975b42b1648_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e3e8fc000224eaa8d179f838cb7031a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i37f513ac48e244eebc3ecfd6dbf5e0a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2639d3c097ee4df19d9460b38ce3c560_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e5bfcd24a084d2ba4ae4e9fd63a2a81_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifaa3e87d3e094c2c82065bdcc86a2d5e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i230f8b81d2ba4f069528c27808330841_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1f42e7ad02b549569ea5beaa0e813a56_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2ff28f2746c54bdaaf782c67ac1f4302_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib96efcc5351148e2b1ec0411f0edc1ba_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iac25314d738441bd880294e17a40ea59_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id1a08827c17347a29bf672041a9ba9ab_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i34f2d24ef5604859814eae53b155dccc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i07da672f055a4104b16e0910367ec926_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1a2ab422b4b24a8fba8a2d881b98b260_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i722f5ea9afa642bf9d0d9d90efe8e13a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9fd41a82276046c7bcf592d2b6dc24da_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i38c33764415f4b3db09298ed152df379_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iaa0252b377d44fb0a78ea5b3634c223a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic7fd0dbb0ae849598e2ca788ff7aaa13_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i86ca63c3b2e447a59ee34b73dfbdad9b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idcb6da36e779490a98df897dc86555e5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i33df105eb613462290a07079358e7409_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i99dc635999d0465e8fcbdc0cee2c1601_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i46b0c7abfa194277afc81cba3b24f8a3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i65b90579b9de4767a853da3e3573d8fa_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id0f1d41da125426189de8e665937a530_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:RDTechnologyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibf77564d8ed145dab51bea04209c327c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id5b59ba800eb4416b405415f49916460_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amgn:MoleculeTypeAxis">amgn:AMG340Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id8fc3ec2171642438fd51d30ae242218_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:RDTechnologyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7940c183b18d43b9ba4da67548953f71_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9a5366d8b02a4ac58034f8465ae23d74_D20210416-20210416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:FivePrimeTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-16</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="i51b02cfd80774125a1d4ff6c778112df_I20210416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:FivePrimeTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-16</instant>
        </period>
    </context>
    <context id="iab9a0edff56e4078be3430ac408a5cf8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">amgn:GensentaIlacSanayiVsTicaretMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7d17ec1f9653493f940934eadb627b3e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">amgn:GensentaIlacSanayiVsTicaretMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1b8b7a38d735412895755cb950726b35_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">amgn:GensentaIlacSanayiVsTicaretMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icee014cde681480aad811d3d8701db0d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iaf9d9ddcf94242e3ad6ec1f3b60ca85f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6547eba45cd04dcbaeebbe712be8ec92_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5e52109f70c0440aa0159863f2da64f0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0a84ebe379724a65826c6f82bd6873e1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ida701b321d2c4d2a891120940d3655c5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ief82f7dcaf42426abffc36664a5809c7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0fdc9fa81ab6432aaa23fe4128d28ae8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i053944749a2f483d9d310db2fc989a2c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7eebec4167d24ee289c7c3c2cca1d35a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib7337cf047dc447782a07d660fabea38_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6c5378764431442fb224f6e38d910099_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic4b87907d6674193b0d2c415cefc0caf_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i353f9f7d24934b85a5752777824c2c7f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib84507297bc345c8b3d5fff781c60e36_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4fef643526f14918bd9831e91914bf50_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i402e9a1690cc42e797f5a6261ca0cbfb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if3ea1a7432a342c2bed9d52592b75cf4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i63940a8eea91432f83d73335dca6a9f4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i05d9d5b7844d40b4a71f85abe0bce65a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6cde61abea0348d2a159b88ebd8184b7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i10be39accc2549a2bdd35da00b4aaa91_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6b97f8b18b7146bf8f5d26e2d38206ab_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie08a8cd0c2ee4df4970b642309711818_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib449607d3a384e9b922bf56ee0f6ad54_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i844d0ba430b845fabf60df607d4a6b2b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2d419bd679714fdcb7cab5ff036d1523_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i78a1a713123344ccbeee9e7f0bd8b286_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3759a6d96c3d4557865f45756f379736_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i13eca2061d94491bbf81135f296046bf_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if6b5b0a2363145d7be3110c83773d028_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia8d35c2137e343349add15c0fca41917_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1ab66a4297fc4a5fa4fbdb2b993c893d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iaa47aecf963c462192f5f09066e709ae_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5dab3465710546408078a65658bbbc86_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8d1ec301cf824dcc9410f3838f666700_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8d51cebbb7fc4745b1461e1227bf4a07_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic60e2a88b0ee40cdae005ed5c6d5e8fc_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i331261ad3dac42c582a5e9011635bd51_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ide9a7be6cf844191ab232452edf77bd6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3b9d8e979224414d8d3ad2e8695072bb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i49646ee726c14e1e97ca5817d76e3e08_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iab5d097d4d764906958b2308fa778f75_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0bb35321c40c4726b08388b4209a9228_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2958c1dc2e954e58aa77a26a6d8e1d7a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i70fcb018e33749d2af04537d60b71f20_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ica9bbd963a304369b99b0572c2fff78c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i81e998920660480b972899798b0bbb3c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if57c433f89bb427d95cc820d738a213b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i49be0bf790014903a4b42b6e1b2727bd_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7d6f96cf75ba4e419a31bf17c86c89c7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib9166886eb5d468090bdacec2d9c6426_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iedd4bef43f2e4c74bdbe761a290688d2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i866f0a6fa4484406b8ad21f3fb76f4a3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7c0b9b0637ae4f75a113b9daf4ffbb97_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id00661e6164d4652a22a0e73d4ff73a6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8c2f46c443024e00a31cb4dc9cd9e34b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9c2e544419be4d83a0548a9dd2cb80a6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8a69d719fa4e41389f7a488fa7f10932_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i12b36c285b3e46d48bdcaa2313f4d40a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic3c63f65b70944d59e9ddddf1020dbf9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i27c7d03606704467ad677af2b7b1c3b1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i60557b562a964b209eb858e7b3cb22e9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iafda85002a2340d3b351231f4da2b4fb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i995fe6b5cc06494dac04f0ca72c967be_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i481df103ecf443b58ab69543c8ebfaa4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7e20cfb3d44545709400adfd0900c274_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i198ddb00bf674c69a7441a2d3a026635_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4ad4acdb144a4163bcbf1216e002c725_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iac22074dabd64d2fbfdc167416335b44_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:EnbrelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia9ab9b8edfdb4a22b19ee432374d19ec_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie2a35d4acbaa4f83be8e10b0e6e0300d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idf38951506aa48f19b8b2388b7885ee1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8d40692061a445c192ae0b68421a236a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0f09cd5a2a344997a29f5dbf9e474e85_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9f4bf88082934cdc8910614dccffc16b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:ProliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i43dfd6a72e0d4e86845ad7349de053e0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i22a251c8f299431d94a6931aca67fc7f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic8de2ea542474f83b6b3eca46a028b44_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i774b5e6996814c4abaaef4d66eabba88_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia32f2b66d9004689a58fa0ee82794077_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic110f3f8f6db447287b324ae25536ba2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtezlaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2702f5653dc64085adaed969aa03d41a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i059b2fc16c164e18b5bc3641f7e47b0a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifd43189867c0477aa56e3dd2bd1a3ca1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i22ff43227695419d9aa80cbc49fe3fac_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idf215bb9f1894adc8cb1984f634e46cb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i417472fa55034ae1828e69637b4f9dc6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:XgevaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if61ddc5649444d2890986cd3b336d8a6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia9501d13f07544aa914a2f0472499317_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5c91bcd0b0614b31b6ed09d75f6a89ee_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i447c6a3b3c654027a8f390447d27092a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i913293415a73440c8b746390caea2fe8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6d14e200ac08498a8babed3b3c0ded3c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:AranespMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1b05f801cd3a4927a0124fb231c84d76_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7e7cc819d92f4e75acbc9963bc7090ef_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia7ae2416c6aa4543a664b0bde8b33563_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib9676f44123d40e2871ec3d2771a7a5f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iecdf3a73b98a42dc9b239601a9ae31de_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i45954dd51b7b41aa96b4593c6fb94f09_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NeulastaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6148be5d2f114eaba7d30900efe31d0c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib505cfceda644a379d36c8eb60ae289b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4f37b029317a4d00a1a498b287de24f5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i280383856aef44de9c38a690e97f94a4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib5d62159edfe46daa8cde42bb90fd594_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i599bea8fe9d342bf8a2319d0c99d8049_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:RepathaevolocumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if33d244e2dcc4deb97f437c4bf8015e5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id4743b11647f495995b2a8eb1612ae62_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i019834958d7c4fdcb462b108564b7504_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if3329340deea4c2893e19564ea8f5d50_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i33575c61bd1a4b6483cadbb17231bd16_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i76d8149329f846d4b8b397d30cbfffdb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:KyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i284e10e01d024a31b71cbe8084385e6a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i18bb25efd7724f2ab8c17abd89376d32_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i799c05d5e6c148739756e62ed52efc0e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9c26221f1ddc4730a672e6feda6527ac_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie8df6d5b75ce4981805065f554e3fc61_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icf0c82557a9f4c5a9dad46e4f1995240_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:NplateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic9080bae4bb24f77958c82064456abff_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i90438b29fb8e47daa853e17a32039dbf_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i69516fc5e36948efb30d55be4c11c00e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i71f5357d2c814ae18ef9d15c743aa395_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iceb2e90867824a3d91fa7756b41e93e0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1f3ade07d4da4313b5b990be550c7fe7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amgn:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5d0a9ca182c34101bf19dd4a000ada97_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia06b5f63bc244d16b92988767f8bc100_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id43e33fcdb65467a8bb28d8ffb21869c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idc7bc4cfc3564596be8443a8279385fb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i46acdac3da2c44dca21c41eba4598137_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i82d3aa8175154da2ba3e9dab9d5064c0_I20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-28</instant>
        </period>
    </context>
    <context id="i8082d2e09a5c4aa0a7f3731849ec0d16_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1ea16251ca3344cd8e26c09cc1395a22_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifbbc44571a8140188c44b0df13007242_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie2f04eaab04b4d2c952875e4954ffda7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idd41271077fb4ca086b8c963378ae207_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c7a0f871105442a9e599228c9451089_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i02847d17ecc24c3f9024cc5f534c04a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea64a31893bd4a61a10bade5fb93931f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic3ee9095509a4235b125b11b137e139e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:AvailableForSalesInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2192ca00bef0437697f96821d3d064c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:AvailableForSalesInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52bfb5d420974f909b489605f4ebb48e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i81cbf2552fde457394dd38fa4c8d3a52_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i508f5bf239c54b9b938463f7ae92fea1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic408702ec02a49bf91a6056997008286_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i496aa2763a92482692aec0e597926c98_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0a1cd1326d554d03be0c62860aaadc16_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic159ef06be114a82aece4d92d6710839_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i888296d1eab64b6b817ca5c5d9f69be8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:BeiGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5cda008dddc94401b22d3259266fc7e7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icdb22de342f041adb8e2b70cbc132e50_D20210930-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-30</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1d79fa0d130e44d19361d654d95e141d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic76acadc687c4a66b5883e78b037a6ad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifbd4bb3072a846dead8e321c6b0cf833_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0f602482804d4aec8fdc3e408b13ed29_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:NeumoraTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iaa0314910b794236a904970854a1e630_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib8b0ba79e4914ce8815964b9387a76dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1fe68111c13942ef9c7a0d951601d88b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i401f6926d97c46c6a10162d5f3c2efde_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i62aa67f340d349a684242e6f5ab5e761_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ife312c8d8cce47d28d37a01320dd5c28_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9d1c8a9209dc4f9fbe9812c8fcc8987d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia61f1d92e9464dd18e99ac1aa3b366de_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1cce03dee4c34b2ea84da100e20fbd24_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i099607de031547a9bb9e43f15bb881fc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic07181533cda4f5e93039975aae670b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac2b57574dd942a2a453e505dabd533e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1fb7461fd5694c57866568ce1e547030_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3fb86733ee024515869430e8dbaa9324_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i571fbd60834f45a8a94ddbcd37f40d78_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e8e7fe1acc74cf88c35c02e48e41455_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic63e1fd5342a4cecb2063e44b0677f36_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia0f38e5021744d62a72f6ec5c21139ea_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i48b3751c36e94ecc8abd5b6bc07fb36c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8cc181592b784672a897b345f8aafb1c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0e0a5eb4088b4f5f9d9e54d6ac0cefa1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icbf9488cc39340f688dc8239b97b3406_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8d83b1f8089e4fe9b0149f04b0874977_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointSixTwoFivePercentNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5811dbeccf214f488187b5c22f177a23_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id9b1443716684a18a0944e9e9de23470_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d5c387b50044b74aa269b57c4e1b18e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7839d25e4a274cde83be70a336e9f23d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8771ce738edc4f2bbcd5cf45e51751ff_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i31014fe22b1e487c920ebfa34bb0d600_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i927ecd67dbbd46f6be54131a567097ee_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3f9bc180a6994a85a80ac8530527b2f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5db64085db894eefb5186c861f5a0216_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i56b164c7fe7e4938a4b2f2cb9f20f1e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i557c138915f74848aec303bcbcbdf1c5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id84e2ad3fd7d4d2ea16c4f1a15e443b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7ebb4dc9f2f4f4db89a7eba86ff7b3c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1f508b06ff8341f99dde537d8acf7445_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointTwoZeroNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07d1843d947d47519f7950d93a5562e9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointSixFivePercent2028NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9e873215313140b1b47d44874f84d297_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OnePointSixFivePercent2028NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a74363bd54f4d66ad0e46ef97698531_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A3002029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id5443e8b322b4d0faa4ade72d57d4e85_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A3002029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i28f107e649274e53ac4e7d54db6713eb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i66c10d0d93a7485babc5ced3a0780a07_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f539453d5ef4ab6bfd15d005af9fe8d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0d9dd73fd402413093a63fd14b1085e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointFourFivePercentNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i34e92919299b42e89aac44fbf306409a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ica06dde7221745f9b345032e886823b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointThreeZeroPercentNotesDue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic445c08da9214730a1fe68dffa9fde2f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointZeroPercent2032NotesMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia0a1796124db4912a03941f9fc2bb729_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointZeroPercent2032NotesMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idbe4cc4a9874400299d9ee262931fff2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A3352032NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0ea8bdcd48224c638ca7517df56948a6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9bc19466dfcd44729418b77c1b6cac7d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointThreeSevenFivePercentNotesDue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if160545557934f3ea7d7aa81db1e5fe6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ied438a5ea64d4044aa5bbdbdd2f08fa8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointNineZeroPercentNotesDue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ce84e57febe49528941c8a79c0b2aba_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if808837e20874be992a0d93186873f98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:SixPointFourZeroPercentNotesDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i044f15b088224513a42ca9d6a15c87ff_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id531ca5db21148f9bc34d2e8bb8f2623_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointOneFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab08d658a45448438680f7c44651a436_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifc8bbf8e715b4026a58db39d1e4ae27a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSevenFivePercentNotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i867b4a6e48054979abbb390f7ca4bea4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointEightZeroPercent2041NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i79f6ba2cbab24ee7a767a43344d52629_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointEightZeroPercent2041NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i869ffcf94f08470aa084a38887e74378_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8efceb2da34f4012a56d28bee80ece4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointNineFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia8f4719ca9b84ee8b1c7b311cb67831d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0fe337886bb743ac9268549dea62a5c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointOneFivePercentNotesDue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3039eef43eab47d88f5e5bde9f8c3c1a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9c41f818916d4143ab5f24b20c47b6b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointSixFivePercentNotesDue2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8baade68d0aa42cd8eabab1268708b15_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i371510a8b04e43fc92b82fca221e37d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointThreeSevenFivePercentNotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6cf9e5efd50b441ba4249ec5547a64d8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ieb4f7f1f524943beb30880ef09f09b08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idebc81edd93d4d2f8a2a03384eb93dbe_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i07b2f991bb9a47f29b3bcd5b53c1cdd5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08a78f74146a4495aeae7b6b14bd80a4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie836805159b74407a69e93d8523fe3ad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ThreePointThreeSevenFivePercentNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ed1c633fdd74b46948dd2c6f7afcf20_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idc5590dec8034b22bdedd784acc302e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i735b048825ca4313aeb532048d7be90b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A300NotesDue20523002052NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iad985efcbfe541aca64199c03a30ee03_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A300NotesDue20523002052NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d18f819d85a44c49e5108e4c3d42378_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4202052NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i53e00d2be34d4b1ea7b97fd526f5d69b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4202052NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibbd916f7493440e69704b449f2dd8102_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i60c317ee474147a8b5d3b80406fb276d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i17997eb7cd9343bd87243e19e6bb8d08_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4402062NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i43ee6e408fa1493196ad37c5887d08e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4402062NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i951998b6f8314c8884444de5fada1e86_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OtherNotesDue2097Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1a44e9649b29466fb790d1a57aca49b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:OtherNotesDue2097Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia45a3444f1b94d7694e25c6b7581e9f6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i31e27323c1154ea898dc24977e5b4dfa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A3002029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7cf0dda19fd445dca8eb54ae4d8870ae_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A3352032NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iecb3cb0076694222ab5165cf391eb7d3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4202052NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if7172737536943c5bd01dbe5c718b01f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4202052NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i531c563577e24bbe82274ae7b057ec74_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4402062NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2f9a632bdc184d86b2d6cf5fa69e05d5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A3352032NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i21ba53c9dd5540c5a2f72a1809b358f5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A3002029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i31a5a20370f74b839ba627dfd4b3d6d2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4402062NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2630ed6736474dd7ad352734abf1fa2f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:A4202052NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iff44a3a4194340a88d27d0d51b2c7873_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:DebtSecuritiesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5a36e5ea4cc14d90aa07055d396cca6d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:DebtSecuritiesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idff629d5adce4075abb77d3576767318_I20220224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amgn:AcceleratedStockRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-24</instant>
        </period>
    </context>
    <context id="i3919d433c5e54fd389f1bef01f418e40_D20220225-20220225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amgn:AcceleratedStockRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-25</startDate>
            <endDate>2022-02-25</endDate>
        </period>
    </context>
    <context id="i303708e74aba47d6a736f376e0cd1a13_D20220225-20220225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amgn:AcceleratedStockRepurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-25</startDate>
            <endDate>2022-02-25</endDate>
        </period>
    </context>
    <context id="i10398ced71924f51bd433d3c641763e9_D20220225-20220225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amgn:AcceleratedStockRepurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-25</startDate>
            <endDate>2022-02-25</endDate>
        </period>
    </context>
    <context id="ie8752374757e479e9f64772ff1f4f9d4_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i264013b24e074db8b98a0699c239c4f9_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i52e8d46fd29746e58d0e0bb604659f08_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i189dc1dfd5134a79a21430cb309a4d7a_D20220908-20220908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-08</startDate>
            <endDate>2022-09-08</endDate>
        </period>
    </context>
    <context id="i8d05e9eee4b64b31a25be9b446338707_D20220803-20220803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-03</startDate>
            <endDate>2022-08-03</endDate>
        </period>
    </context>
    <context id="ic9484214322149e8b56269486f6b1ee4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if90bc40ab2b74d9dbd7c8dc2378a4c5b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i382be9663b374e42986e34c6b0cdaf0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7795fae62ffe42149d98ac8e3ee9adbc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibabad0c6499641edbeeabb37b49f2923_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia5d912228ba649bfa2382a61c3174651_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i08706db8953040b6812a751e8ae1b7e5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idbe6768ff04b4640811983e177893ea9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idd1b9d5af30a49189ced97fd5f9e0133_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifd33995f144e48e6b6a85f69a49618b2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iececd00ead734bc7953b31ce1dccf7c9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i90991e5bbd4f4703b8dab237d26ea063_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i933f3aa296ae418cb60f3b9a2da33c77_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0b5fae63890c4e3292f6b182d8cf346f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7b9fd427a0844181b055f4681aa465eb_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9548198fbd6c4177a20e2e6fba7e0baf_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1f01a7222c3f477bb69c5b052545fbe3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifd86ccb60742427aa61efd89dc5c4569_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iecaa227f3a39471dbc0f18d223f8c464_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9808b39aaba54cfe9085c0980d313291_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amgn:AccumulatedOtherAdjustmentAttributabletoParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iff08a60f020c476cb26a704e747e026e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i156bec7df7e34d13b4f231715e12f0eb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id98e2a58d5f74741901a136b5593f566_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i22e704ef21944a4b8eb938e4ffb99c17_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idd26454e121845348d3b36a5d5d0b4be_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i47f60abf400d4a86a9f3744f80bddf28_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic7cce2fc95f840d0b58664ae7a9a19fa_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9e40834754cb4ae7a332ab8f335a1c40_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i03282f9364de4789b96025daf0d0ef74_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i74c469c59c124e739fad89b0a0b0f7c7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iae85a32427df4f04989f60eeef9b6bc4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i00193fbac18e466684ae5e311d84cef6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3d8850f784604d6b9bb2fd280095d18b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0fd9a5ddb9454b129635afe3c05a87b2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iee625aa2538245daa9d87d5a6f0f740d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i57af36ff3831468c82ff7231dc809b4d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i19fefe53694c4ef6b89048ac7afd4735_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i750f10007cf9428abc683565238431dc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i15ca62a1ecc1459f914da217c657d346_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6c3901a0af154ac48cb709ae944a36f3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i57e8da8b9b31484fa254b68594a6327e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if220d1f3f0f04912b6ba27cf16233cd1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if9fc102b18f140a29f8db148f3f14ac1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i38493d297caf42bf8a474b00e8ce8499_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5a9e16b4969645dc80f505eee050d8e6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i81f067b439ab417c9ce2795ab841e2d7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i46910804ec6546fe9f243b43a084cef9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i54880ede06014f8ca9a628fc84c50f6b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i91f42a5f589a46f1b73dde5f4b870252_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9182dc5218b74eb7a8e483c65d0897f3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i475adb709d5446f3a4125df7b276f9fc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1f0e7a2ada564f7eb301bda6685da54c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if67bff899732472c854d894bb8a6b451_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia55251a67abe461c8b2a09b5a3574ab5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4724b1086cb34ab18e734978bd980565_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9146fbc7ea114428b4ba02cee98c579f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6874786949604cdb824d234c3030e75b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ida17f2fa3cec491f86e599ca3185753d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9c488f99cfba482dbefc73db9e50c640_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i685a8a148b704128a60fc78026d3c3e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic144f91dd75648e08f88041119a4fa00_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f08e0fe42834efe92d00613a0109c40_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8095682c0ef94a339c9e762b31198d03_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9021916491244d8fa2e070974be57f65_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9240e5bb1cb44e2e876685572c682103_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a563d28d08546408272809d7d6f60af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i82eeb36d97d54dd1ab070623986e163d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iedac67f993dd44d1a1c0c76f6096b1f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9cb7f0273f314f8b830b51cffab82493_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if090df5bf17a41b3ac64e37545266583_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">amgn:OtherShortTermInterestBearingSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idcec0bd4ab8240e38c59d5eba500ac8f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95983e1a9dd248b6b5a91e82d2e18001_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i586c22e74161448191ba0b644c8f9eb0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5bcba3fb9ae4401d8255f9419a4e9c3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36abb6d1f7574e63a06ec93cd761c060_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06ded0f429164b4ab474c99ae4db6e67_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i14f51ae9652c4b4a9742afd91ac81e98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0fe78984bfd5425d996816c13821a305_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib54f0b981864432aa40974753a26ac20_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6d1947469e94aadb86219cbb136c914_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i565eb34bf7064ea880a5c569316793d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc87b99380f9465fa749f246800d3c48_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3107f183897d4d47b3ae8ba81bc93c54_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i821465fc68c64ed594b4983fbb106d7b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib38d2c2296ce4775b07ee5a0181057d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2680f1cd22d24318b9fcb7fe45f7425b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amgn:TeneobioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iefbf65ab82c24adaa0645594dc8fcaff_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8defa2bdb0084af3ae0cbfc5424bc98a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8362dfe3f447487fbcfb592560763e40_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i981e48d6e4474ce8b890550799a406fd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i08fbdbb43e0a42089b7e2cf59e5ef985_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8ae26a5ef2c2486bbe9a6346774e6921_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0d3a7502c66a4094ac60caad8191426e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id566b59cbf154fdeb60a87ca0ef35553_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i15d64ffdd06846b7844fc0773809a605_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic91a7bb478ff4fdcb59d644e21f41580_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i007735ddc25943c782bd306e4842d7e1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i218f08d9675e4f2a93d071febe505805_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i312524090a284ea3a18c66e1488acf48_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia79d481c2b0649f0ab76519c77d951cc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amgn:FourPercentPoundSterlingNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i68137429bba74ac28b0ecf3eb2d7ec4c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4d3fea5388d64fee80f159215bb2ffe9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i78bda1111d894ca79b9e9971a476802a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i805f5c4cbf16443d9484e17037e0cf71_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib8c48198203049e49f74000350f415ed_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id07132e210b94637823a00632d45e34d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i85524ff13c9e4c88a235e0f4342b1c43_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibcaf04737d1f428b931744a248c8be92_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0ecd36ab401a4e70a51c743fc9ccdc8d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i11dede7c485142b591bf4c1b589d93f5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie8017a33df2447cf98803b972ba03d31_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if0b85c703fd14ec3b991cc54cfc7ad38_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8ed4d99ca27b46dfb95dbfc0558df5cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8076cfa2bcaa4ab494d93e38c4c28e31_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i17d41c6ab5c14f9380e71043309fbdc8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">amgn:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idd05bb4763c34ecb8925e75416037ff8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">amgn:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic74bae73be3b45d29ba2975a44af1c97_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5ff1b52fa159466d99f80192dcb38c1b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i04f12d226beb4801941ee9ae41184a68_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i58b1f56bd6014a44b958229d8e11e34c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic08e134f84b54cd59491e20413185c0a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i05e8cec02f334b38bc7a7a5dbf123867_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i71fb031f34f648488a945f9c0e957284_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2d46d6b8233243ecac66f70b9060cbd1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic9a2634a12bd4b95b7c8f4f70a665670_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib097da5bd14d41edb20979d3673833c5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ife1360142edd4db88451ac7ac6cbba55_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i80f9a2035b3f4ef6803a4efbdaae94fe_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i60819ab810454638b5cda1c40c6fcbe0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4620a07bcdfd4700a32de4f28a35ac57_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie3f981e832314d97a18ace7194dec829_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i214b98a8995d4320b1feccd543454dfb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5f1f9fe211f40d8bb875fcebcc49a34_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibac2494da7b14b1cbcce6502366b8635_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibbe23a3b8f0d470c8d4a49d6ccea2fa7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6dd87d0fef6646d585035e3b89e9d2db_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i788c2b8522d14ae4b526f2caa3d298ba_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i19dc6da2ca134f33b03794a8e15bdc9a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iddf4e6ee507f42da9c63527f4cd46ce6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icf3a9c3404d34ff4ac73b544cd1e2f86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c607fed913b4d45844cc65fc1906d04_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e470b268fb34c43bee67b9119f09613_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0bf6cd1b2403422ba77e0a6dc045346f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amgn:CrossCurrencySwapContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4eae23293d40463888c07bd1f600a1aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:OtherCurrentNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i565b2e8ffb1b400bb11bbac9aa7a32a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05b40e8931544e10b858fc7bf3becffb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3468cc5757b34eb384cc512b95a07626_D20220527-20220527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2022-05-27</startDate>
            <endDate>2022-05-27</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>amgn:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="chf">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="financial_institution">
        <measure>amgn:financial_institution</measure>
    </unit>
    <unit id="argument">
        <measure>amgn:argument</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80L2ZyYWc6ZDBlMWU1MDc4MDliNDljZGE5OGUyNDYzYjc4ODUxNTgvdGFibGU6ZjE0YjFjMmZjYmZkNGUwODg4YTcwMDQ4Mzc0ZGJkZGMvdGFibGVyYW5nZTpmMTRiMWMyZmNiZmQ0ZTA4ODhhNzAwNDgzNzRkYmRkY18yLTEtMS0xLTEyNzQ1Mg_84d8671e-5db0-4949-8d4e-c8b2d670fb66">0000318154</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80L2ZyYWc6ZDBlMWU1MDc4MDliNDljZGE5OGUyNDYzYjc4ODUxNTgvdGFibGU6ZjE0YjFjMmZjYmZkNGUwODg4YTcwMDQ4Mzc0ZGJkZGMvdGFibGVyYW5nZTpmMTRiMWMyZmNiZmQ0ZTA4ODhhNzAwNDgzNzRkYmRkY18zLTEtMS0xLTEyNzQ1Mg_7cb4d4a3-9e7e-484e-99c8-284d6fee324a">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80L2ZyYWc6ZDBlMWU1MDc4MDliNDljZGE5OGUyNDYzYjc4ODUxNTgvdGFibGU6ZjE0YjFjMmZjYmZkNGUwODg4YTcwMDQ4Mzc0ZGJkZGMvdGFibGVyYW5nZTpmMTRiMWMyZmNiZmQ0ZTA4ODhhNzAwNDgzNzRkYmRkY181LTEtMS0xLTEyNzQ1Mg_ded5b398-f0bb-4110-a4ae-22bc4ac6b89e">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80L2ZyYWc6ZDBlMWU1MDc4MDliNDljZGE5OGUyNDYzYjc4ODUxNTgvdGFibGU6ZjE0YjFjMmZjYmZkNGUwODg4YTcwMDQ4Mzc0ZGJkZGMvdGFibGVyYW5nZTpmMTRiMWMyZmNiZmQ0ZTA4ODhhNzAwNDgzNzRkYmRkY182LTEtMS0xLTEyNzQ1Mg_6707c978-50dd-4bcd-aef4-08141bca261b">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80L2ZyYWc6ZDBlMWU1MDc4MDliNDljZGE5OGUyNDYzYjc4ODUxNTgvdGFibGU6ZjE0YjFjMmZjYmZkNGUwODg4YTcwMDQ4Mzc0ZGJkZGMvdGFibGVyYW5nZTpmMTRiMWMyZmNiZmQ0ZTA4ODhhNzAwNDgzNzRkYmRkY183LTEtMS0xLTEyNzQ1Mg_999bf045-e835-4c36-ae39-c8de69f8795b">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGV4dHJlZ2lvbjpmM2U3MWZmY2YyMWQ0YjU5YjI2NzBkYWFhMTQ3OWI5Ml8xODc0_65264df9-5190-4684-a30c-20c86335701f">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6MzdjNDFjMTQ0Njg1NDMwOWE3NTdmNWIxZjkyZWFlYmIvdGFibGVyYW5nZTozN2M0MWMxNDQ2ODU0MzA5YTc1N2Y1YjFmOTJlYWViYl8wLTAtMS0xLTEyNzQ1Mg_365ae59f-ae66-48f0-b190-fd721cc753ad">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGV4dHJlZ2lvbjpmM2U3MWZmY2YyMWQ0YjU5YjI2NzBkYWFhMTQ3OWI5Ml8xMzE_28fc9518-af29-4afc-8f90-9022ba1e2c14">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6ZWFkMTZmYzYzY2U1NDZiNjllNmQzYmUxMGY5OWIwM2UvdGFibGVyYW5nZTplYWQxNmZjNjNjZTU0NmI2OWU2ZDNiZTEwZjk5YjAzZV8wLTAtMS0xLTEyNzQ1Mg_bb617a9c-2bd7-4382-81c9-5d763641609f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGV4dHJlZ2lvbjpmM2U3MWZmY2YyMWQ0YjU5YjI2NzBkYWFhMTQ3OWI5Ml8xODc1_548bb324-a7ac-42af-9a23-56c314f06f59">001-37702</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGV4dHJlZ2lvbjpmM2U3MWZmY2YyMWQ0YjU5YjI2NzBkYWFhMTQ3OWI5Ml8xODY5_e0b9b112-d8c0-45a3-b825-e0375e2a262d">Amgen Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6ZGMwNGU0N2M0NWQ3NGIwYThmNjUzODY3OTFjYTA5NGQvdGFibGVyYW5nZTpkYzA0ZTQ3YzQ1ZDc0YjBhOGY2NTM4Njc5MWNhMDk0ZF8wLTAtMS0xLTEyNzQ1Mg_71f27e58-bf67-438e-ab06-a12e0d5b73d7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6ZGMwNGU0N2M0NWQ3NGIwYThmNjUzODY3OTFjYTA5NGQvdGFibGVyYW5nZTpkYzA0ZTQ3YzQ1ZDc0YjBhOGY2NTM4Njc5MWNhMDk0ZF8wLTItMS0xLTEyNzQ1Mg_fba2a36a-031b-4d36-b29c-d9efde3c7460">95-3540776</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6ZGMwNGU0N2M0NWQ3NGIwYThmNjUzODY3OTFjYTA5NGQvdGFibGVyYW5nZTpkYzA0ZTQ3YzQ1ZDc0YjBhOGY2NTM4Njc5MWNhMDk0ZF8zLTAtMS0xLTEyNzQ1Mg_42cc8572-dbfb-4004-ad97-8c9cc53f186e">One Amgen Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6ZGMwNGU0N2M0NWQ3NGIwYThmNjUzODY3OTFjYTA5NGQvdGFibGVyYW5nZTpkYzA0ZTQ3YzQ1ZDc0YjBhOGY2NTM4Njc5MWNhMDk0ZF8zLTItMS0xLTEyNzQ1Mg_8fe435e8-e388-4f6e-ad15-44369ab046ab">91320-1799</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6ZGMwNGU0N2M0NWQ3NGIwYThmNjUzODY3OTFjYTA5NGQvdGFibGVyYW5nZTpkYzA0ZTQ3YzQ1ZDc0YjBhOGY2NTM4Njc5MWNhMDk0ZF80LTAtMS0xLTEyNzQ1Mg_8ac92e90-7982-4668-87a4-b1481f226599">Thousand Oaks</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6ZGMwNGU0N2M0NWQ3NGIwYThmNjUzODY3OTFjYTA5NGQvdGFibGVyYW5nZTpkYzA0ZTQ3YzQ1ZDc0YjBhOGY2NTM4Njc5MWNhMDk0ZF81LTAtMS0xLTEyNzQ1Mg_71683f10-e34a-4b49-935d-633a5ee3556b">CA</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGV4dHJlZ2lvbjpmM2U3MWZmY2YyMWQ0YjU5YjI2NzBkYWFhMTQ3OWI5Ml8xODcw_bac79787-0382-4a3d-a9d1-f6b42cf90a73">805</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGV4dHJlZ2lvbjpmM2U3MWZmY2YyMWQ0YjU5YjI2NzBkYWFhMTQ3OWI5Ml8xODcx_dec5da73-0a69-42fa-bc85-f806762bdffe">447-1000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i68c22f15a4f2449f827d166633453d03_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6YzcwYmUzODZmMTA0NDNjZThmNWJmODAwNDFjZTNlNTYvdGFibGVyYW5nZTpjNzBiZTM4NmYxMDQ0M2NlOGY1YmY4MDA0MWNlM2U1Nl8xLTAtMS0xLTEyNzQ1Mg_d070c686-85e9-4ace-86cf-dcad9aa1e9ea">Common stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i68c22f15a4f2449f827d166633453d03_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6YzcwYmUzODZmMTA0NDNjZThmNWJmODAwNDFjZTNlNTYvdGFibGVyYW5nZTpjNzBiZTM4NmYxMDQ0M2NlOGY1YmY4MDA0MWNlM2U1Nl8xLTEtMS0xLTEyNzQ1Mg_143005a8-c673-44f2-948e-0a3277eb6853">AMGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i68c22f15a4f2449f827d166633453d03_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6YzcwYmUzODZmMTA0NDNjZThmNWJmODAwNDFjZTNlNTYvdGFibGVyYW5nZTpjNzBiZTM4NmYxMDQ0M2NlOGY1YmY4MDA0MWNlM2U1Nl8xLTItMS0xLTEyNzQ1Mg_1030c1ed-dba3-4226-9324-af224047cc13">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i33b94f8a0ce843a681a635dc7e7fa22e_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6YzcwYmUzODZmMTA0NDNjZThmNWJmODAwNDFjZTNlNTYvdGFibGVyYW5nZTpjNzBiZTM4NmYxMDQ0M2NlOGY1YmY4MDA0MWNlM2U1Nl8yLTAtMS0xLTEyNzQ1Mg_a271f646-719b-4f81-8d9c-7c2c67d2c904">2.00% Senior Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i33b94f8a0ce843a681a635dc7e7fa22e_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6YzcwYmUzODZmMTA0NDNjZThmNWJmODAwNDFjZTNlNTYvdGFibGVyYW5nZTpjNzBiZTM4NmYxMDQ0M2NlOGY1YmY4MDA0MWNlM2U1Nl8yLTEtMS0xLTEyNzQ1Mg_9e1b9b9b-6a32-4d8e-869c-66c00d17df63">AMGN26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i33b94f8a0ce843a681a635dc7e7fa22e_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6YzcwYmUzODZmMTA0NDNjZThmNWJmODAwNDFjZTNlNTYvdGFibGVyYW5nZTpjNzBiZTM4NmYxMDQ0M2NlOGY1YmY4MDA0MWNlM2U1Nl8yLTItMS0xLTEyNzQ1Mg_5a6e4834-7584-41a1-86b0-70386f9ab0e4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGV4dHJlZ2lvbjpmM2U3MWZmY2YyMWQ0YjU5YjI2NzBkYWFhMTQ3OWI5Ml8xODc2_34e99a4d-1d9c-48d8-80c9-72c493d349b8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGV4dHJlZ2lvbjpmM2U3MWZmY2YyMWQ0YjU5YjI2NzBkYWFhMTQ3OWI5Ml8xODcy_1598bf14-1c05-4561-9d8d-af826d57ee60">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6MGQ3ODU3ZGFjNGI3NDMxMmIwOWViYWQ3OTQyN2E1Y2QvdGFibGVyYW5nZTowZDc4NTdkYWM0Yjc0MzEyYjA5ZWJhZDc5NDI3YTVjZF8wLTAtMS0xLTEyNzQ1Mg_eaf5d86c-983a-442b-9a8d-ff197b9f8970">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6MGQ3ODU3ZGFjNGI3NDMxMmIwOWViYWQ3OTQyN2E1Y2QvdGFibGVyYW5nZTowZDc4NTdkYWM0Yjc0MzEyYjA5ZWJhZDc5NDI3YTVjZF8xLTEtMS0xLTEyNzQ1Mg_f1fe560b-444e-4895-a08a-7a3cb06cbd7e">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGFibGU6MGQ3ODU3ZGFjNGI3NDMxMmIwOWViYWQ3OTQyN2E1Y2QvdGFibGVyYW5nZTowZDc4NTdkYWM0Yjc0MzEyYjA5ZWJhZDc5NDI3YTVjZF8xLTMtMS0xLTEyNzQ1Mg_43a45c94-081b-403f-9a60-07c3f122e1d6">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGV4dHJlZ2lvbjpmM2U3MWZmY2YyMWQ0YjU5YjI2NzBkYWFhMTQ3OWI5Ml8xODcz_16879ede-20d1-48b8-b760-a93d914bbced">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i4cccb85585694ce49af0de31a566d7f3_I20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xL2ZyYWc6ZjNlNzFmZmNmMjFkNGI1OWIyNjcwZGFhYTE0NzliOTIvdGV4dHJlZ2lvbjpmM2U3MWZmY2YyMWQ0YjU5YjI2NzBkYWFhMTQ3OWI5Ml8xODEy_6aad1d35-688b-4c9d-b735-a60247adee2c"
      unitRef="shares">534930850</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3c410d6b2f84e53be5c076dec22d865_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMy0xLTEtMS0xMjc0NTI_98efb387-04ef-4729-a1c3-07bc08108a38"
      unitRef="usd">6281000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78d9e005bccc4060bd5addba903c2c2c_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMy0zLTEtMS0xMjc0NTI_277a94a6-1fc3-4231-9c03-7ed1aae99801"
      unitRef="usd">6114000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38c160a3f1834d5e9d775a1dea85e514_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMy01LTEtMS0xMjc0NTI_2b7895d9-3115-4e52-aca8-3bf5c06f6f46"
      unitRef="usd">12012000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93db18973157470084da5a577ecb7c40_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMy03LTEtMS0xMjc0NTI_9d933c45-ae49-4f60-a9a8-fb0f2099e382"
      unitRef="usd">11706000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71e71b4283ef4881a494fede3403b36c_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfNC0xLTEtMS0xMjc0NTI_8ec274aa-f1e2-4633-b0cc-d1749f3f8ea1"
      unitRef="usd">313000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i768868bd3bfe4a65a96efee550cef847_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfNC0zLTEtMS0xMjc0NTI_c9326106-8dd7-4110-9d63-2c0643f29be6"
      unitRef="usd">412000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43a801ced92f421e934618c8046f564b_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfNC01LTEtMS0xMjc0NTI_c4607a90-be65-47b6-904c-7eca4af12cea"
      unitRef="usd">820000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6bfeed5ecca54e718c3e7aefb7714ac5_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfNC03LTEtMS0xMjc0NTI_2edfd645-a07a-436b-979d-6e2dfabf7c04"
      unitRef="usd">721000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfNS0xLTEtMS0xMjc0NTI_b16b39aa-577f-4daa-abc6-d353b30eb2a4"
      unitRef="usd">6594000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfNS0zLTEtMS0xMjc0NTI_48219afd-faec-4ae6-a460-0d6c74e36385"
      unitRef="usd">6526000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfNS01LTEtMS0xMjc0NTI_42632cb5-f949-434c-a578-e623bd92ed3d"
      unitRef="usd">12832000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfNS03LTEtMS0xMjc0NTI_2bb1f981-ed65-4325-88e9-507edc22801f"
      unitRef="usd">12427000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfOC0xLTEtMS0xMjc0NTI_2ad45c8c-3a76-4907-a088-bcc6bfa54c39"
      unitRef="usd">1510000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfOC0zLTEtMS0xMjc0NTI_effc166a-4125-4b32-8221-09718a859d6b"
      unitRef="usd">1637000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfOC01LTEtMS0xMjc0NTI_dca94957-1cb3-4825-aea4-c262676081b4"
      unitRef="usd">3071000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfOC03LTEtMS0xMjc0NTI_0fddad2a-a882-4bf8-8c3a-0d69faa666d9"
      unitRef="usd">3127000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfOS0xLTEtMS0xMjc0NTI_16529007-cc7a-4188-87f6-629405df75b4"
      unitRef="usd">1039000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfOS0zLTEtMS0xMjc0NTI_e06ff0ee-c1d5-4cf4-be33-f241357a7a5c"
      unitRef="usd">1082000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfOS01LTEtMS0xMjc0NTI_c5e53584-be1c-4a60-82c7-7d31cc53f747"
      unitRef="usd">1998000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfOS03LTEtMS0xMjc0NTI_ccd7e0cc-23e3-4cc1-9595-357d8d5231fb"
      unitRef="usd">2049000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTAtMS0xLTEtMTI3NDUy_81df8c4b-da53-4bad-b868-be96ef4f775b"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTAtMy0xLTEtMTI3NDUy_1a6c607d-6b9d-45b9-800e-da292ab0f540"
      unitRef="usd">1505000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTAtNS0xLTEtMTI3NDUy_f70a66f8-ad5e-49d3-9c00-0b6686c899a2"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTAtNy0xLTEtMTI3NDUy_e0932dfe-6d2d-4056-a3d0-27f87d6b36bd"
      unitRef="usd">1505000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTEtMS0xLTEtMTI3NDUy_351ebcfd-4a89-456e-928d-939b8f170a0e"
      unitRef="usd">1327000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTEtMy0xLTEtMTI3NDUy_0cf80638-3085-4f87-bbb7-e021d8ddeade"
      unitRef="usd">1384000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTEtNS0xLTEtMTI3NDUy_6cb112da-5a05-41ae-bade-76f79507f7da"
      unitRef="usd">2555000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTEtNy0xLTEtMTI3NDUy_f36fe1b1-8af5-4d9a-ad9b-9c86ab2b08ef"
      unitRef="usd">2638000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <amgn:OtherGeneralExpenseIncomeOtherAdjustments
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTItMS0xLTEtMTI3NDUy_f0f26eb3-5cfe-4c5a-8437-7a5f4e2df5f3"
      unitRef="usd">542000000</amgn:OtherGeneralExpenseIncomeOtherAdjustments>
    <amgn:OtherGeneralExpenseIncomeOtherAdjustments
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTItMy0xLTEtMTI3NDUy_97093fff-d110-4e78-9916-36446f2c9fa5"
      unitRef="usd">90000000</amgn:OtherGeneralExpenseIncomeOtherAdjustments>
    <amgn:OtherGeneralExpenseIncomeOtherAdjustments
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTItNS0xLTEtMTI3NDUy_0a3bed7c-3b8b-494c-94bf-b444e83f2f8f"
      unitRef="usd">532000000</amgn:OtherGeneralExpenseIncomeOtherAdjustments>
    <amgn:OtherGeneralExpenseIncomeOtherAdjustments
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTItNy0xLTEtMTI3NDUy_27818426-5dda-45d8-aa5a-5cdd09a2792f"
      unitRef="usd">151000000</amgn:OtherGeneralExpenseIncomeOtherAdjustments>
    <us-gaap:CostsAndExpenses
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTMtMS0xLTEtMTI3NDUy_3b798ac7-ed45-4a6f-9ae8-4969b7d2064f"
      unitRef="usd">4418000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTMtMy0xLTEtMTI3NDUy_159b9a6a-3415-4e05-9159-3a949daa5142"
      unitRef="usd">5698000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTMtNS0xLTEtMTI3NDUy_af97711b-6961-41a5-a648-dbb389a0cf89"
      unitRef="usd">8156000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTMtNy0xLTEtMTI3NDUy_4ec231fc-e621-4907-89aa-02a861cba3df"
      unitRef="usd">9470000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTUtMS0xLTEtMTI3NDUy_4c0958fd-0ff2-479f-af24-0d41efe211d5"
      unitRef="usd">2176000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTUtMy0xLTEtMTI3NDUy_fa33458f-147d-4bb1-80dc-0451833b3459"
      unitRef="usd">828000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTUtNS0xLTEtMTI3NDUy_8ab32a19-e833-42a6-8c97-4c914791781f"
      unitRef="usd">4676000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTUtNy0xLTEtMTI3NDUy_6fbd5c48-36e7-4ca7-ae23-199a0b675754"
      unitRef="usd">2957000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseDebt
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTgtMS0xLTEtMTI3NDUy_370ef145-871a-473f-bb68-c69c2b4bb002"
      unitRef="usd">328000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTgtMy0xLTEtMTI3NDUy_59f9e2a1-9fbc-40ed-8bfc-c6371c615ce1"
      unitRef="usd">281000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTgtNS0xLTEtMTI3NDUy_f4c9b540-2312-4165-a189-9ef5cb00535c"
      unitRef="usd">623000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTgtNy0xLTEtMTI3NDUy_f4767d5d-688a-4027-9850-b85d21d5edf3"
      unitRef="usd">566000000</us-gaap:InterestExpenseDebt>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTktMS0xLTEtMTI3NDUy_ae9c9671-aaba-4635-a022-28135a680f5e"
      unitRef="usd">-317000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTktMy0xLTEtMTI3NDUy_70bc1e7f-0cfe-4fe8-b3e3-5ff994aa7f48"
      unitRef="usd">11000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTktNS0xLTEtMTI3NDUy_bd5a938f-8f70-4c8b-a1f3-48d0b7f2506e"
      unitRef="usd">-847000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMTktNy0xLTEtMTI3NDUy_0644a077-eff2-46eb-a967-4ebb22c32384"
      unitRef="usd">24000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjEtMS0xLTEtMTI3NDUy_8ab80e89-f22d-4a9a-9cdb-4b089c6cfbb8"
      unitRef="usd">1531000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjEtMy0xLTEtMTI3NDUy_c27b88b0-81d3-4921-9b1a-d964d563d9c0"
      unitRef="usd">558000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjEtNS0xLTEtMTI3NDUy_f3e15de9-8828-4e57-9a83-6d76cde58171"
      unitRef="usd">3206000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjEtNy0xLTEtMTI3NDUy_089eb8f8-d4f1-41e9-8d23-b8f8dac0a1cb"
      unitRef="usd">2415000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjMtMS0xLTEtMTI3NDUy_f7dab70f-cfa1-4bdb-b3e0-4188ad7be269"
      unitRef="usd">214000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjMtMy0xLTEtMTI3NDUy_58f52ee1-aeeb-411b-af5e-17ec8802bf6b"
      unitRef="usd">94000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjMtNS0xLTEtMTI3NDUy_d581e9bc-8f49-4c80-8973-b7dcca2d6b50"
      unitRef="usd">413000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjMtNy0xLTEtMTI3NDUy_ebf24536-5812-4cdb-adf4-338b6a452c18"
      unitRef="usd">305000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjUtMS0xLTEtMTI3NDUy_eed72fdd-fa49-4f6b-8634-c30f9b86eec5"
      unitRef="usd">1317000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjUtMy0xLTEtMTI3NDUy_7705fe85-60a5-4897-9e40-138363e3aae4"
      unitRef="usd">464000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjUtNS0xLTEtMTI3NDUy_e5e578c6-7f14-481f-8a08-fbaf41b57de6"
      unitRef="usd">2793000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjUtNy0xLTEtMTI3NDUy_706a3cf2-5c97-4e9f-b4f2-011745b75d78"
      unitRef="usd">2110000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjgtMS0xLTEtMTI3NDUy_19af39e8-f63b-4a54-ba22-57c5a086da9c"
      unitRef="usdPerShare">2.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjgtMy0xLTEtMTI3NDUy_f759bc9e-3472-442b-9bfe-daf8d0db779b"
      unitRef="usdPerShare">0.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjgtNS0xLTEtMTI3NDUy_05a7d363-c342-4348-b36a-974c86c89cdf"
      unitRef="usdPerShare">5.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjgtNy0xLTEtMTI3NDUy_9c24efa2-7409-4318-a2a2-e0c765df5cea"
      unitRef="usdPerShare">3.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjktMS0xLTEtMTI3NDUy_bf4dc8ea-3174-4e71-bfb3-4e2ee44793ad"
      unitRef="usdPerShare">2.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjktMy0xLTEtMTI3NDUy_b58d0705-53b8-49dd-a955-bca176b1f2cc"
      unitRef="usdPerShare">0.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjktNS0xLTEtMTI3NDUy_d3ac1ab1-fca7-48fd-bcc4-278dd55bdaee"
      unitRef="usdPerShare">5.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMjktNy0xLTEtMTI3NDUy_4eb6c7b2-aaf6-4b81-8174-dbca2138e740"
      unitRef="usdPerShare">3.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMzItMS0xLTEtMTI3NDUy_7dfd1b00-21da-4e05-957b-87663292194e"
      unitRef="shares">535000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMzItMy0xLTEtMTI3NDUy_5af9f16d-c0a2-499f-be31-490f7ddc7046"
      unitRef="shares">573000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMzItNS0xLTEtMTI3NDUy_faeaed5d-a971-4fd5-9be5-4081239cd867"
      unitRef="shares">541000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMzItNy0xLTEtMTI3NDUy_c3f14bf2-3f68-486f-b1c9-cb53ab19c34e"
      unitRef="shares">575000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMzMtMS0xLTEtMTI3NDUy_af9e7b0d-a61c-4302-ba8d-ff111ce9e38a"
      unitRef="shares">537000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMzMtMy0xLTEtMTI3NDUy_ec288214-d128-4333-bce6-5c6282bb3024"
      unitRef="shares">576000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMzMtNS0xLTEtMTI3NDUy_3ac2b002-586f-4680-86a2-2d3273878f71"
      unitRef="shares">544000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8xOS9mcmFnOjY5ZDk0ODQ1ZTZiZTQ5NDViNWIzM2YwNWU2YzgyMzQzL3RhYmxlOjkzNDQ4ZTQyNThjNTQ1Mjc5ZjIwNjM2NmJkNDM3MGJjL3RhYmxlcmFuZ2U6OTM0NDhlNDI1OGM1NDUyNzlmMjA2MzY2YmQ0MzcwYmNfMzMtNy0xLTEtMTI3NDUy_09aef0fe-052d-4565-ae09-297b91c266f3"
      unitRef="shares">578000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfMi0xLTEtMS0xMjc0NTI_7cffa87f-2b82-45e6-bc2e-f70198802ac5"
      unitRef="usd">1317000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfMi0zLTEtMS0xMjc0NTI_c0b1b612-8fae-4c72-af79-c267865b9de9"
      unitRef="usd">464000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfMi01LTEtMS0xMjc0NTI_629c2393-37bd-4591-b56d-f62fc5b4a218"
      unitRef="usd">2793000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfMi03LTEtMS0xMjc0NTI_626ba5ea-6066-408a-8dfe-68063acf0ab1"
      unitRef="usd">2110000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNC0xLTEtMS0xMjc0NTI_fc822e82-046a-4c98-a30b-32c75fae150d"
      unitRef="usd">-65000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNC0zLTEtMS0xMjc0NTI_0665f817-3836-4cee-9f29-7b77e3ff76c2"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNC01LTEtMS0xMjc0NTI_811ff15b-a01b-42b6-99fd-e94b1ba1751a"
      unitRef="usd">-116000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNC03LTEtMS0xMjc0NTI_3050cc2e-ad90-45ad-8bcc-62f6f82ebb61"
      unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNS0xLTEtMS0xMjc0NTI_8b162bfa-664b-49d2-80e0-400d9c24bdc4"
      unitRef="usd">156000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNS0zLTEtMS0xMjc0NTI_510d7ad5-e127-4b2b-9ec4-de6fc8664b6a"
      unitRef="usd">-48000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNS01LTEtMS0xMjc0NTI_9e370018-d03d-4e93-a108-d2a1ff104796"
      unitRef="usd">240000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNS03LTEtMS0xMjc0NTI_ec26bd93-00f7-4e58-a1e3-87f5fc0ea247"
      unitRef="usd">142000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNy0xLTEtMS0xMjc0NTI_ab3b9428-c86e-4650-a915-5c5d60fd9e9c"
      unitRef="usd">0</amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNy0zLTEtMS0xMjc0NTI_e54340a1-e2b6-4737-b8d1-83d0de129f00"
      unitRef="usd">-1000000</amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNy01LTEtMS0xMjc0NTI_63289549-fd48-45b4-9f0b-d28c3f2d6287"
      unitRef="usd">0</amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent>
    <amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfNy03LTEtMS0xMjc0NTI_b6de968c-6f4b-4034-a192-d0a7f3931a40"
      unitRef="usd">0</amgn:OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfOC0xLTEtMS0xMjc0NTI_6ff93743-5ed6-4766-88d2-a5f0d7773959"
      unitRef="usd">91000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfOC0zLTEtMS0xMjc0NTI_22f48b1c-a4fc-4374-8c51-fd147d6a7e6d"
      unitRef="usd">-35000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfOC01LTEtMS0xMjc0NTI_e32a9905-2ae2-4745-b983-9d0fca285f9d"
      unitRef="usd">124000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfOC03LTEtMS0xMjc0NTI_b9aa64d1-0284-4b11-b391-3b6f3962ae2c"
      unitRef="usd">117000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfOS0xLTEtMS0xMjc0NTI_4ad31b9b-4757-4a61-b2d2-046e2dedf8d6"
      unitRef="usd">1408000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfOS0zLTEtMS0xMjc0NTI_e4b63295-9f1f-44fe-96a2-fab5893ee433"
      unitRef="usd">429000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfOS01LTEtMS0xMjc0NTI_3e55a7d2-705e-4293-8450-ea5fc77c009c"
      unitRef="usd">2917000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yMi9mcmFnOmE3YzViNDNlM2MzOTQ1Yzk4ZDA3ZjM3YTY3NWNmYzI1L3RhYmxlOmYyOTQ1MTY0MWU5NzQyNzY4NmRlYzk5YjM0MjY5M2M3L3RhYmxlcmFuZ2U6ZjI5NDUxNjQxZTk3NDI3Njg2ZGVjOTliMzQyNjkzYzdfOS03LTEtMS0xMjc0NTI_57eea8ae-1b7f-499f-9c3d-51949cd12ce2"
      unitRef="usd">2227000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfNC0xLTEtMS0xMjc0NTI_444fabd4-fc76-4f79-8c21-120d30b723a6"
      unitRef="usd">5203000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfNC0zLTEtMS0xMjc0NTI_69f8301e-90be-495b-986d-9895bca18f1a"
      unitRef="usd">7989000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfNS0xLTEtMS0xMjc0NTI_c0d4016e-5241-4a41-86af-3ef9600c8c9a"
      unitRef="usd">1980000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfNS0zLTEtMS0xMjc0NTI_6c629c4c-5804-4d0f-8440-368e623d2446"
      unitRef="usd">48000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfNi0xLTEtMS0xMjc0NTI_71e9fee8-dac7-4515-b414-dd65314c6e2c"
      unitRef="usd">5327000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfNi0zLTEtMS0xMjc0NTI_4315544c-92df-4999-8550-ed53e4fa8528"
      unitRef="usd">4895000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfNy0xLTEtMS0xMjc0NTI_c907aaea-edda-4c8e-8b89-bc9ef519a2a9"
      unitRef="usd">4554000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfNy0zLTEtMS0xMjc0NTI_4924663a-1677-4776-a630-c6e73756232f"
      unitRef="usd">4086000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfOC0xLTEtMS0xMjc0NTI_4dda1006-4a2e-42c0-9454-a7c660e28095"
      unitRef="usd">2258000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfOC0zLTEtMS0xMjc0NTI_57bf1d0f-b6d2-4240-b1df-c31d9e46fcb6"
      unitRef="usd">2367000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfOS0xLTEtMS0xMjc0NTI_1a0d0dd4-6849-45f0-aac0-27dfe6317667"
      unitRef="usd">19322000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfOS0zLTEtMS0xMjc0NTI_528c96c1-07a4-430e-8a52-05aec032451b"
      unitRef="usd">19385000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTEtMS0xLTEtMTI3NDUy_5d2213b3-04d5-476c-b664-62a708eda5be"
      unitRef="usd">5158000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTEtMy0xLTEtMTI3NDUy_2a11bbc2-2ac9-428c-9e02-0de5f489bb99"
      unitRef="usd">5184000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTItMS0xLTEtMTI3NDUy_bbe8b7bd-6616-465b-a296-25d51540e9c1"
      unitRef="usd">13927000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTItMy0xLTEtMTI3NDUy_686e098a-4093-4b72-90e4-35d1a23cbba7"
      unitRef="usd">15182000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTMtMS0xLTEtMTI3NDUy_f7b1aa3d-2e1b-4184-a5c0-b9ecccc859f9"
      unitRef="usd">14865000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTMtMy0xLTEtMTI3NDUy_6a0c1239-7b22-4881-b2d2-4e0f3a2ed210"
      unitRef="usd">14890000000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTQtMS0xLTEtMTI3NDUy_01c1887d-889a-49d0-8162-8e5ba0b8f08d"
      unitRef="usd">6022000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTQtMy0xLTEtMTI3NDUy_01a5ca52-2446-4895-a701-d2b3ea37b8af"
      unitRef="usd">6524000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTUtMS0xLTEtMTI3NDUy_7845efd1-b67b-4b44-9535-256738c1017e"
      unitRef="usd">59294000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTUtMy0xLTEtMTI3NDUy_335f11a0-2ccd-4189-8066-930fba4cf8be"
      unitRef="usd">61165000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTktMS0xLTEtMTI3NDUy_038e3e28-1e77-4abe-84c9-ea2e13c6779d"
      unitRef="usd">1256000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMTktMy0xLTEtMTI3NDUy_f3c9e786-24c8-4ca5-b1fe-822981902558"
      unitRef="usd">1366000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjAtMS0xLTEtMTI3NDUy_60b1c2da-689f-440e-8eff-2cf865bf005e"
      unitRef="usd">10545000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjAtMy0xLTEtMTI3NDUy_32bd112a-7472-4b8e-8d0d-fc02a0a76625"
      unitRef="usd">10731000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjEtMS0xLTEtMTI3NDUy_58968aaa-11d4-4c60-ad41-75ec55d26fda"
      unitRef="usd">817000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjEtMy0xLTEtMTI3NDUy_2d47bed5-ffdf-45ca-ad70-dae39060b283"
      unitRef="usd">87000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjItMS0xLTEtMTI3NDUy_b9d151ab-578f-41ca-8beb-5e0aee08371c"
      unitRef="usd">12618000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjItMy0xLTEtMTI3NDUy_c529fa6f-f865-43c7-8e05-263f6ed4c4cd"
      unitRef="usd">12184000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjQtMS0xLTEtMTI3NDUy_3d2cf386-8598-41fa-bf0d-8f946a3b07e5"
      unitRef="usd">35705000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjQtMy0xLTEtMTI3NDUy_679d2ab2-5273-47bb-a461-1648aed10f76"
      unitRef="usd">33222000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjUtMS0xLTEtMTI3NDUy_ea15d1ef-1823-43b4-8e83-66b46e3ccd5f"
      unitRef="usd">5603000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjUtMy0xLTEtMTI3NDUy_5aa3ae72-4417-4416-88e5-487a552678dc"
      unitRef="usd">6594000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjYtMS0xLTEtMTI3NDUy_0e2b092e-af48-4859-bc59-8b883459bc54"
      unitRef="usd">2949000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjYtMy0xLTEtMTI3NDUy_b3cc6dc3-8287-412f-a090-b35ba74fb54f"
      unitRef="usd">2465000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjgtMS0xLTEtMTI3NDUy_ef96204b-1f43-42f9-8436-0ba0a19a913a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMjgtMy0xLTEtMTI3NDUy_0936be25-2ca2-42ae-9cc1-d7c8238e1dc4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzEtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZTgyZGZjMzRiZjdkNDIyZjliMzE0YTBiNTQ2ZTQ0MGFfNDk_1179f78a-e566-493e-bb13-16d0d2c83305"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzEtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZTgyZGZjMzRiZjdkNDIyZjliMzE0YTBiNTQ2ZTQ0MGFfNDk_8c54805f-7110-4941-a70f-24508309fb03"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzEtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZTgyZGZjMzRiZjdkNDIyZjliMzE0YTBiNTQ2ZTQ0MGFfNjM_08dcdff6-1983-4b68-8057-3e36b148ed85"
      unitRef="shares">2750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzEtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZTgyZGZjMzRiZjdkNDIyZjliMzE0YTBiNTQ2ZTQ0MGFfNjM_239e9515-bfb7-4afd-968a-d91717ca51bb"
      unitRef="shares">2750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzEtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZTgyZGZjMzRiZjdkNDIyZjliMzE0YTBiNTQ2ZTQ0MGFfOTc_937917b9-9e00-4b50-bd85-c97fe1bc0f8a"
      unitRef="shares">534900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzEtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZTgyZGZjMzRiZjdkNDIyZjliMzE0YTBiNTQ2ZTQ0MGFfMTE3_d54d4b36-2eba-4751-9779-0a99ded23e3b"
      unitRef="shares">558300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStocksIncludingAdditionalPaidInCapital
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzEtMS0xLTEtMTI3NDUy_addd95e6-bd1e-4854-811d-f173dfacbf5c"
      unitRef="usd">31343000000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
    <us-gaap:CommonStocksIncludingAdditionalPaidInCapital
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzEtMy0xLTEtMTI3NDUy_e4a42bc9-8b7d-4ffb-90a4-78bf4aa18ac7"
      unitRef="usd">32096000000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzItMS0xLTEtMTI3NDUy_785ce116-a1c3-4bad-9517-b516c021a51e"
      unitRef="usd">-28252000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzItMy0xLTEtMTI3NDUy_77445216-a6fa-4dd4-8f2f-cc11317c2efb"
      unitRef="usd">-24600000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzMtMS0xLTEtMTI3NDUy_5dcdaacb-d7bd-4f80-b4bb-00003075f2a0"
      unitRef="usd">-672000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzMtMy0xLTEtMTI3NDUy_0f5a33e2-3a46-4e8c-a256-c6c163de2e96"
      unitRef="usd">-796000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzQtMS0xLTEtMTI3NDUy_0396b42b-a866-4e66-9944-002eaf6bc75d"
      unitRef="usd">2419000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzQtMy0xLTEtMTI3NDUy_6da657fc-9b2d-403e-83fa-40fe1ec3cd8f"
      unitRef="usd">6700000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzUtMS0xLTEtMTI3NDUy_281aca3b-2e09-4910-a081-3e4cbfd099ef"
      unitRef="usd">59294000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yNS9mcmFnOjFkOWIyMTEzN2E3MDRlOGU4YTdmNDc0N2QyZDY5ZDNkL3RhYmxlOmJlZjA0YWYwMTRmMjRhYmZhYTFjNWU2MDUwOWUyMzIyL3RhYmxlcmFuZ2U6YmVmMDRhZjAxNGYyNGFiZmFhMWM1ZTYwNTA5ZTIzMjJfMzUtMy0xLTEtMTI3NDUy_5f9a880b-b17d-46f1-844e-8a3ed78af465"
      unitRef="usd">61165000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9ab9a3aeb1dc401e8f8036824d7fc7ec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMS0xLTEtMS0xMjc0NTI_ca8d810f-c64f-4d0a-aac7-d0ed22f4c11f"
      unitRef="shares">558300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie57786644af74fb49b8f5e29302dab93_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMS0zLTEtMS0xMjc0NTI_cc141bb2-9992-4224-93b5-603b42dc569f"
      unitRef="usd">32096000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id600cdce916f4b66a8dcd23e38e899e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMS01LTEtMS0xMjc0NTI_38b1d731-ca07-4c80-b9ac-79e02d769dff"
      unitRef="usd">-24600000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4015add6967846b88c70abf91e4bfcd3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMS03LTEtMS0xMjc0NTI_dc29c20c-20e7-4079-8cca-5075767d4227"
      unitRef="usd">-796000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMS05LTEtMS0xMjc0NTI_f52649b1-56d3-4832-a710-3cf98eadb34e"
      unitRef="usd">6700000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i4bdfa7c23e874b22a1a66bebad22d916_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMy01LTEtMS0xMjc0NTI_5e44f545-13bd-4c88-93cf-9d9a2c184984"
      unitRef="usd">1476000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMy05LTEtMS0xMjc0NTI_7d1a5091-69d5-48f3-9c71-b16e120bc15f"
      unitRef="usd">1476000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if6bebabfe867463fb2ce8c41e89ce28a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfNC03LTEtMS0xMjc0NTI_c0009812-7249-4cd1-a539-072705017800"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfNC05LTEtMS0xMjc0NTI_c69aae70-5c52-4e7f-b3e9-10540154984a"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfNS0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjplNWYyZDI5ZTYyZmI0NzM0OWVkNmY4YzRiYmY0NmMyMl80MA_2d0b1579-f392-4494-83b7-bfceada9bf00"
      unitRef="usdPerShare">1.94</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i4bdfa7c23e874b22a1a66bebad22d916_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfNS01LTEtMS0xMjc0NTI_167685bf-0a5a-473f-a775-ca9d902a89ef"
      unitRef="usd">1034000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfNS05LTEtMS0xMjc0NTI_6e168e3f-d80a-43b3-8f16-72e3ce3e0557"
      unitRef="usd">1034000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i727569817ab94b17a5a44e5e6554f39c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfNi0xLTEtMS0xMjc0NTI_eea95bb5-6156-47b6-9469-74e604971fe4"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib84a6f83e673473a8ba69ec165a6aa32_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfNi0zLTEtMS0xMjc0NTI_0072a3c3-864a-4563-920d-48690a4ba0cc"
      unitRef="usd">18000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfNi05LTEtMS0xMjc0NTI_51644693-5230-48d0-b696-b98284b96776"
      unitRef="usd">18000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib84a6f83e673473a8ba69ec165a6aa32_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfNy0zLTEtMS0xMjc0NTI_e82b324c-9eb7-43a9-b2e5-6b56e9a6314e"
      unitRef="usd">78000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfNy05LTEtMS0xMjc0NTI_e475f886-f435-423b-bfb1-b08deb3717cc"
      unitRef="usd">78000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib84a6f83e673473a8ba69ec165a6aa32_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfOC0zLTEtMS0xMjc0NTI_9b42f4c7-e534-4d7f-9e01-68f8708df597"
      unitRef="usd">45000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfOC05LTEtMS0xMjc0NTI_87509713-75f9-413b-b8b5-bf6b11272238"
      unitRef="usd">45000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i727569817ab94b17a5a44e5e6554f39c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfOS0xLTEtMS0xMjc0NTI_4085422f-f112-4588-ae0d-65cc0846ac31"
      unitRef="shares">24600000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ib84a6f83e673473a8ba69ec165a6aa32_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfOS0zLTEtMS0xMjc0NTI_50f69e5e-1fc9-44db-a6bf-470f2765cc8c"
      unitRef="usd">900000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i4bdfa7c23e874b22a1a66bebad22d916_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfOS01LTEtMS0xMjc0NTI_9b53439d-925b-41ff-a6fa-349846072f93"
      unitRef="usd">5410000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfOS05LTEtMS0xMjc0NTI_f9e8d8f9-b78f-4238-8444-d9f459c1a202"
      unitRef="usd">6310000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1743609e3cdb4aee821e866d6c0b7a5b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTAtMS0xLTEtMTI3NDUy_e1458fa0-a70e-4dbb-82ec-d82edf049bbc"
      unitRef="shares">534200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia449403700e84ad390099f266af55696_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTAtMy0xLTEtMTI3NDUy_2dc91e6e-9b78-4c60-bb48-ba64e90e639c"
      unitRef="usd">31247000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib52f0a890ada46f0aaeaa5f7a392c87f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTAtNS0xLTEtMTI3NDUy_b7ff808f-f0c3-4ec6-b757-76607f6b2c92"
      unitRef="usd">-29568000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3453133454bb4b68987a91d14ea8ccda_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTAtNy0xLTEtMTI3NDUy_73555a5e-938c-4683-ba32-47fd272cc8ce"
      unitRef="usd">-763000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8de403afe8684433ba669a9d329718c4_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTAtOS0xLTEtMTI3NDUy_637c8cd1-6253-49ba-af90-d1802fbf0aad"
      unitRef="usd">916000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i9c56073392354d1aa5fe73191ec6a1cd_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTItNS0xLTEtMTI3NDUy_15c7800c-1dde-4be6-aaca-b05208aa283b"
      unitRef="usd">1317000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTItOS0xLTEtMTI3NDUy_02976f69-b76f-4ade-b85a-1c4db4101873"
      unitRef="usd">1317000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i950254b1c906440baad1c3cb0d696509_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTMtNy0xLTEtMTI3NDUy_56b134b9-758e-43d5-b8d8-7c3c41fe345f"
      unitRef="usd">91000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTMtOS0xLTEtMTI3NDUy_a77c9249-fcdb-4c22-8820-6cacbf6c8fec"
      unitRef="usd">91000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib013f6621b494621aa9fdc2ca2c9a16a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTQtMS0xLTEtMTI3NDUy_7a926c65-74a5-400b-ae05-a7d12cab2306"
      unitRef="shares">700000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i437ad630ad5c4d0db3b941130901471f_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTQtMy0xLTEtMTI3NDUy_0f92cb6b-16f5-4cba-884e-06e7d363cebc"
      unitRef="usd">45000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTQtOS0xLTEtMTI3NDUy_5b4dbf1b-6bdd-48a6-b231-5ca006a1f108"
      unitRef="usd">45000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i437ad630ad5c4d0db3b941130901471f_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTUtMy0xLTEtMTI3NDUy_f1062324-f191-47e0-84e2-d5df31339d0a"
      unitRef="usd">120000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTUtOS0xLTEtMTI3NDUy_8ac70314-e917-4054-a994-3bac7b005399"
      unitRef="usd">120000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i437ad630ad5c4d0db3b941130901471f_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTYtMy0xLTEtMTI3NDUy_70413ada-d0b2-4197-8629-246a6a1bc4e9"
      unitRef="usd">69000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTYtOS0xLTEtMTI3NDUy_9fbc18f8-246a-4856-acee-a1ade38d8cab"
      unitRef="usd">69000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockholdersEquityOther
      contextRef="i9c56073392354d1aa5fe73191ec6a1cd_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTgtNS0xLTEtMTI3NDUy_c69f909b-7f26-44ad-86a1-f92e3e2344dd"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTgtOS0xLTEtMTI3NDUy_05a01d80-397e-490c-bafa-f0218e061c09"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i69e8f109a2db495c82bf5845b27d710b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTktMS0xLTEtMTI3NDUy_fa226af8-98b0-4f0b-93c7-34cd3a14f57e"
      unitRef="shares">534900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iaa04a5eecd554471bd742d77f0241ab8_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTktMy0xLTEtMTI3NDUy_38cc8bf9-a855-4fc3-bcf2-b47a638daa85"
      unitRef="usd">31343000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3e8fdc8e1afb4a8b8179c89009d5c1aa_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTktNS0xLTEtMTI3NDUy_dfd63f28-2c9d-4cb7-9eb2-6f1131c8bab0"
      unitRef="usd">-28252000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iedbaa8596a604e708e0f5d708642088d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTktNy0xLTEtMTI3NDUy_05430d6e-1034-4283-a5ec-8f87da7ddce4"
      unitRef="usd">-672000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjNjYWQ0MDhjNzBlODQzZTBiM2NiZjI5NmFiOGU4ZjM3L3RhYmxlcmFuZ2U6M2NhZDQwOGM3MGU4NDNlMGIzY2JmMjk2YWI4ZThmMzdfMTktOS0xLTEtMTI3NDUy_70e34e26-b3cf-4256-ae78-7b6868a3621c"
      unitRef="usd">2419000000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i87a50000054d41c4b6c8d975b42b1648_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMS0xLTEtMS0xMjc0NTI_19ff1352-2bd3-4f4e-a04f-635864e50bcc"
      unitRef="shares">578300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8e3e8fc000224eaa8d179f838cb7031a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMS0zLTEtMS0xMjc0NTI_0e6c8421-4f77-4e2d-b4f9-535b7da2427e"
      unitRef="usd">31802000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i37f513ac48e244eebc3ecfd6dbf5e0a0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMS01LTEtMS0xMjc0NTI_783acee0-a9cb-4357-9aba-0c85154c2548"
      unitRef="usd">-21408000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2639d3c097ee4df19d9460b38ce3c560_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMS03LTEtMS0xMjc0NTI_f60e0f71-a67c-421c-af03-35e4716af305"
      unitRef="usd">-985000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1e5bfcd24a084d2ba4ae4e9fd63a2a81_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMS05LTEtMS0xMjc0NTI_658c3c97-c109-4fd3-b64b-f462cbf71f02"
      unitRef="usd">9409000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ifaa3e87d3e094c2c82065bdcc86a2d5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMy01LTEtMS0xMjc0NTI_96015f44-e570-4b79-b9ce-2b40c2c56e61"
      unitRef="usd">1646000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i230f8b81d2ba4f069528c27808330841_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMy05LTEtMS0xMjc0NTI_77ea3087-ba27-4546-97c9-da2f78dbad0c"
      unitRef="usd">1646000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1f42e7ad02b549569ea5beaa0e813a56_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfNC03LTEtMS0xMjc0NTI_2020888a-ff34-4ba3-a5c1-e7fe009e1de0"
      unitRef="usd">152000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i230f8b81d2ba4f069528c27808330841_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfNC05LTEtMS0xMjc0NTI_005ceab4-978c-4f33-acdf-245ac2f1f088"
      unitRef="usd">152000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i230f8b81d2ba4f069528c27808330841_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfNS0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjpjYzkxNjRkZGJmMDg0N2Q2ODMzOTg5NTdkODA5ODY0YV80MQ_1ab6070a-6e7b-493e-ad58-b54298d7e1f4"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ifaa3e87d3e094c2c82065bdcc86a2d5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfNS01LTEtMS0xMjc0NTI_f37906e1-2611-48e3-bff3-f71093c62f1d"
      unitRef="usd">1012000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i230f8b81d2ba4f069528c27808330841_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfNS05LTEtMS0xMjc0NTI_470eb2ef-3e9d-470a-93df-173be42b93e3"
      unitRef="usd">1012000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2ff28f2746c54bdaaf782c67ac1f4302_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfNi0xLTEtMS0xMjc0NTI_b484d178-13b2-4f7b-93d3-a350f182e38e"
      unitRef="shares">700000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib96efcc5351148e2b1ec0411f0edc1ba_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfNi0zLTEtMS0xMjc0NTI_542950ac-2fb8-49ba-83a9-55f4aaefe501"
      unitRef="usd">6000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i230f8b81d2ba4f069528c27808330841_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfNi05LTEtMS0xMjc0NTI_d534c392-2826-455b-b1e1-1782eeda8ed7"
      unitRef="usd">6000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib96efcc5351148e2b1ec0411f0edc1ba_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfNy0zLTEtMS0xMjc0NTI_0ce1e85e-dc15-4499-a597-baa3ba110835"
      unitRef="usd">57000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i230f8b81d2ba4f069528c27808330841_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfNy05LTEtMS0xMjc0NTI_9bf4ec7c-f4b3-42d3-a625-4f6a8b9cf513"
      unitRef="usd">57000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib96efcc5351148e2b1ec0411f0edc1ba_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfOC0zLTEtMS0xMjc0NTI_2f2bfbe1-57a2-42b4-91e3-f15dbc399726"
      unitRef="usd">59000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i230f8b81d2ba4f069528c27808330841_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfOC05LTEtMS0xMjc0NTI_4d0deef2-28ac-40b6-9007-80222207ba9d"
      unitRef="usd">59000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i2ff28f2746c54bdaaf782c67ac1f4302_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfOS0xLTEtMS0xMjc0NTI_381b8623-acdc-48bf-8dbf-f905ab027ab5"
      unitRef="shares">3700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ifaa3e87d3e094c2c82065bdcc86a2d5e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfOS01LTEtMS0xMjc0NTI_19b36ef5-1332-4331-a9e2-9d5192eff93b"
      unitRef="usd">865000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i230f8b81d2ba4f069528c27808330841_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfOS05LTEtMS0xMjc0NTI_94634e65-9e39-49d8-b27e-e2e99fbba96c"
      unitRef="usd">865000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iac25314d738441bd880294e17a40ea59_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTAtMS0xLTEtMTI3NDUy_ab23d296-91b6-4eef-9533-7111f963308f"
      unitRef="shares">575300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id1a08827c17347a29bf672041a9ba9ab_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTAtMy0xLTEtMTI3NDUy_d78c3882-d197-4c04-86cd-a9ccd8ce613a"
      unitRef="usd">31806000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i34f2d24ef5604859814eae53b155dccc_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTAtNS0xLTEtMTI3NDUy_0a9128c1-aef3-4373-9b65-4c3ac5b23091"
      unitRef="usd">-21639000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i07da672f055a4104b16e0910367ec926_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTAtNy0xLTEtMTI3NDUy_f1ebc290-3562-4639-a1ec-6a0f1e2dc5c5"
      unitRef="usd">-833000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1a2ab422b4b24a8fba8a2d881b98b260_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTAtOS0xLTEtMTI3NDUy_33d77b6f-d25d-43fb-9ba1-58090b640507"
      unitRef="usd">9334000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i722f5ea9afa642bf9d0d9d90efe8e13a_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTItNS0xLTEtMTI3NDUy_ec53b806-eb35-405e-9399-992456a1dc91"
      unitRef="usd">464000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTItOS0xLTEtMTI3NDUy_263ed6ab-827e-482d-8cf1-f96187dc991a"
      unitRef="usd">464000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9fd41a82276046c7bcf592d2b6dc24da_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTMtNy0xLTEtMTI3NDUy_da041b43-e7e5-487e-849a-daf5caabfa44"
      unitRef="usd">-35000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTMtOS0xLTEtMTI3NDUy_c6427ff3-ae4a-46c9-9cc2-36c478f34a77"
      unitRef="usd">-35000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i38c33764415f4b3db09298ed152df379_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTUtMS0xLTEtMTI3NDUy_49a995ba-927a-4053-8010-59307d905eb1"
      unitRef="shares">800000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iaa0252b377d44fb0a78ea5b3634c223a_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTUtMy0xLTEtMTI3NDUy_a2a9b6cf-dc82-40af-942b-0f8a1b310acf"
      unitRef="usd">47000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTUtOS0xLTEtMTI3NDUy_b5160310-d87c-4eec-a320-428e47a0718a"
      unitRef="usd">47000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaa0252b377d44fb0a78ea5b3634c223a_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTYtMy0xLTEtMTI3NDUy_b3f5f8ce-1f02-4584-8712-85090009e2e6"
      unitRef="usd">100000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTYtOS0xLTEtMTI3NDUy_134d7096-278d-4866-9616-4a57c50dbca7"
      unitRef="usd">100000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iaa0252b377d44fb0a78ea5b3634c223a_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTctMy0xLTEtMTI3NDUy_188b905e-8043-4562-ab1c-4c547cb25643"
      unitRef="usd">76000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTctOS0xLTEtMTI3NDUy_c19b74a1-be64-42d3-b0cb-ee69a7b02f2f"
      unitRef="usd">76000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i38c33764415f4b3db09298ed152df379_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTgtMS0xLTEtMTI3NDUy_840a967f-0d39-4f5d-993a-79dff7946762"
      unitRef="shares">6500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i722f5ea9afa642bf9d0d9d90efe8e13a_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTgtNS0xLTEtMTI3NDUy_79a3af68-867d-4f26-883c-4bca26b5db92"
      unitRef="usd">1592000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTgtOS0xLTEtMTI3NDUy_72f2cc1f-324a-4539-8006-f4b81bfad01f"
      unitRef="usd">1592000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockholdersEquityOther
      contextRef="i722f5ea9afa642bf9d0d9d90efe8e13a_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTktNS0xLTEtMTI3NDUy_c67a7b15-3e04-4f26-882c-630ad6cff390"
      unitRef="usd">5000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMTktOS0xLTEtMTI3NDUy_d667d0ca-523d-4873-b1c5-cc7e3b673c94"
      unitRef="usd">5000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic7fd0dbb0ae849598e2ca788ff7aaa13_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMjAtMS0xLTEtMTI3NDUy_c92675cf-ed48-402c-86ea-ec28bc6c638f"
      unitRef="shares">569600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i86ca63c3b2e447a59ee34b73dfbdad9b_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMjAtMy0xLTEtMTI3NDUy_295e8ce9-e0f9-49d2-a19d-aa3826da3d6f"
      unitRef="usd">31877000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idcb6da36e779490a98df897dc86555e5_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMjAtNS0xLTEtMTI3NDUy_112fcf27-0fce-4680-af08-bd6bc6b0960e"
      unitRef="usd">-22762000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i33df105eb613462290a07079358e7409_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMjAtNy0xLTEtMTI3NDUy_192e90c5-e0ff-4066-a3da-513a2ad9ba29"
      unitRef="usd">-868000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i99dc635999d0465e8fcbdc0cee2c1601_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8yOC9mcmFnOjE2Y2UzOGRhZTY3NjRiY2Y5NTY5ZjFlYjY3NjM3MTZjL3RhYmxlOjdmN2Q4NjdmNGI5YzRhOTNiMGI1MGMwMmU2MWI2NzZkL3RhYmxlcmFuZ2U6N2Y3ZDg2N2Y0YjljNGE5M2IwYjUwYzAyZTYxYjY3NmRfMjAtOS0xLTEtMTI3NDUy_cc62d23a-7f52-486d-8070-455c49992dbf"
      unitRef="usd">8247000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMy0xLTEtMS0xMjc0NTI_1ac35239-b7b8-4135-9a5c-834539b40e32"
      unitRef="usd">2793000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMy0zLTEtMS0xMjc0NTI_c74edabf-0d84-47ed-be92-c863f938f7aa"
      unitRef="usd">2110000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfNC0xLTEtMS0xMjc0NTI_2bc08a53-48bf-4d2e-9708-3ae4d743e255"
      unitRef="usd">1669000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfNC0zLTEtMS0xMjc0NTI_56e2e5f3-30e9-421e-ba70-8e64ca572ab7"
      unitRef="usd">1696000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfNS0xLTEtMS0xMjc0NTI_0cc8ef05-3333-48bf-9b8f-a8dab518f9e1"
      unitRef="usd">-514000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfNS0zLTEtMS0xMjc0NTI_18a90090-8304-47a6-8e43-8b2ab7c3ffdf"
      unitRef="usd">-137000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfNi0xLTEtMS0xMjc0NTI_0759ae8e-efbf-4a28-aaf6-f19b6e0d3be8"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfNi0zLTEtMS0xMjc0NTI_364f67b4-1cbd-480d-9a57-98961436c1ad"
      unitRef="usd">1505000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfNy0xLTEtMS0xMjc0NTI_5c64bd97-7ad3-4ce9-976b-f11cde71502f"
      unitRef="usd">-497000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfNy0zLTEtMS0xMjc0NTI_cbdb4145-da93-43a8-a690-03a1f4aa26a6"
      unitRef="usd">36000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfOC0xLTEtMS0xNDYxOTM_474f9431-6400-4b69-a875-e47f59cfaa9b"
      unitRef="usd">560000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfOC0zLTEtMS0xNDYyMDE_cb523b56-be03-4b9e-a961-e6f34fd20561"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfOC0xLTEtMS0xMjc0NTI_4ddabf5e-7903-4163-a7e3-e3159fc5ef9f"
      unitRef="usd">-436000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfOC0zLTEtMS0xMjc0NTI_8cf0a282-fd8e-4bdb-b371-cc5d5654568d"
      unitRef="usd">-206000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTAtMS0xLTEtMTI3NDUy_e650ef45-65ca-4661-8069-ba3aa87052c1"
      unitRef="usd">504000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTAtMy0xLTEtMTI3NDUy_7fbfc642-62b8-413c-8779-8c7a16f1c08f"
      unitRef="usd">-35000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTEtMS0xLTEtMTI3NDUy_a61b16ce-65db-46b2-a927-23db687be872"
      unitRef="usd">410000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTEtMy0xLTEtMTI3NDUy_3e9667f5-2784-4c4d-93b7-670e9477a1c5"
      unitRef="usd">167000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTItMS0xLTEtMTI3NDUy_a36d63e3-745a-4b60-ae6e-71f4913d18a0"
      unitRef="usd">-198000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTItMy0xLTEtMTI3NDUy_2d36d802-a5b4-4e24-8f31-c4428883f4c2"
      unitRef="usd">258000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTMtMS0xLTEtMTI3NDUy_bd04df50-d6c1-4e13-b171-aa95c2910e16"
      unitRef="usd">-98000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTMtMy0xLTEtMTI3NDUy_d7523962-88bd-4b21-bb84-27a6e3137070"
      unitRef="usd">-156000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTQtMS0xLTEtMTI3NDUy_3efb31e9-55ea-4c4b-820c-397468eef18f"
      unitRef="usd">-685000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTQtMy0xLTEtMTI3NDUy_3de18174-0937-4d97-ba97-dd872ccd212f"
      unitRef="usd">-930000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <amgn:IncreaseDecreaseInNoncurrentTaxLiability
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTUtMS0xLTEtMTI3NDUy_5b272193-20fd-4bdf-a9c1-491d0840c898"
      unitRef="usd">108000000</amgn:IncreaseDecreaseInNoncurrentTaxLiability>
    <amgn:IncreaseDecreaseInNoncurrentTaxLiability
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTUtMy0xLTEtMTI3NDUy_473b91d4-6c9f-474f-8ce4-a4370261bf4c"
      unitRef="usd">47000000</amgn:IncreaseDecreaseInNoncurrentTaxLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTYtMS0xLTEtMTI3NDUy_ce0d6655-634d-46c4-9c73-181177f4f4ff"
      unitRef="usd">44000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTYtMy0xLTEtMTI3NDUy_fae77fd9-67a3-4770-b230-34713391f265"
      unitRef="usd">120000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTctMS0xLTEtMTI3NDUy_e4b41af5-8697-4fd3-be5d-66a4e956fad0"
      unitRef="usd">4094000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMTctMy0xLTEtMTI3NDUy_995a89ea-214f-42cb-bcba-b92af17fadb0"
      unitRef="usd">4035000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjAtMS0xLTEtMTI3NDUy_239fbdc5-b95e-437b-8d6c-4708e4f5e4fc"
      unitRef="usd">1976000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjAtMy0xLTEtMTI3NDUy_fc5e2762-9c12-4381-8bec-73959ad17fb4"
      unitRef="usd">8000000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjEtMS0xLTEtMTI3NDUy_d277c8b0-79e8-48b5-953b-071f2d5c2010"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjEtMy0xLTEtMTI3NDUy_f2ccac1a-735f-4307-b090-3d4f2d1c8a0b"
      unitRef="usd">4404000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjItMS0xLTEtMTI3NDUy_7df99710-4f65-4153-94fb-4100f62b283d"
      unitRef="usd">47000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjItMy0xLTEtMTI3NDUy_78d1334a-e9d9-4f17-af6e-c0925b6a6289"
      unitRef="usd">6528000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjQtMS0xLTEtMTI3NDUy_57d6c55c-a887-49a2-9ce5-f2e790e61f7f"
      unitRef="usd">436000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjQtMy0xLTEtMTI3NDUy_8323cae6-5ab8-4f78-aef2-7d9a4952d4e8"
      unitRef="usd">351000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjYtMS0xLTEtMTU1MDkx_c1adff2b-0ae1-49b6-98a8-24e25261eb8a"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjYtMy0xLTEtMTU1MDkx_bfbeacd3-63b7-4acf-bd69-cc9891ad15a6"
      unitRef="usd">1626000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjYtMS0xLTEtMTI3NDUy_3e112aa7-8a9e-4d44-89af-398d07cb718b"
      unitRef="usd">-61000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjYtMy0xLTEtMTI3NDUy_4842ac9e-8626-40de-8bef-f71b642a6b96"
      unitRef="usd">65000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjctMS0xLTEtMTI3NDUy_2533e523-dadd-4fc7-80cc-0050a9e0d647"
      unitRef="usd">-2304000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjctMy0xLTEtMTI3NDUy_acb6c31e-2f72-480e-bf85-dcd2b116ccdf"
      unitRef="usd">890000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjktMS0xLTEtMTI3NDUy_9f0fd4e4-712a-415c-9ffd-992bbeaefb16"
      unitRef="usd">3954000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMjktMy0xLTEtMTI3NDUy_cee12795-6ef5-4451-bc52-d120a5400c72"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzItMS0xLTEtMTI3NDUy_68f9f6db-da77-4d36-bf86-b1ea77654598"
      unitRef="usd">6360000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzItMy0xLTEtMTI3NDUy_ddab1d09-8613-4f81-ba67-8f4dc74a61ff"
      unitRef="usd">2452000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzMtMS0xLTEtMTI3NDUy_cd3d82b8-7c9f-4e13-94e0-39b0c3da948d"
      unitRef="usd">2118000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzMtMy0xLTEtMTI3NDUy_513d2895-fe3a-4c87-b01a-194a61d30462"
      unitRef="usd">2024000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzUtMS0xLTEtMTI3NDUy_79bb9c00-5aee-4d18-9b51-f6ddd9184949"
      unitRef="usd">-52000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzUtMy0xLTEtMTI3NDUy_6e1f7139-5c25-45b6-9100-72f8c6058be4"
      unitRef="usd">-85000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzYtMS0xLTEtMTI3NDUy_08af3742-8e36-4a4b-9060-068a399b3bd7"
      unitRef="usd">-4576000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzYtMy0xLTEtMTI3NDUy_66294074-31b7-465d-90e9-b984951e3bc1"
      unitRef="usd">-4561000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzctMS0xLTEtMTI3NDUy_612a09b3-00f1-474e-a200-4390e8605d3e"
      unitRef="usd">-2786000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzctMy0xLTEtMTI3NDUy_4e986712-0484-4642-a3a8-c3971745c7e7"
      unitRef="usd">364000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzgtMS0xLTEtMTI3NDUy_466dd9f4-5561-4663-ba0a-3a57470ef305"
      unitRef="usd">7989000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1e5bfcd24a084d2ba4ae4e9fd63a2a81_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzgtMy0xLTEtMTI3NDUy_70310dc0-2174-461b-84af-844311879e9a"
      unitRef="usd">6266000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzktMS0xLTEtMTI3NDUy_b092823c-ba76-4557-bc9d-973a04eafed3"
      unitRef="usd">5203000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i99dc635999d0465e8fcbdc0cee2c1601_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zMS9mcmFnOjhiZjQ3ZjUzY2FhNzQwNzVhNGMzODA1MWE3MmNhMWY5L3RhYmxlOjU5NjMzNjQzMzg3MTQ0ZDJhMDA4YWI2OWM0ZGEzMGNiL3RhYmxlcmFuZ2U6NTk2MzM2NDMzODcxNDRkMmEwMDhhYjY5YzRkYTMwY2JfMzktMy0xLTEtMTI3NDUy_708b1df7-ed87-4ec9-8fce-db78ba004326"
      unitRef="usd">6630000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zNy9mcmFnOjE3MDY3Y2UxNGZhNzRlNGViMzA3Yjc3OTgyZjJhNjhiL3RleHRyZWdpb246MTcwNjdjZTE0ZmE3NGU0ZWIzMDdiNzc5ODJmMmE2OGJfNDA3OQ_514992b3-9b94-4da7-aac3-c0ecdc9d3b1b">Summary of significant accounting policies&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen Inc. (including its subsidiaries, referred to as &#x201c;Amgen,&#x201d; &#x201c;the Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our&#x201d; or &#x201c;us&#x201d;) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics.&#160;We operate in one business segment: human therapeutics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial information for the three and six months ended June 30, 2022 and 2021, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2021, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Report on Form 10-Q for the period ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity&#x2019;s economic performance and the obligation to absorb losses of or the right to receive benefits from the entity that could potentially be significant to that entity. We do not have any significant interests in any&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization, of $9.0&#160;billion and $8.8 billion as of June 30, 2022 and December 31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard that expanded the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We do not expect the two standards to have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <amgn:NatureOfOperationsPolicyTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zNy9mcmFnOjE3MDY3Y2UxNGZhNzRlNGViMzA3Yjc3OTgyZjJhNjhiL3RleHRyZWdpb246MTcwNjdjZTE0ZmE3NGU0ZWIzMDdiNzc5ODJmMmE2OGJfNDA0MQ_82fe463d-9e01-4711-b415-1bebc01801e0">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen Inc. (including its subsidiaries, referred to as &#x201c;Amgen,&#x201d; &#x201c;the Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our&#x201d; or &#x201c;us&#x201d;) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics.&#160;We operate in one business segment: human therapeutics.&lt;/span&gt;&lt;/div&gt;</amgn:NatureOfOperationsPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zNy9mcmFnOjE3MDY3Y2UxNGZhNzRlNGViMzA3Yjc3OTgyZjJhNjhiL3RleHRyZWdpb246MTcwNjdjZTE0ZmE3NGU0ZWIzMDdiNzc5ODJmMmE2OGJfMjUz_46b37b32-417a-4dcb-9d30-e0d892c936d4"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <amgn:BasisOfPresentationPolicyTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zNy9mcmFnOjE3MDY3Y2UxNGZhNzRlNGViMzA3Yjc3OTgyZjJhNjhiL3RleHRyZWdpb246MTcwNjdjZTE0ZmE3NGU0ZWIzMDdiNzc5ODJmMmE2OGJfNDA2NA_b36ee174-f128-4730-860b-b0ba488d50fa">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial information for the three and six months ended June 30, 2022 and 2021, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2021, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Report on Form 10-Q for the period ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;</amgn:BasisOfPresentationPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zNy9mcmFnOjE3MDY3Y2UxNGZhNzRlNGViMzA3Yjc3OTgyZjJhNjhiL3RleHRyZWdpb246MTcwNjdjZTE0ZmE3NGU0ZWIzMDdiNzc5ODJmMmE2OGJfNDA5Nw_c7230432-2734-486e-b7ec-ad6122e6db8c">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity&#x2019;s economic performance and the obligation to absorb losses of or the right to receive benefits from the entity that could potentially be significant to that entity. We do not have any significant interests in any&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zNy9mcmFnOjE3MDY3Y2UxNGZhNzRlNGViMzA3Yjc3OTgyZjJhNjhiL3RleHRyZWdpb246MTcwNjdjZTE0ZmE3NGU0ZWIzMDdiNzc5ODJmMmE2OGJfNDA0OQ_5cd1e1f7-f12e-4476-b5e4-a45cbab558ce">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zNy9mcmFnOjE3MDY3Y2UxNGZhNzRlNGViMzA3Yjc3OTgyZjJhNjhiL3RleHRyZWdpb246MTcwNjdjZTE0ZmE3NGU0ZWIzMDdiNzc5ODJmMmE2OGJfNDA2MA_c5d57700-fd0d-4148-ba8b-11b4559e51c6">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization, of $9.0&#160;billion and $8.8 billion as of June 30, 2022 and December 31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zNy9mcmFnOjE3MDY3Y2UxNGZhNzRlNGViMzA3Yjc3OTgyZjJhNjhiL3RleHRyZWdpb246MTcwNjdjZTE0ZmE3NGU0ZWIzMDdiNzc5ODJmMmE2OGJfMjEwOQ_8f814c42-d4df-44a1-b62d-1f0dbb06f84b"
      unitRef="usd">9000000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zNy9mcmFnOjE3MDY3Y2UxNGZhNzRlNGViMzA3Yjc3OTgyZjJhNjhiL3RleHRyZWdpb246MTcwNjdjZTE0ZmE3NGU0ZWIzMDdiNzc5ODJmMmE2OGJfMjExNg_42b6f5d9-b8f0-4ad4-b0e5-8faeb10b4608"
      unitRef="usd">8800000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV8zNy9mcmFnOjE3MDY3Y2UxNGZhNzRlNGViMzA3Yjc3OTgyZjJhNjhiL3RleHRyZWdpb246MTcwNjdjZTE0ZmE3NGU0ZWIzMDdiNzc5ODJmMmE2OGJfNDA4Ng_6eae6213-8a83-480c-92d5-d77b0a2f3327">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard that expanded the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We do not expect the two standards to have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfNDc5OQ_d04d13f4-a29a-4dff-be52-5a323961fc30">Acquisitions and divestitures&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of Teneobio, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 19, 2021, we acquired all of the outstanding stock of Teneobio, a privately held, clinical-stage biotechnology company developing a new class of biologics called human heavy-chain antibodies, which are single-chain antibodies composed of the human heavy-chain domain. The transaction, which was accounted for as a business combination, includes Teneobio&#x2019;s proprietary bispecific and multispecific antibody technologies, which complement Amgen&#x2019;s existing antibody capabilities and bispecific T-cell engager (BiTE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) platform and will enable significant acceleration and efficiency in the discovery and development of new molecules to treat diseases across Amgen&#x2019;s core therapeutic areas. Upon its acquisition, Teneobio became a wholly owned subsidiary of Amgen, and its operations have been included in our condensed consolidated financial statements commencing on the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Measurement period adjustments for the six months ended June 30, 2022, included changes to the purchase price allocation and total consideration, resulting in a net increase of $22&#160;million to goodwill. The measurement period adjustments resulted primarily from valuation inputs pertaining to certain acquired assets based on facts and circumstances that existed as of the acquisition date and did not result from events subsequent to the acquisition date. These adjustments did not have a significant impact on Amgen&#x2019;s results of operations during the six months ended June 30, 2022, and would not have had a significant impact on prior-period results if these adjustments had been made as of the acquisition date. The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset &#x2013; research and development technology rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets &#x2013; licensing rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration for this transaction comprised (i) an upfront cash payment of $993&#160;million, which included a working-capital adjustment, and (ii) future contingent milestone payments to Teneobio&#x2019;s former equity holders of up to $1.6&#160;billion in cash, based on the achievement of various development and regulatory milestones with regard to the leading asset (AMG 340, formerly TNB-585) and to various development milestones for other drug candidates. The estimated fair values of the contingent consideration obligations aggregated $299&#160;million as of the acquisition date and were determined using a probability-weighted expected return methodology. The assumptions in this method include the probability of achieving the milestones and the expected payment dates, with such amounts discounted to present value based on our pretax cost of debt. See Note 11, Fair value measurement, for information regarding the estimated fair value of these obligations as of June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair values of acquired IPR&amp;amp;D assets totaled $991&#160;million, of which $784&#160;million relates to AMG 340, that is in a phase 1 clinical trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), and the balance relates to four separate preclinical oncology programs. The R&amp;amp;D technology rights of $115&#160;million relate to Teneobio&#x2019;s proprietary bispecific and multispecific antibody technologies; the amount is being amortized over 10 years by using the straight-line method. Teneobio has also licensed its technology and certain identified targets to various third parties, representing contractual agreements valued at $41&#160;million. The estimated fair values for these intangible assets were determined using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The projected cash flows were based on certain assumptions attributable to the respective intangible asset, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A deferred tax liability of $244&#160;million was recognized on temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $273&#160;million was recorded as goodwill, which is not deductible for tax purposes. The goodwill value represents expected synergies from both AMG 340 and the technologies acquired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounting for this acquisition is preliminary and will be finalized upon completion of our analysis of certain tax-related items as we obtain additional information during the measurement period of up to one year from the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of Five Prime Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 16, 2021, Amgen completed its acquisition of Five Prime for a total cash consideration of $1.6&#160;billion, net of cash acquired. The purchase price was funded with cash on hand. This transaction was accounted for as an asset acquisition because substantially all the value of the assets acquired was concentrated in the intellectual property rights of bemarituzumab, a phase 3 trial-ready, first-in-class program for gastric cancer. Five Prime&#x2019;s operations have been included in our condensed consolidated financial statements commencing after the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the consideration to acquire Five Prime to: the bemarituzumab IPR&amp;amp;D program of $1.5&#160;billion, which was expensed immediately in Acquired IPR&amp;amp;D expense in the Condensed Consolidated Statements of Income; deferred tax assets of $177&#160;million; and other net liabilities of $47&#160;million. The Acquired IPR&amp;amp;D expense was not tax deductible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Divestiture of Gensenta &#x130;la&#xe7; Sanayi ve Ticaret A.&#x15e;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 28, 2022, we entered into a share purchase agreement with Eczac&#x131;ba&#x15f;&#x131; under which Eczac&#x131;ba&#x15f;&#x131; will acquire all of our shares in Gensenta&#x2014;a subsidiary in Turkey. Net assets related to Gensenta of $80&#160;million met the criteria to be classified as held-for-sale and did not meet the criteria to be classified as discontinued operations. Upon closing of the transaction, we expect to receive $135&#160;million in cash. The transaction is expected to close in the third quarter of 2022 upon approval by the Turkish Competition Authority.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022, held-for-sale assets and liabilities of $100&#160;million and $20&#160;million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the three months ended June 30, 2022, we recognized a loss of $560&#160;million recorded to Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign currency translation loss, with valuation allowances to Other current assets and Accrued liabilities in the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i46b0c7abfa194277afc81cba3b24f8a3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0MjQ0NA_9cbadb74-e00f-4d7f-9b94-0be51b569dcd"
      unitRef="usd">22000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMjc0ODc3OTA4NDY5Nw_bd314df0-4649-48ef-ad1c-a12e2d3351c4">The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset &#x2013; research and development technology rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets &#x2013; licensing rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i46b0c7abfa194277afc81cba3b24f8a3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfMS0yLTEtMS0xNDQ4MzA_44241372-d163-45df-8ef4-5b7db988a56d"
      unitRef="usd">993000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions
      contextRef="i46b0c7abfa194277afc81cba3b24f8a3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfMi0yLTEtMS0xNDQ4MzA_59d4e1b9-7a92-4c99-9e56-0e7ab0b66131"
      unitRef="usd">299000000</amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions>
    <amgn:Businessassetacquisitionconsiderationtransferred
      contextRef="i46b0c7abfa194277afc81cba3b24f8a3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfMy0yLTEtMS0xNDQ4MzA_c6f140b2-a842-415e-99b3-3de657dfdc87"
      unitRef="usd">1292000000</amgn:Businessassetacquisitionconsiderationtransferred>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i65b90579b9de4767a853da3e3573d8fa_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfNS0yLTEtMS0xNDQ4MzI_ad889fa1-1c40-476f-83f3-c866975fc3ca"
      unitRef="usd">100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i65b90579b9de4767a853da3e3573d8fa_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfNi0yLTEtMS0xNDQ4MzI_c7fae9b3-9fce-4832-b64c-e975ed8d3d2d"
      unitRef="usd">991000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="id0f1d41da125426189de8e665937a530_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfNy0yLTEtMS0xNDQ4MzI_48120951-303c-4100-8e7b-4563ff67c53d"
      unitRef="usd">115000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ibf77564d8ed145dab51bea04209c327c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfOC0yLTEtMS0xNDQ4MzI_88d7f31b-2a72-43ac-9418-fe0b8f528000"
      unitRef="usd">41000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i65b90579b9de4767a853da3e3573d8fa_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfOS0yLTEtMS0xNDQ4MzI_1ad18265-89f8-4433-8393-abd0794ea189"
      unitRef="usd">273000000</us-gaap:Goodwill>
    <amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities
      contextRef="i65b90579b9de4767a853da3e3573d8fa_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfMTAtMi0xLTEtMTQ0ODMy_057c48e4-a75b-46c7-84b8-8162f5cc5ee1"
      unitRef="usd">16000000</amgn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i65b90579b9de4767a853da3e3573d8fa_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfMTEtMi0xLTEtMTQ0ODMy_8e38ea83-06ae-4d89-b1ed-8e70ebc03bc2"
      unitRef="usd">244000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <amgn:BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet
      contextRef="i65b90579b9de4767a853da3e3573d8fa_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RhYmxlOmM2ZGI0NzM4ZTk4YTRiZjNhZmE5NWZlOWQ2MmI1NmI1L3RhYmxlcmFuZ2U6YzZkYjQ3MzhlOThhNGJmM2FmYTk1ZmU5ZDYyYjU2YjVfMTItMi0xLTEtMTQ0ODMy_ebf360c9-2192-4564-b024-914d8bf716c4"
      unitRef="usd">1292000000</amgn:BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i46b0c7abfa194277afc81cba3b24f8a3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0MjE5Mg_fbb47b7e-abe8-4d13-9de9-e4e9143098a8"
      unitRef="usd">993000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i65b90579b9de4767a853da3e3573d8fa_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0MjIyMQ_65c405bb-688e-4e27-afe0-57f5bed86b72"
      unitRef="usd">1600000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions
      contextRef="i46b0c7abfa194277afc81cba3b24f8a3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0MjI0OA_e801c0cf-36a9-49c7-b54d-072e5eaf9be7"
      unitRef="usd">299000000</amgn:BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i65b90579b9de4767a853da3e3573d8fa_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0MjI3NQ_ad312c9d-d6e1-4cd5-b872-a56ce3f97ae8"
      unitRef="usd">991000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="id5b59ba800eb4416b405415f49916460_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0MjMwMg_18471c99-d1df-43c4-8387-aa992fcbf13c"
      unitRef="usd">784000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="id8fc3ec2171642438fd51d30ae242218_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0MjMyOQ_85e87a1d-c5b4-4759-b83f-7bda2570822a"
      unitRef="usd">115000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="id8fc3ec2171642438fd51d30ae242218_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY2NTcwMg_aafa8313-e4ba-4c3d-b407-7e2132d31383">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i7940c183b18d43b9ba4da67548953f71_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0MjM1NQ_f97bffb4-8199-4805-b3a0-ad281ce6a49a"
      unitRef="usd">41000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i65b90579b9de4767a853da3e3573d8fa_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0MjM5MQ_7f9a1d9f-efb5-4478-bb1b-c4addddc0b13"
      unitRef="usd">244000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:Goodwill
      contextRef="i65b90579b9de4767a853da3e3573d8fa_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0MjQxOA_9c9af170-8b71-4414-a321-4a6fed6d54f0"
      unitRef="usd">273000000</us-gaap:Goodwill>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i9a5366d8b02a4ac58034f8465ae23d74_D20210416-20210416"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfNjA0NzMxMzk4MTM4Mg_b9c00c51-5aa6-4213-8e06-8addad4bf422"
      unitRef="usd">1600000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i9a5366d8b02a4ac58034f8465ae23d74_D20210416-20210416"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfNjA0NzMxMzk4MTk3Ng_da84faf7-b56c-455c-bd72-f3f001663024"
      unitRef="usd">1500000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets
      contextRef="i51b02cfd80774125a1d4ff6c778112df_I20210416"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfNjA0NzMxMzk4MjExMw_8c93f221-2192-4fab-aafa-b733bba0036b"
      unitRef="usd">177000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="i51b02cfd80774125a1d4ff6c778112df_I20210416"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfNjA0NzMxMzk4MjE0Nw_18bacb6f-718d-423f-9012-4f48286e6182"
      unitRef="usd">47000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="iab9a0edff56e4078be3430ac408a5cf8_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfNjA0NzMxMzk3NTU5NA_448664c8-e3e4-4d97-9b64-a6681a31c9a7"
      unitRef="usd">80000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates
      contextRef="i7d17ec1f9653493f940934eadb627b3e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY0Njg5OA_6689defe-c4e7-4847-a8a4-2f4dce2ae2ea"
      unitRef="usd">135000000</us-gaap:ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="iab9a0edff56e4078be3430ac408a5cf8_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfNjA0NzMxMzk4MjM4OQ_1d101574-0f6d-4778-a04f-260c6853bb59"
      unitRef="usd">100000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities
      contextRef="iab9a0edff56e4078be3430ac408a5cf8_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfNjA0NzMxMzk4MjQzMA_46f3949e-becf-4ef1-b170-bea8c2a40067"
      unitRef="usd">20000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i1b8b7a38d735412895755cb950726b35_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80MC9mcmFnOmJkYzk2ODNiZTQxNzRkNGY4MWJlOTZjOWExNGI2NjBiL3RleHRyZWdpb246YmRjOTY4M2JlNDE3NGQ0ZjgxYmU5NmM5YTE0YjY2MGJfMTA5OTUxMTY1NzQyNA_a1dc6833-0821-413f-bd4d-9d06af362274"
      unitRef="usd">560000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RleHRyZWdpb246NGRmYmU0OGYxN2QyNDNhNjk3YmE0NDA5MWNhZTg2MzNfNTQ1_a6cb4f2c-d037-4d5f-8b35-4e546b2e5088">Revenues&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers&#x2019; locations, are presented below. The majority of ROW revenues relates to products sold in Europe.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ENBREL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prolia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Otezla&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XGEVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aranesp&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neulasta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repatha&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KYPROLIS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nplate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ENBREL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prolia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Otezla&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XGEVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aranesp&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neulasta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repatha&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KYPROLIS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nplate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;Hedging gains and losses, which are included in product sales, were not material for the three and six months ended June 30, 2022 and 2021.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RleHRyZWdpb246NGRmYmU0OGYxN2QyNDNhNjk3YmE0NDA5MWNhZTg2MzNfMjY_5dee4a5f-0d7a-4893-8131-cd45fb078287"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RleHRyZWdpb246NGRmYmU0OGYxN2QyNDNhNjk3YmE0NDA5MWNhZTg2MzNfNTQ3_022f01eb-604d-4914-b813-7706f86ba946">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ENBREL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prolia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Otezla&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XGEVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aranesp&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neulasta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repatha&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KYPROLIS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nplate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ENBREL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prolia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Otezla&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XGEVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aranesp&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neulasta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repatha&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KYPROLIS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nplate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;Hedging gains and losses, which are included in product sales, were not material for the three and six months ended June 30, 2022 and 2021.</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icee014cde681480aad811d3d8701db0d_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMy0yLTEtMS0xMjc0NTI_eca83299-162f-4aed-972c-32762c8c9c53"
      unitRef="usd">1036000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf9d9ddcf94242e3ad6ec1f3b60ca85f_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMy00LTEtMS0xMjc0NTI_e66828f7-8292-4a18-a022-96b0f6fffc3c"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6547eba45cd04dcbaeebbe712be8ec92_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMy02LTEtMS0xMjc0NTI_efecf750-fba5-444d-86f9-3e8d4ea3f10e"
      unitRef="usd">1051000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e52109f70c0440aa0159863f2da64f0_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMy04LTEtMS0xMjc0NTI_f23c07ec-b8ee-4856-86fe-3b90ae9da1b8"
      unitRef="usd">1113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a84ebe379724a65826c6f82bd6873e1_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMy0xMC0xLTEtMTI3NDUy_17f5a7a7-1fc0-4be9-ba26-d549fd6657f9"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida701b321d2c4d2a891120940d3655c5_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMy0xMi0xLTEtMTI3NDUy_098339b3-acd3-404a-9404-15caf5d02f80"
      unitRef="usd">1144000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief82f7dcaf42426abffc36664a5809c7_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNC0yLTEtMS0xMjc0NTI_bd1e72e6-c484-4e8d-9184-6d2bec839bde"
      unitRef="usd">611000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0fdc9fa81ab6432aaa23fe4128d28ae8_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNC00LTEtMS0xMjc0NTI_1fce9fcb-e4a2-4221-b466-dc10750f9ed2"
      unitRef="usd">311000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i053944749a2f483d9d310db2fc989a2c_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNC02LTEtMS0xMjc0NTI_27a38e2d-fba8-4de9-a277-b1b0f603c44c"
      unitRef="usd">922000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7eebec4167d24ee289c7c3c2cca1d35a_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNC04LTEtMS0xMjc0NTI_6d3280dd-5ee7-4c5f-bf1d-ffda0ea6427a"
      unitRef="usd">538000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7337cf047dc447782a07d660fabea38_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNC0xMC0xLTEtMTI3NDUy_38bc8cd1-c242-4bcc-94ba-49ba4c5c79e2"
      unitRef="usd">276000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c5378764431442fb224f6e38d910099_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNC0xMi0xLTEtMTI3NDUy_0cdf5029-2ef2-4d21-8d3c-95649b43e24e"
      unitRef="usd">814000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4b87907d6674193b0d2c415cefc0caf_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNi0yLTEtMS0xMjc0NTI_a289ff91-2cb2-4f62-b410-ccd2f8138af0"
      unitRef="usd">487000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i353f9f7d24934b85a5752777824c2c7f_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNi00LTEtMS0xMjc0NTI_379281e9-2c7b-414c-8faa-900abe0b7e9c"
      unitRef="usd">107000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib84507297bc345c8b3d5fff781c60e36_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNi02LTEtMS0xMjc0NTI_b9e3f8a1-1d83-47a3-90c2-5b47e058d350"
      unitRef="usd">594000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4fef643526f14918bd9831e91914bf50_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNi04LTEtMS0xMjc0NTI_253b5a3a-35ab-42d9-8758-1eb04178e9e0"
      unitRef="usd">423000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i402e9a1690cc42e797f5a6261ca0cbfb_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNi0xMC0xLTEtMTI3NDUy_cf5d37cc-fec6-4522-8cf0-f45510e45d08"
      unitRef="usd">111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3ea1a7432a342c2bed9d52592b75cf4_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNi0xMi0xLTEtMTI3NDUy_986306e0-fac8-48c4-8151-04b7c2b0e8c6"
      unitRef="usd">534000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63940a8eea91432f83d73335dca6a9f4_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNy0yLTEtMS0xMjc0NTI_75ea5198-d5bf-4f16-8b4b-29f157e4cac5"
      unitRef="usd">391000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05d9d5b7844d40b4a71f85abe0bce65a_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNy00LTEtMS0xMjc0NTI_32758696-346a-49cd-8fc8-ade8f67ac2ee"
      unitRef="usd">142000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cde61abea0348d2a159b88ebd8184b7_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNy02LTEtMS0xMjc0NTI_84f68c80-1122-4628-afcd-d1a2276adceb"
      unitRef="usd">533000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10be39accc2549a2bdd35da00b4aaa91_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNy04LTEtMS0xMjc0NTI_d19dd0c8-c6db-4048-b0ed-aa53d0e19532"
      unitRef="usd">355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b97f8b18b7146bf8f5d26e2d38206ab_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNy0xMC0xLTEtMTI3NDUy_a571ebe3-d52b-4b31-acdc-2581489795f4"
      unitRef="usd">133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie08a8cd0c2ee4df4970b642309711818_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfNy0xMi0xLTEtMTI3NDUy_e077a524-7103-4324-a293-ca8b7dd06918"
      unitRef="usd">488000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib449607d3a384e9b922bf56ee0f6ad54_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOC0yLTEtMS0xMjc0NTI_26f7d316-8408-427e-a76c-b6c98e1797bc"
      unitRef="usd">132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i844d0ba430b845fabf60df607d4a6b2b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOC00LTEtMS0xMjc0NTI_62818404-ed3b-4c77-b529-dc3ccd8d1e14"
      unitRef="usd">225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d419bd679714fdcb7cab5ff036d1523_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOC02LTEtMS0xMjc0NTI_94dc851e-b871-4b2e-8a0a-8c8b57de3f0f"
      unitRef="usd">357000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78a1a713123344ccbeee9e7f0bd8b286_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOC04LTEtMS0xMjc0NTI_91a52105-4414-4b27-ae84-cb1dbf72250e"
      unitRef="usd">135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3759a6d96c3d4557865f45756f379736_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOC0xMC0xLTEtMTI3NDUy_1766f3c2-604a-42ab-86ed-336b7f99ce1b"
      unitRef="usd">232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13eca2061d94491bbf81135f296046bf_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOC0xMi0xLTEtMTI3NDUy_3cb3e58d-ee57-4d02-b63b-79764298aa02"
      unitRef="usd">367000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6b5b0a2363145d7be3110c83773d028_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS0yLTEtMS0xNDczMDY_2ed269bf-219d-4da1-9b13-c223e98faea0"
      unitRef="usd">263000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8d35c2137e343349add15c0fca41917_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS00LTEtMS0xNDczMDY_4225f32e-7484-4db8-9577-94f561de20c5"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ab66a4297fc4a5fa4fbdb2b993c893d_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS02LTEtMS0xNDczMDY_2665612a-b0a7-4044-86d3-0c38651ed5f5"
      unitRef="usd">310000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa47aecf963c462192f5f09066e709ae_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS04LTEtMS0xNDczMDY_ff51ae53-1578-4919-b398-98ff363cb312"
      unitRef="usd">434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5dab3465710546408078a65658bbbc86_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS0xMC0xLTEtMTQ3MzA2_d78ab2c8-aecf-4c23-8fe4-2d56a2de1ed0"
      unitRef="usd">52000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d1ec301cf824dcc9410f3838f666700_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS0xMi0xLTEtMTQ3MzA2_f2919ca4-033d-480e-9729-3e533408d1bc"
      unitRef="usd">486000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d51cebbb7fc4745b1461e1227bf4a07_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS0yLTEtMS0xNDA2MzU_b5504f28-bb39-4afb-b8e0-364332031b92"
      unitRef="usd">154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic60e2a88b0ee40cdae005ed5c6d5e8fc_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS00LTEtMS0xNDA2MzU_8768f56e-7260-400e-bd17-719639f0d414"
      unitRef="usd">171000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i331261ad3dac42c582a5e9011635bd51_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS02LTEtMS0xNDA2MzU_81e54cc7-b2b6-4b47-af24-d03fa1272f96"
      unitRef="usd">325000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide9a7be6cf844191ab232452edf77bd6_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS04LTEtMS0xNDA2MzU_d39c3417-a258-4324-b83c-1b465a051953"
      unitRef="usd">143000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b9d8e979224414d8d3ad2e8695072bb_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS0xMC0xLTEtMTQwNjM1_1a5073a2-14e9-4721-b30c-ecabcdc7d599"
      unitRef="usd">143000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49646ee726c14e1e97ca5817d76e3e08_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS0xMi0xLTEtMTQwNjM1_a171dad3-84d6-4630-8cfd-601b44f5a9f1"
      unitRef="usd">286000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab5d097d4d764906958b2308fa778f75_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS0yLTEtMS0xMjc0NTI_308d16cc-daad-45d3-9e96-9c2736d21a62"
      unitRef="usd">213000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0bb35321c40c4726b08388b4209a9228_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS00LTEtMS0xMjc0NTI_a4a1d6f7-ec97-4885-b3f3-f8e723a9e520"
      unitRef="usd">104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2958c1dc2e954e58aa77a26a6d8e1d7a_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS02LTEtMS0xMjc0NTI_843b5182-3333-4378-9b0b-c54420f033cf"
      unitRef="usd">317000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70fcb018e33749d2af04537d60b71f20_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS04LTEtMS0xMjc0NTI_aa7ddd72-63c2-423c-af5d-24c671bffd63"
      unitRef="usd">190000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica9bbd963a304369b99b0572c2fff78c_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS0xMC0xLTEtMTI3NDUy_152a5230-9ea6-44b3-9332-032ea24f8242"
      unitRef="usd">90000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81e998920660480b972899798b0bbb3c_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfOS0xMi0xLTEtMTI3NDUy_3743ae25-f13e-4bd2-9bb8-62837cefa1d8"
      unitRef="usd">280000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if57c433f89bb427d95cc820d738a213b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTEtMi0xLTEtMTI3NDUy_53f88d98-4b0d-42b5-97ab-ff1f82c6e908"
      unitRef="usd">156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49be0bf790014903a4b42b6e1b2727bd_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTEtNC0xLTEtMTI3NDUy_eed5b51a-e8ce-4a2f-a310-87e11eba5fe2"
      unitRef="usd">128000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d6f96cf75ba4e419a31bf17c86c89c7_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTEtNi0xLTEtMTI3NDUy_d54d410c-2f6a-4f1f-92d5-cff3e06881c6"
      unitRef="usd">284000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9166886eb5d468090bdacec2d9c6426_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTEtOC0xLTEtMTI3NDUy_6b99791d-e0cb-40a0-b3ad-56864b2da0d4"
      unitRef="usd">136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedd4bef43f2e4c74bdbe761a290688d2_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTEtMTAtMS0xLTEyNzQ1Mg_765b7de0-7687-4a41-8368-097749eeaf57"
      unitRef="usd">109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i866f0a6fa4484406b8ad21f3fb76f4a3_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTEtMTItMS0xLTEyNzQ1Mg_0a4e35b7-abb2-49b8-b916-2e0930575e21"
      unitRef="usd">245000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c0b9b0637ae4f75a113b9daf4ffbb97_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTItMi0xLTEtMTI3NDUy_8c5dbfa6-1346-4a0b-8006-5269984a5855"
      unitRef="usd">1003000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id00661e6164d4652a22a0e73d4ff73a6_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTItNC0xLTEtMTI3NDUy_b2429096-a9e5-4557-afbb-baa99e257759"
      unitRef="usd">585000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c2f46c443024e00a31cb4dc9cd9e34b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTItNi0xLTEtMTI3NDUy_0795b48c-6dae-409c-a247-dc5e1366b192"
      unitRef="usd">1588000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c2e544419be4d83a0548a9dd2cb80a6_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTItOC0xLTEtMTI3NDUy_613050b9-069d-4ffd-86d9-1670041a65cd"
      unitRef="usd">907000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a69d719fa4e41389f7a488fa7f10932_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTItMTAtMS0xLTEyNzQ1Mg_26e41f4a-7f56-48d0-9d4e-260894cf09de"
      unitRef="usd">563000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12b36c285b3e46d48bdcaa2313f4d40a_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTItMTItMS0xLTEyNzQ1Mg_c3bfdf23-fae3-45a7-9faf-d7a69d5f03d5"
      unitRef="usd">1470000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3c63f65b70944d59e9ddddf1020dbf9_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTMtMi0xLTEtMTI3NDUy_f5d44686-5cc6-442f-a16f-23e4b11b9aef"
      unitRef="usd">4446000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27c7d03606704467ad677af2b7b1c3b1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTMtNC0xLTEtMTI3NDUy_bd232228-02f4-448f-b30d-1a00def0e1c1"
      unitRef="usd">1835000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3c410d6b2f84e53be5c076dec22d865_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTMtNi0xLTEtMTI3NDUy_8df0ba21-ce6c-4906-96ca-406870caaa6e"
      unitRef="usd">6281000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60557b562a964b209eb858e7b3cb22e9_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTMtOC0xLTEtMTI3NDUy_2b819407-5df2-4be5-a06f-d971ea973bdf"
      unitRef="usd">4374000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iafda85002a2340d3b351231f4da2b4fb_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTMtMTAtMS0xLTEyNzQ1Mg_bca7bfcd-0bbc-41bb-bd0b-6b88a26a8c03"
      unitRef="usd">1740000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78d9e005bccc4060bd5addba903c2c2c_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTMtMTItMS0xLTEyNzQ1Mg_cf1d2583-bd1c-4735-a244-9fd89ef86220"
      unitRef="usd">6114000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71e71b4283ef4881a494fede3403b36c_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTQtNi0xLTEtMTI3NDUy_8ec274aa-f1e2-4633-b0cc-d1749f3f8ea1"
      unitRef="usd">313000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i768868bd3bfe4a65a96efee550cef847_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTQtMTItMS0xLTEyNzQ1Mg_c9326106-8dd7-4110-9d63-2c0643f29be6"
      unitRef="usd">412000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTUtNi0xLTEtMTI3NDUy_80eea368-b06a-47af-bef4-5ad36b8cd6b6"
      unitRef="usd">6594000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMTUtMTItMS0xLTEyNzQ1Mg_feb82c5a-d6f0-4573-8980-33debad8db59"
      unitRef="usd">6526000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i995fe6b5cc06494dac04f0ca72c967be_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjAtMi0xLTEtMTI3NDUy_1db40b16-5036-4eb8-8d74-1ab403f6a5e9"
      unitRef="usd">1879000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i481df103ecf443b58ab69543c8ebfaa4_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjAtNC0xLTEtMTI3NDUy_564c96e0-b017-43fd-86c8-ef00deca348e"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e20cfb3d44545709400adfd0900c274_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjAtNi0xLTEtMTI3NDUy_dcbea01c-85e0-46fb-b217-1d63aae15e05"
      unitRef="usd">1913000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i198ddb00bf674c69a7441a2d3a026635_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjAtOC0xLTEtMTI3NDUy_47892b36-2cec-4d9d-a07b-9bbff45f65d6"
      unitRef="usd">2007000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ad4acdb144a4163bcbf1216e002c725_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjAtMTAtMS0xLTEyNzQ1Mg_ae1ddbb2-fcee-417d-a8bd-178385d12ee2"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac22074dabd64d2fbfdc167416335b44_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjAtMTItMS0xLTEyNzQ1Mg_2f380621-cd00-4922-8629-e672986aa99f"
      unitRef="usd">2068000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9ab9b8edfdb4a22b19ee432374d19ec_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjEtMi0xLTEtMTI3NDUy_6d82ff04-2e8a-4e63-ab91-9ecf27dc7ec9"
      unitRef="usd">1193000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2a35d4acbaa4f83be8e10b0e6e0300d_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjEtNC0xLTEtMTI3NDUy_1611cc0a-f300-442c-a784-1bfa7aa0b595"
      unitRef="usd">581000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf38951506aa48f19b8b2388b7885ee1_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjEtNi0xLTEtMTI3NDUy_92f327cf-bb38-44da-8bb2-17c9d93aca25"
      unitRef="usd">1774000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d40692061a445c192ae0b68421a236a_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjEtOC0xLTEtMTI3NDUy_dce204f5-b478-454f-af07-94496a734863"
      unitRef="usd">1039000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f09cd5a2a344997a29f5dbf9e474e85_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjEtMTAtMS0xLTEyNzQ1Mg_75a1cecf-de13-4e07-9dda-461cbefef20e"
      unitRef="usd">533000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f4bf88082934cdc8910614dccffc16b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjEtMTItMS0xLTEyNzQ1Mg_0620dbaa-b70e-4d2c-8f95-0d53a5acc651"
      unitRef="usd">1572000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43dfd6a72e0d4e86845ad7349de053e0_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjItMi0xLTEtMTI3NDUy_370543ea-dd01-4f55-8e1a-904f1639a5c7"
      unitRef="usd">837000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22a251c8f299431d94a6931aca67fc7f_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjItNC0xLTEtMTI3NDUy_d9cf91fa-697b-45d3-85b1-e5de77aa780b"
      unitRef="usd">208000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8de2ea542474f83b6b3eca46a028b44_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjItNi0xLTEtMTI3NDUy_e333f79d-11bd-44d3-b773-6e943766a1a1"
      unitRef="usd">1045000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i774b5e6996814c4abaaef4d66eabba88_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjItOC0xLTEtMTI3NDUy_2ca42eda-786f-4fc2-b1ff-525ab2a98d86"
      unitRef="usd">789000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia32f2b66d9004689a58fa0ee82794077_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjItMTAtMS0xLTEyNzQ1Mg_3655d92f-dace-4fa7-a7b8-361e45880974"
      unitRef="usd">221000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic110f3f8f6db447287b324ae25536ba2_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjItMTItMS0xLTEyNzQ1Mg_85eed944-c01f-44e4-a402-8f5303f09e32"
      unitRef="usd">1010000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2702f5653dc64085adaed969aa03d41a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtMi0xLTEtMTM2MjE3_a620bc98-80c5-49da-85ef-ee11df79a305"
      unitRef="usd">759000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i059b2fc16c164e18b5bc3641f7e47b0a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtNC0xLTEtMTM2MjUz_7f9db944-ccb8-403b-aa17-3de29d39a21d"
      unitRef="usd">276000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd43189867c0477aa56e3dd2bd1a3ca1_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtNi0xLTEtMTM2MTkz_b9277ba4-053c-4877-b596-a9f1eb9de11e"
      unitRef="usd">1035000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22ff43227695419d9aa80cbc49fe3fac_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtOC0xLTEtMTM2MjU1_1ab0faa2-8913-402b-9605-936f417631b8"
      unitRef="usd">689000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf215bb9f1894adc8cb1984f634e46cb_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtMTAtMS0xLTEzNjI1Nw_a9c5507c-1d05-4a42-a74a-2f922b6c33e3"
      unitRef="usd">267000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i417472fa55034ae1828e69637b4f9dc6_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtMTItMS0xLTEzNjE5Mw_a850cd5e-c7a8-43ed-833c-351bd405b542"
      unitRef="usd">956000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if61ddc5649444d2890986cd3b336d8a6_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtMi0xLTEtMTI3NDUy_e99fb249-55be-4e86-8698-5203621a4790"
      unitRef="usd">269000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9501d13f07544aa914a2f0472499317_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtNC0xLTEtMTI3NDUy_37c4f019-5624-4def-be70-22ea17c5803b"
      unitRef="usd">446000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c91bcd0b0614b31b6ed09d75f6a89ee_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtNi0xLTEtMTI3NDUy_74c538c7-ad21-46c7-8231-474c45aed05a"
      unitRef="usd">715000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i447c6a3b3c654027a8f390447d27092a_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtOC0xLTEtMTI3NDUy_80560c16-69de-43e3-b77e-eb9894c327e4"
      unitRef="usd">260000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i913293415a73440c8b746390caea2fe8_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtMTAtMS0xLTEyNzQ1Mg_c9068a83-969e-482a-861c-a98bd5df4ee3"
      unitRef="usd">462000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d14e200ac08498a8babed3b3c0ded3c_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjQtMTItMS0xLTEyNzQ1Mg_3153d81b-c7a0-4deb-8ee8-89203d03e816"
      unitRef="usd">722000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b05f801cd3a4927a0124fb231c84d76_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtMi0xLTEtMTQ3Mjk3_cf423d01-c894-4bad-9a49-6238558f578a"
      unitRef="usd">567000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e7cc819d92f4e75acbc9963bc7090ef_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtNC0xLTEtMTQ3Mjk3_e352ea14-b7e6-48fd-b738-96e7f0944b44"
      unitRef="usd">91000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7ae2416c6aa4543a664b0bde8b33563_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtNi0xLTEtMTQ3Mjk3_d630bbd4-28e2-40c5-9f16-b810e2bd20c1"
      unitRef="usd">658000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9676f44123d40e2871ec3d2771a7a5f_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtOC0xLTEtMTQ3Mjk3_026f3b36-52e8-4851-a2be-13025c75fc99"
      unitRef="usd">855000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iecdf3a73b98a42dc9b239601a9ae31de_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtMTAtMS0xLTE0NzI5Nw_98254cdb-ccc7-4173-a2c6-d580eea26ed3"
      unitRef="usd">113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45954dd51b7b41aa96b4593c6fb94f09_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtMTItMS0xLTE0NzI5Nw_9af3c8aa-da84-43f1-b111-0a7b9546e5c3"
      unitRef="usd">968000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6148be5d2f114eaba7d30900efe31d0c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtMi0xLTEtMTI3NDUy_c6fb60d5-7a9e-44b6-b5a2-54b03f07a3ca"
      unitRef="usd">319000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib505cfceda644a379d36c8eb60ae289b_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtNC0xLTEtMTI3NDUy_99238ec0-332f-4ca1-b068-70ac5e5d99d1"
      unitRef="usd">335000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f37b029317a4d00a1a498b287de24f5_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtNi0xLTEtMTI3NDUy_f63649a1-7577-4778-b8b5-0e0d6aca6a7f"
      unitRef="usd">654000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i280383856aef44de9c38a690e97f94a4_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtOC0xLTEtMTI3NDUy_ddb1645e-a6d4-45c2-892f-6efb2bcb42fb"
      unitRef="usd">282000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5d62159edfe46daa8cde42bb90fd594_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtMTAtMS0xLTEyNzQ1Mg_f68eedab-3d7d-425f-9c10-59aabcc52fbd"
      unitRef="usd">290000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i599bea8fe9d342bf8a2319d0c99d8049_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjYtMTItMS0xLTEyNzQ1Mg_b3697fbf-e4d5-427b-953c-a56fbfb3c64b"
      unitRef="usd">572000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if33d244e2dcc4deb97f437c4bf8015e5_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjctMi0xLTEtMTI3NDUy_ef39e21c-24e0-4df5-8fd2-9c5eacb6d583"
      unitRef="usd">409000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4743b11647f495995b2a8eb1612ae62_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjctNC0xLTEtMTI3NDUy_21eec8dc-e620-4979-a41e-d0c93b8450d8"
      unitRef="usd">195000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i019834958d7c4fdcb462b108564b7504_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjctNi0xLTEtMTI3NDUy_0d1082af-f051-4df3-a1fe-04bcd1f4cb09"
      unitRef="usd">604000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3329340deea4c2893e19564ea8f5d50_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjctOC0xLTEtMTI3NDUy_9b3280e4-9521-4726-96c5-e9b1c34e602e"
      unitRef="usd">349000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33575c61bd1a4b6483cadbb17231bd16_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjctMTAtMS0xLTEyNzQ1Mg_dc813de9-e3a8-45b6-8d29-4cb971845ea7"
      unitRef="usd">182000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76d8149329f846d4b8b397d30cbfffdb_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjctMTItMS0xLTEyNzQ1Mg_15791ce5-d1ce-4886-9f68-df9dbba04f96"
      unitRef="usd">531000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i284e10e01d024a31b71cbe8084385e6a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjgtMi0xLTEtMTM2MzQ5_21c432cb-457c-425b-b81b-6376c17b18e5"
      unitRef="usd">312000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18bb25efd7724f2ab8c17abd89376d32_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjgtNC0xLTEtMTM2MzUx_d086c6ab-bd90-4881-937a-615bf09f1210"
      unitRef="usd">238000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i799c05d5e6c148739756e62ed52efc0e_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjktNi0xLTEtMTQwNjc1_57460d25-98fc-495e-b353-74b706058fff"
      unitRef="usd">550000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c26221f1ddc4730a672e6feda6527ac_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjgtOC0xLTEtMTM2MzUz_cd270592-cfa3-4371-9f68-e20a6fb4020e"
      unitRef="usd">248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8df6d5b75ce4981805065f554e3fc61_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjgtMTAtMS0xLTEzNjM1Ng_e7f5acc0-a3d1-4b3f-b29f-3de651ee1d3b"
      unitRef="usd">224000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf0c82557a9f4c5a9dad46e4f1995240_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjktMTItMS0xLTE0MDY3NQ_3f29be7b-5711-4b77-adc7-0c764eba533d"
      unitRef="usd">472000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9080bae4bb24f77958c82064456abff_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjgtMi0xLTEtMTI3NDUy_d1c49172-efa7-4cbc-954f-9edf2108024c"
      unitRef="usd">1939000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90438b29fb8e47daa853e17a32039dbf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjgtNC0xLTEtMTI3NDUy_1a9ff8e6-b1a2-488b-9799-3435b69de097"
      unitRef="usd">1125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69516fc5e36948efb30d55be4c11c00e_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjgtNi0xLTEtMTI3NDUy_2db47c8d-d009-4c82-8f32-5fed4d490a8b"
      unitRef="usd">3064000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71f5357d2c814ae18ef9d15c743aa395_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjgtOC0xLTEtMTI3NDUy_d2195d72-ed8b-452e-bf10-5e95413c46c9"
      unitRef="usd">1759000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iceb2e90867824a3d91fa7756b41e93e0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjgtMTAtMS0xLTEyNzQ1Mg_91b3cf19-d384-45d9-91d8-7c5d009ed085"
      unitRef="usd">1076000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f3ade07d4da4313b5b990be550c7fe7_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjgtMTItMS0xLTEyNzQ1Mg_be5a93a0-13e8-4bf5-a83d-606f9916ab0b"
      unitRef="usd">2835000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d0a9ca182c34101bf19dd4a000ada97_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjktMi0xLTEtMTI3NDUy_fbcba5d6-4f44-4ccc-bf9b-1890c5cf3d41"
      unitRef="usd">8483000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia06b5f63bc244d16b92988767f8bc100_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjktNC0xLTEtMTI3NDUy_25adf2e7-6c09-4e43-8382-b7552d76df7b"
      unitRef="usd">3529000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38c160a3f1834d5e9d775a1dea85e514_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjktNi0xLTEtMTI3NDUy_25d9fa49-904b-403b-af61-39f998c803f2"
      unitRef="usd">12012000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id43e33fcdb65467a8bb28d8ffb21869c_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjktOC0xLTEtMTI3NDUy_2ae15588-f335-40ab-b9ab-b0ea21c13bef"
      unitRef="usd">8277000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc7bc4cfc3564596be8443a8279385fb_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjktMTAtMS0xLTEyNzQ1Mg_6b80561b-b8d1-4a0e-a679-acf929c6e088"
      unitRef="usd">3429000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93db18973157470084da5a577ecb7c40_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMjktMTItMS0xLTEyNzQ1Mg_d6ba994b-94dd-4df2-8a1b-fbd1ec50a758"
      unitRef="usd">11706000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43a801ced92f421e934618c8046f564b_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMzAtNi0xLTEtMTI3NDUy_c4607a90-be65-47b6-904c-7eca4af12cea"
      unitRef="usd">820000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6bfeed5ecca54e718c3e7aefb7714ac5_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMzAtMTItMS0xLTEyNzQ1Mg_2edfd645-a07a-436b-979d-6e2dfabf7c04"
      unitRef="usd">721000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMzEtNi0xLTEtMTI3NDUy_27df0283-0834-4005-8bc7-dd9aad4c351e"
      unitRef="usd">12832000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80My9mcmFnOjRkZmJlNDhmMTdkMjQzYTY5N2JhNDQwOTFjYWU4NjMzL3RhYmxlOmE3ZWZiNDYzZjA4YjRlNjFhZmQxMWVlMjBlOTlhZGQ3L3RhYmxlcmFuZ2U6YTdlZmI0NjNmMDhiNGU2MWFmZDExZWUyMGU5OWFkZDdfMzEtMTItMS0xLTEyNzQ1Mg_f6710791-d3a6-4e32-b4c3-f449ac0ac421"
      unitRef="usd">12427000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfNTU2MA_8e747e9e-6c07-4197-9975-005d195a7329">Income taxes&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rates for the three and six months ended June 30, 2022, were 14.0% and 12.9%, respectively, compared with 16.8% and 12.6%, respectively, for the corresponding periods of the prior year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The decrease in our effective tax rate for the three months ended June 30, 2022, was primarily due to the prior year nondeductible IPR&amp;amp;D expense arising from the acquisition of Five Prime, partially offset by current year unfavorable items including a loss on a nonstrategic divestiture. The increase in our effective tax rate for the six months ended June 30, 2022, was primarily due to current year unfavorable items compared to last year including a loss on a nonstrategic divestiture, partially offset by the prior year nondeductible IPR&amp;amp;D expense arising from the acquisition of Five Prime and changes in earnings mix. The effective tax rates differ from the federal statutory rate primarily as a result of foreign earnings from the Company&#x2019;s operations conducted in Puerto Rico, a territory of the United States treated as a foreign jurisdiction for U.S. tax purposes, that are currently subject to a tax incentive grant through 2035. In addition, the Company&#x2019;s operations conducted in Singapore are subject to a tax incentive grant through 2034. These foreign earnings are also subject to U.S. tax at a reduced rate of 10.5%. See Note 2, Acquisitions and divestitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. territory of Puerto Rico imposes a 4% excise tax on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. We account for the excise tax as a manufacturing cost that is capitalized in Inventories and expensed in Cost of sales when the related products are sold. For U.S. income tax purposes, in 2022, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes can and have arisen with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. Tax authorities, including the IRS, are becoming more aggressive and are particularly focused on such matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, we received an RAR and a modified RAR from the IRS for the years 2010&#x2013;2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for the years 2010&#x2013;2012 that we received in May and July 2021, which seek to increase our U.S. taxable income for the years 2010&#x2013;2012 by an amount that would result in additional federal tax of approximately $3.6&#160;billion plus interest. Any additional tax that could be imposed for the years 2010&#x2013;2012 would be reduced by up to approximately $900&#160;million of repatriation tax previously accrued on our foreign earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In 2020, we received an RAR and a modified RAR from the IRS for the years 2013&#x2013;2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010&#x2013;2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013&#x2013;2015 that we previously reported receiving in April 2022 that seeks to increase our U.S. taxable income for the years 2013&#x2013;2015 by an amount that would result in additional federal tax of approximately $5.1&#160;billion, plus interest. In addition, the Notice asserts penalties of approximately $2.0&#160;billion. Any additional tax that could be imposed for the years 2013&#x2013;2015 would be reduced by up to approximately $2.2&#160;billion of repatriation tax previously accrued on our foreign earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We firmly believe that the IRS positions set forth in the 2010&#x2013;2012 and 2013&#x2013;2015 Notices are without merit. We are contesting the 2010&#x2013;2012 and 2013&#x2013;2015 Notices through the judicial process, and we will seek consolidation of the two periods into one case in the U.S. Tax Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We are currently under examination by the IRS for the years 2016&#x2013;2018 with respect to issues similar to those for the 2010 through 2015 period. In addition, we have examinations by a number of state and foreign tax jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Final resolution of these complex matters is not likely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Item 2. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x2014;Results of Operations, Income Taxes, for further discussion and Part II, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Item 1A, Risk&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Factors&#x2014;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June 30, 2022, the gross amounts of our UTBs increased by $50 million and $95 million, respectively, as a result of tax positions taken during the current year. Substantially all of the UTBs as of June 30, 2022, if recognized, would affect our effective tax rate.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfMTA5OTUxMTYzMzYzOA_8ebd4f61-1f02-414a-a49b-3aa9f57934cf"
      unitRef="number">0.140</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfMTA5OTUxMTYzMzY0Mw_82d66933-8502-498f-b9e8-4a42e7ddd71f"
      unitRef="number">0.129</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfMTA5OTUxMTYzMzYyNA_a5436e9b-99a4-49a8-833f-f97803449c66"
      unitRef="number">0.168</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfMTA5OTUxMTYzMzYzMw_78ca5838-51c3-4baf-a8f4-243e5c3c09af"
      unitRef="number">0.126</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <amgn:ProposedAdditionalIncomeTax
      contextRef="i46acdac3da2c44dca21c41eba4598137_I20210531"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfMjcxNw_5b9dc86f-63b6-4310-84e2-9d122104f4b8"
      unitRef="usd">3600000000</amgn:ProposedAdditionalIncomeTax>
    <amgn:RepatriationTaxOnProposedAdditionalTax
      contextRef="i46acdac3da2c44dca21c41eba4598137_I20210531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfMjgzMA_4b891d7e-fed0-42ec-abb1-29cdf8bed72b"
      unitRef="usd">900000000</amgn:RepatriationTaxOnProposedAdditionalTax>
    <amgn:ProposedAdditionalIncomeTax20132015
      contextRef="i82d3aa8175154da2ba3e9dab9d5064c0_I20220428"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfMzU1Mw_2c601a86-39b4-4e51-92fb-8a7777260dc0"
      unitRef="usd">5100000000</amgn:ProposedAdditionalIncomeTax20132015>
    <amgn:PenaltiesOnProposedAdditionalIncomeTax20132105
      contextRef="i82d3aa8175154da2ba3e9dab9d5064c0_I20220428"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfMzYzMQ_fe81ea6d-9f1f-4109-bfa1-29d73fb85058"
      unitRef="usd">2000000000</amgn:PenaltiesOnProposedAdditionalIncomeTax20132105>
    <amgn:RepatriationTaxOnProposedAdditionalTax20132015
      contextRef="i82d3aa8175154da2ba3e9dab9d5064c0_I20220428"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfMzczMA_6404c708-27f7-4b3d-94b7-580b03a00139"
      unitRef="usd">2200000000</amgn:RepatriationTaxOnProposedAdditionalTax20132015>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfNTM5OQ_db8a9aef-3b44-44b3-9ca0-9dbd22b0241a"
      unitRef="usd">50000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80Ni9mcmFnOmU1Yjg3MjM2OGYzOTRmYjdhNzJiYjdlODUxOGViZDRiL3RleHRyZWdpb246ZTViODcyMzY4ZjM5NGZiN2E3MmJiN2U4NTE4ZWJkNGJfMTY0OTI2NzQ0ODEyNg_91062859-0985-4e20-80a5-2dfe619cbb9b"
      unitRef="usd">95000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RleHRyZWdpb246Mjg0OWE4MjFjZWU5NDY1OTg1NGY2NTkxOWI4MGNlNTNfNzEy_029583b7-8623-476d-ba32-284b75543b6b">Earnings per share&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The computation of basic EPS is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The computations for basic and diluted EPS were as follows (in millions, except per-share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (Numerator):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income for basic and diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares (Denominator):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares for basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares for diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June 30, 2022 and 2021, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RleHRyZWdpb246Mjg0OWE4MjFjZWU5NDY1OTg1NGY2NTkxOWI4MGNlNTNfNzI4_c2ba86f9-7699-4d7c-8fda-a185dbc5ef57">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The computations for basic and diluted EPS were as follows (in millions, except per-share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (Numerator):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income for basic and diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares (Denominator):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares for basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares for diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMy0xLTEtMS0xMjc0NTI_7cffa87f-2b82-45e6-bc2e-f70198802ac5"
      unitRef="usd">1317000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMy0zLTEtMS0xMjc0NTI_c0b1b612-8fae-4c72-af79-c267865b9de9"
      unitRef="usd">464000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMy01LTEtMS0xMjc0NTI_629c2393-37bd-4591-b56d-f62fc5b4a218"
      unitRef="usd">2793000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMy03LTEtMS0xMjc0NTI_626ba5ea-6066-408a-8dfe-68063acf0ab1"
      unitRef="usd">2110000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfNi0xLTEtMS0xMjc0NTI_7dfd1b00-21da-4e05-957b-87663292194e"
      unitRef="shares">535000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfNi0zLTEtMS0xMjc0NTI_5af9f16d-c0a2-499f-be31-490f7ddc7046"
      unitRef="shares">573000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfNi01LTEtMS0xMjc0NTI_faeaed5d-a971-4fd5-9be5-4081239cd867"
      unitRef="shares">541000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfNi03LTEtMS0xMjc0NTI_c3f14bf2-3f68-486f-b1c9-cb53ab19c34e"
      unitRef="shares">575000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfNy0xLTEtMS0xMjc0NTI_0be22578-7143-442c-b218-953d694d5c6f"
      unitRef="shares">2000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfNy0zLTEtMS0xMjc0NTI_7be79d5f-8a63-4f12-aa96-9835a906f852"
      unitRef="shares">3000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfNy01LTEtMS0xMjc0NTI_ff45db96-5992-4c1d-a1b8-f8ed314d2ae2"
      unitRef="shares">3000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfNy03LTEtMS0xMjc0NTI_fabdcb2a-0d4d-4cb9-be4f-f58fd9d84d0b"
      unitRef="shares">3000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfOC0xLTEtMS0xMjc0NTI_8aac8d05-3678-4ed5-8329-4f8b064523d3"
      unitRef="shares">537000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfOC0zLTEtMS0xMjc0NTI_c61f4ae7-e747-475f-a3da-8f285d4c2f7a"
      unitRef="shares">576000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfOC01LTEtMS0xMjc0NTI_94e36912-cca4-4638-b9d5-8fb3927c9cb3"
      unitRef="shares">544000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfOC03LTEtMS0xMjc0NTI_b86242b4-e84d-4c09-9357-793173c6feed"
      unitRef="shares">578000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMTAtMS0xLTEtMTI3NDUy_dc749c09-7ff4-4453-9d29-813bfd6ff6fb"
      unitRef="usdPerShare">2.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMTAtMy0xLTEtMTI3NDUy_e63ab449-fe2f-4465-93ed-e66dd103fcc6"
      unitRef="usdPerShare">0.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMTAtNS0xLTEtMTI3NDUy_a2a88855-fb85-49bc-afab-2aa5ca906086"
      unitRef="usdPerShare">5.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMTAtNy0xLTEtMTI3NDUy_36db706c-25e8-4e34-8a8f-afd8dafa7cec"
      unitRef="usdPerShare">3.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMTEtMS0xLTEtMTI3NDUy_c01100d6-7c08-46c3-8ee4-688bb9bb914f"
      unitRef="usdPerShare">2.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMTEtMy0xLTEtMTI3NDUy_ea357730-cb59-478c-a8df-80cdaf2f0e68"
      unitRef="usdPerShare">0.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMTEtNS0xLTEtMTI3NDUy_907149cb-677e-4227-a72d-a5b74bfb4a01"
      unitRef="usdPerShare">5.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV80OS9mcmFnOjI4NDlhODIxY2VlOTQ2NTk4NTRmNjU5MTliODBjZTUzL3RhYmxlOjk2YWZmNjc0MDY4MTQ1ZGVhMmNlZWUxNWFhYjI1ZDM4L3RhYmxlcmFuZ2U6OTZhZmY2NzQwNjgxNDVkZWEyY2VlZTE1YWFiMjVkMzhfMTEtNy0xLTEtMTI3NDUy_bb79ab30-3b48-4d2a-bc17-a5bf43c46e29"
      unitRef="usdPerShare">3.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfNDk0NzgwMjMzODAzMw_05e15192-87fa-47cd-ac1d-e6a57ecacc5b">Investments&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available-for-sale investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Types of securities as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Types of securities as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents in the above table excludes bank account cash of $770 million and $733&#160;million as of June 30, 2022 and December 31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total interest-bearing securities as of June 30, 2022 and December 31, 2021, mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June 30, 2022 and 2021, realized gains and losses on interest-bearing securities were not material. Realized gains and losses on interest-bearing securities are recorded in Other (expense) income, net, in the Condensed Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We held investments in equity securities with readily determinable fair values (publicly traded securities) of $361 million and $611 million as of June 30, 2022 and December 31, 2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. During the three months ended June 30, 2022 and 2021, net unrealized gains and losses on publicly traded securities were a $106&#160;million net loss and a $25&#160;million net gain, respectively. During the six months ended June 30, 2022 and 2021, net unrealized losses on publicly traded securities were $276&#160;million and $31&#160;million, respectively. Realized gains and losses on sales of publicly traded securities for the three and six months ended June 30, 2022 and 2021, were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We held investments of $280 million and $262 million in equity securities without readily determinable fair values as of June 30, 2022 and December 31, 2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. During the three and six months ended June 30, 2022 and 2021, upward adjustments and downward adjustments on these securities were not material. Adjustments were based on observable price transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity method investments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022 and December 31, 2021, we had an ownership interest in BeiGene of approximately 18.2% and 18.4%, respectively, which is included in Other noncurrent assets in the Condensed Consolidated Balance Sheets and accounted for under the equity method of accounting. We amortize the difference between the fair value of equity securities acquired and our proportionate share of the carrying value of the underlying net assets of BeiGene over the useful lives of the assets that gave rise to this basis difference. This amortization and our share of the results of operations of BeiGene are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (expense) income, net&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in the Condensed Consolidated Statements of Income one quarter in arrears. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June 30, 2022 and 2021, the carrying value of our equity investment was adjusted by our share of BeiGene&#x2019;s net loss of $80&#160;million and net income of $14&#160;million, respectively, and amortization of the basis difference of $48&#160;million and $42&#160;million, respectively. During the six months ended June 30, 2022 and 2021, the carrying value of our equity investment was adjusted by our share of BeiGene&#x2019;s net losses of $188&#160;million and $83&#160;million, respectively, and amortization of the basis difference of $95 million and $84&#160;million, respectively. As of June 30, 2022 and December 31, 2021, the carrying values of our investment in BeiGene totaled $2.5&#160;billion and $2.8&#160;billion, respectively, and the fair values of our investment totaled $3.1&#160;billion and $5.1&#160;billion, respectively. As of June 30, 2022, we believe the carrying value of our equity investment in BeiGene is fully recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Neumora Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2021, we acquired an approximately 25.9% ownership interest in Neumora, a privately held company, for $257&#160;million, which is included in Other noncurrent assets in the Condensed Consolidated Balance Sheets, in exchange for a $100&#160;million cash payment and $157&#160;million in noncash consideration primarily related to future services. Although our equity investment provides us with the ability to exercise significant influence over Neumora, we have elected the fair value option to account for our equity investment. Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period. We believe the fair value option best reflects the economics of the underlying transaction. As of June 30, 2022 and December 31, 2021, our ownership interest in Neumora was approximately 25.7% and 25.9%, respectively, and the fair values of our investment were $131 million and $220 million, respectively. Accordingly, for the reduction in fair value of our investment during the three and six months ended June 30, 2022, we recognized a loss of $39&#160;million and $89&#160;million, respectively, for the reduction in fair value of our investment in Other (expense) income, net, in the Condensed Consolidated Statements of Income. For information on determination of fair values, see Note 11, Fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Limited partnerships&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We held limited partnership investments of $338 million and $573 million as of June 30, 2022 and December 31, 2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. These investments, primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of June 30, 2022, unfunded additional commitments to be made for these investments during the next several years were $209&#160;million. For the three months ended June 30, 2022 and 2021, net unrealized losses from our limited partnership investments were $60&#160;million and $43&#160;million, respectively. For the six months ended June 30, 2022 and 2021, net unrealized gains and losses from our limited partnership investments were a $220&#160;million net loss and a $165&#160;million net gain, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfNTY1OA_b3ddea09-5fac-484d-8c00-7a9e4cbb12a5">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Types of securities as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Types of securities as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8082d2e09a5c4aa0a7f3731849ec0d16_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMS0yLTEtMS0xMjc0NTI_48edb2a7-91c0-4d91-bdbe-99c190340cb8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8082d2e09a5c4aa0a7f3731849ec0d16_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMS00LTEtMS0xMjc0NTI_e4dde22f-4594-4c51-8944-ad782e7f57a6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8082d2e09a5c4aa0a7f3731849ec0d16_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMS02LTEtMS0xMjc0NTI_ba4dfb27-8f00-4259-9082-7d2d74af0195"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8082d2e09a5c4aa0a7f3731849ec0d16_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMS04LTEtMS0xMjc0NTI_4a7017b7-812f-4d6d-8236-77f21a21b0e6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1ea16251ca3344cd8e26c09cc1395a22_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMi0yLTEtMS0xMjc0NTI_f9a1e9de-d1af-4a72-a2ed-41cdba808c11"
      unitRef="usd">1980000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1ea16251ca3344cd8e26c09cc1395a22_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMi00LTEtMS0xMjc0NTI_b3b30cd0-32c0-41aa-9aa8-92910bc8f535"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1ea16251ca3344cd8e26c09cc1395a22_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMi02LTEtMS0xMjc0NTI_5cf75b8e-37d5-4386-84a2-a3c2e213565a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1ea16251ca3344cd8e26c09cc1395a22_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMi04LTEtMS0xMjc0NTI_92cb65e4-4e31-463b-b3c2-614582631e50"
      unitRef="usd">1980000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifbbc44571a8140188c44b0df13007242_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTItMi0xLTEtMTI3NDUy_c5230cb0-0a0c-4cbe-8a92-7f27aabca063"
      unitRef="usd">4433000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifbbc44571a8140188c44b0df13007242_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTItNC0xLTEtMTI3NDUy_39caeaa1-982f-4f04-be56-8d65338fcd7a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifbbc44571a8140188c44b0df13007242_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTItNi0xLTEtMTI3NDUy_0b99db1d-dc87-4e82-86a6-2b3bf4d11032"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifbbc44571a8140188c44b0df13007242_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTItOC0xLTEtMTI3NDUy_97cdc12c-f56a-44d2-aa4d-e666879959c9"
      unitRef="usd">4433000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie2f04eaab04b4d2c952875e4954ffda7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTMtMi0xLTEtMTI3NDUy_e0551b31-4e7b-4ac1-99cd-a09c54420bf4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie2f04eaab04b4d2c952875e4954ffda7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTMtNC0xLTEtMTI3NDUy_8d055f53-b230-4cb7-8afa-44c158019974"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie2f04eaab04b4d2c952875e4954ffda7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTMtNi0xLTEtMTI3NDUy_1a47ef7f-d4d1-4262-9797-2e9f4599b4fb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie2f04eaab04b4d2c952875e4954ffda7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTMtOC0xLTEtMTI3NDUy_f9f867b4-cd5d-4802-9c4e-ac311c0d40fd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTYtMi0xLTEtMTI3NDUy_16a6a31f-a439-4f96-af96-1a7950c93004"
      unitRef="usd">6413000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTYtNC0xLTEtMTI3NDUy_9d403729-dd0f-4f12-9e8c-d4b535b5b515"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTYtNi0xLTEtMTI3NDUy_5967036d-1df0-40ea-ae12-bd105e20a32b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmVkZTc2NmFlN2FlMjRhZjg5NmU3NzkyNzY2MzQxMzE2L3RhYmxlcmFuZ2U6ZWRlNzY2YWU3YWUyNGFmODk2ZTc3OTI3NjYzNDEzMTZfMTYtOC0xLTEtMTI3NDUy_4c2b1348-153b-464d-80f5-5919fd1d6684"
      unitRef="usd">6413000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idd41271077fb4ca086b8c963378ae207_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMS0yLTEtMS0xMjc0NTI_f1a0f231-c3c6-4656-ac13-1e11e911c7e2"
      unitRef="usd">47000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idd41271077fb4ca086b8c963378ae207_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMS00LTEtMS0xMjc0NTI_34c3b0aa-8fa5-45fd-97e3-b53eb09dd566"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idd41271077fb4ca086b8c963378ae207_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMS02LTEtMS0xMjc0NTI_280f1faa-6cf0-4daa-8cb1-b66660082320"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idd41271077fb4ca086b8c963378ae207_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMS04LTEtMS0xMjc0NTI_8819f199-4604-4fd0-b4c7-0fab49fc0bc9"
      unitRef="usd">47000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3c7a0f871105442a9e599228c9451089_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMi0yLTEtMS0xMjc0NTI_22c37691-f54e-4ff6-8568-87ce33ae370a"
      unitRef="usd">1400000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3c7a0f871105442a9e599228c9451089_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMi00LTEtMS0xMjc0NTI_c5564d9c-984e-48f1-b7a0-66c32b45677a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3c7a0f871105442a9e599228c9451089_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMi02LTEtMS0xMjc0NTI_bc843aff-c995-454c-89cf-fe06c6e4fcc6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3c7a0f871105442a9e599228c9451089_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMi04LTEtMS0xMjc0NTI_860273a6-d9e0-4f8b-a5d7-f3c678bbd8d2"
      unitRef="usd">1400000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i02847d17ecc24c3f9024cc5f534c04a2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTItMi0xLTEtMTI3NDUy_084d4764-14ff-40ae-9ed8-ca9a2c10fd36"
      unitRef="usd">5856000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i02847d17ecc24c3f9024cc5f534c04a2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTItNC0xLTEtMTI3NDUy_b7f89837-0d18-4a3a-9780-9be45ea7ed02"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i02847d17ecc24c3f9024cc5f534c04a2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTItNi0xLTEtMTI3NDUy_84aadb83-e67b-43a7-8cf8-a854cc6e33af"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i02847d17ecc24c3f9024cc5f534c04a2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTItOC0xLTEtMTI3NDUy_f963c757-e0de-4a1b-90fa-5949a6a33548"
      unitRef="usd">5856000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iea64a31893bd4a61a10bade5fb93931f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTMtMi0xLTEtMTI3NDUy_2cecfa5b-bad5-497c-85be-bce5ac5e1ba3"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iea64a31893bd4a61a10bade5fb93931f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTMtNC0xLTEtMTI3NDUy_e9ed3b6e-47e6-497f-a62d-d3ef09260ec0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iea64a31893bd4a61a10bade5fb93931f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTMtNi0xLTEtMTI3NDUy_5445ccee-f562-42a3-87e1-3838aec00944"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iea64a31893bd4a61a10bade5fb93931f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTMtOC0xLTEtMTI3NDUy_0b19ba06-8fe8-483e-bbfe-8abfa4bcc315"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTQtMi0xLTEtMTI3NDUy_f83f1f38-c9fd-4267-a1b3-e4a172c2118a"
      unitRef="usd">7304000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTQtNC0xLTEtMTI3NDUy_e268cac4-9225-41b9-94f8-5cefb4163a86"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTQtNi0xLTEtMTI3NDUy_ca7cae39-a9d0-43ee-a23c-adc23a0f1170"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOmQxODM4NDIzOWRkYzRiMWI4YmFlYzE3N2MzZWFmNDMyL3RhYmxlcmFuZ2U6ZDE4Mzg0MjM5ZGRjNGIxYjhiYWVjMTc3YzNlYWY0MzJfMTQtOC0xLTEtMTI3NDUy_21d100df-2cd2-4715-b926-977ca48835b0"
      unitRef="usd">7304000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <amgn:FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfNTYzNg_80b52ac0-3a6d-4594-9968-4d8703e179b4">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amgn:FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic3ee9095509a4235b125b11b137e139e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOjdmNzg4MGJlMDE1NDQzZWRiMWZjNWMwYjRjY2RmYTNkL3RhYmxlcmFuZ2U6N2Y3ODgwYmUwMTU0NDNlZGIxZmM1YzBiNGNjZGZhM2RfMS0yLTEtMS0xMjc0NTI_2abcd866-c052-4c92-8738-31ed9529392e"
      unitRef="usd">4433000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2192ca00bef0437697f96821d3d064c5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOjdmNzg4MGJlMDE1NDQzZWRiMWZjNWMwYjRjY2RmYTNkL3RhYmxlcmFuZ2U6N2Y3ODgwYmUwMTU0NDNlZGIxZmM1YzBiNGNjZGZhM2RfMS00LTEtMS0xMjc0NTI_cb1e9cc2-9325-47ba-94fb-9e0b9fb35097"
      unitRef="usd">7256000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic3ee9095509a4235b125b11b137e139e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOjdmNzg4MGJlMDE1NDQzZWRiMWZjNWMwYjRjY2RmYTNkL3RhYmxlcmFuZ2U6N2Y3ODgwYmUwMTU0NDNlZGIxZmM1YzBiNGNjZGZhM2RfMi0yLTEtMS0xMjc0NTI_9c1f799b-d9fc-4f72-bc12-8bef1fca20e9"
      unitRef="usd">1980000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2192ca00bef0437697f96821d3d064c5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOjdmNzg4MGJlMDE1NDQzZWRiMWZjNWMwYjRjY2RmYTNkL3RhYmxlcmFuZ2U6N2Y3ODgwYmUwMTU0NDNlZGIxZmM1YzBiNGNjZGZhM2RfMi00LTEtMS0xMjc0NTI_2ce5b7c0-ed9e-423a-96ee-ca1851225447"
      unitRef="usd">48000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic3ee9095509a4235b125b11b137e139e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOjdmNzg4MGJlMDE1NDQzZWRiMWZjNWMwYjRjY2RmYTNkL3RhYmxlcmFuZ2U6N2Y3ODgwYmUwMTU0NDNlZGIxZmM1YzBiNGNjZGZhM2RfMy0yLTEtMS0xMjc0NTI_b87bc774-6504-4969-85b7-53a7981214bd"
      unitRef="usd">6413000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2192ca00bef0437697f96821d3d064c5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RhYmxlOjdmNzg4MGJlMDE1NDQzZWRiMWZjNWMwYjRjY2RmYTNkL3RhYmxlcmFuZ2U6N2Y3ODgwYmUwMTU0NDNlZGIxZmM1YzBiNGNjZGZhM2RfMy00LTEtMS0xMjc0NTI_3c23921d-122a-4ef5-b9d2-5c4798a56435"
      unitRef="usd">7304000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:Cash
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfNDY4_5034ef4b-9c8d-4280-ac4b-74bd4c82789a"
      unitRef="usd">770000000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfNDc1_c8377ff0-1991-444b-86b2-86c4f2f33ae2"
      unitRef="usd">733000000</us-gaap:Cash>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i52bfb5d420974f909b489605f4ebb48e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTQ3NQ_33a1dfd7-f8b2-4b74-9911-9a309ebd440f"
      unitRef="usd">361000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i81cbf2552fde457394dd38fa4c8d3a52_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTQ4Mg_9e862bad-4fbd-437d-92eb-253e8eb9df33"
      unitRef="usd">611000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTA5OTUxMTYzMzYwMw_aabc6f95-6e59-41fd-977a-da528a9f3e67"
      unitRef="usd">-106000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTA5OTUxMTYzMzYxNw_3f97788b-b901-48b9-a91c-3abb8c998cca"
      unitRef="usd">25000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTcwMA_ec2cff85-0d3c-4777-afe3-5f1ed0084f8f"
      unitRef="usd">-276000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTcwNw_36e2445c-dc8d-4f51-a087-c456539b20d2"
      unitRef="usd">-31000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTg2Nw_fac8c088-1c31-4478-9ada-ab97599952ef"
      unitRef="usd">280000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTg3NA_a18d05c0-a0d9-4016-ab6d-09ffa8db3d4b"
      unitRef="usd">262000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i508f5bf239c54b9b938463f7ae92fea1_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMjM1Ng_4c2ca0d1-fb75-4bbc-87d4-2fb21eccabed"
      unitRef="number">0.182</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ic408702ec02a49bf91a6056997008286_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMjc0ODc3OTA4Mjk5NA_8e6fba37-4eee-476b-8e2d-0e2fdd6c5263"
      unitRef="number">0.184</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i496aa2763a92482692aec0e597926c98_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzA3MA_4615e039-a47d-4235-aaa2-e773724244e0"
      unitRef="usd">-80000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0a1cd1326d554d03be0c62860aaadc16_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzA3Nw_e840de2e-b7fd-481b-ab64-43a3167c478e"
      unitRef="usd">14000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="i496aa2763a92482692aec0e597926c98_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzEzOQ_c36c3aa1-5824-4a0a-8195-c829bba60ad9"
      unitRef="usd">48000000</amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="i0a1cd1326d554d03be0c62860aaadc16_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzE0Ng_a43cddb2-d59d-4a3d-85a2-8d51158a1456"
      unitRef="usd">42000000</amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic159ef06be114a82aece4d92d6710839_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzI1Mw_c896b102-623f-4ab7-8bd3-616f8cabd30d"
      unitRef="usd">-188000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i888296d1eab64b6b817ca5c5d9f69be8_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzI2MA_1e598e38-08de-494f-87d5-6e954c20eb79"
      unitRef="usd">-83000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="ic159ef06be114a82aece4d92d6710839_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzMyNA_80234bb9-2de5-4a01-b931-4372b1741217"
      unitRef="usd">95000000</amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="i888296d1eab64b6b817ca5c5d9f69be8_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzMzMQ_8366245e-ed78-4b8a-8869-3b6fb8a5b440"
      unitRef="usd">84000000</amgn:EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:EquityMethodInvestments
      contextRef="i508f5bf239c54b9b938463f7ae92fea1_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMjc0ODc3OTA4Mjg4Mg_b9c404ae-1591-4ece-83df-b6eae67f8196"
      unitRef="usd">2500000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ic408702ec02a49bf91a6056997008286_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMjc0ODc3OTA4Mjg5Ng_3ce4ea1f-c580-404f-bc8b-35e6596cd1ee"
      unitRef="usd">2800000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="i508f5bf239c54b9b938463f7ae92fea1_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMjc0ODc3OTA4Mjc4Mg_d8329e4e-f3fb-41b2-ad52-931a15d5dc47"
      unitRef="usd">3100000000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="ic408702ec02a49bf91a6056997008286_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMjc0ODc3OTA4Mjc5Nw_6358c6e0-5358-4e6d-9f4c-3d2425ba23d2"
      unitRef="usd">5100000000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i5cda008dddc94401b22d3259266fc7e7_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzUyNA_45fde6e4-762f-4fde-82bd-2b7e8780c67c"
      unitRef="number">0.259</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i5cda008dddc94401b22d3259266fc7e7_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzU4OA_4fdd58c7-e121-4c7b-81d0-e9d9170a2ad2"
      unitRef="usd">257000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="icdb22de342f041adb8e2b70cbc132e50_D20210930-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzcwMQ_a381fd4c-7ea0-4f2b-a81d-f2fb33c682bc"
      unitRef="usd">100000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:NoncashOrPartNoncashAcquisitionInvestmentsAcquired1
      contextRef="icdb22de342f041adb8e2b70cbc132e50_D20210930-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMzcyMQ_621e974f-bd37-4608-acc3-29e623129807"
      unitRef="usd">157000000</us-gaap:NoncashOrPartNoncashAcquisitionInvestmentsAcquired1>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1d79fa0d130e44d19361d654d95e141d_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfNDI3Mw_34c1d622-f748-43d2-8b40-e8bd19cd857d"
      unitRef="number">0.257</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ic76acadc687c4a66b5883e78b037a6ad_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfNDI4MA_3be8de38-9d4c-4cc6-a89f-5d6d6d112046"
      unitRef="number">0.259</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="i1d79fa0d130e44d19361d654d95e141d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfOTg5NTYwNDY2MDI5NQ_5388bb8e-bf6f-4e03-bcf9-5a84e4d51086"
      unitRef="usd">131000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="ic76acadc687c4a66b5883e78b037a6ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfOTg5NTYwNDY2MDI4OA_731d3464-a3a5-4d43-bc53-b97b253a45c0"
      unitRef="usd">220000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <amgn:EquityMethodInvestmentChangeInCarryingValue
      contextRef="ifbd4bb3072a846dead8e321c6b0cf833_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMjc0ODc3OTA4MjgxMg_214e9501-576e-44c1-80ef-76bd7f7bd006"
      unitRef="usd">39000000</amgn:EquityMethodInvestmentChangeInCarryingValue>
    <amgn:EquityMethodInvestmentChangeInCarryingValue
      contextRef="i0f602482804d4aec8fdc3e408b13ed29_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMjc0ODc3OTA4MjgzNw_2df54689-f84d-4b09-b972-2853e7af5bb8"
      unitRef="usd">89000000</amgn:EquityMethodInvestmentChangeInCarryingValue>
    <us-gaap:AlternativeInvestment
      contextRef="iaa0314910b794236a904970854a1e630_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfNDczNg_20503471-c3e9-4cab-96c1-1d17c1be478d"
      unitRef="usd">338000000</us-gaap:AlternativeInvestment>
    <us-gaap:AlternativeInvestment
      contextRef="ib8b0ba79e4914ce8815964b9387a76dd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfNDc0Mw_03b79955-2125-42ce-a7bf-df2da1958161"
      unitRef="usd">573000000</us-gaap:AlternativeInvestment>
    <us-gaap:InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount
      contextRef="i1fe68111c13942ef9c7a0d951601d88b_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfNTQwMA_2be2c92f-8a97-44bc-aa9e-1faf89aaf23c"
      unitRef="usd">209000000</us-gaap:InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount>
    <amgn:AlternativeInvestmentNetGainLoss
      contextRef="i401f6926d97c46c6a10162d5f3c2efde_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTA5OTUxMTYzNDA0Ng_f5a02be9-ae83-4208-a2eb-a5a4ebb3eae2"
      unitRef="usd">-60000000</amgn:AlternativeInvestmentNetGainLoss>
    <amgn:AlternativeInvestmentNetGainLoss
      contextRef="i62aa67f340d349a684242e6f5ab5e761_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTA5OTUxMTYzNDA2NA_f7f08a04-48a5-4a2d-9034-ae5e2b0d68db"
      unitRef="usd">-43000000</amgn:AlternativeInvestmentNetGainLoss>
    <amgn:AlternativeInvestmentNetGainLoss
      contextRef="ife312c8d8cce47d28d37a01320dd5c28_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTA5OTUxMTYzNDQyNg_92778825-3f71-4524-8816-c0ff3501ed71"
      unitRef="usd">-220000000</amgn:AlternativeInvestmentNetGainLoss>
    <amgn:AlternativeInvestmentNetGainLoss
      contextRef="i9d1c8a9209dc4f9fbe9812c8fcc8987d_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81Mi9mcmFnOmQ3YzI0NjZlNjU0MTRmOTg4YWY3MDQ3NDY3ZTNkNjk0L3RleHRyZWdpb246ZDdjMjQ2NmU2NTQxNGY5ODhhZjcwNDc0NjdlM2Q2OTRfMTA5OTUxMTYzNDQ0Mg_603d4567-7ce2-4645-b0c9-a144137e21e0"
      unitRef="usd">165000000</amgn:AlternativeInvestmentNetGainLoss>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81NS9mcmFnOjlmMGUxZWIwMmY4ZDRkYTlhNmFlMjI0MDBiNzc4ZWM4L3RleHRyZWdpb246OWYwZTFlYjAyZjhkNGRhOWE2YWUyMjQwMGI3NzhlYzhfODQ_dd54cebb-fe7d-4c8b-8519-6370bc0a71de">Inventories&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81NS9mcmFnOjlmMGUxZWIwMmY4ZDRkYTlhNmFlMjI0MDBiNzc4ZWM4L3RleHRyZWdpb246OWYwZTFlYjAyZjhkNGRhOWE2YWUyMjQwMGI3NzhlYzhfODM_8d800b7d-b92d-46e3-a991-2c6fbe94fbae">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81NS9mcmFnOjlmMGUxZWIwMmY4ZDRkYTlhNmFlMjI0MDBiNzc4ZWM4L3RhYmxlOjJhN2YxZjI2YzZhMDRhZGFiZjI5ZWVlYzg5MGI1NTNlL3RhYmxlcmFuZ2U6MmE3ZjFmMjZjNmEwNGFkYWJmMjllZWVjODkwYjU1M2VfMS0xLTEtMS0xMjc0NTI_d1146598-6876-4736-82c5-776eaf06e95b"
      unitRef="usd">779000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81NS9mcmFnOjlmMGUxZWIwMmY4ZDRkYTlhNmFlMjI0MDBiNzc4ZWM4L3RhYmxlOjJhN2YxZjI2YzZhMDRhZGFiZjI5ZWVlYzg5MGI1NTNlL3RhYmxlcmFuZ2U6MmE3ZjFmMjZjNmEwNGFkYWJmMjllZWVjODkwYjU1M2VfMS0zLTEtMS0xMjc0NTI_0510b7e7-b4eb-47d3-9b46-3090502a337d"
      unitRef="usd">647000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81NS9mcmFnOjlmMGUxZWIwMmY4ZDRkYTlhNmFlMjI0MDBiNzc4ZWM4L3RhYmxlOjJhN2YxZjI2YzZhMDRhZGFiZjI5ZWVlYzg5MGI1NTNlL3RhYmxlcmFuZ2U6MmE3ZjFmMjZjNmEwNGFkYWJmMjllZWVjODkwYjU1M2VfMi0xLTEtMS0xMjc0NTI_c7b66cde-b9bb-495a-8b01-2d1ebb3a32dd"
      unitRef="usd">2763000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81NS9mcmFnOjlmMGUxZWIwMmY4ZDRkYTlhNmFlMjI0MDBiNzc4ZWM4L3RhYmxlOjJhN2YxZjI2YzZhMDRhZGFiZjI5ZWVlYzg5MGI1NTNlL3RhYmxlcmFuZ2U6MmE3ZjFmMjZjNmEwNGFkYWJmMjllZWVjODkwYjU1M2VfMi0zLTEtMS0xMjc0NTI_8e7c2f52-b895-4b86-b309-1975662eacfe"
      unitRef="usd">2367000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81NS9mcmFnOjlmMGUxZWIwMmY4ZDRkYTlhNmFlMjI0MDBiNzc4ZWM4L3RhYmxlOjJhN2YxZjI2YzZhMDRhZGFiZjI5ZWVlYzg5MGI1NTNlL3RhYmxlcmFuZ2U6MmE3ZjFmMjZjNmEwNGFkYWJmMjllZWVjODkwYjU1M2VfMy0xLTEtMS0xMjc0NTI_75e6d0b0-ff4b-4b03-bcc9-2dd7881858a6"
      unitRef="usd">1012000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81NS9mcmFnOjlmMGUxZWIwMmY4ZDRkYTlhNmFlMjI0MDBiNzc4ZWM4L3RhYmxlOjJhN2YxZjI2YzZhMDRhZGFiZjI5ZWVlYzg5MGI1NTNlL3RhYmxlcmFuZ2U6MmE3ZjFmMjZjNmEwNGFkYWJmMjllZWVjODkwYjU1M2VfMy0zLTEtMS0xMjc0NTI_00572c50-57db-4d9b-9864-e224b4cece6f"
      unitRef="usd">1072000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81NS9mcmFnOjlmMGUxZWIwMmY4ZDRkYTlhNmFlMjI0MDBiNzc4ZWM4L3RhYmxlOjJhN2YxZjI2YzZhMDRhZGFiZjI5ZWVlYzg5MGI1NTNlL3RhYmxlcmFuZ2U6MmE3ZjFmMjZjNmEwNGFkYWJmMjllZWVjODkwYjU1M2VfNC0xLTEtMS0xMjc0NTI_5dade705-a1a5-44e8-b62e-b7bb5e854692"
      unitRef="usd">4554000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81NS9mcmFnOjlmMGUxZWIwMmY4ZDRkYTlhNmFlMjI0MDBiNzc4ZWM4L3RhYmxlOjJhN2YxZjI2YzZhMDRhZGFiZjI5ZWVlYzg5MGI1NTNlL3RhYmxlcmFuZ2U6MmE3ZjFmMjZjNmEwNGFkYWJmMjllZWVjODkwYjU1M2VfNC0zLTEtMS0xMjc0NTI_93c7face-366b-4912-a72b-a461e768140d"
      unitRef="usd">4086000000</us-gaap:InventoryNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTkyNg_77d1afc0-c7bb-4753-b754-2057086bf2c3">Goodwill and other intangible assets&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the carrying amount of goodwill was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.331%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to goodwill resulting from acquisitions and divestitures, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Composed of adjustments to goodwill resulting from changes to the acquisition date fair values of net assets acquired in the acquisition of Teneobio and the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other intangible assets consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.433%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other intangible&lt;br/&gt;assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other intangible&lt;br/&gt;assets, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed-product-technology rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,769)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing-related rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development technology rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Developed-product-technology rights consists of rights related to marketed products. Licensing rights primarily consists of contractual rights to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and upfront payments associated with royalty obligations for marketed products. Marketing-related rights primarily consists of rights related to the sale and distribution of marketed products. R&amp;amp;D technology rights pertains to technologies used in R&amp;amp;D that have alternative future uses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D consists of R&amp;amp;D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. We review IPR&amp;amp;D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June 30, 2022 and 2021, we recognized amortization associated with our finite-lived intangible assets of $629 million and $652 million, respectively. During the six months ended June 30, 2022 and 2021, we recognized amortization associated with our finite-lived intangible assets of $1.3 billion in both periods. Amortization of intangible assets is primarily included in Cost of sales in the Condensed Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the remaining six months ending December 31, 2022, and the years ending December 31, 2023, 2024, 2025, 2026 and 2027, are $1.3 billion, $2.5 billion, $2.5 billion, $2.4 billion, $1.7 billion and $1.8 billion, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTkyNw_cb3978ff-725c-42d3-bcf3-82bab3917f7c">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the carrying amount of goodwill was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.331%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to goodwill resulting from acquisitions and divestitures, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Composed of adjustments to goodwill resulting from changes to the acquisition date fair values of net assets acquired in the acquisition of Teneobio and the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmE4NGUzZDBmMGIwOTQ1MWRhN2ZmNzA0NTAxMzRjYTI0L3RhYmxlcmFuZ2U6YTg0ZTNkMGYwYjA5NDUxZGE3ZmY3MDQ1MDEzNGNhMjRfMS0xLTEtMS0xMjc0NTI_bf668a03-0ce1-475f-a15e-3246fd55d4ce"
      unitRef="usd">14890000000</us-gaap:Goodwill>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmE4NGUzZDBmMGIwOTQ1MWRhN2ZmNzA0NTAxMzRjYTI0L3RhYmxlcmFuZ2U6YTg0ZTNkMGYwYjA5NDUxZGE3ZmY3MDQ1MDEzNGNhMjRfMi0xLTEtMS0xMjc0NTI_e2993e8f-f70c-4f53-8d37-ab5b23ad9538"
      unitRef="usd">7000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmE4NGUzZDBmMGIwOTQ1MWRhN2ZmNzA0NTAxMzRjYTI0L3RhYmxlcmFuZ2U6YTg0ZTNkMGYwYjA5NDUxZGE3ZmY3MDQ1MDEzNGNhMjRfMy0xLTEtMS0xMjc0NTI_587f5c90-bc13-416f-9d47-a899d3745fcc"
      unitRef="usd">-32000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmE4NGUzZDBmMGIwOTQ1MWRhN2ZmNzA0NTAxMzRjYTI0L3RhYmxlcmFuZ2U6YTg0ZTNkMGYwYjA5NDUxZGE3ZmY3MDQ1MDEzNGNhMjRfNC0xLTEtMS0xMjc0NTI_0200459e-4fe6-4779-afa9-db19ace302c2"
      unitRef="usd">14865000000</us-gaap:Goodwill>
    <amgn:ScheduleOfIntangibleAssetsTableTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTk0MA_46512012-6d1f-416c-bcf1-da4b6607fc00">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other intangible assets consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.433%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other intangible&lt;br/&gt;assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other intangible&lt;br/&gt;assets, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed-product-technology rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,769)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing-related rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development technology rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amgn:ScheduleOfIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia61f1d92e9464dd18e99ac1aa3b366de_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMy0xLTEtMS0xMjc0NTI_6315a2e4-ad23-4c81-8df2-568b5742ed65"
      unitRef="usd">25537000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia61f1d92e9464dd18e99ac1aa3b366de_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMy0zLTEtMS0xMjc0NTI_0fe43f5d-4e03-4c97-a8f1-dcc12ac50b80"
      unitRef="usd">13863000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia61f1d92e9464dd18e99ac1aa3b366de_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMy01LTEtMS0xMjc0NTI_c43d5fd2-61ba-4371-b02d-1b3d99f86dd7"
      unitRef="usd">11674000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1cce03dee4c34b2ea84da100e20fbd24_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMy03LTEtMS0xMjc0NTI_b7919ad8-4a67-4039-9bf1-7dada6c56ad7"
      unitRef="usd">25561000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1cce03dee4c34b2ea84da100e20fbd24_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMy05LTEtMS0xMjc0NTI_ccb6601b-6d96-496c-b00e-e07adf12a10b"
      unitRef="usd">12769000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1cce03dee4c34b2ea84da100e20fbd24_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMy0xMS0xLTEtMTI3NDUy_10d0a39b-53aa-4c33-853f-3fb0306b0087"
      unitRef="usd">12792000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i099607de031547a9bb9e43f15bb881fc_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNC0xLTEtMS0xMjc0NTI_cf3233de-32c5-4688-965f-31847b357a2d"
      unitRef="usd">3864000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i099607de031547a9bb9e43f15bb881fc_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNC0zLTEtMS0xMjc0NTI_ee3c75c0-7fd7-4688-b153-d73d72e60de6"
      unitRef="usd">3050000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i099607de031547a9bb9e43f15bb881fc_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNC01LTEtMS0xMjc0NTI_d7e027d0-7009-4236-b5f4-0e09740237e2"
      unitRef="usd">814000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic07181533cda4f5e93039975aae670b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNC03LTEtMS0xMjc0NTI_afe092f4-c4ae-4cf2-96a8-d1c9dd146e8f"
      unitRef="usd">3807000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic07181533cda4f5e93039975aae670b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNC05LTEtMS0xMjc0NTI_cca39f04-83c6-44e4-b628-7854df9b4ea0"
      unitRef="usd">2973000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic07181533cda4f5e93039975aae670b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNC0xMS0xLTEtMTI3NDUy_97b1659d-c76f-4db5-bd75-ca1dca39bfaf"
      unitRef="usd">834000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iac2b57574dd942a2a453e505dabd533e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNS0xLTEtMS0xMjc0NTI_903ca88b-91d8-48b4-a0ea-f5f8cae08b71"
      unitRef="usd">1326000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iac2b57574dd942a2a453e505dabd533e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNS0zLTEtMS0xMjc0NTI_85931f1a-3a77-46f2-b611-1ed0f6b2dba8"
      unitRef="usd">1125000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iac2b57574dd942a2a453e505dabd533e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNS01LTEtMS0xMjc0NTI_d99bbd97-0fd2-4d0a-af82-320f9428b29b"
      unitRef="usd">201000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1fb7461fd5694c57866568ce1e547030_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNS03LTEtMS0xMjc0NTI_55819cd1-cb42-4f27-953b-acf6bea409cb"
      unitRef="usd">1354000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1fb7461fd5694c57866568ce1e547030_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNS05LTEtMS0xMjc0NTI_9f581cb8-19df-4604-a479-e61655e838f2"
      unitRef="usd">1112000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1fb7461fd5694c57866568ce1e547030_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNS0xMS0xLTEtMTI3NDUy_24eae4aa-eab8-48de-bdcf-9670844d1522"
      unitRef="usd">242000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3fb86733ee024515869430e8dbaa9324_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNi0xLTEtMS0xMjc0NTI_ee77371f-cb6c-4dfd-bcdc-cec223d6a078"
      unitRef="usd">1371000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3fb86733ee024515869430e8dbaa9324_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNi0zLTEtMS0xMjc0NTI_15852ef9-cb0b-44eb-b041-f98a9843b409"
      unitRef="usd">1153000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3fb86733ee024515869430e8dbaa9324_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNi01LTEtMS0xMjc0NTI_236e04a8-247b-4c42-9bfc-b093503d96f9"
      unitRef="usd">218000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i571fbd60834f45a8a94ddbcd37f40d78_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNi03LTEtMS0xMjc0NTI_893d92d6-b95d-4148-ac03-c8446a5956af"
      unitRef="usd">1377000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i571fbd60834f45a8a94ddbcd37f40d78_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNi05LTEtMS0xMjc0NTI_4c704a83-88b9-40f8-91cf-52737987c7a2"
      unitRef="usd">1133000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i571fbd60834f45a8a94ddbcd37f40d78_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNi0xMS0xLTEtMTI3NDUy_ff203832-5bd4-4b17-811b-07129ab6bf63"
      unitRef="usd">244000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNy0xLTEtMS0xMjc0NTI_a4c417bc-8a9d-49b7-a3ae-e6eaa0f02529"
      unitRef="usd">32098000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNy0zLTEtMS0xMjc0NTI_572f7596-d08f-4cef-b06e-4e1d955db7d7"
      unitRef="usd">19191000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNy01LTEtMS0xMjc0NTI_50944a35-5688-4295-9ed8-0359412ce3af"
      unitRef="usd">12907000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNy03LTEtMS0xMjc0NTI_c13ad56a-0b4d-4b2f-b408-b2b3a477227b"
      unitRef="usd">32099000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNy05LTEtMS0xMjc0NTI_452dc62a-6069-4630-90ba-f0229799b787"
      unitRef="usd">17987000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfNy0xMS0xLTEtMTI3NDUy_a6335c8e-02b1-4772-95ef-ec12eaae1f6d"
      unitRef="usd">14112000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i3e8e7fe1acc74cf88c35c02e48e41455_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfOS0xLTEtMS0xMjc0NTI_15bf65db-fcf6-4ad5-8e57-3773dba9aa28"
      unitRef="usd">1020000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i3e8e7fe1acc74cf88c35c02e48e41455_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfOS01LTEtMS0xMjc0NTI_dbc423c3-9528-47bb-902f-95bac9942915"
      unitRef="usd">1020000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic63e1fd5342a4cecb2063e44b0677f36_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfOS03LTEtMS0xMjc0NTI_c875855a-8e41-47d4-93c3-b66aeb3274c1"
      unitRef="usd">1070000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic63e1fd5342a4cecb2063e44b0677f36_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfOS0xMS0xLTEtMTI3NDUy_c6ecef41-d94c-4651-bff6-e5dd8c0fad0b"
      unitRef="usd">1070000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <amgn:IdentifiableIntangibleAssetsGross
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMTAtMS0xLTEtMTI3NDUy_0e6b678b-e805-4cbe-a800-714c5d989822"
      unitRef="usd">33118000000</amgn:IdentifiableIntangibleAssetsGross>
    <amgn:IdentifiableIntangibleAssetsAccumulatedAmortization
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMTAtMy0xLTEtMTI3NDUy_0ddfe3a6-d001-45ae-9afe-2b53ccf016e2"
      unitRef="usd">19191000000</amgn:IdentifiableIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMTAtNS0xLTEtMTI3NDUy_26d655dc-6223-4dee-aee7-fef0e0ebe7b9"
      unitRef="usd">13927000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <amgn:IdentifiableIntangibleAssetsGross
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMTAtNy0xLTEtMTI3NDUy_f5f19720-57e7-450d-b906-480e84abf7f6"
      unitRef="usd">33169000000</amgn:IdentifiableIntangibleAssetsGross>
    <amgn:IdentifiableIntangibleAssetsAccumulatedAmortization
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMTAtOS0xLTEtMTI3NDUy_e6072625-d5d2-4d7d-b7d0-65750dba5c1b"
      unitRef="usd">17987000000</amgn:IdentifiableIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RhYmxlOmNkODFhZDc4YTZmYTQ4YWQ4MWMxYjBlMWFhZmI5MzMyL3RhYmxlcmFuZ2U6Y2Q4MWFkNzhhNmZhNDhhZDgxYzFiMGUxYWFmYjkzMzJfMTAtMTEtMS0xLTEyNzQ1Mg_9939d110-0b9a-4b3c-9503-71fbc21cd3b6"
      unitRef="usd">15182000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTU1OQ_6ae222b2-a62b-4c0b-b774-7428197850f1"
      unitRef="usd">629000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTU2Ng_cc0ec6f5-7360-472c-ae94-2dba65673278"
      unitRef="usd">652000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTA5OTUxMTYyOTk1Mw_39d8da03-cc89-46b4-822d-06075ad68684"
      unitRef="usd">1300000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTA5OTUxMTYyOTk1Mw_50de9ab9-1f31-433a-a024-08a66ae8a414"
      unitRef="usd">1300000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTg4MQ_dcf362e3-45f3-449e-9776-4ee2b9888d19"
      unitRef="usd">1300000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTg4NQ_4fe4eed4-685b-4dba-a3ec-658d05f51802"
      unitRef="usd">2500000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTg4OQ_d55caac2-220e-48c1-9bb6-0d8c437f68f0"
      unitRef="usd">2500000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTg5Mw_98beae63-d1cf-484a-99ad-e07a8b64fe6b"
      unitRef="usd">2400000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTg5Nw_b88929b9-38e3-4e9d-b4b0-f7ee486ce3d8"
      unitRef="usd">1700000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV81OC9mcmFnOmNkYmVhNmM3YmYxYzRjZmM4OTM2OWU2NGQ1NzQzOWI1L3RleHRyZWdpb246Y2RiZWE2YzdiZjFjNGNmYzg5MzY5ZTY0ZDU3NDM5YjVfMTkwNA_09c65854-47a7-4806-912c-0968171accdf"
      unitRef="usd">1800000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTM1MQ_8be075ff-d843-4b41-918a-fff5dc67e881">Financing arrangements&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our borrowings consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% notes due 2023 (2.25% 2023 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% notes due 2024 (3.625% 2024 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.90% notes due 2025 (1.90% 2025 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125% notes due 2025 (3.125% 2025 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% &#x20ac;750 million notes due 2026 (2.00% 2026 euro Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60% notes due 2026 (2.60% 2026 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% &#xa3;475 million notes due 2026 (5.50% 2026 pound sterling Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20% notes due 2027 (2.20% 2027 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20% notes due 2027 (3.20% 2027 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65% notes due 2028 (1.65% 2028 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00% notes due 2029 (3.00% 2029 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00% &#xa3;700 million notes due 2029 (4.00% 2029 pound sterling Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% notes due 2030 (2.45% 2030 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.30% notes due 2031 (2.30% 2031 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% notes due 2032 (2.00% 2032 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.35% notes due 2032 (3.35% 2032 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.375% notes due 2037 (6.375% 2037 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.90% notes due 2038 (6.90% 2038 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% notes due 2039 (6.40% 2039 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15% notes due 2040 (3.15% 2040 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% notes due 2040 (5.75% 2040 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80% notes due 2041 (2.80% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95% notes due 2041 (4.95% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.15% notes due 2041 (5.15% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65% notes due 2042 (5.65% 2042 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.375% notes due 2043 (5.375% 2043 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40% notes due 2045 (4.40% 2045 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.563% notes due 2048 (4.563% 2048 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% notes due 2050 (3.375% 2050 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.663% notes due 2051 (4.663% 2051 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00% notes due 2052 (3.00% 2052 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.20% notes due 2052 (4.20% 2052 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.77% notes due 2053 (2.77% 2053 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40% notes due 2062 (4.40% 2062 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes due 2097&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized bond discounts, premiums and issuance costs, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying value of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no material&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; differences between the effective interest rates and coupon rates of any of our borrowings, except for the 4.563% 2048 Notes, the 4.663% 2051 Notes and the 2.77% 2053 Notes, which have effective interest rates of 6.3%, 5.6% and 5.2%, respectively.&lt;/span&gt;&lt;/div&gt;During the three months ended March 31, 2022, we issued $4.0&#160;billion of debt consisting of $750&#160;million of the 3.00% 2029 Notes, $1.0&#160;billion of the 3.35% 2032 Notes, $1.0&#160;billion of the 4.20% 2052 Notes and $1.25&#160;billion of the 4.40% 2062 Notes. The 3.00% 2029 Notes were issued to finance eligible projects that meet specified criteria to benefit the environment. In the event of a change-in-control triggering event, as defined in the terms of the notes, we may be required to purchase all or a portion of these notes at a price equal to 101% of the principal amount of the notes plus accrued and unpaid interest. In addition, these notes may be redeemed at any time at our option, in whole or in part, at the principal amount of the notes being redeemed plus accrued and unpaid interest and a make-whole amount, which are defined by the terms of the notes. The notes may be redeemed without payment of make-whole amounts if redemption occurs during a specified period of time immediately prior to the maturing of the notes. Such time periods range from two months to six months prior to maturity.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTM0Nw_5089c5cc-a31b-43ec-9c7e-4227856bff3c">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our borrowings consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% notes due 2023 (2.25% 2023 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% notes due 2024 (3.625% 2024 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.90% notes due 2025 (1.90% 2025 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.125% notes due 2025 (3.125% 2025 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% &#x20ac;750 million notes due 2026 (2.00% 2026 euro Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60% notes due 2026 (2.60% 2026 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% &#xa3;475 million notes due 2026 (5.50% 2026 pound sterling Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20% notes due 2027 (2.20% 2027 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20% notes due 2027 (3.20% 2027 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65% notes due 2028 (1.65% 2028 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00% notes due 2029 (3.00% 2029 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00% &#xa3;700 million notes due 2029 (4.00% 2029 pound sterling Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% notes due 2030 (2.45% 2030 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.30% notes due 2031 (2.30% 2031 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% notes due 2032 (2.00% 2032 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.35% notes due 2032 (3.35% 2032 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.375% notes due 2037 (6.375% 2037 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.90% notes due 2038 (6.90% 2038 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40% notes due 2039 (6.40% 2039 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15% notes due 2040 (3.15% 2040 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% notes due 2040 (5.75% 2040 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80% notes due 2041 (2.80% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95% notes due 2041 (4.95% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.15% notes due 2041 (5.15% 2041 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65% notes due 2042 (5.65% 2042 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.375% notes due 2043 (5.375% 2043 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40% notes due 2045 (4.40% 2045 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.563% notes due 2048 (4.563% 2048 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% notes due 2050 (3.375% 2050 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.663% notes due 2051 (4.663% 2051 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00% notes due 2052 (3.00% 2052 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.20% notes due 2052 (4.20% 2052 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.77% notes due 2053 (2.77% 2053 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40% notes due 2062 (4.40% 2062 Notes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes due 2097&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized bond discounts, premiums and issuance costs, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying value of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia0f38e5021744d62a72f6ec5c21139ea_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMS0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjpiZjUwZDk3Y2E0Nzk0NjRjODZhMDRiZWIyNTY0NDg4OV80_149571a9-b665-4ec1-b9d8-d4f53cfb8615"
      unitRef="number">0.0041</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia0f38e5021744d62a72f6ec5c21139ea_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMS0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjpiZjUwZDk3Y2E0Nzk0NjRjODZhMDRiZWIyNTY0NDg4OV83_127ba532-d4f6-44ea-8eea-f3ae43b92622"
      unitRef="chf">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia0f38e5021744d62a72f6ec5c21139ea_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMS0xLTEtMS0xMjc0NTI_64ed0d58-f8ed-4e0b-bc2d-6878ed4d25b6"
      unitRef="usd">733000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i48b3751c36e94ecc8abd5b6bc07fb36c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMS0zLTEtMS0xMjc0NTI_4861110c-0577-4610-a896-777200f5358c"
      unitRef="usd">767000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8cc181592b784672a897b345f8aafb1c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMi0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjpiN2QxNjUyMzMwYTg0OGEzOTNhYTc5MDM0NDdkNjJhZF80_d49f965a-3d05-4e66-a378-e5b3dc4cf62b"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8cc181592b784672a897b345f8aafb1c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMi0xLTEtMS0xMjc0NTI_99c1afef-7763-49ba-9638-9451cef09e5a"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0e0a5eb4088b4f5f9d9e54d6ac0cefa1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMi0zLTEtMS0xMjc0NTI_6e0533cf-590e-4802-90b9-caf28dc02b31"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icbf9488cc39340f688dc8239b97b3406_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMy0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjpmNjE5ZWUwYjMxM2E0MDVhOTgyMzQ5N2E3NTVhZjJiMF80_0318647a-dc96-400b-bbe0-636216ddfb5a"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="icbf9488cc39340f688dc8239b97b3406_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMy0xLTEtMS0xMjc0NTI_cd432f64-97ff-43bb-9e08-6443efadb455"
      unitRef="usd">1400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8d83b1f8089e4fe9b0149f04b0874977_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMy0zLTEtMS0xMjc0NTI_d3009640-d71a-49be-936d-bc07b3f7f384"
      unitRef="usd">1400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5811dbeccf214f488187b5c22f177a23_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNC0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjpmZTg0MmY4NDMyZDQ0MGI4YmMyYzg3YjVkZGExNTU1Zl80_c9da444c-8a52-4dbf-a53b-7180196d851f"
      unitRef="number">0.0190</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5811dbeccf214f488187b5c22f177a23_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNC0xLTEtMS0xMjc0NTI_0dc12b4b-a68e-4075-8ac7-094d7919197c"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id9b1443716684a18a0944e9e9de23470_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNC0zLTEtMS0xMjc0NTI_df0850af-2c2d-47bb-b168-75686d1aa6f4"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1d5c387b50044b74aa269b57c4e1b18e_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNS0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjpkMjc5NDRkMDFkNDg0Yjk0YjUxZmY1YjkxYjUwZmRhZV80_76af1dcb-29e5-4fa7-a087-1e9d2ec642bf"
      unitRef="number">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1d5c387b50044b74aa269b57c4e1b18e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNS0xLTEtMS0xMjc0NTI_e4ef8b8e-e161-476a-adf2-061b2bde28d5"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7839d25e4a274cde83be70a336e9f23d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNS0zLTEtMS0xMjc0NTI_b36b5b62-537d-4a08-9728-a01082ac4d76"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8771ce738edc4f2bbcd5cf45e51751ff_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNi0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjo5NWNmMTA1MGMxYTg0Yzg4YTcwMDkyMzBiNGRmZmU5NF80_88befa30-9175-40d8-9127-5655e893c023"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8771ce738edc4f2bbcd5cf45e51751ff_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNi0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjo5NWNmMTA1MGMxYTg0Yzg4YTcwMDkyMzBiNGRmZmU5NF83_61dc3d43-8901-400b-b0db-a35f80687667"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8771ce738edc4f2bbcd5cf45e51751ff_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNi0xLTEtMS0xMjc0NTI_fd546312-54f5-46bf-b501-56d03f97bd14"
      unitRef="usd">786000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i31014fe22b1e487c920ebfa34bb0d600_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNi0zLTEtMS0xMjc0NTI_f8c23094-d859-4f92-b42d-3548a45b5cab"
      unitRef="usd">853000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i927ecd67dbbd46f6be54131a567097ee_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNy0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjo1YTFhM2FmYjQ3ODg0OTUzYWNhYWZmMDUxYTQzNTM0YV80_97c7282c-56fc-4ab2-849e-d09d0173e9b6"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i927ecd67dbbd46f6be54131a567097ee_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNy0xLTEtMS0xMjc0NTI_7ac66002-2fbc-4858-b101-1deaecb85c0f"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3f9bc180a6994a85a80ac8530527b2f2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNy0zLTEtMS0xMjc0NTI_3c679c95-39e7-4e6b-84c9-24ac3ace6f89"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5db64085db894eefb5186c861f5a0216_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfOC0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjo1MGExNmE1ZmM5ODM0ZGUwYjkwZWQxOWM4NjUzOWU2MF80_2cc33f67-77a5-43ec-bff6-1980ecc07ee2"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5db64085db894eefb5186c861f5a0216_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfOC0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjo1MGExNmE1ZmM5ODM0ZGUwYjkwZWQxOWM4NjUzOWU2MF83_34f21b03-dd9d-46b8-9e87-9ba5f730e4ac"
      unitRef="gbp">475000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5db64085db894eefb5186c861f5a0216_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfOC0xLTEtMS0xMjc0NTI_58f5762f-88bf-4292-9905-039398c0f729"
      unitRef="usd">579000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i56b164c7fe7e4938a4b2f2cb9f20f1e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfOC0zLTEtMS0xMjc0NTI_8cc77857-2480-48c9-92ac-80eed887a95b"
      unitRef="usd">643000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i557c138915f74848aec303bcbcbdf1c5_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfOS0wLTEtMS0xMjc0NTIvdGV4dHJlZ2lvbjpjMDZjMTdmMWRjZDA0ZWJhYjcwMWM3Y2VkY2IxOGEyN180_c77136c9-e08c-478d-a47c-b6a5937dea22"
      unitRef="number">0.0220</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i557c138915f74848aec303bcbcbdf1c5_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfOS0xLTEtMS0xMjc0NTI_dbc40bcb-1505-4afa-88e8-3ef40bfaf2d9"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id84e2ad3fd7d4d2ea16c4f1a15e443b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfOS0zLTEtMS0xMjc0NTI_278386dc-338b-4919-ba75-00bb39a14b09"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if7ebb4dc9f2f4f4db89a7eba86ff7b3c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTAtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246MWFkMDU1ZTQxZWVmNDZhYmE4M2UzYmFhMTg3MTA0YjlfNA_976147e5-52e8-49da-9d05-313127251d67"
      unitRef="number">0.0320</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if7ebb4dc9f2f4f4db89a7eba86ff7b3c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTAtMS0xLTEtMTI3NDUy_ce7d500e-9e62-427a-8dad-404340976fb6"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1f508b06ff8341f99dde537d8acf7445_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTAtMy0xLTEtMTI3NDUy_134233d6-626e-44d8-84ca-5b09f6fb33f4"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i07d1843d947d47519f7950d93a5562e9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTEtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZmYwZjdkZDdiODhhNGE3YWE4ZDhjMjBiZTE5Y2I1ZGJfNA_c9f7477d-b798-4fe1-8324-06f04f29d33d"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i07d1843d947d47519f7950d93a5562e9_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTEtMS0xLTEtMTI3NDUy_916a2a88-6ada-4e8c-a168-5870efae2d27"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9e873215313140b1b47d44874f84d297_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTEtMy0xLTEtMTI3NDUy_2ba268f2-48b9-4281-b3a0-dd5e9e321eeb"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1a74363bd54f4d66ad0e46ef97698531_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTItMC0xLTEtMTI3NDUyL3RleHRyZWdpb246YjQxZjMyMDMxMWI3NDJhMDg2ZmE0N2FkNTA2Y2E1ZTBfNA_920bb73e-d4eb-4f9c-8e75-474f09390104"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1a74363bd54f4d66ad0e46ef97698531_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTItMS0xLTEtMTI3NDUy_d416042d-cd63-413b-911b-8d6e0714cd7f"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id5443e8b322b4d0faa4ade72d57d4e85_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTItMy0xLTEtMTI3NDUy_f68b446d-ffc3-4467-b1e5-29c9832eae11"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28f107e649274e53ac4e7d54db6713eb_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTMtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZTQzNzc1ZjA2MzBhNGM2OThjZDA0OTRhMmIxMDY4OTdfNA_0f58e1c6-88fe-4b16-86d8-6636a48d4b0e"
      unitRef="number">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i28f107e649274e53ac4e7d54db6713eb_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTMtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZTQzNzc1ZjA2MzBhNGM2OThjZDA0OTRhMmIxMDY4OTdfNw_a16fdb4e-297c-40c3-9791-e579c0fdbc28"
      unitRef="gbp">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i28f107e649274e53ac4e7d54db6713eb_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTMtMS0xLTEtMTI3NDUy_8c25d3a4-7871-426c-8196-44cb11d804fd"
      unitRef="usd">853000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i66c10d0d93a7485babc5ced3a0780a07_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTMtMy0xLTEtMTI3NDUy_3a38f9f0-9429-438e-bdc6-4a3365c8b547"
      unitRef="usd">947000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2f539453d5ef4ab6bfd15d005af9fe8d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTQtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246NGI5NTUyMTY5MzFiNGY3NTg4ZGQ1ZWU3YTUyNzViMjhfNA_ed86cae2-a002-4d7e-ab67-943fe8735c72"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2f539453d5ef4ab6bfd15d005af9fe8d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTQtMS0xLTEtMTI3NDUy_0b200458-b595-4489-9799-ff93f078e2ff"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0d9dd73fd402413093a63fd14b1085e8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTQtMy0xLTEtMTI3NDUy_362fc0e0-4e68-4b2c-bc03-a70e3ba63a64"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i34e92919299b42e89aac44fbf306409a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTUtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246M2M2MDE4YzRkYjNjNDlmYTk3YjA2NGRjZjJkNjA3MTBfNA_4bea8cf6-aa7e-4da6-affd-33ca6984a5d4"
      unitRef="number">0.0230</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i34e92919299b42e89aac44fbf306409a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTUtMS0xLTEtMTI3NDUy_ea3eb623-56df-435e-b38b-d955f6a767e8"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ica06dde7221745f9b345032e886823b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTUtMy0xLTEtMTI3NDUy_8224b895-3619-427b-bafd-8549b083597d"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic445c08da9214730a1fe68dffa9fde2f_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTYtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246NzMyNTk2NDUzMDhkNGMxY2I5OWZkMWIwNmE5NTliYmJfNA_9f3ec101-2624-4126-9fc9-27e785feab5a"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic445c08da9214730a1fe68dffa9fde2f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTYtMS0xLTEtMTI3NDUy_5fcf85e2-750c-4c25-9950-923cf6e98df3"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia0a1796124db4912a03941f9fc2bb729_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTYtMy0xLTEtMTI3NDUy_f2ebee32-c9e5-46f5-a3f1-fb72b95e3ba3"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idbe4cc4a9874400299d9ee262931fff2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTctMC0xLTEtMTI3NDUyL3RleHRyZWdpb246NmQxMGFiNjM4M2Y4NDVmMGJmOThjMTdmMDk1YmFiOWNfNA_143226ea-b397-471c-bdc0-ad2255b744cd"
      unitRef="number">0.0335</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="idbe4cc4a9874400299d9ee262931fff2_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTctMS0xLTEtMTI3NDUy_4275d3e8-c3fd-4b59-a26d-183923e36464"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0ea8bdcd48224c638ca7517df56948a6_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTgtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246NzE1MzhmOTg5MzMyNDNiY2E0YjEyNGFjMDU5OWM5YmNfNA_a61b61d9-5d7e-4bb4-aa87-ab8ccd2b543a"
      unitRef="number">0.06375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0ea8bdcd48224c638ca7517df56948a6_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTgtMS0xLTEtMTI3NDUy_3d283000-084c-4259-8c82-21f992a33ae4"
      unitRef="usd">478000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9bc19466dfcd44729418b77c1b6cac7d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTgtMy0xLTEtMTI3NDUy_d1419bfb-3779-4551-979f-d9c7345498be"
      unitRef="usd">478000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if160545557934f3ea7d7aa81db1e5fe6_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTktMC0xLTEtMTI3NDUyL3RleHRyZWdpb246NGNlNzUyMDk0Y2E5NGE5MWIwYzkzMDQyNDkxYmFlMDdfNA_f55c6787-46d6-4e34-9a24-28e00df287a1"
      unitRef="number">0.0690</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if160545557934f3ea7d7aa81db1e5fe6_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTktMS0xLTEtMTI3NDUy_9349432c-d475-4fdb-9093-ed25c4185152"
      unitRef="usd">254000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ied438a5ea64d4044aa5bbdbdd2f08fa8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMTktMy0xLTEtMTI3NDUy_77a55edf-23e2-49da-941f-3f23b944ebe7"
      unitRef="usd">254000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5ce84e57febe49528941c8a79c0b2aba_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjAtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246NjRlOGMwNzYzM2EzNDZlZDhkYzViYzc3OThiZGJkODZfNA_b0e31e76-6844-49a6-ba44-f7de2bcac0c2"
      unitRef="number">0.0640</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5ce84e57febe49528941c8a79c0b2aba_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjAtMS0xLTEtMTI3NDUy_57aa41d4-b66b-4686-bc92-c2f4793417d1"
      unitRef="usd">333000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if808837e20874be992a0d93186873f98_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjAtMy0xLTEtMTI3NDUy_258a227e-3aef-4fc5-944e-9898a0961ede"
      unitRef="usd">333000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i044f15b088224513a42ca9d6a15c87ff_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjEtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246NmVkYjZlMzYwYTExNDEwNTgwMjg2NGM1YTYyMTY0MWFfNA_f208b0c4-41c7-40d3-8433-0834c3183ba4"
      unitRef="number">0.0315</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i044f15b088224513a42ca9d6a15c87ff_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjEtMS0xLTEtMTI3NDUy_548f3b77-ee97-4631-a2b0-bf6da000403e"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id531ca5db21148f9bc34d2e8bb8f2623_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjEtMy0xLTEtMTI3NDUy_9f69207a-8c1d-4b0d-9e8b-2ad3a7d99169"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iab08d658a45448438680f7c44651a436_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjItMC0xLTEtMTI3NDUyL3RleHRyZWdpb246NjAzZmI3ZTI1ZTQzNGNjZTgzNzJmNDRlOTE1N2Q2NWRfNA_2928efc8-dcf8-4a74-8237-bb433fba0da5"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iab08d658a45448438680f7c44651a436_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjItMS0xLTEtMTI3NDUy_32aa3ca5-ae8b-4260-b2e9-5cbeaf0402ab"
      unitRef="usd">373000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifc8bbf8e715b4026a58db39d1e4ae27a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjItMy0xLTEtMTI3NDUy_a82cf8aa-72c1-4c02-bd25-74df6f24ddcb"
      unitRef="usd">373000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i867b4a6e48054979abbb390f7ca4bea4_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjMtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246NTFjNTI5MzJiOWEwNGQ3ZmJlODhkOTA1ZjYzZDFiYTJfNA_05c5b762-e7d2-4a93-9ff6-f5253adbe3b0"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i867b4a6e48054979abbb390f7ca4bea4_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjMtMS0xLTEtMTI3NDUy_eeb30494-40d2-49cf-bded-4d3254b9830d"
      unitRef="usd">1150000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i79f6ba2cbab24ee7a767a43344d52629_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjMtMy0xLTEtMTI3NDUy_ce41eb47-e13a-4a73-9597-55dcee863173"
      unitRef="usd">1150000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i869ffcf94f08470aa084a38887e74378_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjQtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZjFjNzY4MGQ2NzMxNDc3NmIyMzQ3YTE1NjBmMzY3NDNfNA_3ffeb001-3101-4fae-a480-2994c9e7fbab"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i869ffcf94f08470aa084a38887e74378_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjQtMS0xLTEtMTI3NDUy_0055e714-7c55-4449-8ff8-e81417e714f5"
      unitRef="usd">600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8efceb2da34f4012a56d28bee80ece4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjQtMy0xLTEtMTI3NDUy_7df0a2a9-3ef4-4252-a7a4-ab447bb55470"
      unitRef="usd">600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia8f4719ca9b84ee8b1c7b311cb67831d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjUtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246YmI0Y2E5MTJkYTA2NDIzODlmNTY5NjM3OTVmNjE3MWZfNA_9bb1ea32-c8d9-4842-8a4f-44614e8b6c5f"
      unitRef="number">0.0515</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia8f4719ca9b84ee8b1c7b311cb67831d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjUtMS0xLTEtMTI3NDUy_e39329f5-1b8b-4e2c-abc8-a0953152b4dd"
      unitRef="usd">729000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0fe337886bb743ac9268549dea62a5c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjUtMy0xLTEtMTI3NDUy_e1fd0b5d-7d0c-427d-9279-9fbca42b0e3d"
      unitRef="usd">729000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3039eef43eab47d88f5e5bde9f8c3c1a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjYtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246MGZkYWQxOWY4NjVjNDgzOGEzYjlmNmFjMTYwN2RmYTdfNA_8ee28276-4ae1-43b2-afb3-9cb7b248d7b1"
      unitRef="number">0.0565</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3039eef43eab47d88f5e5bde9f8c3c1a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjYtMS0xLTEtMTI3NDUy_3cccef11-28ca-4e01-bd33-4e7ec33b5e0d"
      unitRef="usd">415000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9c41f818916d4143ab5f24b20c47b6b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjYtMy0xLTEtMTI3NDUy_4f3aaf0a-a3e8-4f7d-a6e3-ea0c9563b4f9"
      unitRef="usd">415000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8baade68d0aa42cd8eabab1268708b15_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjctMC0xLTEtMTI3NDUyL3RleHRyZWdpb246OTAxMGY4ODRhYzg0NDZlOGJmZTM2NzdhZTcyYTY3MmNfNA_2c18403b-96d6-46c3-883a-211b68176487"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8baade68d0aa42cd8eabab1268708b15_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjctMS0xLTEtMTI3NDUy_63c8759d-b66f-4397-bcac-278f349a9fd5"
      unitRef="usd">185000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i371510a8b04e43fc92b82fca221e37d1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjctMy0xLTEtMTI3NDUy_680edc23-45a4-4eec-a80f-9026a7e8eadf"
      unitRef="usd">185000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6cf9e5efd50b441ba4249ec5547a64d8_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjgtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246MDQ2NDhmODBmMDg5NDE0ZGEwZDM0NDJkZGUzODdkMzNfNA_32ff5a07-ffc5-49ac-ab4f-d544d1c219ce"
      unitRef="number">0.0440</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6cf9e5efd50b441ba4249ec5547a64d8_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjgtMS0xLTEtMTI3NDUy_73b3f0a3-e8fd-4613-9e66-48dd676b0421"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ieb4f7f1f524943beb30880ef09f09b08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjgtMy0xLTEtMTI3NDUy_9532b396-c5c1-4283-bad7-c09a02527fb2"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idebc81edd93d4d2f8a2a03384eb93dbe_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjktMC0xLTEtMTI3NDUyL3RleHRyZWdpb246MmIxYjVhNDg0NGNkNGJhZTg0YTc0NjEwYjVkYTc5NmZfNA_58522027-2494-44d5-b803-0c5417938962"
      unitRef="number">0.04563</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="idebc81edd93d4d2f8a2a03384eb93dbe_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjktMS0xLTEtMTI3NDUy_889a3635-86f8-4040-ace9-b11ac914dde3"
      unitRef="usd">1415000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i07b2f991bb9a47f29b3bcd5b53c1cdd5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMjktMy0xLTEtMTI3NDUy_85b5134c-eae7-46c0-a144-a6a3b32e6762"
      unitRef="usd">1415000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i08a78f74146a4495aeae7b6b14bd80a4_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzAtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZTNlMTdlN2Y3YzE2NDYxY2IyN2U4MDQzZGFhOGRkMTZfNA_612af431-847b-4e4f-91d6-206ad9f473ae"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i08a78f74146a4495aeae7b6b14bd80a4_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzAtMS0xLTEtMTI3NDUy_69e247f5-9e84-4fe5-b4a6-ddaea002f46e"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie836805159b74407a69e93d8523fe3ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzAtMy0xLTEtMTI3NDUy_59d94c97-dd88-4ffd-b921-9eda139645ef"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7ed1c633fdd74b46948dd2c6f7afcf20_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzEtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246NDA1ZTllOTBhNTU5NDM5NGIxM2I0M2EyYzJlOGZhYzJfNA_24e3d392-41cb-471d-9dce-87542f76bb1a"
      unitRef="number">0.04663</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7ed1c633fdd74b46948dd2c6f7afcf20_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzEtMS0xLTEtMTI3NDUy_2205429f-7159-4eb6-910b-3257ff5820f2"
      unitRef="usd">3541000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="idc5590dec8034b22bdedd784acc302e8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzEtMy0xLTEtMTI3NDUy_821e555b-1667-4ddb-897d-30d571706006"
      unitRef="usd">3541000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i735b048825ca4313aeb532048d7be90b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzItMC0xLTEtMTI3NDUyL3RleHRyZWdpb246MmZmZTExYjU5NzRhNDk1OTg4NTU2MjMzYjU4OGU0YTRfNA_c87ec9b5-5943-4dda-b36f-028197436f1d"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i735b048825ca4313aeb532048d7be90b_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzItMS0xLTEtMTI3NDUy_02ae38d3-9c76-4726-b3ea-c719cd038081"
      unitRef="usd">1350000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iad985efcbfe541aca64199c03a30ee03_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzItMy0xLTEtMTI3NDUy_7b07d682-3bee-4b60-affd-c1bb6fa0fc9a"
      unitRef="usd">1350000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0d18f819d85a44c49e5108e4c3d42378_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzMtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZjJkM2E1YjM2NDk0NDJiZjgzNTY3YTBmYWQ2ODllOTlfNA_4ce7afbd-885b-48d1-b321-4bc048819ce8"
      unitRef="number">0.0420</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0d18f819d85a44c49e5108e4c3d42378_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzMtMS0xLTEtMTI3NDUy_0a72b4cf-b74e-4f2a-86bf-cf026e643f7c"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i53e00d2be34d4b1ea7b97fd526f5d69b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzMtMy0xLTEtMTI3NDUy_a591982f-855e-4ba0-a951-dc74a3d6b12d"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibbd916f7493440e69704b449f2dd8102_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzQtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZTU4NzU2MzI0ZGIyNDNlMWJmMWY5YzllZjQyZDRkMzdfNA_77310c1a-cfe7-4a22-a2f1-c8a8038d8387"
      unitRef="number">0.0277</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibbd916f7493440e69704b449f2dd8102_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzQtMS0xLTEtMTI3NDUy_691f7ecc-3244-49de-8375-7eac3cb84fa7"
      unitRef="usd">940000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i60c317ee474147a8b5d3b80406fb276d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzQtMy0xLTEtMTI3NDUy_00f5bf2e-ac46-4eec-ac1e-e2c2cefe9fb7"
      unitRef="usd">940000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i17997eb7cd9343bd87243e19e6bb8d08_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzUtMC0xLTEtMTI3NDUyL3RleHRyZWdpb246ZjUzZWQwNDU1OTY0NDQ2MGJlNWJiMWFiZWRlNTU3NGJfNA_f3b4211e-1573-45ff-b1a6-02f0045dc200"
      unitRef="number">0.0440</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i17997eb7cd9343bd87243e19e6bb8d08_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzUtMS0xLTEtMTI3NDUy_10e41c18-626e-40e6-99ee-1c7803cafebf"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i43ee6e408fa1493196ad37c5887d08e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzUtMy0xLTEtMTI3NDUy_faac9574-ad06-4c4e-b618-cedf8c1d608b"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i951998b6f8314c8884444de5fada1e86_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzYtMS0xLTEtMTI3NDUy_3399cde9-8b23-4cd2-ab6d-739918916922"
      unitRef="usd">100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1a44e9649b29466fb790d1a57aca49b3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzYtMy0xLTEtMTI3NDUy_b1ade6a8-5423-4897-8376-49e3146e9100"
      unitRef="usd">100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzctMS0xLTEtMTI3NDUy_839b02fc-9757-4ad3-b612-34047708a060"
      unitRef="usd">1245000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzctMy0xLTEtMTI3NDUy_2da8d1ef-4be6-48bb-80a8-cff5af8f4b42"
      unitRef="usd">1213000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzgtMS0xLTEtMTI3NDUy_82a3ad1a-3e87-497f-92f9-686d484530eb"
      unitRef="usd">-210000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzgtMy0xLTEtMTI3NDUy_442dde93-e017-4f5c-b190-c14b89988346"
      unitRef="usd">284000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:OtherLongTermDebt
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzktMS0xLTEtMTI3NDUy_5f520d71-1f70-4a20-852d-3fbe5b4e814a"
      unitRef="usd">13000000</us-gaap:OtherLongTermDebt>
    <us-gaap:OtherLongTermDebt
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfMzktMy0xLTEtMTI3NDUy_98516f02-cbba-46de-86ef-49405d78b097"
      unitRef="usd">15000000</us-gaap:OtherLongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNDAtMS0xLTEtMTI3NDUy_c516d5a6-5a6a-4c29-97f1-1db4c176fd6f"
      unitRef="usd">36522000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNDAtMy0xLTEtMTI3NDUy_cbbfa84c-5e81-42e3-a8b8-4a14335b05af"
      unitRef="usd">33309000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNDEtMS0xLTEtMTI3NDUy_e579a63b-377d-4e98-a04e-1335894c52a5"
      unitRef="usd">817000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNDEtMy0xLTEtMTI3NDUy_3fd1dd78-030b-4dfb-b8d0-2aa82435eced"
      unitRef="usd">87000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNDItMS0xLTEtMTI3NDUy_683a30cc-f45d-4f2d-98cb-c2ee32a8e9f9"
      unitRef="usd">35705000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RhYmxlOmM4N2E4YzhlNTJjYzRmMGJiZGUwNzIxZjM0ZjAwMTI0L3RhYmxlcmFuZ2U6Yzg3YThjOGU1MmNjNGYwYmJkZTA3MjFmMzRmMDAxMjRfNDItMy0xLTEtMTI3NDUy_12744e89-5a01-47ff-82e6-b7f8566fe9a4"
      unitRef="usd">33222000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idebc81edd93d4d2f8a2a03384eb93dbe_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTk5_e448d4d6-2339-43ee-ae06-2761c3c3ad2e"
      unitRef="number">0.04563</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7ed1c633fdd74b46948dd2c6f7afcf20_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMjE4_114c089b-bbda-493e-b853-ad120cfc5f81"
      unitRef="number">0.04663</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibbd916f7493440e69704b449f2dd8102_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMjQw_2d621bd8-fbae-4547-888b-d6c5ea5b9708"
      unitRef="number">0.0277</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="idebc81edd93d4d2f8a2a03384eb93dbe_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMjk0_f3063281-937d-4f3c-9787-b5439b93a133"
      unitRef="number">0.063</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i7ed1c633fdd74b46948dd2c6f7afcf20_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMjk4_a3679515-4e96-45d5-8fc5-499bf5dde497"
      unitRef="number">0.056</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ibbd916f7493440e69704b449f2dd8102_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMzA1_919a5812-ae68-456a-ae08-0a189daf24ad"
      unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia45a3444f1b94d7694e25c6b7581e9f6_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTM3OA_81e602cf-19cc-4e1d-8546-3b4e2b8680cf"
      unitRef="usd">4000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i31e27323c1154ea898dc24977e5b4dfa_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTM4MA_300a4c16-9fe0-4d19-a87c-7f80280ff003"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i31e27323c1154ea898dc24977e5b4dfa_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTM5Mw_fbf4c9c1-10fd-4978-94d0-adb1c33db31f"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7cf0dda19fd445dca8eb54ae4d8870ae_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTM5NQ_86688254-f4f4-4728-8afd-ff932febc89c"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7cf0dda19fd445dca8eb54ae4d8870ae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQwOQ_f3a052a3-a51c-47c0-a628-31ac993ddc04"
      unitRef="number">0.0335</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iecb3cb0076694222ab5165cf391eb7d3_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQxNg_55fff7ea-0e12-4ab1-99fb-96d75fe1a310"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if7172737536943c5bd01dbe5c718b01f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQzMA_a1964a0c-163f-4724-aeb2-ddf7386829bf"
      unitRef="number">0.0420</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i531c563577e24bbe82274ae7b057ec74_I20220331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQzNg_0c59b39f-4e4e-40cc-9024-43a7eea0820e"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i531c563577e24bbe82274ae7b057ec74_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQzOA_4fd020a7-db7f-4452-a205-d300d0cad9f3"
      unitRef="number">0.0440</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i31e27323c1154ea898dc24977e5b4dfa_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQ0NQ_3f107aec-7230-4f68-b5ef-962eb2872963"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <amgn:PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent
      contextRef="i2f9a632bdc184d86b2d6cf5fa69e05d5_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQ1Mg_732a0d9a-2774-451d-b591-9834906554c6"
      unitRef="number">1.01</amgn:PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent>
    <amgn:PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent
      contextRef="i21ba53c9dd5540c5a2f72a1809b358f5_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQ1Mg_dd90c2af-0d47-47fe-9480-d58c44d4afdd"
      unitRef="number">1.01</amgn:PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent>
    <amgn:PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent
      contextRef="i31a5a20370f74b839ba627dfd4b3d6d2_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQ1Mg_ee8018a0-1dfd-44f8-a4df-21eb17129d99"
      unitRef="number">1.01</amgn:PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent>
    <amgn:PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent
      contextRef="i2630ed6736474dd7ad352734abf1fa2f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQ1Mg_eea10978-2cfa-4329-8479-4481f0e4372c"
      unitRef="number">1.01</amgn:PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent>
    <amgn:DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount
      contextRef="iff44a3a4194340a88d27d0d51b2c7873_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQ1Nw_67e07c42-48a0-4637-896f-9c7115562e5e">P2M</amgn:DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount>
    <amgn:DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount
      contextRef="i5a36e5ea4cc14d90aa07055d396cca6d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82MS9mcmFnOjNjMDhiZjlmNzc2ZDRkMmRhYmQ4NGUyMzJjMGIyOTAzL3RleHRyZWdpb246M2MwOGJmOWY3NzZkNGQyZGFiZDg0ZTIzMmMwYjI5MDNfMTA5OTUxMTYzMTQ1OA_cd68e0e7-9f7f-46d3-ae4d-d01494d0bfce">P6M</amgn:DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMjMyMA_ff4bc03f-63b0-4dd8-91e1-7ae633bbe3be">Stockholders&#x2019; equity&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock repurchase program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;First quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 24, 2022, the Company entered into ASR agreements with three third-party financial institutions (Dealers). Under the ASR agreements, the Company made payments in an aggregate amount of $6.0&#160;billion on February 25, 2022, to the Dealers and received and retired an initial 23.3&#160;million shares of the Company&#x2019;s common stock from the Dealers. The payments were recorded as reductions to shareholders&#x2019; equity, consisting of a $5.1&#160;billion increase to accumulated deficit, which reflects the value of the initial shares received, and a $0.9&#160;billion decrease in additional paid-in capital, which reflects the value of the stock that remains to be delivered by the Dealers pending final settlement. The final number of shares to be repurchased by the Company will be based on the daily volume-weighted average stock price of the Company&#x2019;s common stock during the terms of the ASR agreements, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreements. At settlement, under certain circumstances, one or more of the Dealers may be required to deliver additional shares of common stock to the Company, or under certain circumstances, the Company may be required to deliver shares of common stock or to make a cash payment, at its election, to a Dealer. The final settlement under the ASR agreements is scheduled to occur in the third quarter of 2022, subject to an earlier termination under certain limited circumstances, as set forth in the ASR agreements. In total, we repurchased 24.6&#160;million shares of common stock in the first quarter of 2022, including shares received under the ASR agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022, $4.6 billion of authorization remained available under our stock repurchase program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022 and December 2021, the Board of Directors declared a quarterly cash dividend of $1.94 per share, which were paid in June 2022 and March 2022, respectively. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, the Board of Directors declared a quarterly cash dividend of $1.94 per share, which will be paid on September 8, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of AOCI were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;currency&lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash&#160;flow&lt;br/&gt;hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Available-for-sale&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;AOCI&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(844)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of AOCI and into earnings, including related income tax expenses, were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.220%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Components of AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated&lt;br/&gt;Statements of Income locations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contract gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contract (losses) gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Components of AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated&lt;br/&gt;Statements of Income locations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contract gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contract losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <amgn:StockRepurchaseProgramTableTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMjMyMw_c296ffca-d266-4a1e-9239-fbcaef97a89d">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dollars&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;First quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amgn:StockRepurchaseProgramTableTextBlock>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfMi0xLTEtMS0xMjc0NTI_e42f48d6-2f35-456e-a527-02da26b03e89"
      unitRef="shares">24600000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfMi0zLTEtMS0xMjc0NTI_d647dc42-98b0-4529-a077-5fbec72feb6c"
      unitRef="usd">5410000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i230f8b81d2ba4f069528c27808330841_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfMi01LTEtMS0xMjc0NTI_2a7de134-acee-483e-bc79-26e3eafbc1eb"
      unitRef="shares">3700000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i230f8b81d2ba4f069528c27808330841_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfMi03LTEtMS0xMjc0NTI_24d3b8c1-8b6d-4de1-b3e0-b22fcde48ccb"
      unitRef="usd">865000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfMy0xLTEtMS0xMjc0NTI_c700dc64-724d-49d3-9026-3eef24ebbaef"
      unitRef="shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfMy0zLTEtMS0xMjc0NTI_c684e0e3-9a63-429d-ae8a-d22cfab964df"
      unitRef="usd">0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfMy01LTEtMS0xMjc0NTI_377838e8-d515-40e6-8ca4-57c47ae2a4d9"
      unitRef="shares">6500000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfMy03LTEtMS0xMjc0NTI_7146ed82-7ae4-40ea-96ea-05a4a5cd6201"
      unitRef="usd">1592000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfNS0xLTEtMS0xMjc0NTI_3d3fa6f8-bb86-4232-a136-a24e4147d76b"
      unitRef="shares">24600000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfNS0zLTEtMS0xMjc0NTI_f8b64df8-2bcd-4b90-b437-a95a9edf4e2b"
      unitRef="usd">5410000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfNS01LTEtMS0xMjc0NTI_abbab923-0774-422f-889b-4ff79d0bff4f"
      unitRef="shares">10200000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjEyZTM0NDRlZTBkYjRjMTlhZmM5MzI3NGY4YzVlMDhmL3RhYmxlcmFuZ2U6MTJlMzQ0NGVlMGRiNGMxOWFmYzkzMjc0ZjhjNWUwOGZfNS03LTEtMS0xMjc0NTI_d349f4c2-e98b-40b1-80db-f106f67c0a98"
      unitRef="usd">2457000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <amgn:NumberOfThirdPartyFinancialInstitutions
      contextRef="idff629d5adce4075abb77d3576767318_I20220224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMjI5OQ_4ed4c040-a0cd-41b3-a495-f3fb356392b2"
      unitRef="financial_institution">3</amgn:NumberOfThirdPartyFinancialInstitutions>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i3919d433c5e54fd389f1bef01f418e40_D20220225-20220225"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMzM0_fbc23aa8-8c08-4486-b8a8-73d4c7e4226e"
      unitRef="usd">6000000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i3919d433c5e54fd389f1bef01f418e40_D20220225-20220225"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfNDEw_42d2a893-4f0f-4329-a9f2-a1c65196774a"
      unitRef="shares">23300000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i303708e74aba47d6a736f376e0cd1a13_D20220225-20220225"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfNTUw_cf086b1b-f72b-448f-9695-71cc96000252"
      unitRef="usd">5100000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i10398ced71924f51bd433d3c641763e9_D20220225-20220225"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfNjQ5_1db0d22f-e3b5-459e-a87f-cbd1848ccad4"
      unitRef="usd">900000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i04c70061dd094a7aba713ef9504fc0fb_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMTA5OTUxMTYzMDE0OQ_f8d532ce-735b-4784-8003-fbdce0483598"
      unitRef="shares">24600000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMTc0MQ_481cdd8b-62e5-415a-afcc-dc9d809b0c9b"
      unitRef="usd">4600000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ie8752374757e479e9f64772ff1f4f9d4_D20211201-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMTkwMw_0c7005f1-7f3b-44ee-a000-0fc2a23bbd08"
      unitRef="usdPerShare">1.94</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i264013b24e074db8b98a0699c239c4f9_D20220301-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMTkwMw_a08b6268-ccf5-475e-a290-a963fefa0b25"
      unitRef="usdPerShare">1.94</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i264013b24e074db8b98a0699c239c4f9_D20220301-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMTkwMw_ac5f0147-d05a-4672-a5b4-a3518432707b"
      unitRef="usdPerShare">1.94</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i52e8d46fd29746e58d0e0bb604659f08_D20220601-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMTkwMw_f7ac0f6f-730d-40bc-9cb3-830caa93f6bc"
      unitRef="usdPerShare">1.94</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i189dc1dfd5134a79a21430cb309a4d7a_D20220908-20220908"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMjAyOQ_9a840eeb-7b63-4ccd-bdfd-ae7b562eaa3c"
      unitRef="usdPerShare">1.94</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i8d05e9eee4b64b31a25be9b446338707_D20220803-20220803"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMjAyOQ_d10b0cf9-fdb6-4705-9d1f-4cdf73900a14"
      unitRef="usdPerShare">1.94</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMjMyOA_a187d0f9-4d04-461f-83e6-db3ec7027a7e">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of AOCI were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;currency&lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash&#160;flow&lt;br/&gt;hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Available-for-sale&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;AOCI&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(844)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="ic9484214322149e8b56269486f6b1ee4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMS0xLTEtMS0xMjc0NTI_44a22a77-9035-484c-951b-ac356bb16bc2"
      unitRef="usd">-844000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if90bc40ab2b74d9dbd7c8dc2378a4c5b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMS0zLTEtMS0xMjc0NTI_fec9fedf-542d-4be9-80af-f6812a3e479a"
      unitRef="usd">61000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i382be9663b374e42986e34c6b0cdaf0f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMS01LTEtMS0xMjc0NTI_dba84f56-79c5-4bce-88dd-38d3bc73ffef"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7795fae62ffe42149d98ac8e3ee9adbc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMS03LTEtMS0xMjc0NTI_d1c80507-0ef7-4dc1-98b5-b403633bdeaf"
      unitRef="usd">-13000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4015add6967846b88c70abf91e4bfcd3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMS05LTEtMS0xMjc0NTI_e36f6ac1-1822-435f-b8fe-177cf8f7e4b6"
      unitRef="usd">-796000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ibabad0c6499641edbeeabb37b49f2923_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMy0xLTEtMS0xMjc0NTI_9633c7c5-59bf-4dfd-abd1-a9aa420b51d2"
      unitRef="usd">-51000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if6bebabfe867463fb2ce8c41e89ce28a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMy05LTEtMS0xMjc0NTI_17cc77e8-0d9e-43ae-a2ac-e4f4f4fccae6"
      unitRef="usd">-51000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ia5d912228ba649bfa2382a61c3174651_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNC0zLTEtMS0xMjc0NTI_dd51e12b-eab5-4c4a-adf8-de69b8254ea3"
      unitRef="usd">56000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i08706db8953040b6812a751e8ae1b7e5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNC01LTEtMS0xMjc0NTI_eadc6a76-aad0-4fed-939d-14fb04e208fa"
      unitRef="usd">0</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="idbe6768ff04b4640811983e177893ea9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNC03LTEtMS0xMjc0NTI_fd6e9e4c-f9da-43b2-843b-8015f729d1c9"
      unitRef="usd">0</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="if6bebabfe867463fb2ce8c41e89ce28a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNC05LTEtMS0xMjc0NTI_62752f4a-3929-49b8-9e12-804342eadaab"
      unitRef="usd">56000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ia5d912228ba649bfa2382a61c3174651_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNS0zLTEtMS0xMjc0NTI_9e3b5946-3f23-4736-b3fa-cc3b310b8b0a"
      unitRef="usd">51000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i08706db8953040b6812a751e8ae1b7e5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNS01LTEtMS0xMjc0NTI_2255ab2e-dd8c-4120-9937-1ddae90e2150"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="if6bebabfe867463fb2ce8c41e89ce28a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNS05LTEtMS0xMjc0NTI_58d6acec-705e-4462-8d74-764903fa96dc"
      unitRef="usd">51000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ibabad0c6499641edbeeabb37b49f2923_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNy0xLTEtMS0xMjc0NTI_267813bf-9674-44e3-aff2-b595357837b7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ia5d912228ba649bfa2382a61c3174651_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNy0zLTEtMS0xMjc0NTI_0be55b0d-0633-49e2-8f1d-9991206b2f66"
      unitRef="usd">-23000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i08706db8953040b6812a751e8ae1b7e5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNy01LTEtMS0xMjc0NTI_51fa0814-ac8d-4030-a805-afdedbb5bda3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="if6bebabfe867463fb2ce8c41e89ce28a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfNy05LTEtMS0xMjc0NTI_8211a8db-71a2-4557-9085-3d4be02044e7"
      unitRef="usd">-23000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:StockholdersEquity
      contextRef="idd1b9d5af30a49189ced97fd5f9e0133_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfOC0xLTEtMS0xMjc0NTI_ad8466b2-f5b9-4a23-b6cf-086d802533a9"
      unitRef="usd">-895000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifd33995f144e48e6b6a85f69a49618b2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfOC0zLTEtMS0xMjc0NTI_fd04c936-09c1-4958-ac3f-a831dfb702ac"
      unitRef="usd">145000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iececd00ead734bc7953b31ce1dccf7c9_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfOC01LTEtMS0xMjc0NTI_a18348c8-b073-4aeb-878d-6961c40a73c3"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i90991e5bbd4f4703b8dab237d26ea063_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfOC03LTEtMS0xMjc0NTI_a6858e71-af18-429c-b140-53ae2b05c813"
      unitRef="usd">-13000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3453133454bb4b68987a91d14ea8ccda_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfOC05LTEtMS0xMjc0NTI_20fe6132-9511-47aa-865d-68c9b2ef6abb"
      unitRef="usd">-763000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i933f3aa296ae418cb60f3b9a2da33c77_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTAtMS0xLTEtMTI3NDUy_c264eaa9-cafb-4100-9f5c-353b84d15309"
      unitRef="usd">-65000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i950254b1c906440baad1c3cb0d696509_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTAtOS0xLTEtMTI3NDUy_a4a8150b-1a1a-4391-a7a4-93cf36491d1b"
      unitRef="usd">-65000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i0b5fae63890c4e3292f6b182d8cf346f_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTEtMy0xLTEtMTI3NDUy_245a1bf2-970b-439d-9d0c-3a068c87086e"
      unitRef="usd">67000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i7b9fd427a0844181b055f4681aa465eb_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTEtNS0xLTEtMTI3NDUy_d28a4369-38b1-4a77-8145-bc262bf3b71c"
      unitRef="usd">0</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i9548198fbd6c4177a20e2e6fba7e0baf_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTEtNy0xLTEtMTI3NDUy_42bca2de-64da-4340-a77b-8fd79a5880ee"
      unitRef="usd">0</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i950254b1c906440baad1c3cb0d696509_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTEtOS0xLTEtMTI3NDUy_fffa543e-96c7-4141-8629-5ed3a9576212"
      unitRef="usd">67000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i0b5fae63890c4e3292f6b182d8cf346f_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTItMy0xLTEtMTI3NDUy_3eb547fc-13ab-4013-958d-b5fd2b0fe4fb"
      unitRef="usd">132000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i7b9fd427a0844181b055f4681aa465eb_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTItNS0xLTEtMTI3NDUy_ae0b3b10-87e4-424c-bed1-51b6b0b13126"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i950254b1c906440baad1c3cb0d696509_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTItOS0xLTEtMTI3NDUy_e35f4d9e-a7fb-45dd-a400-8268dfaf9c4a"
      unitRef="usd">132000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i933f3aa296ae418cb60f3b9a2da33c77_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTQtMS0xLTEtMTI3NDUy_d74929e5-d389-4b08-af2a-029b075d6fe6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i0b5fae63890c4e3292f6b182d8cf346f_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTQtMy0xLTEtMTI3NDUy_055dc456-27ac-4491-982b-90b2d2dc98ee"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i7b9fd427a0844181b055f4681aa465eb_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTQtNS0xLTEtMTI3NDUy_5fbfe265-6a17-40bb-9212-8a4929e87c58"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i950254b1c906440baad1c3cb0d696509_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTQtOS0xLTEtMTI3NDUy_5b50572e-a5eb-4553-98a3-fc189ee5847b"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:StockholdersEquity
      contextRef="i1f01a7222c3f477bb69c5b052545fbe3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTUtMS0xLTEtMTI3NDUy_7f115945-04c2-4b01-b697-6444ba55c14a"
      unitRef="usd">-960000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifd86ccb60742427aa61efd89dc5c4569_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTUtMy0xLTEtMTI3NDUy_53a1a423-a11f-4643-8f70-69a2dd46f96d"
      unitRef="usd">301000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iecaa227f3a39471dbc0f18d223f8c464_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTUtNS0xLTEtMTI3NDUy_f311ae3b-29af-417c-894c-f4697792a0d3"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9808b39aaba54cfe9085c0980d313291_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTUtNy0xLTEtMTI3NDUy_d18cce15-1417-4617-aa2f-856c12233122"
      unitRef="usd">-13000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iedbaa8596a604e708e0f5d708642088d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjMyZjNjNDkyMTFiYzQ5NWU4MWNjZWQ3NGMyYzUyZjQ0L3RhYmxlcmFuZ2U6MzJmM2M0OTIxMWJjNDk1ZTgxY2NlZDc0YzJjNTJmNDRfMTUtOS0xLTEtMTI3NDUy_1c57f0f4-eaca-4adb-a6d0-7bf104b81b97"
      unitRef="usd">-672000000</us-gaap:StockholdersEquity>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RleHRyZWdpb246ZWViMmVlNTcxZWFmNDViY2EzYjk3OTk5MGQzMjA0Y2RfMjMxOQ_5509cc41-c2b8-4927-adcf-9c4d8e259bd9">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of AOCI and into earnings, including related income tax expenses, were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.220%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Components of AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated&lt;br/&gt;Statements of Income locations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contract gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contract (losses) gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Components of AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated&lt;br/&gt;Statements of Income locations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contract gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contract losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff08a60f020c476cb26a704e747e026e_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMy0yLTEtMS0xMjc0NTI_ace1b77c-dba4-4ffd-9880-cb73d7e6ffdc"
      unitRef="usd">53000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i156bec7df7e34d13b4f231715e12f0eb_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMy00LTEtMS0xMjc0NTI_0f8f3146-6403-4b2b-8dd2-42146a8a2ab6"
      unitRef="usd">-18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id98e2a58d5f74741901a136b5593f566_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfNC0yLTEtMS0xMjc0NTI_e0c91ed7-dd9d-4143-b482-471e0090bdb0"
      unitRef="usd">-185000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i22e704ef21944a4b8eb938e4ffb99c17_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfNC00LTEtMS0xMjc0NTI_aa042993-f19f-4626-ae9e-d2c3021248a4"
      unitRef="usd">46000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="idd26454e121845348d3b36a5d5d0b4be_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfNi0yLTEtMS0xMjc0NTI_2a0b6272-fe62-4c51-a18f-eb5464b64e14"
      unitRef="usd">-132000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i47f60abf400d4a86a9f3744f80bddf28_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfNi00LTEtMS0xMjc0NTI_5cb8b4c2-6fe7-4a32-967a-c80dbf0ee93a"
      unitRef="usd">28000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idd26454e121845348d3b36a5d5d0b4be_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfNy0yLTEtMS0xMjc0NTI_1b9166fe-0572-44ba-b421-b09e9f8d0f51"
      unitRef="usd">-28000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i47f60abf400d4a86a9f3744f80bddf28_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfNy00LTEtMS0xMjc0NTI_334d1229-882b-432d-9124-a5cb11e7e88d"
      unitRef="usd">6000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="idd26454e121845348d3b36a5d5d0b4be_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfOC0yLTEtMS0xMjc0NTI_32e660e3-26ab-497c-9774-e45b8528aa1c"
      unitRef="usd">-104000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i47f60abf400d4a86a9f3744f80bddf28_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfOC00LTEtMS0xMjc0NTI_0e416f98-8030-4af4-bec1-c575124e9b94"
      unitRef="usd">22000000</us-gaap:NetIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7cce2fc95f840d0b58664ae7a9a19fa_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMTctMi0xLTEtMTI3NDUy_33804f22-2fb1-438a-a9e9-7985c07eda78"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e40834754cb4ae7a332ab8f335a1c40_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMTctNC0xLTEtMTI3NDUy_10177215-512d-4ebb-9724-f7352f884442"
      unitRef="usd">-19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i03282f9364de4789b96025daf0d0ef74_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMTgtMi0xLTEtMTI3NDUy_be875354-e111-40bb-bece-15e73b4d99b9"
      unitRef="usd">-263000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i74c469c59c124e739fad89b0a0b0f7c7_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMTgtNC0xLTEtMTI3NDUy_bdd0d176-cefe-4670-9e70-c518eb13409d"
      unitRef="usd">-86000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="iae85a32427df4f04989f60eeef9b6bc4_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMjAtMi0xLTEtMTI3NDUy_d2c3726b-9949-45d0-8aa9-6d4107fd6bc6"
      unitRef="usd">-183000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i00193fbac18e466684ae5e311d84cef6_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMjAtNC0xLTEtMTI3NDUy_700f7658-e359-4d27-ac79-52758fca86d8"
      unitRef="usd">-105000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iae85a32427df4f04989f60eeef9b6bc4_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMjEtMi0xLTEtMTI3NDUy_ea3e6cd1-4988-40f7-8ff0-6222546cc370"
      unitRef="usd">-39000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i00193fbac18e466684ae5e311d84cef6_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMjEtNC0xLTEtMTI3NDUy_82511089-3f21-401f-9197-ba69d6ca9673"
      unitRef="usd">-22000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="iae85a32427df4f04989f60eeef9b6bc4_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMjItMi0xLTEtMTI3NDUy_9818e22c-c0d9-4e30-bb08-cad9dbef2d94"
      unitRef="usd">-144000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i00193fbac18e466684ae5e311d84cef6_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82NC9mcmFnOmVlYjJlZTU3MWVhZjQ1YmNhM2I5Nzk5OTBkMzIwNGNkL3RhYmxlOjg1NTRkOTllMTQzNTQyYWM4NGQ4NDU4ZjIwYzU5ZWM2L3RhYmxlcmFuZ2U6ODU1NGQ5OWUxNDM1NDJhYzg0ZDg0NThmMjBjNTllYzZfMjItNC0xLTEtMTI3NDUy_3517bdad-c21b-4984-a490-2a3947f0f7a7"
      unitRef="usd">-83000000</us-gaap:NetIncomeLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNjg5OA_0c100c10-d7c0-4775-8bdb-ae639bc115b0">Fair value measurement&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations for which all significant inputs are observable either directly or indirectly&#x2014;other than Level 1 inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on inputs that are unobservable and significant to the overall fair value measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The availability of observable inputs can vary among different types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of each major class of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices in&lt;br/&gt;active&#160;markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;other&#160;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value measurement as of June 30, 2022, using:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices in&lt;br/&gt;active&#160;markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;other observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value measurement as of December 31, 2021, using:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest-bearing and equity securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our U.S. Treasury securities, money market mutual funds and equity investments in publicly traded securities are based on quoted market prices in active markets, with no valuation adjustment. The fair value of equity securities without readily determinable fair values are initially valued at the transaction price and subsequently valued based on a combination of market performance and publicly available market information for similar companies that have actively traded equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our foreign currency forward derivative contracts have maturities of three years or less, and all are with counterparties that have minimum credit ratings of A&#x2013; or equivalent by S&amp;amp;P, Moody&#x2019;s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 12, Derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A&#x2013; or equivalent by S&amp;amp;P, Moody&#x2019;s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency-basis swap spreads. See Note 12, Derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our interest rate swap contracts are with counterparties that have minimum credit ratings of A&#x2013; or equivalent by S&amp;amp;P, Moody&#x2019;s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 12, Derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our business acquisitions, we have incurred contingent consideration obligations as discussed below. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and they are reviewed quarterly by management in our R&amp;amp;D and commercial sales organizations. The inputs include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes that increase or decrease the probabilities of achieving the related development, regulatory and commercial events or that shorten or lengthen the time required to achieve such events or that increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net changes in valuations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022 and December 31, 2021, our contingent consideration obligations are primarily the result of our acquisition of Teneobio in October 2021, which obligates us to pay the former shareholders up to $1.6&#160;billion upon achieving separate development and regulatory milestones with regard to various R&amp;amp;D programs. See Note 2, Acquisitions and divestitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of the fair values of other financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimated the fair values of our borrowings by using Level 2 inputs. As of June 30, 2022 and December 31, 2021, the aggregate fair values of our borrowings were $34.4 billion and $37.9 billion, respectively, and the carrying values were $36.5 billion and $33.3 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investment in BeiGene, Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimated the fair value of our investment in BeiGene by using Level 1 inputs. As of June 30, 2022 and December 31, 2021, the fair values were $3.1 billion and $5.1&#160;billion, and the carrying values were $2.5 billion and $2.8&#160;billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June 30, 2022 and 2021, there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis, except with respect to the impairment of net assets in connection with the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNjkwMA_088a8379-e930-48b5-bb96-af2fd39777fe">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of each major class of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices in&lt;br/&gt;active&#160;markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;other&#160;observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value measurement as of June 30, 2022, using:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices in&lt;br/&gt;active&#160;markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;other observable&lt;br/&gt;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value measurement as of December 31, 2021, using:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other short-term interest-bearing securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3d8850f784604d6b9bb2fd280095d18b_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfNS0yLTEtMS0xMzc5Njg_347ba4e8-b28c-414c-bb6f-1f04d2c98365"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0fd9a5ddb9454b129635afe3c05a87b2_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfNS00LTEtMS0xMzc5Njg_3d5cfd0d-046b-451a-8dc7-987bc042bc25"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iee625aa2538245daa9d87d5a6f0f740d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfNS02LTEtMS0xMzc5Njg_9c330a64-c1f5-4d38-9930-2ee33eef9a8a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8082d2e09a5c4aa0a7f3731849ec0d16_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfNS04LTEtMS0xMzc5Njg_716feade-362d-4d5e-a9b4-258c37c5825b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i57af36ff3831468c82ff7231dc809b4d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfNi0yLTEtMS0xMjc0NTI_2447fe83-1ad7-4eac-8556-249efd127271"
      unitRef="usd">1980000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i19fefe53694c4ef6b89048ac7afd4735_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfNi00LTEtMS0xMjc0NTI_518da254-005d-4183-9d0d-107efe9769d8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i750f10007cf9428abc683565238431dc_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfNi02LTEtMS0xMjc0NTI_7f955f10-f807-4ead-9f55-99d1aabbc138"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1ea16251ca3344cd8e26c09cc1395a22_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfNi04LTEtMS0xMjc0NTI_90942ff4-ff40-4235-bbb3-9658b34d6bb7"
      unitRef="usd">1980000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i15ca62a1ecc1459f914da217c657d346_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTYtMi0xLTEtMTI3NDUy_f61b53fb-6dd8-476c-bce4-37a87948cb90"
      unitRef="usd">4433000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6c3901a0af154ac48cb709ae944a36f3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTYtNC0xLTEtMTI3NDUy_88a7e6ca-4f67-4195-93b0-199ab1e91c7a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i57e8da8b9b31484fa254b68594a6327e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTYtNi0xLTEtMTI3NDUy_2fdd8db4-5bf6-460b-a45a-39699dc432de"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifbbc44571a8140188c44b0df13007242_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTYtOC0xLTEtMTI3NDUy_f19901fd-37a0-4659-a6e7-81be9e14c9c9"
      unitRef="usd">4433000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if220d1f3f0f04912b6ba27cf16233cd1_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTctMi0xLTEtMTI3NDUy_7021c511-d893-4abb-97b9-bff151944b7a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if9fc102b18f140a29f8db148f3f14ac1_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTctNC0xLTEtMTI3NDUy_9b755fce-2e3b-46c2-8c25-b6b6671127c2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i38493d297caf42bf8a474b00e8ce8499_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTctNi0xLTEtMTI3NDUy_f1585ff0-d32a-4769-8364-a81c2369424b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie2f04eaab04b4d2c952875e4954ffda7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTctOC0xLTEtMTI3NDUy_ccb4bfcd-bc4a-441e-b482-8ce600bca405"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i52bfb5d420974f909b489605f4ebb48e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTgtMi0xLTEtMTI3NDUy_b8315025-65a9-4a64-a5a2-e358cbb378cb"
      unitRef="usd">361000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5a9e16b4969645dc80f505eee050d8e6_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTgtNC0xLTEtMTI3NDUy_9b8f507c-2341-44e8-b922-d96e60962a4b"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i81f067b439ab417c9ce2795ab841e2d7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTgtNi0xLTEtMTI3NDUy_a356a680-5103-42bd-999d-fdedc74cba60"
      unitRef="usd">131000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMTgtOC0xLTEtMTI3NDUy_c9ca5b1d-7088-4741-957c-c91a936704ec"
      unitRef="usd">492000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i46910804ec6546fe9f243b43a084cef9_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjAtMi0xLTEtMTI3NDUy_f08bb0eb-f3cd-4826-9a17-35bcf2631834"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i54880ede06014f8ca9a628fc84c50f6b_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjAtNC0xLTEtMTI3NDUy_78091614-a9c4-4a80-a076-f903d9e0bd57"
      unitRef="usd">413000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i91f42a5f589a46f1b73dde5f4b870252_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjAtNi0xLTEtMTI3NDUy_0b990567-3bb3-404d-a146-32dfac2c0ad8"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i9182dc5218b74eb7a8e483c65d0897f3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjAtOC0xLTEtMTI3NDUy_382bcebe-a4b1-4c01-995e-3cfda7a70b89"
      unitRef="usd">413000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i475adb709d5446f3a4125df7b276f9fc_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjEtMi0xLTEtMTI3NDUy_80d2b1b2-8ead-4326-aff2-7c2b61f5f950"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i1f0e7a2ada564f7eb301bda6685da54c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjEtNC0xLTEtMTI3NDUy_b885fc81-26b5-4bbd-8637-fcfda3b78840"
      unitRef="usd">29000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="if67bff899732472c854d894bb8a6b451_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjEtNi0xLTEtMTI3NDUy_067715b9-7b23-4cb7-bc3c-5f1abfe930d1"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ia55251a67abe461c8b2a09b5a3574ab5_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjEtOC0xLTEtMTI3NDUy_3297fd05-bcff-4938-a367-202b808a2962"
      unitRef="usd">29000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="i4724b1086cb34ab18e734978bd980565_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjItMi0xLTEtMTI3NDUy_7fa9a2cb-d993-469b-87e3-0f5794923070"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="i9146fbc7ea114428b4ba02cee98c579f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjItNC0xLTEtMTI3NDUy_7af92ba6-44e2-4a77-be8a-d194a93426d3"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="i6874786949604cdb824d234c3030e75b_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjItNi0xLTEtMTI3NDUy_a1b3455a-3661-4767-9c8d-7a1df4e8af80"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="ida17f2fa3cec491f86e599ca3185753d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjItOC0xLTEtMTI3NDUy_6ce2b9f1-31a0-4331-a32c-81b50337c02e"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i52bfb5d420974f909b489605f4ebb48e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjQtMi0xLTEtMTI3NDUy_ab140bf4-4a75-4ee3-a582-bd5b18950a57"
      unitRef="usd">6774000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5a9e16b4969645dc80f505eee050d8e6_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjQtNC0xLTEtMTI3NDUy_2c0a470a-2b63-47e2-9406-59746df47247"
      unitRef="usd">442000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i81f067b439ab417c9ce2795ab841e2d7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjQtNi0xLTEtMTI3NDUy_c9ac9ccc-cb19-4380-bc31-91c04fdfe544"
      unitRef="usd">131000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjQtOC0xLTEtMTI3NDUy_576cf4b4-74b8-42c9-839b-3b59d462c3b9"
      unitRef="usd">7347000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i46910804ec6546fe9f243b43a084cef9_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjgtMi0xLTEtMTI3NDUy_ce3e7a55-ca8a-4553-bcc2-85e502a34d23"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i54880ede06014f8ca9a628fc84c50f6b_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjgtNC0xLTEtMTI3NDUy_7ef0438b-244a-4387-9659-db45e8765532"
      unitRef="usd">30000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i91f42a5f589a46f1b73dde5f4b870252_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjgtNi0xLTEtMTI3NDUy_df606bf5-7d1a-4db7-8d7b-edb61564aacf"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i9182dc5218b74eb7a8e483c65d0897f3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjgtOC0xLTEtMTI3NDUy_b49d4849-c557-4ad8-924e-94e3dbf36418"
      unitRef="usd">30000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i475adb709d5446f3a4125df7b276f9fc_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjktMi0xLTEtMTI3NDUy_ff3d5194-c56c-4c21-ac83-cad04f51dba9"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i1f0e7a2ada564f7eb301bda6685da54c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjktNC0xLTEtMTI3NDUy_9c47e7a7-e303-40f3-8e12-6c8d01f0782f"
      unitRef="usd">503000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="if67bff899732472c854d894bb8a6b451_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjktNi0xLTEtMTI3NDUy_b5b8d9f9-01bb-42b3-9b1a-24db8aebea67"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ia55251a67abe461c8b2a09b5a3574ab5_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMjktOC0xLTEtMTI3NDUy_456f1b5e-3b21-49f0-9203-fcb110ed8d1c"
      unitRef="usd">503000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="i4724b1086cb34ab18e734978bd980565_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzAtMi0xLTEtMTI3NDUy_1e99f60a-5c74-42c4-8bb5-31d6c9ed6cea"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="i9146fbc7ea114428b4ba02cee98c579f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzAtNC0xLTEtMTI3NDUy_9c3cdbe8-bbf9-4f63-b0b5-9dfef5ef868c"
      unitRef="usd">591000000</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="i6874786949604cdb824d234c3030e75b_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzAtNi0xLTEtMTI3NDUy_19725003-75e8-4e60-a9ca-f99ff820fb9d"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="ida17f2fa3cec491f86e599ca3185753d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzAtOC0xLTEtMTI3NDUy_b92e1fcd-64d3-4e21-8fb9-d9e5533da5c7"
      unitRef="usd">591000000</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i52bfb5d420974f909b489605f4ebb48e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzEtMi0xLTEtMTI3NDUy_901d70c8-7c3c-4178-90a4-8f2a8f4c6959"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5a9e16b4969645dc80f505eee050d8e6_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzEtNC0xLTEtMTI3NDUy_fc82a28c-cc50-4359-9928-5636c8c229f4"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i81f067b439ab417c9ce2795ab841e2d7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzEtNi0xLTEtMTI3NDUy_a5174806-4034-4297-9bb1-7161b86b733b"
      unitRef="usd">310000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzEtOC0xLTEtMTI3NDUy_9dc393c2-83d4-4f65-8dce-e0198fa5ee90"
      unitRef="usd">310000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i52bfb5d420974f909b489605f4ebb48e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzItMi0xLTEtMTI3NDUy_3ad7e3ec-4159-4975-a391-e5bf5d35b425"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5a9e16b4969645dc80f505eee050d8e6_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzItNC0xLTEtMTI3NDUy_e30be8fb-85ba-4051-9512-6c0e4846c9fa"
      unitRef="usd">1124000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i81f067b439ab417c9ce2795ab841e2d7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzItNi0xLTEtMTI3NDUy_635d6a4c-4bde-4f7d-8f45-e7ff2b8485d5"
      unitRef="usd">310000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAyZjM4Njc0ZTI4YjQ5YzJhMzA0ZDFkZDZiNTk4MmQ4L3RhYmxlcmFuZ2U6MDJmMzg2NzRlMjhiNDljMmEzMDRkMWRkNmI1OTgyZDhfMzItOC0xLTEtMTI3NDUy_e3432aab-692e-4f3d-bdcc-04d9c3d86b02"
      unitRef="usd">1434000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c488f99cfba482dbefc73db9e50c640_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfNS0yLTEtMS0xMzc5Nzk_614f96bc-6357-4f09-8164-523391bfd1b4"
      unitRef="usd">47000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i685a8a148b704128a60fc78026d3c3e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfNS00LTEtMS0xMzc5Nzk_4bec2e53-3c03-438d-b647-d5a9748dff6f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic144f91dd75648e08f88041119a4fa00_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfNS02LTEtMS0xMzc5Nzk_c2b3129f-c8b2-4c4c-9dad-1342f1a7109e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idd41271077fb4ca086b8c963378ae207_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfNS04LTEtMS0xMzc5Nzk_a3979f02-20b5-4e86-b815-49589250d1b3"
      unitRef="usd">47000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9f08e0fe42834efe92d00613a0109c40_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfNi0yLTEtMS0xMjc0NTI_1ae3149a-a5d2-4e12-b255-a26276e420d2"
      unitRef="usd">1400000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8095682c0ef94a339c9e762b31198d03_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfNi00LTEtMS0xMjc0NTI_1a3393bd-2d89-46a8-9fb7-57b5c9ee317e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9021916491244d8fa2e070974be57f65_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfNi02LTEtMS0xMjc0NTI_41c5ee6c-7745-4224-882b-60862a7a128c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3c7a0f871105442a9e599228c9451089_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfNi04LTEtMS0xMjc0NTI_f8a54c14-f134-4a61-92d6-7881cd9a691d"
      unitRef="usd">1400000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9240e5bb1cb44e2e876685572c682103_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTYtMi0xLTEtMTI3NDUy_f5ab2e23-cc6b-41d4-880a-7304417d89fc"
      unitRef="usd">5856000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0a563d28d08546408272809d7d6f60af_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTYtNC0xLTEtMTI3NDUy_fca2e205-0dd1-4c66-a905-44244534f9a7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i82eeb36d97d54dd1ab070623986e163d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTYtNi0xLTEtMTI3NDUy_fd9648ad-275f-4afa-8b6d-ab9d7e7ae2fb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i02847d17ecc24c3f9024cc5f534c04a2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTYtOC0xLTEtMTI3NDUy_a5b6dab1-76e9-4afa-bb1b-71858f8f569f"
      unitRef="usd">5856000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iedac67f993dd44d1a1c0c76f6096b1f2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTctMi0xLTEtMTI3NDUy_a6459cfa-c57e-4d59-be47-44198bbd9221"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9cb7f0273f314f8b830b51cffab82493_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTctNC0xLTEtMTI3NDUy_bbd0cc25-80a2-42f7-a63f-d659824125be"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if090df5bf17a41b3ac64e37545266583_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTctNi0xLTEtMTI3NDUy_ad87dea4-e3a6-4849-ac00-1e8bfbe25aef"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iea64a31893bd4a61a10bade5fb93931f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTctOC0xLTEtMTI3NDUy_f708972a-6331-4053-baae-66eecaffead1"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i81cbf2552fde457394dd38fa4c8d3a52_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTgtMi0xLTEtMTI3NDUy_4cc24dc2-07cd-4318-8f8b-36af67ca380e"
      unitRef="usd">611000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="idcec0bd4ab8240e38c59d5eba500ac8f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTgtNC0xLTEtMTI3NDUy_aceed23f-b54d-48c9-9dc2-e800fae589cd"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i95983e1a9dd248b6b5a91e82d2e18001_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTgtNi0xLTEtMTI3NDUy_e0fbdbeb-1915-4e28-9d1b-6f832d854a94"
      unitRef="usd">220000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMTgtOC0xLTEtMTI3NDUy_15bd09ef-2581-4568-8190-7ba39d210006"
      unitRef="usd">831000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i586c22e74161448191ba0b644c8f9eb0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjAtMi0xLTEtMTI3NDUy_7fb6ca2a-8281-4e38-9754-b41d88d34f77"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i5bcba3fb9ae4401d8255f9419a4e9c3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjAtNC0xLTEtMTI3NDUy_bbec976d-c7d2-4ab2-8f80-c0d78da46dda"
      unitRef="usd">183000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i36abb6d1f7574e63a06ec93cd761c060_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjAtNi0xLTEtMTI3NDUy_f4957ef7-dc64-425b-a81e-a4b7ff40b2d2"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i06ded0f429164b4ab474c99ae4db6e67_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjAtOC0xLTEtMTI3NDUy_709e4309-8fff-457d-bc25-e089f7d43a47"
      unitRef="usd">183000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i14f51ae9652c4b4a9742afd91ac81e98_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjEtMi0xLTEtMTI3NDUy_0ebae141-10cf-44ff-a00f-7e06748c17d5"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i0fe78984bfd5425d996816c13821a305_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjEtNC0xLTEtMTI3NDUy_a62bbe3d-2f79-4111-9d4a-115a12893e87"
      unitRef="usd">66000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ib54f0b981864432aa40974753a26ac20_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjEtNi0xLTEtMTI3NDUy_8964582d-e1d6-423f-b1b2-381b2dd632a7"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ib6d1947469e94aadb86219cbb136c914_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjEtOC0xLTEtMTI3NDUy_f53fccb9-dc1c-4d01-b629-c8f1aaae7909"
      unitRef="usd">66000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="i565eb34bf7064ea880a5c569316793d2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjItMi0xLTEtMTI3NDUy_a4325529-5504-4775-88fa-3a7559d1ab28"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="ibc87b99380f9465fa749f246800d3c48_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjItNC0xLTEtMTI3NDUy_dc876748-df18-4f11-9b02-68e5bd31c430"
      unitRef="usd">16000000</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="i3107f183897d4d47b3ae8ba81bc93c54_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjItNi0xLTEtMTI3NDUy_11df316d-ae54-44f2-aabd-016a33157e38"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="i821465fc68c64ed594b4983fbb106d7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjItOC0xLTEtMTI3NDUy_c9a8791e-a826-47eb-9b02-add7d2951bab"
      unitRef="usd">16000000</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i81cbf2552fde457394dd38fa4c8d3a52_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjMtMi0xLTEtMTI3NDUy_d71c7317-7efa-4c71-8795-433f00a3abca"
      unitRef="usd">7914000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idcec0bd4ab8240e38c59d5eba500ac8f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjMtNC0xLTEtMTI3NDUy_e57f2118-9290-40c2-b449-e399e63b7ba7"
      unitRef="usd">266000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i95983e1a9dd248b6b5a91e82d2e18001_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjMtNi0xLTEtMTI3NDUy_799becef-fe11-45c2-b208-01b0c66720cc"
      unitRef="usd">220000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjMtOC0xLTEtMTI3NDUy_17a25259-5807-4051-b45a-019f0affad11"
      unitRef="usd">8400000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i586c22e74161448191ba0b644c8f9eb0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjctMi0xLTEtMTI3NDUy_ca300d03-7fb8-4910-8fd7-49a65864888a"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i5bcba3fb9ae4401d8255f9419a4e9c3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjctNC0xLTEtMTI3NDUy_8cc7443a-9cdc-4102-891f-c3ada872d154"
      unitRef="usd">39000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i36abb6d1f7574e63a06ec93cd761c060_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjctNi0xLTEtMTI3NDUy_eb801f9b-d54b-425d-9525-ee01bf3921d6"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i06ded0f429164b4ab474c99ae4db6e67_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjctOC0xLTEtMTI3NDUy_d91393e1-3a37-4639-9031-c116b9f87b41"
      unitRef="usd">39000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i14f51ae9652c4b4a9742afd91ac81e98_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjgtMi0xLTEtMTI3NDUy_9dc6b21c-6af3-4eb3-8be3-a5dd1be3bebf"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i0fe78984bfd5425d996816c13821a305_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjgtNC0xLTEtMTI3NDUy_ba5d7255-265c-4016-bc2f-035227292bd5"
      unitRef="usd">339000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ib54f0b981864432aa40974753a26ac20_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjgtNi0xLTEtMTI3NDUy_e7577848-0940-4910-b1d8-9ae3697e8ee3"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ib6d1947469e94aadb86219cbb136c914_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjgtOC0xLTEtMTI3NDUy_64882c04-c409-4f2f-a34b-4850257d878d"
      unitRef="usd">339000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="i565eb34bf7064ea880a5c569316793d2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjktMi0xLTEtMTI3NDUy_fbf865a7-9872-41c0-80d8-d713c537b2d2"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="ibc87b99380f9465fa749f246800d3c48_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjktNC0xLTEtMTI3NDUy_04b9e6ba-72b8-4423-8820-aed482fc243a"
      unitRef="usd">156000000</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="i3107f183897d4d47b3ae8ba81bc93c54_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjktNi0xLTEtMTI3NDUy_fd36f198-2d77-4f2f-af93-e50a93acb25b"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="i821465fc68c64ed594b4983fbb106d7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMjktOC0xLTEtMTI3NDUy_b323b547-6c08-4b32-94be-dfefd25a3cee"
      unitRef="usd">156000000</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i81cbf2552fde457394dd38fa4c8d3a52_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMzAtMi0xLTEtMTI3NDUy_640d8fb3-d10c-4003-a8e2-8299fef3e344"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="idcec0bd4ab8240e38c59d5eba500ac8f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMzAtNC0xLTEtMTI3NDUy_6047266e-8512-4749-a862-e7d1dff5ae8f"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i95983e1a9dd248b6b5a91e82d2e18001_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMzAtNi0xLTEtMTI3NDUy_a4924502-3acb-4639-9048-bdc969661978"
      unitRef="usd">342000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMzAtOC0xLTEtMTI3NDUy_acc8fbfd-b499-4bf4-855f-652ddbc664df"
      unitRef="usd">342000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i81cbf2552fde457394dd38fa4c8d3a52_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMzEtMi0xLTEtMTI3NDUy_c3398d83-296a-4ca8-8f0e-ae8ac2b3a69e"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="idcec0bd4ab8240e38c59d5eba500ac8f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMzEtNC0xLTEtMTI3NDUy_2926ffc6-809f-42ff-96d0-7d1b06759d3a"
      unitRef="usd">534000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i95983e1a9dd248b6b5a91e82d2e18001_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMzEtNi0xLTEtMTI3NDUy_054f2471-527f-44a1-afce-0a2755fc6597"
      unitRef="usd">342000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjRiNjY4Y2Q3NDNmYTRmYjU4MGEzOGJhYTA3ODAxMWU2L3RhYmxlcmFuZ2U6NGI2NjhjZDc0M2ZhNGZiNTgwYTM4YmFhMDc4MDExZTZfMzEtOC0xLTEtMTI3NDUy_57a55f35-2c80-4792-b3e2-e2801a42807c"
      unitRef="usd">876000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfMjIzOQ_4c20d42c-ff64-447d-aba5-92a07dcd450f">P3Y</us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNjg5MQ_261f3bba-9ea6-4b55-80a3-56a645febd4d">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net changes in valuations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8de403afe8684433ba669a9d329718c4_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfMi0yLTEtMS0xMjc0NTI_c332ac83-dfec-437c-9f9b-cdfc81285c57"
      unitRef="usd">330000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1a2ab422b4b24a8fba8a2d881b98b260_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfMi00LTEtMS0xMjc0NTI_80d9a7c2-5f5a-4441-be02-547cdc213593"
      unitRef="usd">39000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfMi02LTEtMS0xMzg5NTg_36805676-5dd6-47cd-a93d-fbb8b034365a"
      unitRef="usd">342000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1e5bfcd24a084d2ba4ae4e9fd63a2a81_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfMi04LTEtMS0xMzg5NjU_ed3ad7ea-7aee-436a-b9d6-bdc004f16ab5"
      unitRef="usd">33000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <amgn:BusinessCombinationContingentConsiderationArrangementsPayments
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNC0yLTEtMS0xMjc0NTI_59f3e1c9-54ed-44f3-b2d6-b2e75f55d809"
      unitRef="usd">1000000</amgn:BusinessCombinationContingentConsiderationArrangementsPayments>
    <amgn:BusinessCombinationContingentConsiderationArrangementsPayments
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNC00LTEtMS0xMjc0NTI_aded6d36-ceb7-468c-9552-fcd650e88c15"
      unitRef="usd">2000000</amgn:BusinessCombinationContingentConsiderationArrangementsPayments>
    <amgn:BusinessCombinationContingentConsiderationArrangementsPayments
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNC02LTEtMS0xNTE5NDM_7dde3a09-36e4-4324-98a6-712d8df430ef"
      unitRef="usd">3000000</amgn:BusinessCombinationContingentConsiderationArrangementsPayments>
    <amgn:BusinessCombinationContingentConsiderationArrangementsPayments
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNC04LTEtMS0xMzg5NjU_07189bdc-7303-4178-a270-59cd63f9ca77"
      unitRef="usd">3000000</amgn:BusinessCombinationContingentConsiderationArrangementsPayments>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNS0yLTEtMS0xMjc0NTI_5a0543d0-0fb3-4297-87ca-81367fe57933"
      unitRef="usd">-19000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNS00LTEtMS0xMjc0NTI_bbbf4dfa-6325-453a-b067-7b81a3f39091"
      unitRef="usd">11000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNS02LTEtMS0xNTE5NDM_5628f87b-2d1e-4318-bd7e-a580e873de73"
      unitRef="usd">-29000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNS04LTEtMS0xMzg5NjU_38997cac-14fb-490f-8416-f25a30ba723d"
      unitRef="usd">18000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNi0yLTEtMS0xMjc0NTI_f3bc8952-4267-4180-874c-0e27f55893a2"
      unitRef="usd">310000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i99dc635999d0465e8fcbdc0cee2c1601_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNi00LTEtMS0xMjc0NTI_97fb1b34-e3bd-452b-8ce5-5dc7626001dc"
      unitRef="usd">48000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNi02LTEtMS0xMzg5NTg_d155d5de-6a55-41e6-9d27-a99b70977154"
      unitRef="usd">310000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i99dc635999d0465e8fcbdc0cee2c1601_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RhYmxlOjAzODM1YWIyOTVlMjQwMGE5YmFhOTczNDIzNDk4YWM4L3RhYmxlcmFuZ2U6MDM4MzVhYjI5NWUyNDAwYTliYWE5NzM0MjM0OThhYzhfNi04LTEtMS0xMzg5NjU_9ccc496f-1fa7-4810-8fa5-5e0157319387"
      unitRef="usd">48000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="ib38d2c2296ce4775b07ee5a0181057d4_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNTY2MQ_d4977e79-ec56-4079-ab39-f61690e050b7"
      unitRef="usd">1600000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i2680f1cd22d24318b9fcb7fe45f7425b_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNTY2MQ_d7351dee-676f-4853-b0c8-4ac119132407"
      unitRef="usd">1600000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNjE0Mw_bf7fb218-b17b-43a7-a4c8-987be04e32ba"
      unitRef="usd">34400000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNjE1MA_23dbb5b1-c26b-4723-adaa-b54dab3e3e62"
      unitRef="usd">37900000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:LongTermDebt
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfMTA5OTUxMTYzNTQyOA_cc7def2d-5473-4794-8f49-037b1239d3d5"
      unitRef="usd">36500000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNjIwNA_47b52320-527d-4c41-b696-5dec23f72410"
      unitRef="usd">33300000000</us-gaap:LongTermDebt>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="i508f5bf239c54b9b938463f7ae92fea1_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNjU0Mw_66cd64e1-0112-4677-aa63-b33c356bdb27"
      unitRef="usd">3100000000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="ic408702ec02a49bf91a6056997008286_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNjU1MA_146e7045-5358-45a7-a053-342dbcb5cb2e"
      unitRef="usd">5100000000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestments
      contextRef="i508f5bf239c54b9b938463f7ae92fea1_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNjU4Mw_2ba70602-abd0-41d1-a198-b544d6f3b660"
      unitRef="usd">2500000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ic408702ec02a49bf91a6056997008286_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV82Ny9mcmFnOmJkMWJkYmQ5MTY0MzQxMDU5MDNjMjMxOGU1NDcwYzcxL3RleHRyZWdpb246YmQxYmRiZDkxNjQzNDEwNTkwM2MyMzE4ZTU0NzBjNzFfNjU5MA_79d5a076-d62b-47c4-9f8c-d707e1c11cb4"
      unitRef="usd">2800000000</us-gaap:EquityMethodInvestments>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfOTMzMQ_98ed5d33-e7c6-4b02-878f-c61600a04d60">Derivative instruments&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative- trading purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash flow hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates primarily associated with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are partially offset by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales up to a maximum of three years into the future; and at any given point in time, a higher percentage of nearer-term projected product sales are being hedged than in successive periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022 and December 31, 2021, we had outstanding foreign currency forward contracts with aggregate notional amounts of $5.6 billion and $5.7 billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Condensed Consolidated Balance Sheets, and we reclassify them to Product sales in the Condensed Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to Other (expense) income, net, in the Condensed Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional amounts and interest rates of our cross-currency swaps as of June 30, 2022, were as follows (notional amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hedged notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41% 2023 Swiss franc Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% 2026 euro Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% 2026 pound sterling Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00% 2029 pound sterling Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI i&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n the Condensed Consolidated Balance Sheets &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and are amortized into Interest expense, net, in the Condensed Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the six months ended June 30, 2022, and amounts expected to be recognized during the subsequent 12 months are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives in cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of both June 30, 2022 and December 31, 2021, we had interest rate swap contracts with aggregate notional amounts of $6.7&#160;billion that hedge certain portions of our long-term debt issuances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Condensed Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying amounts of hedged liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Current portion of long-term debt includes $82 million and $85 million of carrying value with discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively. Long-term debt includes $399 million and $440 million of carrying value with discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Current portion of long-term debt includes $82 million and $85 million of hedging adjustments on discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively. Long-term debt includes $299 million and $340 million of hedging adjustments on discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impact of hedging transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(623)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Losses) gains on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Losses) gains on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;__________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Gains on hedged items do not exactly offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of June 30, 2022, we expected to reclassify $179 million of net gains on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives not designated as hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of June 30, 2022 and December 31, 2021, the total notional amounts of these foreign currency forward contracts were $550 million and $680 million, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the three and six months ended June 30, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated&lt;br/&gt;Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated&lt;br/&gt;Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging&#160;instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated&lt;br/&gt;Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated&lt;br/&gt;Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our derivative contracts that were in liability positions as of June 30, 2022, contain certain credit-risk-related contingent provisions that would be triggered if (i)&#160;we were to undergo a change in control and (ii)&#160;our or the surviving entity&#x2019;s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cash flow effects of our derivative contracts in the Condensed Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iefbf65ab82c24adaa0645594dc8fcaff_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfMTUxMA_6947c790-069c-4e59-9cdf-cb224f8c9b0f"
      unitRef="usd">5600000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8defa2bdb0084af3ae0cbfc5424bc98a_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfMTUxNw_768761d3-c2c2-452a-b7a2-c0ce731f3395"
      unitRef="usd">5700000000</us-gaap:DerivativeNotionalAmount>
    <amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfOTMyNg_ac7a3bb8-33f9-49f3-91e1-e5008642e494">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional amounts and interest rates of our cross-currency swaps as of June 30, 2022, were as follows (notional amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hedged notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional amounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41% 2023 Swiss franc Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CHF&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00% 2026 euro Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% 2026 pound sterling Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00% 2029 pound sterling Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8362dfe3f447487fbcfb592560763e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfMy0yLTEtMS0xMjc0NTI_94780afe-dd95-4d90-9496-3884e499650d"
      unitRef="chf">700000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i981e48d6e4474ce8b890550799a406fd_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfMy00LTEtMS0xMjc0NTI_258ce02a-374b-4f6e-ab67-a745d2ca314c"
      unitRef="number">0.004</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8362dfe3f447487fbcfb592560763e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfMy02LTEtMS0xMjc0NTI_53714d98-e1dd-40d4-ba97-93fcb0c26052"
      unitRef="usd">704000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i08fbdbb43e0a42089b7e2cf59e5ef985_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfMy04LTEtMS0xMjc0NTI_436cc0f6-badf-47c2-b5d5-8eac47c4e5a2"
      unitRef="number">0.034</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8ae26a5ef2c2486bbe9a6346774e6921_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNC0yLTEtMS0xMjc0NTI_747ac92a-c3dd-436d-9011-80ab8baa393c"
      unitRef="eur">750000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i0d3a7502c66a4094ac60caad8191426e_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNC00LTEtMS0xMjc0NTI_529baad9-5fde-4f67-a6b9-6cac90c6c6e7"
      unitRef="number">0.020</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8ae26a5ef2c2486bbe9a6346774e6921_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNC02LTEtMS0xMjc0NTI_491f0b7f-26c7-4c4d-814d-f90f828c0377"
      unitRef="usd">833000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="id566b59cbf154fdeb60a87ca0ef35553_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNC04LTEtMS0xMjc0NTI_f913827c-8861-46de-b138-ad4e73bd236b"
      unitRef="number">0.039</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i15d64ffdd06846b7844fc0773809a605_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNS0yLTEtMS0xMjc0NTI_3660ab2d-55ee-4609-ad27-c99953537887"
      unitRef="gbp">475000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="ic91a7bb478ff4fdcb59d644e21f41580_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNS00LTEtMS0xMjc0NTI_b9ac7e71-3908-4115-826f-68958cb6f2bf"
      unitRef="number">0.055</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i15d64ffdd06846b7844fc0773809a605_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNS02LTEtMS0xMjc0NTI_d5e14611-d020-4be1-8143-a39cbf5e9a39"
      unitRef="usd">747000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i007735ddc25943c782bd306e4842d7e1_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNS04LTEtMS0xMjc0NTI_2a1e7528-928c-4d3e-a6ee-ad6f8ef6aafe"
      unitRef="number">0.060</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i218f08d9675e4f2a93d071febe505805_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNi0yLTEtMS0xMjc0NTI_2b046c03-b84c-4842-a5bd-039947063616"
      unitRef="gbp">700000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="i312524090a284ea3a18c66e1488acf48_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNi00LTEtMS0xMjc0NTI_4a452cf5-0b69-4521-bc9a-68d9e125d81c"
      unitRef="number">0.040</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i218f08d9675e4f2a93d071febe505805_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNi02LTEtMS0xMjc0NTI_fbe807c9-4e95-4627-91f3-e1c312f0a9a3"
      unitRef="usd">1111000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="ia79d481c2b0649f0ab76519c77d951cc_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmE1ZjJiZmYxZWQ2MjQwZjVhNjNmODZhODQxY2Q5MGEyL3RhYmxlcmFuZ2U6YTVmMmJmZjFlZDYyNDBmNWE2M2Y4NmE4NDFjZDkwYTJfNi04LTEtMS0xMjc0NTI_3009e407-601d-46d7-807c-90aac4997281"
      unitRef="number">0.045</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfOTMxNw_90b95958-d7ca-46c2-8645-c706336c75cd">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives in cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i68137429bba74ac28b0ecf3eb2d7ec4c_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfMi0yLTEtMS0xMjc0NTI_a355b5eb-c80d-47e0-914d-41fbd198b888"
      unitRef="usd">252000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i4d3fea5388d64fee80f159215bb2ffe9_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfMi00LTEtMS0xMjc0NTI_bab29d9d-bd1d-4af4-a68a-13a5e9491cc3"
      unitRef="usd">-46000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i78bda1111d894ca79b9e9971a476802a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfMi02LTEtMS0xMjc0NTI_805b835e-6816-4c96-899d-b507a72c1736"
      unitRef="usd">330000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i805f5c4cbf16443d9484e17037e0cf71_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfMi04LTEtMS0xMjc0NTI_c6cba145-bbf7-4d04-9f63-8badf1b03ac3"
      unitRef="usd">137000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="ib8c48198203049e49f74000350f415ed_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfMy0yLTEtMS0xMjc0NTI_5146f83a-ebd2-47ab-bd56-5306580cd6c6"
      unitRef="usd">-185000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="id07132e210b94637823a00632d45e34d_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfMy00LTEtMS0xMjc0NTI_85599bac-223b-44ef-92b9-555f00c85560"
      unitRef="usd">15000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i85524ff13c9e4c88a235e0f4342b1c43_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfMy02LTEtMS0xMjc0NTI_7fbed6d8-af47-442b-b559-52b4c7a423d2"
      unitRef="usd">-207000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="ibcaf04737d1f428b931744a248c8be92_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfMy04LTEtMS0xMjc0NTI_fa88d394-8d7c-4254-8014-45639576dd6a"
      unitRef="usd">-60000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i0ecd36ab401a4e70a51c743fc9ccdc8d_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfNS0yLTEtMS0xMjc0NTI_e4a55634-3d55-4a11-9020-958acf274552"
      unitRef="usd">67000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i11dede7c485142b591bf4c1b589d93f5_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfNS00LTEtMS0xMjc0NTI_5c80f245-d616-4da8-a510-b597735fd77c"
      unitRef="usd">-31000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="ie8017a33df2447cf98803b972ba03d31_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfNS02LTEtMS0xMjc0NTI_2140871d-649a-42ac-8e8e-5a603ec6f99a"
      unitRef="usd">123000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="if0b85c703fd14ec3b991cc54cfc7ad38_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjcyNWE0OTI0NjI4ODRmZGRhZDFhYjZiMDE3M2FiMjllL3RhYmxlcmFuZ2U6NzI1YTQ5MjQ2Mjg4NGZkZGFkMWFiNmIwMTczYWIyOWVfNS04LTEtMS0xMjc0NTI_5eda7117-856c-4baa-8a68-57aa324c531b"
      unitRef="usd">77000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8ed4d99ca27b46dfb95dbfc0558df5cc_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNDc1Ng_1a2bccef-c603-4214-a25e-e3b9d6798c9b"
      unitRef="usd">6700000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8076cfa2bcaa4ab494d93e38c4c28e31_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNDc1Ng_81b9dd5f-849a-4abb-b81a-2f961923f7db"
      unitRef="usd">6700000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfOTM1MQ_ae4173aa-1555-4426-9b6b-53fb98129a25">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying amounts of hedged liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;____________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Current portion of long-term debt includes $82 million and $85 million of carrying value with discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively. Long-term debt includes $399 million and $440 million of carrying value with discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Current portion of long-term debt includes $82 million and $85 million of hedging adjustments on discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively. Long-term debt includes $299 million and $340 million of hedging adjustments on discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i17d41c6ab5c14f9380e71043309fbdc8_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjAyMjhkMWQwZjMwZTQ2N2RiYjc3ZDhmYzZmZjk3NzIxL3RhYmxlcmFuZ2U6MDIyOGQxZDBmMzBlNDY3ZGJiNzdkOGZjNmZmOTc3MjFfMi0yLTEtMS0xMjc0NTI_a2b67a11-d266-4e84-8641-97168b04f84d"
      unitRef="usd">82000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="idd05bb4763c34ecb8925e75416037ff8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjAyMjhkMWQwZjMwZTQ2N2RiYjc3ZDhmYzZmZjk3NzIxL3RhYmxlcmFuZ2U6MDIyOGQxZDBmMzBlNDY3ZGJiNzdkOGZjNmZmOTc3MjFfMi00LTEtMS0xMjc0NTI_7f01a0e2-5b3c-4852-80f5-fa95981f68bf"
      unitRef="usd">85000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i17d41c6ab5c14f9380e71043309fbdc8_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjAyMjhkMWQwZjMwZTQ2N2RiYjc3ZDhmYzZmZjk3NzIxL3RhYmxlcmFuZ2U6MDIyOGQxZDBmMzBlNDY3ZGJiNzdkOGZjNmZmOTc3MjFfMi02LTEtMS0xMjc0NTI_2f58147c-57b5-405b-b747-5510fda0d22c"
      unitRef="usd">82000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="idd05bb4763c34ecb8925e75416037ff8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjAyMjhkMWQwZjMwZTQ2N2RiYjc3ZDhmYzZmZjk3NzIxL3RhYmxlcmFuZ2U6MDIyOGQxZDBmMzBlNDY3ZGJiNzdkOGZjNmZmOTc3MjFfMi04LTEtMS0xMjc0NTI_7c267851-e90c-42c9-8222-e02e70b1ef06"
      unitRef="usd">85000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ic74bae73be3b45d29ba2975a44af1c97_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjAyMjhkMWQwZjMwZTQ2N2RiYjc3ZDhmYzZmZjk3NzIxL3RhYmxlcmFuZ2U6MDIyOGQxZDBmMzBlNDY3ZGJiNzdkOGZjNmZmOTc3MjFfMy0yLTEtMS0xMjc0NTI_0ec4fd75-bd3d-46b7-8589-b5a5243cea95"
      unitRef="usd">6241000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i5ff1b52fa159466d99f80192dcb38c1b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjAyMjhkMWQwZjMwZTQ2N2RiYjc3ZDhmYzZmZjk3NzIxL3RhYmxlcmFuZ2U6MDIyOGQxZDBmMzBlNDY3ZGJiNzdkOGZjNmZmOTc3MjFfMy00LTEtMS0xMjc0NTI_82e77bb7-7024-4e93-8b0c-38583a990339"
      unitRef="usd">6729000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ic74bae73be3b45d29ba2975a44af1c97_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjAyMjhkMWQwZjMwZTQ2N2RiYjc3ZDhmYzZmZjk3NzIxL3RhYmxlcmFuZ2U6MDIyOGQxZDBmMzBlNDY3ZGJiNzdkOGZjNmZmOTc3MjFfMy02LTEtMS0xMjc0NTI_70eeba52-95f4-4964-943c-ebfadd537f2c"
      unitRef="usd">-292000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i5ff1b52fa159466d99f80192dcb38c1b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjAyMjhkMWQwZjMwZTQ2N2RiYjc3ZDhmYzZmZjk3NzIxL3RhYmxlcmFuZ2U6MDIyOGQxZDBmMzBlNDY3ZGJiNzdkOGZjNmZmOTc3MjFfMy04LTEtMS0xMjc0NTI_77685a37-c3a7-4ab1-9026-6fff311c605d"
      unitRef="usd">199000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <amgn:HedgedLiabilityDiscontinuedFairValueHedge
      contextRef="i17d41c6ab5c14f9380e71043309fbdc8_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNTgxNA_5d6ec789-0acc-460e-b94e-0498a85ad2ef"
      unitRef="usd">82000000</amgn:HedgedLiabilityDiscontinuedFairValueHedge>
    <amgn:HedgedLiabilityDiscontinuedFairValueHedge
      contextRef="idd05bb4763c34ecb8925e75416037ff8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNTgyMQ_e5cc1890-29a1-4c1a-8d46-803a4d2a5ee1"
      unitRef="usd">85000000</amgn:HedgedLiabilityDiscontinuedFairValueHedge>
    <amgn:HedgedLiabilityDiscontinuedFairValueHedge
      contextRef="ic74bae73be3b45d29ba2975a44af1c97_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNTkzNw_44da8f2c-b827-4741-98bb-f01e5fa51fd5"
      unitRef="usd">399000000</amgn:HedgedLiabilityDiscontinuedFairValueHedge>
    <amgn:HedgedLiabilityDiscontinuedFairValueHedge
      contextRef="i5ff1b52fa159466d99f80192dcb38c1b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNTk0NA_3d1fdf22-1754-4258-83c9-683597106005"
      unitRef="usd">440000000</amgn:HedgedLiabilityDiscontinuedFairValueHedge>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i17d41c6ab5c14f9380e71043309fbdc8_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNjA4Mw_eec365ee-c1e3-4f5d-84b9-5e8db496e3ec"
      unitRef="usd">82000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="idd05bb4763c34ecb8925e75416037ff8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNjA5MA_0f8a3f3c-e43a-4bd2-b00f-ec7f920d7251"
      unitRef="usd">85000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ic74bae73be3b45d29ba2975a44af1c97_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNjIwOQ_5faac66a-4e62-411d-9a64-86538931afe3"
      unitRef="usd">299000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i5ff1b52fa159466d99f80192dcb38c1b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNjIxNg_2546d635-ba47-49b4-8186-55fe6f5caedb"
      unitRef="usd">340000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfOTM2Mw_dead3966-7c6b-4995-80e0-c5f75bfb846f">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(623)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The effects of cash flow and fair value hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Losses) gains on cash flow hedging relationships reclassified out of AOCI:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Losses) gains on fair value hedging relationships&#x2014;interest rate swap agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;__________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Gains on hedged items do not exactly offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3c410d6b2f84e53be5c076dec22d865_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfMy0yLTEtMS0xMjc0NTI_98efb387-04ef-4729-a1c3-07bc08108a38"
      unitRef="usd">6281000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfMy00LTEtMS0xMjc0NTI_ae9c9671-aaba-4635-a022-28135a680f5e"
      unitRef="usd">-317000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfMy02LTEtMS0xMjc0NTI_370ef145-871a-473f-bb68-c69c2b4bb002"
      unitRef="usd">328000000</us-gaap:InterestExpenseDebt>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38c160a3f1834d5e9d775a1dea85e514_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfMy04LTEtMS0xMjc0NTI_2b7895d9-3115-4e52-aca8-3bf5c06f6f46"
      unitRef="usd">12012000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfMy0xMC0xLTEtMTI3NDUy_bd5a938f-8f70-4c8b-a1f3-48d0b7f2506e"
      unitRef="usd">-847000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfMy0xMi0xLTEtMTI3NDUy_f4c9b540-2312-4165-a189-9ef5cb00535c"
      unitRef="usd">623000000</us-gaap:InterestExpenseDebt>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04f12d226beb4801941ee9ae41184a68_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfNi0yLTEtMS0xMjc0NTI_545d91d4-95f8-4244-bfc0-6ef8ccef4b3b"
      unitRef="usd">53000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58b1f56bd6014a44b958229d8e11e34c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfNi04LTEtMS0xMjc0NTI_a83f96c2-c790-4bc9-a64a-d7c6e7bd8964"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic08e134f84b54cd59491e20413185c0a_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfNy00LTEtMS0xMjc0NTI_92f94ecf-20b2-44ef-874f-d720d55bac87"
      unitRef="usd">-185000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i05e8cec02f334b38bc7a7a5dbf123867_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfNy0xMC0xLTEtMTI3NDUy_03f8d04d-0ac3-4b88-9284-5dc14e100ca5"
      unitRef="usd">-263000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i71fb031f34f648488a945f9c0e957284_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfMTAtNi0xLTEtMTI3NDUy_ebc59e09-1edf-4bfd-9c51-7c0f764448ec"
      unitRef="usd">157000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i2d46d6b8233243ecac66f70b9060cbd1_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfMTAtMTItMS0xLTEyNzQ1Mg_b60ba282-95e3-4c92-ae9d-73d0621db2d9"
      unitRef="usd">494000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i71fb031f34f648488a945f9c0e957284_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfMTEtNi0xLTEtMTI3NDUy_cd036763-39a9-4203-a817-82fcbd1f7df8"
      unitRef="usd">-135000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i2d46d6b8233243ecac66f70b9060cbd1_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmQ2ZjYyZGZjMDU0MDQ5MTc4Y2YwZDUzZDZlYmZmZjdlL3RhYmxlcmFuZ2U6ZDZmNjJkZmMwNTQwNDkxNzhjZjBkNTNkNmViZmZmN2VfMTEtMTItMS0xLTEyNzQ1Mg_ee5653db-cf49-46a9-8185-2a575a9f00bc"
      unitRef="usd">-450000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78d9e005bccc4060bd5addba903c2c2c_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfMy0yLTEtMS0xMjc0NTI_277a94a6-1fc3-4231-9c03-7ed1aae99801"
      unitRef="usd">6114000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfMy00LTEtMS0xMjc0NTI_70bc1e7f-0cfe-4fe8-b3e3-5ff994aa7f48"
      unitRef="usd">11000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i8c2718d9b6724f68bcf18930085f0507_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfMy02LTEtMS0xMjc0NTI_59f9e2a1-9fbc-40ed-8bfc-c6371c615ce1"
      unitRef="usd">281000000</us-gaap:InterestExpenseDebt>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93db18973157470084da5a577ecb7c40_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfMy04LTEtMS0xMjc0NTI_9d933c45-ae49-4f60-a9a8-fb0f2099e382"
      unitRef="usd">11706000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfMy0xMC0xLTEtMTI3NDUy_0644a077-eff2-46eb-a967-4ebb22c32384"
      unitRef="usd">24000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfMy0xMi0xLTEtMTI3NDUy_f4767d5d-688a-4027-9850-b85d21d5edf3"
      unitRef="usd">566000000</us-gaap:InterestExpenseDebt>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9a2634a12bd4b95b7c8f4f70a665670_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfNi0yLTEtMS0xMjc0NTI_64f24ae0-3b98-4f31-86b9-5037378f802f"
      unitRef="usd">-18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib097da5bd14d41edb20979d3673833c5_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfNi04LTEtMS0xMjc0NTI_c410dfba-9a5f-4973-849b-7b421bf42f88"
      unitRef="usd">-19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ife1360142edd4db88451ac7ac6cbba55_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfNy00LTEtMS0xMjc0NTI_e342777d-96e4-4c27-9514-c0e36d179c7d"
      unitRef="usd">46000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i80f9a2035b3f4ef6803a4efbdaae94fe_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfNy0xMC0xLTEtMTI3NDUy_b047ae22-8a62-4305-a513-b29a31d81e0f"
      unitRef="usd">-86000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i60819ab810454638b5cda1c40c6fcbe0_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfMTAtNi0xLTEtMTI3NDUy_75188da4-c9e9-4de4-9286-7a1a1b793b8b"
      unitRef="usd">-34000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i4620a07bcdfd4700a32de4f28a35ac57_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfMTAtMTItMS0xLTEyNzQ1Mg_ffbee826-3c66-4702-9ed3-ac1254c68d30"
      unitRef="usd">141000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i60819ab810454638b5cda1c40c6fcbe0_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfMTEtNi0xLTEtMTI3NDUy_db135fba-ce7b-449d-90b7-3266d99203f0"
      unitRef="usd">55000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i4620a07bcdfd4700a32de4f28a35ac57_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjZlMDZmNDI3ZGE2ZjRmMmVhN2U5Nzk1MjIyOWMwMTQ5L3RhYmxlcmFuZ2U6NmUwNmY0MjdkYTZmNGYyZWE3ZTk3OTUyMjI5YzAxNDlfMTEtMTItMS0xLTEyNzQ1Mg_684480b2-99d7-4ea7-8440-65332e860b50"
      unitRef="usd">-97000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months
      contextRef="i9027275ed49d4865b0705c7a15256e40_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNzA5MQ_883b9c8e-5776-480b-8acf-7f97686baaec"
      unitRef="usd">179000000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie3f981e832314d97a18ace7194dec829_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNzYzNw_00cd57f9-ed39-4b54-8ef2-f453b32add04"
      unitRef="usd">550000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i214b98a8995d4320b1feccd543454dfb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfNzY0NA_42e2135f-2162-4595-8d4f-b6462dca8ea4"
      unitRef="usd">680000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RleHRyZWdpb246MWY3MDhhOGYzNjY1NDJjZWExNmRhMmI5N2ZmMjE0M2VfOTMyMg_bda652cd-218a-42bc-8ed6-d034e98972f4">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated&lt;br/&gt;Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated&lt;br/&gt;Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging&#160;instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other&#160;noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated&lt;br/&gt;Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Condensed Consolidated&lt;br/&gt;Balance Sheets locations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets/ Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities/ Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ie5f1f9fe211f40d8bb875fcebcc49a34_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjhjMWQzZTM2YmQzNTQzNzY4MmI4MzVhN2E4ZWU4ZjI1L3RhYmxlcmFuZ2U6OGMxZDNlMzZiZDM1NDM3NjgyYjgzNWE3YThlZThmMjVfMy00LTEtMS0xMjc0NTI_1d39180b-b1a6-4792-8bde-bae1dd5ab652"
      unitRef="usd">413000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ibac2494da7b14b1cbcce6502366b8635_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjhjMWQzZTM2YmQzNTQzNzY4MmI4MzVhN2E4ZWU4ZjI1L3RhYmxlcmFuZ2U6OGMxZDNlMzZiZDM1NDM3NjgyYjgzNWE3YThlZThmMjVfMy04LTEtMS0xMjc0NTI_babc9763-59c9-40ab-8cb3-c42c1fe19be3"
      unitRef="usd">30000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ibbe23a3b8f0d470c8d4a49d6ccea2fa7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjhjMWQzZTM2YmQzNTQzNzY4MmI4MzVhN2E4ZWU4ZjI1L3RhYmxlcmFuZ2U6OGMxZDNlMzZiZDM1NDM3NjgyYjgzNWE3YThlZThmMjVfNC00LTEtMS0xMjc0NTI_ffcbc2cd-78fc-4b44-87df-6c2675b057b9"
      unitRef="usd">29000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i6dd87d0fef6646d585035e3b89e9d2db_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjhjMWQzZTM2YmQzNTQzNzY4MmI4MzVhN2E4ZWU4ZjI1L3RhYmxlcmFuZ2U6OGMxZDNlMzZiZDM1NDM3NjgyYjgzNWE3YThlZThmMjVfNC04LTEtMS0xMjc0NTI_c78e93e4-ab29-41de-be23-b9a0fd88d581"
      unitRef="usd">503000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i788c2b8522d14ae4b526f2caa3d298ba_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjhjMWQzZTM2YmQzNTQzNzY4MmI4MzVhN2E4ZWU4ZjI1L3RhYmxlcmFuZ2U6OGMxZDNlMzZiZDM1NDM3NjgyYjgzNWE3YThlZThmMjVfNS00LTEtMS0xMjc0NTI_586ba7f5-130d-427d-bbc6-48da5d17efea"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i19dc6da2ca134f33b03794a8e15bdc9a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjhjMWQzZTM2YmQzNTQzNzY4MmI4MzVhN2E4ZWU4ZjI1L3RhYmxlcmFuZ2U6OGMxZDNlMzZiZDM1NDM3NjgyYjgzNWE3YThlZThmMjVfNS04LTEtMS0xMjc0NTI_6d8a88b4-bd06-4d4a-ba37-34ebf7c3df69"
      unitRef="usd">591000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="iddf4e6ee507f42da9c63527f4cd46ce6_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjhjMWQzZTM2YmQzNTQzNzY4MmI4MzVhN2E4ZWU4ZjI1L3RhYmxlcmFuZ2U6OGMxZDNlMzZiZDM1NDM3NjgyYjgzNWE3YThlZThmMjVfNy00LTEtMS0xMjc0NTI_c0e735f2-2356-4921-ad8a-744db84c8ad2"
      unitRef="usd">442000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="iddf4e6ee507f42da9c63527f4cd46ce6_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOjhjMWQzZTM2YmQzNTQzNzY4MmI4MzVhN2E4ZWU4ZjI1L3RhYmxlcmFuZ2U6OGMxZDNlMzZiZDM1NDM3NjgyYjgzNWE3YThlZThmMjVfNy04LTEtMS0xMjc0NTI_47b03901-c048-43d6-91e0-6ae55d5c196a"
      unitRef="usd">1124000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="icf3a9c3404d34ff4ac73b544cd1e2f86_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmNjZTUzZmRiNzVkZDQwZjlhNjVmOGYwYWY3MzJhM2FmL3RhYmxlcmFuZ2U6Y2NlNTNmZGI3NWRkNDBmOWE2NWY4ZjBhZjczMmEzYWZfMy00LTEtMS0xMjc0NTI_7a4b1dad-43d5-4c36-b121-859056dbf480"
      unitRef="usd">183000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i1c607fed913b4d45844cc65fc1906d04_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmNjZTUzZmRiNzVkZDQwZjlhNjVmOGYwYWY3MzJhM2FmL3RhYmxlcmFuZ2U6Y2NlNTNmZGI3NWRkNDBmOWE2NWY4ZjBhZjczMmEzYWZfMy04LTEtMS0xMjc0NTI_0913470a-dac2-4389-85e5-572ad4b0d0eb"
      unitRef="usd">39000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i7e470b268fb34c43bee67b9119f09613_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmNjZTUzZmRiNzVkZDQwZjlhNjVmOGYwYWY3MzJhM2FmL3RhYmxlcmFuZ2U6Y2NlNTNmZGI3NWRkNDBmOWE2NWY4ZjBhZjczMmEzYWZfNC00LTEtMS0xMjc0NTI_e3012c0b-d751-4737-8dc5-a1dc827b63b4"
      unitRef="usd">66000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i0bf6cd1b2403422ba77e0a6dc045346f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmNjZTUzZmRiNzVkZDQwZjlhNjVmOGYwYWY3MzJhM2FmL3RhYmxlcmFuZ2U6Y2NlNTNmZGI3NWRkNDBmOWE2NWY4ZjBhZjczMmEzYWZfNC04LTEtMS0xMjc0NTI_cb753ccc-caec-4aea-b606-28a51bc5c569"
      unitRef="usd">339000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i4eae23293d40463888c07bd1f600a1aa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmNjZTUzZmRiNzVkZDQwZjlhNjVmOGYwYWY3MzJhM2FmL3RhYmxlcmFuZ2U6Y2NlNTNmZGI3NWRkNDBmOWE2NWY4ZjBhZjczMmEzYWZfNi00LTEtMS0xMjc0NTI_b89727c0-a41c-4d0f-ab30-b8e34fa3e682"
      unitRef="usd">16000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i565b2e8ffb1b400bb11bbac9aa7a32a2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmNjZTUzZmRiNzVkZDQwZjlhNjVmOGYwYWY3MzJhM2FmL3RhYmxlcmFuZ2U6Y2NlNTNmZGI3NWRkNDBmOWE2NWY4ZjBhZjczMmEzYWZfNi04LTEtMS0xMjc0NTI_b927e222-aeff-4237-8e20-2e83a03e3909"
      unitRef="usd">156000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i05b40e8931544e10b858fc7bf3becffb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmNjZTUzZmRiNzVkZDQwZjlhNjVmOGYwYWY3MzJhM2FmL3RhYmxlcmFuZ2U6Y2NlNTNmZGI3NWRkNDBmOWE2NWY4ZjBhZjczMmEzYWZfNy00LTEtMS0xMjc0NTI_2ec93e06-f4cf-4a1a-8e99-6f6cb08da40a"
      unitRef="usd">265000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i05b40e8931544e10b858fc7bf3becffb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83MC9mcmFnOjFmNzA4YThmMzY2NTQyY2VhMTZkYTJiOTdmZjIxNDNlL3RhYmxlOmNjZTUzZmRiNzVkZDQwZjlhNjVmOGYwYWY3MzJhM2FmL3RhYmxlcmFuZ2U6Y2NlNTNmZGI3NWRkNDBmOWE2NWY4ZjBhZjczMmEzYWZfNy04LTEtMS0xMjc0NTI_dd81d1a0-3dba-46ec-9ea8-1f879796eeac"
      unitRef="usd">534000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i399851cc44354bd288c22867c4af295c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83My9mcmFnOjIzMDNmZDNhMDc5MDQ3ZTQ4Y2FjMDBlNmYxYzdhNjNhL3RleHRyZWdpb246MjMwM2ZkM2EwNzkwNDdlNDhjYWMwMGU2ZjFjN2E2M2FfNDk5Mw_d26650e4-c76b-4025-98b7-478715def3ee">Contingencies and commitments&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See our Annual Report on Form 10-K for the year ended December 31, 2021, Part I, Item 1A. Risk Factors&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Our business may be affected by litigation and government investigations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. Although it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain recent developments concerning our legal proceedings and other matters are discussed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ANDA Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Otezla ANDA Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc. v. Apotex Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 14, 2022, Amgen filed a lawsuit in the U.S. District Court for the District of New Jersey (the New Jersey District Court) against Apotex Inc. (Apotex) for infringement of U.S. Patent Nos. 7,427,638, 9,872,854 and 10,092,541, which are listed in the Orange Book for Otezla. This lawsuit was based on Apotex&#x2019;s submission of an ANDA seeking FDA approval to market a generic version of Otezla and seeks an order of the New Jersey District Court making any FDA approval of Apotex&#x2019;s ANDA effective no earlier than the expiration of the applicable patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Repatha Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patent Disputes in the International Region&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 21, 2022, Sanofi Biotechnology SAS filed an action against Amgen GmbH and Amgen (Europe) B.V. before the Regional Court of Dusseldorf alleging that the marketing and sale of Repatha infringes European Patent No. 2,756,004 (the EP&#x2019;004 Patent), seeking infringement damages and injunctive relief. The EP&#x2019;004 Patent is currently in opposition proceedings, initiated by Amgen and an anonymous third party, before the European Patent Office (EPO). A hearing before the Opposition Division of the EPO was held on June 8 and 9, 2022, and the Opposition Division upheld the validity of the claims at issue with narrowing amendments. The parties are awaiting the Opposition Division&#x2019;s written opinion. Amgen filed a Notice of Appeal on July 6, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antitrust Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sensipar Antitrust Class Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 11, 2022, the parties filed motions asking permission to seek interlocutory appeal of the U.S. District Court for the District of Delaware&#x2019;s (the Delaware District Court&#x2019;s) March 11, 2022 order denying Amgen&#x2019;s Motion to Dismiss solely with respect to the reverse payment claim and the various state law claims. The plaintiffs did not oppose Amgen&#x2019;s motion and instead argued all issues should be appealed at this time. Amgen filed its opposition to plaintiffs&#x2019; motion on June 10, 2022, and reply briefs were filed on June 24, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;HUMIRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Biosimilar Antitrust Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2022, the U.S. Court of Appeals for the Seventh Circuit issued an opinion affirming the June 30, 2020 dismissal with prejudice by the U.S. District Court for the Northern District of Illinois of a consolidated complaint against Amgen along with AbbVie Inc., AbbVie Biotechnology Ltd., Samsung Bioepis Co. and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sandoz Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Regeneron Pharmaceuticals, Inc. Antitrust Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 27, 2022, Regeneron Pharmaceuticals, Inc. (Regeneron) filed suit against Amgen in the Delaware District Court for federal and state antitrust and unfair competition violations and tortious interference with prospective business relations. Regeneron alleges that Amgen&#x2019;s sales contracting practices for Repatha, ENBREL and Otezla with key insurers, third-party payors and PBMs have harmed the sales of its product PRALUENT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and focuses on two primary arguments: that Amgen improperly bundled sales of Repatha with ENBREL, Otezla and potentially other products and sought exclusive or de facto exclusive formulary positioning for Repatha. Amgen&#x2019;s initial responsive pleading was filed on August 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Tax Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen Inc. &amp;amp; Subsidiaries v. Commissioner of Internal Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 4, Income taxes, for discussion of the IRS tax dispute and the Company&#x2019;s petition in the U.S. Tax Court.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <amgn:LitigationSettlementNumberOfPrimaryArguments
      contextRef="i3468cc5757b34eb384cc512b95a07626_D20220527-20220527"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMDQ3NWRiNzY2MDRiMDU5MDFlZjc0NzM0NjVlY2YxL3NlYzo3MTA0NzVkYjc2NjA0YjA1OTAxZWY3NDczNDY1ZWNmMV83My9mcmFnOjIzMDNmZDNhMDc5MDQ3ZTQ4Y2FjMDBlNmYxYzdhNjNhL3RleHRyZWdpb246MjMwM2ZkM2EwNzkwNDdlNDhjYWMwMGU2ZjFjN2E2M2FfMTA5OTUxMTY3NDAzNQ_dc7dd81e-eb31-49fb-8770-7ab14735fd7c"
      unitRef="argument">2</amgn:LitigationSettlementNumberOfPrimaryArguments>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M8!(N_KJ9P^N/< 6 ^2UC\JFC%FC?D_%_4$L#!!0    ( +&>!%56:<C;A 8
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M(XUN>FUC6%7Y=K52%IN?GQ;X/(%V#KB_5LKN#=<!NP<O^P=02P,$%     @
ML9X$53>@6+O?"P  NG,  !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6S%
MG6]OV[86QK^*X V[+5#'^F^[2P*L,8G; =V*9KOWQ7!?J#83"Y4E3Y*3]MM?
M2G9-4SP^%IV3[$UKM^1S*#ZB2/YT)%\^%N67:BE$[7Q=97EU-5C6]?KM:%3-
MEV*55!?%6N3R?^Z*<I74\FMY/ZK6I4@6;:55-O)=-QZMDC0?7%^V__:QO+XL
M-G66YN)CZ52;U2HIO[T36?%X-? &W__A4WJ_K)M_&%U?KI-[<2OJ/]<?2_EM
MM%=9I"N15VF1.Z6XNQK\XKWE\;BIT);X3RH>JX//3G,HGXOB2_/E_>)JX#8M
M$IF8UXU$(O]Z$#<BRQHEV8Z_=Z*#?<RFXN'G[^J\/7AY,)^32MP4V7_31;V\
M&DP&SD+<)9NL_E0\_EOL#BAJ].9%5K5_.H^[LN[ F6^JNECM*LL6K-)\^W?R
M==<1!Q6\X$@%?U?![U0(_2,5@EV%H%,A.A8AW%4(.Q7\Z9$*T:Y"U&U2?*1"
MO*L0MWV_[:RVIV=)G5Q?EL6C4S:EI5KSH;6KK2T[.,V;,^NV+N7_IK)>?7U3
MY MYGHB%(S]5198NDEI^N:WE7_($JBNGN)/?BOF799$M1%G]RV%_;]+ZFS-T
M_KR=.:]^?.U4RZ04E9/FSH<TR^3Y4KUQ?CS\>CFJ95.;@*/YKEGOMLWRCS3K
MCZ).,J#:#5[MM\WJLRB;)N_:)#_-B]5*GL)5<PS.7Q]$4^)_@/0,E[XYE$GR
MA9,L%FDS.)+,62?I8BB/=YZL4]EN+ K#H_PRGV]6FZSU0(Z/=)[6F!KOKU;4
M2]DSLC/D!6C97!D>A),5575$?B3/H_W)Y.]/)K^-%QZ)]T[<IWF>YO?.NR1+
M\KEXX]QN?4AJ9R;F%T[@O7%\UW>A,P+5;JZP;ZMU,A=7 WD$E2@?Q.#ZIQ^\
MV/T9.D^V8M-6K+FZ/EQ'X\E%<#EZ.+2<,B2C%.-$8IJ-P=[& +=Q:YZ3M./G
M\]Y4^64MRK18]+)S&R,^<& :NE/=@!NT(99]-C,C!M[$]?60S"PU]+W0G>C%
M.%!L.HGVA;2.#?<=&[:U@B,=^SZ?R]F_$LXKV7OMI]?-91*\O/[UJ<@R1\Z>
MCTFY@,;^NY!RO%"*S2C%&*48)Q+3W(_V[D?HL/I-KA/37%Z!A2-7A,UZ*)VW
M,\DBS3;-)9I]O(5\WJI&!V>B%X=Q9R"AH6W]HQ1C?9K/B2)JOL1[7V+4E]^!
MF7'GTZMFAGS]QLFE=?+J5R=?!;B8B<UCC#K7G1NT$;8.48HQ2C&.=X5FT'AO
MT!@U:)8^I'*1NJCDDFB>R?6$7,WDVKH.\F1L-&3HN5[7%32RK2N48JQ7^SE1
M2,V7R=Z7">K+^ZK:M N%[BJ[60H7>;[;/#ZF]=*18TSN,%;K)/_VTP\3WQO_
M7#EB.],ES0SGK,OBODQ6U?<E(V0IVAS;&6]BK!#=BW%G?4@9D%&*<2(QS??I
MWO?IR_L.^3TUAD!WVD,;:CM\3X9CE.$XD9AFH>>J?;^+FM@N.H<-E%FT<Y^<
M^)+6-O&U^2S /;MK]%#4&3(W>%A;2WI$9*01.96:;LL!CO%06_Y(OCJI'"[S
MVBG%=N=>%XY8K;/BFQ#;<6;KFF?.)%%W(X8WR]JV'B$9:4A.I:;[ILB'AZ./
M3V*]*>=+:8P!G; 9#5>UG=(\DWH, V-2(XW)2-4XE9KNH@(?'DX^$!=!]P+S
M-)_$47=HD4(.4C76ZP@X54S=%45-/'1;?LWRQ1&F^"$I]Q#* QTBA20[-9TJ
M1@95) W*2-4XE9INI4(@'LY =+0H]W0Z5#SMITD3ID$0=D<<*0T!8C9<L;LV
M!(H-?2\.IMW!!)2;! &\1?84Q/!PBO$T]HZ+6X^3N!=])PW*2-4XE9KNIB(>
M'HX\:!"\9S($@,'C3;$>+69,B,(#Q4 ,#Y4[RN$]12Z\R0N2>(\43)"JS4C5
M&*D:IU+33P*%,3R<8YP+Y#T3%/B>YW:'%2F;(%5CI&J<2DV_YZQ(AH^3C./+
MPU\WN;Q NL>7$[BR]3UGUYSVXNE%W+WI3!F4D:IQ*C7=2D4_?)Q^G%@>GO;3
MY X3/^PB*KP1MB,3B"DGO'&74@'%AKX_CKM 'RHWB2?PA.<?9&8\(37CY+(;
M%[<>)U!RAKF-(@W*2-4XE9KNIN(4/D&&QFE7S<T_L)G"FV(]6LR8T&8** 9N
MIJ!R1S=3OB(._DLF:OBD$()4;4:JQDC5.)6:?A(H5N$_3[Z&;V[PP]@85:2(
M@E2-]3D 3A52-T?A#O_9DS9\,U5A&'3A+=X,:Y](B0>I&C_1';I/"F3X.,AX
M\1P!O#W6%]LQD"4PZ2Y42/,^2-4XE9INO^(L_C^0(@+:/C&O6<:ZGQ2L](C(
M2"-R*C7=2X5+?!R7G),QX)NHQ'.[I 2/:^U+CY",-"2G4M.SM14 "7  \@PY
M X&9=S$<=Y-O\&999V_W",E(0W(J-=TW13L"G':<F3. J]K.<#LU+6<@ON@L
M@V:D,1FI&J=2TUU49"4X._,#=,\W3W,OFG;S4O&@UF.+%*7T.P1.%53WY> A
M%IR1M#L$T &3&717_;BT=>^3IFR<;CZG"JCWO*(GP;GY&B<!+JYL?6T#\C4
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M&$3 PQ\ 9 >*@9 =*G<4LD>*/43^"T+VB!0LD*K-2-48J1JG4M-/ D4@(IQ
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M1;(095- _O]=4=3?OS2_E;C_N<[K_P-02P,$%     @ L9X$51E5S2.R @
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M?Q&/?["V0XGUEXE"U7_18V,[(R.4;9469=O8*"AYU?RGW]M [#4P?N &I&U
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MD[R.##?1=?)+"5:IZ%JYK+&FDV<!O%\[C*+^A@\8?SH[^Q]02P,$%     @
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MS!2UO*]_U*6<]5LY=1I4U(!^8=I 1&KK_$!7@W#O&_4,Q[(@'<5ZBA33<5*
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MN=<$!%(Q(X*K0#4LJ2HV&0P5<J^-,BV HN1ML%J48%>R2X)N#OHHLBH*B@.
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MV6"/F5'B\NKZA:SJXW="W2,C0@^L#:3WW+N*U\KBMP9#G&U@Q'O2[0J;J*$
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M)1%F- 'OYP[9KGV@#;KOOF?_ 5!+ P04    " "QG@15)KPR1^ #   ("0
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MLOEPHPT<#!KY^/CDNX\_?VPC=\.]E:Z_+%P%RIH2P_L!*MXE7/30>8G@/-9
M-)IE)C'319DL^/46\;K>3Z"P*=S28.]I*4*=8BO%Q*N5#_0%5=E?<])&5*FK
MBW5*;]<P98MJN>^F?$A!*)*)(-N--9O)!F;,L%_D-)'S2ZQ4RAVGR>A0HHRA
ML::SN7%YNE?DL(EP-KE6D-7X#1K=47@4&>F$W#B.-2.2D H@2744.0:,=&18
M^FR#Z5H$R=2=AXM0\9'PD7AU4M.M D'S=/P[SH@FUJ2LSH=\*C Q:IRM#'<4
MN2L.GWJ&M7'(M!^G<BW@;YS#]48/'L1M>VU^5/O$(55VRA]R.,$>$[YVJ$:K
M;T4NPR<2J^GA0Y,/TDY)PD1-L+3;.3ENH=7ECS?"C3<Y?S Q-MZ;E"]G"B9D
M:0*>3PP\OKRA#:HO:"[^!U!+ P04    " "QG@15Y#\R+'4"  !M!0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6R%5%U/VS 4_2M7&9HVJ2)ITC:L
M:R-1&!J3D!!LXV':@YO<)!:.G=DN@7^_:Z<-G52Z%W]<WW-\KNWC1:?THZD1
M+3PW0IIE4%O;SL/0Y#4VS)RJ%B6ME$HWS-)45Z%I-;+"@QH1QE$T"QO&99 M
M?.Q69PNUL8)+O-5@-DW#],L*A>J6P3C8!>YX55L7"+-%RRJ\1_NCO=4T"P>6
M@C<H#5<2-);+X'P\7TU<OD_XR;$S>V-PE:R5>G23ZV(91$X0"LRM8V#4/>$%
M"N&(2,:?+6<P;.F ^^,=^Y6OG6I9,X,72CSPPM;+X"R  DNV$?9.=5]Q6\_4
M\>5*&-]"U^<F<0#YQEC5;,&DH.&R[]GS]ASV &?1&X!X"XB][GXCK_*2698M
MM.I NVQB<P-?JD>3."[=I=Q;3:N<<#:[ED\HK=(<S2*T1.C"8;X%KWIP_ 9X
M!C=*VMK %UE@\2\^)"&#FGBG9A4?)?RVD:>01".(HS@^PI<,U26>+_E/=2]P
MR4TNE-EHA%_G:V,U/8??ARKN"2>'"9U%YJ9E.2X#\H!!_81!]O[=>!9]/B)W
M,LB='&/_WV4<!1^6ML<(^^-<D:V,Q0)4";9&*)4@?W)9P0<NZ:$)09XQ'^=
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MMR9&LC#F@5_N\HO>D V2I<P\2Q#X]RAO9%FR()CQ6R>SMU/)!_?76^D_!NS
MLA!.WICR%Y7[XJ(WZU$NEZ(I_1>S_DEV>,8L+S.E"T]:M[SCM$=9X[RINL.P
MH%*Z_2^^=7[8.S ;OG(@Z0XDP>Y64;#R5GAQ>6[-FBQS0QHO M1P&L8IS4&Y
M]Q:["N?\Y2=C\K4J2Q(Z)^,+:4EI+_1*+4I)PCGIW?G 0Q/S#[).ZG4K-7E%
MZH1^-MH7COZD<YD?GA_ PIV9R=;,Z^1-@7]N=)_2843),(G?D)?N8*=!7OH>
MV'=/@*\"8+I5+BN-:ZRD?UXMG+=(GG^]Y(96R^AE+5Q09ZX6F;SHH6*<M(^R
M=_GAAW@R_/@&AM$.P^@MZ?]UZ/YWJ;1C^EI(R@KL2G"1YS=A[4;I%8G*--J3
M6=)JR[T6#A)H:4KT D?'.%*!CNIT)V=TK[Y1U::-Y+2A:[E26K.LA2B%SB0=
M43R*9O,A7>6_HC;0'&",-T\:X&64(Q]96E.AYG]KE%-<_RX RM$"G%<>D741
M:32]X_B$IG336"MUMB&$6KM2M!UCIX2.T^2$D_FY,9,Q_7OO+\B[,55M'!
MO'B?I:T3 PM[<<]PRH67M!3*TJ,H&_! *EO>Q2*P6BCK K!_%)Q?I99FH4R
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MC/)^4X@^?B*25.1AY& +C^4V<J(_1Z-,4A$'D1 25^ C(>3.LY2#5(M )GP
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M3$5FRLWX!N4\$*ERD:!LU.QC,&$&?,4F/WI.4(D?2)C<:;86-]_*O'S^;H"
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MO?<%A)GR*ZH$[[A?#;?!+7\1;-*-)?.GG5&Q6#O.ENW=<=O9WI47QC_EZG-
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MYU9DB ./VPPWBRD'5IVC\,LHM)"&32&FQ "A\+U6^1WNNQZAF/L;@+K26NU
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M?4WZ]X?L?Q#WP#_GE0@+):PK=(44QLK&>5S/Q+3QD.M])E9*2/A/5TMKEJK
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MUN,5:(5:%-_MDSL0T==#1%\?CHL.\!@LE&RQ47/-VA?>OZ!&_0N!61JK;6Z
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MA;+D33^LZ3-$[1)H?:F4W09N@_Y[S?\"4$L#!!0    ( +&>!%7B5P.1>@0
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MKE=96S:?S.Z=[O:C4-_2E(YZMO.R@H_8LG6-J3HP,*B*VC^S[YT?C@!I^ 2
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M<]LV$OXK&#7M2#.*Q'=)CNT96[DTN>E+IDYZ'VYN.C )B6A)0@> 4=)??[L
M29,613F.KYU._<$B">SNLXMG%POR?"_D;RIE3)./>5:HBU&J]>YL/E=QRG*J
M9F+'"AC9")E3#;=R.U<[R6ABA/)L[CE.-,\I+T:7Y^;96WEY+DJ=\8*]E425
M>4[EIVN6B?W%R!W5#W[BVU3C@_GE^8YNV0W3[W=O)=S-&RT)SUFAN"B(9)N+
MT95[=KW$^6;"SYSM5>N:H">W0OR&-V^2BY&#@%C&8HT:*/Q\8&N69:@(8/RW
MTCEJ3*)@^[K6_LKX#K[<4L76(OL73W1Z,5J.2,(VM,ST3V+_FE7^A*@O%IDR
M_\F^FNN,2%PJ+?)*&!#DO+"_]&,5AX<(>)6 9W!;0P;E2ZKIY;D4>R)Q-FC#
M"^.JD09PO,!%N=$21CG(Z<N73/(/%"-#>*&T+"'@6I'Q.WJ;,34YGVLP@E/G
M<:7PVBKTCBB,R/>BT*DB_R@2EG3EYP"N0>C5"*^]087_+(L9\9TI\1S/&]#G
M-Q[[1I]_VN,W+8]ID9#7+-GR8DNND"I<<Z;(2Z[B3*A2,O+OJUN8#C3Z3U]4
MK-&@WRBFUIG:T9A=C"!W%),?V.CRFZ_<R'DQX%+0N!0,:;^\@51-RHP1L2&%
M0+;3C-!<E+5CO- ,S&HBJ0:G()=)+(52S^-22E;$GXC:TYWJ\VO8\KN4/<@B
M !-EOU%"S3 L,VN6>4KV((TC&Y%!W0!"'ECA!>1#EL%#-3DCD**0@ 5I=+^?
MW<Q( M)4*K.P+$&D@.6'^YK>=+&>&G=F@?LUPO3)S9XKP"AI$9-K422*K%^_
M(@O'P4GD:_(,K@/BFVMOYCA&+"*LE +-@+)OOEKZ4?""+$('9QB9I>^#S JN
MPUE8R^P 2T(4(,F0HK6T&_DO2+ (<:HU&"Q(9!0%M<'5H#"B#2K+[M1U7;@#
M50.T#!M:AH/D>%_ -I'QWR'R6]@>R!@224V@E,=B6YC'\/!'G3))UB*'O$BQ
MV)N\C$7.#$V1-4E_C4J8@A6')4F0*#%5*=D 5TB*B]W+Y4&X_3F*!"^[?EB"
MHR\0Q*XS5S^NWWP9[$/B=WG^+I6,D=R66(8EEMSPC]T'=Q7.9$G7!*Z_9!E%
MCJN40_YAPN$_MW5UD$XQ&,#:IX E7NC!_W$03>#']QTDCK\@Z\/D;HF-W64X
M(6Y(QIZSF)!QY$S(.Z$AS0[".[:Q1>W1 BWY+EZ[D'# [P49H&;44#,:I.:]
M$&THE^0#S4K6'Z,^,@T;0-ZDMNIDG-[RS&XGR!RC&9['95YF!L-SZ"LX#":_
MPH9O68(DNH?*EE&="L4Z.@UCD(<RL2R$C(*$ BH4"A[ E1(93XS-:YI!K6+D
M!AL&-<"S-97R$\:A+H)@NL>?,:S,NO&C/;DGI&W_ZB!H8>#&/>9T?PC'WN2!
MWF4BMDO8W5P@/V*6WT+5\=VII?NI\;4AM88Z*DTO">@R46R?0T'-(:%O-59M
M3(IEV+KZ[OZ4:.H%KOE=0%$&8GLKSS![M2*_M/ZJL)ZRR8LX*Z&<D&=@L5H[
MP[!G8+R^![$FN'8Y]ERG)(&^!G*3%R7$K;\N].S+1OM!>*8@J';,]-?9I]E]
MO^]@^N!G!V<0.'\F4$.E)PMS'\UAY$^)M'<_TGXWTG\\UH&BO6B*]F*XS;4'
M1[3?*A/<-@N(@7W<854@*$BX9GEOX1XV@H7;UD3T79MC4'5DA2W*%*7:>+OF
M#J(PCU&2;38,-T/L>1C$>R-%WJZ4..]@NYY6ZXIX'K! IQN&[N(=M _=X;=2
M)&6LB:(8"-NMC2L7)Y7;4U(P?=<F5Z/VZ9?*VQ[A1,CO%+:";IJX0I_<$V\T
M_%0IL*E[3U.LEZ[M/A83\^LM;1LR=5S3 "T#.Q!Y/O0RK>4UI:Q>1<1WN!F>
MD6^[O8XXW:B!\QE5BF\XH!:E1CO8<?:<?MKM6HAM$YPS/-=[T;E:.KT#PWU<
M6\+V=/W*QU[DM\<.W3W5=%62G9.D14.WP&FS8F?UT<XN^=@]!L<-%T=&@E70
MZ9B[_7F-K-W!'W'8]8\'(PBQW1U.17<X%=V_<RJZ;H"+:/(1TM+DH3M=.!$>
M1W!H'$;1(Y)P_%W%1WOR^/\E(:3*47*XJ_ZAAR=B$!W3O8S:N@_=_4.3<.P'
M1_,3&N.GR,(P/&9[!<7Z7HO];1V%M(T_$?BB"*@/8<ZPV]@H(']UWA>6O_7Q
MI06S#V,"8843#J0,-)>_T[K!-">>QYR:J@:O2:-[QZ9[IR;3$^)!\B%M7=6A
M5.\S:J0-3[#)Y'>.XK$S914((;'3@XQ&M:U0DCTLW8YR0"+V18UY!ZLLDJ%^
M<-GT@\O!5NU5$RP3NZ1SIN\&ZD$'QKYF<1#!\5=&FR>&=NJU4.NE-A0G%&@]
M:9^>N\W=$=OMP#Y@RF?E[6"=M'M27!W)K"?SZFDABNX UCW7)U=Q+,ON.X(>
MD78,GD$ 3A37SP,"A_G/1Q$Z?O?-\I=AJ"O=(X"LW&IK3SZS  >!9U\:>\'#
M&=CS=N4OSD)W^4@6KIZ4A5'T"!0^@'A"%KJ/P>"&T2,)Z$6A.> $O>^$YZW/
MHCF36_/Q5X%OL%7:+Z3-T^;[\I7]K'HWW7Z<_I[*+>Z$&=N J#-;A",B[0=?
M>Z/%SGQDO15:B]Q<IHR"/S@!QC="Z/H&#31?W2__!U!+ P04    " "QG@15
M3E,;N[<"  #,!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6RM55UK
MVS 4_2O"*Z.%$CM.DWXL,>1C8QMTA(9N#V,/BGWCB,J2*\E)._;C=R4YKEN2
M/(P%$TOR/>?><R4?#[=2/>@U@"%/!1=Z%*R-*6_"4*=K**CNR!($/EE)55"#
M4Y6'NE1 ,P<J>!A'T2 L*!-!,G1K<Y4,964X$S!71%=%0=7S!+C<CH)NL%NX
M8_G:V(4P&98TAP68^W*N<!8V+!DK0&@F!5&P&@7C[LVT;^-=P'<&6]T:$ZMD
M*>6#G7S)1D%D"P(.J;$,%&\;F +GE@C+>*PY@R:E!;;'._9/3CMJ65(-4\E_
ML,RL1\%50#)8T8J;.[G]#+4>5V JN7;_9.MC+Z\#DE;:R*(&8P4%$_Y.G^H^
MM "]Z  @K@'Q&T <'P#T:D#/"?65.5DS:F@R5')+E(U&-CMPO7%H5,.$W<6%
M4?B4(<XD"[][1*Z(9KE@*Y928;"[J:R$82(GI>0L9:#)Z0P,95R?D1/"!)DP
MSG$C]# T6(=E"],ZY\3GC _D')!;*<Q:DX\B@^PU/L3Z&Q'Q3L0D/DKXM1(=
MTHO.21S%,;E?S,CIR1G1D.-Q,WOJFQZGFT&*=%U'U]W1'2FSU_2ZYWA[!WC'
M+TV=[YKZ<[S41N%A_K6OCY[O8C^??<%O=$E3& 7X!FM0&PB2]^^Z@^C#/M'_
MB>R5](M&^L4Q]N1;52Q!V5.&_J.HZT&]/YK\.;)5$\_;=[S6DC9)=QANVKJ.
M9OY'7?U&5_^H+MS2JJ@X-9"A>6""E%%O3R(CM)#*L-]^ :]26?'F^9R4W+UD
M& ./%2NM=NS"R3[]/O^@I?_ZC7X?T8U:(5>=JZC]>VF95QFV#*, E3L?U<0=
M3^\=S6ICU6/G4.%+N/?Y6ZIR)C3AL$)HU+G$<I3W3C\QLG3VLY0&S<P-U_BY
M 64#\/E*2K.;V 3-!RSY"U!+ P04    " "QG@15D=S1=7($    %0  &0
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MS*Q5F1^WY3=:;+(3JZ706J39Y1JH^1RP'<SSE1#ZZ<8.4!YZ3O\'4$L#!!0
M   ( +&>!%4NN)DH) H  #UK   9    >&PO=V]R:W-H965T<R]S:&5E=#,U
M+GAM;+6=;7.C-A>&_XK&[71V9]+8O/@EV\0S24"09S9M9G?;?NCT@X)E6U-
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MFR^%7%5O_KF712&3ZN.2LQG/RAW4[W,IBY<O98+M&[.F_P=02P,$%     @
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M072/FO.7"TK$@IY,H3Q5.C1EZ'TSZG9/2[W:5XRWDT8//6A=#DH3*)H>$^4
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M^A9HJ0@F*A47@LFG6.+$-(*,8++F8(MD@FX@0^!VA@3$*;\#'\'+8@9N;^[
M#3#+IQQ@ EX(%OQ#8^ )IZE,+#EVT[P=FT*&J!R9RRJ<AS(<YTPX+GBB1&PX
MB$B"$@T^[L8''7A3+DV]/LYA?1Z<3L)_<C( KO4!.);C:.)Y[(8_02;A]EGX
M['+OM@8>7>Y=!X]_;^[S7P[^2 JW3E6WX'//\'TF2YK)]/R29XA!0=G=2)=@
M)8FG)U$[^XAOX1)-#+EU<\1VR)C^^8<=6'_IU.V3;-8G6=0G6=PGV;PGLJ,<
M\>H<\;K8IU]D\\9EGL@VK9H47@)($I#@-!<H ='S0I<T)6M0L*KNO9O:KAV.
MS5TS&31&7A@<&\U.C;S .[:)-$2!UR**3XV<\-X]-IIKC&S;JHV.UM"OU]#O
MK+-%N:W+-D"H[#CG*\WOL]+Z))OU21;U21;W23;OB>PH2X(Z2X+.2OM>O.2A
MY"/<R=UXC0YO V]E)TL-W,JW@?+!G2Z#2A=^(WU]UV]576<8UR:&QF'8JJFH
M3X>QQJ%GMXI8%Y2OK^&P5B?L5"=:K>2[/J"K<N.3;_N HV7.L,"JM+M5"4_B
M<5J:=#J_5I-3=VU%^G07O^MNWF5QI,:P5F/XR[72:$SOZ3+45$N[1W4&<JTR
M&H?M?A?UZ3#6./1:S7.N"VJHU^>^UN>^4Y^'H_TJY\G;UY!6B)(M;!;(H-V_
M'SM=7JO$J4=K,+2MYE]K5XGZ]!^?^O<'=FO&\U,C=Q"$>FELZ^T#U>H49]8J
MD/?EJ0A;^K3[2K?;:P72^'Q7H5XCB#412(W:>YO&2HK4[C9FXT!!?FRMB[,B
M#I8T)Z+\8*M'Z_.H3\4I3&O\P1Y%MF8\5N=7Q0'&&WUY^"6_6=>8<)"BE71E
M#4)9Z:P\3RIO!-T6QQFO5 B:%9<;!!/$E(%\OJ)4'&Z4@_I4;_H_4$L#!!0
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M;32B=L.MW7 +/F\/7V' NC1 + A=8[ITSJ&#QZ6C* ?,]K=?:%&T8Y'Q0B=
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M?<Q5EK>5<J+%JOC@SX7&ZT,Q3/""!]($X/N%$/IM8NX0]94Q_ 502P,$%
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MKR'"HL,V0-6=)>,1EJK)5[K8<,!!$A2%NF48?3W"A&J34=+WP"<CMI4AH?#
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M@6L#]7[#F-P/] )E"SO]#E!+ P04    " "QG@154W]N'[0#   V$   &0
M 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6RU6&V/VC@0_BM6KCIMI>TF)! X
M#I!80G1[*B>TJ+T/IW[PAH%8=>S4=J#[[\].0AK8;(Y5<U^([<SSC.?%$P^3
M(Q=?90R@T/>$,CFU8J72L6W+*(8$RSN> M-O=EPD6.FIV-LR%8"W.2BAMNLX
MOIU@PJS9)%];B]F$9XH2!FN!9)8D6#S? ^7'J=6S3@N/9!\KLV#/)BG>PP;4
MIW0M],RN6+8D 28)9TC ;FK->^-P9.1S@<\$CK(V1L:2)\Z_FLG#=FHY9D-
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M+4*#TP46K%J_:C=&5LXC-M*@X[AE@18/R@;@]ZV49K^Q"?H_C>0W4$L#!!0
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MJA?IE@1T;JBUF%+Q3(W%K[] Q_I--_*1P&IQP&4<<!_ZXK/@:0H"(L0+2]:
MQ'R72&UZ#SA.CI,5D^<%1I;OS<SGX['HK?S2JD9R6I*<]I*\#()=O(N(5+E2
M#(5D_Y&L:.AH'I#L(P(3Z*N_!D^=F>M[KIZH71*U>XE^U2^X#R"A4D?6;K&
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MDL?YX8:2D(K,0-U?<2Y?3[+O,>7WM\4/4$L#!!0    ( +&>!%7/_&CQH ,
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M3D 8 WU_R[EZ&!B!ZI\9X5=02P,$%     @ L9X$5=2K+) X&   &E ! !D
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M+(EB,%:G@/8I=))#4TC"% G3),R,;%8QGL'\)8.Y,X-_66VK=O#VT )^.;2
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M3:$TC=(,1>L732M:IF[1\E7=0#;^*ST>: 3>D=([4GE':O>J!R?J' I@VBJ
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MFQ*.=0.H@P^E*92F49HIAG<E/-X-3%L9<!H\B7AB=P-)>X_BZK5'-^ >,_3
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M59UWFC=7%?_K:OW;;HSK_P=02P,$%     @ L9X$54SU#Y1>!@  ["P  !D
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MMMY:NS[@=*%VIXXIYS13/^<$3PB3#<3_4RINUN6![*#:X#SX#U!+ P04
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M1GV6% WR[Z_B.'M[40SP&B=?R]U<_@]02P,$%     @ L9X$51<BF^E@!P
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MU!DDVY!@'B28#PE&@< 4MN=[MN?P!^I<WW1G\^9Q81(:-_9XS^I<7U*Z6*1
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M!\="GU/^'M(#9?15HR2VK":H6CE[)&S2*HA$JQX!2]AH3UWT?U=7^D$/7FM
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MV527L__Y].?-YFY=U6^V^;[?-I97TZ[W&#U0\-J!XG(69UB<97&"X5I5U=#
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M60-\OI'2/&RL@VXDS?X!4$L#!!0    ( +&>!%596^')@ ,  "\.   9
M>&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;+57;6_;-A#^*P>M&!*@C5X<RTYF
M"TAM;/70;$&R;A^*?J"ELT54(EV2ME-@/WY'25&DQE&35?EBB]3=<W</GZ/(
MR5ZJSSI%-'";9T)/G=28S;GKZCC%G.D3N4%!;U92Y<S04*U=O5'(DL(IS]S
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MITP%R.\7I92,>D.]:+9[=7'\+U!+ P04    " "QG@15R=J9WID#  "2$
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M&_=+FYKR?JF\?T8YYTH-2ADWA4:1IBQ97TO@L2H02XF^WD.\!-Z8 *W8?YL
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M21!$D1T!S.X@"# $=B..8 [  X8$07D?W+D?>>O[E-?\XW_T%U!+ P04
M" "QG@15EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M)<O;I>A%(^74E_VE?FA>[?:0[O:_GOT+4$L#!!0    ( +&>!%4>WYE>' (
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M=@*] _4. KT#]0X"O0/U#@*] _4. KT#]0X"O6/RL9) [T"]@T#O0+V#0.]
MO8- [T"]@T#OC'IG KTSZIT)],ZH=R;0.Z/>F4#OC'IG KTSZIT)],Z3GTV^
M4^\Z?AY*O?9\K?'ZWTGU>#ZW7"]_67[MG-SC%YS3;45]_@M02P,$%     @
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M<',O87!P+GAM;%!+ 0(4 Q0    ( +&>!%4WWZZY[P   "L"   1
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M965T,BYX;6Q02P$"% ,4    " "QG@155FG(VX0&  "Q(P  &
M    @(&Z$@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
ML9X$5="E9KR(!0  TQ8  !@              ("!=!D  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( +&>!%5H.>Q'J (  /P&   8
M          " @3(?  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    " "QG@15-Z!8N]\+  "Z<P  &               @($0(@  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ L9X$51E5S2.R @  %@@
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( +&>!%7[/R1[CPH   ,>   9
M      " @7=2  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ L9X$52:\,D?@ P  " D  !D              ("!/5T  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "QG@15,W=8UT8*  !-(P
M&0              @(%480  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( +&>!%7D/S(L=0(  &T%   9              " @=%K  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ L9X$545":-79
M!@  /A$  !D              ("!?6X  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    " "QG@15IM\+V:$%  "'#@  &0
M@(&-=0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( +&>
M!%6M?V7?G <  #D4   9              " @65[  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ L9X$511 -I2Q#   \RD  !D
M         ("!.(,  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    " "QG@15$>HQ%M /  "7.@  &0              @($@D   >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( +&>!%6K5V0WF L  *8>
M   9              " @2>@  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ L9X$51D8_'HX"   T!4  !D              ("!]JL
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " "QG@15\M.3
M\4H#   \!P  &0              @(%EM   >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( +&>!%6URI/Z7P0  $ )   9
M  " @>:W  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
ML9X$5;KY86OU @  MP8  !D              ("!?+P  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    " "QG@15Y(L98,X#   D"P  &0
M            @(&HOP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( +&>!%47M)>G? (  &H%   9              " @:W#  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ L9X$5>)7 Y%Z!
M>0H  !D              ("!8,8  'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    " "QG@15I=(((CP%  "!#0  &0              @($1
MRP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( +&>!%6\
MP[XTQ@0  $X-   9              " @830  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ L9X$5=0B."7G!   Y0X  !D
M     ("!@=4  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +&>!%7H:GT0Y@T   J:   9              "
M@:;T  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ L9X$
M58W$8[)A!   U1H  !D              ("!PP(! 'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    " "QG@15RR>>.!\$  #A$P  &0
M        @(%;!P$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( +&>!%6 M;XL=@0   ,9   9              " @;$+ 0!X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ L9X$556J)4\$ P  /@H
M !D              ("!7A ! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    " "QG@15$@8F]M<"  #Z"0  &0              @(&9$P$
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( +&>!%4XM>+=
M4 (  #T%   9              " @:<6 0!X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ L9X$55KLS9ZV P  &1$  !D
M ("!+AD! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " "Q
MG@15]2*S$3D$  !!%   &0              @($;'0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( +&>!%4]S%*GKP,  ,X.   9
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M970T.2YX;6Q02P$"% ,4    " "QG@15S_QH\: #  #8$   &0
M    @($0- $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (
M +&>!%74JRR0.!@  !I0 0 9              " @><W 0!X;"]W;W)K<VAE
M971S+W-H965T-3$N>&UL4$L! A0#%     @ L9X$54SU#Y1>!@  ["P  !D
M             ("!5E ! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"
M% ,4    " "QG@15#U%KY@@#  #3"@  &0              @('K5@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( +&>!%6ZIH4(!0H
M !:(   9              " @2I: 0!X;"]W;W)K<VAE971S+W-H965T-30N
M>&UL4$L! A0#%     @ L9X$51<BF^E@!P  0T   !D              ("!
M9F0! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " "QG@15
M-<DI2-P&   T.@  &0              @(']:P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4V+GAM;%!+ 0(4 Q0    ( +&>!%77HZL:_A(  %@K 0 9
M      " @1!S 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%
M  @ L9X$5<*<7<P!!   2 X  !D              ("!188! 'AL+W=O<FMS
M:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " "QG@15U3NB(R8#  ">"@
M&0              @(%]B@$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+
M 0(4 Q0    ( +&>!%596^')@ ,  "\.   9              " @=J- 0!X
M;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ L9X$5?RV_P]U
M!@  QC@  !D              ("!D9$! 'AL+W=O<FMS:&5E=',O<VAE970V
M,2YX;6Q02P$"% ,4    " "QG@15R=J9WID#  "2$   &0
M@($]F $ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( +&>
M!%6_I')LH ,  ,L/   9              " @0V< 0!X;"]W;W)K<VAE971S
M+W-H965T-C,N>&UL4$L! A0#%     @ L9X$50^[->@_!0  ^AP  !D
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "QG@15EXJ[',     3 @  "P
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52P4&     $H 2@ ]%   /;H!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>485</ContextCount>
  <ElementCount>261</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>109</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome</Role>
      <ShortName>Condensed Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Summaryofsignificantaccountingpolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Incometaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - Earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Earningspershare</Role>
      <ShortName>Earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2116106 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2126107 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - Goodwill and other intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Goodwillandotherintangibleassets</Role>
      <ShortName>Goodwill and other intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2134109 - Disclosure - Financing arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Financingarrangements</Role>
      <ShortName>Financing arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2138110 - Disclosure - Stockholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Stockholdersequity</Role>
      <ShortName>Stockholders' equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2144111 - Disclosure - Fair value measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Fairvaluemeasurement</Role>
      <ShortName>Fair value measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2149112 - Disclosure - Derivative instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Derivativeinstruments</Role>
      <ShortName>Derivative instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2157113 - Disclosure - Contingencies and commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/Contingenciesandcommitments</Role>
      <ShortName>Contingencies and commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Acquisitions</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Revenues</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Earnings per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/EarningspershareTables</Role>
      <ShortName>Earnings per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Earningspershare</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Investments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Inventories</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - Goodwill and other intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/GoodwillandotherintangibleassetsTables</Role>
      <ShortName>Goodwill and other intangible assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Goodwillandotherintangibleassets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2335307 - Disclosure - Financing arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsTables</Role>
      <ShortName>Financing arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Financingarrangements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2339308 - Disclosure - Stockholders' equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityTables</Role>
      <ShortName>Stockholders' equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Stockholdersequity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2345309 - Disclosure - Fair value measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FairvaluemeasurementTables</Role>
      <ShortName>Fair value measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Fairvaluemeasurement</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2350310 - Disclosure - Derivative instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsTables</Role>
      <ShortName>Derivative instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Derivativeinstruments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Summary of significant accounting policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesDetails</Role>
      <ShortName>Summary of significant accounting policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Acquisitions - Aggregate Consideration Paid (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails</Role>
      <ShortName>Acquisitions - Aggregate Consideration Paid (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/RevenuesDetails</Role>
      <ShortName>Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/RevenuesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/IncometaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Incometaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - Earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/EarningspershareDetails</Role>
      <ShortName>Earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/EarningspershareTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsDetails</Role>
      <ShortName>Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/InvestmentsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - Investments (Fair Values by Classification) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails</Role>
      <ShortName>Investments (Fair Values by Classification) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/InvestmentsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - Investments (Available-for-sale Investments) (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual</Role>
      <ShortName>Investments (Available-for-sale Investments) (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/InvestmentsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Investments (Fair Values by Contractual Maturity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails</Role>
      <ShortName>Investments (Fair Values by Contractual Maturity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/InvestmentsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Investments (Equity Securities) (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual</Role>
      <ShortName>Investments (Equity Securities) (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/InvestmentsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Investments (BeiGene) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsBeiGeneDetails</Role>
      <ShortName>Investments (BeiGene) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/InvestmentsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Investments (Neumora Therapeutics, Inc.) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails</Role>
      <ShortName>Investments (Neumora Therapeutics, Inc.) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/InvestmentsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Investments Investments (Limited Partnership Investments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails</Role>
      <ShortName>Investments Investments (Limited Partnership Investments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/InventoriesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Goodwill and other intangible assets (Goodwill Roll Forward) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails</Role>
      <ShortName>Goodwill and other intangible assets (Goodwill Roll Forward) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/GoodwillandotherintangibleassetsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Goodwill and other intangible assets (Identifiable Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and other intangible assets (Identifiable Intangible Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/GoodwillandotherintangibleassetsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Goodwill and other intangible assets (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual</Role>
      <ShortName>Goodwill and other intangible assets (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/GoodwillandotherintangibleassetsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails</Role>
      <ShortName>Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FinancingarrangementsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Financing arrangements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FinancingarrangementsDetailsTextual</Role>
      <ShortName>Financing arrangements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FinancingarrangementsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - Stockholders' equity (Share Repurchase Program) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityShareRepurchaseProgramDetails</Role>
      <ShortName>Stockholders' equity (Share Repurchase Program) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockholdersequityTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Stockholders' equity (Details Textual) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityDetailsTextualDetails</Role>
      <ShortName>Stockholders' equity (Details Textual) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockholdersequityTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Stockholders' equity (Components of AOCI) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails</Role>
      <ShortName>Stockholders' equity (Components of AOCI) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockholdersequityTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Stockholders' equity (Reclassifications out of AOCI) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails</Role>
      <ShortName>Stockholders' equity (Reclassifications out of AOCI) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/StockholdersequityTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - Fair value measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FairvaluemeasurementDetails</Role>
      <ShortName>Fair value measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FairvaluemeasurementTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2447426 - Disclosure - Fair value measurement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FairvaluemeasurementDetailsTextual</Role>
      <ShortName>Fair value measurement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FairvaluemeasurementTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Fair value measurement (Contingent Consideration Obligations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails</Role>
      <ShortName>Fair value measurement (Contingent Consideration Obligations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/FairvaluemeasurementTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2451428 - Disclosure - Derivative instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual</Role>
      <ShortName>Derivative instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/DerivativeinstrumentsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2452429 - Disclosure - Derivative instruments (Cross-currency Swaps) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails</Role>
      <ShortName>Derivative instruments (Cross-currency Swaps) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/DerivativeinstrumentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2453430 - Disclosure - Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails</Role>
      <ShortName>Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/DerivativeinstrumentsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2454431 - Disclosure - Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails</Role>
      <ShortName>Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/DerivativeinstrumentsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2455432 - Disclosure - Derivative instruments (Summary of Income and Expense Line Items) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails</Role>
      <ShortName>Derivative instruments (Summary of Income and Expense Line Items) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/DerivativeinstrumentsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2456433 - Disclosure - Derivative instruments (Fair Value of Derivatives) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails</Role>
      <ShortName>Derivative instruments (Fair Value of Derivatives) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/DerivativeinstrumentsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="amgn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2458434 - Disclosure - Contingencies and commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/ContingenciesandcommitmentsDetails</Role>
      <ShortName>Contingencies and commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amgen.com/role/Contingenciesandcommitments</ParentRole>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="amgn-20220630.htm">amgn-20220630.htm</File>
    <File>amgn-20220630.xsd</File>
    <File>amgn-20220630_cal.xml</File>
    <File>amgn-20220630_def.xml</File>
    <File>amgn-20220630_lab.xml</File>
    <File>amgn-20220630_pre.xml</File>
    <File>amgn-ex31_2022630xq2.htm</File>
    <File>amgn-ex32_2022630xq2.htm</File>
    <File>exhibit1041-firstamendment.htm</File>
    <File>exhibit1046-collaborationa.htm</File>
    <File>exhibit1047-amendmentno1to.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1114">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="32">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>84
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "amgn-20220630.htm": {
   "axisCustom": 1,
   "axisStandard": 27,
   "contextCount": 485,
   "dts": {
    "calculationLink": {
     "local": [
      "amgn-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "amgn-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "amgn-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amgn-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amgn-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "amgn-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd"
     ]
    }
   },
   "elementCount": 584,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 29,
   "keyStandard": 232,
   "memberCustom": 64,
   "memberStandard": 44,
   "nsprefix": "amgn",
   "nsuri": "http://www.amgen.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.amgen.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Acquisitions",
     "role": "http://www.amgen.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Revenues",
     "role": "http://www.amgen.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Income taxes",
     "role": "http://www.amgen.com/role/Incometaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - Earnings per share",
     "role": "http://www.amgen.com/role/Earningspershare",
     "shortName": "Earnings per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116106 - Disclosure - Investments",
     "role": "http://www.amgen.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126107 - Disclosure - Inventories",
     "role": "http://www.amgen.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - Goodwill and other intangible assets",
     "role": "http://www.amgen.com/role/Goodwillandotherintangibleassets",
     "shortName": "Goodwill and other intangible assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134109 - Disclosure - Financing arrangements",
     "role": "http://www.amgen.com/role/Financingarrangements",
     "shortName": "Financing arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138110 - Disclosure - Stockholders' equity",
     "role": "http://www.amgen.com/role/Stockholdersequity",
     "shortName": "Stockholders' equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144111 - Disclosure - Fair value measurement",
     "role": "http://www.amgen.com/role/Fairvaluemeasurement",
     "shortName": "Fair value measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Statements of Comprehensive Income",
     "role": "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149112 - Disclosure - Derivative instruments",
     "role": "http://www.amgen.com/role/Derivativeinstruments",
     "shortName": "Derivative instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157113 - Disclosure - Contingencies and commitments",
     "role": "http://www.amgen.com/role/Contingenciesandcommitments",
     "shortName": "Contingencies and commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of significant accounting policies (Policies)",
     "role": "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies",
     "shortName": "Summary of significant accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Acquisitions (Tables)",
     "role": "http://www.amgen.com/role/AcquisitionsTables",
     "shortName": "Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Revenues (Tables)",
     "role": "http://www.amgen.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Earnings per share (Tables)",
     "role": "http://www.amgen.com/role/EarningspershareTables",
     "shortName": "Earnings per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - Investments (Tables)",
     "role": "http://www.amgen.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Inventories (Tables)",
     "role": "http://www.amgen.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - Goodwill and other intangible assets (Tables)",
     "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsTables",
     "shortName": "Goodwill and other intangible assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335307 - Disclosure - Financing arrangements (Tables)",
     "role": "http://www.amgen.com/role/FinancingarrangementsTables",
     "shortName": "Financing arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Income",
     "role": "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome",
     "shortName": "Condensed Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:StockRepurchaseProgramTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339308 - Disclosure - Stockholders' equity (Tables)",
     "role": "http://www.amgen.com/role/StockholdersequityTables",
     "shortName": "Stockholders' equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:StockRepurchaseProgramTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345309 - Disclosure - Fair value measurement (Tables)",
     "role": "http://www.amgen.com/role/FairvaluemeasurementTables",
     "shortName": "Fair value measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350310 - Disclosure - Derivative instruments (Tables)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsTables",
     "shortName": "Derivative instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Summary of significant accounting policies (Details)",
     "role": "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesDetails",
     "shortName": "Summary of significant accounting policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Acquisitions - Aggregate Consideration Paid (Details)",
     "role": "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
     "shortName": "Acquisitions - Aggregate Consideration Paid (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i46b0c7abfa194277afc81cba3b24f8a3_D20220101-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "amgn:Businessassetacquisitionconsiderationtransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillPurchaseAccountingAdjustments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Acquisitions - Narrative (Details)",
     "role": "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
     "shortName": "Acquisitions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i1b8b7a38d735412895755cb950726b35_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Revenues (Details)",
     "role": "http://www.amgen.com/role/RevenuesDetails",
     "shortName": "Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "ic3c63f65b70944d59e9ddddf1020dbf9_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Income taxes (Details)",
     "role": "http://www.amgen.com/role/IncometaxesDetails",
     "shortName": "Income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - Earnings per share (Details)",
     "role": "http://www.amgen.com/role/EarningspershareDetails",
     "shortName": "Earnings per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - Investments (Details)",
     "role": "http://www.amgen.com/role/InvestmentsDetails",
     "shortName": "Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - Investments (Fair Values by Classification) (Details)",
     "role": "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails",
     "shortName": "Investments (Fair Values by Classification) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "ic3ee9095509a4235b125b11b137e139e_I20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - Investments (Available-for-sale Investments) (Details Textual)",
     "role": "http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual",
     "shortName": "Investments (Available-for-sale Investments) (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Investments (Fair Values by Contractual Maturity) (Details)",
     "role": "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails",
     "shortName": "Investments (Fair Values by Contractual Maturity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Investments (Equity Securities) (Details Textual)",
     "role": "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual",
     "shortName": "Investments (Equity Securities) (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Investments (BeiGene) (Details)",
     "role": "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
     "shortName": "Investments (BeiGene) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "ic408702ec02a49bf91a6056997008286_I20211231",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i5cda008dddc94401b22d3259266fc7e7_I20210930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Investments (Neumora Therapeutics, Inc.) (Details)",
     "role": "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails",
     "shortName": "Investments (Neumora Therapeutics, Inc.) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i5cda008dddc94401b22d3259266fc7e7_I20210930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i1fe68111c13942ef9c7a0d951601d88b_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Investments Investments (Limited Partnership Investments) (Details)",
     "role": "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails",
     "shortName": "Investments Investments (Limited Partnership Investments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "ib8b0ba79e4914ce8815964b9387a76dd_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AlternativeInvestment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Inventories (Details)",
     "role": "http://www.amgen.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Goodwill and other intangible assets (Goodwill Roll Forward) (Details)",
     "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails",
     "shortName": "Goodwill and other intangible assets (Goodwill Roll Forward) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:ScheduleOfIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Goodwill and other intangible assets (Identifiable Intangible Assets) (Details)",
     "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails",
     "shortName": "Goodwill and other intangible assets (Identifiable Intangible Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:ScheduleOfIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.amgen.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Goodwill and other intangible assets (Details Textual)",
     "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual",
     "shortName": "Goodwill and other intangible assets (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)",
     "role": "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails",
     "shortName": "Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "iecb3cb0076694222ab5165cf391eb7d3_I20220331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Financing arrangements (Details Textual)",
     "role": "http://www.amgen.com/role/FinancingarrangementsDetailsTextual",
     "shortName": "Financing arrangements (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "idebc81edd93d4d2f8a2a03384eb93dbe_I20220630",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:StockRepurchaseProgramTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - Stockholders' equity (Share Repurchase Program) (Details)",
     "role": "http://www.amgen.com/role/StockholdersequityShareRepurchaseProgramDetails",
     "shortName": "Stockholders' equity (Share Repurchase Program) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:StockRepurchaseProgramTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Stockholders' equity (Details Textual) (Details)",
     "role": "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails",
     "shortName": "Stockholders' equity (Details Textual) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockDividendsPerShareDeclared",
       "us-gaap:CommonStockDividendsPerShareCashPaid",
       "us-gaap:CommonStockDividendsPerShareDeclared",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i52e8d46fd29746e58d0e0bb604659f08_D20220601-20220630",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i8de403afe8684433ba669a9d329718c4_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Stockholders' equity (Components of AOCI) (Details)",
     "role": "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails",
     "shortName": "Stockholders' equity (Components of AOCI) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i933f3aa296ae418cb60f3b9a2da33c77_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Stockholders' equity (Reclassifications out of AOCI) (Details)",
     "role": "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails",
     "shortName": "Stockholders' equity (Reclassifications out of AOCI) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "idd26454e121845348d3b36a5d5d0b4be_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - Fair value measurement (Details)",
     "role": "http://www.amgen.com/role/FairvaluemeasurementDetails",
     "shortName": "Fair value measurement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447426 - Disclosure - Fair value measurement (Details Textual)",
     "role": "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual",
     "shortName": "Fair value measurement (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i8de403afe8684433ba669a9d329718c4_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Fair value measurement (Contingent Consideration Obligations) (Details)",
     "role": "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails",
     "shortName": "Fair value measurement (Contingent Consideration Obligations) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "amgn:BusinessCombinationContingentConsiderationArrangementsPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i87a50000054d41c4b6c8d975b42b1648_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "ifaa3e87d3e094c2c82065bdcc86a2d5e_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451428 - Disclosure - Derivative instruments (Details Textual)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual",
     "shortName": "Derivative instruments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i8362dfe3f447487fbcfb592560763e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452429 - Disclosure - Derivative instruments (Cross-currency Swaps) (Details)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
     "shortName": "Derivative instruments (Cross-currency Swaps) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i8362dfe3f447487fbcfb592560763e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i0ecd36ab401a4e70a51c743fc9ccdc8d_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453430 - Disclosure - Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
     "shortName": "Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i0ecd36ab401a4e70a51c743fc9ccdc8d_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454431 - Disclosure - Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails",
     "shortName": "Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i17d41c6ab5c14f9380e71043309fbdc8_I20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455432 - Disclosure - Derivative instruments (Summary of Income and Expense Line Items) (Details)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
     "shortName": "Derivative instruments (Summary of Income and Expense Line Items) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i71fb031f34f648488a945f9c0e957284_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "iddf4e6ee507f42da9c63527f4cd46ce6_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456433 - Disclosure - Derivative instruments (Fair Value of Derivatives) (Details)",
     "role": "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
     "shortName": "Derivative instruments (Fair Value of Derivatives) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "iddf4e6ee507f42da9c63527f4cd46ce6_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i3468cc5757b34eb384cc512b95a07626_D20220527-20220527",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:LitigationSettlementNumberOfPrimaryArguments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "argument",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458434 - Disclosure - Contingencies and commitments (Details)",
     "role": "http://www.amgen.com/role/ContingenciesandcommitmentsDetails",
     "shortName": "Contingencies and commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i3468cc5757b34eb384cc512b95a07626_D20220527-20220527",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amgn:LitigationSettlementNumberOfPrimaryArguments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "argument",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockDividendsPerShareCashPaid",
       "us-gaap:CommonStockDividendsPerShareDeclared",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i264013b24e074db8b98a0699c239c4f9_D20220301-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of significant accounting policies",
     "role": "http://www.amgen.com/role/Summaryofsignificantaccountingpolicies",
     "shortName": "Summary of significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amgn-20220630.htm",
      "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 109,
   "tag": {
    "amgn_A2.00SeniorNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.00% Senior Notes Due 2026 [Member]",
        "label": "2.00% Senior Notes Due 2026 [Member]",
        "terseLabel": "2.00% Senior Notes Due 2026 [Member]"
       }
      }
     },
     "localname": "A2.00SeniorNotesDue2026Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A3002029NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.00% 2029 Notes",
        "label": "3.00% 2029 Notes [Member]",
        "terseLabel": "3.00% 2029 Notes [Member]"
       }
      }
     },
     "localname": "A3002029NotesMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A300NotesDue20523002052NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.00% notes due 2052 (3.00% 2052 Notes)",
        "label": "3.00% notes due 2052 (3.00% 2052 Notes) [Member]",
        "terseLabel": "3.00% notes due 2052 (3.00% 2052 Notes)"
       }
      }
     },
     "localname": "A300NotesDue20523002052NotesMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A3352032NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.35% 2032 Notes",
        "label": "3.35% 2032 Notes [Member]",
        "terseLabel": "3.35% 2032 Notes [Member]"
       }
      }
     },
     "localname": "A3352032NotesMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A4202052NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.20% 2052 Notes",
        "label": "4.20% 2052 Notes [Member]",
        "terseLabel": "4.20% 2052 Notes [Member]"
       }
      }
     },
     "localname": "A4202052NotesMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A4402062NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.40% 2062 Notes",
        "label": "4.40% 2062 Notes [Member]",
        "terseLabel": "4.40% 2062 Notes [Member]"
       }
      }
     },
     "localname": "A4402062NotesMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AMG340Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AMG 340",
        "label": "AMG 340 [Member]",
        "terseLabel": "AMG 340"
       }
      }
     },
     "localname": "AMG340Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AcceleratedStockRepurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated stock repurchase agreement",
        "label": "Accelerated stock repurchase agreement [Member]",
        "terseLabel": "Accelerated stock repurchase agreement"
       }
      }
     },
     "localname": "AcceleratedStockRepurchaseAgreementMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued liabilities/other non-current liabilities.",
        "label": "Accrued Liabilities Other Non Current Liabilities [Member]",
        "verboseLabel": "Accrued liabilities/Other noncurrent liabilities [Member]"
       }
      }
     },
     "localname": "AccruedLiabilitiesOtherNonCurrentLiabilitiesMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AccumulatedOtherAdjustmentAttributabletoParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated Other Adjustment Attributable to Parent [Member]",
        "label": "Accumulated Other Adjustment Attributable to Parent [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherAdjustmentAttributabletoParentMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired research and development technology rights.",
        "label": "Acquired Research And Development Technology Rights [Member]",
        "terseLabel": "Research and Development Technology Rights [Member]"
       }
      }
     },
     "localname": "AcquiredResearchAndDevelopmentTechnologyRightsMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AlternativeInvestmentNetGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alternative Investment, Net Gain (Loss)",
        "label": "Alternative Investment, Net Gain (Loss)",
        "terseLabel": "Net gains (losses) from limited partnership investments"
       }
      }
     },
     "localname": "AlternativeInvestmentNetGainLoss",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_AranespMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aranesp.",
        "label": "Aranesp [Member]",
        "terseLabel": "Aranesp\u00ae (darbepoetin alfa) [Member]"
       }
      }
     },
     "localname": "AranespMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value",
        "label": "Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value",
        "terseLabel": "Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value",
        "label": "Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value",
        "terseLabel": "Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_AvailableForSalesInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sales investments.",
        "label": "Available For Sales Investments [Member]",
        "verboseLabel": "Available-for-sale investments [Member]"
       }
      }
     },
     "localname": "AvailableForSalesInvestmentsMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_BasicAndDilutedEarningPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and diluted earning per share.",
        "label": "Basic And Diluted Earning Per Share [Abstract]",
        "verboseLabel": "Computation of basic and diluted earnings per share"
       }
      }
     },
     "localname": "BasicAndDilutedEarningPerShareAbstract",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_BasisOfPresentationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shows the basis of presentation of financial information for interim periods.",
        "label": "Basis Of Presentation [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfPresentationPolicyTextBlock",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_BeiGeneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BeiGene [Member]",
        "label": "BeiGene [Member]",
        "terseLabel": "Collaborative arrangement with BeiGene, Ltd. [Member]"
       }
      }
     },
     "localname": "BeiGeneMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_BusinessCombinationContingentConsiderationArrangementsPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Payments",
        "label": "Business Combination, Contingent Consideration Arrangements, Payments",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsPayments",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessCombinationContingentConsiderationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration [Roll Forward]",
        "label": "Business Combination, Contingent Consideration [Roll Forward]",
        "terseLabel": "Business Combination, Contingent Consideration [Roll Forward]"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationRollForward",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 2.0,
       "parentTag": "amgn_Businessassetacquisitionconsiderationtransferred",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions",
        "label": "Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions",
        "terseLabel": "Contingent consideration obligation for acquisition"
       }
      }
     },
     "localname": "BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 1.0,
       "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)",
        "verboseLabel": "Other assets, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquired asset acquisition, Assets acquired and Liabilities assumed, net",
        "label": "Business acquired asset acquisition, Assets acquired and Liabilities assumed, net",
        "totalLabel": "Total assets acquired, net"
       }
      }
     },
     "localname": "BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_Businessassetacquisitionconsiderationtransferred": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business asset acquisition, consideration transferred",
        "label": "Business asset acquisition, consideration transferred",
        "totalLabel": "Business asset acquisition, consideration transferred"
       }
      }
     },
     "localname": "Businessassetacquisitionconsiderationtransferred",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_CorporateDebtSecuritiesFinancialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate debt securities financial Member.",
        "label": "Corporate Debt Securities Financial [Member]",
        "terseLabel": "Corporate debt securities - Financial [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesFinancialMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/InvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_CorporateDebtSecuritiesIndustrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate debt securities industrial Member.",
        "label": "Corporate Debt Securities Industrial [Member]",
        "terseLabel": "Corporate debt securities - Industrial [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesIndustrialMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/InvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_CorporateDebtSecuritiesOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate debt securities other.",
        "label": "Corporate Debt Securities Other [Member]",
        "terseLabel": "Corporate debt securities - Other [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesOtherMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/InvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_CrossCurrencySwapContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cross currency swap contracts.",
        "label": "Cross Currency Swap Contracts [Member]",
        "netLabel": "Cross-currency swap contract [Member]",
        "terseLabel": "Cross-currency swap contracts [Member]",
        "verboseLabel": "Cross-currency swap contracts [Member]"
       }
      }
     },
     "localname": "CrossCurrencySwapContractsMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_DebtExchangeAdditionalCashConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt exchange additional cash consideration paid",
        "label": "Debt exchange additional cash consideration",
        "terseLabel": "debt exchange additional cash consideration"
       }
      }
     },
     "localname": "DebtExchangeAdditionalCashConsideration",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Period without Payment of Make Whole Amount",
        "label": "Debt Instrument, Redemption Period without Payment of Make Whole Amount",
        "terseLabel": "Debt Instrument, Redemption Period without Payment of Make Whole Amount"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_DerivativeAssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative assets.",
        "label": "Derivative Assets Fair Value Disclosure [Abstract]",
        "verboseLabel": "Derivatives:"
       }
      }
     },
     "localname": "DerivativeAssetsFairValueDisclosureAbstract",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative financial instruments liabilities fair value disclosure.",
        "label": "Derivative Financial Instruments Liabilities Fair Value Disclosure [Abstract]",
        "verboseLabel": "Derivatives:"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_EnbrelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ENBREL.",
        "label": "ENBREL [Member]",
        "terseLabel": "Enbrel\u00ae (etanercept) [Member]"
       }
      }
     },
     "localname": "EnbrelMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity",
        "label": "Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity"
       }
      }
     },
     "localname": "EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_EquityMethodInvestmentChangeInCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment, change in carrying value",
        "label": "Equity method investment, change in carrying value",
        "terseLabel": "Equity method investment, change in carrying value"
       }
      }
     },
     "localname": "EquityMethodInvestmentChangeInCarryingValue",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets.",
        "label": "Fair Values Of Available For Sale Investments By Classification In Consolidated Balance Sheets [Abstract]",
        "verboseLabel": "Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair values of available-for-sale investments by classification in the consolidated balance sheets.",
        "label": "Fair Values of Available for Sale Investments By Classification In Consolidated Balance Sheets [Table Text Block]",
        "verboseLabel": "Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets.",
        "label": "Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets [Abstract]",
        "verboseLabel": "Fair values of both derivatives designated as hedging instruments and not designated as hedging instruments included in Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]",
        "label": "Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]",
        "terseLabel": "5.50% \u00a3475 million notes due 2026 (5.50% 2026 pound sterling Notes) [Member]",
        "verboseLabel": "5.50% 2026 pound sterling Notes [Member]"
       }
      }
     },
     "localname": "FivePointFiveZeroPercentPoundSterlingNotesDue2026Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePointOneFivePercentNotesDue2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point One Five Percent Notes Due 2041 [Member]",
        "label": "Five Point One Five Percent Notes Due 2041 [Member]",
        "terseLabel": "5.15% notes due 2041 (5.15% 2041 Notes) [Member]"
       }
      }
     },
     "localname": "FivePointOneFivePercentNotesDue2041Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePointSevenFivePercentNotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Seven Five Percent Notes Due 2040 [Member]",
        "label": "Five Point Seven Five Percent Notes Due 2040 [Member]",
        "terseLabel": "5.75% notes due 2040 (5.75% 2040 Notes) [Member]"
       }
      }
     },
     "localname": "FivePointSevenFivePercentNotesDue2040Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePointSixFivePercentNotesDue2042Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Six Five Percent Notes Due 2042 [Member]",
        "label": "Five Point Six Five Percent Notes Due 2042 [Member]",
        "terseLabel": "5.65% notes due 2042 (5.65% 2042 Notes) [Member]"
       }
      }
     },
     "localname": "FivePointSixFivePercentNotesDue2042Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePointThreeSevenFivePercentNotesDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Point Three Seven Five Percent Notes Due 2043 [Member]",
        "label": "Five Point Three Seven Five Percent Notes Due 2043 [Member]",
        "terseLabel": "5.375% notes due 2043 (5.375% 2043 Notes) [Member]"
       }
      }
     },
     "localname": "FivePointThreeSevenFivePercentNotesDue2043Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FivePrimeTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Prime Therapeutics, Inc.",
        "label": "Five Prime Therapeutics, Inc. [Member]",
        "terseLabel": "Five Prime Therapeutics, Inc."
       }
      }
     },
     "localname": "FivePrimeTherapeuticsIncMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ForeignAndOtherGovernmentRelatedDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "foreign and other government-related debt securities",
        "label": "foreign and other government-related debt securities [Member]",
        "terseLabel": "foreign and other government-related debt securities"
       }
      }
     },
     "localname": "ForeignAndOtherGovernmentRelatedDebtSecuritiesMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPercentPoundSterlingNotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Percent Pound Sterling Notes Due 2029 [Member]",
        "label": "Four Percent Pound Sterling Notes Due 2029 [Member]",
        "terseLabel": "4.00% \u00a3700 million notes due 2029 (4.00% 2029 pound sterling Notes) [Member]",
        "verboseLabel": "4.00% 2029 pound sterling Notes [Member]"
       }
      }
     },
     "localname": "FourPercentPoundSterlingNotesDue2029Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]",
        "label": "Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]",
        "terseLabel": "4.563% notes due 2048 (4.563% 2048 Notes) [Member]",
        "verboseLabel": "4.563% notes due 2048 (4.563% 2048 Notes) [Member]"
       }
      }
     },
     "localname": "FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]",
        "label": "Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]",
        "terseLabel": "4.40% notes due 2045 (4.40% 2045 Notes) [Member]"
       }
      }
     },
     "localname": "FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointNineFivePercentNotesDue2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Nine Five Percent Notes Due 2041 [Member]",
        "label": "Four Point Nine Five Percent Notes Due 2041 [Member]",
        "terseLabel": "4.95% notes due 2041 (4.95% 2041 Notes) [Member]"
       }
      }
     },
     "localname": "FourPointNineFivePercentNotesDue2041Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointOneZeroPercentNotesDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point One Zero Percent Notes Due 2021 [Member]",
        "label": "Four Point One Zero Percent Notes Due 2021 [Member]",
        "terseLabel": "4.10% notes due 2021 (4.10% 2021 Notes) [Member]"
       }
      }
     },
     "localname": "FourPointOneZeroPercentNotesDue2021Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]",
        "label": "Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]",
        "terseLabel": "4.663% notes due 2051 (4.663% 2051 Notes) [Member]"
       }
      }
     },
     "localname": "FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_GensentaIlacSanayiVsTicaretMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gensenta Ilac Sanayi vs Ticaret",
        "label": "Gensenta Ilac Sanayi vs Ticaret [Member]",
        "terseLabel": "Gensenta Ilac Sanayi vs Ticaret"
       }
      }
     },
     "localname": "GensentaIlacSanayiVsTicaretMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_HedgedLiabilityDiscontinuedFairValueHedge": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedged Liability, Discontinued Fair Value Hedge",
        "label": "Hedged Liability, Discontinued Fair Value Hedge",
        "terseLabel": "Carrying value with discontinued hedging relationships"
       }
      }
     },
     "localname": "HedgedLiabilityDiscontinuedFairValueHedge",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_HospiraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospira [Member]",
        "label": "Hospira [Member]",
        "terseLabel": "Hospira, Inc. [Member]"
       }
      }
     },
     "localname": "HospiraMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_HumiraBiosimilarAntitrustClassActionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humira Biosimilar Antitrust Class Actions [Member]",
        "label": "Humira Biosimilar Antitrust Class Actions [Member]",
        "terseLabel": "Humira Biosimilar Antitrust Class Actions [Member]"
       }
      }
     },
     "localname": "HumiraBiosimilarAntitrustClassActionsMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_IdentifiableIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifiable intangible assets accumulated amortization.",
        "label": "Identifiable Intangible Assets Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "IdentifiableIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_IdentifiableIntangibleAssetsGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifiable intangible assets gross.",
        "label": "Identifiable Intangible Assets Gross",
        "terseLabel": "Gross carrying amount"
       }
      }
     },
     "localname": "IdentifiableIntangibleAssetsGross",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_IncreaseDecreaseInNoncurrentTaxLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Noncurrent Tax Liability",
        "label": "Increase (Decrease) In Noncurrent Tax Liability",
        "terseLabel": "Long-term tax liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInNoncurrentTaxLiability",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_KANJINTIPatentLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "KANJINTI Patent Litigation [Member]",
        "label": "KANJINTI Patent Litigation [Member]",
        "terseLabel": "KANJINTI Patent Litigation [Member]"
       }
      }
     },
     "localname": "KANJINTIPatentLitigationMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_KyprolisANDAPatentLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kyprolis ANDA Patent Litigation",
        "label": "Kyprolis ANDA Patent Litigation [Member]",
        "terseLabel": "Kyprolis ANDA Patent Litigation"
       }
      }
     },
     "localname": "KyprolisANDAPatentLitigationMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_KyprolisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kyprolis [Member]",
        "label": "Kyprolis [Member]",
        "terseLabel": "KYPROLIS\u00ae (carfilzomib) [Member]"
       }
      }
     },
     "localname": "KyprolisMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails",
      "http://www.amgen.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_LitigationSettlementDamagesSoughtValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Damages Sought, Value",
        "label": "Litigation Settlement, Damages Sought, Value",
        "terseLabel": "Amount awarded from settlement"
       }
      }
     },
     "localname": "LitigationSettlementDamagesSoughtValue",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_LitigationSettlementNumberOfPrimaryArguments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Number Of Primary Arguments",
        "label": "Litigation Settlement, Number Of Primary Arguments",
        "terseLabel": "Litigation Settlement, Number Of Primary Arguments"
       }
      }
     },
     "localname": "LitigationSettlementNumberOfPrimaryArguments",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_LongTermDebtCurrentMaturitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Current Maturities [Member]",
        "label": "Long-Term Debt, Current Maturities [Member]",
        "terseLabel": "Current portion of long-term debt [Member]"
       }
      }
     },
     "localname": "LongTermDebtCurrentMaturitiesMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_LossContingencyAppealPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, appeal period",
        "label": "Loss Contingency, appeal period",
        "terseLabel": "Loss Contingency, appeal period"
       }
      }
     },
     "localname": "LossContingencyAppealPeriod",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amgn_LossContingencyNumberOfLawsuits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Lawsuits",
        "label": "Loss Contingency, Number Of Lawsuits",
        "terseLabel": "Number of lawsuits"
       }
      }
     },
     "localname": "LossContingencyNumberOfLawsuits",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_LossContingencyPatentsExpiredNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Patents Expired, Number",
        "label": "Loss Contingency, Patents Expired, Number",
        "terseLabel": "Number of asserted patents expired"
       }
      }
     },
     "localname": "LossContingencyPatentsExpiredNumber",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_MoleculeTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecule, Type",
        "label": "Molecule, Type [Axis]",
        "terseLabel": "Molecule, Type [Axis]"
       }
      }
     },
     "localname": "MoleculeTypeAxis",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_MoleculeTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecule, Type [Domain]",
        "label": "Molecule, Type [Domain]",
        "terseLabel": "Molecule, Type [Domain]"
       }
      }
     },
     "localname": "MoleculeTypeDomain",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_MortgageAndAssetBackMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage and asset back",
        "label": "Mortgage and asset back [Member]",
        "terseLabel": "Mortgage and asset back"
       }
      }
     },
     "localname": "MortgageAndAssetBackMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NatureOfOperationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as \"predominately\", \"about equally\", or \"major and other\". This element is also referred to as \"Business Description\".",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "Business"
       }
      }
     },
     "localname": "NatureOfOperationsPolicyTextBlock",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_NeulastaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neulasta.",
        "label": "Neulasta [Member]",
        "terseLabel": "Neulasta\u00ae (pegfilgrastim) [Member]"
       }
      }
     },
     "localname": "NeulastaMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NeumoraTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neumora Therapeutics, Inc.",
        "label": "Neumora Therapeutics, Inc. [Member]",
        "terseLabel": "Neumora Therapeutics, Inc. [Member]"
       }
      }
     },
     "localname": "NeumoraTherapeuticsIncMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NovartisPharmaAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis Pharma AG",
        "label": "Novartis Pharma AG [Member]",
        "terseLabel": "Novartis Pharma AG"
       }
      }
     },
     "localname": "NovartisPharmaAGMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NplateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nplate",
        "label": "Nplate [Member]",
        "verboseLabel": "Nplate [Member]"
       }
      }
     },
     "localname": "NplateMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_NumberOfAssertedPatents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Asserted Patents",
        "label": "Number Of Asserted Patents",
        "terseLabel": "Number Of Asserted Patents"
       }
      }
     },
     "localname": "NumberOfAssertedPatents",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_NumberOfThirdPartyFinancialInstitutions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Third-Party Financial Institutions",
        "label": "Number of Third-Party Financial Institutions",
        "terseLabel": "Number of Third-Party Financial Institutions"
       }
      }
     },
     "localname": "NumberOfThirdPartyFinancialInstitutions",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Eight Five Percent Notes Due Two Zero Two One [Member]",
        "label": "One Point Eight Five Percent Notes Due Two Zero Two One [Member]",
        "terseLabel": "1.85% notes due 2021 (1.85% 2021 Notes) [Member]"
       }
      }
     },
     "localname": "OnePointEightFivePercentNotesDueTwoZeroTwoOneMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Nine Zero Percent Notes Due Two Zero Two Five [Member]",
        "label": "One Point Nine Zero Percent Notes Due Two Zero Two Five [Member]",
        "terseLabel": "1.90% notes due 2025 (1.90% 2025 Notes) [Member]"
       }
      }
     },
     "localname": "OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OnePointSixFivePercent2028NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One point six five percent 2028 Notes",
        "label": "One point six five percent 2028 Notes [Member]",
        "terseLabel": "1.65% notes due 2028 (1.65% 2028 Notes) [Member}"
       }
      }
     },
     "localname": "OnePointSixFivePercent2028NotesMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member]",
        "label": "One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member]",
        "verboseLabel": "1.25% 2022 euro Notes [Member]"
       }
      }
     },
     "localname": "OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Two Five Percent Euro Notes due Two Zero Two Two [Member]",
        "label": "One Point Two Five Percent Euro Notes due Two Zero Two Two [Member]",
        "terseLabel": "1.25% \u20ac1,250 million notes due 2022 (1.25% 2022 euro Notes) [Member]"
       }
      }
     },
     "localname": "OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtezlaANDAPatentLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Otezla ANDA Patent Litigation",
        "label": "Otezla ANDA Patent Litigation [Member]",
        "terseLabel": "Otezla ANDA Patent Litigation [Member]"
       }
      }
     },
     "localname": "OtezlaANDAPatentLitigationMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtezlaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Otezla [Member]",
        "label": "Otezla [Member]",
        "terseLabel": "Otezla (apremilast) [Member]"
       }
      }
     },
     "localname": "OtezlaMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Other Adjustment, before Tax",
        "label": "Other Comprehensive Income (Loss), Other Adjustment, before Tax",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent",
        "label": "Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_OtherCurrentNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other current assets/other non-current assets.",
        "label": "Other Current Noncurrent Assets [Member]",
        "verboseLabel": "Other current assets/Other assets [Member]"
       }
      }
     },
     "localname": "OtherCurrentNoncurrentAssetsMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtherGeneralExpenseIncomeOtherAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other General Expense (Income), Other Adjustments",
        "label": "Other General Expense (Income), Other Adjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherGeneralExpenseIncomeOtherAdjustments",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_OtherMortgageAndAssetBackedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Mortgage and asset backed",
        "label": "Other Mortgage and asset backed [Member]",
        "terseLabel": "Other Mortgage and asset backed"
       }
      }
     },
     "localname": "OtherMortgageAndAssetBackedMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtherNotesDue2097Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Notes Due 2097 [Member]",
        "label": "Other Notes Due 2097 [Member]",
        "terseLabel": "Other notes due 2097 [Member]"
       }
      }
     },
     "localname": "OtherNotesDue2097Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products [Member]",
        "label": "Other Products [Member]",
        "terseLabel": "Other products [Member]"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_OtherShortTermInterestBearingSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other short-term interest bearing securities.",
        "label": "Other Short Term Interest Bearing Securities [Member]",
        "verboseLabel": "Other short-term interest-bearing securities [Member]"
       }
      }
     },
     "localname": "OtherShortTermInterestBearingSecuritiesMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/InvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_PatentTrialAndAppealBoardPatentChallengesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent Trial And Appeal Board Patent Challenges [Member]",
        "label": "Patent Trial And Appeal Board Patent Challenges [Member]",
        "terseLabel": "Patent Trial and Appeal Board Patent Challenges [Member]"
       }
      }
     },
     "localname": "PatentTrialAndAppealBoardPatentChallengesMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_PenaltiesOnProposedAdditionalIncomeTax20132105": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Penalties on proposed additional income tax 2013-2015",
        "label": "Penalties on proposed additional income tax 2013-2105",
        "terseLabel": "Penalties on proposed additional income tax 2013-2015"
       }
      }
     },
     "localname": "PenaltiesOnProposedAdditionalIncomeTax20132105",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event",
        "label": "Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event",
        "terseLabel": "Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event"
       }
      }
     },
     "localname": "PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event",
        "label": "Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event",
        "terseLabel": "Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event"
       }
      }
     },
     "localname": "PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amgn_ProliaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prolia.",
        "label": "Prolia [Member]",
        "terseLabel": "Prolia\u00ae (denosumab) [Member]"
       }
      }
     },
     "localname": "ProliaMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ProposedAdditionalIncomeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proposed additional income tax",
        "label": "Proposed additional income tax",
        "terseLabel": "Proposed additional income tax"
       }
      }
     },
     "localname": "ProposedAdditionalIncomeTax",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_ProposedAdditionalIncomeTax20132015": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proposed additional income tax 2013-2015",
        "label": "Proposed additional income tax 2013-2015",
        "terseLabel": "Proposed additional income tax 2013-2015"
       }
      }
     },
     "localname": "ProposedAdditionalIncomeTax20132015",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_RDTechnologyrightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "R &amp; D Technology rights [Member]",
        "label": "R &amp; D Technology rights [Member]",
        "terseLabel": "R &amp; D Technology rights"
       }
      }
     },
     "localname": "RDTechnologyrightsMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_RepathaevolocumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repatha (evolocumab) [Member]",
        "label": "Repatha (evolocumab) [Member]",
        "terseLabel": "Repatha (evolocumab) [Member]"
       }
      }
     },
     "localname": "RepathaevolocumabMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_RepatriationTaxOnProposedAdditionalTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repatriation tax on proposed additional tax",
        "label": "Repatriation tax on proposed additional tax",
        "terseLabel": "Repatriation tax on proposed additional tax"
       }
      }
     },
     "localname": "RepatriationTaxOnProposedAdditionalTax",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_RepatriationTaxOnProposedAdditionalTax20132015": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repatriation tax on proposed additional tax 2013-2015",
        "label": "Repatriation tax on proposed additional tax 2013-2015",
        "terseLabel": "Repatriation tax on proposed additional tax 2013-2015"
       }
      }
     },
     "localname": "RepatriationTaxOnProposedAdditionalTax20132015",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amgn_ScheduleOfIntangibleAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived and indefinite-lived identifiable intangible assets.",
        "label": "Schedule Of Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of identifiable intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsTableTextBlock",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Long-term Debt Instruments Exchanged [Table]",
        "label": "Schedule of Long-term Debt Instruments Exchanged [Table Text Block]",
        "terseLabel": "Schedule of long-term instruments exchanged"
       }
      }
     },
     "localname": "ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps",
        "label": "Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps [Table Text Block]",
        "terseLabel": "Schedule of notional amounts and interest rates for cross-currency swaps"
       }
      }
     },
     "localname": "ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_SensiparAntitrustClassActionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensipar Antitrust Class Actions [Member]",
        "label": "Sensipar Antitrust Class Actions [Member]",
        "terseLabel": "Sensipar Antitrust Class Actions [Member]"
       }
      }
     },
     "localname": "SensiparAntitrustClassActionsMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_SixPointFourZeroPercentNotesDue2039Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point Four Zero Percent Notes Due 2039 [Member]",
        "label": "Six Point Four Zero Percent Notes Due 2039 [Member]",
        "terseLabel": "6.40% notes due 2039 (6.40% 2039 Notes) [Member]"
       }
      }
     },
     "localname": "SixPointFourZeroPercentNotesDue2039Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_SixPointNineZeroPercentNotesDue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point Nine Zero Percent Notes Due 2038 [Member]",
        "label": "Six Point Nine Zero Percent Notes Due 2038 [Member]",
        "terseLabel": "6.90% notes due 2038 (6.90% 2038 Notes) [Member]"
       }
      }
     },
     "localname": "SixPointNineZeroPercentNotesDue2038Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_SixPointThreeSevenFivePercentNotesDue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point Three Seven Five Percent Notes Due 2037 [Member]",
        "label": "Six Point Three Seven Five Percent Notes Due 2037 [Member]",
        "terseLabel": "6.375% notes due 2037 (6.375% 2037 Notes) [Member]"
       }
      }
     },
     "localname": "SixPointThreeSevenFivePercentNotesDue2037Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_StockRepurchaseProgramTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Repurchase Program [Table Text Block]",
        "label": "Stock Repurchase Program [Table Text Block]",
        "terseLabel": "Summary of activity under our stock repurchase program"
       }
      }
     },
     "localname": "StockRepurchaseProgramTableTextBlock",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amgn_TeneobioIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Teneobio Inc.",
        "label": "Teneobio Inc. [Member]",
        "terseLabel": "Teneobio Inc."
       }
      }
     },
     "localname": "TeneobioIncMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TeneobioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Teneobio",
        "label": "Teneobio [Member]",
        "terseLabel": "Teneobio"
       }
      }
     },
     "localname": "TeneobioMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointEightSevenFivePercentNotesDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Eight Seven Five Percent Notes Due 2021 [Member]",
        "label": "Three Point Eight Seven Five Percent Notes Due 2021 [Member]",
        "terseLabel": "3.875% notes due 2021 (3.875% 2021 Notes) [Member]"
       }
      }
     },
     "localname": "ThreePointEightSevenFivePercentNotesDue2021Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointFourFivePercentNotesDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Four Five Percent Notes Due 2020 [Member]",
        "label": "Three Point Four Five Percent Notes Due 2020 [Member]",
        "terseLabel": "3.45% notes due 2020 (3.45% 2020 Notes) [Member]"
       }
      }
     },
     "localname": "ThreePointFourFivePercentNotesDue2020Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointOneFivePercentNotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point One Five Percent Notes Due 2040 [Member]",
        "label": "Three Point One Five Percent Notes Due 2040 [Member]",
        "terseLabel": "3.15% notes due 2040 (3.15% 2040 Notes) [Member]"
       }
      }
     },
     "localname": "ThreePointOneFivePercentNotesDue2040Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point One Two Five Percent Notes Due Two Zero Two Five [Member]",
        "label": "Three Point One Two Five Percent Notes Due Two Zero Two Five [Member]",
        "terseLabel": "3.125% notes due 2025 (3.125% 2025 Notes) [Member]"
       }
      }
     },
     "localname": "ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointSixTwoFivePercentNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Six Two Five Percent Notes Due 2022 [Member]",
        "label": "Three Point Six Two Five Percent Notes Due 2022 [Member]",
        "terseLabel": "3.625% notes due 2022 (3.625% 2022 Notes) [Member]"
       }
      }
     },
     "localname": "ThreePointSixTwoFivePercentNotesDue2022Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointSixTwoFivePercentNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Six Two Five Percent Notes Due 2024 [Member]",
        "label": "Three Point Six Two Five Percent Notes Due 2024 [Member]",
        "terseLabel": "3.625% notes due 2024 (3.625% 2024 Notes) [Member]"
       }
      }
     },
     "localname": "ThreePointSixTwoFivePercentNotesDue2024Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointThreeSevenFivePercentNotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Three Seven Five Percent Notes Due 2050 [Member]",
        "label": "Three Point Three Seven Five Percent Notes Due 2050 [Member]",
        "terseLabel": "3.375% notes due 2050 (3.375% 2050 Notes) [Member]"
       }
      }
     },
     "localname": "ThreePointThreeSevenFivePercentNotesDue2050Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ThreePointTwoZeroNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Two Zero Notes Due 2027 [Member]",
        "label": "Three Point Two Zero Notes Due 2027 [Member]",
        "terseLabel": "3.20% notes due 2027 (3.20% 2027 Notes) [Member]"
       }
      }
     },
     "localname": "ThreePointTwoZeroNotesDue2027Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Percent Euro Notes Due Two Thousand Twenty Six [Member]",
        "label": "Two Percent Euro Notes Due Two Thousand Twenty Six [Member]",
        "terseLabel": "2.00% \u20ac750 million notes due 2026 (2.00% 2026 euro Notes) [Member]",
        "verboseLabel": "2.00% 2026 euro Notes [Member]"
       }
      }
     },
     "localname": "TwoPercentEuroNotesDueTwoThousandTwentySixMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointEightZeroPercent2041NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two point eight zero percent 2041 Notes",
        "label": "Two point eight zero percent 2041 Notes [Member]",
        "terseLabel": "2.80% notes due 2041 (2.80% 2041 Notes) [Member]"
       }
      }
     },
     "localname": "TwoPointEightZeroPercent2041NotesMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointFourFivePercentNotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Four Five Percent Notes Due 2030 [Member]",
        "label": "Two Point Four Five Percent Notes Due 2030 [Member]",
        "terseLabel": "2.45% notes due 2030 (2.45% 2030 Notes) [Member]"
       }
      }
     },
     "localname": "TwoPointFourFivePercentNotesDue2030Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Seven Seven Percent Notes Due Two Zero Five Three",
        "label": "Two Point Seven Seven Percent Notes Due Two Zero Five Three [Member]",
        "terseLabel": "Two Point Seven Seven Percent Notes Due Two Zero Five Three"
       }
      }
     },
     "localname": "TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Seven Zero Percent Notes Due Two Zero Two Two [Member]",
        "label": "Two Point Seven Zero Percent Notes Due Two Zero Two Two [Member]",
        "terseLabel": "2.70% notes due 2022 (2.70% 2022 Notes) [Member]"
       }
      }
     },
     "localname": "TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointSixFiveNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Six Five Notes Due 2022 [Member]",
        "label": "Two Point Six Five Notes Due 2022 [Member]",
        "terseLabel": "2.65% notes due 2022 (2.65% 2022 Notes) [Member]"
       }
      }
     },
     "localname": "TwoPointSixFiveNotesDue2022Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Six Zero Notes Due Two Zero Two Six [Member]",
        "label": "Two Point Six Zero Notes Due Two Zero Two Six [Member]",
        "terseLabel": "2.60% notes due 2026 (2.60% 2026 notes) [Member]"
       }
      }
     },
     "localname": "TwoPointSixZeroNotesDueTwoZeroTwoSixMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointThreeZeroPercentNotesDue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Three Zero Percent Notes Due 2031",
        "label": "Two Point Three Zero Percent Notes Due 2031 [Member]",
        "terseLabel": "2.30% notes due 2031 (2.30% 2031 Notes) [Member]"
       }
      }
     },
     "localname": "TwoPointThreeZeroPercentNotesDue2031Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Two Five Percent Notes Due Two Zero Two Three [Member]",
        "label": "Two Point Two Five Percent Notes Due Two Zero Two Three [Member]",
        "terseLabel": "2.25% notes due 2023 (2.25% 2023 Notes) [Member]"
       }
      }
     },
     "localname": "TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointTwoZeroNotesDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Two Zero Notes Due 2020 [Member]",
        "label": "Two Point Two Zero Notes Due 2020 [Member]",
        "terseLabel": "2.20% notes due 2020 (2.20% 2020 Notes) [Member]"
       }
      }
     },
     "localname": "TwoPointTwoZeroNotesDue2020Member",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]",
        "label": "Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]",
        "terseLabel": "2.20% notes due 2027 (2.20% 2027 Notes) [Member]"
       }
      }
     },
     "localname": "TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_TwoPointZeroPercent2032NotesMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two point zero percent 2032 Notes Member",
        "label": "Two point zero percent 2032 Notes Member [Member]",
        "terseLabel": "2.00% notes due 2032 (2.00% 2032 Notes) [Member]"
       }
      }
     },
     "localname": "TwoPointZeroPercent2032NotesMemberMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_XgevaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XGEVA.",
        "label": "XGEVA [Member]",
        "terseLabel": "XGEVA\u00ae (denosumab) [Member]"
       }
      }
     },
     "localname": "XgevaMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member]",
        "label": "Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member]",
        "terseLabel": "0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) [Member]",
        "verboseLabel": "0.41% 2023 Swiss franc Bonds [Member]"
       }
      }
     },
     "localname": "ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember",
     "nsuri": "http://www.amgen.com/20220630",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "US [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.amgen.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Switzerland, Francs",
        "terseLabel": "Switzerland, Francs"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "terseLabel": "Euro Member Countries, Euro"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "United Kingdom, Pounds"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars",
        "terseLabel": "United States of America, Dollars"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingsExchangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Listings, Exchange [Axis]",
        "terseLabel": "Entity Listings, Exchange [Axis]"
       }
      }
     },
     "localname": "EntityListingsExchangeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_ExchangeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.",
        "label": "Exchange [Domain]",
        "terseLabel": "Exchange [Domain]"
       }
      }
     },
     "localname": "ExchangeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exch_XNGS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]",
        "terseLabel": "The NASDAQ Global Select Market [Member]"
       }
      }
     },
     "localname": "XNGS",
     "nsuri": "http://xbrl.sec.gov/exch/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r0",
      "r122",
      "r127",
      "r133",
      "r214",
      "r391",
      "r392",
      "r393",
      "r405",
      "r406",
      "r474",
      "r475",
      "r476",
      "r477",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative effect of changes in accounting principles, net of tax"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r0",
      "r122",
      "r127",
      "r133",
      "r214",
      "r391",
      "r392",
      "r393",
      "r405",
      "r406",
      "r474",
      "r475",
      "r476",
      "r477",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r0",
      "r122",
      "r127",
      "r133",
      "r214",
      "r391",
      "r392",
      "r393",
      "r405",
      "r406",
      "r474",
      "r475",
      "r476",
      "r477",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r271",
      "r273",
      "r274",
      "r275",
      "r295",
      "r335",
      "r382",
      "r385",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r542",
      "r584",
      "r587",
      "r627",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r271",
      "r273",
      "r274",
      "r275",
      "r295",
      "r335",
      "r382",
      "r385",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r542",
      "r584",
      "r587",
      "r627",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_PartnershipInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Partnership Interest [Member]",
        "terseLabel": "Limited Partnership [Member]"
       }
      }
     },
     "localname": "PartnershipInterestMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r178",
      "r273",
      "r274",
      "r367",
      "r369",
      "r543",
      "r583",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/RevenuesDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r178",
      "r273",
      "r274",
      "r367",
      "r369",
      "r543",
      "r583",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/RevenuesDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r263",
      "r271",
      "r273",
      "r274",
      "r275",
      "r295",
      "r335",
      "r372",
      "r382",
      "r385",
      "r388",
      "r389",
      "r390",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r542",
      "r584",
      "r587",
      "r627",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r263",
      "r271",
      "r273",
      "r274",
      "r275",
      "r295",
      "r335",
      "r372",
      "r382",
      "r385",
      "r388",
      "r389",
      "r390",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r542",
      "r584",
      "r587",
      "r627",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r128",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r128",
      "r133",
      "r269",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r179",
      "r180",
      "r367",
      "r370",
      "r586",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r179",
      "r180",
      "r367",
      "r370",
      "r586",
      "r614",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r128",
      "r133",
      "r269",
      "r383",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r42",
      "r508"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r182",
      "r183"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued liabilities [Member]"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r14",
      "r259"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "verboseLabel": "Accumulated depreciation and amortization on property, plant and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r63",
      "r70",
      "r71",
      "r72",
      "r73",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "verboseLabel": "Cash\u00a0flow hedges [Member]"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r57",
      "r58",
      "r59",
      "r63",
      "r70",
      "r71",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "verboseLabel": "Available-for-sale securities [Member]"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r28",
      "r61",
      "r62",
      "r63",
      "r570",
      "r592",
      "r593"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r70",
      "r71",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r60",
      "r63",
      "r70",
      "r71",
      "r72",
      "r119",
      "r120",
      "r121",
      "r437",
      "r505",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss [Member]",
        "verboseLabel": "AOCI [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r55",
      "r63",
      "r70",
      "r71",
      "r72",
      "r437",
      "r492",
      "r493",
      "r494",
      "r495",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign currency translation [Member]"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average period of amortization"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Tax impact related to employee stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r386",
      "r394",
      "r395"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestment": {
     "auth_ref": [
      "r480",
      "r486"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund.",
        "label": "Alternative Investment",
        "terseLabel": "Alternative investments"
       }
      }
     },
     "localname": "AlternativeInvestment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r100",
      "r241",
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization charges associated with finite-lived intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r197",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Other mortgage- and asset-backed securities [Member]"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/InvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r18",
      "r113",
      "r167",
      "r171",
      "r176",
      "r213",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r433",
      "r438",
      "r489",
      "r506",
      "r508",
      "r548",
      "r568"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r40",
      "r113",
      "r213",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r433",
      "r438",
      "r489",
      "r506",
      "r508"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r258",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Assets, Current"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r191"
     ],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r192"
     ],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r189",
      "r220"
     ],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r193",
      "r195",
      "r562"
     ],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": {
     "auth_ref": [
      "r196",
      "r563"
     ],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.",
        "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value",
        "terseLabel": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r185",
      "r190",
      "r220",
      "r552"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.amgen.com/role/InvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair values",
        "totalLabel": "Total interest-bearing securities",
        "verboseLabel": "Interest-bearing securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/InvestmentsDetails",
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails",
      "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r187",
      "r220"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "verboseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r447",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r381",
      "r384",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r381",
      "r384",
      "r415",
      "r416",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r99",
      "r429"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Net changes in valuations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Maximum additional consideration due contingent on certain milestones"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r424",
      "r425",
      "r427"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r420",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 6.0,
       "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Fair value of assets acquired, cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "auth_ref": [
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": {
     "auth_ref": [
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets",
        "terseLabel": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 2.0,
       "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 3.0,
       "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "Acquired in-process research and development",
        "verboseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r417",
      "r418"
     ],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 4.0,
       "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Fair value of assets acquired, licensing rights"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r12",
      "r508",
      "r596",
      "r597"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r12",
      "r102"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r97",
      "r102",
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r97",
      "r490"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "(Decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash flow hedge [Member]",
        "verboseLabel": "Cash flow hedges [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "terseLabel": "Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "terseLabel": "Gains (losses) on fair value hedging relationships, Hedged items"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r110",
      "r113",
      "r136",
      "r137",
      "r138",
      "r140",
      "r142",
      "r151",
      "r152",
      "r153",
      "r213",
      "r281",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r333",
      "r334",
      "r338",
      "r342",
      "r349",
      "r489",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r50",
      "r553",
      "r574"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Contingencies and commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r277",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Contingencies and commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Contingenciesandcommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Dividends paid per share (in usd per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, dividends declared per share (in usd per share)",
        "verboseLabel": "Dividends declared per share (in usd per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock held by shareholders with par value plus amounts in excess of par value or issuance value (in cases of no-par value stock).",
        "label": "Common Stock Including Additional Paid in Capital [Member]",
        "terseLabel": "Common stock and additional paid-in capital [Member]"
       }
      }
     },
     "localname": "CommonStockIncludingAdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "verboseLabel": "Number of shares of common stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock and additional paid-in capital, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock and additional paid-in capital, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r25",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares",
        "verboseLabel": "Common stock and additional paid-in capital, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStocksIncludingAdditionalPaidInCapital": {
     "auth_ref": [
      "r25",
      "r26",
      "r356"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of par value plus amounts in excess of par value or issuance value for common stock issued.",
        "label": "Common Stocks, Including Additional Paid in Capital",
        "verboseLabel": "Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding\u2014534.9 shares in 2022 and 558.3 shares in 2021"
       }
      }
     },
     "localname": "CommonStocksIncludingAdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r66",
      "r68",
      "r69",
      "r77",
      "r557",
      "r578"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r108",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r80",
      "r543"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r109",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r309",
      "r316",
      "r317",
      "r319",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Financing arrangements"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Financingarrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r19",
      "r21",
      "r22",
      "r112",
      "r117",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r325",
      "r326",
      "r327",
      "r328",
      "r502",
      "r549",
      "r550",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r22",
      "r320",
      "r550",
      "r567"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Long-term debt, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r292",
      "r325",
      "r326",
      "r500",
      "r502",
      "r503"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r47",
      "r323",
      "r500",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r47",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate, stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r48",
      "r112",
      "r117",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r325",
      "r326",
      "r327",
      "r328",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r48",
      "r112",
      "r117",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r318",
      "r325",
      "r326",
      "r327",
      "r328",
      "r350",
      "r353",
      "r354",
      "r355",
      "r499",
      "r500",
      "r502",
      "r503",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r305",
      "r321",
      "r325",
      "r326",
      "r501"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized bond discounts, premiums and issuance costs, net"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Gain",
        "verboseLabel": "Total realized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "verboseLabel": "Total realized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual",
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial obligations in a security form.",
        "label": "Debt Securities Payable [Member]",
        "terseLabel": "Debt Securities Payable [Member]"
       }
      }
     },
     "localname": "DebtSecuritiesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r100",
      "r164"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation, amortization and other"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "DerivativeAssetFairValueNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r52",
      "r53",
      "r54",
      "r450",
      "r524"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Total derivative assets, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r52",
      "r53",
      "r54",
      "r450",
      "r524"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Total derivative liabilities, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed interest rate related to the interest rate derivative.",
        "label": "Derivative, Fixed Interest Rate",
        "verboseLabel": "Interest rates"
       }
      }
     },
     "localname": "DerivativeFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r53",
      "r448",
      "r451",
      "r456",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r472",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Derivativeinstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r445",
      "r448",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r445",
      "r448",
      "r456",
      "r460",
      "r461",
      "r467",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset of Collateral [Abstract]",
        "verboseLabel": "Liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r441",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional amounts"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r440",
      "r442",
      "r443",
      "r445",
      "r446",
      "r453",
      "r456",
      "r465",
      "r466",
      "r469",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument [Member]",
        "verboseLabel": "Derivatives designated as hedging instrument [Member]"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "verboseLabel": "Developed-Product-Technology Rights [Member]"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of revenue by product and by geographic area"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Accrued Liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Inventory"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Other Assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r258",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Other Assets, Current"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r381",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Dividends declared on common stock"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "Earnings per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r78",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r134",
      "r136",
      "r140",
      "r141",
      "r142",
      "r146",
      "r147",
      "r477",
      "r478",
      "r558",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic EPS (in usd per share)",
        "verboseLabel": "Basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r78",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r136",
      "r140",
      "r141",
      "r142",
      "r146",
      "r147",
      "r477",
      "r478",
      "r558",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted EPS (in usd per share)",
        "verboseLabel": "Diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Earningspershare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r70",
      "r71",
      "r72",
      "r119",
      "r120",
      "r121",
      "r124",
      "r130",
      "r132",
      "r150",
      "r214",
      "r349",
      "r356",
      "r391",
      "r392",
      "r393",
      "r405",
      "r406",
      "r476",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r497",
      "r505",
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails",
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Equity Method Investment, Aggregate Cost"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentQuotedMarketValue": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.",
        "label": "Equity Method Investment, Quoted Market Value",
        "terseLabel": "Equity Method Investments,Quoted Market Price"
       }
      }
     },
     "localname": "EquityMethodInvestmentQuotedMarketValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r13",
      "r168",
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Carrying value of equity method investment"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investments accounted under the equity method.",
        "label": "Equity Method Investments, Fair Value Disclosure",
        "terseLabel": "Equity Method Investments, Fair Value Disclosure"
       }
      }
     },
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r8",
      "r20",
      "r488"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r208",
      "r580"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Equity Securities, FV-NI, Unrealized Gain (Loss)"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity securities without readily determinable fair value"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount",
        "terseLabel": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r481",
      "r482",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r307",
      "r325",
      "r326",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r482",
      "r514",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual",
      "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r484",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Fairvaluemeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r307",
      "r373",
      "r374",
      "r379",
      "r380",
      "r482",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted prices in active markets for identical assets (Level 1) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r307",
      "r325",
      "r326",
      "r373",
      "r374",
      "r379",
      "r380",
      "r482",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant other observable inputs (Level 2) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r307",
      "r325",
      "r326",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r482",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant unobservable inputs (Level 3) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": {
     "auth_ref": [
      "r374",
      "r480",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Measured at Net Asset Value Per Share [Member]",
        "terseLabel": "Fair Value Measured at Net Asset Value Per Share [Member]"
       }
      }
     },
     "localname": "FairValueMeasuredAtNetAssetValuePerShareMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r307",
      "r325",
      "r326",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r514",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual",
      "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r447",
      "r453",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives Balance Sheet Location By Derivative Contract Type By Hedging Designation [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r197",
      "r198",
      "r205",
      "r206",
      "r207",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r318",
      "r347",
      "r472",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/InvestmentsDetails",
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r16",
      "r250"
     ],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for the six months ending December 31, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r242",
      "r247",
      "r250",
      "r254",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r250",
      "r545"
     ],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross carrying amounts"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r242",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r250",
      "r544"
     ],
     "calculation": {
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Other intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-Lived Intangible Assets Acquired",
        "terseLabel": "Value of intangible assets acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": {
     "auth_ref": [
      "r470"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "terseLabel": "Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps"
       }
      }
     },
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "verboseLabel": "Foreign currency and cross-currency swap contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "verboseLabel": "Foreign currency and cross-currency swap contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r53",
      "r373",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency contract [Member]",
        "verboseLabel": "Foreign currency contracts [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r373",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Other government-related debt securities - Foreign and other [Member]"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/InvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForwardContractsMember": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.",
        "label": "Forward Contracts [Member]",
        "terseLabel": "Forward Contracts [Member]"
       }
      }
     },
     "localname": "ForwardContractsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingencyPatentsFoundInfringedUponNumber": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of entity's patents that another entity was found to have infringed.",
        "label": "Gain Contingency, Patents Found Infringed upon, Number",
        "terseLabel": "Gain Contingency, Patents Found Infringed upon, Number"
       }
      }
     },
     "localname": "GainContingencyPatentsFoundInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r15",
      "r227",
      "r228",
      "r235",
      "r239",
      "r508",
      "r547"
     ],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 5.0,
       "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet",
       "weight": 1.0
      },
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and other intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Goodwillandotherintangibleassets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r234",
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "terseLabel": "Net increase in goodwill"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r464"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.",
        "label": "Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Hedging adjustments on discontinued hedging relationships"
       }
      }
     },
     "localname": "HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedge": {
     "auth_ref": [
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability hedged in fair value hedging relationship.",
        "label": "Hedged Liability, Fair Value Hedge",
        "terseLabel": "Hedged Liability, Fair Value Hedge"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedge",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities",
        "verboseLabel": "Fair value adjustments"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r445",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r100",
      "r257"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Loss on divestiture"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In-process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r167",
      "r170",
      "r172",
      "r175",
      "r177"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income before income taxes",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r74",
      "r100",
      "r165",
      "r210",
      "r554",
      "r575"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Adjustments for equity method investments",
        "verboseLabel": "Income (Loss) from Equity Method Investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r381",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r261",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r114",
      "r399",
      "r403",
      "r404",
      "r407",
      "r409",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Incometaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Examination [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "terseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r131",
      "r132",
      "r166",
      "r397",
      "r408",
      "r410",
      "r581"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Provision for income taxes",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "verboseLabel": "Accrued income taxes, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "verboseLabel": "Increase (Decrease) in AOCI [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r245",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r245",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r240",
      "r248"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r84",
      "r313",
      "r324",
      "r327",
      "r328"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "negatedTerseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateFairValueHedgeAssetAtFairValue": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all derivative assets designated as interest rate fair value hedging instruments.",
        "label": "Interest Rate Fair Value Hedge Asset at Fair Value",
        "terseLabel": "Interest rate swap contracts"
       }
      }
     },
     "localname": "InterestRateFairValueHedgeAssetAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all derivative liabilities designated as interest rate fair value hedging instruments.",
        "label": "Interest Rate Fair Value Hedge Liability at Fair Value",
        "terseLabel": "Interest rate swap contracts"
       }
      }
     },
     "localname": "InterestRateFairValueHedgeLiabilityAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "netLabel": "Interest rate swap agreements [Member]",
        "terseLabel": "Interest Rate Swap [Member]",
        "verboseLabel": "Interest rate swap contracts [Member]"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/FairvaluemeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterimPeriodCostsNotAllocableDomain": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred.",
        "label": "Interim Period, Costs Not Allocable [Domain]",
        "terseLabel": "Interim Period, Costs Not Allocable [Domain]"
       }
      }
     },
     "localname": "InterimPeriodCostsNotAllocableDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r32",
      "r225"
     ],
     "calculation": {
      "http://www.amgen.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r7",
      "r38",
      "r508"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.amgen.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.amgen.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r34",
      "r225"
     ],
     "calculation": {
      "http://www.amgen.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r33",
      "r225"
     ],
     "calculation": {
      "http://www.amgen.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount": {
     "auth_ref": [
      "r595"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of financial support committed by investment company to investee that is contractually required.",
        "label": "Investment Company, Financial Support to Investee Contractually Required, Amount",
        "terseLabel": "Investment Company, Financial Support to Investee Contractually Required, Amount"
       }
      }
     },
     "localname": "InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Fair values of available-for-sale interest-bearing security investments by contractual maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r204",
      "r546",
      "r564",
      "r613",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r31",
      "r113",
      "r213",
      "r489",
      "r508",
      "r551",
      "r572"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r46",
      "r113",
      "r213",
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r434",
      "r438",
      "r439",
      "r489",
      "r506",
      "r507",
      "r508"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.amgen.com/role/FairvaluemeasurementDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent.",
        "label": "Liability for Uncertainty in Income Taxes, Noncurrent",
        "terseLabel": "Long-term tax liabilities"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing rights"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded from other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "terseLabel": "Amount received from settlement"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation Settlement, Expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r22",
      "r306",
      "r322",
      "r325",
      "r326",
      "r550",
      "r569"
     ],
     "calculation": {
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Carrying value of debt",
        "totalLabel": "Total carrying value of debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedLabel": "Less current portion",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-Term Debt [Member]",
        "terseLabel": "Long-term debt [Member]"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Total long-term debt",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r48",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsSettledNumber": {
     "auth_ref": [
      "r270",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims settled.",
        "label": "Loss Contingency, Claims Settled, Number",
        "terseLabel": "Loss Contingency, Claims Settled, Number"
       }
      }
     },
     "localname": "LossContingencyClaimsSettledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r270",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Loss Contingency, New Claims Filed, Number"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [
      "r270",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": {
     "auth_ref": [
      "r270",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of another entity's patents that the entity has allegedly infringed.",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number",
        "terseLabel": "Number of patents allegedly infringed upon"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r270",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Loss Contingency, Pending Claims, Number"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketingRelatedIntangibleAssetsMember": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketing-related asset, including, but not limited to, internet domain name, newspaper mast head, and trademark.",
        "label": "Marketing-Related Intangible Assets [Member]",
        "terseLabel": "Marketing-Related Rights [Member]"
       }
      }
     },
     "localname": "MarketingRelatedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.",
        "label": "Maximum Length of Time, Foreign Currency Cash Flow Hedge",
        "terseLabel": "Length of time hedged in foreign currency contracts (or less)"
       }
      }
     },
     "localname": "MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "verboseLabel": "Money market mutual funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/InvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfExpenseAxis": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cost or expense.",
        "label": "Nature of Expense [Axis]",
        "terseLabel": "Nature of Expense [Axis]"
       }
      }
     },
     "localname": "NatureOfExpenseAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r97",
      "r98",
      "r101"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r64",
      "r67",
      "r72",
      "r75",
      "r101",
      "r113",
      "r123",
      "r125",
      "r126",
      "r127",
      "r128",
      "r131",
      "r132",
      "r139",
      "r167",
      "r170",
      "r172",
      "r175",
      "r177",
      "r213",
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r478",
      "r489",
      "r555",
      "r576"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net income",
        "terseLabel": "Net income for basic and diluted EPS",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/EarningspershareDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "verboseLabel": "Income (Numerator):"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Other recent accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "ROW [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1": {
     "auth_ref": [
      "r103",
      "r104",
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of investments that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Investments Acquired",
        "terseLabel": "Noncash or Part Noncash Acquisition, Investments Acquired"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionInvestmentsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives not designated as hedging instrument [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual",
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "terseLabel": "Long-term debt, fair value"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableToBanksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a bank.",
        "label": "Notes Payable to Banks [Member]",
        "terseLabel": "Notes [Member]"
       }
      }
     },
     "localname": "NotesPayableToBanksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsDetailsTextual",
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/RevenuesDetails",
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "OCI, before Reclassifications, before Tax, Attributable to Parent",
        "terseLabel": "Unrealized gains"
       }
      }
     },
     "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r167",
      "r170",
      "r172",
      "r175",
      "r177"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r39",
      "r508"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r431",
      "r432",
      "r436"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Gains on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r431",
      "r432",
      "r436"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent",
        "terseLabel": "Cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax": {
     "auth_ref": [
      "r56",
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax",
        "verboseLabel": "Total unrealized gains (losses)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r65",
      "r68",
      "r70",
      "r71",
      "r73",
      "r76",
      "r349",
      "r491",
      "r496",
      "r497",
      "r556",
      "r577"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r65",
      "r68",
      "r431",
      "r432",
      "r436"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive income (loss), net of reclassification adjustments and taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of reclassification adjustments and taxes:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": {
     "auth_ref": [
      "r431",
      "r432",
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r447",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets [Member]"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermDebt": {
     "auth_ref": [
      "r22",
      "r550",
      "r569"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt classified as other.",
        "label": "Other Long-Term Debt",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other items, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other operating income (expense).",
        "label": "Other Operating Income (Expense) [Member]",
        "terseLabel": "Other Operating Income (Expense)"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r88",
      "r91"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchases of common stock (Note 10)"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r89",
      "r426"
     ],
     "calculation": {
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": {
       "order": 1.0,
       "parentTag": "amgn_Businessassetacquisitionconsiderationtransferred",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash paid"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Cash paid for acquisitions, net of cash acquired",
        "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedLabel": "Purchases of equity method investments",
        "terseLabel": "Payments to Acquire Equity Method Investments"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r186"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).",
        "label": "Proceeds from Divestiture of Businesses and Interests in Affiliates",
        "terseLabel": "Proceeds from Divestiture of Businesses and Interests in Affiliates"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Net proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r85",
      "r86",
      "r186"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "verboseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r93",
      "r96"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r85",
      "r86",
      "r186"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "verboseLabel": "Proceeds from sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other revenues [Member]"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/RevenuesDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r260",
      "r508",
      "r565",
      "r573"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r260",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent",
        "terseLabel": "Reclassification adjustments to income"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Member]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Reclassifications out of accumulated other comprehensive income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r246"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails",
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResidentialMortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r188",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by residential real estate mortgage loans.",
        "label": "Residential Mortgage-Backed Securities [Member]",
        "terseLabel": "Residential mortgage-backed securities [Member]"
       }
      }
     },
     "localname": "ResidentialMortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/InvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r27",
      "r356",
      "r508",
      "r571",
      "r591",
      "r593"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r119",
      "r120",
      "r121",
      "r124",
      "r130",
      "r132",
      "r214",
      "r391",
      "r392",
      "r393",
      "r405",
      "r406",
      "r476",
      "r588",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r162",
      "r163",
      "r169",
      "r173",
      "r174",
      "r178",
      "r179",
      "r181",
      "r366",
      "r367",
      "r543"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/RevenuesDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r368",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r63",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Components of accumulated other comprehensive income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual",
      "http://www.amgen.com/role/InvestmentsDetails",
      "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual",
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r194",
      "r196",
      "r199",
      "r200",
      "r201",
      "r203",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsDetails",
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r415",
      "r416",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails",
      "http://www.amgen.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.",
        "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "verboseLabel": "Unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges"
       }
      }
     },
     "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r48",
      "r117",
      "r325",
      "r327",
      "r350",
      "r353",
      "r354",
      "r355",
      "r499",
      "r500",
      "r503",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "verboseLabel": "Schedule of borrowings"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Fair values of derivatives included in the Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Summary of amounts of income and expense line items"
       }
      }
     },
     "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Computation for basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/EarningspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Derivatives in fair value hedging relationships"
       }
      }
     },
     "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/DerivativeinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r242",
      "r249",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r253",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.",
        "label": "Schedule of Interest Rate Derivatives [Table Text Block]",
        "terseLabel": "Schedule of interest rate swaps"
       }
      }
     },
     "localname": "ScheduleOfInterestRateDerivativesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FinancingarrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r35",
      "r36",
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Net Investment Income [Line Items]",
        "terseLabel": "Net Investment Income [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails",
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": {
     "auth_ref": [
      "r82",
      "r84",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.",
        "label": "Investment Income [Table]",
        "terseLabel": "Investment Income [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/InvestmentsBeiGeneDetails",
      "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails",
      "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r110",
      "r151",
      "r152",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r342",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r107",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Summaryofsignificantaccountingpolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r110",
      "r113",
      "r136",
      "r137",
      "r138",
      "r140",
      "r142",
      "r151",
      "r152",
      "r153",
      "r213",
      "r281",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r333",
      "r334",
      "r338",
      "r342",
      "r349",
      "r489",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r51",
      "r70",
      "r71",
      "r72",
      "r119",
      "r120",
      "r121",
      "r124",
      "r130",
      "r132",
      "r150",
      "r214",
      "r349",
      "r356",
      "r391",
      "r392",
      "r393",
      "r405",
      "r406",
      "r476",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r497",
      "r505",
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails",
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails",
      "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r150",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r24",
      "r25",
      "r349",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Issuance of common stock in connection with the Company\u2019s equity award programs, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r24",
      "r25",
      "r356",
      "r387"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock in connection with the Company\u2019s equity award programs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, additional authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "verboseLabel": "Amount available for stock repurchases under a board approved stock repurchase plan"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r24",
      "r25",
      "r349",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Repurchases of common stock, Shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r24",
      "r25",
      "r349",
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedTerseLabel": "Repurchases of common stock",
        "terseLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r24",
      "r25",
      "r349",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Stock repurchased, Shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails",
      "http://www.amgen.com/role/StockholdersequityShareRepurchaseProgramDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r24",
      "r25",
      "r349",
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "terseLabel": "Stock repurchased"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails",
      "http://www.amgen.com/role/StockholdersequityShareRepurchaseProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r25",
      "r29",
      "r30",
      "r113",
      "r184",
      "r213",
      "r489",
      "r508"
     ],
     "calculation": {
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r111",
      "r334",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r356",
      "r357",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/Stockholdersequity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r498",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails",
      "http://www.amgen.com/role/IncometaxesDetails",
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r498",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails",
      "http://www.amgen.com/role/IncometaxesDetails",
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r498",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/ContingenciesandcommitmentsDetails",
      "http://www.amgen.com/role/IncometaxesDetails",
      "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r197",
      "r198",
      "r205",
      "r206",
      "r207",
      "r318",
      "r347",
      "r472",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/InvestmentsDetails",
      "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r116",
      "r373",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Other government-related debt securities - U.S. [Member]"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/InvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "US Government Corporations and Agencies Securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "U.S. Treasury bills [Member]"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/InvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r116",
      "r373",
      "r380",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury notes [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/FairvaluemeasurementDetails",
      "http://www.amgen.com/role/InvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase in unrecognized tax benefits resulting from tax positions taken during the current period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/IncometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.amgen.com/role/EarningspershareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "verboseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r135",
      "r142"
     ],
     "calculation": {
      "http://www.amgen.com/role/EarningspershareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted-average shares for diluted EPS (in shares)",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Shares (Denominator):",
        "verboseLabel": "Shares used in calculation of earnings per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r134",
      "r142"
     ],
     "calculation": {
      "http://www.amgen.com/role/EarningspershareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares for basic EPS (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.amgen.com/role/EarningspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e639-108305"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=126960272&loc=d3e32014-111567"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126972413&loc=SL7495116-110257"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r629": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r630": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r631": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r632": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r633": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r634": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r635": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r636": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r637": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r638": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r639": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r640": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r641": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r642": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>85
<FILENAME>0000318154-22-000041-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000318154-22-000041-xbrl.zip
M4$L#!!0    ( +&>!%5BPZ@D >X" ,\!*  1    86UG;BTR,#(R,#8S,"YH
M=&WLO6V;4T>N-?S]_(H\^7SW4"^J*A773.Z+A)#A/H'D )DYR9>YI)(*G#0V
M8W<3R*]_5*:;MY"!@+OM[782@NV]O6WOM4I:JE))?_V_SQX??_94EZO98OZW
MS_U?W.>?_=\O_OK_'1W][Y?WOOWLYJ*=/M;YR6=?+95.5#[[=7;RZ+-_BJY^
M^:PO%X\_^^=B^<OL*1T=K=_SU>+)\^7LX:.3SX(+X:V#R^M)0FE4RU$MH1Z!
MK_X(2XE'+%XHN\):TO]Y>%UJ9JT2CJI&/0),_0@S^"-QE7KC3 7X_\CUXAV4
M)%QR=L N5>>U%R@1<M+6_?C81R?VZ^P7SE?7GQW/YK_\[?-')R=/KE^[]NNO
MO_[EU_B7Q?+A-5]KO;8^^OG9J>UTN=1Y>_[R[&>\//[+2MM?'BZ>7CL_>FW\
MQO.WS)Z]<>GU&\;%@_/QVFQN5]=Q0\]/_]UW>>T-+EX;AYE6>G[Z:GGR\NQ.
M*UZ?:2^^]15.WGW)5Q]_[61)\U5?+!_3B>$]WNZ.7#CR+R^BS]JC=__L<>3-
MSULM(/CR'W[&V1FO?<$CN]H;;SB_^G_ZCCX=.3R*_OPZSU:S=^%H'^FO_>^=
M;^^W1_J8CF;SU0G-V\M[*#I[]P^S V_\+GK\</[&]>T%G?^E+1ZO3W,YNI=$
M69S.3Y9_Q),7!]^X]CAA]I_NV)M?^H_I.HC]^D7EK1]W=L5\[<7!\U-/5T</
MB9[\GDQG!UY]V>O'-'_XM\]U?O3#_<]M("G)%W]]K"?TV7CKD?[[=/;T;Y]_
MM9B?F'DX>O#\B7WG]N+9WSX_T6<GU]9?\=H7__5?__77D]G)L7XQ;NS1^2W\
MZ[47+_[UVHM+\T*>?_%7F3W];'7R_%C_]KG,5D^.Z?GU^6*N]@5FSZZ/$W7Y
MXN%,1.?KAW;\KMFHY:R]^/QG)_>T_^WS6:P5DV\-("9@"8@M!,RE ?504_O7
MS?57\<X?O8)U3H_'1^OL^M=S^W[/O[*?LZ3CVW/19_^MSS__;"9V:8G_>,XW
M%T^_#?>>_ACOG,K/7S_]Z9OZ\W<_MV=W;OY/O/O/>[.[O_T8[MR\-[MS\X=T
MY^:MXY]^;N[N;W?<W9__<?QC^/'9M_'N\8^_+>*=!S?L]7_\\N//+=S]^8;[
M\><;_KL'-Y[]],\?X]V;[;>[-W_T/_WS[N,[_T#W;?CI^8__;/FGFU\>W_GG
M#_[.S09W;A[/[MX\_OFG;[Y.WWWSPW,[_S>[%GQW\X=G=Q\\?"K?W)KQ-S_D
MGW[^VJY]Z^<[CW_Z^<?'/_UR]YL??OWNYD/X\4'[U;XSW/FMN9^^^7^__/3-
MG;/W_,,^*\U_>O#D\9T']CO^>>?Y3X_OSGYZ_#_NIP<W[/J/'MW][<:O=V\^
M_.WN;_=^^?&Q_?'X_-L'7Y_<N>^>V=_/[_[V/_[.PW\AB-UWKT=FK-T15*A'
M**!'#3E(+JYSSI]_X>R?Z-$G^.NU-V"]2)1OF'.3X>!N'=/# [KO0_>W=Z!;
M&H, 1?/697AK [;6AD?!8,]=-0:@S[_H=+S22P3V7+C<FJT:'?^HM+QEKZP.
M$+\/8O\.B$4E<:QXU!VSZ3;OC@A(CT)@@Z-EQFHF>L"P-82_M^LOY(#Q!V$<
MWH&QV>'2:L&CY$2.@)L<D78PY>7!<Z.0/7_^Q?]<)L)?K87V:T/XZ[G<M"CD
M\\]>J$/[A&<GU\5>.7IL'_OH2.C@H=\+?GP'^"8IN3M(1XHQ'4&+V<"/U3RT
M:*X=2TT&O@_7HO\=_M?>E&-+[3K"(UV]0T6.N.;Z:JW/C2&?K8.NZR>F'?_V
M^6KV^,GQT+WKUQXM!X'>$(Q_>;82N\2U-Z_QXO-??>C9=U@M3I?K9VO!??V,
ME2^X\3&L/+^0KE7A^;.9C.=]ILO/UE](WQG:?'7[O]]4-V^_^8OSE]Z\^I.U
M23M_9G'!\F2P?VUGC^S+.7_^OE?'7GY->>W4?#3D]IM'SI^??\BU-V[4.^];
M'O>I^T30 X"Q(A3Q.><8(45Q<0OW[>SGZ\/A"%X\%?NP9T^.9VUV<D<?LWV$
MS.SHB^F-5\+^V]GJ9#9_N/K:HEJCJ-YX-EM]_L6(<:__[]UO[O_UVCNO]0$?
M<19(7;]_8K=Y?*VOCFFU^J[?/UFT7UY\RODI7RT>F]U:'WAQG3_\U&MO_=!)
M\"5&KM"17%.$2!D]Y9BD%2V=0M #7SZ0+\,,7K\1_N+<?9W/%LN[BQ-=W3Q5
MNVMY'XD#K37&E##E"DVA4G>BT5/*64J/_[J]Y@LZOP-V^<6,S<G9'<#7;M;Y
MD0^[ Z?SV8N?OWI$YK]>_K+'2JO3I7YQ!L#ZX/DESH^=/Q_7>.<=I=C .\D<
MNL5G*;*FYDH6-8MNL7DZ&XJPPT-QM3RY_OUR(:?MY+OE?5T^G35]TYR>';WX
M$0&7,2)>\N%T+7O>!/QL8O7Z#_=O_FDN%)2JSB6V408N.Y9$(DS5Q1;LWS47
M_#D7_($+?\P%_^%<\)MSJ]A\=A2[27F0I%5*2>1%"9,F#Q-PJ[N"WU:\6XW"
M'FN)/A4HSB$()4JE:&.+0=S9^/.'\?<AX^]#\=O<^"M>BV<(&+4#FJ@%4[EJ
M^@1<Y)C;/OG2&W,Y._S=R2-=[HEK?1/.C)B1)7)7H)RH9NVJ*5G88F*I[),[
MO%PXM^(=+="TN*"IU-!-(FF-D#TV=)![RL#[Y!TO?71N8<[)1J6:R&F-$IC=
MQ1:UD'8NQ0.UM$_.\M)'Y^7[SM8-2(%2:Q7H0,@1*GOB7&)+A;?@.R?AI+ %
MX[Y4NT\!NKFK9NJ_1A./J;ODMN&D)N$-''O//")<KR#5,:>LOL28,E'U=0OF
M8U?'Z>OS#=_K\OZ8:'IY+V3VU'[#ZZ>NEW_H9/'2(/[)J8G?O7^\>%/GB\>S
M^;LN>_;KWSO]]<8EKKWY[=\W,U)=**$D%3#KA#FQ*RZU0CX%HXU%9K=WR"B]
M.>_X.NY_;M[QC3O0B4G8[$A- A:E,FA4B=BU4J28UG? ^Q!W;.;5'_EP%#]R
MYO5-#A"/GZKLQ6)QK]C1Q8P!I/1F(?KEW8$_JS-^MY#P];]/1P;;XO&3Q=R>
MKBYQ\>E"H-%4"N8,0+U 9Q,.V),&<X-!#+6XC]#<GK?C4YG-']X0F8UT6#K^
MGF9R>_X5/9F=T/%$H)/L7).FU><.G#.A- E1(RK6JOL#W3T]H=E<Y6M:SL=R
MX43P,4LW%@%RS04A,V(KCKA74TW<F^P//C=:.WU\>CRV,JR#K''>4A^-JSU5
M&VR+QSH5R%@ZE6:#" MP".0I9U;SWR&(C;.W)SKBY+&[^+'U"?,=\354/R5@
M 1MY+GL15X&*R;'BH_::'/3F^N^FKRX!U4G<M[ZF/G?%7"#'SJ$I-C#]5IL&
MI/T;#5NQ9-L'>@1HN:*WH5$M0BF4"$"3YI2@Q_J[Y+WI [VK66(; I01*'>,
MFDN$$@F9<M7F<Z),%,-> WKY\G[[@/L",3L3_4T82!6#6>F<)3?'-ISY;)9E
MKW"^4$WY%C2?H"G-E%9PT12(VJB46)VKM0>+UWHRJYOW$9JM1MB;@XY3Z(ZP
M.A*"; ])B5(O%&MH6/K>0'>I$?;F\!DY\GYDR@,S<,:*A:H7#TK8FM#>X+/M
M"'MSD*&H&4,:,04"Q&C")%>J$D,="]%P>9!MZP[4EK(KT4Q(3"!^&!0MT5>O
M+9-O,H%4IYVS+MM?3*[)!3-#OE67 1P3B6^QL1OS?\G5_4-U)V+ERP>:G8\]
MY^#99)W]152[M- HM$H^T_X!?:FQ\N4#"K&0&$HDJ8$XX;'#ROOHJO-0?-]K
M0+<?*U\^X+DJ=N\J!8N5:VH8N">$Q*%(\8XO+R-AR@/W0E(EB!Q04FV2$MC@
M8RD0I)3N GABW$=HMATK;PBZ:(-*&JJGSB,'$7VI#<=DA]E5\Y)[ ]UEQ\H;
MPD?%-"FFFBD[T.)074]B?V<(#E'V!I\=B)4W!!D62N-6.HL3P3?@W%!J20R!
M?887UM#M00+!93DJM[%$ =1A[YK=M!! ;6")F;N.$1L7NX^TC]!LU5%M#KI8
M>O*1&J & %5N45N7+*8"U9';&^@NU5%M#I^08Y787"VJ(-U7L3C;L0TMC6/J
M;&_PV;:CVAQD7M/(: M 8^-MX%''#+3:H(H4"/WE0;:M.]")1LZ81'456K"8
MTN7$TAIF"S.3OKTG8OI+$I<\J?OG=FQL:%4]1-=')+.F='>YIC V#:'#&(WI
M?@NH3N*^^0Y!"XD+G*"F7)42FTIRBN9Y4]Z_T;#]R?#M#)#> _90(+=1]8VH
M%PPM%VI&@>C"_@%]>9/A6P&4QT;]UE),W@^!S%Z; ^^[4VF>::\!W?)D^%8
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MY:+I:O5N0"<R$EN..MQA-"T#31L/L'14&,FE]#B!W263!'"#>M3UB"9 @R\
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M &>QUMA"KB&'&GWO9XF'!\OQ)V>^8GJ+#3MO))P2LC0!# %:CMBH)%^DCZJ
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MU((L%5W*DT?I_*SS&=A[=*(#IUT:T5/1#=6;P.16E+P'",C Y$)3K=A2J?W
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MBEB9*[!A;(-SGEE47(<PEE/8M!\4:'78'.&LN>P^9:X"2AYZ\J0UI] &2K5
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M,84T-P:1N.GALI8:6/7?;#]B<A;+2KAAMK.SM0196[/8PR!:4B\4-$Y0HKA
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M+=8V#]U4QMB]N.2V14QNQR9?BWP]'Z>.J=#JSPLUZ*M?;===D[RQX)HFHFT
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MN9M5A>CYEM_ZQ*<=2^S8L4W2^Q#IO:3HFXJ66V,J)BE^N!0WIPH,$469D11
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M6L =MEYIGQM(US9S_.!-X1E*\BS3<9"<9T>_W1^JSL,<_<G<;YWDN'PX97Q
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M@4DM%5> 4!0 P$$&9/@,D%@;S@;#!5$<?(UU/K-#V0D E@H 'J4<9 * QP*
MJ6"#\C+/@ZL)N.0HI@\PH#@5P&I-A%0Q=4BN;8IUQ%*KL 0 3U4_,@' HP'
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ME%#G;J@S==0RA\P[P0"'B@$J9 ZDHQ @(@@GCBCEZ-HFY4L8R4N8LZ28,_/
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M!X.FJD+G3&HC'2 TQX!2K('4W@&KO+#0ZCR7>FT3;ES39"%A4,*@^<:@!^Y
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M).=AJRE)^;P&<Y*2GU^9GSY[1["0C$K@+16 ,DU!$',-POH;XK'E6.1)R:^
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M[/(9(V=>"3"L2_+6W65'7&"HX4YO/-EYZ\PI\-IVPD[O>>T1*(K&4KEO.N@
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MDVU"AE.'<-*6.$:P]6EMDS>IM6QAY!)\*V0J9&JH6%QZC+2(Q3L7BS,&OA/
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M^I28P6N;LYZKPJS-9M:"J2M!I@<WG JFWAI39^R@(*4*V%LD*,NII8HA1[Q
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M\ "\$LQJ(L/>12Y,8=CE,>RTCL"BD5(E@:C*_5$\#\@PIY!4.!JN0%'PN=F
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M."BN/:G\\<'774STS</#7X_)]=?I^V'VH9XG=YU1K/1H7AZT^3D5HMQQ8I-
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M%9(G$5M8OCXR)DL>7?(.B+*7MK[:3C<3Y&5_D%\YAZ_MZ$:E"_E2T&M.,Y9
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MZGDC)^N^@G1'-L0S^LT\#FRS[9Y4VSXZ'/1/#@YG)":M7.5_V]Y)/E^U"%V
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M2VOM+C&?-%2%>9CW:]>HP?#3F0!/2F/36Y/N!O5ZAQF;,I5M0M+?GV[]UE/
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M:&VI6(>0<AAO]%[GW-L>T,P(L=[[=8;?^2)1ZY.:\JT4UZELZ68Z^LOP/UF
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MQ-M\2L,A*_W-*)?3PW_U2SXGB61'Q9_2Z?!3QN&/*WMR>S=6\D4LZ)10+$-
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M;,RA<1:@OL^>KTV>QDJW??TCS[6[F^0+SG$:J<2)$,P3X7CP4^LLS2_O7"+
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MZ6RZ3IC+QV'[YYO:?GZI]Z2(H&0,9(G86+,)0CV>'YA1UD1A@W!9U]S[9=J
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M;;*P2FF#Z,4#-:/O%,3=*8A+O*5BK.#6"Y84&@99219(,; "X#%RC"!%HR)
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M7R28$S3WYR(X9P.?NV6_T3$5UVEE#(4=TF'T[$>5-FC5ZJP<YGUBYLH5X[K
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M/GUZM;XT,VEH-F<D7:VW4;T,;_2_>$(_$AD2<]6].IKHT9P<8ZIS<$0//B'
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M9N^(F)DQ,.9I''CZ+D)=:?86H%7O"EPU,SI6'USS)-RCWM@,Y^]N&9^1Q;Q
M([1VOM94IE->;][Q8'S."VHU$)>+:O5GM>"6@9D<F"'C>,<C\PEX5C420ZYU
M;20>>GAVEJ/HBQN6^&WEKY7:%DA+;] ]S9[3>\G)W&/#'Y<&XQ7OMLW\_J]W
M*VX\' EK&FC$Q@JPQ"VV*C'%B.8F>AR(W-VX7]:?<6M\S%8_7SG_@$4S!YB/
M59U.S9\QH+/8[2Q*+I"'6O##O;JCOP]WMN 91Y]:#?JI53_X"E;[G@!+GC7.
M#D^K_IY]^5D_^TC']^IVOG]MY>^WOW]C\-]IX_.GH\WU0PKML<V\'W>P#?W\
M>%;?VDGUO_#I>"X0KF-PU"IDB,>(!T.0"RXB8SPQF''LLS?J?_^?IH3^]EKR
M@13\*_CWJO'/^\'1H&7[,53T\-L%,_P,;/GW"%@8M^S/ HKS 44\#HJ1AQ!I
M/H\L#$?<"X*TX1S9H#2-*@EE90'% HH%%!<"%/\#?Q50G#,HTHFL<9:'Y*A"
M.F%@BE089&#BD0HT*&X3)D844"R@6$#Q24'Q$A"OPV/!O?G@'I^PD*W"1#G
M/9(989 !:<HD4BI18BEQ.+X^,OCF3VY?=Y&Z9JOU,!=IJ71T3[PCT1))!?&6
M,<Y]T)%*CXWWA!EA*7T>SV![<(1"IX]&3RC@-POX-2?=@\E8$DV(*! +X&<5
M19;"RL*)#\["&N<)65HERT;C!0KE+\K].I6[N+V>4]DGW%Z..89]P(C1O!=
MK$7&6HT,-00[KY-@\[/PBKH7=2\.G6=4]PF'CO!)":<C8BH(Q)F62',+"SSS
M-%+"A!2VJ'M1]P>K^_U<%86R/TJM)_P5AGHG1>0YB1S)!7X<<J#12!(N-)6,
M1($7C[+?X9 XCTR'SL;;<:!<^= KRQ2\^)5E"E[\RC(%+WYEF8(7O[),P8M?
M6:;@Q:\L4_#B5Y8I>/$KWWRANCJ\[&GMJ,K543L:] >V54OP/D]RJ.9>;J?[
M%E]XU6ZGY)SG7"AB->&8: U_.1P281@KRLN.\>*[G[8V^O7F>#IN01GV#B-L
ML4?<NXBT-12I1)6USEN8T:55OLS9HW-0+EXYE:+=SZS=9<OX6;6]\<=XW1+C
M;;26(*-S=%S"'+DH)-)!"L9T\D'-;Q.IZ'O1][)G_*SZ/KZZXYS:S)& @M<*
M\:@ITM)*1!USB0=",*-%WXN^ETWCA=;KS?%UW"@?/*$>)2$MXCQ09"VOZK!*
MK8P1QIO%8^UO/HQ]L[\?N[7>/MBPJ!^[1[=EFROQ[4^)=Y$"MP6FZS!WH!W>
M"*J5B-P(GE*PJF2^6&C(JT\Z*B(6@K@<(Q.50]QZDK->!&2Q\8)SBH'0E/BW
MHMKS4NWBJGA6?9]P5>@ "I\$0XXRG!V3"FF;$TIS3X3&Q!A5]+WH^]/K>W%5
M/(F^CZ_OQ'(5DTHH\ "+/)44&644HM$D+HQQ/+FB[T7?'ZSOY2C^$ZOTA)<B
MF:2E<ASY( +B&H-*>QZ1]8P0CP/'*2RB2I<HEA>_LDS!BU\YIT"BX?I$5ZA8
M9,_=5J=O6W-WU\TG#]&HE@.#L0R=0:X,<3X>)5'1W ;HS= G@ZFBP)<"-X%K
M*1Q66'AEB:!"1HY+G-;B<ZGM2?<GD59:1A*RG!G$DY'(YA_$*B.PSS7F^=*J
M7.:/KQ4\=^5Z'>G>"LP6F%TXF"U>Z&>%W0DO-$PN9HH:% +. 7,$3-BH/0K<
M"28<_)\\51K- KP%> OP+ASPENV )P'><;XKC%28R8!(2!AQ'"VR$=#7!8)%
MI-@R.K_M@ *\!7@+\+X0\)80TN< V(G-&>ZI(XQK1 1SB,M<31@G@80A)@42
MI-1OSJ%0N;1_K0KEKEY6XAUJWFI5O.Z>97IU*=-;BLF6SI8RO<]6IG<]^GCD
M8K?&2%6JE[SC4J.E5&\IU5M*]992O:54[]LVO]^3=1T")U01K%1RW%NLI=/>
M2,:4MI'B8=0C(921>6_;OPE#^LO/S?4Z;ZQOG&U^_WJX?09]^[[!M\&PWC[[
MR!I@1N]\_W346*^?3AC2ZQ]Y_6P/UP_J8N?SUX/&YXV?VP?[S>WO?Q_4P9@&
M,[H%S\;ULS^GEN1-Q.($TX(\\Q+L:"&1]80A$@F)AA"O(EU:Y>JUU!HJ$%<@
M[E5#7-DR?TX\G"A+PKAG#EN+=+("<9$",BHRY 2+#IL0A'Q]!=@**!90?)N@
M^)ZVLY\-%">*MU"-$TD BM+GW>R0X=$[@IR$_V&L*:.X@&(!Q0**3PJ*-V\U
M%WR;!=\FJMAH34PBQH#]BSGB*6 $$Z<03M9QDSQV53ZB5V,$O_E,1:7@[C-#
M&O/*XJ05(3AGJ[$F"F,H!5CC@F!MGLZ_]_:C:)X)]Z84W*74,R4-04GP"+B7
M)-)":J25CXS9R!2VN7H7B,\"G6\NROTZE;MXMIY3V2<\6UX(R8/QR.BL[#J!
M_0;SCJ3TC#HNI)IC\N2B[D7=B\_F&=5]PF?CO.;,IH2\,=F1S3W2QB>4(I9>
M1IZ\GY\CNZC[^U/W]QSX_FQJ/>FJD)@J9B4*)F*@[-HA*X)"B7FIM'-!![IX
ME+WDPWGQ*\L4O/B590I>_,HR!2]^99F"%[^R3,&+7UFFX,6O+%/PXE>6*7CQ
M*TO!W7E& ]W+[?0N2G9AJKD*1$7O*?<L&0S_^%P2@7O,+2T[Q@OO?II6<!=K
M'KB2'!&>$N+81F1BT,A;8ZDG. 4FEU;%LA9R@4IW%>U^G=I=MHR?5=LG\@<Z
ME;313"$<B$;<,HN,TA@9%[F(5L6 2P'.HN]/K^]ES_A)]'U\==?<VN T0U'F
M*G7,*J1]TLAJ =,M<U!8*OI>]/W!^EXVC9]#KZ>4LI',*Z%0Q"'".DX<,CA9
M) PW.3$[$UPO'FM_\V'LI>#NHN!=M!+8+=&&N<"M))9@9T,4R1EF&$DE?\5"
M0-N4PKK41Y^L< CF2R!NE$=:N(B<C\)Z$8FS;&F5+% P3%'>UZF\Q1GQK)H^
MX8R()@;F)/ 7%676](2LI $%%A,V5.+HYW<*N>A[T??BC'A6?9_(H<^YR-8$
M2D)2Q*EE2*M($--,6]!U;'@IH5WT_>'Z7L[3STEU)_P-V!'C+)9(IZ@1UPSX
MN$L1:>N2Y<Y[ENL.+1(I+^5"2[G0YYV$4M5C#DM#LK 2.,RQ$8$[HAV/#*P$
M@!UCF66B1)DL_OKQ9=*IDS1+)#&-O$D!J)]4R!+'4.26*.IA1K5=6E7+#/,W
M4]VCP&R!V7<.L\7#]JRP.^EAHU)[ZSDRE K$B3/(\*21\#$Y3B2S^JF2GQ;@
M+<!;@'?A@+>X.I\$>,?YKK?*V\@,LB9@Q%F,R%+FD0V>,HL3(>JI$JP6X"W
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MR'D"Y _6-I*\I3B:G"S>Z$5*%E]T>T$9S<RZ7=1W%O6=H"[41^&4QPBLM(@
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MM-G]K^WV1W]40C(\O'E%.$:B$TB1DANDY!2D1%(2<VHFY$(.<Y58(^L]0V!
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MX$I_AS-Z0[C+H)WG))M+(50;,-!)F )XDXL** Z&,5<J&3&AL4Y?L=3:@#!
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MPWR"VN=<[4%I3;30-I^G7\;DIMHFL]H9"^0@*?K\9/2AZ/.SZ/.DUP +1;W
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M0W7ZKU/E]&A>S,<H \1#PO7O[,;U;H=$&&<I'[GFF;4YAF.P&O31,V#@:?:
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M(98<9E@"1&DUA"7SZ-H7KSJ_QHMJY7^:/K9[^=#(].W(-YY38P90PL9(K (
M$Q%<6>.<R:Y5(IS3FB1?]N\6#9:F'=#VB5$&2PMBN20YEUHC(P6@$M%<.2:4
MI6%I-;O#'^UX*@6V%M@8>@9M+L;0T^OWQ'Y7C,PKX3%2*:BA?CLB& J*!46C
MQ"'*K-]83*9>?)&T.46U7]\Z71D/15%G4=2)+:"@(J8J@*)B;!"G3"(G$D<X
M8J,XIDQ%NK2J25F&W["N>JR(!GAF/EB>1#0,,V.4L#9*A1TN&R8+J,H3&R8V
M@<Y2T%W/;01+/U'@U%:C0+P)@7 9=:HX-7YT2%Q1Y@7FU,^@S853/[U^3]E@
ML,PDS)%F7N8RBCR74=1(:<%#,HY'BY=6Z;)1CPDA*ZK]KM?IPJEG=VY-^-R-
M<D0* \*I9$(\.(%<4 )Y2T)68I<LK,2:+1*I?F='@NJV>QAS CE49<R+X3&.
M]W>16M]ZZH02BH=@.+74<L&BP")8%P"2RL&9Q<.F*451#&;>:NV0(3FT2CN.
M+(X6)9&TMQ%KI\C2*EEF=-9JI:\@4N&-*_-,!TV>7IN+D?#T^CWA>-?",)*(
M1<RJ['A/%(P$0A") 2?I:'!69_TF=#+Q\6L.0GKCJKU8FEV,A)D5==+Q;HQS
MP2B$\P$,'K!%-FF*&,4)YDT[:AQ8\_@-QC877;V(L$M.<4E2$-)P+Y264DCM
M(XF"*\R*XWT157G"\2Z$)L8'@KSCH,J)*F0$<\AZ6'&CY=AX5W%J\09/4;UQ
M99XILO_IM;EPZJ?7[PG'NTF@X-YI1$Q(P*DQV,Q<&10ED4)$S72B%:<FCZD!
M553[7:_3A5//[MR:<+Q3'FWDUJ)H7?9NA8A<\ D9J;#F/!!!05,I+Y'N+Z9U
M7V,OVJ[?'U9#&2;FRO5=:G>FY"K[@!=U39+34H$M'S'E@@@-J,1PU,%9:]CH
M8$YQQ2\26DTK>AN58HHD,!ND1SRD@)P/'OGH*65!6JPJ5QU<LT#[A&53?^Y%
M8I]>FXO9\/3Z/>&*AYD4-"8#^HU=CM=QR&%.4#+:&LV9X]A49H,H\3JO2+47
M2[.+V3"SHDZXXBF3$7.K$>4*%-5SFC.-Y./[A@G,@I$)%)4279;AMZNK IB8
M"Q)KQA,7%B":AP!\C*G$<5"ZN.(74)4G7/':@+K2()$S.=DBX1I9CQGR8/U+
M*XR0.?(N<^H2 __:E'D63OT,VEPX]=/K]X0KGGN55VJ&M'8&<9PT,L0G)"B8
MTD8KK^S0%<\*IWY%JKU8FETX]>S.K0E7?$H4,\TH$BYPQ!U12!/B$%:$&NND
M2Y)E5_S[CH%_N4(^6YV^;=72K>5\'A,,?^\"4&\/H@RFBBH1 S>!:RD<5EC
MRD0$%3)R7-SS"X=@4TI,6.XY4<XC6&+ E#!.(<ML1%%&:W'"5%"SM,KH,C:/
M=@S,JC.O*##@K>' +%;(,P!!L4*>'AHF//M"T:2$D2A@G1#W,2&'940\DF"$
M"$Y5>=/-,C&36W<S1P055%A\5%@L4"A9-><+ !,[!@(;SBT3N=Z41IP:@4P,
M&F$F#"?41U:Y&>FR>7RNC8(";Q$%DG4V.,RQ$0&,8^UX9#$PG:(!ELE$V6Y8
M0!R8V&[PA-D@I$78<; 1' 4BP+%&CCIFN5*4*C>R$29S?A<<>*LX,(N-\ Q
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M$HTONSQ%F/W D=0"+ (@@LBRZ)$4.F"1!-&8+JV"R?NJ12(CP]9)ITC"39(
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M3%;Q'&BB1>C/$/ \E";H@CA-D_ XG4[!XB&YIO:G<ED!R7++\%_K@2=CG0L
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M#5]?PV=;:W]?Q[A_XVP7X_Q -W>V=SI?/I^LKVWF=F^D4O87_5Y>ZW3??TW
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M:_W%3%#>&:>&D1L'0EDBC&<$G-;$,)#$!ZZXS\)K%JK@S0N NI5@F#791Q6
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MQP;Z3F,TFMFK!^F:R:Y?/CZ?=\/4PZW%"<V(X5IDKUO_?<D870ZAA+5&LA
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ME8X3/$I(+!-%L$!B>R"1E_?Y:=N?MFRG4VU M1.TL3>:56!FU)K8KJ[9A?8
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MT$[0F-ZH&I_^Z#0.6GT'I7W)\J >R=[9^/KXT3)^B\=OW/ONV+%UC=UMC][
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M\_#W1&_M&2=5[O/QP4=B(R/<6&1% #TK9UUS5 ADJ:1*PB3C4!^'Q]N4-;:
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MA)?W_9->%9'^,L#\=('>,SJJ-;-*</M;VKGQM5TE_LHQO+LYS5@]?##5E_$
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M0W5N8K.1SH34HZN#-X4A+$4M8I%M$SNT7$LS+09ZU6->:(2^M+ZWJTMGK._
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M\!T;0&?OP-,&G?,R(FLLE/6L;#.?[1HFG_U<<SQ\Q[3I)\9#M2#0'WLT[].
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M9BX/*OUY<@W6SY]H"?KQ#]B\_CR[//_\I:/\^MOYY;LOGZ]P/[OZ<'8)([J
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M* %0'M[K*+VL&,0E30H%QS< 'ZE/@Y@5704H@&NLA!G/F56<!CD30^23J?^
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M/MY'6\JT#P^&0*I1J48W2AG;<@]<C<JU(M?*@B$R^]#72NM-CN5OBMM[D^,
MD(^V?>*\UV 2DT!1"!&T"-C1$H!1->Q1Z_"&SE,AB.$$N W0ABHY*ZJD1#R;
M!V!N&HE5>O!\CX:<1C-H-SUZ"]0#?MRD<03RDY8*#;$9U@#A0(=^SGF&O.S
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MBT(DZ+G*2)7UF<I*X&+\>PZG*@CI>DX9;VBEO^!3YLF=N:@3IF@=A1$,2ST
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MI1?Z1JXPJQ?[2Q9W<VW#_%[S>Q?(2MJTPC6WMN2@$$$3-S WJA02XA\QZK1
MPY2G#=3F>#H364B?' A8G!!5T&$2IXA&@"@S9G##Z%U-54?1JPT[F_^.VO $
ME;X1_KQ,*\2O?7AWBF,@B" PD)N,CSZ'$XVZ-H;'4VZ<31EJQ0-!F&V>&&7F
MU^"^P-$8GO'R%+7I*9'TPY>S&H;#P>B4%4J"^MJRRU!*I#ZF^$L *O1'._JI
MV"228F 8/@^'/)-!""H5R("?:(-+7C^^*F!CL,-2+=AI)GQ2D*'RXHS6X=*I
M6=[O *X_&?B7FVI:8@ (\T$*ZBD%T@G^KN!J8<\""]%//UWEMZBO$E+HB3F=
MS#4&Q]F*@H'-)M*Z61Q07HI3M >U[6DT <ZCR_#W*28&FDLJ._IB^@D'$!8$
M( K@LDQ@5F@Z3?"<,#L.AKS0R6-Z/;23CB:FKQM&?AEV>I&/S= *#)MEP>[2
MUWD-V8Y89XF7*OHR,C<1'$#)FQ23^XEZ,.=*$+F49T)*(\R&^8!RD:(O2'%C
M9>.E#/?YTYD$K7P=?&.'L(MV3/5&YH#(]@,Y,%8@DVR1"HFG,0BBI!R*QFRL
MDR=(>;SA(.G;^[>KSU\N3*"!PPKKIFG;S*&73HLI R_!JH5+N<8U>>DLQNB7
M'*Z&P3+0Y2"3T@4#"TOEA/)[/#29@H,31%5?-LT6T365_@SC&(LEI9HILEO4
M:*F6]#;69[/&IAVM50)Z#OT0 RA.9G@J(]3 <?>I4(@ONE0($A(:@SXI-Z&X
M):4M]QW+1N>9H,LI8:\"[$RJ6V.#]L@Z=-'_@?X;2O3RL8P*="N",C/_1NAV
MW&JS5#"-"@JSDVM,N<+#"4A.Y]/G _CYR^G;W-%#[V'W3LBD71Q&D&M?PT_2
M%G4TU8=>?+A>PV2*MD"6YEUH0W/=<5^4L8U;R:EDV81JPV01[]",$YO PO(I
M<4<5U%$\=I#)C9+C9W&F\+ $&09FTN7E"E"9+M^JZENR"Z]:E4/),/C50""E
M0+.;T&7E6 ;;ESL8,>$+EDU"$._W>036 !RL.9D,#I,':[WOYWB04IVWT1 Z
M[[O,3A5\_D*$3&7W8$Y>%& C>!AY1!O+XVWJ!/)2#!#M$#^A6UC2S6%J1,%J
M,S!0_4&Z2*4&^))O>\HI$$AUJ=<E45QO1>?<6SYK9Q^OI"5+M<H3154MC6 9
M@E#ZAK9:V&,N74S<<)E!D2[?*>(HB,HE !I<89_A.J$EA6G1OBU=6EF?ST'0
ME![$(PX#%4(%(YO#^8N+VZJA[A3%]]D9W@#_WW>4U0G<X*B#^;,9CJPT? (M
M],NHR^E41N\^F@8LQ7AWJ<\7? 9DY6%LA[<'_=8J[EZ,4VM7Q"[7O[[3P,@7
MIF"7F7O*:.9V\A/B<5"0#9**BHUL*@_R+]+"2<N+X'-S/0N_AL.OV!2#3),Y
M9Q3 K0\W)PK1Y[<?4TY7%5K>\&#G?F909^X-3)!O&1-&\$H)\9!CI/\D'5,\
M1=VXLSCDZ"$:HDN1Y5T>!@3MS+]CZ^YG>!<Z<#APV*T[/\6W8$9)S4BFRM+!
M")GT0GMJ=!8S/'/HSV5;>VW%T9KB59M1X"Y/0<:TX.L\*4M^&3%'8*8V.^]F
M AWN.%S"5IE'+<NBZ/F&"KQ/>08/)E,N!&TUU]KJ+@JU0@#7J'A_,%PK\]/(
M)VE&R$VQ)S->_CX0L,7:H%14YW4*_N694BE*$'Q:9DN5+=6RWQ8N.YQD%,]E
M6"^/7J(;%^R?*%"YU\HVJYG)*3# Y0-3-D7!3"-3]\NB>8P+3JJ+]"-(AT^*
MEF7&!@H%'BE/"6EG2 NF52RE9DD?(>O*#^\!*1LZ#P_P8!)?4W+=4OMWN5%9
M4JATQ+9D#2WZ>A:-^CG;>>S$D/X65*24C8@L^'G66<D96=2/"EE97S2$$'&@
M 03L$Y7E$U1V8(#$ .$,?HE7VF@^(4113ECE9EDR$'HK^H<H+$WTN?GH%LA
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MU"(W@7GO8';%:Z< L]' ,7T=DU0-R>0;/\5YIKE BM#0AET$45;'F?]H7DZ
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MO2N0"X;=WH?]^,Z4R?WES>M4V(1-K$16SR"GQ!P_<Q<9A7<]QK)Y@$ZI-C+
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M&G<70,NV M=4W6 2+T9ZJ?9R5B*/%BD22X81-64F;<=*KLK/QAR<QN:U?+>
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MLEL%P==+);S4D82?VV_HWA[EI)3Q_;"JA?S&"SHN>H*&2X=/7Y+_G;JW84Z
M3^GW4,N:^OXCO6US@K7>0;O&_N3)LN^7[^LIRSTBD.88]@Y'QIV51K')E7N
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M_M5DZ1($QX*3@6D1!//.*1:SR&"YB^C,_W?RUQQLQ) E"ZB0:6\*\U8+EGF
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M 87(M!$U@*DB4]H"<DUVD4Q=7_7U8$>C^]:";9W7\1X)TGR(LTVLO Y5<#-
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M\M13]IT,MM:H,,&E95K8VBPZ6&:,0)0V<,ZWNG/G>TC9WTGO6Z;L[R+_IYX
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MMH#UW;-I?R7U8$J_AV_+3@J3E3EQ5SP5G"FTZVCFI4Q,:U LE@C,0!".S([
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MEJ8F)P++!)NLX%B<?@+5VL\G"-IE93J($I]*$'3+UB><@TA*%Y9E+4+,SK(
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MVF@^X.8^TE]S3F%^%Q,I8+F,5,IH2'%HT,.10'PRDN#K#9IS3_EZ35Q#ZFP
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M5K%%@%J&)&6NGD>U&<K9&9H5)-X@&VH#K%7PI .P5M&K;:".9&K64-W3=#A
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MRC+#VX/7A OAJ/6&:<\ZA43W>?ISIL@P(F]PG=/!ZUL-1<J(BWI!<BSQ_1B
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MV<UQE$IJ&90W-*4(20,13&<B=7'@H\\D.87(,T*L?E(-S)<]+G2/1I<^VFA
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MZ*7RF7I#1(B.2,UB:8CA"0>A'# AK6_7P.DY-'5LQHX^DA^\J2,/J8S]9F4
M1L15TT"L*O>=6FJ5L]4LUQZZ_9R:.O;27:^FCGT$/WA31^ V6;-(SO*E?9+@
MQ$N9"+4Y<33O0&7H5"3ZS)HZ[J/N^A)M6"_P$2VJ F]E/CN1<S) HB]#E1(H
MXDU*Q'@4@*4*K:;:V;F;D9P!#RJ*>NN-:N,"S=N$X$F^^WGUHLS=3VE2B-EC
M86O%E^",,$XQ)T62I2E\3!K?7J.-T)J;+=,$=S^OEI4WNU>E?)M@RQREQC@2
ME"O=SI@AUDI&#%"PP@=G;;M.3QL '38X=?5QL_?YU63^]8$L9WBVECC!Q>QQ
M^OK%.+Z;S'?_'?0QKZY1T6_'N '$4M83\3>SR=4HEG_R"JY@'-*GKRGAY_G9
M8HNX3-QYXU"RPI?@5Y*Q9,4#R<J*;"0$G6.G@_'DEG;,'?A0(C^<!7MJDNU%
MFJ9!JE+4.K^5S[LTOX5(@:)A$@7QT2B$J(" 0&O41$HA"$VC:;=M;(4U'"?/
M@3E;?=(Z:F\:L+A%]SZOX;Y$WUOC/T5O7 /*P$9)@&O<%QCG&0TG%DSMLM8N
MN(ZY7U92Z%;"5-)&4\8\[@E\7PY<".?Q#4&+G5,B,QKP3@A%2F]]!$FYRNU&
MF.R$]O>>5F5/JZ?^ID.8-KY)M]@O:1 J&$3'*46<0JN2F&9(YCPR[HV'U&[4
M[VYLQ^WC6TVY_?:X_333LEGA[-X+>_]]VG0E=C^0<7NQMGJ#\>_>3#YC68HR
M.1N/"EP9S4"<-93D&*QUT27E0F7.M5O-\.6MM7R5$]/TL:M85^)XO)9E^HG7
MCALE"(-<VKDS1ZP'B[:'R-0D::'Z[*G-2(YUBWXJ--D\:?40=;6;QGL/U2K[
MK .NMD.<'V$ZSCUY#;T]284#A#XD*8(+(E+.2-*YV!,F$LLRVJ<@M#?6,1]:
MS',9C@Q/W(H/R84^LF[B/NYP9U87-88YQD,FP6H\S)DHASGZ)V #FH%1:J#U
M7<<G81UM-O.!.GQD?]=50)MV>_$6Y:HO+UIR3BM'T,%PI3[8$ALM)]Q&+8+/
M@N7:6\0&&&?"@4,%W#2LM"$QR$D>9$0"EJF.I;5N(LZS1'R$C,9]IAYJ*_\4
M\SA/U *MIKJF<: -.09=L/V=M]E;BWTR\_91P=!YFQ0W6HN;*N%)2R*Y"KC3
MEF^C9M+''*G0SYX>A^1M-F-''\D/GK=))8_94=RY<RI&4G2E'L>0Q(1/> @K
MQVK3XCGE;?;27:^\S3Z"'SQOTP*>HME[(GCQV1 +<<)&8JQ144K0>*R>8][F
M/NJN+]'A\C8#.D@^4$,BAUB2"469]E"Z##&#J[54I-KAT&>1MWG(:U]!U U,
MR$T&]N+8$]DX%20ERNI$I/"Y6,^9".LT#4%G:VL/F]J&Y6^/I+[*&I3!;\)U
M\]YT0=;(%]F.ZCB>2!WM=:#$ :)O<-#L0!@\L&Q#("*4VTVJ,O$.7P@J,].:
M(T1=NQ7'T*1XPO\8FA-])%Y[AMRR:<QR/MF[R3@L?[=(_EK91)1ZLT@M8PH,
MD2X @1PHB4I;&4WF')ZL#.CXK.'MBUIJF;23:6VWXB*$Z?7=Q.M1FBT (](;
MS ^&H"W-8DVSYR(3Z@):13IH/!^%)MS;7!)D0LB^$P7Z/_L\*-%8Y@U.B/LD
M?D!=E8*F'O>_R$6QD,-B4#(GQJL,BH+5U;NF;,/R[+E15=@-W)''M+W!)2$9
M+S-"DB5?SEM+? R*Z$ I)&YX-IV:S?<@P38L9T."*L+>ZDC4JR4L+A4Z46D<
M$"*,(_[@VVB^R! ^H':PPZ<>6BO8%_A:;6#6,4?EN5)42*H]JCK@5BPY@/8\
MRLL.GW_HP-;9[,%#?KO-272E!8Y""X(Y@09%M)'88!A1((P7E$I8+^&N,+AU
M&YK#IAJC6K\LWJE/:3Y?YAO^ M_@2YI]FEQ_^3I?Q  NF>0\2>T(9U255D":
MH!XTD?@*<B&HITYT,DFZ/6_X7::2LA\.):XOVP8I&9M07GR;7./7/P&?$<LX
MQ\61^0&F\Y^7,3(9LP[$A(CB,&@D09FR:X(!+[A(W-5N9-X3XK-GSQ"J:6#$
M/I3"SP\P7]2Z7%VE+RE>_7P[SF6L<XKOKI?=_(/A%GPD(A?_'G@@8+,C(ID<
M\V(B;^WN*/T0G@^/VBFFHAE\,\C] =0EHO?Y-_AS=CV:SRX54"N8SR0QCYLE
M6$,<<$FR9T$S _BE6_.4)Q[T['5?79H-@N9;X'VX0GG-1SG/+I/V,1FP1/'
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M*2L"6*ER]7Y&'6"=*TL.5L$&FAP8<]Q@3=T&0Z:C;S#]>3']LNS*=$FE F4
M". V5T(BC$#VD40K<<NS00-T<U7Z//79<Z&MG#<PHG)L$@6PS%U6P@(N61//
M2XNVN)B)0ATQ@FLI>6(BMMTK5DB&:LXSR*:PEWA/I:O.IVL_2_]U75RP'_BE
MY+XO\E=5L%*X<M9IRDJI/6YGTG"BN/56.,4CU+XHW0+E6#4$-92\/@NO@K ;
M7'UN@+4:V-0!6*/L_ZV@CC0-KX;JGJ;# 7(?E!B&NQQ]9H3'5'9/E8EC+*#W
MY+U5^%(X(9XW(9Z:B3<H'_J(NST/;G(-O4(SQC!)G"_W:QP-8,<9.M32FX#
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MT_<G-5]6ZV^@^:;F.$_"_/3L:;XLUWBP4IQX/-HK?A*%ME+OEW#O23%6_1#
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M*8(!13*,8HD#Y1:U:=?OU(BQ$1LT<N^\J-5%(SIH9 >?REPXULVP'0D[.AP
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ML;B!NJ,[L&3?P+P5T[K"LAOB%H0\!([#NQ)K4<&+M= _:EH&6[EK+^-&\B&
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MW,]^'$?"U_F. SV,>X;CN(K/SFET7-HSD6N^R)=J;@Y-O=?3^^(FURN )H?
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M>?R"'IM.;_^^TJNT7Y1>NLF=\["W>JC4^\5K5I:/VIQH_"HBB@72"R>(<)1
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M2(5)*C3EFQPTB8PA#X( 9DE"XC2B&2/<J0Z(1:=38_T3-3K!;VO!':-LK0;
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M#T\/']7L;G7_67^O'M3[^4)5=[/F"$\\[T7 3"0T9 !3 O+")E\E9G])E52
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MX?@)R.OB?M_9KR_6"7$^V_7Y^CYO/+XF@BN<\Y2!E&408":M/<4HR%66&MM
M**B%3T:Q*^7QXI(!TH\U^:O%7O[JJO6DFS89JMLXD\5!$N&$R;\_+5?;Q"$!
MA>&O'5PW:V3 (>N9TQRRC;?528U*-TFK5.])IR(!/$ ><1=I1I,WW ,ZGSSA
M/LU>D=CQPW+YI.3;IT4UN_M2)X7[7VSZI-9U>92TXAG9FK.2-#?[,QOXA_/<
M[GV+ C"H-,!8$K./8U(IY%7,T%N$L5EY5O@ZO=[A5JZRA_6SF1+UW*[KJIK1
MKEF!S9[;[)'+-GUDPGZRA4P>%_.[!7OPI.> <71CY'Y'IV<2_M;LL!OQ;Y):
MZ)NFR!>HY3;\^FR7Q>1VL;#QG/;G=:&']_.%5M7J:1'1D2$<S9@Y ?T$&#YG
M8!! )W,*AK446F)A7LU6GV>J_MD>U,]6G^8KM7S[9 Q8#-LM&\52%RGEH,S-
M_V!"K#L7S(!D/"U2H4N)G&I/^W4[-LK,?X/YOR8S*V<BGU1B)4U>-;^M?ZY5
M"+KG<!\*ATN07@#NF?6:J@)6Z,1(G33_;.1N8$W>KA'O%5[?R@VQ81ZTB$,<
MN -*._B@=KG*@U-K Q=\\-'PN/:#U]N!+KV-$;$T%L-7]6B^JWNSM'S6.^>J
MDT)ATQ\D0$-% "[+$G!%<L#S,N=2I92DV=J?Q<ULOMQI@%-+SZR_%?3XVN.5
M'98$IIX!3 [8NQFZD? <ZL2T$;8.I=^*:T'=O32)Z('KC$XLG]O+'0[K9>L,
MP)%?K?N;8?3S^FE9S=32NMOP:E:O=F_F,YM$PW1K?EI6LDZJ,9]];)/2/$]*
M5A0YQ!E0)<J,%<JEI2(*B/E?*!4J,@;]KEX#I!C?Y>Q68KMQWXJ<S/FTNJM_
M]-R8APR.UE!HS#)0I+9D,9$I8"7.@8#"[!"*3&"._.M ]#Q  Q:*V)2&X$U9
M@_Y'1&E*6*$E,-," 9RR A!%S8@47')8PDQBY5LY8I#QZ+^TA.EAT*%P6\U[
M!K?GY7TM?;(COG5HW9#3G@8WR4:'> O^%0!&L@!")!C4)+@"HD,;X9JF0@_^
MC;UO[9*Z1-1G71LB=3FT3$*NS'8%X((;KLL*#4B>(R!Q*EBI*"*%Y_G^F9[&
M=B95RV=-Z-;A**#TW'E474_;(V#5,SGYP11P1'X!@F@GX>?Z&?C ^X*ZQ^?:
MEUZXDA"^V^O%"5-I6E*8@E2B%&!90L!+J8"0'+$LSZ@F(H@%ZN;'-O4WTB5_
MU?*%3OL&.\^Y[HU(W[=FSF"$3^X]G6//Z*;QEYG&>XJ=G;O[3X568>&K;=6$
MM2?75]/#.ZU5G32]/?!D-L62X@6$9E6G$)D]90G-JFZ> @Q2"<WL3CEWBID)
MZGULTWTCHDU.V;@;&NO*<_/BA[\;)_2&:L^446<#V I^LW7CM++?)%O M^+'
M+,82@%JTFBP^?0]<FB4 EN,*+2&-^!=J>=M>UOV_3VQA^I@^?U6/\\5J(F4.
M"4$E0 4N 6:J!"PG!%")2FFH2V>YDQW2T<?8V&DM9K*1,VD$=2_,<@[-;A:*
MA%'?7.,-CU<AE@L !-5@.=?F8.57+BBU6WGETJ-AQDJ3@[8MX+)):2J-59*7
MJ0:0FZT%3A$"5*7,3.XB-X./$)&>2=!.]C/">X9&P#8AMF=ZV--8NAD85^/3
M\^1>5S59 ]1'%MA.#"*9!:?[&'3Y[U3S<)GO?M@_#NRK]::L#[Y(8387F9*@
MH"(W&P];?EO+%%!!--6*<YHIU[BO3:MC6[+MQJY:KBK!ILD?BMEBF\T&VN,,
M<1^V[ND<#,8 1P<!.'B%<AWI?47HUK:MP4*UCL3?#<TZ_F-H<JVE,B_=W\[D
M6_5#3>>/=ACJ27YKB] LE*SC#K[?L]GW^\7\Z>[^Q!7$?RZJU4K-/FL]H31-
M,5+0S%TJ[,U  0C+%4AS6!9*ID4NO(X/8@LX-D)8*Y%4,_!H$ZLME\FBU;D.
MP9);K7T3?$4>6C?#X24'K&?2^KH[+CO*-94SDLU0-B%=*Z-@TFJ8G+ZH;;4$
M<ZUCIB7K9P"B)32++-[ J=#Z ?<XB5I/_80N$_N!HI^?5I_U3B["<[%I;^</
MK)I---2,2LH!RVQ93 D)H"0K %.I++C*:)HSOT7A&G'&M@0<:I/,G^IXS]U<
MCQU1HG\U6GFG?[QJ1%W7@J'&J7?F[W>( D@^!K+1*/TJ808F\!C '=-UE%9#
M2W/:3+!GZSF]^R6F3];U[O?Y7/ZLIM-)*; AW+0 DF0IP$*5QD9'&"C"5:J1
MR(CV2DKE*\#8"'@K_[E*=+XU.#T'Q(U-^X2Y9_[<0?A,?>+DU4;^9*W ^0B/
M@)J<8=A%J\SIV?W ]3G#P#FNTAG83IS$X#M\^[9)C3U1/&-4(P9([:*8J@+0
M(LU FFI-4\$E\ZL7=;G+L7';B83AU^4)/X&RJS$8$[O>#;[#_.&O=I%L!8Y(
M4.[H])18_$2'+YID_#P EQ*.=[P97/O<V&H;GZS7303#MWME-N,S>2ME7:F;
M3=]62S&=V[/LY>MG\X_'^9)-?S>;\\>E::+A/OM,[;#]9*S"Q]97>UF?Y#.)
MF"2( PVM69;IS)AE1 (I!!="J0RJS,\L&T+LL1'>6H&DUB#YQ.S^*\!#>Z!!
M=S7]QC:4??MN^(]B2)WV 4&-5^-]"*&'K@\_X$"<J"T_9.^!;C%"S)]FJ^57
M)53UPSH%?U*K]A9^DA8%4K@HS->2VP+**@<TA;E9/<JBI%H5U@7?SSNFH[OQ
M.<E\7S"I;#+#5M9EG>#0TU>F"V!'EYE(H/7M.=.*F6SE7&>RNIU.YS_K!&4V
M7<";A3+??F+SRVW\;"(ZUSB@%<O'IJNK85UM')0^\KAQ>2<PE$?<*_ED*WAU
MU(-O0E54*E I< 8X*S7 5&'S$Z& 9BQ'JC0;:H2]PGR<NQZ;@;F6W)[_O^\^
MTPJ+$7(?%#=>Z@?JOAV$XJ'L'WSD#5BLP"3WCH<-6O(&Y"B@R;^%ZU(L?9^W
M]^1_;$I];JL23BC+"EUB;G;990%P*0B@& E04(P1E! IJ,*R+'7VZS2_!DVT
M]&4WS5*,JJA.\+OQ5CQ(!\ZUM)JO?8&2K<@[-5#C9UMR@BARPJ7N/E\DYY(3
M#.?2+KF]?&7,]+LZ@Z^]"9[/;*?U&9"09<Z*4@&F"0&82PY8:79R#$/$8%ED
M*?8J9=K9V]C,J4;&9"OD=?D43@+L:"?%@JUGGO%&+#SZN@N)V,'8)_MZF=CL
M+K7/AFIWON0?&/%-J!E;5/,_9\M')2I=*=GZ7F%1\A3F$N \+0$FM 2$%CE(
M$<:ZI&4AA=-6K+.7L='$6E!/=[=N)+MY(1H^O6^57*'Q"I^XJ/H5X13GVQXL
MO.*B>KOA%I<?]I_@'XUAT60*?&,,\.^F@?:K9&E*9,H1@(S;$(K46 *,()!R
M4LA2*:7=(IF[.AG;]-[*:0OP^CJU=L)Y>9+' *GG.>Z-C]=4OP3 %3/];-.#
M3?1+RNW.\XO/AN<K>%\M!9O^;\46[\UOEA.<X53E>0:HU I@K#C@-$V!T&;"
MI[K0N9L39D<?8YODFX#\1L[$"IK4DOHG+#B$LWN61P*I[TMO?WR",A:<0>"J
MC 6';0Z>L>",4J<R%IQ[-#2]TJ+ZP6Q^DTW*Q?>L6M3U0SZI;=Q]*I0N"PA!
MH9"QW1$N[;)NZP&+@I522XV)WRVM8\_CN[!=B^M]O.B*M=N&OP?\^F:(C<3;
M5*XWR;<G_G<E5O;<\0^VM!>Y1GJ;$W2_6A%7>KY0R6>METU!N3?SJ?626QBJ
MZ2-]@B>\T?(LN?4Z<(8E+RB.<ROYO1Y&9/9:F2WOORSF/RJIY.OG/Y?VCJ;U
M8YG=W=HD3O6DW<PS3'*D"IJ!3%);K<)L53C&!4"IPJ6$L!"L].,T?R'&1V]6
M@41/YS^7B?T4DOE:^(1MI/=,Y1(P-FX<V"_>/=.A+8Q9@[T6/^'/R2NK05+-
M_I9LE$BV6O3"=.$@1B*]  $&Y;]P@ ZI\(J6KKRZ^5C-U ?SXW*BB.:PD KD
MA8( 2U0"7FH)",P%P12FGE$EQUV,;>>VD^G5RIC40H9>T6R!]+R7"8*G[\-7
M/V3"KV*.E(]]_[+MX&4N78X4/'O3<OQD0"'&[P:_INC7]Y_S_Z,6\VVUKZQL
M"]-Q0<V.+2- <5T"K&D*&,HTX'DA"E) @IC31'?M<&S3'OV6I?O%%[,R>=7\
MMOXYO/BB"_S=]- 'J#V312UM6P+0R)M8@?=*_QE(>\+2H\9B9$P'JJX8!5N_
MLHH>0'465'1I9[A2BAY:[151]'FOET0'KY__8'^?+^IR!UL;(\\(P3++ 1,Y
M!QB7R!AKD )<:&U^53#$O!R70X08&Z\?)3PXX50;;.<%C9*;)=@W]CW3OT,6
MA'Z,R&MP&R8#PFD1QI0%H1,DSTP(W6T%&+.O5?6[FJEVK<_R(L]X8>Q4K3.
MD=FI$IOI)<U(*;(B993GSF;K7M-C([+Z!)O/%\V1.-N>=B<_J]5]TLI^DWQ<
MR=]"+*M]7!WLT6"T>J:>5J[K,?"P(X.Q&,AB=,;$SRH\J7:G_;?_QG"6WDE)
M]VRZTT\$7B_,9YN#\";F]MVO1S5;J@E!*878ULM4*;1%,Q6@-LHL)84JJ410
M:B\3[6Q/8Z.O)F7<*]5(][>DJH4-B%X]CZWC+4 ,Q/H^[-^1<9U8[U4K9L1$
M+!>AB'5D?[:?84_F+ZE[= !_\84P>NB("_M],5\N)R37%.4I!;G,2!.XQ1A*
M05GRE*$R(SKW*C=YJ<.QD44M5"*,D?-<7R4^U%'!?CQQ$60WNH@)7<^LT1T[
M>I/4\L9C#U=D(I'(Q>X&Y1)7Y0\IQ?F]0&99NTJ\WGI-_$=E*&PA[I\_VNS*
M=9"09!*5!<6@%'D!,#'V"%%E!CAG.2UEKC1WJC_AU^W86,:*FM2R)AMAZWSG
MGV[_5U!DEB/ZCL03'=.^Z><*./W)QPN=6!3DUNFP1.0%Q!$=^;T=Z%:@IE.;
M"M/LKA9L6B<:>C T:%T6[%G&VGR'&,F480%*3DJ A5" ER(#"@N>LY+@@E,_
M!RNWCGVFT#!.5:W<-\E=(WD]B]B>[)[^"&XCX$9,\5'MF9@V</Z^ ^>^T$DK
M=41G!B^48CDXN'4ZK-.#%Q!'CA!^;P><)W]5CVRUJ.H#N._LU^?9E\7\T<SQ
MG71HYM>30FF442U!(0PG89U)P-)4@;R$.249H04IG0^:W?H<F[VT*W6R8K\2
M\Y_'5G!#3VO)[9\\SEP=\7<XD(Z/:L_$]** >IQNQP=VH&/O& #[G8C[0=5Y
M5.[8U'!GZ'ZZ[1VN>[X:0..?YC_88E4MO]RSQ0.[_;V]PRETCG@&&=#,AAY2
MP]C$UEPD&!5$%7D&D5.BX8X^QD;3:RF31LSD]G</\C@#HP/[7@].[X?JA[B$
M7!&> <B#3:\':B#V]/B0_$BR&X%.4CSSZG DV"W['NE=>#1L,VU3E+ZI\^Z:
MS:&H5)L>L10HS2C7H" R!Y@@ 0BD-F5*3C66&2&$^ISHG>YF;%1GI4SVQ S+
M0WD&5+?]\/50]4Q\ 2AY;W>[08BTO3W3R:#;V6Y%#[>O%YX.HX 3U0\W?:S,
M3\M*MNFX=V)BEV_N[8\?9K?U9=IG?>:53=0EG% M,I6G$"@AA&62$C"$(= 2
MY412!AF7/IPRD-QC(RD;N2=J)99)-4M^L.E3DRO=CZ.&&G4WTAOA6/;,HJ?+
MVFXU2/94V U'MRG%:\7M\#>J-R'IIU^]V<:[Q^/G@<<K$N$/)?6@*\C 0W&X
M) W=?6 1B!^LFMJU\OU\\8U-U5O%5]L4I3MEC^I;\S]G"\6FU3^5M ONZSKY
M0WW&!6%&E,X!4X@ ++$&-$LI0&6)N?G:4H+).O?Q=_>%+(IP3M2VGR#Y^V"N
M-T\;F9.I^;=O[I(XH^>V$@TW&$/E/>&KG03*-\E&06"$!5;%F[UBO,V(;15K
MJUBT*5"^QSC:[ 7K6!4OHL@T;&F,F# >U="(VGA@9OK%7#Z)57LV1B6!!484
MZ%3D  O, "50 4JESHM<YI1YG4WLM3XV:[\5+ED:Z)>>!XRGX7.CP6!0>J:S
M-1[Q(@\Z-8Z5^'VO[6$3O)]2ZRB1^\F'0K-^S,4_OJK'MCR"?&NH8G;W12VJ
MN:P=@B8IDRR'L@ HRV@3N<!4D0.14B41+9DB7NZ"%WL<VZ2N!4X66XE]TX%<
M0MAMCD?%K>=YWT"V(VS22)LTXMXTGH(QDX<X8A,ME\BE_@9.+>*H_G&F$=<7
M0Q*/_)SO1LF;5H79,:Z#Y=O?FO]\4S_4;'V31DHE:5D"DJ$,8"930" 3(!64
M(87,;L[-6@@58&S<DYU,3))%24P2,#P.-\$]@]XS<=F$&@>I-5H-=E)L;/YD
M?ZCU& I_G^0F_8[#4,E.^AH/SP0HX6!V)T0):'? !"GA6N\G3+FBG3"K]L]O
MW\W.=OFT>'Y=3:?;#?!Z&NE2Y$J;925C&N"\CL--S4\\E1Q!!7E:^)BTW=V-
M;4WY\[=OOR5K@1-N) [=JEZ V<VNC0=>SVO#G]^VJ%E1=\[I>MC@NL$2R9Z]
MT-F@QJR;XH>6K.-;P46IU^=F=22[K7VT4/=JMJQ^J"8V>.UQF&6YRA %)84%
MP(AD@!<T!5+P%)>91"F'/LSBW//82&;WC'I>1_^+7='KBX5 UG$?C52B0A09
M!BEDV/ \-OL*10N "(&\0$(6,/.N%QY_/(:)*[K]_.9#[X@[WMKT@6+/[%_#
M=[M:+2K^U-2Y7!E;E"WJC*C1V=\;H7@5Q!W[';J<N!\<)VJ+>S80ME)\5<+F
MNJIT)>J=T7NCRNU<5&T9\^9D97/1LOLY?9\W'],$8U%PI'*0L3H2$DO 668L
M5,7+E*2<">:4U"J>2&-;6PXU2IC\^]-RM:E)VV27\:.X" /GQGW##D?/I'@T
M$G49 $N5-TFKT.;(=WLE?7.&1^/19SR0(_%J!($&)=QX !XR<<26PVN4?5\P
MP_RV^Z_J<;Y832@7!4-2 V.^&[M=\PP046A0%) I@73!H-.Y<U<G8Z/1316N
MK:!)(ZE_E;(C0+O),!9,/=-; $)!=<K.07!5H;*C1@>O5'9.K5.ERLX^ZS_)
M/QK,IU_NYS/UZ:G9E)>%2#E' ,.4 TRY,A95*0 K=2DR@7E9.%E4IQH?VZ2N
MY4MJ 9-&0O?)? 3<Y4E\#1P]3UX/)+PF[3F5@R;K46.#3=)S:NQ.SK//7'$;
M_*ZZNU_M7 -D*8;U54![@L#27".F%" 2IS81C-G^"%MS1LI,XTR69G?D?0-\
MH=.Q3>+L-W)PZXNAO?4E]:VO^?GZ6]]+P^!QTQL1W %N=Q_KVT1E94[^:2\-
M']O[Q"VP?>(:<(,;$=\!;VT=<(Y\.>N(D].%[*6VAK^$==3NY,6KZ[L!M/Y!
MFO;,9LYNT YS&NX<NMT^&)NN^F?SU4N2:RDR"5)E3[BP+LUFJR2 (I@C+7F>
ME7 =F.% \@$B.,V9_?"+ >]+V(ZD'A04,A0.--\7O .5HMB1_D09BEW8;X>#
MW6,5Z!G^@5:$O6&HML/ FF%@9[[^WR(M$5> V+E<A+0[W-)QA=9[R\@U[81=
MHVRJ7#97,S8Z99+A@A<84Z"QD@!K(@'-2PH$(1H357 LX&0U7[&IV[W(B3Z\
M]@&;GOJ;-=NZKB%7&J= =+NCN!*:GBE]B\HZ.;X5,&)F_ [U(UT'G.IAT//]
M#A4/#^R['@TM;R:LKXYZJYK_?IA]F/TP%#-?5&HY42579G*G -;S7!(.>%E
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MHA RFSS6W\FW%5NLAAV-PX[[&Y'7ZJZ:S>S&]S4S?Q#&0&LDCX@U2QE%*<U
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M42F@B&J%:(F8= IM[.QE=,;BCH2>@3;=:'8S0#2,^K;UO.!QGOA.ZG=->]/
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MG7S;Q_7M>B[T"[!OH;SH0 ]:&R\.X &5\+Q@NUS\SJVY@>O=>>EX7.+.[_6
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MFR1DQ7[Y7DH[C8(;=\7&MF?6ZLBB\NIC ^NG!E8C=SS*\D$I$EDY=3DH3?F
M<$A07N\&)]H^;'TS%[ BDJ%"@BS+",!$%("+# &4*YSBU%8(0CX.,QU]C<U#
MYLT)"O).CGT66#>2B017S]SBR"HWR>UJM:CXTZJ^0EO-DR]LT57)("3K]26X
MXN6W/MO3T)FL+ZE\(F?UQ5?\F&2Y6$T^5JOJKKZS>L.6S6%F*J34&%,@,&<
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M8GPC^2+"HH6#3%)KK+%?#H:+5 Z"Y%Z<<QB*$5;+![NFJA:YKC_N3?GSUGX
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MR%X@"7A3_[;Z^8+"3P'3X6$[]@1RS]JKCJ%7,?6*[]-!=1*5PQ "<DCAIG[
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MGVF"T.XB]7)5T9P@5A#)-87""*NIJ;7[!<74JNLD140P;55Y2-WN4 :"%/(
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M&'F5SFD?:?A2.5Z2'2V-X_=F>(+(V[DUTS;7/J1)39Z2#&)1Y)!P8X_3>9)
M:U1*4?"$(N-5R?9@Y+$IXXHYG[L>9P!KUZD7P="SZO1&("CQXZBT41D?^R,-
MENIQ5(#='(_C#\1&',7JX\P.56GRJE3U1&J68YP8R 2W9[P\L4O0" H+20O$
M"R&U$F'!Q@,:8UN,-_)>JZ>I=KD7G^:S.VB)/@#'.-AROFRJNP=6ESX&L6\
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M-E58,PD:+D'%)K!\AO8@? EDN]KJ!)Z>-5(P,A&]!D](?T&/P9<C#MQ;\(1
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MH)JW4QA?:NEN![^H0>Y-^?/VQ_QH#T:$UGDW HM,R0PB4Q4QUPIRA!*8&7M
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M/'XMG+@!Q[(%Q^CYN+;PKZ_;N$^_-)_U;V_?5'_1/\QD\[=O_@-02P,$%
M  @ LIX$53UX2<\RM0  JA,( !4   !A;6=N+3(P,C(P-C,P7W!R92YX;6SL
MO5F36SF2+OC>OR*GYG50B7UIZ^YK6O/*KE+22,K.GGFA.0!'!+L8I)ID**7^
M]==!,O9%7'!X3LBN5:5B/\>7#PYWP)=_^1_?SB:_?,7Y8CR;_NO?Q-_YWW[!
M:9KE\?3D7__VQ^?7S/_M?_S;/_W3O_Q?C/W'\X]O?WDY2^=G.%W^\F*.L,3\
MRU_CY>DO?V9<_..7,I^=_?+G;/Z/\5=@[-]6?_1B]N7[?'QRNOQ%<BEO_W3^
MSR9+ER X%IP,3(L@F'=.L9A%!LM=1&?^GY-_SL%&#%FR@ J9]J8P;[5@F0<H
M*5IP.JX>.AE/__'/]9\("_R%F)LN5E_^Z]].E\LO__SKKW_]]=??O\7YY.^S
M^<FODG/UZ\5O_VWSZ]_N_/Y?:O7;(H3PZ^JGE[^Z&-_WB_18\>M__/[V4SK%
M,V#CZ6()TU1?L!C_\V+US;>S!,N5S'](UR\/_D;]BEW\&JO?8D(R)?[^;9'_
M]F__],LO:W',9Q/\B.67^O&/CV]NO!+.3G#Z]S0[^[7^]-<7,\+"!SBIM*[^
M=OG]"_[KWQ;CLR^3R^^=SK'\Z]_H+Z>L*I5;Q>L;_^^K/_[UZN5?YK@@O*R8
M?4O?V#RCOFT/0O#;$J<9U]Q=O&(R2S=^:5)E.YM?_.4$(DY6WQUE'(]63WX6
M%\LYI.5(>N70"<%$-HGIH"6#9!.S:)*.5NH4S4V^*\T+(GJEB@6FOY_,OOY*
M#_ZURJ)^LA+*2B!W7K<6S'YTOYHNQ\LQ+CY#G."HR 3H@F: *M*"<)[12G!,
M>J=1!\N+/XSN&Z^[2?=UE3Z;IU]F\XQS,AX7[X-YNJ/>F\#=_,:O7V!.#V+I
M=#S)%W]=K4@+;2UG+62WU@S1^[=?B.V"\SGFMVO%/,C=BK4EV51<_>;!2O_^
M=KQ8DD%>O/J63F%Z@L^^C1<C3)XG8H0I;073"3@#FXD5#8'8R-&I=#@"[GUW
M?W X0)&WX7"X5/O&QH;NE[,S&$]'Q4<E;(XL&05$>10,8D&6:#M5)B*BDX?A
MX<;[>L9  ^W-FHBR1Q @43WZCW>_?1H9)[1P3C,K V>:<V0^>\NXL8@A@'!%
M;:'[^L"U\NMG5]J_?%&/2C] 0[-#Q-6C?L\7[ 3@R^@3B1BKT_UB HO%^_)I
M.4O_6.&]@,%@(+"H'#$"B: N56!>0A9.$>1Y>$3O!19Q1?7F31O=3Y:+B^]<
M8>"'Q&R%#3G,3:&MI < F>OT;Y9,3M)@28Y!D9HB+:3/! G'9JM+4LY8%QMC
MY2X5_1B0QNJ=-97U$- R.SN;35<,_(YG$><CX-(X9P)3H5!8GJVC>-M%QAUX
M)0Q"U- :++>)Z!<KAVKU-D@.$G&/&*EA_NB9_#OGGW ZGLW?S9:X>'F.I#^[
MX<07XB10&)9H(R:Y:,\@9\.\2D)AD3S<CD3NGAW\^#7]["^-X=!8FGU'("M/
M_,VTS.9G%P<\^(9,[&(4K'75F6)&!4)W,IP8T)9E9UQ,7AJ>Q!8>Z8^BT_O>
MO150U# =D892[1D;%P?%G^EW1UZX:'UV3#FLF.9 #C<F)J40)GJ90O0'H>'Z
MV_J.3 _7W*R!& >B_O_W'.;TQ,GWC_AE-E^.E':!>Y^8H<V.:>2"^9* 4<B%
M2GNDS= U0<*M%_<<G70#BD.$.Q!\?,#Y>)9?3?-+<LU'"L$4<$!.4-U22\DL
M)%68(/?<!JT%:-L$'3=>V_.&T0TV]A?L0)#Q>0[3Q;@*98-N[CCMH;2+%I^0
M8C0B'YSR9 (%H([D=>%C >P.F\BM-V^%#_W$\'&0> ?A=[X>3_#=^<IG#K)8
M[YQ@8*-G6A=@@0=@UO*44\ZYR,/LQNTW;@4)\T0@<9 X!P&%CW@RKE>$T^4[
M.,.1=)"*\<B$XB0(KB.%4$4S;CTW/.@<\F/'HMO"X>9;MX*$?5*0.$"L@X#%
M"Q+<'"9OIAF__2_\/N*Z1".38H++S'06NOI'CK9" 1$2#[8)+FZ]=BM@N"<%
MC$,$VS,RGM'FE^L&^'H")R/CH"2A!9.VD*4+D;,@<Z)_>(W/D\SR,)_BQNNV
M0H)_(DC87Y #<3!?CQ<))O\?POPU?6<Q2DH&H8MD+F,]S[.<132&'"#2J'>@
MN&T3FMYZ\5:H"$\$%2V$.RA\K..H-1/1H:%M+S KZY&]B+0!"H-,>>'!A>!E
MR@T1<NW5VYUI\2<)DGTEW#-,7IS/YS> ?A%K$Y4FFDABD+[>)0K#@G*$_,*C
M#"0?A=LD8SR24OC F[<#R5,Y^6PBWT&XH6^F:3:G&'LEF-4=](O9.3E0WU_,
M,HY0:2V%R"PE,H\KK[I>]3#TV@B"O??V,*.R!1';(>>I'(^VEOH@0/09OKW)
M),MQ&:\SQS>Q.BC+L=X]II+(]7:<8O7DB9%,7GCBWDFK&\#G@==O!YRG<G;:
M3M*#@,RSG$DAB\V'*AXQ\CS$4')@R7I'D5HMJ0! AK)8"SG8!(\E=FP+EWM>
MO1U4GLHQ:AL)#PDF+^C3]_//L[^F(T!CA22[& -0,.>S(J$(P2PW/D)UY&V+
M<Y([+]X.(D_K6/4PZ0X)(*L]]/W\PWSV=3Q-. (#J@B9F9.:@,Z%9['XP@H9
MR1!U=%$>F'#^R-NW@\K3.FYM(.<AX>7#;+&$R?\__K)RN')T09"S1;( RS3%
M=PRT0&:DDARRTV!*.[3<>/=V6'E:)[ 'R[COZ+GR,$=8T9V,52HZ0WLD4:NU
M$@P2&E:$CR*BM2GB0=BX_K;MT/!43F'WEF//^G\[JR<_I[/IQ9TCL5]DQ,1*
M<(FPNZH!-L *MQ21$;+-@8E!M]^X'0Z>RKGK0?+L&0N?,)W/22!"QL_CY01'
MRI*ET@X81>2<:5/(CI&+Q&+42F+@4N7#3M!NOW&[[+"G<KQZD#Q[QL+G.=3>
M Y^^G\799!153$7;PFP]Y=,Q)!9YYLP*K\#'D.G_!P'AQNNV0\%3.3_=7Y(#
M,0<7)7^KW /@.6M%]LN8>N@K P5-&H!E+R IPV5N9!*NOW4[0#R58]&#Y3J(
MX&)S+;!.6JOX)H74^T63-9"#RS $P;0K-?6UV)K@*,&XG 7P@_#QV-NWP\G3
M.@5M(.=!X.7-E)X&:3G^BB]A"1NV1EH7Y86N9W-$O>:\,,\EL 12*!,5V@/[
M?CSV]NWP\K2.0AO(>1!XJ6F0\Q>PQ)/9_/LH!LV]]X9Q[BBB,CI01 6"*1YE
MTH&"J]RBR<:-EVZ'CJ=U"KJ_5 <!BD]G,)D\/U^0-!:+D1+&61XML\[):@/)
ME\K<L9"+22'&8GB+HZP;+]T.%$_KO'-_J0X"%*_.<'Y".^-O\]E?R],7L[,O
M,/T^2D5@(=X9<D,BB03P %&30Y4X.HY1Z1:.R+TOWPXD3^N@\W I#P(LGTYQ
M,KF@7J5 ?&O/G*E-[Q1$YFE79(&,'X#.UL<6-R?7W[D=-)[*J>>!,AT$(JYU
M!/AT2D)<O#]?UCZ!-6@?B20T9N%KL;!BVDO'HO:%Z:QDU#;'W*2@Y3$:MD/,
M4SD?;2SS9@CZEU_OB)>8_<>>S1NG&:<+S/3)8C89Y]J@\[+GR6)6ZEJ9XRG]
M#GGI-3_J;,\^CWN\IT5+R$/9.[![Y)TV,N_+^BW/IOF>=U]V+;1)\Q3(J4DB
MU^-71Y@M]!GM5,)E1?_CC\6:!W5IVH[$0QO(O,/E^H%O9^3)&<Y]1B^8"!QK
M9Y/ 8KV5U"(4G9VU2K?F]P8! VDRU $Z;G>5V5_N>QNPKSB/LT9]A]XO3RDJ
MO"N;R@VQ]KY\AF\?ZO$3:6ZYG(_C^;)VUO@\^[#2Q*4(M91H0I04,/B:F2<X
MB\(DYG3!8$T4(K1N;=6(]'Z;VAP3JGWH>@"MM1YB^_5LCN.3Z?J8+'U?56/7
MTS/B?II77TW6,,C_>;Y85AUM(:11E4%)&)G#NNZ#1.9#*/2ES9E[^NZC!8XM
M%T(G#/9KV7N!\);+J'\\#7BQ506]@,7IZ\GLK_^)^01_@_&T?O-9H9=_Q%2;
M>UVF>U>!D5C6$@!(6C@;68G>UVY<F07PJ;9SBF"=UKD\EIK4>FO9CXM^=YDA
M+YLC(6/ :^/95QA/JKPIV%[ !#>WQ&-<[&8JHD6014A&*J+ 7'.HK=DS0T72
MB,II48[E@S5BJ9^V0$]AU?2!F;Y;8#ZFC]7/JN58U*]P&_V,%&233:PWH<50
ML.8U \\-$YHV7&>=0GFK$.>!IIF-">NGV=$04-^[F@>\2VPI_Y&+2;FZ'UKC
M*KM),H\!F'%82DTZ5;+UT<^!)/?3R6D(>.]#Y_M#?+:$2:MFU[<YO>!RI$5$
MYV1DP2O.=)*<@0;.L@LV "J1PV-=:_=L>_T0.?TZ(,<\'&JEDV;P.NJU3(<W
M,<>[?.GPOF7]Z,N772*.\P@\1,V\-;Y.>_$L*N$9"!E-%BDJ>*ST?9_5^@ I
MS29\K#M'&QY+S-(Q;[@FO]AYYB/GS!90'D$(HQZ[_3WHPJC'>5\M]?W@9(_=
M)=RC6[:8+T<?YK-\GI;OYY]P_G6<UH..O-"@,^WWH?#(=#".1:,+?2DA"(C9
MBJW\+'K!-7305U?(>.C= [E=VT./LX9"'08H%K0G;SA8;*82",ZY,TZP%&J/
M<(.R5I=[EC'IVF@K&K/5%<!VR+A+0#_P:*/3NP Y4, #B.@VC&R&2TA1O#.^
M=KR1B>($\J-B=ID\-4D1!"0?W6/YS/OL+#<(Z!T=ARITUDJZPX'&E416D>"&
MEY!,5@9J!\="O%2!1*N!<1LM "TKFUN?YSY&3S]7&)T#YW#9#P!'EWORV\LT
M/2>3!>%K0JY6M?HXL&"M9;I8C2)Q44IKU_PN%0-)KMC?4VDDX % Y"-^Q>DY
M+JXF^=HB/#>66="U!(3$$7G,3&0HJ)02 5MO1+=I&(@CNZ=.9PT%/(ADL T'
MKTE2+V;3%1-_CI>G+\X72XH&YZ^^I<EYS=-]5H_>%UAO8BDBS 6SD4Q*18N*
M^&(>2'9.""6* \WS8\46!Z!H%S+[!=IAR+@?9ITI:0"FZL5LL=KL7WW[4@^\
MKN2F8Y%1T'KD"ASMRE*RB'7>6TS!)Y#&Z-8FZR%:!K*SM3%=300^"!-6.7E?
M?IO-\G5O\=-LDD<I<A5,KC-5L,8'23 OG*VMF;C #-)C:TOU,#4]3]9LHN][
M0-1 ] .P/Q])&T3 *;'QDJSM9/:E+K6-L*X,;/JO\S$1]V9*D42J#09) *-"
M:]#47K9UO" MOAHX&%68EHD;3I]%^]B<O?WVP[W)[7FB9Q<P/);R!F'N[F>V
M;OW+"PY74>WG4YA^/IW/SD].+ZI]7\S.XGBZTO6?\_%RB=/WI8Q4!I4=<G)%
M0J:5ZH&%;,A=*!3UYN(A/3HTM!U\]^>AWSO;(V+Z2&H>@$'^A)-)+4#&*<YA
M0E)XEL_&T]5@I-KM8B/K4;V"<J$49E5MTUF;HD1N@&%T/OJ0N9&M,X6WHZS?
MC*Y.(-F!2GJUJ%>I9QN6-ARL;T)7/[C*K%R,H@!T1D26(Q<D.IU84,8P8[*W
M"+17^%NG:X_E#F[SRGZSI)IBJ$-9#\!8W1;52 IEB]&&!:EE+>&0#$3@S*>(
M)#E+@=MCC=-:1*W]3,;K/-S86\P#2()[_P6KJ9R>7"L?A=HN%!TRFRA8TEI0
MG,1+9$Y!TL"C"(]V+MDK=_,N&0-)>FMSM'&HF > E%5?+UQ<Q# O,2Y'8(,K
MCFA&17%T;=C$? R&\2@E>)6**:UMRCUD].O7-$;*H6+>'2EAC90IGM14OL_-
M=J!WL^GL)NPOW#'$+**6OD:THN9BD(UT/#,I0#N=72(/K3%L'B2F7X>F,7C:
MB'P WLN5F;RX81A/SXFIC1V=31?/:\W1QE?[#-]P\?MX.IM?]!^D!42;\LVG
MO*(0=?G]=UR>SN@G7_'"L;-2F2*S9ES7>=?1*Q8!)"O$EW4%14RMC_./R%Z_
M/E=SXSA,6 QB>]ZPO%GQSRFF*>/E*/L,A0O%1(U_=>;(HJ@GBNATT6#DE@FB
M.Z/[#BG]C#_N%(F'B7L09[<W.\= Y!)MB$R!Y$P[2]N$$LA<$#Q+5U.K6Z?K
M[-ZQIWESNJYVX[U%.P![\@KF4[*LBP\X7W5(NXR64\P9O:_].'/MKT>A+EB+
MK!3+N=3)%-\Z.GR(EGX&)G>$EB8"'X1)N<W)<UB,$X6[$$(AU%-L2QXH@B:C
MZ('Y1(LB"^>E:!TKWDM(OW?>;;3\ ^CL+O!!XN;E>').$>E(>A1<Y,B"R^2)
M!8\,DN=,& ICA#,AR=;-C!X@I=^+ZJ-@9Q^A#P(]?^+XY)0H?T8/A9/-]*/W
MY4Y[STNID;&NV6\DIE1;!R-XDIHB(:IB 54H(CTV 74?6.U*8T_3WCO:X3K5
MT)/"X-I .ZLX%]XR&;#6ZH?*'B^, @@7N8@N-Z^LV(G ?G?*;M&R)S1W5]R0
M<;FQ]7<[(&</H6@3:X&](5&24*%$RT1442HI9"ZM??P=2>QW)QX"-ILHKR$Z
M.^^4\!PF,$WXZ11QN;C)P %-$FX^M:/^"(^0WKX5]>OQE%XVALF'V6*\6A$7
M*/32:\/)6@D;ZV0-S1E(B@C(I\LEQJ31/S9%[\#^TP_2=:AU6V6@75WGQU!2
M3*$PC$+7JX[ 8@%D#D04H'G*N77RX$T*!E)/U H)M^W1 >(>Q&:XIG\SE^J2
M#;39.UL/;F'5@BX#1<LI,:?J-8#Q#D+K+>]>0OH%SR&ZO1<FAXAY$&BI34%K
MPR/Z4&^*OL*DW@X]6[Z ^?P[;;?_#I-S'"E5NWS6]I\1Z1_4U1FDL"@8$PUJ
MDVSSE)FM"!L"F@Z"P.UTJ^;:& 3(+OMHOI[-/]WHHUGS/ZZ^NABFEPLDD#HS
MX4-M.>LLBS8@R;'V>%,4H&/KC7Q'$OOUS]L#KTL-#0."*<W.:2U]Q(2TKHC3
M=[B\X,9Y5QE23-6&:SHKP;RCS2"9*#(H97WS<J+'Z.DW-; #<+62_2"05),H
MIO0KWXF)$23- T=1[SH+TSZ2HQG!L>*]=A*]T[%UJM?U]_>;&M@>*7O+=A#(
M6.?47Q?**&II;"8>N*]9-LEO:M!Y"$#;=+8QM\;'72KZS0%LCY(#Y3P(K-PD
M7X2(D2-%'J46\(@46="Z7CNX@CI$VFQ;9S'MCI#.LN@ZV''VENX 4E,^S&N2
MZ_+[APE,:SY?C02^;%K-CVPH1067&:!(ZY#5.[*,F>=H(S$HK6N,E,?H&8(?
MW"2<;R;T05B7-Z2$Z<F8/*VUB(B)RZ+LVCO@K_%D,K(IRT(^%C.YT+(P0&&D
M4(F%$E&#CE':UGD'V] U!.^W":2:*V$0T+JD7,8@3/+ 7*8X4.=(]CF3:)(N
MX 0$,*)UT+031#IV>YM 9"]A#J!^X9H']FXV31>AG$$ 5]M"8C!,JTA83KPP
MGJ4V5J)%WSH%[EY"AN#O-H''X6(>A,E8<S#" IE31$_\<T_Q'%<L(*&].+0Q
M)2&3:EV(LG[S$+S;AG<..PER /[LVS'$\60]-FF:5T.I3V<3$OIB79MR*9IL
M1$J(F?Q\Y$Q'59A7%EG.R*67)L;F\X.WI6T@C<BZNO/L1$6#L#W7.+L=8,H4
M?,GDT$LM2& 2H7;+-BR($!372ICFI[X/4]/O358W^G\89(>H8A"PNCC2_@#?
MZWGVY6%VB88[%YGR&FIC;,E\JI;9&%.RXJ!MZ_JB^RD9#)P.TO0#]P@'"'TH
MX)F?TWOO2&DD=$+IE*48$.J9EZ"=W?EZRX;%Z22-\:T'HCQ(3+];7G<0:B#Z
M0:#H[6QZ\AGG9_6"]H()X X<>,6RM'5$&3F7H="77!D=G$-57.OKAGO(Z/<$
MIR/D'"KN 43M]Z$^>.T]KR/,4#!M<R;\9\Z2%AR$XB%BZY!]3TO3V7%.5W@Y
M3-A#B-NN(?[:\0.Z%'@4G*$SM7+*.A9UL4RG5"<S:@^Y=1A_/R6#V: Z=)D/
M5\$P]JJ-L+Z_GLW_F":<+V$\78W;7 >QUX^W4(F2I9.TZ'ABFJ-F7DADEM:'
M\*9H$*U]Z!W(&\S>UGV<UEI9 ]@!5P>JUX1XC1,PTB#WAIF<:A3A/(.4@24A
MDO+!2ML\K?YA:@:S(W:'LD:J&(1Y>S$[.QNO^^JLAL?6OCTG.$W$UL@(!X*3
MC)ST)",+)"/K!<L>0*/E+D/K4Z9'R.GW:N0HP&JEC$$@ZQ$9H2LB>N!,070U
M^! LEJQ8RDJ(R*UUIK4?=N#Y>&=7+$?!52-5# )6=8W,IBN.%F^F%]WZ<U[M
M[S#Y ./\9OH"OHPIEJ@W5HJ7R%DQ4=7KIL*"(NZR<4(%8[S#+BS8MO3U78[6
M!A7W&+%.%#0(^'W$ZE)BOFC.\2RE\[/S22TE?8EEG,84*_M,1CEZ$IFAE0J.
MUBSDPE3)'%&H;0?_[@"Z'U/5]RU@)U!KK(P!>/G7.%AYF;28B)13G"[&7_&J
M9=D[7+XO=7"7L;YV#.6U?U!DNJC$/ ^<B6!U4B*#;1YQ[DABW\VB.P%>EVH:
MA)F[*[>1SE"D+Y8IZVLK(YN9USDP"8J;8%-!:)US>9>*OAM*=X*F X4]A//6
M'WBQHU"DT-XJBEGJ/J^Y9B%+P0R09((J0J>N3L8>HJG?IJ?'3ELX7"W-8';<
M=B0?5NHXQ>4XD<-]@Y=6O4ENON(8C4H>8>J874NT1RS%*!:\!Z836A8@ 7,:
MA4&34/O6?=J.T;7D6@1#@GX_7[TSKPK8+WKQC:"6]G"(+*>:"REXKBEKM'P@
MB*R4\VAE8]:W(*OO@+(Q9AX)+9LH9A"NUC6FUAVCGITO3V?S\7]C'FD>7 Y1
M,I7(Y&O(C@6!D4DK2TS2VP0=HNPV.7W'D,=#UT&*&":JKO<A,R8ZHVAY@*K>
M95"!@:; I$0LG)>2DFC=I.(Q>OH.$8^-JWU5\91:PEU*=3$K]_C>K?RP'[RF
M(U]L%^;:^V./! MDE[2)2;!@@Z1@P7+F,5'8**,M/(!NGT2W%6&''T=L7O*Y
M9L]2V*(14TH,JB'6NB06=.(,N#<V.2V=:#['\P8%@_&S&F'A[HG$WO(>P"'J
M)?5KB=3#N=ET=:GZ;5S[)'ON$X?:M<4SK41D(9"_*$1PW'+'2VK=$.Q1@@:"
MI3TT_1!H#A;[ #!TBX>7LS,83T=UG*C6WM:L67(#2J*X(MG 8@2; 2/7L;7C
M="\A \',X8J^W?+^8*D/ #K7_+W?L78$'I6:\U@GC^:HR!1S2489H XA L[1
M<,RJ=6W$'2)Z'JYQN&(?]JKWD/+08K0?791O6 P>N7>ESK 2=5)1BBRJ0FM+
M)4B*!ZM$:_]N9R)[GL31)= ZT-( [-7M6_0-%Q%-#ISV?I\++2?M#(O>2!:U
MS"$Y&T1NW:[G?DKZ/1YH#Z@&\AX :K:X M\P9HHJ%'$89K"6ITFAF-?@F"5'
M("4T GGK:&UKXOJ]3VZ/K6ZTTB/<%O/EZ,6:)>+@52F8EA]P/I[E]^59GGU9
MJ:JZG4BB<:O6:-[Y>@&O&.2DF*WM%B797QNVNHNB%UY#&'UUA:YM:1G(.?G^
M$5TG0A\XB#:+3VKDTD!BR:DZHD-9%I0,3$89M*L%(N(8,.HSS.M&^SM :P]5
M#!Q<S_)_GJ^G%U]87UJ,P43-4B3#JS'5WFG1,I6\4[IH7]16!PF'6JM;= T7
M</M@8A=K=HB"!N"-W3,/SF000FO!8B(I:4W6'S 9IFS(WA$-B;>N"KM+Q4"N
M]AH>;NXGX % A+R_.<("7^+ZXYOIW<N#C[/)Y/5L_A?,\T@6ZS4'P43MT*9S
M3:2(CGS1PIW4ILX6[& \^2XD#N04=$]$W!U;WIEZ!H"^1R_!=>!2VRB8TJ'*
M31(OQDJ6M!$QQ9AL\P'$!^<C=(:K3H&P2VK"+EK9&V%?5ALQK:7YLJO$]4@K
MLG:69$4&SK0*-=*E5:E!EI!-)LO?>ICGGMG&G<6$Q\34@1H8#)+>X?*JDF/D
M7<HB2,&2E$2X#N0[D+5G$I+UD-%SWSH3[P8!_3I2Q\3/_G(?P#:W5360$-%!
MBL *UOL!80/SJ!0+POKB>9"2=S)9HT6E5F=GH<>$6',M#0!Y+\=?QQFG>7%M
M3Z_#V$;6<[04&C-G4FVN:BR+N=83!5X0A3.Z^>7S0[3TV\+AF AKHHW=4176
MJ)KB2;T!^-SP>*'>?BX6YYA?GL_).5R?GZQ]QM6_SV&5(WGVA=;32J,CR4'S
M@'56"0+3 16+4(?;F" U%U&FT+KD:P\R^^W^<'2_K$,=#B*EX@$F5R4B#_!8
MLN06+)!+*NH8"V<9*$/<&BVT"]*XV/J<8W<J^RU6' !,6VEP #OUU5GSXO/L
M@4R2%:?Q-J<?D42]&"_Q$\Z_CA.N1?,1T^QDNGK*>LBJ21F)9<62@EJ+["G<
MDE$Q*6P*(G-EFF<)=<W35OCW/P/^!X6.8:V6C[A*;/@\(_?\S_'RM,J?#$2=
M^WJ_88@&G>*<+(&NH_5"Y"P&*YB*&AR$VNFV^3#>_<G="N/A)\-XISH=F /]
M$;^<S]-I9>G9E!;F<CR_SQ<;25&XSP!,6!?J1"7.O#>&:1*II9C4.]N^BF=[
M^K8['N<_ U [4]M30^9F>GN(BLO@F:U9_5I6498:RT:T!64T CHY2=^.O.UP
M^5/<VW2EM('!\H;L5H=VHYR=\JD81JN)O!>I/2/^0G7X<T3R;*"T/H=_@)3M
MX/:37NGLKHP!N)*/WW9&+SF4R*RI#?/K*0=Y$I*YE+1&I/@R=-@J<L\[Z)_B
MPJ>96@Z\.GPUS5U=08=D?7!>,S*8F;A0EM'7Y,-F6B3:9H6F=2W%GE?0XJ>X
MX#E0!4V!U'.KA6[Z7^WRSEZ:,!RU0]8C5?C&2(D1.$L1=6W?ALQG+$Q&I:,$
MPU-WK0JZ[,APS6A?WG5=]&"B%3ZA#WF4,49"$H7IY"@PK2 S$H!DQ'7F)!D#
MOO7YRS9T#21OL!EN'ME0V^BFF>]V5%M8[UM?3V9_+3JQ>E=//X)]>X"5]I;L
M\D57C4T!9.39,24*X<1XR\ HP30*+6D#K5THNS-@=^AID-55G_EA/JL+(S__
M_@>)_<WT/>W<4*<M/$M+6C*KCIF7O9]R$:JF?P!$XIO6'H.$P'ATH&411>C6
MSMON5 [&IAV&H'N2P;I4UR#NK&\FO%%88TIRECEK:Q<#K2BZKA<U.@=3?#9:
M=H"V'1,-.P-2U_I^--=P%]$/ CDOD=Z=QBOMT.<37*EIFI^=S>;+\7^O+TQ,
M\%D;KIA)GGCA%$N'U>@^887A5NC@FN=_;4%7OPG11\99<T4-!'[K%Z^7T&?X
MMFHS31]?T#?'R\7(JQR=-(:9$H@C6PNNE)!D_B%E"5!L\WF+/Z*IWSSJH\.N
MH8(&<(#[D;1%!)P2$R_Q*TYF7ZK/\6RQP.6S1/'3?-/UX/,I3#^?SF?G)Z?/
MSQ?C*2YJ'F8<3U>*_G,^7I+?_+Z4D:"U%8LN+!99ZN1D3D%0,"Q[D05W05AL
M/ZJE+0_]9FT?&="] F  "^#*67E-JE@?&?R.R],9R?PK;E(J1MEK9T,"EE3-
MVE3",?)?,@,7:1M10F1L?>:T%6']IG\?&:KM536<R]DW9U]@/%_'>W7.[]OQ
M5\RK5;CX/'N.+\>++^1CY/=EI%)&J8%$!A3V:9OK@ GN&*?0K_;,KG,+6T-Q
M6^+Z3?T^-AP[4=D 3.+*WM<)K"3,]9I[]:UFB^&(IR*"=XDLNC>,B,\LIIQ8
M5C+[G(Q0MG4D_2 Q_>9O'QEK;51RJ+GKJ&G"I= VN;A7@WJ4LR)%R70JGB1F
M/0M)!V:M3[F TN1/M]]UMZ2NW_SIXV^]72AM$#'W7=Z>I30[7V72)AQ_734Z
ML<1"=B&SD@4)+WF*Z&J EP+($JT-,;8NO=J&KJ'U56B#BA^"[T %#=0.5B]V
M2G]49U,7=#;7V=0QU:+&8@0+TB&S*B7-8^(QMN[?\2A!0VNV<"2@[:N2@2)L
MY49<[1$K7Y4DQI67)"+OH$[2#(F!5YH5[@P'B\$UOX[<CK*A-6@X$N8.5M)
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M,WU6"J$?EH1^@P"0K6.Q2HGD99E/@,RB=1HCIM!^1OG^Y YY),=!1[I'TN
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M"[!H7#"1.<]:ET[]5[BQVPLO!]_8[:.\;E'YZM.G9?Y$$OQIL;JZB$P*IIP
M+"S1#K<!/',:)'?>1F>TS:T+;@>0=7;F<DPD'JZP#C#X#K_?C"U>;%R@IY+F
M:'61Z!4X(2(HA1)""0@:/;?&%\]BZP-]*&UG?/5V#!I'45T'D/QC,8^X^OQV
M^0Z75YMO[KCJ=R=TW?"=^(65T;.428Z&!5#DH(-7C(.,3MG 373-FW8<0.89
MW\,= ]2Q%=H!9I_8>KN&KD;'2TI60TKKH:M(DF2%OO5)*Y7J.,L370L?.DVW
MSYNZ]@?[T>J;.M&SFZV?/N/\4W[SHQ#CYA+2)^:UEPYX'=*@Z$@ 9X(%+Z2T
MK,3 TX/;X[W*:W8N.@AMYA^#ME%UTOO%\)TO?YM]F9%TZVFPB>$>C]8\\JIX
MW]6:7AX?Q>KIKY-5T"(&)L#*=5<&[\%K0K9'$<BBQ6A9ZXNJ,[A.3M%E*3D'
M#,K73BFZ/M=!,OM%.BE"L:J#)P?G=9V\#]*:72?OH\@./,F!#?880QZE*I!$
MK9&DXX:DZ$FH.4<MG K.M&XY?0X-,D^#DL.Z9NZCLIZ .*@#7\" 5C.$[)0A
M?R@A.)8DN2J)G!B.%+NU;B;WS^N:N1="CNJ:N8^Z.L1B>G7U1[YZM5IM2BC?
MY>6'SZ2)[45K5EJ9%,!(60<E4K2&+&C@S&KKF2XZM;[$V8_"3M#8'BHO@+*A
MWCI Y>T1\Y'^Q4W?6V&+<2% %*[48Z0 6ID@(V-1Z-HOM'6/P\=4G-WMS/%'
M\)&JZ Y,&\EL7M%LMD<IN13O'!@;&6T/'@%E21 C.DLGAZ) >%1P[:*JE^#C
M,+T_"Z.CE3 AK%;+JXM[60?Z2&)MPX35PH3D+7!>)Z7YHNH<%+*[!9V*4EH;
M!U4-TBIW4$3?W2+H60)Z LWQ6EZT%GD'YNBHY*A+/DCZ#YSC]0&?00@I)#",
M]F;T+G#=NFAA].*OGNZ/CS\O3Z;>#J#\ZI(^:T[Z_)9OF;V002EOZC%1KW!4
MM@5<L0DPH=%.,N5UZ]=R.PDYNWS)@3AX.++K:*5T@*P[]S>++U]Q_OW7V1SG
M<8:7'ZZ_5O%]7-S\E9SO3+>^_/X^WUQS;_IJJFB$=M92<%7;0VE.P97Q!FK!
M4(HI.9];Y_+:4'YV@48;[$Z@]JEODG=N5PKE?[3V]BIP'SVQ(*O#5'O*8R1Y
M"D:G$4:N],.ZV:=FT+ZPTMD=UL=AKKWTN[THGA/^ZL3* V]^M_^\S57N3F(:
MWLW6S_]^6U;RXXI,&B?0&$9.'9D"Y7($9QE%K\+PP(L528V10'J"G!8'Y(./
MKF,=7]/?^?."6ZVY#AE2K+>!HD0(Q&OM@V=Y<%$7T?KIVG/T3!^3ML#$KK.J
MB08:]A4:R7"LHZ)CS<?F0YH:D5V$G<"4%(),(E\"L@UTW'!+!T\D[&@63"8_
M.\2'8^%[-B7W3][U(C]=+^O66HOW%M1(J%4$7D@L"E#!UP;ZJ=ZDI22U3SPW
M+V<92EN_)F8?K#R?2VBDF?[-S9&%:@\^I:G!&;NP["D494FG1]:1#BI);FA4
MH8[A4V"\R_1)UN8P1B [MO/R'O_ZG9SY)05X*_*ZWY;WI*#EMSI//#$7G9-T
M8L;U?$ '(2L$YIEF/*ND_!B=6)ZGJE\KLP\^GG1DVFACTC:)CWCZS\7RSS?S
M=\M%S*L'3,E,L9N3M?<C_:)R"A 8<C Y>\D3U\6,!K&GR9HV\S,ZQAKIHR^0
M_3J;SU9T5/]KL4@/F+*.9(2J=B 3=5)Y[?,3F(<@M)#TK==YM%#L:;*F3?6,
M#K)&^N@+9,3'15$I.B8T2$G6EYQ)!*_([=,A6*O1)&9;=^*ZN_ZTK^Q&A\V^
M$CX\W[>XPLN1_.B*^;]FEY<X3XNKSW28TP?./\TH7,!:'':05_WB9Q[O8^]'
M=B./>[OHJWEZ\V.]=0W=:@?&T$NG3*RW9X;.IY#J^W,6P7)MHG<\JN;O%O8B
M\%A+,VBQVYC38I')%@&9&U5G-Y)/6.?2<YL4KR.\HVY=,[4?A=-ZZ^-AZZ']
M&E%O7=YHO&0J#L]6#OSD\:W=B'G-_7"IBHD$& 5<E=ISPR?PF@L@3UTR;06J
MU'JHP4EMWFV&;;OL[491"8U5&H&8M+0GK02/T@./)>7H2"J^]<.+9\@Y)VNV
M#VJ>SGD>IY&I[_7OYF[O"^Q![M:%C#E'!B[4JR)'OF>(G@-/Q?' . 6_YB7#
MM=>*TV88QD?2>.(_R^-P^^?O%Y>7ORZ6=13Q$0GV(U8;_]@<RNHD1ZE(F**/
MDJQ5-A2B9DV0"Q:TR004SIQPK6_/)@D?[@B_AN4<=>&@;+V7RJ6 B\:",*XV
MYI28Q5CNPQTRSNGHW <E3P4"AVJ@@[K/+0L7DNQ^4*Z U2G5GL(60I 6B@H\
M26<-MZU[^6S7[@,N!ROQ"5#L)=&#D?"5C/(B?;C"Y553/+R[7L;/N,JO8JQ%
M@'7(4?I?U]LV;*'$K (Q9$A*M&DL!U^,!D03)$86A6J=9!]$6!^>5FLDM=-%
M1P:'!)1GG^8WY17Q^\<ESE>7:U7]* 75&$IBEH'D(9,O*FLI:+; =$ZH0XI<
MC768O4S=M#<Z8T&ML58ZPMN%%SR38)#HMA&4M 5HAR30I0B3E$DVCN4.3GN-
M,]H!MX]$CSS@?IFGB:*Y-XF6F)59#6(?N9/CA75#EAT_OMN;^4D"O8"1<U4B
M\$!^O.)DFX+/#GQ&RY4L:'WK]V\3Y4S?D&S+;#Z[RK_-ON5'2V\>4WJ?-:?-
M6.C\!\5$ ">0@[36,Y,QISSF]*B7*>S#WV^/K>>J21OKK8.#]06>7G__'?_7
M8OG3)5F2=3,#%6- 61BX5 -M1>P%8S*!*3#KA6+<M.YKO">)_;Q?;8V61P48
MXZFN?V3>,O<'?LD_6@,YYS/CP&P-UI%5%FM77"%S\LX9+]J_,-B;S*GK84>$
MS7X0/5J'7<!T4Y59:^5JFRHZD7ZN#=067VMDOVFVD00YUXH[2*).^)4J@]-,
M@\W:)^7(GRSMI]P/(*QK*!X/CT=P;*VK+@ X>#__]N/E;S1<1,<]A!#((4+!
MR1?BNB:>O/;.IY)/;"AWTMG/>_Y^SO+#E-@_4'_Y.UY>I]G\TX_,A/.!9XX2
MM*@;W#(+/@4/(F<2,5'(2NO+C'UI[-I^-D#-?C ]3H4=0/1VQ__ZTF[/DDGO
M6*3=KG-] YWKVYX$/&DF>$ E6>MTQ7#J^KA!.65LWE1?'2#Q&7X>>>C&!^MK
M[3YM*?+0=:@S9'VM]I%:2T=\Z]:'^1[D]1*/MT7(P[ZR(ZFK;R3N=- 5[6>,
M6D'F*=81H )0(GGIB045A7#8W+7<D\2)FQV/!97AD#Q:;QW <A.WY?0QQ\_S
MQ>7BT_?WLT^?B;F;*,[E0$+3"*(&<,I+"<&2UV.0&:%#0>U:MWQ\@:1N87<\
M'!;CZ::+UX2_S6*>KVK)QJ=EOFE/ONW+:M'[$"UD9DA,+G)PO+8E#[$HIE4Q
MMG6'@2>)F=;K.R7 VNBC ROV.R[_S+46Z'V^Q*L=DMOTZDU9!JDD;1CF*6:C
M<(W<8F+-:H$\)*%YZ_D!PRB;MG[FE) ;05-3O[78#K?<G0U]PG9+[XL).4"R
MM9NY5PQ<9 $<)N$C6J8?5I@^U5?Q@-6G+<$Y!=Q.HY@.+-\SPKS-50E9<DK6
M KD%#)0)M1^<=Y"T"G4P#</0.@,XA*Y>TM)3A;2'*:AOT/UK6<LBN51:)JZ
M1.5HRXH$+FD)D<F<A<<B0^NAXB_1U&W8<" *AL-L?Y7T#;%7,5Y_N5Y[#Z^^
M+)97FPD/%]%:HW54$%VNL[6$@U"8K/%^4,X9CK)U3>O^5'8;7(P.PQ9JVQ^8
M_@:8\_RI+OSQ%/BLC5P8,J&=2U#[&9 ,"T+PJB;G+>IZ*XZL=;>.YRGJ-L(8
M'7?[JJ-97YT#PXGGRHQO3'G$R+RJ\Z)US?LXEP%S-.!3,CHESQ[EY)Z('5Y<
MJH]W'>-=@(T@\*FCT>>X><H$JV(E*A]!9F7K778&QR6)3A<I)?<FYW@TH(XY
M$$=_#C(AQ%HHY=ASL5%ARB/#^[B2H10;!/<*K*[5/:Z.BD:*L34K02I71+:M
MVYH,H6L0"O7YHG T'9UE%[K-:YW:AN,:+\=XL?1@A?$?)SW'TB3OD%)@T7GI
M(=V\AR/GRQF/4"SCR4;%7/-H[*3OD.[:ZL=M7BYTS+Y$+B%P-'70,P/'/*?
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M?<>Q)XG3WF>,"KOV*IJZB.J6M]\6\T\?\_++@ZWUR]_Q<SU$T@,F0W2!%Z?
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M<XQK S9PX[)6FC4O/!Y*V[3P; R*AY ;0S]=(.]FWL*=)YK?_IA=&&&T5\Q
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M4=)&^7!^?<.-<Q(6>YEQ,M6&Z@]'79U#MPI:C2,9XT36H4@PD12H#$G&\8S
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MTY63<5 E3C0&O4Y8G7I5G?H Z*,#M+3?BH FAV?M M)]]5Q?N&M3F'<("#J
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M?/8YEYL-7A;K=50,M#.Y3GHLU7,L()TW+$93G&L]+>8Q6J:%4*<^>1/%=>!
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M%%EF%PWBL)CPD*<.P]%YG7./)?3Q.]OMWJ@O 5?Y/__C_P%02P,$%     @
MLIX$51%WE[#@"   D$T  !@   !A;6=N+65X,S%?,C R,C8S,'AQ,BYH=&WM
M7&USVS82_GZ_ E6FJ3.C5TN.;5GQC%_DBV9ZB:OJFNFG#DB (LX@P0*@9-VO
MOUV >K$EN_*EM167F8EC$F^[BV>?78 [Z7UW^?EB].MUG\0VD>3ZW^<_#BY(
MI=9H?&E?-!J7HTOR<?2O'TFGWFR1D::I$5:HE,I&H_^I0BJQM5FWT9A.I_5I
MNZ[TN#$:-G"J3D,J97B=658Y[>$;^,DI._U'[[M:C5RJ,$]X:DFH.;6<D=R(
M=$R^,&YN2*U6]+I0V4R+<6S)?G-_GWQ1^D9,J&^WPDI^.I^GU_#/O89;I!<H
M-COM,3$A@GVHB#!JT?>=X*!UW#SJ'+6/CSD]; >'[T,>'1\<!)W?6B!D [K[
M,<;.)/]0241:BSFNW^WLUP\/,GLR%<S&W5:S^7WE3E?+;VV-2C%.NTY@:(T4
MJ%<TATHJW7W3='].L*46T43(6?>'D4BX(9_XE Q50M,?J@:,7#-<B\AW-.*_
M'%:$Q=WCU MT"/-(D?*Y@*U]%*E_&XM 6-)N]1K8>Z[4NFI4CT&[0%FKDNX1
M3+ZB00@&Y?J%5+CH#T>#J\'%V6CP^=//=]785H'_Y,:*:/:7:]#9J,&@"K,$
M7%MR5B?GFK(IG57)14R%AKF)BHB-.3E75#-\+7A$^K<\S*V8</(YBD3(-:$I
M(]>:&\'02V#,63+F*1FD8;U*H /J!_-0^_;-P=')$\R44<; U6J21R#P9L/Y
M5R+%M;LU[/1"IFS5YYH]_^KW+-6L'Z 9!B2FL$V:3P2? F_96!CR4TXU>(R<
MD2'/%&R\2LF5T@EI-6L_W=T\V*[C5[M=^SNW7>?4P";!=B0S<I.JJ>1LS*M^
MUWY?[)KVN\84"),J"$JP%A4I..&,Y*G5.0==($PEA2]2DL"3%E22B(;P2A.5
M .U:Y?NM=4AYR(VA>H9=$GK#'04LYC3PCH%8L*1TX:[@B%!H"&_0+87A( D#
M8IC&(HR)R?''<OR4:UY,@@HDPDB(@QA2I\+&H*#)>.@$Q'DS$$TQ4',"PQ@)
M9IL-\JJQVOYVL,I))%+  ,)IN>=5%R,4-.N5=I%&0#P4DS3X/90Y@SD!5QLW
MN KH%/B8 4 0VXAY*9?@+7!C[@D!_L%<'EC%'KF$#H!8!;!R"QLG64A-3"*I
MIF8.9\W'PEA((BVA^-)K /)65U!IYL(\(O>K!F9GYX YNK-W;]\<[;<.3TP!
MO2(70:I1/G?9,^_<Q@X(U=Q!"" A LEQJPD'! =2F!A'8+<$F!;9%I^9,*%4
M)H=QR,%:28^E3*N0,WAMR!Y AW' HL='_S:,:3KFY SH;9A+Z-%JTUKK8(][
M*5H'S#_Y1X&I;>HQC/,3Y, 5:'N H2Q;+Q3=62B"A5#/^X"''I@Y?%6ZUGZ_
MV]#=H^]V!;OOZ\<MM,,EI-!CW$(7,?\87U4,YB'-S?9#,*H&'+!2K.3CM,HU
M3 "<-A'&,27TXJF;!]/V)<>N,K;FDCKP%8%Z":!JP>;8*(!O01:CI&#N\&SR
M  X*@FJ!"@B?3K@8DN),N<$0[]S5N'S \2J<SD$@.#:[01DPK AS29%E02TG
MQ#)5@!$^\=B<.<&[@.,0X&Z8B;.O8NB=AWFP0S!O=]9AOC7)K:%]>WK<&O3@
M*!,XQ<)0:E1*,0Y0 WZ 22T"'([!<[ !_ 4-A!1VACG#IF71]1PN'="\U]SI
MNI(4NW!S6RB4Y3H#R!N7XX2ATLP)X-)C.)Q!ZB(!S]#",W0I[ *IO\<TN)[(
M@/%?-ZK#'4*U)^_^A,K<,1QN.8\BR$7%!#;+;,@I%WG)%HSM'^^GF069(8AA
M(+"M\<ELH'+[L 3;Q!2ZZ,TQ9X^><@HCP?Q<X#R4>YN 9 Z-N-2K123;(406
M/.LW^Y&SB;LT*%)%UV<C1I_ LY@LJ##,-8)D)3)OF#51QL)[O+^%N4P($Q7B
MD;T'AD2 =F# >[T+P>$(Q]U]!UZ%I/E"KG=>JIB:11J#W.F\@S,75)P[%80_
M(U+<<%E<?MSK7_UJ$WVU'^SZB?#@]9P(W>4IFSM1=<EM2+JK\%W2' +P"0G-
M6N:\D(Y"]FR5-HL<PKV *9-$6,OY(R$EP,MZ;&<"Y'.3[ '(@<$-1@CX%W/X
MN6?RWW,!XCLOS-/078F\*P]^SYL[G$G(!<%6 A"(!W \RH>" UZ*^+\X@$TY
MO<& [G-#%])=5NNN=>=W6D]"87%6\M<?&TB0,AAH^((#'T1LD0O#$("=PN]%
M+JLPD%*8/ '0@)&<,D7LV7@/^/KSA-T[CYU!$A!I()@J8($[6@0TN:OY G95
M'T-%.E%RPC&0IG1<?&'0!9/R))-JQJ%U&BO/G?0.J &$?TJ64=\2&LZS>M8=
MXHH. <"2ZQH86]+,\.[\EQ-@^4S265>DSF1NT,G=Z?"+^@2C!>0>!;8<IGQS
M\;']^+A^V#S$[^U6PU\V7[CX%%]WG^(;EJVW=8[JQ\V'FYOUUH-M?]*T#2>R
M%QL,8S*:?JBT*_,!!72Z^]DM:6WVL?OF4=GS.QDHZT5C2$*.4[KNO(^] .OY
M&(0EG:JKTE@@J;#-T]1&)[JOLT?#BZA=.7W[I@.>Y'Z2X>?S_G#DONH/SRZ_
MG/UZ1]<M][I)O!,]8I_"I6"OT>&(N^<C<U6_)>.ME4'\109[NA^]J%DVEX*4
MMO&VV:(>9MU4#1=>-L2O>_5;F?(%;%U_TS[A#U9T%2&JN1Q" _#$W#X\Y/E+
MJ!ZHFME4_+6TS'85<9U%15RLEU@:\UH *>U-C4:@7Y=*<&I3>6K5G#?+:2_
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MJ^Z5)P6M.++6S"GOT-I^Y.)[9@V5YEK58<X%'HH68IF03-)!]<<P9#)+R'K
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MRRCFQ/Z07*]++'6)I2ZQU"66^_E^[]=DRL_B*T3FRTR'_P%02P,$%     @
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M)R$D^#MHO?J OAAN09"T =M1KF#HZA\&CE3_Y H;EX)M:1M6J$!\(N@.%%?
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M1MS:^B)N+1]Q-QQO:VN)MPH=^J&+<,0*9H\B]'*# @T4W94C<'2X[]A\:,T
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M+!T^!BGF,LI 0H #^@@LNCORW]&SQ5,,E(N?>7DF 9EC1;@<8W)=T@XRD;;
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MV8V$]P*^X41_T0,Y=(;6(."'(. X]?!?,I"NZ,6\*Z3OQ;P[M 8Q?^%P<:R
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M5@OONX4Z6L54S</E1 E;%_ T5\)BP+3PTLCH;TP=X&OI8BN&CZV^G0[- 'N
MH,\IKUO1PED_7BU39:625-[$1@3<&+Z>1F)>?\TF'Q2-+D.H'A2WPH>G\\39
MQH2#K,I!PK8B$'!JK#!&+*YR=/0ZKK*T_L:)Z<4F]&(NOAAET/C32"Y0'L$.
M1RG6,G[&S1)91X46C6+K\"T9JFACNMCM2P*C9=P6F8$#XN!BF2^?".5?VR&M
M$:C34_UK70Y8(<KVDR+O;1.91I=5%$0F2-3.:1A%Z8)(]5X\-"J\(IV/M\@V
M\"4&3VB=P-!8RH@>UXD+C(FMT<"BGC3YM3^<-Y$:RVB)WR,DQ&[Q1^1^91ZH
M6"Q@$TDB!>Z&F^^&#[M!OZ9_9,6BU/9D.'L2B13N"4OZ),$!B*BN=!X&<@E7
M44TR*C"\5$91&*EXOLFZHM'U% 7&SZG>*)X?E-K^2SWM7!@_D=@&Y@]@B=2F
MAQH%_N*Z"IVWC=-%)':RCY"#!]P"2<E;O#(ELQ*.<170S&;@8D32U$T<4WU\
M%S*]^'3ZT:#XBVFJ2!GPOP@9AC19)/^3JH@T2.S,Q+TQYL:*Z[$E&9XH1[!
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MG"W.*:*%PM%246COZ\<V[+5^*EC;3L[6)&2+)V=A9DP3SH5'M[4<5TH S+O
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MI0$28DUG& #SI:PQP%Q'[V]K?W>;1F]_'-X.G3,TW2/G_<6;#S<.@13)#%#
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MCT[PMO$L;$WQQ[N3D^OF^*.5.8::D[#[T,46=-3!6;LW^(# VG"RR*S?[6-
M<9E;SI:(XC@-W9KVEGK$L??M)+^5 8*)G3<AVAN5U A67W"9@I8/_CM?($A#
M. W@E<E,T #Q5+J!KXD2GZU%.[3K5U^*(FGK#AZ+FT&RNB9QTKERMQ<M*7=;
M^0OK*2L.NV:<;*VI52E@6#3 U'-ZS-P**S45,]<80>3'<U*@XLOQ_$P]+:KR
M[: ",%* U<E E,P<J&*C70&Y+"LYY)P,35? 9CN:W&EF6PVX;1L+LZPNO4C%
MG] (9%R?*,*</6'P; ^*B(T#)Q]]$@8#''?ESO3(9E26OH_Y#=!.<XH99."E
M/&G$9? 5/8X4?!'ZT[/JLP<6V"I0,!93TS%(H6*C;_BZ(F0?38N@ZPR^U4!/
MF, G?S)(@3@O)=&]\S3MHMCD;QIH8]RA.(WNY9(V,;Q7IJ_>3.L0DXE045P<
MZL$N$ WR2&C(+N5MS!4>W 6SDN.03(C2!.$I3V(UOT8,)CT"I6-@ER\:B7C\
M5?*=(S&M@+FV1OH2A% >1*JYX,EQI,[Q30-!4K.#Z<L,8>A[.#QTMN[T==TC
M8L-P0ZFF@ ?Z#L"?FZ!\9?41;AB:&=5E NMZ(6M0=P9+ENGT&N"5=8PQVL7D
MDYDN3/5Q,DG\;%AXS;#AP9-&$^M[9D\[=K;.\S?>=K:L*-)VQ^ ]7S08WK/L
M+AA#QE<&+MDE A< B=>@_]C1PNZ1N36@G=32(VF$&EKJ21KIS!M^ZT7B06,^
M%:9MK")YQV7[NU>C_^4A&XBVBV/U^'0F!@"RQ@:%$NE^:0."3;3->F&WG5W;
M;6>FQZK^%^L5T0MG:\W3M[]6_77.VOGNI=]/Y[LO(.I2Q%O,*21MA2#83?;R
MG&!/W</A=R^>_DH,? N=N08%_Q%,D%$]#GVO<V0=???2TL?3]9N,X_AN\S;&
M*2P@P'&N!:AF^I6;(4T7&BU44 ,+S=U+F?ZAB2C=0Y1'UFM0-)Q9#\X3,<<,
M*:@ H2B!:D-V(^5S5Q,#V\@FIF4\M/'D!C15 )F(IF395BM\: I?ZHS7(G<A
M.]7ACJ_F^:*]VX2<U4^_&GTZ>-9\%-6FV,4C/89^/89^(9/X*/S\RBGW=1CZ
MQ0=O+'[^!M<!M::Q_AWGJ*X)#+MY4.8ZA48 Y:49C37XYG2R$>(*5P52^Q56
MH,FI<C7H+Z<Y[;PCC[I#]!;3KL/C(^W!=H^?.]*Y"IRCEE3@;,[ATAJ8A7>H
M' (4("RZ2Y-9&*EF0,_E.)_3;(UDIJ:+2 1F7H!=PWHO-4H"STDS&/^F+'!J
MOVKU1N;=P7U"('"J/H;[IGR!&0B'ZYE(#W6_1GX84$TP_.4A\&<"IQB;S? R
MP1>>&>7C O"9FZQM6P.VD N$\V$R41BN:8XT9&T"R(;7W->DJ\%)R^J& 6Y+
M&$NP2B><BE@EYL5I&83&'P*O<QLG0YTM& -,[P6ACX/RQ3&<^;2-FF4]S$+L
M+/*H*$E/GF:#P4MY7C4:H&@CA"I(N-")'D(6;J;GL9@^X9=S@:O#.<.?!_<,
MN6;/ZKA?MXB9FH-_"[N1DIT_YCXD+?3_(S74'-8!83651F[3+5\HS%-8Y723
M!;0UB!._A2E8?"+Z%#?+#N:\3[XZ/9 ]JU/*OQF8=B"J'F>$@0UFK:/60 )<
MO+VY;193%3HN,&,89<9#WBMQ(TUW3]8J,7AB4T+[F:PU+?@7L%WS0$VPYZY=
M.,\C@A&GJB7RMK,W,2UQ&\Q>K6G)-T19$IYKSU\MX:_6=&@#42A(Y]R)S[)!
MS3M_GMQES0>X,M: Z7S!S;[XD95&-2#*]'FCMAY>:(/9O#7-MQ?!!/.5'%JF
M(ZD)AN'CCM$G%RSCI_8+;_1)VYHNR8L\R/'\G)='8Y4G!1VNF#.E5C)J;R.H
M?;U@^.><4C\F9IM$PI/ K6XD-SFG>-2:G"+S5AC%,[5P+FG?FZ#*'W6^82?6
M,<[AOH["B=KLPZHU>:3?,8I;4)3-9Z3'-.=L,G.U)B?#S)5-_97-F-D*>JU)
M^Y?OUO5=$[8G#V("MZM[Y>D^!Z)A C0L(L LTBA.$8 4X8&C1+F^=.",YTI#
M-&(YA45]#HWBV\UVV%J3%N(SXC:14E=BS^<J@;^:( J-/2EN3YNP/?E)$1OR
MN89\?_V,>!*^3U%@=X>[I8I:_4G+I/BX-1FX/^32N<FK8MX2SG2#HHSH &=%
M&.A$ :FG)B.'CSJ+TJESPBC=/)@]S*.-$PV;G28Q>-%57+'M<D'&&X5C )2K
MX?&I@/XOW]O<?!PI.<%KQF'X*5Y52<'QT@I-'$_&P.P,O>K4D@UK-AXBE.(@
MGSMG:BIT6X+&J&T2=SY-GZ^KMF_!P=":K.D?0?BP\UOXT!Q]13@C(IBJ<3ZL
MTOQ) RC5?U*&"L32)PW>9$^F7! Z$V$UV?&Q&.=JZ$!:[&P]S"1#]PO,Y1-"
M*4A]$")"]1R^"CT&2T*D*;S5)]@H7WI3R?_<F84/'*WCV<^(T/1)^3[.Y40P
M6\0Z&E"?&4[,$+JN.D[]I("5I!'^^33"8L<D_*RL/PMM< S(Y,+&41U9[<T)
MY2H[,+S0Y3I+WB4!I^F2B]#PDO^D0L.;!DD4TK 1,<A629A7L1NIA9G'%4Z2
M!Q$Q480_Q5*WV;S088<@V%R!1@5@% 7#7Y^&BR4W20WT](\,URJ_>*S,>]O?
M8R.%+EHK(FD/'<<P+[QG<< 1'(-(5;@\<VZ1$W254+FB:%!;2\1]H=12KN_&
M4U*R&VUP"..X-6GY]R&*9Q,,F<>&QD8X,9X2\"!ZH,HU[VUR1.RX-5GX=4V5
MS\]BI6+E(@KVFA[W&EC_0AD;=[/9DVQBNY,U:S0J/N*]%-YJDZYSS4#'G6@&
M>J8SA.W "H0+0GFCHL8"4ZK^S><XE3M:"Y#WU"VW@J/! H@)L9]A/FU!B B.
MBFONR64MHA18K:)F/JG=]#GX$@P%==E9-S%BRZ.DL()_Q9(7.&5$HQ#4K;KF
MYF#;@N&J6]#CK'D=H4+U0'AM^^:VF!..$P&4T=/:5C]ODR=('K>FTJ;*)TWP
M\1XYMGS/V:JN?Z--I-:4SQ3I8BKC"T;2\T<1ZN959:..BG9304MDMM4#SI_4
MGJ**5QR\VI7,< @4-Q+XN8\>F^VA 3 <5^ )I!-ZK/Z9@3BT5F;-]VV>ZBI0
M?;-T5Y.D<*-3H,>M*>JZU%SDG 2)VCD-HRCEZN?WXL'Y4X6,6MT<!U$X]V91
MNANT;N'LB^' %L9-B=/QOR5)0Y+PR+GB&:"GI3Z$J0^V^,11\ F>D8MT#/L+
M7B2&18/,T,9A36% <=5[!:_'R)W<^DHC@44FG0@FCT@JCB1,&NRQ553>2/_
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M3-Q^V\3K"48DHA 1!K]H1G+>Q^B3\KM7,0^2LI])T!8\!FN V(? LTFJO\%
MEPI24?<G</3. E0O3FCF&].M OE XTKPD;YDA:PW9QH),A%0:TL>P\*)B4C2
MSM+U._(S4#&PVO#UU0F>I#([2?5=)H-">B,#=L-]P-P%R"%OC8QPL;'IM2RG
M-VQBQ2ELC]3MI;!MB3[8;<(,,B[ &P(39P3*@H9?-R!NQ8G2D..CR;G_PO$!
M;->LN>;6D-)!EJ4E,5UP) S!!0; .7.JP =;=ZST4*+Y C@V_ZKP^R0")8/Y
MQQB>',?F;Y,]I ?\FR97QDGH?LKOQA_BR9)&$A81AK"N> F+1/X>F.@(P61D
M26$TFR>$'EQ([&QYVUO[VT:FX/.4X7/ \'%G(IA*A,O"KT<O]P\8E0NDRY,>
MSE+R90:6%^J72@-LCM:);*^ S#&HQ^K)H3[()2!P9W15&&4)0^Z%&+>/^6;/
MP1-$!1MM[C>YN*(@L&!:2V?DW"$.;H/DUIHR1@B]!"ZCAY7)-"F EE,<>BYE
MPM8"B8K*P(<=\XIQDGH,>U[3<5-R3/=&SNGP[?!FZ" :^]'K_='><&^T)3@C
MA?%R\)<1X9O5O@Y"#W0WJ-T+FG^;9?@9XH+M!MM:(,=>+Q8/&Z,S2UMALEN(
MLSX?:Y7M% A)"I$_V>-/AHYSTLQ9M7KA6^/M A,VP/04I4TU&\\3,B5C*,DY
M&$4)5?Y(4#-29P(SFBDX]]W-#FTTN8RC>M;M;?Y9M_<MSKKQ-S_K&L4F&]UZ
M-OK^$ K?5";W-U\F][^%3+K?3R8W40A:4TU"''+0./O'MCV9>[G%,LG!]E:
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M#3JVUY'VF_4:M>$4:7+5(9TBUB$/3T3L .0Z;G1_YI/D!-;*:0F?S*9E#FZ
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M$(EJ5?(@4G9REXMYK,LY4@?WP*DJL93E0!2B0)F^I"^LLK;>IR:B0\7SQ@7
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M5D\&Q6ERXYA(G%5B6 =D*0WH;.'0[L!#O&2NX__"N;0]T EQ_!VB8[E)<;J
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M@<,1NI!^L@3;E6K*Z'C9I.^_DRO+C.7BVU&@Q#(%]D;F(MY--*T94\K;@4\
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M"E3)QN\[V4BYOT ULXW9YQ^=%LIH_(RGVQM#?)_ZS.+UFQW;X/8^Z'#2O%S
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M.IH'_"PZ@(U39C'A=3Y=D1C &,H1,\QI4=*_Y?+"ZZ]6YA K,L[SM*M(6\P
MG(,%D:0+,Q$J7M@JKHA+M'_/.3<&KBM^/T5.%)("J=9W[/#7::08HF>?G,3[
M ^"YJ#-S.O>"41]2HP&;?F9;ZHU)=UA##Q-!1WTJPO0)Z]O)L;_D![1P<LNS
MBUPAK*PB7^(M$I"C6ZLTSD, IC@+\L.0^)RI$:#RV. -\!A8/R;G!W55?7E6
M#CS&3KPE7IJUM_ \ :P0C3_48HV!:,"*5E:=W<GP(>L8.E 6S4]/8+.^> 5F
M45!ZCD-Y;?(#;NDA#"&R*!3X</8+_N]3SAA$B9I59MFY<VL"W^_1#H+[1-Z7
MR_$[O9&681<AF9@H[=\J<SX8*_>EB31$D8P$,H,C>J" /ES)\L,9$#[=3Y "
M"F\A2D T37(@1*:FG2-F].O>F/_[ QLZ5?)N@)?,:WR98L9V?"J$QBTO47 .
M0\^R A1),4>0L39ML+R+TFXWSXZQ>S*^RL!C,>,R*V?<"$('MX1HSU=8%!WE
M5QEP*(!CE' CL7*/!N:+ZG!(YOE\!&XE_%@@]T,:+[J(!&("\'L8Z0*9O-FH
M/A,0T?'@WBUOZ'';3TN7GU1YPTU5_"$P_ANCN:K): .]/CY5_@U*>=ZIA=T#
MD:["O6&4?W[P\MYLV4]R1!O#^EZ,[F_KOL&A)1 [W&FI\E'PB] <N"P:_PR*
MJG'0$4K'[-S$H!DWVLJ/I"F7;I#[#AWL'/-? HDC*0:EZ925JJYACL4<XR9&
MH5F'P+R3&3EE3"BD1)H!V# 3\68N+/0K\]B[I<>%EB%SL4;'9UUQ N-%41FA
MK]/A;ZH,-4EH.U><UJ*QTBL"4^-YPC?J=-@ 1N+X6"C/F+%:G]CFMANUX4G9
MMTX#S6RG6]@2=DE5%Z-R2\7?%("-^\@,XG/86&9SL1VHES3J5*ZCJS3S43*C
MWL2U7$4 M@1(C<R'TH\/Y0QM"NM-;AQM.OQB(H*0N>,NJ0PQ4MZ/I7L@TK<9
M&8[%_:R+[P@F*@(T>G6A>?+N1E=H:U1V/B'X0@_0# O->+Z/T(P=N5CV#(ZX
MN&R9+9SL)AE4:M,A11 $TI)\,89BPL@],39J:P]1K<EM$L\;YRU[$]VB<;>!
M@/L-=#Z:2U(RI\/$9?JIBCDZ&4LXZL?(H6*NNN[V2@*2_00V?>:VU8U#13J/
M!;,O$)/$,SP#RFR#@:$K<5) J@$SIL)TMUG1OP>>+@L(QKM>5[D(.SIM<XP0
M>TXG#-?A$.Y(RKG;]M]1,D:WY7:^N[XF:.*S\Y"C>75O CYW?I_E"^(8!55<
M$S4LDS.XYJZCOST1"8(UTWLE,5HBNR_HA*F[]8(@<'*98;LR,TD^8G2.]'XH
MD1X&&'^>'Z<B$P*XM9M'4ZAV#)X]'P)U0@XLA=0]31 @C(9*Y-E 6(K]#@*%
MH!:]E"JF=<2E7ZM0B5(7].,5F>:2#XY:7D#@A>LTH1FOV]0>SFE"W604_N0F
M6,6T!@R/.\.DIP++$I59)DFY@IPC"@SB-1N;PL295/?55=LL0;=U H>N^>E;
MPD*Q"R]72H%0HH*0-_@ 7PW%1?(7>"=F<^?DLTSQM"K'-VY<\(VQV=+5/*^E
MZ^U&-:C%A-GTK&>N]8*Z3;R%X-C#+2YB+3<.M*+4N9>.HHZ,1^[-J,11OF8Y
MNVA-#W>==$S0AG<7 X?4[PX&OT>FO_?Z<.@1[-H7".W^ESQ?6+)\<MFE)D&!
M22.H$R]-H3FI%$/PA"P)),LPG=7NM3;^/#I&V'V;UZ)4KLVCSNV\(7MK]@!B
MJD90I(=\RU6UJAMFF45\*0I6(;PT-^'1X>.A^RZ<,((4R";7E,KQN\))M MJ
MQ$JJ4>>;L)^GG)+F,=(Z!,%DQ_-R24H!P,(8<%G9DX.)]:SZ%AU7]B4HV^'P
M^[Y&M=+2@OAJL:H759/CKZ]AR=S(X44OF<Q_S5ZK"3#')B+W-0'1J4H&UFT9
M^B<"O\V&>)-PJ ^0W+607.J;1%. YR7S)O!>H-<H*VM>4375N "P:!? +2<^
M$="ZI-[$VV1MM8 ]X+MJ]G#.KLTBHO5=1\/7(9%($3BE(JRW5<9QX&VX?Z,<
M,.6\H7=DYJC"F-?6E6[@C[!64Y>=EZ%+5ZG&3^HGY0Q$2524*BD//2^#0UZ'
MB%=WB0>>9<N;4,*&:%99R7":HO&6^9-D0"9ZZ$H2]JTPF!HAEXB;_F8\M0;<
MV9RYN_C!\:;6O709HPB%V$8F+JR%0V**WEW:VM26@,S<;PW[&&7((%6'N[7.
MKW/*9E&/$,C;"0!1C+#YSTNLD7&23W<F\).:-U=C#FR.S:M6$P_N81Z05H#B
MM9 /M-7,;MC*.:N[6CZJIH\6U?A+#BX3$1+C8G&+<I\2(:_O32+DV+@1^;)'
M^!2SZ+UD=AL@ FR'\=RL.VW-2M(U8K0NF$.T5'C,M:U!(UGR!^RM$C.QL^2(
M'  ^E[GF14C<>:X+T]+.[9!]/3M*74>=_Z[[T%-'Q@:S%!G3MSL_2L)^[=8Y
M&-\ZER?5?I4?H54JV,V-$UW=Y'DT1XU]^CHNCJ#U43B<$$I#/_'BQ%8+O-C3
MQW>10?&CW M$3>#98BTNW]UJHS(U+D:<*'M">A5T3GE<F-3H\1;3*7B@P7:4
M*\DYCA53SA'$YA&+"\N'BJBKB+YXJ(C^.H9T+6DN2]4[3\R.O"XJM^C!@_6A
M&XY4#,4;:E"+<=$@L S&3A_88)R4\^BSX#K13"![67?!'G4//:3#Q_UQD9ZL
M=Y&T651O:^>];UA$)@*AT<TCR712(VB<="CU<N$4[<&YA\0RH*>(0.4@;%C7
M]89D<\'V6IK3JPE:.\/?.=B.UCK1/_ [HW"GJ /=9PV,US\D_&V*;W#\OF#6
M5\DJ$3+,SRE1WIBD!TDO,VO)K.BG35WC+ YHGN?+34\^P-'EC3E[O6H_&)G"
MF9T"8F A9B31T(JOI*XN2 !%1P_>L:?BZMZX0E;PRQ\ 934+PT(IW[R'EB -
MO"7S$/!Q8Q.+:_/5G4>-LF<=04H/B.U^5:/!EL1VGT[.WGX\>W_TX?@D.;\X
M^O#FZ.S-^9X<$R_N$;F=2N489^#(9GMWS07A<=2!4^0R:^S%6W)NVW35;K0K
MZ+31C[BNB@S <S"LF+!<YME<B&U0M<G79TT9CQ1%;<*%A2NOG#CUO)!DW*/
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M/&4/97Q;QG_Y4,;_=8W-+4: =0=-*&W2<=@H(=>#%\G@(Z_\X4'K[(R0)ZC
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M;'+)[9(U+WV_3HW#QST^-IZ2]@P1T.WXW)!A_ !CJ=J747YY5O*RXKURX5=
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MG<B*L5"6)NC.TAW]UR?_Z>)"=Z9/?O(MFR]F>1_$R/4>27A<K@NB89$_"(>
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M(+^)]KL4B)2O*IU70(IK7$/A_B67:YI02XH]R/3>1G_/)?MO\WX@B<6W;^S
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M[/JR!)T7:C-_;U6AMXX]K+5WM-;N2UVA966SJ(WU9>@#OQ,N''MTBS:(?JC
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MKG&S5PG?G3/?"<1OFA4SM"^CVKYQ1XW"X#EQCQG&"=;MYM$4?(W!L^>LYS.
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M@%V->45!9\:^M)\]Z5]W]RFI3*^ >;V^S$J$!,&;1>9R #5^0U;S2U5O"=!
M[ ?\<U47S:10)ZA9_@MQ)XFN'CDSIBMTU>DS<^Y67SFMFEDX#OP+O@KD3211
MY+[/VM,.1(['.?92ELS4P/C"?6Z@?=*_#NV@D *>$^E?NO6F>_-'!<$7$/N@
MY ;@RU8>?A9E<455><@;<K1H\1RIQ&HW>IU(+!*#3HVMKDUP:79/!3?L0@/$
M?\W]RH*),\N&%VZ+ F=TDP:*"C;_I\0&H&YB=AUBF\T?IRC57+..,L2]S9)*
M'LNK5-@3V .WN$+7!LRA_K)8@K^8N:],\FD&/^4V,VP\UK!J$S*OA.,(OR.
M'2CK4@,0![>IT\8L^&TOI&$5B$'4)Z-J!9T7)4&088JM>$1R750SW/9EF+;D
METM09&8*;> LY=?=\I(3;R'9\&B4&W=Y2A'<")QWM(:*X(D4J1H$8Z-<&@1T
M38$X<M\J402U5^=9?V#(<I[!P4$X67B7^2BKN94:BQL<.@*Q"'Q$:(.Z&IN8
M$1K<!,T8!S+&CY!M0.@=+[8O;[$_H,6G3)WN68&T0_&&>9J68B4F9":,#_WH
MN*KK%>5R;(G#7&&?MF9_$!_AUA0&+DLS+2E+3>VC<09$015+R5"_CB5OHZN)
M>G=J[Z1EO,T6+Y:QN"0@I),CMW&X,DZEK;_^NBOO#1B@3UI:&ZD4$)K3ZY!<
ME2(<_U![O%_M>'TQ!EL7-W8A&6R5@QBFOD)+1^2O)5N(Q;(K$[">R&W_*IVO
M?NM*YSTX(?N4-L03DO<;'Y)$]*.JA8R3)1:\4#57D H(L)FTHF2N@TA92__T
M:[6:32B0),IK6SPIYM!OR_4)I;>2HM1=78Q6\E'])1=BBR:;<2^81<X0",7O
MRI52G^LP0&>N*2#4M@4\QSR8:34:K]1,CS;T42S[L'K[<\"JU5LT#D2&0M^X
M%C:)C+M272.THQ9;3M<]U=[?)^7]N9;'*^[ L1XE.F?^ 65=. M0H[NZ_,VZ
MVW&Q6=4?8<O-BEQ5[/)RO)J/:DP9 ;E,=EW54C)M[=AN%],1Z.!QJE6<T'/9
MO^7>LTS#ARI2CT^PN*ITX970QX:%%60G$"_"#$$VXU=B^\1"G)T42'?'YG)L
MHB$6HB%A,;M9>GC1IR^3XX.W!V<'"93V7_[E\.#)Z\,]2XH_Z6&F ]>%S4:J
MG$=9>0;#K!&-#>E&[>S=.^U9HF/=.\4^ P6T\*5XULK5C>BX*R5A#9TB:%+4
MJMB[5]^?CH-M7CT!ALR^5J^,F>NCC#8J;#>/FB9,Q.^]<.3>3R95WGBD[>-9
M5LR;EGR$8'KTWQ2M_#XOI9?]6DHN&$3@I\<V;/W9>B5]DW4-CH,Q%$5N\R\$
MLC"7)9@%D82 :)E4^]H$?W:!^!:H3<@87 D'@"WGN:V51FLH"A'G=XJTQZ+)
M'_%F1;E:YI;*P]Y[GF/P:7QXXUKEBRL@W0#'FARF1OIK5TWC^E3N9FR$E;RF
MX1$F;BR-.$L<6YU#"-T$C%2Q1A>OC<ZG7(+??L,"[SA?EU[;K_WZJH_[E1UY
M&_EJ.[MFMVUQ_N_=^WW=K_?KVO$H8<943*HU/?\&^YD.4DQF*5Q%-@%")*1\
MQ "O##U!7]"XJB,]9) &X'5B<_. IRIFG"SQ\V*=)LYB&* N3DE%R'] +_'<
MYO>SLEQI^P7/G0/=0^.>!?F$[#=B1NW'EOPM#-]>94(.'_=G:]S*[96$!D.A
M6-T(-X,27M0T-YM7,S0!S+(Q-HW(V7M5S: D"Y5<SHNX+"$)1F*K/32,-S"F
M5,NB=JQ9KU_F855&5F6/JBD,. 2K GS"8)3]#NG&,3,QSU"#74?T[61F7J\D
MKGV/KC$>G/&%H>2_6G;'Y%$9#BIGN@JN-8&PO@@0-R'^ >@ ,U]%:_P5U>KD
M,4;YM.*6O;U?<#TJ@ 0AF^7'<=KO<#QWAVMAX+U?+[)'J7W)[0=%5WBI""@$
MTG%.\W-YU@D@0$5'._S44\N;/;9;]PJ09MYSCY+OP8;U$G+[@]'JS\;;LF_J
MV+B!)>".^M BY;!](P#H\\AB^+^HON\#(,H'1+U^ $3MVAKTR(6'B6!%$8<9
M_NF(X3L&"@L\>-TU]LW?>]HWX))>99"X,)_.;H1(-Z0%IQ1;DV?U^"J]90(/
M5@'03U&^8JV2^4T"/6+539ZGPBB>4==545[G#2I&B3BY]4V_M]E%$5-E**ZS
MA][ITQ[Y0I1O=AX&=N"!]I;.,Q3+)I]-4U*5GTZ-_:H; &9"8%FQLHJL(?I7
M^'.5G4CQQ4,65Z/*K^$#M_H:YID<0<8$-)W@-E>81>[8*+( B>X,;NNO\\&R
MNLS1)MJ?,"TO_&>_&,FX]DYOY,R?):["[](G'9(MZ! R>)/#D895?LE('"DE
M^EI_@8(B]S$QC=K6R[O48S]\_.S@V3:FX0E\;;?&H4>NT6/?/CBB'T>-&EVF
M3 R#S()H)V8D'UO:?RTRL_>,-2$%1W-4S M"7-,'M6N+)<!*=B,H)JS(5V5.
M7X,L2?Q"_$EXI4N2M*4+ 63R,LEGI)]TG<U64$>H;K/R<%K7+KUGC[=;>KL[
ME09"PM3^_WZ+:O(1[#\1ZG+9@XA\S<11;SM_K+J4]VH>UT_D)^H@'WR]HK.H
MJHE2+#;#PV20#?W9)1@Y76-)VN^>Y'9FXG[2'KRLJDDRS;!%OYA#-SSKB%4(
MY6G,@<BG3$:,7J"="%'+[(9/F&&:#$9X_SK_"H12^N93KJ=Y/\2]-A@/N=U"
M?]\V?K1^1)4WT9F&_8E;VX'<:8?*YKSC!=7_Y;1^/7&4QY-\5<QR"2M@ IE%
MBW #5BN-^G=F2*" T.^JU@02:Z??\J(MLF+"5A=Z4]GJ3L0@P]UP.>#W745T
ME)?YM(#.O>^W*;CX8.R74$I;)IY*78=WR"2X3E4@B%E^2*O^]S!<U]L8+F<-
M<";760-6^2M 43KWOBZ6RW[UKCJ5[Y./UZ/$1)>/M\&Q2SL\NQ0ZLLR&7:92
MN*+=B@)W\.H)W%3>:)_.6IVX3P;[FH@7E*6*D"\T^[B4>I1-")92-(]@V35T
MBO(LS 6LZ0&/53PLU@LP-Q'-'KB&KI<NK0J55JFCM3TWYPK -*S>4#*JJB\-
M$ZM;#-XD-U\"/%P-5:1)TW7V!-1/^.2.>RJFBJXE-1! 1]?76D!YL\R(+3^D
MC6(@?Y-(,(GC%JL#JES7^3[NDAX5A(-=PLL.?*@%1L:LO=1F_S6O-P +A/![
M0DHV>Q>_9IW>R^<%VB"S37 _?<T<K; $3K4Z6R!/+1+N!*R*&2BY@D^,D8J9
MNK&<9<OL"W* 1Q@R.G9H]][<NS+M\\?WNDS[6VRLT?J-Y4+W+,%3#EU#((+G
M.A1FBI?2K+ TLY%3$D^^[HI,=OMU*.<2-/:]X-PC[E_R'\Y'K(G.$0>X6!)-
MJ-('%V8+/I'COBX?YP[S[IW2E@B#C/#\ES_D'C$\]>?TWH0>HIJ&@(=VC1WJ
M8R=)A%T/TT1^IRI]5ZKE9CG:<I*"[?,Q[/]R?W9%?[K1-^X*)S38E[VA%\W^
M+)G^=+%O6C(H<9F9NV,UOS?T>"?_>7SRZ2(Y.D_.3RZ2MQ_/+OZ6G'Y(+OYV
M>IX<G5V<'K\[,;Y\,EBOES!,DT_FVQ].SO"#H_=_G'PPEX:?G+_[1_+F]/SX
MW='I>_/A/^@+[]XEZZ^8RL_3Y/3]IW>G)V_2Y-Q\]?/%Q[-_)!_/DH\7?SLY
M^_OI^4F:_/W4#-I\]]/)\45R\=$,_B0Y_OCNW=%?/Y[AQ<WHSCZ^^6P^/?UP
M<?+NG?G>YZ-W\,=/)V<7_TAYP'_[^/G\Y/W1V;^?N\?Q_L87N3@[>B-_HXGZ
MX^SDY+UYE!1&!@^)HTO./__U3QC3^Z.+"_//L_^?O3?M:AQ)%H;_BD[WO7U@
MKO%@LU?=V^=00%4S704U!=WSS'QY3]I*@[IDR:,%FOGU;T1D:K5D;+!Q2HZ>
M.05X267LD9&Q7'R&[5Q]4GLL?N_RZNSS;^?X)GY=XP'6^6A]N?AV]@O\<?KA
M\O,E;O;C)>SLY@:)99W21B_/?OM\^LWZ^MNWK]>(D-]//U^>7]X2GJZNKRZO
M/GZ#E>E)N&(E$JQOEY]^N;W9(-UA3MN"YW3'9V?L1*D#\MD1 P=O/]>L.JZN
M;U'R0"JO4L95? \\]?OE#0@>B"$P[N75Q;D%KU]<@B2J3]P"1R>B>O'_;I$Q
M08!_^TSB\?';]1?-V?_4X?L;Z\.WB].S7Y!]$[5T8FV!8@%A/*-O:>F\V4:N
MOP'NQN?W>MBV$W;Q\?(<'G)YBB*D+L24YD/5LXWB!^!8%[_C1OYQ"=HID7^4
M,5(.'RZLSY>G'^"Y>ML:5-QD*O4@6[<@UA\_@JB>WEYH&85W8 <W%W__36V!
MI)WVHWX_O_P&VP7]!@J,WO[ZV]7E[>7O%[CNQ?^[ /UW"DKO_/3+Z2=8<RO3
M%9^O;VX1<% )H(L^_'9S29H!OO;I^OH< =D&)?3Q(^#^'%^%;_[V#7__\$]X
M'=%9!**T^TLBX)7&):G9TY00WU"+7WS"Q5+2%+4:]ID'1 $.+CY=XW91VU]<
MG5TH% /_ $J_7-XJ='[X?/E)FP)8Z>(RMS/ .&#IXLO5Y<=_3N%><0L:E4_
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MV76'UL2T04&.Z^BPO!-0B#V7P)<$X[=0AY,/I)L54F0>S=:]H D?J8>Y3>$
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MS/@8EM,>P^)?KFT3L>5[=7[*,-,HR>H%0:OP\C4RX($]D)]+8.6Q1Y,%TPF
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MS\^^Q IHI@(JX!=)G#0#*UVO^4'=*;74FEBY\U6TT>YYJLNL+7!>71]OX?3
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M.@*]K8)S>/[.X@3Y^W"MOIPPC*76#;:<2,\.L_Y*#\"WMH-I^R'-H\#<,@6
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M@>]N4&3QK7(7EN%YQ61/@+G7?6]>8L'D_)-CP&%NLUD$+<0;:Y65@ZK1&5G
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MJG4BQ:FB;.!/U4E;B[5$Y4:"B]@AH<X'ES'%R-%)^N7\^OK3].9E'O0V,?/
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M:=F%^_G; WDPZJUPKIRB?AGK8\>V7;FNH@_LU_*B#OV+86L5LU\,1*?NW%1
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M_'X7^+%G[V@X[&/\WWM6CR_"UU(.D/P,9IT6DY59AUF'R<K&E\6 Q8#%@,6
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MW2)O6F+@/T@+X!?6Q!5#>>^[(/8__;A_]#Z,!"@6!_!Q[PSO%58&T@HD?9"
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M[FE4)+JW,.J''X"M@$OFQ\$0-@N;\B>1,P;0GM2Q$+TU![:34KBC^# +KPR
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M"="2(2F5H@+MAS3.-M(I;!T?GKDR"?%(,=N6*U#*!S)ZE-(KRKFIPJPC_O\
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M!8Z'4>I$5!_B*+2E+#CQB?(E9K H7JV#TIZ@\QN#-_"$K A:Z'LB<,E5(]D
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M'A)A%L"'XSWY+HA0S'=VAK"U8#1TY.GMYDY]]G"H8POZ1DQEH@ FH$?+NO@
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MXO?3"0/..L$/&, ]=T5@CN$NY[:%%_;?%Q>L>LX:E^<7H*K7S@\_J:-X86L
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M"+<5[I#!LG'2MH5=3I^'PT4-F.L1D4:??"S5XX%('3.). '1,B]0X%,C4(Q
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MA30U2\@#U./CB2M>=Z0,WAB\D?L'U\&E#CML",@QZ_/,IK'HLSR) SCV]-%
M2+C@[O1_A)VT'\*K/($%S(&#38P5);D?1+EH;<ZY:+R(ZV$ .8=]+XL!H0$!
M P*O53JPN^U4Q3,PB<P#*4U(P%5]'1SSU,301-N@Y:KT+X>B$(DK48&#.<V;
M5V?W<GEVYAR;<[SI3DIR/[&(EEQT"9/06(!185-CI]37K_HQ(5D^Y=(3EQX(
MZ__$]J-T!CI)C'$BXXID8LAPHT[J#/T8>V/K="M\!G_._IKS4@P=T#=L%4L5
MLA @09^$"87"I$0_  I$^-:B7I,IND#]B]#5_" L--8V<%68'%&3([H];R8
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MIS)MDTPCPK;I88H]37S/Q/<VW>7-0L7W?OO>ON[V_\VN[F[[#W<FP&<"?";
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MNJ$F17!]PI-ZPT.DB?B,O<U__NFB\>F:#P3VW:5?)"TT/NM!.COAFS7US?O
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M"8&M&J.=8#VFZ-G"4K47JH(C+Y.6EGBL+KF0A1WY6UF^/Q%8>%&2/A@>^A[
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MT;,0NMH63>6TTT*>[8$,8EEGY@_<Q'V:R3U 2UQV)5U$[D71J2PI;V;TQ.L
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M,.X" &%M9VXM,C R,C V,S N>'-D4$L! A0#%     @ LIX$5:,O54Z;'0
MV"$! !4              ( !3 4# &%M9VXM,C R,C V,S!?8V%L+GAM;%!+
M 0(4 Q0    ( +*>!%47JYGHBXL  ,?T!0 5              "  1HC P!A
M;6=N+3(P,C(P-C,P7V1E9BYX;6Q02P$"% ,4    " "RG@15'&.K%2X; 0"N
MHPL %0              @ '8K@, 86UG;BTR,#(R,#8S,%]L86(N>&UL4$L!
M A0#%     @ LIX$53UX2<\RM0  JA,( !4              ( !.<H$ &%M
M9VXM,C R,C V,S!?<')E+GAM;%!+ 0(4 Q0    ( +*>!%41=Y>PX @  )!-
M   8              "  9Y_!0!A;6=N+65X,S%?,C R,C8S,'AQ,BYH=&U0
M2P$"% ,4    " "RG@15#:C2L-(%   G)0  &               @ &TB 4
M86UG;BUE>#,R7S(P,C(V,S!X<3(N:'1M4$L! A0#%     @ LIX$54O%N)Y=
M&@  4;X  !X              ( !O(X% &5X:&EB:70Q,#0Q+69I<G-T86UE
M;F1M96YT+FAT;5!+ 0(4 Q0    ( +*>!%6\,G<%%*L! !I;%P >
M      "  56I!0!E>&AI8FET,3 T-BUC;VQL86)O<F%T:6]N82YH=&U02P$"
M% ,4    " "RG@15$WWJ@XX6   U\0  '@              @ &E5 < 97AH
M:6)I=#$P-#<M86UE;F1M96YT;F\Q=&\N:'1M4$L%!@     +  L ^@(  &]K
$!P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
